PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Monia, BP; Johnston, JF; Sasmor, H; Cummins, LL				Monia, BP; Johnston, JF; Sasmor, H; Cummins, LL			Nuclease resistance and antisense activity of modified oligonucleotides targeted to Ha-ras	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BLADDER-CARCINOMA ONCOGENE; XENOPUS OOCYTES; OLIGODEOXYNUCLEOTIDES; DEGRADATION; STABILITY; RNA; PHOSPHOROTHIOATES; EXPRESSION; PROBES; SERUM	We have previously described structure-activity studies on a 17-mer uniform phosphorothioate antisense sequence targeted to human Ha-ras. In an effort to further improve the pharmacological properties of antisense oligonucleotides, structure-activity studies on this 17-mer sequence were expanded to examine both the effects of replacing phosphorothioate backbone linkages with phosphodiester linkages and the effects of incorporating various 2'-sugar modifications into phosphorothioate and phosphodiester oligonucleotides on oligonucleotide stability against nucleases in vitro and on antisense activity in cells. Replacement of three or more phosphorothioate Linkages with phosphodiester linkages greatly compromised both nuclease resistance and antisense activity, and these effects correlated directly with the number of phosphodiester linkages incorporated into the oligonucleotide. However, substantial nuclease resistance, sufficient for obtaining potent antisense effects in cells, was conferred to phosphodiester oligonucleotides by incorporation of appropriate 2'-alkoxy sugar modifications. Nuclease stability and antisense activity imparted by these sugar modifications in phosphodiester backbones correlated with the size of the 2'-alkoxy substituent (pentoxy > propoxy > methoxy > deoxy). Furthermore, antisense activity mediated by oligonucleotides that exhibit partial resistance to nucleolytic degradation was dependent on both oligonucleotide concentration and the duration of oligonucleotide treatment.	ISIS PHARMACEUT,DIV MED CHEM,CARLSBAD,CA 92008	Isis Pharmaceuticals Inc	Monia, BP (corresponding author), ISIS PHARMACEUT,DEPT MOLEC PHARMACOL,2292 FARADAY AVE,CARLSBAD,CA 92008, USA.							AGRAWAL S, 1991, P NATL ACAD SCI USA, V88, P7595, DOI 10.1073/pnas.88.17.7595; AGRAWAL S, 1995, BIOCHEM PHARMACOL, V50, P571, DOI 10.1016/0006-2952(95)00160-2; Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; BACON TA, 1988, J BIOCHEM BIOPH METH, V16, P311, DOI 10.1016/0165-022X(88)90065-6; CAZENAVE C, 1987, NUCLEIC ACIDS RES, V15, P10507, DOI 10.1093/nar/15.24.10507; Cook P.D., 1993, ANTISENSE RES APPL, P149; COOK PD, 1991, ANTI-CANCER DRUG DES, V6, P585; CORNISH KG, 1993, PHARM COMMUN, V3, P239; CROOKE RM, 1995, J PHARMACOL EXP THER, V275, P462; Crooke S. T., 1995, THERAPEUTIC APPL OLI, P63; CROOKE ST, 1995, BIOCHEM J, V312, P599, DOI 10.1042/bj3120599; CROOKE ST, 1996, IN PRESS J PHARM EXP; CUMMINS LL, 1995, NUCLEIC ACIDS RES, V23, P2019, DOI 10.1093/nar/23.11.2019; DEAN NM, 1994, J BIOL CHEM, V269, P16416; ECKSTEIN F, 1985, ANNU REV BIOCHEM, V54, P367, DOI 10.1146/annurev.bi.54.070185.002055; FISHER TL, 1993, NUCLEIC ACIDS RES, V21, P3857, DOI 10.1093/nar/21.16.3857; GALBRAITH WM, 1994, ANTISENSE RES DEV, V4, P201, DOI 10.1089/ard.1994.4.201; GAO WY, 1991, MOL PHARMACOL, V41, P223; GUINOSSO CJ, 1991, NUCLEOS NUCLEOT, V10, P259, DOI 10.1080/07328319108046455; GUVAKOVA MA, 1995, J BIOL CHEM, V270, P2620, DOI 10.1074/jbc.270.6.2620; HOKE GD, 1991, NUCLEIC ACIDS RES, V19, P5743, DOI 10.1093/nar/19.20.5743; IRIBARREN AM, 1990, P NATL ACAD SCI USA, V87, P7747, DOI 10.1073/pnas.87.19.7747; KAWASAKI AM, 1993, J MED CHEM, V36, P831, DOI 10.1021/jm00059a007; LINN SM, 1993, NUCLEASES, P1; MONIA BP, 1992, J BIOL CHEM, V267, P19954; MONIA BP, 1993, J BIOL CHEM, V268, P14514; MORVAN F, 1987, NUCLEIC ACIDS RES, V15, P3421, DOI 10.1093/nar/15.8.3421; PERBOST M, 1989, BIOCHEM BIOPH RES CO, V165, P742, DOI 10.1016/S0006-291X(89)80029-4; PISETSKY DS, 1994, LIFE SCI, V54, P101, DOI 10.1016/0024-3205(94)00780-2; REDDY EP, 1983, SCIENCE, V220, P1061, DOI 10.1126/science.6844927; REDDY EP, 1982, NATURE, V300, P149, DOI 10.1038/300149a0; SHAW JP, 1991, NUCLEIC ACIDS RES, V19, P747, DOI 10.1093/nar/19.4.747; SPROAT BS, 1989, NUCLEIC ACIDS RES, V17, P3373, DOI 10.1093/nar/17.9.3373; STEIN CA, 1988, NUCLEIC ACIDS RES, V16, P3209, DOI 10.1093/nar/16.8.3209; TIDD DM, 1989, BRIT J CANCER, V60, P343, DOI 10.1038/bjc.1989.283; WOOLF TM, 1990, NUCLEIC ACIDS RES, V18, P1763, DOI 10.1093/nar/18.7.1763	36	130	153	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 14	1996	271	24					14533	14540		10.1074/jbc.271.24.14533	http://dx.doi.org/10.1074/jbc.271.24.14533			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UQ660	8662854	hybrid			2022-12-25	WOS:A1996UQ66000088
J	Hutchcroft, JE; Tsai, B; Bierer, BE				Hutchcroft, JE; Tsai, B; Bierer, BE			Differential phosphorylation of the T lymphocyte costimulatory receptor CD28 - Activation-dependent changes and regulation by protein kinase C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL TRANSDUCTION; TYROSINE KINASE; RESPONSES; ANTIGEN; CELLS	Treatment of T lymphocytes with phorbol ester and anti-CD28 monoclonal antibody (mAb) can induce proliferation and interleukin 2 production by triggering still undefined intracellular signaling pathways. We have developed a deglycosylation procedure that allows the precise identification of a distinct CD28 protein band, facilitating the analysis of activation-dependent changes in the phosphorylation state of CD28. Phorbol 12-myristate 13-acetate (PMA) treatment induced the in vitro phosphorylation of CD28 on threonine as detected in immune complex kinase assays. This effect of PMA was (i) rapid, preceding a PMA-induced increase in CD28 surface expression; (ii) occurred using kinase buffer containing either manganese or magnesium; and cells, and in a Jurkat subclone, J. Cam1, that is deficient in Lek tyrosine kinase activity. In contrast, anti-CD28 monoclonal antibody stimulation led to in vitro phosphorylation of CD28 on tyrosine that was manganese-dependent and required Lek tyrosine kinase activity, as it was undetectable in J. Cam1 cells. Importantly, CD28 was phosphotyrosine antibodies after stimulation with anti-CD28 monoclonal antibody. The in vivo tyrosine phosphorylation of Cd28 was inhibited by PMA treatment and was absent in J. Cam1 cells. Thus, the CD28 coreceptor can trigger different intracellular signaling pathways, depending upon the nature of the initial co-stimulatory signal.	DANA FARBER CANC INST, DIV PEDIAT ONCOL, BOSTON, MA 02115 USA; BRIGHAM & WOMENS HOSP, DIV HEMATOL ONCOL, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DEPT MED, BOSTON, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School				Bierer, Barbara/0000-0001-6448-8170	NIAID NIH HHS [AI35297] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI035297] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ARUFFO A, 1987, P NATL ACAD SCI USA, V84, P8573, DOI 10.1073/pnas.84.23.8573; AUGUST A, 1994, INT IMMUNOL, V6, P769, DOI 10.1093/intimm/6.5.769; AUGUST A, 1994, BIOCHEM BIOPH RES CO, V199, P1466, DOI 10.1006/bbrc.1994.1396; AUGUST A, 1994, P NATL ACAD SCI USA, V91, P9347, DOI 10.1073/pnas.91.20.9347; BIERER BE, 1993, CURR OPIN HEMATOL, P149; BLUM H, 1987, ELECTROPHORESIS, V8, P93, DOI 10.1002/elps.1150080203; GMUNDER H, 1984, EUR J BIOCHEM, V142, P153, DOI 10.1111/j.1432-1033.1984.tb08263.x; HARDING FA, 1992, NATURE, V356, P607, DOI 10.1038/356607a0; HUTCHCROFT JE, 1994, P NATL ACAD SCI USA, V91, P3260, DOI 10.1073/pnas.91.8.3260; HUTCHCROFT JE, 1995, P NATL ACAD SCI USA, V92, P8808, DOI 10.1073/pnas.92.19.8808; JELINEK T, 1993, BIOTECHNIQUES, V15, P629; JUNE CH, 1994, IMMUNOL TODAY, V15, P321, DOI 10.1016/0167-5699(94)90080-9; KAPELLER R, 1994, BIOESSAYS, V16, P565, DOI 10.1002/bies.950160810; LINSLEY PS, 1993, ANNU REV IMMUNOL, V11, P191, DOI 10.1146/annurev.iy.11.040193.001203; LU YL, 1992, J IMMUNOL, V149, P24; LU YL, 1995, EUR J IMMUNOL, V25, P533, DOI 10.1002/eji.1830250234; LU YL, 1994, EUR J IMMUNOL, V24, P2732, DOI 10.1002/eji.1830241124; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; PAGES F, 1994, NATURE, V369, P327, DOI 10.1038/369327a0; PRASAD KVS, 1994, P NATL ACAD SCI USA, V91, P2834, DOI 10.1073/pnas.91.7.2834; RAAB M, 1995, P NATL ACAD SCI USA, V92, P8891, DOI 10.1073/pnas.92.19.8891; STEIN PH, 1994, MOL CELL BIOL, V14, P3392, DOI 10.1128/MCB.14.5.3392; STRAUS DB, 1992, CELL, V70, P585, DOI 10.1016/0092-8674(92)90428-F; TRUITT KE, 1994, J EXP MED, V179, P1071, DOI 10.1084/jem.179.3.1071; VANDENBERGHE P, 1992, J EXP MED, V175, P951, DOI 10.1084/jem.175.4.951	25	19	19	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 7	1996	271	23					13362	13370		10.1074/jbc.271.23.13362	http://dx.doi.org/10.1074/jbc.271.23.13362			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UP385	8662792	hybrid			2022-12-25	WOS:A1996UP38500012
J	Rodriguez, MS; Wright, J; Thompson, J; Thomas, D; Baleux, F; Virelizier, JL; Hay, RT; ArenzanaSeisdedos, F				Rodriguez, MS; Wright, J; Thompson, J; Thomas, D; Baleux, F; Virelizier, JL; Hay, RT; ArenzanaSeisdedos, F			Identification of lysine residues required for signal-induced ubiquitination and degradation of I kappa B-alpha in vivo	ONCOGENE			English	Article						I-kappa B; NF-kappa B; signal induced proteolysis	BINDING-PROTEIN EBP1; INHIBITOR; ACTIVATION; MEMBERS; FAMILY; DNA	Activation of transcription factor NF-kappa B involves signal-induced degradation of the protein inhibitor I kappa B-alpha and release of NF-kappa B which translocates to the nucleus where it influences transcription of responsive genes, Although multiple regions of I kappa B-alpha are involved in this process, the N-terminal region of the protein has been identified as a regulatory region that is required for signal induced phosphorylation and degradation, The sensitivity of I kappa B-alpha degradation to peptide aldehydes which inhibit of the proteasome and the detection of forms of I kappa B-alpha indicate that I kappa B-alpha is degraded by the ubiquitin-proteasome pathway. To identify lysine residues that represent the ubiquitin addition, a series of lysine to mutations were introduced into I kappa B-alpha and the mutant proteins tested for their ability to function in vivo, Exposure of COS7 cells, cotransfected with I kappa B-alpha and a TNF-responsive NF-kappa B reporter gene, resulted in stimulation of reporter activity as a consequence of I kappa B-alpha degradation, In contrast, this effect was drastically reduced when an I kappa B-alpha mutant carrying serine to alanine changes at amino-acids, 32 and 36, which blocks both signal-induced phosphorylation and ubiquitin conjugation of the protein, was co-transfected with the reporter gene. Likewise, a mutant form of I kappa B-alpha containing lysine to arginine changes at positions 21 and 22 (K21R, K22R) severely reduces TNF-induced activation of the NF-kappa B-dependent reporter gene, Examination of the metabolism of mutant I kappa B-alpha molecules reveals that, while the K21R, K22R mutant inhibits the DNA-binding activity of NF-kappa B and undergoes signal induced phosphorylation, it is neither ubiquitinated nor degraded in response to TNF, Thus, it is likely that after signal-induced phosphorylation of I kappa B-alpha. on serine residues 32 and 36, lysine residues 21 and 22 are major sites of ubiquitin ligation which target the protein for rapid degradation by the proteasome.	INST PASTEUR,UNITE IMMUNOL VIRALE,F-75015 PARIS,FRANCE; INST PASTEUR,UNITE CHIM ORGAN,F-75015 PARIS,FRANCE; UNIV ST ANDREWS,SCH BIOL & MED SCI,ST ANDREWS KY16 9AL,FIFE,SCOTLAND	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; University of St Andrews			Hay, Ronald T/F-9338-2011; Arenzana-Seisdedos, Fernando/E-5835-2016	Hay, Ronald T/0000-0001-7113-9024; 				ALKALAY I, 1995, MOL CELL BIOL, V15, P1294; ARENZANASEISDEDOS F, 1995, MOL CELL BIOL, V15, P2689; AUPHAN N, 1995, SCIENCE, V270, P286, DOI 10.1126/science.270.5234.286; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; Baldi L, 1996, J BIOL CHEM, V271, P376, DOI 10.1074/jbc.271.1.376; BARROGA CF, 1995, P NATL ACAD SCI USA, V92, P7637, DOI 10.1073/pnas.92.17.7637; BEG AA, 1993, GENE DEV, V7, P2064, DOI 10.1101/gad.7.11.2064; BEG AA, 1995, GENE DEV, V9, P2736, DOI 10.1101/gad.9.22.2736; BROCKMAN JA, 1995, MOL CELL BIOL, V15, P2809; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; CHEN ZJ, 1995, GENE DEV, V9, P1586, DOI 10.1101/gad.9.13.1586; CHIAO PJ, 1994, P NATL ACAD SCI USA, V91, P28, DOI 10.1073/pnas.91.1.28; CLARK L, 1989, J MOL BIOL, V206, P615, DOI 10.1016/0022-2836(89)90570-6; CLARK L, 1989, NUCLEIC ACIDS RES, V17, P499, DOI 10.1093/nar/17.2.499; DESHAIES RJ, 1995, EMBO J, V14, P303, DOI 10.1002/j.1460-2075.1995.tb07004.x; DEVERAUX Q, 1994, J BIOL CHEM, V269, P7059; DIDONATO JA, 1995, MOL CELL BIOL, V15, P1302; FEHRENTZ JA, 1985, INT J PEPT PROT RES, V26, P236; FINCO TS, 1994, P NATL ACAD SCI USA, V91, P11884, DOI 10.1073/pnas.91.25.11884; FUJITA T, 1992, GENE DEV, V6, P775, DOI 10.1101/gad.6.5.775; GHOSH G, 1995, NATURE, V373, P303, DOI 10.1038/373303a0; GILMORE TD, 1993, TRENDS GENET, V9, P427, DOI 10.1016/0168-9525(93)90106-R; HASKILL S, 1991, CELL, V65, P1281, DOI 10.1016/0092-8674(91)90022-Q; HAY RT, 1993, BIOCHEM SOC T, V21, P926, DOI 10.1042/bst0210926; ISRAEL A, 1995, TRENDS GENET, V11, P203, DOI 10.1016/S0168-9525(00)89045-9; JAFFRAY E, 1995, MOL CELL BIOL, V15, P2166; KORNITZER D, 1994, EMBO J, V13, P6021, DOI 10.1002/j.1460-2075.1994.tb06948.x; LEBAIL O, 1993, EMBO J, V12, P5043, DOI 10.1002/j.1460-2075.1993.tb06197.x; LIN YC, 1995, P NATL ACAD SCI USA, V92, P552, DOI 10.1073/pnas.92.2.552; Liou HC, 1993, CURR OPIN CELL BIOL, V5, P477, DOI 10.1016/0955-0674(93)90014-H; MELLITS KH, 1993, NUCLEIC ACIDS RES, V21, P5059, DOI 10.1093/nar/21.22.5059; MIYAMOTO S, 1994, P NATL ACAD SCI USA, V91, P12740, DOI 10.1073/pnas.91.26.12740; MIYAMOTO S, 1995, ADV CANCER RES, V66, P255, DOI 10.1016/S0065-230X(08)60257-2; MULLER CW, 1995, NATURE, V373, P311, DOI 10.1038/373311a0; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; PEREZ P, 1995, MOL CELL BIOL, V15, P3523; RODRIGUEZ MS, 1995, MOL CELL BIOL, V15, P2413; Roff M, 1996, J BIOL CHEM, V271, P7844, DOI 10.1074/jbc.271.13.7844; SCHEINMAN RI, 1995, SCIENCE, V270, P283, DOI 10.1126/science.270.5234.283; SCHERER DC, 1995, P NATL ACAD SCI USA, V92, P11259, DOI 10.1073/pnas.92.24.11259; SCHMITZ ML, 1991, EMBO J, V10, P3805, DOI 10.1002/j.1460-2075.1991.tb04950.x; SCHWOB E, 1994, CELL, V79, P233, DOI 10.1016/0092-8674(94)90193-7; SUN SC, 1993, SCIENCE, V259, P1912, DOI 10.1126/science.8096091; SUN SC, 1994, MOL CELL BIOL, V14, P7377, DOI 10.1128/MCB.14.11.7377; THANOS D, 1995, CELL, V80, P529, DOI 10.1016/0092-8674(95)90506-5; TRAENCKNER EBM, 1995, EMBO J, V14, P2876, DOI 10.1002/j.1460-2075.1995.tb07287.x; TRAENCKNER EBM, 1994, EMBO J, V13, P5433, DOI 10.1002/j.1460-2075.1994.tb06878.x; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; VLACH J, 1995, VIROLOGY, V208, P753, DOI 10.1006/viro.1995.1207; WHITESIDE ST, 1995, MOL CELL BIOL, V15, P5339; YAGLOM J, 1995, MOL CELL BIOL, V15, P731	52	126	131	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN 6	1996	12	11					2425	2435						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UQ220	8649784				2022-12-25	WOS:A1996UQ22000021
J	deCock, H; vanBlokland, S; Tommassen, J				deCock, H; vanBlokland, S; Tommassen, J			In vitro insertion and assembly of outer membrane protein PhoE of Escherichia coli K-12 into the outer membrane - Role of Triton X-100	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OMPF PORIN; INVITRO TRIMERIZATION; LIPOPOLYSACCHARIDE; ARCHITECTURE; PARTICLES; FUSION; GENE	The assembly of the in vitro synthesized outer membrane protein PhoE into purified outer membranes was investigated, The assembly appeared to be strongly stimulated by the presence of low amounts of Triton X-100 (optimal 0.08%, w/v). The role of Triton X-100 in the in vitro system was further examined. Pretreating outer membranes with Triton X-100 did not make the membranes competent for correct assembly, indicating that the detergent did not act on the membrane but at the protein level. PhoE became assembly-incompetent with a half-life of approximately 12 min and 90 s at 37 degrees C in the absence and presence, respectively, of 0.08% Triton X-100, Apparently, Triton X-100 induces an assembly-competent state in the PhoE protein with a very short half-life. Furthermore, the efficiency of correct assembly of PhoE was greatly reduced when outer membranes of deep rough lipopolysaccharide mutants were used, indicating an important role of lipopolysaccharides in the assembly of the porin.	UNIV UTRECHT,DEPT MOLEC CELL BIOL,3584 CH UTRECHT,NETHERLANDS	Utrecht University	deCock, H (corresponding author), UNIV UTRECHT,BIOMEMBRANE INST,PADUALAAN 8,3584 CH UTRECHT,NETHERLANDS.		de Cock, Hans/B-7790-2011; Tommassen, Jan/I-1690-2016	de Cock, Hans/0000-0002-8420-6764; Tommassen, Jan/0000-0001-7633-4945				AMES GF, 1974, J BACTERIOL, V117, P406, DOI 10.1128/JB.117.2.406-416.1974; BOLLA JM, 1988, EMBO J, V7, P3595, DOI 10.1002/j.1460-2075.1988.tb03237.x; BOSCH D, 1986, J MOL BIOL, V189, P449, DOI 10.1016/0022-2836(86)90316-5; CASADABAN MJ, 1976, J MOL BIOL, V104, P541, DOI 10.1016/0022-2836(76)90119-4; CASADABAN MJ, 1980, J MOL BIOL, V138, P179, DOI 10.1016/0022-2836(80)90283-1; DECOCK H, 1989, BIOCHIM BIOPHYS ACTA, V985, P313, DOI 10.1016/0005-2736(89)90418-5; DECOCK H, 1990, J BIOL CHEM, V265, P4646; DECOCK H, 1990, BIOCHIMIE, V72, P177, DOI 10.1016/0300-9084(90)90143-5; DEVRIJE T, 1987, BIOCHIM BIOPHYS ACTA, V900, P63, DOI 10.1016/0005-2736(87)90278-1; DIEDRICH DL, 1990, J BACTERIOL, V172, P5307, DOI 10.1128/jb.172.9.5307-5311.1990; DIRIENZO JM, 1979, CELL, V17, P155, DOI 10.1016/0092-8674(79)90303-9; EISELE JL, 1990, J BIOL CHEM, V265, P10217; FREUDL R, 1985, EMBO J, V4, P3593, DOI 10.1002/j.1460-2075.1985.tb04122.x; LAIRD MW, 1994, J BACTERIOL, V176, P2259, DOI 10.1128/JB.176.8.2259-2264.1994; LUGTENBERG B, 1983, BIOCHIM BIOPHYS ACTA, V737, P51, DOI 10.1016/0304-4157(83)90014-X; LUGTENBERG B, 1975, FEBS LETT, V58, P254, DOI 10.1016/0014-5793(75)80272-9; NIKAIDO H, 1985, MICROBIOL REV, V49, P1; PAGES JM, 1988, EUR J BIOCHEM, V176, P655, DOI 10.1111/j.1432-1033.1988.tb14327.x; PARK SH, 1988, SCIENCE, V239, P1033, DOI 10.1126/science.3278378; RIED J, 1988, J MOL BIOL, V263, P7753; SEN K, 1991, J BIOL CHEM, V266, P11295; SEN K, 1990, P NATL ACAD SCI USA, V87, P743, DOI 10.1073/pnas.87.2.743; SEN K, 1991, J BACTERIOL, V173, P926, DOI 10.1128/jb.173.2.926-928.1991; STRUYVE M, 1991, J MOL BIOL, V218, P141, DOI 10.1016/0022-2836(91)90880-F; TOMMASSEN J, 1984, J BACTERIOL, V157, P327, DOI 10.1128/JB.157.1.327-329.1984; TOMMASSEN J, 1981, J BACTERIOL, V147, P118, DOI 10.1128/JB.147.1.118-123.1981; VANALPHEN L, 1978, J BACTERIOL, V134, P1089, DOI 10.1128/JB.134.3.1089-1098.1978; VANALPHEN L, 1979, BIOCHIM BIOPHYS ACTA, V556, P233, DOI 10.1016/0005-2736(79)90045-2; VANALPHEN L, 1985, EUR J BIOCHEM, V147, P401; VANDERLEY P, 1986, J BACTERIOL, V168, P449, DOI 10.1128/jb.168.1.449-451.1986; VANDERLEY P, 1985, EUR J BIOCHEM, V147, P401; VANGELDER P, 1994, EUR J BIOCHEM, V226, P783; VERKLEIJ A, 1977, BIOCHIM BIOPHYS ACTA, V466, P269, DOI 10.1016/0005-2736(77)90224-3; VERKLEIJ AJ, 1976, BIOCHIM BIOPHYS ACTA, V426, P581, DOI 10.1016/0005-2736(76)90401-6; ZARDENETA G, 1994, ANAL BIOCHEM, V223, P1, DOI 10.1006/abio.1994.1537	35	41	41	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 31	1996	271	22					12885	12890		10.1074/jbc.271.22.12885	http://dx.doi.org/10.1074/jbc.271.22.12885			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UN474	8662743	hybrid			2022-12-25	WOS:A1996UN47400032
J	Okumura, K; Sakaguchi, G; Takagi, S; Naito, K; Mimori, T; Igarashi, H				Okumura, K; Sakaguchi, G; Takagi, S; Naito, K; Mimori, T; Igarashi, H			Sp1 family proteins recognize the U5 repressive element of the long terminal repeat of human T cell leukemia virus type I through binding to the CACCC core motif	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR; GENE-EXPRESSION; KU-PROTEIN; RESPONSIVE ELEMENT; PROMOTER; DNA; HTLV; SITE; SEQUENCES; PHOSPHORYLATION	We have identified several nuclear proteins binding to the U5 repressive element (U5RE) at the U5 region of the human T cell leukemia virus type I (HTLV-I) long terminal repeat (LTR). In gel mobility shift assays with the U5RE DNA probe, Jurkat T cell nuclear proteins generated five different complexes, named U5RE binding protein complexes (U5RP)-A1, -A2, -A3, -B, and -C. Only U5RP-C was affected by pretreatment with an excess of poly(dI-dC) and was immunodepressed by anti-Ku/p80 antibodies, suggesting that U5RP-C is a nonspecific complex involving Ku antigen, UV cross-linking showed at least six nuclear proteins involved in the other complexes, including U5R9-A1, -A2, -A3, and -B. The sequence of the binding core element of these specific complexes, determined by competition assays and gel mobility shift assays using a series of the U5RE mutants, is CACCC which is identical to that for the Sp1 transcription factor. LTR with a mutant U5RE, which has no ability to bind with the nuclear proteins, showed stronger promoter activity than LTR with the wild U5RE, suggesting that the specific interaction of these U5RE-binding proteins might result in the U5-mediated repression. U5RP-A1 was supershifted by anti-Sp1 antibodies and U5RP-A2 and -B were supershifted by anti-Sp3 antibodies, suggesting that Sp1 or Sp3 is involved in U5RP-A1 or U5RP-A2 and -B, respectively. Although the other nuclear proteins remain to be characterized, these findings suggest that U5RE-binding proteins in U5RP-A1, -A2, -A3, and -B are involved in HTLV-I gene repression.	SHIONOGI INST MED SCI, SETTSU, OSAKA 566, JAPAN; KEIO UNIV, SCH MED, DEPT INTERNAL MED, DIV RHEUMATOL, TOKYO 160, JAPAN	Shionogi & Company Limited; Keio University								BOSSELUT R, 1990, EMBO J, V9, P3137, DOI 10.1002/j.1460-2075.1990.tb07511.x; BRIGGS MR, 1986, SCIENCE, V234, P47, DOI 10.1126/science.3529394; DIERKS P, 1983, CELL, V32, P695, DOI 10.1016/0092-8674(83)90055-7; DIGNAM JD, 1983, METHOD ENZYMOL, V101, P582; DYNAN WS, 1983, CELL, V35, P79, DOI 10.1016/0092-8674(83)90210-6; DYNAN WS, 1985, P NATL ACAD SCI USA, V82, P4915, DOI 10.1073/pnas.82.15.4915; DYNAN WS, 1983, CELL, V32, P669, DOI 10.1016/0092-8674(83)90053-3; FISCHER KD, 1993, J BIOL CHEM, V268, P23915; GARTENHAUS RB, 1991, BLOOD, V78, P2956; GIDONI D, 1984, NATURE, V312, P409, DOI 10.1038/312409a0; GIDONI D, 1985, SCIENCE, V230, P511, DOI 10.1126/science.2996137; GONZALEZ GA, 1989, NATURE, V337, P749, DOI 10.1038/337749a0; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRIFFITH AJ, 1992, J BIOL CHEM, V267, P331; HAGEN G, 1992, NUCLEIC ACIDS RES, V20, P5519, DOI 10.1093/nar/20.21.5519; HAGEN G, 1994, EMBO J, V13, P3843, DOI 10.1002/j.1460-2075.1994.tb06695.x; HINUMA Y, 1981, P NATL ACAD SCI-BIOL, V78, P6476, DOI 10.1073/pnas.78.10.6476; INAGAKI N, 1992, P NATL ACAD SCI USA, V89, P1045, DOI 10.1073/pnas.89.3.1045; KADONAGA JT, 1987, CELL, V51, P1079, DOI 10.1016/0092-8674(87)90594-0; KASHANCHI F, 1994, J VIROL, V68, P561, DOI 10.1128/JVI.68.1.561-565.1994; KASHANCHI F, 1993, J VIROL, V67, P2894, DOI 10.1128/JVI.67.5.2894-2902.1993; KINGSLEY C, 1992, MOL CELL BIOL, V12, P4251, DOI 10.1128/MCB.12.10.4251; LAMPH WW, 1990, P NATL ACAD SCI USA, V87, P4320, DOI 10.1073/pnas.87.11.4320; LEE B, 1989, TOHOKU J EXP MED, V157, P1, DOI 10.1620/tjem.157.1; MAJELLO B, 1994, NUCLEIC ACIDS RES, V22, P4914, DOI 10.1093/nar/22.23.4914; MARRIOTT SJ, 1990, MOL CELL BIOL, V10, P4192, DOI 10.1128/MCB.10.8.4192; MIMORI T, 1986, J BIOL CHEM, V261, P2274; MIMORI T, 1986, J BIOL CHEM, V261, P375; MOEHIZUKI M, 1992, LANCET, V339, P1110; MURATA Y, 1994, J BIOL CHEM, V269, P20674; NAKAMURA M, 1989, Virus Genes, V2, P147, DOI 10.1007/BF00315258; NICHOLSON RC, 1990, EMBO J, V9, P4443, DOI 10.1002/j.1460-2075.1990.tb07895.x; NYBORG JK, 1990, J BIOL CHEM, V265, P8237; OHTANI K, 1987, EMBO J, V6, P389, DOI 10.1002/j.1460-2075.1987.tb04767.x; OKUMURA K, 1994, FEBS LETT, V356, P94, DOI 10.1016/0014-5793(94)01243-1; OSAME M, 1986, LANCET, V1, P1031; PAILLARD S, 1991, NUCLEIC ACIDS RES, V19, P5619, DOI 10.1093/nar/19.20.5619; POIESZ BJ, 1981, NATURE, V294, P268, DOI 10.1038/294268a0; SEIKI M, 1990, VIROLOGY, V176, P81, DOI 10.1016/0042-6822(90)90232-G; SEIKI M, 1988, P NATL ACAD SCI USA, V85, P7124, DOI 10.1073/pnas.85.19.7124; SEIKI M, 1983, P NATL ACAD SCI-BIOL, V80, P3618, DOI 10.1073/pnas.80.12.3618; SUZUKI T, 1993, P NATL ACAD SCI USA, V90, P610, DOI 10.1073/pnas.90.2.610; UDVADIA AJ, 1995, P NATL ACAD SCI USA, V92, P3953, DOI 10.1073/pnas.92.9.3953; WAGNER S, 1993, SCIENCE, V262, P395, DOI 10.1126/science.8211160; XU X, 1994, MOL CELL BIOL, V14, P5371, DOI 10.1128/MCB.14.8.5371; YOSHIDA M, 1982, P NATL ACAD SCI-BIOL, V79, P2031, DOI 10.1073/pnas.79.6.2031; ZHANG WW, 1992, BIOCHEM BIOPH RES CO, V186, P574, DOI 10.1016/S0006-291X(05)80847-2	47	32	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 31	1996	271	22					12944	12950		10.1074/jbc.271.22.12944	http://dx.doi.org/10.1074/jbc.271.22.12944			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UN474	8662723	hybrid			2022-12-25	WOS:A1996UN47400042
J	Salzet, M; VergerBocquet, M; Bulet, P; Beauvillain, JC; Malecha, J				Salzet, M; VergerBocquet, M; Bulet, P; Beauvillain, JC; Malecha, J			Purification, sequence analysis, and cellular localization of a prodynorphin-derived peptide related to the alpha-Neo-endorphin in the rhynchobdellid leech Theromyzon tessulatum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OPIOID-PEPTIDES; NERVOUS-SYSTEM; SUPRAESOPHAGEAL GANGLION; ERPOBDELLA-OCTOCULATA; MYTILUS-EDULIS; END-PRODUCTS; ENKEPHALINS; NEURONS; BRAIN; PROOPIOMELANOCORTIN	Cells immunoreactive to an antiserum specifically directed against vertebrate alpha-Neo-endorphin (alpha-NE) were detected in the internal wall of anterior and posterior suckers of the rhynchobdellid leech Theromyzon Tessulatum. These cells have morphological and ultrastructural characteristics close to the ''releasing gland cells'' of adhesive organs. The epitope recognized by anti-alpha-NE was contained in granules having a diameter of 0.2-0.3 mu m. Previous works involving the brain of this leech demonstrate the existence of similar to 14 neurons immunoreactive to the anti-alpha-NE. Following an extensive purification including high pressure gel permeation and reversed-phase high performance Liquid chromatography, epitopes contained in both suckers and central nervous system were isolated. Purity of the isolated peptides was controlled by capillary electrophoresis. Their sequences were determined by a combination of automated Edman degradation, electrospray mass spectrometry measurement, and coelution experiments in reversed-phase high performance liquid chromatography with synthetic alpha-NE. The results demonstrate that epitopes recognized by the anti-alpha-NE in the suckers and the central nervous system are identical to vertebrate alpha-NE (YGGFL-RKYPK). This finding constitutes the first biochemical characterization of a prodynorphin-derived peptide in invertebrates. Moreover the isolation of this peptide in the annelida establishes the very ancient phylogenetic origin of alpha-NE as well as its conservation in evolution.	INST BIOL MOLEC & CELLULAIRE, CNRS, UPR 9022, F-67084 STRASBOURG, FRANCE; INSERM, LAB NEUROENDOCRINOL & PHYSIOPATHOL NEURONALE, U422, F-59045 LILLE, FRANCE	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Institut National de la Sante et de la Recherche Medicale (Inserm)	Salzet, M (corresponding author), UNIV SCI & TECH LILLE FLANDRES ARTOIS, CTR BIOL CELLULAIRE, LAB PHYLOGENIE MOLEC ANNELIDES, DRED, F-59655 VILLENEUVE DASCQ, FRANCE.		Salzet, Michel/A-7675-2011; BULET, Philippe/C-8557-2014	Salzet, Michel/0000-0003-4318-0817; BULET, Philippe/0000-0001-9016-265X				BOER HH, 1985, PEPTIDES, V6, P459, DOI 10.1016/0196-9781(85)90414-0; BRINKHURST RO, 1989, HYDROBIOLOGIA, V180, P7, DOI 10.1007/BF00027533; DHAINAUTCOURTOIS N, 1986, NEUROCHEM INT, V8, P327, DOI 10.1016/0197-0186(86)90006-9; DORES RM, 1993, CELL PHYSIOL BIOCHEM, V3, P231, DOI 10.1159/000154686; DORES RM, 1992, GEN COMP ENDOCR, V88, P292, DOI 10.1016/0016-6480(92)90262-I; DORES RM, 1993, BRAIN BEHAV EVOLUT, V42, P69, DOI 10.1159/000114141; DORES RM, 1990, GEN COMP ENDOCR, V77, P489, DOI 10.1016/0016-6480(90)90241-D; DUVAUXMIRET O, 1992, ANN NY ACAD SCI, V650, P245; DUVAUXMIRET O, 1991, ADV NEUROIMMUNOL, V1, P41, DOI 10.1016/S0960-5428(06)80031-8; DUVAUXMIRET O, 1992, NEW BIOL, V2, P93; DUVE H, 1988, CELL TISSUE RES, V251, P399, DOI 10.1007/BF00215849; FALLON JH, 1990, HDB CHEM NEUROANATOM, V9, P1; FARNESI RM, 1981, J MORPHOL, V170, P195, DOI 10.1002/jmor.1051700206; FRANCESCHI C, 1992, J IMMUNOL RES-ITALY, V4, P53; GELDER SR, 1988, CAN J ZOOL, V66, P2057, DOI 10.1139/z88-303; GOLDSMITH LA, 1992, PHYSL BIOCH MOL BIOL; GUBLER U, 1987, MOL CLONING HORMONE, P229; HOGG N, 1983, J NEUROSCI RES, V9, P445, DOI 10.1002/jnr.490090410; HOLT PC, 1989, HYDROBIOLOGIA, V180, P1, DOI 10.1007/BF00027532; KREAM RM, 1980, J BIOL CHEM, V255, P9218; LAURENT V, 1995, NEUROSCI LETT, V190, P175, DOI 10.1016/0304-3940(95)11533-3; LEUNG MK, 1984, P NATL ACAD SCI-BIOL, V81, P955, DOI 10.1073/pnas.81.3.955; LUSCHEN W, 1991, P NATL ACAD SCI USA, V88, P8671, DOI 10.1073/pnas.88.19.8671; MALECHA J, 1989, CAN J ZOOL, V67, P636, DOI 10.1139/z89-091; MULLER KJ, 1981, NEUROBIOLOGY LEECH, P255; PATEY G, 1986, ANN ENDOCRINOL-PARIS, V47, P71; REUTER M, 1989, ARCH HISTOL CYTOL, V52, P253, DOI 10.1679/aohc.52.Suppl_253; SALZET M, 1993, EUR J BIOCHEM, V217, P897, DOI 10.1111/j.1432-1033.1993.tb18319.x; SALZET M, 1994, FEBS LETT, V348, P102, DOI 10.1016/0014-5793(94)00581-8; SALZET M, 1992, COMP BIOCHEM PHYS C, V102, P483, DOI 10.1016/0742-8413(92)90147-Y; SALZET M, 1993, BRAIN RES, V631, P247, DOI 10.1016/0006-8993(93)91542-Z; SALZET M, 1995, J BIOL CHEM, V270, P1575, DOI 10.1074/jbc.270.4.1575; SALZET M, 1995, FEBS LETT, V357, P187, DOI 10.1016/0014-5793(94)01358-8; SCHARRER B, 1990, AM ZOOL, V30, P887; SCHARRER B, 1994, NEUROPEPTIDES NEUROI; SEI CA, 1989, BRAIN RES, V479, P162, DOI 10.1016/0006-8993(89)91347-4; STEFANO GB, 1991, ADV NEUROIMMUNOL, V1, P71, DOI 10.1016/S0960-5428(06)80033-1; STEFANO GB, 1989, P NATL ACAD SCI USA, V86, P626, DOI 10.1073/pnas.86.2.626; STEFANO GB, 1982, CELL MOL NEUROBIOL, V2, P167, DOI 10.1007/BF00711145; STEFANO GB, 1992, CELL MOL NEUROBIOL, V12, P357, DOI 10.1007/BF00711538; STEWART RR, 1985, BRAIN RES, V332, P150, DOI 10.1016/0006-8993(85)90398-1; TYLER S, 1976, ZOOMORPHOLOGIE, V84, P1, DOI 10.1007/BF02568557; VERGERBOCQUET M, 1992, CAN J ZOOL, V70, P856, DOI 10.1139/z92-122; VERGERBOCQUET M, 1987, CELL TISSUE RES, V250, P63, DOI 10.1007/BF00214655; VERGERBOCQUET M, 1987, COMP ENDOCRINOL, V6, P195; VERGERBOCQUET M, 1988, COMP ENDOCRINOL LIFE, V7, P21; WEIGL AM, 1994, T AM MICROSC SOC, V113, P276, DOI 10.2307/3226623; WEISBLAT DA, 1980, DEV BIOL, V76, P58, DOI 10.1016/0012-1606(80)90362-0	48	22	22	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 31	1996	271	22					13191	13196		10.1074/jbc.271.22.13191	http://dx.doi.org/10.1074/jbc.271.22.13191			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UN474	8662671				2022-12-25	WOS:A1996UN47400077
J	Scholz, C; Zarnt, T; Kern, G; Lang, K; Burtscher, H; Fischer, G; Schmid, FX				Scholz, C; Zarnt, T; Kern, G; Lang, K; Burtscher, H; Fischer, G; Schmid, FX			Autocatalytic folding of the folding catalyst FKBP12	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CIS-TRANS-ISOMERASE; PEPTIDYL-PROLYL ISOMERASE; BINDING-PROTEIN; IMMUNOSUPPRESSANT FK506; PROLINE ISOMERIZATION; COLLAGEN; DENATURATION; CYCLOPHILIN; RAPAMYCIN; RESIDUES	Prolyl isomerases are folding enzymes and thus have the potential to catalyze their own folding. We show here that the folding of cytosolic FKBP12 (FK 506 binding protein) is an autocatalytic process both for the mature protein and for a fusion protein with an aminoterminal extension of 16 residues. Native FKBP contains seven trans-prolyl peptide bonds, and the cis-to-trans isomerizations of some or all of them constitute the slow, rate-limiting events in folding. The rate of an autocatalytic reaction increases with reactant concentration, because the product catalyzes its own formation. Accordingly, the folding of the fusion protein was more than 10-fold accelerated when the protein concentration was increased from 0.05 mu M to 10 mu M. At high concentrations of both forms of FKBP12 autocatalysis was very efficient, and the observed folding rate seemed to approach the rate of the fast direct folding reaction of the protein molecules with the correct (all trans) peptidyl prolyl bond conformation.	UNIV BAYREUTH,BIOCHEM LAB,D-95440 BAYREUTH,GERMANY; MAX PLANCK GESELL,ARBEITSGRP ENZYMOL PEPTIDBINDUNG,D-06120 HALLE,GERMANY; BOEHRINGER MANNHEIM GMBH,BIOCHEM RES CTR,D-82377 PENZBERG,GERMANY	University of Bayreuth; Max Planck Society								BACHINGER HP, 1987, J BIOL CHEM, V262, P17144; BRANDTS JF, 1975, BIOCHEMISTRY-US, V14, P4953, DOI 10.1021/bi00693a026; BUCHNER J, 1991, BIOCHEMISTRY-US, V30, P1586, DOI 10.1021/bi00220a020; CHENG MY, 1990, NATURE, V348, P455, DOI 10.1038/348455a0; DODGE RW, 1994, J PROTEIN CHEM, V13, P409, DOI 10.1007/BF01901697; EGAN DA, 1993, BIOCHEMISTRY-US, V32, P1920, DOI 10.1021/bi00059a006; ENGEL J, 1991, ANNU REV BIOPHYS BIO, V20, P137, DOI 10.1146/annurev.biophys.20.1.137; FISCHER G, 1994, ANGEW CHEM INT EDIT, V33, P1415, DOI 10.1002/anie.199414151; FISCHER G, 1984, BIOMED BIOCHIM ACTA, V43, P1101; GALAT A, 1995, PROG BIOPHYS MOL BIO, V63, P67, DOI 10.1016/0079-6107(94)00009-X; HANI J, 1995, FEBS LETT, V365, P198, DOI 10.1016/0014-5793(95)00471-K; HARDING MW, 1989, NATURE, V341, P758, DOI 10.1038/341758a0; HARRISON RK, 1992, J AM CHEM SOC, V114, P3464, DOI 10.1021/ja00035a046; HARRISON RK, 1990, BIOCHEMISTRY-US, V29, P3813, DOI 10.1021/bi00468a001; IKEGUCHI M, 1986, BIOCHEMISTRY-US, V25, P6965, DOI 10.1021/bi00370a034; JACKSON SE, 1991, BIOCHEMISTRY-US, V30, P10428, DOI 10.1021/bi00107a010; JULLIEN M, 1981, J MOL BIOL, V145, P265, DOI 10.1016/0022-2836(81)90343-0; KATO S, 1982, BIOCHEMISTRY-US, V21, P38, DOI 10.1021/bi00530a007; KREBS H, 1979, EUR J BIOCHEM, V100, P359, DOI 10.1111/j.1432-1033.1979.tb04178.x; LANG K, 1987, NATURE, V329, P268, DOI 10.1038/329268a0; LIN LN, 1988, BIOCHIM BIOPHYS ACTA, V956, P256, DOI 10.1016/0167-4838(88)90142-2; LISSIN NM, 1990, NATURE, V348, P339, DOI 10.1038/348339a0; MATOUSCHEK A, 1995, P NATL ACAD SCI USA, V92, P6319, DOI 10.1073/pnas.92.14.6319; MATOUSCHEK A, 1990, NATURE, V346, P440, DOI 10.1038/346440a0; MATTHEWS CR, 1993, ANNU REV BIOCHEM, V62, P653, DOI 10.1146/annurev.bi.62.070193.003253; MICHNICK SW, 1991, SCIENCE, V252, P836, DOI 10.1126/science.1709301; MOORE JM, 1991, NATURE, V351, P248, DOI 10.1038/351248a0; Pace C N, 1986, Methods Enzymol, V131, P266; RAHFELD JU, 1994, FEBS LETT, V352, P180, DOI 10.1016/0014-5793(94)00932-5; RAHFELD JU, 1994, FEBS LETT, V343, P65, DOI 10.1016/0014-5793(94)80608-X; RASSOW J, 1995, MOL CELL BIOL, V15, P2654; SANTORO MM, 1988, BIOCHEMISTRY-US, V27, P8063, DOI 10.1021/bi00421a014; SCHMID F. X., 1986, ENZYME STRUCTURE L, P71; Schmid Franz X., 1992, P197; SCHMID FX, 1993, ANNU REV BIOPH BIOM, V22, P123, DOI 10.1146/annurev.bb.22.060193.001011; SCHMID FX, 1978, P NATL ACAD SCI USA, V75, P4764, DOI 10.1073/pnas.75.10.4764; SCHMID FX, 1993, ADV PROTEIN CHEM, V44, P25, DOI 10.1016/S0065-3233(08)60563-X; SCHMIDT B, 1995, FEBS LETT, V372, P169, DOI 10.1016/0014-5793(95)00951-5; SIEKIERKA JJ, 1989, NATURE, V341, P755, DOI 10.1038/341755a0; STANDAERT RF, 1990, NATURE, V346, P671, DOI 10.1038/346671a0; STEINMANN B, 1991, J BIOL CHEM, V266, P1299; STOLLER G, 1995, EMBO J, V14, P4939, DOI 10.1002/j.1460-2075.1995.tb00177.x; TODD MJ, 1994, SCIENCE, V265, P659, DOI 10.1126/science.7913555; VANDUYNE GD, 1993, J MOL BIOL, V229, P105, DOI 10.1006/jmbi.1993.1012; VEERARAGHAVAN S, 1994, BIOCHEMISTRY-US, V33, P687, DOI 10.1021/bi00169a009; VEERARAGHAVAN S, 1995, PROTEIN SCI S2, V4, P72; ZARNT T, 1995, BIOCHEM J, V305, P159, DOI 10.1042/bj3050159	47	14	17	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 31	1996	271	22					12703	12707		10.1074/jbc.271.22.12703	http://dx.doi.org/10.1074/jbc.271.22.12703			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UN474	8662669	hybrid			2022-12-25	WOS:A1996UN47400005
J	Gary, JD; Lin, WJ; Yang, MC; Herschman, HR; Clarke, S				Gary, JD; Lin, WJ; Yang, MC; Herschman, HR; Clarke, S			The predominant protein-arginine methyltransferase from Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MYELIN BASIC-PROTEIN; RNA-BINDING PROTEINS; YEAST NSR1 PROTEIN; GENE DISRUPTION; NUCLEOLAR RNA; CYTOCHROME-C; BOVINE BRAIN; METHYLASE-I; HEAT-SHOCK; PURIFICATION	We have identified the major enzymatic activity responsible for the S-adenosyl-L-methionine-dependent methylation of arginine residues (EC 2.1.1.23) in proteins of the yeast Saccharomyces cerevisiae. The RMT1 (protein-arginine methyltransferase), formerly ODP1, gene product encodes a 348-residue polypeptide of 39.8 kDa that catalyzes both the N-G-mono- and N-G,N-G-asymmetric dimethylation of arginine residues in a variety of endogenous yeast polypeptides. A yeast strain in which the chromosomal RMT1 gene was disrupted is viable, but the level of N-G,N-G-[H-3]dimethylarginine residues detected in intact cells incubated with S-adenosyl-L-[methyl-H-3]methionine is reduced to less than 15% of the levels found in the parent strain, while the N-G-[H-3]monomethylarginine content is reduced to less than 30%. We show that soluble extract from parent cells, but not from mutant rmt1 cells, catalyzes the in vitro methylation of endogenous polypeptides of 55, 41, 38, 34, and 30 kDa. The hypomethylated form of these five polypeptides, as well as that of several others, can be mono- and asymmetrically dimethylated by incubating the mutant rmt1 extract with a purified, bacterially produced, glutathione S-transferase-RMT1 fusion protein and S-adenosyl-L-[methyl-H-3]methionine. This glutathione S-transferase-RMT1 fusion protein is also able to methylate a number of mammalian polypeptides including histones, recombinant heterogeneous ribonucleoprotein A1, cytochrome c, and myoglobin, but cannot methylate myelin basic protein. RMT1 appears to be a yeast homolog of a recently characterized mammalian protein-arginine methyltransferase whose activity may be modulated by mitotic stimulation of cells.	UNIV CALIF LOS ANGELES,DEPT CHEM & BIOCHEM,LOS ANGELES,CA 90095; UNIV CALIF LOS ANGELES,INST MOLEC BIOL,LOS ANGELES,CA 90095; UNIV CALIF LOS ANGELES,DEPT BIOL CHEM,LOS ANGELES,CA 90095	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM026020, R01GM026020] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM29797, GM26020] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; AMUR SG, 1986, J NEUROSCI RES, V16, P367, DOI 10.1002/jnr.490160204; ARIS JP, 1991, P NATL ACAD SCI USA, V88, P931, DOI 10.1073/pnas.88.3.931; Bailey JL, 1967, TECHNIQUES PROTEIN C, P340; BALDWIN GS, 1971, SCIENCE, V171, P579, DOI 10.1126/science.171.3971.579; BERBEN G, 1991, YEAST, V7, P475, DOI 10.1002/yea.320070506; BEYER AL, 1977, CELL, V11, P127, DOI 10.1016/0092-8674(77)90323-3; BOSSIE MA, 1992, MOL BIOL CELL, V3, P875, DOI 10.1091/mbc.3.8.875; BROSTOFF S, 1971, P NATL ACAD SCI USA, V68, P765, DOI 10.1073/pnas.68.4.765; BURGESS WH, 1991, CELL REGUL, V2, P87, DOI 10.1091/mbc.2.2.87; CALNAN BJ, 1991, SCIENCE, V252, P1167, DOI 10.1126/science.252.5009.1167; Clarke S, 1993, CURR OPIN CELL BIOL, V5, P977, DOI 10.1016/0955-0674(93)90080-A; DESROSIERS R, 1988, J BIOL CHEM, V263, P4686; ENOUF J, 1979, CANCER RES, V39, P4497; FAROOQUI JZ, 1985, J BIOL CHEM, V260, P537; FELDMANN H, 1994, EMBO J, V13, P5795, DOI 10.1002/j.1460-2075.1994.tb06923.x; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FLETCHER BS, 1991, J BIOL CHEM, V266, P14511; GARY JD, 1995, J BIOL CHEM, V270, P4076, DOI 10.1074/jbc.270.8.4076; GHOSH SK, 1990, BIOCHIM BIOPHYS ACTA, V1039, P142, DOI 10.1016/0167-4838(90)90179-J; GHOSH SK, 1988, J BIOL CHEM, V263, P19024; GIRARD JP, 1992, EMBO J, V11, P673, DOI 10.1002/j.1460-2075.1992.tb05099.x; GOTTSCHLING H, 1962, NATURE, V196, P829, DOI 10.1038/196829a0; GRANA X, 1995, ONCOGENE, V11, P211; HENRIQUEZ R, 1990, J BIOL CHEM, V265, P2209; HOFFMAN CS, 1987, GENE, V57, P267, DOI 10.1016/0378-1119(87)90131-4; HRYCYNA CA, 1993, BIOCHEMISTRY-US, V32, P11293, DOI 10.1021/bi00093a005; HRYCYNA CA, 1994, BIOCHEMISTRY-US, V33, P9806, DOI 10.1021/bi00198a053; JONG AYS, 1987, MOL CELL BIOL, V7, P2947, DOI 10.1128/MCB.7.8.2947; KAGAN RM, 1995, BIOCHEMISTRY-US, V34, P10794, DOI 10.1021/bi00034a012; KAGAN RM, 1994, ARCH BIOCHEM BIOPHYS, V310, P417, DOI 10.1006/abbi.1994.1187; KARN J, 1977, J BIOL CHEM, V252, P7307; KIM S, 1990, PROTEIN METHYLATION, P77; KONDO K, 1992, J BIOL CHEM, V267, P16259; KONDO K, 1992, J BIOL CHEM, V267, P16252; KUJUBU DA, 1993, J NEUROSCI RES, V36, P58, DOI 10.1002/jnr.490360107; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAW RE, 1992, MOL CELL BIOL, V12, P103, DOI 10.1128/MCB.12.1.103; LEE HW, 1977, BIOCHEMISTRY-US, V16, P78, DOI 10.1021/bi00620a013; LEE WC, 1991, J CELL BIOL, V113, P1, DOI 10.1083/jcb.113.1.1; LIN WJ, 1996, IN PRESS J BIOL CHEM, V271; LISCHWE MA, 1985, J BIOL CHEM, V260, P14304; LISCHWE MA, 1985, BIOCHEMISTRY-US, V24, P6025, DOI 10.1021/bi00343a001; LISCHWE MA, 1990, PROTEIN METHYLATION, P97; LIU Q, 1995, MOL CELL BIOL, V15, P2800; LOUBBARDI A, 1995, J BACTERIOL, V177, P1817, DOI 10.1128/jb.177.7.1817-1823.1995; MAYEDA A, 1993, MOL CELL BIOL, V13, P2993, DOI 10.1128/MCB.13.5.2993; MAYEDA A, 1992, CELL, V68, P365, DOI 10.1016/0092-8674(92)90477-T; MCEWEN JE, 1986, J BIOL CHEM, V261, P1872; MIYAKE M, 1973, J NEUROCHEM, V20, P859, DOI 10.1111/j.1471-4159.1973.tb00046.x; NAJBAUER J, 1993, J BIOL CHEM, V268, P10501; NAJBAUER J, 1991, ANAL BIOCHEM, V197, P412, DOI 10.1016/0003-2697(91)90413-N; NAKAJIMA T, 1971, BIOCHIM BIOPHYS ACTA, V230, P212, DOI 10.1016/0304-4165(71)90206-6; PAIK WK, 1967, BIOCHEM BIOPH RES CO, V29, P14, DOI 10.1016/0006-291X(67)90533-5; PAIK WK, 1968, J BIOL CHEM, V243, P2108; PAIK WK, 1969, ARCH BIOCHEM BIOPHYS, V134, P632, DOI 10.1016/0003-9861(69)90327-0; PAIK WK, 1980, BIOCHEM BIOPH RES CO, V97, P8, DOI 10.1016/S0006-291X(80)80126-4; RAJPUROHIT R, 1994, J BIOL CHEM, V269, P1075; RAJPUROHIT R, 1994, BIOCHEM J, V304, P903, DOI 10.1042/bj3040903; RAJPUROHIT R, 1992, BIOCHIM BIOPHYS ACTA, V1122, P183, DOI 10.1016/0167-4838(92)90322-5; RAWAL N, 1992, BIOCHEM J, V287, P929, DOI 10.1042/bj2870929; RAWAL N, 1994, BIOCHEM J, V300, P483, DOI 10.1042/bj3000483; Rose MD., 1990, METHODS YEAST GENETI; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; ROUAULT JP, 1992, EMBO J, V11, P1663, DOI 10.1002/j.1460-2075.1992.tb05213.x; Sambrook J., 2002, MOL CLONING LAB MANU; Scharf SJ, 1990, PCR PROTOCOLS GUIDE, P84; SCHIMMANG T, 1989, EMBO J, V8, P4015, DOI 10.1002/j.1460-2075.1989.tb08584.x; SCHLUCKEBIER G, 1995, J MOL BIOL, V247, P16, DOI 10.1006/jmbi.1994.0117; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; VARNUM BC, 1994, J CELL PHYSIOL, V158, P205, DOI 10.1002/jcp.1041580125; WANG C, 1992, ARCH BIOCHEM BIOPHYS, V297, P169, DOI 10.1016/0003-9861(92)90656-H; XIE HY, 1993, J BIOL CHEM, V268, P13364; XIE HY, 1994, J BIOL CHEM, V269, P1981; YOUNG PR, 1987, BIOCHEM BIOPH RES CO, V145, P1112, DOI 10.1016/0006-291X(87)91552-X	75	175	178	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 24	1996	271	21					12585	12594		10.1074/jbc.271.21.12585	http://dx.doi.org/10.1074/jbc.271.21.12585			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UL660	8647869	hybrid			2022-12-25	WOS:A1996UL66000071
J	Petersen, RB; Parchi, P; Richardson, SL; Urig, CB; Gambetti, P				Petersen, RB; Parchi, P; Richardson, SL; Urig, CB; Gambetti, P			Effect of the D178N mutation and the codon 129 polymorphism on the metabolism of the prion protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CREUTZFELDT-JAKOB DISEASE; NEURO-BLASTOMA CELLS; LINKED OLIGOSACCHARIDES; NEUROBLASTOMA-CELLS; MOLECULAR-CLONING; SCRAPIE AGENT; MOUSE-BRAIN; GENE; CDNA; PRP	Prion diseases are thought to be caused by the conversion of the normal, or cellular, prion protein (PrPC) into an abnormal protease-resistant conformation (PrPres). There are three familial forms of human prion disease, Creutzfeldt-Jakob disease (CJD), Gerstmann-Straussler-Scheinker syndrome, and fatal familial insomnia (FFI) which are all expressed at advanced age despite the congenital presence of the mutant prion protein (PrPM). The cellular mechanisms that result in the age-dependent conversion of PrPM into PrPres and the unique phenotypes associated with each PrPM are unknown. FFI and a familial type of Creutzfeldt-Jakob disease (CJD(178)), share the D178N mutation in the PrP gene but have distinct phenotypes linked to codon 129, the site of a methionine/valine polymorphism (129M/V). We analyzed PrP processing in cells transfected with constructs reproducing the FFI and CJD(178) genotypes. The D178N mutation results in instability of the mutant PrP which is partially corrected by N-glycosylation. Hence, only the glycosylated forms of PrPM reach the cell surface whereas the unglycosylated form is degraded. The unglycosylated PrPM is also under-represented in the brain of FFI patients validating the cell model. These results offer new insight into the effect of the D178N mutation on the metabolism of the prion protein.			Petersen, RB (corresponding author), CASE WESTERN RESERVE UNIV,DEPT PATHOL,INST PATHOL,2085 ADELBERT RD,CLEVELAND,OH 44106, USA.		Petersen, Robert/B-5075-2011; Parchi, Piero/L-9833-2015	Petersen, Robert/0000-0002-3154-0072; Parchi, Piero/0000-0002-9444-9524	NIA NIH HHS [AG-08992, AG-08155] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R35AG008992, R37AG008155] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BOSQUE PJ, 1992, NEUROLOGY, V42, P1864, DOI 10.1212/WNL.42.10.1864; CAUGHEY B, 1991, J BIOL CHEM, V266, P18217; CAUGHEY B, 1990, J VIROL, V64, P1093, DOI 10.1128/JVI.64.3.1093-1101.1990; CAUGHEY B, 1988, P NATL ACAD SCI USA, V85, P4657, DOI 10.1073/pnas.85.13.4657; CAUGHEY B, 1989, J VIROL, V63, P175, DOI 10.1128/JVI.63.1.175-181.1989; CHEN SG, 1995, J BIOL CHEM, V270, P19173, DOI 10.1074/jbc.270.32.19173; ELBEIN AD, 1987, ANNU REV BIOCHEM, V56, P497, DOI 10.1146/annurev.biochem.56.1.497; FRA A, 1993, SUBCELLULAR BIOCH, V21; GAMBETTI P, 1995, BRAIN PATHOL, V5, P43, DOI 10.1111/j.1750-3639.1995.tb00576.x; GOLDFARB LG, 1992, SCIENCE, V258, P806, DOI 10.1126/science.1439789; HAMBOR JE, 1988, P NATL ACAD SCI USA, V85, P4010, DOI 10.1073/pnas.85.11.4010; HAMILTON JA, 1992, BIOCHIM BIOPHYS ACTA, V1139, P9, DOI 10.1016/0925-4439(92)90075-X; HARRIS DA, 1993, BIOCHEMISTRY-US, V32, P1009, DOI 10.1021/bi00055a003; HELENIUS A, 1994, MOL BIOL CELL, V5, P253, DOI 10.1091/mbc.5.3.253; HENIKOFF S, 1987, GENETICS, V117, P711; HOPE J, 1986, EMBO J, V5, P2591, DOI 10.1002/j.1460-2075.1986.tb04539.x; HUANG ZW, 1994, P NATL ACAD SCI USA, V91, P7139, DOI 10.1073/pnas.91.15.7139; JETHMALANI SM, 1994, J BIOL CHEM, V269, P23603; KASCSAK RJ, 1987, J VIROL, V61, P3688, DOI 10.1128/JVI.61.12.3688-3693.1987; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; KRETZSCHMAR HA, 1986, DNA-J MOLEC CELL BIO, V5, P315, DOI 10.1089/dna.1986.5.315; LEHMANN S, 1995, J BIOL CHEM, V270, P24589, DOI 10.1074/jbc.270.41.24589; Lehmann S, 1996, J BIOL CHEM, V271, P1633, DOI 10.1074/jbc.271.3.1633; LIPPINCOTTSCHWARTZ J, 1991, CELL, V67, P601, DOI 10.1016/0092-8674(91)90534-6; LOCHT C, 1986, P NATL ACAD SCI USA, V83, P6372, DOI 10.1073/pnas.83.17.6372; MONARI L, 1994, P NATL ACAD SCI USA, V91, P2839, DOI 10.1073/pnas.91.7.2839; NEARY K, 1991, J VIROL, V65, P1031, DOI 10.1128/JVI.65.2.1031-1034.1991; NGUYEN J, 1995, BIOCHEMISTRY-US, V34, P4186, DOI 10.1021/bi00013a006; PAN KM, 1992, PROTEIN SCI, V1, P1343, DOI 10.1002/pro.5560011014; PAN KM, 1993, P NATL ACAD SCI USA, V90, P10962, DOI 10.1073/pnas.90.23.10962; PARCHI P, 1995, ANN NEUROL, V38, P21, DOI 10.1002/ana.410380107; PARCHI P, 1995, CURR OPIN NEUROL, V8, P286, DOI 10.1097/00019052-199508000-00007; PRUSINER SB, 1994, ANNU REV NEUROSCI, V17, P311, DOI 10.1146/annurev.ne.17.030194.001523; ROBAKIS NK, 1986, P NATL ACAD SCI USA, V83, P6377, DOI 10.1073/pnas.83.17.6377; ROSS RA, 1983, J NATL CANCER I, V71, P741; SAFAR J, 1993, J BIOL CHEM, V268, P20276; SAMPATH D, 1992, J BIOL CHEM, V267, P4440; SCOTT MRD, 1988, PROTEIN ENG, V2, P69, DOI 10.1093/protein/2.1.69; STAHL N, 1993, BIOCHEMISTRY-US, V32, P1991, DOI 10.1021/bi00059a016; TARABOULOS A, 1992, MOL BIOL CELL, V3, P851, DOI 10.1091/mbc.3.8.851; VIDUGIRIENE J, 1994, J CELL BIOL, V127, P333, DOI 10.1083/jcb.127.2.333	41	125	126	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 24	1996	271	21					12661	12668		10.1074/jbc.271.21.12661	http://dx.doi.org/10.1074/jbc.271.21.12661			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UL660	8647879	hybrid			2022-12-25	WOS:A1996UL66000081
J	Sone, N; Tsuchiya, N; Inoue, M; Noguchi, S				Sone, N; Tsuchiya, N; Inoue, M; Noguchi, S			Bacillus stearothermophilus qcr operon encoding Rieske FeS protein, cytochrome b(6), and a novel-type cytochrome c(1) of quinol-cytochrome c reductase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYANOBACTERIUM NOSTOC PCC-7906; THERMOPHILIC BACTERIUM PS3; IRON-SULFUR PROTEIN; NUCLEOTIDE-SEQUENCE; TERMINAL OXIDASES; BC1 COMPLEX; GENE; SUBTILIS; CLONING; CHLOROPLASTS	The qcr of Bacillus stearothermophilus K1041 encoding three subunits of the quinol-cytochrome c oxidoreductase (cytochrome reductase, b(6)c(1) complex) was cloned and sequenced. The gene (qcrA) for a Rieske FeS protein of 19,144 Da with 169 amino acid residues, and the gene (qcrC) for cytochrome c(1) of 27,342 Da with 250 amino acid residues were found at adjacent upstream and downstream sides of the previously reported qcrB (petB) for cytochrome b(6) of subunit 25,425 Da with 224 residues (Sone, N., Sawa, C., Sone, T., and Noguchi, S. (1995) J. Biol. Chem. 270, 10612-10617). The three structural genes for thermophilic Bacillus cytochrome reductase form a transcriptional unit. In the deduced amino acid sequence for the FeS protein, the domain including four cysteines and two histidines binding the 2Fe-2S cluster was conserved. Its N-terminal part more closely resembled the cyanobacteria-plastid type than the proteobacteria-mitochondria type when their sequences were compared. The amino acid sequence of cytochrome c(1) was not similar to either type; the thermophilic Bacillus cytochrome c(1) is composed of an N-terminal part corresponding to subunit IV with three membrane spanning segments, and a C-terminal part of cytochrome c reminiscent of cytochrome c-551 of thermophilic Bacillus. The subunit IV in the enzyme of cyanobacteria and plastids is the counterpart of C-terminal part of cytochrome b of proteobacteria and mitochondria. These characteristics indicate that Bacillus cytochrome b(6)c(1) complex is unique.			Sone, N (corresponding author), KYUSHU INST TECHNOL,DEPT BIOCHEM ENGN & SCI,680 KAWAZU,IIZUKA,FUKUOKA 820,JAPAN.							BECKMANN JD, 1987, J BIOL CHEM, V262, P8901; CASTRESANA J, 1994, EMBO J, V13, P2516, DOI 10.1002/j.1460-2075.1994.tb06541.x; DAVIDSON E, 1990, J MOL BIOL, V195, P23; DEGLIESPOSTI M, 1993, BIOCHIM BIOPHYS ACTA, V1143, P243, DOI 10.1016/0005-2728(93)90197-N; FUJIWARA Y, 1993, BIOCHIM BIOPHYS ACTA, V1141, P213; GABELLINI N, 1988, J BIOENERG BIOMEMBR, V20, P59, DOI 10.1007/BF00762138; GARCIAHORSMAN JA, 1991, MOL MICROBIOL, V5, P197, DOI 10.1111/j.1365-2958.1991.tb01840.x; HAUSKA G, 1988, J BIOENERG BIOMEMBR, V20, P211, DOI 10.1007/BF00768395; HREGGVIDSSON GO, 1991, BIOCHIM BIOPHYS ACTA, V1058, P52, DOI 10.1016/S0005-2728(05)80268-3; ISHIZUKA M, 1990, J BIOCHEM-TOKYO, V108, P866, DOI 10.1093/oxfordjournals.jbchem.a123294; KALLAS T, 1988, J BIOL CHEM, V263, P14334; KALLAS T, 1988, P NATL ACAD SCI USA, V85, P5794, DOI 10.1073/pnas.85.16.5794; KUTOH E, 1988, J BIOL CHEM, V263, P9020; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAURAEUS M, 1991, EUR J BIOCHEM, V197, P699, DOI 10.1111/j.1432-1033.1991.tb15961.x; MAKINO K, 1986, J MOL BIOL, V192, P549, DOI 10.1016/0022-2836(86)90275-5; MAYES SR, 1991, PLANT MOL BIOL, V17, P289, DOI 10.1007/BF00039508; NISHIKIMI M, 1989, BIOCHEM BIOPH RES CO, V159, P19, DOI 10.1016/0006-291X(89)92398-X; PRINCE RC, 1995, TRENDS BIOCHEM SCI, V20, P217, DOI 10.1016/S0968-0004(00)89018-0; ROBERTSON DE, 1990, BIOCHEMISTRY-US, V29, P11249, DOI 10.1021/bi00503a014; ROCKE CD, 1987, CURR GENET, V17, P69; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SANTANA M, 1992, J BIOL CHEM, V267, P10225; SCHUTZ M, 1994, PHOTOSYNTH RES, V39, P163, DOI 10.1007/BF00029383; SHIGA Y, 1993, J BACTERIOL, V175, P7130, DOI 10.1128/JB.175.22.7130-7137.1993; SONE N, 1994, FEMS MICROBIOL LETT, V122, P203, DOI 10.1111/j.1574-6968.1994.tb07168.x; SONE N, 1987, J BIOL CHEM, V262, P15386; SONE N, 1991, J BIOCHEM-TOKYO, V110, P1016, DOI 10.1093/oxfordjournals.jbchem.a123671; SONE N, 1995, J BIOL CHEM, V270, P10612, DOI 10.1074/jbc.270.18.10612; SONE N, 1995, J BIOL CHEM, V270, P22076; SONE N, 1982, BIOCHIM BIOPHYS ACTA, V682, P216, DOI 10.1016/0005-2728(82)90101-3; STEPPUHN J, 1987, MOL GEN GENET, V210, P171, DOI 10.1007/BF00337775; TRUMPOWER BL, 1990, J BIOL CHEM, V265, P11409; TRUMPOWER BL, 1994, ANNU REV BIOCHEM, V63, P675, DOI 10.1146/annurev.bi.63.070194.003331; USUI S, 1991, J BIOL CHEM, V266, P15644; VANDEROOST J, 1994, FEMS MICROBIOL LETT, V121, P1, DOI 10.1016/0378-1097(94)90137-6; VANDEROOST J, 1991, MOL MICROBIOL, V5, P2063; VERBIST J, 1989, MOL GEN GENET, V219, P445, DOI 10.1007/BF00259618; VONWACHENFELDT C, 1990, J BIOL CHEM, V265, P13939; VONWACHENFELDT C, 1990, FEMS MICROBIOL LETT, V100, P91; WIDGER WR, 1984, P NATL ACAD SCI-BIOL, V81, P674, DOI 10.1073/pnas.81.3.674; YU J, 1995, J BACTERIOL, V177, P6751, DOI 10.1128/jb.177.23.6751-6760.1995	42	37	40	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 24	1996	271	21					12457	12462		10.1074/jbc.271.21.12457	http://dx.doi.org/10.1074/jbc.271.21.12457			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UL660	8647852	hybrid			2022-12-25	WOS:A1996UL66000054
J	McCormick, SPA; Ng, JK; Veniant, M; Boren, J; Pierotti, V; Flynn, LM; Grass, DS; Connolly, A; Young, SG				McCormick, SPA; Ng, JK; Veniant, M; Boren, J; Pierotti, V; Flynn, LM; Grass, DS; Connolly, A; Young, SG			Transgenic mice that overexpress mouse apolipoprotein B - Evidence that the DNA sequences controlling intestinal expression of the apolipoprotein B gene are distant from the structural gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN	An 87-kilobase (kb) P1 bacteriophage clone (p649) spanning the mouse apolipoprotein (apo) B gene was used to generate transgenic mice that express high levels of mouse apoB. Plasma levels of apoB, low density lipoprotein cholesterol, and low density lipoprotein triglycerides were increased, and high density lipoprotein cholesterol levels were decreased in the transgenic mice, compared with nontransgenic littermate controls. Although p649 contained 33 kb of 5'-flanking sequences and 11 kb of 3'-flanking sequences, the tissue pattern of transgene expression was different from that of the endogenous apoB gene. RNA slot blots and RNase protection analysis indicated that the transgene was expressed in the liver but not in the intestine, whereas the endogenous apoB gene was expressed in both tissues. To confirm the absence of transgene expression in the intestine, the mouse apoB transgenic mice were mated with the apoB knockout mice, and transgenic mice that were homozygous for the apoB knockout mutation were obtained. Because of the absence of transgene expression in the intestine, those mice lacked all intestinal apoB synthesis, resulting in a marked accumulation of fats within the intestinal villus enterocytes. The current studies, along with prior studies of human apoB transgenic animals, strongly suggest that the DNA sequence element(s) controlling intestinal expression of the apoB gene is located many kilobases from the structural gene.	UNIV CALIF SAN FRANCISCO,CARDIOVASC RES INST,SAN FRANCISCO,CA 94141; UNIV CALIF SAN FRANCISCO,DEPT MED,SAN FRANCISCO,CA 94141; DNX TRANSGEN,PRINCETON,NJ 08540	University of California System; University of California San Francisco; University of California System; University of California San Francisco	McCormick, SPA (corresponding author), UNIV CALIF SAN FRANCISCO,GLADSTONE INST CARDIOVASC DIS,POB 419100,SAN FRANCISCO,CA 94141, USA.			McCormick, Sally/0000-0001-9857-0703; Young, Stephen/0000-0001-7270-3176	NHLBI NIH HHS [HL47660] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL047660] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		CALLOW MJ, 1994, P NATL ACAD SCI USA, V91, P2130, DOI 10.1073/pnas.91.6.2130; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CORSINI A, 1992, ATHEROSCLEROSIS, V93, P95, DOI 10.1016/0021-9150(92)90203-S; FAN JL, 1995, ARTERIOSCL THROM VAS, V15, P1889, DOI 10.1161/01.ATV.15.11.1889; FARESE RV, 1995, P NATL ACAD SCI USA, V92, P1774, DOI 10.1073/pnas.92.5.1774; HAVEL RJ, 1955, J CLIN INVEST, V34, P1345, DOI 10.1172/JCI103182; Kane J.B., 1989, METABOLIC BASIS INHE, P1139; KNOTT TJ, 1986, NUCLEIC ACIDS RES, V14, P7501, DOI 10.1093/nar/14.18.7501; LINTON MF, 1993, J CLIN INVEST, V92, P3029, DOI 10.1172/JCI116927; MCCORMICK SPA, 1994, GENET ANAL TECH APPL, V11, P1588; PETERSON KR, 1993, P NATL ACAD SCI USA, V90, P7593, DOI 10.1073/pnas.90.16.7593; PURCELLHUYNH DA, 1995, J CLIN INVEST, V95, P2246, DOI 10.1172/JCI117915; SATO Y, 1993, J BIOL CHEM, V268, P17705; SCULLY RE, 1992, NEW ENGL J MED, V327, P628; TAYLOR JM, 1993, CURR OPIN LIPIDOL, V4, P84, DOI 10.1097/00041433-199304000-00002; Young SG, 1995, J CLIN INVEST, V96, P2932, DOI 10.1172/JCI118365; YOUNG SG, 1987, J CLIN INVEST, V79, P1831, DOI 10.1172/JCI113025; Young Stephen G., 1994, Current Opinion in Lipidology, V5, P94, DOI 10.1097/00041433-199404000-00005	18	50	51	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 17	1996	271	20					11963	11970		10.1074/jbc.271.20.11963	http://dx.doi.org/10.1074/jbc.271.20.11963			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UL250	8662599	hybrid			2022-12-25	WOS:A1996UL25000059
J	Shen, HG; SosaPeinado, A; Mueller, DM				Shen, HG; SosaPeinado, A; Mueller, DM			Intragenic suppressors of P-loop mutations in the beta-subunit of the mitochondrial ATPase in the yeast Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCINE-RICH SEQUENCE; HIGH-EFFICIENCY TRANSFORMATION; BINDING CHANGE MECHANISM; COLI H+-ATPASE; ESCHERICHIA-COLI; CATALYTIC SITE; OXIDATIVE-PHOSPHORYLATION; DIRECTED MUTAGENESIS; SHUTTLE VECTORS; F1-ATPASE	Three intragenic second site suppressors, P353L, T237I, and L390F, were identified that suppressed two mutations in, and one adjacent to, the P-loop in the beta-subunit of the yeast F-1-ATPase. The crystal structure of bovine F-1-ATPase (Abrahams, J. P., Leslie, A. G. W., Lutter, R., and Walker, J. E. (1994) Nature 370, 621-628) shows that these suppressor residues are located in the nucleotide-binding domain. Specific hypotheses have been formulated that suggest the conformational coupling of the P-loop with the suppressor sites, P353L is in a ''catch'' region, which forms unique interactions with the gamma-subunit in the three different conformational states of the catalytic site. The identification of this suppressor mutation demonstrates genetically that the catch region is conformationally coupled to the P-loop. T237I is shown to interact with Lys-209, which occurs just after the P-loop. This suggests that this interaction changes the conformation of the P-loop to suppress the initial mutation, L390F interacts with Ala-181, which is adjacent to the P-loop, The mechanism of this suppression is suggested to occur through the interactions of L390F with Ala-181. These results identify critical interactions that modulate the structure of the P-loop and thus the biochemistry of the enzyme.	CHICAGO MED SCH, DEPT BIOL CHEM, N CHICAGO, IL 60064 USA	Chicago Medical School					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044412] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01GM44412] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; BECKER DM, 1991, METHOD ENZYMOL, V194, P182; BOYER PD, 1973, P NATL ACAD SCI USA, V70, P2837, DOI 10.1073/pnas.70.10.2837; BOYER PD, 1989, FASEB J, V3, P2164, DOI 10.1096/fasebj.3.10.2526771; BOYER PD, 1993, BIOCHIM BIOPHYS ACTA, V1140, P215, DOI 10.1016/0005-2728(93)90063-L; DREUSICKE D, 1988, J MOL BIOL, V203, P1021, DOI 10.1016/0022-2836(88)90126-X; DUNCAN TM, 1992, J BIOENERG BIOMEMBR, V24, P453, DOI 10.1007/BF00762362; FRY DC, 1986, P NATL ACAD SCI USA, V83, P907, DOI 10.1073/pnas.83.4.907; FUTAI M, 1992, J BIOENERG BIOMEMBR, V24, P463, DOI 10.1007/BF00762363; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; GRABER P, 1992, J BIOENERG BIOMEMBR, V24, P493, DOI 10.1007/BF00762367; GRUBMEYER C, 1982, J BIOL CHEM, V257, P2092; IWAMOTO A, 1993, J BIOL CHEM, V268, P3156; IWAMOTO A, 1991, J BIOL CHEM, V266, P16350; JURNAK F, 1985, SCIENCE, V230, P32, DOI 10.1126/science.3898365; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAWRENCE CW, 1991, METHOD ENZYMOL, V194, P273; LEE RSF, 1991, BIOCHEMISTRY-US, V30, P6842, DOI 10.1021/bi00242a006; Leung DW, 1989, TECHNIQUE, V1, P11; Maniatis T., 1982, MOL CLONING; *MOL SIM INC, 1995, QUANTA VERSION 4 1 1; MUELLER DM, 1989, BIOCHEM BIOPH RES CO, V164, P381, DOI 10.1016/0006-291X(89)91730-0; MUHLRAD D, 1992, YEAST, V8, P79, DOI 10.1002/yea.320080202; ODAKA M, 1994, J BIOCHEM-TOKYO, V115, P789, DOI 10.1093/oxfordjournals.jbchem.a124410; PAI EF, 1990, EMBO J, V9, P2351, DOI 10.1002/j.1460-2075.1990.tb07409.x; RAYMENT I, 1993, SCIENCE, V261, P50, DOI 10.1126/science.8316857; RICHTER ML, 1995, IN PRESS ADV PHOTOSY; SANDER C, 1991, PROTEINS, V9, P56, DOI 10.1002/prot.340090107; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SENIOR AE, 1988, PHYSIOL REV, V68, P177, DOI 10.1152/physrev.1988.68.1.177; SENIOR AE, 1992, J BIOL CHEM, V267, P21471; SHEN HG, 1994, J BIOL CHEM, V269, P9424; SIKORSKI RS, 1989, GENETICS, V122, P19; STORY RM, 1992, NATURE, V355, P374, DOI 10.1038/355374a0; STRATHERN JN, 1991, METHOD ENZYMOL, V194, P319; TAKEYAMA M, 1990, J BIOL CHEM, V265, P21279; TODD RD, 1980, J BIOL CHEM, V255, P5461; WALKER JE, 1984, BIOCHIM BIOPHYS ACTA, V768, P164, DOI 10.1016/0304-4173(84)90003-X; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WALKER JE, 1985, J MOL BIOL, V184, P677, DOI 10.1016/0022-2836(85)90313-4; ZOLLER MJ, 1984, DNA-J MOLEC CELL BIO, V3, P479, DOI 10.1089/dna.1.1984.3.479	41	5	5	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 17	1996	271	20					11844	11851		10.1074/jbc.271.20.11844	http://dx.doi.org/10.1074/jbc.271.20.11844			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UL250	8662632	hybrid			2022-12-25	WOS:A1996UL25000043
J	Rao, G; Alland, L; Guida, P; SchreiberAgus, N; Chen, K; Chin, L; Rochelle, JM; Seldin, MF; Skoultchi, AI; DePinho, RA				Rao, G; Alland, L; Guida, P; SchreiberAgus, N; Chen, K; Chin, L; Rochelle, JM; Seldin, MF; Skoultchi, AI; DePinho, RA			Mouse Sin3A interacts with and can functionally substitute for the aminoterminal repression domain of the Myc antagonist Mxi1	ONCOGENE			English	Article						mSin3A; Mxi1; Myc; repression; cotransformation; PAH domain	C-MYC; ERYTHROLEUKEMIA-CELLS; DNA-BINDING; TRANSCRIPTIONAL REPRESSION; SACCHAROMYCES-CEREVISIAE; LINKAGE MAP; EXPRESSION; PROTEIN; DIFFERENTIATION; ONCOGENE	Mxi1 is a basic region helix-loop-helix leucine zipper (bHLH/LZ) protein that, in association with Max, antagonizes Myc oncogenic activities. A possible mechanistic basis for Mxi1-mediated repression was provided by the recent demonstration that the repressive potential of Mxi1 correlates with its ability to physically associate with mSin3B, one of two mammalian homologues of the yeast transcriptional repressor SIN3. Here, we sought to characterize more fully the physical properties of the second homologue, mSin3A and to determine whether the recruitment of mSin3A by Mxi1 is indeed required for anti-Myc activity. Transient transfection of mammalian cells showed that the mSin3A protein can associate with the strong repressive isoform of Mxi1 (Mxi1-SR) and that, like other Myc superfamily members, both mSin3A and Mxi1-SR localize to the nucleus. From a developmental standpoint, a comparative analysis of Myc, Mxi1-SR and Sin3A expression during postnatal mouse development and in differentiating mouse erythroleukemia (MEL) cells revealed that dramatic and reciprocal changes in Myc and Mxi1-SR mRNA levels are accompanied by minimal stage-specific changes in mSin3A gene expression. This constant expression profile, coupled with the observation that over-expression of mSin3A does not augment the anti-Myc activity of Mxi1-SR in the rat embryo fibroblast (REF) transformation assay, suggests that mSin3A is not a limiting factor in the regulation of Myc superfamily function. Finally, a mSin3A-Mxi1 fusion protein, in which the amino terminal mSin3-interacting domain of Mxi1-SR was replaced with the full-length mSin3A, exhibited a level of repression activity equivalent to, or greater than, the level of repression obtained with Mxi1-SR. Taken together, these observations directly demonstrate that the amino-terminal repression domain of Mxi1-SR functions solely to recruit mSin3A and possibly other proteins like mSin3A and this association is necessary for the anti-Myc activity of Mxi1-SR.	YESHIVA UNIV ALBERT EINSTEIN COLL MED, DEPT MICROBIOL & IMMUNOL, BRONX, NY 10461 USA; YESHIVA UNIV ALBERT EINSTEIN COLL MED, DEPT CELL BIOL, BRONX, NY 10461 USA; YESHIVA UNIV ALBERT EINSTEIN COLL MED, DEPT MED, BRONX, NY 10461 USA; YESHIVA UNIV ALBERT EINSTEIN COLL MED, DIV PEDIAT HEMATOL ONCOL, BRONX, NY 10461 USA; YESHIVA UNIV ALBERT EINSTEIN COLL MED, DIV DERMATOL, BRONX, NY 10461 USA; DUKE UNIV, MED CTR, DEPT MED, DURHAM, NC 27710 USA; DUKE UNIV, MED CTR, DEPT MICROBIOL, DURHAM, NC 27710 USA	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Duke University; Duke University				DePinho, Ronald/0000-0002-5625-577X	NATIONAL CANCER INSTITUTE [R37CA016368, T32CA009173] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [T32AG000194] Funding Source: NIH RePORTER; NCI NIH HHS [RT32CA-09173, 5R37CA16368] Funding Source: Medline; NIA NIH HHS [2T32AG00194] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		AYER DE, 1995, CELL, V80, P767, DOI 10.1016/0092-8674(95)90355-0; AYER DE, 1993, CELL, V72, P211, DOI 10.1016/0092-8674(93)90661-9; AYER DE, 1993, GENE DEV, V7, P2110, DOI 10.1101/gad.7.11.2110; BARBU V, 1989, NUCLEIC ACIDS RES, V17, P7115, DOI 10.1093/nar/17.17.7115; BEIJERSBERGEN RL, 1994, EMBO J, V13, P4080, DOI 10.1002/j.1460-2075.1994.tb06725.x; BISHOP D T, 1985, Genetic Epidemiology, V2, P349, DOI 10.1002/gepi.1370020404; BLACKWOOD EM, 1992, GENE DEV, V6, P71, DOI 10.1101/gad.6.1.71; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; BOULIKAS T, 1994, J CELL BIOCHEM, V55, P32, DOI 10.1002/jcb.240550106; CHEN J, 1995, NAT MED, V1, P638, DOI 10.1038/nm0795-638; CHIN L, 1995, P NATL ACAD SCI USA, V92, P8488, DOI 10.1073/pnas.92.18.8488; COPPOLA JA, 1986, NATURE, V320, P760, DOI 10.1038/320760a0; DAVIS S, 1994, SCIENCE, V266, P816, DOI 10.1126/science.7973638; DELGADO MD, 1995, ONCOGENE, V10, P1659; DEPINHO RA, 1991, ADV CANCER RES, V57, P1; DMITROVSKY E, 1986, NATURE, V322, P748, DOI 10.1038/322748a0; DUNN BK, 1994, CELL GROWTH DIFFER, V5, P847; EAGLE LR, 1995, NAT GENET, V9, P249, DOI 10.1038/ng0395-249; EDELHOFF S, 1994, ONCOGENE, V9, P665; EVAN GI, 1993, CURR OPIN GENET DEV, V3, P44, DOI 10.1016/S0959-437X(05)80339-9; FASANO O, 1983, Journal of Molecular and Applied Genetics, V2, P173; Green EL, 1981, GENETICS PROBABILITY, P77; GU W, 1994, SCIENCE, V264, P251, DOI 10.1126/science.8146655; GUPTA S, 1993, P NATL ACAD SCI USA, V90, P3216, DOI 10.1073/pnas.90.8.3216; HALLECK MS, 1995, GENOMICS, V26, P403, DOI 10.1016/0888-7543(95)80229-F; HAN KY, 1993, GENE DEV, V7, P491, DOI 10.1101/gad.7.3.491; HIRSCHHORN JN, 1992, GENE DEV, V6, P2288, DOI 10.1101/gad.6.12a.2288; HOWARD TA, 1991, GENOMICS, V10, P207, DOI 10.1016/0888-7543(91)90502-6; KELEHER CA, 1992, CELL, V68, P709, DOI 10.1016/0092-8674(92)90146-4; KOSKINEN PJ, 1995, CELL GROWTH DIFFER, V6, P623; KWON H, 1994, NATURE, V370, P477, DOI 10.1038/370477a0; LACHMAN HM, 1986, P NATL ACAD SCI USA, V83, P6480, DOI 10.1073/pnas.83.17.6480; LACHMAN HM, 1984, NATURE, V310, P592, DOI 10.1038/310592a0; LAHOZ EG, 1994, P NATL ACAD SCI USA, V91, P5503, DOI 10.1073/pnas.91.12.5503; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LARSSON LG, 1994, ONCOGENE, V9, P1247; LICHT JD, 1990, NATURE, V346, P76, DOI 10.1038/346076a0; MADDEN SL, 1991, SCIENCE, V253, P1550, DOI 10.1126/science.1654597; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; MORGENBESSER SD, 1994, SEMIN CANCER BIOL, V5, P21; MUKHERJEE B, 1992, GENE DEV, V6, P1480, DOI 10.1101/gad.6.8.1480; NAWAZ Z, 1994, MOL GEN GENET, V245, P724, DOI 10.1007/BF00297279; NISHIZAWA M, 1994, MOL GEN GENET, V245, P301, DOI 10.1007/BF00290110; PERSSON H, 1984, SCIENCE, V225, P718, DOI 10.1126/science.6463648; PRENDERGAST GC, 1991, CELL, V65, P395, DOI 10.1016/0092-8674(91)90457-A; PROCHOWNIK EV, 1986, NATURE, V322, P848, DOI 10.1038/322848a0; PULVERER BJ, 1994, ONCOGENE, V9, P59; ROY B, 1985, CELL BIO INT, V19, P307; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SAUER F, 1995, NATURE, V375, P162, DOI 10.1038/375162a0; SCHREIBERAGUS N, 1995, CELL, V80, P777, DOI 10.1016/0092-8674(95)90356-9; SELDIN MF, 1991, GENOMICS, V9, P678, DOI 10.1016/0888-7543(91)90361-H; SHIMIZU E, 1995, GENE, V152, P283, DOI 10.1016/0378-1119(94)00722-5; TZAMARIAS D, 1995, GENE DEV, V9, P821, DOI 10.1101/gad.9.7.821; TZAMARIAS D, 1994, NATURE, V369, P758, DOI 10.1038/369758a0; VASTRIK I, 1995, J CELL BIOL, V128, P1197, DOI 10.1083/jcb.128.6.1197; VIDAL M, 1991, MOL CELL BIOL, V11, P6306, DOI 10.1128/MCB.11.12.6306; WANG HM, 1993, MOL CELL BIOL, V13, P1805, DOI 10.1128/MCB.13.3.1805; WANG HM, 1990, MOL CELL BIOL, V10, P5927, DOI 10.1128/MCB.10.11.5927; WATKINS S, 1995, CURRENT PROTOCOLS MO; WILLIAMS FE, 1991, MOL CELL BIOL, V11, P3307, DOI 10.1128/MCB.11.6.3307; ZERVOS AS, 1993, CELL, V72, P223, DOI 10.1016/0092-8674(93)90662-A; ZIMMERMAN KA, 1986, NATURE, V319, P780, DOI 10.1038/319780a0	63	43	44	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 7	1996	12	5					1165	1172						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UA884	8649810				2022-12-25	WOS:A1996UA88400027
J	Sei, Y; Whitesell, L; Kustova, Y; Paul, IA; Morse, HC; Skolnick, P; Basile, AS				Sei, Y; Whitesell, L; Kustova, Y; Paul, IA; Morse, HC; Skolnick, P; Basile, AS			Altered brain fyn kinase in a murine acquired immunodeficiency syndrome	FASEB JOURNAL			English	Article						AIDS; animal model; brain; dementia; fyn; glutamate; murine leukemia virus; tyrosine phosphorylation	RETROVIRUS-INDUCED IMMUNODEFICIENCY; LONG-TERM POTENTIATION; CENTRAL-NERVOUS-SYSTEM; TYROSINE KINASES; RECEPTOR; ACTIVATION; AIDS; MICE; HIPPOCAMPUS; PROTEIN	Mice infected with the replication-defective virus (BM5def) in the LP-BM5 murine leukemia virus (MuLV) mixture develop an immune deficiency syndrome and encephalopathy characterized by impaired spatial learning and memory as demonstrated in the Morris water maze. However, the molecular mechanism (or mechanisms) underlying this cognitive deficit remains unknown. Here we report that brain fyn kinase, which has been proposed to be involved in spatial learning and memory, was unresponsive to glutamatergic stimulation in mice with MAIDS. Thus, whereas application of glutamate to hippocampal slices from control mice increased fyn protein tyrosine kinase (PTK) activity more than 2.5-fold, these changes were significantly impaired in LP-BM5 MuLV-infected mice. Moreover, mice with MAIDS exhibited an abnormal histological distribution of fyn PTK in the hippocampus, These findings suggest that virus-associated disruption of fyn kinase-mediated signaling contributes to the cognitive deficits observed in mice with MAIDS and other retrovirus-induced encephalopathies.	NIDDKD,NEUROSCI LAB,NIH,BETHESDA,MD 20892; NCI,CLIN PHARMACOL BRANCH,TUMOR CELL BIOL SECT,NIH,BETHESDA,MD 20892; NIAID,IMMUNOPATHOL LAB,NIH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)				Morse, Herbert/0000-0002-9331-3705	NIAID NIH HHS [N01 AI 45203] Funding Source: Medline	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BADING H, 1991, SCIENCE, V253, P912, DOI 10.1126/science.1715095; BASHIR ZI, 1993, NATURE, V363, P347, DOI 10.1038/363347a0; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; BOJE KM, 1992, BRAIN RES, V587, P250, DOI 10.1016/0006-8993(92)91004-X; CHATTOPADHYAY SK, 1989, P NATL ACAD SCI USA, V86, P3862, DOI 10.1073/pnas.86.10.3862; COOKE M P, 1989, New Biologist, V1, P66; GAZZINELLI RT, 1992, J IMMUNOL, V148, P182; GELBARD HA, 1994, J VIROL, V68, P4628, DOI 10.1128/JVI.68.7.4628-4635.1994; GRANT SGN, 1992, SCIENCE, V258, P1903, DOI 10.1126/science.1361685; HA JH, 1995, J NEUROCHEM, V64, P1896; HEYES MP, 1989, ANN NEUROL, V26, P275; KLINKEN SP, 1988, J IMMUNOL, V140, P1123; KLINMAN DM, 1989, J IMMUNOL, V142, P1144; LIPTON SA, 1995, NEW ENGL J MED, V332, P934, DOI 10.1056/NEJM199504063321407; LIPTON SA, 1991, NEURON, V7, P111, DOI 10.1016/0896-6273(91)90079-F; MAKINO M, 1992, J IMMUNOL, V149, P1707; MCARTHUR JC, 1994, RES P ARNMD, V72, P251; MCLEAN IW, 1974, J HISTOCHEM CYTOCHEM, V22, P1077, DOI 10.1177/22.12.1077; MORRIS RGM, 1986, NATURE, V319, P774, DOI 10.1038/319774a0; MORSE HC, 1992, AIDS, V6, P607, DOI 10.1097/00002030-199207000-00001; Nishida K, 1996, J NEUROCHEM, V66, P433; ODELL TJ, 1991, NATURE, V353, P558, DOI 10.1038/353558a0; PIANI D, 1994, J IMMUNOL, V152, P3578; SAITO K, 1993, BIOCHEM J, V291, P11, DOI 10.1042/bj2910011; SEI Y, 1992, FASEB J, V6, P3008, DOI 10.1096/fasebj.6.11.1644264; SEI Y, 1992, J NEUROIMMUNOL, V37, P131, DOI 10.1016/0165-5728(92)90164-G; SEI Y, J NEUROCHEM, V66, P296; SEI Y, AIDS RES HUM RETROV, V11, P753; SWOPE SL, 1993, J BIOL CHEM, V268, P25152; UMEMORI H, 1992, MOL BRAIN RES, V16, P303, DOI 10.1016/0169-328X(92)90239-8; WHITESELL L, 1992, CANCER RES, V52, P1721; YAGI T, 1993, ONCOGENE, V8, P3343	32	12	12	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	FEB	1996	10	2					339	344		10.1096/fasebj.10.2.8641568	http://dx.doi.org/10.1096/fasebj.10.2.8641568			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	TY962	8641568				2022-12-25	WOS:A1996TY96200019
J	Durkin, ME; Gautam, M; Loechel, F; Sanes, JR; Merlie, JP; Albrechtsen, R; Wewer, UM				Durkin, ME; Gautam, M; Loechel, F; Sanes, JR; Merlie, JP; Albrechtsen, R; Wewer, UM			Structural organization of the human and mouse laminin beta 2 chain genes, and alternative splicing at the 5' end of the human transcript	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN S-LAMININ; COLLAGEN-IV; NEUROMUSCULAR-JUNCTION; MULTIDOMAIN PROTEIN; ADHESION MOLECULE; SYNAPTIC CLEFT; MESSENGER-RNAS; FACTOR AP-2; SEQUENCE; EXPRESSION	We have determined the structural organization of the human and mouse genes that encode the laminin beta 2 chain (s-laminin), an essential component of the basement membranes of the neuromuscular synapse and the kidney glomerulus. The human and mouse genes have a nearly identical exon-intron organization and are the smallest laminin chain genes characterized to date, due to the unusually small size of their introns, The laminin beta 2 chain genes of both species consist of 33 exons that span less than or equal to 12 kilobase pairs of genomic DNA. The exon-intron pattern of the laminin beta 2 chain gene is also highly similar to that of the human genes encoding the homologous laminin beta 1 and beta 3 chains. The putative promoter regions of the human and mouse laminin beta 2 chain genes have features characteristic of the promoters of genes that have a limited tissue expression. Considerable conservation of the intron sequences of the mouse and human genes was observed. The first intron of the human gene, located 1 base pair upstream of the translation start codon, contains a non-consensus 5' splice site, This intron was shown to be inefficiently spliced in humans, suggesting that post-transcriptional mechanisms may be involved in the regulation of laminin beta 2 chain gene expression.	UNIV COPENHAGEN, INST PATHOL ANAT, LAB MOLEC PATHOL, DK-2100 COPENHAGEN, DENMARK; WASHINGTON UNIV, SCH MED, DEPT MOLEC BIOL & PHARMACOL, ST LOUIS, MO 63110 USA; WASHINGTON UNIV, SCH MED, DEPT ANAT & NEUROBIOL, ST LOUIS, MO 63110 USA	University of Copenhagen; Washington University (WUSTL); Washington University (WUSTL)				Albrechtsen, Reidar/0000-0003-4180-1827				ALAKOKKO L, 1995, BIOCHEM J, V308, P923, DOI 10.1042/bj3080923; BOORSTEIN WR, 1989, METHOD ENZYMOL, V180, P347; BRINSTER RL, 1988, P NATL ACAD SCI USA, V85, P836, DOI 10.1073/pnas.85.3.836; BRUGGEMAN LA, 1992, ONCOGENE, V7, P1497; BURBELO PD, 1991, J BIOL CHEM, V266, P22297; BURGESON RE, 1994, MATRIX BIOL, V14, P209, DOI 10.1016/0945-053X(94)90184-8; Champliaud MF, 1996, J CELL BIOL, V132, P1189, DOI 10.1083/jcb.132.6.1189; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHRISTIANO AM, 1994, GENOMICS, V21, P169, DOI 10.1006/geno.1994.1239; DEININGER PL, 1981, J MOL BIOL, V151, P17, DOI 10.1016/0022-2836(81)90219-9; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; EDMONDSON DG, 1993, J BIOL CHEM, V268, P755; ENGVALL E, 1990, CELL REGUL, V1, P731, DOI 10.1091/mbc.1.10.731; Engvall E, 1996, J CELL BIOCHEM, V61, P493; FAISST S, 1992, NUCLEIC ACIDS RES, V20, P3, DOI 10.1093/nar/20.1.3; FINK GR, 1987, CELL, V49, P5, DOI 10.1016/0092-8674(87)90746-X; GENERSCH E, 1995, EMBO J, V14, P791, DOI 10.1002/j.1460-2075.1995.tb07057.x; GERECKE DR, 1994, J BIOL CHEM, V269, P11073; GLUKHOVA M, 1993, DEV BIOL, V157, P437, DOI 10.1006/dbio.1993.1147; GREEN TL, 1992, J BIOL CHEM, V267, P2014; HAWKINS JD, 1988, NUCLEIC ACIDS RES, V16, P9893, DOI 10.1093/nar/16.21.9893; Hay E.D., 1991, CELL BIOL EXTRACELLU, DOI 10.1007/978-1-4615-3770-0; HUNTER DD, 1992, J COMP NEUROL, V323, P238, DOI 10.1002/cne.903230208; HUNTER DD, 1989, CELL, V59, P905, DOI 10.1016/0092-8674(89)90613-2; HUNTER DD, 1989, NATURE, V338, P229, DOI 10.1038/338229a0; HUNTER DD, 1992, NEURON, V8, P399, DOI 10.1016/0896-6273(92)90269-J; IIVANAINEN A, 1995, MATRIX BIOL, V14, P489, DOI 10.1016/0945-053X(95)90006-3; IMAGAWA M, 1987, CELL, V51, P251, DOI 10.1016/0092-8674(87)90152-8; JAAKKOLA S, 1993, J NEUROCYTOL, V22, P215, DOI 10.1007/BF01246360; JACKSON IJ, 1991, NUCLEIC ACIDS RES, V19, P3795; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; LARSEN F, 1992, GENOMICS, V13, P1095, DOI 10.1016/0888-7543(92)90024-M; LINDBLOM A, 1994, EUR J BIOCHEM, V219, P383, DOI 10.1111/j.1432-1033.1994.tb19950.x; MATSUI C, 1995, J BIOL CHEM, V270, P23496, DOI 10.1074/jbc.270.40.23496; MINER JH, 1995, J BIOL CHEM, V270, P28523, DOI 10.1074/jbc.270.48.28523; MINER JH, 1994, J CELL BIOL, V127, P879, DOI 10.1083/jcb.127.3.879; MITCHELL PJ, 1991, GENE DEV, V5, P105, DOI 10.1101/gad.5.1.105; MONTELL DJ, 1988, CELL, V53, P463, DOI 10.1016/0092-8674(88)90166-3; NIELSEN FC, 1990, J BIOL CHEM, V265, P13431; NOAKES PG, 1995, NATURE, V374, P258, DOI 10.1038/374258a0; NOAKES PG, 1995, NAT GENET, V10, P400, DOI 10.1038/ng0895-400; OKANO R, 1992, BIOCHIM BIOPHYS ACTA, V1132, P49, DOI 10.1016/0167-4781(92)90051-Z; PIKKARAINEN T, 1987, J BIOL CHEM, V262, P10454; PORTER BE, 1993, GENOMICS, V16, P278, DOI 10.1006/geno.1993.1178; PORTER BE, 1995, NEURON, V14, P549, DOI 10.1016/0896-6273(95)90311-9; PULKKINEN L, 1995, GENOMICS, V25, P192, DOI 10.1016/0888-7543(95)80125-6; PULKKINEN L, 1994, GENOMICS, V24, P357, DOI 10.1006/geno.1994.1627; REING J, 1992, J BIOL CHEM, V267, P23143; RICHARDS AJ, 1994, GENOMICS, V22, P237, DOI 10.1006/geno.1994.1372; Rohrbach DH, 1993, MOL CELLULAR ASPECTS; ROUSSELLE P, 1991, J CELL BIOL, V114, P567, DOI 10.1083/jcb.114.3.567; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SANES JR, 1990, J CELL BIOL, V111, P1685, DOI 10.1083/jcb.111.4.1685; SASAKI M, 1987, P NATL ACAD SCI USA, V84, P935, DOI 10.1073/pnas.84.4.935; SMITH CWJ, 1989, CELL, V56, P749, DOI 10.1016/0092-8674(89)90678-8; SOININEN R, 1989, J BIOL CHEM, V264, P13565; SUGIMOTO M, 1994, P NATL ACAD SCI USA, V91, P11679, DOI 10.1073/pnas.91.24.11679; TANAKA S, 1993, J BIOL CHEM, V268, P8862; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; VAILLY J, 1994, GENOMICS, V21, P286, DOI 10.1006/geno.1994.1263; VUOLTEENAHO R, 1990, J BIOL CHEM, V265, P15611; WAHLE E, 1992, ANNU REV BIOCHEM, V61, P419; WEWER UM, 1995, NEUROLOGY, V45, P2099, DOI 10.1212/WNL.45.11.2099; WEWER UM, 1994, LAB INVEST, V71, P719; WEWER UM, 1994, GENOMICS, V24, P243, DOI 10.1006/geno.1994.1612; YAMADA H, 1995, LAB INVEST, V72, P715; YURCHENCO PD, 1994, CURR OPIN CELL BIOL, V6, P674, DOI 10.1016/0955-0674(94)90093-0; ZUKER M, 1981, NUCLEIC ACIDS RES, V9, P133, DOI 10.1093/nar/9.1.133	70	27	28	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 7	1996	271	23					13407	13416		10.1074/jbc.271.23.13407	http://dx.doi.org/10.1074/jbc.271.23.13407			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UP385	8662701	hybrid			2022-12-25	WOS:A1996UP38500018
J	Klebanow, ER; Poon, D; Zhou, S; Weil, PA				Klebanow, ER; Poon, D; Zhou, S; Weil, PA			Isolation and characterization of TAF25, an essential yeast gene that encodes an RNA polymerase II-specific TATA-binding protein-associated factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR TFIIIB; HUMAN ESTROGEN-RECEPTOR; SACCHAROMYCES-CEREVISIAE; CLONED GENES; EXPRESSION; TBP; IDENTIFICATION; PURIFICATION; COMPONENTS; PROMOTERS	We describe the cloning and analysis of TAF25, a previously uncharacterized yeast gene that encodes a yeast TATA-binding protein-associated factor or yTAF or M(r) = 25,000. The gene encoding yTAF25 is a single copy essential gene, and the protein sequence deduced from TAF25 exhibits sequence similarity to a metazoan hTAF(II). The results for immunological studies confirm that yTAF25 is a subunit of a large multiprotein TATA-binding protein-yeast TATA-binding protein-associated factor complex that contains a subset of the total number of the yTAFs present in yeast cell extracts. Both genetic and biochemical analyses demonstrate that yTAF25 can interact directly with itself. Transcriptional data show that the activity of the multiprotein complex containing yTAF25 is RNA polymerase II-specific, thus indicating that TAF25 encodes a bona fide yeast RNA polymerase II TAF. Hence the protein encoded by TAF25 has been termed yTAF (II)25.	VANDERBILT UNIV,SCH MED,DEPT PHYSIOL & MOLEC BIOPHYS,NASHVILLE,TN 37232; UNIV CALIF BERKELEY,HOWARD HUGHES MED INST,DEPT MOLEC & CELLULAR BIOL,BERKELEY,CA 94720	Vanderbilt University; Howard Hughes Medical Institute; University of California System; University of California Berkeley					NCI NIH HHS [CA09385] Funding Source: Medline; NIGMS NIH HHS [GM52461] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009385] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R56GM052461, R01GM052461] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; [Anonymous], 1991, Methods Enzymol, V194, P1; AUBLE DT, 1993, GENE DEV, V7, P844, DOI 10.1101/gad.7.5.844; AUBLE DT, 1994, GENE DEV, V8, P1920, DOI 10.1101/gad.8.16.1920; BARBERIS A, 1995, CELL, V81, P359, DOI 10.1016/0092-8674(95)90389-5; BARLEV NA, 1995, J BIOL CHEM, V270, P19337, DOI 10.1074/jbc.270.33.19337; BARTHOLOMEW B, 1991, MOL CELL BIOL, V11, P5181, DOI 10.1128/MCB.11.10.5181; BERBEN G, 1991, YEAST, V7, P475, DOI 10.1002/yea.320070506; BLANAR MA, 1992, SCIENCE, V256, P1014, DOI 10.1126/science.1589769; BOCKE JD, 1987, METHOD ENZYMOL, V154, P164; BURATOWSKI S, 1992, CELL, V71, P221, DOI 10.1016/0092-8674(92)90351-C; CHATTERJEE S, 1995, NATURE, V374, P820, DOI 10.1038/374820a0; CHEN BPC, 1994, GENE, V139, P73, DOI 10.1016/0378-1119(94)90525-8; CHEN JL, 1994, CELL, V79, P93, DOI 10.1016/0092-8674(94)90403-0; CHIANG CM, 1993, EMBO J, V12, P2749, DOI 10.1002/j.1460-2075.1993.tb05936.x; COLBERT T, 1992, GENE DEV, V6, P1940, DOI 10.1101/gad.6.10.1940; COLGAN J, 1992, GENE DEV, V6, P304, DOI 10.1101/gad.6.2.304; COMAI L, 1994, SCIENCE, V266, P1966, DOI 10.1126/science.7801123; COMAI L, 1992, CELL, V68, P965, DOI 10.1016/0092-8674(92)90039-F; CORMACK BP, 1993, SCIENCE, V262, P244, DOI 10.1126/science.8211143; CORMACK BP, 1992, CELL, V69, P685, DOI 10.1016/0092-8674(92)90232-2; DAVIS JL, 1992, MOL CELL BIOL, V12, P1879, DOI 10.1128/MCB.12.4.1879; DYNLACHT BD, 1991, CELL, V66, P563, DOI 10.1016/0092-8674(81)90019-2; GARTENBERG MR, 1990, P NATL ACAD SCI USA, V87, P6034, DOI 10.1073/pnas.87.16.6034; GREEN S, 1986, NATURE, V320, P134, DOI 10.1038/320134a0; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; GUARENTE L, 1983, METHOD ENZYMOL, V101, P181; Harlow E., 1988, ANTIBODIES LAB MANUA; HENRY NL, 1994, GENE DEV, V8, P2868, DOI 10.1101/gad.8.23.2868; HENRY RW, 1995, NATURE, V374, P653, DOI 10.1038/374653a0; HERMAN PK, 1990, MOL CELL BIOL, V10, P6742, DOI 10.1128/MCB.10.12.6742; HERNANDEZ N, 1993, GENE DEV, V7, P1291, DOI 10.1101/gad.7.7b.1291; HUET J, 1992, NUCLEIC ACIDS RES, V20, P6451, DOI 10.1093/nar/20.24.6451; JACQ X, 1994, CELL, V79, P107, DOI 10.1016/0092-8674(94)90404-9; KARNITZ L, 1989, MOL CELL BIOL, V9, P1929, DOI 10.1128/MCB.9.5.1929; KASSAVETIS GA, 1992, CELL, V71, P1055, DOI 10.1016/0092-8674(92)90399-W; KASSAVETIS GA, 1995, P NATL ACAD SCI USA, V92, P9786, DOI 10.1073/pnas.92.21.9786; KIM YJ, 1994, CELL, V77, P599, DOI 10.1016/0092-8674(94)90221-6; KLAGES N, 1995, NATURE, V374, P822, DOI 10.1038/374822a0; KLEKAMP MS, 1986, J BIOL CHEM, V261, P2819; KOLESKE AJ, 1994, NATURE, V368, P466, DOI 10.1038/368466a0; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LEES JA, 1989, J STEROID BIOCHEM, V34, P33, DOI 10.1016/0022-4731(89)90063-0; LIU HP, 1992, GENETICS, V132, P665; LOBO SM, 1991, GENE DEV, V5, P1477, DOI 10.1101/gad.5.8.1477; LOPEZDELEON A, 1992, CELL, V71, P211, DOI 10.1016/0092-8674(92)90350-L; MARSOLIER MC, 1994, P NATL ACAD SCI USA, V91, P11938, DOI 10.1073/pnas.91.25.11938; MENGUS G, 1995, EMBO J, V14, P1520, DOI 10.1002/j.1460-2075.1995.tb07138.x; PIERRAT B, 1994, GENE, V143, P193, DOI 10.1016/0378-1119(94)90096-5; POON D, 1993, J BIOL CHEM, V268, P15325; POON D, 1994, J BIOL CHEM, V269, P23135; POON D, 1995, P NATL ACAD SCI USA, V92, P8224, DOI 10.1073/pnas.92.18.8224; POON D, 1993, J BIOL CHEM, V268, P5005; REESE JC, 1994, NATURE, V371, P523, DOI 10.1038/371523a0; RIGBY PWJ, 1993, CELL, V72, P7, DOI 10.1016/0092-8674(93)90042-O; Sambrook J., 2002, MOL CLONING LAB MANU; SCHROEDER SC, 1994, J BIOL CHEM, V269, P28335; SCHULTZ MC, 1992, CELL, V69, P697, DOI 10.1016/0092-8674(92)90233-3; SCHULTZ MC, 1991, P NATL ACAD SCI USA, V88, P1004, DOI 10.1073/pnas.88.3.1004; SHELDON M, 1995, CURR BIOL, V5, P43, DOI 10.1016/S0960-9822(95)00014-5; SILVERMAN N, 1994, P NATL ACAD SCI USA, V91, P11665, DOI 10.1073/pnas.91.24.11665; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; SWAFFIELD J, 1995, NATURE, V374, P89; TAGGART AKP, 1992, CELL, V71, P1015, DOI 10.1016/0092-8674(92)90396-T; TASSET D, 1990, CELL, V62, P1177, DOI 10.1016/0092-8674(90)90394-T; THOMPSON CM, 1995, P NATL ACAD SCI USA, V92, P4587, DOI 10.1073/pnas.92.10.4587; TJIAN R, 1994, CELL, V77, P5, DOI 10.1016/0092-8674(94)90227-5; TORA L, 1989, CELL, V59, P477, DOI 10.1016/0092-8674(89)90031-7; TYERS M, 1992, EMBO J, V11, P1773, DOI 10.1002/j.1460-2075.1992.tb05229.x; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WHITE RJ, 1994, SCIENCE, V266, P448, DOI 10.1126/science.7939686; WHITE RJ, 1992, TRENDS GENET, V8, P284, DOI 10.1016/0168-9525(92)90255-3; YEUNG KC, 1994, GENE DEV, V8, P2097, DOI 10.1101/gad.8.17.2097; ZHOU Q, 1992, GENE DEV, V6, P1964, DOI 10.1101/gad.6.10.1964; ZOMERDIJK JCBM, 1994, SCIENCE, V266, P2015, DOI 10.1126/science.7801130	75	34	35	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 7	1996	271	23					13706	13715		10.1074/jbc.271.23.13706	http://dx.doi.org/10.1074/jbc.271.23.13706			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UP385	8662725	hybrid			2022-12-25	WOS:A1996UP38500062
J	Popp, B; Court, DA; Benz, R; Neupert, W; Lill, R				Popp, B; Court, DA; Benz, R; Neupert, W; Lill, R			The role of the N and C termini of recombinant Neurospora mitochondrial porin in channel formation and voltage-dependent gating	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANION-SELECTIVE CHANNEL; OUTER-MEMBRANE; ESCHERICHIA-COLI; PROTEIN; PURIFICATION; CRASSA; CDNA; CLONING; EXPRESSION; IMPORT	To investigate the role of the N and C termini in channel function and voltage-dependent gating of mitochondrial porin, we expressed wild-type and mutant porins from Neurospora crassa as His-tag fusion products in Escherichia coli, Large quantities of the proteins were purified by chromatography across a nickle-nitrilotriacetic acid-agarose column under denaturing conditions. The purified His-tagged wild-type protein could be functionally reconstituted in the presence of detergent and sterol and behaved in black lipid bilayer membranes indistinguishably from native porin isolated from Neurospora crassa mitochondria. Mutants of porin lacking part of the N terminus (Delta N2-12porin, Delta N3-20porin), part of the C terminus (Delta C269-283porin), or both (Delta N2-12/Delta C269-283porin) also showed channel forming activity. The mutant porin lacking the C terminus had a smaller single channel conductance than the wild-type protein, but its other biophysical properties were identical. Delta N2-12porin and Delta N3-20porin formed noisy channels with decreased channel stability. These channels were still voltage-dependent. Delta N2-12/Delta C269-283porin lost channel stability and had altered gating characteristics. These results are discussed with respect to different models that have been proposed in the literature for the structure of mitochondrial porin channels.	UNIV WURZBURG,THEODOR BOVERI INST BIOZENTRUM,LEHRSTUHL BIOTECHNOL,D-97074 WURZBURG,GERMANY; UNIV MUNICH,INST PHYSIOL CHEM PHYS BIOCHEM & ZELLBIOL,D-80336 MUNICH,GERMANY	University of Wurzburg; University of Munich				Lill, Roland/0000-0002-8345-6518; Benz, Roland/0000-0002-9510-9265; Court, Deborah A./0000-0003-1919-8339				BAUER K, 1989, J BIOL CHEM, V264, P16393; BENZ R, 1978, BIOCHIM BIOPHYS ACTA, V511, P305, DOI 10.1016/0005-2736(78)90269-9; BENZ R, 1994, BBA-REV BIOMEMBRANES, V1197, P167, DOI 10.1016/0304-4157(94)90004-3; BLACHLYDYSON E, 1990, SCIENCE, V247, P1233, DOI 10.1126/science.1690454; BLACHLYDYSON E, 1994, GENOMICS, V20, P62, DOI 10.1006/geno.1994.1127; BLACHLYDYSON E, 1993, J BIOL CHEM, V268, P1835; CARBONARA F, 1996, IN PRESS J BIOENERG; COLOMBINI M, 1980, J MEMBRANE BIOL, V53, P79, DOI 10.1007/BF01870576; COLOMBINI M, 1979, NATURE, V279, P643, DOI 10.1038/279643a0; COWAN SW, 1992, NATURE, V358, P727, DOI 10.1038/358727a0; Davis R.H., 1970, 789 METHODS ENZYMOLO, VVolume 17, P79, DOI DOI 10.1016/0076-6879(71)17168-6; DEPINTO V, 1989, EUR J BIOCHEM, V183, P179; DEPINTO V, 1987, BIOCHIM BIOPHYS ACTA, V894, P109, DOI 10.1016/0005-2728(87)90180-0; DEPINTO V, 1987, BIOCHIM BIOPHYS ACTA, V905, P499, DOI 10.1016/0005-2736(87)90480-9; DEPINTO V, 1991, BIOCHEMISTRY-US, V30, P10191, DOI 10.1021/bi00106a017; FISCHER K, 1994, J BIOL CHEM, V269, P25754; FREITAG H, 1982, EUR J BIOCHEM, V123, P629; GUO XW, 1995, J STRUCT BIOL, V114, P41, DOI 10.1006/jsbi.1995.1004; HA HJ, 1993, J BIOL CHEM, V268, P12143; HAMAJIMA S, 1988, J BIOCHEM-TOKYO, V104, P362, DOI 10.1093/oxfordjournals.jbchem.a122474; HEINS L, 1994, J BIOL CHEM, V269, P26402; KAYSER H, 1989, BIOL CHEM H-S, V370, P1265; KLEENE R, 1987, EMBO J, V6, P2627, DOI 10.1002/j.1460-2075.1987.tb02553.x; LINDEN M, 1982, BIOCHEM J, V208, P77, DOI 10.1042/bj2080077; MANNELLA CA, 1986, BIOPHYS J, V49, P307, DOI 10.1016/S0006-3495(86)83643-8; MANNELLA CA, 1989, FEBS LETT, V253, P231, DOI 10.1016/0014-5793(89)80965-2; MIHARA K, 1985, EMBO J, V4, P769, DOI 10.1002/j.1460-2075.1985.tb03695.x; OBRIEN RL, 1965, J BIOL CHEM, V240, P4527; PENG S, 1992, BIOPHYS J, V62, P123, DOI 10.1016/S0006-3495(92)81799-X; PFAFF E, 1968, EUR J BIOCHEM, V5, P222, DOI 10.1111/j.1432-1033.1968.tb00361.x; PFALLER R, 1985, J BIOL CHEM, V260, P8188; PFANNER N, 1985, EMBO J, V4, P2819, DOI 10.1002/j.1460-2075.1985.tb04009.x; POPP B, 1995, BIOCHEMISTRY-US, V34, P3352, DOI 10.1021/bi00010a026; ROOS N, 1982, BIOCHIM BIOPHYS ACTA, V686, P204, DOI 10.1016/0005-2736(82)90114-6; SCHEIN SJ, 1976, J MEMBRANE BIOL, V30, P99, DOI 10.1007/BF01869662; STANLEY S, 1995, J BIOL CHEM, V270, P16694, DOI 10.1074/jbc.270.28.16694; THOMAS L, 1993, P NATL ACAD SCI USA, V90, P5446, DOI 10.1073/pnas.90.12.5446; TROLL H, 1992, J BIOL CHEM, V267, P21072; VILLAREJO MR, 1974, J BACTERIOL, V120, P466, DOI 10.1128/JB.120.1.466-474.1974; WEISS MS, 1991, SCIENCE, V254, P1617; ZALMAN LS, 1980, J BIOL CHEM, V255, P1771; ZIZI M, 1995, J MEMBRANE BIOL, V144, P121	42	66	67	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 7	1996	271	23					13593	13599		10.1074/jbc.271.23.13593	http://dx.doi.org/10.1074/jbc.271.23.13593			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UP385	8662769	hybrid			2022-12-25	WOS:A1996UP38500045
J	Harhaj, EW; Maggirwar, SB; Sun, SC				Harhaj, EW; Maggirwar, SB; Sun, SC			Inhibition of p105 processing by NF-kappa B proteins in transiently transfected cells	ONCOGENE			English	Article						NF-kappa B; p105; protein processing; RelA; c-Rel	HUMAN-IMMUNODEFICIENCY-VIRUS; LONG TERMINAL REPEAT; DNA-BINDING SUBUNIT; TRANS-ACTIVATOR PROTEIN; NUCLEAR-LOCALIZATION; PRECURSOR P105; 65-KD SUBUNIT; PHORBOL ESTER; MESSENGER-RNA; REL ONCOGENE	Regulation of the transcription factor NF-kappa B involves proteasome-mediated processing of the NF-kappa B1 p105 precursor protein, which generates the p50 subunit of NF-kappa B. The processing of p105 occurs constitutively in vivo but can be markedly enhanced by various cellular activation agents, although the underlying regulatory mechanism is not yet clear, In the present study, we demonstrate that signal-mediated induction of p105 processing in human T cells is associated with de novo synthesis of this precursor protein, Transient transfection studies performed in COS7 cells revealed that the newly synthesized p105 protein appears to be more rapidly processed compared to its accumulated form that is already associated with the processed product p50, Interestingly, the processing rate of p105 is markedly inhibited in cells co-transfected with p50 or other NF-kappa B subunits, including RelA and c-Rel, that physically interact with p105, These findings suggest that the processing of p105 is subject to negative regulation by the various NF-kappa B subunits, We further demonstrate that p105 undergoes degradation in lipopolysaccharide-stimulated human monocytic cells. However, the inducible degradation of p105 is not coupled with the generation of p50, Together, these studies demonstrate that the processing and inducible degradation of p105 are differentially regulated.	PENN STATE UNIV,MILTON S HERSHEY MED CTR,COLL MED,DEPT MICROBIOL & IMMUNOL,HERSHEY,PA 17033	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health					NATIONAL CANCER INSTITUTE [R01CA068471] Funding Source: NIH RePORTER; NCI NIH HHS [1R01 CA 68471-01] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; BAEUERLE PA, 1989, GENE DEV, V3, P1689, DOI 10.1101/gad.3.11.1689; BAEUERLE PA, 1990, HORMONAL CONTROL REG, P409; BALLARD DW, 1992, P NATL ACAD SCI USA, V89, P1875, DOI 10.1073/pnas.89.5.1875; BEG AA, 1993, GENE DEV, V7, P2064, DOI 10.1101/gad.7.11.2064; BOURS V, 1992, MOL CELL BIOL, V12, P685, DOI 10.1128/MCB.12.2.685; BOURS V, 1990, NATURE, V348, P76, DOI 10.1038/348076a0; BROCKMAN JA, 1995, MOL CELL BIOL, V15, P2809; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; COGSWELL PC, 1993, J IMMUNOL, V150, P2794; DOERRE S, 1993, P NATL ACAD SCI USA, V90, P1023, DOI 10.1073/pnas.90.3.1023; DONALD R, 1995, J BIOL CHEM, V270, P9, DOI 10.1074/jbc.270.1.9; FAN CM, 1991, NATURE, V354, P395, DOI 10.1038/354395a0; FINCO TS, 1995, IMMUNITY, V3, P263, DOI 10.1016/1074-7613(95)90112-4; GANCHI PA, 1992, MOL BIOL CELL, V3, P1339, DOI 10.1091/mbc.3.12.1339; GHOSH S, 1990, CELL, V62, P1019, DOI 10.1016/0092-8674(90)90276-K; GILMORE TD, 1990, CELL, V62, P841, DOI 10.1016/0092-8674(90)90257-F; HOLBROOK NJ, 1987, VIROLOGY, V157, P211, DOI 10.1016/0042-6822(87)90330-8; KAUFMAN JD, 1987, MOL CELL BIOL, V7, P3759, DOI 10.1128/MCB.7.10.3759; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; LENARDO MJ, 1989, CELL, V58, P227, DOI 10.1016/0092-8674(89)90833-7; MELLITS KH, 1993, NUCLEIC ACIDS RES, V21, P5059, DOI 10.1093/nar/21.22.5059; MERCURIO F, 1993, GENE DEV, V7, P705, DOI 10.1101/gad.7.4.705; MEYER R, 1991, P NATL ACAD SCI USA, V88, P966, DOI 10.1073/pnas.88.3.966; MUESING MA, 1987, CELL, V48, P691, DOI 10.1016/0092-8674(87)90247-9; NABEL G, 1987, NATURE, V326, P711, DOI 10.1038/326711a0; NAUMANN M, 1993, EMBO J, V12, P213, DOI 10.1002/j.1460-2075.1993.tb05647.x; NOLAN GP, 1991, CELL, V64, P961, DOI 10.1016/0092-8674(91)90320-X; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; RICE NR, 1992, CELL, V71, P243, DOI 10.1016/0092-8674(92)90353-E; RUBEN SM, 1991, SCIENCE, V251, P1490, DOI 10.1126/science.2006423; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; SIEKEVITZ M, 1987, SCIENCE, V238, P1575, DOI 10.1126/science.2825351; SUN SC, 1994, P NATL ACAD SCI USA, V91, P1346, DOI 10.1073/pnas.91.4.1346; TEN RM, 1992, EMBO J, V11, P195, DOI 10.1002/j.1460-2075.1992.tb05042.x; TONGSTARKSEN SE, 1987, P NATL ACAD SCI USA, V84, P6845, DOI 10.1073/pnas.84.19.6845; TRAENCKNER EBM, 1995, EMBO J, V14, P2876, DOI 10.1002/j.1460-2075.1995.tb07287.x; ZHENG S, 1993, J BIOL CHEM, V268, P17233	38	27	28	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN 6	1996	12	11					2385	2392						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UQ220	8649779				2022-12-25	WOS:A1996UQ22000016
J	Shiraiwa, N; Inohara, N; Okada, S; Yuzaki, M; Shoji, S; Ohta, S				Shiraiwa, N; Inohara, N; Okada, S; Yuzaki, M; Shoji, S; Ohta, S			An additional form of rat Bcl-x, Bcl-x beta, generated by an unspliced RNA, promotes apoptosis in promyeloid cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRE-B-CELLS; PROTOONCOGENE BCL-2; SEQUENCE SIMILARITY; FOLLICULAR LYMPHOMA; DNA FRAGMENTATION; GENE; DEATH; EXPRESSION; SURVIVAL; PROTEIN	The bcl-2 oncogene product delays apoptotic cell death and prolongs the cell survival, We cloned two bcl-2-related cDNAs from a rat thymus cDNA library by low stringency hybridization with a rat bcl-2 fragment as a probe. One of these, designated bcl-x alpha, was a counterpart of the human bcl-x(L) reported previously as a bcl-2-related gene (Boise, L. H., Gonzalez-Garcia, M., Postema, C. E., Ding, L., Lindsten, T., Turka, L. A., Mao, M., Nunez, G., and Thompson, C. B. (1993) Cell 74, 597-608). The other, designated bcl-x beta, was novel and found to be generated by an unspliced mRNA, whereas bcl-x alpha was generated from a spliced transcript. The splice junction exactly corresponded to that found in the bcl-2 gene. bcl-x beta was specifically expressed in cerebellum, heart, and thymus. When bcl-x beta directed by a strong promoter was introduced into an interleukin-3-dependent promyeloid cell line, FDC-P1, DNA fragmentation was observed even in the growing state in the presence of interleukin-3 although not in the control transfectants. This finding suggests that the rat bcl-x beta gene product promotes apoptosis in the promyeloid cells.	NIPPON MED COLL, INST GERONTOL, DIV BIOCHEM, NAKAHARA KU, KAWASAKI, KANAGAWA 211, JAPAN; JICHI MED SCH, DEPT BIOCHEM, MINAMI KAWACHI, TOCHIGI 32904, JAPAN; UNIV TSUKUBA, INST MED, DEPT NEUROL, TSUKUBA, IBARAKI 305, JAPAN	Nippon Medical School; Jichi Medical University; University of Tsukuba			Yuzaki, Michisuke/K-5328-2013	Yuzaki, Michisuke/0000-0002-5750-3544				ALLSOPP TE, 1993, CELL, V73, P295, DOI 10.1016/0092-8674(93)90230-N; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; BORNER C, 1994, J CELL BIOL, V126, P1059, DOI 10.1083/jcb.126.4.1059; BORZILLO GV, 1992, ONCOGENE, V7, P869; CHITTENDEN T, 1995, NATURE, V374, P733, DOI 10.1038/374733a0; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLEARY ML, 1986, CELL, V47, P19, DOI 10.1016/0092-8674(86)90362-4; COHEN JJ, 1991, ADV IMMUNOL, V50, P55; EGUCHI Y, 1992, NUCLEIC ACIDS RES, V20, P4187, DOI 10.1093/nar/20.16.4187; FANG W, 1994, J IMMUNOL, V153, P4388; FARROW SN, 1995, NATURE, V374, P731, DOI 10.1038/374731a0; FIELDS BA, 1995, NATURE, V374, P739, DOI 10.1038/374739a0; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GONZALEZGARCIA M, 1995, P NATL ACAD SCI USA, V92, P4304, DOI 10.1073/pnas.92.10.4304; GONZALEZGARCIA M, 1994, DEVELOPMENT, V120, P3033; GOTTSCHALK AR, 1994, P NATL ACAD SCI USA, V91, P7350, DOI 10.1073/pnas.91.15.7350; HENDERSON S, 1993, P NATL ACAD SCI USA, V90, P8479, DOI 10.1073/pnas.90.18.8479; HENGARTNER MO, 1992, NATURE, V356, P494, DOI 10.1038/356494a0; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; Huynh TV, 1985, DNA CLONING TECHNIQU, V1, P49; KAWASAKI ES, 1988, P NATL ACAD SCI USA, V85, P5698, DOI 10.1073/pnas.85.15.5698; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; KIEFER MC, 1995, NATURE, V374, P736, DOI 10.1038/374736a0; KOZOPAS KM, 1993, P NATL ACAD SCI USA, V90, P3516, DOI 10.1073/pnas.90.8.3516; KRAJEWSKI S, 1993, CANCER RES, V53, P4701; KRAJEWSKI S, 1994, CANCER RES, V54, P5501; LIN EY, 1993, J IMMUNOL, V151, P1979; LOO DT, 1993, P NATL ACAD SCI USA, V90, P7951, DOI 10.1073/pnas.90.17.7951; MCDONNELL TJ, 1989, CELL, V57, P79, DOI 10.1016/0092-8674(89)90174-8; MIYASHITA T, 1992, CANCER RES, V52, P5407; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; MONAGHAN P, 1992, J HISTOCHEM CYTOCHEM, V40, P1819, DOI 10.1177/40.12.1453000; NEGRINI M, 1987, CELL, V49, P455, DOI 10.1016/0092-8674(87)90448-X; NEILAN JG, 1993, J VIROL, V67, P4391, DOI 10.1128/JVI.67.7.4391-4394.1993; NUNEZ G, 1990, J IMMUNOL, V144, P3602; OKAYAMA H, 1987, METHOD ENZYMOL, V154, P3; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; OPPENHEIM RW, 1991, ANNU REV NEUROSCI, V14, P453, DOI 10.1146/annurev.ne.14.030191.002321; PEARSON GR, 1987, VIROLOGY, V160, P151, DOI 10.1016/0042-6822(87)90055-9; POTTER H, 1984, P NATL ACAD SCI-BIOL, V81, P7161, DOI 10.1073/pnas.81.22.7161; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SCOLLAY R, 1988, IMMUNOL REV, V104, P81, DOI 10.1111/j.1600-065X.1988.tb00760.x; SEDLAK TW, 1995, P NATL ACAD SCI USA, V92, P7834, DOI 10.1073/pnas.92.17.7834; SENTMAN CL, 1991, CELL, V67, P879, DOI 10.1016/0092-8674(91)90361-2; STRASSER A, 1991, CELL, V67, P889, DOI 10.1016/0092-8674(91)90362-3; TANAKA S, 1993, J BIOL CHEM, V268, P10920; TSO JY, 1985, NUCLEIC ACIDS RES, V13, P2485, DOI 10.1093/nar/13.7.2485; TSUJIMOTO Y, 1986, P NATL ACAD SCI USA, V83, P5214, DOI 10.1073/pnas.83.14.5214; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; WILLIAMS GT, 1993, CELL, V74, P777, DOI 10.1016/0092-8674(93)90457-2; WILLIAMS GT, 1990, NATURE, V343, P76, DOI 10.1038/343076a0; Wyllie A H, 1980, Int Rev Cytol, V68, P251; YANG E, 1995, CELL, V80, P285, DOI 10.1016/0092-8674(95)90411-5; ZEHAVA CL, 1990, J BIOL CHEM, V265, P4929	55	69	71	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 31	1996	271	22					13258	13265		10.1074/jbc.271.22.13258	http://dx.doi.org/10.1074/jbc.271.22.13258			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UN474	8662675	hybrid			2022-12-25	WOS:A1996UN47400088
J	Theopold, U; Samakovlis, C; ErdjumentBromage, H; Dillon, N; Axelsson, B; Schmidt, O; Tempst, P; Hultmark, D				Theopold, U; Samakovlis, C; ErdjumentBromage, H; Dillon, N; Axelsson, B; Schmidt, O; Tempst, P; Hultmark, D			Helix pomatia lectin, an inducer of Drosophila immune response, binds to hemomucin, a novel surface mucin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STRICTOSIDINE SYNTHASE; RAUVOLFIA-SERPENTINA; T-CELLS; EXPRESSION; PROTEINS; SEQUENCE; GENE; CD43; ENHANCEMENT; LEUKOSIALIN	We describe the isolation and initial characterization of hemomucin, a novel Drosophila surface mucin that is likely to be involved in the induction of antibacterial effector molecules after binding a snail lectin (Helix pomatia A hemagglutinin). Two proteins of 100 and 220 kDa were purified from the membrane fraction of a Drosophila blood cell line using lectin columns. The two proteins are products of the same gene, as demonstrated by peptide sequencing. The corresponding cDNAs code for a product that contains an amino-terminal putative transmembrane domain, a domain related to the plant enzyme strictosidine synthase, and a mucin-like domain in the carboxyl-terminal part of the protein. The gene is expressed throughout development. In adult flies, high expression is found in hemocytes, in specialized regions of the gut, and in the ovary, where the protein is deposited onto the egg surface. In the gut, the mucin co-localizes with the peritrophic membrane. The cytogenetic location of the gene is on the third chromosome in the region 97F-98A.	UNIV STOCKHOLM, DEPT MOLEC BIOL, S-10691 STOCKHOLM, SWEDEN; UNIV STOCKHOLM, DEPT IMMUNOL, S-10691 STOCKHOLM, SWEDEN; MEM SLOAN KETTERING CANC CTR, PROGRAM MOLEC BIOL, NEW YORK, NY 10021 USA	Stockholm University; Stockholm University; Memorial Sloan Kettering Cancer Center	Theopold, U (corresponding author), UNIV ADELAIDE, DEPT CROP PROTECT, WAITE CAMPUS, GLEN OSMOND, SA 5064, AUSTRALIA.		Theopold, Ulrich/P-7205-2015; Dillon, Natalie L/B-7168-2015; Hultmark, Dan/C-5058-2013	Theopold, Ulrich/0000-0002-1009-8254; Hultmark, Dan/0000-0002-6506-5855; Erdjument-Bromage, Hediye/0000-0003-0224-3594	NATIONAL CANCER INSTITUTE [P30CA008748] Funding Source: NIH RePORTER; NCI NIH HHS [5 P30 CA08748-29] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDERSSON M, 1995, EMBO J, V14, P1615, DOI 10.1002/j.1460-2075.1995.tb07150.x; AXELSSON B, 1988, J IMMUNOL, V141, P2912; AXELSSON B, 1989, SCAND J IMMUNOL, V30, P539, DOI 10.1111/j.1365-3083.1989.tb02461.x; AXELSSON B, 1978, EUR J IMMUNOL, V8, P757, DOI 10.1002/eji.1830081102; BASSE F, 1994, BBA-BIOMEMBRANES, V1190, P217, DOI 10.1016/0005-2736(94)90077-9; BIERER BE, 1988, IMMUNOL ALLERGY CLIN, V8, P51; BOMAN HG, 1991, EUR J BIOCHEM, V201, P23, DOI 10.1111/j.1432-1033.1991.tb16252.x; BRACHER D, 1992, ARCH BIOCHEM BIOPHYS, V294, P717, DOI 10.1016/0003-9861(92)90746-J; BROWN MS, 1991, CURR OPIN LIPIDOL, V2, P65; CASTEELSJOSSON K, 1994, J BIOL CHEM, V269, P28569; CAVENER DR, 1991, NUCLEIC ACIDS RES, V19, P3185, DOI 10.1093/nar/19.12.3185; COCIANCICH S, 1994, PARASITOL TODAY, V10, P132, DOI 10.1016/0169-4758(94)90260-7; DAVIS LG, 1986, BASIC METHODS MOL BI, P143; DEMEREC M, 1950, BIOL DROSOPHILA, P425; DIAMOND MS, 1991, CELL, V65, P961, DOI 10.1016/0092-8674(91)90548-D; ELICONE C, 1994, J CHROMATOGR A, V676, P121, DOI 10.1016/0021-9673(94)00089-1; ERDJUMENTBROMAGE H, 1994, PROTEIN SCI, V3, P2435, DOI 10.1002/pro.5560031227; Gateff E., 1980, INVERTEBRATE SYSTEMS, P517; GEROMANOS S, 1994, TECHNIQUES IN PROTEIN CHEMISTRY V, P143; Gupta Ayodhya P., 1991, P19; Harlow E., 1988, ANTIBODIES LAB MANUA; HILKENS J, 1992, TRENDS BIOCHEM SCI, V17, P359, DOI 10.1016/0968-0004(92)90315-Z; HULTMARK D, 1993, TRENDS GENET, V9, P178, DOI 10.1016/0168-9525(93)90165-E; ISHIKAWA N, 1994, IMMUNOLOGY, V81, P480; KUTCHAN TM, 1988, FEBS LETT, V237, P40, DOI 10.1016/0014-5793(88)80167-4; KYLSTEN P, 1990, EMBO J, V9, P217, DOI 10.1002/j.1460-2075.1990.tb08098.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEMAITRE B, 1995, EMBO J, V14, P536, DOI 10.1002/j.1460-2075.1995.tb07029.x; LITVINOV SV, 1993, J BIOL CHEM, V268, P21364; MANTLE M, 1993, INFECT IMMUN, V61, P4131, DOI 10.1128/IAI.61.10.4131-4138.1993; NAPPI AJ, 1984, SCIENCE, V225, P1166, DOI 10.1126/science.6433482; NASSEL DR, 1985, NEUROSCIENCE, V15, P293, DOI 10.1016/0306-4522(85)90136-8; PALLANT A, 1989, P NATL ACAD SCI USA, V86, P1328, DOI 10.1073/pnas.86.4.1328; PARK JK, 1991, NATURE, V350, P706, DOI 10.1038/350706a0; PEARSON A, 1995, P NATL ACAD SCI USA, V92, P4056, DOI 10.1073/pnas.92.9.4056; PETERSEN UM, 1995, EMBO J, V14, P3146, DOI 10.1002/j.1460-2075.1995.tb07317.x; RAYCHOWDHURY R, 1989, SCIENCE, V244, P1163, DOI 10.1126/science.2786251; RIZKI TM, 1983, SCIENCE, V220, P73, DOI 10.1126/science.6402819; SAITO A, 1994, P NATL ACAD SCI USA, V91, P9725, DOI 10.1073/pnas.91.21.9725; SAMAKOVLIS C, 1992, BIOCHEM BIOPH RES CO, V188, P1169, DOI 10.1016/0006-291X(92)91354-S; SAMAKOVLIS C, 1990, EMBO J, V9, P2969, DOI 10.1002/j.1460-2075.1990.tb07489.x; SCHROIT AJ, 1991, BIOCHIM BIOPHYS ACTA, V1071, P313, DOI 10.1016/0304-4157(91)90019-S; SHI BB, 1994, PARASITE IMMUNOL, V16, P553, DOI 10.1111/j.1365-3024.1994.tb00310.x; SHIMIZU Y, 1993, NATURE, V366, P630, DOI 10.1038/366630a0; SHORT JM, 1988, NUCLEIC ACIDS RES, V16, P7583, DOI 10.1093/nar/16.15.7583; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; TEMPST P, 1990, ELECTROPHORESIS, V11, P537, DOI 10.1002/elps.1150110704; Tempst Paul, 1994, Methods (Orlando), V6, P248, DOI 10.1006/meth.1994.1027; THEOPOLD U, 1995, MOL CELL BIOL, V15, P824; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; VONHEIJNE G, 1990, PROTEIN ENG, V4, P109, DOI 10.1093/protein/4.2.109; WICKER C, 1990, J BIOL CHEM, V265, P22493; YANO Y, 1994, BIOCHEM J, V299, P303, DOI 10.1042/bj2990303	53	84	88	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 31	1996	271	22					12708	12715		10.1074/jbc.271.22.12708	http://dx.doi.org/10.1074/jbc.271.22.12708			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UN474	8662683	hybrid			2022-12-25	WOS:A1996UN47400006
J	Shiffman, D; Brooks, EE; Brooks, AR; Chan, CS; Milner, PG				Shiffman, D; Brooks, EE; Brooks, AR; Chan, CS; Milner, PG			Characterization of the human cyclin-dependent kinase 2 gene - Promoter analysis and gene structure	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN CDC2 GENE; CELL-CYCLE; PROTEIN-KINASES; EXPRESSION; TRANSCRIPTION	Cyclin-dependent kinase 2 is a serine/threonine protein kinase essential for progression of the mammalian cell cycle from G(1) to S phase, CDK2 mRNA has been shown to be induced by serum in several cultured cell types. Therefore, we set out to identify elements that regulate the transcription of the human CDK2 gene and to characterize its structure. This paper describes the cloning of a similar to 2.4-kilobase pair genomic DNA fragment from the upstream region of the human CDK2 gene, This fragment contains five transcription initiation sites within a 72-nucleotide stretch, A 200-base pair sub-fragment that confers 70% of maximal basal promoter activity was shown to contain two synergistically acting Sp1 sites. However, a much larger DNA fragment containing similar to 1.7 kilobase pairs of upstream sequence is required for induction of promoter activity following serum stimulation. The intron exon boundaries of seven exons in this gene were also identified, and this information will be useful for analyzing genomic abnormalities associated with CDK2.			Shiffman, D (corresponding author), CV THERAPEUT, 3172 PORTER DR, PALO ALTO, CA 94304 USA.							Ausubel FM, 1994, CURRENT PROTOCOLS MO; Azizkhan Jane C., 1993, Critical Reviews in Eukaryotic Gene Expression, V3, P229; BARNES WM, 1994, P NATL ACAD SCI USA, V91, P2216, DOI 10.1073/pnas.91.6.2216; Brooks AR, 1996, J BIOL CHEM, V271, P9090, DOI 10.1074/jbc.271.15.9090; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DALTON S, 1992, EMBO J, V11, P1797, DOI 10.1002/j.1460-2075.1992.tb05231.x; DEMETRICK DJ, 1994, CYTOGENET CELL GENET, V66, P72, DOI 10.1159/000133669; FUCHS R, 1994, COMPUT APPL BIOSCI, V10, P171; GENG Y, 1993, P NATL ACAD SCI USA, V90, P10315, DOI 10.1073/pnas.90.21.10315; GHOSH D, 1993, NUCLEIC ACIDS RES, V21, P3117, DOI 10.1093/nar/21.13.3117; GRANA X, 1995, ONCOGENE, V11, P211; HENGLEIN B, 1994, P NATL ACAD SCI USA, V91, P5490, DOI 10.1073/pnas.91.12.5490; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; HERBER, 1994, ONCOGENE, V9, P2105; HINDLEY J, 1984, GENE, V31, P129, DOI 10.1016/0378-1119(84)90203-8; HORIGUCHIYAMADA J, 1994, MOL CELL BIOCHEM, V132, P31, DOI 10.1007/BF00925672; KU DH, 1993, J BIOL CHEM, V268, P2255; LIAO SM, 1995, NATURE, V374, P193, DOI 10.1038/374193a0; MEYERSON M, 1991, COLD SPRING HARB SYM, V56, P177; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; MULLER H, 1994, P NATL ACAD SCI USA, V91, P2945, DOI 10.1073/pnas.91.8.2945; NINOMIYATSUJI J, 1991, P NATL ACAD SCI USA, V88, P9006, DOI 10.1073/pnas.88.20.9006; OCHMAN H, 1989, PCR TECHNOLOGY PRINC, P105; OLIVE M, 1994, GENE, V151, P81, DOI 10.1016/0378-1119(94)90635-1; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; PINES J, 1994, SEMIN CANCER BIOL, V5, P305; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; SCHIEFFER E, 1995, RESTENOSIS SUMMIT, V7, P23; SCHNEIDER KR, 1994, SCIENCE, V266, P122, DOI 10.1126/science.7939631; SHIEKHATTAR R, 1995, NATURE, V374, P283, DOI 10.1038/374283a0; SHIFFMAN D, 1993, J BACTERIOL, V175, P6767, DOI 10.1128/jb.175.21.6767-6774.1993; TANGUAY DA, 1994, MOL IMMUNOL, V31, P643, DOI 10.1016/0161-5890(94)90173-2; TSAI LH, 1993, ONCOGENE, V8, P1593; TSAI LH, 1991, NATURE, V353, P174, DOI 10.1038/353174a0; VANDENHEUVEL S, 1993, SCIENCE, V262, P2050, DOI 10.1126/science.8266103; WANG J, 1990, NATURE, V343, P555, DOI 10.1038/343555a0	36	34	34	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 24	1996	271	21					12199	12204		10.1074/jbc.271.21.12199	http://dx.doi.org/10.1074/jbc.271.21.12199			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UL660	8647814	hybrid			2022-12-25	WOS:A1996UL66000016
J	Durante, W; Liao, L; Iftikhar, I; Cheng, K; Schafer, AI				Durante, W; Liao, L; Iftikhar, I; Cheng, K; Schafer, AI			Platelet-derived growth factor regulates vascular smooth muscle cell proliferation by inducing cationic amino acid transporter gene expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ORNITHINE DECARBOXYLASE ACTIVITY; ECOTROPIC RETROVIRUS RECEPTOR; POLYAMINE METABOLISM; ENDOTHELIAL-CELLS; HEPATOMA-CELLS; PUTRESCINE; MOUSE; ATHEROSCLEROSIS; IDENTIFICATION; PATHOGENESIS	Since recent studies demonstrated that platelet derived growth factor (PDGF) induces vascular smooth muscle cell (SMC) proliferation by stimulating polyamine synthesis, we examined whether the transcellular transport of L-ornithine, the cationic amino acid precursor of polyamines, could regulate the mitogenic response of PDGF. Treatment of SMC with PDGF stimulated DNA and putrescine synthesis, and this was enhanced further by increasing the extracellular concentration of L-ornithine. The potentiating effect of L-ornithine was reversed by the competitive inhibitor of cationic amino acid transport, methyl-L-arginine, or by preventing putrescine formation with alpha-difluoromethylornithine. Cationic amino acid uptake by SMC was Na+-independent and was mediated by both a high and low affinity carrier system. Treatment of SMC with PDGF initially (0-2 h) decreased basic amino acid transport, while longer exposures (6-24 h) progressively increased uptake. Kinetic studies indicated that PDGF-induced inhibition was associated with a decrease in affinity for cationic amino acids, while the stimulation was mediated by an increase in transport capacity. Endogenous PDGF released by collagen-activated platelets likewise up-regulated cationic amino acid transport in SMC. Reverse transcriptase-polymerase chain reaction detected the presence of mRNA encoding two distinct cationic amino acid transporter (CAT) proteins, CAT-1 and CAT-2B. Treatment of SMC with PDGF strongly induced the expression CAT-2B mRNA and modestly elevated the level of CAT-1 mRNA, These results demonstrate that PDGF-induced polyamine synthesis and SMC mitogenesis are dependent on the transcellular transport of L-ornithine. The capacity of PDGF to up-regulate the transport of L-ornithine by inducing the expression of the genes for CAT-1 and CAT-2B may modulate its mitogenic effect by providing SMC with the necessary intracellular precursor for polyamine biosynthesis.	BAYLOR COLL MED,DEPT MED,HOUSTON,TX 77030; BAYLOR COLL MED,DEPT PHARMACOL,HOUSTON,TX 77030	Baylor College of Medicine; Baylor College of Medicine	Durante, W (corresponding author), VET AFFAIRS MED CTR,BLDG 109,RM 116,2002 HOLCOMBE BLVD,HOUSTON,TX 77030, USA.				NHLBI NIH HHS [HL 36045] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL036045] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALBRITTON LM, 1989, CELL, V57, P659, DOI 10.1016/0092-8674(89)90134-7; BYUS CV, 1991, J CELL PHYSIOL, V149, P9, DOI 10.1002/jcp.1041490103; CLOSS EI, 1993, J BIOL CHEM, V268, P20796; CLOSS EI, 1993, J VIROL, V67, P2097, DOI 10.1128/JVI.67.4.2097-2102.1993; CLOSS EI, 1993, J BIOL CHEM, V268, P7538; DURANTE W, 1995, AM J PHYSIOL-HEART C, V268, pH1158; DURANTE W, 1994, BLOOD, V83, P1831; DURANTE W, 1995, BIOCHEM J, V308, P231, DOI 10.1042/bj3080231; GARG UC, 1989, J CLIN INVEST, V83, P1774, DOI 10.1172/JCI114081; GONZALEZ GG, 1991, CANCER RES, V51, P2932; Kakuda DK, 1993, TRANSGENE, V1, P91; KIM JW, 1991, NATURE, V352, P725, DOI 10.1038/352725a0; LAMAS S, 1991, AM J PHYSIOL, V261, pC634, DOI 10.1152/ajpcell.1991.261.4.C634; LOW BC, 1995, J BIOL CHEM, V270, P27577, DOI 10.1074/jbc.270.46.27577; LOW BC, 1993, J CELL PHYSIOL, V156, P626, DOI 10.1002/jcp.1041560323; MACLEOD CL, 1990, MOL CELL BIOL, V10, P3663, DOI 10.1128/MCB.10.7.3663; MACLEOD CL, 1994, J EXP BIOL, V196, P109; PEGG AE, 1988, CANCER RES, V48, P759; ROSS R, 1986, NEW ENGL J MED, V314, P488, DOI 10.1056/NEJM198602203140806; ROSS R, 1986, CELL, V46, P155, DOI 10.1016/0092-8674(86)90733-6; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHWARTZ SM, 1986, CIRC RES, V58, P427, DOI 10.1161/01.RES.58.4.427; SCOTTBURDEN T, 1989, HYPERTENSION, V13, P295, DOI 10.1161/01.HYP.13.4.295; SESSA WC, 1990, P NATL ACAD SCI USA, V87, P8607, DOI 10.1073/pnas.87.21.8607; TABOR CW, 1984, ANNU REV BIOCHEM, V53, P749, DOI 10.1146/annurev.bi.53.070184.003533; TABOR CW, 1976, ANNU REV BIOCHEM, V45, P285, DOI 10.1146/annurev.bi.45.070176.001441; THYBERG J, 1987, EXP CELL RES, V170, P160, DOI 10.1016/0014-4827(87)90125-X; WANG H, 1991, NATURE, V352, P729, DOI 10.1038/352729a0; WHITE MF, 1985, BIOCHIM BIOPHYS ACTA, V822, P355, DOI 10.1016/0304-4157(85)90015-2; WU VS, 1984, BIOCHIM BIOPHYS ACTA, V804, P89, DOI 10.1016/0167-4889(84)90102-2; ZIERLER RE, 1982, ARCH SURG-CHICAGO, V117, P1408	32	41	42	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 17	1996	271	20					11838	11843		10.1074/jbc.271.20.11838	http://dx.doi.org/10.1074/jbc.271.20.11838			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UL250	8662668	hybrid			2022-12-25	WOS:A1996UL25000042
J	Luo, Y; Karpichev, IV; Kohanski, RA; Small, GM				Luo, Y; Karpichev, IV; Kohanski, RA; Small, GM			Purification, identification, and properties of a Saccharomyces cerevisiae oleate-activated upstream activating sequence-binding protein that is involved in the activation of POX1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTIONAL CONTROL; GENE; PROLIFERATION; YEAST; OXIDASE; MUTANTS; GAL4; DNA	Peroxisomes have a central function in lipid metabolism, and it is well established that these organelles are inducible by many compounds including fatty acids. Peroxisomes are the sole site for the beta-oxidation of fatty acids in yeast. The first and rate limiting enzyme of this cycle is fatty acyl-CoA oxidase. The gene encoding this enzyme in Saccharomyces cerevisiae (POX1) undergoes a complex regulation that is dependent on the growth environment. When this yeast is grown in medium containing oleic acid as the main carbon source, peroxisomes are induced and POX1 expression is activated. When cells are grown in the presence of glucose, the expression of POX1 mRNA is repressed, whereas growth on a carbon source such as glycerol or raffinose causes derepression. This rigorous regulation is brought about by the complex interactions between trans-acting factors and cis-elements in the POX1 promoter. Previously, we characterized regulatory elements in the promoter region of POX1 that are involved in the repression and activation of this gene (Wang, T., Luo, Y., and Small, G. M. (1994) J. Biol. Chem. 269, 24480-24485). In this study we have purified and identified an oleate-activated transcription factor (Oaf1p) that binds to the activating sequence (UAS1) in the POX1 gene. The protein has a predicted molecular mass of approximately 118 kDa.	CUNY MT SINAI SCH MED,DEPT CELL BIOL ANAT,NEW YORK,NY 10029; CUNY MT SINAI SCH MED,DEPT BIOCHEM,NEW YORK,NY 10029	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai								Ausubel FM, 1994, CURRENT PROTOCOLS MO; BUSSEY H, 1995, P NATL ACAD SCI USA, V92, P3809, DOI 10.1073/pnas.92.9.3809; CHELSTOWSKA A, 1995, J BIOL CHEM, V270, P18141, DOI 10.1074/jbc.270.30.18141; CREUSOT F, 1988, J MOL BIOL, V204, P263, DOI 10.1016/0022-2836(88)90574-8; DMOCHOWSKA A, 1990, GENE, V88, P247, DOI 10.1016/0378-1119(90)90038-S; EINERHAND AWC, 1991, EUR J BIOCHEM, V200, P113, DOI 10.1111/j.1432-1033.1991.tb21056.x; EINERHAND AWC, 1993, EUR J BIOCHEM, V214, P323, DOI 10.1111/j.1432-1033.1993.tb17927.x; EINERHAND AWC, 1995, MOL CELL BIOL, V15, P3405; ERDMANN R, 1989, P NATL ACAD SCI USA, V86, P5419, DOI 10.1073/pnas.86.14.5419; FERNANDEZ J, 1995, TECH PROT CHEM, V6, P135, DOI 10.1016/S1080-8914(06)80019-0; FERNANDEZ J, 1992, ANAL BIOCHEM, V201, P255, DOI 10.1016/0003-2697(92)90336-6; GUARENTE L, 1984, CELL, V36, P503, DOI 10.1016/0092-8674(84)90243-5; HIMMELFARB HJ, 1990, CELL, V63, P1299, DOI 10.1016/0092-8674(90)90425-E; JOHNSTON M, 1987, MICROBIOL REV, V51, P458, DOI 10.1128/MMBR.51.4.458-476.1987; KADONAGA JT, 1986, P NATL ACAD SCI USA, V83, P5889, DOI 10.1073/pnas.83.16.5889; KOS W, 1995, BBA-GENE STRUCT EXPR, V1264, P79, DOI 10.1016/0167-4781(95)00127-3; KUNAU WH, 1988, BIOCHEM SOC T, V16, P418, DOI 10.1042/bst0160418; LAUGHON A, 1984, MOL CELL BIOL, V4, P260, DOI 10.1128/MCB.4.2.260; LEWIN AS, 1990, MOL CELL BIOL, V10, P1399, DOI 10.1128/MCB.10.4.1399; LIAO XS, 1993, CELL, V72, P61, DOI 10.1016/0092-8674(93)90050-Z; MYLIN LM, 1989, GENE DEV, V3, P1157, DOI 10.1101/gad.3.8.1157; Oshima Y, 1982, MOL BIOL YEAST SACCH, P159; ROSENKRANTZ M, 1986, MOL CELL BIOL, V6, P4509, DOI 10.1128/MCB.6.12.4509; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; Sambrook J., 2002, MOL CLONING LAB MANU; SIMON M, 1992, YEAST, V8, P303, DOI 10.1002/yea.320080407; STANWAY CA, 1995, CURR GENET, V27, P404, DOI 10.1007/BF00311208; THOMAS BJ, 1989, CELL, V56, P619, DOI 10.1016/0092-8674(89)90584-9; VEENHUIS M, 1987, YEAST, V3, P77, DOI 10.1002/yea.320030204; WANG TW, 1994, J BIOL CHEM, V269, P24480; WANG TW, 1992, NUCLEIC ACIDS RES, V20, P3495, DOI 10.1093/nar/20.13.3495; WU C, 1987, SCIENCE, V238, P1247, DOI 10.1126/science.3685975; ZHANG JW, 1993, J CELL BIOL, V123, P1133, DOI 10.1083/jcb.123.5.1133	33	58	61	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 17	1996	271	20					12068	12075		10.1074/jbc.271.20.12068	http://dx.doi.org/10.1074/jbc.271.20.12068			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UL250	8662598	hybrid			2022-12-25	WOS:A1996UL25000073
J	ManzanoWinkler, B; Novina, CD; Roy, AL				ManzanoWinkler, B; Novina, CD; Roy, AL			TFII is required for transcription of the naturally TATA-less but initiator-containing V beta promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA POLYMERASE-II; BINDING PROTEIN; COMPLEX; SPECIFICITY; SEQUENCE; USF	The proximal or core promoter of a typical eukaryotic protein coding gene comprises distinct elements, TATA and/or initiator (Inr). The existence of TATA or Inr at the core promoter suggests that the mechanism of transcription initiation mediated by these two genetic elements may be different. Accordingly, it has been demon strated that the transcriptional requirements for the TATA-containing, Inr-less (TATA(+)Inr(-)) promoters are different from the transcriptional requirements for the TATA-less, Inr-containing (TATA(-)Inr(+)) promoters. Although both types of promoters require the transcription initiation factor (TFIID) in addition to other common initiation factors, a TATA(-)Inr(+) promoter requires accessory component(s). Here we have employed in vitro analyses to address the transcription factor requirements for a TATA(-)Inr(+) promoter. We demonstrate that in addition to TFIID, a naturally occurring TATA(-)Inr(+-) promoter requires TFII-I, an Inr element-dependent transcription factor. Consistent with its Inr element-dependent activities, TFII-I is dispensable for a TATA(+)Inr(-) promoter. Furthermore, we demonstrate that both TFII-I and TFIID activities in nuclear extracts are temperature-sensitive. However, TFII-I is heat-inactivated at temperatures lower than that required to inactivate TFIID. Therefore, differential heat treatment of nuclear extracts provides an assay to discriminate between transcriptional requirements at TATA(+)Inr(-) and TATA(-)Inr(+) promoters.	TUFTS UNIV,SCH MED,DEPT PATHOL,DIV IMMUNOL,SACKLER SCH GRAD STUDIES,BOSTON,MA 02111	Tufts University								ANDERSON SJ, 1988, P NATL ACAD SCI USA, V85, P3551, DOI 10.1073/pnas.85.10.3551; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; BURATOWSKI S, 1989, CELL, V56, P549, DOI 10.1016/0092-8674(89)90578-3; CARACAMO J, 1991, P NATL ACAD SCI USA, V88, P8052; CHIANG CM, 1993, EMBO J, V12, P2749, DOI 10.1002/j.1460-2075.1993.tb05936.x; DIGNAM JD, 1983, METHOD ENZYMOL, V101, P583; DU H, 1993, EMBO J, V12, P501, DOI 10.1002/j.1460-2075.1993.tb05682.x; HANSEN SK, 1995, CELL, V82, P565, DOI 10.1016/0092-8674(95)90029-2; JOHANSSON E, 1995, J BIOL CHEM, V270, P30162, DOI 10.1074/jbc.270.50.30162; KAUFMANN J, 1994, GENE DEV, V8, P821, DOI 10.1101/gad.8.7.821; MALDONADO E, 1990, MOL CELL BIOL, V10, P6335, DOI 10.1128/MCB.10.12.6335; MARTINEZ E, 1994, EMBO J, V13, P3115, DOI 10.1002/j.1460-2075.1994.tb06610.x; NAKAJIMA N, 1988, MOL CELL BIOL, V8, P4028, DOI 10.1128/MCB.8.10.4028; PARVIN JD, 1992, CELL, V68, P1135, DOI 10.1016/0092-8674(92)90084-P; PARVIN JD, 1993, CELL, V73, P533, DOI 10.1016/0092-8674(93)90140-L; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; PURNELL BA, 1994, GENE DEV, V8, P830, DOI 10.1101/gad.8.7.830; ROEDER RG, 1991, TRENDS BIOCHEM SCI, V16, P402, DOI 10.1016/0968-0004(91)90164-Q; ROY AL, 1994, INDIAN J BIOCHEM BIO, V31, P14; ROY AL, 1993, NATURE, V365, P359, DOI 10.1038/365359a0; ROY AL, 1991, NATURE, V354, P245, DOI 10.1038/354245a0; ROY AL, 1993, NATURE, V365, P355, DOI 10.1038/365355a0; SETO E, 1991, NATURE, V354, P241, DOI 10.1038/354241a0; SMALE ST, 1989, CELL, V57, P103, DOI 10.1016/0092-8674(89)90176-1; SMALE ST, 1990, P NATL ACAD SCI USA, V87, P4509, DOI 10.1073/pnas.87.12.4509; USHEVA A, 1994, CELL, V76, P1115, DOI 10.1016/0092-8674(94)90387-5; VANDYKE MW, 1988, SCIENCE, V241, P1335, DOI 10.1126/science.3413495; VERRIJZER CP, 1995, CELL, V81, P1115, DOI 10.1016/S0092-8674(05)80016-9; ZAWEL L, 1992, Current Opinion in Cell Biology, V4, P488, DOI 10.1016/0955-0674(92)90016-6; ZAWEL L, 1995, ANNU REV BIOCHEM, V64, P533	30	60	61	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 17	1996	271	20					12076	12081		10.1074/jbc.271.20.12076	http://dx.doi.org/10.1074/jbc.271.20.12076			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UL250	8662630	hybrid			2022-12-25	WOS:A1996UL25000074
J	Preece, G; Murphy, G; Ager, A				Preece, G; Murphy, G; Ager, A			Metalloproteinase-mediated regulation of L-selectin levels on leucocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-TERMINAL DOMAIN; PROTEIN-KINASE-C; CELL-SURFACE; CHEMOTACTIC FACTORS; HOMING RECEPTOR; ADHESION; ACTIVATION; LYMPHOCYTES; INHIBITORS; INVIVO	Leucocyte (L)-selectin can be proteolytically cleaved in the membrane proximal extracellular region to yield a soluble fragment that contains the functional lectin and epidermal growth factor domains. A variety of stimuli are known to stimulate L-selectin shedding including chemoattractants, phorbol esters, and L-selectin cross-linking; however, the enzymes that regulate L-selectin expression are not characterized, In this study we have used phorbol ester to stimulate endoproteolytic release of L-selectin and identified a major role for a cell surface metalloproteinase (L-selectin sheddase) in this process. The hydroxamic acid based inhibitor of zinc-dependent matrix metalloproteinases Ro 31-9790 completely prevented shedding of cell surface L-selectin from leucocytes in mouse, rat, and man, L-selectin was susceptible to cleavage by known matrix metalloproteinases. Recombinant human fibroblast collagenase (MMP1) reduced the number of L-selectin-positive lymphocytes to a similar extent as phorbol ester activation, and stromelysin (MMP3) had a partial effect on L-selectin expression, Gelatinases A (MMP2) and B (MMP9) were without effect, Lymphocytes did not express fibroblast collagenase or stromelysin at the cell surface, and tissue inhibitor of metalloproteinases (TIMP) did not affect L-selectin levels, L-selectin sheddase was not detected in media harvested from phorbol ester stimulated lymphocytes and was only able to cleave L selectin in the cis but not the trans configuration. These results suggest that endoproteolytic release of L-selectin from the leucocyte surface is mediated by a metalloproteinase (L-selectin sheddase), which is distinguishable from known matrix metalloproteinases. Understanding the regulation of L-selectin sheddase will be critical for controlling leucocyte migration from the blood.	NATL INST MED RES,DIV CELLULAR IMMUNOL,LONDON NW7 1AA,ENGLAND; STRANGEWAYS RES LAB,DEPT CELL & MOLEC BIOL,CAMBRIDGE CB1 4RN,ENGLAND	MRC National Institute for Medical Research				Ager, Ann/0000-0002-5763-8908				ARBONES ML, 1994, IMMUNITY, V1, P247, DOI 10.1016/1074-7613(94)90076-0; BAZIL V, 1993, P NATL ACAD SCI USA, V90, P3792, DOI 10.1073/pnas.90.9.3792; BAZIL V, 1994, J IMMUNOL, V152, P1314; BUHRER C, 1992, SCAND J IMMUNOL, V35, P107, DOI 10.1111/j.1365-3083.1992.tb02839.x; CHEN AJ, 1995, J EXP MED, V182, P519, DOI 10.1084/jem.182.2.519; CROWE PD, 1995, J EXP MED, V181, P1205, DOI 10.1084/jem.181.3.1205; GALLATIN WM, 1983, NATURE, V304, P30, DOI 10.1038/304030a0; GEARING AJH, 1994, NATURE, V370, P555, DOI 10.1038/370555a0; Johnson W H, 1987, J Enzyme Inhib, V2, P1, DOI 10.3109/14756368709030352; JUNG TM, 1990, J IMMUNOL, V144, P3130; JUTILA MA, 1991, CELL IMMUNOL, V132, P201, DOI 10.1016/0008-8749(91)90019-8; KAHN J, 1994, J CELL BIOL, V125, P461, DOI 10.1083/jcb.125.2.461; KANSAS GS, 1993, J EXP MED, V177, P833, DOI 10.1084/jem.177.3.833; KAYAGAKI N, 1995, J EXP MED, V182, P1777, DOI 10.1084/jem.182.6.1777; KISHIMOTO TK, 1989, SCIENCE, V245, P1238, DOI 10.1126/science.2551036; LABOW MA, 1994, IMMUNITY, V1, P709, DOI 10.1016/1074-7613(94)90041-8; LAWRENCE MB, 1995, EUR J IMMUNOL, V25, P1025, DOI 10.1002/eji.1830250425; LAWRENCE MB, 1994, IMMUNITY, V1, P137, DOI 10.1016/1074-7613(94)90107-4; LAWRENCE MB, 1991, CELL, V65, P859, DOI 10.1016/0092-8674(91)90393-D; LEY K, 1991, BLOOD, V77, P2553; MACKAY CR, 1993, CURR OPIN IMMUNOL, V5, P423, DOI 10.1016/0952-7915(93)90063-X; MAYADAS TN, 1993, CELL, V74, P541, DOI 10.1016/0092-8674(93)80055-J; MCEVER RP, 1994, CURR OPIN IMMUNOL, V6, P75, DOI 10.1016/0952-7915(94)90037-X; MCGEEHAN GM, 1994, NATURE, V370, P558, DOI 10.1038/370558a0; MIGAKI GI, 1995, J EXP MED, V182, P549, DOI 10.1084/jem.182.2.549; MOHLER KM, 1994, NATURE, V370, P218, DOI 10.1038/370218a0; MULLBERG J, 1995, J IMMUNOL, V155, P5198; MURPHY G, 1992, BIOCHEM J, V283, P637, DOI 10.1042/bj2830637; MURPHY G, 1992, J BIOL CHEM, V267, P9612; MURPHY G, 1991, BIOCHEMISTRY-US, V30, P8097, DOI 10.1021/bi00247a001; NAGASE H, 1990, BIOCHEMISTRY-US, V29, P5783, DOI 10.1021/bi00476a020; OCONNELL JP, 1994, J BIOL CHEM, V269, P14967; PALECANDA A, 1992, EUR J IMMUNOL, V22, P1279, DOI 10.1002/eji.1830220524; SATO H, 1994, NATURE, V370, P61, DOI 10.1038/370061a0; SCHLEIFFENBAUM B, 1992, J CELL BIOL, V119, P229, DOI 10.1083/jcb.119.1.229; SIEGELMAN MH, 1990, CELL, V61, P611, DOI 10.1016/0092-8674(90)90473-R; SMITH CW, 1991, J CLIN INVEST, V87, P609, DOI 10.1172/JCI115037; SPERTINI O, 1991, LEUKEMIA, V5, P300; SPRINGMAN EB, 1990, P NATL ACAD SCI USA, V87, P364, DOI 10.1073/pnas.87.1.364; TWOMEY B, 1990, BIOCHEM BIOPH RES CO, V171, P1087, DOI 10.1016/0006-291X(90)90795-O; UMEZAWA H, 1983, PROTEINASE INHIBITOR, P3; VONANDRIAN UH, 1991, P NATL ACAD SCI USA, V88, P7538, DOI 10.1073/pnas.88.17.7538; WATSON SR, 1991, NATURE, V349, P164, DOI 10.1038/349164a0; WOESSNER JF, 1991, FASEB J, V5, P2145, DOI 10.1096/fasebj.5.8.1850705; ZHANG LS, 1994, J IMMUNOL, V153, P3745	45	192	194	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 17	1996	271	20					11634	11640		10.1074/jbc.271.20.11634	http://dx.doi.org/10.1074/jbc.271.20.11634			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UL250	8662605	hybrid			2022-12-25	WOS:A1996UL25000011
J	Wilson, MP; Majerus, PW				Wilson, MP; Majerus, PW			Isolation of inositol 1,3,4-trisphosphate 5/6-kinase, cDNA cloning, and expression of the recombinant enzyme	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER; RECEPTOR ACTIVATION; METABOLISM; PHOSPHORYLATION; PHOSPHATES; CELLS; 1,3,4,6-TETRAKISPHOSPHATE; TETRAKISPHOSPHATE; 1,3-BISPHOSPHATE; TRISPHOSPHATE	Inositol 1,3,4-trisphosphate 5/6-kinase was purified 12,900-fold from calf brain using chromatography on heparin-agarose and affinity elution with inositol hexakisphosphate. The final preparation contained proteins of 48 and 36-38 kDa. All of these proteins had the same amino-terminal sequence and were enzymatically active. The smaller species represent proteolysis products with carboxyl-terminal truncation. The K-m of the enzyme for inositol 1,3,4-trisphosphate was 80 nM with a V-max of 60 nmol of product/min/mg of protein. The amino acid sequence of the tryptic peptide HSKLLARPAG-GLVGERTCNAXP matched the protein sequence encoded by a human expressed sequence tag clone (GB T09063) at 16 of 22 residues. The expressed sequence tag clone was used to screen a human fetal brain cDNA library to obtain a cDNA clone of 1991 base pairs (bp) that predicts a protein of 46 kDa. The clone encodes the amino-terminal amino acid sequence obtained from the purified calf brain preparation, suggesting that it represents its human homologue. The cDNA was expressed as a fusion protein in Escherichia coli and was found to have inositol 1,3,4-trisphosphate 5/6-kinase activity. Remarkably, both the purified calf brain and recombinant proteins produced both inositol 1,3,4,6-tetrakisphosphate and inositol 1,3,4,5-tetrakisphosphate as products in a ratio of 2.3-5:1. This finding proves that a single kinase phosphorylates inositol in both the D5 and D6 positions. Northern blot analysis identified a transcript of 3.6 kilobases in all tissues with the highest levels in brain. The composite cDNA isolated contains 3054 bp with a poly(A) tail, suggesting that 500-600 bp of 5' sequence remains to be identified.			Wilson, MP (corresponding author), WASHINGTON UNIV,SCH MED,DIV HEMATOL ONCOL,660 S EUCLID,BOX 8125,ST LOUIS,MO 63110, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL016634, T32HL007088, R37HL016634, P50HL014147] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 14147, HL 16634, HL 07088] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABDULLAH M, 1992, J BIOL CHEM, V267, P22340; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BALLA T, 1987, J BIOL CHEM, V262, P9952; BANSAL VS, 1987, J BIOL CHEM, V262, P9444; BARON CB, 1995, J BIOL CHEM, V270, P20459, DOI 10.1074/jbc.270.35.20459; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BUONO P, 1990, EUR J BIOCHEM, V192, P805, DOI 10.1111/j.1432-1033.1990.tb19294.x; CALDWELL KK, 1991, J BIOL CHEM, V266, P18378; CHOI KY, 1990, SCIENCE, V248, P64, DOI 10.1126/science.2157285; COCCO L, 1995, ADV ENZYME REGUL, V35, P23, DOI 10.1016/0065-2571(94)00004-M; Damen JE, 1996, P NATL ACAD SCI USA, V93, P1689, DOI 10.1073/pnas.93.4.1689; DOWNES CP, 1982, BIOCHEM J, V203, P169, DOI 10.1042/bj2030169; HANSEN CA, 1988, FEBS LETT, V236, P53, DOI 10.1016/0014-5793(88)80284-9; HUG H, 1993, BIOCHEM J, V291, P329, DOI 10.1042/bj2910329; HUGHES PJ, 1994, BBA-MOL CELL RES, V1223, P57, DOI 10.1016/0167-4889(94)90073-6; HUGHES PJ, 1989, J BIOL CHEM, V264, P19871; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LISCOVITCH M, 1995, CELL, V81, P659, DOI 10.1016/0092-8674(95)90525-1; MAYR GW, 1991, BIOCHEM J, V280, P631, DOI 10.1042/bj2800631; MENNITI FS, 1993, J BIOL CHEM, V268, P3850; NORRIS FA, 1995, J BIOL CHEM, V270, P16128, DOI 10.1074/jbc.270.27.16128; SHEARS SB, 1989, J BIOL CHEM, V264, P19879; SHEARS SB, 1987, BIOCHEM J, V246, P139, DOI 10.1042/bj2460139; SHEARS SB, 1991, PHARMACOL THERAPEUT, V49, P79, DOI 10.1016/0163-7258(91)90023-F; STEPHENS LR, 1988, BIOCHEM J, V253, P721, DOI 10.1042/bj2530721; YORK JD, 1990, P NATL ACAD SCI USA, V87, P9548, DOI 10.1073/pnas.87.24.9548; ZHANG XL, 1995, P NATL ACAD SCI USA, V92, P4853, DOI 10.1073/pnas.92.11.4853	28	68	76	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 17	1996	271	20					11904	11910		10.1074/jbc.271.20.11904	http://dx.doi.org/10.1074/jbc.271.20.11904			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UL250	8662638	hybrid			2022-12-25	WOS:A1996UL25000052
J	Reid, BG; Flynn, GC				Reid, BG; Flynn, GC			GroEL binds to and unfolds rhodanese posttranslationally	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEINS; ESCHERICHIA-COLI; MOLECULAR CHAPERONE; LIVER RHODANESE; SPECIFICITY; LYSOZYME; SYSTEMS; DNAK; BIP	The Escherichia coli chaperone GroEL is a member of a class of molecular chaperones that possesses a stacked double ring structure containing seven subunits per ring, with approximately 60-kDa subunits. It has been suggested that newly synthesized proteins may interact with a eukaryotic homolog of GroEL co-translationally, thereby sequestering the unfolded protein from other proteins in the cell. To test whether it is essential for GroEL to form a stable interaction with a nascent polypeptide co-translationally, we translated the well studied GroEL substrate rhodanese in bacterial and wheat germ translation extracts. We found that rhodanese formed stable complexes with GroEL solely posttranslationally. Upon binding to GroEL, the protease resistant N-terminal domain of rhodanese unfolds. This interaction with GroEL leads to productive folding of the full-length rhodanese. We conclude that GroEL is able to assist in the folding of newly synthesized proteins following release from the ribosome and that GroEL can unfold a trapped protein folding intermediate of rhodanese.	UNIV OREGON,INST MOLEC BIOL,EUGENE,OR 97403; UNIV OREGON,DEPT CHEM,EUGENE,OR 97403	University of Oregon; University of Oregon								BECKMANN RP, 1990, SCIENCE, V248, P850, DOI 10.1126/science.2188360; BLOBEL G, 1970, J CELL BIOL, V45, P130, DOI 10.1083/jcb.45.1.130; BLONDELGUINDI S, 1993, CELL, V75, P717, DOI 10.1016/0092-8674(93)90492-9; BOCHKAREVA ES, 1992, J BIOL CHEM, V267, P6796; BRAIG K, 1994, NATURE, V371, P578, DOI 10.1038/371578a0; CHEN BL, 1992, BIOCHEMISTRY-US, V31, P1464, DOI 10.1021/bi00120a025; ERIKSSON AE, 1993, J MOL BIOL, V229, P747, DOI 10.1006/jmbi.1993.1077; FEDOROV AN, 1992, J MOL BIOL, V228, P351, DOI 10.1016/0022-2836(92)90825-5; FLYNN GC, 1991, NATURE, V353, P726, DOI 10.1038/353726a0; FRYDMAN J, 1994, NATURE, V370, P111, DOI 10.1038/370111a0; GAITANARIS GA, 1994, MOL MICROBIOL, V14, P861, DOI 10.1111/j.1365-2958.1994.tb01322.x; GRAGEROV A, 1992, P NATL ACAD SCI USA, V89, P10341, DOI 10.1073/pnas.89.21.10341; Harlow E., 1988, ANTIBODIES LAB MANUA; HARTL FU, 1994, TRENDS BIOCHEM SCI, V19, P20, DOI 10.1016/0968-0004(94)90169-4; HEMMINGSEN SM, 1988, NATURE, V333, P330, DOI 10.1038/333330a0; KIM S, 1994, TRENDS BIOCHEM SCI, V19, P543, DOI 10.1016/0968-0004(94)90058-2; KUDLICKI W, 1994, J MOL BIOL, V244, P319, DOI 10.1006/jmbi.1994.1732; LAMINET AA, 1990, EMBO J, V9, P2315, DOI 10.1002/j.1460-2075.1990.tb07403.x; LANGER T, 1992, NATURE, V356, P683, DOI 10.1038/356683a0; LANGER T, 1992, EMBO J, V11, P4757, DOI 10.1002/j.1460-2075.1992.tb05581.x; MALKIN LI, 1967, J MOL BIOL, V26, P329, DOI 10.1016/0022-2836(67)90301-4; MARTIN J, 1991, NATURE, V352, P36, DOI 10.1038/352036a0; MATSUMURA M, 1989, SCIENCE, V243, P792, DOI 10.1126/science.2916125; MENDOZA JA, 1991, J BIOL CHEM, V266, P13587; MENDOZA JA, 1991, J BIOL CHEM, V266, P13044; PERARA E, 1986, SCIENCE, V232, P348, DOI 10.1126/science.3961485; PJURA PE, 1990, BIOCHEMISTRY-US, V29, P2592, DOI 10.1021/bi00462a023; PLOEGMAN JH, 1978, NATURE, V273, P124, DOI 10.1038/273124a0; Sambrook J., 2002, MOL CLONING LAB MANU; SMITH KE, 1995, J BIOL CHEM, V270, P21517, DOI 10.1074/jbc.270.37.21517; TODD MJ, 1994, SCIENCE, V265, P659, DOI 10.1126/science.7913555; WEILAND KL, 1991, BIOCHEM J, V275, P227, DOI 10.1042/bj2750227; WEISSMAN JS, 1994, CELL, V78, P693, DOI 10.1016/0092-8674(94)90533-9; YAFFE MB, 1992, NATURE, V358, P245, DOI 10.1038/358245a0; ZHANG T, 1993, BIOCHEMISTRY-US, V32, P12311, DOI 10.1021/bi00097a006; ZIEMIENOWICZ A, 1993, J BIOL CHEM, V268, P25425; ZUBAY G, 1973, ANNU REV GENET, V7, P267, DOI 10.1146/annurev.ge.07.120173.001411	37	22	22	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 22	1996	271	12					7212	7217		10.1074/jbc.271.12.7212	http://dx.doi.org/10.1074/jbc.271.12.7212			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UB157	8636159	hybrid			2022-12-25	WOS:A1996UB15700094
J	Hecker, D; Page, G; Lohrum, M; Weiland, S; Scheidtmann, KH				Hecker, D; Page, G; Lohrum, M; Weiland, S; Scheidtmann, KH			Complex regulation of the DNA-binding activity of p53 by phosphorylation: Differential effects of individual phosphorylation sites on the interaction with different binding motifs	ONCOGENE			English	Article						DNA-binding; p53; phosphorylation; okadaic acid; tumor suppressor protein	LARGE T-ANTIGEN; TUMOR-SUPPRESSOR PROTEIN; CASEIN KINASE-II; CELL-CYCLE CONTROL; WILD-TYPE; RAT-CELLS; 3T3 CELLS; TRANSCRIPTION; SEQUENCE; ONCOGENE	The tumor suppressor protein p53 exists in different phosphorylation states depending on the cellular environment and perhaps the stage of the cell cycle. These different phosphorylation states can be mimicked in the baculovirus expression system by employing the phosphatase inhibitor okadaic acid. Hyperphosphorylation of p53, particularly of Ser313 and/or Ser309, stimulated its DNA binding activity (Fuchs, Hecker and Scheidtmann, Eur. J. Biochem. 228, 625, 1995). Here we show that hyperphosphorylation of p53 has different effects on its DNA-binding activity, depending on the phosphorylation sites and the binding motif: (i) Phosphorylation of amino-terminal sites appeared to reduce binding to the RGC consensus motif, whereas additional phosphorylation of both, Ser313 and Ser309 led to enhanced binding. (ii) Upon hyperphosphorylation, binding to the RGC motif was enhanced whereas binding to the p53 response element of the bax1 gene promoter was diminished. (iii) DNA binding was also greatly enhanced by antibodies Pab 122 and 421 directed against the carboxyl terminus, but this latter effect was superimposed by the phosphorylation state of p53. Thus, the DNA binding activity of p53 appears to be regulated in a complex way in that (i) binding to a given sequence motif may be regulated by differential phosphorylation and/or by interaction with other factors; (ii) binding to different motifs may be modulated in opposite ways. Thus, the different genes that are regulated by p53 may be differently affected by these parameters.	UNIV BONN,INST GENET,ABT MOLEK GENET,D-53117 BONN,GERMANY	University of Bonn								BALL RK, 1984, EMBO J, V3, P1485, DOI 10.1002/j.1460-2075.1984.tb02000.x; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; BAUDIER J, 1992, P NATL ACAD SCI USA, V89, P11627, DOI 10.1073/pnas.89.23.11627; BISCHOFF JR, 1990, P NATL ACAD SCI USA, V87, P4766, DOI 10.1073/pnas.87.12.4766; BOSHART M, 1991, CELL, V66, P849, DOI 10.1016/0092-8674(91)90432-X; BRAIN R, 1994, ONCOGENE, V9, P1775; DRAPKIN R, 1994, NATURE, V368, P769, DOI 10.1038/368769a0; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELLEDGE SJ, 1994, CURR OPIN CELL BIOL, V6, P847, DOI 10.1016/0955-0674(94)90055-8; EWEN ME, 1995, GENE DEV, V9, P204, DOI 10.1101/gad.9.2.204; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FRITSCHE M, 1993, ONCOGENE, V8, P307; FUCHS B, 1995, EUR J BIOCHEM, V228, P625, DOI 10.1111/j.1432-1033.1995.0625m.x; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; GURNEY EG, 1980, J VIROL, V34, P752, DOI 10.1128/JVI.34.3.752-763.1980; HALL PA, 1993, ONCOGENE, V8, P203; HARPER JW, 1993, CELL, V75, P805; HEBEL M, 1986, Z NATURFORSCH C, V41, P94; HERRMANN CPE, 1991, ONCOGENE, V6, P877; HUPP TR, 1994, CURR BIOL, V4, P865, DOI 10.1016/S0960-9822(00)00195-0; HUPP TR, 1995, J BIOL CHEM, V270, P18165, DOI 10.1074/jbc.270.30.18165; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; JAMAL S, 1995, ONCOGENE, V10, P2095; JAYARAMAN L, 1995, CELL, V81, P1021, DOI 10.1016/S0092-8674(05)80007-8; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; KLAUSING K, 1988, J VIROL, V62, P1258, DOI 10.1128/JVI.62.4.1258-1265.1988; KORSMEYER SJ, 1993, SEMIN CANCER BIOL, V4, P327; LANE DP, 1990, GENE DEV, V4, P1, DOI 10.1101/gad.4.1.1; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LEE S, 1995, CELL, V81, P1013, DOI 10.1016/S0092-8674(05)80006-6; LEESMILLER SP, 1992, MOL CELL BIOL, V12, P5041, DOI 10.1128/MCB.12.11.5041; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LIN D, 1992, P NATL ACAD SCI USA, V89, P9210, DOI 10.1073/pnas.89.19.9210; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; LUO K, 1990, ONCOGENE, V5, P921; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; MCVEY D, 1989, NATURE, V341, P503, DOI 10.1038/341503a0; MEEK DW, 1988, MOL CELL BIOL, V8, P461, DOI 10.1128/MCB.8.1.461; MEEK DW, 1990, EMBO J, V9, P3253, DOI 10.1002/j.1460-2075.1990.tb07524.x; MILNE DM, 1992, NUCLEIC ACIDS RES, V20, P5565, DOI 10.1093/nar/20.21.5565; MILNE DM, 1992, ONCOGENE, V7, P1361; MILNE DM, 1994, J BIOL CHEM, V269, P9253; MILNER J, 1990, EMBO J, V9, P2885, DOI 10.1002/j.1460-2075.1990.tb07478.x; MIYASHITA T, 1995, CELL, V80, P293; MOHR IJ, 1987, EMBO J, V6, P153, DOI 10.1002/j.1460-2075.1987.tb04733.x; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; MOSNER B, 1995, EMBO J, V14, P4442; MULLER E, 1995, ONCOGENE, V10, P1175; MULLER E, 1993, ONCOGENE, V8, P2193; OBEROSLER P, 1993, EMBO J, V12, P2389, DOI 10.1002/j.1460-2075.1993.tb05893.x; OKAMOTO K, 1994, EMBO J, V13, P4816, DOI 10.1002/j.1460-2075.1994.tb06807.x; OREN M, 1992, CANCER METAST REV, V11, P141, DOI 10.1007/BF00048060; PATSCHINSKY T, 1992, J VIROL, V66, P3846, DOI 10.1128/JVI.66.6.3846-3859.1992; RAGIMOV N, 1993, ONCOGENE, V8, P1183; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; SAMAD A, 1986, P NATL ACAD SCI USA, V83, P897, DOI 10.1073/pnas.83.4.897; SCHEIDTMANN KH, 1982, J VIROL, V44, P116, DOI 10.1128/JVI.44.1.116-133.1982; SCHEIDTMANN KH, 1990, J VIROL, V64, P672, DOI 10.1128/JVI.64.2.672-679.1990; SCHEIDTMANN KH, 1994, INT J ONCOL, V5, P1353; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; SHIO Y, 1992, P NATL ACAD SCI USA, V89, P5206; SOUSSI T, 1988, NUCLEIC ACIDS RES, V16, P11384, DOI 10.1093/nar/16.23.11384; STEINMEYER K, 1988, ONCOGENE, V3, P501; STURZBECHER HW, 1990, ONCOGENE, V5, P795; SUMMERS MD, 1987, TEXAS EXP STATION B, V1555; TACK LC, 1992, J VIROL, V66, P1312, DOI 10.1128/JVI.66.3.1312-1320.1992; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; WADEEVANS A, 1985, EMBO J, V4, P699, DOI 10.1002/j.1460-2075.1985.tb03686.x; WANG XW, 1995, NAT GENET, V10, P188, DOI 10.1038/ng0695-188; WANG Y, 1992, P NATL ACAD SCI USA, V89, P4231, DOI 10.1073/pnas.89.10.4231; WANG Y, 1993, GENE DEV, V7, P2575, DOI 10.1101/gad.7.12b.2575; WANG Y, 1995, NATURE, V376, P88, DOI 10.1038/376088a0; WEINTRAUB H, 1991, P NATL ACAD SCI USA, V88, P4570, DOI 10.1073/pnas.88.11.4570; WEISSKER SN, 1992, ONCOGENE, V7, P1921; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; WU Y, 1994, EMBO J, V13, P4823, DOI 10.1002/j.1460-2075.1994.tb06808.x; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7; ZAUBERMAN A, 1995, ONCOGENE, V10, P2361	82	78	80	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR 7	1996	12	5					953	961						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UA884	8649812				2022-12-25	WOS:A1996UA88400002
J	KhannaGupta, A; Lopingco, MC; Savinelli, T; Zibello, T; Berliner, N; Perkins, AS				KhannaGupta, A; Lopingco, MC; Savinelli, T; Zibello, T; Berliner, N; Perkins, AS			Retroviral insertional activation of the EVI1 oncogene does not prevent G-CSF-induced maturation of the murine pluripotent myeloid cell line 32Dcl3	ONCOGENE			English	Article						G-CSF; myeloid leukemia; evil	COLONY-STIMULATING FACTOR; ZINC FINGER GENE; TRANSFORMING GENE; GRANULOCYTIC DIFFERENTIATION; EXPRESSION; SEQUENCE; LEUKEMIA; BINDING; PROTEIN; DNA	Evil is a myeloid-specific protooncogene that encodes 145 kDa and 88 kDa proteins via alternative splicing, Overexpression of the gene via retroviral insertion in murine tumors or chromosomal rearrangement in human tumors is associated with myeloid leukemias and myelodysplasias; however, the mechanism by which such overexpression leads to transformation is not clear, It has been postulated that overexpression of evil acts to block normal myelopoiesis. In attempts to assess the effect of overexpression of evil on myelopoiesis, we chose to utilize the IL-3-dependent murine 32Dcl3 cell line, which has been shown to differentiate in culture in response to G-CSP. Previous experiments with this cell line, which Ne have confirmed, showed that overexpression of evil, mediated by retroviral vector transfer, caused a block to G-CSF-induced cell survival and differentiation, We report here that the naive 32Dcl3 cell line contains a rearrangement of the evil locus and constitutively overexpresses evil mRNA and protein; this expression is downregulated only slightly during G-CSF-induced myeloid maturation, The steady state levels, molecular weight and DNA binding characteristics of the EVI1 protein in these cells is comparable to that seen in NFS 58, a myeloid leukemia cell line with retroviral insertion at evil, The observed ability of the murine 32Dcl3 cells to fully differentiate in the presence of G-CSF while evil continues to be expressed indicates that, at the levels expressed in naive 32Dcl3, evil does not block G-CSF-induced survival and differentiation, Thus, retroviral insertions at evil may have been selected for in 32Dcl3 cells due to effects other than that on G-CSF-induced cell survival.	YALE UNIV, SCH MED, DEPT PATHOL, NEW HAVEN, CT 06520 USA; YALE UNIV, SCH MED, DEPT INTERNAL MED, NEW HAVEN, CT 06520 USA	Yale University; Yale University					NIDDK NIH HHS [DK42347] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK042347] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BORDEREAUX D, 1990, ONCOGENE, V5, P925; CHATTOPADHYAY SK, 1980, J VIROL, V36, P499, DOI 10.1128/JVI.36.2.499-505.1980; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DELWEL R, 1993, MOL CELL BIOL, V13, P4291, DOI 10.1128/MCB.13.7.4291; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FICHELSON S, 1992, LEUKEMIA, V6, P93; FUNABIKI T, 1994, ONCOGENE, V9, P1575; GREENBERGER JS, 1983, FED PROC, V42, P2762; KADONAGA JT, 1986, P NATL ACAD SCI USA, V83, P5889, DOI 10.1073/pnas.83.16.5889; KREIDER BL, 1992, SCIENCE, V255, P1700, DOI 10.1126/science.1372755; KREIDER BL, 1993, P NATL ACAD SCI USA, V90, P6454, DOI 10.1073/pnas.90.14.6454; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEVY ER, 1994, BLOOD, V83, P1348; MIGLIACCIO G, 1989, J CELL BIOL, V109, P833, DOI 10.1083/jcb.109.2.833; MITANI K, 1994, EMBO J, V13, P504, DOI 10.1002/j.1460-2075.1994.tb06288.x; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; MORISHITA K, 1990, ONCOGENE, V5, P963; MORISHITA K, 1992, MOL CELL BIOL, V12, P183, DOI 10.1128/MCB.12.1.183; MORISHITA K, 1992, P NATL ACAD SCI USA, V89, P3937, DOI 10.1073/pnas.89.9.3937; MORISHITA K, 1988, CELL, V54, P831, DOI 10.1016/S0092-8674(88)91175-0; MORISHITA K, 1990, ONCOGENE, V5, P1419; MUCENSKI ML, 1988, MOL CELL BIOL, V8, P301, DOI 10.1128/MCB.8.1.301; NUCIFORA G, 1994, P NATL ACAD SCI USA, V91, P4004, DOI 10.1073/pnas.91.9.4004; OTTEN AD, 1988, MOL ENDOCRINOL, V2, P143, DOI 10.1210/mend-2-2-143; OVAL J, 1992, LEUKEMIA, V6, P446; PATEL G, 1993, MOL CELL BIOL, V13, P2269, DOI 10.1128/MCB.13.4.2269; PERKINS AS, 1991, MOL CELL BIOL, V11, P2665, DOI 10.1128/MCB.11.5.2665; PERKINS AS, 1991, DEVELOPMENT, V111, P479; PIERCE JH, 1988, SCIENCE, V239, P628, DOI 10.1126/science.3257584; ROVERA G, 1987, ONCOGENE, V1, P29; RUSSELL M, 1994, BLOOD, V84, P1243, DOI 10.1182/blood.V84.4.1243.bloodjournal8441243; SAWYERS CL, 1991, CELL, V64, P337, DOI 10.1016/0092-8674(91)90643-D; SUZUKAWA K, 1994, BLOOD, V84, P2681; TANAKA T, 1994, J BIOL CHEM, V269, P24020; VALTIERI M, 1987, J IMMUNOL, V138, P3829	35	28	28	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 1	1996	12	3					563	569						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TV597	8637713				2022-12-25	WOS:A1996TV59700013
J	Donald, RGK; Carter, D; Ullman, B; Roos, DS				Donald, RGK; Carter, D; Ullman, B; Roos, DS			Insertional tagging, cloning, and expression of the Toxoplasma gondii hypoxanthine-xanthine-guanine phosphoribosyltransferase gene - Use as a selectable marker for stable transformation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; MUTAGENESIS; SEQUENCE; CELLS; DNA; APICOMPLEXA; ARABIDOPSIS; ALLOPURINOL; METABOLISM; MUTATIONS	A nonhomologous integration vector was used to identify the Toxoplasma gondii hypoxanthine-xanthine-guanine phosphoribosyl transferase (HXGPRT) gene by insertional mutagenesis. Parasite mutants resistant to 6-thioxanthine arose at a frequency of similar to 3 x 10(-7). Genomic DNA flanking the insertion sites was retrieved by marker rescue and used to identify molecular clones exhibiting unambiguous homology to H(X)GPRT genes from other species. Sequence analysis of vector/genome junction sites reveals that integration of the linearized vector occurred with minimal rearrangement of either vector or target sequences, although the addition of filler DNA and small duplications or deletions of genomic sequences at the transgene termini was observed. Two differentially spliced classes of cDNA clones were identified, both of which complement hpt and gpt mutations in Escherichia coli. Kinetic analysis of purified recombinant enzyme revealed no significant differences between the two isoforms. Internally deleted clones spanning the genomic locus were used to create ''knock-out'' parasites, which lack all detectable HXGPRT activity. Complete activity could be restored to these knock out mutants by transient transformation with either genomic DNA or cDNA-derived minigenes encoding both enzyme isoforms. Stable HXGPRT(+) transformants were isolated under selection with mycophenolic acid, demonstrating the feasibility of HXGPRT as both a positive and negative selectable marker for stable transformation of T. gondii.	UNIV PENN, DEPT BIOL, PHILADELPHIA, PA 19104 USA; OREGON HLTH SCI UNIV, DEPT BIOCHEM & MOLEC BIOL, PORTLAND, OR 97201 USA	University of Pennsylvania; Oregon Health & Science University			Donald, Robert George Konrad/GNP-4958-2022; Carter, Darrick/N-3304-2016	Roos, David Siker/0000-0001-6725-4089; Carter, Darrick/0000-0001-5901-3402	NIAID NIH HHS [AI-31808, AI-28724, AI-23682] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI028724, U19AI031808, R01AI023682, R37AI028724, U01AI031808, R37AI023682] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALLEN TE, 1994, MOL BIOCHEM PARASIT, V65, P233, DOI 10.1016/0166-6851(94)90075-2; ALLEN TE, 1993, NUCLEIC ACIDS RES, V21, P5431, DOI 10.1093/nar/21.23.5431; BERG DE, 1984, COLD SPRING HARB SYM, V49, P215; Black M, 1995, MOL BIOCHEM PARASIT, V74, P55, DOI 10.1016/0166-6851(95)02483-2; BOOTHROYD JC, 1994, METHODS MOL GENET, V6, P1; BRENNER DA, 1984, COLD SPRING HARB SYM, V49, P151, DOI 10.1101/SQB.1984.049.01.018; CAVALIERSMITH T, 1993, MICROBIOL REV, V57, P953, DOI 10.1128/MMBR.57.4.953-994.1993; CRAIG SP, 1991, P NATL ACAD SCI USA, V88, P2500, DOI 10.1073/pnas.88.6.2500; DONALD RGK, 1994, MOL BIOCHEM PARASIT, V63, P243, DOI 10.1016/0166-6851(94)90060-4; DONALD RGK, 1995, P NATL ACAD SCI USA, V92, P5749, DOI 10.1073/pnas.92.12.5749; DONALD RGK, 1993, P NATL ACAD SCI USA, V90, P11703, DOI 10.1073/pnas.90.24.11703; EADS JC, 1994, CELL, V78, P325, DOI 10.1016/0092-8674(94)90301-8; EHRLICH SD, 1993, GENE, V135, P161, DOI 10.1016/0378-1119(93)90061-7; ELLIS J, 1993, GENE, V126, P163, DOI 10.1016/0378-1119(93)90363-8; FELDMANN KA, 1991, PLANT J, V1, P71, DOI 10.1111/j.1365-313X.1991.00071.x; FERNANDES AP, 1993, P NATL ACAD SCI USA, V90, P11608, DOI 10.1073/pnas.90.24.11608; GAGNON S, 1993, MOL BIOCHEM PARASIT, V60, P145, DOI 10.1016/0166-6851(93)90037-X; GALLERANO RH, 1990, AM J TROP MED HYG, V43, P159, DOI 10.4269/ajtmh.1990.43.159; GARFINKEL DJ, 1988, GENETICS, V120, P95; HENIKOFF S, 1993, TRENDS BIOCHEM SCI, V18, P267, DOI 10.1016/0968-0004(93)90179-Q; HERSHEY HV, 1986, GENE, V43, P287, DOI 10.1016/0378-1119(86)90218-0; HILLIS DM, 1993, SYST BIOL, V42, P182, DOI 10.2307/2992540; HOGLUND M, 1992, GENE, V116, P215, DOI 10.1016/0378-1119(92)90518-T; JOCHIMSEN B, 1975, MOL GEN GENET, V143, P85, DOI 10.1007/BF00269424; KIM K, 1993, SCIENCE, V262, P911, DOI 10.1126/science.8235614; KLECKNER N, 1983, MOBILE GENETIC ELEME, P261; KONCZ C, 1992, PLANT MOL BIOL, V20, P963, DOI 10.1007/BF00027166; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LUFT BJ, 1992, CLIN INFECT DIS, V15, P211, DOI 10.1093/clinids/15.2.211; MACKAY LC, 1993, GENET RES, V61, P177; Maniatis T., 1982, MOL CLONING; MARTINEZ S, 1992, NEW ENGL J MED, V326, P741, DOI 10.1056/NEJM199203123261105; MCCLARY JA, 1989, BIOTECHNIQUES, V7, P282; MCKEOWN M, 1992, ANNU REV CELL BIOL, V8, P133, DOI 10.1146/annurev.cb.08.110192.001025; Merrihew RV, 1996, MOL CELL BIOL, V16, P10; MESSINA M, 1995, GENE, V165, P213, DOI 10.1016/0378-1119(95)00548-K; MORTENSEN R, 1993, CURRENT PROTOCOLS S, V23; OPPERDOES FR, 1987, ANNU REV MICROBIOL, V41, P127, DOI 10.1146/annurev.mi.41.100187.001015; PARKERTHORNBURG J, 1987, CELL, V51, P763, DOI 10.1016/0092-8674(87)90099-7; PARMLEY SF, 1994, MOL BIOCHEM PARASIT, V66, P283, DOI 10.1016/0166-6851(94)90155-4; PELHAM HR, 1984, CELL, V37, P979; Pfefferkorn E.R., 1990, P26; PFEFFERKORN ER, 1978, EXP PARASITOL, V44, P26, DOI 10.1016/0014-4894(78)90077-2; PFEFFERKORN ER, 1984, INFECT IMMUN, V44, P211, DOI 10.1128/IAI.44.2.211-216.1984; PFEFFERKORN ER, 1978, J PARASITOL, V64, P486, DOI 10.2307/3279789; PFEFFERKORN ER, 1994, EXP PARASITOL, V79, P374, DOI 10.1006/expr.1994.1099; ROOS DS, 1994, METHOD CELL BIOL, V45, P27; ROOS DS, 1993, J BIOL CHEM, V268, P6269; ROTH DB, 1991, NUCLEIC ACIDS RES, V19, P7201, DOI 10.1093/nar/19.25.7201; ROTH DB, 1986, MOL CELL BIOL, V6, P4295, DOI 10.1128/MCB.6.12.4295; SCHULER GD, 1991, PROTEINS, V9, P180, DOI 10.1002/prot.340090304; SCHULER GD, 1996, IN PRESS METHODS ENZ; SCHWARTZMAN JD, 1982, EXP PARASITOL, V53, P77, DOI 10.1016/0014-4894(82)90094-7; SCHWARTZMAN JD, 1981, J PARASITOL, V67, P150, DOI 10.2307/3280627; SIBLEY LD, 1994, P NATL ACAD SCI USA, V91, P5508, DOI 10.1073/pnas.91.12.5508; SOLDATI D, 1995, MOL CELL BIOL, V15, P87, DOI 10.1128/MCB.15.1.87; SOLDATI D, 1993, SCIENCE, V260, P349, DOI 10.1126/science.8469986; Swofford D. L., 1991, PAUP PHYLOGENETIC AN; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; ULLMAN B, 1995, INFECT AGENT DIS, V4, P29; Ullman Buddy, 1995, MBL (Marine Biology Laboratory) Lectures in Biology, V12, P123; VICKERMAN K, 1994, INT J PARASITOL, V24, P1317, DOI 10.1016/0020-7519(94)90198-8; WOLTERS J, 1991, BIOSYSTEMS, V25, P75, DOI 10.1016/0303-2647(91)90014-C	64	335	345	0	6	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 14	1996	271	24					14010	14019		10.1074/jbc.271.24.14010	http://dx.doi.org/10.1074/jbc.271.24.14010			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UQ660	8662859	hybrid			2022-12-25	WOS:A1996UQ66000015
J	AlvarezDominguez, C; Barbieri, AM; Beron, W; WandingerNess, A; Stahl, PD				AlvarezDominguez, C; Barbieri, AM; Beron, W; WandingerNess, A; Stahl, PD			Phagocytosed live Listeria monocytogenes influences rab5-regulated in vitro phagosome-endosome fusion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTP-BINDING PROTEIN; RAB GERANYLGERANYL TRANSFERASE; MACROPHAGES; HEMOLYSIN; VESICLES; COMPLEMENT; TRANSPORT; INVITRO; GROWTH; SYSTEM	Survival or destruction of a pathogen following phagocytosis depends, in part, on fusion events between the phagosome and the endosomal or lysosomal compartments. Here we use an in vitro assay to show that phagosome-endosome fusion is regulated by the small GTPase rab5 and that fusion events are influenced by an internalized live organism, Listeria monocytogenes (LM), We compare the in vitro fusion of phagosomes containing heat-killed organisms (dead LM) with that of phagosomes containing a Live nonhemolytic mutant (live LM(hly-)). Unlike the wild-type organism, LM(hly-) remains trapped inside the phagosome. Phagosome-endosome fusion was reconstituted using biotinylated organisms and endosomes containing horseradish peroxidase conjugated with avidin, With both Five LM(hly-) and dead LM preparations, in vitro phagosome-endosome fusion was time-, temperature-, and cytosol-dependent. Live LM(hly-) phagosomes exhibited a faster rate of fusion, Fusion in both preparations was regulated by rab5 and possibly by other GTPases. Anti-rab5 antibodies and immunodepletion of cytostolic rab5 inhibited fusion. Addition of glutatione S-transferase-rab5 in the GTP form stimulated phagosome-endosome fusion, whereas addition of a dominant negative mutant of rab5 blocked fusion. Purified live LM(hly-) phagosomal membranes were enriched in rab5 as revealed by Western blotting, compared with dead LM phagosomes. Fusion of endosomes with dead LM containing phagosomes required ATP and was inhibited by ATP depletion and by N-ethylmaleimide (NEM) and anti-NEM-sensitive factor (NSF) antibodies, Unexpectedly, phagosome-endosome fusion with live LM(hly-)-containing phagosomes was not inhibited by ATP depletion nor by NEM or anti-NSF antibodies. Western blot analysis revealed that live LM(hly-)-containing phagosomes were enriched for membrane-bound NSF, while dead LM containing phagosomes contained low or undetectable quantities, Washing live LM(hly-)-containing phagosomes with 0.5 M KCl removed NSF associated with the membranes and rendered them NEM, ATP, anti-NSF antibody sensitive for fusion. We conclude that rab5 regulates phagosome-endosome fusion and that live microorganisms can up-regulate this process by recruiting rab5 to the membrane.	ST LOUIS UNIV,SCH MED,DEPT PHYSIOL & CELL BIOL,ST LOUIS,MO 63110; UNIV NACL CUYO,FAC CIENCIAS MED,CONICET,INST HISTOL & EMBRIOL,MENDOZA,ARGENTINA; NORTHWESTERN UNIV,DEPT BIOCHEM MOLEC BIOL & CELL BIOL,EVANSTON,IL 60208	Saint Louis University; Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET); University Nacional Cuyo Mendoza; Northwestern University			Wandinger-Ness, Angela/J-9104-2012; Alvarez-Dominguez, Carmen/J-4675-2014; Stahl, Philip/D-6315-2012	Wandinger-Ness, Angela/0000-0003-0613-3157; Alvarez-Dominguez, Carmen/0000-0002-4585-6959; 				ALEXANDROV K, 1994, EMBO J, V13, P5262, DOI 10.1002/j.1460-2075.1994.tb06860.x; ALVAREZDOMINGUEZ C, 1993, INFECT IMMUN, V61, P3664, DOI 10.1128/IAI.61.9.3664-3672.1993; ANDRES DA, 1993, CELL, V73, P1091, DOI 10.1016/0092-8674(93)90639-8; BARBIERI MA, 1994, J BIOL CHEM, V269, P18720; BERON W, 1995, ARCH BIOCHEM BIOPHYS, V317, P337, DOI 10.1006/abbi.1995.1172; BOMSEL M, 1992, MOL BIOL CELL, V3, P1317, DOI 10.1091/mbc.3.12.1317; BOUVIER G, 1994, J LEUKOCYTE BIOL, V55, P729, DOI 10.1002/jlb.55.6.729; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CLUFF CW, 1990, INFECT IMMUN, V58, P3601, DOI 10.1128/IAI.58.11.3601-3612.1990; COSSART P, 1989, INFECT IMMUN, V57, P3629, DOI 10.1128/IAI.57.11.3629-3636.1989; DECHASTELLIER C, 1994, INFECT IMMUN, V62, P543, DOI 10.1128/IAI.62.2.543-553.1994; DESJARDINS M, 1994, J BIOL CHEM, V269, P32194; DESJARDINS M, 1994, J CELL BIOL, V124, P677, DOI 10.1083/jcb.124.5.677; DIAZ R, 1988, J BIOL CHEM, V263, P6093; DIRACSVEJSTRUP AB, 1994, J BIOL CHEM, V269, P15427; DREVETS DA, 1991, INFECT IMMUN, V59, P2645, DOI 10.1128/IAI.59.8.2645-2652.1991; ELAZAR Z, 1994, J BIOL CHEM, V269, P794; GALLIARD JL, 1987, INFECT IMMUN, V55, P2822; GARRETT MD, 1994, EMBO J, V13, P1718, DOI 10.1002/j.1460-2075.1994.tb06436.x; GOUD B, 1991, Current Opinion in Cell Biology, V3, P626, DOI 10.1016/0955-0674(91)90033-U; GRAY ML, 1966, BACTERIOL REV, V30, P309, DOI 10.1128/MMBR.30.2.309-382.1966; GRIFFITHS G, 1984, J ULTRA MOL STRUCT R, V89, P65, DOI 10.1016/S0022-5320(84)80024-6; GRUENBERG J, 1989, J CELL BIOL, V108, P1301, DOI 10.1083/jcb.108.4.1301; GRUENBERG J, 1992, Current Opinion in Cell Biology, V4, P593, DOI 10.1016/0955-0674(92)90077-P; HARDING CV, 1992, J CELL BIOL, V119, P531, DOI 10.1083/jcb.119.3.531; IKONEN E, 1995, CELL, V81, P571, DOI 10.1016/0092-8674(95)90078-0; JONES S, 1994, INFECT IMMUN, V62, P5608, DOI 10.1128/IAI.62.12.5608-5613.1994; KOCKS C, 1992, CELL, V68, P521, DOI 10.1016/0092-8674(92)90188-I; KUHN M, 1988, INFECT IMMUN, V56, P79, DOI 10.1128/IAI.56.1.79-82.1988; LANG T, 1985, BIOL CELL, V53, P149, DOI 10.1111/j.1768-322X.1985.tb00362.x; LI GP, 1994, J BIOL CHEM, V269, P14631; LI GP, 1993, J BIOL CHEM, V268, P24475; MAYORGA LS, 1991, J BIOL CHEM, V266, P6511; MAYORGA LS, 1989, SCIENCE, V244, P1475, DOI 10.1126/science.2499930; MAYORGA LS, 1989, CELL REGUL, V1, P113, DOI 10.1091/mbc.1.1.113; Mengaud J, 1996, CELL, V84, P923, DOI 10.1016/S0092-8674(00)81070-3; OTSUKA FL, 1984, J NUCL MED, V25, P1343; PITT A, 1992, J CLIN INVEST, V90, P1978, DOI 10.1172/JCI116077; PITT A, 1992, J BIOL CHEM, V267, P126; PORTNOY DA, 1988, J EXP MED, V167, P1459, DOI 10.1084/jem.167.4.1459; QIU Y, 1994, J CELL BIOL, V125, P595, DOI 10.1083/jcb.125.3.595; RODRIGUEZ L, 1994, MOL BIOL CELL, V5, P773, DOI 10.1091/mbc.5.7.773; SASAKI T, 1990, J BIOL CHEM, V265, P2333; SEABRA MC, 1991, CELL, V65, P429, DOI 10.1016/0092-8674(91)90460-G; SEABRA MC, 1992, J BIOL CHEM, V267, P14497; SHIRATAKI H, 1992, J BIOL CHEM, V267, P10946; SLOT JW, 1991, J CELL BIOL, V113, P123, DOI 10.1083/jcb.113.1.123; SOLDATI T, 1993, MOL BIOL CELL, V4, P425, DOI 10.1091/mbc.4.4.425; STURGILLKOSZYCKI S, 1994, SCIENCE, V263, P678, DOI 10.1126/science.8303277; TILNEY LG, 1989, J CELL BIOL, V109, P1597, DOI 10.1083/jcb.109.4.1597; TOKUYASU KT, 1980, HISTOCHEM J, V12, P381, DOI 10.1007/BF01011956; ULLRICH O, 1994, NATURE, V368, P157, DOI 10.1038/368157a0; WATTENBERG BW, 1992, J CELL BIOL, V118, P1321, DOI 10.1083/jcb.118.6.1321; WEINBERG DS, 1981, J IMMUNOL, V126, P794; WHITEHEART SW, 1994, J CELL BIOL, V126, P945, DOI 10.1083/jcb.126.4.945; Zerial M, 1993, CURR OPIN CELL BIOL, V5, P613, DOI 10.1016/0955-0674(93)90130-I; ZIEGLER K, 1981, J IMMUNOL, V127, P1869	57	112	116	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 7	1996	271	23					13834	13843		10.1074/jbc.271.23.13834	http://dx.doi.org/10.1074/jbc.271.23.13834			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UP385	8662791	hybrid			2022-12-25	WOS:A1996UP38500080
J	Herrmann, C; Volknandt, W; Wittich, B; Kellner, R; Zimmermann, H				Herrmann, C; Volknandt, W; Wittich, B; Kellner, R; Zimmermann, H			The major vault protein (MVP100) is contained in cholinergic nerve terminals of electric ray electric organ	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYNAPTIC VESICLES; RIBONUCLEOPROTEIN-PARTICLES; SMALL RNA; SV2; GLYCOPROTEIN; PROTEOGLYCAN; COMPLEX; BRAIN	A protein of M(r) 100,000 (MVP100) is highly enriched in the electromotor system of electric rays, Biochemical analysis indicates that MVP100 is contained in the cholinergic nerve terminals of Torpedo electric organ as part of a large cytosolic complex. On sucrose density gradient centrifugation MVP100 comigrates with synaptic vesicles or synaptosomes. It can be partially separated from synaptic vesicles by gel filtration or glycerol velocity gradient centrifugation. Within the complex MVP100 behaves like a hydrophobic protein and is protected against proteolytic attack. MVP100 can be immunodetected by are antibody against phosphotyrosine, and it becomes phosphorylated on incubation with [gamma-P-32]ATP. By screening an electric ray electric lobe cDNA library the primary structure of MVP100 was analyzed MVP100 is highly homologous to the major vault proteins of slime mold and rat and to the human lung resistance-related protein. Compared with non-neural tissues the expression of MVP100 is highest in brain and enriched in the electric lobe that contains the somata of the electromotor neurons. Immunoelectron microscopic analysis reveals a close association of MVP100 and synaptic vesicles in the nerve terminals of the electric organ.	UNIV FRANKFURT, INST ZOOL, AK NEUROCHEM, BIOZENTRUM, D-60439 FRANKFURT, GERMANY; EUROPEAN MOLEC BIOL LAB, D-69012 HEIDELBERG, GERMANY	Goethe University Frankfurt; European Molecular Biology Laboratory (EMBL)								BAJJALIEH SM, 1992, SCIENCE, V257, P1271, DOI 10.1126/science.1519064; BENFENATI F, 1993, NEUROCHEM INT, V23, P27, DOI 10.1016/0197-0186(93)90140-Z; BORDIER C, 1981, J BIOL CHEM, V256, P1604; BUCKLEY K, 1985, J CELL BIOL, V100, P1284, DOI 10.1083/jcb.100.4.1284; CHUGANI DC, 1991, J NEUROSCI, V11, P256; CHUGANI DC, 1993, J CELL SCI, V106, P23; CLIFTOGRADY L, 1990, J CELL BIOL, V110, P1693, DOI 10.1083/jcb.110.5.1693; ELLMAN GL, 1961, BIOCHEM PHARMACOL, V7, P88, DOI 10.1016/0006-2952(61)90145-9; FEANY MB, 1992, CELL, V70, P861, DOI 10.1016/0092-8674(92)90319-8; JANETZKO A, 1989, NEUROSCIENCE, V32, P65, DOI 10.1016/0306-4522(89)90108-5; KEDERSHA NL, 1990, J CELL BIOL, V110, P895, DOI 10.1083/jcb.110.4.895; KEDERSHA NL, 1990, MOL BIOL REP, V14, P121, DOI 10.1007/BF00360441; KEDERSHA NL, 1986, J CELL BIOL, V103, P699, DOI 10.1083/jcb.103.3.699; KICKHOEFER VA, 1994, GENE, V151, P257, DOI 10.1016/0378-1119(94)90667-X; KICKHOEFER VA, 1993, J BIOL CHEM, V268, P7868; LI ZY, 1983, J NEUROCHEM, V40, P338, DOI 10.1111/j.1471-4159.1983.tb11288.x; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; Rome L, 1991, Trends Cell Biol, V1, P47, DOI 10.1016/0962-8924(91)90088-Q; SCHAFFNE.W, 1973, ANAL BIOCHEM, V56, P502, DOI 10.1016/0003-2697(73)90217-0; SCHEFFER GL, 1995, NAT MED, V1, P578, DOI 10.1038/nm0695-578; SCRANTON TW, 1993, J NEUROCHEM, V61, P29, DOI 10.1111/j.1471-4159.1993.tb03535.x; SHERIDAN MN, 1965, J CELL BIOL, V24, P129, DOI 10.1083/jcb.24.1.129; SPECTOR T, 1978, ANAL BIOCHEM, V86, P142, DOI 10.1016/0003-2697(78)90327-5; STANLEY PE, 1969, ANAL BIOCHEM, V29, P381, DOI 10.1016/0003-2697(69)90323-6; VASU SK, 1995, J BIOL CHEM, V270, P16588, DOI 10.1074/jbc.270.28.16588; VASU SK, 1993, J BIOL CHEM, V268, P15356; VILALTA A, 1994, J BIOL CHEM, V269, P29752; VOLKNANDT W, 1988, NEUROCHEM INT, V12, P337, DOI 10.1016/0197-0186(88)90172-6; VOLKNANDT W, 1990, NEUROCHEM INT, V16, P539, DOI 10.1016/0197-0186(90)90014-K; VOLKNANDT W, 1986, J NEUROCHEM, V47, P1449, DOI 10.1111/j.1471-4159.1986.tb00778.x; VOLKNANDT W, 1990, EMBO J, V9, P2465, DOI 10.1002/j.1460-2075.1990.tb07424.x; VOLKNANDT W, 1991, MOL BRAIN RES, V11, P283, DOI 10.1016/0169-328X(91)90037-X	32	40	41	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 7	1996	271	23					13908	13915		10.1074/jbc.271.23.13908	http://dx.doi.org/10.1074/jbc.271.23.13908			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UP385	8662815	hybrid			2022-12-25	WOS:A1996UP38500090
J	Parker, A; Clarke, JB; Busby, WH; Clemmons, DR				Parker, A; Clarke, JB; Busby, WH; Clemmons, DR			Identification of the extracellular matrix binding sites for insulin-like growth factor-binding protein 5	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-CLONING; FORMS; BETAGLYCAN; MEMBRANE; RECEPTOR; SERUM; BETA; RAT	Fibroblast extracellular matrix (ECM) contains two forms of insulin-like growth factor-binding proteins (IGFBPs), IGFBP-3 and IGFBP-5, These studies were undertaken to identify the regions within IGFBP-5 that mediate its binding to fibroblast ECM, Synthetic peptides were prepared that were homologous with two regions of basic amino acids within IGFBP-5 (Arg(201)-Arg(218) and Ala(131)-Thr(141)), Increasing concentrations of both peptides competed with IGFBP-5 for binding to ECM but the Arg(201)-Arg(218) peptide was more potent, Mutagenesis was used to define the effect of substituting for these basic residues on ECM binding, Substitution for two peptide B residues K134A and R136A reduced binding by 40%, Substitution of a single basic residue within the peptide A region (K211N) reduced binding to ECM by 49%, Substitution for R211N, K134A, and R136A reduced binding by 52%. More extensive substitutions in the peptide A region, e.g. K211N,R214A,K217A,R218N, resulted in a greater (e.g. 88%) decrease. The positional location of basic residues appeared to be more important than the total number of substitutions since the mutant K202N,R206A,R207A had a 79% reduction in ECM binding, Two basic regions of IGFBP-5 contribute to its binding to ECM, but the region containing amino acids 201-218 has a greater contribution. ECM binding is mediated by charged residues and acts to stabilize IGFBP-5 by protecting it from proteolysis.	UNIV N CAROLINA, DEPT MED, DIV ENDOCRINOL, SCH MED, CHAPEL HILL, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine					NIA NIH HHS [AG-02331] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R01AG002331, R37AG002331] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ANDRES JL, 1989, J CELL BIOL, V109, P3137, DOI 10.1083/jcb.109.6.3137; ARAI T, 1994, ENDOCRINOLOGY, V135, P2358, DOI 10.1210/en.135.6.2358; ARAI T, 1994, J BIOL CHEM, V269, P20388; Ausubel FM, 1994, CURRENT PROTOCOLS MO; BASHKIN P, 1989, BIOCHEMISTRY-US, V28, P1737, DOI 10.1021/bi00430a047; BAXTER RC, 1991, MODERN CONCEPTS INSU, P371; BUSBY WH, 1988, J BIOL CHEM, V263, P14203; CAMACHOHUBNER C, 1992, J BIOL CHEM, V267, P11949; FOLKMAN J, 1988, AM J PATHOL, V130, P393; HOSSENLOPP P, 1986, ANAL BIOCHEM, V154, P138, DOI 10.1016/0003-2697(86)90507-5; JONES JI, 1993, J CELL BIOL, V121, P679, DOI 10.1083/jcb.121.3.679; KEIFER MC, 1991, J BIOL CHEM, V266, P9043; KNUTSON BS, 1988, J CLIN INVEST, V80, P1082; LAIHO M, 1989, CANCER RES, V49, P2533; LOPEZCASILLAS F, 1993, CELL, V73, P1435, DOI 10.1016/0092-8674(93)90368-Z; MADRI JA, 1991, J CELL BIOCHEM, V45, P123, DOI 10.1002/jcb.240450202; MERRIFIELD RB, 1964, J AM CHEM SOC, V86, P304, DOI 10.1021/ja01056a056; NAM TJ, 1994, ENDOCRINOLOGY, V135, P1385, DOI 10.1210/en.135.4.1385; OLSEN BR, 1989, CONNECT TISSUE RES, V23, P1115; ROBERTS R, 1988, NATURE, V332, P376, DOI 10.1038/332376a0; RUOSLAHTI E, 1988, ANNU REV CELL BIOL, V4, P229, DOI 10.1146/annurev.cb.04.110188.001305; SAMBROOK J, 1989, MOL CLONING LAB MANU, P13454; SCHASTEEN CS, 1991, MOL IMMUNOL, V28, P17, DOI 10.1016/0161-5890(91)90082-U; SEIFFERT D, 1991, J BIOL CHEM, V266, P2824; SHIMASAKI S, 1991, J BIOL CHEM, V266, P10646; SHIMASAKI S, 1991, MOL ENDOCRINOL, V5, P938, DOI 10.1210/mend-5-7-938; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W; YOON JB, 1987, J BIOL CHEM, V262, P4284	28	67	69	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 7	1996	271	23					13523	13529		10.1074/jbc.271.23.13523	http://dx.doi.org/10.1074/jbc.271.23.13523			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UP385	8662813	hybrid, Green Published			2022-12-25	WOS:A1996UP38500034
J	Burnham, MR; Harte, MT; Richardson, A; Parsons, JT; Bouton, AH				Burnham, MR; Harte, MT; Richardson, A; Parsons, JT; Bouton, AH			The identification of p130(cas)-binding proteins and their role in cellular transformation	ONCOGENE			English	Article						p130(cas); SRC; CRK; SH2 domain; SH3 domain	PHOSPHOTYROSINE-CONTAINING PROTEINS; CRK ONCOGENE PRODUCT; SRC SH2 DOMAIN; STABLE ASSOCIATION; V-CRK; TYROSINE PHOSPHORYLATION; MONOCLONAL-ANTIBODIES; BINDING; PP60SRC; CELLS	Adaptor proteins play an important role in signal transduction by regulating the establishment and maintenance of functionally important protein complexes, A recently described member of this group of proteins is p130(cas) (CAS), which contains numerous sequence motifs predicted to be involved in mediating protein-protein interactions, We propose that adaptor molecules like GAS may help determine the response of a cell to a particular signal by interacting with specific subsets of cellular proteins. To test this hypothesis, we have identified potential binding partners of CAS that may play a role in cellular transformation by the oncoproteins v-SRC and/or v-CRK. We show that individual domains of CAS associate with specific subsets of proteins in vitro, and that many of these interactions are dependent on the state of tyrosine-phosphorylation of GAS. Sequences necessary for interacting with the focal adhesion kinase pp125(FAK) (FAK), v-SRC and v-CRK have been mapped to distinct regions of CAS. In addition, the identification of a number of putative GAS-binding partners that are present in crk-transformed cell extracts but undetectable in normal and src-transformed cell extracts supports a model in which unique protein complexes are formed in response to different signals.	UNIV VIRGINIA, DEPT MICROBIOL, CHARLOTTESVILLE, VA 22908 USA; UNIV VIRGINIA, CTR CANC, CHARLOTTESVILLE, VA 22908 USA	University of Virginia; University of Virginia			Richardson, Alan/E-7615-2010; Richardson, Alan/I-4631-2015	Richardson, Alan/0000-0003-1825-3375	NATIONAL CANCER INSTITUTE [P01CA040042, R01CA029243, R37CA029243] Funding Source: NIH RePORTER; NCI NIH HHS [CA 29243, CA 40042] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AUVINEN M, 1995, MOL CELL BIOL, V15, P6513; BIBBINS KB, 1993, MOL CELL BIOL, V13, P7278, DOI 10.1128/MCB.13.12.7278; BIRGE RB, 1992, J BIOL CHEM, V267, P10588; BIRGE RB, 1993, MOL CELL BIOL, V13, P4648, DOI 10.1128/MCB.13.8.4648; BOUTON AH, 1991, MOL CARCINOGEN, V4, P145, DOI 10.1002/mc.2940040210; BOUTON AH, 1991, MOL CELL BIOL, V11, P945, DOI 10.1128/MCB.11.2.945; CARRAWAY KL, 1994, CELL, V78, P5, DOI 10.1016/0092-8674(94)90564-9; CHARDIN P, 1995, FEBS LETT, V369, P47, DOI 10.1016/0014-5793(95)00578-W; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; DEJONG R, 1995, J BIOL CHEM, V270, P21468, DOI 10.1074/jbc.270.37.21468; ECK MJ, 1993, NATURE, V362, P87, DOI 10.1038/362087a0; FELLER SM, 1994, TRENDS BIOCHEM SCI, V19, P453, DOI 10.1016/0968-0004(94)90129-5; FELLER SM, 1994, EMBO J, V13, P2341, DOI 10.1002/j.1460-2075.1994.tb06518.x; FENG SB, 1994, SCIENCE, V266, P1241, DOI 10.1126/science.7526465; HARTE MT, 1996, IN PRESS J BIOL CHEM; HILDEBRAND JD, 1995, IN PRESS MOL BIOL CE; HILDEBRAND JD, 1996, IN PRESS MOL CELL BI, V16; Ishino M, 1995, ONCOGENE, V11, P2331; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; KAMPS MP, 1988, ONCOGENE, V2, P305; KANNER SB, 1991, EMBO J, V10, P1689, DOI 10.1002/j.1460-2075.1991.tb07693.x; KANNER SB, 1989, ONCOGENE, V4, P295; KANNER SB, 1990, P NATL ACAD SCI USA, V87, P3328, DOI 10.1073/pnas.87.9.3328; Keller Susanne R., 1994, Trends in Cell Biology, V4, P115, DOI 10.1016/0962-8924(94)90065-5; LIM WA, 1994, NATURE, V372, P375, DOI 10.1038/372375a0; MATSUDA M, 1990, SCIENCE, V248, P1537, DOI 10.1126/science.1694307; MATSUDA M, 1991, MOL CELL BIOL, V11, P1607, DOI 10.1128/MCB.11.3.1607; MATSUDA M, 1994, MOL CELL BIOL, V14, P5495, DOI 10.1128/MCB.14.8.5495; MAYER BJ, 1988, NATURE, V332, P272, DOI 10.1038/332272a0; MAYER BJ, 1990, P NATL ACAD SCI USA, V87, P2638, DOI 10.1073/pnas.87.7.2638; Mayer Bruce J., 1993, Trends in Cell Biology, V3, P8, DOI 10.1016/0962-8924(93)90194-6; MYERS MG, 1994, TRENDS BIOCHEM SCI, V19, P289, DOI 10.1016/0968-0004(94)90007-8; NOJIMA Y, 1995, J BIOL CHEM, V270, P15398, DOI 10.1074/jbc.270.25.15398; OGAWA S, 1994, ONCOGENE, V9, P1669; PARSONS SJ, 1984, J VIROL, V51, P272, DOI 10.1128/JVI.51.2.272-282.1984; PASCAL SM, 1994, CELL, V77, P461, DOI 10.1016/0092-8674(94)90160-0; PATCH LA, 1995, J CELL SCI, V108, P1371; PAWSON T, 1993, CURR BIOL, V3, P434, DOI 10.1016/0960-9822(93)90350-W; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; POLTE TR, 1995, P NATL ACAD SCI USA, V92, P10678, DOI 10.1073/pnas.92.23.10678; REN RB, 1994, GENE DEV, V8, P783, DOI 10.1101/gad.8.7.783; REYNOLDS AB, 1989, MOL CELL BIOL, V9, P3951, DOI 10.1128/MCB.9.9.3951; SAKAI R, 1994, J BIOL CHEM, V269, P32740; SAKAI R, 1994, EMBO J, V13, P3748, DOI 10.1002/j.1460-2075.1994.tb06684.x; SCHAFFHAUSEN B, 1995, BBA-REV CANCER, V1242, P61, DOI 10.1016/0304-419X(95)00004-Y; SCHALLER MD, 1995, MOL CELL BIOL, V15, P2635; SEUFFERLEIN T, 1994, J BIOL CHEM, V269, P9345; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; VUORI K, 1995, J BIOL CHEM, V270, P22259, DOI 10.1074/jbc.270.38.22259; WAKSMAN G, 1993, CELL, V72, P779, DOI 10.1016/0092-8674(93)90405-F; WAKSMAN G, 1992, NATURE, V358, P646, DOI 10.1038/358646a0; YU HT, 1994, CELL, V76, P933, DOI 10.1016/0092-8674(94)90367-0; ZACHARY I, 1992, J BIOL CHEM, V267, P19031; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	54	92	93	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 6	1996	12	11					2467	2472						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UQ220	8649789				2022-12-25	WOS:A1996UQ22000026
J	Marin, MC; Fernandez, A; Bick, RJ; Brisbay, S; Buja, M; Snuggs, M; McConkey, DJ; vonEschenbach, AC; Keating, MJ; McDonnell, TJ				Marin, MC; Fernandez, A; Bick, RJ; Brisbay, S; Buja, M; Snuggs, M; McConkey, DJ; vonEschenbach, AC; Keating, MJ; McDonnell, TJ			Apoptosis suppression by bcl-2 is correlated with the regulation of nuclear and cytosolic Ca2+	ONCOGENE			English	Article						apoptosis; cell death; bcl-2; calcium	PROGRAMMED CELL-DEATH; RAT-LIVER NUCLEI; DNA FRAGMENTATION; ENDOPLASMIC-RETICULUM; CA-2+ CONCENTRATION; OXIDATIVE STRESS; PROSTATE-CANCER; CALCIUM; PROTEIN; ONCOPROTEIN	Bcl-2 expression is associated with the progression of prostate cancer from androgen-dependence to androgen-independence, Bcl-2 is an integral membrane protein which localizes to mitochondria, endoplasmic reticulum, and the nuclear envelope, Using spectrofluorometry and laser confocal microscopy, the ability of bcl-2 to modulate intracellular Ca2+ was examined in the Dunning G prostate carcinoma cell line following apoptosis induction by adriamycin, Adriamycin and thapsigargin, an endoplasmic reticulum Ca2+-pump inhibitor, were effective inducers of apoptosis in control, but not bcl-2 transfected, cells, Treatment with adriamycin was accompanied by a sustained rise in cytoplasmic Ca2+ in control and bcl-2 transfected cells, An increase in intranuclear Ca2+ was observed in control cells only, Apoptosis induction by thapsigargin was associated with an increase in cytoplasmic Ca2+ in control cells that was not detected in the resistant bcl-2 transfectants, Ca2+ was excluded from nuclei isolated from bcl-2 expressing cells, but was sequestered in control nuclei, following the addition of ATP, These findings suggest that bcl-2 may regulate levels of intranuclear Ca2+ independently of cytosolic Ca2+ levels, The ability of bcl-2 to modulate, directly or indirectly, sustained increases in both cytosolic and intranuclear Ca2+ may provide a common basis for bcl-2 function in different subcellular compartments.	UNIV TEXAS,MD ANDERSON CANC CTR,DEPT MOLEC PATHOL,HOUSTON,TX 77030; UNIV TEXAS,MD ANDERSON CANC CTR,DEPT CELL BIOL,HOUSTON,TX 77030; UNIV TEXAS,MD ANDERSON CANC CTR,DEPT UROL,HOUSTON,TX 77030; UNIV TEXAS,MD ANDERSON CANC CTR,DEPT HEMATOL,HOUSTON,TX 77030; UNIV TEXAS,HLTH SCI CTR,DEPT PATHOL & LAB MED,HOUSTON,TX 77030	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; University of Texas Health Science Center Houston			Marín Vieira, María del Carmen/B-8108-2015; Marin, Maria C/G-1040-2010	Marín Vieira, María del Carmen/0000-0002-7149-287X; Marin, Maria C/0000-0002-7149-287X; Buja, Louis Maximilian/0000-0001-8386-7029	NATIONAL CANCER INSTITUTE [R01CA062597] Funding Source: NIH RePORTER; NCI NIH HHS [CA62597, CA09255] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALLBRITTON NL, 1994, P NATL ACAD SCI USA, V91, P12458, DOI 10.1073/pnas.91.26.12458; BAFFY G, 1993, J BIOL CHEM, V268, P6511; BAKHSHI A, 1985, CELL, V41, P899, DOI 10.1016/S0092-8674(85)80070-2; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; Bornkamm G W, 1995, Curr Top Microbiol Immunol, V194, P323; CLEARY ML, 1986, CELL, V47, P19, DOI 10.1016/0092-8674(86)90362-4; COBBOLD PH, 1987, BIOCHEM J, V248, P313, DOI 10.1042/bj2480313; COLOMBEL M, 1993, AM J PATHOL, V143, P390; CORNELIUSSEN B, 1994, NATURE, V368, P760, DOI 10.1038/368760a0; DEJONG D, 1994, CANCER RES, V54, P256; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; ENGLISH HF, 1989, PROSTATE, V15, P233, DOI 10.1002/pros.2990150304; FERNANDEZ A, 1995, J IMMUNOL, V155, P5133; FERNANDEZ A, 1995, ONCOGENE, V10, P769; FURUYA Y, 1994, CANCER RES, V54, P6167; GENTILE V, 1992, J CELL BIOL, V119, P463, DOI 10.1083/jcb.119.2.463; GERASIMENKO OV, 1995, CELL, V80, P439, DOI 10.1016/0092-8674(95)90494-8; GIVOL I, 1994, CELL GROWTH DIFFER, V5, P419; GREBER UF, 1995, J CELL BIOL, V128, P5, DOI 10.1083/jcb.128.1.5; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; HOCKENBERY DM, 1991, P NATL ACAD SCI USA, V88, P6961, DOI 10.1073/pnas.88.16.6961; JACOBSON MD, 1994, EMBO J, V13, P1899, DOI 10.1002/j.1460-2075.1994.tb06459.x; JACOBSON MD, 1995, NATURE, V374, P814, DOI 10.1038/374814a0; JACOBSON MD, 1993, NATURE, V361, P365, DOI 10.1038/361365a0; JONES DP, 1983, J BIOL CHEM, V258, P6390; JONES DP, 1989, J BIOL CHEM, V264, P6398; KAMADA S, 1995, CANCER RES, V55, P354; KANE DJ, 1993, SCIENCE, V262, P1274, DOI 10.1126/science.8235659; KASS GEN, 1992, BIOCHEM PHARMACOL, V44, P1995, DOI 10.1016/0006-2952(92)90102-O; KERR JFR, 1972, BRIT J CANCER, V26, P238; KRAJEWSKI S, 1993, CANCER RES, V53, P4701; KYPRIANOU N, 1988, PROSTATE, V13, P103, DOI 10.1002/pros.2990130203; KYPRIANOU N, 1990, CANCER RES, V50, P3748; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAM M, 1994, P NATL ACAD SCI USA, V91, P6569, DOI 10.1073/pnas.91.14.6569; LEEK RD, 1994, BRIT J CANCER, V69, P135, DOI 10.1038/bjc.1994.22; LING YH, 1993, CANCER RES, V53, P1845; LITHGOW T, 1994, CELL GROWTH DIFFER, V5, P411; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; MARTIKAINEN P, 1990, PROSTATE, V17, P175, DOI 10.1002/pros.2990170302; MCDONNELL TJ, 1992, CANCER RES, V52, P6940; MCDONNELL TJ, 1991, NATURE, V349, P254, DOI 10.1038/349254a0; MCDONNELL TJ, 1989, CELL, V57, P79, DOI 10.1016/0092-8674(89)90174-8; MIYASHITA T, 1992, CANCER RES, V52, P5407; MOCALI A, 1995, EXP CELL RES, V216, P388, DOI 10.1006/excr.1995.1049; MONAGHAN P, 1992, J HISTOCHEM CYTOCHEM, V40, P1819, DOI 10.1177/40.12.1453000; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P255; MUSCHEL RJ, 1995, CANCER RES, V55, P995; NAKAYAMA K, 1994, P NATL ACAD SCI USA, V91, P3700, DOI 10.1073/pnas.91.9.3700; NICOTERA P, 1989, P NATL ACAD SCI USA, V86, P453, DOI 10.1073/pnas.86.2.453; NICOTERA P, 1988, TOXICOLOGY, V52, P55, DOI 10.1016/0300-483X(88)90196-5; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; POTMESIL M, 1988, ANTHRACYCLINE ANTHRA, P447; Powis G., 1987, METABOLISM ACTION AN, P211; ROCHE E, 1994, CELL CALCIUM, V16, P331, DOI 10.1016/0143-4160(94)90097-3; SENTMAN CL, 1991, CELL, V67, P879, DOI 10.1016/0092-8674(91)90361-2; SHIMIZU S, 1995, NATURE, V374, P811, DOI 10.1038/374811a0; SILVESTRINI R, 1994, J NATL CANCER I, V86, P499, DOI 10.1093/jnci/86.7.499; SKLADANOWSKI A, 1993, BIOCHEM PHARMACOL, V46, P375, DOI 10.1016/0006-2952(93)90512-U; STEHNOBITTEL L, 1995, NEURON, V14, P163, DOI 10.1016/0896-6273(95)90250-3; STEINMAN HM, 1995, J BIOL CHEM, V270, P3487; STRASSER A, 1991, CELL, V67, P889, DOI 10.1016/0092-8674(91)90362-3; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; TOTI FM, 1983, J CLIN ONCOL, V1, P477; TSUJIMOTO Y, 1985, SCIENCE, V229, P1390, DOI 10.1126/science.3929382; TU SM, 1995, CANCER LETT, V93, P147, DOI 10.1016/0304-3835(95)03795-X; VEIS DJ, 1993, CELL, V75, P229, DOI 10.1016/0092-8674(93)80065-M; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0; YIN XM, 1994, NATURE, V369, P321, DOI 10.1038/369321a0; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; YUAN JY, 1992, DEVELOPMENT, V116, P309	73	158	162	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN 6	1996	12	11					2259	2266						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UQ220	8649765				2022-12-25	WOS:A1996UQ22000002
J	Axelson, M; Larsson, O				Axelson, M; Larsson, O			27-Hydroxylated low density lipoprotein (LDL) cholesterol can be converted to 7 alpha,27-dihydroxy-4-cholesten-3-one (cytosterone) before suppressing cholesterol production in normal human fibroblasts - Evidence that an altered metabolism of LDL cholesterol can underlie a defective feedback control in malignant cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COENZYME-A REDUCTASE; OXYSTEROL-BINDING-PROTEIN; BILE-ACID PRECURSORS; CULTURED MOUSE CELLS; 3-HYDROXY-3-METHYLGLUTARYL COENZYME; OXYGENATED STEROLS; BIOLOGICAL-ACTIVITIES; CYCLOSPORINE-A; INHIBITION; RECEPTOR	The formation of oxysterols in cultured human fibroblasts and their physiological roles as intracellular regulators of cholesterol production have been investigated. In the presence of low density lipoproteins (LDL), normal fibroblasts converted LDL cholesterol to 27-hydroxycholesterol, which was further metabolized to 7 alpha,27-dihydroxycholesterol, 7 alpha,27-dihydroxy-4-cholesten-3-one, and 7 alpha-hydroxy-3-oxo-4-cholestenoic acid. Autooxidation products of cholesterol contaminating the lipoproteins were also metabolized in the cells. 7 alpha-Hydroxycholesterol was converted to 7 alpha-hydroxy-3-cholesten-3-one prior to 27-hydroxylation and further oxidation to 7 alpha-hydroxy-3-oxo-4-cholestenoic acid. 7 beta-Hydroxycholesterol and 7-oxocholesterol were 27-hydroxylated and then oxidized to C-27-acids. Oxidation of the 7 beta-hydroxy group also occurred. 25-Hydroxycholesterol was 7 alpha-hydroxylated and further oxidized to 7 alpha,25-dihydroxy-4-cholesten-3-one. 25-Hydroxylation of sterols was observed only under specific conditions. In contrast, only small amounts of oxysterols were formed in virus-transformed human fibroblasts when incubated with lipoproteins. This was due to very low activities of the 27- and 7 alpha-hydroxylating enzymes. The rate of oxidation at C-3 was also decreased moderately. A defective suppression of 3-hydroxy-3-methylglutaryl coenzyme A reductase by LDL and autooxidation products of cholesterol observed in the transformed fibroblasts could be caused by the deficiencies of the sterol-metabolizing enzymes, since these cells responded normally to the sterol metabolites 7 alpha,27-dihydroxy-4-cholesten-3-one, 7 alpha,25-dihydroxy-4-cholesten-3-one, and 27-hydroxy-7-oxo-cholesterol. These metabolites, which all possessed an oxo group with a conjugated double bond in the steroid nucleus and a hydroxyl group in the side chain, did not seem to require further metabolism in order to be active. An impaired response to LDL was also seen in other human tumor cells, including breast carcinoma, colonic carcinoma, and malignant melanoma cells. Common to all the malignant cells was an intracellular shortage of 7 alpha,27-dihydroxy-4-cholesten-3-one caused by a decreased formation or an increased metabolism.	KAROLINSKA HOSP,DEPT TUMOR PATHOL,S-17176 STOCKHOLM,SWEDEN	Karolinska Institutet; Karolinska University Hospital	Axelson, M (corresponding author), KAROLINSKA HOSP,DEPT CLIN CHEM,S-17176 STOCKHOLM,SWEDEN.							ARUNACHALAM T, 1981, J ORG CHEM, V46, P2966, DOI 10.1021/jo00327a025; AXELSON M, 1995, J LIPID RES, V36, P290; AXELSON M, 1990, J STEROID BIOCHEM, V36, P631, DOI 10.1016/0022-4731(90)90182-R; AXELSON M, 1991, J BIOL CHEM, V266, P17770; AXELSON M, 1995, J BIOL CHEM, V270, P15102, DOI 10.1074/jbc.270.25.15102; BROWN MS, 1974, J BIOL CHEM, V249, P789; BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311; BROWN MS, 1976, SCIENCE, V191, P150, DOI 10.1126/science.174194; BROWN MS, 1975, CELL, V6, P307, DOI 10.1016/0092-8674(75)90182-8; BROWN MS, 1974, J BIOL CHEM, V249, P7306; CAVENEE WK, 1981, J BIOL CHEM, V256, P2675; DAHLBACKSJOBERG H, 1993, BIOCHEM J, V293, P203, DOI 10.1042/bj2930203; DAWSON PA, 1989, J BIOL CHEM, V264, P16798; DZELETOVIC S, 1995, ANAL BIOCHEM, V225, P73, DOI 10.1006/abio.1995.1110; EDWARDS PA, 1979, J LIPID RES, V20, P40; FIELDING CJ, 1995, J LIPID RES, V36, P211; FIESER LF, 1967, REAGENTS ORGANIC SYN, P1059; GOLDSTEIN JL, 1977, ANNU REV BIOCHEM, V46, P897, DOI 10.1146/annurev.bi.46.070177.004341; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; GOLDSTEIN JL, 1975, J BIOL CHEM, V250, P8487; GUPTA A, 1986, J BIOL CHEM, V261, P8348; HWANG PL, 1991, BIOESSAYS, V13, P583, DOI 10.1002/bies.950131108; KANDUTSCH AA, 1980, J BIOL CHEM, V255, P813; KANDUTSCH AA, 1973, J BIOL CHEM, V248, P8408; KANDUTSCH AA, 1978, SCIENCE, V201, P498, DOI 10.1126/science.663671; KANDUTSCH AA, 1974, J BIOL CHEM, V249, P6057; KIM HS, 1989, J LIPID RES, V30, P247; KUDO K, 1989, J LIPID RES, V30, P1097; LEIGHTON JK, 1991, MOL CELL BIOL, V11, P2049, DOI 10.1128/MCB.11.4.2049; LISCUM L, 1989, J CELL BIOL, V108, P1625, DOI 10.1083/jcb.108.5.1625; METHERALL JE, 1989, J BIOL CHEM, V264, P15634; MICHELL A, 1978, CANCER RES, V38, P4474; Myant N., 2012, CHOLESTEROL METABOLI, DOI [10.1016/B978-0-12-512300-6.50007-7, DOI 10.1016/B978-0-12-512300-6.50007-7]; PAYNE DW, 1995, J BIOL CHEM, V270, P1888; PENTCHEV PG, 1987, FASEB J, V1, P40, DOI 10.1096/fasebj.1.1.3609608; POLSKY FI, 1973, J CLIN INVEST, V52, pA65; PRINCEN HMG, 1991, BIOCHEM J, V275, P501, DOI 10.1042/bj2750501; RIDGWAY ND, 1992, J CELL BIOL, V116, P307, DOI 10.1083/jcb.116.2.307; SHODA J, 1993, HEPATOLOGY, V17, P395; SHODA J, 1993, STEROIDS, V58, P119, DOI 10.1016/0039-128X(93)90048-R; SIPERSTEIN M. D., 1970, Current Topics in Cell. Regulation, V2, P65; SIPERSTEIN MD, 1966, CANCER RES, V26, P7; SIPERSTEIN MD, 1984, J LIPID RES, V25, P1462; SKREDE S, 1986, J CLIN INVEST, V78, P729, DOI 10.1172/JCI112633; TAYLOR FR, 1984, J BIOL CHEM, V259, P2382; WEINSTEIN DB, 1979, CIRCULATION, V59, P54; ZHANG J, 1995, BBA-LIPID LIPID MET, V1256, P353	47	25	27	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 31	1996	271	22					12724	12736		10.1074/jbc.271.22.12724	http://dx.doi.org/10.1074/jbc.271.22.12724			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UN474	8662693	hybrid			2022-12-25	WOS:A1996UN47400008
J	Cioce, V; Csaky, KG; Chan, AML; Bottaro, DP; Taylor, WG; Jensen, R; Aaronson, SA; Rubin, JS				Cioce, V; Csaky, KG; Chan, AML; Bottaro, DP; Taylor, WG; Jensen, R; Aaronson, SA; Rubin, JS			Hepatocyte growth factor (HGF)/NK1 is a naturally occurring HGF scatter factor variant with partial agonist antagonist activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-AFFINITY RECEPTOR; EPITHELIAL-CELLS; MOLECULAR-CLONING; FIBROBLAST GROWTH; MET RECEPTOR; MESSENGER-RNA; HORMONE GENE; PROTEIN; IDENTIFICATION; PURIFICATION	Hepatocyte growth factor/scatter factor (HGF/SF) stimulates cell proliferation, motility, and morphogenesis by activation of its receptor, the c-Met tyrosine kinase. HGF/SF is structurally related to plasminogen, including an amino-terminal hairpin loop, four kringle domains, and a serine protease-like region. A truncated HGF/SF isoform, designated HGF/NK2, which extends through the second kringle domain and behaves as a competitive HGF/SF antagonist, was previously shown to be encoded by an alternative HGF/SF transcript. In this study, we describe a second naturally occurring HGF/SF variant, HGF/NK1, consisting of the HGF/SF amino-terminal sequence and first kringle domain. This product is encoded by a 2-kilobase alternative transcript containing intronic sequence that was contiguous with exon K1b. Analysis of baculovirus-expressed HGF/NR1 revealed that this isoform possesses the heparin binding properties of HGF/SF and modest mitogenic and scattering activity relative to HGF/SF. However, at a 40-fold molar excess, HGF/NK1 inhibited HGF/SF-dependent DNA synthesis. HGF/NK1 stimulated tyrosine phosphorylation of Met, and covalent affinity crosslinking demonstrated a direct HGF/NK1-receptor interaction. These findings establish that the HGF/SF gene encodes multiple alternative products, which include not only a mitogenic agonist (HGF/SF) and a pure antagonist (HGF/NK2) but also a molecule with partial agonist/antagonist properties.	NCI, DBS, LCMB, NIH, BETHESDA, MD 20892 USA; MT SINAI MED CTR, DERALD H RUTTENBERT CANC CTR, NEW YORK, NY 10029 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Icahn School of Medicine at Mount Sinai			Chan, Andrew Man-Lok/J-9497-2013; Chan, Andrew/AAC-1145-2020; Bottaro, Donald P/AAF-3853-2020; Bottaro, Donald P/F-8550-2010	Chan, Andrew Man-Lok/0000-0001-9923-5464; Chan, Andrew/0000-0001-9923-5464; Bottaro, Donald P/0000-0002-5057-5334; Bottaro, Donald P/0000-0002-5057-5334				AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; BOTTARO DP, 1990, J BIOL CHEM, V265, P12767; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; CHAN AML, 1991, SCIENCE, V254, P1382, DOI 10.1126/science.1720571; COOPER CS, 1984, NATURE, V311, P29, DOI 10.1038/311029a0; FINCH PW, 1989, SCIENCE, V245, P752, DOI 10.1126/science.2475908; FUJII T, 1994, J IMMUNOL, V153, P5516; GAK E, 1992, FEBS LETT, V311, P17, DOI 10.1016/0014-5793(92)81356-Q; GALIMI F, 1994, J CELL BIOL, V127, P1743, DOI 10.1083/jcb.127.6.1743; GANDINO L, 1991, J BIOL CHEM, V266, P16098; GANDINO L, 1994, J BIOL CHEM, V269, P1815; GANDINO L, 1990, ONCOGENE, V5, P721; GHERARDI E, 1991, CANCER CELL-MON REV, V3, P227; GHERARDI E, 1990, NATURE, V346, P228, DOI 10.1038/346228b0; JACKSON RL, 1991, PHYSIOL REV, V71, P481, DOI 10.1152/physrev.1991.71.2.481; KAN M, 1991, BIOCHEM BIOPH RES CO, V174, P331, DOI 10.1016/0006-291X(91)90524-B; KMIECIK TE, 1992, BLOOD, V80, P2454; KOMADA M, 1993, ONCOGENE, V8, P2381; KOMADA M, 1994, J BIOL CHEM, V269, P16131; LAROCHELLE WJ, 1990, SCIENCE, V248, P1541, DOI 10.1126/science.2163109; LOKKER NA, 1992, EMBO J, V11, P2503, DOI 10.1002/j.1460-2075.1992.tb05315.x; LOKKER NA, 1993, J BIOL CHEM, V268, P17145; LONGATI P, 1994, ONCOGENE, V9, P49; LUCKOW VA, 1989, VIROLOGY, V170, P31, DOI 10.1016/0042-6822(89)90348-6; MACLEOD JN, 1992, J BIOL CHEM, V267, P14219; MIYAZAWA K, 1991, BIOCHEMISTRY-US, V30, P9170, DOI 10.1021/bi00102a007; MIYAZAWA K, 1989, BIOCHEM BIOPH RES CO, V163, P967, DOI 10.1016/0006-291X(89)92316-4; MIYAZAWA K, 1991, EUR J BIOCHEM, V197, P15, DOI 10.1111/j.1432-1033.1991.tb15876.x; MONTESANO R, 1991, CELL, V67, P901, DOI 10.1016/0092-8674(91)90363-4; NAKA D, 1993, EXP CELL RES, V209, P317, DOI 10.1006/excr.1993.1316; NAKA D, 1992, J BIOL CHEM, V267, P20114; NAKAMURA T, 1989, NATURE, V342, P440, DOI 10.1038/342440a0; NALDINI L, 1992, EMBO J, V11, P4825, DOI 10.1002/j.1460-2075.1992.tb05588.x; NALDINI L, 1991, EMBO J, V10, P2867, DOI 10.1002/j.1460-2075.1991.tb07836.x; PARK M, 1987, P NATL ACAD SCI USA, V84, P6379, DOI 10.1073/pnas.84.18.6379; PATTHY L, 1984, FEBS LETT, V171, P131, DOI 10.1016/0014-5793(84)80473-1; PONTING CP, 1992, BLOOD COAGUL FIBRIN, V3, P605, DOI 10.1097/00001721-199210000-00012; PONZETTO C, 1994, CELL, V77, P261, DOI 10.1016/0092-8674(94)90318-2; RADOVICK S, 1990, MOL ENDOCRINOL, V4, P476, DOI 10.1210/mend-4-3-476; RAPRAEGER AC, 1991, SCIENCE, V252, P1705, DOI 10.1126/science.1646484; ROSEN EM, 1994, J CELL BIOL, V127, P1783, DOI 10.1083/jcb.127.6.1783; ROSEN EM, 1991, EXP SUPPL, V59, P76; RUBIN JS, 1989, P NATL ACAD SCI USA, V86, P802, DOI 10.1073/pnas.86.3.802; RUBIN JS, 1991, P NATL ACAD SCI USA, V88, P415, DOI 10.1073/pnas.88.2.415; RUBIN JS, 1993, BIOCHIM BIOPHYS ACTA, V1155, P357, DOI 10.1016/0304-419X(93)90015-5; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; SCHMIDT C, 1995, NATURE, V373, P699, DOI 10.1038/373699a0; SEKI T, 1991, GENE, V102, P213; SHIMA N, 1991, CELL BIOL INT REP, V15, P397, DOI 10.1016/0309-1651(91)90128-6; SHIMA N, 1991, BIOCHEM BIOPH RES CO, V180, P1151, DOI 10.1016/S0006-291X(05)81187-8; SMITH CWJ, 1989, ANNU REV GENET, V23, P527, DOI 10.1146/annurev.genet.23.1.527; SPIVAKKROIZMAN T, 1994, CELL, V79, P1015, DOI 10.1016/0092-8674(94)90032-9; SPRINGHORN JP, 1994, J BIOL CHEM, V269, P5132; STOKER M, 1985, J CELL SCI, V77, P209; STOKER M, 1987, NATURE, V327, P239, DOI 10.1038/327239a0; UEHARA Y, 1995, NATURE, V373, P702, DOI 10.1038/373702a0; VILLAMORUZZI E, 1993, J BIOL CHEM, V268, P18176; WEIDNER KM, 1995, P NATL ACAD SCI USA, V92, P2597, DOI 10.1073/pnas.92.7.2597; WEIDNER KM, 1990, J CELL BIOL, V111, P2097, DOI 10.1083/jcb.111.5.2097; WEIDNER KM, 1993, J CELL BIOL, V121, P145, DOI 10.1083/jcb.121.1.145; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W; ZIONCHECK TF, 1995, J BIOL CHEM, V270, P16871, DOI 10.1074/jbc.270.28.16871	62	124	131	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 31	1996	271	22					13110	13115		10.1074/jbc.271.22.13110	http://dx.doi.org/10.1074/jbc.271.22.13110			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UN474	8662798	hybrid, Green Published			2022-12-25	WOS:A1996UN47400065
J	Dittmar, KD; Hutchison, KA; OwensGrillo, JK; Pratt, WB				Dittmar, KD; Hutchison, KA; OwensGrillo, JK; Pratt, WB			Reconstitution of the steroid receptor center dot hsp90 heterocomplex assembly system of rabbit reticulocyte lysate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEINS; CELL-FREE SYSTEM; GLUCOCORTICOID RECEPTOR; PROGESTERONE-RECEPTOR; BACTERIAL DNAJ; HSP90; COMPLEXES; BINDING; EXISTS; HSP70	Rabbit reticulocyte lysate contains a multiprotein system that assembles steroid receptors into a heterocomplex with hsp90. In the case of the glucocorticoid receptor (GR), the receptor must be bound to hsp90 to bind steroid, and assembly of the GR . hsp90 complex restores the hormone binding domain of the receptor to the steroid binding conformation. Using both direct assay of heterocomplex assembly by Western blotting and indirect assay of assembly by steroid binding, it has previously been determined that the assembly system is both ATP/Mg2+-dependent and K+-dependent and that hsp70 and an acidic 23-kDa protein (p23) are required to form a functional GR . hsp90 complex. It is also thought that a 60-kDa protein (p60) may be required for progesterone receptor hsp90 heterocomplex assembly, but a complete heterocomplex assembly system has never been reconstituted from individual components. In this work, we separate the proteins of rabbit reticulocyte lysate into three fractions by DEAE chromatography and then reconstitute the GR . hsp90 heterocomplex assembly system in a manner that requires the presence of each fraction. Fraction A contains most of the hsp70 and all of the p60 in lysate, and elimination of p60 by immunoadsorption inactivates this fraction, with bioactivity being restored by the addition of bacterially expressed human p60. The activity of fraction A is replaced by a combination of highly purified rabbit hsp70 and lysate from p60-expressing bacteria. Fraction B contains hsp90, and its activity is replaced by purified rabbit hsp90. Fraction C contains p23, and its activity is replaced in the recombined system by highly purified bacterially expressed human p23. A minimal GR . hsp90 heterocomplex assembly system was reconstituted with purified rabbit hsp70 and hsp90 and bacterially expressed human p23 and p60. This reports the first reconstitution of this apparently ubiquitous protein folding/heterocomplex assembly system.	UNIV MICHIGAN,SCH MED,DEPT PHARMACOL,ANN ARBOR,MI 48109	University of Michigan System; University of Michigan					NCI NIH HHS [T32CA09676] Funding Source: Medline; NIDDK NIH HHS [DK31573] Funding Source: Medline; NIGMS NIH HHS [GM07767] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009676] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK031573, R37DK031573] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007767] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BRESNICK EH, 1989, J BIOL CHEM, V264, P4992; CAPLAN AJ, 1991, J CELL BIOL, V114, P609, DOI 10.1083/jcb.114.4.609; ERHART JC, 1988, ONCOGENE, V3, P595; HOHFELD J, 1995, CELL, V83, P589; HONORE B, 1992, J BIOL CHEM, V267, P8485; HUTCHISON KA, 1995, J BIOL CHEM, V270, P18841, DOI 10.1074/jbc.270.32.18841; HUTCHISON KA, 1994, J BIOL CHEM, V269, P27894; HUTCHISON KA, 1992, J BIOL CHEM, V267, P14047; HUTCHISON KA, 1992, J BIOL CHEM, V267, P2902; HUTCHISON KA, 1993, BIOCHEMISTRY-US, V32, P3953, DOI 10.1021/bi00066a015; HUTCHISON KA, 1994, J BIOL CHEM, V269, P5043; JOHNSON JL, 1995, MOL ENDOCRINOL, V9, P670, DOI 10.1210/me.9.6.670; JOHNSON JL, 1994, MOL CELL BIOL, V14, P1956, DOI 10.1128/MCB.14.3.1956; JOHNSON JL, 1994, J BIOL CHEM, V269, P24989; KIMURA Y, 1995, NATURE, V268, P1362; NICOLET CM, 1989, MOL CELL BIOL, V9, P3638, DOI 10.1128/MCB.9.9.3638; OHTSUKA K, 1993, BIOCHEM BIOPH RES CO, V197, P235, DOI 10.1006/bbrc.1993.2466; OWENSGRILLO JK, 1995, J BIOL CHEM, V270, P20479, DOI 10.1074/jbc.270.35.20479; PERDEW GH, 1991, J BIOL CHEM, V266, P6708; PRATT WB, 1993, J BIOL CHEM, V268, P21455; RUFF VA, 1992, J BIOL CHEM, V267, P21285; SANCHEZ ER, 1990, BIOCHEMISTRY-US, V29, P5145, DOI 10.1021/bi00473a021; SCHERRER LC, 1990, J BIOL CHEM, V265, P21397; SMITH DF, 1992, J BIOL CHEM, V267, P1350; SMITH DF, 1990, MOL ENDOCRINOL, V4, P1704, DOI 10.1210/mend-4-11-1704; SMITH DF, 1993, MOL ENDOCRINOL, V7, P1418, DOI 10.1210/me.7.11.1418; SMITH DF, 1993, MOL ENDOCRINOL, V7, P4, DOI 10.1210/me.7.1.4; SMITH DF, 1993, J BIOL CHEM, V268, P18365; SMITH DF, 1995, MOL CELL BIOL, V15, P6804; SMITH DF, 1993, MOL CELL BIOL, V13, P869, DOI 10.1128/MCB.13.2.869; Stancato LF, 1996, BIOCHEMISTRY-US, V35, P554, DOI 10.1021/bi9511649; STANCATO LF, 1993, J BIOL CHEM, V268, P21711; WALSH CT, 1992, J BIOL CHEM, V267, P13115; WHITELAW ML, 1991, J BIOL CHEM, V266, P6708; WHITESELL L, 1994, P NATL ACAD SCI USA, V91, P8324, DOI 10.1073/pnas.91.18.8324	35	141	143	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 31	1996	271	22					12833	12839		10.1074/jbc.271.22.12833	http://dx.doi.org/10.1074/jbc.271.22.12833			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UN474	8662785	hybrid			2022-12-25	WOS:A1996UN47400024
J	Zhang, JZ; Redman, CM				Zhang, JZ; Redman, CM			Assembly and secretion of fibrinogen - Involvement of amino-terminal domains in dimer formation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELECTRON-MICROSCOPY; MOLECULAR-STRUCTURE; DISULFIDE BONDS; CELLS; IDENTIFICATION; MUTAGENESIS; EXPRESSION; EFFICIENT; VECTORS; CHAINS	Fibrinogen is a dimer with each half-molecule composed of three different chains (A alpha, B beta, gamma). Previous studies showed that amino-terminal disulfide bonds, as well as the disulfide rings that flank the ''coiled-coil'' region, are necessary for chain assembly and secretion (Zhang, J. Z., and Redman, C. M. (1994) J. Biol. Chem. 269, 652-658). We now determine whether other amino-terminal domains are involved in linking the half-molecules. Fibrinogen chains, with deletions at the amino terminus, were co-expressed in COS cells together with normal fibrinogen chains. Elimination of the first 8 amino acids of the B beta chain did not affect dimer assembly, but deletion of amino acid residues 9-72 had a small inhibitory effect on dimer formation. Deletion of the first 72 amino acids of the B beta chain further inhibited dimer formation and resulted in nearly equal amounts of half-molecule and dimeric fibrinogen being formed and secreted. Deletion of the first 80 residues, which includes the cysteine residues that form the amino-terminal disulfide ring, completely eliminated dimer formation, and only half-molecules were secreted. By contrast deletion of the first 41 amino acid residues of the A alpha chain or the first 15 residues of the gamma chain, which correspond to B beta Delta 1-72, did not affect chain assembly and secretion. However, co-expression of both A alpha Delta 1-41 and gamma Delta 1-15 with normal B beta, inhibited dimer formation. Taken together, these results indicate that in addition to disulfide bonds, noncovalent interactions of other amino-terminal amino acid residues in the three fibrinogen chains also participate in dimer formation.	NEW YORK BLOOD CTR,LINDSLEY F KIMBALL RES INST,NEW YORK,NY 10021	New York Blood Center					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL037457] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL37457] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BLOMBACK B, 1972, ANN NY ACAD SCI, V202, P77, DOI 10.1111/j.1749-6632.1972.tb16323.x; BLOMBACK B, 1968, NATURE, V218, P130, DOI 10.1038/218130a0; BLOMBACK B, 1976, THROMB RES, V8, P639, DOI 10.1016/0049-3848(76)90245-0; BOUMA H, 1978, THROMB RES, V13, P557, DOI 10.1016/0049-3848(78)90142-1; CULLEN BR, 1987, METHOD ENZYMOL, V152, P684; DANISHEFSKY K, 1990, BIOCHIM BIOPHYS ACTA, V1048, P202, DOI 10.1016/0167-4781(90)90057-9; DOOLITTLE RF, 1978, J MOL BIOL, V120, P311, DOI 10.1016/0022-2836(78)90070-0; DOOLITTLE RF, 1984, ANNU REV BIOCHEM, V53, P195, DOI 10.1146/annurev.bi.53.070184.001211; FOWLER WE, 1979, J MOL BIOL, V134, P241, DOI 10.1016/0022-2836(79)90034-2; FU YP, 1992, BIOCHEMISTRY-US, V31, P11968, DOI 10.1021/bi00163a002; HALL CE, 1959, J BIOPHYS BIOCHEM CY, V5, P11, DOI 10.1083/jcb.5.1.11; HENSCHEN A, 1983, ANN NY ACAD SCI, V408, P28, DOI 10.1111/j.1749-6632.1983.tb23232.x; HENSCHEN A, 1964, ARK KEMI, V22, P355; HOEPRICH PD, 1983, BIOCHEMISTRY-US, V22, P2049, DOI 10.1021/bi00278a003; HUANG SM, 1993, BIOCHEM BIOPH RES CO, V190, P488, DOI 10.1006/bbrc.1993.1074; IWANAGA S, 1967, BIOCHIM BIOPHYS ACTA, V147, P606, DOI 10.1016/0005-2795(67)90025-6; KAUFMAN RJ, 1991, NUCLEIC ACIDS RES, V19, P4485, DOI 10.1093/nar/19.16.4485; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LIU CY, 1985, J BIOL CHEM, V260, P4390; MOSESSON MW, 1981, J MOL BIOL, V153, P695, DOI 10.1016/0022-2836(81)90414-9; RAO SPS, 1991, J MOL BIOL, V222, P89, DOI 10.1016/0022-2836(91)90739-S; ROY SN, 1990, J BIOL CHEM, V265, P6389; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; WEISEL JW, 1981, NATURE, V289, P263, DOI 10.1038/289263a0; YU S, 1984, J BIOL CHEM, V259, P574; ZHANG JZ, 1992, J BIOL CHEM, V267, P21727; ZHANG JZ, 1994, J BIOL CHEM, V269, P652; ZHANG JZ, 1993, J BIOL CHEM, V268, P11278; ZOLLER MJ, 1982, NUCLEIC ACIDS RES, V10, P6487, DOI 10.1093/nar/10.20.6487	29	16	17	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 24	1996	271	21					12674	12680		10.1074/jbc.271.21.12674	http://dx.doi.org/10.1074/jbc.271.21.12674			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UL660	8647881	hybrid			2022-12-25	WOS:A1996UL66000083
J	Clementz, T; Bednarski, JJ; Raetz, CRH				Clementz, T; Bednarski, JJ; Raetz, CRH			Function of the htrB high temperature requirement gene of Escherichia coli in the acylation of lipid A - HtrB catalyzed incorporation of laurate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UDP-N-ACETYLGLUCOSAMINE; PHOSPHATIDYLGLYCEROL-DEFICIENT MUTANT; DESORPTION MASS-SPECTROMETRY; NUCLEAR MAGNETIC-RESONANCE; SALMONELLA-TYPHIMURIUM; 3-DEOXY-D-MANNO-OCTULOSONIC ACID; NULL MUTATIONS; A PRECURSORS; 3-DEOXY-D-MANNOOCTULOSONATE-8-PHOSPHATE SYNTHETASE; STRUCTURAL DETERMINATION	By assaying lysates of Escherichia coli generated with the hybrid lambda bacteriophages of an ordered library (Kohara, Y., Akiyama, K., and Isono, K. (1987) Cell 50, 495-508), we identified two clones (lambda 232 and lambda 233) capable of overexpressing the lauroyl transferase that functions after 3-deoxy-D-manno-octulosonic acid (Kdo) addition in lipid A biosynthesis (Brozek, K. A., and Raetz, C. R. H. (1990) J. Biol. Chem. 265, 15410-15417). The E. coli DNA inserts in lambda 232 and lambda 233 suggested that a known gene (htrB) required for rapid growth above 33 degrees C might encode the lauroyl transferase. Using the intermediate (Kdo)(2)-lipid IVA as the laurate acceptor, extracts of strains with transposon insertions in htrB were found to contain no lauroyl transferase activity. Cells harboring hybrid htrB(+) plasmids overproduced transferase activity 100-200-fold. The overproduced transferase was solubilized with a non-ionic detergent and purified further by DEAE-Sepharose chromatography. With lauroyl acyl carrier protein as the donor, the purified enzyme rapidly incorporated one laurate residue into (Kdo)(2)-lipid IVA. The rate of laurate incorporation was reduced by several orders of magnitude when either one or both Kdos were absent in the acceptor. With a matched set of acyl-acyl carrier proteins, the enzyme incorporated laurate 3-8 times faster than decanoate or myristate, respectively. Transfer of palmitate, palmitoleate, or R-3-hydroxymyristate was very slow. Taken together with previous studies, our findings indicate that htrB encodes a key, late functioning acyltransferase of lipid A biosynthesis.	DUKE UNIV,MED CTR,DEPT BIOCHEM,DURHAM,NC 27710	Duke University			Bednarski, Jeff/GLN-6651-2022		NIGMS NIH HHS [GM-51310] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051310] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSON MS, 1993, J BIOL CHEM, V268, P19858; ANDERSON MS, 1987, J BIOL CHEM, V262, P5159; Ausubel F. M., 1988, CURRENT PROTOCOLS MO; BEALL B, 1987, J BACTERIOL, V169, P5408, DOI 10.1128/jb.169.12.5408-5415.1987; BELUNIS CJ, 1992, J BIOL CHEM, V267, P9988; BORODOVSKY M, 1994, TRENDS BIOCHEM SCI, V19, P309, DOI 10.1016/0968-0004(94)90067-1; BROZEK KA, 1989, J BIOL CHEM, V264, P6956; BROZEK KA, 1987, J BIOL CHEM, V262, P5170; BROZEK KA, 1990, J BIOL CHEM, V265, P15410; CLEMENTZ T, 1991, J BIOL CHEM, V266, P9687; CLEMENTZ T, 1995, FASEB J, V9, pA1311; COLEMAN J, 1988, J BACTERIOL, V170, P1268, DOI 10.1128/jb.170.3.1268-1274.1988; DICKER IB, 1992, MOL MICROBIOL, V6, P817, DOI 10.1111/j.1365-2958.1992.tb01532.x; ELFERINK RPJO, 1995, J CLIN INVEST, V95, P31, DOI 10.1172/JCI117658; FLEISCHMANN RD, 1995, SCIENCE, V269, P496, DOI 10.1126/science.7542800; GORDON JI, 1991, J BIOL CHEM, V266, P8647; HAGEN FS, 1991, BIOCHEMISTRY-US, V30, P8415, DOI 10.1021/bi00098a020; HAMPTON RY, 1992, METHOD ENZYMOL, V209, P466; JACKOWSKI S, 1994, J BIOL CHEM, V269, P2921; KARIBIAN D, 1993, J BACTERIOL, V175, P2988, DOI 10.1128/JB.175.10.2988-2993.1993; KAROW M, 1992, J BACTERIOL, V174, P702, DOI 10.1128/jb.174.3.702-710.1992; KAROW M, 1993, MOL MICROBIOL, V7, P69, DOI 10.1111/j.1365-2958.1993.tb01098.x; KAROW M, 1991, MOL MICROBIOL, V5, P2285, DOI 10.1111/j.1365-2958.1991.tb02159.x; KAROW M, 1991, J BACTERIOL, V173, P741, DOI 10.1128/jb.173.2.741-750.1991; KAROW M, 1992, J BACTERIOL, V174, P7407, DOI 10.1128/jb.174.22.7407-7418.1992; KELLY TM, 1993, J BIOL CHEM, V268, P19866; KOHARA Y, 1987, CELL, V50, P495, DOI 10.1016/0092-8674(87)90503-4; LEE NG, 1995, J BIOL CHEM, V270, P27151, DOI 10.1074/jbc.270.45.27151; MCGRATH BC, 1991, J BACTERIOL, V173, P649, DOI 10.1128/jb.173.2.649-654.1991; Miller J.H., 1972, EXPT MOL GENETICS; MORRISON DC, 1992, BACTERIAL ENDOTOXIC, V1; MYERS KR, 1992, BIOCONJUGATE CHEM, V3, P540, DOI 10.1021/bc00018a013; Osborn MJ., 1979, BACTERIAL OUTER MEMB, P15; PARK JT, 1987, ESCHERICHIA COLI SAL, V1, P663; POSTBEITTENMILLER D, 1991, J BIOL CHEM, V266, P1858; QURESHI N, 1988, J BIOL CHEM, V263, P11971; QURESHI N, 1986, J MICROBIOL METH, V5, P65, DOI 10.1016/0167-7012(86)90002-3; QURESHI N, 1982, J BIOL CHEM, V257, P1808; RAETZ CRH, 1993, J BACTERIOL, V175, P5745, DOI 10.1128/JB.175.18.5745-5753.1993; RAETZ CRH, 1990, ANNU REV BIOCHEM, V59, P129, DOI 10.1146/annurev.bi.59.070190.001021; RAETZ CRH, 1995, SCIENCE, V270, P997, DOI 10.1126/science.270.5238.997; RAETZ CRH, 1985, J BIOL CHEM, V260, P6080; RAETZ CRH, 1996, IN PRESS ESCHERICHIA, V1; RICK PD, 1977, J BIOL CHEM, V252, P4904; RICK PD, 1977, J BIOL CHEM, V252, P4895; RIETSCHEL ET, 1994, FASEB J, V8, P217, DOI 10.1096/fasebj.8.2.8119492; ROCK CO, 1979, J BIOL CHEM, V254, P7116; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; Somerville JE, 1996, J CLIN INVEST, V97, P359, DOI 10.1172/JCI118423; STRAIN SM, 1985, J BIOL CHEM, V260, P6089; TAKAYAMA K, 1983, J BIOL CHEM, V258, P4245; TAKAYAMA K, 1983, J BIOL CHEM, V258, P7379; VAARA M, 1992, FEMS MICROBIOL LETT, V97, P249, DOI 10.1016/0378-1097(92)90344-N; WHITE KA, 1995, FASEB J, V9, pA1376; YODER MD, 1995, FASEB J, V9, P335, DOI 10.1096/fasebj.9.5.7896002; Young K, 1995, J BIOL CHEM, V270, P30384, DOI 10.1074/jbc.270.51.30384	56	158	166	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 17	1996	271	20					12095	12102		10.1074/jbc.271.20.12095	http://dx.doi.org/10.1074/jbc.271.20.12095			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UL250	8662613	hybrid			2022-12-25	WOS:A1996UL25000077
J	Drakopoulou, E; ZinnJustin, S; Guenneugues, M; Gilquin, B; Menez, A; Vita, C				Drakopoulou, E; ZinnJustin, S; Guenneugues, M; Gilquin, B; Menez, A; Vita, C			Changing the structural context of a functional beta-hairpin - Synthesis and characterization of a chimera containing the curaremimetic loop of a snake toxin in the scorpion alpha/beta scaffold	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR-MAGNETIC-RESONANCE; PROTEIN DESIGN; K+ CHANNELS; 3-DIMENSIONAL STRUCTURE; H-1-NMR SPECTRA; HIGH-AFFINITY; CHARYBDOTOXIN; BINDING; SPECTROSCOPY; NEUROTOXIN	An approach to obtain new active proteins is the incorporation of all or a part of a well defined active site onto a natural structure acting as a structural scaffold. According to this strategy we tentatively engineered a new curaremimetic molecule by transferring the functional central loop of a snake toxin, sequence 26-37, sandwiched between two hairpins, onto the structurally similar beta-hairpin of the scorpion toxin charybdotoxin, stabilized by a short helix. The resulting chimeric molecule, only 31 amino acids long, was produced by solid phase synthesis, refolded, and purified to homogeneity. As shown by structural analysis performed by CD and NMR spectroscopy, the chimera maintained the expected alpha/beta fold characteristic of scorpion toxins and presented a remarkable structural stability. The chimera competitively displaces the snake curaremimetic toxin alpha from the acetylcholine receptor at 10(-5) M concentrations. Antibodies, elicited in rabbits against the chimera, recognize the parent snake toxin and prevent its binding to the acetylcholine receptor, thus neutralizing its toxic function. All these data demonstrate that the strategy of active site transfer to the charybdotoxin scaffold has general applications in the engineering of novel ligands for membrane receptors and in vaccine design.	CTR ETUD SACLAY,DEPT INGN ETUD PROT,CEA,F-91190 GIF SUR YVETTE,FRANCE	CEA; UDICE-French Research Universities; Universite Paris Saclay								AUE WP, 1976, J CHEM PHYS, V64, P2229, DOI 10.1063/1.432450; BONTEMS F, 1992, BIOCHEMISTRY-US, V31, P7756, DOI 10.1021/bi00149a003; BONTEMS F, 1991, EUR J BIOCHEM, V196, P19, DOI 10.1111/j.1432-1033.1991.tb15780.x; BONTEMS F, 1991, SCIENCE, V254, P1521, DOI 10.1126/science.1720574; BOUGIS PE, 1986, BIOCHEMISTRY-US, V25, P7235, DOI 10.1021/bi00370a070; BRAXTON S, 1992, BIOCHEMISTRY-US, V31, P7796, DOI 10.1021/bi00149a008; BRUIX M, 1993, BIOCHEMISTRY-US, V32, P715, DOI 10.1021/bi00053a041; BrUnger A. T., 1992, X PLOR VERSION 3 1 S; CHANG YH, 1990, P NATL ACAD SCI USA, V87, P2823, DOI 10.1073/pnas.87.7.2823; CHICHE L, 1993, PROTEIN ENG, V6, P675, DOI 10.1093/protein/6.7.675; CHOO Y, 1994, NATURE, V372, P642, DOI 10.1038/372642a0; CORFIELD PWR, 1989, J BIOL CHEM, V264, P9239; CUNNINGHAM BC, 1990, SCIENCE, V247, P1461, DOI 10.1126/science.2321008; Dauplais M, 1995, BIOCHEMISTRY-US, V34, P16563, DOI 10.1021/bi00051a004; DAVIS DG, 1985, J AM CHEM SOC, V107, P2820, DOI 10.1021/ja00295a052; DEGRADO WF, 1989, SCIENCE, V243, P622, DOI 10.1126/science.2464850; DESJARLAIS JR, 1993, P NATL ACAD SCI USA, V90, P2256, DOI 10.1073/pnas.90.6.2256; DESJARLAIS JR, 1995, CURR OPIN BIOTECH, V6, P460, DOI 10.1016/0958-1669(95)80076-X; EAKER DL, 1967, JPN J MICROBIOL, V11, P353, DOI 10.1111/j.1348-0421.1967.tb00356.x; FARID RS, 1994, BIOCHEM SOC T, V22, P689, DOI 10.1042/bst0220689; FERNANDEZ I, 1994, BIOCHEMISTRY-US, V33, P14256, DOI 10.1021/bi00251a038; FIELDS C G, 1991, Peptide Research, V4, P95; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; GORAJ K, 1990, PROTEIN ENG, V3, P259, DOI 10.1093/protein/3.4.259; GUNTERT P, 1991, J MOL BIOL, V217, P517, DOI 10.1016/0022-2836(91)90754-T; HARPER JW, 1989, BIOCHEMISTRY-US, V28, P1875, DOI 10.1021/bi00430a067; HECHT MH, 1990, SCIENCE, V249, P884, DOI 10.1126/science.2392678; HYNES TR, 1989, NATURE, V339, P73, DOI 10.1038/339073a0; JOHNSON BA, 1992, BIOCHEMISTRY-US, V31, P8151, DOI 10.1021/bi00150a006; JOHNSON BA, 1994, BIOCHEMISTRY-US, V33, P15061, DOI 10.1021/bi00254a015; JONES PT, 1986, NATURE, V321, P522, DOI 10.1038/321522a0; KAUMAYA PTP, 1992, J BIOL CHEM, V267, P6338; KNORR R, 1989, TETRAHEDRON LETT, V30, P1927, DOI 10.1016/S0040-4039(00)99616-3; KOBSCONRAD S, 1993, J BIOL CHEM, V268, P25285; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KREZEL AM, 1995, PROTEIN SCI, V4, P1478, DOI 10.1002/pro.5560040805; KUMAR A, 1980, BIOCHEM BIOPH RES CO, V95, P1, DOI 10.1016/0006-291X(80)90695-6; LEONETTI M, 1990, J IMMUNOL, V145, P4214; LI B, 1995, SCIENCE, V270, P1657, DOI 10.1126/science.270.5242.1657; LIPPENS G, 1995, BIOCHEMISTRY-US, V34, P13, DOI 10.1021/bi00001a003; MARTINEAU P, 1991, BIO-TECHNOL, V9, P170, DOI 10.1038/nbt0291-170; MENEZ A, 1992, P ROY SOC EDINB B, V99, P83, DOI 10.1017/S0269727000013075; MEUNIER S, 1993, BIOCHEMISTRY-US, V32, P11969, DOI 10.1021/bi00096a005; MILLER C, 1985, NATURE, V313, P316, DOI 10.1038/313316a0; MUTTER M, 1989, ANGEW CHEM INT EDIT, V28, P535, DOI 10.1002/anie.198905353; NEYTON J, 1991, J GEN PHYSIOL, V97, P641, DOI 10.1085/jgp.97.4.641; OZATO K, 1980, J IMMUNOL, V124, P533; PIERRET B, 1995, INT J PEPT PROT RES, V46, P471; PILLET L, 1993, J BIOL CHEM, V268, P909; QUINN TP, 1994, P NATL ACAD SCI USA, V91, P8747, DOI 10.1073/pnas.91.19.8747; RAINES RT, 1995, J BIOL CHEM, V270, P17180, DOI 10.1074/jbc.270.29.17180; RANCE M, 1983, BIOCHEM BIOPH RES CO, V117, P479, DOI 10.1016/0006-291X(83)91225-1; REGAN L, 1991, CURR OPIN BIOTECH, V2, P544, DOI 10.1016/0958-1669(91)90079-K; ROBERTS BL, 1992, P NATL ACAD SCI USA, V89, P2429, DOI 10.1073/pnas.89.6.2429; ROBERTSON DE, 1994, NATURE, V368, P425, DOI 10.1038/368425a0; SCHWEITZ H, 1989, FEBS LETT, V250, P519, DOI 10.1016/0014-5793(89)80788-4; SOBEL A, 1980, EUR J BIOCHEM, V110, P13, DOI 10.1111/j.1432-1033.1980.tb04838.x; STAMPE P, 1994, BIOCHEMISTRY-US, V33, P443, DOI 10.1021/bi00168a008; Strickland E H, 1974, CRC Crit Rev Biochem, V2, P113, DOI 10.3109/10409237409105445; SZARDENINGS M, 1995, PROTEIN ENG, V8, P45, DOI 10.1093/protein/8.1.45; TANAKA T, 1994, PROTEIN ENG, V7, P969, DOI 10.1093/protein/7.8.969; TOMA S, 1991, BIOCHEMISTRY-US, V30, P97, DOI 10.1021/bi00215a015; TREMEAU O, 1986, FEBS LETT, V208, P236, DOI 10.1016/0014-5793(86)81024-9; TREMEAU O, 1995, J BIOL CHEM, V270, P9362, DOI 10.1074/jbc.270.16.9362; VASQUEZ J, 1989, J MED CHEM, V264, P20902; VITA C, 1995, P NATL ACAD SCI USA, V92, P6404, DOI 10.1073/pnas.92.14.6404; VITA C, 1993, EUR J BIOCHEM, V217, P157, DOI 10.1111/j.1432-1033.1993.tb18231.x; VITA C, 1993, PEPTIDES 1992, P641; WAXDAL MJ, 1968, BIOCHEMISTRY-US, V7, P1959, DOI 10.1021/bi00845a046; WEBER M, 1974, MOL PHARMACOL, V10, P1; WELLS JA, 1990, BIOCHEMISTRY-US, V29, P8509, DOI 10.1021/bi00489a001; WITHRICH K, 1986, NMR PROTEIN NUCLEIC; WOLFSON AJ, 1993, BIOCHEMISTRY-US, V32, P5327, DOI 10.1021/bi00071a007; ZANETTI M, 1992, NATURE, V355, P476, DOI 10.1038/355476a0; ZINNJUSTIN S, 1992, BIOCHEMISTRY-US, V31, P11335, DOI 10.1021/bi00161a011	75	64	65	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 17	1996	271	20					11979	11987		10.1074/jbc.271.20.11979	http://dx.doi.org/10.1074/jbc.271.20.11979			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UL250	8662609	hybrid			2022-12-25	WOS:A1996UL25000061
J	Laura, RP; Dizhoor, AM; Hurley, JB				Laura, RP; Dizhoor, AM; Hurley, JB			The membrane guanylyl cyclase, retinal guanylyl cyclase-1, is activated through its intracellular domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ATP-REGULATORY MODULE; ADENINE-NUCLEOTIDES; RECEPTOR; PURIFICATION	Retinal guanylyl cyclase-1 (RetGC-1) is a membrane guanylyl cyclase found in photoreceptor outer segments. It consists of an apparent extracellular domain (ECD) linked by a single transmembrane segment to an intracellular domain (ICD). Guanylyl cyclase activating protein-2 (GCAP-2) is a Ca2+-binding protein that activates RetGC-1 in a Ca2+-sensitive manner. To establish whether GCAP-2 stimulates RetGC-1 through the ECD or ICD, we made deletion mutants lacking either the ECD or both the ECD and transmembrane domains (TMD) of RetGC-1, Recombinant wild type RetGC-1 and both deletion mutants were expressed in HEK 293 cells, and their sensitivities to GCAP-2, Ca2+, and ATP were compared. Our data demonstrate that both deletion mutants are regulated similarly to wild type RetGC-1 with indistinguishable EC(50) values for Ca2+ and similar K-1/2 values for activation by GCAP-2, This shows that GCAP-2 functions through the ICD of RetGC-1 and that removal of the ECD and TMD do not significantly alter regulation by these factors. Our data also show that ATP potentiates stimulation of guanylyl cyclase activity by GCAP-2 and that neither the ECD nor the TMD of RetGC-1 participate in its regulation by ATP.	UNIV WASHINGTON, HOWARD HUGHES MED INST, SEATTLE, WA 98195 USA; UNIV WASHINGTON, DEPT BIOCHEM, SEATTLE, WA 98195 USA	Howard Hughes Medical Institute; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle				Dizhoor, Alexander/0000-0001-6770-9186	NEI NIH HHS [EY06641] Funding Source: Medline	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		CHEN CK, 1995, J BIOL CHEM, V270, P18060, DOI 10.1074/jbc.270.30.18060; CHINKERS M, 1991, J BIOL CHEM, V266, P4088; DIZHOOR AM, 1995, J BIOL CHEM, V270, P25200, DOI 10.1074/jbc.270.42.25200; DIZHOOR AM, 1991, SCIENCE, V251, P915, DOI 10.1126/science.1672047; DIZHOOR AM, 1994, NEURON, V12, P1345, DOI 10.1016/0896-6273(94)90449-9; DUDA T, 1993, FEBS LETT, V315, P143, DOI 10.1016/0014-5793(93)81151-O; FESENKO EE, 1985, NATURE, V313, P310, DOI 10.1038/313310a0; GARBERS DL, 1994, J BIOL CHEM, V269, P30741; GARBERS DL, 1992, CELL, V71, P1; GORACZNIAK RM, 1994, BIOCHEM J, V302, P455, DOI 10.1042/bj3020455; GORACZNIAK RM, 1992, BIOCHEM J, V282, P533, DOI 10.1042/bj2820533; GORCZYCA WA, 1994, BIOCHEMISTRY-US, V33, P3217, DOI 10.1021/bi00177a011; GORCZYCA WA, 1995, J BIOL CHEM, V270, P22029, DOI 10.1074/jbc.270.37.22029; GORCZYCA WA, 1994, P NATL ACAD SCI USA, V91, P4014, DOI 10.1073/pnas.91.9.4014; GORMAN CM, 1990, DNA PROTEIN ENG TECH, V2, P4; GRAYKELLER MP, 1994, NEURON, V13, P849, DOI 10.1016/0896-6273(94)90251-8; HAKKI S, 1990, BIOCHEMISTRY-US, V29, P1088, DOI 10.1021/bi00456a035; Horton MR, 1991, DIRECTED MUTAGENESIS, P217; KOCH KW, 1988, NATURE, V334, P64, DOI 10.1038/334064a0; KOCH KW, 1994, EUR J BIOCHEM, V222, P589, DOI 10.1111/j.1432-1033.1994.tb18901.x; KOCH KW, 1991, J BIOL CHEM, V266, P8634; KOLLER KJ, 1992, MOL CELL BIOL, V12, P2581, DOI 10.1128/MCB.12.6.2581; LAGNADO L, 1992, NEURON, V8, P995, DOI 10.1016/0896-6273(92)90122-T; LIU XR, 1994, EXP EYE RES, V59, P761, DOI 10.1006/exer.1994.1162; LOWE DG, 1995, P NATL ACAD SCI USA, V92, P5535, DOI 10.1073/pnas.92.12.5535; MARALA RB, 1991, FEBS LETT, V281, P73, DOI 10.1016/0014-5793(91)80361-6; MARKS PW, 1991, ANAL BIOCHEM, V193, P61, DOI 10.1016/0003-2697(91)90044-T; MCNAUGHTON PA, 1990, PHYSIOL REV, V70, P847, DOI 10.1152/physrev.1990.70.3.847; SHYJAN AW, 1992, NEURON, V9, P727, DOI 10.1016/0896-6273(92)90035-C; TSIEN R, 1989, METHOD ENZYMOL, V172, P230; VAANDRAGER AB, 1993, J BIOL CHEM, V268, P2174; VAANDRAGER AB, 1993, J BIOL CHEM, V268, P19598; WILSON EM, 1995, BIOCHEMISTRY-US, V34, P4696, DOI 10.1021/bi00014a025; WOLBRING G, 1995, BIOCHEMISTRY-US, V34, P4689, DOI 10.1021/bi00014a024; Wong SKF, 1995, J BIOL CHEM, V270, P30818, DOI 10.1074/jbc.270.51.30818; YANG RB, 1995, P NATL ACAD SCI USA, V92, P602, DOI 10.1073/pnas.92.2.602	36	115	116	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 17	1996	271	20					11646	11651		10.1074/jbc.271.20.11646	http://dx.doi.org/10.1074/jbc.271.20.11646			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UL250	8662612	hybrid			2022-12-25	WOS:A1996UL25000013
J	Lee, SST; Buters, JTM; Pineau, T; FernandezSalguero, P; Gonzalez, FJ				Lee, SST; Buters, JTM; Pineau, T; FernandezSalguero, P; Gonzalez, FJ			Role of CYP2E1 in the hepatotoxicity of acetaminophen	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCED HEPATIC NECROSIS; PARA-BENZOQUINONE IMINE; RIBONUCLEIC-ACID; TREATED RABBITS; HUMAN-LIVER; IN-VITRO; ETHANOL; RAT; CYTOCHROME-P-450; METABOLISM	CYP2E1, a cytochrome P-450 that is well conserved across mammalian species, metabolizes ethanol and many low molecular weight toxins and cancer suspect agents. The cyp2e1 gene was isolated, and a mouse line that lacks expression of CYP2E1 was generated by homologous recombination in embryonic stem cells. Animals deficient in expression of the enzyme were fertile, developed normally, and exhibited no obvious phenotypic abnormalities, thus indicating that CYP2E1 has no critical role in mammalian development and physiology in the absence of external stimuli. When cyp2e1 knockout mice were challenged with the common analgesic acetaminophen, they were found to be considerably less sensitive to its hepatotoxic effects than wild-type animals, indicating that this P-450 is the principal enzyme responsible for the metabolic conversion of the drug to its active hepatotoxic metabolite.	NCI,MOLEC CARCINOGENESIS LAB,NIH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			BUTERS, JEROEN/AAF-6949-2020; Fernandez-Salguero, Pedro M./J-8437-2014; Buters, Jeroen T/G-5070-2011	Fernandez-Salguero, Pedro M./0000-0003-2839-5027; Buters, Jeroen/0000-0003-3581-5472				AOYAMA T, 1989, MOL CARCINOGEN, V1, P253, DOI 10.1002/mc.2940010408; BRADLEY A, 1987, TERATOCARCINOMA EMBR, P133; CASAZZA JP, 1984, J BIOL CHEM, V259, P231; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CONN MJ, 1991, OXIDATIVE DAMAGE REP, P726; DAHLIN DC, 1984, P NATL ACAD SCI-BIOL, V81, P1327, DOI 10.1073/pnas.81.5.1327; FITZPATRICK FA, 1988, PHARMACOL REV, V40, P229; GONZALEZ FJ, 1986, MOL CELL BIOL, V6, P2969, DOI 10.1128/MCB.6.8.2969; GONZALEZ FJ, 1990, TRENDS GENET, V6, P182, DOI 10.1016/0168-9525(90)90174-5; GONZALEZ FJ, 1989, PHARMACOL REV, V40, P243; GUENGERICH FP, 1991, CHEM RES TOXICOL, V4, P168, DOI 10.1021/tx00020a008; HOGAN B, 1986, MANIPULATING MOUSE E; HONG JY, 1987, BIOCHEM BIOPH RES CO, V142, P1077, DOI 10.1016/0006-291X(87)91525-7; JOLLOW DJ, 1973, J PHARMACOL EXP THER, V187, P195; KOOP DR, 1984, MOL PHARMACOL, V25, P494; KOOP DR, 1982, J BIOL CHEM, V257, P8472; KOOP DR, 1985, J BIOL CHEM, V260, P3607; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAETHEM RM, 1993, J BIOL CHEM, V268, P12912; LAIRD PW, 1991, NUCLEIC ACIDS RES, V19, P4293, DOI 10.1093/nar/19.15.4293; LEE SST, 1995, MOL CELL BIOL, V15, P3012; LEHRACH H, 1977, BIOCHEMISTRY-US, V16, P4743, DOI 10.1021/bi00640a033; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; LIEBER CS, 1970, J BIOL CHEM, V245, P2505; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MITCHELL JR, 1973, J PHARMACOL EXP THER, V187, P211; NAGATA K, 1987, J BIOL CHEM, V262, P2787; Nelson DR, 1996, PHARMACOGENETICS, V6, P1, DOI 10.1097/00008571-199602000-00002; PETERSON FJ, 1980, LIFE SCI, V27, P1705, DOI 10.1016/0024-3205(80)90646-3; POTTER WZ, 1973, J PHARMACOL EXP THER, V187, P203; PRASAD JS, 1990, BIOCHEM PHARMACOL, V40, P1989, DOI 10.1016/0006-2952(90)90228-D; RAUCY JL, 1989, ARCH BIOCHEM BIOPHYS, V271, P270, DOI 10.1016/0003-9861(89)90278-6; SHAW S, 1983, DIGEST DIS SCI, V28, P585, DOI 10.1007/BF01299917; SNAWDER JE, 1994, PHARMACOGENETICS, V4, P43, DOI 10.1097/00008571-199402000-00006; SNAWDER JE, 1994, BIOCHEM BIOPH RES CO, V203, P532, DOI 10.1006/bbrc.1994.2215; SONG BJ, 1989, J BIOL CHEM, V264, P3568; SONG BJ, 1986, J BIOL CHEM, V261, P6689; SONG BJ, 1987, MOL ENDOCRINOL, V1, P542, DOI 10.1210/mend-1-8-542; SONG BJ, 1995, DRUG ALCOHOL ABUSE R, V6, P227; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; YAMANO S, 1989, BIOCHEMISTRY-US, V28, P7340, DOI 10.1021/bi00444a029	42	476	486	1	29	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 17	1996	271	20					12063	12067		10.1074/jbc.271.20.12063	http://dx.doi.org/10.1074/jbc.271.20.12063			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UL250	8662637	Green Submitted, hybrid			2022-12-25	WOS:A1996UL25000072
J	West, CM; ScottWard, T; Tengumnuay, P; vanderWel, H; Kozarov, E; Huynh, A				West, CM; ScottWard, T; Tengumnuay, P; vanderWel, H; Kozarov, E; Huynh, A			Purification and characterization of an alpha 1,2-L-fucosyltransferase, which modifies the cytosolic protein FP21, from the cytosol of Dictyostelium	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARCINOMA NCI-H69 CELLS; T7 EXPRESSION SYSTEM; GDP-L-FUCOSE; CYTOPLASMIC PROTEINS; HUMAN SERUM; GLYCOSYLATION; ACID; OLIGOSACCHARIDES; TRANSFERASE; SEQUENCE	A novel fucosyltransferase (cFTase) activity has been enriched over 10(6)-fold from the cytosolic compartment of Dictyostelium based on transfer of [H-3]fucose from GDP-[H-3]fucose to Gal beta 1,3GlcNAc beta-paranitrophenyl (paranitrophenyl-lacto-N-bioside or pNP-LNB). The activity behaved as a single component during purification over DEAE-, phenyl-, Reactive Blue-4-, GDP-adipate-, GDP-hexanolamine-, and Superdex gel filtration resins. The purified activity possessed an apparent M(r) of 95 x 10(3), was Mg2+-dependent with a neutral pH optimum, and exhibited a K-m for GDP-fucose of 0.34 mu M, a K-m for pNP-LNB of 0.6 mM, and a V-max for pNP-LNB of 620 nmol/min/mg protein. SDS-polyacrylamide gel electrophoresis analysis of the Superdex elution profile identified a polypeptide with an apparent M(r) of 85 x 10(3), which coeluted with the cFTase activity and could be specifically photolabeled with the donor substrate inhibitor GDP-hexanolaminyl-azido-I-125-salicylate. Based on substate analogue studies, exoglycosidase digestions, and co-chromatography with fucosylated standards, the product of the reaction with pNP-LNB was Fuc alpha 1,2Gal beta 1,3GlcNAc beta-pNP. The cFTase preferred substrates with a Gal beta 1,3 linkage, and thus its acceptor substrate specificity resembles the human Secretor-type alpha 1,2-FTase. Afucosyl isoforms of the FP21 glycoprotein, GP21-I and GP21-II, were purified from the cytosol of a Dictyostelium mutant and found to be substrates for the cFTase, which exhibited an apparent K-m of 0.21 mu M and an apparent V-max of 460 nmol/min/mg protein toward GP21-II. The highly purified cFTase was inhibited by the reaction products Fuc alpha 1,2Gal beta 1,3GlcNAc beta-pNP and FP21-II. FP21-I and recombinant FP21 were not inhibitory, suggesting that acceptor substrate specificity is based primarily on carbohydrate recognition. A cytosolic location for this step of FP21 glycosylation is implied by the isolation of the cFTase from the cytosolic fraction, its high affinity for its substrates, and its failure to be detected in crude membrane preparations.			West, CM (corresponding author), UNIV FLORIDA, COLL MED, DEPT ANAT & CELL BIOL, GAINESVILLE, FL 32610 USA.				NIGMS NIH HHS [GM-37539] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037539] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAENZIGER JU, 1994, FASEB J, V8, P1019, DOI 10.1096/fasebj.8.13.7926366; BEYER TA, 1980, J BIOL CHEM, V255, P5373; CHEN H, 1995, GENOMICS, V27, P389, DOI 10.1006/geno.1995.1068; CHOU TY, 1995, J BIOL CHEM, V270, P18961, DOI 10.1074/jbc.270.32.18961; DOHENY KF, 1993, CELL, V73, P761, DOI 10.1016/0092-8674(93)90255-O; DONG DLY, 1994, J BIOL CHEM, V269, P19321; DUBENDORFF JW, 1991, J MOL BIOL, V219, P45, DOI 10.1016/0022-2836(91)90856-2; FIELD MC, 1995, GLYCOBIOLOGY, V5, P463, DOI 10.1093/glycob/5.5.463; FRITZ TA, 1994, J BIOL CHEM, V269, P300; GONZALEZYANES B, 1992, J BIOL CHEM, V267, P9595; HALTIWANGER RS, 1992, BIOCHEM SOC T, V20, P264, DOI 10.1042/bst0200264; HALTIWANGER RS, 1992, J BIOL CHEM, V267, P9005; Hart Gerald W., 1992, Current Opinion in Cell Biology, V4, P1017, DOI 10.1016/0955-0674(92)90134-X; HART GW, 1989, ANNU REV BIOCHEM, V58, P841; HASHIMOTO F, 1983, ANAL BIOCHEM, V129, P192, DOI 10.1016/0003-2697(83)90068-4; HEESEPECK A, 1995, PLANT CELL, V7, P1459, DOI 10.1105/tpc.7.9.1459; HIRSCHBERG CB, 1987, ANNU REV BIOCHEM, V56, P63, DOI 10.1146/annurev.bi.56.070187.000431; HITOSHI S, 1995, J BIOL CHEM, V270, P8844, DOI 10.1074/jbc.270.15.8844; HOCHULI E, 1988, BIO-TECHNOL, V6, P1321, DOI 10.1038/nbt1188-1321; HOLMES EH, 1990, J BIOL CHEM, V265, P13150; HOLMES EH, 1992, ARCH BIOCHEM BIOPHYS, V296, P562, DOI 10.1016/0003-9861(92)90611-Y; KELLY RJ, 1995, J BIOL CHEM, V270, P4640, DOI 10.1074/jbc.270.9.4640; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; KOZAROV E, 1995, J BIOL CHEM, V270, P3022, DOI 10.1074/jbc.270.7.3022; KYPRIANOU P, 1990, GLYCOCONJUGATE J, V7, P573, DOI 10.1007/BF01189078; LARSEN RD, 1990, P NATL ACAD SCI USA, V87, P6674, DOI 10.1073/pnas.87.17.6674; LEPENDU J, 1982, AM J HUM GENET, V34, P402; LU ZQ, 1995, VIROLOGY, V206, P339, DOI 10.1016/S0042-6822(95)80049-2; MUDGAPALLI A, 1994, J BIOL CHEM, V269, P11327; NATSUKA S, 1994, CURR OPIN STRUC BIOL, V4, P683, DOI 10.1016/S0959-440X(94)90166-X; NUNEZ HA, 1976, BIOCHEMISTRY-US, V15, P3843, DOI 10.1021/bi00662a030; OZOLS J, 1990, METHOD ENZYMOL, V182, P587; PALCIC MM, 1988, GLYCOCONJUGATE J, V5, P49, DOI 10.1007/BF01048331; RAJAN VP, 1989, J BIOL CHEM, V264, P11158; REDDY GP, 1991, ANAL BIOCHEM, V198, P278, DOI 10.1016/0003-2697(91)90425-S; RODEN L, 1994, J BIOL CHEM, V269, P11509; SARNESTO A, 1990, J BIOL CHEM, V265, P15067; SARNESTO A, 1992, J BIOL CHEM, V267, P2737; SEDMAK JJ, 1977, ANAL BIOCHEM, V79, P544, DOI 10.1016/0003-2697(77)90428-6; STUDIER FW, 1991, J MOL BIOL, V219, P37, DOI 10.1016/0022-2836(91)90855-Z; THALMANN I, 1990, LARYNGOSCOPE, V100, P99; THALMANN I, 1993, HEARING RES, V64, P191, DOI 10.1016/0378-5955(93)90005-L; THURIN J, 1995, J BIOL CHEM, V270, P26577, DOI 10.1074/jbc.270.44.26577; VEYNA NA, 1994, J NEUROCHEM, V62, P456; WEIJER CJ, 1984, J CELL SCI, V70, P111; WRAY W, 1981, ANAL BIOCHEM, V118, P197, DOI 10.1016/0003-2697(81)90179-2; YAZAWA S, 1990, ANAL BIOCHEM, V187, P374, DOI 10.1016/0003-2697(90)90472-L; ZHANG H, 1995, CELL, V82, P915, DOI 10.1016/0092-8674(95)90271-6	48	24	24	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 17	1996	271	20					12024	12035		10.1074/jbc.271.20.12024	http://dx.doi.org/10.1074/jbc.271.20.12024			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UL250	8662604	hybrid			2022-12-25	WOS:A1996UL25000067
J	Wolosker, H; deSouza, DO; deMeis, L				Wolosker, H; deSouza, DO; deMeis, L			Regulation of glutamate transport into synaptic vesicles by chloride and proton gradient	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-BRAIN; FUNCTIONAL RECONSTITUTION; ENERGY-DEPENDENCE; H+-ATPASE; ACID; BIOENERGETICS	Glutamate uptake into synaptic vesicles is driven by an electrochemical proton gradient formed across the membrane by a vacuolar H+-ATPase. Chloride has a biphasic effect on glutamate transport, which it activates at low concentrations (2-8 mM) and inhibits at high concentrations (>20 mM). Stimulation with 4 mM chloride was due to an increase in the V-max of transport, whereas inhibition by high chloride concentrations was related to an increase in K-m to glutamate. Both stimulation and inhibition by Cl- were observed in the presence of A23187 or (NH4)(2)SO4, two substances that dissipate the proton gradient (Delta pH). With the use of these agents, we show that the transmembrane potential regulates the apparent affinity for glutamate, whereas the Delta pH antagonizes the effect of high chloride concentrations and is important for retaining glutamate inside the vesicles. Selective dissipation of Delta pH in the presence of chloride led to a significant glutamate efflux from the vesicles and promoted a decrease in the velocity of glutamate uptake. The H+-ATPase activity was stimulated when the Delta pH component was dissipated. Glutamate efflux induced by chloride was saturable, and half-maximal effect was attained in the presence of 30 mM Cl-. The results indicate that: (i) both transmembrane potential and Delta pH modulate the glutamate uptake at different levels and (ii) chloride affects glutamate transport by two different mechanisms. One is related to a change of the proportions between the transmembrane potential and the Delta pH components of the electrochemical proton gradient, and the other involves a direct interaction of the anion with the glutamate transporter.	UNIV FED RIO GRANDE SUL,INST BIOCIENCIAS,DEPT BIOQUIM,BR-90050 PORTO ALEGRE,RS,BRAZIL	Universidade Federal do Rio Grande do Sul	Wolosker, H (corresponding author), UNIV FED RIO DE JANEIRO,DEPT BIOQUIM MED,INST CIENCIAS BIOMED,CCS,CIDADE UNIVERSITARIA,BR-21941590 RIO JANEIRO,BRAZIL.			Wolosker, Herman/0000-0001-5508-9194				Alberts B. D., 1989, MOL BIOL CELL, P301; CIDON S, 1989, J BIOL CHEM, V264, P8281; DISBROW JK, 1982, BIOCHEM BIOPH RES CO, V108, P1221, DOI 10.1016/0006-291X(82)92130-1; DUFOUR JP, 1982, J BIOL CHEM, V257, P9365; Fiske CH, 1925, J BIOL CHEM, V66, P375; FLOOR E, 1990, J NEUROCHEM, V55, P1663, DOI 10.1111/j.1471-4159.1990.tb04954.x; HARTINGER J, 1993, J BIOL CHEM, V268, P23122; HELL JW, 1990, J BIOL CHEM, V265, P2111; HELL JW, 1988, EMBO J, V7, P3023, DOI 10.1002/j.1460-2075.1988.tb03166.x; JAHN R, 1994, ANNU REV NEUROSCI, V17, P219, DOI 10.1146/annurev.ne.17.030194.001251; JOHNSON RG, 1976, J GEN PHYSIOL, V298, P1; KANNER BI, 1983, BIOCHIM BIOPHYS ACTA, V726, P293, DOI 10.1016/0304-4173(83)90013-7; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAYCOX PR, 1988, J BIOL CHEM, V263, P15423; MAYCOX PR, 1990, TRENDS NEUROSCI, V13, P83, DOI 10.1016/0166-2236(90)90178-D; MCMAHON HT, 1991, BIOCHIM BIOPHYS ACTA, V1059, P243, DOI 10.1016/S0005-2728(05)80210-5; MORIYAMA Y, 1993, ARCH BIOCHEM BIOPHYS, V305, P278, DOI 10.1006/abbi.1993.1423; MORIYAMA Y, 1995, J BIOL CHEM, V270, P22314, DOI 10.1074/jbc.270.38.22314; NAITO S, 1983, J BIOL CHEM, V258, P696; NAITO S, 1985, J NEUROCHEM, V44, P99, DOI 10.1111/j.1471-4159.1985.tb07118.x; PRESSMAN BC, 1976, ANNU REV BIOCHEM, V45, P501, DOI 10.1146/annurev.bi.45.070176.002441; ROMANI A, 1992, ARCH BIOCHEM BIOPHYS, V298, P1, DOI 10.1016/0003-9861(92)90086-C; Shepherd G. M., 1988, NEUROBIOLOGY; SHIOI J, 1990, BIOCHEM J, V267, P63, DOI 10.1042/bj2670063; SUDHOF TC, 1995, NATURE, V375, P645, DOI 10.1038/375645a0; TABB JS, 1992, J BIOL CHEM, V267, P15412; VANDYKE RW, 1988, J BIOL CHEM, V263, P2603	27	107	109	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 17	1996	271	20					11726	11731		10.1074/jbc.271.20.11726	http://dx.doi.org/10.1074/jbc.271.20.11726			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UL250	8662610	hybrid			2022-12-25	WOS:A1996UL25000024
J	Su, C; Oliw, EH				Su, C; Oliw, EH			Purification and characterization of linoleate 8-dioxygenase from the fungus Gaeumannomyces graminis as a novel hemoprotein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROSTAGLANDIN ENDOPEROXIDE SYNTHASE; ACTIVE-SITE IRON; ASPERGILLUS-NIDULANS; ACID; METABOLITES; IDENTIFICATION; LIPOXYGENASES; BIOSYNTHESIS; OXYGENATION; INHIBITORS	The fungus Gaeumannomyces graminis, which causes the major root disease of wheat known as ''take-all,'' can metabolize linoleic acid to (8R)-hydroperoxylinoleic acid. The enzyme linoleate 8-dioxygenase abstracts hydrogen and introduces molecular oxygen in an antarafacial way at C-8. We have now purified the enzyme 1000-fold to a specific activity of 1.8 mu mol/min/mg of protein. Acetone powder of mycelia of G. graminis was subjected to extraction and ammonium sulfate precipitation with solubilization. The 8-dioxygenase was purified by hydrophobic interaction chromatography, size-exclusion chromatography, anion-exchange chromatography, and immobilized metal ion affinity chromatography. The active enzyme appeared to consist of four subunits since the active enzyme had an apparent molecular mass of 520 kDa determined by gel filtration, while SDS-polyacrylamide gel electrophoresis showed a protein band of 130 kDa. Spectroscopy indicated the presence of heme. The characteristic pyridine ferrohemochrome alpha-band was found at 557 nm and the beta-band at 525 nm. The purified protein showed an absorption maximum at 408 nm (gamma, Soret). The absorption maximum shifted to 429 nm after reduction with dithionite and to 421 nm after treatment of the reduced enzyme with carbon monoxide. BW A4C, a hydroxamic acid derivative, inhibited the enzyme by >90% at 10 mu M. The pH optimum was 7.2-7.4, the isoelectric point was 5.2 by chromatofocusing, and the K-m values were 8 mu M for linoleic acid and 30 mu M for oxygen. We conclude that linoleate 8-dioxygenase appears to be a tetrameric hemoprotein distinct from other fatty-acid dioxygenases.			Su, C (corresponding author), UPPSALA UNIV, BIOMED CTR, DEPT PHARMACEUT BIOSCI, DIV BIOCHEM PHARMACOL, BOX 591, S-75124 UPPSALA, SWEDEN.			Oliw, Ernst/0000-0002-7986-8130				ABELSON PH, 1995, SCIENCE, V269, P1027, DOI 10.1126/science.269.5227.1027; BOWERS WS, 1986, SCIENCE, V232, P105, DOI 10.1126/science.232.4746.105; BOYINGTON JC, 1993, SCIENCE, V260, P1482, DOI 10.1126/science.8502991; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRODOWSKY ID, 1992, BIOCHIM BIOPHYS ACTA, V1124, P59, DOI 10.1016/0005-2760(92)90126-G; BRODOWSKY ID, 1992, J BIOL CHEM, V267, P14738; BRODOWSKY ID, 1993, BIOCHIM BIOPHYS ACTA, V1168, P68, DOI 10.1016/0005-2760(93)90267-D; BRODOWSKY ID, 1994, EUR J PHARMACOL, V254, P43, DOI 10.1016/0014-2999(94)90368-9; BRODOWSKY ID, 1994, ACTA U UPSAL, V123, P1; CAPDEVILA J, 1981, P NATL ACAD SCI-BIOL, V78, P5362, DOI 10.1073/pnas.78.9.5362; CHAMPE SP, 1989, J BACTERIOL, V171, P3982, DOI 10.1128/jb.171.7.3982-3988.1989; ELLIOTT WJ, 1986, J BIOL CHEM, V261, P6719; GARDNER HW, 1991, BIOCHIM BIOPHYS ACTA, V1084, P221, DOI 10.1016/0005-2760(91)90063-N; HAMBERG M, 1967, J BIOL CHEM, V242, P5336; HAMBERG M, 1994, ARCH BIOCHEM BIOPHYS, V309, P77, DOI 10.1006/abbi.1994.1087; HLA T, 1992, P NATL ACAD SCI USA, V89, P7384, DOI 10.1073/pnas.89.16.7384; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEEDS JM, 1993, J BIOL CHEM, V268, P17781; MAEZONO K, 1990, BIOCHEM BIOPH RES CO, V170, P176, DOI 10.1016/0006-291X(90)91256-R; MAZUR P, 1990, TETRAHEDRON LETT, V31, P3837, DOI 10.1016/S0040-4039(00)97482-3; MCMILLAN RM, 1992, TRENDS PHARMACOL SCI, V13, P323, DOI 10.1016/0165-6147(92)90100-K; MINOR W, 1993, BIOCHEMISTRY-US, V32, P6320, DOI 10.1021/bi00076a003; NELSON DR, 1993, DNA CELL BIOL, V12, P1, DOI 10.1089/dna.1993.12.1; NELSON MJ, 1991, J BIOL CHEM, V266, P8225; OHSAWA K, 1983, ANAL BIOCHEM, V135, P409, DOI 10.1016/0003-2697(83)90703-0; OLIW EH, 1994, PROG LIPID RES, V33, P329, DOI 10.1016/0163-7827(94)90029-9; OLIW EH, 1993, ARCH BIOCHEM BIOPHYS, V305, P288, DOI 10.1006/abbi.1993.1425; OLIW EH, 1993, ARCH BIOCHEM BIOPHYS, V300, P434, DOI 10.1006/abbi.1993.1059; PAUL KG, 1953, ACTA CHEM SCAND, V7, P1284, DOI 10.3891/acta.chem.scand.07-1284; PICOT D, 1994, NATURE, V367, P243, DOI 10.1038/367243a0; PORTER DA, 1995, LIPIDS, V30, P277; SCHUTZ G, 1972, J BIOL CHEM, V247, P5327; SIEDOW JN, 1991, ANNU REV PLANT PHYS, V42, P145, DOI 10.1146/annurev.pp.42.060191.001045; SMITH WL, 1991, BIOCHIM BIOPHYS ACTA, V1083, P1, DOI 10.1016/0005-2760(91)90119-3; SU C, 1995, LIPIDS, V30, P43, DOI 10.1007/BF02537040; TSAI AL, 1994, J BIOL CHEM, V269, P5085; TUNON P, 1984, J BIOCHEM BIOPH METH, V9, P171, DOI 10.1016/0165-022X(84)90008-3; Webb E. C., 1992, ENZYME NOMENCLATURE; YAMAMOTO S, 1992, BIOCHIM BIOPHYS ACTA, V1128, P117, DOI 10.1016/0005-2760(92)90297-9	39	54	56	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 14	1996	271	24					14112	14118		10.1074/jbc.271.24.14112	http://dx.doi.org/10.1074/jbc.271.24.14112			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UQ660	8662736	hybrid			2022-12-25	WOS:A1996UQ66000029
J	Yoo, SJ; Seol, JH; Shin, DH; Rohrwild, M; Kang, MS; Tanaka, K; Goldberg, AL; Chung, CH				Yoo, SJ; Seol, JH; Shin, DH; Rohrwild, M; Kang, MS; Tanaka, K; Goldberg, AL; Chung, CH			Purification and characterization of the heat shock proteins HslV and HslU that form a new ATP-dependent protease in Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTIGEN PRESENTATION; SENSITIVE METHOD; CLP PROTEASE; PROTEOLYSIS; UBIQUITIN; TI; COMPONENT; CONTAINS; DISTINCT; SEQUENCE	The hslVU operon in Escherichia coli encodes two heat shock proteins, HslV, a 19-kDa protein homologous to beta-type subunits of the 20 S proteasomes, and HslU, a 50-kDa protein related to the ATPase ClpX We have recently shown that HslV and HslU can function together as a novel ATP-dependent protease, the HslVU protease. We have now purified both proteins to apparent homogeneity from extracts of E. coli carrying the hslVU operon on a multicopy plasmid. HslU by itself cleaved ATP, and pure HslV is a weak peptidase degrading certain hydrophobic peptides. HslU dramatically stimulated peptide hydrolysis by HslV when ATP is present. With a 1:4 molar ratio of HslV to HslU, approximately a 200-fold increase in peptide hydrolysis was observed. HslV stimulated the ATPase activity of HslU 2-4-fold, but had little influence on the affinity of HslU to ATP. The nonhydrolyzable ATP analog, beta,gamma-methylene-ATP, did not support peptide hydrolysis. Other nucleotides (CTP, dATP) that were slowly hydrolyzed by HslU allowed some peptide hydrolysis. Therefore, ATP cleavage appears essential for the HslV activity. Upon gel filtration on a Sephacryl S-300 column, HslV behaved as a 250-kDa oligomer (i.e. 12-14 subunits), and HslU behaved as a 100-kDa protein (i.e. a dimer) in the absence of ATP, but as a 450-kDa multimer (8-10 subunits) in its presence. Therefore ATP appears necessary for oligomerization of HslU. Thus the HslVU protease appears to be a two-component protease in which HslV harbors the peptidase activity, while HslU provides an essential ATPase activity.	SEOUL NATL UNIV, COLL NAT SCI, DEPT BIOL MOLEC, SEOUL 151742, SOUTH KOREA; SEOUL NATL UNIV, COLL NAT SCI, RES CTR CELL DIFFERENTIAT, SEOUL 151742, SOUTH KOREA; HARVARD UNIV, SCH MED, DEPT CELL BIOL, BOSTON, MA 02115 USA; UNIV TOKUSHIMA, INST ENZYME RES, TOKUSHIMA 770, JAPAN	Seoul National University (SNU); Seoul National University (SNU); Harvard University; Harvard Medical School; Tokushima University			Shin, Donghun/A-2092-2012		NIGMS NIH HHS [GM46147] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046147] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ames B. N., 1966, METHOD ENZYMOL, P115, DOI DOI 10.1016/0076-6879(66)08014-5; ARMON T, 1990, J BIOL CHEM, V265, P20723; BLAKE MS, 1984, ANAL BIOCHEM, V136, P175, DOI 10.1016/0003-2697(84)90320-8; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHUANG SE, 1993, J BACTERIOL, V175, P5242, DOI 10.1128/JB.175.16.5242-5252.1993; CHUANG SE, 1993, GENE, V134, P1, DOI 10.1016/0378-1119(93)90167-2; CHUNG CH, 1993, SCIENCE, V262, P372, DOI 10.1126/science.8211156; CIECHANOVER A, 1994, CELL, V79, P13, DOI 10.1016/0092-8674(94)90396-4; FEHLING HJ, 1994, SCIENCE, V265, P1234, DOI 10.1126/science.8066463; FENTEANY G, 1995, SCIENCE, V268, P726, DOI 10.1126/science.7732382; GOLDBERG AL, 1992, NATURE, V357, P375, DOI 10.1038/357375a0; GOLDBERG AL, 1992, EUR J BIOCHEM, V203, P9, DOI 10.1111/j.1432-1033.1992.tb19822.x; GOTTESMAN S, 1990, P NATL ACAD SCI USA, V87, P3513, DOI 10.1073/pnas.87.9.3513; GOTTESMAN S, 1993, J BIOL CHEM, V268, P22618; GOTTESMAN S, 1992, MICROBIOL REV, V56, P592, DOI 10.1128/MMBR.56.4.592-621.1992; HWANG BJ, 1988, J BIOL CHEM, V263, P8727; HWANG BJ, 1987, P NATL ACAD SCI USA, V84, P5550, DOI 10.1073/pnas.84.16.5550; KATAYAMAFUJIMURA Y, 1987, J BIOL CHEM, V262, P4477; KESSEL M, 1995, J MOL BIOL, V250, P587, DOI 10.1006/jmbi.1995.0400; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEHNHERR H, 1995, P NATL ACAD SCI USA, V92, P3274, DOI 10.1073/pnas.92.8.3274; MAURIZI MR, 1992, EXPERIENTIA, V48, P178, DOI 10.1007/BF01923511; MHAMMEDIALAOUI A, 1994, MOL MICROBIOL, V11, P1109, DOI 10.1111/j.1365-2958.1994.tb00387.x; MICHALEK MT, 1993, NATURE, V363, P552, DOI 10.1038/363552a0; PALMER A, 1994, EUR J CELL BIOL, V64, P163; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; PETERS JM, 1994, J BIOL CHEM, V269, P7709; RECHSTEINER M, 1993, J BIOL CHEM, V268, P6065; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; ROHRWILD M, 1996, IN PRESS P NATL ACAD; SEEMULLER E, 1995, SCIENCE, V268, P579, DOI 10.1126/science.7725107; SEOL JH, 1995, J BIOL CHEM, V270, P8087, DOI 10.1074/jbc.270.14.8087; SEOL JH, 1994, J BIOL CHEM, V269, P29468; SEUFERT W, 1992, EMBO J, V11, P3077, DOI 10.1002/j.1460-2075.1992.tb05379.x; SQUIRES C, 1992, J BACTERIOL, V174, P1081, DOI 10.1128/jb.174.4.1081-1085.1992; TANAHASHI N, 1993, ENZYME PROTEIN, V47, P241, DOI 10.1159/000468683; TOMOYASU T, 1995, EMBO J, V14, P2551, DOI 10.1002/j.1460-2075.1995.tb07253.x; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WOO KM, 1989, J BIOL CHEM, V264, P2088	40	107	111	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 14	1996	271	24					14035	14040		10.1074/jbc.271.24.14035	http://dx.doi.org/10.1074/jbc.271.24.14035			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UQ660	8662828	hybrid			2022-12-25	WOS:A1996UQ66000018
J	Zhang, YH; Saez, R; Leal, MA; Chan, AML				Zhang, YH; Saez, R; Leal, MA; Chan, AML			Synergism between two growth regulatory pathways: Cooperative transformation of NIH3T3 cells by G alpha(12) and c-raf-1	ONCOGENE			English	Article						oncogene; NIH3T3; G alpha(12); raf; ras; transformation	EXPRESSION CDNA CLONING; ALPHA-SUBUNITS; GENE-PRODUCT; RAS; ONCOGENES; ACTIVATION; CANCER; TUMORS	The alpha-subunit of the heterotrimeric G-protein, G(12), has been shown to induce cellular transformation when overexpressed or oncogenically activated in rodent fibroblasts. To investigate the interaction between G alpha(12) transforming pathway and the Ras-Raf-MAPK pathway, we examined the ability of mitogenic signaling molecules in cooperating with G alpha(12) in transforming NIH3T3 fibroblasts, We observed a striking cooperative effect on focus-forming ability when G alpha(12) and c-raf-1 cDNAs were co-transfected into NIH3T3 cells, NIH3T3 cells coexpressing both G alpha(12) and c-raf-1 resulted in the constitutive activation of the mitogenic-activated protein kinase (MAPK), In addition, the levels of GTP-bound Ras were elevated in G alpha(12) transformed NIH3T3 cells, Our results provide a model for studying the effects of simultaneous activation of two distinct growth regulatory pathways in cellular transformation.					Chan, Andrew Man-Lok/J-9497-2013; Chan, Andrew/AAC-1145-2020	Chan, Andrew Man-Lok/0000-0001-9923-5464; Chan, Andrew/0000-0001-9923-5464				BIRNBAUMER L, 1992, CELL, V71, P1069, DOI 10.1016/S0092-8674(05)80056-X; BISHOP JM, 1991, CELL, V64, P235, DOI 10.1016/0092-8674(91)90636-D; BOS JL, 1989, CANCER RES, V49, P4682; CANO E, 1995, TRENDS BIOCHEM SCI, V20, P117, DOI 10.1016/S0968-0004(00)88978-1; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CHAN AML, 1993, MOL CELL BIOL, V13, P762, DOI 10.1128/MCB.13.2.762; COOK SJ, 1993, SCIENCE, V262, P1069, DOI 10.1126/science.7694367; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; CRESPO P, 1994, J BIOL CHEM, V269, P21103; CRESPO P, 1994, NATURE, V369, P418, DOI 10.1038/369418a0; CUADRADO A, 1993, ONCOGENE, V8, P2443; FAURE M, 1994, J BIOL CHEM, V269, P7841; GAK E, 1992, FEBS LETT, V311, P17, DOI 10.1016/0014-5793(92)81356-Q; HAN JW, 1991, SCIENCE, V252, P576, DOI 10.1126/science.1902323; KOCH WJ, 1994, P NATL ACAD SCI USA, V91, P12706, DOI 10.1073/pnas.91.26.12706; LACAL JC, 1986, P NATL ACAD SCI USA, V83, P5400, DOI 10.1073/pnas.83.15.5400; LANDIS CA, 1989, NATURE, V340, P692, DOI 10.1038/340692a0; LYONS J, 1990, SCIENCE, V249, P655, DOI 10.1126/science.2116665; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MIKI T, 1991, P NATL ACAD SCI USA, V88, P5167, DOI 10.1073/pnas.88.12.5167; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; NEER EJ, 1995, CELL, V80, P249, DOI 10.1016/0092-8674(95)90407-7; PENDERGAST GC, 1995, ONCOGENE, V10, P2289; PORRAS A, 1992, J BIOL CHEM, V267, P21124; PUMIGLIA KM, 1995, J BIOL CHEM, V270, P14251, DOI 10.1074/jbc.270.24.14251; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; QIU RG, 1995, P NATL ACAD SCI USA, V92, P11781, DOI 10.1073/pnas.92.25.11781; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; STRATHMANN MP, 1991, P NATL ACAD SCI USA, V88, P5582, DOI 10.1073/pnas.88.13.5582; VOYNOYASENETSKAYA TA, 1994, ONCOGENE, V9, P2559; WEINBERG RA, 1991, SCIENCE, V254, P1138, DOI 10.1126/science.1659741; WIGLER M, 1977, CELL, V11, P223, DOI 10.1016/0092-8674(77)90333-6; XU HP, 1994, MOL CELL BIOL, V14, P50, DOI 10.1128/MCB.14.1.50; XU NZ, 1993, P NATL ACAD SCI USA, V90, P6741, DOI 10.1073/pnas.90.14.6741	34	11	11	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN 6	1996	12	11					2377	2383						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UQ220	8649778				2022-12-25	WOS:A1996UQ22000015
J	Zhu, D; Bourguignon, L				Zhu, D; Bourguignon, L			Overexpression of CD44 in p185(neu)-transfected NIH3T3 cells promotes an up-regulation of hyaluronic acid-mediated membrane-cytoskeleton interaction and cell adhesion	ONCOGENE			English	Article						CD44; p184(neu); hyaluronic acid; cytoskeleton; cell adhesion	TRANSMEMBRANE GLYCOPROTEIN; PROTO-ONCOGENE; RECEPTOR CD44; HUMAN-BREAST; EXPRESSION; BINDING; NEU; MOLECULE; GP85; AMPLIFICATION	CD44 is a transmembrane glycoprotein known to bind hyaluronic acid (HA) in its extracellular domain and to contain at least one ankyrin-binding site in its cytoplasmic domain. In this study we have examined CD44 expression in a mouse fibroblast cell line transfected with the p185(neu) oncogene cDNA. The results of RT-PCR and Southern blot analyses reveal that CD44s (CD44 standard form) transcript is expressed in both p185(neu)-transfected cells and untransfected cells. Using surface iodination, anti-CD44 immunoprecipitation and immune-binding assays, we have found that the number of CD44s molecules expressed on the surface of p185(neu)-transfected cells are at least 4.5-fold higher than those detected on untransfected cells. Overexpression of surface CD44s in p185(neu)-transfected cells results in a dramatic enhancement of HA-mediated cell adhesion. Scatchard plot analysis indicates that CD44s in p185(neu)-transfected cells binds directly and specifically to ankyrin. The binding affinity between CD44s and ankyrin in p185(neu)-transfected cells (K-d approximate to 0.19 nM) appears to be somewhat higher than that found in the untransfected cells (K-d approximate to 0.30 nM). Double immunofluorescence staining and confocal microscopic analyses indicate that HA induces the HA receptor (i.e. CD44s) to form adhesion plaque-like structures, and causes an accumulation of intracellular ankyrin directly underneath HA receptor (CD44s)-adhesion plaque-like structures in p185(neu)-transfected cells (but not in untransfected cells). These findings suggest that overexpression of CD44s and up-regulation of CD44s-ankyrin interaction by p185(neu) oncogene may be one of the pre-requisite steps in regulating tumor cell behavior.	UNIV MIAMI,SCH MED,DEPT CELL BIOL & ANAT,MIAMI,FL 33101	University of Miami					NATIONAL CANCER INSTITUTE [R01CA066163] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM036353] Funding Source: NIH RePORTER; NCI NIH HHS [CA66163] Funding Source: Medline; NIGMS NIH HHS [GM36353] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARUFFO A, 1990, CELL, V61, P1303, DOI 10.1016/0092-8674(90)90694-A; BARTOLAZZI A, 1994, J EXP MED, V180, P53, DOI 10.1084/jem.180.1.53; BENNETT V, 1983, METHOD ENZYMOL, V96, P313; BERGER MS, 1988, CANCER RES, V48, P1238; BOURGUIGNON LYW, 1991, J BIOL CHEM, V266, P11761; BOURGUIGNON LYW, 1993, J IMMUNOL, V151, P6634; CARTER WG, 1988, J BIOL CHEM, V263, P4193; COOPER DL, 1995, NAT MED, V1, P635, DOI 10.1038/nm0795-635; CULTY M, 1990, J CELL BIOL, V111, P2765, DOI 10.1083/jcb.111.6.2765; DIGIOVANNA MP, 1995, CANCER RES, V55, P1646; FRAKER PJ, 1978, BIOCHEM BIOPH RES CO, V80, P849, DOI 10.1016/0006-291X(78)91322-0; GUNTHERT U, 1991, CELL, V65, P13, DOI 10.1016/0092-8674(91)90403-L; GUY CT, 1992, P NATL ACAD SCI USA, V89, P10578, DOI 10.1073/pnas.89.22.10578; HAYNES BF, 1989, IMMUNOL TODAY, V10, P423, DOI 10.1016/0167-5699(89)90040-6; HAYNES BF, 1991, CANCER CELL-MON REV, V3, P347; HIRANO H, 1994, INT IMMUNOL, V6, P49, DOI 10.1093/intimm/6.1.49; HYNES NE, 1994, BBA-REV CANCER, V1198, P165, DOI 10.1016/0304-419X(94)90012-4; IIDA N, 1995, J CELL PHYSIOL, V162, P127, DOI 10.1002/jcp.1041620115; ISACKE CM, 1994, J CELL SCI, V107, P2353; JALKANEN S, 1992, J CELL BIOL, V116, P817, DOI 10.1083/jcb.116.3.817; JAMAL HH, 1994, ONCOGENE, V9, P417; KALOMIRIS EL, 1989, J BIOL CHEM, V264, P8113; KALOMIRIS EL, 1988, J CELL BIOL, V106, P317; KUPPNER MC, 1992, INT J CANCER, V50, P572, DOI 10.1002/ijc.2910500414; LOKESHWAR VB, 1992, J BIOL CHEM, V267, P22073; LOKESHWAR VB, 1994, J CELL BIOL, V126, P1099, DOI 10.1083/jcb.126.4.1099; LOKESHWAR VB, 1991, J BIOL CHEM, V266, P17983; PADHY LC, 1982, CELL, V28, P865, DOI 10.1016/0092-8674(82)90065-4; PARK JB, 1989, CANCER RES, V49, P6605; PELES E, 1993, BIOESSAYS, V15, P815, DOI 10.1002/bies.950151207; RALL CJN, 1995, CANCER RES, V55, P1831; SCREATON GR, 1992, P NATL ACAD SCI USA, V89, P12160, DOI 10.1073/pnas.89.24.12160; SHI DR, 1992, MOL CARCINOGEN, V5, P213, DOI 10.1002/mc.2940050308; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; STERN DF, 1986, MOL CELL BIOL, V6, P1729, DOI 10.1128/MCB.6.5.1729; SY MS, 1991, J EXP MED, V174, P859, DOI 10.1084/jem.174.4.859; TANABE KK, 1993, LANCET, V341, P725, DOI 10.1016/0140-6736(93)90490-8; TSUKITA S, 1994, J CELL BIOL, V126, P391, DOI 10.1083/jcb.126.2.391; UNDERHILL C, 1992, J CELL SCI, V103, P293; WELSH CF, 1995, J CELL PHYSIOL, V164, P605, DOI 10.1002/jcp.1041640319; XIE YM, 1994, BIOCHEM BIOPH RES CO, V203, P1589, DOI 10.1006/bbrc.1994.2368; YU DH, 1992, J BIOL CHEM, V267, P10203; YU DH, 1994, CANCER RES, V54, P3260; YU DH, 1991, ONCOGENE, V6; ZHANG LR, 1995, CANCER RES, V55, P428	45	21	22	1	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN 6	1996	12	11					2309	2314						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UQ220	8649770				2022-12-25	WOS:A1996UQ22000007
J	Herwald, H; Renne, T; Meijers, JCM; Chung, DW; Page, JD; Colman, RW; MullerEsterl, W				Herwald, H; Renne, T; Meijers, JCM; Chung, DW; Page, JD; Colman, RW; MullerEsterl, W			Mapping of the discontinuous kininogen binding site of prekallikrein - A distal binding segment is located in the heavy chain domain A4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-WEIGHT KININOGEN; HUMAN-PLASMA PREKALLIKREIN; BLOOD-COAGULATION FACTOR; 4 TANDEM REPEATS; FACTOR-XI; FUNCTIONAL-PROPERTIES; POLYACRYLAMIDE GELS; HAGEMAN-FACTOR; KALLIKREIN; PROTEINS	Prekallikrein, the precursor to the serine proteinase kallikrein, circulates in plasma in an equimolar complex with H-kininogen. The binding to H-kininogen is mediated by the kallikrein heavy chain consisting of four ''apple'' domains, A1-A4, which attaches to H-kininogen with high specificity and affinity (K-D = 83 nM). At least two distinct portions of the kallikrein heavy chain form this H-kininogen binding site: a proximal segment located in the NH2-terminal fragment of the heavy chain encompassing A1, and distal segment(s) located in COOH-terminal fragment spanning domains A2-A4. The proximal binding segment has been located to amino acid positions 56-86 of A1. To precisely map the distal binding segment, we have identified monoclonal antibodies directed to the COOH-terminal fragment which interfere with the H-kininogen-prekallikrein complex formation. Monoclonal antibody 13G11 binds to recombinant apple domain A4 but not to domain A3 of the prekallikrein heavy chain. Deletion mutagenesis of domain A4 narrowed down the target epitope of 13G11 to the center portion of domain A4, positions 284-331. Direct binding studies of H-kininogen to various domain A4 constructs revealed that the distal H-kininogen binding portion is located on a segment of 48 residues, which overlaps the 13G11 epitope. Hence the tight interaction of H-kininogen add prekallikrein is mediated by at least two separate sequence segments located in domains A1 and A4, respectively, of the prekallikrein heavy chain. The isolated distal binding segment significantly prolongs the partial thromboplastin time of reconstituted Williams plasma thus stressing the critical role of the prekallikrein-H-kininogen complex formation in the initiation of the endogenous blood coagulation cascade.	UNIV MAINZ,INST PHYSIOL CHEM & PATHOBIOCHEM,D-55099 MAINZ,GERMANY; UNIV UTRECHT HOSP,DEPT HAEMATOL,3508 GA UTRECHT,NETHERLANDS; UNIV WASHINGTON,DEPT BIOCHEM,SEATTLE,WA 98195; TEMPLE UNIV,SCH MED,SOL SHERRY THROMBOSIS RES CTR,PHILADELPHIA,PA 19140	Johannes Gutenberg University of Mainz; Utrecht University; Utrecht University Medical Center; University of Washington; University of Washington Seattle; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University			Meijers, J.C.M./S-5981-2019; Herwald, Heiko/AAN-3708-2021; Sessum, Rachel/F-7312-2015	Meijers, J.C.M./0000-0002-4198-6780; Herwald, Heiko/0000-0002-8111-2842; Sessum, Rachel/0000-0002-2444-7056; Renne, Thomas/0000-0003-4594-5975	NHLBI NIH HHS [HL16929] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BAGLIA FA, 1991, J BIOL CHEM, V266, P24190; BAGLIA FA, 1995, BLOOD, V85, P2078, DOI 10.1182/blood.V85.8.2078.bloodjournal8582078; BAGLIA FA, 1995, J BIOL CHEM, V270, P6734, DOI 10.1074/jbc.270.12.6734; BAGLIA FA, 1992, J BIOL CHEM, V267, P4247; Baglia FA, 1996, J BIOL CHEM, V271, P3652; BAGLIA FA, 1993, J BIOL CHEM, V268, P3838; BERGER D, 1986, J BIOL CHEM, V261, P324; CHUNG DW, 1986, BIOCHEMISTRY-US, V25, P2410, DOI 10.1021/bi00357a017; COCHRANE CG, 1973, J EXP MED, V138, P1564, DOI 10.1084/jem.138.6.1564; COLMAN RW, 1985, BLOOD, V65, P311; FUJIKAWA K, 1986, BIOCHEMISTRY-US, V25, P2417, DOI 10.1021/bi00357a018; Gros E., 1967, METHOD ENZYMOL, V11, P238; GUSTAFSON EJ, 1989, J CLIN INVEST, V84, P28, DOI 10.1172/JCI114151; HASAN AAK, 1994, J BIOL CHEM, V269, P31822; HASAN AAK, 1995, J BIOL CHEM, V270, P19256, DOI 10.1074/jbc.270.33.19256; HEERWALD H, 1995, J BIOL CHEM, V270, P14634; HENDERSON LM, 1994, BLOOD, V84, P474; HERWALD H, 1993, J BIOL CHEM, V268, P14527; HEUKESHOVEN J, 1985, ELECTROPHORESIS, V6, P103, DOI 10.1002/elps.1150060302; HOCK J, 1990, J BIOL CHEM, V265, P12005; ICHINOSE A, 1986, J BIOL CHEM, V261, P3486; JOHANNESSEN M, 1990, THROMB HAEMOSTASIS, V63, P54; KAPLAN AP, 1987, BLOOD, V70, P1; KAUFMANN J, 1993, J BIOL CHEM, V268, P9079; KYHSEANDERSEN J, 1984, J BIOCHEM BIOPH METH, V10, P203, DOI 10.1016/0165-022X(84)90040-X; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MAINA CV, 1988, GENE, V74, P365, DOI 10.1016/0378-1119(88)90170-9; MANDLE R, 1977, J BIOL CHEM, V252, P6097; MANDLE R, 1977, P NATL ACAD SCI USA, V73, P4179; MCMULLEN BA, 1991, BIOCHEMISTRY-US, V30, P2050, DOI 10.1021/bi00222a007; MEIJERS JCM, 1992, BLOOD, V79, P1435; MEIJERS JCM, 1992, BIOCHEMISTRY-US, V31, P4680, DOI 10.1021/bi00134a021; PAGE JD, 1991, J BIOL CHEM, V266, P8143; PAGE JD, 1994, ARCH BIOCHEM BIOPHYS, V314, P159, DOI 10.1006/abbi.1994.1424; PROCTOR RR, 1961, AM J CLIN PATHOL, V36, P212; SALVESEN G, 1986, BIOCHEM J, V234, P429, DOI 10.1042/bj2340429; SCHAPIRA M, 1982, J CLIN INVEST, V69, P1199, DOI 10.1172/JCI110557; SCHAPIRA M, 1982, J CLIN INVEST, V69, P462, DOI 10.1172/JCI110470; SCHMAIER AH, 1988, J BIOL CHEM, V263, P16327; TAIT JF, 1987, J BIOL CHEM, V262, P11651; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VANDERGRAAF F, 1982, J BIOL CHEM, V257, P4300; VELOSO D, 1987, BLOOD, V70, P1053; VOGEL R, 1990, J BIOL CHEM, V265, P12494; YOU JL, 1993, PEPTIDES, V14, P867, DOI 10.1016/0196-9781(93)90061-K	45	37	38	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 31	1996	271	22					13061	13067		10.1074/jbc.271.22.13061	http://dx.doi.org/10.1074/jbc.271.22.13061			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UN474	8662705	hybrid			2022-12-25	WOS:A1996UN47400059
J	Bakos, E; Hegedus, T; Hollo, Z; Welker, E; Tusnady, GE; Zaman, GJR; Flens, MJ; Varadi, A; Sarkadi, B				Bakos, E; Hegedus, T; Hollo, Z; Welker, E; Tusnady, GE; Zaman, GJR; Flens, MJ; Varadi, A; Sarkadi, B			Membrane topology and glycosylation of the human multidrug resistance-associated protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACTERIAL TRANSPORT PROTEINS; MDR1 P-GLYCOPROTEIN; INSECT CELLS; GENE; ORIENTATION; EXPRESSION; HOMOLOGY; CDNA; SITE	The membrane topology of the human multidrug resistance-associated protein (MRP) was examined by flow cytometry phenotyping, immunoblotting, and limited proteolysis in drug-resistant human and baculovirus-infected insect cells, expressing either the glycosylated or the underglycosylated forms of this protein, Inhibition of N-linked glycosylation in human cells by tunicamycin did not inhibit the transport function or the antibody recognition of MRP, although its apparent molecular mass was reduced from 180 kDa to 150 kDa. Extracellular addition of trypsin or chymotrypsin had no effect either on the function or on the molecular mass of MRP, while in isolated membranes limited proteolysis produced three large membrane-bound fragments, These experiments and the alignment of the MRP sequence with the human cystic fibrosis transmembrane conductance regulator (CFTR) suggest that human MRP, similarly to CFTR, contains a tandem repeat of six transmembrane helices, each followed by a nucleotide binding domain, and that the C-terminal membrane-bound region is glycosylated. However, the N-terminal region of MRP contains an additional membrane-bound, glycosylated area with four or five transmembrane helices, which seems to be a characteristic feature of MRP-like ATP-binding cassette transporters.	NATL INST HAEMATOL & IMMUNOL, H-1113 BUDAPEST, HUNGARY; HUNGARIAN ACAD SCI, BIOL RES CTR, INST ENZYMOL, H-1113 BUDAPEST, HUNGARY; NETHERLANDS CANC INST, 1080 HV AMSTERDAM, NETHERLANDS; FREE UNIV AMSTERDAM HOSP, DEPT PATHOL, 1080 HV AMSTERDAM, NETHERLANDS	Hungarian Academy of Sciences; Hungarian Biological Research Center; Hungarian Research Centre for Natural Sciences; Netherlands Cancer Institute; Vrije Universiteit Amsterdam; VU UNIVERSITY MEDICAL CENTER			Hegedus, Tamas/P-8625-2015; Sarkadi, Balazs/I-5024-2013; Welker, Ervin/AAC-6493-2022; Tusnády, Gábor E/A-3207-2009; Varadi, Andras/A-2055-2012; Tusnády, Gábor E./AAI-1136-2021	Hegedus, Tamas/0000-0002-5195-749X; Tusnády, Gábor E/0000-0001-8105-0285; Tusnády, Gábor E./0000-0001-8105-0285				CHANG XB, 1994, J BIOL CHEM, V269, P18572; CHEN CJ, 1986, CELL, V47, P381, DOI 10.1016/0092-8674(86)90595-7; COLE SPC, 1993, SCIENCE, V260, P879, DOI 10.1126/science.8098549; COLE SPC, 1992, SCIENCE, V258, P1650, DOI 10.1126/science.1360704; ENDICOTT JA, 1989, ANNU REV BIOCHEM, V58, P137, DOI 10.1146/annurev.bi.58.070189.001033; FELLER N, 1995, FEBS LETT, V368, P385, DOI 10.1016/0014-5793(95)00677-2; FLENS MJ, 1994, CANCER RES, V54, P4557; GERMANN UA, 1990, BIOCHEMISTRY-US, V29, P2295, DOI 10.1021/bi00461a013; GOTTESMAN MM, 1993, ANNU REV BIOCHEM, V62, P385, DOI 10.1146/annurev.bi.62.070193.002125; GROS P, 1986, CELL, V47, P371, DOI 10.1016/0092-8674(86)90594-5; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; Hollo Z, 1996, FEBS LETT, V383, P99, DOI 10.1016/0014-5793(96)00237-2; HOLLO Z, 1994, BBA-BIOMEMBRANES, V1191, P384, DOI 10.1016/0005-2736(94)90190-2; HOMOLYA L, 1993, J BIOL CHEM, V268, P21493; Homolya L, 1996, BRIT J CANCER, V73, P849, DOI 10.1038/bjc.1996.151; JEDLITSCHKY G, 1994, CANCER RES, V54, P4833; KAST C, 1995, BIOCHEMISTRY-US, V34, P4402, DOI 10.1021/bi00013a032; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LOO TW, 1995, J BIOL CHEM, V270, P843, DOI 10.1074/jbc.270.2.843; MCGRATH T, 1989, BIOCHEM PHARMACOL, V38, P3611, DOI 10.1016/0006-2952(89)90134-2; NILSSON I, 1993, J BIOL CHEM, V268, P5798; Paulusma CC, 1996, SCIENCE, V271, P1126, DOI 10.1126/science.271.5252.1126; SARKADI B, 1992, J BIOL CHEM, V267, P4854; SCHINKEL AH, 1993, J BIOL CHEM, V268, P7474; SZCZYPKA MS, 1994, J BIOL CHEM, V269, P22853; VERSANTVOORT CHM, 1995, BRIT J CANCER, V72, P82, DOI 10.1038/bjc.1995.281; YOSHIMURA A, 1989, J BIOL CHEM, V264, P16282; ZAMAN GJR, 1995, P NATL ACAD SCI USA, V92, P7690, DOI 10.1073/pnas.92.17.7690; ZAMAN GJR, 1994, P NATL ACAD SCI USA, V91, P8822, DOI 10.1073/pnas.91.19.8822; ZHANG JT, 1991, J BIOL CHEM, V266, P18224; ZHANG JT, 1993, J BIOL CHEM, V268, P15101	32	195	197	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 24	1996	271	21					12322	12326		10.1074/jbc.271.21.12322	http://dx.doi.org/10.1074/jbc.271.21.12322			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UL660	8647833	hybrid			2022-12-25	WOS:A1996UL66000035
J	Bielawska, A; Greenberg, MS; Perry, D; Jayadev, S; Shayman, JA; McKay, C; Hannun, YA				Bielawska, A; Greenberg, MS; Perry, D; Jayadev, S; Shayman, JA; McKay, C; Hannun, YA			(1S,2R)-D-erythro-2-(N-myristoylamino)-1-phenyl-1-propanol as an inhibitor of ceramidase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; D-ERYTHRO-SPHINGOSINE; D-THREO-SPHINGOSINE; CELL-FREE SYSTEM; GLUCOSYLCERAMIDE SYNTHASE; HL-60 CELLS; SPHINGOMYELIN METABOLISM; MEDIATED BIOLOGY; PHOSPHOLIPASE-D; L-SERINE	In this study, we have examined the cellular and biochemical activities of the ceramide analog (1S,2R)-D-erythro-2-(N-myristoylamino)-1-phenyl-1-propanol (D-erythro-MAPP). Addition of 5 mu M D-e-MAPP to HL-60 human promyelocytic leukemia cells resulted in a concentration- and time-dependent growth suppression accompanied by an arrest in the G(0)/G(1) phase of the cell cycle; thus mimicking the action of exogenous ceramides. Its enantiomer L-e-MAPP was without effect. Two lines of evidence suggested that D-e-MAPP may not function as a direct analog of ceramide. First, D-e-MAPP possesses a stereochemical configuration opposite to that of D-erythro-ceramide. Second, D-e-MAPP failed to activate ceramide-activated protein phosphatase in vitro. Therefore, we examined if D-e-MAPP functioned indirectly by modulating endogenous ceramide levels. The addition of D-e-MAPP to cells, but not L-e-MAPP, caused a time- and concentration-dependent elevation in endogenous ceramide levels reaching greater than 3-fold over base-line following 24 h of treatment. Both D-e-MAPP and L-e-MAPP underwent similar uptake by HL-60 cells. D-e-MAPP was poorly metabolized, and remained intact in cells, whereas L-e-MAPP underwent a time- and concentration-dependent metabolism; primarily through N-deacylation. In vitro, L-e-MAPP was metabolized by alkaline ceramidase to an extent similar to that seen with C-16-ceramide, D-e-MAPP was not metabolized. Instead, D-e-MAPP inhibited alkaline ceramidase activity in vitro with an IC50 of 1-5 mu M. D-e-MAPP did not modulate the activity of other ceramide metabolizing enzymes in vitro or in cells, and it was a poor inhibitor of acid ceramidase (IC50 > 500 mu M). Finally, D-e-MAPP inhibited the metabolism of L-e-MAPP in cells. These studies demonstrate that D-e-MAPP functions as an inhibitor of alkaline ceramidase in vitro and in cells resulting in elevation in endogenous levels of ceramide with the consequent biologic effects of growth suppression and cell cycle arrest. These studies point to an important role for ceramidases in the regulation of endogenous levels of ceramide.	DUKE UNIV, MED CTR, DEPT MED, DURHAM, NC 27710 USA; DUKE UNIV, MED CTR, DEPT PEDIAT, DURHAM, NC 27710 USA; UNIV MICHIGAN, MED CTR, DEPT MED, ANN ARBOR, MI 48109 USA	Duke University; Duke University; University of Michigan System; University of Michigan					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK045067] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM043825, R37GM043825] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK45067] Funding Source: Medline; NIGMS NIH HHS [GM43825] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABE A, 1992, J BIOCHEM-TOKYO, V111, P191, DOI 10.1093/oxfordjournals.jbchem.a123736; BALLOU LR, 1992, J BIOL CHEM, V267, P20044; BARBOUR S, 1992, J CELL PHYSIOL, V150, P610, DOI 10.1002/jcp.1041500322; BERNARDO K, 1995, J BIOL CHEM, V270, P11098, DOI 10.1074/jbc.270.19.11098; BIELAWSKA A, 1993, J BIOL CHEM, V268, P26226; BIELAWSKA A, 1992, FEBS LETT, V307, P211, DOI 10.1016/0014-5793(92)80769-D; BIELAWSKA A, 1992, J BIOL CHEM, V267, P18493; BUEHRER BM, 1993, ADV LIPID RES, V26, P59; CARTER HE, 1956, J BIOL CHEM, V221, P879; CHAO MV, 1995, MOL CELL NEUROSCI, V6, P91, DOI 10.1006/mcne.1995.1009; CHAO R, 1992, J BIOL CHEM, V267, P23459; CHEN WW, 1981, ARCH BIOCHEM BIOPHYS, V208, P444, DOI 10.1016/0003-9861(81)90531-2; CORONEOS E, 1995, J BIOL CHEM, V270, P23305, DOI 10.1074/jbc.270.40.23305; DBAIBO GS, 1995, P NATL ACAD SCI USA, V92, P1347, DOI 10.1073/pnas.92.5.1347; DOBROWSKY RT, 1993, J BIOL CHEM, V268, P15523; DOBROWSKY RT, 1992, J BIOL CHEM, V267, P5048; DOBROWSKY RT, 1994, SCIENCE, V265, P1596, DOI 10.1126/science.8079174; DRESSLER KA, 1992, SCIENCE, V255, P1715, DOI 10.1126/science.1313189; FISHBEIN JD, 1993, J BIOL CHEM, V268, P9255; GARNER P, 1988, J ORG CHEM, V53, P4395, DOI 10.1021/jo00253a039; GATT S, 1969, METHOD ENZYMOL, V14, P139; GOLDKORN T, 1991, J BIOL CHEM, V266, P16092; GOMEZMUNOZ A, 1994, J BIOL CHEM, V269, P8937; HAKOMORI SI, 1981, ANNU REV BIOCHEM, V50, P733, DOI 10.1146/annurev.bi.50.070181.003505; HANNUN YA, 1986, J BIOL CHEM, V261, P2604; HANNUN YA, 1994, J BIOL CHEM, V269, P3125; HANNUN YA, 1995, TRENDS BIOCHEM SCI, V20, P73, DOI 10.1016/S0968-0004(00)88961-6; HANNUN YA, 1991, METHOD ENZYMOL, V201, P316; HEROLD P, 1988, HELV CHIM ACTA, V71, P354, DOI 10.1002/hlca.19880710208; INOKUCHI J, 1990, CANCER RES, V50, P6731; INOKUCHI JI, 1989, J CELL PHYSIOL, V141, P573, DOI 10.1002/jcp.1041410316; JAYADEV S, 1995, J BIOL CHEM, V270, P2047, DOI 10.1074/jbc.270.5.2047; JONES MJ, 1995, J BIOL CHEM, V270, P5007, DOI 10.1074/jbc.270.10.5007; KISS Z, 1992, BIOCHIM BIOPHYS ACTA, V1124, P300, DOI 10.1016/0005-2760(92)90143-J; KISS Z, 1995, FEBS LETT, V365, P146, DOI 10.1016/0014-5793(95)00445-F; KOLESNICK R, 1995, J EXP MED, V181, P1949, DOI 10.1084/jem.181.6.1949; LAULEDERKIND SJF, 1995, J EXP MED, V182, P599, DOI 10.1084/jem.182.2.599; LAVIE Y, 1990, J BIOL CHEM, V265, P3868; LINARDIC CM, 1994, J BIOL CHEM, V269, P23530; LISCOVITCH M, 1992, TRENDS BIOCHEM SCI, V17, P393, DOI 10.1016/0968-0004(92)90007-V; MATHIAS S, 1993, SCIENCE, V259, P519, DOI 10.1126/science.8424175; MERRILL AH, 1990, BIOCHIM BIOPHYS ACTA, V1044, P1, DOI 10.1016/0005-2760(90)90211-F; MERRILL AH, 1992, NUTR REV, V50, P78; MERRILL AH, 1986, J BIOL CHEM, V261, P2610; MERRILL AH, 1989, BIOCHEMISTRY-US, V28, P3138, DOI 10.1021/bi00434a004; MERRILL AH, 1992, METHOD ENZYMOL, V209, P427; NAKAMURA T, 1994, J BIOL CHEM, V269, P18384; NIMKAR S, 1988, TETRAHEDRON LETT, V29, P3037, DOI 10.1016/0040-4039(88)85079-2; OBEID LM, 1993, SCIENCE, V259, P1769, DOI 10.1126/science.8456305; OKAZAKI T, 1989, J BIOL CHEM, V264, P19076; OKAZAKI T, 1990, J BIOL CHEM, V265, P15823; PUSHKAREVA M, 1995, BIOCHEMISTRY-US, V34, P1885, DOI 10.1021/bi00006a009; QUINTANS J, 1994, BIOCHEM BIOPH RES CO, V202, P710, DOI 10.1006/bbrc.1994.1988; RANI CSS, 1995, J BIOL CHEM, V270, P2859, DOI 10.1074/jbc.270.6.2859; SLIFE CW, 1989, J BIOL CHEM, V264, P10371; SPENCE MW, 1986, BIOCHEM CELL BIOL, V64, P400, DOI 10.1139/o86-056; SPIEGEL S, 1994, BREAST CANCER RES TR, V31, P337, DOI 10.1007/BF00666166; STOFFEL W, 1973, CHEM PHYS LIPIDS, V11, P318, DOI 10.1016/0009-3084(73)90068-6; SUGITA M, 1975, BIOCHIM BIOPHYS ACTA, V398, P125, DOI 10.1016/0005-2760(75)90176-9; TEPPER CG, 1995, P NATL ACAD SCI USA, V92, P8443, DOI 10.1073/pnas.92.18.8443; UEMURA K, 1991, J BIOCHEM-TOKYO, V110, P96, DOI 10.1093/oxfordjournals.jbchem.a123549; VANECHTEN G, 1993, J BIOL CHEM, V268, P5341; VENABLE ME, 1994, J BIOL CHEM, V269, P26040; WANG E, 1991, J BIOL CHEM, V266, P14486; WERTZ PW, 1990, FEBS LETT, V268, P110, DOI 10.1016/0014-5793(90)80985-R; Wiegandt H, 1985, GLYCOLIPIDS, V10, P199, DOI DOI 10.1016/S0167-7306(08)60022-8; WOLFF RA, 1994, J BIOL CHEM, V269, P19605; YANAGA F, 1992, FEBS LETT, V314, P297, DOI 10.1016/0014-5793(92)81493-6; YATOMI Y, 1995, BLOOD, V86, P193, DOI 10.1182/blood.V86.1.193.bloodjournal861193	69	185	202	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 24	1996	271	21					12646	12654		10.1074/jbc.271.21.12646	http://dx.doi.org/10.1074/jbc.271.21.12646			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UL660	8647877	hybrid			2022-12-25	WOS:A1996UL66000079
J	Drake, FH; Dodds, RA; James, IE; Connor, JR; Debouck, C; Richardson, S; LeeRykaczewski, E; Coleman, L; Rieman, D; Barthlow, R; Hastings, G; Gowen, M				Drake, FH; Dodds, RA; James, IE; Connor, JR; Debouck, C; Richardson, S; LeeRykaczewski, E; Coleman, L; Rieman, D; Barthlow, R; Hastings, G; Gowen, M			Cathepsin K, but not cathepsins B, L, or S, is abundantly expressed in human osteoclasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYSTEINE PROTEINASE-INHIBITOR; BONE-RESORPTION; RAT OSTEOCLAST; LOCALIZATION	Random high throughput sequencing of a human osteoclast cDNA library was employed to identify novel osteoclast-expressed genes. Of the 5475 ESTs obtained, approximately 4% encoded cathepsin K, a novel cysteine protease homologous to cathepsins S and L; ESTs for other cathepsins were rare. In addition, ESTs for cathepsin K were absent or at low frequency in cDNA libraries from numerous other tissues and cells. In situ hybridization in osteoclastoma and osteophyte confirmed that cathepsin K mRNA was highly expressed selectively in osteoclasts; cathepsins S, L, and B were not detectable. Cathepsin K was not detected by in situ hybridization in a panel of other tissues. Western blot of human osteoclastoma or fetal rat humerus demonstrated bands of 38 and 27 kDa, consistent with sizes predicted for pro- and mature cathepsin K. Immunolocalization in osteoclastoma and osteophyte showed intense punctate staining of cathepsin K exclusively in osteoclasts, with a polar distribution that was more intense at the bone surface. The abundant expression of cathepsin K selectively in osteoclasts strongly suggests that it plays a specialized role in bone resorption. Furthermore, the data suggest that random sequencing of ESTs from cDNA libraries is a valuable approach for identifying novel cell-selective genes.	SMITHKLINE BEECHAM PHARMACEUT,DEPT MOLEC GENET,KING OF PRUSSIA,PA 19406; HUMAN GENOME SCI INC,ROCKVILLE,MD 20850	GlaxoSmithKline; GlaxoSmithKline; Human Genome Sciences Inc	Drake, FH (corresponding author), SMITHKLINE BEECHAM PHARMACEUT,DEPT CELLULAR BIOCHEM,POB 1539,KING OF PRUSSIA,PA 19406, USA.							ADAMS MD, 1992, NATURE, V355, P632, DOI 10.1038/355632a0; ADAMS MD, 1995, NATURE, V377, P3; ADAMS MD, 1991, SCIENCE, V252, P1651, DOI 10.1126/science.2047873; Baron Roland, 1993, P3; Bossard MJ, 1996, J BIOL CHEM, V271, P12517, DOI 10.1074/jbc.271.21.12517; BROMME D, 1995, BIOL CHEM H-S, V376, P379, DOI 10.1515/bchm3.1995.376.6.379; DELAISSE JM, 1980, BIOCHEM J, V192, P365, DOI 10.1042/bj1920365; DELAISSE JM, 1987, BONE, V8, P305, DOI 10.1016/8756-3282(87)90007-X; DELAISSE JM, 1991, BIOCHEM J, V279, P167, DOI 10.1042/bj2790167; DELAISSE JM, 1984, BIOCHEM BIOPH RES CO, V125, P441, DOI 10.1016/0006-291X(84)90560-6; DODDS RA, 1994, J HISTOCHEM CYTOCHEM, V42, P599, DOI 10.1177/42.5.8157931; Drake FH, 1994, J BONE MINER RES, V9, pS177; EVERTS V, 1992, J CELL PHYSIOL, V150, P221, DOI 10.1002/jcp.1041500202; GOTO T, 1992, HISTOCHEMISTRY, V97, P13, DOI 10.1007/BF00271276; GOTO T, 1994, HISTOCHEMISTRY, V101, P33, DOI 10.1007/BF00315829; GOTO T, 1993, HISTOCHEMISTRY, V99, P411, DOI 10.1007/BF00717054; HILL PA, 1994, J CELL BIOCHEM, V56, P118, DOI 10.1002/jcb.240560116; INAOKA T, 1995, BIOCHEM BIOPH RES CO, V206, P89, DOI 10.1006/bbrc.1995.1013; KAKEGAWA H, 1993, FEBS LETT, V321, P247, DOI 10.1016/0014-5793(93)80118-E; KREMER M, 1995, J CELL BIOCHEM, V57, P271, DOI 10.1002/jcb.240570211; LERNER UH, 1992, J BONE MINER RES, V7, P433; Li Y. P., 1994, Molecular Biology of the Cell, V5, p335A; LI YP, 1995, J BONE MINER RES, V10, P1197; MACIEWICZ RA, 1988, BIOCHEM J, V256, P433, DOI 10.1042/bj2560433; OHSAWA Y, 1993, J HISTOCHEM CYTOCHEM, V41, P1075, DOI 10.1177/41.7.8515049; PAGE AE, 1992, BIOCHIM BIOPHYS ACTA, V1116, P57, DOI 10.1016/0304-4165(92)90128-H; RIFKIN BR, 1991, BIOCHEM BIOPH RES CO, V179, P63, DOI 10.1016/0006-291X(91)91334-9; SANNES PL, 1986, J HISTOCHEM CYTOCHEM, V34, P983, DOI 10.1177/34.8.3016074; SASAKI T, 1993, CELL TISSUE RES, V271, P177, DOI 10.1007/BF00297556; SHI GP, 1995, FEBS LETT, V357, P129, DOI 10.1016/0014-5793(94)01349-6; TAGAMI K, 1994, FEBS LETT, V342, P308, DOI 10.1016/0014-5793(94)80522-9; TEZUKA K, 1994, J BIOL CHEM, V269, P1106; VANNOORDEN CJF, 1989, J HISTOCHEM CYTOCHEM, V37, P617, DOI 10.1177/37.5.2703699; ZELLER R, 1991, CURRENT PROTOCOLS MO	34	599	638	0	24	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 24	1996	271	21					12511	12516		10.1074/jbc.271.21.12511	http://dx.doi.org/10.1074/jbc.271.21.12511			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UL660	8647859	hybrid			2022-12-25	WOS:A1996UL66000061
J	Ghislain, JJ; Fish, EN				Ghislain, JJ; Fish, EN			Application of genomic DNA affinity chromatography identifies multiple interferon-alpha-regulated Stat2 complexes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAMMA SIGNAL-TRANSDUCTION; PROTEIN-TYROSINE KINASE; TRANSCRIPTION FACTOR; GROWTH-FACTOR; CELL-LINE; GENE; ELEMENT; ISGF3; POLYPEPTIDE; ACTIVATION	Interferon-alpha (IFN-alpha)-induced signal transduction is mediated by the phosphorylation-activation of the signal transducer and activator of transcription (STAT) proteins Stat1, Stat2, and Stat3. Previous studies have shown that these activated STATs dimerize to form four distinct STAT complexes which translocate to the nucleus and activates transcription by binding to specific promoter elements. The interferon-stimulated gene factor-3 (ISGF3) consists of Stat2 and Stat1 heterodimers in association with a DNA binding protein, p48, that binds to the interferon stimulated response element. Homo- and heterodimers of Stat1 and Stat3 bind to the palindromic interferon response element (pIRE). In this report we demonstrate the utility of a biochemical procedure that we have developed, based on genomic DNA affinity chromatography, for the identification of IFN-alpha-induced STAT complexes. Using this approach, we identified ISGF3-independent Stat2 containing STAT complexes. Results from the analysis of Stat2 complexes in the electrophoretic mobility shift assay were consistent with genomic DNA affinity chromatography results and identified a Stat2:1 complex that binds with low affinity to the pIRE of the interferon regulatory factor-1 gene. Immunoprecipitation studies of Stat2 revealed an IFN-alpha dependent co-precipitation of both Stat1 and Stat3. Taken together, our results suggest that IFN-alpha activates, in addition to ISGF3, other Stat2-containing STAT complexes, one of which binds to an element related to the interferon regulatory factor-1 pIRE.	UNIV TORONTO,DEPT MICROBIOL,TORONTO,ON M5S 1A8,CANADA	University of Toronto								AKIRA S, 1994, CELL, V77, P63, DOI 10.1016/0092-8674(94)90235-6; BLUYSSEN HAR, 1995, P NATL ACAD SCI USA, V92, P5645, DOI 10.1073/pnas.92.12.5645; COHEN B, 1988, EMBO J, V7, P1411, DOI 10.1002/j.1460-2075.1988.tb02958.x; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; EILERS A, 1994, MOL CELL BIOL, V14, P1364, DOI 10.1128/MCB.14.2.1364; FU XY, 1992, P NATL ACAD SCI USA, V89, P7840, DOI 10.1073/pnas.89.16.7840; FU XY, 1992, CELL, V70, P323, DOI 10.1016/0092-8674(92)90106-M; FU XY, 1990, P NATL ACAD SCI USA, V87, P8555, DOI 10.1073/pnas.87.21.8555; GREENLUND AC, 1994, EMBO J, V13, P1591, DOI 10.1002/j.1460-2075.1994.tb06422.x; GUILLE MJ, 1994, EUR J BIOCHEM, V219, P547, DOI 10.1111/j.1432-1033.1994.tb19970.x; HAQUE SJ, 1994, J BIOL CHEM, V269, P19523; HEIM MH, 1995, SCIENCE, V267, P1347, DOI 10.1126/science.7871432; HORVATH CM, 1995, GENE DEV, V9, P984, DOI 10.1101/gad.9.8.984; HOU JZ, 1994, SCIENCE, V265, P1701, DOI 10.1126/science.8085155; IHLE JN, 1995, TRENDS GENET, V11, P69, DOI 10.1016/S0168-9525(00)89000-9; IMPROTA T, 1994, P NATL ACAD SCI USA, V91, P4776, DOI 10.1073/pnas.91.11.4776; JOHN J, 1991, MOL CELL BIOL, V11, P4189, DOI 10.1128/MCB.11.8.4189; KANNO Y, 1993, MOL CELL BIOL, V13, P3951, DOI 10.1128/MCB.13.7.3951; KHAN KD, 1993, P NATL ACAD SCI USA, V90, P6806, DOI 10.1073/pnas.90.14.6806; LEUNG S, 1995, MOL CELL BIOL, V15, P1312; LEVY DE, 1988, GENE DEV, V2, P383, DOI 10.1101/gad.2.4.383; LEVY DE, 1989, GENE DEV, V3, P1362, DOI 10.1101/gad.3.9.1362; MULLER M, 1993, NATURE, V366, P129, DOI 10.1038/366129a0; MULLER M, 1993, EMBO J, V12, P4221, DOI 10.1002/j.1460-2075.1993.tb06106.x; PESTKA S, 1987, ANNU REV BIOCHEM, V56, P727, DOI 10.1146/annurev.biochem.56.1.727; Qureshi SA, 1996, MOL CELL BIOL, V16, P288; QURESHI SA, 1995, P NATL ACAD SCI USA, V92, P3829, DOI 10.1073/pnas.92.9.3829; RAZ R, 1994, J BIOL CHEM, V269, P24391; SADOWSKI HB, 1993, NATURE, V362, P79, DOI 10.1038/362079a0; SADOWSKI HB, 1993, SCIENCE, V261, P1739, DOI 10.1126/science.8397445; SCHAEFER TS, 1995, P NATL ACAD SCI USA, V92, P9097, DOI 10.1073/pnas.92.20.9097; SCHINDLER C, 1992, SCIENCE, V257, P809, DOI 10.1126/science.1496401; SCHINDLER U, 1995, IMMUNITY, V2, P689, DOI 10.1016/1074-7613(95)90013-6; SEEGERT D, 1994, J BIOL CHEM, V269, P8590; SHUAI K, 1994, CELL, V76, P821, DOI 10.1016/0092-8674(94)90357-3; SIMS SH, 1993, MOL CELL BIOL, V13, P690, DOI 10.1128/MCB.13.1.690; STAHL N, 1995, SCIENCE, V267, P1349, DOI 10.1126/science.7871433; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VEALS SA, 1992, MOL CELL BIOL, V12, P3315, DOI 10.1128/MCB.12.8.3315; VELAZQUEZ L, 1992, CELL, V70, P313, DOI 10.1016/0092-8674(92)90105-L; WAKAO H, 1994, EMBO J, V13, P2182, DOI 10.1002/j.1460-2075.1994.tb06495.x; ZHANG XK, 1995, SCIENCE, V267, P1990, DOI 10.1126/science.7701321; ZHONG Z, 1994, P NATL ACAD SCI USA, V91, P4806, DOI 10.1073/pnas.91.11.4806	43	56	59	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 24	1996	271	21					12408	12413		10.1074/jbc.271.21.12408	http://dx.doi.org/10.1074/jbc.271.21.12408			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UL660	8647845	hybrid			2022-12-25	WOS:A1996UL66000047
J	Maiyar, AC; Huang, AJ; Phu, PT; Cha, HH; Firestone, GL				Maiyar, AC; Huang, AJ; Phu, PT; Cha, HH; Firestone, GL			p53 stimulates promoter activity of the sgk serum/glucocorticoid-inducible serine/threonine protein kinase gene in rodent mammary epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WILD-TYPE P53; TATA-BINDING PROTEIN; TUMOR-SUPPRESSOR; DNA-BINDING; EXPRESSION; TRANSCRIPTION; SEQUENCE; IDENTIFICATION; DIFFERENTIATION; COMPLEXES	sgk is a novel member of the serine/threonine protein kinase gene family that is transcriptionally regulated by serum and glucocorticoids in mammary epithelial cells. To functionally determine if the sgk promoter is regulated by the p53 tumor suppressor protein in mammary cells, a series of sgk promoter fragments with 5'-deletions were linked to the bacterial chloramphenicol acetyltransferase gene (sgk-CAT) and transiently cotransfected into nontumorigenic NMuMG or transformed Con8Hd6 mammary epithelial cells with p53 expression plasmids. Wild-type p53, but not mutant p53, strongly stimulated sgk promoter activity in both mammary epithelial cell lines. These effects were mediated by specific regions within the sgk promoter containing p53 DNA-binding sites. The sgk p53 sequence at -1380 to -1345 (site IV) was sufficient to confer p53-dependent transactivation to a heterologous promoter, and p53 was capable of binding to this sequence in vitro as assessed by gel shift analysis. In the nontumorigenic NMuMG epithelial cell line, cotransfection of wild-type p53 strongly stimulated the activities of both the sgk promoter and the well characterized p53-responsive p21/Waf1 promoter, whereas in Rat a fibroblasts, wild-type p53 repressed the basal activities of both promoters, revealing that sgk and p21/Waf1 are similarly regulated in a cell type-specific manner. Taken together, these results demonstrate that sgk is a new transcriptional target of p53 in mammary epithelial cells and represent the first example of a hormone-regulated protein kinase gene with a functionally defined p53 promoter recognition element.	UNIV CALIF BERKELEY,DEPT MOLEC & CELL BIOL,BERKELEY,CA 94720; UNIV CALIF BERKELEY,CANC RES LAB,BERKELEY,CA 94720	University of California System; University of California Berkeley; University of California System; University of California Berkeley					NCI NIH HHS [CA-05388] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA005388] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AGOFF SN, 1993, SCIENCE, V259, P84, DOI 10.1126/science.8418500; AITKEN A, 1995, TRENDS BIOCHEM SCI, V20, P95, DOI 10.1016/S0968-0004(00)88971-9; AOYAMA N, 1992, P NATL ACAD SCI USA, V89, P5403, DOI 10.1073/pnas.89.12.5403; BAND V, 1993, EMBO J, V12, P1847, DOI 10.1002/j.1460-2075.1993.tb05833.x; BARGONETTI J, 1991, CELL, V65, P1083, DOI 10.1016/0092-8674(91)90560-L; BARTEK J, 1990, INT J CANCER, V46, P839, DOI 10.1002/ijc.2910460515; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHEN CA, 1988, BIOTECHNIQUES, V6, P632; CHIN KV, 1992, SCIENCE, V255, P459, DOI 10.1126/science.1346476; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; CLAY FJ, 1993, P NATL ACAD SCI USA, V90, P4882, DOI 10.1073/pnas.90.11.4882; DAMERON KM, 1994, SCIENCE, V265, P1582, DOI 10.1126/science.7521539; DEB SP, 1994, ONCOGENE, V9, P1341; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DONEHOWER LA, 1993, BIOCHIM BIOPHYS ACTA, V1155, P181, DOI 10.1016/0304-419X(93)90004-V; DONEHOWER LA, 1995, GENE DEV, V9, P882, DOI 10.1101/gad.9.7.882; DONOHUE PJ, 1995, J BIOL CHEM, V270, P10351, DOI 10.1074/jbc.270.17.10351; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELIYAHU D, 1989, P NATL ACAD SCI USA, V86, P8763, DOI 10.1073/pnas.86.22.8763; ELIYAHU D, 1988, ONCOGENE, V3, P313; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FOORD O, 1993, MOL CELL BIOL, V13, P1378, DOI 10.1128/MCB.13.3.1378; FRIEND S, 1994, SCIENCE, V265, P334, DOI 10.1126/science.8023155; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; GINSBERG D, 1991, P NATL ACAD SCI USA, V88, P9979, DOI 10.1073/pnas.88.22.9979; GOLSTEYN RM, 1994, J CELL SCI, V107, P1509; GREENBLATT MS, 1994, CANCER RES, V54, P4855; HALAZONETIS TD, 1993, EMBO J, V12, P1021, DOI 10.1002/j.1460-2075.1993.tb05743.x; HAMANAKA R, 1994, CELL GROWTH DIFFER, V5, P249; HOLTRICH U, 1994, P NATL ACAD SCI USA, V91, P1736, DOI 10.1073/pnas.91.5.1736; HORIKOSHI N, 1995, MOL CELL BIOL, V15, P227, DOI 10.1128/MCB.15.1.227; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; IMAIZUMI K, 1994, MOL BRAIN RES, V26, P189, DOI 10.1016/0169-328X(94)90090-6; JACKSON P, 1994, BIOCHEM BIOPH RES CO, V203, P133, DOI 10.1006/bbrc.1994.2159; JANKNECHT R, 1993, BIOCHIM BIOPHYS ACTA, V1155, P346, DOI 10.1016/0304-419X(93)90014-4; JUVEN T, 1993, ONCOGENE, V8, P3411; KARIN M, 1994, CURR OPIN CELL BIOL, V6, P415, DOI 10.1016/0955-0674(94)90035-3; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; LEVY N, 1993, MOL CELL BIOL, V13, P7942, DOI 10.1128/MCB.13.12.7942; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MARTIN DW, 1993, J BIOL CHEM, V268, P13062; MCMAHON SB, 1992, FASEB J, V6, P2707, DOI 10.1096/fasebj.6.9.1612295; MERCER WE, 1991, P NATL ACAD SCI USA, V88, P1958, DOI 10.1073/pnas.88.5.1958; MERLO GR, 1995, J CELL BIOL, V128, P1185, DOI 10.1083/jcb.128.6.1185; MIYASHITA T, 1995, CELL, V80, P293; MIYASHITA T, 1994, CANCER RES, V54, P3131; MORRISON D, 1994, SCIENCE, V266, P56, DOI 10.1126/science.7939645; NEUMANN JR, 1987, BIOTECHNIQUES, V5, P444; OKAMOTO K, 1994, EMBO J, V13, P4816, DOI 10.1002/j.1460-2075.1994.tb06807.x; OREN M, 1992, FASEB J, V6, P3169, DOI 10.1096/fasebj.6.13.1397838; OSIFCHIN NE, 1994, J BIOL CHEM, V269, P6383; OWENS RB, 1974, J NATL CANCER I, V52, P1375, DOI 10.1093/jnci/52.4.1375; OZBUN MA, 1995, ADV CANCER RES, V66, P71, DOI 10.1016/S0065-230X(08)60252-3; PEVNY L, 1991, NATURE, V349, P257, DOI 10.1038/349257a0; PIETENPOL JA, 1993, NATURE, V365, P17, DOI 10.1038/365017a0; RICHARDS JS, 1995, RECENT PROG HORM RES, V50, P223; RUNNEBAUM IB, 1991, P NATL ACAD SCI USA, V88, P10657, DOI 10.1073/pnas.88.23.10657; SABBATINI P, 1995, MOL CELL BIOL, V15, P1060; SANG BC, 1994, ONCOGENE, V9, P853; SANTHANAM U, 1991, P NATL ACAD SCI USA, V88, P7605, DOI 10.1073/pnas.88.17.7605; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; SHIIO Y, 1992, P NATL ACAD SCI USA, V89, P5206, DOI 10.1073/pnas.89.12.5206; SHIN TH, 1995, MOL CELL BIOL, V15, P4694; SHIVAKUMAR CV, 1995, MOL CELL BIOL, V15, P6785; SIMMONS DL, 1992, MOL CELL BIOL, V12, P4164, DOI 10.1128/MCB.12.9.4164; SKOLNIK EY, 1993, SCIENCE, V260, P1953, DOI 10.1126/science.8316835; SUBLER MA, 1994, ONCOGENE, V9, P1351; SUBLER MA, 1992, J VIROL, V66, P4757, DOI 10.1128/JVI.66.8.4757-4762.1992; THANOS D, 1995, CELL, V80, P529, DOI 10.1016/0092-8674(95)90506-5; THUT CJ, 1995, SCIENCE, V267, P100, DOI 10.1126/science.7809597; TRUANT R, 1995, J VIROL, V69, P1851, DOI 10.1128/JVI.69.3.1851-1859.1995; TRUANT R, 1993, J BIOL CHEM, V268, P2284; UEBA T, 1994, P NATL ACAD SCI USA, V91, P9009, DOI 10.1073/pnas.91.19.9009; UMEK RM, 1991, SCIENCE, V251, P288, DOI 10.1126/science.1987644; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; WAZER DE, 1994, MOL CELL BIOL, V14, P2468, DOI 10.1128/MCB.14.4.2468; WEBSTER MK, 1993, MOL CELL BIOL, V13, P2031, DOI 10.1128/MCB.13.4.2031; WEBSTER MK, 1993, J BIOL CHEM, V268, P11482; ZAMBETTI GP, 1992, GENE DEV, V6, P1143, DOI 10.1101/gad.6.7.1143; ZAUBERMAN A, 1993, EMBO J, V12, P2799, DOI 10.1002/j.1460-2075.1993.tb05941.x; ZHAO JQ, 1994, MOL CELL BIOL, V14, P8483, DOI 10.1128/MCB.14.12.8483	83	64	66	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 24	1996	271	21					12414	12422		10.1074/jbc.271.21.12414	http://dx.doi.org/10.1074/jbc.271.21.12414			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UL660	8647846	hybrid			2022-12-25	WOS:A1996UL66000048
J	Tolkatchev, D; Yu, L; Yu, CA				Tolkatchev, D; Yu, L; Yu, CA			Potential induced redox reactions in mitochondrial and bacterial cytochrome b-c(1) complexes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IRON-SULFUR PROTEIN; ELECTRON-TRANSFER; ENERGY TRANSDUCTION; RESPIRATORY-CHAIN; C REDUCTASE; PHOSPHOLIPIDS; CHEMILUMINESCENCE; OXIDOREDUCTASE; RECONSTITUTION; ORGANIZATION	Purified cytochrome b-c(1) complexes from beef heart mitochondria and Rhodobacter sphaeroides were reconstituted into potassium-loaded asolectin liposomes for studies of the energy-dependent electron transfer reactions within the complexes, Both complexes in a ubiquinone-sufficient state exhibit antimycin-sensitive reduction of cytochromes b (both low and high potential ones) upon induction of a diffusion potential by valinomycin in the presence of ascorbate. Addition of N,N,N',N'-tetramethyl-p-phenylenediamine (TMPD) to the ascorbate-reduced potassium-loaded asolectin proteoliposomes resulted in reduction of cytochrome b(562). Upon addition of valinomycin, the induced diffusion potential caused a partial reoxidation of cytochrome b(562) and partial reduction of cytochrome b(566) in beef heart cytochrome b-c(1) complex in the presence of antimycin and/or myxothiazol. Surprisingly, when ubiquinone-depleted beef heart cytochrome b-c(1) complex liposomes were treated under the same conditions, no cytochrome b(566) reduction was observed but only the oxidation of cytochrome b(562), and the oxidation was not oxygen-dependent. We explain this effect by b(566), iron-sulfur protein short-circuiting under these conditions, assuming that both antimycin and myxothiazol markedly affect subunit b conformation, The electrochemical midpoint potential of heme b(566) appears to be significantly higher than that of heme b(562) in the presence of myxothiazol, which cannot be accounted for only by the potential-driven electron transfer between these two hemes plus the shift in chemical midpoint potentials caused by myxothiazol. A model for energy coupling consistent with structural findings by Ohnishi et al. (Ohnishi, T., Schagger, H., Meinhardt, S. W., LoBrutto, R., Link, T. A., and von Jagow, G. (1989) J. Biol. Chem. 264, 735-744) is presented. This model is a compromise between pure ''redox-loop'' and pure ''proton-pump'' mechanisms. Reoxidation of high potential heme b is observed in an antimycin or antimycin plus myxothiazol-inhibited, ascorbate plus TMPD-prereduced R. sphaeroides b-c(1) complex, upon membrane potential development, suggesting that a similar electron transfer mechanism is also operating in the bacterial complex.			Tolkatchev, D (corresponding author), OKLAHOMA STATE UNIV,DEPT BIOCHEM & MOLEC BIOL,STILLWATER,OK 74078, USA.		Tolkatchev, Dmitri/B-7631-2019		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM030721, R37GM030721] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM30721] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BEATTIE DS, 1982, J BIOL CHEM, V257, P4745; GOPHER A, 1980, J BIOENERG BIOMEMBR, V12, P349, DOI 10.1007/BF00748764; GUTWENIGER H, 1977, BIOCHIM BIOPHYS ACTA, V459, P216, DOI 10.1016/0005-2728(77)90023-8; GWAK SH, 1986, BIOCHEMISTRY-US, V25, P7675, DOI 10.1021/bi00371a059; KAMENSKY Y, 1985, FEBS LETT, V181, P95, DOI 10.1016/0014-5793(85)81120-0; KAMENSKY YA, 1979, DOKL AKAD NAUK SSSR, V249, P994; KONSTANTINOV AA, 1990, BIOCHIM BIOPHYS ACTA, V1018, P138, DOI 10.1016/0005-2728(90)90234-U; KONSTANTINOV AA, 1981, CHEMIOSMOTIC PROTON, P123; KONSTANTINOV AA, 1988, CYTOCHROME SYSTEMS M, P751; KUNZ WS, 1984, FEBS LETT, V172, P261, DOI 10.1016/0014-5793(84)81137-0; KUNZ WS, 1983, FEBS LETT, V155, P237, DOI 10.1016/0014-5793(82)80611-X; LEUNG KH, 1975, J BIOL CHEM, V250, P8467; LJUNGDAHL O, 1987, BIOCHIM BIOPHYS ACTA, V891, P227; MCCURLEY JP, 1990, BIOCHIM BIOPHYS ACTA, V1020, P176, DOI 10.1016/0005-2728(90)90049-A; MIKI T, 1994, J BIOL CHEM, V269, P1827; MITCHELL P, 1976, J THEOR BIOL, V62, P327, DOI 10.1016/0022-5193(76)90124-7; NAKANO M, 1990, METHOD ENZYMOL, V186, P585; NAKANO M, 1990, METHOD ENZYMOL, V186, P227; NELSON BD, 1974, BIOCHIM BIOPHYS ACTA, V357, P358, DOI 10.1016/0005-2728(74)90025-5; OHNISHI T, 1989, J BIOL CHEM, V264, P735; ROBERTSON DE, 1988, BIOCHIM BIOPHYS ACTA, V935, P273, DOI 10.1016/0005-2728(88)90223-X; SONE N, 1977, J BIOCHEM-TOKYO, V81, P519, DOI 10.1093/oxfordjournals.jbchem.a131485; TRUMPOWER BL, 1990, J BIOL CHEM, V265, P11409; TRUMPOWER BL, 1981, BIOCHIM BIOPHYS ACTA, V639, P129, DOI 10.1016/0304-4173(81)90008-2; VONJAGOW G, 1986, J BIOENERG BIOMEMBR, V18, P157, DOI 10.1007/BF00743462; VONJAGOW G, 1984, J BIOL CHEM, V259, P6318; WEST IC, 1988, BIOCHIM BIOPHYS ACTA, V933, P35, DOI 10.1016/0005-2728(88)90053-9; WEST IC, 1988, CHTOCHROME SYSTEMS M, P679; YU C, 1980, BIOCHIM BIOPHYS ACTA, V591, P409, DOI 10.1016/0005-2728(80)90172-3; YU CA, 1980, BIOCHEMISTRY-US, V19, P5715, DOI 10.1021/bi00566a008; YU CA, 1987, BIOENERGETICS STRUCT, P81; YU L, 1984, J BIOL CHEM, V259, P5752	32	10	10	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 24	1996	271	21					12356	12363		10.1074/jbc.271.21.12356	http://dx.doi.org/10.1074/jbc.271.21.12356			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UL660	8647838	hybrid			2022-12-25	WOS:A1996UL66000040
J	Yang, TP; Agellon, LB; Walsh, A; Breslow, JL; Tall, AR				Yang, TP; Agellon, LB; Walsh, A; Breslow, JL; Tall, AR			Alternative splicing of the human cholesteryl ester transfer protein gene in transgenic mice - Exon exclusion modulates gene expression in response to dietary or developmental change	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-DENSITY LIPOPROTEINS; MESSENGER-RNA; APOLIPOPROTEIN-E; HUMAN-PLASMA; INHIBITION; HYPERCHOLESTEROLEMIA; MECHANISM	The plasma cholesteryl ester transfer protein (CETP) mediates the transfer of cholesteryl ester from high density lipoprotein to other lipoproteins. The human CETP gene produces two forms of mRNA, with or without exon 9 (E9)-derived sequences. To study the function and regulation of alternative splicing of the CETP gene, transgenic mice were prepared 1) with the metallothionein (mT) promoter driving an E9-deleted construct (mT.CETP(-E9) transgene), and 2) with the natural flanking regions (NFR) controlling expression of genomic sequences which permit alternative splicing of E9 (NFR.CETP(+/-E9) transgene). With zinc induction, the mT.CETP(-E9) transgene gave rise to abundant E9-deleted CETP mRNA in liver and small intestine, but only relatively small amounts of E9-deleted protein were found in plasma. The E9-deleted form of CETP was inactive in lipid transfer and produced no changes in plasma lipoprotein profile. The NFR.CETP(+/-E9) transgene gave rise to full-length (FL) and E9-deleted forms of CETP mRNA in liver and spleen. In response to hypercholesterolemia induced by diet and breeding into an apoE gene knock-out background, the FL CETP mRNA was induced more than the E9-deleted mRNA, resulting in a 2-fold increase in ratio of FL/E9-deleted mRNA. The expression of CETP mRNA was found to be developmentally regulated. In NFR.CETP(+/-E9) transgenic mice CETP mRNA levels were markedly increased in the liver and small intestine in the perinatal period and decreased in adult mice, whereas CETP mRNA in the spleen was low in perinatal mice and increased in adults. The developmental increase in CETP mRNA in the liver and spleen was preceded by an increased ratio of FL/E9-deleted forms. Thus, the E9-deleted mRNA appears to be poorly translated and/or secreted, and the cognate protein is inactive in lipid transfer and lipoprotein metabolism. CETP gene expression was found to be highly regulated in a tissue-specific fashion during development. Increased CETP gene expression during development or in response to hypercholesterolemia is associated with preferential accumulation of the full-length CETP mRNA.	COLUMBIA UNIV,DEPT MED,DIV MOLEC MED,NEW YORK,NY 10032; ROCKEFELLER UNIV,LAB BIOCHEM GENET,NEW YORK,NY 10021	Columbia University; Rockefeller University			Tall, Alan/AAT-8528-2021; Breslow, Jan L/B-7544-2008		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL054591] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 54591] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AGELLON LB, 1990, BIOCHEMISTRY-US, V29, P1372, DOI 10.1021/bi00458a004; AGELLON LB, 1991, J BIOL CHEM, V266, P10796; BARTER P, 1994, CLIN EXP PHARMACOL P, V21, P663, DOI 10.1111/j.1440-1681.1994.tb02569.x; BROWN ML, 1989, NATURE, V342, P448, DOI 10.1038/342448a0; DECKELBAUM RJ, 1986, J BIOL CHEM, V261, P5201; DRAYNA D, 1987, NATURE, V327, P632, DOI 10.1038/327632a0; FIELDING PE, 1994, BIOCHEMISTRY-US, V33, P6981, DOI 10.1021/bi00188a030; HAYEK T, 1995, J CLIN INVEST, V96, P2071, DOI 10.1172/JCI118255; HESLER CB, 1988, J BIOL CHEM, V263, P5020; INAZU A, 1992, BIOCHEMISTRY-US, V31, P2352, DOI 10.1021/bi00123a021; JIANG XC, 1992, J CLIN INVEST, V90, P1290, DOI 10.1172/JCI115993; JIANG XC, 1991, J BIOL CHEM, V266, P4631; JIANG XC, 1993, J BIOL CHEM, V268, P27406; JIANG XC, 1995, BIOCHEMISTRY-US, V34, P7258, DOI 10.1021/bi00021a042; KUNITAKE ST, 1992, P NATL ACAD SCI USA, V89, P6993, DOI 10.1073/pnas.89.15.6993; MAHLEY RW, 1988, SCIENCE, V240, P622, DOI 10.1126/science.3283935; MasucciMagoulas L, 1996, J CLIN INVEST, V97, P154, DOI 10.1172/JCI118384; PLUMP AS, 1992, CELL, V71, P343, DOI 10.1016/0092-8674(92)90362-G; QUINET E, 1993, J BIOL CHEM, V268, P16891; SWENSON TL, 1989, J BIOL CHEM, V264, P14318; TALL A, 1995, ANNU REV BIOCHEM, V64, P235; TALL A, 1986, J CLIN INVEST, V77, P1163, DOI 10.1172/JCI112417; TALL AR, 1990, J CLIN INVEST, V86, P379, DOI 10.1172/JCI114722; ZHANG SH, 1992, SCIENCE, V258, P468, DOI 10.1126/science.1411543; ZHONG S, 1996, IN PRESS J CLIN INVE	25	29	30	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 24	1996	271	21					12603	12609		10.1074/jbc.271.21.12603	http://dx.doi.org/10.1074/jbc.271.21.12603			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UL660	8647871	hybrid			2022-12-25	WOS:A1996UL66000073
J	Arber, N; Sutter, T; Miyake, M; Kahn, SM; Venkatraj, VS; Sobrino, A; Warburton, D; Holt, PR; Weinstein, IB				Arber, N; Sutter, T; Miyake, M; Kahn, SM; Venkatraj, VS; Sobrino, A; Warburton, D; Holt, PR; Weinstein, IB			Increased expression of cyclin D1 and the RB tumor suppressor gene in c-K-ras transformed rat enterocytes	ONCOGENE			English	Article						retinoblastoma; cyclin D1; ras; colon cancer	HUMAN CANCER; COLORECTAL CARCINOMAS; RETINOBLASTOMA GENE; ESOPHAGEAL CANCER; OVEREXPRESSION; AMPLIFICATION; CELLS; CHROMOSOME-13; ABNORMALITIES; FIBROBLASTS	Activating mutations in the c-g-ras gene occur in about 40% of human colorectal carcinomas, yet the role of this oncogene in tumorigenesis is not known. We have developed a model cell culture system to study this problem, utilizing the immortalized but non-tumorigenic epithelial cell line IEC18, originally derived from normal rat intestine epithelium. These cells were cotransfected with the drug resistance selectable marker tk-neo and the plasmid pMIKcys, which encodes a mini human c-K-vas gene (15 kb) containing a cysteine mutation at codon 12, Drug resistant clones were isolated. Clones which also expressed the activated c-K-ras gene displayed a transformed morphology, decreased doubling time, increased level of diacylglycerol, anchorage independent growth in soft agar and an aneuploid karyotype and they were also tumorigenic when injected into nude mice. These clones also displayed increased expression, at both the mRNA and protein levels, of cyclin D1 and Rb. These findings may be of clinical relevance since human colorectal tumors also frequently display increased expression of both cyclin D1 and Rb. This model system may be useful for understanding the role and interrelationship between activation of the c-K-uas oncogene and increased expression of cyclin D1 and Rb in colorectal tumorigenesis.	COLUMBIA UNIV COLL PHYS & SURG,COLUMBIA PRESBYTERIAN CANC CTR,NEW YORK,NY 10032; COLUMBIA UNIV,CTR RADIOL RES,NEW YORK,NY 10032; COLUMBIA UNIV,DEPT GENET & DEV,NEW YORK,NY 10032; COLUMBIA UNIV,ST LUKES ROOSEVELT HOSP CTR,NEW YORK,NY 10032	Columbia University; Columbia University; Columbia University; Columbia University; Mount Sinai St. Luke's; Mount Sinai West				holt, peter/0000-0002-8469-2766; Arber, Nadir/0000-0001-5283-6991				ARBER N, 1996, IN PRESS GASTROENTER; BARTKOVA J, 1994, INT J CANCER, V58, P568, DOI 10.1002/ijc.2910580420; BOKOCH GM, 1993, FASEB J, V7, P750, DOI 10.1096/fasebj.7.9.8330683; BOWCOCK AM, 1989, CYTOGENET CELL GENET, V51, P966; CHAMBERS AF, 1993, CRIT REV ONCOGENESIS, V4, P95; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; FEARON ER, 1993, J NATL CANCER I, V85, P1978, DOI 10.1093/jnci/85.24.1978; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FILMUS J, 1994, ONCOGENE, V9, P3627; GOPE R, 1990, J NATL CANCER I, V82, P310, DOI 10.1093/jnci/82.4.310; GROSS-BELLARD MM, 1973, EUR J BIOCHEM, V36, P32, DOI 10.1111/j.1432-1033.1973.tb02881.x; HINDS PW, 1994, P NATL ACAD SCI USA, V91, P709, DOI 10.1073/pnas.91.2.709; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; HOVIG E, 1992, GENE CHROMOSOME CANC, V5, P97, DOI 10.1002/gcc.2870050202; JIANG W, 1993, P NATL ACAD SCI USA, V90, P9026, DOI 10.1073/pnas.90.19.9026; JIANG W, 1993, ONCOGENE, V8, P3447; JIANG W, 1992, CANCER RES, V52, P2980; KAHN S, 1987, ANTICANCER RES, V7, P639; KATO J, 1993, GENE DEV, V7, P331; KEYOMARSI K, 1993, P NATL ACAD SCI USA, V90, P1112, DOI 10.1073/pnas.90.3.1112; LAMMIE GA, 1991, CANCER CELL-MON REV, V3, P413; LEACH FS, 1993, CANCER RES, V53, P1986; LOTHE RA, 1992, J NATL CANCER I, V84, P1100, DOI 10.1093/jnci/84.14.1100; LOVEC H, 1994, ONCOGENE, V9, P323; MARSHALL MS, 1993, TRENDS BIOCHEM SCI, V18, P250, DOI 10.1016/0968-0004(93)90175-M; MITELMAN F, 1992, ISCN GUIDELINES CA S; MULLER H, 1994, P NATL ACAD SCI USA, V91, P2945, DOI 10.1073/pnas.91.8.2945; ONO T, 1993, JPN J GENET, V68, P617, DOI 10.1266/jjg.68.617; PAI JK, 1991, P NATL ACAD SCI USA, V88, P598, DOI 10.1073/pnas.88.2.598; PHAN SC, 1991, CANCER RES, V51, P1571; PINES J, 1994, CELL, V79, P573; PRENDERGAST GC, 1995, ONCOGENE, V10, P2289; PRICE BD, 1989, J BIOL CHEM, V264, P16638; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; TUCK AB, 1991, J NATL CANCER I, V83, P485; WANG TC, 1994, NATURE, V369, P669, DOI 10.1038/369669a0; WILDRICK DM, 1994, MOL CARCINOGEN, V10, P1, DOI 10.1002/mc.2940100102; ZHANG YJ, 1993, BIOCHEM BIOPH RES CO, V196, P1010, DOI 10.1006/bbrc.1993.2350	38	81	81	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY 2	1996	12	9					1903	1908						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UK498	8649851				2022-12-25	WOS:A1996UK49800009
J	Barrett, MT; Galipeau, PC; Sanchez, CA; Emond, MJ; Reid, BJ				Barrett, MT; Galipeau, PC; Sanchez, CA; Emond, MJ; Reid, BJ			Determination of the frequency of loss of heterozygosity in esophageal adenocarcinoma by cell sorting, whole genome amplification and microsatellite polymorphisms	ONCOGENE			English	Article						allelotype; esophageal adenocarcinoma; polymorphisms	BARRETTS-ESOPHAGUS; GENETIC ALTERATIONS; ALLELOTYPE; CANCERS; PROGRESSION; DYSPLASIA	It is well established that the progression to human cancer is characterized by the evolution of clones of cells with accumulated genetic abnormalities. However, technical difficulties limit the ability to study this process in some premalignant and malignant conditions. For example, the progression to esophageal adenocarcinoma in the premalignant condition Barrett's esophagus is characterized by the evolution of genetic and cell cycle abnormalities, but it has been difficult to characterize this process completely because of the small size of biopsies and the relative abundance of genetically normal stromal cells in some esophageal adenocarcinomas and premalignant mucosa. We have combined how cytometric cell sorting to obtain purified populations of neoplastic cells with whole genome amplification and analysis of microsatellite polymorphisms to determine the frequency of allelic loss on every nonacrocentric autosomal arm in 20 esophageal adenocarcinomas and two high-grade dysplasias. DNA samples of purified how-sorted aneuploid and corresponding normal tissue were amplified with a degenerate 15mer primer. Aliquots of these reactions were then screened with forty-three highly polymorphic simple sequence repeat markers in PCR-based assays. Allelic losses were observed at polymorphic loci in 38 of the 40 chromosome arms that were analysed and the median fractional allelic loss (FAL) observed in the samples was 0.28. The background allelic loss frequency was estimated at 0.23 with the highest rates of loss observed at 17p (100%), 5q (80%), 9P (64%), 13q (43%), 18q (43%) acid Ip (41%). These data represent the first comprehensive allelotype of esophageal adenocarcinoma and show the feasibility of multiloci analyses with small highly purified human biopsy material.	UNIV WASHINGTON,DEPT MED,DIV GASTROENTEROL,SEATTLE,WA 98195; FRED HUTCHINSON CANC RES CTR,DIV PUBL HLTH SCI,SEATTLE,WA 98104; UNIV WASHINGTON,DEPT BIOSTAT,SEATTLE,WA 98195	University of Washington; University of Washington Seattle; Fred Hutchinson Cancer Center; University of Washington; University of Washington Seattle			Reid, Brian John/AFT-8587-2022	Reid, Brian John/0000-0002-9613-979X; Galipeau, Patricia/0000-0001-7961-7430	NCI NIH HHS [R0 1 CA61202, 5 PO 1 CA42792] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA042792, R01CA061202] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARRETT MT, 1995, NUC ACIDS RES, V23, P3368; BLOT WJ, 1991, JAMA-J AM MED ASSOC, V265, P1287, DOI 10.1001/jama.265.10.1287; BLOUNT PL, 1993, P NATL ACAD SCI USA, V90, P3221, DOI 10.1073/pnas.90.8.3221; BLOUNT PL, 1994, CANCER RES, V54, P2292; BOYNTON RF, 1991, CANCER RES, V51, P5766; FULTS D, 1990, CANCER RES, V50, P5784; HAMILTON SR, 1988, HUM PATHOL, V19, P942, DOI 10.1016/S0046-8177(88)80010-8; HIROHASHI S, 1991, CANCER CELL-MON REV, V3, P49; HUANG Y, 1992, CANCER RES, V52, P6525; MELTZER SJ, 1991, P NATL ACAD SCI USA, V88, P4976, DOI 10.1073/pnas.88.11.4976; MELTZER SJ, 1994, CANCER RES, V54, P3370; NAGAI H, 1995, CANCER RES, V55, P1752; NESHAT K, 1994, COLD SPRING HARB SYM, V59, P577, DOI 10.1101/SQB.1994.059.01.065; PEIFFER SL, 1995, CANCER RES, V55, P1922; PHILLIPS RW, 1991, GASTROENTEROL CLIN N, V20, P791; POWELL SM, 1994, GASTROENTEROLOGY, V107, P1759, DOI 10.1016/0016-5085(94)90818-4; REID BJ, 1988, HUM PATHOL, V19, P166, DOI 10.1016/S0046-8177(88)80344-7; REID BJ, 1992, GASTROENTEROLOGY, V102, P1212; SATO T, 1990, CANCER RES, V50, P7184; SCHLEIERMACHER G, 1994, GENE CHROMOSOME CANC, V10, P275, DOI 10.1002/gcc.2870100409; SHIBAGAKI I, 1994, CANCER RES, V54, P2996; SILVERBERG E, 1990, CA-CANCER J CLIN, V40, P9, DOI 10.3322/canjclin.40.1.9; SNABES MC, 1994, P NATL ACAD SCI USA, V91, P6181, DOI 10.1073/pnas.91.13.6181; SUZUKI H, 1995, HUM MOL GENET, V4, P1883, DOI 10.1093/hmg/4.10.1883; TARMIN L, 1994, CANCER RES, V54, P6094; THRASHBINGHAM CA, 1995, P NATL ACAD SCI USA, V92, P2854, DOI 10.1073/pnas.92.7.2854; TSUCHIYA E, 1992, CANCER RES, V52, P2478; VOGELSTEIN B, 1989, SCIENCE, V244, P207, DOI 10.1126/science.2565047; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; YAMAGUCHI T, 1992, CANCER RES, V52, P419; ZHANG L, 1992, P NATL ACAD SCI USA, V89, P5847, DOI 10.1073/pnas.89.13.5847; ZHOU XL, 1994, ONCOGENE, V9, P3737	32	113	116	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY 2	1996	12	9					1873	1878						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UK498	8649847				2022-12-25	WOS:A1996UK49800005
J	Fan, GS; Ma, XM; Kren, BT; Steer, CJ				Fan, GS; Ma, XM; Kren, BT; Steer, CJ			The retinoblastoma gene product inhibits TGF-beta 1 induced apoptosis in primary rat hepatocytes and human HuH-7 hepatoma cells	ONCOGENE			English	Article						retinoblastoma; hepatocyte; apoptosis; transforming growth factor-beta 1 (TGF-beta 1); cell cycle; E2F-1	TRANSFORMING GROWTH FACTOR-BETA-1; TGF-BETA; PROTEIN PHOSPHATASES; LIVER-REGENERATION; DEATH; EXPRESSION; INDUCTION; PHOSPHORYLATION; QUANTIFICATION; PROLIFERATION	Transforming growth factor-beta 1 (TGF-beta 1) can induce rapid growth arrest and apoptosis in hepatic cells. Its growth suppressive effects appear to be linked to decreased phosphorylation of the protein product of the retinoblastoma gene, pRb. To characterize the role of pRb in apoptosis, we examined endogenous retinoblastoma gene (Rb) expression following treatment with TGF-beta 1, okadaic acid, or antisense Rb S-oligonucleotides in cultured primary rat hepatocytes acid human hepatoma HuH-7 cells. We also investigated the effects on apoptosis of Rb overexpression following transfection with vectors containing wild-type Rb in HuH-7 cells. Our results indicated that transfection with Rb antisense S-oligonucleotides blocked the expression of pRb in cultured primary hepatocytes and induced apoptosis. Treatment of HuH-7 cells with TGF-beta 1 inhibited expression and phosphorylation of pRb, and also induced apoptosis. Furthermore, 93% of viable preapoptotic cells were arrested in the G(1) phase of the cell cycle. Incubation with the phosphatase inhibitor okadaic acid maintained pRb in its phosphorylated state, and resulted in significant apoptosis. Overexpression of wild-type Rb inhibited TGF-beta 1 induced apoptosis in HuH-7 cells. In contrast, overexpression of transcription factor E2F-1, a known target for the activity of pRb, caused significant apoptosis. However, coexpression of Rb suppressed E2F-1 induced apoptosis in HuH-7 cells. Our results suggest that inhibition of pRb expression is associated with hepatocyte apoptosis. Furthermore, E2F-1 appears to be a target in the pathway through which pRb modulates the apoptotic threshold in hepatic cells. Finally, the data suggest that these cells exit the cell cycle during the G(1) phase before progressing into apoptosis and pRb may be a negative regulator of this process.	UNIV MINNESOTA, DEPT MED, MINNEAPOLIS, MN 55455 USA; UNIV MINNESOTA, DEPT CELL BIOL, MINNEAPOLIS, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities								ALBERTS AS, 1993, P NATL ACAD SCI USA, V90, P388, DOI 10.1073/pnas.90.2.388; ARENDS MJ, 1991, INT REV EXP PATHOL, V32, P223; BERNARDS R, 1989, P NATL ACAD SCI USA, V86, P6474, DOI 10.1073/pnas.86.17.6474; BISSELL DM, 1995, J CLIN INVEST, V96, P447, DOI 10.1172/JCI118055; BURSCH W, 1993, BRIT J CANCER, V67, P531, DOI 10.1038/bjc.1993.98; CLARKE AR, 1992, NATURE, V359, P328, DOI 10.1038/359328a0; COHEN JJ, 1991, ADV IMMUNOL, V50, P55; COHEN P, 1989, FEBS LETT, V250, P596, DOI 10.1016/0014-5793(89)80803-8; EWEN ME, 1993, CELL, V74, P1009, DOI 10.1016/0092-8674(93)90723-4; FAN GS, 1995, CELL GROWTH DIFFER, V6, P1463; FUKUDA K, 1993, HEPATOLOGY, V18, P945, DOI 10.1002/hep.1840180428; GENG Y, 1993, P NATL ACAD SCI USA, V90, P10315, DOI 10.1073/pnas.90.21.10315; GRUPPUSO PA, 1990, CANCER RES, V50, P1464; HAASKOGAN DA, 1995, EMBO J, V14, P461, DOI 10.1002/j.1460-2075.1995.tb07022.x; HALDAR S, 1995, P NATL ACAD SCI USA, V92, P4507, DOI 10.1073/pnas.92.10.4507; HAUPT Y, 1995, ONCOGENE, V10, P1563; HELVERING LM, 1993, CANCER LETT, V71, P133, DOI 10.1016/0304-3835(93)90108-L; JAKOWLEW SB, 1991, CELL REGUL, V2, P535, DOI 10.1091/mbc.2.7.535; KAN M, 1989, P NATL ACAD SCI USA, V86, P7432, DOI 10.1073/pnas.86.19.7432; LAIHO M, 1990, CELL, V62, P175, DOI 10.1016/0092-8674(90)90251-9; LAZEBNIK YA, 1993, J CELL BIOL, V123, P7, DOI 10.1083/jcb.123.1.7; LEE EYHP, 1992, NATURE, V359, P288, DOI 10.1038/359288a0; LEE EYHP, 1994, GENE DEV, V8, P2008, DOI 10.1101/gad.8.17.2008; LEE WH, 1987, NATURE, V329, P642, DOI 10.1038/329642a0; LOCKSHIN RA, 1990, J GERONTOL, V45, pB135, DOI 10.1093/geronj/45.5.B135; MARIASH CN, 1986, J BIOL CHEM, V261, P9583; Massague J, 1992, CURR OPIN GENET DEV, V2, P28, DOI 10.1016/S0959-437X(05)80317-X; MEIKRANTZ W, 1995, J CELL BIOCHEM, V58, P160, DOI 10.1002/jcb.240580205; MOSES HL, 1990, CELL, V63, P245, DOI 10.1016/0092-8674(90)90155-8; NAKABAYASHI H, 1982, CANCER RES, V42, P3858; OBERHAMMER F, 1991, CANCER RES, V51, P2478; OBERHAMMER FA, 1992, P NATL ACAD SCI USA, V89, P5408, DOI 10.1073/pnas.89.12.5408; ORMEROD MG, 1992, J IMMUNOL METHODS, V153, P57, DOI 10.1016/0022-1759(92)90305-D; ORMEROD MG, 1993, ACTA ONCOL, V32, P417, DOI 10.3109/02841869309093620; PAN HC, 1994, GENE DEV, V8, P1285, DOI 10.1101/gad.8.11.1285; QIN XQ, 1992, GENE DEV, V6, P953, DOI 10.1101/gad.6.6.953; QIN XQ, 1994, P NATL ACAD SCI USA, V91, P10918, DOI 10.1073/pnas.91.23.10918; RAFF MC, 1992, NATURE, V356, P397, DOI 10.1038/356397a0; RAO L, 1992, P NATL ACAD SCI USA, V89, P7742, DOI 10.1073/pnas.89.16.7742; ROTELLO RJ, 1991, P NATL ACAD SCI USA, V88, P3412, DOI 10.1073/pnas.88.8.3412; SCHMID I, 1994, CYTOMETRY, V15, P12, DOI 10.1002/cyto.990150104; SCHULTEHERMANN R, 1993, ENVIRON HEALTH PERSP, V101, P87, DOI 10.2307/3431847; SCHWARZ JK, 1995, P NATL ACAD SCI USA, V92, P483, DOI 10.1073/pnas.92.2.483; SELVAKUMARAN M, 1994, MOL CELL BIOL, V14, P2352, DOI 10.1128/MCB.14.4.2352; SEN S, 1992, FEBS LETT, V307, P122, DOI 10.1016/0014-5793(92)80914-3; STEIN CA, 1988, NUCLEIC ACIDS RES, V16, P3209, DOI 10.1093/nar/16.8.3209; TRUMP BF, 1995, FASEB J, V9, P219, DOI 10.1096/fasebj.9.2.7781924; TSUKIDATE K, 1993, AM J PATHOL, V143, P918; WAGNER RW, 1994, NATURE, V372, P333, DOI 10.1038/372333a0; WALKER PR, 1993, BIOTECHNIQUES, V15, P1032; WHITE AE, 1994, GENE DEV, V8, P666, DOI 10.1101/gad.8.6.666; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602; Wyllie A H, 1980, Int Rev Cytol, V68, P251; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0; YAN ZF, 1992, ONCOGENE, V7, P801; YATSUNAMI J, 1993, CANCER RES, V53, P239	56	119	122	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 2	1996	12	9					1909	1919						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UK498	8649852				2022-12-25	WOS:A1996UK49800010
J	Powell, SM; Cummings, OW; Mullen, JA; Asghar, A; Fuga, G; Piva, P; Minacci, C; Megha, T; Tosi, P; Jackson, CE				Powell, SM; Cummings, OW; Mullen, JA; Asghar, A; Fuga, G; Piva, P; Minacci, C; Megha, T; Tosi, P; Jackson, CE			Characterization of the APC gene in sporadic gastric adenocarcinomas	ONCOGENE			English	Article						gastric carcinoma; adenomatous polyposis coli (APC); mutations; loss of heterozygosity; molecular genetics	FAMILIAL ADENOMATOUS POLYPOSIS; PANCREATIC-CANCER; SOMATIC MUTATIONS; COLORECTAL-CANCER; FREQUENT LOSS; COLI GENE; HETEROZYGOSITY; CARCINOMA; LOCI; MCC	The prominent role of the APC gene in colorectal tumor development is well established. However, its role in tumorigenesis in other tissues is not clear. Hence, DNA from 30 primary sporadic gastric adenocarcinomas was obtained from patients living in a high risk area of the world (North-Central Italy) in order to further define APC's role in gastric tumorigenesis. We thoroughly examined that region of APC which is commonly mutated in colorectal tumors using proven sensitive methods. The IVS protein assay and DNA sequence analysis of APC codons 686 through 1693 revealed no intragenic mutations. However, allelic loss of loci near APC was detected in 7 (28%) of 25 informative gastric adenocarcinomas using two 5q dinucleotide repeat markers for LOH analysis. These results suggest that genetic alteration of a region of APC commonly mutated in colorectal cancer is not a common event during sporadic gastric tumor development, at least in patients from North-Central Italy. Further analysis of chromosome 5q might identify another gene to be significantly altered in these gastric cancers.	INDIANA UNIV, SCH MED, DEPT PATHOL, INDIANAPOLIS, IN 46202 USA; UNIV SIENA, IST ANAT EISTOL PATOL, I-53100 SIENA, ITALY; HENRY FORD HOSP, DEPT MED, DETROIT, MI 48202 USA	Indiana University System; Indiana University-Purdue University Indianapolis; University of Siena; Henry Ford Health System; Henry Ford Hospital	Powell, SM (corresponding author), INDIANA UNIV, SCH MED, DEPT MED, 975 W WALNUT ST IB 424, INDIANAPOLIS, IN 46202 USA.				NCI NIH HHS [1R29CA67000-01] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		*AM JOINT COMM CAN, 1993, MAN STAG CANC; CHONG JM, 1994, CANCER RES, V54, P4595; CORREA P, 1994, CANCER SURV, V20, P55; DAMICO D, 1992, CANCER RES, V52, P1996; FAWCETT TW, 1991, USB EDITORIAL COMMEN, V17, P19; FUCHS CS, 1995, NEW ENGL J MED, V333, P32, DOI 10.1056/NEJM199507063330107; GOELZ SE, 1985, BIOCHEM BIOPH RES CO, V130, P118, DOI 10.1016/0006-291X(85)90390-0; GRODEN J, 1991, CELL, V66, P589, DOI 10.1016/0092-8674(81)90021-0; HAN HJ, 1993, CANCER RES, V53, P5087; HORII A, 1992, CANCER RES, V52, P3231; HORII A, 1992, CANCER RES, V52, P6696; HUANG Y, 1992, CANCER RES, V52, P6525; JACKSON CE, 1980, CANCER, V45, P599, DOI 10.1002/1097-0142(19800201)45:3<599::AID-CNCR2820450328>3.0.CO;2-8; JEN J, 1994, NEW ENGL J MED, V331, P213, DOI 10.1056/NEJM199407283310401; JEN J, 1994, CANCER RES, V54, P5523; KINZLER KW, 1991, SCIENCE, V253, P661, DOI 10.1126/science.1651562; LAUREN P, 1965, ACTA PATHOL MIC SC, V64, P31, DOI 10.1111/apm.1965.64.1.31; MCKIE AB, 1993, INT J CANCER, V55, P598, DOI 10.1002/ijc.2910550414; MIRONOV NM, 1994, CANCER RES, V54, P41; MIYOSHI Y, 1992, P NATL ACAD SCI USA, V89, P4452, DOI 10.1073/pnas.89.10.4452; Miyoshi Yasuo, 1992, Human Molecular Genetics, V1, P229; NAGASE H, 1993, HUM MUTAT, V2, P425, DOI 10.1002/humu.1380020602; NAKATSURU S, 1993, HUM MOL GENET, V2, P1463, DOI 10.1093/hmg/2.9.1463; NAKATSURU S, 1992, HUM MOL GENET, V1, P559, DOI 10.1093/hmg/1.8.559; OFFERHAUS GJA, 1992, GASTROENTEROLOGY, V102, P1980, DOI 10.1016/0016-5085(92)90322-P; OGASAWARA S, 1994, VIRCHOWS ARCH, V424, P607, DOI 10.1007/BF01069740; PARK JG, 1992, DIS COLON RECTUM, V35, P996, DOI 10.1007/BF02253505; PELTOMAKI P, 1993, CANCER RES, V53, P5853; POWELL SM, 1992, NATURE, V359, P235, DOI 10.1038/359235a0; POWELL SM, 1994, GASTROENTEROLOGY, V107, P1759, DOI 10.1016/0016-5085(94)90818-4; POWELL SM, 1993, NEW ENGL J MED, V329, P1982, DOI 10.1056/NEJM199312303292702; RHYU MG, 1994, GASTROENTEROLOGY, V106, P1584, DOI 10.1016/0016-5085(94)90414-6; SANO T, 1991, CANCER RES, V51, P2926; SEYMOUR AB, 1994, CANCER RES, V54, P2761; SHIAO YH, 1994, AM J PATHOL, V144, P511; SMITH KJ, 1993, P NATL ACAD SCI USA, V90, P2846, DOI 10.1073/pnas.90.7.2846; SPIRIO L, 1991, NUCLEIC ACIDS RES, V19, P6348, DOI 10.1093/nar/19.22.6348; STEMMERMANN G, 1994, HUM PATHOL, V25, P968, DOI 10.1016/0046-8177(94)90056-6; STRICKLER JG, 1994, CANCER RES, V54, P4750; TAHARA E, 1993, J CANCER RES CLIN, V119, P265, DOI 10.1007/BF01212724; TAMURA G, 1993, JPN J CANCER RES, V84, P1015, DOI 10.1111/j.1349-7006.1993.tb02794.x; TAMURA G, 1994, CANCER RES, V54, P1149; UCHINO S, 1993, INT J CANCER, V54, P759, DOI 10.1002/ijc.2910540509; UTSUNOMIYA J, 1990, HEREDITARY COLORECTA, P3; VASEN HFA, 1991, LANCET, V338, P877, DOI 10.1016/0140-6736(91)91520-5; VOGELSTEIN B, 1993, TRENDS GENET, V9, P138, DOI 10.1016/0168-9525(93)90209-Z; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; WHELAN SL, 1993, IARC SCI PUBLICATION, V12; WIJNEN J, 1991, NUCLEIC ACIDS RES, V19, P6965, DOI 10.1093/nar/19.24.6965-a	49	20	22	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 2	1996	12	9					1953	1959						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UK498	8649856				2022-12-25	WOS:A1996UK49800014
J	Algar, EM; Khromykh, T; Smith, SI; Blackburn, DM; Bryson, GJ; Smith, PJ				Algar, EM; Khromykh, T; Smith, SI; Blackburn, DM; Bryson, GJ; Smith, PJ			A WT1 antisense oligonucleotide inhibits proliferation and induces apoptosis in myeloid leukaemia cell lines	ONCOGENE			English	Article						WT1; leukaemia; apoptosis	WILMS-TUMOR; GENE; IDENTIFICATION; MUTATIONS; PROTEINS	The response of the CML-BC cell line, K562, the myelomonocytic cell line MM6 and the promyelocytic leukaemia cell line HL-60, to a 15 mer WT1 antisense oligonucleotide, targeted to the translation initiation site of the WT1 mRNA was examined. K562 cells exposed to 0.4 mu M antisense oligonucleotide showed markedly reduced proliferation which was associated with reduced cell viability. Sense, scrambled and mutant antisense oligonucleotides had no effect on the proliferation of K562 cells. MM6 cells exposed to 0.4 mu M antisense oligonucleotide also showed significantly reduced cellular proliferation which was also accompanied by loss of cell viability. In the K562 and MM6 antisense cultures that exhibited reduced cell viability, both DNA fragmentation and morphological features consistent with apoptosis could be identified. In contrast the growth of HL-60 cells was unaffected by exposure to oligonucleotide. In each of the cell WT1 antisense oligonucleotide abrogated WT1 protein expression, and analysis of WT1 coding sequence in these cells showed that no oncogenic point mutations in the gene were present. We propose therefore that in some myeloid leukaemia cell lines, the expression of a normal WT1 protein is necessary for cell proliferation and that it plays a role in maintaining the viability of some leukaemia cells.	UNIV QUEENSLAND,ROYAL BRISBANE HOSP,DEPT PATHOL,HERSTON,QLD 4006,AUSTRALIA; ROYAL CHILDRENS HOSP,DEPT HAEMATOL & ONCOL,PARKVILLE,VIC 3052,AUSTRALIA	Royal Brisbane & Women's Hospital; University of Queensland; Royal Children's Hospital Melbourne	Algar, EM (corresponding author), UNIV QUEENSLAND,SCH MED,DEPT PATHOL,HERSTON RD,HERSTON,QLD 4006,AUSTRALIA.		Algar, Elizabeth/B-3770-2012; Khromykh, Tatiana/D-3952-2017	Khromykh, Tatiana/0000-0001-6629-6885				BAIRD PN, 1992, ONCOGENE, V7, P2141; CHANDLER D, 1994, HUM PATHOL, V25, P789, DOI 10.1016/0046-8177(94)90248-8; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; ENGLERT C, 1995, EMBO J, V14, P4662, DOI 10.1002/j.1460-2075.1995.tb00148.x; GESSLER M, 1990, NATURE, V343, P774, DOI 10.1038/343774a0; HAASKOGAN DA, 1995, EMBO J, V14, P461, DOI 10.1002/j.1460-2075.1995.tb07022.x; HABER DA, 1992, CANCER SURV, V12, P105; HABER DA, 1991, P NATL ACAD SCI USA, V88, P9618, DOI 10.1073/pnas.88.21.9618; INOUE K, 1994, BLOOD, V84, P3071, DOI 10.1182/blood.V84.9.3071.3071; KREIDBERG JA, 1993, CELL, V74, P679, DOI 10.1016/0092-8674(93)90515-R; KUDOH T, 1995, P NATL ACAD SCI USA, V92, P4517, DOI 10.1073/pnas.92.10.4517; LARSSON SH, 1995, CELL, V81, P391, DOI 10.1016/0092-8674(95)90392-5; LITTLE MH, 1992, P NATL ACAD SCI USA, V89, P4791, DOI 10.1073/pnas.89.11.4791; LOTEM J, 1991, BLOOD, V78, P953; LOTEM J, 1989, BLOOD, V74, P579; MAHESWARAN S, 1995, GENE DEV, V9, P2143, DOI 10.1101/gad.9.17.2143; MAHESWARAN S, 1993, P NATL ACAD SCI USA, V90, P5100, DOI 10.1073/pnas.90.11.5100; MIYAGI T, 1993, LEUKEMIA, V7, P970; MORRIS JF, 1991, ONCOGENE, V6, P2339; PHELAN SA, 1994, CELL GROWTH DIFFER, V5, P677; PRITCHARDJONES K, 1994, HUM MOL GENET, V3, P1633, DOI 10.1093/hmg/3.9.1633; RUPPRECHT HD, 1994, J BIOL CHEM, V269, P6198; SEKIYA M, 1994, BLOOD, V83, P1876; SIMMS L, 1996, IN PRESS EUR J CANC; Walker N I, 1988, Methods Achiev Exp Pathol, V13, P18; WANG ZY, 1995, ONCOGENE, V10, P1243; YAM LT, 1971, AM J CLIN PATHOL, V55, P283	27	138	150	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR 7	1996	12	5					1005	1014						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UA884	8649791				2022-12-25	WOS:A1996UA88400008
J	Lee, CP; Gu, Q; Xiong, Y; Mitchell, RA; Ernster, L				Lee, CP; Gu, Q; Xiong, Y; Mitchell, RA; Ernster, L			P/O ratios reassessed: Mitochondrial P/O ratios consistently exceed 1.5 with succinate and 2.5 with NAD-linked substrates	FASEB JOURNAL			English	Article						mitochondria; oxidative phosphorylation; ATP synthesis	ATP-SITE RATIOS; OXIDATIVE-PHOSPHORYLATION; MECHANISTIC STOICHIOMETRY; PROTON TRANSLOCATION; ELECTRON-TRANSPORT; CHARGE-SITE; H+-SITE; GRADIENT; COMPLEX	The efficiency of ATP synthesis coupled to cell respiration, commonly referred to as the P/O ratio, has been the subject of extensive studies for more than 50 years. The general conclusion from these studies is that respiring mitochondria can convert external ADP to ATP at a maximal P/O ratio of 3 for NAD-linked substrates and 2 for succinate. However, in recent years the validity of these ''integral'' values has been questioned on both mechanistic and thermodynamic grounds, and a mechanistic P/O ratio of 2.5 for NAD-linked substrates and 1.5 for succinate have been concluded on the basis of experiments with isolated mitochondria. These values have been widely adopted in the scientific literature, including several recent textbooks. In this paper we report that under optimal conditions with respect to preparation and assay procedures, the P/O ratios obtained with isolated rat liver mitochondria consistently exceed 2.5 with NAD-linked substrates and 1.5 with succinate. These results, although not excluding ''nonintegral'' P/O ratios due to various energy-dissipating side reactions, warrant caution in accepting the reported lower values and, in general, in referring to mechanistic considerations unless the underlying molecular mechanisms are understood.	WAYNE STATE UNIV, SCH MED, DEPT BIOCHEM, DETROIT, MI 48201 USA; UNIV STOCKHOLM, ARRHENIUS LABS NAT SCI, DEPT BIOCHEM, S-10691 STOCKHOLM, SWEDEN	Wayne State University; Stockholm University				Xiong, Ye/0000-0001-9770-6031	NATIONAL CENTER FOR RESEARCH RESOURCES [S07RR005384] Funding Source: NIH RePORTER; NCRR NIH HHS [S07-RR05384-30] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		ALEXANDRE A, 1978, P NATL ACAD SCI USA, V75, P5296, DOI 10.1073/pnas.75.11.5296; AZZONE GF, 1994, BBA-BIOENERGETICS, V1187, P140, DOI 10.1016/0005-2728(94)90100-7; AZZONE GF, 1979, J BIOL CHEM, V254, P206; AZZONE GF, 1971, EUR J BIOCHEM, V19, P97, DOI 10.1111/j.1432-1033.1971.tb01292.x; BEATTIE DS, 1993, J BIOENERG BIOMEMBR, V25, P233, DOI 10.1007/BF00762585; BEATTIE DS, 1993, J BIOENERG BIOMEMBR, V25, P191, DOI 10.1007/BF00762581; BEAVIS AD, 1986, EUR J BIOCHEM, V158, P315, DOI 10.1111/j.1432-1033.1986.tb09753.x; BERRY EA, 1983, J BIOL CHEM, V258, P1474; BOYER PD, 1977, ANNU REV BIOCHEM, V46, P955, DOI 10.1146/annurev.bi.46.070177.004515; BOYER PD, 1965, OXIDASES RELATED RED, P994; BRAND MD, 1994, BIOCHEM J, V297, P27, DOI 10.1042/bj2970027; BRAND MD, 1994, BBA-BIOENERGETICS, V1187, P132, DOI 10.1016/0005-2728(94)90099-X; Brand MD, 1994, BIOCH LOND, V16, P20; CHANCE B, 1956, ADV ENZYMOL REL S BI, V17, P65; ERNSTER L, 1993, FASEB J, V7, P1520, DOI 10.1096/fasebj.7.15.8262336; ERNSTER L, 1994, BIOCHEM SOC T, V22, P253, DOI 10.1042/bst0220253; ERNSTER L, 1984, S BIOL HUNGARICA, V26, P13; ERNSTER L, 1992, NEW COMPREHENSIVE BI, V23; Ernster L., 1995, BIOCHIM BIOPHYS ACTA, V1271, P195; FERGUSON SJ, 1986, TRENDS BIOCHEM SCI, V11, P351, DOI 10.1016/0968-0004(86)90197-0; FERGUSONMILLER S, 1993, J BIOENERG BIOMEMBR, V25, P69, DOI 10.1007/BF00762848; Hinkle P.C., 1981, CHEMIOSMOTIC PROTON, P49; HINKLE PC, 1991, BIOCHEMISTRY-US, V30, P3576, DOI 10.1021/bi00228a031; HOEK JB, 1992, NEW COMPR BIOCH, V23, P421; HOGEBOOM GH, 1946, J BIOL CHEM, V165, P615; HOGEBOOM GH, 1948, J BIOL CHEM, V172, P619; KENNEDY EP, 1949, J BIOL CHEM, V179, P957; KLINGENBERG M, 1977, EUR J BIOCHEM, V73, P125, DOI 10.1111/j.1432-1033.1977.tb11298.x; LARDY HA, 1952, J BIOL CHEM, V195, P215; LEE CP, 1979, MUSCLE NERVE, V2, P340, DOI 10.1002/mus.880020504; LEE CP, 1989, BIOCHIM BIOPHYS ACTA, V1000, P371, DOI 10.1016/S0006-3002(89)80032-0; LEE CP, 1968, EUR J BIOCHEM, V3, P385, DOI 10.1111/j.1432-1033.1967.tb19541.x; LEHNINGER AL, 1949, J BIOL CHEM, V181, P415; LEMASTERS JJ, 1984, J BIOL CHEM, V259, P3123; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MITCHELL P, 1961, NATURE, V191, P144, DOI 10.1038/191144a0; Moran LA, 1994, BIOCHEMISTRY; NEDERGAARD J, 1992, NEW COMPREHENSIVE BI, V23, P385; NICHOLLS B, 1984, NEW COMPR BIOCH, V9, P29; NICHOLS DG, 1992, BIOENERGETICS, V2; Ochoa S, 1943, J BIOL CHEM, V151, P493; OHNISHI T, 1993, J BIOENERG BIOMEMBR, V25, P325, DOI 10.1007/BF00762457; PALMIERI F, 1992, NEW COMPREHENSIVE BI, V23, P359; Pedersen P L, 1978, Methods Cell Biol, V20, P411, DOI 10.1016/S0091-679X(08)62030-0; PEDERSEN PL, 1993, J BIOENERG BIOMEMBR, V25, P431, DOI 10.1007/BF01108400; POZZAN T, 1979, J BIOL CHEM, V254, P200; REYNAFARJE B, 1976, J BIOL CHEM, V251, P7442; ROSSI E, 1969, EUR J BIOCHEM, V7, P418, DOI 10.1111/j.1432-1033.1969.tb19626.x; SLATER EC, 1953, NATURE, V172, P975, DOI 10.1038/172975a0; Sottocasa G. L., 1967, METHOD ENZYMOL, V10, P448; STONER CD, 1987, J BIOL CHEM, V262, P10445; Stryer L., 1995, BIOCHEMISTRY-US, V4th ed.; TRUMPOWER BL, 1990, J BIOL CHEM, V265, P11409; VERCESI A, 1978, J BIOL CHEM, V253, P6379; WESTERHOFF HV, 1992, NEW COMPREHENSIVE BI, V23, P2; WIKSTROM MKF, 1977, NATURE, V266, P271, DOI 10.1038/266271a0; Zubay G., 1993, BIOCHEMISTRY	57	47	47	0	12	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	1996	10	2					345	350		10.1096/fasebj.10.2.8641569	http://dx.doi.org/10.1096/fasebj.10.2.8641569			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	TY962	8641569				2022-12-25	WOS:A1996TY96200020
J	Chan, D; Weng, YM; Hocking, AM; Golub, S; McQuillan, DJ; Bateman, JF				Chan, D; Weng, YM; Hocking, AM; Golub, S; McQuillan, DJ; Bateman, JF			Site-directed mutagenesis of human type X collagen - Expression of alpha 1(X) NC1, NC2, and helical mutations in vitro and in transfected cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OSTEOGENESIS IMPERFECTA; CARTILAGE; GENE; CHONDROCYTES; LOCALIZATION; ORGANIZATION; TRANSITION; SEQUENCE; REGIONS; SYSTEM	Type X collagen is a short chain collagen expressed in the hypertrophic zone of calcifying cartilage during skeletal development and bone growth. The alpha 1(X) homotrimer consists of three protein domains, a short triple helix (COL1) flanked by nonhelical amino-terminal (NC2) and carboxyl-terminal (NC1) domains. While mutations of the NC1 domain result in Schmid metaphyseal chondrodysplasia, which suggests a critical role for this protein domain, little biochemical detail is known about type X collagen synthesis, secretion, and the mechanisms of molecular assembly, To study these processes, a range of mutations were produced in human alpha 1(X) cDNA and the biochemical consequences determined by in vitro expression, using T7-driven coupled transcription and translation, and by transient transfection of cells, Three NC1 mutants, which were designed to be analogous to Schmid mutations (1952de1C, 1963del10, and Y598D), were unable to assemble into type X collagen homotrimers in vitro, but the mutant chains did not associate with, or interfere with, the efficiency of normal chain assembly in co-translations with a normal construct, Expression in transiently transfected cells confirmed that mutant type X collagen assembly was also compromised in vivo. The mutant chains were not secreted from the cells but did not accumulate intracellularly, suggesting that the unassociated mutant chains were rapidly degraded, In-frame deletions within the helix (amino acid residues 72-354) and the NC2 domain (amino acid residues 21-54) were also produced. In contrast to the NC1 mutations, these mutations did not prevent. assembly, Mutant homotrimers and mutant-normal heterotrimers were formed in vitro, and the mutant homotrimers formed in transiently transfected cells bars. assembled into pepsin-stable triple helical molecules which were secreted.	UNIV MELBOURNE,ROYAL CHILDRENS HOSP,DEPT PAEDIAT,ORTHOPAED MOL BIOL RES UNIT,PARKVILLE,VIC 3052,AUSTRALIA	Royal Children's Hospital Melbourne; University of Melbourne			Chan, Danny/C-4203-2009	Chan, Danny/0000-0003-3824-5778; Bateman, John/0000-0001-8542-0730				APTE SS, 1993, MATRIX, V13, P165, DOI 10.1016/S0934-8832(11)80075-2; BATEMAN JF, 1984, BIOCHEM J, V217, P103, DOI 10.1042/bj2170103; BERG RA, 1973, BIOCHEM BIOPH RES CO, V52, P115, DOI 10.1016/0006-291X(73)90961-3; BONAVENTURE J, 1995, HUM GENET, V96, P58, DOI 10.1007/BF00214187; BRASS A, 1992, FEBS LETT, V303, P126, DOI 10.1016/0014-5793(92)80503-9; Byers Peter H., 1993, P317; CHAN D, 1995, J BIOL CHEM, V270, P4558, DOI 10.1074/jbc.270.9.4558; CHAN D, 1995, J BIOL CHEM, V270, P1747, DOI 10.1074/jbc.270.4.1747; CHESSLER SD, 1993, J BIOL CHEM, V268, P18226; DHARMAVARAM RM, 1994, HUM MOL GENET, V3, P507, DOI 10.1093/hmg/3.3.507; FUERST TR, 1986, P NATL ACAD SCI USA, V83, P8122, DOI 10.1073/pnas.83.21.8122; GRANT WT, 1987, J BIOL CHEM, V262, P9844; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; JACENKO O, 1993, NATURE, V365, P56, DOI 10.1038/365056a0; KIELTY CM, 1985, BIOCHEM J, V227, P545, DOI 10.1042/bj2270545; KWAN APL, 1991, J CELL BIOL, V114, P597, DOI 10.1083/jcb.114.3.597; LAMANDE SR, 1995, J BIOL CHEM, V270, P8642, DOI 10.1074/jbc.270.15.8642; LUVALLE P, 1988, J BIOL CHEM, V263, P18378; MCINTOSH I, 1993, NAT GENET, V4, P219, DOI 10.1038/ng0793-219; MCINTOSH I, 1995, HUM MUTAT, V5, P121, DOI 10.1002/humu.1380050204; MCINTOSH I, 1994, HUM MOL GENET, V3, P303, DOI 10.1093/hmg/3.2.303; MIDDLETON RB, 1993, BIOCHEM J, V296, P511, DOI 10.1042/bj2960511; NERLICH AG, 1992, HISTOCHEMISTRY, V98, P275, DOI 10.1007/BF00270010; REICHENBERGER E, 1992, FEBS LETT, V311, P305, DOI 10.1016/0014-5793(92)81126-7; REICHENBERGER E, 1991, DEV BIOL, V148, P562, DOI 10.1016/0012-1606(91)90274-7; RICH DP, 1990, NATURE, V347, P358, DOI 10.1038/347358a0; ROSATI R, 1994, NAT GENET, V8, P129, DOI 10.1038/ng1094-129; SCHMID TM, 1990, DEV BIOL, V138, P53, DOI 10.1016/0012-1606(90)90176-J; SCHMID TM, 1983, J BIOL CHEM, V258, P9504; THOMAS JT, 1991, BIOCHEM J, V280, P617, DOI 10.1042/bj2800617; WALLIS GA, 1994, AM J HUM GENET, V54, P169	31	46	46	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 7	1996	271	23					13566	13572		10.1074/jbc.271.23.13566	http://dx.doi.org/10.1074/jbc.271.23.13566			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UP385	8662807	hybrid			2022-12-25	WOS:A1996UP38500041
J	Goodfellow, HR; Sardini, A; Ruetz, S; Callaghan, R; Gros, P; McNaughton, PA; Higgins, CF				Goodfellow, HR; Sardini, A; Ruetz, S; Callaghan, R; Gros, P; McNaughton, PA; Higgins, CF			Protein kinase C-mediated phosphorylation does not regulate drug transport by the human multidrug resistance P-glycoprotein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VINBLASTINE ACCUMULATION; EXPRESSION SYSTEM; CARCINOMA-CELLS; VACCINIA VIRUS; P388/ADR CELLS; HL60 CELLS; STAUROSPORINE; GENE; IDENTIFICATION; MODULATION	P-glycoprotein (P-gp) is an active transporter that can confer multidrug resistance by pumping cytotoxic drugs out of cells and tumors, P-gp is phosphorylated at several sites in the ''linker'' region, which separates the two halves of the molecule, To examine the role of phosphorylation in drug transport, we mutated P-gp such that it could no longer be phosphorylated by protein kinase C (PRC), When expressed in yeast, the ability of the mutant proteins to confer drug resistance, or to mediate [H-3]vinblastine accumulation in secretory vesicles, was indistinguishable from that of wild type P-gp. A matched pair of mammalian cell lines were generated expressing wild type P-gp and a non-phosphorylatable mutant protein. Mutation of the phosphorylation sites did not alter P-gp expression or its subcellular localization The transport properties of the mutant and wild type proteins were indistinguishable. Thus, phosphorylation of the linker of P-gp by PRC does not affect the rate of drug transport, In fight of these data, the use of agents that alter PRC activity to reverse multidrug resistance in the clinic should be considered with caution.	MCGILL UNIV,DEPT BIOCHEM,MONTREAL,PQ H3G 1Y6,CANADA; JOHN RADCLIFFE HOSP,INST MOLEC MED,NUFFIELD DEPT CLIN BIOCHEM,IMPERIAL CANC RES LABS,OXFORD OX3 9DU,ENGLAND; UNIV LONDON KINGS COLL,DEPT PHYSIOL,LONDON WC2R 2LS,ENGLAND; MCGILL UNIV,DEPT BIOCHEM,MONTREAL,PQ H3G 1Y6,CANADA	McGill University; University of Oxford; University of London; King's College London; McGill University			Callaghan, Richard/B-7032-2012; Callaghan, Richard/ABG-1638-2020	Callaghan, Richard/0000-0001-6136-3532; Callaghan, Richard/0000-0001-6136-3532; McNaughton, Peter/0000-0003-1946-9610				ABRAHAM I, 1990, EXP CELL RES, V189, P133, DOI 10.1016/0014-4827(90)90265-C; AHMAD S, 1994, BIOCHEMISTRY-US, V33, P10313, DOI 10.1021/bi00200a011; BATES SE, 1992, BIOCHEMISTRY-US, V31, P6366, DOI 10.1021/bi00143a002; BATES SE, 1993, BIOCHEMISTRY-US, V32, P9156, DOI 10.1021/bi00086a022; BLOBE GC, 1993, J BIOL CHEM, V268, P658; CALLAGHAN R, 1993, J BIOL CHEM, V268, P16059; CANOGAUCI DF, 1987, BIOCHEM PHARMACOL, V36, P2115, DOI 10.1016/0006-2952(87)90139-0; CARLSEN SA, 1977, BIOCHIM BIOPHYS ACTA, V467, P238, DOI 10.1016/0005-2736(77)90199-7; CHAMBERS TC, 1990, J BIOL CHEM, V265, P7679; CHAMBERS TC, 1994, BIOCHEM J, V299, P309, DOI 10.1042/bj2990309; CHAMBERS TC, 1993, J BIOL CHEM, V268, P4592; CHAMBERS TC, 1992, MOL PHARMACOL, V41, P1008; CHAUDHARY PM, 1992, ONCOL RES, V4, P281; CHIN KV, 1992, J CELL PHYSIOL, V152, P87, DOI 10.1002/jcp.1041520112; CJHAMBERS TC, 1995, BIOCHEMISTRY-US, V34, P14156; CORNWELL MM, 1986, P NATL ACAD SCI USA, V261, P7762; ELROYSTEIN O, 1989, P NATL ACAD SCI USA, V86, P6126, DOI 10.1073/pnas.86.16.6126; FAN D, 1992, ANTICANCER RES, V12, P661; FINE RL, 1988, P NATL ACAD SCI USA, V85, P582, DOI 10.1073/pnas.85.2.582; FUERST TR, 1986, P NATL ACAD SCI USA, V83, P8122, DOI 10.1073/pnas.83.21.8122; FUJIKI Y, 1982, J CELL BIOL, V93, P97, DOI 10.1083/jcb.93.1.97; GERMANN UA, 1995, J BIOENERG BIOMEMBR, V27, P53, DOI 10.1007/BF02110331; GILL DR, 1992, CELL, V71, P23, DOI 10.1016/0092-8674(92)90263-C; GOTTESMAN MM, 1993, ANNU REV BIOCHEM, V62, P385, DOI 10.1146/annurev.bi.62.070193.002125; HARDY SP, 1995, EMBO J, V14, P68, DOI 10.1002/j.1460-2075.1995.tb06976.x; HIGGINS CF, 1992, TRENDS BIOCHEM SCI, V17, P18, DOI 10.1016/0968-0004(92)90419-A; HIGGINS CF, 1995, CELL, V82, P693, DOI 10.1016/0092-8674(95)90465-4; HOMOLYA L, 1993, J BIOL CHEM, V268, P21493; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE SA, 1992, CANCER RES, V52, P3750; LELONG IH, 1994, BIOCHEMISTRY-US, V33, P8921, DOI 10.1021/bi00196a009; LUCKIE DB, 1994, AM J PHYSIOL, V267, pC650, DOI 10.1152/ajpcell.1994.267.2.C650; MA LD, 1991, J BIOL CHEM, V266, P5593; MIYAMOTO K, 1993, J PHARM PHARMACOL, V45, P43, DOI 10.1111/j.2042-7158.1993.tb03677.x; MIYAMOTO KI, 1992, CANCER LETT, V64, P177, DOI 10.1016/0304-3835(92)90079-B; OBRIAN CA, 1989, FEBS LETT, V246, P78, DOI 10.1016/0014-5793(89)80257-1; ORR GA, 1993, J BIOL CHEM, V268, P25054; PALYOOR ST, 1987, BIOCHEM BIOPH RES CO, V148, P718; RIORDAN JR, 1989, SCIENCE, V245, P1066; RUETZ S, 1994, J BIOL CHEM, V269, P12277; SAMPSON KE, 1993, CANCER LETT, V68, P7, DOI 10.1016/0304-3835(93)90213-S; SARDINI A, 1994, J CELL SCI, V107, P3281; SATO W, 1990, BIOCHEM BIOPH RES CO, V173, P1252, DOI 10.1016/S0006-291X(05)80921-0; STAATS J, 1990, J BIOL CHEM, V265, P4084; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; UCHIUMI T, 1993, FEBS LETT, V326, P11, DOI 10.1016/0014-5793(93)81750-T; VALVERDE MA, 1992, NATURE, V355, P830, DOI 10.1038/355830a0; VERNET T, 1987, GENE, V52, P225, DOI 10.1016/0378-1119(87)90049-7; WAKUSAWA S, 1993, J ANTIBIOT, V46, P353, DOI 10.7164/antibiotics.46.353; WAKUSAWA S, 1992, ANTICANCER RES, V12, P2021; WALWORTH NC, 1987, J CELL BIOL, V105, P163, DOI 10.1083/jcb.105.1.163; WU G, 1991, CANCER COMMUN, P181	52	115	118	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 7	1996	271	23					13668	13674		10.1074/jbc.271.23.13668	http://dx.doi.org/10.1074/jbc.271.23.13668			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UP385	8662768	hybrid			2022-12-25	WOS:A1996UP38500056
J	Leem, JY; Nishimura, C; Kurata, S; Shimada, I; Kobayashi, A; Natori, S				Leem, JY; Nishimura, C; Kurata, S; Shimada, I; Kobayashi, A; Natori, S			Purification and characterization of N-beta-alanyl-5-S-glutathionyl-3,4-dihydroxyphenylalanine, a novel antibacterial substance of sarcophaga peregrina (flesh fly)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-FREE IMMUNITY; GENE-CLUSTER; MOLECULAR-CLONING; SARCOTOXIN-I; KAPPA-B; PROTEIN; EXPRESSION; HEMOLYMPH; CECROPIA; LARVAE	We purified a novel antibacterial substance from immunized adult Sarcophaga and determined its molecular structure to be N-beta-alanyl-5-S-glutathionyl 3,4-dihydroxyphenylalanine (5-S-GAD), We synthesized 5-S-GAD enzymatically from N-beta-alanyl-3,4-dihydroxyphenylalanine (beta-Ala-Dopa) and reduced glutathione (GSH), The antibacterial activity of 5-S-GAD was found to be due to its production of H2O2. This is a novel antibacterial mechanism as it differs from the mechanisms of known antibacterial peptides, Two possible roles of 5-S-GAD in insect immunity, suppression of bacterial growth and activation of a Rel family transcription factor, are proposed.	UNIV TOKYO,FAC PHARMACEUT SCI,BUNKYO KU,TOKYO 113,JAPAN	University of Tokyo								ANDO K, 1988, BIOCHEMISTRY-US, V13, P59; ANDO K, 1987, BIOCHEMISTRY-US, V27, P226; BABA K, 1987, J BIOCHEM-TOKYO, V102, P69, DOI 10.1093/oxfordjournals.jbchem.a122042; BODNARYK RP, 1969, COMP BIOCHEM PHYSIOL, V30, P909, DOI 10.1016/0010-406X(69)90046-2; BOMAN HG, 1991, EUR J BIOCHEM, V201, P23, DOI 10.1111/j.1432-1033.1991.tb16252.x; BOMAN HG, 1981, TRENDS BIOCHEM SCI, V6, P306, DOI 10.1146/annurev.mi.41.100187.000535; BOMAN HG, 1991, CELL, V65, P205, DOI 10.1016/0092-8674(91)90154-Q; BULET P, 1993, J BIOL CHEM, V268, P14893; DUNN PE, 1986, ANNU REV ENTOMOL, V31, P321, DOI 10.1146/annurev.en.31.010186.001541; ISHIKAWA M, 1992, BIOCHEM J, V287, P573, DOI 10.1042/bj2870573; ISHIKAWA T, 1993, STRUCTURE FUNCTION G, P211; ITO S, 1983, BIOCHEM PHARMACOL, V32, P2079, DOI 10.1016/0006-2952(83)90429-X; KANAI A, 1989, FEBS LETT, V258, P199, DOI 10.1016/0014-5793(89)81652-7; KANAI A, 1990, MOL CELL BIOL, V10, P6114, DOI 10.1128/MCB.10.12.6114; KOBAYASHI A, 1993, MOL CELL BIOL, V13, P4049, DOI 10.1128/MCB.13.7.4049; KYLSTEN P, 1990, EMBO J, V9, P217, DOI 10.1002/j.1460-2075.1990.tb08098.x; MATSUMOTO N, 1986, BIOCHEM J, V239, P717, DOI 10.1042/bj2390717; MATSUYAMA K, 1988, J BIOL CHEM, V263, P17117; MATSUYAMA K, 1988, J BIOL CHEM, V263, P17112; MEYER M, 1994, CHEM-BIOL INTERACT, V91, P91, DOI 10.1016/0009-2797(94)90029-9; Natori S., 1987, UCLA (University of California Los Angeles) Symposia on Molecular and Cellular Biology New Series, V49, P369; NATORI S, 1977, J INSECT PHYSIOL, V23, P1169, DOI 10.1016/0022-1910(77)90149-4; OKADA M, 1985, J BIOL CHEM, V260, P7174; OKADA M, 1983, BIOCHEM J, V211, P727, DOI 10.1042/bj2110727; SUGIYAMA H, 1994, J BIOCHEM, V116, P1171, DOI 10.1093/oxfordjournals.jbchem.a124645; SUN SC, 1995, EUR J BIOCHEM, V231, P93, DOI 10.1111/j.1432-1033.1995.0093f.x; SUN SC, 1991, EUR J BIOCHEM, V196, P247, DOI 10.1111/j.1432-1033.1991.tb15811.x; SUN SC, 1992, EUR J BIOCHEM, V204, P885, DOI 10.1111/j.1432-1033.1992.tb16708.x; TAKAHASHI H, 1986, J INSECT PHYSIOL, V32, P771, DOI 10.1016/0022-1910(86)90080-6	29	64	71	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 7	1996	271	23					13573	13577		10.1074/jbc.271.23.13573	http://dx.doi.org/10.1074/jbc.271.23.13573			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UP385	8662858	hybrid			2022-12-25	WOS:A1996UP38500042
J	Park, RK; Liu, YB; Durden, DL				Park, RK; Liu, YB; Durden, DL			A role for Shc, Grb2, and Raf-1 in Fc gamma RI signal relay	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-AFFINITY RECEPTOR; NATURAL-KILLER CELLS; TYROSINE PHOSPHORYLATION; LYMPHOKINE GENES; PROTEIN-KINASES; CROSS-LINKING; NADPH OXIDASE; U937 CELLS; LINE U937; T-CELL	The activation of the serine/threonine kinase, Raf-1, serves to connect upstream protein tyrosine kinases to downstream signaling events. We previously reported that Fc gamma RI stimulation of interferon gamma-differentiated U937 cells (termed U937IF cells) induces a mobility shift in Erk2. Herein, we report that cross-linking of Fc gamma RI receptor in U937IF cells induces a marked tyrosine phosphorylation of Raf-1 (10-fold increase). Tyrosine phosphorylation of Raf-1 is induced by Fc gamma RI activation and not by PMA (1 mu g/ml), N-formyl-Met-Leu-Phe (1 mu M), calcium ionophore (1 mu M), thrombin (0.05 unit/ml), Fc gamma RII, or Fc gamma RIII stimulation. The kinetics of Raf-1 tyrosine phosphorylations is rapid, reaching peak levels 1-2 min after Fc gamma RI activation, and the tyrosine phosphorylation of Raf-1 precedes the activation of the respiratory burst. Fc gamma RI cross-linking induces the tyrosine phosphorylation of Shc; tyrosine-phosphorylated Shc bind to Grb2 forming a Shc-Grb2 complex. The data provide evidence that the Fc gamma RI receptor signals via the upstream activation of nonreceptor protein tyrosine kinases, which leads to the subsequent activation of RAs family GTPases and serine/threonine kinases, RAf-1 and mitogen-activated protein kinase.	CHILDRENS HOSP LOS ANGELES, DEPT PEDIAT, DIV HEMATOL ONCOL, NEIL BOGART MEM LABS, LOS ANGELES, CA 90027 USA; UNIV SO CALIF, SCH MED, LOS ANGELES, CA 90027 USA	Children's Hospital Los Angeles; University of Southern California								ABO A, 1992, J BIOL CHEM, V267, P16767; ANDERSON CL, 1982, J EXP MED, V156, P1794, DOI 10.1084/jem.156.6.1794; ANEGON I, 1988, J EXP MED, V167, P452, DOI 10.1084/jem.167.2.452; BALDARI CT, 1995, ONCOGENE, V10, P1141; BOKOCH GM, 1994, CURR OPIN IMMUNOL, V6, P98, DOI 10.1016/0952-7915(94)90040-X; BOKOCH GM, 1991, SCIENCE, V254, P1794, DOI 10.1126/science.1763330; BOLEN JB, 1993, ONCOGENE, V8, P2025; BOLEN JB, 1993, ONCOGENE, V8, P2031; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; CAMBIER JC, 1992, CURR OPIN IMMUNOL, V4, P257, DOI 10.1016/0952-7915(92)90074-O; CAMBIER JC, 1995, IMMUNOL TODAY, V16, P110, DOI 10.1016/0167-5699(95)80105-7; CAMBIER JC, 1995, J IMMUNOL, V155, P3281; CARROLL MP, 1990, J BIOL CHEM, V265, P19812; CASSATELLA MA, 1989, J EXP MED, V169, P549, DOI 10.1084/jem.169.2.549; DENT P, 1994, P NATL ACAD SCI USA, V91, P9544, DOI 10.1073/pnas.91.20.9544; DURDEN DL, 1994, BIOCHEM J, V299, P569, DOI 10.1042/bj2990569; DURDEN DL, 1995, J IMMUNOL, V154, P4039; DURDEN DL, 1994, BLOOD, V84, P2102; DUSI S, 1994, BIOCHEM J, V304, P243, DOI 10.1042/bj3040243; ELBENNA J, 1994, J BIOL CHEM, V269, P6729; ERNST LK, 1993, P NATL ACAD SCI USA, V90, P6023, DOI 10.1073/pnas.90.13.6023; FABIAN JR, 1994, P NATL ACAD SCI USA, V91, P5982, DOI 10.1073/pnas.91.13.5982; FABIAN JR, 1993, MOL CELL BIOL, V13, P7170, DOI 10.1128/MCB.13.11.7170; FREEMAN JLR, 1994, BIOCHEMISTRY-US, V33, P13431, DOI 10.1021/bi00249a031; FRIDMAN M, 1994, J BIOL CHEM, V269, P30105; FUKAMACHI H, 1993, INT ARCH ALLERGY IMM, V102, P15, DOI 10.1159/000236546; FUKAMACHI H, 1993, INT ARCH ALLER A IMM, V102, P25; GABIG TG, 1995, BLOOD, V85, P804, DOI 10.1182/blood.V85.3.804.bloodjournal853804; GABIG TG, 1995, BLOOD, V85, P811; GUPTA S, 1994, J BIOL CHEM, V269, P17349; HEIDECKER G, 1992, ADV CANCER RES, V58, P53, DOI 10.1016/S0065-230X(08)60290-0; HEIDECKER G, 1990, MOL CELL BIOL, V10, P2503, DOI 10.1128/MCB.10.6.2503; HEYWORTH PG, 1993, MOL BIOL CELL, V4, P261, DOI 10.1091/mbc.4.3.261; HUANG MM, 1992, J BIOL CHEM, V267, P5467; JING YK, 1994, JPN J CANCER RES, V85, P645, DOI 10.1111/j.1349-7006.1994.tb02408.x; KAZLAUSKAS A, 1991, CELL REGUL, V2, P413, DOI 10.1091/mbc.2.6.413; KINET JP, 1992, CURR OPIN IMMUNOL, V4, P43, DOI 10.1016/0952-7915(92)90122-U; KINET JP, 1992, CURR OPIN IMMUNOL, V4, P48; KOVACINA KS, 1990, J BIOL CHEM, V265, P12115; LAI CC, 1993, MOL CELL BIOL, V13, P1345, DOI 10.1128/MCB.13.3.1345; LI SF, 1995, EMBO J, V14, P685, DOI 10.1002/j.1460-2075.1995.tb07047.x; LIAO F, 1992, P NATL ACAD SCI USA, V89, P3659, DOI 10.1073/pnas.89.8.3659; LOONEY RJ, 1986, J IMMUNOL, V136, P1641; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; MORRISON DK, 1989, CELL, V58, P649, DOI 10.1016/0092-8674(89)90100-1; MORRISON DK, 1988, P NATL ACAD SCI USA, V85, P8855, DOI 10.1073/pnas.85.23.8855; MORRISON DK, 1993, J BIOL CHEM, V268, P17309; MORRISON DK, 1988, MOL CELL BIOL, V8, P176, DOI 10.1128/MCB.8.1.176; MORRISON DK, 1990, CANCER CELL-MON REV, V2, P377; NEL AE, 1990, J IMMUNOL, V145, P971; PAOLINI R, 1991, NATURE, V353, P855, DOI 10.1038/353855a0; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PESADA J, 1992, SCIENCE, V255, P212; PFEFFERKORN LC, 1995, J BIOL CHEM, V270, P8164, DOI 10.1074/jbc.270.14.8164; PFEFFERKORN LC, 1995, J BIOL CHEM, V270, P8171; PRIGMORE E, 1995, J BIOL CHEM, V270, P10717, DOI 10.1074/jbc.270.18.10717; PULMIGLIA K, 1995, MOL CELL BIOL, V15, P398; RAVETCH JV, 1991, ANNU REV IMMUNOL, V9, P457, DOI 10.1146/annurev.iy.09.040191.002325; RAVICHANDRAN KS, 1993, SCIENCE, V262, P902, DOI 10.1126/science.8235613; ROBERTS PJ, 1991, J IMMUNOL, V147, P3104; ROBERTS TM, 1992, NATURE, V360, P534, DOI 10.1038/360534a0; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; SALCINI AE, 1994, ONCOGENE, V9, P2827; STANTON VP, 1989, MOL CELL BIOL, V9, P639, DOI 10.1128/MCB.9.2.639; TURNER B, 1991, P NATL ACAD SCI USA, V88, P1227, DOI 10.1073/pnas.88.4.1227; VANAELST L, 1993, P NATL ACAD SCI USA, V90, P6213, DOI 10.1073/pnas.90.13.6213; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WILLIAMS K, 1994, EUR J IMMUNOL, V24, P3031, DOI 10.1002/eji.1830241217	68	35	36	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 7	1996	271	23					13342	13348		10.1074/jbc.271.23.13342	http://dx.doi.org/10.1074/jbc.271.23.13342			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UP385	8662746	hybrid			2022-12-25	WOS:A1996UP38500009
J	Schreiber, M; Rajarathnam, K; McFadden, G				Schreiber, M; Rajarathnam, K; McFadden, G			Myxoma virus T2 protein, a tumor necrosis factor (TNF) receptor homolog, is secreted as a monomer and dimer that each bind rabbit TNF alpha, but the dimer is a more potent TNF inhibitor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VACCINIA VIRUS; 55-KDA RECEPTOR; GAMMA RECEPTOR; LIGAND-BINDING; EXPRESSION; TYPE-1; CELLS; GENES; IDENTIFICATION; AUGMENTATION	The myxoma virus T2 (M-T2) gene expresses a secreted protein that contains significant sequence similarity to the ligand binding domains of the cellular tumor necrosis factor (TNF) receptors, specifically inhibits the cytolytic activity of rabbit TNF alpha and is an important virulence factor for myxoma virus infection in rabbits, M-T2 protein was overexpressed from vaccinia virus vectors, purified to apparent homogeneity, and found to specifically protect mouse and rabbit cells from lysis by rabbit TNF alpha at molar ratios comparable with the soluble versions of the host tumor necrosis factor receptors. M-T2 secreted from virus-infected cells is detected as both a monomer and a disulfide-linked dimer, both of which were shown by Scatchard analysis to bind rabbit TNF alpha (K-d values of 170 pM and 195 pM, respectively), values that are comparable with the affinities of mammalian TNFs with their receptors. In contrast to the rabbit ligand, M-T2 interacts with mouse TNF alpha with a much lower affinity, K-d of 1.7 nM, and was unable to inhibit the cytolytic activity of this ligand on mouse cells, Although both monomeric and dimeric forms bound rabbit TNF alpha with comparable affinity, the dimeric M-T2 protein was a far more potent inhibitor of rabbit TNF alpha, presumably because it can more effectively prevent dimerization of TNF receptors than can the M-T2 monomer.	UNIV ALBERTA, DEPT BIOCHEM, EDMONTON, AB T6G 2H7, CANADA	University of Alberta								ADERKA D, 1985, CELL IMMUNOL, V92, P218, DOI 10.1016/0008-8749(85)90003-6; AGGARWAL BB, 1992, TUMOR NECROSIS FACTO, P61; ALCAMI A, 1995, IMMUNOL TODAY, V16, P474, DOI 10.1016/0167-5699(95)80030-1; ALCAMI A, 1995, J VIROL, V69, P4633; ALCAMI A, 1992, CELL, V71, P153, DOI 10.1016/0092-8674(92)90274-G; ARMITAGE RJ, 1994, CURR OPIN IMMUNOL, V6, P407, DOI 10.1016/0952-7915(94)90119-8; ASHKENAZI A, 1991, P NATL ACAD SCI USA, V88, P10535, DOI 10.1073/pnas.88.23.10535; BAZZONI F, 1995, P NATL ACAD SCI USA, V92, P5376, DOI 10.1073/pnas.92.12.5376; BEUTLER B, 1991, PEPTIDE GROWTH FACTO, P39; BUTLER DM, 1994, CYTOKINE, V6, P616, DOI 10.1016/1043-4666(94)90049-3; COLAMONICI OR, 1995, J BIOL CHEM, V270, P15974, DOI 10.1074/jbc.270.27.15974; DAVISON AJ, 1990, NUCLEIC ACIDS RES, V18, P4285, DOI 10.1093/nar/18.14.4285; DEBETS R, 1994, IMMUNOL TODAY, V15, P455, DOI 10.1016/0167-5699(94)90187-2; DECLERCQ W, 1995, CYTOKINE, V7, P701, DOI 10.1006/cyto.1995.0082; FENNER F, 1965, MYXOMATOSIS; FOUNTOULAKIS M, 1990, J BIOL CHEM, V265, P13268; GARFIN DE, 1990, METHOD ENZYMOL, V182, P425; GOODWIN RG, 1991, MOL CELL BIOL, V11, P3020, DOI 10.1128/MCB.11.6.3020; HAAKFRENDSCHO M, 1994, J IMMUNOL, V152, P1347; HALE KK, 1995, CYTOKINE, V7, P26, DOI 10.1006/cyto.1995.1004; Harlow E., 1988, ANTIBODIES LAB MANUA; HELDIN CH, 1995, CELL, V80, P213, DOI 10.1016/0092-8674(95)90404-2; HIGUCHI M, 1992, J BIOL CHEM, V267, P20892; HOWARD OMZ, 1993, P NATL ACAD SCI USA, V90, P2335, DOI 10.1073/pnas.90.6.2335; HU FQ, 1994, VIROLOGY, V204, P343, DOI 10.1006/viro.1994.1539; KOFF WC, 1986, LYMPHOKINE RES, V5, P215; LASTER SM, 1994, SEMIN VIROL, V5, P431, DOI 10.1006/smvy.1994.1049; LEWIS M, 1991, P NATL ACAD SCI USA, V88, P2830, DOI 10.1073/pnas.88.7.2830; LIDBURY BA, 1995, CYTOKINE, V7, P157, DOI 10.1006/cyto.1995.1021; LOETSCHER H, 1991, J BIOL CHEM, V266, P18324; LORENCE RM, 1988, J NATL CANCER I, V80, P1305, DOI 10.1093/jnci/80.16.1305; MACEN JL, 1993, VIROLOGY, V195, P348, DOI 10.1006/viro.1993.1385; MARSTERS SA, 1992, J BIOL CHEM, V267, P5747; MCFADDEN G, 1994, SEMIN VIROL, V5, P421, DOI 10.1006/smvy.1994.1048; MCFADDEN G, 1995, J LEUKOCYTE BIOL, V57, P731, DOI 10.1002/jlb.57.5.731; MCFADDEN G, 1995, VIROCEPTORS VIROKINE; MCFADDEN G, 1994, ENCY VIROLOGY, P1153; MOSSMAN K, 1995, VIROLOGY, V208, P762, DOI 10.1006/viro.1995.1208; MOSSMAN K, 1995, J BIOL CHEM, V270, P3031, DOI 10.1074/jbc.270.7.3031; OLSSON I, 1993, EUR CYTOKINE NETW, V4, P169; OPGENORTH A, 1992, J VIROL, V66, P4720, DOI 10.1128/JVI.66.8.4720-4731.1992; PENNICA D, 1992, J BIOL CHEM, V267, P21172; PENNICA D, 1992, BIOCHEMISTRY-US, V31, P1134, DOI 10.1021/bi00119a023; PEPPEL K, 1991, J EXP MED, V174, P1483, DOI 10.1084/jem.174.6.1483; PFIZENMAIER K, 1992, TUMOR NECROSIS FACTO, P439; ROTHE J, 1992, IMMUNOL RES, V11, P81, DOI 10.1007/BF02918612; SAMBHI SK, 1991, P NATL ACAD SCI USA, V88, P4025, DOI 10.1073/pnas.88.9.4025; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SCHREIBER M, 1994, VIROLOGY, V204, P692, DOI 10.1006/viro.1994.1585; SHAKHOV AN, 1990, GENE, V95, P215, DOI 10.1016/0378-1119(90)90364-W; SMITH CA, 1994, CELL, V76, P959, DOI 10.1016/0092-8674(94)90372-7; SMITH CA, 1995, VIROCEPTORS VIROKINE, P29; SMITH GL, 1994, TRENDS MICROBIOL, V2, P80; SMITH RA, 1992, TUMOR NECROSIS FACTO, P131; SPRIGGS MK, 1992, CELL, V71, P145, DOI 10.1016/0092-8674(92)90273-F; SPRIGGS MK, 1994, VIRUS RES, V33, P1, DOI 10.1016/0168-1702(94)90013-2; SUGARMAN HJ, 1985, SCIENCE, V230, P942; SYMONS JA, 1995, CELL, V81, P551, DOI 10.1016/0092-8674(95)90076-4; TARTAGLIA LA, 1992, IMMUNOL TODAY, V13, P151, DOI 10.1016/0167-5699(92)90116-O; TARTAGLIA LA, 1992, J BIOL CHEM, V267, P4304; TARTAGLIA LA, 1993, CELL, V73, P213, DOI 10.1016/0092-8674(93)90222-C; TARTAGLIA LA, 1993, J BIOL CHEM, V268, P18542; THOMA B, 1990, J EXP MED, V172, P1019, DOI 10.1084/jem.172.4.1019; TRACEY KJ, 1994, ANNU REV MED, V45, P491, DOI 10.1146/annurev.med.45.1.491; UPTON C, 1992, SCIENCE, V258, P1369, DOI 10.1126/science.1455233; UPTON C, 1991, VIROLOGY, V184, P370, DOI 10.1016/0042-6822(91)90853-4; VANDENABEELE P, 1995, TRENDS CELL BIOL, V5, P392, DOI 10.1016/S0962-8924(00)89088-1; WELLS JA, 1994, CURR OPIN CELL BIOL, V6, P163, DOI 10.1016/0955-0674(94)90132-5; WIEGMANN K, 1992, J BIOL CHEM, V267, P17997; WOLD WSM, 1993, J CELL BIOCHEM, V53, P329, DOI 10.1002/jcb.240530410; WONG GHW, 1992, J IMMUNOL, V149, P3350; WONG GHW, 1986, NATURE, V323, P819, DOI 10.1038/323819a0; [No title captured]	73	61	66	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 7	1996	271	23					13333	13341		10.1074/jbc.271.23.13333	http://dx.doi.org/10.1074/jbc.271.23.13333			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UP385	8662837	hybrid			2022-12-25	WOS:A1996UP38500008
J	Condie, R; Herring, A; Koh, WS; Lee, M; Kaminski, NE				Condie, R; Herring, A; Koh, WS; Lee, M; Kaminski, NE			Cannabinoid inhibition of adenylate cyclase-mediated signal transduction and interleukin 2 (IL-2) expression in the murine T-cell line, EL4.IL-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; INDEPENDENT ANTIGENS; RESPONSE ELEMENT; MOLECULAR-BASIS; MESSENGER-RNA; CYCLIC-AMP; RECEPTOR; CAMP; CREB; TRANSCRIPTION	Cannabinoid receptors negatively regulate adenylate cyclase through a pertussis toxin-sensitive GTP-binding protein. In the present studies, signaling via the adenylate cyclase/cAMP pathway was investigated in the murine thymoma-derived T-cell line, EL4.IL-2. Northern analysis of EL4.IL-2 cells identified the presence of 4-kilobase CB2 but not CB1 receptor-subtype mRNA transcripts. Southern analysis of genomic DNA digests for the CB2 receptor demonstrated identical banding patterns for EL4.IL-2 cells and mouse-derived DNA, both of which were dissimilar to DNA isolated from rat, Treatment of EL4.IL-2 cells with either cannabinol or Delta(9)-THC disrupted the adenylate cyclase signaling cascade by inhibiting forskolin-stimulated cAMP accumulation which consequently led to a decrease in protein kinase A activity and the binding of transcription factors to a CRE consensus sequence. Likewise, an inhibition of phorbol 12-myristate 13-acetate (PMA)/ionomycin-induced interleukin 2 (IL-2) protein secretion, which correlated to decreased IL-2 gene transcription, was induced by both cannabinol and Delta(9)-THC. Further, cannabinoid treatment also decreased PMA/ionomycin-induced nuclear factor binding to the AP-1 proximal site of the IL-2 promoter. Conversely, forskolin enhanced PMA/ionomycin-induced AP-1 binding. These findings suggest that inhibition of signal transduction via the adenylate cyclase/cAMP pathway induces T-cell dysfunction which leads to a diminution in IL-2 gene transcription.	MICHIGAN STATE UNIV,DEPT PHARMACOL & TOXICOL,E LANSING,MI 48824; MICHIGAN STATE UNIV,DEPT PATHOL,E LANSING,MI 48824	Michigan State University; Michigan State University					NATIONAL INSTITUTE ON DRUG ABUSE [R01DA009171, R01DA007908] Funding Source: NIH RePORTER; NIDA NIH HHS [DA07908, DA09171] Funding Source: Medline	NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA))		ANDERSSON B, 1971, CELL IMMUNOL, V2, P411, DOI 10.1016/0008-8749(71)90052-9; AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; BOUABOULA M, 1993, EUR J BIOCHEM, V214, P173, DOI 10.1111/j.1432-1033.1993.tb17910.x; BURGERING BMT, 1993, EMBO J, V12, P4211, DOI 10.1002/j.1460-2075.1993.tb06105.x; CHEN D, 1993, MOL CELL BIOL, V13, P228, DOI 10.1128/MCB.13.1.228; CHOMCZYNSKI P, 1995, ANAL BIOCHEM, V225, P163, DOI 10.1006/abio.1995.1126; CHOMCZYNSKI P, 1993, BIOTECHNIQUES, V15, P532; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHSUED TM, 1976, J IMMUNOL, V116, P1579; CLAMAN HN, 1976, PROG ALLERGY, V16, P40; COOK SJ, 1993, SCIENCE, V262, P1069, DOI 10.1126/science.7694367; DASH PK, 1991, P NATL ACAD SCI USA, V88, P5061, DOI 10.1073/pnas.88.11.5061; DUNNETT CW, 1955, J AM STAT ASSOC, V50, P1096, DOI 10.2307/2281208; FARRAR JJ, 1980, J IMMUNOL, V125, P2555; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; FRANCIS DA, 1995, INT IMMUNOL, V7, P151, DOI 10.1093/intimm/7.2.151; FRIEDMAN H, 1995, IMMUNOTOXICOLOGY IMM, P303; GERY I, 1972, J IMMUNOL, V108, P1088; GILLILAND G, 1990, P NATL ACAD SCI USA, V87, P2725, DOI 10.1073/pnas.87.7.2725; Gilliland G., 1990, PCR PROTOCOLS GUIDE, P60; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; GRAVES LM, 1993, P NATL ACAD SCI USA, V90, P10300, DOI 10.1073/pnas.90.21.10300; HADDEN JW, 1972, P NATL ACAD SCI USA, V69, P3024, DOI 10.1073/pnas.69.10.3024; HAFNER S, 1994, MOL CELL BIOL, V14, P6696; HAGIWARA M, 1992, CELL, V70, P105, DOI 10.1016/0092-8674(92)90537-M; HAI T, 1991, P NATL ACAD SCI USA, V88, P3720, DOI 10.1073/pnas.88.9.3720; HERKENHAM M, 1990, P NATL ACAD SCI USA, V87, P1932, DOI 10.1073/pnas.87.5.1932; HORDIJK PL, 1994, J BIOL CHEM, V269, P3534; HOWLETT AC, 1988, MOL PHARMACOL, V33, P297; HOWLETT AC, 1985, MOL PHARMACOL, V27, P429; HOWLETT AC, 1986, MOL PHARMACOL, V29, P307; HSUEH YP, 1995, J BIOL CHEM, V270, P18094, DOI 10.1074/jbc.270.30.18094; IVASHKIV LB, 1990, MOL CELL BIOL, V10, P1609, DOI 10.1128/MCB.10.4.1609; JOHNSON KW, 1988, P NATL ACAD SCI USA, V85, P6072, DOI 10.1073/pnas.85.16.6072; KAMINSKI NE, 1992, MOL PHARMACOL, V42, P736; KAMINSKI NE, 1994, BIOCHEM PHARMACOL, V48, P1899, DOI 10.1016/0006-2952(94)90588-6; KAMINSKI NE, 1995, IMMUNOTOXICOLOGY IMM, P349; KAMMER GM, 1988, IMMUNOL TODAY, V9, P222, DOI 10.1016/0167-5699(88)91220-0; KLEIN TW, 1991, J TOXICOL ENV HEALTH, V32, P465, DOI 10.1080/15287399109531496; KOH WS, 1995, BIOCHEM BIOPH RES CO, V206, P703, DOI 10.1006/bbrc.1995.1099; LEE HJ, 1995, J BIOL CHEM, V270, P17541, DOI 10.1074/jbc.270.29.17196; LEE KC, 1976, EUR J IMMUNOL, V6, P63, DOI 10.1002/eji.1830060114; LITTLE PJ, 1989, PHARMACOL BIOCHEM BE, V32, P661, DOI 10.1016/0091-3057(89)90014-2; MATSUDA LA, 1990, NATURE, V346, P561, DOI 10.1038/346561a0; MCGUIRE KL, 1987, EMBO J, V6, P939, DOI 10.1002/j.1460-2075.1987.tb04842.x; MECHOULAM R, 1995, BIOCHEM PHARMACOL, V50, P83, DOI 10.1016/0006-2952(95)00109-D; MOLLER G, 1971, CELL IMMUNOL, V2, P309, DOI 10.1016/0008-8749(71)90065-7; MOSIER DE, 1968, P NATL ACAD SCI USA, V61, P542, DOI 10.1073/pnas.61.2.542; MUNRO S, 1993, NATURE, V365, P61, DOI 10.1038/365061a0; NAKANO Y, 1993, LIFE SCI, V52, P41, DOI 10.1016/0024-3205(93)90287-D; NOVAK TJ, 1990, MOL CELL BIOL, V10, P6325, DOI 10.1128/MCB.10.12.6325; PEPE S, 1994, CYTOMETRY, V15, P73, DOI 10.1002/cyto.990150112; Russell D H, 1978, Adv Cyclic Nucleotide Res, V9, P493; SCHATZ AR, 1993, IMMUNOPHARMACOLOGY, V26, P129, DOI 10.1016/0162-3109(93)90005-B; SCHATZ AR, 1992, LIFE SCI, V51, P25; SEVETSON BR, 1993, P NATL ACAD SCI USA, V90, P10305, DOI 10.1073/pnas.90.21.10305; SHENG M, 1991, SCIENCE, V252, P1427, DOI 10.1126/science.1646483; SHENG M, 1990, NEURON, V4, P571, DOI 10.1016/0896-6273(90)90115-V; SHIRE D, 1995, J BIOL CHEM, V270, P3726, DOI 10.1074/jbc.270.8.3726; SIEGEL MD, 1995, J BIOL CHEM, V270, P24548, DOI 10.1074/jbc.270.41.24548; SMITH JW, 1971, J CLIN INVEST, V50, P432, DOI 10.1172/JCI106510; THOMAS BF, 1992, J PHARMACOL EXP THER, V263, P1383; TSURUTA L, 1995, J IMMUNOL, V154, P5255; VANDENHEUVEL JP, 1994, CANCER RES, V54, P62; VANDENHEUVEL JP, 1993, BIOTECHNIQUES, V14, P395; VOGEL Z, 1993, J NEUROCHEM, V61, P352, DOI 10.1111/j.1471-4159.1993.tb03576.x; WATSON PA, 1994, J BIOL CHEM, V269, P28893; WU J, 1993, SCIENCE, V262, P1065, DOI 10.1126/science.7694366; YOKOTA T, 1985, P NATL ACAD SCI USA, V82, P68, DOI 10.1073/pnas.82.1.68	69	105	108	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 31	1996	271	22					13175	13183		10.1074/jbc.271.22.13175	http://dx.doi.org/10.1074/jbc.271.22.13175			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UN474	8662742	hybrid			2022-12-25	WOS:A1996UN47400075
J	FujitaYoshigaki, J; Dohke, Y; HaraYokoyama, M; Kamata, Y; Kozaki, S; Furuyama, S; Sugiya, H				FujitaYoshigaki, J; Dohke, Y; HaraYokoyama, M; Kamata, Y; Kozaki, S; Furuyama, S; Sugiya, H			Vesicle-associated membrane protein 2 is essential for cAMP-regulated exocytosis in rat parotid acinar cells - The inhibition of cAMP-dependent amylase release by botulinum neurotoxin B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIC-AMP; NEUROTRANSMITTER RELEASE; TETANUS TOXIN; KINASE-C; CALCIUM; SYNAPTOBREVIN; SYNAPTOTAGMIN; SECRETION; ANTIBODIES; MACHINERY	Amylase exocytosis of the parotid gland is mediated by intracellular cAMP. To investigate whether cAMP-dependent secretion has a mechanism similar to that of regulated neuroexocytosis, we examined the expression of synaptosome-associated proteins. In rat parotid acinar cells, we found 25 (p25) and 18 kDa (p18) proteins reacted with antibodies against Rab3A and vesicle-associated membrane protein 2 (VAMP-2), respectively. On the other hand, syntaxin 1 and SNAP-25, which interact with VAMP-2 at synapses, were undetectable. Rab3A-like p25 and VAMP-2-like p18 were also expressed in other exocrine acinar cells. The latter was localized at secretory granule membranes, and the former was detected in secretory granule and cytosolic fractions. The antibody against VAMP-2 used in this study did not react with cellubrevin, and p18 was cleaved with botulinum neurotoxin B. Thus, we identified p18 as VAMP-2. Botulinum neurotoxin B inhibited the cAMP-induced amylase release from streptolysin O-permeabilized acinar cells. Therefore, VAMP-2 is required for cAMP-regulated amylase release in rat parotid acinar cells. This is the first report that VAMP-2 is involved in regulated exocytosis that is independent of Ca2+.	UNIV OSAKA PREFECTURE,DEPT AGR,SAKAI,OSAKA 593,JAPAN	Osaka Metropolitan University	FujitaYoshigaki, J (corresponding author), NIHON UNIV,SCH DENT,DEPT PHYSIOL,2-870-1 SAKAE CHO NISHI,MATSUDO,CHIBA 271,JAPAN.		Yoshigaki, Junko/AAE-6702-2020	Fujita-Yoshigaki, Junko/0000-0002-3271-6498				AMMALA C, 1993, NATURE, V363, P356, DOI 10.1038/363356a0; BALDYSWALIGORSKA A, 1987, BIOCHIM BIOPHYS ACTA, V929, P190, DOI 10.1016/0167-4889(87)90175-3; BENNETT MK, 1992, J CELL BIOL, V116, P761, DOI 10.1083/jcb.116.3.761; BENNETT MK, 1993, P NATL ACAD SCI USA, V90, P2559, DOI 10.1073/pnas.90.7.2559; BERNFELD P, 1955, METHOD ENZYMOL, V1, P149, DOI 10.1016/0076-6879(55)01021-5; BERRIDGE MJ, 1985, SCI AM, V253, P142, DOI 10.1038/scientificamerican1085-142; BLASI J, 1993, NATURE, V365, P160, DOI 10.1038/365160a0; BLASI J, 1993, EMBO J, V12, P4821, DOI 10.1002/j.1460-2075.1993.tb06171.x; BURGESS GM, 1983, J BIOL CHEM, V258, P5336; BURNHAM DB, 1982, CELL TISSUE RES, V222, P201; Butcher F R, 1980, Adv Cyclic Nucleotide Res, V13, P215; FERRONOVICK S, 1994, NATURE, V370, P191, DOI 10.1038/370191a0; GAISANO HY, 1994, J BIOL CHEM, V269, P17062; GALLI T, 1994, J CELL BIOL, V125, P1015, DOI 10.1083/jcb.125.5.1015; GASSER KW, 1990, AM J PHYSIOL, V259, pC413, DOI 10.1152/ajpcell.1990.259.3.C413; JENA BP, 1994, J CELL BIOL, V124, P43, DOI 10.1083/jcb.124.1.43; KOZAKI S, 1974, INFECT IMMUN, V10, P750, DOI 10.1128/IAI.10.4.750-756.1974; LEVEQUE C, 1992, P NATL ACAD SCI USA, V89, P3625, DOI 10.1073/pnas.89.8.3625; LINK E, 1992, BIOCHEM BIOPH RES CO, V189, P1017, DOI 10.1016/0006-291X(92)92305-H; MACRAE MB, 1990, BIOCHEM J, V271, P635, DOI 10.1042/bj2710635; MIZOGUCHI A, 1990, J BIOL CHEM, V265, P11872; MOLLARD GFV, 1990, P NATL ACAD SCI USA, V87, P1988; NONET ML, 1993, CELL, V73, P1291, DOI 10.1016/0092-8674(93)90357-V; OBATA K, 1986, BRAIN RES, V375, P37, DOI 10.1016/0006-8993(86)90956-X; OHO C, 1995, NEUROSCI LETT, V186, P208, DOI 10.1016/0304-3940(95)11317-P; POULAIN B, 1993, J NEUROCHEM, V61, P1175, DOI 10.1111/j.1471-4159.1993.tb03640.x; PRENTKI M, 1987, PHYSIOL REV, V67, P1185, DOI 10.1152/physrev.1987.67.4.1185; QUISSELL DO, 1979, P NATL ACAD SCI USA, V76, P2789, DOI 10.1073/pnas.76.6.2789; QUISSELL DO, 1993, BIOL SALIVARY GLANDS, P181; REGAZZI R, 1995, EMBO J, V14, P2723, DOI 10.1002/j.1460-2075.1995.tb07273.x; SCHIAVO G, 1992, NATURE, V359, P832, DOI 10.1038/359832a0; SKEHEL PA, 1995, SCIENCE, V269, P1580, DOI 10.1126/science.7667638; SOLLNER T, 1993, CELL, V75, P409, DOI 10.1016/0092-8674(93)90376-2; SOLLNER T, 1993, NATURE, V362, P319; SUDHOF TC, 1995, NATURE, V375, P645, DOI 10.1038/375645a0; SUDHOF TC, 1993, CELL, V75, P1; SUGIYA H, 1987, BIOCHEM J, V244, P647, DOI 10.1042/bj2440647; TAKAHASHI M, 1991, BRAIN RES, V551, P279, DOI 10.1016/0006-8993(91)90942-O; TAKUMA T, 1986, BIOCHIM BIOPHYS ACTA, V887, P113, DOI 10.1016/0167-4889(86)90130-8; TRIMBLE WS, 1991, ANNU REV NEUROSCI, V14, P93, DOI 10.1146/annurev.ne.14.030191.000521; YAMASAKI S, 1994, J BIOL CHEM, V269, P12764; YOSHIDA A, 1992, J BIOL CHEM, V267, P24925	42	71	75	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 31	1996	271	22					13130	13134		10.1074/jbc.271.22.13130	http://dx.doi.org/10.1074/jbc.271.22.13130			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UN474	8662834	hybrid			2022-12-25	WOS:A1996UN47400068
J	Valnickova, Z; Thogersen, IB; Christensen, S; Chu, CT; Pizzo, SV; Enghild, JJ				Valnickova, Z; Thogersen, IB; Christensen, S; Chu, CT; Pizzo, SV; Enghild, JJ			Activated human plasma carboxypeptidase B is retained in the blood by binding to alpha(2)-macroglobulin and pregnancy zone protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HISTIDINE-RICH GLYCOPROTEIN; CARBOXY-TERMINAL LYSINE; ALPHA-2-PLASMIN INHIBITOR; PLASMINOGEN-BINDING; MOLECULAR-CLONING; AFFINITY; ALPHA-2-MACROGLOBULIN; IDENTIFICATION; PURIFICATION; FIBRIN	A 66-kDa glycosylated carboxypeptidase, plasma procarboxypeptidase B (pro-plasma CPB), has recently been identified in human blood (Eaten, D, L,, Malloy, B, E., Tsai, S. P,, Henzel, W,, and Drayna, D, (1991) J. Biol, Chem. 266, 21833-21838), The pro-enzyme binds to plasminogen and the active enzyme is specific for COOH-terminal Lys or Arg residues, These properties implicate a role in the fibrinolytic or coagulation system, However, we show that the molecular mass of the active plasma CPB is approximately 36 kDa, which is below the glomerular filtration limit. Since activated plasma CPB no longer binds plasminogen, the active enzyme may not be retained in the circulation. To investigate this, we performed plasma elimination studies in mice which showed that I-125-plasma CPB remains in the circulation despite its small size, Native polyacrylamide gel electrophoresis of blood samples removed from the mice revealed that plasma CPB migrated as a high molecular weight band, Similar bands were observed in vitro when I-125-plasma CPB was added to plasma from humans and other species, The plasma CPB-binding proteins were purified from human plasma and identified as alpha(2)-macroglobulin (alpha(2)M) and pregnancy zone protein, Only the active enzyme bound to the two alpha-macroglobulins, and the interaction was specific for alpha(2)M in its native conformation, but not its receptor recognized forms, The complex between human alpha(2)M and plasma CPB dissociated during SDS-polyacrylamide gel electrophoresis and transverse urea gel electrophoresis suggesting that the interaction was noncovalent and depended on the tertiary structure of the native alpha(2)M molecule. The catalytic activity of plasma CPB was not significantly affected by its binding to alpha(2)M, The specific binding of plasma CPB to alpha-macroglobulins suggest that these proteins may function as a ''shuttle'' in vivo to modulate the clearance of plasma CPB from the circulatory system.	DUKE UNIV,MED CTR,DEPT PATHOL,DURHAM,NC 27710	Duke University			Chu, Charleen T/B-1601-2008	Chu, Charleen T/0000-0002-5052-8271; Christensen, Soren/0000-0003-2500-0085; Enghild, Jan Johannes/0000-0001-9292-9172	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL024066, R01HL024066, R01HL049542] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL24066, HL49542] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BAJZAR L, 1995, J BIOL CHEM, V270, P14477, DOI 10.1074/jbc.270.24.14477; BARRETT AJ, 1973, BIOCHEM J, V133, P709, DOI 10.1042/bj1330709; BORTH W, 1992, FASEB J, V6, P3345, DOI 10.1096/fasebj.6.15.1281457; BURGOS FJ, 1991, BIOCHEMISTRY-US, V30, P4082, DOI 10.1021/bi00230a038; BURY AF, 1981, J CHROMATOGR, V213, P491, DOI 10.1016/S0021-9673(00)80500-2; CHU CT, 1994, LAB INVEST, V71, P792; CLEMMENSEN I, 1986, EUR J BIOCHEM, V156, P327, DOI 10.1111/j.1432-1033.1986.tb09586.x; CLEMMENSEN I, 1981, EUR J BIOCHEM, V120, P105, DOI 10.1111/j.1432-1033.1981.tb05675.x; DEUTSCH DG, 1970, SCIENCE, V170, P1095, DOI 10.1126/science.170.3962.1095; DEVRIENDT K, 1991, BIOCHIM BIOPHYS ACTA, V1088, P95, DOI 10.1016/0167-4781(91)90157-H; EATON DL, 1991, J BIOL CHEM, V266, P21833; ENGHILD JJ, 1994, J BIOL CHEM, V269, P20159; ERDOS EG, 1963, ANN NY ACAD SCI, V104, P222, DOI 10.1111/j.1749-6632.1963.tb17666.x; Goldenberg D.P, 1989, PROTEIN STRUCTURE PR, P225; GONIAS SL, 1992, EXP HEMATOL, V20, P302; HENDRIKS D, 1985, CLIN CHEM, V12, P1936; HIGGINS DL, 1987, BIOCHEMISTRY-US, V26, P7786, DOI 10.1021/bi00398a038; HORTIN GL, 1988, BIOCHEM BIOPH RES CO, V155, P591, DOI 10.1016/S0006-291X(88)80535-7; HUNTER WM, 1962, NATURE, V194, P495, DOI 10.1038/194495a0; ICHINOSE A, 1984, THROMB RES, V33, P401, DOI 10.1016/0049-3848(84)90079-3; IMBER MJ, 1981, J BIOL CHEM, V256, P8124; LAMARRE J, 1991, LAB INVEST, V65, P3; LENICH C, 1991, THROMB RES, V64, P69, DOI 10.1016/0049-3848(91)90206-C; LIJNEN HR, 1980, J BIOL CHEM, V255, P214; MANWELL C, 1977, BIOCHEM J, V165, P487, DOI 10.1042/bj1650487; MAST AE, 1991, BIOCHEMISTRY-US, V30, P1723, DOI 10.1021/bi00220a039; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MILES LA, 1991, BIOCHEMISTRY-US, V30, P1682, DOI 10.1021/bi00220a034; PANNELL R, 1988, J CLIN INVEST, V81, P853, DOI 10.1172/JCI113394; PLUMMER TH, 1981, METHOD ENZYMOL, V80, P442; REECK GR, 1972, BIOCHEMISTRY-US, V21, P3947; SALVESEN G, 1993, METHOD ENZYMOL, V233, P121; SASAKI T, 1986, J BIOCHEM-TOKYO, V99, P1699, DOI 10.1093/oxfordjournals.jbchem.a135645; SAYERS CA, 1980, BIOCHEM J, V189, P255, DOI 10.1042/bj1890255; SKIDGEL RA, 1988, TRENDS PHARMACOL SCI, V9, P299, DOI 10.1016/0165-6147(88)90015-6; SKIDGEL RA, 1995, METHOD ENZYMOL, V248, P653; SOTTRUPJENSEN L, 1984, J BIOL CHEM, V259, P8318; TAN AK, 1995, BIOCHEMISTRY-US, V34, P5811, DOI 10.1021/bi00017a012; TAN FL, 1990, J BIOL CHEM, V265, P13; TRANTHANG C, 1986, EUR J BIOCHEM, V160, P599, DOI 10.1111/j.1432-1033.1986.tb10080.x; TSAI SP, 1992, GENOMICS, V14, P549, DOI 10.1016/S0888-7543(05)80268-X; WANG W, 1994, J BIOL CHEM, V269, P15937; WIMAN B, 1980, BIOCHEM J, V191, P229, DOI 10.1042/bj1910229	43	38	41	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 31	1996	271	22					12937	12943		10.1074/jbc.271.22.12937	http://dx.doi.org/10.1074/jbc.271.22.12937			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UN474	8662763	hybrid			2022-12-25	WOS:A1996UN47400041
J	Weaver, CD; Yao, TL; Powers, AC; Verdoorn, TA				Weaver, CD; Yao, TL; Powers, AC; Verdoorn, TA			Differential expression of glutamate receptor subtypes in rat pancreatic islets	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BURSTING ELECTRICAL-ACTIVITY; GLUCAGON-SECRETION; AMPA SUBTYPE; BETA-CELLS; KAINATE; CHANNELS; SUBUNITS; BRAIN; ACID; OSCILLATIONS	Immunocytochemistry was carried out on sections of rat pancreas to localize the expression of glutamate receptor subunits and the major pancreatic peptide hormones. Glutamate receptor expression was concentrated in pancreatic islets, and each islet cell type expressed different neuronal glutamate receptors of the alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid (AMPA) and kainate classes. AMPA receptor subunits were expressed in alpha, beta, and pancreatic polypeptide cells, whereas kainate receptors were found predominantly in alpha and delta cells. Patch clamp electrophysiology was used to measure the functional properties of islet cell glutamate receptors, L-glutamate and other glutamate receptor agonists evoked currents in islet cells that were blocked by the selective AMPA receptor antagonist, 6-cyano-7-nitroquinoxaline-2,3-dione and potentiated by cyclothiazide in a manner indistinguishable from that of neuronal AMPA receptors. Activation of islet cell AMPA receptors produced steady-state cation currents that depolarized the cells an average of 20.7 +/- 5.4 mV (n = 6), Currents mediated by functional kainate receptors were also observed in a line of transformed pancreatic alpha cells, Thus, L-glutamate probably regulates islet physiology via actions at both AMPA and kainate receptor classes, The pattern of receptor expression suggests that glutamate receptor activation may have multiple, complex consequences for islet physiology.	VANDERBILT UNIV,DEPT PHARMACOL,SCH MED,NASHVILLE,TN 37232; VANDERBILT UNIV,DIV ENDOCRINOL,SCH MED,NASHVILLE,TN 37232	Vanderbilt University; Vanderbilt University					NINDS NIH HHS [NS 09788, R01 NS 30945] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [F32NS009788, R01NS030945] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ASHCROFT FM, 1994, J CELL BIOCHEM, V55, P54, DOI 10.1002/jcb.240550007; BERTRAND G, 1993, EUR J PHARMACOL, V237, P45, DOI 10.1016/0014-2999(93)90091-U; BERTRAND G, 1992, BRIT J PHARMACOL, V106, P354, DOI 10.1111/j.1476-5381.1992.tb14340.x; BOXALL AR, 1995, NEUROCHEM RES, V20, P605, DOI 10.1007/BF01694543; EGEBJERG J, 1991, NATURE, V351, P745, DOI 10.1038/351745a0; ESHHAR N, 1993, NEUROSCIENCE, V57, P943, DOI 10.1016/0306-4522(93)90040-M; GILON P, 1992, J BIOL CHEM, V267, P20713; GONOI T, 1994, J BIOL CHEM, V269, P16989; HAMAGUCHI K, 1990, DIABETES, V39, P415, DOI 10.2337/diabetes.39.4.415; HEIMBERG H, 1993, EMBO J, V12, P2873, DOI 10.1002/j.1460-2075.1993.tb05949.x; HERB A, 1992, NEURON, V8, P775, DOI 10.1016/0896-6273(92)90098-X; HUETTNER JE, 1990, NEURON, V5, P255, DOI 10.1016/0896-6273(90)90163-A; HUME RI, 1991, SCIENCE, V253, P1028, DOI 10.1126/science.1653450; HUNTLEY GW, 1993, J NEUROSCI, V13, P2965; INAGAKI N, 1995, FASEB J, V9, P686, DOI 10.1096/fasebj.9.8.7768362; JACOBSSON G, 1994, P NATL ACAD SCI USA, V91, P12487, DOI 10.1073/pnas.91.26.12487; JETTON TL, 1992, P NATL ACAD SCI USA, V89, P2619, DOI 10.1073/pnas.89.7.2619; JONAS P, 1994, NEURON, V12, P1281, DOI 10.1016/0896-6273(94)90444-8; LACY PE, 1967, DIABETES, V16, P35, DOI 10.2337/diab.16.1.35; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LERNMARK A, 1974, DIABETOLOGIA, V10, P431, DOI 10.1007/BF01221634; LONGO EA, 1991, J BIOL CHEM, V266, P9314; NAKANISHI S, 1992, SCIENCE, V258, P597, DOI 10.1126/science.1329206; PARTIN KM, 1993, NEURON, V11, P1069, DOI 10.1016/0896-6273(93)90220-L; PETRALIA RS, 1992, J COMP NEUROL, V318, P329, DOI 10.1002/cne.903180309; PETRALIA RS, 1994, J COMP NEUROL, V349, P85, DOI 10.1002/cne.903490107; PETRALIA RS, 1994, J NEUROSCI, V14, P667; POWERS AC, 1990, DIABETES, V39, P406, DOI 10.2337/diabetes.39.4.406; ROGERS SW, 1994, SCIENCE, V265, P648, DOI 10.1126/science.8036512; RORSMAN P, 1989, NATURE, V341, P233, DOI 10.1038/341233a0; RORSMAN P, 1991, BIOCHEM PHARMACOL, V41, P1783, DOI 10.1016/0006-2952(91)90116-M; SANCHEZANDRES JV, 1995, J PHYSIOL-LONDON, V486, P223, DOI 10.1113/jphysiol.1995.sp020804; SANTOS RM, 1991, PFLUG ARCH EUR J PHY, V418, P417, DOI 10.1007/BF00550880; SCHOEPFER R, 1994, PROG NEUROBIOL, V42, P353, DOI 10.1016/0301-0082(94)90076-0; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SOMMER B, 1992, EMBO J, V11, P1651, DOI 10.1002/j.1460-2075.1992.tb05211.x; SORENSON RL, 1991, DIABETES, V40, P1365, DOI 10.2337/diabetes.40.11.1365; TWYMAN RE, 1995, NEURON, V14, P755, DOI 10.1016/0896-6273(95)90219-8; VALDEOLMILLOS M, 1989, FEBS LETT, V259, P19, DOI 10.1016/0014-5793(89)81484-X; VERDOORN TA, 1991, SCIENCE, V252, P1715, DOI 10.1126/science.1710829; VERDOORN TA, 1994, MOL PHARMACOL, V45, P475; VINCENT SR, 1983, NEUROENDOCRINOLOGY, V36, P197, DOI 10.1159/000123456; VONBLANKENFELD G, 1995, PFLUG ARCH EUR J PHY, V430, P381, DOI 10.1007/BF00373913; WENTHOLD RJ, 1992, J BIOL CHEM, V267, P501; WONG LA, 1993, MOL PHARMACOL, V44, P504	45	93	95	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 31	1996	271	22					12977	12984		10.1074/jbc.271.22.12977	http://dx.doi.org/10.1074/jbc.271.22.12977			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UN474	8662728	hybrid			2022-12-25	WOS:A1996UN47400047
J	Wuillemin, WA; Eldering, E; Citarella, F; deRuig, CP; tenCate, H; Hack, CE				Wuillemin, WA; Eldering, E; Citarella, F; deRuig, CP; tenCate, H; Hack, CE			Modulation of contact system proteases by glycosaminoglycans - Selective enhancement of the inhibition of factor XIa	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BLOOD-COAGULATION FACTOR; PLASMA THROMBOPLASTIN ANTECEDENT; MOLECULAR-WEIGHT KININOGEN; ACTIVATED HAGEMAN-FACTOR; FACTOR-XIIA; ANTITHROMBIN-III; KALLIKREIN-C1-INHIBITOR COMPLEXES; DEXTRAN SULFATE; CL-INHIBITOR; INACTIVATION	We investigated the influence of dextran sulfate, heparin, heparan sulfate, and dermatan sulfate on the inhibition of FXIa (where FXIa is activated factor XI, for example), FXIIa, and kallikrein by C1 inhibitor, alpha(1)-antitrypsin, alpha(2)-antiplasmin, and antithrombin III. The second-order rate constants for the inhibition of FXIa by C1 inhibitor, alpha(1)-antitrypsin, alpha(2)-antiplasmin, and antithrombin III, in the absence of glycosaminoglycans, were 1.8, 0.1, 0.43, and 0.32 x 10(3) M(-1) s(-1) respectively. The rate constants of the inactivation df FXIa by C1 inhibitor and by antithrombin III increased up to 117-fold in the presence of glycosaminoglycans. These data predicted that considering the plasma concentration of the inhibitors, C1 inhibitor would be the main inhibitor of FXIa in plasma in the presence of glycosaminoglycans. Results of experiments in which the formation of complexes between serine protease inhibitors and FXIa was studied in plasma agreed with this prediction. Glycosaminoglycans did not enhance the inhibition of alpha-FXIIa, beta-FXIIa, or kallikrein by C1 inhibitor. Thus, physiological glycosaminoglycans selectively enhance inhibition of FXIa without affecting the activity of FXIIa and kallikrein, suggesting that glycosaminoglycans may modulate the biological effects of contact activation, by inhibiting intrinsic coagulation without affecting the fibrinolytic potential of FXIIa/kallikrein.	UNIV AMSTERDAM,CENT LAB,NETHERLANDS RED CROSS BLOOD TRANSFUS SERV,AMSTERDAM,NETHERLANDS; UNIV AMSTERDAM,CLIN & EXPTL IMMUNOL LAB,AMSTERDAM,NETHERLANDS; UNIV ROMA LA SAPIENZA,DIPARTIMENTO BIOPATOL UMANA,SEZ BIOL CELLULARE,I-00161 ROME,ITALY; UNIV AMSTERDAM,ACAD MED CTR,CTR HEMOSTASIS THROMBOSIS ATHEROSCLEROSIS & I,1066 CX AMSTERDAM,NETHERLANDS; SLOTERVAART HOSP,DEPT INTERNAL MED,1066 CX AMSTERDAM,NETHERLANDS; FREE UNIV AMSTERDAM HOSP,DEPT INTERNAL MED,1081 HV AMSTERDAM,NETHERLANDS	University of Amsterdam; University of Amsterdam; Sapienza University Rome; University of Amsterdam; Academic Medical Center Amsterdam; Slotervaart Hospital; Vrije Universiteit Amsterdam; VU UNIVERSITY MEDICAL CENTER			Cate, Hugo ten/AAM-4000-2021; Levi, Marcel/AAZ-8559-2020					AUSPRUNK DH, 1981, AM J PATHOL, V103, P353; BEELER DL, 1986, BLOOD, V67, P1488; BODE W, 1994, FIBRINOLYSIS, V8, P161, DOI 10.1016/0268-9499(94)90714-5; BOUMA BN, 1983, BLOOD, V62, P1123; BOUMA BN, 1977, J BIOL CHEM, V252, P6432; BOURIN MC, 1993, BIOCHEM J, V289, P313, DOI 10.1042/bj2890313; COLMAN RW, 1984, J CLIN INVEST, V73, P1249, DOI 10.1172/JCI111326; DAMUS PS, 1973, NATURE, V246, P355, DOI 10.1038/246355a0; DAVIE EW, 1991, BIOCHEMISTRY-US, V30, P10363, DOI 10.1021/bi00107a001; DORS DM, 1992, THROMB HAEMOSTASIS, V67, P644; EVANS DL, 1992, BIOCHEMISTRY-US, V31, P12629, DOI 10.1021/bi00165a013; FORBES CD, 1970, J LAB CLIN MED, V76, P809; FROMMHERZ KJ, 1991, J BIOL CHEM, V266, P15356; FUJIKAWA K, 1986, BIOCHEMISTRY-US, V25, P2417, DOI 10.1021/bi00357a018; HARPEL PC, 1985, J BIOL CHEM, V260, P4257; HECK LW, 1974, J EXP MED, V140, P1615, DOI 10.1084/jem.140.6.1615; IHRCKE NS, 1993, IMMUNOL TODAY, V14, P500, DOI 10.1016/0167-5699(93)90265-M; KAPLAN AP, 1987, BLOOD, V70, P1; KITCHENS CS, 1991, SEMIN THROMB HEMOST, V17, P55, DOI 10.1055/s-2007-1002590; KJELLEN L, 1991, ANNU REV BIOCHEM, V60, P443, DOI 10.1146/annurev.bi.60.070191.002303; KOMIYAMA Y, 1988, THROMB RES, V50, P329, DOI 10.1016/0049-3848(88)90234-4; KURACHI K, 1977, BIOCHEMISTRY-US, V16, P5831, DOI 10.1021/bi00645a030; LINDAHL U, 1994, THROMB RES, V75, P1, DOI 10.1016/0049-3848(94)90136-8; MARCUM JA, 1984, J CLIN INVEST, V74, P341, DOI 10.1172/JCI111429; MEIJERS JCM, 1988, BIOCHEMISTRY-US, V27, P959, DOI 10.1021/bi00403a018; NUIJENS JH, 1988, BLOOD, V72, P1841; NUIJENS JH, 1987, THROMB HAEMOSTASIS, V58, P778; OSHIMA G, 1989, BIOL CHEM H-S, V370, P715, DOI 10.1515/bchm3.1989.370.2.715; PIXLEY R, 1983, BIOCHEMISTRY-US, V22, P4810, DOI 10.1021/bi00289a030; PIXLEY RA, 1987, ARCH BIOCHEM BIOPHYS, V256, P490, DOI 10.1016/0003-9861(87)90606-0; PIXLEY RA, 1985, J BIOL CHEM, V260, P1723; PIXLEY RA, 1986, FASEB J, V45, P1638; POOLE AR, 1986, BIOCHEM J, V236, P1; POTEMPA J, 1994, J BIOL CHEM, V269, P15957; RENT R, 1976, CLIN EXP IMMUNOL, V23, P264; ROSENBERG RD, 1986, CIBA FOUND S, V124, P47; SAITO H, 1977, BLOOD, V50, P377; SAITO H, 1979, P NATL ACAD SCI USA, V76, P2013, DOI 10.1073/pnas.76.4.2013; SCHAPIRA M, 1981, BIOCHEMISTRY-US, V20, P2738, DOI 10.1021/bi00513a006; SCHAPIRA M, 1982, J CLIN INVEST, V69, P462, DOI 10.1172/JCI110470; SCHAPIRA M, 1987, SEMIN THROMB HEMOST, V13, P69, DOI 10.1055/s-2007-1003476; SCOTT CF, 1982, J CLIN INVEST, V69, P844, DOI 10.1172/JCI110524; SCOTT CF, 1989, BLOOD, V73, P1873; SIM RB, 1980, BIOCHIM BIOPHYS ACTA, V612, P433, DOI 10.1016/0005-2744(80)90126-6; SOONS H, 1987, BIOCHEMISTRY-US, V26, P4624, DOI 10.1021/bi00389a005; TANKERSLEY DL, 1983, BLOOD, V62, P448; VANDERGRAAF F, 1983, J BIOL CHEM, V258, P9669; WUILLEMIN WA, 1995, BLOOD, V85, P1517, DOI 10.1182/blood.V85.6.1517.bloodjournal8561517	48	87	90	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 31	1996	271	22					12913	12918		10.1074/jbc.271.22.12913	http://dx.doi.org/10.1074/jbc.271.22.12913			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UN474	8662679	hybrid			2022-12-25	WOS:A1996UN47400037
J	Fagan, KA; Mahey, R; Cooper, DMF				Fagan, KA; Mahey, R; Cooper, DMF			Functional co-localization of transfected Ca2+-stimulable adenylyl cyclases with capacitative Ca2+ entry sites	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DENDRITIC SPINES; NCB-20 CELLS; CALCIUM; EXPRESSION; CALMODULIN; STIMULATION; INHIBITION; CLONING; PROTEIN	Three adenylyl cyclases (ACI, ACIII, and ACVIII) have been described, which are putatively Ca2+-stimulable, based on in vitro assays, However, it is not clear that these enzymes can be regulated by physiological rises in [Ca2+](i) when expressed in intact cells. Furthermore, it is not known whether transfected adenylyl cyclases might display the strict requirement for capacitative Ca2+ entry that is shown by the Ca2+-inhibitable ACVI, which is indigenous to C6-2B glioma cells (Chiono, M., Mahey, R., Tate, G., and Cooper, D. M. F. (1995) J. Biol. Chem. 270, 1149-1155). In the present study, ACI, ACIII, and ACVIII were heterologously expressed in HEK 293 cells, and conditions were devised that distinguished capacitative Ca2+ entry from both internal release and nonspecific elevation in [Ca2+](i) around the plasma membrane. Remarkably, not only were ACI and ACVIII largely insensitive to Ca2+ release from stores, but they were robustly stimulated only by capacitative Ca2+ entry and not at all by a substantial increase in [Ca2+](i) at the plasma membrane elicited by ionophore. (ACIII, reflecting its feeble in vitro sensitivity to Ca2+, was unaffected by any [Ca2+](i) rise.) These results suggest a quite unsuspected, essential association of Ca2+-sensitive adenylyl cyclases with capacitative Ca2+ entry sites, even when expressed heterologously.	UNIV COLORADO, HLTH SCI CTR, DEPT PHARMACOL, DENVER, CO 80262 USA; UNIV COLORADO, HLTH SCI CTR, PROGRAM NEUROSCI, DENVER, CO 80262 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver					NIGMS NIH HHS [GM 32483] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032483] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLBRITTON NL, 1992, SCIENCE, V258, P1812, DOI 10.1126/science.1465619; AUGUSTINE GJ, 1991, ANN NY ACAD SCI, V635, P365, DOI 10.1111/j.1749-6632.1991.tb36505.x; BIRD GS, 1992, J BIOL CHEM, V267, P18382; BOYAJIAN CL, 1991, J BIOL CHEM, V266, P4995; CALDWELL KK, 1992, CELL CALCIUM, V13, P107, DOI 10.1016/0143-4160(92)90004-C; CALI JJ, 1994, J BIOL CHEM, V269, P12190; CARR DW, 1992, P NATL ACAD SCI USA, V89, P16816; CHEEK TR, 1989, J CELL SCI, V93, P211; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHIONO M, 1995, J BIOL CHEM, V270, P1149, DOI 10.1074/jbc.270.3.1149; CHOI EJ, 1992, BIOCHEMISTRY-US, V31, P6492, DOI 10.1021/bi00143a019; CHOI EJ, 1992, J BIOL CHEM, V267, P12440; COOPER DMF, 1994, BIOCHEM J, V297, P437, DOI 10.1042/bj2970437; COOPER DMF, 1995, NATURE, V374, P421, DOI 10.1038/374421a0; EVANS T, 1984, MOL PHARMACOL, V26, P395; GLANTZ SB, 1992, MOL BIOL CELL, V3, P1215, DOI 10.1091/mbc.3.11.1215; GUTHRIE PB, 1991, NATURE, V354, P76, DOI 10.1038/354076a0; IYENGAR R, 1993, FASEB J, V7, P768, DOI 10.1096/fasebj.7.9.8330684; KASAI H, 1994, TRENDS NEUROSCI, V17, P95, DOI 10.1016/0166-2236(94)90112-0; KATSUSHIKA S, 1992, P NATL ACAD SCI USA, V89, P8774, DOI 10.1073/pnas.89.18.8774; KRUPINSKI J, 1989, SCIENCE, V244, P1558, DOI 10.1126/science.2472670; LISANTI MP, 1994, J CELL BIOL, V126, P111, DOI 10.1083/jcb.126.1.111; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MONS N, 1995, P NATL ACAD SCI USA, V92, P8473, DOI 10.1073/pnas.92.18.8473; MORGAN AJ, 1994, BIOCHEM J, V300, P665, DOI 10.1042/bj3000665; MULLER W, 1991, NATURE, V354, P73, DOI 10.1038/354073a0; Putney James W. Jr, 1992, Advances in Second Messenger and Phosphoprotein Research, V26, P143; PUTNEY JW, 1990, CELL CALCIUM, V11, P611, DOI 10.1016/0143-4160(90)90016-N; SALOMON Y, 1974, ANAL BIOCHEM, V58, P541, DOI 10.1016/0003-2697(74)90222-X; SIHRA TS, 1992, J BIOL CHEM, V267, P1983; TANG WJ, 1991, J BIOL CHEM, V266, P8595; TAUSSIG R, 1995, J BIOL CHEM, V270, P1, DOI 10.1074/jbc.270.1.1; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; WALLACH J, 1994, FEBS LETT, V338, P257, DOI 10.1016/0014-5793(94)80279-3; WAYMAN GA, 1994, J BIOL CHEM, V269, P25400; WAYMAN GA, 1995, J BIOL CHEM, V270, P21480, DOI 10.1074/jbc.270.37.21480; YOSHIMURA M, 1992, P NATL ACAD SCI USA, V89, P6716, DOI 10.1073/pnas.89.15.6716	37	146	146	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 24	1996	271	21					12438	12444		10.1074/jbc.271.21.12438	http://dx.doi.org/10.1074/jbc.271.21.12438			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UL660	8647849	hybrid			2022-12-25	WOS:A1996UL66000051
J	Fox, JC; Shanley, JR				Fox, JC; Shanley, JR			Antisense inhibition of basic fibroblast growth factor induces apoptosis in vascular smooth muscle cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NIH 3T3 CELLS; EXTRACELLULAR-MATRIX; DNA-SYNTHESIS; TRANSFORMATION; PROLIFERATION; EXPRESSION; FGF; SIGNAL; DEATH; COMPLEMENTARY	Basic fibroblast growth factor (bFGF), a potent mitogen for many cell types, is expressed by vascular smooth muscle cells and plays a prominent role in the proliferative response to vascular injury. Basic FGF has also been implicated as a survival factor for a variety of quiescent or terminally differentiated cells. Autocrine mechanisms could potentially mediate both proliferation and cell survival. To probe such autocrine pathways, endogenous bFGF production was inhibited in cultured rat vascular smooth muscle cells by the expression of antisense bFGF RNA. Inhibition of endogenous bFGF production induced apoptosis in these cells independent of proliferation, and apoptosis could be prevented by exogenous bFGF but not serum or epidermal growth factor. The induction of apoptosis was associated with an inappropriate entry into S phase. These data demonstrate that interruption of autocrine bFGF signaling results in apoptosis of vascular smooth muscle cells, and that the mechanism involves disruption of normal cell cycle regulation.			Fox, JC (corresponding author), UNIV PENN,DEPT MED,STELLAR CHANCE LABS 809C,422 CURIE BLVD,PHILADELPHIA,PA 19104, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL026831, R01HL026831, K08HL002939] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL26831, HL02939] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARAKI S, 1990, BIOCHEM BIOPH RES CO, V168, P1194, DOI 10.1016/0006-291X(90)91155-L; BECKER D, 1989, EMBO J, V8, P3685, DOI 10.1002/j.1460-2075.1989.tb08543.x; BENNETT MR, 1994, CIRC RES, V74, P525, DOI 10.1161/01.RES.74.3.525; BENNETT MR, 1995, J CLIN INVEST, V95, P2266, DOI 10.1172/JCI117917; BERKNER KL, 1988, BIOTECHNIQUES, V6, P616; BIKFALVI A, 1995, J CELL BIOL, V129, P233, DOI 10.1083/jcb.129.1.233; BLAM SB, 1988, ONCOGENE, V3, P129; BLOTTNER D, 1992, EXP NEUROL, V118, P35, DOI 10.1016/0014-4886(92)90020-Q; Brigstock DR, 1990, GROWTH FACTORS, V4, DOI 10.3109/08977199009011009; BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; CHO A, 1995, CIRC RES, V76, P168, DOI 10.1161/01.RES.76.2.168; ENSOLI B, 1994, J CLIN INVEST, V94, P1736, DOI 10.1172/JCI117521; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FLAUMENHAFT R, 1989, J CELL PHYSIOL, V140, P75, DOI 10.1002/jcp.1041400110; FOX JC, 1994, MOL CELL BIOL, V14, P4244, DOI 10.1128/MCB.14.6.4244; FRENCH BA, 1994, CIRCULATION, V90, P2402, DOI 10.1161/01.CIR.90.5.2402; FUKS Z, 1994, CANCER RES, V54, P2582; GENG YJ, 1995, AM J PATHOL, V147, P251; GOSPODAROWICZ D, 1988, EUR J CELL BIOL, V46, P144; GOSPODAROWICZ D, 1987, ENDOCR REV, V8, P95, DOI 10.1210/edrv-8-2-95; HAIMOVITZFRIEDMAN A, 1994, CANCER RES, V54, P2591; ISNER JM, 1995, CIRCULATION, V91, P2703, DOI 10.1161/01.CIR.91.11.2703; KINOSHITA T, 1995, ONCOGENE, V10, P2207; LIBBY P, 1983, J CELL PHYSIOL, V115, P217, DOI 10.1002/jcp.1041150217; LINDNER V, 1991, P NATL ACAD SCI USA, V88, P3739, DOI 10.1073/pnas.88.9.3739; LOUIS JC, 1993, EUR J NEUROSCI, V5, P1610, DOI 10.1111/j.1460-9568.1993.tb00230.x; MOSCATELLI D, 1989, J CELL BIOL, V109, P2519, DOI 10.1083/jcb.109.5.2519; MURPHY PR, 1992, MOL ENDOCRINOL, V6, P877, DOI 10.1210/me.6.6.877; OLSON NE, 1992, AM J PATHOL, V140, P1017; PITTMAN RN, 1993, J NEUROSCI, V13, P3669; QIN XQ, 1994, P NATL ACAD SCI USA, V91, P10918, DOI 10.1073/pnas.91.23.10918; QUARTO N, 1991, CELL REGUL, V2, P699, DOI 10.1091/mbc.2.9.699; QUARTO N, 1989, ONCOGENE RES, V5, P101; RAO L, 1992, P NATL ACAD SCI USA, V89, P7742, DOI 10.1073/pnas.89.16.7742; RENAUD F, 1994, J CELL PHYSIOL, V158, P435, DOI 10.1002/jcp.1041580307; ROGELJ S, 1988, NATURE, V331, P173, DOI 10.1038/331173a0; RUKENSTEIN A, 1991, J NEUROSCI, V11, P2552; SATO Y, 1991, BIOCHEM BIOPH RES CO, V174, P1260, DOI 10.1016/0006-291X(91)91557-S; SHAN B, 1994, MOL CELL BIOL, V14, P8166, DOI 10.1128/MCB.14.12.8166; SHIMASAKI S, 1988, BIOCHEM BIOPH RES CO, V157, P256, DOI 10.1016/S0006-291X(88)80041-X; SHULDINER AR, 1993, PCR PROTOCOLS CURREN, P169; SPEIR E, 1992, CIRC RES, V71, P251, DOI 10.1161/01.RES.71.2.251; SUGI Y, 1993, DEV BIOL, V157, P28, DOI 10.1006/dbio.1993.1109; TAMM I, 1991, P NATL ACAD SCI USA, V88, P3372, DOI 10.1073/pnas.88.8.3372; TERRELL GE, 1991, MATRIX, V11, P108, DOI 10.1016/S0934-8832(11)80214-3; UNSICKER K, 1992, DEV BRAIN RES, V65, P285, DOI 10.1016/0165-3806(92)90191-X; VINDELOV LL, 1990, CYTOMETRY, V11, P753, DOI 10.1002/cyto.990110702; VLODAVSKY I, 1991, J CELL BIOCHEM, V45, P167, DOI 10.1002/jcb.240450208; WANG HG, 1995, J CELL BIOL, V129, P1103, DOI 10.1083/jcb.129.4.1103; YANG YP, 1993, P NATL ACAD SCI USA, V90, P4601, DOI 10.1073/pnas.90.10.4601; YAO RJ, 1995, SCIENCE, V267, P2003, DOI 10.1126/science.7701324; YASUDA T, 1995, J NEUROSCI RES, V40, P306, DOI 10.1002/jnr.490400304; YAYON A, 1990, P NATL ACAD SCI USA, V87, P5346, DOI 10.1073/pnas.87.14.5346	53	97	99	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 24	1996	271	21					12578	12584		10.1074/jbc.271.21.12578	http://dx.doi.org/10.1074/jbc.271.21.12578			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UL660	8647868	hybrid			2022-12-25	WOS:A1996UL66000070
J	Hurme, R; Berndt, KD; Namork, E; Rhen, M				Hurme, R; Berndt, KD; Namork, E; Rhen, M			DNA binding exerted by a bacterial gene regulator with an extensive coiled-coil domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEUCINE ZIPPER; TRANSCRIPTION FACTORS; VIRULENCE PLASMID; PROTEIN; DESIGN	Although quite common in the eukaryotic cell, bacterial proteins with an extensive coiled-coil domain are still relatively rare. One of the few thus far documented examples, TlpA from Salmonella typhimurium, is characterized by a remarkably long (250 amino acids) alpha-helical coiled-coil domain. Herein, we demonstrate that TlpA is a novel, sequence-specific DNA-binding protein. Several tlpA deletion mutants have been constructed, and their corresponding protein products were purified and tested for DNA binding. Two of the mutant proteins were shown to be deficient in DNA binding. Both mutants were analyzed by circular dichroism and electron microscopy, supporting the notion that mutant proteins were largely intact despite lacking the amino acid residues necessary for DNA binding. In vivo studies with transcriptional tlpA-lacZ fusions demonstrated that TlpA acts as a repressor. Using the repressor phenotype as a readout, the chain exchange previously described in vitro could also be confirmed in vivo. We believe the coiled-coil domain acts not only as a dimerization interface but could also serve a role as a flexible modulator of the protein-DNA interaction.	KAROLINSKA INST,DEPT MED BIOCHEM & BIOPHYS,S-17177 STOCKHOLM,SWEDEN; NATL INST PUBL HLTH,ELECTRON MICROSCOPE UNIT,N-0403 TORSHOV,OSLO,NORWAY	Karolinska Institutet	Hurme, R (corresponding author), KAROLINSKA INST,CTR MICROBIOL & TUMOR BIOL,BOX 280,S-17177 STOCKHOLM,SWEDEN.		Berndt, Kurt/J-8574-2015	Berndt, Kurt/0000-0002-3049-967X				BAXEVANIS AD, 1993, CURR OPIN GENET DEV, V3, P278, DOI 10.1016/0959-437X(93)90035-N; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; CAREY J, 1991, METHOD ENZYMOL, V208, P103; COHEN C, 1994, SCIENCE, V263, P488, DOI 10.1126/science.8290957; COHEN C, 1990, PROTEINS, V7, P1, DOI 10.1002/prot.340070102; CRICK FHC, 1953, ACTA CRYSTALLOGR, V6, P689, DOI 10.1107/S0365110X53001964; FISCHETTI VA, 1989, CLIN MICROBIOL REV, V2, P285, DOI 10.1128/CMR.2.3.285-314.1989; FOSTER JW, 1995, ANNU REV MICROBIOL, V49, P145, DOI 10.1146/annurev.micro.49.1.145; FRIEDMAN AM, 1995, SCIENCE, V268, P1721, DOI 10.1126/science.7792597; HURME R, 1994, J BIOL CHEM, V269, P10675; JAGURA-BURDZY G, 1992, J MOL BIOL, V225, P651, DOI 10.1016/0022-2836(92)90392-W; JANCSO A, 1991, J BIOL CHEM, V266, P5891; KOSKI P, 1992, J BIOL CHEM, V267, P12258; LEVCHENKO I, 1994, GENE, V145, P65, DOI 10.1016/0378-1119(94)90323-9; LUPAS A, 1995, J MOL BIOL, V248, P180, DOI 10.1006/jmbi.1995.0210; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; MARMORSTEIN R, 1994, GENE DEV, V8, P2504, DOI 10.1101/gad.8.20.2504; MAXON ME, 1990, P NATL ACAD SCI USA, V87, P7076, DOI 10.1073/pnas.87.18.7076; MCLACHLAN AD, 1975, J MOL BIOL, V98, P293, DOI 10.1016/S0022-2836(75)80119-7; MILLER JH, 1972, EXPT MOL GENETICS, P325; MORA R, 1988, ANAL BIOCHEM, V172, P368, DOI 10.1016/0003-2697(88)90457-5; NIKI H, 1992, EMBO J, V11, P5101, DOI 10.1002/j.1460-2075.1992.tb05617.x; NOONAN B, 1995, MOL MICROBIOL, V17, P379, DOI 10.1111/j.1365-2958.1995.mmi_17020379.x; OSHEA EK, 1989, SCIENCE, V243, P538, DOI 10.1126/science.2911757; OSHEA EK, 1991, SCIENCE, V254, P539, DOI 10.1126/science.1948029; RHEN M, 1993, MOL MICROBIOL, V10, P45, DOI 10.1111/j.1365-2958.1993.tb00902.x; RON D, 1992, GENE DEV, V6, P439, DOI 10.1101/gad.6.3.439; Sambrook J., 2002, MOL CLONING LAB MANU; SASSEDWIGHT S, 1990, CELL, V62, P945, DOI 10.1016/0092-8674(90)90269-K; SESSA G, 1993, EMBO J, V12, P3507, DOI 10.1002/j.1460-2075.1993.tb06025.x; WEBER IT, 1987, J MOL BIOL, V198, P311, DOI 10.1016/0022-2836(87)90315-9	31	37	40	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 24	1996	271	21					12626	12631		10.1074/jbc.271.21.12626	http://dx.doi.org/10.1074/jbc.271.21.12626			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UL660	8647874	hybrid			2022-12-25	WOS:A1996UL66000076
J	Segade, F; Hurle, B; Claudio, E; Ramos, S; Lazo, PS				Segade, F; Hurle, B; Claudio, E; Ramos, S; Lazo, PS			Identification of an additional member of the cytochrome c oxidase subunit VIIa family of proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESPIRATORY-CHAIN COMPONENTS; NUCLEOTIDE-SEQUENCE; TRANSCRIPT LEVELS; THYROID-HORMONE; 2 ISOFORMS; CDNA; PURIFICATION; SEPARATION; EXPRESSION; SKELETAL	We report the cloning, nucleotide sequence, evolutionary analysis, and intracellular localization of SIG81, a silica-induced cDNA from mouse macrophages. The cDNA encodes a 111-amino acid protein with extensive sequence identity with members of the mammalian cytochrome c oxidase subunit VIIa (COX7a) family. A human SIG81 sequence >80% identical with the mouse cDNA was deduced from homologous sequences in the human expressed tags data base. The deduced aminoterminal region shows features common to mitochondrial targeting sequences. A phylogenetic analysis of the carboxyl-terminal domain homologous to COX7a identifies SIG81 as a divergent member of the family with an ancient origin. Southern blot analysis showed that the mouse genome contains two to three copies of the SIG81 gene. Northern blot analysis revealed that the SIG81 transcript is approximately 1 kb and expressed in every tissue tested, with higher levels of expression observed in kidney and liver. Antibodies raised against a glutathione S-transferase SIG81 fusion protein detected a 13.5-kDa protein that co-fractionates with mitochondrial localized enzymatic activity. Taken together, our data suggest that SIG81 is a novel member of the COX7a family that is constitutively expressed in mouse cells.	UNIV OVIEDO, DEPT BIOQUIM & BIOL MOLEC, E-33006 OVIEDO, SPAIN	University of Oviedo			Lazo, Pranvera/I-5299-2019; Lazo, Pedro/C-4087-2008	Lazo, Pranvera/0000-0002-7202-4058; Lazo, Pedro/0000-0002-1278-6878				ANTHONY G, 1990, FEBS LETT, V277, P97, DOI 10.1016/0014-5793(90)80817-3; ARNAUDO E, 1992, GENE, V119, P299, DOI 10.1016/0378-1119(92)90287-Y; BLAHOS J, 1995, J BIOL CHEM, V270, P20285, DOI 10.1074/jbc.270.35.20285; CALDER KM, 1991, MOL MICROBIOL, V5, P1769, DOI 10.1111/j.1365-2958.1991.tb01926.x; CAPALDI RA, 1990, ANNU REV BIOCHEM, V59, P569, DOI 10.1146/annurev.bi.59.070190.003033; CAPITANIO N, 1994, BIOCHEMISTRY-US, V33, P12521, DOI 10.1021/bi00207a020; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHRZANOWSKALIGHTOWLERS ZMA, 1993, BIOCHEM BIOPH RES CO, V196, P328, DOI 10.1006/bbrc.1993.2252; CLAUDIO E, 1995, AM J RESP CELL MOL, V13, P547, DOI 10.1165/ajrcmb.13.5.7576690; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; ENDERS C, 1990, NUCLEIC ACIDS RES, V18, P7143, DOI 10.1093/nar/18.23.7143; FABRIZI GM, 1989, NUCLEIC ACIDS RES, V17, P7107, DOI 10.1093/nar/17.17.7107; FRANGIONI JV, 1993, ANAL BIOCHEM, V210, P179, DOI 10.1006/abio.1993.1170; FREUD R, 1994, EUR J BIOCHEM, V221, P1111, DOI 10.1111/j.1432-1033.1994.tb18831.x; Harlow E., 1988, ANTIBODIES LAB MANUA; HARTL FU, 1989, BIOCHIM BIOPHYS ACTA, V988, P1, DOI 10.1016/0304-4157(89)90002-6; HERRMANN BG, 1987, METHOD ENZYMOL, V152, P180; KADENBACH B, 1981, FEBS LETT, V135, P1, DOI 10.1016/0014-5793(81)80932-5; KADENBACH B, 1983, ANAL BIOCHEM, V129, P517, DOI 10.1016/0003-2697(83)90586-9; KADENBACH B, 1991, J BIOENERG BIOMEMBR, V23, P321, DOI 10.1007/BF00762225; KENNAWAY NG, 1990, PEDIATR RES, V28, P529; Kimura MA, 1985, NEUTRAL THEORY MOL E; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LUCIAKOVA K, 1992, EUR J BIOCHEM, V207, P253, DOI 10.1111/j.1432-1033.1992.tb17045.x; LUCIAKOVA K, 1992, EUR J BIOCHEM, V207, P247, DOI 10.1111/j.1432-1033.1992.tb17044.x; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SEELAN RS, 1989, NUCLEIC ACIDS RES, V17, P6410, DOI 10.1093/nar/17.15.6410; SEELAN RS, 1991, J BIOL CHEM, V266, P19752; SEELAN RS, 1993, GENOMICS, V18, P527; SEGADE F, 1995, J IMMUNOL, V154, P2384; STORRIE B, 1990, METHOD ENZYMOL, V182, P203; TAANMAN JW, 1992, J BIOL CHEM, V267, P22481; VANBEEUMEN JJ, 1990, FEBS LETT, V263, P213, DOI 10.1016/0014-5793(90)81376-Y; VANDENBOGERT C, 1992, BIOCHIM BIOPHYS ACTA, V1099, P118, DOI 10.1016/0005-2728(92)90207-I; VANITALLIE CM, 1990, ENDOCRINOLOGY, V127, P55, DOI 10.1210/endo-127-1-55; VANKUILENBURG ABP, 1992, EUR J BIOCHEM, V203, P193	41	20	20	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 24	1996	271	21					12343	12349		10.1074/jbc.271.21.12343	http://dx.doi.org/10.1074/jbc.271.21.12343			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UL660	8647836	hybrid			2022-12-25	WOS:A1996UL66000038
J	Ugi, S; Maegawa, H; Kashiwagi, A; Adachi, M; Olefsky, JM; Kikkawa, R				Ugi, S; Maegawa, H; Kashiwagi, A; Adachi, M; Olefsky, JM; Kikkawa, R			Expression of dominant negative mutant SHPTP2 attenuates phosphatidylinositol 3'-kinase activity via modulation of phosphorylation of insulin receptor substrate-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE-PHOSPHATASE; SH2-CONTAINING PHOSPHOTYROSINE PHOSPHATASE; SRC HOMOLOGY-2 DOMAINS; SIGNAL TRANSDUCTION; SH3 DOMAINS; CORKSCREW; 3-KINASE; SUBUNIT; KINASE; ASSOCIATION	To clarify the role of protein-tyrosine phosphatase (PTPase) containing Src homology 2 regions (SHPTP2) in insulin signaling, either wild-type or mutant SHPTP2 (Delta PTP; lacking full PTPase domain) was expressed in Rat 1 fibroblasts overexpressing human insulin receptors. In response to insulin, phosphorylation of insulin receptor substrate 1 (IRS-1), IRS-1-associated PTPase activities and phosphatidylinositol (PI) 3'-kinase activities were slightly enhanced in wild-type cells when compared with those in the parent cells transfected with hygromycin-resistant gene alone. In contrast, introduction of Delta PTP inhibited insulin-induced association of IRS 1 with endogenous SHPTP2 and impaired both insulin-stimulated phosphorylation of IRS-1 and activation of PI 3'-kinase. Furthermore, decreased content of p85 subunit of PI 3'-kinase was also found in mutant cells. Consistently, the insulin-stimulated mitogen-activated protein kinase activities and DNA synthesis were also enhanced in wild-type cells, but impaired in mutant cells. Thus, the interaction of SHPTP2 with IRS-1 may be associated with modulation of phosphorylation levels of IRS-1, resulting in the changes of PI 3'-kinase and mitogen-activated protein kinase activity. Furthermore, an impaired insulin signaling in mutant cells may be partly reflected in a decreased content of p85 protein of PI 3'-kinase.	SHIGA UNIV MED SCI,DEPT MED 3,OTSU,SHIGA 52021,JAPAN; SAPPORO MED COLL,DEPT MED 1,SAPPORO,HOKKAIDO 060,JAPAN; UNIV CALIF SAN DIEGO,DEPT MED,LA JOLLA,CA 92093	Shiga University of Medical Science; Sapporo Medical University; University of California System; University of California San Diego			Kashiwagi, Atsunori/H-8712-2019	Maegawa, Hiroshi/0000-0002-4611-8149				ADACHI M, 1992, FEBS LETT, V314, P335, DOI 10.1016/0014-5793(92)81500-L; AHMAD S, 1993, P NATL ACAD SCI USA, V90, P2197, DOI 10.1073/pnas.90.6.2197; BENNETT AM, 1994, P NATL ACAD SCI USA, V91, P7335, DOI 10.1073/pnas.91.15.7335; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; FENG GS, 1993, SCIENCE, V259, P1607, DOI 10.1126/science.8096088; FISHER EH, 1991, SCIENCE, V253, P401; FREEMAN RM, 1992, P NATL ACAD SCI USA, V89, P11239, DOI 10.1073/pnas.89.23.11239; HAUSDORFF SF, 1995, J BIOL CHEM, V270, P12965, DOI 10.1074/jbc.270.22.12965; HAUSDORFF SF, 1994, J BIOL CHEM, V269, P21391; KAHN CR, 1994, DIABETES, V43, P1066, DOI 10.2337/diab.43.8.1066; KAZLAUSKAS A, 1993, P NATL ACAD SCI USA, V90, P6939, DOI 10.1073/pnas.90.15.6939; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KUHNE MR, 1993, J BIOL CHEM, V268, P11479; LECHLEIDER RJ, 1993, J BIOL CHEM, V268, P13434; LECHLEIDER RJ, 1993, J BIOL CHEM, V268, P21478; MAEGAWA H, 1993, BIOCHEM BIOPH RES CO, V194, P208, DOI 10.1006/bbrc.1993.1805; MAEGAWA H, 1995, J BIOL CHEM, V270, P7724, DOI 10.1074/jbc.270.13.7724; MAEGAWA H, 1994, BIOCHEM BIOPH RES CO, V199, P780, DOI 10.1006/bbrc.1994.1297; MCCLAIN DA, 1987, J BIOL CHEM, V262, P14663; MCGUIRE TF, 1993, J BIOL CHEM, V268, P22227; MILARSKI KL, 1994, J BIOL CHEM, V269, P21239; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; NOGUCHI T, 1994, MOL CELL BIOL, V14, P6674, DOI 10.1128/MCB.14.10.6674; OKAMOTO M, 1993, BIOCHEM J, V290, P327, DOI 10.1042/bj2900327; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; PERKINS LA, 1992, CELL, V70, P225, DOI 10.1016/0092-8674(92)90098-W; SAAD MJA, 1994, MOL ENDOCRINOL, V8, P545, DOI 10.1210/me.8.5.545; STAUBS PA, 1994, J BIOL CHEM, V269, P27186; SUGIMOTO S, 1994, J BIOL CHEM, V269, P13614; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; SUN XJ, 1993, MOL CELL BIOL, V13, P7418, DOI 10.1128/MCB.13.12.7418; TAKAGI Y, 1995, ATHEROSCLEROSIS, V113, P19, DOI 10.1016/0021-9150(94)05422-F; TAKATA Y, 1991, J BIOL CHEM, V266, P9135; TANG TL, 1995, CELL, V80, P473, DOI 10.1016/0092-8674(95)90498-0; UGI S, 1994, FEBS LETT, V340, P216, DOI 10.1016/0014-5793(94)80141-X; VOGEL W, 1993, SCIENCE, V259, P1611, DOI 10.1126/science.7681217; XIAO S, 1994, J BIOL CHEM, V269, P21244; YAMAUCHI K, 1995, J BIOL CHEM, V270, P17716, DOI 10.1074/jbc.270.30.17716; YAMAUCHI K, 1995, P NATL ACAD SCI USA, V92, P664, DOI 10.1073/pnas.92.3.664; YONEZAWA K, 1992, J BIOL CHEM, V267, P25958	40	43	43	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 24	1996	271	21					12595	12602		10.1074/jbc.271.21.12595	http://dx.doi.org/10.1074/jbc.271.21.12595			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UL660	8647870	hybrid			2022-12-25	WOS:A1996UL66000072
J	vanHeerden, PS; Towers, GHN; Lewis, NG				vanHeerden, PS; Towers, GHN; Lewis, NG			Nitrogen metabolism in lignifying Pinus taeda cell cultures	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR-MAGNETIC-RESONANCE; LEMNA-MINOR-L; AROGENATE DEHYDROGENASE; TYROSINE BIOSYNTHESIS; REGULATORY PROPERTIES; L-PHENYLALANINE; HIGHER-PLANTS; N-15; ASSIMILATION; GLUTAMINE	The primary metabolic fate of phenylalanine, following its deamination in plants, is conscription of its carbon skeleton for lignin, suberin, flavonoid, and related metabolite formation. Since this accounts for similar to 30-40% of all organic carbon, an effective means of recycling the liberated ammonium ion must be operative. In order to establish how this occurs, the uptake and metabolism of various N-15-labeled precursors (N-15-Phe, (NH4Cl)-N-15, N-15-Gln, and N-15-Glu) in lignifying Pinus taeda cell cultures was investigated, using a combination of high performance liquid chromatography, N-15 NMR, and gas chromatography-mass spectrometry analyses. It was found that the ammonium ion released during active phenylpropanoid metabolism was not made available for general amino acid/protein synthesis. Rather it was rapidly recycled back to regenerate phenylalanine, thereby providing an effective means of maintaining active phenylpropanoid metabolism with no additional nitrogen requirement. These results strongly suggest that, in lignifying cells, ammonium ion reassimilation is tightly compartmentalized.	WASHINGTON STATE UNIV,INST BIOL CHEM,PULLMAN,WA 99164	Washington State University				Lewis, Norman/0000-0001-5742-032X				ALTENBURGER R, 1991, ARCH MICROBIOL, V156, P471, DOI 10.1007/BF00245394; AMRHEIN N, 1977, PLANT SCI LETT, V8, P313, DOI 10.1016/0304-4211(77)90148-1; BYNG G, 1981, PHYTOCHEMISTRY, V20, P289; CALLIES R, 1992, PLANT PHYSIOL, V100, P1584, DOI 10.1104/pp.100.3.1584; CONNELLY JA, 1986, Z NATURFORSCH C, V41, P69; DAVIN LB, 1992, RECENT ADV PHYTOCHEM, V26, P325; DEWICK PM, 1985, NAT PROD REP, V2, P495, DOI 10.1039/np9850200495; DOUGALL DK, 1980, BIOCH PLANTS, V2, P627; DOUGLAS CJ, 1992, RECENT ADV PHYTOCHEM, V26, P63; DURZAN DJ, 1983, PLANT PHYSL TREATISE, V8, P55; EBERHARDT TL, 1993, J BIOL CHEM, V268, P21088; FLOSS HG, 1985, RECENT ADV PHYTOCHEM, V20, P13; GAINES CG, 1982, PLANTA, V156, P233, DOI 10.1007/BF00393730; Gross G.G., 1985, BIOSYNTHESIS BIODEGR, P229; HAGEN SR, 1993, FOOD CHEM, V46, P319, DOI 10.1016/0308-8146(93)90127-2; Hanson K. R., 1981, The biochemistry of plants. A comprehensive treatise. Volume 7. Secondary plant products., P577; JENSEN RA, 1985, RECENT ADV PHYTOCHEM, V20, P57; JUNG E, 1986, P NATL ACAD SCI USA, V83, P7231, DOI 10.1073/pnas.83.19.7231; KANAMORI K, 1988, J BIOL CHEM, V263, P2817; KOUKOL J, 1961, J BIOL CHEM, V236, P2692; KUESEL AC, 1989, ARCH MICROBIOL, V151, P434, DOI 10.1007/BF00416603; LEA PJ, 1974, NATURE, V251, P614, DOI 10.1038/251614a0; Lewis N.G., 1989, CHEM SIGNIFICANCE CO, P23, DOI [DOI 10.1007/978-1-4684-7511-1_2, 10.1007/978-1-4684-7511-1_2]; MARTIN F, 1986, NEW PHYTOL, V102, P85, DOI 10.1111/j.1469-8137.1986.tb00800.x; MARTIN F, 1985, FEBS LETT, V182, P350, DOI 10.1016/0014-5793(85)80331-8; MAXWELL CA, 1990, PLANT PHYSIOL, V93, P1552, DOI 10.1104/pp.93.4.1552; McLafferty F. W., 1993, INTERPRETATION MASS; MIFLIN BJ, 1975, BIOCHEM J, V149, P403, DOI 10.1042/bj1490403; MONSELISE EB, 1987, NEW PHYTOL, V107, P341, DOI 10.1111/j.1469-8137.1987.tb00186.x; NOSE M, 1995, PHYTOCHEMISTRY, V39, P71, DOI 10.1016/0031-9422(95)95268-Y; OAKS A, 1985, ANNU REV PLANT PHYS, V36, P345; PANKHURST CE, 1979, J EXP BOT, V30, P1109, DOI 10.1093/jxb/30.6.1109; RAZAL RA, 1994, PHYTOCHEM ANALYSIS, V5, P98, DOI 10.1002/pca.2800050303; Razal RA, 1996, PHYTOCHEMISTRY, V41, P31, DOI 10.1016/0031-9422(95)00628-1; RHODES D, 1975, PLANTA, V125, P201, DOI 10.1007/BF00385596; RHODES D, 1989, PLANT PHYSIOL, V89, P1161, DOI 10.1104/pp.89.4.1161; RHODES D, 1976, PLANTA, V129, P203, DOI 10.1007/BF00398258; ROBINSON SA, 1991, PLANT PHYSIOL, V95, P509, DOI 10.1104/pp.95.2.509; RONZIO RA, 1969, BIOCHEMISTRY-US, V8, P1066, DOI 10.1021/bi00831a038; SIEHL DL, 1986, Z NATURFORSCH C, V41, P79; SIEHL DL, 1988, ARCH BIOCHEM BIOPHYS, V260, P822, DOI 10.1016/0003-9861(88)90513-9; THORPE TA, 1989, PLANT PHYSIOL, V91, P193, DOI 10.1104/pp.91.1.193; WIGHTMAN F, 1978, PHYTOCHEMISTRY, V17, P1455, DOI 10.1016/S0031-9422(00)94622-3	43	57	58	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 24	1996	271	21					12350	12355		10.1074/jbc.271.21.12350	http://dx.doi.org/10.1074/jbc.271.21.12350			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UL660	8647837	hybrid			2022-12-25	WOS:A1996UL66000039
J	Bogdanov, M; Sun, JZ; Kaback, HR; Dowhan, W				Bogdanov, M; Sun, JZ; Kaback, HR; Dowhan, W			A phospholipid acts as a chaperone in assembly of a membrane transport protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LAC CARRIER PROTEIN; ESCHERICHIA-COLI; MONOCLONAL-ANTIBODIES; PERMEASE; COMPONENTS; MUTANTS; SYSTEM; GENE	A mutant of Escherichia coli lacking phosphatidylethanolamine (PE) and a monoclonal antibody (mAb 4B1) directed against a conformationally sensitive epitope (4B1) of lactose permease were used to establish a novel role for a phospholipid in the assembly of a membrane protein, Epitope 4B1 is readily detectable in spheroplasts and right-side-out membrane vesicles from PE-containing but not from PE-deficient cells expressing lactose permease. Lactose permease from PE-containing membranes, but not from PE-deficient membranes, subjected to sodium dodecyl sulfate (SDS)-polyacrylamide gel electrophoresis and Western blot analysis is also recognized by mAb 4B1, If total E. coli phospholipids or PE (but not phosphatidylcholine, phosphatidylglycerol, or cardiolipin) are blotted on nitrocellulose sheets (Eastern blot) prior to transfer of proteins from SDS-polyacrylamide gels, the permease from PE-deficient cells regains its recognition by mAb 4B1, Therefore, PE is required during assembly to form epitope 4B1, but, once formed, sufficient ''conformational memory'' is retained in the permease to either retain or reform this epitope in the absence of PE, Lactose permease lacking epitope 4B1 can be induced to form the epitope if partially denatured and then renatured in the presence of PE specifically, These results establish for the first time a role for PE as a molecular chaperone in the assembly of the lactose permease.	UNIV TEXAS,SCH MED,DEPT BIOCHEM & MOLEC BIOL,HOUSTON,TX 77225; UNIV CALIF LOS ANGELES,INST MOLEC BIOL,DEPT PHYSIOL & MICROBIOL,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,INST MOLEC BIOL,DEPT MOLEC GENET,LOS ANGELES,CA 90024	University of Texas System; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles			Bogdanov, Mikhail/J-3695-2017		NIGMS NIH HHS [GM20487] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BIBI E, 1990, P NATL ACAD SCI USA, V87, P4325, DOI 10.1073/pnas.87.11.4325; BOGDANOV M, 1995, J BIOL CHEM, V270, P732, DOI 10.1074/jbc.270.2.732; CARRASCO N, 1989, BIOCHEMISTRY-US, V28, P2533, DOI 10.1021/bi00432a028; CARRASCO N, 1986, BIOCHEMISTRY-US, V25, P4486, DOI 10.1021/bi00364a004; CARRASCO N, 1984, BIOCHEMISTRY-US, V23, P3681, DOI 10.1021/bi00311a017; CARRASCO N, 1982, P NATL ACAD SCI-BIOL, V79, P6894, DOI 10.1073/pnas.79.22.6894; CHEN CC, 1984, J BIOL CHEM, V259, P150; DECHAVIGNY A, 1991, J BIOL CHEM, V266, P5323; Dougherty DA, 1996, SCIENCE, V271, P163, DOI 10.1126/science.271.5246.163; DOWHAN W, 1992, METHOD ENZYMOL, V209, P7; FEDOROV AN, 1992, J MOL BIOL, V228, P351, DOI 10.1016/0022-2836(92)90825-5; FRILLINGOS S, 1994, BIOCHEMISTRY-US, V33, P8074, DOI 10.1021/bi00192a012; HERZLINGER D, 1984, BIOCHEMISTRY-US, V23, P3688, DOI 10.1021/bi00311a018; HINKLE PC, 1990, BIOCHEMISTRY-US, V29, P10989, DOI 10.1021/bi00501a017; JUNG K, 1994, BIOCHEMISTRY-US, V33, P3980, DOI 10.1021/bi00179a026; KABACK HR, 1994, J EXP BIOL, V196, P183; PAGE MGP, 1988, J BIOL CHEM, V263, P15897; SCHEIN CH, 1990, BIO-TECHNOL, V8, P308, DOI 10.1038/nbt0490-308; SEELIG J, 1993, NEW DEV LIPID PROTEI, P441; Seto-Young D, 1985, J MEMBRANE BIOL, V84, P256; Sun JZ, 1996, BIOCHEMISTRY-US, V35, P990, DOI 10.1021/bi952166w; TAKI T, 1994, ANAL BIOCHEM, V221, P312, DOI 10.1006/abio.1994.1418; THURMOND RL, 1991, BIOPHYS J, V59, P108, DOI 10.1016/S0006-3495(91)82203-2; VANVEEN HW, 1993, J BIOL CHEM, V268, P19377	24	169	176	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 17	1996	271	20					11615	11618		10.1074/jbc.271.20.11615	http://dx.doi.org/10.1074/jbc.271.20.11615			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UL250	8662750	hybrid			2022-12-25	WOS:A1996UL25000006
J	Dayan, G; BaubichonCortay, H; Jault, JM; Cortay, JC; Deleage, G; DiPietro, A				Dayan, G; BaubichonCortay, H; Jault, JM; Cortay, JC; Deleage, G; DiPietro, A			Recombinant N-terminal nucleotide-binding domain from mouse P-glycoprotein - Overexpression, purification, and role of cysteine 430	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONFER MULTIDRUG RESISTANCE; CYSTIC-FIBROSIS; ATPASE ACTIVITY; ENERGY-TRANSFER; CATALYTIC SITE; ALPHA-SUBUNIT; GENE; PROTEINS; HYDROLYSIS; BACTERIA	Varying length cDNAs encoding the N-terminal nucleotide-binding domain (NBD1) from mouse mdr1 P-glycoprotein were prepared on the basis of structure predictions. Corresponding recombinant proteins were overexpressed in Escherichia coli, and the shortest one containing amino acids 395-581 exhibited the highest solubility. Insertion of an N-terminal hexahistidine tag allowed domain purification by nickel-chelate affinity chromatography. NBD1 efficiently interacted with nucleotides. Fluorescence methods showed that ATP bound at millimolar concentrations and its 2',3'-O-(2,4,6-trinitrophenyl) derivative at micromolar concentrations, while the 2'(3')-N-methylanthraniloyl derivative had intermediate affinity. Photoaffinity labeling was achieved upon irradiation with 8-azido-ATP. The domain exhibited ATPase activity with a K-m for MgATP in the millimolar range, and ATP hydrolysis was competitively inhibited by micromolar 2',3'-O-(2,4,6-trinitrophenyl)-ATP. NBD1 contained a single cysteine residue, at position 430, that was derivatized with radiolabeled N-ethylmaleimide. Cysteine modification increased 6-fold the K-d for 2'(3')-N-methylanthraniloyl-ATP and prevented 8-azido-ATP photolabeling. ATPase activity was inhibited with a 5-fold increase in the K-m for MgATP. The results suggest that chemical modification of Cys-430 is involved in the N-ethylmaleimide inhibition of whole P-glycoprotein by altering substrate interaction.	UNIV LYON 1,LAB BIOCHIM STRUCTURALE & FONCT,INST BIOL & CHIMIE PROTEINES,UPR 412 CNRS,F-69367 LYON 07,FRANCE; UNIV LYON 1,MOLEC BIOL LAB,INST BIOL & CHIMIE PROTEINES,UPR 412 CNRS,F-69367 LYON 07,FRANCE; UNIV LYON 1,LAB CONFORMAT PROTEINES,INST BIOL & CHIMIE PROTEINES,UPR 412 CNRS,F-69367 LYON 07,FRANCE	UDICE-French Research Universities; Universite Claude Bernard Lyon 1; UDICE-French Research Universities; Universite Claude Bernard Lyon 1; UDICE-French Research Universities; Universite Claude Bernard Lyon 1			Deléage, Gilbert/F-7163-2010; jault, jean-michel/G-2086-2012	Deléage, Gilbert/0000-0003-1939-1614; jault, jean-michel/0000-0003-1743-2777; Cortay, Jean-Claude/0000-0003-3676-8436				ALSHAWI MK, 1993, J BIOL CHEM, V268, P4197; ALSHAWI MK, 1994, J BIOL CHEM, V269, P8986; AMBUDKAR SV, 1992, P NATL ACAD SCI USA, V89, P8472, DOI 10.1073/pnas.89.18.8472; AZZARIA M, 1989, MOL CELL BIOL, V9, P5289, DOI 10.1128/MCB.9.12.5289; BALZI E, 1994, BBA-BIOENERGETICS, V1187, P152, DOI 10.1016/0005-2728(94)90102-3; BAUBICHONCORTAY H, 1994, J BIOL CHEM, V269, P22983; BEAUDET L, 1995, J BIOL CHEM, V270, P17159, DOI 10.1074/jbc.270.29.17159; Boger J, 1986, 6 INT C IMM TOR, P250; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHILDS S, 1995, CANCER RES, V55, P2029; CORTAY JC, 1994, J BIOL CHEM, V269, P14885; CROOP JM, 1989, MOL CELL BIOL, V9, P1346, DOI 10.1128/MCB.9.3.1346; DEVAULT A, 1990, MOL CELL BIOL, V10, P1652, DOI 10.1128/MCB.10.4.1652; DIVITA G, 1993, J BIOL CHEM, V268, P13178; DOIGE CA, 1993, ANNU REV MICROBIOL, V47, P291, DOI 10.1146/annurev.micro.47.1.291; DOIGE CA, 1992, BIOCHIM BIOPHYS ACTA, V1109, P161, DOI 10.1016/0005-2736(92)90079-2; ERIKSSON S, 1993, J BIOL CHEM, V268, P1805; EVANS GL, 1995, J BIOENERG BIOMEMBR, V27, P43, DOI 10.1007/BF02110330; FALSON P, 1993, BIOCHEMISTRY-US, V32, P10387, DOI 10.1021/bi00090a014; GADSBY DC, 1994, TRENDS BIOCHEM SCI, V19, P513, DOI 10.1016/0968-0004(94)90141-4; GEORGES E, 1990, P NATL ACAD SCI USA, V87, P152, DOI 10.1073/pnas.87.1.152; Geourjon C, 1995, COMPUT APPL BIOSCI, V11, P681; GEOURJON C, 1993, COMPUT APPL BIOSCI, V9, P87; GERMANN UA, 1995, J BIOENERG BIOMEMBR, V27, P53, DOI 10.1007/BF02110331; GOTTESMAN MM, 1993, ANNU REV BIOCHEM, V62, P385, DOI 10.1146/annurev.bi.62.070193.002125; GROS P, 1986, CELL, V47, P371, DOI 10.1016/0092-8674(86)90594-5; HAKES DJ, 1992, ANAL BIOCHEM, V202, P293, DOI 10.1016/0003-2697(92)90108-J; HAMADA H, 1988, CANCER RES, V48, P4936; HARTMAN J, 1992, J BIOL CHEM, V267, P6455; HIGGINS CF, 1986, NATURE, V323, P448, DOI 10.1038/323448a0; HIRATSUKA T, 1983, BIOCHIM BIOPHYS ACTA, V742, P496, DOI 10.1016/0167-4838(83)90267-4; JAULT JM, 1993, J BIOL CHEM, V268, P20762; KO YH, 1993, J BIOL CHEM, V268, P24330; KO YH, 1995, J BIOL CHEM, V270, P22093, DOI 10.1074/jbc.270.38.22093; KORONAKIS V, 1993, MOL MICROBIOL, V8, P1163, DOI 10.1111/j.1365-2958.1993.tb01661.x; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEPAGE P, 1995, M S-MED SCI, V11, P357, DOI 10.4267/10608/2215; LOO TW, 1994, J BIOL CHEM, V269, P7750; LOO TW, 1995, J BIOL CHEM, V270, P21839, DOI 10.1074/jbc.270.37.21839; LOO TW, 1995, J BIOL CHEM, V270, P22957, DOI 10.1074/jbc.270.39.22957; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MOORE KJM, 1994, BIOCHEMISTRY-US, V33, P14550, DOI 10.1021/bi00252a023; MORBACH S, 1993, J BIOL CHEM, V268, P18617; MULLER KM, 1994, J BIOL CHEM, V269, P14032; PARKER JMR, 1986, BIOCHEMISTRY-US, V25, P5425, DOI 10.1021/bi00367a013; SARKADI B, 1992, J BIOL CHEM, V267, P4854; SHAPIRO AB, 1994, J BIOL CHEM, V269, P3745; SHARMA S, 1995, J BIOL CHEM, V270, P14085, DOI 10.1074/jbc.270.23.14085; SHAROM FJ, 1995, BIOCHEM J, V308, P381, DOI 10.1042/bj3080381; SHIMABUKU AM, 1992, J BIOL CHEM, V267, P4308; SIMON SM, 1994, P NATL ACAD SCI USA, V91, P3497, DOI 10.1073/pnas.91.9.3497; STINSON RA, 1973, BIOCHEM J, V131, P719, DOI 10.1042/bj1310719; UEDA K, 1992, J BIOL CHEM, V267, P24248; ULLMAN B, 1995, J BIOENERG BIOMEMBR, V27, P77, DOI 10.1007/BF02110334; URBATSCH IL, 1994, BIOCHEMISTRY-US, V33, P7069, DOI 10.1021/bi00189a008; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WOODWARD SKA, 1991, BIOCHEMISTRY-US, V30, P422, DOI 10.1021/bi00216a017	58	67	69	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 17	1996	271	20					11652	11658		10.1074/jbc.271.20.11652	http://dx.doi.org/10.1074/jbc.271.20.11652			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UL250	8662620	hybrid			2022-12-25	WOS:A1996UL25000014
J	Ferby, IM; Waga, I; Hoshino, M; Kume, K; Shimizu, T				Ferby, IM; Waga, I; Hoshino, M; Kume, K; Shimizu, T			Wortmannin inhibits mitogen-activated protein kinase activation by platelet-activating factor through a mechanism independent of p85/p110-type phosphatidylinositol 3-kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLONY-STIMULATING FACTOR; LIGHT CHAIN KINASE; PHOSPHOLIPID TURNOVER; SIGNAL-TRANSDUCTION; MAP KINASES; PHOSPHORYLATION; NEUTROPHILS; GENERATION; RECEPTORS; MEMBRANE	We have shown previously that wortmannin partially inhibits mitogen-activated protein kinase (MAPK) activated by platelet-activating factor (PAF) in guinea pig neutrophils (Ferby, M. I., Waga, I., Sakanaka, C., Kume, K., and Shimizu, T. (1994) J. Biol. Chem. 269, 30485-30488), To identify whether p85-dependent phosphatidylinositol 3-kinase is a target molecule of wortmannin in this inhibitory process, we established a murine macrophage cell line (P388D1), inducibly expressing a dominant-negative p85, Delta p85, Upon induction of Delta p85 by isopropyl-beta-D-thiogalactopyranoside, PAF still induced unaltered activation of MAPK, which was inhibited completely by wortmannin and 1,2-bis-(O-aminophenoxy)-ethane-N,N,N',N'-tetraacetic acid acetoxymethyl ester in an additive manner. Thus, PAF activates MAPK in P388D1 cells via two distinct pathways, one calcium-dependent and another calcium-independent, but wortmannin-sensitive. The inhibition of calcium-independent activation of MAPK by wortmannin does not involve p85-dependent phosphatidylinositol 3-kinase.	UNIV TOKYO, FAC MED, DEPT BIOCHEM, BUNKYO KU, TOKYO 113, JAPAN	University of Tokyo			Ferby, Ingvar/B-7895-2008	Kume, Kazuhiko/0000-0003-4232-1657; Ferby, Ingvar/0000-0002-3435-1728				ALVAREZ E, 1991, J BIOL CHEM, V266, P15277; ASMIS R, 1994, BIOCHEM J, V298, P543, DOI 10.1042/bj2980543; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; CHAO W, 1993, BIOCHEM J, V292, P617, DOI 10.1042/bj2920617; CREWS CM, 1993, CELL, V74, P215, DOI 10.1016/0092-8674(93)90411-I; DHAR A, 1991, J BIOL CHEM, V266, P18797; EAGER KB, 1986, METHOD ENZYMOL, V121, P59; ESCOBEDO JA, 1991, CELL, V65, P75, DOI 10.1016/0092-8674(91)90409-R; FERBY IM, 1994, J BIOL CHEM, V269, P30485; FRANKLIN RA, 1993, J IMMUNOL, V151, P1802; GARDNER AM, 1993, J BIOL CHEM, V268, P17896; HANAHAN DJ, 1986, ANNU REV BIOCHEM, V55, P483, DOI 10.1146/annurev.bi.55.070186.002411; HARA K, 1994, P NATL ACAD SCI USA, V91, P7415, DOI 10.1073/pnas.91.16.7415; HASHIMOTO Y, 1994, BBA-MOL CELL RES, V1223, P163, DOI 10.1016/0167-4889(94)90222-4; HAYASHI H, 1991, LIPIDS, V26, P1193, DOI 10.1007/BF02536530; HONDA Z, 1994, J BIOL CHEM, V269, P2307; INGRAHAM LM, 1982, BLOOD, V59, P1259; KOTANI K, 1994, EMBO J, V13, P2313, DOI 10.1002/j.1460-2075.1994.tb06515.x; KURUVILLA A, 1994, J IMMUNOL, V153, P5433; LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E; MAKISHIMA M, 1993, BIOCHIM BIOPHYS ACTA, V1176, P245, DOI 10.1016/0167-4889(93)90051-P; NAKANISHI S, 1992, J BIOL CHEM, V267, P2157; NEMENOFF RA, 1993, J BIOL CHEM, V268, P1960; NINOMIYA N, 1994, J BIOL CHEM, V269, P22732; Nishioka N, 1995, FEBS LETT, V377, P393, DOI 10.1016/0014-5793(95)01382-2; OKADA T, 1994, J BIOL CHEM, V269, P3563; OKUDA K, 1992, BLOOD, V79, P2880; PELECH SL, 1992, SCIENCE, V257, P1355, DOI 10.1126/science.1382311; PINCKARD RN, 1992, J IMMUNOL, V148, P3528; PRESCOTT SM, 1990, J BIOL CHEM, V265, P17381; REINHOLD SL, 1990, FASEB J, V4, P208, DOI 10.1096/fasebj.4.2.2105252; SAKANAKA C, 1994, BIOCHEM BIOPH RES CO, V205, P18, DOI 10.1006/bbrc.1994.2623; SAMIEI M, 1993, BIOCHIM BIOPHYS ACTA, V1176, P287, DOI 10.1016/0167-4889(93)90057-V; SCHULAM PG, 1991, J IMMUNOL, V146, P1642; SHUKLA SD, 1991, LIPIDS, V26, P1028, DOI 10.1007/BF02536496; SHUTE JK, 1990, BIOCHEM PHARMACOL, V40, P2013, DOI 10.1016/0006-2952(90)90231-9; SKOLNIK EY, 1991, CELL, V65, P83, DOI 10.1016/0092-8674(91)90410-Z; STEPHENS L, 1994, CELL, V77, P83, DOI 10.1016/0092-8674(94)90237-2; STEPHENS L, 1993, J BIOL CHEM, V268, P17162; STEPHENS LR, 1993, BIOCHIM BIOPHYS ACTA, V1179, P27, DOI 10.1016/0167-4889(93)90072-W; STOYANOV B, 1995, SCIENCE, V269, P690, DOI 10.1126/science.7624799; THOMASON PA, 1994, J BIOL CHEM, V269, P16525; VALONE FH, 1982, J IMMUNOL, V129, P1637; WAGA I, 1993, BIOCHEM BIOPH RES CO, V197, P465, DOI 10.1006/bbrc.1993.2502; WOSCHOLSKI R, 1994, FEBS LETT, V342, P109, DOI 10.1016/0014-5793(94)80482-6	45	76	76	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 17	1996	271	20					11684	11688		10.1074/jbc.271.20.11684	http://dx.doi.org/10.1074/jbc.271.20.11684			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UL250	8662643	hybrid			2022-12-25	WOS:A1996UL25000018
J	Quignon, F; Renard, CA; Tiollais, P; Buendia, MA; Transy, C				Quignon, F; Renard, CA; Tiollais, P; Buendia, MA; Transy, C			A functional N-myc2 retroposon in ground squirrels: Implications for hepadnavirus-associated carcinogenesis	ONCOGENE			English	Article						N-myc; hepadnavirus; carcinogenesis; viral determinants; host determinants	HEPATITIS-B VIRUS; WOODCHUCK LIVER-TUMORS; FOCUS-FORMING VIRUSES; HEPATOCELLULAR-CARCINOMA; C-MYC; ACTIVATION; GENE; EXPRESSION; INFECTION; REGION	Three hepatitis B viruses infecting humans, woodchucks and ground squirrels increase the risk of hepatocellular carcinoma in their respective hosts. The woodchuck hepatitis B virus (WHV), unlike the two other viruses, induces a rapid carcinogenic process characterized by direct activation of myc proto-oncogenes by insertion of viral DNA. The highly preferred target of insertional mutagenesis in woodchucks is N-myc2, an intronless N-myc gene. Strikingly, N-myc2 has no human homolog and the homologous N-myc2 locus previously detected in the ground squirrel genome, remains silent during hepatocarcinogenesis. Therefore, N-myc2 may represent a critical host determinant in the evolution of the disease associated with hepadnavirus infection. To address this question, we performed a structural and functional analysis of the ground squirrel N-myc2 locus. We show that ground squirrel N-myc2 is highly homologous to its woodchuck counterpart and is a functional protooncogene, Existence of a functional N-myc2 gene as a potential target for insertional activation by viral DNA is therefore not restricted to the woodchuck species. This suggests that viral rather than host factors determine the higher oncogenic phenotype of WHV as compared to the two other mammalian hepadnaviruses.	INST PASTEUR,INSERM,UNITE RECOMBINAISON & EXPRESS GENET,U163,F-75724 PARIS 15,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris			Quignon, Frédérique/P-4249-2017					ATHAS GB, 1994, CRIT REV ONCOGENESIS, V5, P169, DOI 10.1615/CritRevOncog.v5.i2-3.40; BEASLEY RP, 1981, LANCET, V2, P1129; BUENDIA MA, 1992, ADV CANCER RES, V59, P167, DOI 10.1016/S0065-230X(08)60306-1; DAVIS BR, 1987, P NATL ACAD SCI USA, V84, P4875, DOI 10.1073/pnas.84.14.4875; FOUREL G, 1994, EMBO J, V13, P2526, DOI 10.1002/j.1460-2075.1994.tb06542.x; FOUREL G, 1992, MOL CELL BIOL, V12, P5336, DOI 10.1128/MCB.12.12.5336; FOUREL G, 1990, NATURE, V347, P294, DOI 10.1038/347294a0; FOUREL G, 1990, NUCLEIC ACIDS RES, V18, P4918, DOI 10.1093/nar/18.16.4918; HAGIWARA T, 1992, EUR J BIOCHEM, V209, P945, DOI 10.1111/j.1432-1033.1992.tb17367.x; HANSEN LJ, 1993, MOL CELL BIOL, V13, P659, DOI 10.1128/MCB.13.1.659; HOLLAND CA, 1989, J VIROL, V63, P1284, DOI 10.1128/JVI.63.3.1284-1292.1989; KEKULE AS, 1990, NATURE, V343, P457, DOI 10.1038/343457a0; LAUER U, 1992, J VIROL, V66, P5284, DOI 10.1128/JVI.66.9.5284-5289.1992; LEE WMF, 1985, MOL CELL BIOL, V5, P3345, DOI 10.1128/MCB.5.12.3345; LI JP, 1990, NATURE, V343, P762, DOI 10.1038/343762a0; LI JP, 1991, J VIROL, V65, P2408, DOI 10.1128/JVI.65.5.2408-2414.1991; MARION PL, 1986, P NATL ACAD SCI USA, V83, P4543, DOI 10.1073/pnas.83.12.4543; MORRISON HL, 1995, J VIROL, V69, P446, DOI 10.1128/JVI.69.1.446-455.1995; POPPER H, 1987, P NATL ACAD SCI USA, V84, P866, DOI 10.1073/pnas.84.3.866; SCHUERMANN M, 1990, NUCLEIC ACIDS RES, V18, P4945, DOI 10.1093/nar/18.16.4945; SEEGER C, 1991, J VIROL, V65, P1673, DOI 10.1128/JVI.65.4.1673-1679.1991; SUMMERS J, 1978, P NATL ACAD SCI USA, V75, P4533, DOI 10.1073/pnas.75.9.4533; TRANSY C, 1992, P NATL ACAD SCI USA, V89, P3874, DOI 10.1073/pnas.89.9.3874; TRANSY C, 1994, J VIROL, V68, P5291, DOI 10.1128/JVI.68.8.5291-5295.1994; TSICHLIS PN, 1991, P NATL ACAD SCI USA, V88, P4611, DOI 10.1073/pnas.88.11.4611; VANLOHUIZEN M, 1990, BIOCHIM BIOPHYS ACTA, V1032, P213, DOI 10.1016/0304-419X(90)90005-L; VASTRIK I, 1994, CRIT REV ONCOGENESIS, V5, P59, DOI 10.1615/CritRevOncog.v5.i1.30; WEI Y, 1992, J VIROL, V66, P5265, DOI 10.1128/JVI.66.9.5265-5276.1992	28	3	5	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY 2	1996	12	9					2011	2017						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UK498	8649862				2022-12-25	WOS:A1996UK49800020
J	Shridhar, V; Rivard, S; Shridhar, R; Mullins, C; Bostick, L; Sakr, W; Grignon, D; Miller, OJ; Smith, DI				Shridhar, V; Rivard, S; Shridhar, R; Mullins, C; Bostick, L; Sakr, W; Grignon, D; Miller, OJ; Smith, DI			A gene from human chromosomal band 3p21.1 encodes a highly conserved arginine-rich protein and is mutated in renal cell carcinomas	ONCOGENE			English	Article						arginine-rich protein; cryptic repeat; 3p21.1 gene; mutations; renal cell carcinoma	LUNG-CANCER; REGION 3P21; SEQUENCE; AMINOACYLASE-1; IDENTIFICATION; POLYMERASE; EXPRESSION	We have identified a gene, called ARP for Arginine-rich protein, in human chromosomal band 3p21. It is approximately 600 Kb telomeric to the ACY1 locus (Miller et al., 1989) and encodes a previously unidentified 234 amino acid long, highly basic protein. This gene is highly conserved at the DNA and RNA level. It is found in all species including hamster, rat, mouse, bovine and yeast. We have detected a point mutation (ATG(50) to AGG) or deletion of ATG(50) in 10 of 21 sporadic renal cell carcinomas. The mutable region is in an imperfect trinucleotide repeat in the coding region which is nonpolymorphic among 50 normal individuals examined. The point mutation (ATG(50) to AGG) or deletion of codon 50 removes a methionine and increases the stretch of arginines encoded by the AGG repeats in the ARP gene.	WAYNE STATE UNIV,SCH MED,DEPT MOLEC BIOL & GENET,DETROIT,MI 48201; WAYNE STATE UNIV,SCH MED,DEPT INTERNAL MED,DETROIT,MI 48201; WAYNE STATE UNIV,SCH MED,DEPT PATHOL,DETROIT,MI 48201	Wayne State University; Wayne State University; Wayne State University					NATIONAL CANCER INSTITUTE [R01CA048031] Funding Source: NIH RePORTER; NCI NIH HHS [CA48031] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AZUMA T, 1989, J BIOL CHEM, V264, P16748; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BEBENEK K, 1990, P NATL ACAD SCI USA, V87, P4946, DOI 10.1073/pnas.87.13.4946; CALNAN BJ, 1991, SCIENCE, V252, P1167, DOI 10.1126/science.252.5009.1167; CHUNG MY, 1993, NAT GENET, V5, P254, DOI 10.1038/ng1193-254; DALY MC, 1993, AM J HUM GENET, V53, pA290; DRABKIN H, 1990, GENOMICS, V8, P435, DOI 10.1016/0888-7543(90)90029-T; ECKERT KA, 1990, NUCLEIC ACIDS RES, V18, P3739, DOI 10.1093/nar/18.13.3739; ERLANDSSON R, 1990, ONCOGENE, V5, P1207; GEMMILL RM, 1991, GENOMICS, V11, P93, DOI 10.1016/0888-7543(91)90105-N; GIBBS JB, 1984, P NATL ACAD SCI-BIOL, V81, P5704, DOI 10.1073/pnas.81.18.5704; GINZINGER DG, 1992, AM J HUM GENET, V50, P826; GOSTOUT B, 1993, AM J HUM GENET, V52, P1182; HATTORI M, 1986, ANAL BIOCHEM, V152, P232, DOI 10.1016/0003-2697(86)90403-3; KILLARY AM, 1992, P NATL ACAD SCI USA, V89, P10877, DOI 10.1073/pnas.89.22.10877; KOK K, 1987, NATURE, V330, P578, DOI 10.1038/330578a0; KOK K, 1993, P NATL ACAD SCI USA, V90, P6071, DOI 10.1073/pnas.90.13.6071; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; MEARS JG, 1978, P NATL ACAD SCI USA, V75, P1222, DOI 10.1073/pnas.75.3.1222; MILLER YE, 1990, GENOMICS, V8, P149, DOI 10.1016/0888-7543(90)90237-O; MILLER YE, 1989, J CLIN INVEST, V83, P2120, DOI 10.1172/JCI114125; NAGEL S, 1995, CANCER RES, V55, P2866; ORITA M, 1989, GENOMICS, V5, P874, DOI 10.1016/0888-7543(89)90129-8; RALL LB, 1987, METHOD ENZYMOL, V146, P239; SHRIDHAR V, 1994, CANCER RES, V54, P2084; SHRIDHAR V, 1994, SOMAT CELL MOLEC GEN, V20, P255, DOI 10.1007/BF02254716; SLEDDENS HFBM, 1992, NUCLEIC ACIDS RES, V20, P1427; SMITH DI, 1989, AM J HUM GENET, V45, P443; WEBER JL, 1993, HUM MOL GENET, V2, P1123, DOI 10.1093/hmg/2.8.1123; WEBER JL, 1993, HUM MOL GENET, V2, P2866; YAMAKAWA K, 1993, AM J HUM GENET, V53, pA390; Young A., 1991, FOCUS, V13, P137	32	40	45	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY 2	1996	12	9					1931	1939						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UK498	8649854				2022-12-25	WOS:A1996UK49800012
J	Srivenugopal, KS; AliOsman, F				Srivenugopal, KS; AliOsman, F			Deletions and rearrangements inactivate the p16(INK4) gene in human glioma cells	ONCOGENE			English	Article						p16(INK4); cell cycle; human glioma; CdK inhibitor; retinoblastoma protein		Structural alterations in the p16(INK4) gene were examined in early passage human glioma cell lines and related to the expression of p16 transcripts and protein. Using the Southern blot approach, we observed both homozygous and hemizygous deletions, as well as rearrangements of the p16 and p15 genes in 5 of the 7 cell lines (71%). Two cell lines, MGR3 and HBT28, revealed hemizygous deletion of the p16 and p15 genes combined with indistinguishable rearrangements of the remaining p15-p16 locus that resulted in loss of exon 2 sequences for p15 and p16, but retention of p16 exon 1; neither of these cell lines expressed p16 mRNA. Data for a third cell line, MGR2, indicated a similar, but rearrangement involving the p15 and p16 MGR2, which retained a single wild-type p15-p16 locus, showed expression of p16 transcript, but not of p16 protein as indicated by Western blot analysis. All the glioma cell lines expressed similar levels of the retinoblastoma protein and no amplification of the cyclin-dependent kinase 4 gene. These results demonstrate that human glioma cells contain p16 gene microdeletions and rearrangements that contribute to inactivation of the cell cycle regulatory protein.			Srivenugopal, KS (corresponding author), UNIV TEXAS,MD ANDERSON CANC CTR,DEPT EXPT PEDIAT,BOX 169,1515 HOLCOMBE BLVD,HOUSTON,TX 77030, USA.				NATIONAL CANCER INSTITUTE [R01CA064900] Funding Source: NIH RePORTER; NCI NIH HHS [CA 64900] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALIOSMAN F, 1987, J NEUROPATH EXP NEUR, V46, P371, DOI 10.1097/00005072-198705000-00126; ALIOSMAN F, 1990, CANCER RES, V50, P6976; ARAP W, 1995, CANCER RES, V55, P1351; CAIRNS P, 1994, SCIENCE, V265, P415, DOI 10.1126/science.8023167; CALDAS C, 1994, NAT GENET, V8, P27, DOI 10.1038/ng0994-27; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DURO D, 1995, ONCOGENE, V11, P21; GONZALEZZULUETA M, 1995, CANCER RES, V55, P4531; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; HE J, 1994, CANCER RES, V54, P5804; HEBERT J, 1994, BLOOD, V84, P4038, DOI 10.1182/blood.V84.12.4038.bloodjournal84124038; HERMAN JG, 1995, CANCER RES, V55, P4525; HUSSUSSIAN CJ, 1994, NAT GENET, V8, P15, DOI 10.1038/ng0994-15; JEN J, 1994, CANCER RES, V54, P6353; KAMB A, 1994, SCIENCE, V265, P416, DOI 10.1126/science.265.5170.416; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; KATO J, 1993, GENE DEV, V7, P331; LI Y, 1994, CANCER RES, V54, P6078; LI YJ, 1995, ONCOGENE, V11, P597; LIU Q, 1995, ONCOGENE, V10, P1061; MAO L, 1995, CANCER RES, V55, P2995; MEAD LJ, 1994, CANCER RES, V54, P2307; MORI T, 1994, CANCER RES, V54, P3396; NISHIKAWA R, 1995, CANCER RES, V55, P1941; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; OKAMOTO A, 1994, P NATL ACAD SCI USA, V91, P11045, DOI 10.1073/pnas.91.23.11045; OTTERSON GA, 1995, ONCOGENE, V11, P1211; OTTERSON GA, 1994, ONCOGENE, V9, P3375; SCHMIDT EE, 1994, CANCER RES, V54, P6321; SERRANO M, 1995, SCIENCE, V267, P249, DOI 10.1126/science.7809631; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SONODA Y, 1995, ONCOGENE, V11, P2145; SPRUCK CH, 1994, NATURE, V370, P183, DOI 10.1038/370183a0; STONE S, 1995, ONCOGENE, V11, P987; STONE S, 1995, CANCER RES, V55, P2988; Ueki K, 1996, CANCER RES, V56, P150; WALKER DG, 1995, CANCER RES, V55, P20; XIONG Y, 1993, GENE DEV, V7, P1572, DOI 10.1101/gad.7.8.1572; XU L, 1994, CANCER RES, V54, P5262; YEUDALL WA, 1994, CARCINOGENESIS, V15, P2683, DOI 10.1093/carcin/15.12.2683	40	21	21	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY 2	1996	12	9					2029	2034						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UK498	8649864				2022-12-25	WOS:A1996UK49800022
J	Charlesworth, A; Broad, S; Rozengurt, E				Charlesworth, A; Broad, S; Rozengurt, E			The bombesin/GRP receptor transfected into Rat-1 fibroblasts couples to phospholipase C activation, tyrosine phosphorylation of p125(FAK) and paxillin and cell proliferation	ONCOGENE			English	Article						neuropeptides; growth factors; Ca2+ mobilisation; protein kinase C	SWISS 3T3 CELLS; PROTEIN-KINASE-C; GASTRIN-RELEASING PEPTIDE; LUNG-CARCINOMA CELLS; MOLECULAR-CLONING; MAJOR SUBSTRATE; GROWTH-FACTOR; DNA-SYNTHESIS; STIMULATION; VASOPRESSIN	Bombesin elicits multiple signalling pathways in various cell types, It is not clear, however, whether these responses are mediated by a single receptor subtype or by different subtypes that couple preferentially to specific pathways. To resolve this we transfected the mouse bombesin/GRP receptor into Rat-1 fibroblasts and investigated the pathways activated by bombesin, Expression of the transfected receptors was verified by binding of [I-125]GRP and two clones were selected, BOR5 and BOR15. Bombesin stimulation of BOR5 and BOR15 cells caused intracellular Ca2+ mobilisation and increased the phosphorylation of 80K/MARCKS, a prominent protein kinase C substrate, The transfected receptor conferred a proliferative response to bombesin demonstrated by incorporation of [H-3]thymidine after 18 h and an increase in total cell numbers after 1-2 days. In BOR5 and BOR15 cells, bombesin rapidly stimulated the tyrosine phosphorylation of multiple proteins M(r) 110000-130000 and 70000-80000 including p125(FAK) and paxillin, at low concentrations (half maximum 0.3 nM). The specific bombesin/GRP receptor antagonist, D-F-5-Phe(6), D-Ala(11)-Bombesin(6-13)OMe, inhibited an the above responses. These results show that phospholipase C activation, cell growth and tyrosine phosphorylation emanate from a single class of bombesin receptor.	IMPERIAL CANC RES FUND, LONDON WC2A 3PX, ENGLAND	Cancer Research UK								ASHKENAZI A, 1987, SCIENCE, V238, P672, DOI 10.1126/science.2823384; BATTEY JF, 1991, P NATL ACAD SCI USA, V88, P395, DOI 10.1073/pnas.88.2.395; BOLD RJ, 1994, J CELL PHYSIOL, V161, P519, DOI 10.1002/jcp.1041610315; BROOKS SF, 1991, EMBO J, V10, P2497, DOI 10.1002/j.1460-2075.1991.tb07789.x; BUHL AM, 1995, J BIOL CHEM, V270, P24631, DOI 10.1074/jbc.270.42.24631; CARNEY DN, 1987, CANCER RES, V47, P821; COBB BS, 1994, MOL CELL BIOL, V14, P147, DOI 10.1128/MCB.14.1.147; CORJAY MH, 1991, J BIOL CHEM, V266, P18771; COY DH, 1992, PEPTIDES, V13, P775, DOI 10.1016/0196-9781(92)90186-7; CUTTITTA F, 1985, NATURE, V316, P823, DOI 10.1038/316823a0; FATHI Z, 1993, J BIOL CHEM, V268, P5979; GORBULEV V, 1992, EUR J BIOCHEM, V208, P405, DOI 10.1111/j.1432-1033.1992.tb17201.x; GRADY EF, 1995, J BIOL CHEM, V270, P4603, DOI 10.1074/jbc.270.9.4603; HANKS SK, 1992, P NATL ACAD SCI USA, V89, P8487, DOI 10.1073/pnas.89.18.8487; HIGGINS TE, 1992, P NATL ACAD SCI USA, V89, P4240, DOI 10.1073/pnas.89.10.4240; HILDEBRAND JD, 1995, MOL BIOL CELL, V6, P637, DOI 10.1091/mbc.6.6.637; KOCH WJ, 1994, P NATL ACAD SCI USA, V91, P12706, DOI 10.1073/pnas.91.26.12706; LEE SB, 1995, CURR OPIN CELL BIOL, V7, P183, DOI 10.1016/0955-0674(95)80026-3; NANBERG E, 1988, EMBO J, V7, P2741, DOI 10.1002/j.1460-2075.1988.tb03128.x; RANKIN S, 1994, FEBS LETT, V354, P315, DOI 10.1016/0014-5793(94)01148-6; RODRIGUEZPENA A, 1986, EMBO J, V5, P77, DOI 10.1002/j.1460-2075.1986.tb04180.x; ROZENGURT E, 1983, P NATL ACAD SCI-BIOL, V80, P2936, DOI 10.1073/pnas.80.10.2936; ROZENGURT E, 1986, SCIENCE, V234, P161, DOI 10.1126/science.3018928; ROZENGURT E, 1992, Current Opinion in Cell Biology, V4, P161, DOI 10.1016/0955-0674(92)90027-A; ROZENGURT E, 1995, CANCER SURV, V24, P81; ROZENGURT E, 1995, OXFORD TXB ONCOLOGY, P12; SALGIA R, 1995, J BIOL CHEM, V270, P5039, DOI 10.1074/jbc.270.10.5039; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; SECKL M, 1993, J BIOL CHEM, V268, P9548; SECKL MJ, 1995, J BIOL CHEM, V270, P6984, DOI 10.1074/jbc.270.12.6984; SETHI T, 1992, CANCER RES, V52, pS2737; SINNETTSMITH J, 1993, J BIOL CHEM, V268, P14261; SPINDEL ER, 1990, MOL ENDOCRINOL, V4, P1956, DOI 10.1210/mend-4-12-1956; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; TURNER CE, 1994, J CELL SCI, V107, P1583; WADA E, 1991, NEURON, V6, P421, DOI 10.1016/0896-6273(91)90250-4; ZACHARY I, 1986, J CELL BIOL, V102, P2211, DOI 10.1083/jcb.102.6.2211; ZACHARY I, 1985, P NATL ACAD SCI USA, V82, P7616, DOI 10.1073/pnas.82.22.7616; ZACHARY I, 1991, P NATL ACAD SCI USA, V88, P4577, DOI 10.1073/pnas.88.11.4577; ZACHARY I, 1991, J BIOL CHEM, V266, P24126; ZACHARY I, 1987, DEV BIOL, V124, P295, DOI 10.1016/0012-1606(87)90483-0; ZACHARY I, 1993, J BIOL CHEM, V268, P22060; ZACHARY I, 1992, J BIOL CHEM, V267, P19031; ZACHARY I, 1987, EMBO J, V6, P2233, DOI 10.1002/j.1460-2075.1987.tb02495.x; ZACHARY I, 1987, J BIOL CHEM, V262, P3947	45	41	41	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 21	1996	12	6					1337	1345						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UC067	8649836				2022-12-25	WOS:A1996UC06700019
J	Marchetti, A; Doglioni, C; Barbareschi, M; Buttitta, F; Pellegrini, S; Bertacca, G; Chella, A; Merlo, G; Angeletti, CA; DallaPalma, P; Bevilacqua, G				Marchetti, A; Doglioni, C; Barbareschi, M; Buttitta, F; Pellegrini, S; Bertacca, G; Chella, A; Merlo, G; Angeletti, CA; DallaPalma, P; Bevilacqua, G			p21 RNA and protein expression in non-small cell lung carcinomas: Evidence of p53-independent expression and association with tumoral differentiation	ONCOGENE			English	Article						p21/WAF1/CIP1/SDI1/mda-6; p53; lung cancer; histology; differentiation	P53; PROLIFERATION; INHIBITOR; MARKERS; KINASES	p21, the product of the WAF1/CIP1/SDI1/mda-6 gene, is an inhibitor of cyclin-dependent kinases. In cell cultures p21 is induced by p53-dependent and p53-independent pathways by DNA damage and induction of differentiation. We investigated p21 RNA and immunohistochemical expression in 43 non-small cell lung carcinomas and corresponding normal lung samples previously investigated for p53 and WAF1 gene status and p53 protein expression. p21 RNA and protein expression in normal and neoplastic tissues were strictly associated (P=0.0001). In normal tissue p21 RNA was expressed at low levels and p21 immunoreactivity was seen in scattered differentiated bronchial, alveolar and stromal cells. In the majority of neoplasms p21 protein and RNA were expressed at higher levels than in the corresponding normal tissues: p21 overexpression was seen in 27 (63%) and 28 (65%) cases respectively. p21 was expressed independently from p53 gene/protein alterations. p21 overexpression was more frequent in well differentiated tumors (P=0.01 and P=0.022 for RNA and protein respectively), and p21 immunoreactivity was usually seen in foci of more pronounced differentiation. We conclude that p21 expression is related to tumor differentiation, and that p53-independent p21 expression is a common feature of in vivo neoplasms.	UNIV PISA,SERV THORAC SURG,I-56100 PISA,ITALY; CITY HOSP BELLUNO,DEPT HISTOPATHOL,BELLUNO,ITALY; SANTA CHIARA HOSP,DEPT HISTOPATHOL,TRENT,ITALY; FRIEDRICH MIESCHER INST,CH-4002 BASEL,SWITZERLAND	University of Pisa; ULSS 1 Dolomiti; Ospedale di Belluno; Santa Chiara Hospital; Friedrich Miescher Institute for Biomedical Research	Marchetti, A (corresponding author), UNIV PISA,INST PATHOL & HISTOL,VIA ROME 57,I-56100 PISA,ITALY.		Pellegrini, Silvia/C-3770-2011; PELLEGRINI, SILVIA/ABG-8822-2021; Barbareschi, Mattia/AAF-2043-2020	PELLEGRINI, SILVIA/0000-0003-0556-0165; BEVILACQUA, GENEROSO/0000-0001-8857-2609; DOGLIONI, Claudio/0000-0002-4969-5216				[Anonymous], 1982, Am J Clin Pathol, V77, P123; BARBARESCHI M, 1992, J PATHOL, V166, P343, DOI 10.1002/path.1711660405; BARBARESCHI M, 1992, AM J CLIN PATHOL, V98, P408, DOI 10.1093/ajcp/98.4.408; CATTORETTI G, 1992, J PATHOL, V168, P357, DOI 10.1002/path.1711680404; CHEDID M, 1994, ONCOGENE, V9, P3021; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELDEIRY WS, 1995, CANCER RES, V55, P2910; HALEVY O, 1995, SCIENCE, V267, P1018, DOI 10.1126/science.7863327; HARPER JW, 1993, CELL, V75, P805; Jiang Hongping, 1993, Molecular and Cellular Differentiation, V1, P285; JIANG HP, 1994, ONCOGENE, V9, P3397; JOHNSON M, 1994, MOL CARCINOGEN, V11, P59, DOI 10.1002/mc.2940110202; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; MARCHETTI A, 1993, CANCER RES, V53, P4665; MARCHETTI A, 1993, CANCER RES, V53, P2846; MARCHETTI A, 1995, INT J ONCOL, V6, P187; MICHIELI P, 1994, CANCER RES, V54, P3391; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; PARKER SB, 1995, SCIENCE, V267, P1024, DOI 10.1126/science.7863329; SHIOHARA M, 1994, BLOOD, V84, P3781, DOI 10.1182/blood.V84.11.3781.bloodjournal84113781; STEINMAN RA, 1994, ONCOGENE, V9, P3389; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0	24	138	145	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR 21	1996	12	6					1319	1324						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UC067	8649834				2022-12-25	WOS:A1996UC06700017
J	Taniguchi, T; Takaishi, K; Murayama, T; Ito, M; Iwata, N; Chihara, K; Sasaki, T; Takai, Y; Matsui, T				Taniguchi, T; Takaishi, K; Murayama, T; Ito, M; Iwata, N; Chihara, K; Sasaki, T; Takai, Y; Matsui, T			Cholecystokinin-B/gastrin receptors mediate rapid formation of actin stress fibers	ONCOGENE			English	Article						stress fiber; cholecystokinin; gastrin; rho p21; PDGF	PROTEIN RHO GDI; SWISS 3T3 CELLS; TYROSINE KINASE; HUMAN BRAIN; ADP-RIBOSYLTRANSFERASE; CLOSTRIDIUM-BOTULINUM; GASTRIN RECEPTOR; FOCAL ADHESIONS; GROWTH; CLONING	Specific receptors for brain-gut peptide hormones, cholecystokinin (CCK) and gastrin, are expressed in a variety of human tumor cells, CCK and gastrin promote the growth of NIH3T3 cells into which the CCK-B/gastrin receptor had been introduced via a eukaryotic expression vector. In this study, we have examined the effect of CCK-8 on the actin cytoskeleton by using two mouse fibroblast cell lines expressing human CCK-B/gastrin receptors. Treatment with very low concentrations of CCK-8 (10(-10) M) induced the formation of actin stress fibers within one minute. Stress fiber formation increased for 30 min, In contrast, a potent mitogen for fibroblasts, platelet-derived growth factor (PDGF), initially induced membrane ruffling and, later, a weak formation of stress fibers. Microinjection of rho GDP dissociation inhibitor or Clostridium botulinum ADP-ribosyltransferase C3 which is known to impair the function of a small GTP-binding protein, rho p21, inhibited the stress fiber formation by CCK-8 as well as by PDGF. These results indicate that CCK-B/gastrin receptor could regulate stress fiber formation in a rho p21-dependent manner. The signals from CCK-B/gastrin receptor might affect cell growth as well as cell motility or adhesion by regulating the actin cytoskeleton.	KOBE UNIV,SCH MED,DEPT MED,DIV 3,KOBE 650,JAPAN; OSAKA UNIV,SCH MED,DEPT BIOCHEM & MOLEC BIOL,SUITA,OSAKA 565,JAPAN	Kobe University; Osaka University			Matsui, Toshimitsu/E-8065-2010	Matsui, Toshimitsu/0000-0002-2536-7584				CHARDIN P, 1989, EMBO J, V8, P1087, DOI 10.1002/j.1460-2075.1989.tb03477.x; HOOSEIN NM, 1988, CANCER RES, V48, P7179; ISHIZUKA J, 1992, ANN SURG, V215, P528, DOI 10.1097/00000658-199205000-00016; ITO M, 1993, J BIOL CHEM, V268, P18300; ITO M, 1994, CELL GROWTH DIFFER, V5, P1127; JOHNSON LR, 1988, PHYSIOL REV, V68, P456, DOI 10.1152/physrev.1988.68.2.456; KORNBERG L, 1992, J BIOL CHEM, V267, P23439; LEE YM, 1993, J BIOL CHEM, V268, P8164; MATSUMORI Y, 1995, CANCER RES, V55, P276; MICHIELS F, 1995, NATURE, V375, P338, DOI 10.1038/375338a0; MIURA Y, 1993, J BIOL CHEM, V268, P510; NEMOTO Y, 1991, J BIOL CHEM, V266, P19312; NISHIYAMA T, 1994, MOL CELL BIOL, V14, P2447, DOI 10.1128/MCB.14.4.2447; PEPPELENBOSCH MP, 1995, CELL, V81, P849, DOI 10.1016/0092-8674(95)90005-5; PISEGNA JR, 1992, BIOCHEM BIOPH RES CO, V189, P296, DOI 10.1016/0006-291X(92)91557-7; RAUFMAN JP, 1984, AM J PHYSIOL, V247, pG95, DOI 10.1152/ajpgi.1984.247.1.G95; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1994, EMBO J, V13, P2600, DOI 10.1002/j.1460-2075.1994.tb06550.x; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; RUBIN EJ, 1988, MOL CELL BIOL, V8, P418, DOI 10.1128/MCB.8.1.418; Sacerdote P, 1988, Peptides, V9 Suppl 1, P29, DOI 10.1016/0196-9781(88)90219-7; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; SEKINE A, 1989, J BIOL CHEM, V264, P8602; SETHI T, 1991, CANCER RES, V51, P3621; SILEN ML, 1993, TRENDS ENDOCRIN MET, V4, P131, DOI 10.1016/1043-2760(93)90037-F; TAKAISHI K, 1993, MOL CELL BIOL, V13, P72, DOI 10.1128/MCB.13.1.72; TANIGUCHI T, 1994, ONCOGENE, V9, P861; ZACHARY I, 1992, J BIOL CHEM, V267, P19031; ZHENG Y, 1995, J BIOL CHEM, V270, P9031, DOI 10.1074/jbc.270.16.9031; ZIMONJIC DB, 1994, CYTOGENET CELL GENET, V65, P184, DOI 10.1159/000133628	30	26	26	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR 21	1996	12	6					1357	1360						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UC067	8649838				2022-12-25	WOS:A1996UC06700021
J	Boulakia, CA; Chen, G; Ng, FWH; Teodoro, JG; Branton, PE; Nicholson, DW; Poirier, GG; Shore, GC				Boulakia, CA; Chen, G; Ng, FWH; Teodoro, JG; Branton, PE; Nicholson, DW; Poirier, GG; Shore, GC			Bcl-2 and adenovirus E1B 19 kDA protein prevent E1A-induced processing of CPP32 and cleavage of poly(ADP-ribose) polymerase	ONCOGENE			English	Article						apoptosia; E1A; PARP; CPP32; Bcl-2; E1B 19K	PROGRAMMED CELL-DEATH; C-ELEGANS; GENE CED-3; APOPTOSIS; TRANSFORMATION; POLYPEPTIDES; ASSOCIATION; INDUCTION; ENZYME	The E1A oncoproteins of adenovirus type 5 are potent inducers of apoptotic cell death. To manifest growth promoting and transforming properties, therefore, E1A requires the co-expression of a suppressor of apoptosis. During normal viral infection, this function is provided by the E1B 19 kDa protein. However, the cellular suppressor Bcl-2 can substitute for 19K during infection, and both proteins can effectively cooperate with E1A to facilitate transformation of primary cells in culture. How E1A induces apoptosis and at what point(s) on this pathway Bcl-2 and E1B 19K act are not presently known. Here, we demonstrate that E1A-induced apoptosis is accompanied by specific endo-proteolytic cleavage of poly(ADP-ribose) polymerase (PARP), an event that is linked to the Ced-3/ICE apoptotic pathway in other systems. PARP cleavage was also observed in p53-null cells infected with 19K(-) virus expressing 13S EIA. In addition to PARP cleavage, expression of E1A caused processing of the zymogen form of CPP32, a Ced-3/ICE protease that cleaves PARP and is required for apoptosis in mammalian cells. These events were prevented when EIA was co-expressed with E1B 19K or BCL-2, which places these suppressors of apoptosis either at or upstream of processing of pro-CPP32.	MCGILL UNIV,DEPT BIOCHEM,MONTREAL,PQ H3G 1Y6,CANADA; MERCK FROSST CTR THERAPEUT RES,DEPT BIOCHEM & MOLEC BIOL,POINTE CLAIRE,PQ H9R 4P8,CANADA; CHU LAVAL,RES CTR,DEPT MOLEC ENDOCRINOL,POLY ADP RIBOSE METAB GRP,ST FOY,PQ G1V 4G2,CANADA	McGill University; Merck & Company; Laval University			Teodoro, Joe/AFT-2440-2022	Teodoro, Joe/0000-0002-3713-6839; Poirier, Guy/0000-0002-4869-1424				BARBEAU D, 1994, ONCOGENE, V9, P359; BOYD JM, 1994, CELL, V79, P341, DOI 10.1016/0092-8674(94)90202-X; BURKLE A, 1992, EXP CLIN IMMUNOGENET, V9, P230; CHEN G, 1995, EXP CELL RES, V221, P55, DOI 10.1006/excr.1995.1351; DEBBAS M, 1993, GENE DEV, V7, P546, DOI 10.1101/gad.7.4.546; EARNSHAW WC, 1995, TRENDS CELL BIOL, V5, P217, DOI 10.1016/S0962-8924(00)89006-6; ECKNER R, 1994, GENE DEV, V8, P869, DOI 10.1101/gad.8.8.869; EGAN C, 1989, ONCOGENE, V4, P383; EGAN C, 1988, MOL CELL BIOL, V8, P869; ELLIS HM, 1986, CELL, V44, P817, DOI 10.1016/0092-8674(86)90004-8; FAUCHEU C, 1995, EMBO J, V14, P1914, DOI 10.1002/j.1460-2075.1995.tb07183.x; FERNANDESALNEMRI T, 1995, CANCER RES, V55, P2737; FERNANDESALNEMRI T, 1994, J BIOL CHEM, V269, P30761; GU Y, 1995, J BIOL CHEM, V270, P18715, DOI 10.1074/jbc.270.32.18715; HARLOW E, 1986, MOL CELL BIOL, V6, P1579, DOI 10.1128/MCB.6.5.1579; HARVEY DM, 1991, GENE DEV, V5, P2365; HENGARTNER MO, 1994, CURR OPIN GENET DEV, V4, P581, DOI 10.1016/0959-437X(94)90076-F; JUAREZSALINAS H, 1979, NATURE, V282, P740, DOI 10.1038/282740a0; KAMENS J, 1995, J BIOL CHEM, V270, P15250, DOI 10.1074/jbc.270.25.15250; KAUFMANN SH, 1989, CANCER RES, V49, P5870; KAUFMANN SH, 1993, CANCER RES, V53, P3976; KUMAR S, 1995, TRENDS BIOCHEM SCI, V20, P198, DOI 10.1016/S0968-0004(00)89007-6; KUMAR S, 1994, GENE DEV, V8, P1613, DOI 10.1101/gad.8.14.1613; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; LI P, 1995, CELL, V80, P401, DOI 10.1016/0092-8674(95)90490-5; LOWE SW, 1993, GENE DEV, V7, P535, DOI 10.1101/gad.7.4.535; MARTIN SJ, 1995, CELL, V82, P349, DOI 10.1016/0092-8674(95)90422-0; MCLORIE W, 1991, J GEN VIROL, V72, P1467, DOI 10.1099/0022-1317-72-6-1467; MIURA M, 1993, CELL, V75, P653, DOI 10.1016/0092-8674(93)90486-A; MORAN E, 1987, CELL, V48, P177, DOI 10.1016/0092-8674(87)90418-1; MUNDAY NA, 1995, J BIOL CHEM, V270, P15870, DOI 10.1074/jbc.270.26.15870; MYMRYK JS, 1994, ONCOGENE, V9, P1187; NGUYEN M, 1994, J BIOL CHEM, V269, P16521; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; OLTVAI ZN, 1994, CELL, V79, P189, DOI 10.1016/0092-8674(94)90188-0; RAO L, 1992, P NATL ACAD SCI USA, V89, P7742, DOI 10.1073/pnas.89.16.7742; REED JC, 1994, J CELL BIOL, V124, P1, DOI 10.1083/jcb.124.1.1; TANAKA Y, 1984, J BIOL CHEM, V259, P6579; TEODORO JG, 1995, ONCOGENE, V11, P467; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; THORNBERRY NA, 1992, NATURE, V356, P768, DOI 10.1038/356768a0; WANG L, 1994, CELL, V78, P739, DOI 10.1016/S0092-8674(94)90422-7; WANG ZQ, 1995, GENE DEV, V9, P509, DOI 10.1101/gad.9.5.509; WHITE E, 1992, MOL CELL BIOL, V12, P2570, DOI 10.1128/MCB.12.6.2570; WHITE E, 1991, J VIROL, V65, P2968, DOI 10.1128/JVI.65.6.2968-2978.1991; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; WHYTE P, 1988, J VIROL, V62, P257, DOI 10.1128/JVI.62.1.257-265.1988; WYLLIE AH, 1984, J PATHOL, V142, P67, DOI 10.1002/path.1711420112; YEE SP, 1985, VIROLOGY, V147, P142, DOI 10.1016/0042-6822(85)90234-X; YEW PR, 1994, GENE DEV, V8, P190, DOI 10.1101/gad.8.2.190; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9	52	144	149	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB 1	1996	12	3					529	535						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TV597	8637709				2022-12-25	WOS:A1996TV59700009
J	Panagopoulos, I; Hoglund, M; Mertens, F; Mandahl, N; Mitelman, F; Aman, P				Panagopoulos, I; Hoglund, M; Mertens, F; Mandahl, N; Mitelman, F; Aman, P			Fusion of the EWS and CHOP genes in myxoid liposarcoma	ONCOGENE			English	Article						myxoid liposarcoma; translocation; EWS gene; CHOP gene; PCR; fusion gene	TRANSLOCATION; TUMORS	The translocation t(12;16)(q13;pll), which cytogenetically characterizes myxoid liposarcomas (MLS), results in a fusion of the CHOP gene in 12q13 and the I;US gene in 16p11, creating a chimeric FUS/CHOP gene. We have identified two cases of MLS with translocations giving rise to recombination between 12q13 and 22q12. The result was a fusion of the N-terminal part of the EWS gene in 22q12, involved in a number of mesenchymal tumor types, with the CHOP gene and the creation of an EWS/CHOP chimeric gene. The presence of the EWS/CHOP chimeric gene in MLS Shows that (i) the N-terminal part of FUS may be replaced by the N-terminal part of EWS in a CHOP fusion oncoprotein (ii) the two N-terminal parts, when fused to certain transcription factors, have a common or very similar oncogenic potential and (iii) the tumorigenic process in MLS and the morphogenetically distinctly different EWS-associated tumor types may be related.			Panagopoulos, I (corresponding author), UNIV LUND HOSP,DEPT CLIN GENET,S-22185 LUND,SWEDEN.			Panagopoulos, Ioannis/0000-0003-2159-5341; Aman, Pierre/0000-0002-1482-8875; Hoglund, Mattias/0000-0001-9283-4421; Mitelman, Felix/0000-0002-3757-7212; Mertens, Fredrik/0000-0002-6278-5232				AMAN P, 1992, GENE CHROMOSOME CANC, V5, P278, DOI 10.1002/gcc.2870050403; CROZAT A, 1993, NATURE, V363, P640, DOI 10.1038/363640a0; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; GERALD WL, 1995, P NATL ACAD SCI USA, V92, P1028, DOI 10.1073/pnas.92.4.1028; GIOVANNINI M, 1994, J CLIN INVEST, V94, P489, DOI 10.1172/JCI117360; ICHIKAWA H, 1994, CANCER RES, V54, P2865; JEON IS, 1995, ONCOGENE, V10, P1229; LADANYI M, 1994, CANCER RES, V54, P2837; MANDAHL N, 1988, HUM GENET, V79, P203, DOI 10.1007/BF00366238; PANAGOPOULOS I, 1994, GENE CHROMOSOME CANC, V11, P256, DOI 10.1002/gcc.2870110408; PANAGOPOULOS I, 1994, CANCER RES, V54, P6500; PARK JS, 1992, GENE, V116, P259, DOI 10.1016/0378-1119(92)90523-R; PLOUGASTEL B, 1993, GENOMICS, V18, P609, DOI 10.1016/S0888-7543(05)80363-5; RABBITTS TH, 1993, NAT GENET, V4, P175, DOI 10.1038/ng0693-175; SORENSEN PHB, 1994, NAT GENET, V6, P146, DOI 10.1038/ng0294-146; ZINSZNER H, 1994, GENE DEV, V8, P2513, DOI 10.1101/gad.8.21.2513; ZUCMAN J, 1993, NAT GENET, V4, P341, DOI 10.1038/ng0893-341; ZUCMAN J, 1993, EMBO J, V12, P4481, DOI 10.1002/j.1460-2075.1993.tb06137.x; 1991, GUIDELINES CANCER CY	19	223	233	1	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB 1	1996	12	3					489	494						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TV597	8637704				2022-12-25	WOS:A1996TV59700004
J	Shimazaki, Y; Nishiki, T; Omori, A; Sekiguchi, M; Kamata, Y; Kozaki, S; Takahashi, M				Shimazaki, Y; Nishiki, T; Omori, A; Sekiguchi, M; Kamata, Y; Kozaki, S; Takahashi, M			Phosphorylation of 25-kDa synaptosome-associated protein - Possible involvement in protein kinase C-mediated regulation of neurotransmitter release	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LONG-TERM POTENTIATION; PC12 CELLS; IDENTIFICATION; SYNAPTOTAGMIN; ACTIVATION; RECEPTORS; CALCIUM; FAMILY; FUSION	Protein kinase C-mediated phosphorylation of a 25-kDa synaptosome-associated protein (SNAP-25) was examined in living PC12 cells, Phorbol 12-myristate 13 acetate treatment enhanced high potassium-induced [H-3]-norepinephrine release, and a 28-kDa protein recognized by an anti-SNAP-25 antibody was phosphorylated on Ser residues. The molecular size of the phosphorylated band decreased slightly following treatment with Clostridium botulinum type A neurotoxin, whereas the band disappeared after treatment with botulinum type E neurotoxin, indicating that the 28-kDa protein was SNAP-25, A phosphorylation is likely to occur at Ser(187), as this is the only Ser residue located between the cleavage sites of botulinum type A and E neurotoxins, SNAP-25 of PC12 cells was phosphorylated by purified protein kinase C in vitro, and the amount of syntaxin co immunoprecipitated with SNAP-25 was decreased by phosphorylation, These results suggest that the phosphorylation of SNAP-25 may be involved in protein kinase C-mediated regulation of catecholamine release from PC12 cells.	MITSUBISHI KASEI INST LIFE SCI,MACHIDA,TOKYO 194,JAPAN; UNIV OSAKA PREFECTURE,COLL AGR,DEPT VET SCI,SAKAI,OSAKA 593,JAPAN	Osaka Metropolitan University								BENNETT MK, 1993, CELL, V74, P863, DOI 10.1016/0092-8674(93)90466-4; BENNETT MK, 1993, J NEUROSCI, V13, P1701; BINZ T, 1994, J BIOL CHEM, V269, P1617; BLACKSHEAR PJ, 1993, J BIOL CHEM, V268, P1501; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; CHAPMAN ER, 1994, J BIOL CHEM, V269, P27427; COGGINS PJ, 1991, J NEUROCHEM, V56, P1095, DOI 10.1111/j.1471-4159.1991.tb11398.x; FERRONOVICK S, 1994, NATURE, V370, P191, DOI 10.1038/370191a0; HAYASHI T, 1994, EMBO J, V13, P5051, DOI 10.1002/j.1460-2075.1994.tb06834.x; HIGASHI H, 1992, J BIOL CHEM, V267, P9831; HUNT JM, 1994, NEURON, V12, P1269, DOI 10.1016/0896-6273(94)90443-X; ISOSAKI M, 1994, JPN J PHARMACOL, V64, P217, DOI 10.1254/jjp.64.217; KENNELLY PJ, 1991, J BIOL CHEM, V266, P15555; KITAMURA M, 1968, BIOCHIM BIOPHYS ACTA, V168, P207, DOI 10.1016/0005-2795(68)90144-X; MALINOW R, 1988, NATURE, V335, P820, DOI 10.1038/335820a0; MILLER RJ, 1985, TRENDS NEUROSCI, V8, P463, DOI 10.1016/0166-2236(85)90169-9; MITSUI K, 1990, FEBS LETT, V268, P157, DOI 10.1016/0014-5793(90)80997-W; MONTECUCCO C, 1994, MOL MICROBIOL, V13, P1, DOI 10.1111/j.1365-2958.1994.tb00396.x; NICOLL RA, 1995, NATURE, V377, P115, DOI 10.1038/377115a0; Niemann Heiner, 1994, Trends in Cell Biology, V4, P179, DOI 10.1016/0962-8924(94)90203-8; NISHIKI T, 1994, J BIOL CHEM, V269, P10498; OHO C, 1995, NEUROSCI LETT, V186, P208, DOI 10.1016/0304-3940(95)11317-P; OYLER GA, 1989, J CELL BIOL, V109, P3039, DOI 10.1083/jcb.109.6.3039; POZZAN T, 1984, J CELL BIOL, V99, P628, DOI 10.1083/jcb.99.2.628; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; SCHELLER RH, 1995, NEURON, V14, P893; SCHIAVO G, 1993, FEBS LETT, V335, P99, DOI 10.1016/0014-5793(93)80448-4; SHOJIKASAI Y, 1992, SCIENCE, V256, P1820, DOI 10.1126/science.256.5065.1820; SHOJIKASAI Y, 1994, FEBS LETT, V353, P315, DOI 10.1016/0014-5793(94)01069-2; SOLLNER T, 1993, CELL, V75, P409, DOI 10.1016/0092-8674(93)90376-2; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; SUDHOF TC, 1995, NATURE, V375, P645, DOI 10.1038/375645a0; SUGII S, 1975, INFECT IMMUN, V12, P1262, DOI 10.1128/IAI.12.6.1262-1270.1975; TAKAHASHI M, 1989, BIOCHEM BIOPH RES CO, V163, P1182, DOI 10.1016/0006-291X(89)92345-0; TAKAHASHI M, 1991, BRAIN RES, V551, P279, DOI 10.1016/0006-8993(91)90942-O; YOSHIDA A, 1992, J BIOL CHEM, V267, P24925	36	215	222	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 14	1996	271	24					14548	14553		10.1074/jbc.271.24.14548	http://dx.doi.org/10.1074/jbc.271.24.14548			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UQ660	8662851	hybrid			2022-12-25	WOS:A1996UQ66000090
J	Jakus, J; Yeudall, WA				Jakus, J; Yeudall, WA			Growth inhibitory concentrations of EGF induce p21 (WAF1/Cip1) and alter cell cycle control in squamous carcinoma cells	ONCOGENE			English	Article						epidermal growth factor; p21; WAF1; Cip1; PCNA; cyclin dependent kinase	HUMAN EPIDERMOID CARCINOMA; DEPENDENT KINASES; A431 CELLS; RECEPTOR; CULTURE; PROTEIN; HEAD; NECK; DIFFERENTIATION; OVEREXPRESSION	Previous studies have reported inhibition of A431 squamous carcinoma cell growth by nanomolar concentrations of epidermal growth factor (EGF), a potent mitogen for cells of epithelial origin, In this study, we examined potential mechanisms through which inhibition of keratinocyte growth mediated by EGF might occur by analysing components of the cell cycle regulatory machinery in A431, HN6 and HN30 keratinocytes in the presence of growth inhibitory or growth stimulatory doses of EGF, Treatment of cells with 25 pM EGF produced an increase in [H-3]thymidine incorporation in A431, HN6 and HN30 cells, with respect to control cultures, Exposure to 2.5 nM EGF reduced [H-3]thymidine incorporation in A431 cells and HN6 cells to 11% and 70% of control levels, respectively, whereas HN30 cells continued to proliferate in the presence of EGF, [H-3]thymidine incorporation assays carried out over 24 h revealed repression of DNA synthesis in A431 cells after 12 h exposure to 2.5 nM EGF compared to untreated cells, Flow cytometry studies demonstrated accumulation of cells in G(0)/G(1) after addition of 2.5 nM, but not 25 pM EGF, Western blot analysis revealed elevation of p21 (WAF1/CIP1/SDI1) protein levels in A431 and HN6 cells under growth-inhibitory conditions, Stimulatory doses of EGF did not induce p21 in these cells, Northern blot hybridization demonstrated elevated levels of p21 mRNA within 4 h of exposure of A431 cells to 2.5 nM EGF, which remained elevated above basal levels at 24 h, In vitro kinase assays demonstrated temporal differences in CDK2, and CDK6 activities which were related to EGF concentration, Immunocomplex Western blotting demonstrated increased association of p21 with CDK2 and CDK6 in A431 cells treated with 2.5 nM EGF, Furthermore, temporal alterations in the association of PCNA with p21 and with CDK6 were observed, The data indicate that p21 is a likely mediator of EGF-induced growth-inhibition, probably through mechanisms involving sequestration of PCNA and inhibition of CDK activity.	NIDR,CELLULAR DEV & ONCOL LAB,MOLEC CARCINOGENESIS GRP,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)								BARNES DW, 1982, J CELL BIOL, V93, P1, DOI 10.1083/jcb.93.1.1; BRAVO R, 1985, EMBO J, V4, P1193, DOI 10.1002/j.1460-2075.1985.tb03759.x; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; BUSS JE, 1982, P NATL ACAD SCI-BIOL, V79, P2574, DOI 10.1073/pnas.79.8.2574; CARDINALI M, 1995, INT J CANCER, V61, P98, DOI 10.1002/ijc.2910610117; CARPENTER G, 1979, ANNU REV BIOCHEM, V48, P193, DOI 10.1146/annurev.bi.48.070179.001205; CARPENTER G, 1987, ANNU REV BIOCHEM, V56, P881, DOI 10.1146/annurev.biochem.56.1.881; DIFIORE PP, 1987, CELL, V51, P1063, DOI 10.1016/0092-8674(87)90592-7; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FABRICANT RN, 1977, P NATL ACAD SCI USA, V74, P565, DOI 10.1073/pnas.74.2.565; GAME SM, 1992, INT J CANCER, V52, P461, DOI 10.1002/ijc.2910520322; GILL GN, 1981, NATURE, V293, P305, DOI 10.1038/293305a0; HALEVY O, 1995, SCIENCE, V267, P1018, DOI 10.1126/science.7863327; Harlow E., 1989, ANTIBODIES LAB MANUA; HARPER JW, 1993, CELL, V75, P805; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; ISHITOYA J, 1989, BRIT J CANCER, V59, P559, DOI 10.1038/bjc.1989.113; JIANG HP, 1994, ONCOGENE, V9, P3397; KEARSLEY JH, 1990, BRIT J CANCER, V61, P821, DOI 10.1038/bjc.1990.184; KONGER RL, 1993, J CELL PHYSIOL, V156, P515, DOI 10.1002/jcp.1041560310; LI R, 1994, NATURE, V371, P534, DOI 10.1038/371534a0; LI Y, 1994, ONCOGENE, V9, P2261; MERLINO GT, 1984, SCIENCE, V224, P417, DOI 10.1126/science.6200934; MICHIELI P, 1994, CANCER RES, V54, P3391; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; NURSE P, 1994, CELL, V79, P547, DOI 10.1016/0092-8674(94)90539-8; OZANNE B, 1986, J PATHOL, V149, P9, DOI 10.1002/path.1711490104; PARKER SB, 1995, SCIENCE, V267, P1024, DOI 10.1126/science.7863329; PRIME SS, 1994, BRIT J CANCER, V69, P8, DOI 10.1038/bjc.1994.2; RHEINWALD JG, 1977, NATURE, V265, P421, DOI 10.1038/265421a0; ROSDY M, 1988, IN VITRO CELL DEV, V22, P295; SACHS L, 1987, CANCER RES, V47, P1981; SKAPEK SX, 1995, SCIENCE, V267, P1022, DOI 10.1126/science.7863328; SOMERS KD, 1992, CANCER RES, V52, P5997; STANTON P, 1994, BRIT J CANCER, V70, P427, DOI 10.1038/bjc.1994.322; STEINMAN RA, 1994, ONCOGENE, V9, P3389; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; WAGA S, 1994, NATURE, V369, P207, DOI 10.1038/369207a0; WIRTH PJ, 1987, CANCER RES, V47, P2831; XIONG Y, 1993, GENE DEV, V7, P1572, DOI 10.1101/gad.7.8.1572; YEUDALL WA, 1994, CARCINOGENESIS, V15, P2683, DOI 10.1093/carcin/15.12.2683	42	85	86	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN 6	1996	12	11					2369	2376						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UQ220	8649777				2022-12-25	WOS:A1996UQ22000014
J	AlRabiee, R; Lee, EJ; Grant, GA				AlRabiee, R; Lee, EJ; Grant, GA			The mechanism of velocity modulated allosteric regulation in D-3-phosphoglycerate dehydrogenase - Cross-linking adjacent regulatory domains with engineered disulfides mimics effector binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article								D-3-Phosphoglycerate dehydrogenase (PGDH) (EC 1.1.1.95) from Escherichia coli is an allosterically regulated enzyme of the V-max type, It is a tetramer of identical subunits and each subunit is made up of three identifiable domains, the cofactor binding domain, the substrate binding domain, and the regulatory domain, Each subunit contacts two other subunits through adjacent cofactor binding domains and through adjacent regulatory domains, L-Serine, the physiological effector, inhibits catalytic activity by apparently tethering regulatory domains from adjacent subunits together through the formation of hydrogen bonds to each subunit, This investigation demonstrates that cross-linking adjacent regulatory domains with engineered disulfides produces catalytic inhibition in the absence of inhibitor in a manner similar to that produced by the inhibitor, The inhibition due to cross-linking can be completely reversed in a concentration dependent manner by dithiothreitol, The active mutant enzyme, containing the engineered cysteines in the reduced state, retains its ability to be inhibited by L-serine, although at a 100-fold higher concentration, Hill plots of the serine inhibition of mutant and native enzyme indicate that the number of interacting sites remains at 2 in the mutant enzyme, The reversible inhibition of enzyme activity that results from tethering adjacent regulatory domains with engineered disulfides suggests that these domains move in some manner relative to one another during the active to inhibited state transition, These observations support the model which predicts that catalytic activity is regulated by the movement of rigid domains about flexible hinges and that effector binding prevents this by locking the regulatory domains in a state that produces an open active site cleft.	WASHINGTON UNIV,SCH MED,DEPT MOLEC BIOL & PHARMACOL,ST LOUIS,MO 63110	Washington University (WUSTL)								CORMACK B, 1991, CURRENT PROTOCOLS MO; CRANKSHAW MW, 1996, CURRENT PROTOCOLS PR; EHRLICH JI, 1994, BIOCHEMISTRY-US, V33, P8890, DOI 10.1021/bi00196a005; Grant GA, 1996, PROTEIN SCI, V5, P34; HURLEY JH, 1993, SCIENCE, V259, P673, DOI 10.1126/science.8430315; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIU WZ, 1994, BIOCHEMISTRY-US, V33, P10120, DOI 10.1021/bi00199a040; PHILLIPS NFB, 1992, BIOCHEMISTRY-US, V31, P9445, DOI 10.1021/bi00154a017; RODRIGUEZAPARICIO LB, 1989, BIOCHEMISTRY-US, V28, P3070, DOI 10.1021/bi00433a050; SCHRAMM VL, 1974, J BIOL CHEM, V249, P1729; SCHULLER DJ, 1995, NAT STRUCT BIOL, V2, P69, DOI 10.1038/nsb0195-69; SCHULLER DJ, 1989, J BIOL CHEM, V264, P2645; SUGIMOTO E, 1968, J BIOL CHEM, V243, P2090; SUGIMOTO E, 1968, J BIOL CHEM, V243, P2081; TOBEY KL, 1986, J BIOL CHEM, V261, P2179	15	34	39	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 31	1996	271	22					13013	13017		10.1074/jbc.271.22.13013	http://dx.doi.org/10.1074/jbc.271.22.13013			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UN474	8662776	hybrid			2022-12-25	WOS:A1996UN47400052
J	Gedrich, RW; Gilfillan, MC; Duckett, CS; VanDongen, JL; Thompson, CB				Gedrich, RW; Gilfillan, MC; Duckett, CS; VanDongen, JL; Thompson, CB			CD30 contains two binding sites with different specificities for members of the tumor necrosis factor receptor-associated factor family of signal transducing proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REED-STERNBERG CELLS; HODGKINS-DISEASE; MONOCLONAL-ANTIBODY; LYMPHOID-CELLS; KI-1 ANTIGEN; SUBSET; EXPRESSION; ACTIVATION; MOLECULE; DEFINES	CD30 is a member of the tumor necrosis factor (TNF) receptor family of proteins. CD30 can regulate proliferation of lymphocytes and may also play an important role in human immunodeficiency virus replication, However, little is known about CD30 signal transduction. We performed a yeast two-hybrid library screen with the cytoplasmic domain of CD30 and isolated multiple independent cDNAs encoding human tumor necrosis factor receptor-associated factor (TRAF) 1, TRAF2, and GRAF1 (TRAF3). The ability of TRAF1, TRAF2, and CRAF1 to associate with CD30 was confirmed using an in vitro coprecipitation assay, further demonstrating that the interaction was specific and direct. The TRAF-binding domain of CD30 was mapped to the COOH-terminal 36 amino acid residues, which contained two independent binding sites. CRAF1 bound only a single site, which contained the sequence PEQET, whereas TRAF1 and TRAF2 were capable of binding to either the PEQET site or an additional downstream domain. These data indicate that the TRSF protein binding pattern of CD30 differs from other TNF receptor family members and suggest that signaling specificity through TNF receptor family proteins may be achieved through differences in their abilities to bind TRAF proteins.	UNIV CHICAGO,GWEN KNAPP CTR LUPUS & IMMUNOL RES,DEPT MED,CHICAGO,IL 60637; UNIV CHICAGO,COMM IMMUNOL,CHICAGO,IL 60637; UNIV CHICAGO,HOWARD HUGHES MED INST,DEPT MOLEC GENET & CELL BIOL,CHICAGO,IL 60637	University of Chicago; University of Chicago; Howard Hughes Medical Institute; University of Chicago				Duckett, Colin/0000-0001-9413-2263	NIAID NIH HHS [P01 AI35294] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI035294] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ANDREESEN R, 1984, BLOOD, V63, P1299; BANCHEREAU J, 1994, ANNU REV IMMUNOL, V12, P881, DOI 10.1146/annurev.iy.12.040194.004313; BERBERICH I, 1994, J IMMUNOL, V153, P4357; BISWAS P, 1995, IMMUNITY, V2, P587; CHENG GH, 1995, SCIENCE, V267, P1494, DOI 10.1126/science.7533327; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; CHOI MSK, 1995, EUR J IMMUNOL, V25, P1352, DOI 10.1002/eji.1830250533; CLEVELAND JL, 1995, CELL, V81, P479, DOI 10.1016/0092-8674(95)90068-3; DELPRETE G, 1995, IMMUNOL TODAY, V16, P76, DOI 10.1016/0167-5699(95)80092-1; DELPRETE G, 1995, J EXP MED, V182, P1655, DOI 10.1084/jem.182.6.1655; DELPRETE G, 1995, FASEB J, V9, P81, DOI 10.1096/fasebj.9.1.7821763; DUCKETT CS, 1996, IN PRESS EMBO J; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; DURKOP H, 1992, CELL, V68, P421, DOI 10.1016/0092-8674(92)90180-K; ELLIS TM, 1993, J IMMUNOL, V151, P2380; FALINI B, 1995, BLOOD, V85, P1; FROESE P, 1987, J IMMUNOL, V139, P2081; GRUSS HJ, 1994, BLOOD, V83, P2045; GRUSS HJ, 1995, BLOOD, V85, P3378, DOI 10.1182/blood.V85.12.3378.bloodjournal85123378; Hay BA, 1995, CELL, V83, P1253, DOI 10.1016/0092-8674(95)90150-7; HECHT TT, 1985, J IMMUNOL, V134, P4231; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; HU HM, 1994, J BIOL CHEM, V269, P30069; INUI S, 1990, EUR J IMMUNOL, V20, P1747, DOI 10.1002/eji.1830200819; ISHIDA T, 1995, J IMMUNOL, V155, P5527; IVASHKIV LB, 1995, IMMUNITY, V3, P1, DOI 10.1016/1074-7613(95)90152-3; JOSIMOVICALASEVIC O, 1989, EUR J IMMUNOL, V19, P157, DOI 10.1002/eji.1830190125; KIM YJ, 1993, J IMMUNOL, V151, P1255; LAEGREID A, 1994, J BIOL CHEM, V269, P7785; LEWIS BA, 1995, J VIROL, V69, P1628, DOI 10.1128/JVI.69.3.1628-1636.1995; Liston P, 1996, NATURE, V379, P349, DOI 10.1038/379349a0; MAGGI E, 1995, IMMUNITY, V3, P251, DOI 10.1016/1074-7613(95)90094-2; MANETTI R, 1994, J EXP MED, V180, P2407, DOI 10.1084/jem.180.6.2407; MCDONALD PP, 1995, EUR J IMMUNOL, V25, P2870, DOI 10.1002/eji.1830251024; MOSIALOS G, 1995, CELL, V80, P389, DOI 10.1016/0092-8674(95)90489-1; NAWROCKI JF, 1988, J IMMUNOL, V141, P672; PFREUNDSCHUH M, 1988, ANTICANCER RES, V8, P217; REGNIER CH, 1995, J BIOL CHEM, V270, P25715, DOI 10.1074/jbc.270.43.25715; Rothe M, 1995, CELL, V83, P1243, DOI 10.1016/0092-8674(95)90149-3; ROTHE M, 1995, SCIENCE, V269, P1424, DOI 10.1126/science.7544915; ROTHE M, 1994, CELL, V78, P681, DOI 10.1016/0092-8674(94)90532-0; SARMA V, 1995, J BIOL CHEM, V270, P12343, DOI 10.1074/jbc.270.21.12343; SATO T, 1995, FEBS LETT, V358, P113, DOI 10.1016/0014-5793(94)01406-Q; SCHWAB U, 1982, NATURE, V299, P65, DOI 10.1038/299065a0; SCHWARTING R, 1989, BLOOD, V74, P1678; SMITH CA, 1993, CELL, V73, P1349, DOI 10.1016/0092-8674(93)90361-S; SONG HY, 1995, EUR J IMMUNOL, V309, P825; STANGER BZ, 1995, CELL, V81, P513, DOI 10.1016/0092-8674(95)90072-1; STEIN H, 1985, BLOOD, V66, P848; TARTAGLIA LA, 1991, P NATL ACAD SCI USA, V88, P9292, DOI 10.1073/pnas.88.20.9292; TARTAGLIA LA, 1993, J IMMUNOL, V151, P4637; TSUBATA T, 1993, NATURE, V364, P645, DOI 10.1038/364645a0	52	149	152	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 31	1996	271	22					12852	12858		10.1074/jbc.271.22.12852	http://dx.doi.org/10.1074/jbc.271.22.12852			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UN474	8662842	hybrid			2022-12-25	WOS:A1996UN47400027
J	Hartmann, T; Bergsdorf, C; Sandbrink, R; Tienari, PJ; Multhaup, G; Ida, N; Bieger, S; Dyrks, T; Weidemann, A; Masters, CL; Beyreuther, K				Hartmann, T; Bergsdorf, C; Sandbrink, R; Tienari, PJ; Multhaup, G; Ida, N; Bieger, S; Dyrks, T; Weidemann, A; Masters, CL; Beyreuther, K			Alzheimer's disease beta A4 protein release and amyloid precursor protein sorting are regulated by alternative splicing	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IDENTIFICATION; LOCALIZATION; BIOGENESIS; EXPRESSION; PEPTIDE; CELLS	We show here that alternative splicing influences the polarized secretion of amyloid precursor protein (APP) as well as the release of its proteolytic 3-4-kDa fragments beta A4 and p3. In Madin-Darby canine kidney II cells stably transfected with various APP isoforms and APP mutants, APPsec was consistently secreted basolaterally. In contrast, Madin-Darby canine kidney II cells transfected with L-APP677, which occurs naturally by alternative splicing of exon 15, secreted this isoform both apically and basolaterally, while maintaining the basolateral sorting of endogenous APPsec. This suggests that the alternative splicing of APP exon 15 modulates the polarized sorting of secretory APP. The same alternative splicing event also decreased the production of beta A4 relative to p3. This is the first example of alternative splicing regulating polarized trafficking of a secretory protein.	UNIV HEIDELBERG,DEPT ANAT & CELL BIOL,D-69120 HEIDELBERG,GERMANY; SCHERING AG,D-13353 BERLIN,GERMANY; UNIV MELBOURNE,DEPT PATHOL,MELBOURNE,VIC 3052,AUSTRALIA	Ruprecht Karls University Heidelberg; Schering AG; University of Melbourne	Hartmann, T (corresponding author), UNIV HEIDELBERG,ZENTRUM MOLEK BIOL,INF 282,D-69120 HEIDELBERG,GERMANY.		Hartmann, Tobias/AAB-8297-2022; Tienari, Pentti J/A-4893-2012	Hartmann, Tobias/0000-0001-7481-6430				CHANAT E, 1993, EMBO J, V12, P2159, DOI 10.1002/j.1460-2075.1993.tb05864.x; DESTROOPER B, 1995, J BIOL CHEM, V270, P4058, DOI 10.1074/jbc.270.8.4058; DYRKS T, 1992, J BIOL CHEM, V267, P18210; DYRKS T, 1988, EMBO J, V7, P949, DOI 10.1002/j.1460-2075.1988.tb02900.x; DYRKS T, 1993, FEBS LETT, V335, P89, DOI 10.1016/0014-5793(93)80446-2; EVIN G, 1994, AMYLOID, V1, P263, DOI 10.3109/13506129409146118; FIEDLER K, 1995, CELL, V81, P309, DOI 10.1016/0092-8674(95)90380-1; HAASS C, 1993, CELL, V75, P1039, DOI 10.1016/0092-8674(93)90312-E; HAASS C, 1993, J BIOL CHEM, V268, P3021; HAASS C, 1995, J CELL BIOL, V128, P537, DOI 10.1083/jcb.128.4.537; HAASS C, 1994, P NATL ACAD SCI USA, V91, P1564, DOI 10.1073/pnas.91.4.1564; HARTMANN T, 1994, NEUROBIOL AGING, V15, P551; HILBICH C, 1993, J BIOL CHEM, V268, P26571; HUNZIKER W, 1989, J CELL BIOL, V109, P3291, DOI 10.1083/jcb.109.6.3291; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; KONIG G, 1992, J BIOL CHEM, V267, P10804; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE ACY, 1995, J BIOL CHEM, V270, P12641; LO ACY, 1994, J BIOL CHEM, V269, P30966; MARUYAMA K, 1994, BIOCHEM BIOPH RES CO, V202, P1517, DOI 10.1006/bbrc.1994.2103; MATTER K, 1994, J CELL BIOL, V126, P991, DOI 10.1083/jcb.126.4.991; MULLER G, 1988, EMBO J, V7, P2723, DOI 10.1002/j.1460-2075.1988.tb03126.x; PANGALOS MN, 1995, J BIOL CHEM, V270, P10388, DOI 10.1074/jbc.270.18.10388; Sandbrink R, 1996, ANN NY ACAD SCI, V777, P281, DOI 10.1111/j.1749-6632.1996.tb34433.x; SANDBRINK R, 1994, J BIOL CHEM, V269, P14227; SANDBRINK R, 1994, J BIOL CHEM, V269, P1510; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SELKOE DJ, 1994, J NEUROPATH EXP NEUR, V53, P438, DOI 10.1097/00005072-199409000-00003; SHIOI J, 1995, J BIOL CHEM, V270, P11839, DOI 10.1074/jbc.270.20.11839; SIMONS K, 1994, CELL BIOL LAB HDB, V1, P225; THINAKARAN G, 1994, J BIOL CHEM, V269, P22099; WASCO W, 1993, NAT GENET, V5, P95, DOI 10.1038/ng0993-95; WEIDEMANN A, 1989, CELL, V57, P115, DOI 10.1016/0092-8674(89)90177-3	33	30	32	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 31	1996	271	22					13208	13214		10.1074/jbc.271.22.13208	http://dx.doi.org/10.1074/jbc.271.22.13208			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UN474	8662794	hybrid			2022-12-25	WOS:A1996UN47400080
J	Blanchoin, L; Didry, D; Carlier, MF; Pantaloni, D				Blanchoin, L; Didry, D; Carlier, MF; Pantaloni, D			Kinetics of association of myosin subfragment-1 to unlabeled and pyrenyl-labeled actin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RABBIT SKELETAL-MUSCLE; F-ACTIN; TROPONIN-TROPOMYOSIN; HEAVY-MEROMYOSIN; BINDING; COMPLEX; ABSENCE; POLYMERIZATION; CONTRACTION; INTERACTS	The kinetics of reaction of myosin subfragment-1 (S-1) with F-actin have been monitored by the changes in light scattering and in pyrenyl-actin fluorescence at 20 degrees C, pH 7.5, and physiological ionic strength. The association rate constant of S-1 to F-actin decreases about 10-fold as the molar ratio of bound S-1 increases from 0 to 1. This decrease in k(+) is most likely due to the steric hindrance of available binding sites by initially bound S-1. The apparent rate constant for association of S-1 to bare filaments is 9 mu M(-1) s(-1), a value 1 order of magnitude higher than the one previously estimated from experiments in which S-1 was in excess over F-actin. The anticooperative binding kinetics of S-1 to F-actin are consistent with the negative cooperativity displayed in the equilibrium binding curves of S-1 to pyrenyl-F-actin. Fluorescence titration curves of partially labeled pyrenyl-F-actin by S-1 are sigmoidal, consistent with a 4-fold higher affinity of S-1 for unlabeled than for labeled actin. This conclusion is strengthened by kinetic data of S-1 binding to partially labeled F-actin, which exhibit a biphasic behavior due to the slower dissociation of S-1 from unlabeled than from labeled actin.	CNRS,ENZYMOL LAB,F-91198 GIF SUR YVETTE,FRANCE	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay								ANDREEV OA, 1992, J MUSCLE RES CELL M, V13, P523, DOI 10.1007/BF01737995; ANDREEV OA, 1993, BIOPHYS J, V65, P1027, DOI 10.1016/S0006-3495(93)81161-5; ANDREEV OA, 1993, BIOCHEMISTRY-US, V32, P12046, DOI 10.1021/bi00096a015; ARATA T, 1991, J BIOCHEM-TOKYO, V109, P335; BLANCHOIN L, 1995, J BIOL CHEM, V270, P7125, DOI 10.1074/jbc.270.13.7125; CANTOR CR, 1980, BIOPHYSICAL CHEM 3, P861; CARLIER MF, 1994, J BIOL CHEM, V269, P3829; COATES JH, 1985, BIOCHEM J, V232, P351, DOI 10.1042/bj2320351; COMBEAU C, 1992, J BIOL CHEM, V267, P14038; CRIDDLE AH, 1985, BIOCHEM J, V232, P343, DOI 10.1042/bj2320343; ELZINGA M, 1984, P NATL ACAD SCI-BIOL, V81, P6599, DOI 10.1073/pnas.81.21.6599; FINLAYSON B, 1969, BIOCHEMISTRY-US, V8, P811, DOI 10.1021/bi00831a008; GEEVES MA, 1982, FEBS LETT, V140, P11, DOI 10.1016/0014-5793(82)80509-7; GORDON DJ, 1976, J BIOL CHEM, V251, P7474; GREENE LE, 1982, FEBS LETT, V139, P233, DOI 10.1016/0014-5793(82)80859-4; INOUE A, 1972, J BIOCHEM-TOKYO, V74, P923; KABSCH W, 1990, NATURE, V347, P37, DOI 10.1038/347037a0; KNIGHT P, 1980, BIOCHEMISTRY-US, V19, P4682, DOI 10.1021/bi00561a022; KOUYAMA T, 1981, EUR J BIOCHEM, V114, P33; LORENZ M, 1995, J MOL BIOL, V246, P108, DOI 10.1006/jmbi.1994.0070; MARGOSSIAN SS, 1973, J MOL BIOL, V74, P313, DOI 10.1016/0022-2836(73)90376-8; MARGOSSIAN SS, 1982, METHOD ENZYMOL, V85, P55; MARSTON S, 1975, BIOCHEMISTRY-US, V14, P3868, DOI 10.1021/bi00688a021; MCLEANFLETCHER S, 1980, BIOCHEM BIOPH RES CO, V96, P18; MIKI M, 1976, FEBS LETT, V66, P98, DOI 10.1016/0014-5793(76)80594-7; MOCKRIN SC, 1980, BIOCHEMISTRY-US, V19, P5359, DOI 10.1021/bi00564a033; MORNET D, 1981, BIOCHEMISTRY-US, V20, P2110, DOI 10.1021/bi00511a007; RAYMENT I, 1993, SCIENCE, V261, P58, DOI 10.1126/science.8316858; RAYMENT I, 1993, SCIENCE, V261, P50, DOI 10.1126/science.8316857; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; TAWADA K, 1969, BIOCHIM BIOPHYS ACTA, V172, P311, DOI 10.1016/0005-2728(69)90073-5; TAYLOR EW, 1991, J BIOL CHEM, V266, P294; TESI C, 1990, BIOCHEMISTRY-US, V29, P1846, DOI 10.1021/bi00459a026; VALENTINRANC C, 1991, J BIOL CHEM, V266, P17872; VIBERT P, 1982, J MOL BIOL, V157, P299, DOI 10.1016/0022-2836(82)90236-4; WHITE HD, 1976, BIOCHEMISTRY-US, V15, P5818, DOI 10.1021/bi00671a020; YAMAMOTO K, 1990, BIOCHEMISTRY-US, V29, P844, DOI 10.1021/bi00455a035; YASUI M, 1984, J BIOCHEM-TOKYO, V96, P1673, DOI 10.1093/oxfordjournals.jbchem.a134999; YOUNG M, 1967, P NATL ACAD SCI USA, V58, P2393, DOI 10.1073/pnas.58.6.2393	39	21	21	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 24	1996	271	21					12380	12386		10.1074/jbc.271.21.12380	http://dx.doi.org/10.1074/jbc.271.21.12380			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UL660	8647841	hybrid			2022-12-25	WOS:A1996UL66000043
J	Banyai, L; Tordai, H; Patthy, L				Banyai, L; Tordai, H; Patthy, L			Structure and domain-domain interactions of the gelatin-binding site of human 72-kiiodalton type IV collagenase (gelatinase A, matrix metalloproteinase 2)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; BOVINE SEMINAL PLASMA; SECONDARY-STRUCTURE; GROWTH-FACTOR; PROTEIN; FIBRONECTIN; PDC-109; METASTASIS; ACTIVATION; INVASION	We have shown previously that all three fibronectin type II modules of gelatinase A contribute to its gelatin affinity. In the present investigation we have studied the structure and module-module interactions of this gelatin-binding domain by circular dichroism spectroscopy and differential scanning calorimetry. Comparison of the T-m values of the thermal transitions of isolated type II modules with those of bimodular or trimodular proteins has shown that the second type II module is significantly more stable in the trimodular protein coll 123 (T-m = 54 degrees C) than in the single-module protein coll 2 (T-m = 44 degrees C) or in the bimodular proteins coll 23 (T-m = 47 degrees C) and coll 12 (T-m = 48 degrees C). Analysis of the enthalpy changes associated with thermal unfolding of the second type II module suggests that it is stabilized by domain-domain interactions in coll 123. We propose that intimate contacts exist between the three tandem type II units and they form a single gelatin-binding site. Based on the three-dimensional structures of homologous metalloproteases and type II modules, a model is proposed in which the three type II units form an extension of the substrate binding cleft of gelatinase A.	HUNGARIAN ACAD SCI,BIOL RES CTR,INST ENZYMOL,H-1518 BUDAPEST,HUNGARY	Hungarian Academy of Sciences; Hungarian Biological Research Center; Hungarian Research Centre for Natural Sciences			Patthy, Laszlo/A-2353-2013; Patthy, Laszlo/Q-6058-2019	Tordai, Hedvig/0000-0002-0875-5569				ALLAN JA, 1995, BIOCHEM J, V309, P299, DOI 10.1042/bj3090299; BANYAI L, 1991, FEBS LETT, V282, P23, DOI 10.1016/0014-5793(91)80436-7; BANYAI L, 1994, BIOCHEM J, V298, P403, DOI 10.1042/bj2980403; BODE W, 1994, EMBO J, V13, P1263, DOI 10.1002/j.1460-2075.1994.tb06378.x; BORKAKOTI N, 1994, STRUCT BIOL, V1, P106; CASTELLINO FJ, 1986, ARCH BIOCHEM BIOPHYS, V247, P312, DOI 10.1016/0003-9861(86)90589-8; CHANG CT, 1978, ANAL BIOCHEM, V91, P13, DOI 10.1016/0003-2697(78)90812-6; Chou P Y, 1978, Adv Enzymol Relat Areas Mol Biol, V47, P45; COLLIER IE, 1992, J BIOL CHEM, V267, P6776; COLLIER IE, 1988, J BIOL CHEM, V263, P6579; CONSTANTINE KL, 1992, J MOL BIOL, V223, P281, DOI 10.1016/0022-2836(92)90731-X; ESCH FS, 1983, BIOCHEM BIOPH RES CO, V113, P861, DOI 10.1016/0006-291X(83)91078-1; FABER HR, 1995, STRUCTURE, V3, P551, DOI 10.1016/S0969-2126(01)00189-7; FRIDMAN R, 1992, J BIOL CHEM, V267, P15398; GOOLEY PR, 1994, STRUCT BIOL, V1, P111; HE CS, 1989, P NATL ACAD SCI USA, V86, P2632, DOI 10.1073/pnas.86.8.2632; ISHIZAKI J, 1994, J BIOL CHEM, V269, P5897; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI J, 1995, STRUCTURE, V3, P541, DOI 10.1016/S0969-2126(01)00188-5; LIBRACH CL, 1991, J CELL BIOL, V113, P437, DOI 10.1083/jcb.113.2.437; LIOTTA LA, 1991, CELL, V64, P327, DOI 10.1016/0092-8674(91)90642-C; LOVEJOY B, 1994, BIOCHEMISTRY-US, V33, P8207, DOI 10.1021/bi00193a006; LOVEJOY B, 1994, SCIENCE, V263, P375, DOI 10.1126/science.8278810; MACH H, 1992, ANAL BIOCHEM, V200, P74, DOI 10.1016/0003-2697(92)90279-G; MATRISIAN LM, 1992, BIOESSAYS, V14, P455, DOI 10.1002/bies.950140705; MCMULLEN BA, 1985, J BIOL CHEM, V260, P5328; MIYAZAWA K, 1993, J BIOL CHEM, V268, P10024; MORGAN DO, 1987, NATURE, V329, P301, DOI 10.1038/329301a0; MURPHY G, 1994, J BIOL CHEM, V269, P6632; MURPHY G, 1992, BIOCHEM J, V283, P637, DOI 10.1042/bj2830637; MURPHY G, 1991, BIOCHEM J, V277, P277, DOI 10.1042/bj2770277; PATTHY L, 1984, FEBS LETT, V171, P131, DOI 10.1016/0014-5793(84)80473-1; PEITSCH MC, 1995, BIO-TECHNOL, V13, P658, DOI 10.1038/nbt0795-658; ROST B, 1994, PROTEINS, V19, P55, DOI 10.1002/prot.340190108; SEIDAH NG, 1987, BIOCHEM J, V243, P195, DOI 10.1042/bj2430195; SENIOR RM, 1991, J BIOL CHEM, V266, P7870; SPURLINO JC, 1994, PROTEINS, V19, P98, DOI 10.1002/prot.340190203; STAMS T, 1994, STRUCT BIOL, V1, P119; STEFFENSEN B, 1995, J BIOL CHEM, V270, P11555, DOI 10.1074/jbc.270.19.11555; STETLERSTEVENSON WG, 1993, FASEB J, V7, P1434, DOI 10.1096/fasebj.7.15.8262328; STOCKER W, 1965, CURR OPIN STRUC BIOL, V5, P383; TAYLOR ME, 1990, J BIOL CHEM, V265, P12156; VASSALLI JD, 1994, NATURE, V370, P14, DOI 10.1038/370014a0; WILHELM SM, 1989, J BIOL CHEM, V264, P17213; YE QZ, 1995, BIOCHEMISTRY-US, V34, P4702, DOI 10.1021/bi00014a026	45	43	44	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 17	1996	271	20					12003	12008		10.1074/jbc.271.20.12003	http://dx.doi.org/10.1074/jbc.271.20.12003			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UL250	8662603	hybrid			2022-12-25	WOS:A1996UL25000064
J	Doring, F; Degtiar, VE; Grabner, M; Striessnig, J; Hering, S; Glossmann, H				Doring, F; Degtiar, VE; Grabner, M; Striessnig, J; Hering, S; Glossmann, H			Transfer of L-type calcium channel IVS6 segment increases phenylalkylamine sensitivity of alpha(1A)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SKELETAL-MUSCLE; FUNCTIONAL EXPRESSION; MESSENGER-RNAS; RECEPTOR; D600; MECHANISM; BLOCKERS; SUBUNIT; HEART; CELLS	Conditioned (''use-dependent'') inhibition by phenylalkylamines (PAAs) is a characteristic property of L-type calcium (Ca2+) channels. To determine the structural elements of the PAA binding domain we transferred sequence stretches of the pore-forming regions of repeat III and/or IV from the skeletal muscle alpha(1) subunit (alpha(1S)) to the class A alpha(1) subunit (alpha(1A)) and expressed these chimeras together with beta(1a) and alpha(2)/delta subunits in Xenopus oocytes. The corresponding barium currents (I-Ba) were tested for PAA sensitivity during trains of depolarizing test pulses (conditioned block). I-Ba of oocytes expressing the alpha(1A) subunit were only weakly inhibited by PAAs (less than 10% conditioned block of I-Ba during a 100-ms pulse train of 0.1 Hz). Transfer of the transmembrane segment IVS6 from alpha(1S) to alpha(1A) produced an enhancement of PAA sensitivity of the resulting alpha(1A)/alpha(1S) chimera comparable to L-type alpha(1) subunits (about 35% conditioned block of I-Ba during a 100-ms pulse train of 0.1 Hz). Our results demonstrate that substitution of 11 amino acids within the segment IVS6 of alpha(1A) with the corresponding residues of alpha(1S) is sufficient to transfer L-type PAA sensitivity into the low sensitive class A Ca2+ channel.	INST BIOCHEM PHARMAKOL, A-6020 INNSBRUCK, AUSTRIA				Glossmann, Hartmut/AAL-9790-2020; Striessnig, Joerg/S-9334-2017	Striessnig, Joerg/0000-0002-9406-7120; Doring, Frank/0000-0003-1017-1498; glossmann, hartmut h./0000-0002-7392-3266				Bezprozvanny Ilya, 1995, Biophysical Journal, V68, pA260; BIRNBAUMER L, 1994, NEURON, V13, P505, DOI 10.1016/0896-6273(94)90021-3; BOURINET E, 1994, EMBO J, V13, P5032, DOI 10.1002/j.1460-2075.1994.tb06832.x; CATTERALL WA, 1992, TRENDS PHARMACOL SCI, V13, P256, DOI 10.1016/0165-6147(92)90079-L; CATTERALL WA, 1995, ANNU REV BIOCHEM, V64, P493, DOI 10.1146/annurev.biochem.64.1.493; DUNLAP K, 1995, TRENDS NEUROSCI, V18, P89, DOI 10.1016/0166-2236(95)93882-X; ELLIS SB, 1988, SCIENCE, V241, P1661, DOI 10.1126/science.2458626; GLOSSMANN H, 1990, REV PHYSIOL BIOCH P, V114, P1; GOLL A, 1986, N-S ARCH PHARMACOL, V334, P303, DOI 10.1007/BF00508786; Grabner M, 1996, NEURON, V16, P207, DOI 10.1016/S0896-6273(00)80037-9; GRABNER M, 1991, P NATL ACAD SCI USA, V88, P727, DOI 10.1073/pnas.88.3.727; HERING S, 1989, CIRC RES, V64, P928, DOI 10.1161/01.RES.64.5.928; HERING S, 1993, METHOD PHARMACOL, V7, P189; Hille B., 1992, IONIC CHANNELS EXCIT; HOCKERMAN GH, 1995, J BIOL CHEM, V270, P22119, DOI 10.1074/jbc.270.38.22119; HOFMANN F, 1994, ANNU REV NEUROSCI, V17, P399, DOI 10.1146/annurev.neuro.17.1.399; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; KRIEG PA, 1984, NUCLEIC ACIDS RES, V12, P7057, DOI 10.1093/nar/12.18.7057; LEE KS, 1983, NATURE, V302, P790, DOI 10.1038/302790a0; MCDONALD TF, 1984, J PHYSIOL-LONDON, V352, P217, DOI 10.1113/jphysiol.1984.sp015288; METHFESSEL C, 1986, PFLUG ARCH EUR J PHY, V407, P577, DOI 10.1007/BF00582635; MIKAMI A, 1989, NATURE, V340, P230, DOI 10.1038/340230a0; MITTERDORFER J, 1994, FEBS LETT, V352, P141, DOI 10.1016/0014-5793(94)00938-4; MORI Y, 1991, NATURE, V350, P398, DOI 10.1038/350398a0; NAKAI J, 1994, P NATL ACAD SCI USA, V91, P1014, DOI 10.1073/pnas.91.3.1014; RUTH P, 1989, SCIENCE, V245, P1115, DOI 10.1126/science.2549640; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SATHER WA, 1993, NEURON, V11, P291, DOI 10.1016/0896-6273(93)90185-T; SNUTCH TP, 1991, NEURON, V7, P45, DOI 10.1016/0896-6273(91)90073-9; STRIESSNIG J, 1990, P NATL ACAD SCI USA, V87, P9108, DOI 10.1073/pnas.87.23.9108; TANABE T, 1987, NATURE, V328, P313, DOI 10.1038/328313a0; TANG SQ, 1993, NEURON, V11, P1013, DOI 10.1016/0896-6273(93)90215-D; WANG ZY, 1995, J PHYSIOL-LONDON, V486, P131, DOI 10.1113/jphysiol.1995.sp020797; ZHANG JF, 1994, NATURE, V372, P97, DOI 10.1038/372097a0	34	47	47	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 17	1996	271	20					11745	11749		10.1074/jbc.271.20.11745	http://dx.doi.org/10.1074/jbc.271.20.11745			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UL250	8662622	hybrid			2022-12-25	WOS:A1996UL25000027
J	Pillinger, MH; Feoktistov, AS; Capodici, C; Solitar, B; Levy, J; Oei, TT; Philips, MR				Pillinger, MH; Feoktistov, AS; Capodici, C; Solitar, B; Levy, J; Oei, TT; Philips, MR			Mitogen-activated protein kinase in neutrophils and enucleate neutrophil cytoplasts - Evidence for regulation of cell-cell adhesion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE EXCHANGE FACTOR; MAP KINASE; POLYMORPHONUCLEAR LEUKOCYTES; TYROSINE PHOSPHORYLATION; RECEPTOR; GRB2; RAS; INSULIN; GRANULOCYTES; INHIBITION	We employed neutrophils and enucleate neutrophil cytoplasts to study the activation of the mitogen-activated protein kinases (MAPKs) p44(erk1) and p42(erk2) in neutrophils by inflammatory agonists that engage G protein-linked receptors. Formyl-methionyl-leucyl-phenylalanine (FMLP) rapidly and transiently activated MAPK in neutrophils and cytoplasts, consistent with a role in signaling for neutrophil functions. FMLP stimulated p21(ras) activation in neutrophils and Raf-1 translocation from cytosol to plasma membrane in cytoplasts, with kinetics consistent with events upstream of MAPK activation. Insulin, a protein tyrosine kinase receptor (PTKR) agonist, stimulated neutrophil MAPK activation, demonstrating an intact system of PTKR signaling in these post-mitotic cells. FMLP- and insulin-stimulated MAPK activation in cytoplasts were inhibited by Bt(2)cAMP, consistent with signaling through Raf-1 and suggesting a mechanism for cAMP inhibition of neutrophil function. However, Bt(2)cAMP had no effect on FMLP-stimulated MAPK activation in neutrophils. The extent of MAPK activation by various chemoattractants correlated with their capacity to stimulate neutrophil and cytoplast homotypic aggregation. Consistent with its effects on MAPK, Bt(2)cAMP inhibited FMLP-stimulated aggregation in cytoplasts but not neutrophils. Insulin had no independent effect but primed neutrophils for aggregation in response to FMLP. Our studies support a p21(ras)-, Raf-1-dependent pathway for MAPK activation in neutrophils and suggest that neutrophil adhesion may be regulated, in part, by MAPK.			Pillinger, MH (corresponding author), NYU,MED CTR,DIV RHEUMATOL NB16N1,SCH MED,DEPT MED,550 1ST AVE,NEW YORK,NY 10016, USA.			Mark, Philips/0000-0002-1179-8156; Pillinger, Michael/0000-0003-3168-1542	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL019721] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI036244] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR011949, R37AR011949] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL19721-19] Funding Source: Medline; NIAID NIH HHS [AI36244] Funding Source: Medline; NIAMS NIH HHS [AR11949-28] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BOYUM A, 1968, SCAND J CLIN LAB INV, VS 21, P77; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; CAVALOT F, 1992, HORM METAB RES, V24, P225, DOI 10.1055/s-2007-1003298; CAVALOT F, 1993, HORM METAB RES, V25, P321, DOI 10.1055/s-2007-1002109; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; COBB MH, 1994, SEMIN CANCER BIOL, V5, P261; COOK SJ, 1993, SCIENCE, V262, P1069, DOI 10.1126/science.7694367; CRESPO P, 1994, NATURE, V369, P418, DOI 10.1038/369418a0; CREWS CM, 1992, P NATL ACAD SCI USA, V89, P8205, DOI 10.1073/pnas.89.17.8205; DUSI S, 1994, BIOCHEM J, V304, P243, DOI 10.1042/bj3040243; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; ERIKSON AK, 1990, J BIOL CHEM, V265, P19728; ERVENS J, 1991, BIOCHEM SOC T, V19, P59, DOI 10.1042/bst0190059; FAURE M, 1995, MOL BIOL CELL, V6, P1025, DOI 10.1091/mbc.6.8.1025; FUSSGANGER RD, 1976, J BIOL CHEM, V251, P2761; GARDNER AM, 1993, J BIOL CHEM, V268, P17896; GRINSTEIN S, 1992, J BIOL CHEM, V267, P18122; GRINSTEIN S, 1993, J BIOL CHEM, V268, P20223; GUMBINER BM, 1993, NEURON, V11, P551, DOI 10.1016/0896-6273(93)90068-3; HOWE LR, 1993, J BIOL CHEM, V268, P20717; JOHNSON GL, 1994, J CELL BIOCHEM, V54, P415, DOI 10.1002/jcb.240540408; KAMESHITA I, 1989, ANAL BIOCHEM, V183, P139, DOI 10.1016/0003-2697(89)90181-4; KASE H, 1987, BIOCHEM BIOPH RES CO, V142, P436, DOI 10.1016/0006-291X(87)90293-2; KORCHAK HM, 1983, P NATL ACAD SCI-BIOL, V80, P4968, DOI 10.1073/pnas.80.16.4968; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MYERS MG, 1994, MOL CELL BIOL, V14, P3577, DOI 10.1128/MCB.14.6.3577; PAPKOFF J, 1994, MOL CELL BIOL, V14, P463, DOI 10.1128/MCB.14.1.463; PHILIPS MR, 1995, J BIOL CHEM, V270, P11514, DOI 10.1074/jbc.270.19.11514; PHILIPS MR, 1988, J CLIN INVEST, V82, P495, DOI 10.1172/JCI113623; RESZKA AA, 1995, P NATL ACAD SCI USA, V92, P8881, DOI 10.1073/pnas.92.19.8881; ROOS D, 1983, J CELL BIOL, V97, P368, DOI 10.1083/jcb.97.2.368; SKOLNIK EY, 1993, SCIENCE, V260, P1953, DOI 10.1126/science.8316835; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; THOMPSON HL, 1993, BIOCHEM J, V290, P483, DOI 10.1042/bj2900483; TORRES M, 1993, J IMMUNOL, V150, P1563; WARD Y, 1994, NATURE, V367, P651, DOI 10.1038/367651a0; WARTMANN M, 1994, J BIOL CHEM, V269, P6695; WORTHEN GS, 1994, J CLIN INVEST, V94, P815, DOI 10.1172/JCI117401; WU J, 1993, SCIENCE, V262, P1065, DOI 10.1126/science.7694366; YU H, 1995, J BIOL CHEM, V270, P15719, DOI 10.1074/jbc.270.26.15719	44	63	63	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 17	1996	271	20					12049	12056		10.1074/jbc.271.20.12049	http://dx.doi.org/10.1074/jbc.271.20.12049			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UL250	8662646	hybrid			2022-12-25	WOS:A1996UL25000070
J	Whalen, SG; Gingras, AC; Amankwa, L; Mader, S; Branton, PE; Aebersold, R; Sonenberg, N				Whalen, SG; Gingras, AC; Amankwa, L; Mader, S; Branton, PE; Aebersold, R; Sonenberg, N			Phosphorylation of eIF-4E on serine 209 by protein kinase C is inhibited by the translational repressors, 4E-binding proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EUKARYOTIC INITIATION FACTOR-4F; PHASE SEQUENCE-ANALYSIS; CAP-BINDING-PROTEIN; PHORBOL ESTERS; GROWTH-FACTOR; FACTOR 4E; LEVEL; SITE; TRANSFORMATION; PICOMOLE	Translation initiation in eukaryotes is facilitated by the mRNA 5' cap structure (m(7)GpppX, where X is any nucleotide) that binds the multisubunit initiation factor eIF4F through one of its subunits, eIF4E. eIF4E is a phosphoprotein whose phosphorylation state positively correlates with cell growth. Protein kinase C phosphorylates eIF4E in vitro, and possibly in vivo. Using recombinant eIF4E incubated in vitro with purified protein kinase C and analyzed by solid-phase phosphopeptide sequencing in combination with high performance liquid chromatography coupled to mass spectrometry, we demonstrated that the third amino acid of the peptide SGSTTK (Ser(209)) is the major site of phosphorylation. This finding is consistent with the newly assigned in vivo phosphorylation site of eIF4E (Joshi, B., Cai, A L., Keiper, B. D., Minich, W. B., Mendez, R., Beach, C. M., Stepinski, J., Stolarski, R., Darzynkiewicz, E., and Rhoads, R. E. (1995) J. Biol. Chem. 270, 14597-14603). A S209A mutation resulted in dramatically reduced phosphorylation, both in vitro and in vivo. Furthermore, the mutant protein was phosphorylated on threonine (most probably threonine 210) in vivo. Here we show that in the presence of the recently characterized translational repressors 4E-BP1 or 4E-BP2, phosphorylation of eIF4E by protein kinase C is strongly reduced. This suggests a two-step model for the phosphorylation (and activation) of eIF4E by growth factors and hormones: first, dissociation of eIF4E from 4E-BPs, followed by eIF4E phosphorylation.	MCGILL UNIV, DEPT BIOCHEM, MONTREAL, PQ H3G 1Y6, CANADA; MCGILL UNIV, MCGILL CANC CTR, MONTREAL, PQ H3G 1Y6, CANADA; UNIV BRITISH COLUMBIA, BIOMED RES CTR, VANCOUVER, BC V6R 1Z3, CANADA; UNIV WASHINGTON, DEPT MOLEC BIOTECHNOL, SEATTLE, WA 98195 USA	McGill University; McGill University; University of British Columbia; University of Washington; University of Washington Seattle			Gingras, Anne-Claude/E-9982-2010; Gingras, Anne-Claude/ABA-8341-2020	Gingras, Anne-Claude/0000-0002-6090-4437; Gingras, Anne-Claude/0000-0002-6090-4437				AEBERSOLD R, 1991, ANAL BIOCHEM, V199, P51, DOI 10.1016/0003-2697(91)90268-X; AEBERSOLD R, 1990, ANAL BIOCHEM, V187, P56, DOI 10.1016/0003-2697(90)90417-8; AMICK GD, 1992, BIOCHEM BIOPH RES CO, V183, P431, DOI 10.1016/0006-291X(92)90499-B; Beretta L, 1996, EMBO J, V15, P658, DOI 10.1002/j.1460-2075.1996.tb00398.x; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BU X, 1993, J BIOL CHEM, V268, P4975; DONALDSON RW, 1991, J BIOL CHEM, V266, P3162; DUNCAN R, 1987, J BIOL CHEM, V262, P380; EDERY I, 1988, GENE, V74, P517, DOI 10.1016/0378-1119(88)90184-9; FLYNN A, 1995, J BIOL CHEM, V270, P21684, DOI 10.1074/jbc.270.37.21684; Frederickson R M, 1992, Semin Cell Biol, V3, P107; FREDERICKSON RM, 1991, MOL CELL BIOL, V11, P2896, DOI 10.1128/MCB.11.5.2896; FREDERICKSON RM, 1992, MOL CELL BIOL, V12, P1239, DOI 10.1128/MCB.12.3.1239; GINGRAS AC, 1996, IN PRESS P NATL ACAD; GRAFF JR, 1995, INT J CANCER, V60, P255; GRAVES LM, 1995, P NATL ACAD SCI USA, V92, P7222, DOI 10.1073/pnas.92.16.7222; HAGHIGHAT A, 1995, EMBO J, V14, P5701, DOI 10.1002/j.1460-2075.1995.tb00257.x; HAYSTEAD TAJ, 1994, J BIOL CHEM, V269, P23185; HIREMATH LS, 1985, J BIOL CHEM, V260, P7843; HU CB, 1994, P NATL ACAD SCI USA, V91, P3730, DOI 10.1073/pnas.91.9.3730; JOSHI B, 1995, J BIOL CHEM, V270, P14597, DOI 10.1074/jbc.270.24.14597; KAUFMAN RJ, 1993, J BIOL CHEM, V268, P11902; LAZARISKARATZAS A, 1990, NATURE, V345, P544, DOI 10.1038/345544a0; LIN TA, 1995, J BIOL CHEM, V270, P18531, DOI 10.1074/jbc.270.31.18531; LIN TA, 1994, SCIENCE, V266, P653, DOI 10.1126/science.7939721; MADER S, 1995, MOL CELL BIOL, V15, P4990; MAKKINJE A, 1995, J BIOL CHEM, V270, P14824, DOI 10.1074/jbc.270.24.14824; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MINICH WB, 1994, P NATL ACAD SCI USA, V91, P7668, DOI 10.1073/pnas.91.16.7668; MORLEY SJ, 1991, J BIOL CHEM, V266, P4669; MORLEY SJ, 1989, J BIOL CHEM, V264, P2401; MORLEY SJ, 1990, J BIOL CHEM, V265, P10611; PAUSE A, 1994, NATURE, V371, P762, DOI 10.1038/371762a0; PEARSON RB, 1991, METHOD ENZYMOL, V200, P62; RINKERSCHAEFFER CW, 1993, INT J CANCER, V55, P841, DOI 10.1002/ijc.2910550525; RYCHLIK W, 1987, J BIOL CHEM, V262, P10434; SMITH M R, 1990, New Biologist, V2, P648; SMITH MR, 1991, NEW BIOL, V3, P601; Sonenberg N, 1996, TRANSLATIONAL CONTRO, P245; TREMBLAY ML, 1988, J BIOL CHEM, V263, P6375; TUAZON PT, 1989, J BIOL CHEM, V264, P2773; TUAZON PT, 1990, J BIOL CHEM, V265, P10617; VONMONTEUFFEL S, 1996, IN PRESS P NATL ACAD; WAYS DK, 1992, J BIOL CHEM, V267, P4799; WETTENHALL REH, 1991, METHOD ENZYMOL, V201, P186	45	81	87	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 17	1996	271	20					11831	11837		10.1074/jbc.271.20.11831	http://dx.doi.org/10.1074/jbc.271.20.11831			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UL250	8662663	hybrid			2022-12-25	WOS:A1996UL25000041
J	Xu, X; Zeng, WZ; Muallem, S				Xu, X; Zeng, WZ; Muallem, S			Regulation of the inositol 1,4,5-trisphosphate-activated Ca2+ channel by activation of G proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CELLS; PANCREATIC ACINAR-CELLS; CALCIUM RELEASE; ENDOPLASMIC-RETICULUM; ADENINE-NUCLEOTIDES; LUMINAL CA2+; RECEPTOR; STORES; TRISPHOSPHATE; KINASE	Streptolysin O-permeable pancreatic acini were used to study the regulation of the inositol 1,4,5-trisphosphate (IP3)-activated Ca2+ channel (IPACC) by agonists and antagonists, Measurements of the apparent affinity for IP3 (KappIP3) showed that the IPACC is dynamically controlled during cell stimulation and inhibition, i.e. agonists decreased and antagonists increased KappIP3. KappIP3 was also independently regulated by thimerosal, Ca2+ content of the stores, the incubation temperature, activation of protein kinases, and inhibition of protein phosphatases, but none of these mechanisms contributed to the regulation by agonists and antagonists, Incubating the cells with low concentration of GTP gamma S or AlF3 reproduced the effect of the agonist on KappIP3. Moreover, low [GTP gamma S] allowed activation of the IPACC by agonists at basal levels of IP3 and markedly impaired channel inactivation by antagonists, Channel sensitization by GTP gamma S also restored the ability of thimerosal to mobilize Ca2+ from internal stores with no change in cellular IP3 levels, The combination of low [GTP gamma S] and thimerosal locked the channel in an open, antagonist-insensitive state. All modulatory effects of GTP gamma S are independent of phospholipase C activation and IP3 production. We propose that the dynamic regulation of the IPACC by a G protein-dependent mechanism can play a major role in triggering and maintaining Ca2+ oscillations at low agonist concentrations when minimal or no changes in IP3 level take place.	UNIV TEXAS, SW MED CTR, DEPT PHYSIOL, DALLAS, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK038938, R01DK046591] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 38938, DK 46591] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BABICH M, 1991, ENDOCRINOLOGY, V129, P1463, DOI 10.1210/endo-129-3-1463; BAUMANN O, 1989, J COMP PHYSIOL A, V165, P627, DOI 10.1007/BF00610994; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BEZPROZVANNY I, 1991, NATURE, V351, P751, DOI 10.1038/351751a0; BIRD GS, 1993, J BIOL CHEM, V268, P17917; CAMERON AM, 1995, CELL, V83, P463, DOI 10.1016/0092-8674(95)90124-8; CHALLISS RAJ, 1990, BIOCHEM J, V265, P421, DOI 10.1042/bj2650421; COMBETTES L, 1992, FEBS LETT, V301, P287, DOI 10.1016/0014-5793(92)80258-I; FERRIS CD, 1990, P NATL ACAD SCI USA, V87, P2147, DOI 10.1073/pnas.87.6.2147; FINCH EA, 1991, SCIENCE, V252, P443, DOI 10.1126/science.2017683; GHOSH TK, 1989, NATURE, V340, P236, DOI 10.1038/340236a0; GHOSH TK, 1988, J BIOL CHEM, V263, P11075; Gill Donald L., 1992, Advances in Second Messenger and Phosphoprotein Research, V26, P265; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; HAJNOCZKY G, 1994, J BIOL CHEM, V269, P10280; HAJNOCZKY G, 1993, BIOCHEM J, V293, P413, DOI 10.1042/bj2930413; HIDAKA H, 1984, BIOCHEMISTRY-US, V23, P5036, DOI 10.1021/bi00316a032; HORSTMAN DA, 1988, J BIOL CHEM, V263, P15297; IINO M, 1991, J GEN PHYSIOL, V98, P681, DOI 10.1085/jgp.98.4.681; IINO M, 1990, J GEN PHYSIOL, V95, P1103, DOI 10.1085/jgp.95.6.1103; JOSEPH SK, 1995, J BIOL CHEM, V270, P3588, DOI 10.1074/jbc.270.8.3588; KAPLIN AI, 1994, J BIOL CHEM, V269, P28972; KINDMAN LA, 1993, BIOCHEMISTRY-US, V32, P1270, DOI 10.1021/bi00056a011; LYNCH CJ, 1985, J BIOL CHEM, V260, P1593; MANGER JP, 1989, J BIOL CHEM, V264, P8821; Martell A. E., 1976, CRITICAL STABILITY C, V3; MISSIAEN L, 1991, NATURE, V352, P241, DOI 10.1038/352241a0; MISSIAEN L, 1992, NATURE, V357, P599, DOI 10.1038/357599a0; MUALLEM S, 1989, J BIOL CHEM, V264, P205; Muallem Shmuel, 1992, Advances in Second Messenger and Phosphoprotein Research, V26, P351; NUNN DL, 1992, MOL PHARMACOL, V41, P115; PARYS JB, 1993, PFLUG ARCH EUR J PHY, V424, P516, DOI 10.1007/BF00374916; PARYS JB, 1993, J BIOL CHEM, V268, P25206; PINES M, 1995, IN PRESS J BONE MINE; PITTET D, 1989, J BIOL CHEM, V264, P18489; ROONEY TA, 1991, J BIOL CHEM, V266, P12272; ROSS EM, 1977, J BIOL CHEM, V252, P5761; SHUTTLEWORTH TJ, 1992, J BIOL CHEM, V267, P3573; TARVER AP, 1987, J BIOL CHEM, V262, P17268; THORN P, 1992, PFLUG ARCH EUR J PHY, V422, P173, DOI 10.1007/BF00370417; TORTORICI G, 1994, J BIOL CHEM, V269, P29621; ZHANG BX, 1992, J BIOL CHEM, V267, P24387; ZHANG BX, 1993, J BIOL CHEM, V268, P10997; ZHANG BX, 1994, J BIOL CHEM, V269, P17132; ZHAO H, 1990, J BIOL CHEM, V265, P14822	45	41	41	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 17	1996	271	20					11737	11744		10.1074/jbc.271.20.11737	http://dx.doi.org/10.1074/jbc.271.20.11737			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UL250	8662624	hybrid			2022-12-25	WOS:A1996UL25000026
J	Pollock, RE; Lang, AQ; Luo, JX; ElNaggar, AK; Yu, DH				Pollock, RE; Lang, AQ; Luo, JX; ElNaggar, AK; Yu, DH			Soft tissue sarcoma metastasis from clonal expansion of p53 mutated tumor cells	ONCOGENE			English	Article						sarcoma; p53 suppressor gene; clonal heterogeneity; metastasis; loss of heterozygosity	MUTATIONS; GENE; BONE	Although soft tissue sarcoma has a high incidence of p53 mutations, it is not clear if such alterations facilitate tumor growth and metastasis. In this study, fresh autologous normal lymphocytes, normal muscle, primary and metastatic sarcoma tissues from a single synovial sarcoma patient were examined for p53-related alterations that potentially associated with sarcoma tumor development and metastasis. Normal tissues contain two wild-type p53 alleles. Primary sarcoma had one chromosome 17p p53 allelic deletion without apparent p53 mutation in the other allele. However, metastatic tumor had deletion of one p53 allele with an exon 5 codon 135 missense mutation in the other allele. This p53 gene point mutation in the metastasis was associated with the production of mutated p53 protein. A small clone of cells harboring the identical p53 gene point mutation was identified in the primary tumor using mutant allele specific PCR amplification, albeit at levels much less than in the metastatic sarcoma. This single patient example indicate that soft tissue sarcoma metastasis can develop from clonal expansion of primary tumor cells bearing p53 mutations.	UNIV TEXAS,MD ANDERSON CANC CTR,DEPT TUMOR BIOL,HOUSTON,TX 77030; UNIV TEXAS,MD ANDERSON CANC CTR,DEPT PATHOL,HOUSTON,TX 77030	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Pollock, RE (corresponding author), UNIV TEXAS,MD ANDERSON CANC CTR,DEPT SURG ONCOL,1515 HOLCOMBE BLVD,HOUSTON,TX 77030, USA.			Yu, Dihua/0000-0001-6231-9381	NATIONAL CANCER INSTITUTE [R29CA060488, R01CA060488, R01CA067802] Funding Source: NIH RePORTER; NCI NIH HHS [CA60488, CA67802] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALVEGARD TA, 1989, J CLIN ONCOL, V7, P1845, DOI 10.1200/JCO.1989.7.12.1845; BEAHRS OH, 1992, MANUAL STAGING CANCE; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; DROBNJAK M, 1994, J NATL CANCER I, V86, P549, DOI 10.1093/jnci/86.7.549; FELIX CA, 1992, CANCER RES, V52, P2243; GREENBLATT MS, 1994, CANCER RES, V54, P4855; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HSU SM, 1981, J HISTOCHEM CYTOCHEM, V29, P577, DOI 10.1177/29.4.6166661; HU GY, 1992, BRIT J HAEMATOL, V81, P489, DOI 10.1111/j.1365-2141.1992.tb02979.x; KOMURO H, 1993, CANCER RES, V53, P5284; LATRES E, 1994, AM J PATHOL, V145, P345; LIOTTA LA, 1991, CELL, V64, P327, DOI 10.1016/0092-8674(91)90642-C; MENON AG, 1990, P NATL ACAD SCI USA, V87, P5435, DOI 10.1073/pnas.87.14.5435; MERCER WE, 1990, P NATL ACAD SCI USA, V87, P6166, DOI 10.1073/pnas.87.16.6166; NOWELL PC, 1976, SCIENCE, V194, P23, DOI 10.1126/science.959840; PINKEL D, 1986, COLD SPRING HARB SYM, V51, P151, DOI 10.1101/SQB.1986.051.01.018; SIDRANSKY D, 1992, NATURE, V355, P846, DOI 10.1038/355846a0; TAKEDA S, 1993, HUM MUTAT, V2, P112, DOI 10.1002/humu.1380020209; TOGUCHIDA J, 1992, CANCER RES, V52, P6194; WADAYAMA B, 1993, BRIT J CANCER, V68, P1134, DOI 10.1038/bjc.1993.493; YANG JC, 1993, CANC PRINCIPLES PRAC, P1436; YU DH, 1990, P NATL ACAD SCI USA, V87, P4499, DOI 10.1073/pnas.87.12.4499	22	38	39	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY 2	1996	12	9					2035	2039						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UK498	8649865				2022-12-25	WOS:A1996UK49800023
J	Robinson, C; Light, Y; Groves, R; Mann, D; Marais, R; Watson, R				Robinson, C; Light, Y; Groves, R; Mann, D; Marais, R; Watson, R			Cell-cycle regulation of B-Myb protein expression: Specific phosphorylation during the S phase of the cell cycle	ONCOGENE			English	Article						B-Myb; cell cycle; phosphorylation; cyclin dependent kinase	C-MYB; HEMATOPOIETIC-CELLS; A-MYB; PROLIFERATION; TRANSCRIPTION; ACTIVATION; CDC2	Previous studies revealed that transcription of B-Myb, which encodes a transcription factor related to the c-Myb proto-oncoprotein, is cell-cycle regulated by an E2F transcription factor-mediated repression mechanism operating in G(0)/G(1). To begin to determine the consequences of transcriptional regulation on B-Myb function, we report here further studies of B-Myb protein expression in the cell cycle. We found that G(0)-arrest of serum-deprived mouse fibroblasts was achieved without significant reduction in B-Myb levels, moreover, overexpression of B-Myb in stably transfected cells did not prevent their entry into G(0). Following serum-induction of arrested fibroblasts, B-Myb abundance increased as cells entered S phase to levels significantly greater than found in cycling cells. This was accompanied by the appearance of a novel phosphorylated form of B-Myb (112 kDa) of distinctly lower electrophoretic mobility than B-Myb present in G(1) (110 kDa). The 112 kDa species was S phase-specific even in transfected cells overexpressing B-Myb. Consistent with modification in the S phase of the cell cycle, preliminary evidence suggested that a cyclin A/cdk2, but not cyclin E/cdk2 or cyclin D1/cdk4, complex could induce a similar electrophoretic mobility change in baculovirus-specified B-Myb. These findings show that B-Myb expression may be subject to two levels of control during the cell cycle, transcription and protein phosphorylation.	ST MARYS HOSP,SCH MED,LUDWIG INST CANC RES,LONDON W2 1PG,ENGLAND; INST CANC RES,CHESTER BEATTY LABS,LONDON SW3 6JB,ENGLAND; IMPERIAL CANC RES FUND,LONDON WC2A 3PX,ENGLAND	Imperial College London; Ludwig Institute for Cancer Research; Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; Cancer Research UK								ARSURA M, 1992, BLOOD, V79, P2708; BOUWMEESTER T, 1994, ONCOGENE, V9, P1029; DRAETTA GF, 1994, CURR OPIN CELL BIOL, V6, P842, DOI 10.1016/0955-0674(94)90054-X; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FOOS G, 1992, EMBO J, V11, P4619, DOI 10.1002/j.1460-2075.1992.tb05564.x; GOLAY J, 1991, BLOOD, V77, P149; GOLAY J, 1994, ONCOGENE, V9, P2469; HARPER JW, 1993, CELL, V75, P805; KITAGAWA M, 1995, ONCOGENE, V10, P229; KREK W, 1994, CELL, V78, P161, DOI 10.1016/0092-8674(94)90582-7; LAM EWF, 1994, EMBO J, V13, P871, DOI 10.1002/j.1460-2075.1994.tb06330.x; LAM EWF, 1995, GENE, V160, P277, DOI 10.1016/0378-1119(95)00184-8; LAM EWF, 1992, ONCOGENE, V7, P1885; LAM EWF, 1993, EMBO J, V12, P2705, DOI 10.1002/j.1460-2075.1993.tb05932.x; LEES JA, 1991, EMBO J, V10, P4279, DOI 10.1002/j.1460-2075.1991.tb05006.x; LIN D, 1992, P NATL ACAD SCI USA, V89, P9210, DOI 10.1073/pnas.89.19.9210; LIN D, 1994, P NATL ACAD SCI USA, V91, P10079, DOI 10.1073/pnas.91.21.10079; LUSCHER B, 1992, J CELL BIOL, V118, P775, DOI 10.1083/jcb.118.4.775; LYON J, 1994, CRIT REV ONCOGENESIS, V5, P373, DOI 10.1615/CritRevOncog.v5.i4.30; MIZUGUCHI G, 1990, J BIOL CHEM, V265, P9280; NAKAGOSHI H, 1993, J BIOL CHEM, V268, P14161; NOMURA N, 1988, NUCLEIC ACIDS RES, V16, P11075, DOI 10.1093/nar/16.23.11075; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; PARRY D, 1995, EMBO J, V14, P503, DOI 10.1002/j.1460-2075.1995.tb07026.x; PETERS G, 1994, NATURE, V371, P204, DOI 10.1038/371204a0; REISS K, 1991, J CELL PHYSIOL, V148, P338, DOI 10.1002/jcp.1041480303; SALA A, 1992, P NATL ACAD SCI USA, V89, P10415, DOI 10.1073/pnas.89.21.10415; TAKEMOTO Y, 1994, FEBS LETT, V350, P55, DOI 10.1016/0014-5793(94)00733-0; TASHIRO S, 1995, ONCOGENE, V10, P1699; WANG Y, 1995, NATURE, V376, P88, DOI 10.1038/376088a0; WATSON RJ, 1993, NUCLEIC ACIDS RES, V21, P267, DOI 10.1093/nar/21.2.267; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2	32	62	65	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY 2	1996	12	9					1855	1864						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UK498	8649845				2022-12-25	WOS:A1996UK49800003
J	Ohta, M; Nagai, H; Nyunoya, H; Shimotohno, K				Ohta, M; Nagai, H; Nyunoya, H; Shimotohno, K			Src-homology domain 2 is responsible for transcriptional suppression induced by expression of Lck	ONCOGENE			English	Article						Lck; Src; SH2; transcriptional suppression; tyrosine kinase	TYROSINE-PROTEIN-KINASE; RETROVIRUS PROMOTER INSERTION; SIGNAL TRANSDUCTION; CD4 RECEPTOR; SH3 DOMAINS; P56LCK; ACTIVATION; IDENTIFICATION; CELLS; GENE	Overexpression of Lck was shown, by our previous study, to suppress gene transcription from various viral and cellular promoters. The suppression of transcription from human T-cell leukemia virus promoter by Lck was independent of the presence of the enhancer core sequences within the long terminal repeat. The suppression of transcription was observed with Lck mutants that had either diminished or enhanced tyrosine-kinase activity. A mutant lacking the myristylation site also suppressed transcription. From the analysis with various deletion mutants of Lck, it was suggested that Src-homology domain 2 (SH2) is both necessary and sufficient for the suppression of transcription. A similar effect was also observed with the SH2 domain of the v-src gene. Thus, overexpression of Lck could suppress gene expression through a unique function of the SH2 domain.	NATL CANC CTR, RES INST, DIV VIROL, TOKYO 104, JAPAN	National Cancer Center - Japan			Nyunoya, Hiroshi/C-9705-2013	Nyunoya, Hiroshi/0000-0002-3237-9639				ABRAHAM N, 1990, MOL CELL BIOL, V10, P5197, DOI 10.1128/MCB.10.10.5197; ABRAHAM N, 1991, NATURE, V350, P62, DOI 10.1038/350062a0; ADLER HT, 1988, J VIROL, V62, P4113, DOI 10.1128/JVI.62.11.4113-4122.1988; BARBER EK, 1989, P NATL ACAD SCI USA, V86, P3277, DOI 10.1073/pnas.86.9.3277; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; COOPER JA, 1993, CELL, V73, P1051, DOI 10.1016/0092-8674(93)90634-3; FUJII M, 1989, MOL CELL BIOL, V9, P2493, DOI 10.1128/MCB.9.6.2493; GLAICHENHAUS N, 1991, CELL, V64, P511, DOI 10.1016/0092-8674(91)90235-Q; HATAKEYAMA M, 1991, SCIENCE, V252, P1523, DOI 10.1126/science.2047859; KAMPS MP, 1988, ONCOGENE, V2, P305; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KOGA Y, 1986, EUR J IMMUNOL, V16, P1643, DOI 10.1002/eji.1830161229; LUO KX, 1990, MOL CELL BIOL, V10, P5305, DOI 10.1128/MCB.10.10.5305; MARENGERE LEM, 1994, NATURE, V369, P502, DOI 10.1038/369502a0; MARTH JD, 1988, NATURE, V332, P171, DOI 10.1038/332171a0; MARTH JD, 1985, CELL, V43, P393, DOI 10.1016/0092-8674(85)90169-2; MOLINA TJ, 1992, NATURE, V357, P161, DOI 10.1038/357161a0; NYUNOYA H, 1990, AIDS RES HUM RETROV, V6, P1311, DOI 10.1089/aid.1990.6.1311; OHTA M, 1990, JPN J CANCER RES, V81, P440, DOI 10.1111/j.1349-7006.1990.tb02588.x; OHTA M, 1988, J VIROL, V62, P4445, DOI 10.1128/JVI.62.12.4445-4451.1988; OVERDUIN M, 1992, CELL, V70, P697, DOI 10.1016/0092-8674(92)90437-H; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; RUDD CE, 1988, P NATL ACAD SCI USA, V85, P5190, DOI 10.1073/pnas.85.14.5190; SADOWSKI I, 1986, MOL CELL BIOL, V6, P4396, DOI 10.1128/MCB.6.12.4396; SEIDELDUGAN C, 1992, MOL CELL BIOL, V12, P1835, DOI 10.1128/MCB.12.4.1835; SHAW AS, 1989, CELL, V59, P627, DOI 10.1016/0092-8674(89)90008-1; SHIMOTOHNO K, 1986, P NATL ACAD SCI USA, V83, P8112, DOI 10.1073/pnas.83.21.8112; TURNER JM, 1990, CELL, V60, P755, DOI 10.1016/0092-8674(90)90090-2; VEILLETTE A, 1989, NATURE, V338, P257, DOI 10.1038/338257a0; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; VEILLETTE A, 1989, MOL CELL BIOL, V9, P4441, DOI 10.1128/MCB.9.10.4441; VORONOVA AF, 1986, NATURE, V319, P682, DOI 10.1038/319682a0; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	34	0	0	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 7	1996	12	5					989	997						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UA884	8649816				2022-12-25	WOS:A1996UA88400006
J	Garbuglia, M; Verzini, M; Giambanco, I; Spreca, A; Donato, R				Garbuglia, M; Verzini, M; Giambanco, I; Spreca, A; Donato, R			Effects of calcium-binding proteins (S-100a(o), S-100a, S-100b) on desmin assembly in vitro	FASEB JOURNAL			English	Article						S-100 proteins; desmin intermediate filaments; calcium	INTERMEDIATE FILAMENT NETWORKS; FIBRILLARY ACIDIC PROTEIN; CONSENSUS SEQUENCE MOTIF; VIMENTIN FILAMENTS; TYROSINE PHOSPHORYLATION; S100 PROTEIN; CALPACTIN-I; ANNEXIN-II; MITOSIS; CELLS	S-100a(o), the alpha alpha isoform of a subfamily of Ca2+-binding proteins of the EF-hand type expressed in cardiac and skeletal muscle cells, is reported to inhibit the assembly of the intermediate filament subunit desmin and to stimulate the disassembly of desmin intermediate filaments in the presence of micromolar levels of free Ca2+, These effects are dose-dependent with respect to the S-100a(o) concentration and maximal at a desmin/S-100a(o) (dimer) molar ratio of similar to 2, Other members of the S-100 subfamily [S-100a (alpha beta) and S-100b (beta beta)] and the unfractionated mixture of S-100a plus S-100b produce qualitatively similar effects on desmin assembly, with a potency that depends on the fraction of S-100 alpha subunit (the most potent) or S-100 beta subunit (the least potent) present in the S-100 isoforms tested, A binding stoichiometry of 2 mol of desmin/mol of S-100a(o) (dimer) and an affinity in the submicromolar range are calculated, The S-100 beta subunit also interacts with desmin, but with a lower affinity compared with S-100 alpha. By contrast, the S-100-like proteins calcyclin and p11 neither interact with desmin nor affect desmin assembly, The present data suggest that S-100a(o) might play a role in the regulation of the state of assembly of desmin intermediate filaments.	UNIV PERUGIA,DEPT EXPTL MED & BIOCHEM SCI,SECT ANAT,I-06126 PERUGIA,ITALY	University of Perugia				Giambanco, Ileana/0000-0003-0286-6302	Telethon [591] Funding Source: Medline; Fondazione Telethon Funding Source: Custom	Telethon(Fondazione Telethon); Fondazione Telethon(Fondazione Telethon)		ALBERS K, 1992, INT REV CYTOL, V134, P243, DOI 10.1016/S0074-7696(08)62030-6; ANGELIDES KJ, 1989, J CELL BIOL, V108, P1495, DOI 10.1083/jcb.108.4.1495; AUBIN JE, 1980, EXP CELL RES, V129, P149, DOI 10.1016/0014-4827(80)90340-7; BENNETT GS, 1979, J CELL BIOL, V82, P577, DOI 10.1083/jcb.82.2.577; BIANCHI R, 1992, BIOCHIM BIOPHYS ACTA, V1160, P67, DOI 10.1016/0167-4838(92)90039-G; BIANCHI R, 1993, J BIOL CHEM, V268, P12669; BIANCHI R, 1994, BBA-MOL CELL RES, V1223, P354, DOI 10.1016/0167-4889(94)90095-7; BIANCHI R, 1994, BBA-MOL CELL RES, V1223, P361, DOI 10.1016/0167-4889(94)90096-5; BIANCHI R, 1995, BIOCHEM BIOPH RES CO, V209, P910; BURWINKEL F, 1994, HISTOCHEMISTRY, V101, P113, DOI 10.1007/BF00269357; CELIS JE, 1983, J CELL BIOL, V97, P1429, DOI 10.1083/jcb.97.5.1429; CHOU YH, 1989, P NATL ACAD SCI USA, V86, P1885, DOI 10.1073/pnas.86.6.1885; CHOU YH, 1990, CELL, V62, P1063, DOI 10.1016/0092-8674(90)90384-Q; COOPER JA, 1982, METHOD ENZYMOL, V85, P182; DONATO R, 1991, CELL CALCIUM, V12, P713, DOI 10.1016/0143-4160(91)90040-L; DONATO R, 1988, J BIOL CHEM, V263, P106; DONATO R, 1989, CELL CALCIUM, V10, P81, DOI 10.1016/0143-4160(89)90048-1; DONATO R, 1984, BIOCHEM BIOPH RES CO, V124, P850, DOI 10.1016/0006-291X(84)91035-0; EVANS RM, 1982, CELL, V29, P43, DOI 10.1016/0092-8674(82)90088-5; FRANKE WW, 1984, EXP CELL RES, V154, P567, DOI 10.1016/0014-4827(84)90181-2; FREEMAN MR, 1989, EXP CELL RES, V182, P370, DOI 10.1016/0014-4827(89)90242-5; FUCHS E, 1994, ANNU REV BIOCHEM, V63, P345, DOI 10.1146/annurev.biochem.63.1.345; GARBUGLIA M, 1995, BIOCHEM BIOPH RES CO, V208, P901, DOI 10.1006/bbrc.1995.1420; GARD DL, 1980, CELL, V19, P263, DOI 10.1016/0092-8674(80)90408-0; GEISLER N, 1980, EUR J BIOCHEM, V111, P425, DOI 10.1111/j.1432-1033.1980.tb04957.x; GEORGATOS SD, 1993, FEBS LETT, V318, P101, DOI 10.1016/0014-5793(93)80001-B; GERACE L, 1980, CELL, V19, P277, DOI 10.1016/0092-8674(80)90409-2; GERKE V, 1985, EMBO J, V4, P2917, DOI 10.1002/j.1460-2075.1985.tb04023.x; GERKE V, 1984, EMBO J, V3, P227, DOI 10.1002/j.1460-2075.1984.tb01789.x; GERKE V, 1985, J BIOL CHEM, V260, P1688; GLENNEY JR, 1985, P NATL ACAD SCI USA, V82, P7884, DOI 10.1073/pnas.82.23.7884; GLENNEY JR, 1989, J CELL BIOL, V108, P569, DOI 10.1083/jcb.108.2.569; GLENNEY JR, 1986, J BIOL CHEM, V261, P485; HAGIWARA M, 1988, J BIOL CHEM, V263, P6438; HAIMOTO H, 1988, EUR J BIOCHEM, V171, P409, DOI 10.1111/j.1432-1033.1988.tb13805.x; HARAFUJI H, 1980, J BIOCHEM, V87, P1305, DOI 10.1093/oxfordjournals.jbchem.a132868; HATZFELD M, 1992, J CELL BIOL, V116, P157, DOI 10.1083/jcb.116.1.157; HEXHAM JM, 1986, BIOCHEM BIOPH RES CO, V134, P248, DOI 10.1016/0006-291X(86)90554-1; IKEBUCHI NW, 1990, J BIOL CHEM, V265, P3393; INAGAKI M, 1990, J BIOL CHEM, V265, P4722; IVANENKOV VV, 1995, J BIOL CHEM, V270, P14651, DOI 10.1074/jbc.270.24.14651; KOUKLIS PD, 1992, J CELL SCI, V102, P31; KUZNICKI J, 1989, FEBS LETT, V254, P141, DOI 10.1016/0014-5793(89)81026-9; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAZARIDES E, 1980, NATURE, V283, P249, DOI 10.1038/283249a0; LI SH, 1994, J CELL BIOL, V124, P827; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MILLER RK, 1991, J CELL BIOL, V113, P843, DOI 10.1083/jcb.113.4.843; NAKAMURA Y, 1991, GLIA, V4, P101, DOI 10.1002/glia.440040112; NICHOLL ID, 1994, EMBO J, V13, P945, DOI 10.1002/j.1460-2075.1994.tb06339.x; OTTAVIANO Y, 1985, J BIOL CHEM, V260, P624; PARRY D A D, 1992, Current Opinion in Cell Biology, V4, P94, DOI 10.1016/0955-0674(92)90064-J; Pendergast F. G., 1983, J BIOL CHEM, V258, P7541; QUINLAN RA, 1991, BIOESSAYS, V13, P597, DOI 10.1002/bies.950131110; RAMBOTTI MG, 1990, J HISTOCHEM CYTOCHEM, V38, P1583, DOI 10.1177/38.11.2212618; ROTH J, 1993, BLOOD, V82, P1875; STEINERT PM, 1988, ANNU REV BIOCHEM, V57, P593, DOI 10.1146/annurev.bi.57.070188.003113; Stewart M, 1993, CURR OPIN CELL BIOL, V5, P3, DOI 10.1016/S0955-0674(05)80002-X; TAKENAGA K, 1994, J CELL BIOL, V124, P757, DOI 10.1083/jcb.124.5.757; THIEL C, 1992, J CELL SCI, V103, P733; TOKUMITSU H, 1992, J BIOL CHEM, V267, P8919; TOKUYASU KT, 1984, J CELL BIOL, V98, P1961, DOI 10.1083/jcb.98.6.1961; VIKSTROM KL, 1989, P NATL ACAD SCI USA, V86, P549, DOI 10.1073/pnas.86.2.549; VIKSTROM KL, 1992, J CELL BIOL, V118, P121, DOI 10.1083/jcb.118.1.121	64	44	44	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	FEB	1996	10	2					317	324		10.1096/fasebj.10.2.8641565	http://dx.doi.org/10.1096/fasebj.10.2.8641565			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	TY962	8641565				2022-12-25	WOS:A1996TY96200016
J	VanRollins, M; Kaduce, TL; Fang, X; Knapp, HR; Spector, AA				VanRollins, M; Kaduce, TL; Fang, X; Knapp, HR; Spector, AA			Arachidonic acid diols produced by cytochrome P-450 monooxygenases are incorporated into phospholipids of vascular endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FATTY-ACIDS; 15-HYDROXYEICOSATETRAENOIC ACID; 5,6-EPOXYEICOSATRIENOIC ACID; EPOXYEICOSATRIENOIC ACIDS; EICOSAPENTAENOIC ACID; EPOXYGENASE; METABOLISM; CYCLOOXYGENASE; PHOSPHATIDYLINOSITOL; ESTERIFICATION	Epoxyeicosatrienoic acids (EETs) are synthesized by cytochrome P-450 monooxygenases and released into the blood. When taken up by vascular endothelial and smooth muscle cells, the EETs are primarily esterified to phospholipids or converted to dihydroxyeicosatetraenoic acids (DHETs) and released. In the present studies, radiolabeled 8,9-, 11,12-, and 14,15-DHETs released into the medium from vascular smooth muscle cells were isolated and incubated for 4-16 h with cultured bovine aortic endothelial cells. The uptake ranged from 2 to 50% for the three regioisomers. Hydrolysis of the endothelial lipids and gas chromatographic-mass spectral analyses of the products indicated that all three DHET regioisomers were incorporated intact into phosphatidylcholine and phosphatidylinositol. Similar incubations with EETs confirmed that small amounts of DHETs were also esterified to endothelial phospholipids. These studies indicate that DHETs are incorporated into phospholipids either at the time of EET conversion to DHET or upon release and re-uptake of DHETs. Beside demonstrating for the first time that fatty acid diols are incorporated intact into endothelial lipids, these studies raise the possibility that both EETs and DHETs remain long enough in the vascular wall to produce chronic vasoactive effects.	UNIV IOWA, COLL MED, DEPT INTERNAL MED, IOWA CITY, IA 52242 USA; UNIV IOWA, COLL MED, DEPT BIOCHEM, IOWA CITY, IA 52242 USA; UNIV IOWA, COLL MED, DEPT PHARMACOL, IOWA CITY, IA 52242 USA	University of Iowa; University of Iowa; University of Iowa			Spector, Arthur/AAG-9860-2020		NHLBI NIH HHS [HL-49264, HL-48877] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL048877, P01HL049264] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BALAZY M, 1991, J BIOL CHEM, V266, P23561; BALLOU LR, 1987, P NATL ACAD SCI USA, V84, P6990, DOI 10.1073/pnas.84.20.6990; BERNSTROM K, 1992, J BIOL CHEM, V267, P3686; BRADEN GR, 1991, CLIN RES, V39, pA183; BREZINSKI ME, 1990, P NATL ACAD SCI USA, V87, P6248, DOI 10.1073/pnas.87.16.6248; CAPDEVILA JH, 1992, J BIOL CHEM, V267, P21720; CAPDEVILA JH, 1992, FASEB J, V6, P731, DOI 10.1096/fasebj.6.2.1537463; CARROLL MA, 1993, J BIOL CHEM, V268, P12260; CATELLA F, 1990, P NATL ACAD SCI USA, V87, P5893, DOI 10.1073/pnas.87.15.5893; FANG X, 1995, J LIPID RES, V36, P1236; FOLCH J, 1957, J BIOL CHEM, V226, P497; GIORDANO MJ, 1992, J NEUROCHEM, V58, P374, DOI 10.1111/j.1471-4159.1992.tb09321.x; GOLDSMITH JC, 1981, LAB INVEST, V45, P191; HARDER DR, 1995, J VASC RES, V32, P79, DOI 10.1159/000159080; ISAACSON Y, 1990, CHEM PHYS LIPIDS, V52, P217, DOI 10.1016/0009-3084(90)90117-A; KARARA A, 1992, BIOCHEM BIOPH RES CO, V182, P1320, DOI 10.1016/0006-291X(92)91877-S; KNAPP HR, 1991, CLIN RES, V39, pA185; LEGRAND AB, 1991, J BIOL CHEM, V266, P7570; MADHUN ZT, 1991, J CLIN INVEST, V88, P456, DOI 10.1172/JCI115325; MCGIFF JC, 1991, ANNU REV PHARMACOL, V31, P339, DOI 10.1146/annurev.pa.31.040191.002011; MORROW JD, 1992, P NATL ACAD SCI USA, V89, P10721, DOI 10.1073/pnas.89.22.10721; MURPHY RC, 1993, HDB LIPID RES, V7, P107; OLIW EH, 1994, PROG LIPID RES, V33, P329, DOI 10.1016/0163-7827(94)90029-9; PFISTER SL, 1991, AM J PHYSIOL, V261, pH843, DOI 10.1152/ajpheart.1991.261.3.H843; PRITCHARD KA, 1990, AM J PATHOL, V136, P1383; RICHARDS CF, 1986, BIOCHIM BIOPHYS ACTA, V875, P569, DOI 10.1016/0005-2760(86)90079-2; ROSOLOWSKY M, 1991, ADV PROSTAG THROMB L, V21, P213; ROSOLOWSKY M, 1990, CIRC RES, V66, P608, DOI 10.1161/01.RES.66.3.608; SHEN XY, 1988, BIOCHEMISTRY-US, V27, P996, DOI 10.1021/bi00403a024; SPECTOR AA, 1981, J CLIN INVEST, V68, P1003, DOI 10.1172/JCI110322; SPECTOR AA, 1988, PROG LIPID RES, V27, P271, DOI 10.1016/0163-7827(88)90009-4; SPECTOR AA, 1994, WORLD REV NUTR DIET, V75, P8; STENSON WF, 1983, PROSTAGLANDINS, V26, P253, DOI 10.1016/0090-6980(83)90093-X; STENSON WF, 1979, J CLIN INVEST, V64, P1457, DOI 10.1172/JCI109604; TURK J, 1990, METHOD ENZYMOL, V187, P175; VANROLLINS M, 1995, BBA-LIPID LIPID MET, V1256, P263, DOI 10.1016/0005-2760(95)00029-C; VANROLLINS M, 1993, J LIPID RES, V34, P1931; VANROLLINS M, 1995, J LIPID RES, V36, P952; VANROLLINS M, 1990, LIPIDS, V25, P481, DOI 10.1007/BF02538092; VANROLLINS M, 1989, J LIPID RES, V30, P275; VANROLLINS M, 1982, METHOD ENZYMOL, V86, P518; VANROLLINS M, 1984, J LIPID RES, V25, P507; ZELDIN DC, 1993, J BIOL CHEM, V268, P6402; ZHANG JY, 1992, BIOCHEM BIOPH RES CO, V183, P138, DOI 10.1016/0006-291X(92)91619-2; ZHU Y, 1995, HYPERTENSION, V25, P854, DOI 10.1161/01.HYP.25.4.854	45	72	72	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 14	1996	271	24					14001	14009		10.1074/jbc.271.24.14001	http://dx.doi.org/10.1074/jbc.271.24.14001			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UQ660	8662855	hybrid			2022-12-25	WOS:A1996UQ66000014
J	Baker, RT; Williamson, NA; Wettenhall, REH				Baker, RT; Williamson, NA; Wettenhall, REH			The yeast homolog of mammalian ribosomal protein S30 is expressed from a duplicated gene without a ubiquitin-like protein fusion sequence - Evolutionary implications	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-END RULE; SACCHAROMYCES-CEREVISIAE; ESCHERICHIA-COLI; FUNCTIONAL-ANALYSIS; TRANSFORMATION; CLONING; BIOGENESIS; EXTENSION; ENCODES; VECTORS	In mammals, the 59-residue ribosomal protein S30 (rpS30)is synthesized as a fusion to a 74-residue ubiquitin-like protein, which is cleaved to yield mature rpS30. An artificial fusion of this ubiquitin-like protein to E. coli beta-galactosidase was not cleaved when expressed in yeast (Saccharomyces cerevisiae), indicating that yeast lack this cleaving activity, The yeast rpS30 homolog (yrpS30) was purified and sequenced to reveal a 63-residue protein with 61% sequence identity to mammalian rpS30, Degenerate oligonucleotides based on the yrpS30 sequence were used to isolate full-length yrpS30 cDNAs, Sequence analysis of five cDNA clones revealed that yrpS30 is not synthesized as a fusion to a ubiquitin-like protein but is extended at its N terminus by a single methionine residue, The corresponding gene was identified in the GenBank(TM) data base by sequence alignment and termed RPS30A, The gene consists of two exons separated by a 430-base pair intron, which contains consensus splicing elements, Exon 1 encodes the initiator methionine residue and is preceded by canonical yeast ribosomal protein gene promoter elements, Exon 2 encodes the 62-residue mature yrpS30, Genomic hybridization reveals that the RPS30A gene is duplicated. Disruption of the RPS30A gene is not lethal but confers a slow growth phenotype. Ribosomes in the mutant strains contain an authentic yrpS30 protein, indicating that a functional yrpS30 is expressed from the duplicated gene but that the reduced capacity for yrpS30 synthesis restricted the growth rate. Analysis of avail able DNA sequence data bases reveals that rpS30 is synthesized as a fusion to a ubiquitin-like protein in nematodes and mammals but unfused in yeast, plants, and protazoa.	UNIV MELBOURNE, RUSSELL GRIMWADE SCH BIOCHEM & MOL BIOL, MELBOURNE, VIC 3052, AUSTRALIA	University of Melbourne	Baker, RT (corresponding author), AUSTRALIAN NATL UNIV, JOHN CURTIN SCH MED RES, MOLEC GENET GRP, POB 334, CANBERRA, ACT 2601, AUSTRALIA.		Williamson, Nicholas A/O-9812-2016	Williamson, Nicholas A/0000-0002-2173-3452				ARNASON T, 1994, MOL CELL BIOL, V14, P7876, DOI 10.1128/MCB.14.12.7876; BACHMAIR A, 1986, SCIENCE, V234, P179, DOI 10.1126/science.3018930; BAKER R, 1991, NUCLEIC ACIDS RES, V19, P1945, DOI 10.1093/nar/19.8.1945; BAKER RT, 1994, J BIOL CHEM, V269, P25381; BAKER RT, 1991, P NATL ACAD SCI USA, V88, P1090, DOI 10.1073/pnas.88.4.1090; BAKER RT, 1991, NUCLEIC ACIDS RES, V19, P1035, DOI 10.1093/nar/19.5.1035; BAKER RT, 1992, J BIOL CHEM, V267, P23364; BARTEL B, 1990, EMBO J, V9, P3179, DOI 10.1002/j.1460-2075.1990.tb07516.x; BUTT TR, 1989, P NATL ACAD SCI USA, V86, P2540, DOI 10.1073/pnas.86.8.2540; CHAN YL, 1995, BIOCHEM BIOPH RES CO, V215, P682, DOI 10.1006/bbrc.1995.2518; CHAU V, 1989, SCIENCE, V243, P1576, DOI 10.1126/science.2538923; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; ECKER DJ, 1989, J BIOL CHEM, V264, P7715; FINLEY D, 1987, CELL, V48, P1035, DOI 10.1016/0092-8674(87)90711-2; FINLEY D, 1989, NATURE, V338, P394, DOI 10.1038/338394a0; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; GUARENTE L, 1982, P NATL ACAD SCI-BIOL, V79, P7410, DOI 10.1073/pnas.79.23.7410; HOFFMAN CS, 1987, GENE, V57, P267, DOI 10.1016/0378-1119(87)90131-4; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JOHNSON ES, 1992, EMBO J, V11, P497, DOI 10.1002/j.1460-2075.1992.tb05080.x; JOHNSON ES, 1995, J BIOL CHEM, V270, P17442, DOI 10.1074/jbc.270.29.17442; JONES D, 1993, J BIOL CHEM, V268, P19545; KALOGEROPOULOS A, 1995, YEAST, V11, P555, DOI 10.1002/yea.320110605; KAS K, 1992, BIOCHEM BIOPH RES CO, V187, P927, DOI 10.1016/0006-291X(92)91286-Y; LUND PK, 1985, J BIOL CHEM, V260, P7609; MAGER WH, 1990, BIOCHIM BIOPHYS ACTA, V1050, P351, DOI 10.1016/0167-4781(90)90193-6; MICHIELS L, 1993, ONCOGENE, V8, P2537; MORRICE NA, 1994, FEBS LETT, V351, P171, DOI 10.1016/0014-5793(94)00854-X; NICK HP, 1985, ANAL BIOCHEM, V148, P93, DOI 10.1016/0003-2697(85)90632-3; OLVERA J, 1993, J BIOL CHEM, V268, P17967; OZKAYNAK E, 1987, EMBO J, V6, P1429, DOI 10.1002/j.1460-2075.1987.tb02384.x; PAPA FR, 1993, NATURE, V366, P313, DOI 10.1038/366313a0; PLANTA RJ, 1988, TRENDS GENET, V4, P64, DOI 10.1016/0168-9525(88)90042-X; REDMAN KL, 1989, NATURE, V338, P438, DOI 10.1038/338438a0; ROTHSTEIN R, 1991, METHOD ENZYMOL, V194, P281; SABIN EA, 1989, BIO-TECHNOL, V7, P705, DOI 10.1038/nbt0789-705; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; SPENCE J, 1995, MOL CELL BIOL, V15, P1265; TEEM JL, 1983, P NATL ACAD SCI-BIOL, V80, P4403, DOI 10.1073/pnas.80.14.4403; TOBIAS JW, 1991, J BIOL CHEM, V266, P12021; VARSHAVSKY A, 1992, CELL, V69, P725, DOI 10.1016/0092-8674(92)90285-K; Warner J R, 1978, Methods Cell Biol, V20, P45, DOI 10.1016/S0091-679X(08)62008-7; WOOLFORD JL, 1991, MOL CELLULAR BIOL YE, V1, P587; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; YOO Y, 1989, J BIOL CHEM, V264, P17078	47	20	24	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 7	1996	271	23					13549	13555		10.1074/jbc.271.23.13549	http://dx.doi.org/10.1074/jbc.271.23.13549			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UP385	8662789	hybrid			2022-12-25	WOS:A1996UP38500038
J	Rohde, M; Warthoe, P; Gjetting, T; Lukas, J; Bartek, J; Strauss, M				Rohde, M; Warthoe, P; Gjetting, T; Lukas, J; Bartek, J; Strauss, M			The retinoblastoma protein modulates expression of genes coding for diverse classes of proteins including components of the extracellular matrix	ONCOGENE			English	Article						retinoblastoma protein; gene regulation; thrombospondin; endothelin; differential display; DDRT-PCR	TRANSFORMING GROWTH FACTOR-BETA-1; CELL-CYCLE; SUSCEPTIBILITY GENE; MESSENGER-RNA; DIFFERENTIAL DISPLAY; BINDING PROTEIN; PRODUCT; TRANSCRIPTION; SEQUENCE; CLONING	The product of the retinoblastoma susceptibility gene, pRb, is a negative regulator of cell growth. It functions by regulating the activity of transcription factors. Rb represses some genes by sequestering or inactivating the positive transcription factor E2F and seems to activate some others by interacting with factors like Spl or ATF-2, However, there are only a few examples of genes which are positively regulated by pRb. In order to find out if there are common mechanisms for promoter regulation by pRb, we were interested to identify more genes which are either stimulated or repressed by pRb, Using the method of differential display (DDRT-PCR) in combination with nuclear run-on analyses we were able to detect a number of genes which are upregulated by ectopic expression of the Rb gene in Rb-deficient mammary carcinoma cells, We could demonstrate not only stimulation of the endogenous mutant Rb gene but also positive regulation of genes coding for diverse classes of proteins, including the endothelial growth and the proteoglycans versican and PG40, As a second approach, we investigated gene expression in cell lines established from Rb deficient heterozygous and homozygous knockout mouse embryos and normal mice, We have identified several genes the expression of which correlates positively or negatively with the presence of Rb. These data provide further evidence for pRb being a master regulator of a complex network of gene activities defining the difference between dividing and resting or differentiated cells.	DANISH CANC SOC,DIV TUMOR BIOL,DEPT CELL CYCLE & CANC,DK-2100 COPENHAGEN,DENMARK; HUMBOLDT UNIV BERLIN,MPG GRP,MAX DELBRUCK CTR MOLEC MED,D-13122 BERLIN,GERMANY	Danish Cancer Society; Helmholtz Association; Max Delbruck Center for Molecular Medicine; Humboldt University of Berlin			Gjetting, Torben/A-6066-2012	Warthoe, peterwarthoe@gmail.com/0000-0003-3840-5460; Lukas, Jiri/0000-0001-9087-506X				BALEY PA, 1990, J CLIN INVEST, V85, P1320, DOI 10.1172/JCI114570; BARTEK J, 1992, ONCOGENE, V7, P101; Bauer D, 1994, PCR Methods Appl, V4, pS97; BAUER D, 1993, NUCLEIC ACIDS RES, V21, P4272, DOI 10.1093/nar/21.18.4272; BLOCH KD, 1989, J BIOL CHEM, V264, P10851; BORNSTEIN P, 1992, FASEB J, V6, P3290, DOI 10.1096/fasebj.6.14.1426766; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; CHEN LI, 1994, MOL CELL BIOL, V14, P4380, DOI 10.1128/MCB.14.7.4380; CLARKE AR, 1992, NATURE, V359, P328, DOI 10.1038/359328a0; DEFEOJONES D, 1991, NATURE, V352, P251, DOI 10.1038/352251a0; ECONOMOS K, 1992, CANCER RES, V52, P554; EWEN ME, 1995, GENE DEV, V9, P204, DOI 10.1101/gad.9.2.204; FRAMSON P, 1993, J BIOL CHEM, V268, P4989; FRIEND SH, 1987, P NATL ACAD SCI USA, V84, P9059, DOI 10.1073/pnas.84.24.9059; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; GILL RM, 1994, CELL GROWTH DIFFER, V5, P467; GJETTING T, 1995, BIOL CHEM H-S, V376, P441; GOODRICH DW, 1991, CELL, V67, P293, DOI 10.1016/0092-8674(91)90181-W; GU W, 1993, CELL, V72, P309, DOI 10.1016/0092-8674(93)90110-C; GUNG YK, 1987, SCIENCE, V236, P1675; HAGEMEIER C, 1993, P NATL ACAD SCI USA, V90, P1580, DOI 10.1073/pnas.90.4.1580; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; HARBOUR JW, 1988, SCIENCE, V241, P353, DOI 10.1126/science.2838909; HELIN K, 1992, CELL, V70, P337, DOI 10.1016/0092-8674(92)90107-N; HOROWITZ JM, 1989, SCIENCE, V243, P937, DOI 10.1126/science.2521957; HOROWITZ JM, 1990, P NATL ACAD SCI USA, V87, P2775, DOI 10.1073/pnas.87.7.2775; INOUE A, 1989, J BIOL CHEM, V264, P14954; IRUELAARISPE ML, 1993, DEV DYNAM, V197, P40, DOI 10.1002/aja.1001970105; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; KIM SJ, 1991, P NATL ACAD SCI USA, V88, P3052, DOI 10.1073/pnas.88.8.3052; KIM SJ, 1992, MOL CELL BIOL, V12, P2455, DOI 10.1128/MCB.12.6.2455; KIM SJ, 1992, NATURE, V358, P331, DOI 10.1038/358331a0; KOUZARIDES T, 1995, SEMIN CANCER BIOL, V6, P91, DOI 10.1006/scbi.1995.0012; KRUSIUS T, 1986, P NATL ACAD SCI USA, V83, P7683, DOI 10.1073/pnas.83.20.7683; LAHAV J, 1993, BIOCHIM BIOPHYS ACTA, V1182, P1, DOI 10.1016/0925-4439(93)90146-R; LAIHO M, 1990, CELL, V62, P175, DOI 10.1016/0092-8674(90)90251-9; LEE EYHP, 1988, SCIENCE, V241, P218, DOI 10.1126/science.3388033; Lee Hu-Hui, 1995, Gene Expression, V4, P95; LEE ME, 1990, J BIOL CHEM, V265, P10446; LEE WH, 1987, SCIENCE, V235, P1394, DOI 10.1126/science.3823889; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; LIANG P, 1993, NUCLEIC ACIDS RES, V21, P3269, DOI 10.1093/nar/21.14.3269; LIANG P, 1995, IN PRESS METHODS ENZ; LUDLOW JW, 1990, CELL, V60, P387, DOI 10.1016/0092-8674(90)90590-B; LUKAS J, 1995, MOL CELL BIOL, V15, P2600; LUKAS J, 1994, J CELL BIOL, V125, P625, DOI 10.1083/jcb.125.3.625; MIHARA K, 1989, SCIENCE, V246, P1300, DOI 10.1126/science.2588006; MORRIS GF, 1991, J VIROL, V65, P6397, DOI 10.1128/JVI.65.12.6397-6406.1991; MULLER H, 1994, P NATL ACAD SCI USA, V91, P2945, DOI 10.1073/pnas.91.8.2945; NASO MF, 1994, J BIOL CHEM, V269, P32999; PARK K, 1994, J BIOL CHEM, V269, P6083; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; ROBBINS PD, 1990, NATURE, V346, P668, DOI 10.1038/346668a0; RUSTGI AK, 1991, NATURE, V352, P541, DOI 10.1038/352541a0; SCHNEIDER JW, 1994, SCIENCE, V264, P1467, DOI 10.1126/science.8197461; SCHONHERR E, 1991, J BIOL CHEM, V266, P17640; SHAN B, 1992, MOL CELL BIOL, V12, P5620, DOI 10.1128/MCB.12.12.5620; SHAN B, 1994, MOL CELL BIOL, V14, P299, DOI 10.1128/MCB.14.1.299; SHAO ZH, 1995, P NATL ACAD SCI USA, V92, P3115, DOI 10.1073/pnas.92.8.3115; STRAUSS M, 1990, ONCOGENE, V5, P1223; STRAUSS M, 1995, NAT MED, V1, P1245, DOI 10.1038/nm1295-1245; TANG A, 1988, SCIENCE, V242, P263, DOI 10.1126/science.3175651; UDVADIA AJ, 1995, P NATL ACAD SCI USA, V92, P3953, DOI 10.1073/pnas.92.9.3953; WANG CY, 1993, SCIENCE, V260, P1330, DOI 10.1126/science.8493578; Warthoe Peter, 1995, P421; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WEINTRAUB SJ, 1995, NATURE, V375, P812, DOI 10.1038/375812a0; WOLF YG, 1994, J CLIN INVEST, V93, P1172, DOI 10.1172/JCI117070; YANAGISAWA M, 1988, NATURE, V332, P411, DOI 10.1038/332411a0; ZIMMERMANN DR, 1989, EMBO J, V8, P2975, DOI 10.1002/j.1460-2075.1989.tb08447.x	70	24	24	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN 6	1996	12	11					2393	2401						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UQ220	8649780				2022-12-25	WOS:A1996UQ22000017
J	Deng, G; Royle, G; Wang, S; Crain, K; Loskutoff, DJ				Deng, G; Royle, G; Wang, S; Crain, K; Loskutoff, DJ			Structural and functional analysis of the plasminogen activator inhibitor-1 binding motif in the somatomedin B domain of vitronectin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-ENDOTHELIAL CELLS; EXTRACELLULAR-MATRIX; S-PROTEIN; THROMBIN; CLONING; LATENT; PLASMA; IDENTIFICATION; INACTIVATION; SPECIFICITY	Plasminogen activator inhibitor 1 (PAI-1) binds to the somatomedin B (SMB) domain of vitronectin (VN), a domain present in at least seven other proteins. In this study, we investigate the PAI-1 binding activity of these SMB homologs and attempt to more specifically localize the PAI-1 binding site within this domain. SMB(VN) and several of its homologs were expressed in Escherichia coli, purified, and tested for PAI-1 binding activity in a competitive ligand binding assay. Although recombinant SMB(VN) was fully active in this assay, none of the homologs bound to PAT-1 or competed with VN for PAI-1 binding. These inactive homologs are structurally related to SMB(VN), having 33-45% sequence identity and containing all 8 cysteines at conserved positions. Thus, homolog-scanning experiments were conducted by exchanging progressively larger portions of the NH2- or COOH-terminal regions of active SMB(VN) with the corresponding regions of the inactive homologs. These experiments revealed that the minimum PAI-1-binding sequence was present in the central region (residues 12-30) of SMB(VN). Alanine scanning mutagenesis further demonstrated that each of the 8 cysteines as well as Gly(12), Asp(22), Leu(24), Try(27), Tyr(28) and Asp(34) were critical for PAI-1 binding and were required to stabilize PAI-1 activity. These results indicate that the PAI-1 binding motif is localized to residues 12-30 of SMB(VN) and suggest that this motif is anchored in the active conformation by disulfide bonds.	Scripps Res Inst, RES INST, DEPT VASC BIOL, LA JOLLA, CA 92037 USA	Scripps Research Institute					NHLBI NIH HHS [HL31950, HL07195-19, HL09400-01] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007195, F32HL009400, P01HL031950] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BAUGHMAN G, 1992, J IMMUNOL, V149, P1488; BERKENPAS MB, 1995, EMBO J, V14, P2969, DOI 10.1002/j.1460-2075.1995.tb07299.x; BUCKLEY MF, 1990, J BIOL CHEM, V265, P17506; DANO K, 1985, ADV CANCER RES, V44, P139, DOI 10.1016/S0065-230X(08)60028-7; DECLERCK PJ, 1988, J BIOL CHEM, V263, P15454; DEISSLER H, 1995, J BIOL CHEM, V270, P9849, DOI 10.1074/jbc.270.17.9849; DENG G, 1995, THROMB HAEMOSTASIS, V74, P66; EHRLICH HJ, 1990, J BIOL CHEM, V265, P13029; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; GRUNDMANN U, 1990, DNA CELL BIOL, V9, P243, DOI 10.1089/dna.1990.9.243; HEKMAN CM, 1988, BIOCHEMISTRY-US, V27, P2911, DOI 10.1021/bi00408a037; HEKMAN CM, 1985, J BIOL CHEM, V260, P11581; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; HUBER R, 1989, BIOCHEMISTRY-US, V28, P8951, DOI 10.1021/bi00449a001; JENNE D, 1985, EMBO J, V4, P3153, DOI 10.1002/j.1460-2075.1985.tb04058.x; KOOISTRA T, 1986, BIOCHEM J, V239, P497, DOI 10.1042/bj2390497; KOST C, 1992, J BIOL CHEM, V267, P12098; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAWRENCE DA, 1994, J BIOL CHEM, V269, P15223; LEVIN EG, 1987, BLOOD, V70, P1090; LOSKUTOFF DJ, 1989, PROG HEMOST THROMB, V9, P87; LUPU F, 1993, ARTERIOSCLER THROMB, V13, P1090, DOI 10.1161/01.ATV.13.7.1090; MERBERG DM, 1993, INT CONGR SER, V1042, P45; MIMURO J, 1987, BLOOD, V70, P721; MIMURO J, 1989, J BIOL CHEM, V264, P5058; MIMURO J, 1993, BIOCHEMISTRY-US, V32, P2314, DOI 10.1021/bi00060a024; MOTTONEN J, 1992, NATURE, V355, P270, DOI 10.1038/355270a0; MURATA J, 1994, J BIOL CHEM, V269, P30479; NASKI MC, 1993, J BIOL CHEM, V268, P12367; PEARSON A, 1995, P NATL ACAD SCI USA, V92, P4056, DOI 10.1073/pnas.92.9.4056; SAKSELA O, 1988, ANNU REV CELL BIOL, V4, P93, DOI 10.1146/annurev.cb.04.110188.000521; SALONEN EM, 1989, J BIOL CHEM, V264, P6339; SATO R, 1990, J BIOL CHEM, V265, P21232; SCHLEEF RR, 1985, J LAB CLIN MED, V106, P408; SEIFFERT D, 1991, P NATL ACAD SCI USA, V88, P9402, DOI 10.1073/pnas.88.21.9402; SEIFFERT D, 1991, J BIOL CHEM, V266, P2824; SEIFFERT D, 1994, J BIOL CHEM, V269, P2659; SEIFFERT D, 1991, BIOCHIM BIOPHYS ACTA, V1078, P23, DOI 10.1016/0167-4838(91)90087-G; SIGURDARDOTTIR O, 1994, BBA-PROTEIN STRUCT M, V1208, P104, DOI 10.1016/0167-4838(94)90166-X; TOMASINI BR, 1990, PROGR HEMOSTASIS THR, P269; TUCKER HM, 1995, NAT STRUCT BIOL, V2, P442, DOI 10.1038/nsb0695-442; VANMEIJER M, 1995, FIBRINOLYSIS, V9, P263, DOI 10.1016/S0268-9499(95)80015-8; WIMAN B, 1988, FEBS LETT, V242, P125, DOI 10.1016/0014-5793(88)80999-2	44	97	101	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 31	1996	271	22					12716	12723		10.1074/jbc.271.22.12716	http://dx.doi.org/10.1074/jbc.271.22.12716			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UN474	8662688				2022-12-25	WOS:A1996UN47400007
J	HaraYokoyama, M; Kukimoto, I; Nishina, H; Kontani, K; Hirabayashi, Y; Irie, F; Sugiya, H; Furuyama, S; Katada, T				HaraYokoyama, M; Kukimoto, I; Nishina, H; Kontani, K; Hirabayashi, Y; Irie, F; Sugiya, H; Furuyama, S; Katada, T			Inhibition of NAD(+) glycohydrolase and ADP-ribosyl cyclase activities of leukocyte cell surface antigen CD38 by gangliosides	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN TYROSINE KINASES; HL-60 CELLS; MOLECULE; DIFFERENTIATION; ACTIVATION; COMPLEXES; ACID	We have recently reported that gangliosides act as inhibitors of ADP-ribosyltransferases and NAD(+) glycohydrolases (NADase) of pertussis toxin and the C3 exoenzyme from Clostridium botulinum (Hara-Yokoyama, M., Hirabayashi, Y., Irie, F., Syuto, B., Moriishi, H., Susya, H., and Furuyama, S. (1995) J. Biol. Chem. 270, 8115-8121). Here, we investigated the effect of gangliosides on the enzymatic activity of leukocyte cell surface antigen CD38, which is identified as an ecto-NADase (Kontani, K., Nishina, H., Ohoka, Y., Takahashi, K., and Katada, T. (1993) J. Biol. Chem. 268, 16895-16898). Gangliosides G(M1a) and G(Q1b alpha) inhibited the NADase activity in the immunoprecipitate of anti-CD38 antibody from the membrane extract of retinoic acid-treated human leukemic HL-60 cells. Gangliosides also inhibited the NADase activity of the extracellular domain of CD38 antigen that was deprived of the transmembrane domain and was expressed in Escherichia coli as a fusion protein with maltose-binding protein (MBP-CD38). The order of the inhibitory effect of purified ganglioside species on the NADase activity on MBP-CD38 was as follows: G(Q1b alpha) > G(T1b), G(Q1b) > G(D1a), G(D1b), G(M1a),G(M1b), G(D3), G(M3). G(Q1b alpha) inhibited the NADase of MBP-CD38 in a noncompetitive manner versus NAD(+) with a K-i value of about 0.3 mu M. Neither ceramide nor the oligosaccharide moiety of G(Q1b alpha) had an effect on the NADase activity. G(Q1b alpha) G(T1b), and G(Q1b) also efficiently inhibited the ADP-ribosyl cyclase activity of MBP-CD38. At present, gangliosides are the only endogenous species that can block the enzymatic activity of CD38 antigen. The present results suggest a potential role of gangliosides as inhibitors of the ecto-NADases.	UNIV TOKYO,FAC PHARMACEUT SCI,DEPT PHYSIOL CHEM,BUNKYO KU,TOKYO 113,JAPAN; TOKYO INST TECHNOL,DEPT LIFE SCI,MIDORI KU,YOKOHAMA,KANAGAWA 227,JAPAN; INST PHYS & CHEM RES,FRONTIER RES PROGRAM,LAB GLYCOCELL BIOL,WAKO,SAITAMA 35101,JAPAN	University of Tokyo; Tokyo Institute of Technology; RIKEN	HaraYokoyama, M (corresponding author), NIHON UNIV,SCH DENT,DEPT PHYSIOL,2-870-1 SAKAE CHO NISHI,MATSUDO,CHIBA 271,JAPAN.		Kukimoto, I/I-3995-2019	Kukimoto, I/0000-0001-9080-1642; Hirabayashi, Yoshio/0000-0002-5774-7354				ANDO S, 1992, J BIOCHEM, V111, P287, DOI 10.1093/oxfordjournals.jbchem.a123751; ANDO S, 1989, J BIOL CHEM, V264, P3478; BOHUSLAV J, 1993, EUR J IMMUNOL, V23, P825, DOI 10.1002/eji.1830230409; CINEK T, 1992, J IMMUNOL, V149, P2262; FRA AM, 1994, J BIOL CHEM, V269, P30745; FUNARO A, 1990, J IMMUNOL, V145, P2390; HARAYOKOYAMA M, 1995, J BIOL CHEM, V270, P8115, DOI 10.1074/jbc.270.14.8115; HELLMICH MR, 1991, CELL REGUL, V2, P193, DOI 10.1091/mbc.2.3.193; HIRABAYASHI Y, 1988, J CHROMATOGR, V445, P377, DOI 10.1016/S0021-9673(01)84550-7; HIRABAYASHI Y, 1992, J BIOL CHEM, V267, P12973; HIRATA Y, 1994, FEBS LETT, V356, P244, DOI 10.1016/0014-5793(94)01279-2; HOWARD M, 1993, SCIENCE, V262, P1056, DOI 10.1126/science.8235624; INAGEDA K, 1995, J BIOCHEM-TOKYO, V117, P125, DOI 10.1093/oxfordjournals.jbchem.a124698; JACKSON DG, 1990, J IMMUNOL, V144, P2811; KAISHO T, 1994, P NATL ACAD SCI USA, V91, P5325, DOI 10.1073/pnas.91.12.5325; KIRKHAM PA, 1994, IMMUNOLOGY, V83, P513; KONTANI K, 1993, J BIOL CHEM, V268, P16895; Kontani K, 1996, J BIOL CHEM, V271, P1534; KUMAGAI MA, 1995, J EXP MED, V181, P1101, DOI 10.1084/jem.181.3.1101; LI Q, 1994, BIOCHEM BIOPH RES CO, V202, P629, DOI 10.1006/bbrc.1994.1974; MAEHAMA T, 1995, J BIOL CHEM, V270, P22747, DOI 10.1074/jbc.270.39.22747; MALAVASI F, 1992, INT J CLIN LAB RES, V22, P73, DOI 10.1007/BF02591400; MUTOH T, 1995, P NATL ACAD SCI USA, V92, P5087, DOI 10.1073/pnas.92.11.5087; NOJIRI H, 1991, J BIOL CHEM, V266, P4531; POWELL LD, 1994, J BIOL CHEM, V269, P10628; SHIMA T, 1969, J BIOL CHEM, V244, P6632; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; STATES DJ, 1992, TRENDS BIOCHEM SCI, V17, P495, DOI 10.1016/0968-0004(92)90337-9; STEFANOVA I, 1991, SCIENCE, V254, P1016, DOI 10.1126/science.1719635; SVENNERHOLM L, 1964, J LIPID RES, V5, P145; TAKAHASHI K, 1995, FEBS LETT, V371, P204, DOI 10.1016/0014-5793(95)00914-U; TAKI T, 1986, J BIOL CHEM, V261, P3075; WANG J, 1994, J IMMUNOL, V153, P4048; YAMASHITA Y, 1995, IMMUNOLOGY, V85, P248; YOHE HC, 1976, J BIOL CHEM, V251, P7083; ZHOU QG, 1994, J BIOL CHEM, V269, P1959; ZUPO S, 1994, EUR J IMMUNOL, V24, P1218, DOI 10.1002/eji.1830240532	37	29	30	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 31	1996	271	22					12951	12955		10.1074/jbc.271.22.12951	http://dx.doi.org/10.1074/jbc.271.22.12951			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UN474	8662799	hybrid			2022-12-25	WOS:A1996UN47400043
J	Poon, RYC; Jiang, W; Toyoshima, H; Hunter, T				Poon, RYC; Jiang, W; Toyoshima, H; Hunter, T			Cyclin-dependent kinases are inactivated by a combination of p21 and Thr-14/Tyr-15 phosphorylation after UV-induced DNA damage	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IONIZING-RADIATION; MICE DEFICIENT; P53; APOPTOSIS; PROTEIN; CELLS; INHIBITION; INDUCTION; SUBUNIT; ANTIGEN	The cyclin-dependent kinase (CDK) inhibitor p21 is induced by the tumor suppressor gene product p53 and is thought to be important for the arrest of the cell cycle following DNA damage. Here we have investigated the contribution of p21 in inhibiting different cyclin-CDK complexes that drive different cell cycle transitions following UV irradiation-induced DNA damage in normal human fibroblasts and immortalized rodent fibroblasts. When cells were exposed to a low dose of UV irradiation, both p53 and p21 were induced; the protein kinase activities associated with Cdc2, Cdk2, and Cdk4 were inhibited; and there was a good correlation between their inhibition and binding to p21. p21 alone is likely to be sufficient for the inhibition of Cdk2 because all the cyclin-complexed forms of Cdk2 were associated with p21 after irradiation. In contrast, only a small proportion of Cdk4 and Cdc2 was complexed with p21, although the level of Cdk4 associated with either p21 or p27 was increased after irradiation. Furthermore, recombinant p21 added to an unirradiated cell lysate at the same level as that induced by irradiation damage inhibited only the kinase activity associated with Cdk2. Cdc2 is likely to be inhibited by Thr-14/Tyr-15 phosphorylation after irradiation because Cdc2 was tyrosine-phosphorylated, and recombinant Cdc25 was able to increase its kinase activity significantly. Taken together, these results suggest that different CDKs are inhibited by different mechanisms following UV-induced DNA damage: Cdk2 is inhibited by the elevated level of p21; Cdk4 is inhibited by cooperation of p21 with other CDK inhibitors, like p27, and possibly by phosphorylation; and Cdc2 is inhibited by Thr-14/Tyr-15 phosphorylation. It is likely that these underlying mechanisms that inactivate CDKs are similar for other kinds of DNA damage.	SALK INST BIOL STUDIES,LA JOLLA,CA 92037	Salk Institute				Poon, Randy/0000-0001-5571-6231; Jiang, Wei/0000-0002-2309-9571	NCI NIH HHS [CA39780, CA14195] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R35CA039780, P30CA014195] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		APRELIKOVA O, 1995, J BIOL CHEM, V270, P18195, DOI 10.1074/jbc.270.31.18195; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; CHAN FKM, 1995, MOL CELL BIOL, V15, P2682; CHEN JJ, 1995, NATURE, V374, P386, DOI 10.1038/374386a0; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; DI LEONARDO A, 1994, GENE DEV, V8, P2540, DOI 10.1101/gad.8.21.2540; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FLORESROZAS H, 1994, P NATL ACAD SCI USA, V91, P8656; GOUBIN F, 1995, ONCOGENE, V10, P2281; GREENBLATT MS, 1994, CANCER RES, V54, P4855; GU Y, 1993, NATURE, V366, P707, DOI 10.1038/366707a0; GUAN KL, 1994, GENE DEV, V8, P2939, DOI 10.1101/gad.8.24.2939; GUO K, 1995, MOL CELL BIOL, V15, P3823; HALEVY O, 1995, SCIENCE, V267, P1018, DOI 10.1126/science.7863327; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; HARPER JW, 1995, MOL BIOL CELL, V6, P387, DOI 10.1091/mbc.6.4.387; HARPER JW, 1993, CELL, V75, P805; HEICHMAN KA, 1994, CELL, V79, P557, DOI 10.1016/0092-8674(94)90541-X; HERZINGER T, 1995, ONCOGENE, V11, P2151; JIANG HP, 1994, ONCOGENE, V9, P3397; KASTAN MB, 1991, CANCER RES, V51, P6304; KING RW, 1994, CELL, V79, P563, DOI 10.1016/0092-8674(94)90542-8; KOBAYASHI H, 1991, COLD SH Q B, V56, P437; KUMAGAI A, 1995, MOL BIOL CELL, V6, P199, DOI 10.1091/mbc.6.2.199; LEE MH, 1995, GENE DEV, V9, P639, DOI 10.1101/gad.9.6.639; LI R, 1994, NATURE, V371, P534, DOI 10.1038/371534a0; LI Y, 1994, ONCOGENE, V9, P22621; LOTEM J, 1993, BLOOD, V82, P1092, DOI 10.1182/blood.V82.4.1092.bloodjournal8241092; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; LUO Y, 1995, NATURE, V375, P159, DOI 10.1038/375159a0; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; MATSUOKA S, 1995, GENE DEV, V9, P650, DOI 10.1101/gad.9.6.650; MICHIELI P, 1994, CANCER RES, V54, P3391; MISSERO C, 1995, P NATL ACAD SCI USA, V92, P5451, DOI 10.1073/pnas.92.12.5451; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; MUELLER PR, 1995, SCIENCE, V270, P86, DOI 10.1126/science.270.5233.86; MUSCHEL RJ, 1993, CANCER RES, V53, P1128; NAKANISHI M, 1995, EMBO J, V14, P555, DOI 10.1002/j.1460-2075.1995.tb07031.x; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; PARKER SB, 1995, SCIENCE, V267, P1024, DOI 10.1126/science.7863329; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; PONTEN F, 1995, J INVEST DERMATOL, V105, P402, DOI 10.1111/1523-1747.ep12321071; POON RYC, 1995, MOL BIOL CELL, V6, P1197, DOI 10.1091/mbc.6.9.1197; POON RYC, 1994, J CELL SCI, V107, P2789; POON RYC, 1993, EMBO J, V12, P3123, DOI 10.1002/j.1460-2075.1993.tb05981.x; POON RYC, 1995, SCIENCE, V270, P90, DOI 10.1126/science.270.5233.90; QUELLE DE, 1995, CELL, V83, P993; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHEIKH MS, 1994, ONCOGENE, V9, P3407; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SHIVJI MKK, 1994, CURR BIOL, V4, P1062, DOI 10.1016/S0960-9822(00)00244-X; SMYTHE C, 1992, CELL, V68, P787, DOI 10.1016/0092-8674(92)90153-4; STEINMAN RA, 1994, ONCOGENE, V9, P3389; STRAUSFELD UP, 1994, CURR BIOL, V4, P876, DOI 10.1016/S0960-9822(00)00196-2; TERADA Y, 1995, NATURE, V376, P358, DOI 10.1038/376358a0; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; Tyrrell RM, 1996, BIOESSAYS, V18, P139, DOI 10.1002/bies.950180210; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; WALDMAN T, 1995, CANCER RES, V55, P5187; WARBRICK E, 1995, CURR BIOL, V5, P275, DOI 10.1016/S0960-9822(95)00058-3; WASEEM NH, 1990, J CELL SCI, V96, P121; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; ZHANG H, 1994, GENE DEV, V8, P1750, DOI 10.1101/gad.8.15.1750; ZHANG W, 1995, CANCER RES, V55, P668	71	163	164	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 31	1996	271	22					13283	13291		10.1074/jbc.271.22.13283	http://dx.doi.org/10.1074/jbc.271.22.13283			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UN474	8662825	hybrid			2022-12-25	WOS:A1996UN47400091
J	Ye, S; Eriksson, P; Hamsten, A; Kurkinen, M; Humphries, SE; Henney, AM				Ye, S; Eriksson, P; Hamsten, A; Kurkinen, M; Humphries, SE; Henney, AM			Progression of coronary atherosclerosis is associated with a common genetic variant of the human stromelysin-1 promoter which results in reduced gene expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERLEUKIN-1; PROTEIN; METALLOPROTEINASES; INHIBITORS; ACTIVATOR; BINDING; PLAQUES; CELLS	There is a common polymorphism in the promoter sequence of the human stromelysin-1 gene, with one allele having a run of six adenosines (6A) and the other five adenosines (5A), We have previously reported, in a 3-year follow-up study of patients with coronary atherosclerosis, that those patients who are homozygous for the 6A allele show a more rapid progression of the disease, In this study, we have investigated whether the 5A/6A promoter polymorphism plays a role in the regu- lation of stromelysin-1 gene expression, In transient transfection experiments, a stromelysin-1 promoter construct with 6A at the polymorphic site was found to express less of the chloramphenicol acetyltransferase reporter gene than a construct containing 5A. Electrophoretic mobility shift assay and DNase I footprinting revealed the interaction of one or more nuclear protein(s) with the DNA sequence at the 5A/6A polymorphic site. The binding of one of the nucleoprotein factors was more readily detectable with an oligonucleotide probe corresponding to the 6A allele as compared with a probe corresponding to the 5A allele. Replacing the core binding sequence with a random DNA sequence abolished the interaction between the nuclear protein(s) and the probe and also increased reporter gene expression in transiently transfected cells. Thus, the common 5A/6A polymorphism of the human stromelysin-1 promoter appears to play an important role in regulating stromelysin-1 gene expression and may be involved in the progression of coronary heart disease.	UNIV LONDON UNIV COLL, SCH MED, DEPT MED, DIV CARDIOVASC GENET, LONDON WC1E 6JJ, ENGLAND; KAROLINSKA HOSP, KING GUSTAF V RES INST, ATHEROSCLEROSIS RES UNIT, S-17176 STOCKHOLM, SWEDEN; WAYNE STATE UNIV, SCH MED, DEPT PATHOL, DETROIT, MI 48202 USA; WAYNE STATE UNIV, SCH MED, CTR MOLEC MED & GENET, DETROIT, MI 48202 USA	University of London; University College London; UCL Medical School; Karolinska Institutet; Karolinska University Hospital; Wayne State University; Wayne State University			Ye, Shu/C-4067-2009; Ye, Shu/R-6384-2017	Ye, Shu/0000-0002-4126-4278; Humphries, Stephen E/0000-0002-8221-6547; Eriksson, Per/0000-0002-5635-2692				ALKSNIS M, 1991, J BIOL CHEM, V266, P10078; ANDERSON GM, 1993, J BIOL CHEM, V268, P22650; ANGOTTI E, 1994, J BIOL CHEM, V269, P17371; BOUGHARIOS G, 1994, CLIN CHIM ACTA, V231, P69, DOI 10.1016/0009-8981(94)90255-0; BROWN DL, 1995, CIRCULATION, V91, P2125, DOI 10.1161/01.CIR.91.8.2125; DAVIES MJ, 1990, CIRCULATION, V82, P38; DAWSON SJ, 1993, J BIOL CHEM, V268, P10739; DIAZMECO MT, 1991, J BIOL CHEM, V266, P22597; DOLLERY CM, 1995, CIRC RES, V77, P863, DOI 10.1161/01.RES.77.5.863; ERIKSSON P, 1995, P NATL ACAD SCI USA, V92, P1851, DOI 10.1073/pnas.92.6.1851; FRISCH SM, 1987, J BIOL CHEM, V262, P16300; GALIS ZS, 1995, ANN NY ACAD SCI, V748, P501; GALIS ZS, 1994, J CLIN INVEST, V94, P2493, DOI 10.1172/JCI117619; GIOVANNA B, 1991, NUCLEIC ACIDS RES, V19, P3723; HANEMAAIJER R, 1993, BIOCHEM J, V296, P803, DOI 10.1042/bj2960803; HENNEY AM, 1991, P NATL ACAD SCI USA, V88, P8154, DOI 10.1073/pnas.88.18.8154; HUMPHRIES SE, 1995, ARTERIOSCL THROM VAS, V15, P96, DOI 10.1161/01.ATV.15.1.96; IMAI K, 1995, J BIOL CHEM, V270, P6691, DOI 10.1074/jbc.270.12.6691; JACOBSON SG, 1995, NAT GENET, V11, P27, DOI 10.1038/ng0995-27; KALB VF, 1977, ANAL BIOCHEM, V82, P362, DOI 10.1016/0003-2697(77)90173-7; KERR LD, 1988, SCIENCE, V242, P1424, DOI 10.1126/science.2462278; KERR LD, 1990, CELL, V61, P267, DOI 10.1016/0092-8674(90)90807-Q; LIBBY P, 1995, CIRCULATION, V91, P2844, DOI 10.1161/01.CIR.91.11.2844; LIOTTA LA, 1991, CELL, V64, P327, DOI 10.1016/0092-8674(91)90642-C; MATRISIAN LM, 1990, TRENDS GENET, V6, P121, DOI 10.1016/0168-9525(90)90126-Q; MURPHY G, 1985, BIOESSAYS, V2, P55, DOI 10.1002/bies.950020204; MURPHY G, 1991, British Journal of Rheumatology, V30, P25; Murphy G, 1992, Matrix Suppl, V1, P224; Murphy Gillian, 1993, P287; NEWBY AC, 1994, BASIC RES CARDIOL, V89, P59; NIKKARI ST, 1995, CIRCULATION, V92, P1393, DOI 10.1161/01.CIR.92.6.1393; QUINONES S, 1994, BIOCHEM J, V302, P471, DOI 10.1042/bj3020471; QUINONES S, 1989, J BIOL CHEM, V264, P8339; RICHARDSON PD, 1989, LANCET, V2, P941; SANZ L, 1994, J BIOL CHEM, V269, P10044; SHAPIRO SD, 1995, J BIOL CHEM, V270, P6351, DOI 10.1074/jbc.270.11.6351; SIRUMCONNOLLY K, 1991, NUCLEIC ACIDS RES, V19, P335, DOI 10.1093/nar/19.2.335; STARY HC, 1995, ARTERIOSCL THROM VAS, V15, P1512, DOI 10.1161/01.ATV.15.9.1512; TYAGI SC, 1995, ATHEROSCLEROSIS, V116, P43, DOI 10.1016/0021-9150(95)05520-7; WEBER BHF, 1994, NAT GENET, V8, P352, DOI 10.1038/ng1294-352; WOESSNER JF, 1991, FASEB J, V5, P2145, DOI 10.1096/fasebj.5.8.1850705; YANG M, U56422 GENB; YE S, 1995, THROMB HAEMOSTASIS, V74, P837; YE S, 1995, BRIT HEART J, V73, P209	44	416	441	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 31	1996	271	22					13055	13060		10.1074/jbc.271.22.13055	http://dx.doi.org/10.1074/jbc.271.22.13055			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UN474	8662692	hybrid			2022-12-25	WOS:A1996UN47400058
J	Baumann, C; Otridge, J; Gollnick, P				Baumann, C; Otridge, J; Gollnick, P			Kinetic and thermodynamic analysis of the interaction between TRAP (trp RNA-binding attenuation protein) of Bacillus subtilis and trp leader RNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OPERATOR INTERACTION; ESCHERICHIA-COLI; RIBOSOMAL-RNA; OPERON; EXPRESSION; EQUILIBRIUM; ACID	In Bacillus subtilis, expression of the tryptophan biosynthetic genes is regulated in response to tryptophan by an RNA-binding protein called TRAP (trp RNA-binding attenuation protein). TRAP has been shown to contain 11 identical subunits arranged in a symmetrical ring. Kinetic and thermodynamic parameters of the interaction between tryptophan-activated TRAP and trp leader RNA were studied. Results from glycerol gradients and mobility shift gels indicate that two TRAP 11-mers bind to each trp leader RNA. A filter binding assay was used to determine an apparent binding constant of 8.0 +/- 1.3 x 10(9) M(-1) (K-d = 0.12 +/- 0.02 nM) for TRAP and an RNA containing residues +36 to +92 of the trp leader RNA in 1 mM L-tryptophan at 37 degrees C. The temperature dependence of K-app was somewhat unexpected demonstrating that the Delta H of the interaction is highly unfavorable at +15.9 kcal mol(-1). Therefore, the interaction is completely driven by a Delta S of +97 cal mol(-1) K-1. The interaction between tryptophan-activated TRAP and trp leader RNA displayed broad salt and pH activity profiles. Finally, the rate of RNA dissociation from the RNA . TRAP . tryptophan ternary complex was found to be very slow in high concentrations of tryptophan (>40 mu M) but increased in lower tryptophan concentrations. This suggests that dissociation of tryptophan from the ternary complex is the rate-limiting step in RNA dissociation.	SUNY BUFFALO,DEPT BIOL SCI,BUFFALO,NY 14260	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo								ANTSON AA, 1994, J MOL BIOL, V244, P1, DOI 10.1006/jmbi.1994.1698; ANTSON AA, 1995, NATURE, V374, P693, DOI 10.1038/374693a0; BABITZKE P, 1995, P NATL ACAD SCI USA, V92, P7916, DOI 10.1073/pnas.92.17.7916; BABITZKE P, 1995, J BIOL CHEM, V270, P12452, DOI 10.1074/jbc.270.21.12452; BABITZKE P, 1993, P NATL ACAD SCI USA, V90, P133, DOI 10.1073/pnas.90.1.133; BABITZKE P, 1994, J BIOL CHEM, V269, P16597; BEAUDETTE NV, 1980, CRC CR REV BIOCH MOL, V9, P145, DOI 10.3109/10409238009105433; BURD CG, 1994, SCIENCE, V265, P615, DOI 10.1126/science.8036511; CAMMACK KA, 1970, BIOCHEM J, V117, P745, DOI 10.1042/bj1170745; CAREY J, 1983, BIOCHEMISTRY-US, V22, P2610, DOI 10.1021/bi00280a003; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DRAPER DE, 1995, ANNU REV BIOCHEM, V64, P593, DOI 10.1146/annurev.bi.64.070195.003113; GOLLNICK P, 1994, MOL MICROBIOL, V11, P991, DOI 10.1111/j.1365-2958.1994.tb00377.x; HOFFMAN RJ, 1995, J BACTERIOL, V177, P839, DOI 10.1128/jb.177.3.839-842.1995; HURLBURT BK, 1992, J BIOL CHEM, V267, P16783; KURODA MI, 1988, J BACTERIOL, V170, P3080, DOI 10.1128/jb.170.7.3080-3088.1988; MERINO E, 1995, J BACTERIOL, V177, P6362, DOI 10.1128/jb.177.22.6362-6370.1995; MILLIGAN JF, 1989, BIOCHEMISTRY-US, V28, P2849, DOI 10.1021/bi00433a016; MOUGEL M, 1986, BIOCHEMISTRY-US, V25, P2756, DOI 10.1021/bi00358a003; OTRIDGE J, 1993, P NATL ACAD SCI USA, V90, P128, DOI 10.1073/pnas.90.1.128; RIGGS AD, 1970, J MOL BIOL, V48, P67, DOI 10.1016/0022-2836(70)90219-6; ROMANIUK PJ, 1985, NUCLEIC ACIDS RES, V13, P5369, DOI 10.1093/nar/13.14.5369; Sambrook J., 2002, MOL CLONING LAB MANU; SHIMOTSU H, 1986, J BACTERIOL, V166, P461, DOI 10.1128/jb.166.2.461-471.1986; SLICE LW, 1992, BIOCHEMISTRY-US, V31, P12062, DOI 10.1021/bi00163a014; SLOCK J, 1990, J BACTERIOL, V172, P7211, DOI 10.1128/jb.172.12.7211-7226.1990; SU SL, 1990, BIOCHEMISTRY-US, V29, P6033, DOI 10.1021/bi00477a022; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; WITHERELL GW, 1989, BIOCHEMISTRY-US, V28, P71, DOI 10.1021/bi00427a011; YANG M, 1995, J BACTERIOL, V177, P4272, DOI 10.1128/jb.177.15.4272-4278.1995; YANOFSKY C, 1991, J BACTERIOL, V173, P6009, DOI 10.1128/jb.173.19.6009-6017.1991	31	58	59	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 24	1996	271	21					12269	12274		10.1074/jbc.271.21.12269	http://dx.doi.org/10.1074/jbc.271.21.12269			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UL660	8647825	hybrid			2022-12-25	WOS:A1996UL66000027
J	Chacko, S; Padlan, EA; Portolano, S; McLachlan, SM; Rapoport, B				Chacko, S; Padlan, EA; Portolano, S; McLachlan, SM; Rapoport, B			Structural studies of human autoantibodies - Crystal structure of a thyroid peroxidase autoantibody Fab	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EGG-WHITE LYSOZYME; 3-DIMENSIONAL STRUCTURE; HUMAN-IMMUNOGLOBULIN; RESOLUTION; FRAGMENT; CLONING; DISEASE; GENES; EXPRESSION; REPERTOIRE	The three-dimensional structure of the Fab of TR1.9, a high-affinity IgG1,kappa human autoantibody to thyroid peroxidase, was determined crystallographically to a resolution of 2.0 Angstrom. The combining site was found to be relatively flat, like other antibodies to large proteins, Sequence differences from the most closely related germline genes mainly occur at positions occupied by residues with outward-pointing side chains. An increased deformability of the second and third complementarity determining regions of the heavy chain may result from the replacement of two germline asparagines and the presence of several glycines, and may allow ''induced fit'' in the binding to antigen. Four exposed charged residues, resulting from the use of a particular D (diversity) and J (joining) segments in the assembly of the heavy chain, may contribute to the high affinity of antigen binding. The crystal structure of TR1.9 Fab is the first for a human IgG high-affinity autoantibody.	NIDDK, NIH, MOLEC BIOL LAB, BETHESDA, MD 20895 USA; UNIV CALIF SAN FRANCISCO, THYROID MOL BIOL UNIT 111T, SAN FRANCISCO, CA 94121 USA; VET AFFAIRS MED CTR, SAN FRANCISCO, CA 94121 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); University of California System; University of California San Francisco; US Department of Veterans Affairs; Veterans Health Administration (VHA)					NIDDK NIH HHS [DK 36182] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK036182] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; BRUENGER AT, 1992, X PLOR SYSTEM CRYSTA; CHAZENBALK GD, 1993, J CLIN INVEST, V92, P62, DOI 10.1172/JCI116600; CHOTHIA C, 1989, NATURE, V342, P877, DOI 10.1038/342877a0; CONNOLLY ML, 1983, J APPL CRYSTALLOGR, V16, P548, DOI 10.1107/S0021889883010985; DAVIES DR, 1989, IMMUNE RESPONSE TO STRUCTURALLY DEFINED PROTEINS : THE LYSOZYME MODEL, P125; EDELMAN GM, 1969, P NATL ACAD SCI USA, V63, P78, DOI 10.1073/pnas.63.1.78; EIGENBROT C, 1994, PROTEINS, V18, P49, DOI 10.1002/prot.340180107; EPP O, 1975, BIOCHEMISTRY-US, V14, P4943, DOI 10.1021/bi00693a025; FAN ZC, 1992, J MOL BIOL, V228, P188, DOI 10.1016/0022-2836(92)90500-J; FERSHT AR, 1985, NATURE, V314, P235, DOI 10.1038/314235a0; GUDDAT LW, 1993, P NATL ACAD SCI USA, V90, P4271, DOI 10.1073/pnas.90.9.4271; HARATA K, 1994, ACTA CRYSTALLOGR D, V50, P250, DOI 10.1107/S0907444993013290; HE XM, 1992, P NATL ACAD SCI USA, V89, P7154, DOI 10.1073/pnas.89.15.7154; HUANG DB, 1994, BIOCHEMISTRY-US, V33, P14848, DOI 10.1021/bi00253a024; JANCARIK J, 1991, J APPL CRYSTALLOGR, V24, P409, DOI 10.1107/S0021889891004430; JAUME JC, 1995, J CLIN ENDOCR METAB, V80, P1000, DOI 10.1210/jc.80.3.1000; JONES TA, 1985, METHOD ENZYMOL, V115, P157; Kabat E. A., 1991, SEQUENCES PROTEINS I; KABSCH W, 1993, J APPL CRYSTALLOGR, V26, P795, DOI 10.1107/S0021889893005588; KLEIN R, 1993, EUR J IMMUNOL, V23, P3248, DOI 10.1002/eji.1830231231; KOSHLAND DE, 1973, SCI AM, V229, P52, DOI 10.1038/scientificamerican1073-52; LUZZATI V, 1953, ACTA CRYSTALLOGR, V6, P142, DOI 10.1107/S0365110X53000508; MARQUART M, 1980, J MOL BIOL, V141, P369, DOI 10.1016/0022-2836(80)90252-1; MCLACHLAN SM, 1992, ENDOCR REV, V13, P192, DOI 10.1210/er.13.2.192; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; NISHIKAWA T, 1994, J CLIN ENDOCR METAB, V78, P944, DOI 10.1210/jc.78.4.944; PADLAN EA, 1995, FASEB J, V9, P133, DOI 10.1096/fasebj.9.1.7821752; PADLAN EA, 1990, PROTEINS, V7, P112, DOI 10.1002/prot.340070203; PADLAN EA, 1994, MOL IMMUNOL, V31, P169, DOI 10.1016/0161-5890(94)90001-9; PADLAN EA, 1994, ANTIBODY ANTIGEN COM; PASCUAL V, 1992, J RHEUMATOL, V19, P50; PORTOLANO S, 1993, J IMMUNOL, V151, P2839; PORTOLANO S, 1992, J CLIN INVEST, V90, P720, DOI 10.1172/JCI115943; PORTOLANO S, 1991, BIOCHEM BIOPH RES CO, V179, P372, DOI 10.1016/0006-291X(91)91380-U; PORTOLANO S, 1993, J IMMUNOL, V150, P880; POSNER B, 1993, GENE, V128, P111, DOI 10.1016/0378-1119(93)90161-U; PRUMMEL MF, 1994, MOL CELL ENDOCRINOL, V102, P161, DOI 10.1016/0303-7207(94)90109-0; RAPOPORT B, 1995, IMMUNOL TODAY, V16, P43, DOI 10.1016/0167-5699(95)80070-0; RYPNIEWSKI WR, 1993, BIOCHEMISTRY-US, V32, P9851, DOI 10.1021/bi00088a041; Sasisekharan V., 1962, COLLAGEN, P39; SAUL FA, 1992, PROTEINS, V14, P363, DOI 10.1002/prot.340140305; SHIN EK, 1991, EMBO J, V10, P3641, DOI 10.1002/j.1460-2075.1991.tb04930.x; STRONG RK, 1991, BIOCHEMISTRY-US, V30, P3739, DOI 10.1021/bi00229a022; TOMLINSON IM, 1992, J MOL BIOL, V227, P776, DOI 10.1016/0022-2836(92)90223-7; WILSON IA, 1994, CURR OPIN STRUC BIOL, V4, P857, DOI 10.1016/0959-440X(94)90267-4; WILSON KP, 1992, J BIOL CHEM, V267, P10842; [No title captured]	48	31	31	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 24	1996	271	21					12191	12198		10.1074/jbc.271.21.12191	http://dx.doi.org/10.1074/jbc.271.21.12191			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UL660	8647813	hybrid			2022-12-25	WOS:A1996UL66000015
J	Kobayashi, A; Sogawa, K; FujiiKuriyama, Y				Kobayashi, A; Sogawa, K; FujiiKuriyama, Y			Cooperative interaction between AhR center dot Arnt and Sp1 for the drug-inducible expression of CYP1A1 gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEIN; CYTOCHROME P-450C GENE; PLANAR AROMATIC-COMPOUNDS; DNA-BINDING ACTIVITY; DIOXIN RECEPTOR; REGULATORY ELEMENTS; TRANSCRIPTION; CLONING; 2,3,7,8-TETRACHLORODIBENZO-PARA-DIOXIN; IDENTIFICATION	Expression of CYP1A1 gene is regulated in a substrate-inducible manner through at least two kinds of regulatory DNA elements in addition to the TATA sequence, XRE (xenobiotic responsive element), and BTE (basic transcription element), a GC box sequence, The trans-acting factor on the XRE is a heterodimer consisting of arylhydrocarbon receptor (AhR) and AhR nuclear translocator (Arnt), while Sp1 acts as a regulatory factor on the BTE. We have investigated how these factors interact with one another to induce expression of the CYP1A1 gene. Both in vivo transfection assays using Drosophila Schneider line 2 (SL2) cells, which is devoid of endogenous Sp1, AhR, and Arnt, and in vitro transcription assays using baculovirus-expressed AhR, Amt, and Sp1 proteins revealed that these factors enhanced synergistically expression of the reporter genes driven by a model CYP1A1 promoter, consisting of four repeated XRE sequences and a BTE sequence, in agree ment with previous observation (Yanagida, A., Sogawa, K., Yasumoto, K., and Fujii-Kuriyama, Y. (1990) Mol. Cell. Biol. 10, 1470-1475). We have proved by coimmunoprecipitation assays and DNase I footprinting that both AhR and Arnt interact with the zinc finger domain of Sp1 via their basic HLH/PAS domains. When either the AhR Amt heterodimer or Sp1 was bound to its cognate DNA element, DNA binding of the second factor was facilitated Survey of DNA sequences in the promoter region shows that the XRE and GC box elements are commonly found in the genes whose expressions are induced by polycyclic aromatic hydrocarbons, suggesting that the two regulatory DNA elements and their cognate trans-acting factors constitute a common mechanism for induction of a group of drug-metabolizing enzymes.	TOHOKU UNIV, FAC SCI, DEPT CHEM, SENDAI, MIYAGI 98077, JAPAN	Tohoku University			Kobayashi, Akira/AAN-8003-2020	Kobayashi, Akira/0000-0001-9727-1218				ASMAN DC, 1993, J BIOL CHEM, V268, P12530; BERGHARD A, 1993, MOL CELL BIOL, V13, P677, DOI 10.1128/MCB.13.1.677; BURBACH KM, 1992, P NATL ACAD SCI USA, V89, P8185, DOI 10.1073/pnas.89.17.8185; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; DENIS M, 1988, BIOCHEM BIOPH RES CO, V155, P801, DOI 10.1016/S0006-291X(88)80566-7; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; EMA M, 1992, BIOCHEM BIOPH RES CO, V184, P246, DOI 10.1016/0006-291X(92)91185-S; Emi Y, 1996, J BIOL CHEM, V271, P3952, DOI 10.1074/jbc.271.7.3952; FAVREAU LV, 1991, J BIOL CHEM, V266, P4556; FUJISAWASEHARA A, 1986, NUCLEIC ACIDS RES, V14, P1465; FUJISAWASEHARA A, 1987, NUCLEIC ACIDS RES, V15, P4179, DOI 10.1093/nar/15.10.4179; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HOEY T, 1993, CELL, V72, P247, DOI 10.1016/0092-8674(93)90664-C; JAIN S, 1994, J BIOL CHEM, V269, P31518; KOBAYASHI A, 1995, J BIOCHEM-TOKYO, V117, P91, DOI 10.1093/oxfordjournals.jbchem.a124727; LEE JS, 1993, P NATL ACAD SCI USA, V90, P6145, DOI 10.1073/pnas.90.13.6145; MATSUSHITA N, 1993, J BIOL CHEM, V268, P21002; MCGUIRE J, 1994, MOL CELL BIOL, V14, P2438, DOI 10.1128/MCB.14.4.2438; MERIKA M, 1995, MOL CELL BIOL, V15, P2437; MOROHASHI KI, 1990, J BIOCHEM-TOKYO, V108, P1050, DOI 10.1093/oxfordjournals.jbchem.a123304; NOCERA PPD, 1983, P NATL ACAD SCI USA, V80, P7095; PERDEW GH, 1988, J BIOL CHEM, V263, P13802; PERKINS ND, 1993, EMBO J, V12, P3551, DOI 10.1002/j.1460-2075.1993.tb06029.x; POLAND A, 1982, ANNU REV PHARMACOL, V22, P517, DOI 10.1146/annurev.pa.22.040182.002505; PONGRATZ I, 1992, J BIOL CHEM, V267, P13728; PROKIPCAK RD, 1988, ARCH BIOCHEM BIOPHYS, V267, P811, DOI 10.1016/0003-9861(88)90091-4; REYES H, 1992, SCIENCE, V256, P1193, DOI 10.1126/science.256.5060.1193; RUSHMORE TH, 1990, P NATL ACAD SCI USA, V87, P3826, DOI 10.1073/pnas.87.10.3826; SETO E, 1993, NATURE, V365, P462, DOI 10.1038/365462a0; SOGAWA K, 1995, P NATL ACAD SCI USA, V92, P1936, DOI 10.1073/pnas.92.6.1936; SOGAWA K, 1995, J CANCER RES CLIN, V121, P612, DOI 10.1007/BF01197779; SOGAWA K, 1986, P NATL ACAD SCI USA, V83, P8044, DOI 10.1073/pnas.83.21.8044; SUMMERS MD, 1987, TEXAS AGR EXPT STATI, V1555, P1; WHITELAW M, 1993, MOL CELL BIOL, V13, P2504, DOI 10.1128/MCB.13.4.2504; WHITLOCK JP, 1990, ANNU REV PHARMACOL, V30, P251; WILHELMSSON A, 1990, EMBO J, V9, P69, DOI 10.1002/j.1460-2075.1990.tb08081.x; YANAGIDA A, 1990, MOL CELL BIOL, V10, P1470, DOI 10.1128/MCB.10.4.1470; YASUMOTO K, 1993, THESIS TOHOKU U SEND	38	124	125	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 24	1996	271	21					12310	12316		10.1074/jbc.271.21.12310	http://dx.doi.org/10.1074/jbc.271.21.12310			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UL660	8647831	hybrid			2022-12-25	WOS:A1996UL66000033
J	Komissarov, AA; Calcutt, MJ; Marchbank, MT; Peletskaya, EN; Deutscher, SL				Komissarov, AA; Calcutt, MJ; Marchbank, MT; Peletskaya, EN; Deutscher, SL			Equilibrium binding studies of recombinant anti-single-stranded DNA Fab - Role of heavy chain complementarity-determining regions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ULTRAVIOLET CIRCULAR-DICHROISM; VARIABLE REGIONS; ANTIBODIES; PROTEIN; AUTOANTIBODY; MICE	We previously isolated nucleic acid-binding antibody fragments (Fab) from bacteriophage display libraries representing the immunoglobulin repertoire of autoimmune mice to expedite the analysis of antibody-DNA recognition, In the present study, the binding properties of one such anti-DNA Fab, high affinity single-stranded (ss) DNA-binding Fab (DNA-1), were defined using equilibrium gel filtration and fluorescence titration, Results demonstrated that DNA-1 had a marked preference for oligo(dT) (100 nM dissociation constant) and required oligo(dT) >5 nucleotides in length, A detailed analysis of the involvement of the individual heavy chain (H) complementarity determining regions (CDR) ensued using previously constructed HCDR transplantation mutants between DNA-1 and low affinity ssDNA-binding Fab (D5), a Fab that binds poorly to DNA (Calcutt, M. J. Komissarov, A. A., Marchbank, M. T., and Deutscher, S. L. (1996) Gene (Amst.) 168, 9-14), Circular dichroism studies indicated that the wild type and mutant Fab studied were of similar overall secondary structure and may contain similar combining site shapes. The conversion of D5 to a high affinity oligo(dT)-binding Fab occurred only in the presence of DNA-1 HCDR3. Results with site-specific mutants in HCDR1 further suggested a role of residue 33 in interaction with nucleic acid, The results of these studies are compared with previously published data on DNA-antibody recognition.	UNIV MISSOURI, SCH MED, DEPT BIOCHEM, COLUMBIA, MO 65212 USA	University of Missouri System; University of Missouri Columbia					NIGMS NIH HHS [GM-47979] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM047979] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARBAS SM, 1995, P NATL ACAD SCI USA, V92, P2529, DOI 10.1073/pnas.92.7.2529; BARRY MM, 1994, J BIOL CHEM, V269, P3623; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAHMS S, 1980, J MOL BIOL, V138, P149, DOI 10.1016/0022-2836(80)90282-X; CALCUTT MJ, 1993, GENE, V137, P77, DOI 10.1016/0378-1119(93)90254-Z; Calcutt MJ, 1996, GENE, V168, P9, DOI 10.1016/0378-1119(95)00717-2; CHOTHIA C, 1987, J MOL BIOL, V196, P901, DOI 10.1016/0022-2836(87)90412-8; CYGLER M, 1987, J BIOL CHEM, V262, P643; DEUTSCHER SL, 1988, P NATL ACAD SCI USA, V85, P3299, DOI 10.1073/pnas.85.10.3299; GULLIVER GA, 1994, J BIOL CHEM, V269, P7934; GULLIVER GA, 1995, BIOCHEMISTRY-US, V34, P5158, DOI 10.1021/bi00015a029; GULLIVER GA, 1994, J BIOL CHEM, V269, P24040; HERRON JN, 1991, PROTEINS, V11, P159, DOI 10.1002/prot.340110302; Higuchi R, 1990, PCR PROTOCOLS GUIDE, P177; HUMMEL JP, 1962, BIOCHIM BIOPHYS ACTA, V63, P530, DOI 10.1016/0006-3002(62)90124-5; Kabat E. A., 1987, SEQUENCES PROTEINS I, DOI 10.1016/0003-2697(84)90805-4; KIM CS, 1994, BIOCHEMISTRY-US, V33, P14197, DOI 10.1021/bi00251a031; KOWALCZYKOWSKI SC, 1981, J MOL BIOL, V145, P75, DOI 10.1016/0022-2836(81)90335-1; KRISHNAN MR, 1993, J IMMUNOL, V150, P4948; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LASCOMBE MB, 1989, P NATL ACAD SCI USA, V86, P607, DOI 10.1073/pnas.86.2.607; MARION TN, 1992, IMMUNOL REV, V128, P123, DOI 10.1111/j.1600-065X.1992.tb00835.x; POLYMENIS M, 1994, J IMMUNOL, V152, P5318; POWELL MD, 1993, BIOCHEMISTRY-US, V32, P12538, DOI 10.1021/bi00097a034; RADIC MZ, 1993, J IMMUNOL, V150, P4966; RADIC MZ, 1994, ANNU REV IMMUNOL, V12, P487, DOI 10.1146/annurev.iy.12.040194.002415; RADIC MZ, 1989, COLD SPRING HARB SYM, V54, P933; RUMBLEY CA, 1993, J BIOL CHEM, V268, P13667; SANG BC, 1989, J BIOMOL STRUCT DYN, V7, P693, DOI 10.1080/07391102.1989.10508514; SCHWARTZ RS, 1985, J CLIN INVEST, V75, P321, DOI 10.1172/JCI111704; SHLOMCHIK M, 1990, J EXP MED, V171, P265, DOI 10.1084/jem.171.1.265; Tan E.M., 1989, ADV IMMUNOL, V44, P151, DOI [10.1016/S0065-2776(08)60641-0, DOI 10.1016/S0065-2776(08)60641-0]; WOODY RW, 1978, BIOPOLYMERS, V17, P1451, DOI 10.1002/bip.1978.360170606	33	29	29	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 24	1996	271	21					12241	12246		10.1074/jbc.271.21.12241	http://dx.doi.org/10.1074/jbc.271.21.12241			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UL660	8647821	hybrid			2022-12-25	WOS:A1996UL66000023
J	Ward, DG; Cavieres, JD				Ward, DG; Cavieres, JD			Binding of 2'(3')-O-(2,4,6-trinitrophenyl)ADP to soluble alpha beta protomers of Na,K-ATPase modified with fluorescein isothiocyanate - Evidence for two distinct nucleotide sites	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSPORT ADENOSINE-TRIPHOSPHATASE; AMINO-ACID-SEQUENCE; (NA+ + K+)-ATPASE; ACTIVE-SITE; SODIUM-PUMP; CONFORMATIONAL-CHANGES; POTASSIUM-TRANSPORT; MAMMALIAN KIDNEY; REACTIVE SITE; ATP SITE	The overall reaction of well defined solubilized protomers of Na,K-ATPase (one alpha plus one beta subunit) retains the dual ATP dependence observed with the membrane-bound enzyme, with distinctive ATP effects in the submicromolar and submillimolar ranges (Ward, D. G., and Cavieres, J. D. (1993) Proc. Natl. Acad. Sci. U. S. A. 90, 5332-5336). We have now found that the K+-phosphatase activity of the alpha beta protomers is still inhibited by 2'(3')-O-(2,4,6-trinitrophenyl)adenosine 5'-diphosphate (TNP-ADP). What is most significant is that the TNP-ADP effect can be observed clearly with protomeric enzyme whose high affinity ATP site has been blocked covalently with fluorescein isothiocyanate. We conclude that nucleotides can bind at two discrete sites in each protomeric unit of Na,K-ATPase.	UNIV LEICESTER,DEPT CELL PHYSIOL & PHARMACOL,LEICESTER LE1 9HN,LEICS,ENGLAND	University of Leicester				Ward, Douglas/0000-0002-2328-1445	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ABBOTT AJ, 1991, BIOCHEMISTRY-US, V30, P1692, DOI 10.1021/bi00220a035; AMLER E, 1992, BIOPHYS J, V61, P553, DOI 10.1016/S0006-3495(92)81859-3; ASKARI A, 1987, J BIOENERG BIOMEMBR, V19, P359, DOI 10.1007/BF00768539; BROTHERUS JR, 1983, BIOCHIM BIOPHYS ACTA, V731, P290, DOI 10.1016/0005-2736(83)90021-4; BUXBAUM E, 1991, EUR J BIOCHEM, V195, P407, DOI 10.1111/j.1432-1033.1991.tb15720.x; CARILLI CT, 1982, J BIOL CHEM, V257, P5601; CAVIERES JD, 1987, FEBS LETT, V225, P145, DOI 10.1016/0014-5793(87)81147-X; CAVIERES JD, 1975, NATURE, V255, P338, DOI 10.1038/255338a0; CHETVERIN AB, 1986, FEBS LETT, V196, P121, DOI 10.1016/0014-5793(86)80225-3; Cleland W. W, 1970, ENZYMES, V2, P1; DAVIS RL, 1988, BIOCHIM BIOPHYS ACTA, V953, P26, DOI 10.1016/0167-4838(88)90006-4; ERDMANN E, 1973, BIOCHIM BIOPHYS ACTA, V307, P386, DOI 10.1016/0005-2736(73)90104-1; FARLEY RA, 1984, J BIOL CHEM, V259, P9532; FORBUSH B, 1988, J BIOL CHEM, V263, P7961; FORTES PAG, 1985, FED PROC, V44, P1443; Glynn I. M., 1985, ENZYMES BIOL MEMBR, P35; GLYNN IM, 1982, J PHYSIOL-LONDON, V330, P17, DOI 10.1113/jphysiol.1982.sp014326; JORGENSEN PL, 1974, BIOCHIM BIOPHYS ACTA, V356, P36, DOI 10.1016/0005-2736(74)90292-2; JORGENSEN PL, 1975, BIOCHIM BIOPHYS ACTA, V401, P399, DOI 10.1016/0005-2736(75)90239-4; JORGENSEN PL, 1986, BIOCHEMISTRY-US, V26, P2889; KAKAR SS, 1987, J BIOL CHEM, V262, P42; KANAZAWA T, 1967, J BIOCHEM-TOKYO, V61, P555, DOI 10.1093/oxfordjournals.jbchem.a128586; KAPLAN JH, 1982, ANN NY ACAD SCI, V402, P292, DOI 10.1111/j.1749-6632.1982.tb25750.x; KARLISH SJD, 1980, J BIOENERG BIOMEMBR, V12, P111, DOI 10.1007/BF00744678; KIRLEY TL, 1984, BIOCHEM BIOPH RES CO, V125, P767, DOI 10.1016/0006-291X(84)90605-3; KOEPSELL H, 1982, J BIOL CHEM, V257, P733; KUDOH F, 1979, J BIOCHEM, V86, P1023, DOI 10.1093/oxfordjournals.jbchem.a132595; LAZDUNSKI M, 1976, PROG BIOORG CHEM, V3, P82; MOCZYDLOWSKI EG, 1981, J BIOL CHEM, V256, P2346; NAGAI K, 1966, BIOCHIM BIOPHYS ACTA, V128, P410, DOI 10.1016/0926-6593(66)90193-7; OHTA T, 1986, P NATL ACAD SCI USA, V83, P2071, DOI 10.1073/pnas.83.7.2071; OTTOLENGHI P, 1983, BIOCHIM BIOPHYS ACTA, V727, P89, DOI 10.1016/0005-2736(83)90372-3; OVCHINNIKOV YA, 1987, FEBS LETT, V217, P111, DOI 10.1016/0014-5793(87)81253-X; POST RL, 1972, J BIOL CHEM, V247, P6530; ROBINSON JD, 1969, BIOCHEMISTRY-US, V8, P3348, DOI 10.1021/bi00836a032; Schachman H.K., 1959, ULTRACENTRIFUGATION; SCHEINERBOBIS G, 1993, BIOCHEMISTRY-US, V32, P9592, DOI 10.1021/bi00088a011; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SMITH RL, 1980, J BIOL CHEM, V255, P9852; TRAN CM, 1986, BIOCHIM BIOPHYS ACTA, V860, P9, DOI 10.1016/0005-2736(86)90492-X; TRAN CM, 1994, J BIOL CHEM, V269, P6558; TRAN CM, 1994, BIOCHEMISTRY-US, V33, P4140, DOI 10.1021/bi00180a006; WALTON TJH, 1994, J PHYSIOL-LONDON, V477P, pP26; WARD DG, 1993, P NATL ACAD SCI USA, V90, P5332, DOI 10.1073/pnas.90.11.5332; WARD DG, 1994, J PHYSIOL-LONDON, V482, pP42; XU KY, 1989, BIOCHEMISTRY-US, V28, P5764, DOI 10.1021/bi00440a010	46	48	48	0	34	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 24	1996	271	21					12317	12321		10.1074/jbc.271.21.12317	http://dx.doi.org/10.1074/jbc.271.21.12317			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UL660	8647832	hybrid			2022-12-25	WOS:A1996UL66000034
J	Howles, PN; Carter, CP; Hui, DY				Howles, PN; Carter, CP; Hui, DY			Dietary free and esterified cholesterol absorption in cholesterol esterase (bile salt-stimulated lipase) gene-targeted mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BRUSH-BORDER MEMBRANE; LEUKEMIA INHIBITORY FACTOR; EMBRYONIC STEM-CELLS; ACYL COENZYME-A; RAT-LIVER; INTESTINAL-CELLS; HYDROLASE; EXPRESSION; ACYLTRANSFERASE; TRANSPORT	The involvement of pancreatic cholesterol esterase (bile salt-stimulated lipase) in cholesterol absorption through the intestine has been controversial. We have addressed this issue by using homologous recombination in embryonic stem cells to produce mice lacking a functional cholesterol esterase gene. Cholesterol esterase knockout mice and their wild type counterparts were fed a bolus dose of [H-3]cholesterol and a trace amount of [beta-C-14]sitosterol by gavage. The ratio of the two radiolabels excreted in the feces over a 24-h period was found to be similar in the control and cholesterol esterase-null mice, Similar results were observed when the radiolabeled sterols were supplied in an emulsion with phospholipid and triolein or in lipid vesicles with phosphatidylcholine. Cholesterol absorption results were similar between the control and cholesterol esterase-null mice regardless of whether the animals were fed a low fat diet or a high fat/high cholesterol diet. The rate of [H-3]cholesterol appearance in the serum of the gene-targeted mice paralleled that observed in control animals. In contrast to these results, when experiments were performed with [H-3]cholesteryl oleate instead of [H-3]cholesterol, a higher amount of the H-3 radiolabel was found excreted in feces and dramatically less of the radiolabel was detected in the serum of the cholesterol esterase-null mice in comparison with that detected in control animals. Serum cholesterol levels were not significantly different between control and cholesterol esterase-null mice fed either control or an atherogenic diet. These results indicate that cholesterol esterase is responsible for mediating intestinal absorption of cholesteryl esters but does not play a primary role in free cholesterol absorption.	UNIV CINCINNATI,COLL MED,DEPT PATHOL & LAB MED,CINCINNATI,OH 45267	University System of Ohio; University of Cincinnati					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK040917] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK40917] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BHAT SG, 1982, BIOCHEM BIOPH RES CO, V109, P486, DOI 10.1016/0006-291X(82)91747-8; BRODTEPPLEY J, 1995, BBA-MOL BASIS DIS, V1272, P69, DOI 10.1016/0925-4439(95)00083-G; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; CAMULLI ED, 1989, BIOCHIM BIOPHYS ACTA, V1005, P177, DOI 10.1016/0005-2760(89)90184-7; CHEN Q, 1989, BIOCHIM BIOPHYS ACTA, V1004, P372, DOI 10.1016/0005-2760(89)90086-6; CHEN Q, 1994, BBA-LIPID LIPID MET, V1210, P239, DOI 10.1016/0005-2760(94)90127-9; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; CLARK SB, 1984, J LIPID RES, V25, P148; DIPERSIO LP, 1990, J BIOL CHEM, V265, P16801; DIPERSIO LP, 1994, BIOCHEMISTRY-US, V33, P3442, DOI 10.1021/bi00177a038; DOETSCHMAN TC, 1985, J EMBRYOL EXP MORPH, V87, P27; DUELAND S, 1993, J LIPID RES, V34, P923; FERNANDEZ E, 1989, BIOCHIM BIOPHYS ACTA, V1001, P249, DOI 10.1016/0005-2760(89)90107-0; FONTAINE RN, 1991, BIOCHEMISTRY-US, V30, P7008, DOI 10.1021/bi00242a028; GALLO LL, 1984, J LIPID RES, V25, P604; GALLO LL, 1987, J LIPID RES, V28, P381; GALLO LL, 1977, P SOC EXP BIOL MED, V156, P277; GOSSLER A, 1986, P NATL ACAD SCI USA, V83, P9065, DOI 10.1073/pnas.83.23.9065; GRUNDY SM, 1968, J LIPID RES, V9, P374; HARRISON EH, 1988, BIOCHIM BIOPHYS ACTA, V963, P28, DOI 10.1016/0005-2760(88)90334-7; HERNELL O, 1994, J PEDIATR-US, V125, pS56, DOI 10.1016/S0022-3476(06)80737-7; HUANG Y, 1990, J LIPID RES, V31, P2029; KIM HS, 1988, NUCLEIC ACIDS RES, V16, P8887, DOI 10.1093/nar/16.18.8887; KIRK EA, 1995, J LIPID RES, V36, P1522; KISSEL JA, 1989, BIOCHIM BIOPHYS ACTA, V1006, P227, DOI 10.1016/0005-2760(89)90201-4; KRAUSE BR, 1993, J LIPID RES, V34, P279; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAIRD PW, 1991, NUCLEIC ACIDS RES, V19, P4293, DOI 10.1093/nar/19.15.4293; LI QT, 1993, BIOCHIM BIOPHYS ACTA, V1166, P145, DOI 10.1016/0005-2760(93)90090-V; LIPKA G, 1995, J BIOL CHEM, V270, P5917, DOI 10.1074/jbc.270.11.5917; LOPEZCANDALES A, 1993, BIOCHEMISTRY-US, V32, P12085, DOI 10.1021/bi00096a019; MCKEAN ML, 1992, FASEB J, V6, pA1388; MONCECCHI D, 1991, J BIOL CHEM, V266, P9885; MOREAU JF, 1988, NATURE, V336, P690, DOI 10.1038/336690a0; NAGY A, 1993, P NATL ACAD SCI USA, V90, P8424, DOI 10.1073/pnas.90.18.8424; PHILLIPS GB, 1960, BIOCHIM BIOPHYS ACTA, V41, P361, DOI 10.1016/0006-3002(60)90026-3; RIGTRUP KM, 1992, BIOCHEMISTRY-US, V31, P2920, DOI 10.1021/bi00126a011; RUDD EA, 1987, BIOCHIM BIOPHYS ACTA, V918, P106, DOI 10.1016/0005-2760(87)90184-6; Sambrook J., 2002, MOL CLONING LAB MANU; SCHROEDER F, 1993, MOL CELL BIOCHEM, V123, P73, DOI 10.1007/BF01076477; SHAMIR R, 1995, BIOCHEMISTRY-US, V34, P6351, DOI 10.1021/bi00019a013; SMITH AG, 1988, NATURE, V336, P688, DOI 10.1038/336688a0; THOMSON ABR, 1993, CAN J PHYSIOL PHARM, V71, P531, DOI 10.1139/y93-078; THURNHOFER H, 1991, BIOCHIM BIOPHYS ACTA, V1064, P275, DOI 10.1016/0005-2736(91)90312-V; TRABER MG, 1990, GASTROENTEROLOGY, V98, P96, DOI 10.1016/0016-5085(90)91296-I; TREADWELL CR, 1968, HANDBOOK PHYSIOLOG 6, V3, P1407; WATT SM, 1981, J LIPID RES, V22, P157; WILLIAMS RL, 1988, NATURE, V336, P684, DOI 10.1038/336684a0; WILSON MD, 1994, J LIPID RES, V35, P943; WINKLER KE, 1992, BIOCHIM BIOPHYS ACTA, V1126, P151; ZILVERSMIT DB, 1974, J LIPID RES, V15, P465; ZOLFAGHARI R, 1989, P NATL ACAD SCI USA, V86, P6913, DOI 10.1073/pnas.86.18.6913	52	159	166	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 22	1996	271	12					7196	7202		10.1074/jbc.271.12.7196	http://dx.doi.org/10.1074/jbc.271.12.7196			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UB157	8636157	hybrid			2022-12-25	WOS:A1996UB15700092
J	Thomas, A; ElRouby, S; Reed, JC; Krajewski, S; Silber, R; Potmesil, M; Newcomb, EW				Thomas, A; ElRouby, S; Reed, JC; Krajewski, S; Silber, R; Potmesil, M; Newcomb, EW			Drug-induced apoptosis in B-cell chronic lymphocytic leukemia: Relationship between p53 gene mutation and bcl-2/bax proteins in drug resistance	ONCOGENE			English	Article						bcl-2; bax; chronic lymphocytic leukemia; drug resistance; apoptosis	DEATH; EXPRESSION; DIFFERENTIATION	We investigated the relationship among chemosensitivity to drug-induced apoptosis in vitro, the presence of p53 gene mutations, and the expression of bcl-2 and bax proteins in B-cells from B-cell chronic lymphocytic leukemia (B-CLL) patients. Apoptosis was induced with a camptothecin analogue, 9-amino-20(s)-camptothecin, or a purine analogue, fludarabine. Cell death was monitored by propidium iodide staining and FACS analysis. Drug-induced apoptosis in B-CLL cells was p53-independent. Immunoblot analysis of bcl-2 and bax expression revealed a correlation between drug-induced apoptosis and the ratio of endogenous levels of bcl-2 to bax proteins. B-CLL cells with none to low bcl-2/bax ratios were drug-sensitive as compared to cells with high ratios that were drug-resistant Prior to drug treatment, bax protein migrated as a single species of 21 kDa. Following drug-induced apoptosis, anti-bax specific protein complexes of 36-42 kDa were up-regulated. Using two-dimensional gel electrophoresis, bax complexes were disrupted under reducing conditions to reveal homo- and heterodimers of 18 and 21 kDa suggesting that disulfide interactions were required for complex formation. The de novo appearance of the 18 kDa anti-bax specific protein together with its increased expression in drug-sensitive B-CLL B-cells undergoing cell death suggests a role for this protein in the regulation of apoptosis.	NYU, SCH MED, DEPT PATHOL, NEW YORK, NY 10016 USA; NYU, SCH MED, DEPT MED, NEW YORK, NY 10016 USA; NYU, SCH MED, DEPT RADIOL, NEW YORK, NY 10016 USA; KAPLAN COMPREHENS CANC CTR, NEW YORK, NY 10016 USA; LA JOLLA CANC RES FDN, CANC RES CTR, LA JOLLA, CA 92037 USA	New York University; New York University; New York University; Sanford Burnham Prebys Medical Discovery Institute					NATIONAL CANCER INSTITUTE [U10CA060138] Funding Source: NIH RePORTER; NCI NIH HHS [CA-60138] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		APTE SS, 1995, GENOMICS, V26, P592, DOI 10.1016/0888-7543(95)80180-T; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; DOHNER H, 1995, BLOOD, V85, P1580, DOI 10.1182/blood.V85.6.1580.bloodjournal8561580; ELROUBY S, 1993, BLOOD, V82, P3452; FOON KA, 1990, ANN INTERN MED, V113, P525, DOI 10.7326/0003-4819-113-7-525; FRANKEL RH, 1992, CANCER RES, V52, P1427; HANADA M, 1995, J BIOL CHEM, V270, P11962, DOI 10.1074/jbc.270.20.11962; HANADA M, 1993, BLOOD, V82, P1820; HICKMAN JA, 1992, CANCER METAST REV, V11, P121, DOI 10.1007/BF00048059; KORSMEYER SJ, 1992, BLOOD, V80, P879; KOZOPAS KM, 1993, P NATL ACAD SCI USA, V90, P3516, DOI 10.1073/pnas.90.8.3516; KRAJEWSKI S, 1994, AM J PATHOL, V145, P1323; KRAJEWSKI S, 1995, CANCER RES, V55, P4471; LOWE SW, 1994, SCIENCE, V266, P807, DOI 10.1126/science.7973635; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; MAPARA MY, 1993, EUR J IMMUNOL, V23, P702, DOI 10.1002/eji.1830230320; MIYASHITA T, 1995, CELL, V80, P293; MIYASHITA T, 1994, ONCOGENE, V9, P1799; MIYASHITA T, 1994, CANCER RES, V54, P3131; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; REED JC, 1994, J CELL BIOL, V124, P1, DOI 10.1083/jcb.124.1.1; ROBERTSON LE, 1993, BLOOD, V81, P143; SCHENA M, 1992, BLOOD, V79, P2981; SELVAKUMARAN M, 1994, ONCOGENE, V9, P1791; SILBER R, 1994, BLOOD, V84, P3440; TAKAYAMA S, 1995, CELL, V80, P279, DOI 10.1016/0092-8674(95)90410-7; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; WATTEL E, 1994, BLOOD, V84, P3148, DOI 10.1182/blood.V84.9.3148.3148; YANG E, 1995, CELL, V80, P285, DOI 10.1016/0092-8674(95)90411-5; YIN XM, 1994, NATURE, V369, P321, DOI 10.1038/369321a0; ZHAN QM, 1994, ONCOGENE, V9, P3743	31	277	287	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR 7	1996	12	5					1055	1062						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UA884	8649796				2022-12-25	WOS:A1996UA88400013
J	Wang, YP; Becker, D				Wang, YP; Becker, D			Differential expression of the cyclin-dependent kinase inhibitors p16 and p21 in the human melanocytic system	ONCOGENE			English	Article						melanocytes; melanoma progression; cyclin-dependent kinase inhibitors; retinoblastoma gene product	RETINOBLASTOMA PROTEIN; TUMOR PROGRESSION; MELANOMA; HOMOLOGY; BINDING	To determine whether loss or inactivation of the putative tumor-suppressor gene, p16, represents an initiating or a secondary event in the progression of human melanoma, we evaluated the status of this gene in early and advanced-stage melanomas of sporadic origin. The results of this analysis revealed p16 deletions in 4/6 primary and 6/14 metastatic melanoma cell lines but not in 3/3 metastatic melanoma specimens. Surprisingly, p16 deletions were also detected in 8/8 benign compound nevi and in 1/3 normal human melanocyte isolates. To investigate whether these deletions in benign and malignant stages of the human melanocytic system were specific for p16, we analysed the same specimens and cell lines for expression of p21, another cyclin-dependent kinase inhibitor and potential tumor suppressor. In contrast to p16, expression of p21 was detected in 3/3 melanocytes, in 3/3 benign nevi, and in greater than 50% of malignant melanoma cell lines and specimens. Finally, because of the recently documented inverse relationship between expression of p16 and pRb protein in a variety of tumor cell lines, we analysed some of the p16-positive and negative melanoma cell lines for the presence of pRb protein. The results demonstrated pRb protein in each of these cell Lines. Taken together, although this study revealed deletions of the p16 gene in a significant number of sporadic primary and metastatic melanoma cell lines, they were also detected in benign nevus specimens and in some normal human melanocyte isolates. Thus, these findings cast some doubt on the role of this gene as being causal to the onset and progression of human melanoma, in particular, sporadic melanoma.	UNIV PITTSBURGH,DEPT MED,PITTSBURGH,PA 15213	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh								ALMENDRAL JM, 1987, P NATL ACAD SCI USA, V84, P1575, DOI 10.1073/pnas.84.6.1575; BECKER D, 1989, GENOMICS, V4, P97, DOI 10.1016/0888-7543(89)90320-0; BECKER D, 1992, ONCOGENE, V7, P2302; CALDAS C, 1994, NAT GENET, V8, P27, DOI 10.1038/ng0994-27; CANNONALBRIGHT LA, 1992, SCIENCE, V258, P1148, DOI 10.1126/science.1439824; CHEN JJ, 1995, NATURE, V374, P386, DOI 10.1038/374386a0; CLARK WH, 1988, ARCH DERMATOL, V124, P1207, DOI 10.1001/archderm.124.8.1207; CLARK WH, 1986, HUM PATHOL, V17, P443, DOI 10.1016/S0046-8177(86)80032-6; CLARK WH, 1984, HUM PATHOL, V15, P1147, DOI 10.1016/S0046-8177(84)80310-X; CLARK WH, 1991, BRIT J CANCER, V64, P101; DOWDY SF, 1993, CELL, V73, P499, DOI 10.1016/0092-8674(93)90137-F; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELDER DE, 1993, SEMIN DIAGN PATHOL, V10, P18; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; EWEN ME, 1994, CANCER METAST REV, V13, P45, DOI 10.1007/BF00690418; FOUNTAIN JW, 1992, P NATL ACAD SCI USA, V89, P10557, DOI 10.1073/pnas.89.21.10557; GRUIS NA, 1995, NAT GENET, V10, P351, DOI 10.1038/ng0795-351; HANKS SK, 1987, P NATL ACAD SCI USA, V84, P388, DOI 10.1073/pnas.84.2.388; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; HARPER JW, 1993, CELL, V75, P805; HERLYN M, 1987, LAB INVEST, V56, P461; HUSSUSSIAN CJ, 1994, NAT GENET, V8, P15, DOI 10.1038/ng0994-15; KAMB A, 1994, NAT GENET, V8, P22, DOI 10.1038/ng0994-22; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; KATO J, 1993, GENE DEV, V7, P331; KOH J, 1995, NATURE, V375, P506, DOI 10.1038/375506a0; LUKAS J, 1995, NATURE, V375, P503, DOI 10.1038/375503a0; MEDEMA RH, 1995, P NATL ACAD SCI USA, V92, P6289, DOI 10.1073/pnas.92.14.6289; MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686; MEYERSON M, 1994, MOL CELL BIOL, V14, P2077, DOI 10.1128/MCB.14.3.2077; MORI T, 1994, CANCER RES, V54, P3396; NIKAJIMAIIJIMA S, 1995, P NATL ACAD SCI USA, V82, P6133; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; OHTA M, 1994, CANCER RES, V54, P5269; OKAMOTO A, 1994, P NATL ACAD SCI USA, V91, P11045, DOI 10.1073/pnas.91.23.11045; Parmiter A., 1988, MALIGNANT MELANOMA B, P47; PARRY D, 1995, EMBO J, V14, P503, DOI 10.1002/j.1460-2075.1995.tb07026.x; REED JA, 1995, CANCER RES, V55, P2713; RODECK U, 1987, INT J CANCER, V40, P687, DOI 10.1002/ijc.2910400520; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SPRUCK CH, 1994, NATURE, V370, P183, DOI 10.1038/370183a0; TRENT JM, 1992, CUTANEOUS MELANOMA, P1001; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0	43	30	30	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR 7	1996	12	5					1069	1075						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UA884	8649798				2022-12-25	WOS:A1996UA88400015
J	Rommel, C; Radziwill, G; Lovric, J; Noeldeke, J; Heinicke, T; Jones, D; Aitken, A; Moelling, K				Rommel, C; Radziwill, G; Lovric, J; Noeldeke, J; Heinicke, T; Jones, D; Aitken, A; Moelling, K			Activated Ras displaces 14-3-3 protein from the amino terminus of c-Raf-1	ONCOGENE			English	Article						Ras; Raf; 14-3-3 protein; signal transduction	KINASE-KINASE; RAF-1 KINASE; PHOSPHORYLATION; AUTOPHOSPHORYLATION; PURIFICATION; ANTIBODIES; ONCOGENE; DOMAIN; BRAIN; MIL	The serine/threonine protein kinase c-Raf-1 interacts with a number of cellular proteins including 14-3-3 isoforms which may be regulators or substrates of c-Raf-1 in signal transduction pathways, In vivo and in vitro binding analyses of c-Raf-1 and mutant proteins with 14-3-3 zeta indicate bivalent binding of 14-3-3 zeta to the amino terminus as well as to the carboxy terminus of c-Raf-1, Although 14-3-3 zeta and Ras use different binding regions on the amino terminal regulatory domain of c-Raf-1 (c-Raf-NT), 14-3-3 zeta is displaced from the amino terminus upon binding of activated Ras, In contrast, if c-Raf-1 full length is analysed instead of the separately expressed c-Raf-NT, binding of 14-3-3 zeta is only slightly effected by co-expression of activated Ras, This is explained by a second binding site of 14-3-3 zeta at the carboxy terminus of c-Raf-1. The mutant c-Raf-NT (S259A) cannot bind 14-3-3 zeta, suggesting a regulatory role of this in vivo phosphorylation site, However, c-Raf-NT phosphorylated or unphosphorylated at S259, is able to bind 14-3-3 zeta, Even though 14-3-3 zeta can be phosphorylated in vivo, only the unphosphorylated form binds to the amino terminus of c-Raf-1, The data presented indicate, that 14-3-3 zeta binds to c-Raf-1 in a bivalent fashion in unstimulated cells, 14-3-3 zeta is displaced from the amino terminus but not from the carboxy terminus of c-Raf-1 by binding of activated Ras to c-Raf-1.	UNIV ZURICH, INST MED VIROL, CH-8028 ZURICH, SWITZERLAND; NATL INST MED RES, LAB PROT STRUCT, LONDON NW7 1AA, ENGLAND	University of Zurich; MRC National Institute for Medical Research				Lovric, Josip/0000-0002-0338-6581				AITKEN A, 1995, J BIOL CHEM, V270, P5706, DOI 10.1074/jbc.270.11.5706; AITKEN A, 1995, TRENDS BIOCHEM SCI, V20, P95, DOI 10.1016/S0968-0004(00)88971-9; AITKEN A, 1992, TRENDS BIOCHEM SCI, V17, P498, DOI 10.1016/0968-0004(92)90339-B; ALESSI DR, 1994, EMBO J, V13, P1610, DOI 10.1002/j.1460-2075.1994.tb06424.x; BEIMLING P, 1994, BIOCHEM BIOPH RES CO, V204, P841, DOI 10.1006/bbrc.1994.2536; BRASELMANN S, 1995, EMBO J, V14, P4839, DOI 10.1002/j.1460-2075.1995.tb00165.x; BRUDER JT, 1992, GENE DEV, V6, P545, DOI 10.1101/gad.6.4.545; CHOW YH, 1995, J BIOL CHEM, V270, P14100, DOI 10.1074/jbc.270.23.14100; CONKLIN DS, 1995, P NATL ACAD SCI USA, V92, P7892, DOI 10.1073/pnas.92.17.7892; DAUM G, 1994, TRENDS BIOCHEM SCI, V19, P474, DOI 10.1016/0968-0004(94)90133-3; DENHEZ F, 1988, EMBO J, V7, P541, DOI 10.1002/j.1460-2075.1988.tb02843.x; DENT P, 1995, MOL CELL BIOL, V15, P4125; DENT P, 1994, P NATL ACAD SCI USA, V91, P9544, DOI 10.1073/pnas.91.20.9544; DUNBAR BS, 1990, METHOD ENZYMOL, V182, P441; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FABIAN JR, 1994, P NATL ACAD SCI USA, V91, P5982, DOI 10.1073/pnas.91.13.5982; FABIAN JR, 1993, MOL CELL BIOL, V13, P7170, DOI 10.1128/MCB.13.11.7170; FANTL WJ, 1994, NATURE, V371, P612, DOI 10.1038/371612a0; FORD JC, 1994, SCIENCE, V265, P533, DOI 10.1126/science.8036497; FREED E, 1994, SCIENCE, V265, P1713, DOI 10.1126/science.8085158; FU H, 1994, SCIENCE, V266, P126, DOI 10.1126/science.7939632; GALAKTIONOV K, 1995, GENE DEV, V9, P1046, DOI 10.1101/gad.9.9.1046; Gorman CM, 1990, DNA PROTEIN ENG TECH, V2, P1; GROSS M, 1985, MOL CELL BIOL, V5, P1015, DOI 10.1128/MCB.5.5.1015; HEIDECKER G, 1992, ADV CANCER RES, V58, P53, DOI 10.1016/S0065-230X(08)60290-0; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; IRIE K, 1994, SCIENCE, V265, P1716, DOI 10.1126/science.8085159; JAMAL S, 1995, ONCOGENE, V10, P2095; JOHN J, 1988, J BIOL CHEM, V263, P11792; JONES DH, 1995, FEBS LETT, V368, P55, DOI 10.1016/0014-5793(95)00598-4; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; KYRIAKIS JM, 1993, J BIOL CHEM, V268, P16009; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; LI SF, 1995, EMBO J, V14, P685, DOI 10.1002/j.1460-2075.1995.tb07047.x; LI SF, 1993, P NATL ACAD SCI USA, V90, P9247, DOI 10.1073/pnas.90.20.9247; LIU D, 1995, NATURE, V376, P191, DOI 10.1038/376191a0; LOVRIC J, 1994, FEBS LETT, V343, P15, DOI 10.1016/0014-5793(94)80598-9; MARAIS R, 1995, EMBO J, V14, P3136, DOI 10.1002/j.1460-2075.1995.tb07316.x; MARTIN H, 1993, FEBS LETT, V331, P296, DOI 10.1016/0014-5793(93)80356-Y; MARX J, 1993, SCIENCE, V262, P988, DOI 10.1126/science.8257559; MCCONNELL JE, 1995, DEV BIOL, V169, P218, DOI 10.1006/dbio.1995.1139; MICHAUD NR, 1995, MOL CELL BIOL, V15, P3390; MOELLING K, 1984, NATURE, V312, P558, DOI 10.1038/312558a0; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; MORRISON DK, 1993, J BIOL CHEM, V268, P17309; NASSAR M, 1995, NATURE, V375, P554, DOI 10.1038/375554a0; NIEHOF M, 1995, BIOCHEM BIOPH RES CO, V206, P46, DOI 10.1006/bbrc.1995.1007; NIEHOF M, 1994, BIOCHEM BIOPH RES CO, V203, P1560, DOI 10.1006/bbrc.1994.2364; PAGES G, 1994, EMBO J, V13, P3003, DOI 10.1002/j.1460-2075.1994.tb06599.x; PALLAS DC, 1994, SCIENCE, V265, P535, DOI 10.1126/science.8036498; RADZIWILL G, 1995, P NATL ACAD SCI USA, V92, P1421, DOI 10.1073/pnas.92.5.1421; REUTHER GW, 1994, SCIENCE, V266, P129, DOI 10.1126/science.7939633; ROBINSON K, 1994, BIOCHEM J, V299, P853, DOI 10.1042/bj2990853; RUTHERFORD SL, 1994, CELL, V79, P1129, DOI 10.1016/0092-8674(94)90003-5; SAMUELS ML, 1993, MOL CELL BIOL, V13, P6241, DOI 10.1128/MCB.13.10.6241; SCHRAMM K, 1994, BIOCHEM BIOPH RES CO, V201, P740, DOI 10.1006/bbrc.1994.1763; SHIMIZU K, 1994, J BIOL CHEM, V269, P22917; STANCATO LF, 1993, J BIOL CHEM, V268, P21711; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; SUEN KL, 1995, ONCOGENE, V11, P825; TOKER A, 1990, EUR J BIOCHEM, V191, P421, DOI 10.1111/j.1432-1033.1990.tb19138.x; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WANG HG, 1994, ONCOGENE, V9, P2751; WARNE PH, 1993, NATURE, V364, P352, DOI 10.1038/364352a0; WARTMANN M, 1994, J BIOL CHEM, V269, P6695; Xiao Bing, 1995, Nature (London), V376, P188, DOI 10.1038/376188a0; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0	68	124	126	1	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 1	1996	12	3					609	619						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TV597	8637718				2022-12-25	WOS:A1996TV59700018
J	Wright, SC; Zheng, H; Zhong, J				Wright, SC; Zheng, H; Zhong, J			Tumor cell resistance to apoptosis due to a defect in the activation of sphingomyelinase and the 24 kDa apoptotic protease (AP24)	FASEB JOURNAL			English	Article						humor necrosis factor; IV light; sphingomyelinase; DNA fragmentation	NECROSIS-FACTOR; DNA FRAGMENTATION; SURFACE ANTIGEN; PHOSPHORYLATION; INHIBITORS; PHOSPHATASE; VARIANTS; CERAMIDE; DEATH; ACID	Signal transduction pathways involved in apoptotic cell death are poorly understood, although recent studies have implicated sphingomyelin hydrolysis and generation of the second messenger, ceramide, Previous work in this laboratory demonstrated that a serine protease termed AP24 was activated by TNF or UV light and induced DNA fragmentation in isolated nuclei, This study extended these findings to examine the role of these enzymes in apoptosis of the U937 cell line and the mechanism of resistance of its variant, U9-TR, Although this subclone was selected by growth in TNF, it was unexpectedly found to resist apoptosis induced by UV light, but was still sensitive to anti-Fas-induced DNA fragmentation, Here we show that in contrast to normal U937 cells, UV light and TNF both failed to activate neutral or acidic sphingomyelinase or AP24 in the U9-TR variant, However, anti-Fas activated both neutral and acidic sphingomyelinase in the variant comparable to that seen in parental U937, The U9-TR variant could be sensitized to TNF or UV light activation of both sphingomyelinase and DNA fragmentation by the protein phosphatase inhibitors okadaic acid and calyculin A, Furthermore, exogenous bacterial-derived sphingomyelinase caused U9-TR activation of AP24 and DNA fragmentation comparable to that in the parental U937, Exposure of permeabilized U937 cells to ceramide caused internucleosomal DNA cleavage that was blocked by an inhibitor of AP24, Taken altogether, these findings demonstrate that TNF or UV light activate sphingomyelinase that leads to generation of ceramide resulting in activation of AP24 and DNA fragmentation in sensitive cells, A selective defect in signals leading to sphingomyelinase activation can confer resistance to apoptosis even though the variant is still sensitive to downstream apoptotic signals such as nuclear DNA fragmentation by activated exogenous AP24.			Wright, SC (corresponding author), PALO ALTO INST MOLEC MED,2642 WYANDOTTE ST,MT VIEW,CA 94043, USA.				NATIONAL CANCER INSTITUTE [R01CA068223] Funding Source: NIH RePORTER; NCI NIH HHS [CA68223] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		CHARTIER L, 1991, CELL MOTIL CYTOSKEL, V18, P26, DOI 10.1002/cm.970180104; CIFONE MG, 1993, J EXP MED, V177, P1547; DOBROWSKY RT, 1992, J BIOL CHEM, V267, P5048; DRESSLER KA, 1992, SCIENCE, V255, P1715, DOI 10.1126/science.1313189; DUVALL E, 1986, IMMUNOL TODAY, V7, P115, DOI 10.1016/0167-5699(86)90152-0; HAIMOVITZFRIEDMAN A, 1994, J EXP MED, V180, P525, DOI 10.1084/jem.180.2.525; HANNUN YA, 1993, ADV LIPID RES, V25, P43; HAYSTEAD TAJ, 1989, NATURE, V337, P78, DOI 10.1038/337078a0; ITOH N, 1991, CELL, V66, P233, DOI 10.1016/0092-8674(91)90614-5; JARVIS WD, 1994, J BIOL CHEM, V269, P31685; JARVIS WD, 1994, P NATL ACAD SCI USA, V91, P73, DOI 10.1073/pnas.91.1.73; JAYADEV S, 1994, J BIOL CHEM, V269, P5757; KINDER DH, 1985, J MED CHEM, V28, P1917, DOI 10.1021/jm00150a027; KINDER DH, 1992, INVAS METAST, V12, P309; LIU J, 1993, J BIOL CHEM, V268, P3047; MATHIAS S, 1993, ADV LIPID RES, V25, P65; OBEID LM, 1993, SCIENCE, V259, P1769, DOI 10.1126/science.8456305; OEHM A, 1992, J BIOL CHEM, V267, P10709; OKAZAKI T, 1994, J BIOL CHEM, V269, P4070; Walker N I, 1988, Methods Achiev Exp Pathol, V13, P18; WIEGMANN K, 1994, CELL, V78, P1005, DOI 10.1016/0092-8674(94)90275-5; WONG GHW, 1994, J IMMUNOL, V152, P1751; WRIGHT SC, 1992, J CELL BIOCHEM, V48, P344, DOI 10.1002/jcb.240480403; WRIGHT SC, 1993, J CELL BIOCHEM, V53, P222, DOI 10.1002/jcb.240530307; WRIGHT SC, 1992, CANCER IMMUNOL IMMUN, V34, P399, DOI 10.1007/BF01741751; WRIGHT SC, 1994, FASEB J, V8, P654, DOI 10.1096/fasebj.8.9.8005393; WRIGHT SC, 1994, J EXP MED, V180, P2113, DOI 10.1084/jem.180.6.2113	27	58	61	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	FEB	1996	10	2					325	332		10.1096/fasebj.10.2.8641566	http://dx.doi.org/10.1096/fasebj.10.2.8641566			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	TY962	8641566				2022-12-25	WOS:A1996TY96200017
J	Richards, JP; Bachinger, HP; Goodman, RH; Brennan, RG				Richards, JP; Bachinger, HP; Goodman, RH; Brennan, RG			Analysis of the structural properties of cAMP-responsive element-binding protein (CREB) and phosphorylated CREB	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR CREB; CIRCULAR-DICHROISM SPECTRA; NUCLEAR FACTOR CREB; DNA-BINDING; SECONDARY STRUCTURE; TRANSACTIVATION DOMAIN; ACTIVATION DOMAINS; GENE-TRANSCRIPTION; GCN4; EXPRESSION	The transcription factor CREB (cAMP responsive element binding protein) is activated by protein kinase A (PKA) phosphorylation of a single serine residue. To investigate possible mechanisms of CREB regulation by phosphorylation, we initiated a structural and biophysical characterization of the full-length, wild-type CREB protein, an altered CREB protein (CREB/SER) in which the three cysteine residues in the DNA-binding domain were replaced with serine residues and a truncated protein (ACT265) which encompasses the entire activation domain of CREB. Circular dichroism (CD) reveals that CREB and CREB/SER have identical secondary structures and contain approximately 20% alpha-helix, 9% beta-strand, 34% beta-turn, and 37% random coil structures. PKA phosphorylation does not alter the CD spectra, and therefore the secondary structure, of CREB or of CREB bound to DNA. Protease cleavage patterns indicate that PKA phosphorylation does not induce a global conformational change in CREB. Furthermore, PKA phosphorylation does not change the DNA binding affinity of CREB for either canonical or non-canonical CRE sequences as measured by a fluorescence anisotropy DNA binding assay. Since PKA phosphorylation of CREB results in its specific binding to the transcriptional coactivators CREB-binding protein and p300, we suggest that the PKA activation of CREB occurs by the production of specific, complementary interactions with these proteins, rather than through the previously proposed mechanisms of a phosphorylation-dependent conformational change or increased DNA binding affinity.	OREGON HLTH SCI UNIV,DEPT BIOCHEM & MOLEC BIOL,PORTLAND,OR 97201; OREGON HLTH SCI UNIV,SHRINERS HOSP CRIPPLED CHILDREN,PORTLAND,OR 97201; OREGON HLTH SCI UNIV,VOLLUM INST,PORTLAND,OR 97201	Oregon Health & Science University; Oregon Health & Science University; Oregon Health & Science University				Brennan, Richard/0000-0001-7647-485X	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK045423] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK45423] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABATE C, 1990, SCIENCE, V249, P1157, DOI 10.1126/science.2118682; ANDERSON MG, 1994, NUCLEIC ACIDS RES, V22, P3194, DOI 10.1093/nar/22.15.3194; ARANY Z, 1995, NATURE, V374, P81, DOI 10.1038/374081a0; ARIAS J, 1994, NATURE, V370, P226, DOI 10.1038/370226a0; BOURTCHULADZE R, 1994, CELL, V79, P59, DOI 10.1016/0092-8674(94)90400-6; BRINDLE P, 1993, NATURE, V364, P821, DOI 10.1038/364821a0; CHECOVICH WJ, 1995, NATURE, V375, P254, DOI 10.1038/375254a0; CHRIVIA JC, 1993, NATURE, V365, P8575; COMPTON LA, 1987, J BIOL CHEM, V262, P13039; COMPTON LA, 1986, ANAL BIOCHEM, V155, P155, DOI 10.1016/0003-2697(86)90241-1; DAHLMANWRIGHT K, 1995, P NATL ACAD SCI USA, V92, P1699, DOI 10.1073/pnas.92.5.1699; DASH PK, 1991, P NATL ACAD SCI USA, V88, P5061, DOI 10.1073/pnas.88.11.5061; DEGROOT RP, 1994, ONCOGENE, V9, P463; DEGROOT RP, 1993, EMBO J, V12, P3903, DOI 10.1002/j.1460-2075.1993.tb06068.x; DONALDSON L, 1992, J BIOL CHEM, V267, P1411; FOULKES NS, 1992, NATURE, V355, P80, DOI 10.1038/355080a0; GONZALEZ GA, 1991, MOL CELL BIOL, V11, P1306, DOI 10.1128/MCB.11.3.1306; GONZALEZ GA, 1989, NATURE, V337, P749, DOI 10.1038/337749a0; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; GOODMAN RH, 1990, ANNU REV NEUROSCI, V13, P111, DOI 10.1146/annurev.neuro.13.1.111; HEYDUK T, 1993, NATURE, V364, P548, DOI 10.1038/364548a0; HEYDUK T, 1990, P NATL ACAD SCI USA, V87, P1744, DOI 10.1073/pnas.87.5.1744; HOEFFLER JP, 1991, MOL ENDOCRINOL, V5, P256, DOI 10.1210/mend-5-2-256; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; Jackson S P, 1992, Trends Cell Biol, V2, P104, DOI 10.1016/0962-8924(92)90014-E; JOHNSON NP, 1994, P NATL ACAD SCI USA, V91, P4840, DOI 10.1073/pnas.91.11.4840; KARIN M, 1994, CURR OPIN CELL BIOL, V6, P415, DOI 10.1016/0955-0674(94)90035-3; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; LEE CQ, 1990, EMBO J, V9, P4455, DOI 10.1002/j.1460-2075.1990.tb07896.x; LEE KAW, 1993, BIOCHIM BIOPHYS ACTA, V1174, P221, DOI 10.1016/0167-4781(93)90191-F; LETILLY V, 1993, BIOCHEMISTRY-US, V32, P7753, DOI 10.1021/bi00081a021; LORIAUX MM, 1993, P NATL ACAD SCI USA, V90, P9046, DOI 10.1073/pnas.90.19.9046; LUNDBLAD JR, 1995, NATURE, V374, P85, DOI 10.1038/374085a0; MANAVALAN P, 1987, ANAL BIOCHEM, V167, P76, DOI 10.1016/0003-2697(87)90135-7; MARTIN SC, 1990, FEBS LETT, V272, P103, DOI 10.1016/0014-5793(90)80458-U; MERINO A, 1989, J BIOL CHEM, V264, P21266; MEYER TE, 1993, ENDOCR REV, V14, P269, DOI 10.1210/er.14.3.269; MONTMINY MR, 1990, METABOLISM, V39, P6, DOI 10.1016/0026-0495(90)90198-L; NGUYEN TV, 1990, J NEUROSCI, V10, P2825; NICHOLS M, 1992, EMBO J, V11, P3337, DOI 10.1002/j.1460-2075.1992.tb05412.x; OAS TG, 1990, BIOCHEMISTRY-US, V29, P2891, DOI 10.1021/bi00464a001; OHARE P, 1992, BIOCHEMISTRY-US, V31, P4150, DOI 10.1021/bi00131a035; ONEIL KT, 1990, SCIENCE, V249, P774, DOI 10.1126/science.2389143; ONEIL KT, 1991, BIOCHEMISTRY-US, V30, P9030, DOI 10.1021/bi00101a017; PATEL L, 1990, NATURE, V347, P572, DOI 10.1038/347572a0; PERCIPALLE P, 1995, EMBO J, V14, P3200, DOI 10.1002/j.1460-2075.1995.tb07322.x; QUINN PG, 1993, J BIOL CHEM, V268, P16999; RAMWANI JJ, 1989, BIOCHEMISTRY-US, V28, P6538, DOI 10.1021/bi00442a002; SANTIAGORIVERA ZI, 1993, PROTEIN SCI, V2, P1461, DOI 10.1002/pro.5560020910; SAUDEK V, 1991, BIOCHEMISTRY-US, V30, P1310, DOI 10.1021/bi00219a022; SHENG M, 1991, SCIENCE, V252, P1427, DOI 10.1126/science.1646483; SHENG M, 1990, NEURON, V4, P571, DOI 10.1016/0896-6273(90)90115-V; SUN PQ, 1992, MOL ENDOCRINOL, V6, P1858, DOI 10.1210/me.6.11.1858; TRIEZENBERG SJ, 1995, CURR OPIN GENET DEV, V5, P190, DOI 10.1016/0959-437X(95)80007-7; VANHOY M, 1993, CELL, V72, P587, DOI 10.1016/0092-8674(93)90077-4; WEIH F, 1990, GENE DEV, V4, P1437, DOI 10.1101/gad.4.8.1437; WEISS MA, 1990, NATURE, V347, P575, DOI 10.1038/347575a0; WEISS MA, 1990, BIOCHEMISTRY-US, V29, P8020, DOI 10.1021/bi00487a004; WILMOT CM, 1988, J MOL BIOL, V203, P221, DOI 10.1016/0022-2836(88)90103-9; XING LP, 1993, MOL ENDOCRINOL, V7, P1484, DOI 10.1210/me.7.11.1484; YAMAMOTO KK, 1990, CELL, V60, P611, DOI 10.1016/0092-8674(90)90664-Z; YAMAMOTO KK, 1988, NATURE, V334, P494, DOI 10.1038/334494a0; YEAGLE PL, 1990, BIOCHEMISTRY-US, V29, P1508, DOI 10.1021/bi00458a023; YIN JCP, 1994, CELL, V79, P49, DOI 10.1016/0092-8674(94)90399-9; ZHANG XY, 1992, ANAL BIOCHEM, V201, P366, DOI 10.1016/0003-2697(92)90353-9	65	110	113	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 7	1996	271	23					13716	13723		10.1074/jbc.271.23.13716	http://dx.doi.org/10.1074/jbc.271.23.13716			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UP385	8662719	hybrid			2022-12-25	WOS:A1996UP38500063
J	Kraft, HJ; Mosselman, S; Smits, HA; Hohenstein, P; Piek, E; Chen, Q; Artzt, K; vanZoelen, EJJ				Kraft, HJ; Mosselman, S; Smits, HA; Hohenstein, P; Piek, E; Chen, Q; Artzt, K; vanZoelen, EJJ			Oct-4 regulates alternative platelet-derived growth factor alpha receptor gene promoter in human embryonal carcinoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EARLY MOUSE EMBRYOGENESIS; OCTAMER BINDING-PROTEINS; TRANSCRIPTION FACTORS; POU DOMAIN; KIT GENE; PDGF-A; EXPRESSION; ACID; TERATOCARCINOMA; ACTIVATION	Expression of the platelet-derived growth factor alpha-receptor (PDGF alpha R) gene is tightly controlled in mammalian embryogenesis. A well established model system to study human embryogenesis is the embryonal carcinoma cell line Tera2, We have shown previously that retinoic acid-differentiated Tera2 cells express two PDGF alpha R transcripts of 6.4 kilobase pairs (kb) (encoding the full-length receptor) and 3.0 kb, respectively, whereas in contrast, undifferentiated Tera2 cells express PDFG alpha R transcripts of 1.5 kb and 5.0 kb, Here we show that this switch in PDGF alpha R expression pattern during differentiation of Tera2 cells results from alternative promoter use, In undifferentiated cells, a second promoter is used, which is located in intron 12 of the PDGF alpha R gene, Functional analysis shows that this promoter contains a consensus octamer motif, which can be bound by the POU domain transcription factor Oct-4, Oct-4 is expressed in undifferentiated Tera2 cells but not in retinoic acid-induced differentiated cells, Mutation of the octamer motif decreases promoter activity, while ectopic expression of Oct-4 in differentiated Tera2 cells specifically enhances the activity of this PDGF alpha R promoter, Therefore, we suggest that an important aspect in the maintenance of the undifferentiated state of human embryonal carcinoma cells results from Oct-4 expression, which thereupon activates this PDGF alpha R promoter.	UNIV NIJMEGEN,DEPT CELL BIOL,6525 ED NIJMEGEN,NETHERLANDS; UNIV TEXAS,DEPT ZOOL,AUSTIN,TX 78712	Radboud University Nijmegen; University of Texas System; University of Texas Austin			Hohenstein, Peter/Y-2428-2018	Hohenstein, Peter/0000-0001-8548-4734				AFINK GB, 1995, ONCOGENE, V10, P1667; ANDREWS PW, 1988, BIOCHIM BIOPHYS ACTA, V948, P17, DOI 10.1016/0304-419X(88)90003-0; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; Damjanov I, 1991, Recent Results Cancer Res, V123, P1; FAISST S, 1992, NUCLEIC ACIDS RES, V20, P3, DOI 10.1093/nar/20.1.3; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; HAMPE A, 1989, ONCOGENE RES, V4, P9; HOSLER BA, 1993, MOL CELL BIOL, V13, P2919, DOI 10.1128/MCB.13.5.2919; JAIN VK, 1991, ANAL BIOCHEM, V199, P119, DOI 10.1016/0003-2697(91)90278-2; JAYE M, 1992, BIOCHIM BIOPHYS ACTA, V1135, P185, DOI 10.1016/0167-4889(92)90136-Y; KITAMI Y, 1995, J CLIN INVEST, V96, P558, DOI 10.1172/JCI118068; LEE KH, 1990, MOL CELL BIOL, V10, P2237, DOI 10.1128/MCB.10.5.2237; MERCOLA M, 1990, DEV BIOL, V138, P114, DOI 10.1016/0012-1606(90)90181-H; MOSSELMAN S, 1994, CANCER RES, V54, P220; NISTER M, 1991, J BIOL CHEM, V266, P16755; OKAMOTO K, 1990, CELL, V60, P461, DOI 10.1016/0092-8674(90)90597-8; ORRURTREGER A, 1992, DEVELOPMENT, V115, P289; PALMIERI SL, 1992, MECH DEVELOP, V39, P181, DOI 10.1016/0925-4773(92)90045-L; PEEK R, 1992, NUCLEIC ACIDS RES, V20, P4865, DOI 10.1093/nar/20.18.4865; PETCH LA, 1990, MOL CELL BIOL, V10, P2973, DOI 10.1128/MCB.10.6.2973; ROSFJORD E, 1994, BIOCHEM BIOPH RES CO, V203, P1795, DOI 10.1006/bbrc.1994.2395; ROSSI P, 1992, DEV BIOL, V152, P203, DOI 10.1016/0012-1606(92)90172-D; Sambrook J., 2002, MOL CLONING LAB MANU; SCHATTEMAN GC, 1992, DEVELOPMENT, V115, P125; SCHOLER HR, 1990, NATURE, V344, P435, DOI 10.1038/344435a0; SCHOLER HR, 1989, EMBO J, V8, P2551, DOI 10.1002/j.1460-2075.1989.tb08393.x; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SMITH EA, 1991, P NATL ACAD SCI USA, V88, P4811, DOI 10.1073/pnas.88.11.4811; STEPHENSON DA, 1991, P NATL ACAD SCI USA, V88, P6, DOI 10.1073/pnas.88.1.6; TANAKA M, 1992, CELL, V68, P755, DOI 10.1016/0092-8674(92)90150-B; VANDENBARK GR, 1992, ONCOGENE, V7, P1259; VANZOELEN EJJ, 1989, DEV BIOL, V133, P272, DOI 10.1016/0012-1606(89)90318-7; VERRIJZER CP, 1993, BIOCHIM BIOPHYS ACTA, V1173, P1, DOI 10.1016/0167-4781(93)90237-8; VU TH, 1989, MOL CELL BIOL, V9, P4563, DOI 10.1128/MCB.9.10.4563; WANG CY, 1994, P NATL ACAD SCI USA, V91, P7061, DOI 10.1073/pnas.91.15.7061; WANG CY, 1990, MOL CELL BIOL, V10, P6781, DOI 10.1128/MCB.10.12.6781; Wegner M, 1993, CURR OPIN CELL BIOL, V5, P488, DOI 10.1016/0955-0674(93)90015-I; WEIMA SM, 1988, DIFFERENTIATION, V38, P203, DOI 10.1111/j.1432-0436.1988.tb00214.x; YUAN HB, 1995, GENE DEV, V9, P2635, DOI 10.1101/gad.9.21.2635	39	45	50	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 31	1996	271	22					12873	12878		10.1074/jbc.271.22.12873	http://dx.doi.org/10.1074/jbc.271.22.12873			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UN474	8662786	hybrid, Green Published			2022-12-25	WOS:A1996UN47400030
J	Ibeanu, GC; Ghanayem, BI; Linko, P; Li, LP; Pedersen, LG; Goldstein, JA				Ibeanu, GC; Ghanayem, BI; Linko, P; Li, LP; Pedersen, LG; Goldstein, JA			Identification of residues 99, 220, and 221 of human cytochrome P450 2C19 as key determinants of omeprazole hydroxylase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; AMINO-ACID; SUBSTRATE-SPECIFICITY; LAURATE (OMEGA-1)-HYDROXYLASE; SEQUENCE REQUIREMENTS; CATALYTIC ACTIVITY; MOLECULAR-MODEL; ENZYMES; BINDING; 15-ALPHA-HYDROXYLASE	Human P450 2C19 is selective for 4'-hydroxylation of S-mephenytoin and 5-hydroxylation of omeprazole, while the structurally homologous P450 2C9 has low activity toward these substrates. To identify the critical amino acids that determine the specificity of human P450 2C19, we constructed chimeras of P450 2C9 replacing various proposed substrate binding sites (SRS) with those of P450 2C19 and then replaced individual residues of P450 2C9 by site directed mutagenesis. The 339 NH2-terminal amino acid residues (SRS-1--SRS-4) and amino acids 160-383 (SRS-2--SRS-5) of P450 2C19 conferred omeprazole 5-hydroxylase activity to P450 2C9. In contrast, the COOH terminus of P450 2C19 (residues 340-490 including SRS-5 and SRS-6), residues 228-339 (SRS-3 and SRS-4) and residues 292-383 (part of SRS-4 and SRS-B) conferred only modest increases in activity. A single mutation Ile(99) --> His increased omeprazole 5-hydroxylase to similar to 51% of that of P450 2C19. A chimera spanning residues 160-227 of P450 2C19 also exhibited omeprazole 5-hydroxylase activity which was dramatically enhanced by the mutation Ile(99) --> His, A combination of two mutations, Ile(99) --> His and Ser(200) --> Pro, converted P450 2C9 to an enzyme with a turnover number for omeprazole 5-hydroxylation, which resembled that of P450 2C19. Mutation of Pro(221) --> Thr enhanced this activity. Residue 99 is within SRS-1, but amino acids 220 and 221 are in the F-G loop and outside any known SRS. Mutation of these three amino acids did not confer significant S-mephenytoin 5-hydroxylase activity to P450 2C9, although chimeras containing SRS-1--SRS-4 and SRS-2--SRS-5 of P450 2C19 exhibited activity toward this substrate. Our results thus indicate that amino acids 99, 220, and 221 are key residues that determine the specificity of P450 2C19 for omeprazole.	NIEHS, NIH, RES TRIANGLE PK, NC 27709 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)			Li, Leping/F-6497-2019; Pedersen, Lee G/E-3405-2013	Li, Leping/0000-0003-4208-0259; Pedersen, Lee G/0000-0003-1262-9861				AOYAMA T, 1989, J BIOL CHEM, V264, P21327; ATKINS WM, 1988, J BIOL CHEM, V263, P18842; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; FALETTO MB, 1992, J BIOL CHEM, V267, P2032; GHANAYEM BI, 1994, 6 N AM INT SOC STUD, P50; GOLDSTEIN JA, 1994, PHARMACOGENETICS, V4, P285, DOI 10.1097/00008571-199412000-00001; GOLDSTEIN JA, 1994, BIOCHEMISTRY-US, V33, P1743, DOI 10.1021/bi00173a017; GOTOH O, 1992, J BIOL CHEM, V267, P83; GUENGERICH FP, 1991, J BIOL CHEM, V266, P10019; HALPERT JR, 1993, J BIOL CHEM, V268, P4453; HASEMANN CA, 1995, STRUCTURE, V3, P41, DOI 10.1016/S0969-2126(01)00134-4; HASLER JA, 1994, MOL PHARMACOL, V46, P338; HE YA, 1994, BIOCHEMISTRY-US, V33, P4419, DOI 10.1021/bi00180a040; IMAI Y, 1989, BIOCHEM BIOPH RES CO, V158, P717, DOI 10.1016/0006-291X(89)92780-0; IWASAKI M, 1993, J BIOL CHEM, V268, P759; IWASAKI M, 1995, BIOCHEMISTRY-US, V34, P5054, DOI 10.1021/bi00015a016; IWASAKI M, 1993, BIOCHEM J, V291, P569, DOI 10.1042/bj2910569; JOHNSON EF, 1992, TRENDS PHARMACOL SCI, V13, P122, DOI 10.1016/0165-6147(92)90042-5; JOHNSON EF, 1992, FASEB J, V6, P700, DOI 10.1096/fasebj.6.2.1537459; JUVONEN RO, 1991, J BIOL CHEM, V266, P16431; KEDZIE KM, 1991, J BIOL CHEM, V266, P22515; KRONBACH T, 1989, P NATL ACAD SCI USA, V86, P8262, DOI 10.1073/pnas.86.21.8262; KRONBACH T, 1991, BIOCHEMISTRY-US, V30, P6097, DOI 10.1021/bi00239a003; LAUGHTON CA, 1993, J STEROID BIOCHEM, V44, P399, DOI 10.1016/0960-0760(93)90243-P; LAUGHTON CA, 1990, BIOCHEM BIOPH RES CO, V171, P1160, DOI 10.1016/0006-291X(90)90806-X; LEWIS DFV, 1992, J COMPUT AID MOL DES, V6, P235, DOI 10.1007/BF00123379; LIN D, 1993, ENDOCRINOLOGY, V132, P2498, DOI 10.1210/en.132.6.2498; LINDBERG RLP, 1989, NATURE, V339, P632, DOI 10.1038/339632a0; Luo Zongshu, 1994, Archives of Biochemistry and Biophysics, V309, P52; MATSUNAGA E, 1990, J BIOL CHEM, V265, P17197; NELSON DR, 1993, DNA CELL BIOL, V12, P1, DOI 10.1089/dna.1993.12.1; NELSON DR, 1989, BIOCHEMISTRY-US, V28, P656, DOI 10.1021/bi00428a036; OEDA K, 1985, DNA-J MOLEC CELL BIO, V4, P203, DOI 10.1089/dna.1985.4.203; OMURA T, 1964, J BIOL CHEM, V239, P2370; PORTER TD, 1991, J BIOL CHEM, V266, P13469; POULOS TL, 1987, J MOL BIOL, V195, P687, DOI 10.1016/0022-2836(87)90190-2; RICHARDSON TH, 1994, J BIOL CHEM, V269, P23937; ROSE MD, 1990, METHODS YEAST GENETI, P180; STRAUB P, 1993, J BIOL CHEM, V268, P21997; STRAUB P, 1993, ARCH BIOCHEM BIOPHYS, V306, P521, DOI 10.1006/abbi.1993.1547; SULLIVAN TH, 1996, IN PRESS PHARMACOGEN; SZKLARZ GD, 1995, BIOCHEMISTRY-US, V34, P14312, DOI 10.1021/bi00044a008; UNO T, 1992, J BIOCHEM-TOKYO, V112, P155, DOI 10.1093/oxfordjournals.jbchem.a123856; UNO T, 1989, J BIOCHEM-TOKYO, V106, P569, DOI 10.1093/oxfordjournals.jbchem.a122897; ZVELEBIL MJJM, 1991, PROTEIN ENG, V4, P271, DOI 10.1093/protein/4.3.271	46	82	83	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 24	1996	271	21					12496	12501		10.1074/jbc.271.21.12496	http://dx.doi.org/10.1074/jbc.271.21.12496			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UL660	8647857	hybrid			2022-12-25	WOS:A1996UL66000059
J	Simos, G; Maison, C; Georgatos, SD				Simos, G; Maison, C; Georgatos, SD			Characterization of p18, a component of the lamin B receptor complex and a new integral membrane protein of the avian erythrocyte nuclear envelope	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HAMSTER OVARY CELLS; BENZODIAZEPINE RECEPTOR; INTERMEDIATE FILAMENTS; MOLECULAR-CLONING; ATTACHMENT SITE; PLASMA-MEMBRANE; GENE ENCODES; BINDING; EXPRESSION; VIMENTIN	Employing avian erythrocytes, we have previously isolated a multimeric complex consisting of the lamin B receptor (LBR, or p58), the nuclear lamins, an LBR-specific kinase, a 34-kDa protein, and an 18-kDa polypeptide termed p18. As the LBR kinase and the 34-kDa component have been recently characterized, we now proceed in the characterization of p18. We show here that p18 is an integral membrane protein specific to the erythrocyte nuclear envelope which binds to LBR and B-type lamins. NH2-terminal sequencing indicates that p18 is distinct from other nuclear envelope components, but has similarity to the mitochondrial isoquinoline-binding protein. In situ analysis by immunoelectron microscopy and examination of digitonin-permeabilized cells by indirect immunofluorescence show that p18, unlike LBR and other lamin-binding proteins, is equally distributed between the inner and outer nuclear membrane. Furthermore, cycloheximide inhibition experiments reveal that the fraction of p18 that resides in the outer nuclear membrane does not represent nascent chains en route to the inner nuclear membrane, but rather material in equilibrium with the p18 that partitions with the inner nuclear membrane. The paradigm of p18 suggests that transmembrane complexes formed by the nuclear lamins and LBR provide potential docking sites for integral membrane proteins of the nuclear envelope that equilibrate between the rough endoplasmic reticulum and the inner nuclear membrane.	EUROPEAN MOLEC BIOL LAB,CELL BIOL PROGRAM,D-69117 HEIDELBERG,GERMANY; UNIV CRETE,DEPT BASIC SCI,FAC MED,GR-71110 IRAKLION,CRETE,GREECE	European Molecular Biology Laboratory (EMBL); University of Crete			Simos, George/AAH-2596-2021	Georgatos, Spyros/0000-0002-2078-7467; Simos, George/0000-0001-5453-3185				BAILER SM, 1991, J CELL BIOL, V114, P389, DOI 10.1083/jcb.114.3.389; BERGMANN JE, 1983, J CELL BIOL, V97, P1777, DOI 10.1083/jcb.97.6.1777; CHAUDHARY N, 1993, J CELL BIOL, V122, P295, DOI 10.1083/jcb.122.2.295; CHEN WN, 1991, YEAST, V7, P305, DOI 10.1002/yea.320070313; COURVALIN JC, 1992, J BIOL CHEM, V267, P19035; DJABALI K, 1991, CELL, V64, P109, DOI 10.1016/0092-8674(91)90213-I; FOISNER R, 1993, CELL, V73, P1267, DOI 10.1016/0092-8674(93)90355-T; FURUKAWA K, 1995, EMBO J, V14, P1626, DOI 10.1002/j.1460-2075.1995.tb07151.x; Galfre G, 1981, Methods Enzymol, V73, P3; GEORGATOS SD, 1987, J CELL BIOL, V105, P117, DOI 10.1083/jcb.105.1.117; GEORGATOS SD, 1989, J CELL BIOL, V108, P2069, DOI 10.1083/jcb.108.6.2069; GEORGATOS SD, 1994, J CELL BIOCHEM, V55, P69, DOI 10.1002/jcb.240550108; GEORGATOS SD, 1994, CURR OPIN CELL BIOL, V6, P347, DOI 10.1016/0955-0674(94)90025-6; GEORGATOS SD, 1987, J CELL BIOL, V105, P105, DOI 10.1083/jcb.105.1.105; Gerace Larry, 1994, Trends in Cell Biology, V4, P127, DOI 10.1016/0962-8924(94)90067-1; GOLDSTEI.G, 1974, NATURE, V247, P11, DOI 10.1038/247011a0; GOLDSTEIN G, 1979, SCIENCE, V204, P1309, DOI 10.1126/science.451537; GREEN J, 1981, J MOL BIOL, V152, P663, DOI 10.1016/0022-2836(81)90122-4; GRIFFITHS G, 1984, J ULTRA MOL STRUCT R, V89, P65, DOI 10.1016/S0022-5320(84)80024-6; HARRIS CA, 1994, P NATL ACAD SCI USA, V91, P6283, DOI 10.1073/pnas.91.14.6283; HARRIS JR, 1971, J ULTRA MOL STRUCT R, V36, P8, DOI 10.1016/S0022-5320(71)80085-0; JAMIESON JD, 1968, J CELL BIOL, V39, P580, DOI 10.1083/jcb.39.3.580; KRAINER AR, 1991, CELL, V66, P383, DOI 10.1016/0092-8674(91)90627-B; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE C, 1987, ANAL BIOCHEM, V166, P308, DOI 10.1016/0003-2697(87)90579-3; LORENZ RT, 1992, DNA CELL BIOL, V11, P685, DOI 10.1089/dna.1992.11.685; LUO Y, 1994, J VIROL, V68, P3850, DOI 10.1128/JVI.68.6.3850-3856.1994; MAISON C, 1993, J CELL BIOL, V123, P1491, DOI 10.1083/jcb.123.6.1491; MARTIN L, 1995, J BIOL CHEM, V270, P8822, DOI 10.1074/jbc.270.15.8822; MEIER J, 1994, EMBO J, V13, P1888, DOI 10.1002/j.1460-2075.1994.tb06458.x; MERDES A, 1991, J CELL BIOL, V115, P397, DOI 10.1083/jcb.115.2.397; Nikolakaki E, 1996, J BIOL CHEM, V271, P8365, DOI 10.1074/jbc.271.14.8365; PADAN R, 1990, J BIOL CHEM, V265, P7808; PAROLA AL, 1991, J BIOL CHEM, V266, P14082; PINDER JC, 1995, BLOOD, V85, P2951, DOI 10.1182/blood.V85.10.2951.bloodjournal85102951; POWELL L, 1990, J CELL BIOL, V111, P2225, DOI 10.1083/jcb.111.6.2225; RANGES GE, 1982, J EXP MED, V156, P1057, DOI 10.1084/jem.156.4.1057; RIOND J, 1991, EUR J BIOCHEM, V195, P305, DOI 10.1111/j.1432-1033.1991.tb15707.x; RIOND J, 1989, FEBS LETT, V245, P238, DOI 10.1016/0014-5793(89)80229-7; SCHULER E, 1994, J BIOL CHEM, V269, P11312; SENIOR A, 1988, J CELL BIOL, V107, P2029, DOI 10.1083/jcb.107.6.2029; SHIMANUKI M, 1992, MOL BIOL CELL, V3, P263, DOI 10.1091/mbc.3.3.263; SIMOS G, 1992, EMBO J, V11, P4027, DOI 10.1002/j.1460-2075.1992.tb05496.x; SIMOS G, 1994, FEBS LETT, V346, P225, DOI 10.1016/0014-5793(94)00479-X; SMITH S, 1993, J CELL BIOL, V120, P631, DOI 10.1083/jcb.120.3.631; SMITH S, 1994, P NATL ACAD SCI USA, V91, P10124, DOI 10.1073/pnas.91.21.10124; SOULLAM B, 1993, J CELL BIOL, V120, P1093, DOI 10.1083/jcb.120.5.1093; SOULLAM B, 1995, J CELL BIOL, V130, P15, DOI 10.1083/jcb.130.1.15; SPRENGEL R, 1989, J BIOL CHEM, V264, P20415; TORRISI MR, 1985, J CELL BIOL, V101, P1300, DOI 10.1083/jcb.101.4.1300; TORRISI MR, 1987, J CELL BIOL, V104, P733, DOI 10.1083/jcb.104.3.733; WORMAN HJ, 1990, J CELL BIOL, V111, P1535, DOI 10.1083/jcb.111.4.1535; WORMAN HJ, 1988, P NATL ACAD SCI USA, V85, P8531, DOI 10.1073/pnas.85.22.8531; YE Q, 1994, J BIOL CHEM, V269, P11306; ZENTGRAF H, 1971, J BIOL CHEM, V246, P2986	55	33	34	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 24	1996	271	21					12617	12625		10.1074/jbc.271.21.12617	http://dx.doi.org/10.1074/jbc.271.21.12617			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UL660	8647873	hybrid			2022-12-25	WOS:A1996UL66000075
J	Hankins, GR; DeSouza, AT; Bentley, RC; Patel, MR; Marks, JR; Iglehart, JD; Jirtle, RL				Hankins, GR; DeSouza, AT; Bentley, RC; Patel, MR; Marks, JR; Iglehart, JD; Jirtle, RL			M6P/IGF2 receptor: A candidate breast tumor suppressor gene	ONCOGENE			English	Article						loss of heterozygosity; M6P/IGF2 receptor; breast cancer; mutation; tumor suppressor	FACTOR-II RECEPTOR; MANNOSE 6-PHOSPHATE BINDING; GROWTH-FACTOR-BETA; EXPRESSION CLONING; CANCER; PROTEIN; TAMOXIFEN; KINASE; HETEROZYGOSITY; POLYMORPHISM	The mannose 6-phosphate/insulin-like growth factor 2 receptor (M6P/IGF2r) functions in the activation of TGF beta, a potent growth inhibitor for most cell types, the degradation of the mitogen, IGF2, and the intracellular trafficking of lysosomal enzymes, We have found its expression to be significantly reduced in both rat and human hepatocellular carcinomas (HCCs) and recently reported loss of heterozygosity (LOH) at this locus with mutations in the remaining allele in human liver tumors, Using the polymerase chain reaction, we utilized two polymorphisms in the 3' untranslated region of M6P/IGF2r to screen breast tumors for LOH, Forty of 62 (65%) patients were informative (heterozygous) and 12/40 (30%) breast tumors had LOH; 5/19 (26%) carcinomas in situ (CIS) and 7/21 (33%) invasive carcinomas, To investigate the early molecular genetic events in breast carcinogenesis, we screened the CIS with LOH for mutations, In 2/5 (40%) of these tumors, missense mutations were found in the remaining allele that gave rise to significant amino acid substitutions. These findings provide evidence that M6P/IGF2r allelic loss is an early event in the etiology of breast cancer, and that this gene functions as a tumor suppressor gene in the breast.	DUKE UNIV, MED CTR, DEPT RADIAT ONCOL, DURHAM, NC 27710 USA; DUKE UNIV, MED CTR, DEPT PATHOL, DURHAM, NC 27710 USA; DUKE UNIV, MED CTR, DEPT SURG, DURHAM, NC 27710 USA; ZENECA PHARMACEUT, DEPT SAFETY MED, MACCLESFIELD SK10 4TG, CHESHIRE, ENGLAND	Duke University; Duke University; Duke University					NATIONAL CANCER INSTITUTE [R01CA025951] Funding Source: NIH RePORTER; NCI NIH HHS [CA 25951] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARNES DM, 1993, J CELL BIOCHEM, P132; BASSING CH, 1994, SCIENCE, V263, P87, DOI 10.1126/science.8272871; BLACKSHEAR PJ, 1992, J BIOL CHEM, V267, P13540; BLACKSHEAR PJ, 1993, J BIOL CHEM, V268, P1501; BUTTA A, 1992, CANCER RES, V52, P4261; CATHERINO WH, 1993, DRUG SAFETY, V8, P381, DOI 10.2165/00002018-199308050-00005; CHEN RH, 1993, SCIENCE, V260, P1335, DOI 10.1126/science.8388126; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DAHMS NM, 1989, J BIOL CHEM, V264, P12115; DAHMS NM, 1993, J BIOL CHEM, V268, P5457; DAHMS NM, 1994, J BIOL CHEM, V269, P3802; DEBLESER PJ, 1995, HEPATOLOGY, V21, P1429, DOI 10.1016/0270-9139(95)90066-7; DENNIS PA, 1991, P NATL ACAD SCI USA, V88, P580, DOI 10.1073/pnas.88.2.580; DESOUZA AT, 1995, NAT GENET, V11, P447, DOI 10.1038/ng1295-447; DESOUZA AT, 1995, ONCOGENE, V10, P1725; DEVILEE P, 1991, ONCOGENE, V6, P1705; DICKSON RB, 1990, J STEROID BIOCHEM, V37, P795, DOI 10.1016/0960-0760(90)90422-H; DICKSON RB, 1996, DIS BREAST, P221; DUTRILLAUX B, 1990, CANCER GENET CYTOGEN, V49, P203, DOI 10.1016/0165-4608(90)90143-X; FORSYTH IA, 1991, BAILLIERE CLIN ENDOC, V5, P809, DOI 10.1016/S0950-351X(10)80016-3; GOTO J, 1992, NUCLEIC ACIDS RES, V20, P923, DOI 10.1093/nar/20.4.923; HEBERT E, 1994, BRIT J CANCER, V69, P120, DOI 10.1038/bjc.1994.19; HEDRUM A, 1994, BIOTECHNIQUES, V17, P118; Hol F. A., 1992, Human Molecular Genetics, V1, P347, DOI 10.1093/hmg/1.5.347; IWASE H, 1995, BRIT J CANCER, V71, P448, DOI 10.1038/bjc.1995.91; JIRTLE RL, 1993, CANCER RES, V53, P3849; JIRTLE RL, 1994, CARCINOGENESIS, V15, P1473, DOI 10.1093/carcin/15.8.1473; JORDAN VC, 1993, CANCER, V72, P1, DOI 10.1002/1097-0142(19930701)72:1<1::AID-CNCR2820720102>3.0.CO;2-F; KNUDSON AG, 1993, P NATL ACAD SCI USA, V90, P10914, DOI 10.1073/pnas.90.23.10914; KORETH J, 1995, J PATHOL, V176, P11, DOI 10.1002/path.1711760104; KORNFELD S, 1992, ANNU REV BIOCHEM, V61, P307, DOI 10.1146/annurev.bi.61.070192.001515; LAUREYS G, 1988, GENOMICS, V3, P224, DOI 10.1016/0888-7543(88)90083-3; LEVINE AJ, 1993, ANNU REV BIOCHEM, V62, P623, DOI 10.1146/annurev.bi.62.070193.003203; LIN HY, 1992, CELL, V68, P775, DOI 10.1016/0092-8674(92)90152-3; LOPEZCASILLAS F, 1991, CELL, V67, P785, DOI 10.1016/0092-8674(91)90073-8; LOPEZCASILLAS F, 1993, CELL, V73, P1435, DOI 10.1016/0092-8674(93)90368-Z; LOUIS DN, 1992, AM J PATHOL, V141, P777; LYONS RM, 1988, J CELL BIOL, V106, P1659, DOI 10.1083/jcb.106.5.1659; MARS WM, 1990, CANCER METAST REV, V9, P35, DOI 10.1007/BF00047587; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; MELTZER SJ, 1993, PCR PROTOCOLS CURREN, P137; MENASCE LP, 1993, GENOMICS, V17, P263, DOI 10.1006/geno.1993.1320; MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215; MORGAN DO, 1987, NATURE, V329, P301, DOI 10.1038/329301a0; MORROW M, 1996, DIS BREAST, P355; OMALLEY FP, 1994, LAB INVEST, V71, P67; ORPHANOS V, 1995, BRIT J CANCER, V71, P666, DOI 10.1038/bjc.1995.132; ORPHANOS V, 1995, BRIT J CANCER, V71, P290, DOI 10.1038/bjc.1995.58; OSBORNE CK, 1989, MOL ENDOCRINOL, V3, P1701, DOI 10.1210/mend-3-11-1701; RADFORD DM, 1995, CANCER RES, V55, P3399; SACKS NPM, 1993, EUR J CANCER, V29A, P426, DOI 10.1016/0959-8049(93)90401-Z; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHMIDT B, 1995, J BIOL CHEM, V270, P14975, DOI 10.1074/jbc.270.25.14975; SLEAT DE, 1995, CANCER RES, V55, P3424; SMITH HS, 1993, J CELL BIOCHEM, P144; STRATTON MR, 1995, J PATHOL, V175, P195, DOI 10.1002/path.1711750207; SUE SR, 1995, ANN SURG, V222, P171, DOI 10.1097/00000658-199508000-00009; SWANSON GM, 1993, CANCER, V72, P788, DOI 10.1002/1097-0142(19930801)72:3<788::AID-CNCR2820720326>3.0.CO;2-C; SZEBENYI G, 1994, GENOMICS, V19, P120, DOI 10.1006/geno.1994.1021; TROCK BJ, 1996, DIS BREAST, P213; WANG XF, 1991, CELL, V67, P797, DOI 10.1016/0092-8674(91)90074-9; WEISSENBACH J, 1992, NATURE, V359, P794, DOI 10.1038/359794a0; WESTLUND B, 1991, J BIOL CHEM, V266, P23233; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; ZENKLUSEN JC, 1995, ONCOGENE, V11, P359; ZENKLUSEN JC, 1994, P NATL ACAD SCI USA, V91, P12155, DOI 10.1073/pnas.91.25.12155; ZHAO Y, 1993, CANCER RES, V53, P2901; ZHUANG ZP, 1995, CANCER RES, V55, P467	68	197	202	1	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 2	1996	12	9					2003	2009						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UK498	8649861				2022-12-25	WOS:A1996UK49800019
J	Lehar, SM; Naeht, M; Jacks, T; Vater, CA; Chittenden, T; Guild, BC				Lehar, SM; Naeht, M; Jacks, T; Vater, CA; Chittenden, T; Guild, BC			Identification and cloning of EI24, a gene induced by p53 in etoposide-treated cells	ONCOGENE			English	Article						p53; gene induction; differential display; apoptosis	TUMOR-SUPPRESSOR; WILD-TYPE; APOPTOSIS; EXPRESSION; PROTEIN; THYMOCYTES; RECEPTOR; SEQUENCE	To search for candidate genes involved in p53-mediated apoptosis, the differential display technique was used to identify RNA species whose expression was altered in murine NIH3T3 cells treated with the cytotoxic drug etoposide. We report here the isolation and characterization of EI24, a novel gene whose 2.4 kb mRNA is induced following etoposide treatment. Induction of EI24 mRNA by etoposide required expression of wild-type p53 in murine embryonic fibroblasts which had been transformed with the oncogenes E1A and T24 H-ras; and overexpression of functional p53 in these cells was sufficient to induce expression of the EI24 mRNA. The EI24 mRNA was also induced in a p53-dependent manner by ionizing irradiation of primary murine thymocytes. Isolation of a full-length EI24 cDNA revealed that its protein product bears homology to CELF37C12.2, a Caenorhabditis elegans protein of unknown function.	APOPTOSIS TECHNOL INC,CAMBRIDGE,MA 02139; MIT,CTR CANC RES,HOWARD HUGHES MED INST,CAMBRIDGE,MA 02139	Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT)								BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; BUCKBINDER L, 1994, P NATL ACAD SCI USA, V91, P10640, DOI 10.1073/pnas.91.22.10640; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; DANIELIAN PS, 1993, MOL ENDOCRINOL, V7, P232, DOI 10.1210/me.7.2.232; DONEHOWER LA, 1993, BIOCHIM BIOPHYS ACTA, V1155, P181, DOI 10.1016/0304-419X(93)90004-V; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; GREENBLATT MS, 1994, CANCER RES, V54, P4855; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; LITTLEWOOD TD, 1995, NUCLEIC ACIDS RES, V23, P1686, DOI 10.1093/nar/23.10.1686; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LOWE SW, 1994, P NATL ACAD SCI USA, V91, P2026, DOI 10.1073/pnas.91.6.2026; LOWE SW, 1993, GENE DEV, V7, P535, DOI 10.1101/gad.7.4.535; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; MICHIELI P, 1994, CANCER RES, V54, P3391; MIYASHITA T, 1995, CELL, V80, P293; MIYASHITA T, 1994, ONCOGENE, V9, P1799; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; OKAMOTO K, 1994, EMBO J, V13, P4816, DOI 10.1002/j.1460-2075.1994.tb06807.x; OLTVAI ZN, 1994, CELL, V79, P189, DOI 10.1016/0092-8674(94)90188-0; PRIVES C, 1993, GENE DEV, V7, P529, DOI 10.1101/gad.7.4.529; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; ROEMER K, 1993, P NATL ACAD SCI USA, V90, P9252, DOI 10.1073/pnas.90.20.9252; Sambrook J., 2002, MOL CLONING LAB MANU; SHAKLEFORD GM, 1987, CELL, V50, P89; STELLER H, 1995, SCIENCE, V267, P1445, DOI 10.1126/science.7878463; STRASSER A, 1994, CELL, V79, P329, DOI 10.1016/0092-8674(94)90201-1; WALKER PR, 1991, CANCER RES, V51, P1078; WILSON R, 1994, NATURE, V368, P32, DOI 10.1038/368032a0; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; ZAMBETTI GP, 1992, GENE DEV, V6, P1143, DOI 10.1101/gad.6.7.1143; ZHAN QM, 1994, ONCOGENE, V9, P3743	36	71	74	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR 21	1996	12	6					1181	1187						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UC067	8649819				2022-12-25	WOS:A1996UC06700002
J	Aoki, T; Sano, Y; Yamamoto, T; Inoue, J				Aoki, T; Sano, Y; Yamamoto, T; Inoue, J			The ankyrin repeats but not the PEST-like sequences are required for signal-dependent degradation of I kappa B alpha	ONCOGENE			English	Article						ankyrin repeats; degradation; I kappa-B; PEST sequence; phosphorylation	TUMOR-NECROSIS-FACTOR; DNA-BINDING; TRANSCRIPTION FACTORS; PRECURSOR P105; ACTIVATION; REL; PHOSPHORYLATION; I-KAPPA-B/MAD-3; ASSOCIATION; EXPRESSION	The nuclear activity of Rel/NF kappa B transcription factors is tightly regulated from the cytoplasmic compartment by an inhibitory subunit called I kappa B alpha. I kappa B alpha is rapidly phosphorylated and degraded in response to the stimulation through tumor necrosis factor alpha (TNF alpha) receptor, interleukin-1 receptor or CD40. To explore the molecular mechanisms of signal-induced depletion of I kappa B alpha, we have delineated the domain in I kappa B alpha that is required for TNF alpha-induced phosphorylation and rapid degradation of I kappa B alpha. In contrast to the previous reports, the PEST-like sequences, which are present in the carboxyl-terminal region of I kappa B alpha, are demonstrated here to be dispensable for TNF alpha-induced degradation but could be required for signal-independent degradation, as in the case of Cactus, Drosophila homologue of I kappa B. Furthermore, the ankyrin repeats, which are essential for forming a complex with Rel and RelA, are required for TNF alpha-induced degradation suggesting that the putative I kappa B protease could interact with I kappa B alpha in complex with RelA or could recognize the structure of ankyrin repeats. Our data also indicate that neither the ankyrin repeats nor the PEST-like sequences, are essential for TNF alpha-induced phosphorylation.	UNIV TOKYO,INST MED SCI,DEPT ONCOL,MINATO KU,TOKYO 108,JAPAN	University of Tokyo								ALKALAY I, 1995, MOL CELL BIOL, V15, P1294; BAUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141; BAUERLE PA, 1988, SCIENCE, V242, P540; BEG AA, 1992, GENE DEV, V6, P1899, DOI 10.1101/gad.6.10.1899; BEG AA, 1993, MOL CELL BIOL, V13, P3301, DOI 10.1128/MCB.13.6.3301; BELVIN MP, 1995, GENE DEV, V9, P783, DOI 10.1101/gad.9.7.783; BERBERICH I, 1994, J IMMUNOL, V153, P4357; BOURS V, 1993, CELL, V72, P729, DOI 10.1016/0092-8674(93)90401-B; BROCKMAN JA, 1995, MOL CELL BIOL, V15, P2809; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; CHEN ZJ, 1995, GENE DEV, V9, P1586, DOI 10.1101/gad.9.13.1586; CORDLE SR, 1993, J BIOL CHEM, V268, P11803; DAVIS N, 1991, SCIENCE, V253, P1268, DOI 10.1126/science.1891714; DEMARTIN R, 1993, EMBO J, V12, P2773, DOI 10.1002/j.1460-2075.1993.tb05938.x; DIDONATO JA, 1995, MOL CELL BIOL, V15, P1302; ERNST MK, 1995, MOL CELL BIOL, V15, P872; FINCO TS, 1994, P NATL ACAD SCI USA, V91, P11884, DOI 10.1073/pnas.91.25.11884; GANCHI PA, 1992, MOL BIOL CELL, V3, P1339, DOI 10.1091/mbc.3.12.1339; HASKILL S, 1991, CELL, V65, P1281, DOI 10.1016/0092-8674(91)90022-Q; HATADA EN, 1992, P NATL ACAD SCI USA, V89, P2489, DOI 10.1073/pnas.89.6.2489; HATADA EN, 1993, EMBO J, V12, P2781, DOI 10.1002/j.1460-2075.1993.tb05939.x; HENKEL T, 1993, NATURE, V365, P182, DOI 10.1038/365182a0; HENKEL T, 1992, CELL, V68, P1121, DOI 10.1016/0092-8674(92)90083-O; INOUE J, 1992, CELL, V68, P1109, DOI 10.1016/0092-8674(92)90082-N; INOUE JI, 1992, P NATL ACAD SCI USA, V89, P4333, DOI 10.1073/pnas.89.10.4333; JAFFRAY E, 1995, MOL CELL BIOL, V15, P2166; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LIN YC, 1995, P NATL ACAD SCI USA, V92, P552, DOI 10.1073/pnas.92.2.552; MELLITS KH, 1993, NUCLEIC ACIDS RES, V21, P5059, DOI 10.1093/nar/21.22.5059; MIYAMOTO S, 1994, P NATL ACAD SCI USA, V91, P12740, DOI 10.1073/pnas.91.26.12740; OSBORN L, 1989, P NATL ACAD SCI USA, V86, P2336, DOI 10.1073/pnas.86.7.2336; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; RICE NR, 1992, CELL, V71, P243, DOI 10.1016/0092-8674(92)90353-E; RICE NR, 1993, EMBO J, V12, P4685, DOI 10.1002/j.1460-2075.1993.tb06157.x; RODIGUEZ MS, 1995, MOL CELL BIOL, V15, P2413; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; SCOTT ML, 1993, GENE DEV, V7, P1266, DOI 10.1101/gad.7.7a.1266; SUN SC, 1993, SCIENCE, V259, P1912, DOI 10.1126/science.8096091; TEWARI M, 1992, MOL CELL BIOL, V12, P2898, DOI 10.1128/MCB.12.6.2898; TRAENCKNER EBM, 1995, EMBO J, V14, P2876, DOI 10.1002/j.1460-2075.1995.tb07287.x; TRAENCKNER EBM, 1994, EMBO J, V13, P5433, DOI 10.1002/j.1460-2075.1994.tb06878.x; WHITESIDE ST, 1995, MOL CELL BIOL, V15, P5339; ZABEL U, 1993, EMBO J, V12, P201, DOI 10.1002/j.1460-2075.1993.tb05646.x	43	24	24	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR 7	1996	12	5					1159	1164						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UA884	8649809				2022-12-25	WOS:A1996UA88400026
J	Givehchian, M; Woerner, SM; Lacroix, J; Zoller, M; Drings, P; Becker, H; Kayser, K; Ridder, R; Doeberitz, MV				Givehchian, M; Woerner, SM; Lacroix, J; Zoller, M; Drings, P; Becker, H; Kayser, K; Ridder, R; Doeberitz, MV			Expression of CD44 splice variants in normal respiratory epithelium and bronchial carcinomas: No evidence for altered CD44 splicing in metastasis	ONCOGENE			English	Article						lung cancer; bronchial epithelium; adhesion molecules; RT-PCR; immunohistology	SMALL-CELL CARCINOMA; ADHESION MOLECULE; RECEPTOR CD44; LUNG-CANCER; ESTABLISHMENT; HYALURONATE; BEHAVIOR; PRODUCTS; LINES	Expression of alternatively spliced CD44 adhesion molecules has been implicated in metastatic spread of various rodent and human tumors. To determine whether specific CD44 splice variants contribute to metastatic spread of bronchial cancers, we compared the expression of CD44 splice variants in normal bronchial epithelium and bronchial cancers, including tumors which already spread to regional lymph nodes or distant organs. Variant CD44 expression was analysed by immunohistochemistry using variant exon-specific monoclonal antibodies. The precise composition of CD44 transcripts was delineated by exon-specific RT-PCR. The concurring data obtained by both methods revealed that high levels of standard CD44 and variants v5 and v6 as well as low levels of variants v7 and v10 are expressed both in normal bronchial epithelium and squamous cell lung cancers. No CD44 expression was observed in the highly metastatic small cell lung cancers and adenocarcinomas with the exception of bronchioalveolar cancers showing weak expression of standard CD44. These data suggest that expression of alternatively spliced CD44 molecules in the bronchial tract is related to the distinct differentiation of the respiratory epithelium. No correlation between expression of specific CD44 splice variants and metastasis of bronchial cancers was observed.	DEUTSCH KREBSFORSCHUNGSZENTRUM, FSP ANGEW TUMORVIROL 6, NEUENHEIMER FELD 242, D-69120 HEIDELBERG, GERMANY; THORAXKLIN HEIDELBERG, D-69126 HEIDELBERG, GERMANY	Helmholtz Association; German Cancer Research Center (DKFZ); Ruprecht Karls University Heidelberg			Woerner, Stefan/A-2187-2010					ABBASI AM, 1993, EUR J CANCER, V29A, P1995, DOI 10.1016/0959-8049(93)90461-N; [Anonymous], 1982, AM J CLIN PATHOL, V77, P123; ARCH R, 1992, SCIENCE, V257, P682, DOI 10.1126/science.1496383; ARUFFO A, 1990, CELL, V61, P1303, DOI 10.1016/0092-8674(90)90694-A; CARNEY DN, 1985, CANCER RES, V45, P2913; COMBARET V, 1995, EUR J CANCER, V31A, P545, DOI 10.1016/0959-8049(95)00027-G; COOPER DL, 1995, NAT MED, V1, P635, DOI 10.1038/nm0795-635; GAZDAR AF, 1980, CANCER RES, V40, P3502; GROSS N, 1995, EUR J CANCER, V31A, P471, DOI 10.1016/0959-8049(95)00029-I; GUNTHERT U, 1991, CELL, V65, P13, DOI 10.1016/0092-8674(91)90403-L; HARN HJ, 1991, BIOCHEM BIOPH RES CO, V178, P1127, DOI 10.1016/0006-291X(91)91009-2; HAYNES BF, 1991, CANCER CELL-MON REV, V3, P347; HEIDER KH, 1993, CANCER RES, V53, P4197; HOFMANN M, 1991, CANCER RES, V51, P5292; HONG RL, 1995, ONCOLOGY-BASEL, V52, P334; HONG RL, 1995, CANCER LETT, V89, P81, DOI 10.1016/0304-3835(95)90161-2; ICHIKAWA W, 1994, PATHOBIOLOGY, V62, P172, DOI 10.1159/000163907; IIDA N, 1995, J CELL PHYSIOL, V162, P127, DOI 10.1002/jcp.1041620115; JACKSON DG, 1994, INT J CANCER, P110; JALKANEN S, 1986, SCIENCE, V233, P556, DOI 10.1126/science.3726548; KAUFMANN M, 1995, LANCET, V345, P615, DOI 10.1016/S0140-6736(95)90521-9; KOOPMAN G, 1993, J EXP MED, V177, P897, DOI 10.1084/jem.177.4.897; KUGELMAN LC, 1992, J INVEST DERMATOL, V99, P886; LIEBER M, 1976, INT J CANCER, V17, P62, DOI 10.1002/ijc.2910170110; LINNOILA I, 1990, HEMATOL ONCOL CLIN N, V4, P1027; LIU AY, 1994, CANCER LETT, V76, P63, DOI 10.1016/0304-3835(94)90135-X; MANTENHORST E, 1995, INT J CANCER, V64, P182, DOI 10.1002/ijc.2910640307; MATSUMURA Y, 1994, BRIT MED J, V308, P619, DOI 10.1136/bmj.308.6929.619; MATSUMURA Y, 1992, LANCET, V340, P1053, DOI 10.1016/0140-6736(92)93077-Z; OSTERLIND K, 1986, J CLIN ONCOL, V4, P1307, DOI 10.1200/JCO.1986.4.9.1307; PENNO MB, 1994, CANCER RES, V54, P1381; PISANI P, 1993, INT J CANCER, V55, P891, DOI 10.1002/ijc.2910550604; RALL CJN, 1995, CANCER RES, V55, P1831; RISTAMAKI R, 1995, J PATHOL, V176, P259, DOI 10.1002/path.1711760308; RUDY W, 1993, CANCER RES, V53, P1262; SALMI M, 1993, J CELL BIOL, V122, P431, DOI 10.1083/jcb.122.2.431; SCREATON GR, 1992, P NATL ACAD SCI USA, V89, P12160, DOI 10.1073/pnas.89.24.12160; SEITER S, 1993, J EXP MED, V177, P443, DOI 10.1084/jem.177.2.443; STAUDER R, 1995, BLOOD, V85, P2885, DOI 10.1182/blood.V85.10.2885.bloodjournal85102885; TAKEUCHI K, 1995, JPN J CANCER RES, V86, P292, DOI 10.1111/j.1349-7006.1995.tb03053.x; TANABE KK, 1993, LANCET, V341, P725, DOI 10.1016/0140-6736(93)90490-8; UNDERHILL C, 1992, J CELL SCI, V103, P293; VANWEERING DHJ, 1993, PCR METH APPL, V3, P100; WASHIMI O, 1994, JPN J CANCER RES, V85, P1112, DOI 10.1111/j.1349-7006.1994.tb02915.x; Woerner SM, 1995, CLIN CANCER RES, V1, P1125; YOKOZAKI H, 1994, CANCER LETT, V83, P229, DOI 10.1016/0304-3835(94)90324-7; ZOLLER M, 1995, J MOL MED, V73, P425	47	30	31	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 7	1996	12	5					1137	1144						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UA884	8649806				2022-12-25	WOS:A1996UA88400023
J	Kirsch, KH; Korradi, Y; Johnson, JP				Kirsch, KH; Korradi, Y; Johnson, JP			Mader: A novel nuclear protein over expressed in human melanomas	ONCOGENE			English	Article						delayed early response gene; proline rich; MUC18	MESSENGER-RNA DEGRADATION; HUMAN-MALIGNANT MELANOMA; TUMOR PROGRESSION; CELL-ADHESION; SEQUENCE; IDENTIFICATION; STIMULATION; ACTIVATION; ANTIGEN; DOMAINS	Mader is a novel delayed early response gene encoding a nuclear protein. Upregulation of the Mader 2.7 kb mRNA requires protein synthesis and can be induced in a variety of human cell lines by serum stimulation and in freshly isolated lymphocytes by mitogens. mRNA levels reach a maximum by 2 h and return to basal levels by 6 h. Mader is highly conserved as cross-hybridizing DNA sequences were observed in species as diverse as Rhesus and S. cerevisiae. The Mader protein of approximately 55 kD has two proline rich domains and contains 15 potential phosphorylation sites, a nuclear localization signal, and multiple S(T)PXX motifs that are characteristic of regulatory DNA binding proteins. Monoclonal antibodies produced against Mader confirm that it is localized to the nucleus. These features of Mader suggest that it may play a role in growth regulation. Although Mader mRNA can be detected in most cell lines, only occasional immunoreactive cells were detected in normal human tissues. In contrast, uniform strong nuclear staining was observed in all malignant melanomas examined. The fact that only one of six benign melanocytic nevi examined showed evidence of Mader expression suggests that over-expression of Mader protein may be associated with the malignant transformation of melanocytes.	UNIV MUNICH,INST IMMUNOL,D-80336 MUNICH,GERMANY	University of Munich				Kirsch, Kathrin/0000-0003-1532-1715				ALBELDA SM, 1990, CANCER RES, V50, P6757; ALBINO AP, 1994, MELANOMA RES, V4, P35, DOI 10.1097/00008390-199402000-00006; CANNONALBRIGHT LA, 1992, SCIENCE, V258, P1148, DOI 10.1126/science.1439824; CASTRESANA JS, 1993, INT J CANCER, V55, P562, DOI 10.1002/ijc.2910550407; CRABTREE GR, 1989, SCIENCE, V243, P355, DOI 10.1126/science.2783497; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; DUGAICZYK A, 1983, BIOCHEMISTRY-US, V22, P1605, DOI 10.1021/bi00276a013; GARRIGUES HJ, 1986, J CELL BIOL, V103, P1699, DOI 10.1083/jcb.103.5.1699; GRANA X, 1995, ONCOGENE, V11, P211; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; Johnson JP, 1996, CURR TOP MICROBIOL, V213, P95; JOHNSON JP, 1989, P NATL ACAD SCI USA, V86, P641, DOI 10.1073/pnas.86.2.641; KELLY K, 1983, CELL, V35, P306; KLEIN CE, 1991, J INVEST DERMATOL, V96, P281, DOI 10.1111/1523-1747.ep12464485; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LANAHAN A, 1992, MOL CELL BIOL, V12, P3919, DOI 10.1128/MCB.12.9.3919; LEHMANN JM, 1989, P NATL ACAD SCI USA, V86, P9891, DOI 10.1073/pnas.86.24.9891; LEVINE AJ, 1993, ANNU REV BIOCHEM, V62, P623, DOI 10.1146/annurev.bi.62.070193.003203; LIU L, 1995, ONCOGENE, V11, P405; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; MARSHALL MA, 1991, MOL CELL BIOL, V11, P55, DOI 10.1128/MCB.11.1.55; MARTINPADURA I, 1991, CANCER RES, V51, P2239; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; MCGREGOR JM, 1993, BRIT J DERMATOL, V128, P606, DOI 10.1111/j.1365-2133.1993.tb00253.x; MENDELSOHL J, 1995, MOL BASIS CANC; MERMOD N, 1989, CELL, V58, P741, DOI 10.1016/0092-8674(89)90108-6; NATHANS D, 1988, COLD SPRING HARB SYM, V53, P983; OHTA M, 1994, CANCER RES, V54, P5269; OKAYAMA H, 1987, METHOD ENZYMOL, V154, P3; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; REED JA, 1995, CANCER RES, V55, P2713; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; RIHS HP, 1991, EMBO J, V10, P633, DOI 10.1002/j.1460-2075.1991.tb07991.x; ROBBINS J, 1991, CELL, V64, P615, DOI 10.1016/0092-8674(91)90245-T; SACHS AB, 1993, CELL, V74, P413, DOI 10.1016/0092-8674(93)80043-E; SERS C, 1993, P NATL ACAD SCI USA, V90, P8514, DOI 10.1073/pnas.90.18.8514; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SUZUKI M, 1989, J MOL BIOL, V207, P61, DOI 10.1016/0022-2836(89)90441-5; SUZUKI M, 1990, NATURE, V344, P562, DOI 10.1038/344562a0; TREISMAN R, 1985, CELL, V42, P889, DOI 10.1016/0092-8674(85)90285-5; VOGELSTEIN B, 1993, TRENDS GENET, V9, P138, DOI 10.1016/0168-9525(93)90209-Z; [No title captured]	44	28	29	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR 7	1996	12	5					963	971						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UA884	8649813				2022-12-25	WOS:A1996UA88400003
J	vandenDobbelsteen, DJ; Nobel, CSI; Schlegel, J; Cotgreave, IA; Orrenius, S; Slater, AFG				vandenDobbelsteen, DJ; Nobel, CSI; Schlegel, J; Cotgreave, IA; Orrenius, S; Slater, AFG			Rapid and specific efflux of reduced glutathione during apoptosis induced by anti-Fas/AP0-1 antibody	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OXIDATIVE STRESS; LYMPHOID-CELLS; PROTEIN; TRANSPORT; DISULFIDES; INHIBITION; EXPRESSION	Although human JURKAT T lymphocytes induced to undergo apoptosis with anti-Fas/APO-1 antibody were observed to rapidly lose reduced glutathione (GSH), increased concentrations of oxidized products were not detectable, Unexpectedly, the reduced tripeptide was instead quantitatively recovered in the incubation medium of the cells, As GSH loss was blocked by bromosulfophthalein and dibromosulfophthalein, known inhibitors of hepatocyte GSH transport, a specific export rather than nonspecific leakiness through plasma membranes is proposed to be responsible, Apoptosis was de layed when GSH-diethylesters were used to elevate intracellular GSH, although the high capacity of the activated efflux system quickly negated the benefit of this treatment. Stimulation of GSH efflux provides a novel mechanism whereby Fas/APO-1 ligation can deplete GSH. We speculate that it enhances the oxidative tonus of a responding cell without requiring an increase in the production of reactive oxygen species.	KAROLINSKA INST, DIV TOXICOL, INST ENVIRONM MED, S-17177 STOCKHOLM, SWEDEN	Karolinska Institutet			Nobel, Stefan/F-9491-2010	Nobel, Stefan/0000-0003-1671-2291				Akerboom T., 1990, GLUTATHIONE METABOLI, P45; AMEISEN JC, 1995, CELL DEATH DIFFER, V2, P285; BALLATORI N, 1994, J BIOL CHEM, V269, P19731; BALLATORI N, 1985, AM J PHYSIOL, V248, pG238, DOI 10.1152/ajpgi.1985.248.2.G238; BEAVER JP, 1995, EUR J CELL BIOL, V68, P47; BELLOMO G, 1987, BIOCHEM PHARMACOL, V36, P1313, DOI 10.1016/0006-2952(87)90087-6; BROWN DG, 1993, J BIOL CHEM, V268, P3037; BURTON K, 1956, BIOCHEM J, V62, P315, DOI 10.1042/bj0620315; BUTTKE TM, 1994, IMMUNOL TODAY, V15, P7, DOI 10.1016/0167-5699(94)90018-3; COTGREAVE IA, 1986, J BIOCHEM BIOPH METH, V13, P231, DOI 10.1016/0165-022X(86)90102-8; DETHMERS JK, 1981, P NATL ACAD SCI-BIOL, V78, P7492, DOI 10.1073/pnas.78.12.7492; DOLLE RE, 1994, J MED CHEM, V37, P563, DOI 10.1021/jm00031a003; ECK HP, 1989, BIOL CHEM H-S, V370, P101, DOI 10.1515/bchm3.1989.370.1.101; EISCHEN CM, 1994, J IMMUNOL, V153, P1947; ENARI M, 1995, NATURE, V375, P78, DOI 10.1038/375078a0; FARISS MW, 1987, METHOD ENZYMOL, V143, P101; FERNANDEZCHECA JC, 1993, J BIOL CHEM, V268, P2324; FLORES SC, 1993, P NATL ACAD SCI USA, V90, P7632, DOI 10.1073/pnas.90.16.7632; GARCIARUIZ C, 1995, J BIOL CHEM, V270, P15946, DOI 10.1074/jbc.270.27.15946; GHIBELLI L, 1995, BIOCHEM BIOPH RES CO, V216, P313, DOI 10.1006/bbrc.1995.2626; Gougeon M L, 1995, Cell Death Differ, V2, P1; GRIFFITH OW, 1979, P NATL ACAD SCI USA, V76, P2249, DOI 10.1073/pnas.76.5.2249; HABIG WH, 1974, J BIOL CHEM, V249, P7130; HUG H, 1994, FEBS LETT, V351, P311, DOI 10.1016/0014-5793(94)00852-3; JACOBSON MD, 1995, NATURE, V374, P814, DOI 10.1038/374814a0; KANNAN R, 1995, INVEST OPHTH VIS SCI, V36, P9171; LEVY EJ, 1993, P NATL ACAD SCI USA, V90, P9171, DOI 10.1073/pnas.90.19.9171; LOS M, 1995, NATURE, V375, P81, DOI 10.1038/375081a0; MARTIN SJ, 1995, CELL, V82, P349, DOI 10.1016/0092-8674(95)90422-0; MATSUDA M, 1991, J IMMUNOL, V147, P3837; MEISTER A, 1983, ANNU REV BIOCHEM, V52, P711, DOI 10.1146/annurev.bi.52.070183.003431; MEISTER A, 1994, CANCER RES, V54, pS1969; MULLER M, 1994, P NATL ACAD SCI USA, V91, P13033, DOI 10.1073/pnas.91.26.13033; MUSCHEL RJ, 1995, CANCER RES, V55, P995; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; NOBEL CSI, 1995, J BIOL CHEM, V270, P26202, DOI 10.1074/jbc.270.44.26202; PRUETT SB, 1989, IMMUNOBIOLOGY, V179, P308, DOI 10.1016/S0171-2985(89)80037-3; SATO T, 1995, SCIENCE, V268, P411, DOI 10.1126/science.7536343; Schlegel J, 1996, J BIOL CHEM, V271, P1841, DOI 10.1074/jbc.271.4.1841; SCHUPPE I, 1992, BIOCHEM PHARMACOL, V44, P1757, DOI 10.1016/0006-2952(92)90069-U; SHIMIZU S, 1995, NATURE, V374, P811, DOI 10.1038/374811a0; SLATER AFG, 1995, BBA-MOL BASIS DIS, V1271, P59, DOI 10.1016/0925-4439(95)00010-2; SLATER AFG, 1995, BIOCHEM J, V306, P771, DOI 10.1042/bj3060771; STAAL FJT, 1992, LANCET, V339, P909, DOI 10.1016/0140-6736(92)90939-Z; SZE G, 1993, AM J PHYSIOL, V265, pG1128, DOI 10.1152/ajpgi.1993.265.6.G1128; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; TEWARI M, 1995, J BIOL CHEM, V270, P3255, DOI 10.1074/jbc.270.7.3255; WEIS M, 1995, EXP CELL RES, V219, P699, DOI 10.1006/excr.1995.1281; WESTENDORP MO, 1995, NATURE, V375, P497, DOI 10.1038/375497a0; WESTENDORP MO, 1995, EMBO J, V14, P546, DOI 10.1002/j.1460-2075.1995.tb07030.x; WHELAN G, 1970, J LAB CLIN MED, V75, P542; Wyllie A H, 1980, Int Rev Cytol, V68, P251; YI JR, 1995, P NATL ACAD SCI USA, V92, P1495, DOI 10.1073/pnas.92.5.1495; YI JR, 1994, J CLIN INVEST, V93, P1841, DOI 10.1172/JCI117170; ZAMAN GJR, 1995, P NATL ACAD SCI USA, V92, P7690, DOI 10.1073/pnas.92.17.7690	55	304	306	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 28	1996	271	26					15420	15427		10.1074/jbc.271.26.15420	http://dx.doi.org/10.1074/jbc.271.26.15420			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UV299	8662848	hybrid			2022-12-25	WOS:A1996UV29900021
J	Heisler, LM; Feng, GH; Jin, DJ; Gross, CA; Landick, R				Heisler, LM; Feng, GH; Jin, DJ; Gross, CA; Landick, R			Amino acid substitutions in the two largest subunits of Escherichia coli RNA polymerase that suppress a defective rho termination factor affect different parts of the transcription complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-SUBUNIT; RIFAMPICIN-RESISTANT; 3-DIMENSIONAL STRUCTURE; FUNCTIONAL TOPOGRAPHY; REPLICATION CONTROL; CONSERVED REGIONS; TERNARY COMPLEXES; CRYSTAL-STRUCTURE; CHAIN INITIATION; KLENOW FRAGMENT	Among the earliest rpoBC mutations identified are three suppressors of the conditional lethal rho allele, rho201. These three mutations are of particular interest because, unlike rpoB8, they do not increase termination at all rho-dependent and p-independent terminators. rpoB211 and rpoB212 both change Asn-1072 to His in conserved region H of rpoB (beta N1072H), whereas rpoC214 changes Arg-352 to Cys in conserved region C of rpoC (beta'R352C). Both substitutions significantly reduce the overall rate of transcript elongation in vitro relative to wild-type RNA polymerase; however, they probably slow elongation for different reasons. The nucleotide triphosphate concentrations required at the T7 A1 promoter for both abortive trinucleotide synthesis and for promoter escape are much greater for beta N1072H. In contrast, beta'R352C and two adjacent substitutions (beta'G351S and beta'S350F), but not beta N1072H, formed open complexes of greatly reduced stability. The sequence in this region of beta' modestly resembles a region of Escherichia coli DNA polymerase I that contacts the phosphate backbone of DNA in co crystals. Core determinants affecting open complex formation do not reside exclusively in beta', however, since the Rif(r) mutation rpoB2 in beta also dramatically destabilized open complexes. We suggest that the principal defects of the two Rho-suppressing substitutions may differ, perhaps reflecting a greater role of beta region H in nucleoside triphosphate binding and nucleotide addition and of beta' region C in contacts to the DNA strands that could be important for translocation. Although both probably suppress rho201 by slowing RNA chain elongation, these differences may lead to terminator specificity that depends on the rate-limiting step at different sites.	UNIV WISCONSIN, DEPT BACTERIOL, MADISON, WI 53706 USA; WASHINGTON UNIV, DEPT BIOL, ST LOUIS, MO 63130 USA; NCI, MOLEC BIOL LAB, NATL INST HLTH, BETHESDA, MD 20892 USA	University of Wisconsin System; University of Wisconsin Madison; Washington University (WUSTL); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI019635] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM038660, R37GM038660, R01GM038660] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 19635] Funding Source: Medline; NIGMS NIH HHS [GM 38660] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLISON LA, 1985, CELL, V42, P599, DOI 10.1016/0092-8674(85)90117-5; ARNDT KM, 1988, J MOL BIOL, V202, P271, DOI 10.1016/0022-2836(88)90457-3; BEESE LS, 1993, SCIENCE, V260, P352, DOI 10.1126/science.8469987; BERTRANDBURGGRAF E, 1984, NUCLEIC ACIDS RES, V12, P1697, DOI 10.1093/nar/12.3.1697; BIGGS J, 1985, CELL, V42, P611, DOI 10.1016/0092-8674(85)90118-7; BORUKHOV S, 1991, J BIOL CHEM, V266, P23921; BORUKHOV S, 1993, CELL, V72, P459, DOI 10.1016/0092-8674(93)90121-6; BORUKHOV S, 1991, J BIOL CHEM, V266, P23932; BURGESS RR, 1975, BIOCHEMISTRY-US, V14, P4634, DOI 10.1021/bi00692a011; CAI H, 1987, J BIOL CHEM, V262, P298; CHAMBERLIN MJ, 1979, J BIOL CHEM, V254, P61; CHAMBERLIN MJ, 1995, HARVEY LECT, V88, P1; CHAN CL, 1994, TRANSCRIPTION MECHAN, P297; CHEN CYA, 1987, J BIOL CHEM, V262, P11292; CHENCHIK AA, 1982, MOL BIOL, V16, P34; CLERGET M, 1995, J MOL BIOL, V248, P768, DOI 10.1006/jmbi.1995.0259; DARST SA, 1989, NATURE, V340, P730, DOI 10.1038/340730a0; DARST SA, 1991, CELL, V66, P121, DOI 10.1016/0092-8674(91)90144-N; DAS A, 1978, P NATL ACAD SCI USA, V75, P4828, DOI 10.1073/pnas.75.10.4828; DIECI G, 1995, EMBO J, V14, P3766, DOI 10.1002/j.1460-2075.1995.tb00046.x; DISSINGER S, 1991, J MOL BIOL, V219, P11, DOI 10.1016/0022-2836(91)90853-X; DOMBROSKI AJ, 1992, CELL, V70, P501, DOI 10.1016/0092-8674(92)90174-B; DOWER WJ, 1988, NUCLEIC ACIDS RES, V16, P6127, DOI 10.1093/nar/16.13.6127; ERIE DA, 1992, ANNU REV BIOPH BIOM, V21, P379, DOI 10.1146/annurev.bb.21.060192.002115; FALKENBURG D, 1987, J MOL BIOL, V195, P929, DOI 10.1016/0022-2836(87)90496-7; FENG GH, 1994, J BIOL CHEM, V269, P22282; FISHER RF, 1983, J BIOL CHEM, V258, P8146; GRACHEV MA, 1987, EUR J BIOCHEM, V163, P113, DOI 10.1111/j.1432-1033.1987.tb10743.x; GRACHEV MA, 1989, EUR J BIOCHEM, V180, P577, DOI 10.1111/j.1432-1033.1989.tb14684.x; GRAGEROV AI, 1980, MOL GEN GENET, V180, P399, DOI 10.1007/BF00425854; GROSS C, 1976, J BACTERIOL, V128, P382, DOI 10.1128/JB.128.1.382-389.1976; GUARENTE L, 1979, J MOL BIOL, V129, P295, DOI 10.1016/0022-2836(79)90283-3; GUARENTE LP, 1978, P NATL ACAD SCI USA, V75, P294, DOI 10.1073/pnas.75.1.294; HAGER DA, 1990, BIOCHEMISTRY-US, V29, P7890, DOI 10.1021/bi00486a016; HANNA MM, 1983, P NATL ACAD SCI-BIOL, V80, P4238, DOI 10.1073/pnas.80.14.4238; HEISLER LM, 1993, J BIOL CHEM, V268, P25369; HINKLE DC, 1972, J MOL BIOL, V70, P157, DOI 10.1016/0022-2836(72)90531-1; HINKLE DC, 1972, J MOL BIOL, V70, P209, DOI 10.1016/0022-2836(72)90534-7; HUDSON G, 1988, J MOL BIOL, V200, P45; ITO K, 1993, MOL MICROBIOL, V9, P285, DOI 10.1111/j.1365-2958.1993.tb01690.x; ITO K, 1991, J BACTERIOL, V173, P1492, DOI 10.1128/jb.173.4.1492-1501.1991; JIN DJ, 1988, J MOL BIOL, V202, P245, DOI 10.1016/0022-2836(88)90455-X; JIN DJ, 1991, J BIOL CHEM, V266, P14478; JIN DJ, 1992, P NATL ACAD SCI USA, V89, P1453, DOI 10.1073/pnas.89.4.1453; JIN DJ, 1988, J MOL BIOL, V202, P45, DOI 10.1016/0022-2836(88)90517-7; JIN DJ, 1994, J MOL BIOL, V236, P72, DOI 10.1006/jmbi.1994.1119; KASHLEV M, 1990, SCIENCE, V248, P1006, DOI 10.1126/science.1693014; KOHLSTAEDT LA, 1992, SCIENCE, V256, P1783, DOI 10.1126/science.1377403; KRUMMEL B, 1989, BIOCHEMISTRY-US, V28, P7829, DOI 10.1021/bi00445a045; KRUMMEL B, 1990, THESIS U CALIFORNIA; Kubori T, 1996, J MOL BIOL, V256, P449, DOI 10.1006/jmbi.1996.0100; LANDICK R, 1990, GENE DEV, V4, P1623, DOI 10.1101/gad.4.9.1623; LARIONOV OA, 1990, MOL GEN GENET, V176, P105; LEE DN, 1992, J MOL BIOL, V228, P759, DOI 10.1016/0022-2836(92)90862-E; LEE DN, 1994, J BIOL CHEM, V269, P22293; LEE JY, 1991, P NATL ACAD SCI USA, V88, P6018, DOI 10.1073/pnas.88.14.6018; LEFFERS H, 1989, J MOL BIOL, V206, P1, DOI 10.1016/0022-2836(89)90519-6; LEVIN JR, 1987, J MOL BIOL, V196, P85, DOI 10.1016/0022-2836(87)90512-2; LISITSYN NA, 1984, MOL GEN GENET, V196, P173, DOI 10.1007/BF00334112; LOWE PA, 1979, BIOCHEMISTRY-US, V18, P1344, DOI 10.1021/bi00574a034; MANDEL M, 1970, J MOL BIOL, V53, P159, DOI 10.1016/0022-2836(70)90051-3; MARTIN E, 1992, J BIOL CHEM, V267, P20175; MCCLURE WR, 1978, J BIOL CHEM, V253, P8941; Miller J.H., 1992, SHORT COURSE BACTERI, P150; MUSTAEV A, 1991, J BIOL CHEM, V266, P23927; MUSTAEV A, 1993, J BIOL CHEM, V268, P19185; NOMURA T, 1984, MOL GEN GENET, V193, P8, DOI 10.1007/BF00327407; NUDLER E, 1994, SCIENCE, V265, P793, DOI 10.1126/science.8047884; OKADA M, 1978, NUCLEIC ACIDS RES, V5, P1845, DOI 10.1093/nar/5.6.1845; OLLIS DL, 1985, NATURE, V313, P762, DOI 10.1038/313762a0; PANNY SR, 1974, FEBS LETT, V48, P241, DOI 10.1016/0014-5793(74)80477-1; PATEL DD, 1989, J VIROL, V63, P1076, DOI 10.1128/JVI.63.3.1076-1086.1989; PELLETIER H, 1994, SCIENCE, V264, P1891, DOI 10.1126/science.7516580; PETERSEN SK, 1991, J BACTERIOL, V173, P5200, DOI 10.1128/jb.173.16.5200-5206.1991; PFEFFER SR, 1977, J BIOL CHEM, V252, P5403; PLATT T, 1994, MOL MICROBIOL, V11, P983, DOI 10.1111/j.1365-2958.1994.tb00376.x; POLESKY AH, 1990, J BIOL CHEM, V265, P14579; POLYAKOV A, 1995, CELL, V83, P365, DOI 10.1016/0092-8674(95)90114-0; RASMUSSEN KV, 1983, J BACTERIOL, V154, P443, DOI 10.1128/JB.154.1.443-451.1983; RIVA M, 1990, J BIOL CHEM, V265, P16498; ROBLEDO R, 1991, J MOL BIOL, V220, P613, DOI 10.1016/0022-2836(91)90104-E; SAGITOV V, 1993, J BIOL CHEM, V268, P2195; Sanbrook J., 1989, MOL CLONING LAB MANU; SEVERINOV K, 1993, J BIOL CHEM, V268, P14820; SEVERINOV K, 1995, P NATL ACAD SCI USA, V92, P4591, DOI 10.1073/pnas.92.10.4591; SEVERINOV K, 1995, J BIOL CHEM, V270, P23926, DOI 10.1074/jbc.270.41.23926; Siegel I, 1975, ENZYME KINETICS; SMAGOWICZ WJ, 1978, NUCLEIC ACIDS RES, V5, P1919, DOI 10.1093/nar/5.6.1919; SOUSA R, 1993, NATURE, V364, P593, DOI 10.1038/364593a0; STEITZ TA, 1994, SCIENCE, V266, P2022, DOI 10.1126/science.7528445; STUDIER FW, 1975, J MOL BIOL, V94, P283, DOI 10.1016/0022-2836(75)90083-2; TANAKA M, 1983, MOL GEN GENET, V192, P51, DOI 10.1007/BF00327646; TAVORMINA PL, 1996, IN PRESS J BACTERIOL; THOMPSON NE, 1992, BIOCHEMISTRY-US, V31, P7003, DOI 10.1021/bi00145a019; WANG DG, 1995, CELL, V81, P341, DOI 10.1016/0092-8674(95)90387-9; WEILBAECHER R, 1994, GENE DEV, V8, P2913, DOI 10.1101/gad.8.23.2913; YANOFSKY C, 1981, J BACTERIOL, V145, P1334, DOI 10.1128/JB.145.3.1334-1341.1981; ZAYCHIKOV E, 1995, P NATL ACAD SCI USA, V92, P1739, DOI 10.1073/pnas.92.5.1739; ZILLIG W, 1970, COLD SPRING HARB SYM, V35, P47, DOI 10.1101/SQB.1970.035.01.010	99	19	19	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 14	1996	271	24					14572	14583		10.1074/jbc.271.24.14572	http://dx.doi.org/10.1074/jbc.271.24.14572			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UQ660	8662850	hybrid			2022-12-25	WOS:A1996UQ66000094
J	Lucas, M; Mazzone, T				Lucas, M; Mazzone, T			Cell surface proteoglycans modulate net synthesis and secretion of macrophage apolipoprotein E	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPARAN-SULFATE; CULTURED-CELLS; APOPROTEIN-E; DIFFERENTIATION; INHIBITION; EXPRESS; BINDING; GROWTH	Using a macrophage cell line that constitutively expresses a human apoliprotein E (apoE) cDNA, we have investigated the post-translational metabolism of endogenously produced apoE. Inhibition of lysosomal or cysteine proteases led to significant inhibition of apoE degradation but did not increase apoE secretion, indicating that cellular degradation is not limiting for apoE secretion in macrophages. Treatment of macrophages with inhibitors of proteoglycan synthesis (4-methylum-belliferyl-beta-D-xyloside) or sulfation (sodium chlorate) enhanced the release of apoE from cells and significantly attenuated the increase in secretion produced by incubation with phosphatidylcholine vesicles (PV). These observations suggested that a significant fraction of the apoE retained by cells (and released by incubation with PV) was associated with proteoglycans. Treatment of cells with exogenous heparinase led to a greater than 4-fold increase in apoE secretion and similarly attenuated the response to PV, suggesting that apoE was trapped in an extracellular proteoglycan matrix. This conclusion was confirmed in studies showing that PV could enhance the release of apoE from cells during an incubation at 4 degrees C, but this enhanced release was abolished in proteoglycan-depleted cells. Incubation with lactoferrin at 4 or 37 degrees C produced the existence of a cell surface pool of apoE. Pulse-chase studies showed that the apoE trapped in the proteoglycan matrix was susceptible to rapid cellular degradation such that net synthesis of apoE (secreted plus cell-associated) was increased significantly in proteoglycan-depleted cells compared with control cells as early as 45 min during a chase period.	RUSH MED COLL, DEPT MED, CHICAGO, IL 60612 USA; RUSH MED COLL, DEPT BIOCHEM, CHICAGO, IL 60612 USA	Rush University; Rush University					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL039653] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 39653] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BATZRI S, 1973, BIOCHIM BIOPHYS ACTA, V298, P1015, DOI 10.1016/0005-2736(73)90408-2; CAREY DJ, 1987, J CELL BIOL, V105, P1013, DOI 10.1083/jcb.105.2.1013; DAHAN S, 1994, J CELL BIOL, V127, P1859, DOI 10.1083/jcb.127.6.1859; DENG JT, 1995, J LIPID RES, V36, P2129; EDWARDS IJ, 1995, ARTERIOSCL THROM VAS, V15, P400, DOI 10.1161/01.ATV.15.3.400; HAMILTON RL, 1990, J LIPID RES, V31, P1589; HUMPHRIES DE, 1989, METHOD ENZYMOL, V179, P428; JI ZS, 1994, J BIOL CHEM, V269, P2764; JI ZS, 1993, J BIOL CHEM, V268, P10160; JI ZS, 1994, ARTERIOSCLER THROMB, V14, P2025, DOI 10.1161/01.ATV.14.12.2025; KRUTH HS, 1995, J CELL BIOL, V129, P133, DOI 10.1083/jcb.129.1.133; LASKIN JD, 1991, HEPATOLOGY, V14, P306, DOI 10.1016/0270-9139(91)91420-6; LEBLOND L, 1993, J BIOL CHEM, V268, P1670; MAZZONE T, 1992, J BIOL CHEM, V267, P1081; MAZZONE T, 1994, J LIPID RES, V35, P1345; RAPRAEGER A, 1989, J CELL BIOL, V109, P2509, DOI 10.1083/jcb.109.5.2509; RAPRAEGER AC, 1991, SCIENCE, V252, P1705, DOI 10.1126/science.1646484; REYLAND ME, 1991, J BIOL CHEM, V266, P21099; ROSENFELD ME, 1993, ARTERIOSCLER THROMB, V13, P1382, DOI 10.1161/01.ATV.13.9.1382; SCHLESSINGER J, 1995, CELL, V83, P357, DOI 10.1016/0092-8674(95)90112-4; SHIMADA K, 1987, ARTERIOSCLEROSIS, V7, P627, DOI 10.1161/01.ATV.7.6.627; STAUDERMAN ML, 1993, J LIPID RES, V34, P190; YE SQ, 1993, J BIOL CHEM, V268, P8497; YEAMAN C, 1993, J CELL PHYSIOL, V157, P413, DOI 10.1002/jcp.1041570226	24	58	58	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 7	1996	271	23					13454	13460		10.1074/jbc.271.23.13454	http://dx.doi.org/10.1074/jbc.271.23.13454			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UP385	8662812	hybrid			2022-12-25	WOS:A1996UP38500025
J	Cavrois, M; Gessain, A; WainHobson, S; Wattel, E				Cavrois, M; Gessain, A; WainHobson, S; Wattel, E			Proliferation of HTLV-1 infected circulating cells in vivo in all asymptomatic carriers and patients with TSP/HAM	ONCOGENE			English	Article						HTLV-1; adult T-cell leukemia; leukemogenesis	VIRUS TYPE-I; TROPICAL SPASTIC PARAPARESIS; POLYMERASE CHAIN-REACTION; BLOOD MONONUCLEAR-CELLS; CYTOTOXIC LYMPHOCYTES-T; PROVIRAL DNA; PERIPHERAL-BLOOD; LEUKEMIA LYMPHOMA; MYELOPATHY; P53	Assuming that the clonal expansion of T cells harbouring the human T-cell leukemia virus type 1 (HTLV-1) provirus is a central feature of HTLV-1 infection, the identification of such cells was sought among a series of 19 asymptomatic carriers and 19 cases of tropical spastic paraparesis/HTLV-1 associated myelopathy (TSP/HAM) devoid of malignancy, Two PCR based protocols designed to amplify the host cell-HTLV-1 proviral integration sites were used, In all cases large numbers of proliferating clones could be identified, The proportion of some clones was >1/1500 peripheral blood mononuclear cells (PBMCs) with the suggestion that their number increased as a function of age among asymptomatic carriers.	INST RECH CANC LILLE,U124 INSERM,LILLE,FRANCE; INST PASTEUR,UNITE EPIDEMIOL VIRUS ONCOGENES,PARIS,FRANCE; INST PASTEUR,UNITE RETROVIROL MOL,PARIS,FRANCE; CHU,SERV MALAD SANG,LILLE,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Universite de Lille - ISITE; CHU Lille								BLATTNER WA, 1989, ANN INTERN MED, V111, P4, DOI 10.7326/0003-4819-111-1-4; CAVROIS M, 1995, RES VIROLOGY, V146, P179, DOI 10.1016/0923-2516(96)80578-4; CESARMAN E, 1992, BLOOD, V80, P3205; CHEN YX, 1995, INT J CANCER, V60, P798; CLARK JM, 1988, NUCLEIC ACIDS RES, V16, P9677, DOI 10.1093/nar/16.20.9677; DINCAN M, 1994, LEUKEMIA, V8, P682; FURUKAWA Y, 1992, BLOOD, V80, P1012; GESSAIN A, 1990, BLOOD, V75, P428; GESSAIN A, 1985, LANCET, V2, P407; GESSAIN A, 1992, ANN INTERN MED, V117, P933, DOI 10.7326/0003-4819-117-11-933; HATTA Y, 1995, BLOOD, V85, P2699, DOI 10.1182/blood.V85.10.2699.bloodjournal85102699; HAUSEN HZ, 1991, SCIENCE, V254, P1167, DOI 10.1126/science.1659743; IKEDA S, 1990, CANCER DETECT PREV, V14, P431; IKEDA S, 1993, BLOOD, V82, P2017; JACOBSON S, 1992, ANN NEUROL, V32, P651, DOI 10.1002/ana.410320508; KIRA J, 1991, ANN NEUROL, V29, P194, DOI 10.1002/ana.410290214; KORBER B, 1991, J VIROL, V65, P5471, DOI 10.1128/JVI.65.10.5471-5476.1991; KUBOTA R, 1993, J NEUROIMMUNOL, V42, P147, DOI 10.1016/0165-5728(93)90004-I; MANNS A, 1991, TRANSFUSION, V31, P67, DOI 10.1046/j.1537-2995.1991.31191096189.x; MATSUMURA M, 1993, INT J CANCER, V55, P220, DOI 10.1002/ijc.2910550209; NAGAI H, 1991, JPN J CANCER RES, V82, P1421, DOI 10.1111/j.1349-7006.1991.tb01815.x; NAKADA K, 1987, INT J CANCER, V40, P145, DOI 10.1002/ijc.2910400203; PARKER CE, 1992, VIROLOGY, V188, P628, DOI 10.1016/0042-6822(92)90517-S; POWERS DC, 1993, J INFECT DIS, V167, P584, DOI 10.1093/infdis/167.3.584; SAKASHITA A, 1992, BLOOD, V79, P477; SHINZATO O, 1991, BLOOD, V78, P2082; SUMMERS BA, 1978, LANCET, V1, P187; UCHIYAMA T, 1977, BLOOD, V50, P481, DOI 10.1182/blood.V50.3.481.481; WATTEL E, 1992, J ACQ IMMUN DEF SYND, V5, P943; WATTEL E, 1995, J VIROL, V69, P2863, DOI 10.1128/JVI.69.5.2863-2868.1995; WHANGPENG J, 1985, J NATL CANCER I, V74, P357; WILEY CA, 1988, AM J PATHOL, V133, P355; YAMATO K, 1993, JPN J CANCER RES, V84, P4, DOI 10.1111/j.1349-7006.1993.tb02775.x	33	74	75	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN 6	1996	12	11					2419	2423						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UQ220	8649783				2022-12-25	WOS:A1996UQ22000020
J	Hawes, BE; Luttrell, LM; vanBiesen, T; Lefkowitz, RJ				Hawes, BE; Luttrell, LM; vanBiesen, T; Lefkowitz, RJ			Phosphatidylinositol 3-kinase is an early intermediate in the G beta gamma-mediated mitogen-activated protein kinase signaling pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MYELOID DERIVED CELLS; RECEPTOR; NEUTROPHILS; FIBROBLASTS; ASSOCIATION; EXPRESSION; P21(RAS)	The beta gamma-subunit of G(i) mediates mitogen-activated protein (MAP) kinase activation through a signaling pathway involving Shc tyrosine phosphorylation, subsequent formation of a multiprotein complex including Shc, Grb2, and Sos, and sequential activation of Ras, Raf, and MEK. The mechanism by which G beta gamma mediates tyrosine phosphorylation of Shc, however, is unclear. This study assesses the role of phosphatidylinositol 3-kinase (PI-3K) in G beta gamma-mediated MAP kinase activation, We show that G(i)-coupled receptor- and G beta gamma-stimulated MAP kinase activation is attenuated by the PI-3K inhibitors wortmannin and LY294002 or by overexpression of a dominant negative mutant of the p85 subunit of PI-3K, Wortmannin and LY294002 also inhibit G(i)-coupled receptor-stimulated Ras activation. The PI-3K inhibitors do not affect MAP kinase activation stimulated by overexpression of Sos, a constitutively active mutant of Ras, or a constitutively active mutant of MEK. These results demonstrate that PI-3K activity is required in the G beta gamma-mediated MAP kinase signaling pathway at a point upstream of Sos and Ras activation.	DUKE UNIV, MED CTR, HOWARD HUGHES MED INST, DURHAM, NC 27710 USA	Duke University; Howard Hughes Medical Institute			Lefkowitz, Robert/AAW-2649-2021	Luttrell, Louis/0000-0003-2805-6949	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL016037, R01HL016037] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 16037] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALBLAS J, 1993, J BIOL CHEM, V268, P22235; ARONHEIM A, 1994, CELL, V78, P949, DOI 10.1016/0092-8674(94)90271-2; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; COREY S, 1993, EMBO J, V12, P2681, DOI 10.1002/j.1460-2075.1993.tb05929.x; CRESPO P, 1994, NATURE, V369, P418, DOI 10.1038/369418a0; DEVRIESSMITS AMM, 1992, NATURE, V357, P602, DOI 10.1038/357602a0; Dhanasekaran N., 1995, Endocrine Reviews, V16, P259; FAURE M, 1994, J BIOL CHEM, V269, P7851; FERBY IM, 1994, J BIOL CHEM, V269, P30485; GIBBS JB, 1990, J BIOL CHEM, V265, P20437; HARA K, 1994, P NATL ACAD SCI USA, V91, P7415, DOI 10.1073/pnas.91.16.7415; HARRISONFINDIK D, 1995, ONCOGENE, V10, P1385; HAWES BE, 1994, J BIOL CHEM, V269, P15776; HAWES BE, 1995, J BIOL CHEM, V270, P17148, DOI 10.1074/jbc.270.29.17148; HORDIJK PL, 1994, J BIOL CHEM, V269, P645; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; HU QJ, 1995, SCIENCE, V268, P100, DOI 10.1126/science.7701328; KOBILKA BK, 1987, SCIENCE, V238, P650, DOI 10.1126/science.2823383; KOCH WJ, 1994, P NATL ACAD SCI USA, V91, P12706, DOI 10.1073/pnas.91.26.12706; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; LUTTRELL LM, 1995, J BIOL CHEM, V270, P16495, DOI 10.1074/jbc.270.28.16495; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MELOCHE S, 1992, MOL BIOL CELL, V3, P63, DOI 10.1091/mbc.3.1.63; PLEIMAN CM, 1994, SCIENCE, V263, P1609, DOI 10.1126/science.8128248; PTASZNIK A, 1995, J BIOL CHEM, V270, P19969, DOI 10.1074/jbc.270.34.19969; RAMEH LE, 1995, CELL, V83, P821, DOI 10.1016/0092-8674(95)90195-7; RAVICHANDRAN KS, 1995, MOL CELL BIOL, V15, P593; SAKANAKA C, 1994, BIOCHEM BIOPH RES CO, V205, P18, DOI 10.1006/bbrc.1994.2623; SALEEM A, 1995, J BIOL CHEM, V270, P10380, DOI 10.1074/jbc.270.18.10380; SASAOKA T, 1994, J BIOL CHEM, V269, P32621; STEPHENS L, 1993, EMBO J, V12, P2265, DOI 10.1002/j.1460-2075.1993.tb05880.x; STEPHENS L, 1994, CELL, V77, P83, DOI 10.1016/0092-8674(94)90237-2; STEPHENS L, 1993, J BIOL CHEM, V268, P17162; STEPHENS LR, 1991, NATURE, V351, P33, DOI 10.1038/351033a0; STOYANOV B, 1995, SCIENCE, V269, P690, DOI 10.1126/science.7624799; THELEN M, 1994, P NATL ACAD SCI USA, V91, P4960, DOI 10.1073/pnas.91.11.4960; THOMASON PA, 1994, J BIOL CHEM, V269, P16525; TOUHARA K, 1995, P NATL ACAD SCI USA, V92, P9284, DOI 10.1073/pnas.92.20.9284; TRAYNORKAPLAN AE, 1988, NATURE, V334, P353, DOI 10.1038/334353a0; TRAYNORKAPLAN AE, 1989, J BIOL CHEM, V264, P15668; UI M, 1995, TRENDS BIOCHEM SCI, V20, P303, DOI 10.1016/S0968-0004(00)89056-8; vanBiesen T, 1996, J BIOL CHEM, V271, P1266, DOI 10.1074/jbc.271.3.1266; VANBIESEN T, 1995, NATURE, V376, P781, DOI 10.1038/376781a0; VANCORVEN EJ, 1993, P NATL ACAD SCI USA, V90, P1257, DOI 10.1073/pnas.90.4.1257; VICIANA PR, 1994, NATURE, V370, P527; WINITZ S, 1994, J BIOL CHEM, V269, P1889; YAMANASHI Y, 1992, P NATL ACAD SCI USA, V89, P1118, DOI 10.1073/pnas.89.3.1118; ZHANG J, 1995, J BIOL CHEM, V270, P6589, DOI 10.1074/jbc.270.12.6589	49	317	322	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 24	1996	271	21					12133	12136		10.1074/jbc.271.21.12133	http://dx.doi.org/10.1074/jbc.271.21.12133			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UL660	8647803	hybrid			2022-12-25	WOS:A1996UL66000005
J	Shyadehi, AZ; Lamb, DC; Kelly, SL; Kelly, DE; Schunck, WH; Wright, JN; Corina, D; Akhtar, M				Shyadehi, AZ; Lamb, DC; Kelly, SL; Kelly, DE; Schunck, WH; Wright, JN; Corina, D; Akhtar, M			The mechanism of the acyl-carbon bond cleavage reaction catalyzed by recombinant sterol 14 alpha-demethylase of Candida albicans (other names are: Lanosterol 14 alpha-demethylase, P-450(14DM), and CYP51)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN PLACENTAL AROMATASE; CHOLESTEROL-BIOSYNTHESIS; CYTOCHROME-P-450; PURIFICATION; DEMETHYLASE; ENZYMES; EXPRESSION; YEAST	The Candida albicans sterol 14 alpha-demethylase gene (P-450(14DM), CYP51) was transferred to the yeast plasmid YEp51 placing it under the control of the GAL10 promoter. The resulting construct (YEp51:CYP51) when transformed into the yeast strain GRF18 gave a clone producing 1.5 mu mol of P-450/liter of culture, the microsomal fraction of which contained up to 2.5 nmol of P-450/mg of protein. Two oxygenated precursors for the 14 alpha-demethylase, 3 beta-hydroxylanost-7-en-32-al and 3 beta-hydroxylanost-7-en-32-ol, variously labeled with H-2 and O-18 at C-32 were synthesized. In this study the conversion of [32-H-2,32-O-16]- and [32-H-2,32-O-18]3 beta-hydroxylanost-7-en-32-al with the recombinant 14 alpha-demethylase was performed under O-16(2) or O-18(2) and the released formic acid analyzed by mass spectrometry. The results showed that in the acyl-carbon bond cleavage step (i.e. the deformylation process) the original carbonyl oxygen at C-32 of the precursor is retained in formic acid and the second oxygen of formate is derived from molecular oxygen; precisely the same scenario that has previously been observed for the acyl-carbon cleavage steps catalyzed by aromatase (P-450(arom)) and 17 alpha-hydroxylase-17,20-lyase (P-450(17 alpha),CYP17). In the light of these results the mechanism of the acyl-carbon bond cleavage step catalyzed by the 14 alpha-demethylase is considered.	UNIV SOUTHAMPTON, DEPT BIOCHEM, SOUTHAMPTON SO16 7PX, HANTS, ENGLAND; UNIV SHEFFIELD, DEPT BIOCHEM & MOLEC BIOL, SHEFFIELD S10 2UH, S YORKSHIRE, ENGLAND; MAX DELBRUCK CTR MOLEC MED, D-13122 BERLIN, GERMANY	University of Southampton; University of Sheffield; Helmholtz Association; Max Delbruck Center for Molecular Medicine								AKHTAR M, 1993, J STEROID BIOCHEM, V44, P375, DOI 10.1016/0960-0760(93)90241-N; AKHTAR M, 1994, PURE APPL CHEM, V66, P2387, DOI 10.1351/pac199466102387; AKHTAR M, 1994, BIOCHEMISTRY-US, V33, P4410, DOI 10.1021/bi00180a039; AKHTAR M, 1994, J CHEM SOC PERK T 1, P263, DOI 10.1039/p19940000263; AKHTAR M, 1978, BIOCHEM J, V169, P449, DOI 10.1042/bj1690449b; AKHTAR M, 1982, BIOCHEM J, V201, P569, DOI 10.1042/bj2010569; AKHTAR M, 1991, NAT PROD REP, V8, P527, DOI 10.1039/np9910800527; AOYAMA Y, 1987, J BIOL CHEM, V262, P1239; BARTON DHR, 1970, J CHEM SOC C, P1033, DOI 10.1039/j39700001033; BATTEN PL, 1972, J CHEM SOC PERK T 1, P739, DOI 10.1039/p19720000739; CORBIN CJ, 1988, P NATL ACAD SCI USA, V85, P8948, DOI 10.1073/pnas.85.23.8948; CORINA DL, 1973, ANAL BIOCHEM, V53, P571, DOI 10.1016/0003-2697(73)90108-5; FISCHER RT, 1991, J BIOL CHEM, V266, P6124; GUENGERICH FP, 1991, METHOD ENZYMOL, V206, P130; HITCHCOCK CA, 1989, BIOCHEM J, V263, P573, DOI 10.1042/bj2630573; KALB VF, 1987, DNA-J MOLEC CELL BIO, V6, P529, DOI 10.1089/dna.1987.6.529; KELLY SL, 1993, BIOCHEM SOC T, V21, P1034, DOI 10.1042/bst0211034; KELLY SL, 1995, BIOCHEM BIOPH RES CO, V207, P910, DOI 10.1006/bbrc.1995.1272; LAI MH, 1989, NUCLEIC ACIDS RES, V17, P804, DOI 10.1093/nar/17.2.804; LEEROBICHAUD P, 1995, BIOCHEMISTRY-US, V34, P14104, DOI 10.1021/bi00043a015; OH SS, 1993, J STEROID BIOCHEM, V44, P389, DOI 10.1016/0960-0760(93)90242-O; OMURA T, 1964, J BIOL CHEM, V239, P2370; SANTOS MAS, 1993, EMBO J, V12, P607, DOI 10.1002/j.1460-2075.1993.tb05693.x; SCHELLER U, 1994, J BIOL CHEM, V269, P12779; SKINNER SJM, 1969, BIOCHEM J, V114, P75, DOI 10.1042/bj1140075; SONO H, 1991, BIOCHIM BIOPHYS ACTA, V1078, P388, DOI 10.1016/0167-4838(91)90161-R; SONODA Y, 1993, BIOCHIM BIOPHYS ACTA, V1170, P92; STEVENSON DE, 1988, J CHEM SOC PERK T 1, P2043, DOI 10.1039/p19880002043; SWINNEY DC, 1994, BIOCHEMISTRY-US, V33, P2185, DOI 10.1021/bi00174a027; TAN L, 1986, EUR J BIOCHEM, V156, P243, DOI 10.1111/j.1432-1033.1986.tb09574.x; TRZASKOS J, 1986, J BIOL CHEM, V261, P4651; VAZ ADN, 1991, J AM CHEM SOC, V113, P5886, DOI 10.1021/ja00015a066	32	114	121	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 24	1996	271	21					12445	12450		10.1074/jbc.271.21.12445	http://dx.doi.org/10.1074/jbc.271.21.12445			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UL660	8647850	hybrid			2022-12-25	WOS:A1996UL66000052
J	Bogenhagen, DF				Bogenhagen, DF			Interaction of mtTFB and mtRNA polymerase at core promoters for transcription of Xenopus laevis mtDNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MITOCHONDRIAL RNA-POLYMERASE; SACCHAROMYCES-CEREVISIAE; POLYACRYLAMIDE GELS; YEAST MITOCHONDRIA; SPECIFICITY FACTOR; DNA; PROTEINS; NUCLEAR; SUBUNIT; GENE	Transcription of Xenopus laevis mitochondrial DNA requires mtRNA polymerase and a dissociable factor, xl-mtTFB, that is distinct from the HMG-box factor known as mtTFA. This paper presents the purification of mtTFB and characterizes its DNA binding properties. xl-mtTFB activity copurifies with a 40-kDa polypeptide on silver-stained protein gels. Activity can be recovered following elution of this 40-kDa polypeptide from an SDS-polyacrylamide gel. xl-mtTFB is capable of binding to DNA, but this binding is relatively nonspecific and is easily competed by heterologous DNA.			Bogenhagen, DF (corresponding author), SUNY STONY BROOK,DEPT PHARMACOL SCI,STONY BROOK,NY 11794, USA.				NIGMS NIH HHS [GM29681] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM029681] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANTOSHECHKIN I, 1995, MOL CELL BIOL, V15, P7032; BISWAS TK, 1987, J BIOL CHEM, V262, P13690; BISWAS TK, 1992, J MOL BIOL, V226, P335, DOI 10.1016/0022-2836(92)90951-F; BOGENHAGEN DF, 1988, MOL CELL BIOL, V8, P2910, DOI 10.1128/MCB.8.7.2910; BOGENHAGEN DF, 1988, MOL CELL BIOL, V8, P2917, DOI 10.1128/MCB.8.7.2917; CAIRNS SS, 1986, J BIOL CHEM, V261, P8481; DAIRAGHI DJ, 1995, J MOL BIOL, V249, P11, DOI 10.1006/jmbi.1995.9889; DIFFLEY JFX, 1992, J BIOL CHEM, V267, P3368; DIFFLEY JFX, 1991, P NATL ACAD SCI USA, V88, P7864, DOI 10.1073/pnas.88.17.7864; FISHER RP, 1992, J BIOL CHEM, V267, P3358; FISHER RP, 1987, CELL, V50, P247, DOI 10.1016/0092-8674(87)90220-0; HAGER DA, 1980, ANAL BIOCHEM, V109, P76, DOI 10.1016/0003-2697(80)90013-5; JAEHNING JA, 1993, MOL MICROBIOL, V8, P1, DOI 10.1111/j.1365-2958.1993.tb01197.x; JANG SH, 1991, J BIOL CHEM, V266, P22671; KELLY JL, 1986, J BIOL CHEM, V261, P348; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LISOWSKY T, 1988, MOL GEN GENET, V214, P218, DOI 10.1007/BF00337714; MANGUS DA, 1994, J BIOL CHEM, V269, P26568; MASTERS BS, 1987, CELL, V51, P89, DOI 10.1016/0092-8674(87)90013-4; PARISI MA, 1991, SCIENCE, V252, P965, DOI 10.1126/science.2035027; RIEMEN G, 1993, MOL GEN GENET, V237, P49, DOI 10.1007/BF00282783; SCHINKEL AH, 1987, J BIOL CHEM, V262, P12785; SCHINKEL AH, 1988, EMBO J, V7, P3255, DOI 10.1002/j.1460-2075.1988.tb03192.x; SHADEL GS, 1995, MOL CELL BIOL, V15, P2101; SHADEL GS, 1993, J BIOL CHEM, V268, P16083; WRAY W, 1981, ANAL BIOCHEM, V118, P197, DOI 10.1016/0003-2697(81)90179-2; XU BJ, 1992, NUCLEIC ACIDS RES, V20, P1053, DOI 10.1093/nar/20.5.1053	27	36	37	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 17	1996	271	20					12036	12041						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UL250	8662670				2022-12-25	WOS:A1996UL25000068
J	Myette, JR; Niles, EG				Myette, JR; Niles, EG			Characterization of the vaccinia virus RNA 5'-triphosphatase and nucleoside triphosphate phosphohydrolase activities - Demonstration that both activities are carried out at the same active site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA; CAPPING ENZYME; (GUANINE-7-)METHYLTRANSFERASE COMPLEX; GUANYLYLTRANSFERASE; VIRIONS; TRANSCRIPTION; PURIFICATION; ASSOCIATION; MECHANISM; SUBUNITS	D1R(1-545), an active subdomain of the large subunit of vaccinia virus mRNA capping enzyme possessing ATPase, RNA 5'-triphosphatase, and guanylyltransferase activities, was expressed in Escherichia coli and shown to be functionally equivalent to the heterodimeric enzyme (Myette, J. R., and Niles, E. G. (1996) J. Biol. Chem. 271, 11936-11944). A detailed characterization of the phosphohydrolytic activities of D1R(1-545) demonstrates that, in addition to ATPase and RNA 5'-triphosphatase activities, the capping enzyme also possesses a general nucleoside triphosphate phosphohydrolase activity that lacks a preference for the nucleoside base or sugar. Nucleoside triphosphate and mRNA saturation kinetics are markedly different, with RNA exhibiting a K-m and turnover number 100- and 10-fold less, respectively, than those values measured for any NTP. The linear competitive inhibition of RNA 5'-triphosphatase activity by ATP, and the relative manner by which both ATPase and RNA 5'-triphosphatase activities are inhibited by specific oligonucleotides, kinetically demonstrate that each activity is carried out at a common active site. Direct UV photo-cross-linking of either P-32-radiolabeled ATP or 23-mer triphosphorylated RNA, followed by cyanogen bromide cleavage of the photo-linked enzyme, localizes the major binding site for both ATP and RNA to a region between amino acids 1 and 221. The inability of ATP to competitively inhibit either E similar to GMP formation or the transfer of GMP to RNA kinetically differentiates the phosphohydrolase active site from the guanylyltransferase active site.	SUNY BUFFALO,SCH MED & BIOMED SCI,CTR ADV MOL BIOL IMMUNOL,BUFFALO,NY 14214	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo	Myette, JR (corresponding author), SUNY BUFFALO,SCH MED & BIOMED SCI,DEPT BIOCHEM,BUFFALO,NY 14214, USA.				NIAID NIH HHS [AI28824] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI028824] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BAYLISS CD, 1995, J BIOL CHEM, V270, P1550, DOI 10.1074/jbc.270.4.1550; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BROYLES SS, 1987, MOL CELL BIOL, V7, P7, DOI 10.1128/MCB.7.1.7; CONG PJ, 1993, J BIOL CHEM, V268, P7256; CONG PJ, 1992, J BIOL CHEM, V267, P16424; ENSINGER MJ, 1975, P NATL ACAD SCI USA, V72, P2525, DOI 10.1073/pnas.72.7.2525; HAGLER J, 1992, SCIENCE, V255, P983, DOI 10.1126/science.1546295; HIGMAN MA, 1992, J BIOL CHEM, V267, P16430; HIGMAN MA, 1994, J BIOL CHEM, V269, P14982; MAO XD, 1994, J BIOL CHEM, V269, P24472; MARTIN SA, 1976, J BIOL CHEM, V251, P7313; MARTIN SA, 1975, J BIOL CHEM, V250, P9322; MCGEOCH DJ, 1988, J VIROL, V62, P444, DOI 10.1128/JVI.62.2.444-453.1988; MOSS B, 1976, VIROLOGY, V72, P341, DOI 10.1016/0042-6822(76)90163-X; Myette JR, 1996, J BIOL CHEM, V271, P11936, DOI 10.1074/jbc.271.20.11936; NILES EG, 1993, J BIOL CHEM, V268, P24986; NILES EG, 1994, BIOCHEMISTRY-US, V33, P9898, DOI 10.1021/bi00199a011; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SHUMAN S, 1981, P NATL ACAD SCI-BIOL, V78, P187, DOI 10.1073/pnas.78.1.187; SHUMAN S, 1987, J BIOL CHEM, V262, P12372; SHUMAN S, 1990, J BIOL CHEM, V265, P11967; SHUMAN S, 1980, J BIOL CHEM, V255, P1588; SHUMAN S, 1989, J BIOL CHEM, V264, P9690; TUTAS DJ, 1977, J BIOL CHEM, V252, P3092; VENKATESAN S, 1980, J BIOL CHEM, V255, P903; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WENGLER G, 1993, VIROLOGY, V197, P265, DOI 10.1006/viro.1993.1587	27	42	42	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 17	1996	271	20					11945	11952		10.1074/jbc.271.20.11945	http://dx.doi.org/10.1074/jbc.271.20.11945			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UL250	8662636	hybrid			2022-12-25	WOS:A1996UL25000057
J	Janknecht, R; Nordheim, A				Janknecht, R; Nordheim, A			Regulation of the c-fos promoter by the ternary complex factor Sap-1a and its coactivator CBP	ONCOGENE			English	Article						c-fos; coactivator CBP; CREB; Ets protein Sap-1a; signaling; transcription	SERUM RESPONSE ELEMENT; TRANSCRIPTION FACTOR; PROTEIN ELK-1; EXPRESSION; ACTIVATION; PHOSPHORYLATION; INHIBITION; KINASE; BINDS; SRF	The c-fos proto-oncogene is activated by a plethora of signals via the transcription factors Sap-1a and CREB. Recently, the coactivator CBP has been demonstrated to act in concert with CREB when CREB is phosphorylated by protein kinase A. We show that CBP also binds directly to Sap-1a. While phosphorylation of Sap-1a by mitogen-activated protein kinases is not necessary for CBP/Sap-1a interaction, functional cooperation between these two proteins requires Sap-1a to become phosphorylated. CBP-antagonists impair Sap-1a-mediated transactivation. Similarly, the CBP antagonist E1A suppresses c-fos upregulation by phosphorylated CREB, indicating that CBP is a central component of c-fos regulation. Furthermore, CBP is phosphorylated by protein kinase A in vitro and the transactivation potential of the carboxyterminal region of CBP is enhanced in the presence of active protein kinase A in vivo. Thus, CBP, in addition to CREB, is a target for cAMP-dependent signaling. However, combined phosphorylation of CBP by protein kinase A and mitogen-activated protein kinases appears to be non-cooperative, suggesting that CBP serves the function of a dampening integrator of two different signaling pathways.			Janknecht, R (corresponding author), HANNOVER MED SCH,INST MOLEC BIOL,D-30623 HANNOVER,GERMANY.			Janknecht, Ralf/0000-0003-1741-1562				ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; ARANY Z, 1995, NATURE, V374, P81, DOI 10.1038/374081a0; ARIAS J, 1994, NATURE, V370, P226, DOI 10.1038/370226a0; BANNISTER AJ, 1995, EMBO J, V14, P4758, DOI 10.1002/j.1460-2075.1995.tb00157.x; BRUDER JT, 1992, GENE DEV, V6, P545, DOI 10.1101/gad.6.4.545; Cahill M.A., 1995, INDUCIBLE GENE EXPRE, V2, P39; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; COOK SJ, 1993, SCIENCE, V262, P1069, DOI 10.1126/science.7694367; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; CURRAN T, 1992, TRANSCRIPTIONAL REGU, P797; DALTON S, 1992, CELL, V68, P597, DOI 10.1016/0092-8674(92)90194-H; DAVIS RJ, 1994, TRENDS BIOCHEM SCI, V19, P470, DOI 10.1016/0968-0004(94)90132-5; FRODIN M, 1994, J BIOL CHEM, V269, P6207; GIOVANE A, 1994, GENE DEV, V8, P1502, DOI 10.1101/gad.8.13.1502; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; GRIGORIADIS AE, 1994, SCIENCE, V266, P443, DOI 10.1126/science.7939685; HAFNER S, 1994, MOL CELL BIOL, V14, P6696; HERNANDEZ N, 1993, GENE DEV, V7, P1291, DOI 10.1101/gad.7.7b.1291; HERRERA RE, 1989, NATURE, V340, P68, DOI 10.1038/340068a0; HIPSKIND RA, 1991, NATURE, V354, P531, DOI 10.1038/354531a0; JANKNECHT R, 1995, ONCOGENE, V10, P1209; JANKNECHT R, 1995, CARCINOGENESIS, V16, P443, DOI 10.1093/carcin/16.3.443; JANKNECHT R, 1993, BIOCHIM BIOPHYS ACTA, V1155, P346, DOI 10.1016/0304-419X(93)90014-4; JANKNECHT R, 1992, NUCLEIC ACIDS RES, V20, P3317, DOI 10.1093/nar/20.13.3317; JANKNECHT R, 1993, EMBO J, V12, P5097, DOI 10.1002/j.1460-2075.1993.tb06204.x; JANKNECHT R, 1994, ONCOGENE, V9, P1273; JANKNECHT R, 1992, GENE, V121, P321, DOI 10.1016/0378-1119(92)90137-E; JANKNECHT R, 1995, IMMUNOBIOLOGY, V193, P137, DOI 10.1016/S0171-2985(11)80536-X; JOHNSON RS, 1992, CELL, V71, P577, DOI 10.1016/0092-8674(92)90592-Z; KITABAYASHI I, 1995, EMBO J, V14, P3496, DOI 10.1002/j.1460-2075.1995.tb07356.x; KORTENJANN M, 1994, MOL CELL BIOL, V14, P4815, DOI 10.1128/MCB.14.7.4815; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; LEE JS, 1995, GENE DEV, V9, P1188, DOI 10.1101/gad.9.10.1188; LOPEZ M, 1994, MOL CELL BIOL, V14, P3292, DOI 10.1128/MCB.14.5.3292; LUNDBLAD JR, 1995, NATURE, V374, P85, DOI 10.1038/374085a0; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MATTHIAS P, 1989, NUCLEIC ACIDS RES, V17, P6418, DOI 10.1093/nar/17.15.6418; MELOCHE S, 1992, MOL BIOL CELL, V3, P63, DOI 10.1091/mbc.3.1.63; NORMAN C, 1988, CELL, V55, P989, DOI 10.1016/0092-8674(88)90244-9; PETRIJ F, 1995, NATURE, V376, P348, DOI 10.1038/376348a0; PRICE MA, 1995, EMBO J, V14, P2589, DOI 10.1002/j.1460-2075.1995.tb07257.x; PRYWES R, 1988, P NATL ACAD SCI USA, V85, P7206, DOI 10.1073/pnas.85.19.7206; RUTHER U, 1989, ONCOGENE, V4, P861; SAEZ E, 1995, CELL, V82, P721, DOI 10.1016/0092-8674(95)90469-7; SASSONECORSI P, 1988, GENE DEV, V2, P1529, DOI 10.1101/gad.2.12a.1529; SCHALASTA G, 1990, MOL CELL BIOL, V10, P5558, DOI 10.1128/MCB.10.10.5558; SHAW PE, 1989, CELL, V56, P563, DOI 10.1016/0092-8674(89)90579-5; SHORE P, 1994, MOL CELL BIOL, V14, P3283, DOI 10.1128/MCB.14.5.3283; TREISMAN R, 1994, CURR OPIN GENET DEV, V4, P96, DOI 10.1016/0959-437X(94)90097-3; WANG ZQ, 1992, NATURE, V360, P741, DOI 10.1038/360741a0; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106; WU J, 1993, SCIENCE, V262, P1065, DOI 10.1126/science.7694366; YACIUK P, 1991, MOL CELL BIOL, V11, P5389, DOI 10.1128/MCB.11.11.5389	53	122	122	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY 2	1996	12	9					1961	1969						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UK498	8649857				2022-12-25	WOS:A1996UK49800015
J	Oridate, N; Esumi, N; Lotan, D; Hong, WK; RochetteEgly, C; Chambon, P; Lotan, R				Oridate, N; Esumi, N; Lotan, D; Hong, WK; RochetteEgly, C; Chambon, P; Lotan, R			Implication of retinoic acid receptor gamma in squamous differentiation and response to retinoic acid in head and neck SqCC/Y1 squamous carcinoma cells	ONCOGENE			English	Article						retinoic acid; squamous differentiation; nuclear receptor; retinoic acid receptor gamma	EPIDERMAL GROWTH-FACTOR; ANCHORAGE-INDEPENDENT GROWTH; GENE-EXPRESSION; TERMINAL DIFFERENTIATION; NEGATIVE REGULATION; MOUSE; PROMOTER; IMMUNODETECTION; PHOSPHORYLATION; TRANSFORMATION	Nuclear retinoic acid receptors are considered to be the mediators of most of the effects of retinoic acid (RA) on gene expression. To explore the role of RA receptor gamma (RAR gamma) in the growth and differentiation of SqCC/Y1 head and neck squamous carcinoma cells, they were transfected with RAR gamma sense and antisense expression vectors and stable clones in which RAR gamma expression was either increased or blocked were isolated. The growth inhibitory effect of RA in monolayer culture was enhanced in the sense transfectants and decreased in the antisense ones. The ability to form colonies in semisolid medium was abolished by RA in the sense transfectants, while the antisense transfected clones exhibited heterogeneous responses. The expression of the squamous differentiation markers cytokeratin K1, transglutaminase type I, and involucrin was increased in the absence of exogenous retinoid in a sense transfected clone and decreased in an antisense transfected clone. RA suppressed squamous differentiation in both types of transfectant. The expression of epidermal growth factor receptor (EGFR) was higher in the antisense and lower in the sense transfectant than in the parental cells and RA decreased EGFR mRNA level in the parental and the sense transfectant but not in the antisense transfectant. In addition activator protein-1 (AP-1) binding activity was decreased by the RA treatment in the sense clones, but not in the antisense ones. These results suggest that RAR gamma mediates the effects of RA on the cell growth both in monolayer culture and in semisolid medium possibly through AP-1 suppression.	UNIV TEXAS, MD ANDERSON CANC CTR, DEPT TUMOR BIOL, HOUSTON, TX 77030 USA; UNIV TEXAS, MD ANDERSON CANC CTR, DEPT THORAC HEAD & NECK MED ONCOL, HOUSTON, TX 77030 USA; IGBMC, GENET MOLEC EUCARYOTES LAB, F-67085 STRASBOURG, FRANCE	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; Institut National de la Sante et de la Recherche Medicale (Inserm)			Oridate, Nobuhiko/G-5365-2012; Oridate, Nobuhiko/ABC-4116-2020	Oridate, Nobuhiko/0000-0002-6968-3028	NCI NIH HHS [P01 CA 52051] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA052051] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANESKIEVICH BJ, 1992, MOL CELL BIOL, V12, P4862, DOI 10.1128/MCB.12.11.4862; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; BLUMENBERG M, 1992, J INVEST DERMATOL, V98, pS42, DOI 10.1111/1523-1747.ep12462194; BOYLAN JF, 1995, MOL CELL BIOL, V15, P843; BOYLAN JF, 1993, P NATL ACAD SCI USA, V90, P9601, DOI 10.1073/pnas.90.20.9601; CARLBERG C, 1994, MOL ENDOCRINOL, V8, P757, DOI 10.1210/me.8.6.757; CARPENTER G, 1987, ANNU REV BIOCHEM, V56, P881, DOI 10.1146/annurev.biochem.56.1.881; Chambon Pierre, 1994, Seminars in Cell Biology, V5, P115, DOI 10.1006/scel.1994.1015; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHEN JY, 1995, EMBO J, V14, P1187, DOI 10.1002/j.1460-2075.1995.tb07102.x; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; DETHE H, 1990, NATURE, V343, P177, DOI 10.1038/343177a0; DONG ZG, 1994, P NATL ACAD SCI USA, V91, P609, DOI 10.1073/pnas.91.2.609; ECKERT RL, 1986, CELL, V46, P583, DOI 10.1016/0092-8674(86)90884-6; ELDER JT, 1991, J INVEST DERMATOL, V96, P425, DOI 10.1111/1523-1747.ep12469889; FANJUL A, 1994, NATURE, V372, P107, DOI 10.1038/372107a0; FISHER GJ, 1994, J BIOL CHEM, V269, P20629; FLOYD EE, 1989, MOL CELL BIOL, V9, P4846, DOI 10.1128/MCB.9.11.4846; GIGUERE V, 1994, GENE DEV, V8, P538, DOI 10.1101/gad.8.5.538; Gudas Lorraine J., 1994, P443; HIROSE T, 1995, BIOCHEM BIOPH RES CO, V211, P83, DOI 10.1006/bbrc.1995.1781; HU L, 1991, CANCER RES, V51, P3972; HUDSON LG, 1989, MOL ENDOCRINOL, V3, P400, DOI 10.1210/mend-3-2-400; HUSMANN M, 1991, MOL CELL BIOL, V11, P4097, DOI 10.1128/MCB.11.8.4097; KING I, 1989, CANCER RES, V49, P5677; KRUST A, 1989, P NATL ACAD SCI USA, V86, P5310, DOI 10.1073/pnas.86.14.5310; LOHNES D, 1993, CELL, V73, P643, DOI 10.1016/0092-8674(93)90246-M; LOTAN R, 1982, EXP CELL RES, V141, P79, DOI 10.1016/0014-4827(82)90070-2; LOTAN R, 1993, J CELL BIOCHEM, P167; Mangelsdorf David J., 1994, P319; Maniatis T, 1989, MOL CLONING; MIQUEL C, 1992, MOL BIOL REP, V17, P35; MOASSER MM, 1994, ONCOGENE, V9, P833; MOASSER MM, 1995, ONCOGENE, V10, P1537; NAGPAL S, 1995, J BIOL CHEM, V270, P923, DOI 10.1074/jbc.270.2.923; NICHOLSON RC, 1990, EMBO J, V9, P4443, DOI 10.1002/j.1460-2075.1990.tb07895.x; ORIDATE N, 1995, IN PRESS IN VITRO CE; Oridate Nobuhiko, 1994, Molecular and Cellular Differentiation, V2, P413; Pfahl Magnus, 1994, Seminars in Cell Biology, V5, P95, DOI 10.1006/scel.1994.1013; PITMAN SW, 1983, P AM ASSOC CANC RES, V24, P5; REISS M, 1991, CANCER RES, V51, P6254; REISS M, 1985, J NATL CANCER I, V74, P1015; ROCHETTEEGLY C, 1991, J CELL BIOL, V115, P535, DOI 10.1083/jcb.115.2.535; ROCHETTEEGLY C, 1992, MOL ENDOCRINOL, V6, P2197, DOI 10.1210/me.6.12.2197; RUBERTE E, 1990, DEVELOPMENT, V108, P213; RUDD CJ, 1993, CANCER LETT, V73, P41, DOI 10.1016/0304-3835(93)90186-D; SCHULE R, 1991, P NATL ACAD SCI USA, V88, P6092, DOI 10.1073/pnas.88.14.6092; SHEIKH MS, 1994, J BIOL CHEM, V269, P21440; STEINERT PM, 1985, J BIOL CHEM, V260, P7142; SUNDQVIST K, 1991, CANCER COMMUN-US, V3, P331, DOI 10.3727/095535491820873731; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; ULLRICH A, 1984, NATURE, V309, P418, DOI 10.1038/309418a0; VOLLBERG TM, 1992, MOL ENDOCRINOL, V6, P667, DOI 10.1210/mend.6.5.1318502; Wan H., 1995, Proceedings of the American Association for Cancer Research Annual Meeting, V36, P510; WILSON TE, 1993, MOL CELL BIOL, V13, P5794, DOI 10.1128/MCB.13.9.5794; XU XC, 1994, CANCER RES, V54, P3580; ZHANG LX, 1995, J BIOL CHEM, V270, P6022, DOI 10.1074/jbc.270.11.6022; ZHENG ZS, 1992, CELL GROWTH DIFFER, V3, P225; ZHENG ZS, 1990, CANCER RES, V50, P1201; ZOU CP, 1994, CANCER RES, V54, P5479	60	46	46	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 2	1996	12	9					2019	2028						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UK498	8649863				2022-12-25	WOS:A1996UK49800021
J	Juang, SH; Carvajal, ME; Whitney, M; Liu, YC; Carraway, CAC				Juang, SH; Carvajal, ME; Whitney, M; Liu, YC; Carraway, CAC			Tyrosine phosphorylation at the membrane-microfilament interface: A p185(neu)-associated signal transduction particle containing Src, Abl and phosphorylated p58, a membrane- and microfilament-associated retroviral gag-like protein	ONCOGENE			English	Article						signal transduction particle; tyrosine kinase; src; Ab1; p185(neu); membrane microfilament	EPIDERMAL GROWTH-FACTOR; RAT MAMMARY ADENOCARCINOMA; TUMOR-CELL MICROVILLI; ROUS-SARCOMA VIRUS; C-ABL; GENE-PRODUCT; ASCITES ADENOCARCINOMA; GLYCOPROTEIN COMPLEX; SIALOMUCIN COMPLEX; PHALLOIDIN SHIFT	Microfilaments are associated with the microvillar membrane in the 13762 ascites rat mammary carcinoma cells by stable interaction with a large, multimeric signal transduction particle (STP) containing the (proto)oncogene receptor p185(neu). In vitro kinase assays on isolated microvilli and microvillar fractions enriched in the putative signal transduction particle showed a high specific activity of tyrosine kinase activity compared to that of membranes from EGF receptor-overexpressing A431 cells maximally activated by EGF. Assays of velocity sedimentation fractions from microvillar lysates in the presence and absence of the exogenous tyrosine kinase substrate poly-glu-tyr polypeptide (poly-E(4)Y) suggested association of the tyrosine kinase activity with STP-enriched microvillar fractions. The particulate fractions also contained discrete endogenous tyrosine-phosphorylated proteins, including prominent bands of approximate to 42 and 58 kDa. Addition of ATP to these fractions resulted in a rapid increase in tyrosine phosphorylation of these and several other proteins, as detected by antiphosphotyrosine blots. Immunoprecipitation and immunoblotting with anti-phosphotyrosine antibody of SDS-solubilized ascites cells and microfilament core fractions showed nine major bands; the electrophoretic mobilities of most of these in the cell immunoprecipitate and microfilament core were the same. In vivo and in situ phosphorylation, phosphoamino acid analysis, immunoprecipitation, 2-dimensional isoelectric focusing/SDS PAGE and immunoblot analysis showed that one of the prominent substrates is p58E(gag), a retroviral Gag-like cytoplasmic STP component implicated in stabilizing microfilament-membrane interactions. Immunoblotting identified two peripheral membrane tyrosine kinases, p60(src) and p120(abl), stably associated with the p185(neu)-containing signal transduction particle. These results provide further evidence for the constitutive activation of this aggressive mammary tumor and suggest a role for phosphorylation of p58S(gag) in organization of the STP at the membrane-microfilament interface in these cells.	UNIV MIAMI,SCH MED,DEPT BIOCHEM & MOLEC BIOL,MIAMI,FL 33101; UNIV MIAMI,SCH MED,DEPT CELL BIOL & ANAT,MIAMI,FL 33101	University of Miami; University of Miami			Rolle, Marsha W/D-8286-2012		NATIONAL CANCER INSTITUTE [R01CA052498] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033795] Funding Source: NIH RePORTER; NCI NIH HHS [CA 52498] Funding Source: Medline; NIGMS NIH HHS [GM 33795] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; BRAUN S, 1984, J BIOL CHEM, V259, P2051; BURR JG, 1980, P NATL ACAD SCI-BIOL, V77, P3484, DOI 10.1073/pnas.77.6.3484; CARRAWAY C A C, 1992, P123; CARRAWAY CAC, 1983, P NATL ACAD SCI-BIOL, V80, P430, DOI 10.1073/pnas.80.2.430; CARRAWAY CAC, 1986, BIOCHIM BIOPHYS ACTA, V885, P68, DOI 10.1016/0167-4889(86)90039-X; CARRAWAY CAC, 1985, EXP CELL RES, V161, P150, DOI 10.1016/0014-4827(85)90499-9; CARRAWAY CAC, 1982, BIOCHIM BIOPHYS ACTA, V719, P126; CARRAWAY CAC, 1991, J BIOL CHEM, V266, P16238; CARRAWAY CAC, 1985, EXP CELL RES, V157, P71, DOI 10.1016/0014-4827(85)90153-3; CARRAWAY CAC, 1993, J BIOL CHEM, V268, P5582; CARRAWAY CAC, 1996, IN PRESS TREATISE CY; CARRAWAY CAC, 1983, EXP CELL RES, V143, P301; CARRAWAY KL, 1980, NATURE, V285, P508, DOI 10.1038/285508a0; CARRAWAY KL, 1982, J CELL BIOL, V94, P624, DOI 10.1083/jcb.94.3.624; CARRAWAY KL, 1995, BIOESSAYS, V17, P171, DOI 10.1002/bies.950170212; CARRAWAY KL, 1989, BIOCHIM BIOPHYS ACTA, V988, P147, DOI 10.1016/0304-4157(89)90017-8; CARRAWAY KL, 1979, J CELL BIOL, V83, P529, DOI 10.1083/jcb.83.3.529; CHINKERS M, 1979, J CELL BIOL, V83, P260, DOI 10.1083/jcb.83.1.260; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; FRANZ WM, 1989, EMBO J, V8, P137, DOI 10.1002/j.1460-2075.1989.tb03358.x; GALLAY P, 1995, CELL, V80, P379, DOI 10.1016/0092-8674(95)90488-3; HAMAGUCHI M, 1987, P NATL ACAD SCI USA, V84, P2312, DOI 10.1073/pnas.84.8.2312; HORVATH AR, 1992, EMBO J, V11, P855, DOI 10.1002/j.1460-2075.1992.tb05123.x; HOWARD SC, 1982, JNCI-J NATL CANCER I, V69, P33; HUGGINS JW, 1980, EXP CELL RES, V127, P27; HUNTER T, 1985, ANNU REV BIOCHEM, V54, P897, DOI 10.1146/annurev.biochem.54.1.897; Hunter T, 1989, CURR OPIN CELL BIOL, V1, P1168, DOI 10.1016/S0955-0674(89)80068-7; HYNES NE, 1993, SEMIN CANCER BIOL, V4, P19; JACKSON P, 1989, EMBO J, V8, P449, DOI 10.1002/j.1460-2075.1989.tb03397.x; JUANG SH, 1994, J BIOL CHEM, V269, P15067; JUNG G, 1985, J CELL BIOCHEM, V28, P243, DOI 10.1002/jcb.240280402; KADOWAKI T, 1986, J BIOL CHEM, V261, P6141; KELLIE S, 1988, BIOESSAYS, V8, P25, DOI 10.1002/bies.950080107; KRUEGER JG, 1983, CURR TOP MICROBIOL I, V107, P52; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LO SH, 1994, CANCER METAST REV, V13, P9, DOI 10.1007/BF00690415; LOEB DM, 1987, J VIROL, V61, P2420, DOI 10.1128/JVI.61.8.2420-2427.1987; LUI Y, 1989, J BIOL CHEM, V264, P1208; MCWHIRTER JR, 1991, MOL CELL BIOL, V11, P1553, DOI 10.1128/MCB.11.3.1553; OFARRELL PZ, 1977, CELL, V12, P1133, DOI 10.1016/0092-8674(77)90176-3; OKAMURA H, 1994, ONCOGENE, V9, P2293; PELECH SL, 1986, BIOCHEMISTRY-US, V25, P8348, DOI 10.1021/bi00374a002; PLUSKAL MG, 1986, BIOTECHNIQUES, V4, P272; RIJKEN PJ, 1991, J CELL SCI, V100, P491; ROHRSCHNEIDER LR, 1980, P NATL ACAD SCI-BIOL, V77, P3514, DOI 10.1073/pnas.77.6.3514; SHENG ZQ, 1992, J BIOL CHEM, V267, P16341; SOBUE K, 1988, BIOCHEM BIOPH RES CO, V157, P1383, DOI 10.1016/S0006-291X(88)81028-3; SRIVASTAVA AK, 1989, BIOCHIM BIOPHYS ACTA, V996, P13, DOI 10.1016/0167-4838(89)90087-3; TAKATA K, 1988, J CELL BIOL, V106, P1757, DOI 10.1083/jcb.106.5.1757; THOM D, 1977, BIOCHEM J, V168, P187, DOI 10.1042/bj1680187; VANDERPUYE OA, 1988, EXP CELL RES, V178, P211, DOI 10.1016/0014-4827(88)90392-8; VANETTEN RA, 1989, CELL, V58, P669, DOI 10.1016/0092-8674(89)90102-5; VANETTEN RA, 1994, J CELL BIOL, V124, P325, DOI 10.1083/jcb.124.3.325	54	21	22	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR 7	1996	12	5					1033	1042						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UA884	8649794				2022-12-25	WOS:A1996UA88400011
J	Fredericks, ZL; Pitcher, JA; Lefkowitz, RJ				Fredericks, ZL; Pitcher, JA; Lefkowitz, RJ			Identification of the G protein-coupled receptor kinase phosphorylation sites in the human beta(2)-adrenergic receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-ADRENERGIC-RECEPTOR; BETA-2-ADRENERGIC RECEPTOR; RHODOPSIN KINASE; ADENYLATE-CYCLASE; BOVINE RHODOPSIN; GAMMA-SUBUNITS; DESENSITIZATION; MECHANISM; AGONIST	Rapid desensitization of G protein-coupled receptors is mediated, at least in part, by their phosphorylation by the G protein-coupled receptor kinases (GRKs), However, only in the case of rhodopsin have the actual sites of receptor phosphorylation been unambiguously determined, Although previous studies have implicated the cytoplasmic tail of the beta(2)-adrenergic receptor (beta(2)AR) as the site of GRK-mediated phosphorylation, the identities of the phosphorylated residues were unknown, Here we report the identification of the sites of GRK2- and GRK5-mediated beta(2)AR phosphorylation. The phosphorylation sites of both serine/threonine kinases reside exclusively in a 40-amino acid peptide located at the extreme carboxyl terminus of the beta(2)AR. Of the seven phosphorylatable residues within this peptide, sin are phosphorylated by GRK5 (Thr-384, Thr-393, Ser-396, Ser-401, Ser-407, and Ser-411) and four are phosphorylated by GRK2 (Thr-384, Ser-396, Ser-401, and Ser-407) at equivalent phosphorylation stoichiometries (similar to 1.0 mol P-i/mol receptor), In addition to the GRK5-specific phosphorylation of Thr-393 and Ser-411, differences in the distribution of phosphate between sites are observed for GRK2 and GRK5. Increasing the stoichiometry of GRK2-mediated beta(2)AR phosphorylation from similar to 1.0 to 5.0 mol P-i/mol receptor increases the stoichiometry of phosphorylation of Thr-384, Ser-396, Ser-401, and Ser-407 rather than increasing the number of phosphoacceptor sites. The location of multiple GRK2 and GRB5 phosphoacceptor sites at the extreme carboxyl terminus of the beta(2)AR is highly reminiscent of GRK1-mediated phosphorylation of rhodopsin.	DUKE UNIV,MED CTR,DEPT MED,HOWARD HUGHES MED INST,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT BIOCHEM,HOWARD HUGHES MED INST,DURHAM,NC 27710	Duke University; Howard Hughes Medical Institute; Duke University; Howard Hughes Medical Institute			Lefkowitz, Robert/AAW-2649-2021; Pitcher, Julie/ABH-2078-2020		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL016037, R01HL016037] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL16037] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ATON BR, 1984, BIOCHEMISTRY-US, V23, P1737, DOI 10.1021/bi00303a024; BENOVIC JL, 1984, BIOCHEMISTRY-US, V23, P4510, DOI 10.1021/bi00315a002; BOUVIER M, 1988, NATURE, V333, P370, DOI 10.1038/333370a0; CASEY PJ, 1989, BIOCHEMISTRY-US, V28, P611, DOI 10.1021/bi00428a029; CERIONE RA, 1983, NATURE, V306, P562, DOI 10.1038/306562a0; DOHLMAN HG, 1987, J BIOL CHEM, V262, P14282; EASON MG, 1995, J BIOL CHEM, V270, P4681, DOI 10.1074/jbc.270.9.4681; GIANNINI E, 1995, J BIOL CHEM, V270, P19166, DOI 10.1074/jbc.270.32.19166; HAUSDORFF WP, 1989, J BIOL CHEM, V264, P12657; HAUSDORFF WP, 1991, P NATL ACAD SCI USA, V88, P2979, DOI 10.1073/pnas.88.8.2979; INGLESE J, 1993, J BIOL CHEM, V268, P23735; MCDOWELL JH, 1993, BIOCHEMISTRY-US, V32, P4968, DOI 10.1021/bi00069a036; OHGURO H, 1993, BIOCHEMISTRY-US, V32, P5718, DOI 10.1021/bi00072a030; OHGURO H, 1995, J BIOL CHEM, V270, P14259, DOI 10.1074/jbc.270.24.14259; OHGURO H, 1994, BIOCHEMISTRY-US, V33, P1023, DOI 10.1021/bi00170a022; ONORATO JJ, 1991, BIOCHEMISTRY-US, V30, P5118, DOI 10.1021/bi00235a002; PALCZEWSKI K, 1989, BIOCHEMISTRY-US, V28, P8764, DOI 10.1021/bi00448a013; PALCZEWSKI K, 1991, J BIOL CHEM, V266, P12949; PALCZEWSKI K, 1995, J BIOL CHEM, V270, P15294, DOI 10.1074/jbc.270.25.15294; PAPAC DI, 1993, BIOCHEMISTRY-US, V32, P5930, DOI 10.1021/bi00074a002; PITCHER JA, 1995, J BIOL CHEM, V270, P11707, DOI 10.1074/jbc.270.20.11707; PITCHER JA, 1992, SCIENCE, V257, P1264, DOI 10.1126/science.1325672; PREMONT RT, 1994, J BIOL CHEM, V269, P6832; PREMONT RT, 1995, FASEB J, V9, P175, DOI 10.1096/fasebj.9.2.7781920; PROSSNITZ ER, 1995, J BIOL CHEM, V270, P1130, DOI 10.1074/jbc.270.3.1130; PULLEN N, 1994, BIOCHEMISTRY-US, V33, P14536, DOI 10.1021/bi00252a021; SAMAMA P, 1993, J BIOL CHEM, V268, P4625; STRASSER RH, 1986, P NATL ACAD SCI USA, V83, P6362, DOI 10.1073/pnas.83.17.6362; WILDEN U, 1982, BIOCHEMISTRY-US, V21, P3014, DOI 10.1021/bi00541a032	29	197	200	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 7	1996	271	23					13796	13803		10.1074/jbc.271.23.13796	http://dx.doi.org/10.1074/jbc.271.23.13796			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UP385	8662852	hybrid			2022-12-25	WOS:A1996UP38500074
J	Junius, FK; ODonoghue, SI; Nilges, M; Weiss, AS; King, GF				Junius, FK; ODonoghue, SI; Nilges, M; Weiss, AS; King, GF			High resolution NMR solution structure of the leucine zipper domain of the c-Jun homodimer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							X-RAY STRUCTURE; COILED COILS; 3-DIMENSIONAL STRUCTURES; GCN4; PROTEINS; DNA; RECOGNITION; COMPLEX; REGION	The solution structure of the c-Jun leucine zipper domain has been determined to high resolution using a new calculation protocol designed to handle highly ambiguous sets of interproton distance restraints, The domain comprises a coiled coil of parallel alpha-helices in which most of the hydrophobic residues are buried at the highly symmetrical dimer interface; this Interface extends over 10 helical turns and is the most elongated protein domain solved to date using MMR methods, The backbone fold is very similar to that seen in crystal structures of the GCN4 and Jun-Fos leucine zippers; however, in contrast with these crystal structures, the Jun leucine zipper dimer appears to be devoid of favorable intermolecular electrostatic interactions, A polar asparagine residue, located at the dimer interface, forms the sole point of asymmetry in the structure; furthermore, the side chain of this residue is disordered due to motional averaging, This residue, which is highly conserved in the leucine zipper family of transcription factors, provides a destabilizing influence that is likely to facilitate the rapid exchange of zipper strands in vivo.	UNIV SYDNEY,DEPT BIOCHEM,SYDNEY,NSW 2006,AUSTRALIA; EUROPEAN MOLEC BIOL LAB,D-69012 HEIDELBERG,GERMANY	University of Sydney; European Molecular Biology Laboratory (EMBL)			Weiss, Anthony S/F-8103-2010; Nilges, Michael/E-4803-2011; King, Glenn F/J-5059-2012; Weiss, Anthony S/GYV-0157-2022; O'Donoghue, Sean/A-9522-2012	Weiss, Anthony S/0000-0002-8106-4836; Nilges, Michael/0000-0002-1451-8092; King, Glenn F/0000-0002-2308-2200; O'Donoghue, Sean/0000-0001-9520-6623				Angel P. E., 1994, FOS JUN FAMILIES TRA; BACON D, 1988, J MOL GRAPHICS, V6, P219, DOI 10.1016/S0263-7855(98)80030-1; BENEDETTI E, 1992, BIOPOLYMERS, V32, P453, DOI 10.1002/bip.360320424; BLAKE DJ, 1995, TRENDS BIOCHEM SCI, V20, P133, DOI 10.1016/S0968-0004(00)88986-0; BRUNGER AT, 1993, XPLOR USER MANUAL VE; BURGERING MJM, 1993, FEBS LETT, V330, P105, DOI 10.1016/0014-5793(93)80929-O; CRICK FHC, 1953, ACTA CRYSTALLOGR, V6, P689, DOI 10.1107/S0365110X53001964; ELLENBERGER TE, 1992, CELL, V71, P1223, DOI 10.1016/S0092-8674(05)80070-4; FERREDAMARE AR, 1993, NATURE, V363, P38, DOI 10.1038/363038a0; GLOVER JNM, 1995, NATURE, V373, P257, DOI 10.1038/373257a0; HARBURY PB, 1993, SCIENCE, V262, P1401, DOI 10.1126/science.8248779; HURST HC, 1994, PROTEIN PROFILE, V1, P123; JOHN M, 1994, J BIOL CHEM, V269, P16247; JUNIUS FK, 1993, EUR J BIOCHEM, V214, P415, DOI 10.1111/j.1432-1033.1993.tb17937.x; JUNIUS FK, 1995, BIOCHEMISTRY-US, V34, P6164, DOI 10.1021/bi00018a020; KONIG P, 1993, J MOL BIOL, V233, P139, DOI 10.1006/jmbi.1993.1490; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LUMB KJ, 1995, SCIENCE, V268, P436, DOI 10.1126/science.7716550; Lumb KJ, 1996, SCIENCE, V271, P1137, DOI 10.1126/science.271.5252.1137; LUMB KJ, 1995, BIOCHEMISTRY-US, V34, P8642, DOI 10.1021/bi00027a013; Mackay JP, 1996, BIOCHEMISTRY-US, V35, P4867, DOI 10.1021/bi952761y; MCLACHLAN AD, 1975, J MOL BIOL, V98, P293, DOI 10.1016/S0022-2836(75)80119-7; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; NILGES M, 1993, PROTEINS, V17, P297, DOI 10.1002/prot.340170307; NILGES M, 1991, PROTEIN ENG, V4, P649, DOI 10.1093/protein/4.6.649; NILGES M, 1988, FEBS LETT, V229, P317, DOI 10.1016/0014-5793(88)81148-7; ODONOGHUE SI, 1993, PROTEIN ENG, V6, P557, DOI 10.1093/protein/6.6.557; ODONOGHUE SI, 1996, IN PRESS J BIOMOL NM; OSHEA EK, 1991, SCIENCE, V254, P539, DOI 10.1126/science.1948029; OSHEA EK, 1992, CELL, V68, P699, DOI 10.1016/0092-8674(92)90145-3; PATEL LR, 1994, P NATL ACAD SCI USA, V91, P7360, DOI 10.1073/pnas.91.15.7360; RILEY LG, 1994, EUR J BIOCHEM, V219, P877, DOI 10.1111/j.1432-1033.1994.tb18569.x; SEO J, 1993, PROTEINS, V15, P223, DOI 10.1002/prot.340150302; SIPPL MJ, 1993, PROTEINS, V17, P355, DOI 10.1002/prot.340170404; WENDT H, 1995, BIOCHEMISTRY-US, V34, P4097, DOI 10.1021/bi00012a028; ZHAO DQ, 1994, J MOL BIOL, V239, P601, DOI 10.1006/jmbi.1994.1402; ZHOU NE, 1994, PROTEIN ENG, V7, P1365, DOI 10.1093/protein/7.11.1365	39	85	89	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 7	1996	271	23					13663	13667		10.1074/jbc.271.23.13663	http://dx.doi.org/10.1074/jbc.271.23.13663			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UP385	8662824	hybrid			2022-12-25	WOS:A1996UP38500055
J	Pieper, RO; Patel, S; Ting, SA; Futscher, BW; Costello, JF				Pieper, RO; Patel, S; Ting, SA; Futscher, BW; Costello, JF			Methylation of CpG island transcription factor binding sites is unnecessary for aberrant silencing of the human MGMT gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA METHYLATION; O6-METHYLGUANINE-DNA METHYLTRANSFERASE; CHROMOSOME INACTIVATION; CYTOSINE METHYLATION; CHROMATIN STRUCTURE; KINASE GENE; HPRT GENE; EXPRESSION; PROMOTER; MARKERS	Aberrant transcriptional inactivation of the non-X-linked human O-6-methylguanine DNA methyltransferase (MGMT) gene has been associated with loss of open chromatin structure and increases in cytosine methylation in the Sp1-binding region of the 5'-CpG island of the gene, To examine the necessity of these events for gene silencing, we]save isolated and characterized a subline of human MGMT+ T98G glioma cells, The subline, T98Gs, does not express MGMT activity or MGMT mRNA, and exhibits no in vivo DNA-protein interactions at Sp1-like binding sites in the MGMT 5'-CpG island. While the MGMT CPG island is less accessible to exogenously added restriction enzymes in T98Gs nuclei than in T98G nuclei, it is similarly methylated in both T98G and T98Gs cell lines 5' and 3' to the transcription factor binding sites, and similarly unmethylated in the region encompassing the binding sites, Inappropriate transcriptional inactivation of MGMT, therefore, does not require methylation of transcription factor binding sites within the 5'-CpG island. Rather, MGMT gene silencing and transcription factor exclusion from T98Gs MGMT CpG island binding sites is most closely associated with condensed chromatin structure, which is in turns indirectly influenced by distant sites of methylation.	LOYOLA UNIV,DEPT PHARMACOL,DIV HEMATOL ONCOL,MAYWOOD,IL 60153; LOYOLA UNIV,PROGRAM MOLEC BIOL,MAYWOOD,IL 60153; UNIV ARIZONA,ARIZONA CANC CTR,TUCSON,AZ 85724; LUDWIG INST CANC RES,SAN DIEGO,CA 92093	Loyola University Chicago; Loyola University Chicago; Arizona Center Cancer Care; University of Arizona; Ludwig Institute for Cancer Research	Pieper, RO (corresponding author), LOYOLA UNIV,MED CTR,DEPT MED,DIV HEMATOL ONCOL,2160 S 1ST AVE,MAYWOOD,IL 60153, USA.				NATIONAL CANCER INSTITUTE [R29CA055064, R01CA055064] Funding Source: NIH RePORTER; NCI NIH HHS [CA55064] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BIRD AP, 1987, TRENDS GENET, V3, P342, DOI 10.1016/0168-9525(87)90294-0; BUSCHHAUSEN G, 1987, P NATL ACAD SCI USA, V84, P1177, DOI 10.1073/pnas.84.5.1177; CARLSON M, 1994, CURR OPIN CELL BIOL, V6, P396, DOI 10.1016/0955-0674(94)90032-9; COSTELLO JF, 1994, J BIOL CHEM, V269, P17228; COSTELLO JF, 1994, MOL CELL BIOL, V14, P6515, DOI 10.1128/MCB.14.10.6515; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; Futscher B W, 1989, Cancer Commun, V1, P65; GARDINERGARDEN M, 1987, J MOL BIOL, V196, P261, DOI 10.1016/0022-2836(87)90689-9; HANSEN RS, 1988, MOL CELL BIOL, V8, P4692, DOI 10.1128/MCB.8.11.4692; HARRINGTON MA, 1988, P NATL ACAD SCI USA, V85, P2066, DOI 10.1073/pnas.85.7.2066; HARRIS LC, 1991, NUCLEIC ACIDS RES, V19, P6163, DOI 10.1093/nar/19.22.6163; HERMAN JG, 1994, P NATL ACAD SCI USA, V91, P9700, DOI 10.1073/pnas.91.21.9700; HOLLER M, 1988, GENE DEV, V2, P1127, DOI 10.1101/gad.2.9.1127; HORNSTRA IK, 1994, MOL CELL BIOL, V14, P1419, DOI 10.1128/MCB.14.2.1419; ISSA JPJ, 1994, NAT GENET, V7, P536, DOI 10.1038/ng0894-536; KASS SU, 1993, MOL CELL BIOL, V13, P7372, DOI 10.1128/MCB.13.12.7372; KESHET I, 1986, CELL, V44, P535, DOI 10.1016/0092-8674(86)90263-1; KING BL, 1994, AM J PATHOL, V144, P486; KOVESDI I, 1987, P NATL ACAD SCI USA, V84, P2180, DOI 10.1073/pnas.84.8.2180; KROES RA, 1995, CARCINOGENESIS, V16, P2255, DOI 10.1093/carcin/16.9.2255; KWIATKOWSKI DJ, 1992, GENOMICS, V12, P229, DOI 10.1016/0888-7543(92)90370-8; LARSEN F, 1992, GENOMICS, V13, P1095, DOI 10.1016/0888-7543(92)90024-M; LEE WH, 1994, P NATL ACAD SCI USA, V91, P11733, DOI 10.1073/pnas.91.24.11733; LEE YW, 1995, MOL CELL BIOL, V15, P2547; LOCK LF, 1987, CELL, V48, P39, DOI 10.1016/0092-8674(87)90353-9; LOCK LF, 1986, MOL CELL BIOL, V6, P914, DOI 10.1128/MCB.6.3.914; Maxam A M, 1980, Methods Enzymol, V65, P499; MCGREW MJ, 1993, BIOTECHNIQUES, V15, P722; MEEHAN RR, 1989, CELL, V58, P499, DOI 10.1016/0092-8674(89)90430-3; MEEHAN RR, 1992, NUCLEIC ACIDS RES, V20, P5085, DOI 10.1093/nar/20.19.5085; NAKATSU Y, 1993, MUTAT RES, V293, P119, DOI 10.1016/0921-8777(93)90063-M; PEGG AE, 1990, CANCER RES, V50, P6119; PFEIFER GP, 1990, GENE DEV, V4, P1277, DOI 10.1101/gad.4.8.1277; PFIEFER GP, 1989, SCIENCE, V246, P810; PIEPER RO, 1991, CANCER COMMUN, V3, P241, DOI 10.3727/095535491820873092; RIDEOUT WM, 1994, MOL CELL BIOL, V14, P6143, DOI 10.1128/MCB.14.9.6143; SELKER EU, 1990, TRENDS BIOCHEM SCI, V15, P103, DOI 10.1016/0968-0004(90)90193-F; SINGERSAM J, 1990, MOL CELL BIOL, V10, P4987, DOI 10.1128/MCB.10.9.4987; TETER B, 1994, J NEUROSCI RES, V39, P680, DOI 10.1002/jnr.490390609; VONWRONSKI MA, 1994, CARCINOGENESIS, V15, P577, DOI 10.1093/carcin/15.4.577; WATT F, 1988, GENE DEV, V2, P1136, DOI 10.1101/gad.2.9.1136; WU SW, 1987, CANCER RES, V47, P6229	42	50	51	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 7	1996	271	23					13916	13924		10.1074/jbc.271.23.13916	http://dx.doi.org/10.1074/jbc.271.23.13916			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UP385	8662860	hybrid			2022-12-25	WOS:A1996UP38500091
J	Seyfert, VL; Allman, D; He, YS; Staudt, LM				Seyfert, VL; Allman, D; He, YS; Staudt, LM			Transcriptional repression by the proto-oncogene BCL-6	ONCOGENE			English	Article						BCL-6; repression; lymphoma; POZ domain	GERMINAL-CENTERS; CONSERVED DOMAIN; GENE; DROSOPHILA; PROTEINS; IDENTIFICATION; TRANSLOCATIONS; EXPRESSION; ACTIVATORS; LYMPHOMAS	In up to 45% of reported cases of the non-Hodgkin's lymphoma, diffuse large cell lymphoma, there are translocations of the BCL-6 gene, which are presumed to deregulate its expression, The BCL-6 protein, which is unmutated in these lymphomas, contains six Kruppel-like zinc fingers at its carboxy terminus and a 121 amino acid domain at its amino terminus, termed the POZ domain, which bears homology with amino terminal domains in a subset zinc finger transcription factors, In this study, we tested whether BCL-6 regulates transcription and if the POZ domain has a role in this function. The BCL-6 POZ domain, when fused to the GAL4 DNA binding domain, strongly repressed transcriptional activation initiated from several different promoters including the SV40 enhancer/promoter. Repression was also observed when the fusion protein was bound at a distance of 200 bp 5' of the promoter, When the GAL4/BCL6 POZ domain fusion protein was expressed in yeast, it was able to homodimerize in the nucleus, Nevertheless, in contrast with mammalian cells, the fusion protein did not repress transcription, To test the ability of the full length BCl-6 protein to repress transcription when bound to DNA through its zinc finger DNA binding domain, high affinity BCL-6 binding sites were selected from a pool of random oligonucleotides. Full length BCL-6 was able to strongly repress transcription when bound to its cognate site cloned upstream of the thymidine kinase promoter, This repression was mediated, in large measure, by the POZ domain, although a variant of BCL-6 lacking the POZ domain was able to repress transcription modestly, The ability of BCL-6 to function as a transcriptional repressor may contribute to its ability to transform B lymphocytes in diffuse large cell lymphoma.	NCI,METAB BRANCH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			Staudt, Louis/AAC-5324-2019					Ausubel FM., 2006, ENZYMATIC MANIPULATI; AYER DE, 1995, CELL, V80, P767, DOI 10.1016/0092-8674(95)90355-0; BANCHEREAU J, 1994, ANNU REV IMMUNOL, V12, P881, DOI 10.1146/annurev.iy.12.040194.004313; BARDWELL VJ, 1994, GENE DEV, V8, P1664, DOI 10.1101/gad.8.14.1664; BARON BW, 1993, P NATL ACAD SCI USA, V90, P5262, DOI 10.1073/pnas.90.11.5262; BASTARD C, 1994, BLOOD, V83, P2423; BEREK C, 1991, CELL, V67, P1121, DOI 10.1016/0092-8674(91)90289-B; BOSHART M, 1992, GENE, V110, P129, DOI 10.1016/0378-1119(92)90456-Y; BRENT R, 1985, CELL, V43, P729, DOI 10.1016/0092-8674(85)90246-6; CATTORETTI G, 1995, BLOOD, V86, P45, DOI 10.1182/blood.V86.1.45.bloodjournal86145; CHEN W, 1995, MOL CELL BIOL, V15, P3424; CHEN Z, 1994, P NATL ACAD SCI USA, V91, P1178, DOI 10.1073/pnas.91.3.1178; CHEN Z, 1993, EMBO J, V12, P1161, DOI 10.1002/j.1460-2075.1993.tb05757.x; DALLERY E, 1995, ONCOGENE, V10, P2171; DIBELLO PR, 1991, GENETICS, V129, P385; DORN R, 1993, P NATL ACAD SCI USA, V90, P11376, DOI 10.1073/pnas.90.23.11376; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; GAIDANO G, 1994, BLOOD, V84, P397; GAUSS GH, 1992, NUCLEIC ACIDS RES, V20, P6739, DOI 10.1093/nar/20.24.6739; HARRISON SD, 1990, EMBO J, V9, P207, DOI 10.1002/j.1460-2075.1990.tb08097.x; HENTHORN P, 1988, P NATL ACAD SCI USA, V85, P6342, DOI 10.1073/pnas.85.17.6342; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JACOB J, 1991, NATURE, V354, P389, DOI 10.1038/354389a0; JOHNSON AD, 1995, CELL, V81, P655, DOI 10.1016/0092-8674(95)90524-3; JONES KA, 1985, CELL, V42, P559, DOI 10.1016/0092-8674(85)90113-8; KAWAMATA N, 1994, BIOCHEM BIOPH RES CO, V204, p3P66; KELEHER CA, 1992, CELL, V68, P709, DOI 10.1016/0092-8674(92)90146-4; KERCKAERT JP, 1993, NAT GENET, V5, P66, DOI 10.1038/ng0993-66; LOCOCO F, 1994, BLOOD, V83, P1757, DOI 10.1182/blood.V83.7.1757.bloodjournal8371757; MA J, 1987, CELL, V51, P113, DOI 10.1016/0092-8674(87)90015-8; MAGRATH IT, 1990, NONHODGKINS LYMPHOMA, P1; MARTIN KJ, 1990, NATURE, V346, P147, DOI 10.1038/346147a0; MEYERS S, 1993, MOL CELL BIOL, V13, P6336, DOI 10.1128/MCB.13.10.6336; MIKI T, 1994, BLOOD, V83, P217; NAKAMURA Y, 1995, BRIT J HAEMATOL, V90, P404, DOI 10.1111/j.1365-2141.1995.tb05166.x; NUMOTO M, 1993, NUCLEIC ACIDS RES, V21, P3767, DOI 10.1093/nar/21.16.3767; OHNO H, 1994, JPN J CANCER RES, V85, P592, DOI 10.1111/j.1349-7006.1994.tb02401.x; ONDEK B, 1987, EMBO J, V6, P1017, DOI 10.1002/j.1460-2075.1987.tb04854.x; ONIZUKA T, 1995, BLOOD, V86, P28, DOI 10.1182/blood.V86.1.28.bloodjournal86128; OTSUKI T, 1995, BLOOD, V85, P2877, DOI 10.1182/blood.V85.10.2877.bloodjournal85102877; RAFF JW, 1994, EMBO J, V13, P5977, DOI 10.1002/j.1460-2075.1994.tb06943.x; Rose MD., 1990, METHODS YEAST GENETI; ROSENBERG UB, 1986, NATURE, V319, P336, DOI 10.1038/319336a0; SAHA S, 1993, NATURE, V363, P648, DOI 10.1038/363648a0; Sambrook J., 2002, MOL CLONING LAB MANU; WALES MM, 1995, NAT MED, V1, P570, DOI 10.1038/nm0695-570	47	189	193	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN 6	1996	12	11					2331	2342						12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UQ220	8649773				2022-12-25	WOS:A1996UQ22000010
J	Bai, WL; Weigel, NL				Bai, WL; Weigel, NL			Phosphorylation of Ser(211) in the chicken progesterone receptor modulates its transcriptional activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STEROID-HORMONE RECEPTORS; DNA-BINDING DOMAIN; VITAMIN-D RECEPTOR; CASEIN KINASE-II; GLUCOCORTICOID RECEPTOR; ESTROGEN-RECEPTOR; DEPENDENT PHOSPHORYLATION; PROTEIN-KINASE; ACTIVATION; SITE	The chicken progesterone receptor has been shown to be phosphorylated in vivo at four major sites. Previous studies have shown that mutation of one of the hormone-dependent phosphorylation sites, Ser(530), to alanine decreases the transcriptional activity of the receptor under conditions where ligand is limited. Here, we present evidence for the functional significance of another phosphorylation site, Ser(211). Mutation of Set-211 to alanine results in a decrease in the transcriptional activity of the receptor and affects the phosphorylation-dependent decrease in mobility of the receptor in SDS-polyacrylamide gel electrophoresis. The degree of reduction in transcriptional activity is dependent on both the cell type and the reporters used in the studies but is independent of hormone concentration, suggesting that phosphorylation at Ser(211) regulates the activity of the receptor through a mechanism distinct from Ser(530) phosphorylation.	BAYLOR COLL MED, DEPT CELL BIOL, HOUSTON, TX 77030 USA	Baylor College of Medicine			Bai, Wenlong/A-8977-2013	Bai, Wenlong/0000-0002-9536-0556	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P30HD007495, R01HD022061] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [F32DK009151] Funding Source: NIH RePORTER; NICHD NIH HHS [HD22061, HD-07495] Funding Source: Medline; NIDDK NIH HHS [F32 DK009151, 1F32 DK09151-01] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALI S, 1993, EMBO J, V12, P1153, DOI 10.1002/j.1460-2075.1993.tb05756.x; ALLGOOD VE, 1993, J BIOL CHEM, V268, P20870; ARNOLD SF, 1994, MOL ENDOCRINOL, V8, P1208, DOI 10.1210/me.8.9.1208; Bai Wenlong, 1995, V51, P289; BAI WL, 1994, MOL ENDOCRINOL, V8, P1465, DOI 10.1210/me.8.11.1465; BAILLY A, 1986, EMBO J, V5, P3235, DOI 10.1002/j.1460-2075.1986.tb04634.x; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BECK CA, 1992, MOL ENDOCRINOL, V6, P607, DOI 10.1210/me.6.4.607; BOCQUEL MT, 1989, NUCLEIC ACIDS RES, V17, P2581, DOI 10.1093/nar/17.7.2581; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; BRADSHAW MS, 1988, MOL ENDOCRINOL, V2, P1286, DOI 10.1210/mend-2-12-1286; BRIAN S, 1988, GENE, V67, P271; CARSONJURICA MA, 1990, J STEROID BIOCHEM, V34, P1; CASTORIA G, 1993, BIOCHEMISTRY-US, V32, P1740, DOI 10.1021/bi00058a007; DAVIS IJ, 1994, MOL CELL BIOL, V14, P3469, DOI 10.1128/MCB.14.5.3469; DAYANI N, 1990, BIOCHEMISTRY-US, V29, P2691, DOI 10.1021/bi00463a011; DENNER LA, 1990, J BIOL CHEM, V265, P16548; DENNER LA, 1989, ENDOCRINOLOGY, V125, P3051, DOI 10.1210/endo-125-6-3051; DENNER LA, 1990, SCIENCE, V250, P1740, DOI 10.1126/science.2176746; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; GLINEUR C, 1989, ONCOGENE, V4, P1247; GREEN S, 1988, TRENDS GENET, V4, P309, DOI 10.1016/0168-9525(88)90108-4; GRONEMEYER H, 1987, EMBO J, V6, P3985, DOI 10.1002/j.1460-2075.1987.tb02741.x; GRONEMEYER H, 1991, ANNU REV GENET, V25, P89, DOI 10.1146/annurev.ge.25.120191.000513; HILLIARD GM, 1994, BIOCHEMISTRY-US, V33, P4300, DOI 10.1021/bi00180a026; HIRATA Y, 1993, J BIOL CHEM, V268, P24808; HSIEH JC, 1991, P NATL ACAD SCI USA, V88, P9315, DOI 10.1073/pnas.88.20.9315; HSU SC, 1992, EMBO J, V11, P3457, DOI 10.1002/j.1460-2075.1992.tb05425.x; JEWELL CM, 1995, ENDOCRINE SOC, P423; JOEL PB, 1995, MOL ENDOCRINOL, V9, P1041, DOI 10.1210/me.9.8.1041; JURUTKA PW, 1993, J BIOL CHEM, V268, P6791; KATO S, 1995, SCIENCE, V270, P1491, DOI 10.1126/science.270.5241.1491; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LEGOFF P, 1994, J BIOL CHEM, V269, P4458; MASON SA, 1993, J BIOL CHEM, V268, P21501; MORENO S, 1990, CELL, V61, P549, DOI 10.1016/0092-8674(90)90463-O; MULKHOPADHYAY NK, 1992, J BIOL CHEM, V267, P3325; OLEASERRANO N, 1985, EUR J CANCER CLIN ON, V21, P965, DOI 10.1016/0277-5379(85)90116-6; OMALLEY B, 1990, MOL ENDOCRINOL, V4, P363, DOI 10.1210/mend-4-3-363; OMALLEY BW, 1992, MOL ENDOCRINOL, V6, P1359, DOI 10.1210/me.6.9.1359; OMALLEY BW, 1991, RECENT PROG HORM RES, V47, P1; ORTI E, 1992, ENDOCR REV, V13, P105, DOI 10.1210/er.13.1.105; POLETTI A, 1993, BIOCHEMISTRY-US, V32, P9563, DOI 10.1021/bi00088a007; POLETTI A, 1993, MOL ENDOCRINOL, V7, P241, DOI 10.1210/me.7.2.241; POWER RF, 1991, SCIENCE, V254, P1636, DOI 10.1126/science.1749936; RAYMOURE WJ, 1985, NATURE, V314, P745, DOI 10.1038/314745a0; TAKIMOTO GS, 1992, P NATL ACAD SCI USA, V89, P3050, DOI 10.1073/pnas.89.7.3050; TSAI MJ, 1994, ANNU REV BIOCHEM, V63, P451, DOI 10.1146/annurev.biochem.63.1.451; WEIGEL NL, 1989, ENDOCRINOLOGY, V125, P2494, DOI 10.1210/endo-125-5-2494; WEIGEL NL, 1992, MOL ENDOCRINOL, V6, P8, DOI 10.1210/me.6.1.8; WEIGEL NL, 1993, ADV PROT PHOSPHAT, V7, P237; WEIGEL NL, 1994, MECH STEROID HORMONE, P93; WEIGEL NL, 1990, RECEPTOR PURIFICATIO, P259; ZHANG Y, 1994, ENDOCRINE SOC, P630; ZHANG YX, 1994, MOL ENDOCRINOL, V8, P577, DOI 10.1210/me.8.5.577; ZHANG YX, 1994, J BIOL CHEM, V269, P31034; ZHANG YX, 1995, MOL ENDOCRINOL, V9, P1029, DOI 10.1210/me.9.8.1029	57	32	33	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 31	1996	271	22					12801	12806		10.1074/jbc.271.22.12801	http://dx.doi.org/10.1074/jbc.271.22.12801			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UN474	8662804	hybrid			2022-12-25	WOS:A1996UN47400019
J	SteinerMordoch, S; Shirvan, A; Schuldiner, S				SteinerMordoch, S; Shirvan, A; Schuldiner, S			Modification of the pH profile and tetrabenazine sensitivity of rat VMAT1 by replacement of aspartate 404 with glutamate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHROMAFFIN GRANULE MEMBRANE; BETA-ADRENERGIC-RECEPTOR; AMINE TRANSPORTER; RESERPINE BINDING; VESICLES	Vesicular monoamine transporters (VMAT) catalyze transport of serotonin, dopamine, epinephrine, and norepinephrine into subcellular storage organelles in a variety of cells. Accumulation of the neurotransmitter depends on the proton electrochemical gradient (Delta<(mu)over tilde>(H+)) across the organelle membrane and involves VMAT-mediated exchange of two lumenal protons with one cytoplasmic amine. Mutagenic analysis of the role of two conserved Asp residues located in transmembrane segments X and XI of rat VMAT type I reveals an important role of these two residues in catalysis. Replacement of Asp 431 with either Glu or Ser inhibits VMAT-mediated [H-3]serotonin transport. The mutated proteins are unimpaired in ligand recognition as measured with the high affinity ligand [H-3]reserpine or coupling to the proton electrochemical gradient as judged by its ability to accelerate [H-3]reserpine binding. Therefore, the Asp residue is needed as such in this position and even a conservative replacement with Glu generates a protein that can catalyze only partial reactions but cannot complete the transport cycle. Replacement of Asp 404 with either Ser or Cys inhibits all VMAT-mediated reactions measured. However, replacement with Glu generated a protein that catalyzed [H-3]serotonin transport with modified properties. Whereas the mutated protein binds [H-3]reserpine to normal levels and the pH optimum of this reaction is only slightly affected, the optimum pH for transport activity shifted to the acid side and became very sharp; in addition the sensitivity to the inhibitor tetrabenazine increased significantly in this mutated protein. The results point to the need of a carboxyl moiety in position 404. A slight change in its relative location or in the environment around it has a significant effect on the pK of group(s) involved in steps after ligand recognition and coupling to the first H+.	HEBREW UNIV JERUSALEM,ALEXANDER SILBERMAN INST LIFE SCI,IL-91904 JERUSALEM,ISRAEL	Hebrew University of Jerusalem			Schuldiner, Shimon/F-7628-2012	Schuldiner, Shimon/0000-0002-4874-6237	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS016708, R56NS016708] Funding Source: NIH RePORTER; NINDS NIH HHS [NS16708] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AMARA SG, 1993, ANNU REV NEUROSCI, V16, P73, DOI 10.1146/annurev.ne.16.030193.000445; ERICKSON JD, 1992, P NATL ACAD SCI USA, V89, P10993, DOI 10.1073/pnas.89.22.10993; FUERST TR, 1986, P NATL ACAD SCI USA, V83, P8122, DOI 10.1073/pnas.83.21.8122; GASNIER B, 1985, BIOCHEMISTRY-US, V24, P1239, DOI 10.1021/bi00326a028; HOWELL M, 1994, FEBS LETT, V338, P16, DOI 10.1016/0014-5793(94)80108-8; ISAMBERT MF, 1981, FEBS LETT, V136, P13, DOI 10.1016/0014-5793(81)81205-7; IWATA S, 1995, NATURE, V376, P660, DOI 10.1038/376660a0; JOHNSON RG, 1988, PHYSIOL REV, V68, P232, DOI 10.1152/physrev.1988.68.1.232; KANNER BI, 1987, CRIT REV BIOCHEM MOL, V22, P1, DOI 10.3109/10409238709082546; KITAYAMA S, 1992, P NATL ACAD SCI USA, V89, P7782, DOI 10.1073/pnas.89.16.7782; LANYI JK, 1992, BIOCHIM BIOPHYS ACTA, V1099, P102, DOI 10.1016/0167-4838(92)90458-P; LANYI JK, 1993, BIOCHIM BIOPHYS ACTA, V1183, P241, DOI 10.1016/0005-2728(93)90226-6; LIU YJ, 1992, CELL, V70, P539, DOI 10.1016/0092-8674(92)90425-C; LIU YJ, 1994, J CELL BIOL, V127, P1419, DOI 10.1083/jcb.127.5.1419; MERICKEL A, 1995, J BIOL CHEM, V270, P25798, DOI 10.1074/jbc.270.43.25798; NIRENBERG M, 1995, IN PRESS P NATL ACAD; NJUS D, 1986, BIOCHIM BIOPHYS ACTA, V853, P237, DOI 10.1016/0304-4173(87)90003-6; OKAMURA MY, 1992, ANNU REV BIOCHEM, V61, P861; PETER D, 1993, GENOMICS, V18, P720, DOI 10.1016/S0888-7543(05)80383-0; PETER D, 1994, J BIOL CHEM, V269, P7231; PETER D, 1995, IN PRESS J NEUROSCI; RUDNICK G, 1990, BIOCHEMISTRY-US, V29, P603, DOI 10.1021/bi00455a002; RUDNICK G, 1989, J BIOL CHEM, V264, P14865; SCHERMAN D, 1984, MOL PHARMACOL, V25, P113; SCHERMAN D, 1981, EUR J BIOCHEM, V116, P535, DOI 10.1111/j.1432-1033.1981.tb05369.x; SCHULDINER S, 1978, P NATL ACAD SCI USA, V75, P3713, DOI 10.1073/pnas.75.8.3713; SCHULDINER S, 1994, J NEUROCHEM, V62, P2067; SCHULDINER S, 1995, PHYSIOL REV, V75, P369, DOI 10.1152/physrev.1995.75.2.369; SHIRVAN A, 1994, FEBS LETT, V356, P145, DOI 10.1016/0014-5793(94)01252-0; STRADER CD, 1988, J BIOL CHEM, V263, P10267; STRADER CD, 1987, P NATL ACAD SCI USA, V84, P4384, DOI 10.1073/pnas.84.13.4384; SUCHI R, 1992, BIOCHEMISTRY-US, V31, P12500, DOI 10.1021/bi00164a029; SUCHI R, 1991, BIOCHEMISTRY-US, V30, P6490, DOI 10.1021/bi00240a020; TSUKIHARA T, 1995, SCIENCE, V269, P1069, DOI 10.1126/science.7652554; WEAVER JA, 1982, EUR J PHARMACOL, V80, P437, DOI 10.1016/0014-2999(82)90093-0; WEIHE E, 1994, J MOL NEUROSCI, V5, P149, DOI 10.1007/BF02736730	36	41	43	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 31	1996	271	22					13048	13054		10.1074/jbc.271.22.13048	http://dx.doi.org/10.1074/jbc.271.22.13048			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UN474	8662678	hybrid			2022-12-25	WOS:A1996UN47400057
J	Wright, LS; Bertics, PJ; Siegel, FL				Wright, LS; Bertics, PJ; Siegel, FL			Calmodulin N-methyltransferase - Kinetics, mechanism, and inhibitors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENOSYL-L-METHIONINE; DEPENDENT ENZYMES; CELL-GROWTH; NAD KINASE; RAT-BRAIN; PROTEIN; BINDING; PHOSPHODIESTERASE; METHYLATION; DNA	The present study was undertaken to determine kinetic and inhibition parameters and the mechanism of S-adenosyl-L-methionine:calmodulin-L-lysine N-6-methyl-transferase (EC 2.1.1.60, CLNMT), an enzyme for which calmodulin is a substrate. Partially purified CLNMT isolated from rat testes had a V-max of 540 pmol/min/mg and K-m values for mushroom demethylcalmodulin and S-adenosyl-L-methionine of 230 nM and 2.0 mu M, respectively. Kinetic analysis indicated a complex Bi Bi sequential kinetic mechanism for CLNMT where S-adenosyl-L-methionine binds initially and is followed by demethylcalmodulin binding. When the effects of 20 different compounds that are either inhibitors of calmodulin-specific or methylation-specific functions were examined, CLNMT displayed a pattern of inhibition which differs from that seen with calmodulin-activated enzymes. The product of calmodulin methylation, fully trimethylated calmodulin, and nonmethylatable VU-3 calmodulin acted as competitive inhibitors of CLNMT, with K-i values of 310 and 400 nM, respectively. Of the 13 compounds tested, which are inhibitors of calmodulin-dependent cyclic nucleotide phosphodiesterase, only the calmodulin-binding domain from Ca2+/calmodulin-dependent kinase II, melittin, and calmidazolium were effective inhibitors of CLNMT and each exhibited a complex pattern of inhibition with K-is values of 21, 50, and 65 nM, respectively. The only potent methylation-specific inhibitor was S-adenosyl-L-homocysteine, which also displayed a complex pattern of inhibition.	UNIV WISCONSIN,SCH MED,DEPT PEDIAT,MADISON,WI 53705; UNIV WISCONSIN,SCH MED,DEPT BIOMOL CHEM,MADISON,WI 53705; UNIV WISCONSIN,SCH MED,WAISMAN CTR,MADISON,WI 53705	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison					NICHD NIH HHS [HD03352] Funding Source: Medline; NINDS NIH HHS [NS24669] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [P30HD003352] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS024669] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BACHS O, 1992, BIOCHIM BIOPHYS ACTA, V1113, P259, DOI 10.1016/0304-4157(92)90041-8; BARBES C, 1990, FEMS MICROBIOL LETT, V69, P239; BARBOSA E, 1978, J BIOL CHEM, V253, P7698; BARNETTE MS, 1983, BIOCHEM PHARMACOL, V32, P2929, DOI 10.1016/0006-2952(83)90398-2; BERGER SJ, 1987, EXP CELL RES, V169, P149, DOI 10.1016/0014-4827(87)90233-3; BORCHARDT RT, 1979, TRANSMETHYLATION, P197; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Cleland W W, 1979, Methods Enzymol, V63, P103; COX R, 1985, BIOCHEM INT, V10, P63; DELORENZO RJ, 1982, FED PROC, V41, P2265; EPEL D, 1981, CELL, V23, P543, DOI 10.1016/0092-8674(81)90150-1; GALLIEN CL, 1984, EXP CELL RES, V155, P397, DOI 10.1016/0014-4827(84)90200-3; GIETZEN K, 1983, BIOCHIM BIOPHYS ACTA, V736, P109, DOI 10.1016/0005-2736(83)90175-X; GIETZEN K, 1982, BIOCHEM J, V207, P541, DOI 10.1042/bj2070541; GIETZEN K, 1980, BIOCHEM BIOPH RES CO, V94, P674, DOI 10.1016/0006-291X(80)91285-1; GRECO WR, 1982, COMPUT BIOMED RES, V15, P39, DOI 10.1016/0010-4809(82)90051-9; GREGORI L, 1985, J BIOL CHEM, V260, P5232; GUERINI D, 1984, J BIOL CHEM, V259, P5172; HAN CH, 1993, BIOCHEMISTRY-US, V32, P13974, DOI 10.1021/bi00213a030; HEGEMANN L, 1991, EUR J PHARM-MOLEC PH, V207, P17, DOI 10.1016/S0922-4106(05)80032-X; HIDAKA H, 1985, CALMODULIN ANTAGONIS, P13; JOHNSON BA, 1993, NEUROCHEM RES, V18, P87, DOI 10.1007/BF00966926; JOYAL JL, 1994, J BIOL CHEM, V269, P30039; KATOH N, 1982, BIOCHEM J, V202, P217, DOI 10.1042/bj2020217; KLEE CB, 1982, ADV PROTEIN CHEM, V35, P213, DOI 10.1016/S0065-3233(08)60470-2; KUZNICKI J, 1981, FEBS LETT, V130, P141, DOI 10.1016/0014-5793(81)80683-7; LEUNG PC, 1984, J BIOL CHEM, V259, P2742; LEVIN RM, 1976, MOL PHARMACOL, V12, P581; LUTHRA MG, 1982, BIOCHIM BIOPHYS ACTA, V692, P271, DOI 10.1016/0005-2736(82)90531-4; MAVRI J, 1994, PROTEINS, V18, P381, DOI 10.1002/prot.340180408; MAZZEI GJ, 1984, BIOCHEM PHARMACOL, V33, P125, DOI 10.1016/0006-2952(84)90379-4; MEANS AR, 1994, FEBS LETT, V347, P1, DOI 10.1016/0014-5793(94)00492-7; MORINO H, 1987, J NEUROCHEM, V48, P1201, DOI 10.1111/j.1471-4159.1987.tb05647.x; MURTAUGH TJ, 1986, J NEUROCHEM, V47, P164; NEIL SMA, 1993, BRIT J DERMATOL, V128, P143; NEWTON DL, 1984, J BIOL CHEM, V259, P4419; OH SH, 1990, PLANT PHYSIOL, V93, P880, DOI 10.1104/pp.93.3.880; OH SH, 1992, ARCH BIOCHEM BIOPHYS, V297, P28, DOI 10.1016/0003-9861(92)90636-B; OH SH, 1992, THESIS U TENNESSEE K; PAYNE ME, 1988, J BIOL CHEM, V263, P7190; PECH LL, 1994, BBA-GEN SUBJECTS, V1199, P183, DOI 10.1016/0304-4165(94)90114-7; PFEIFER GP, 1983, BIOCHIM BIOPHYS ACTA, V740, P323, DOI 10.1016/0167-4781(83)90141-0; PROZIALECK WC, 1983, ANNU REP MED CHEM, V18, P203; QUADRONI M, 1994, J BIOL CHEM, V269, P16116; RASMUSSEN C, 1993, J BIOL CHEM, V268, P23788; RASMUSSEN CD, 1989, TRENDS NEUROSCI, V12, P433, DOI 10.1016/0166-2236(89)90092-1; RAWAL N, 1994, BIOCHEM J, V300, P483, DOI 10.1042/bj3000483; REICH NO, 1991, BIOCHEMISTRY-US, V30, P2933, DOI 10.1021/bi00225a029; REID DG, 1990, J BIOL CHEM, V265, P9744; ROBERTS DM, 1986, J BIOL CHEM, V261, P1491; ROBERTS DM, 1985, BIOCHEMISTRY-US, V24, P5090, DOI 10.1021/bi00340a020; ROBERTS DM, 1992, ANNU REV PLANT PHYS, V43, P375, DOI 10.1146/annurev.pp.43.060192.002111; ROBERTS DM, 1993, P NATL ACAD SCI USA, V89, P8394; ROUFOGALIS BD, 1983, CAN J BIOCHEM CELL B, V61, P927, DOI 10.1139/o83-118; ROWE PM, 1986, J BIOL CHEM, V261, P7060; ROWE PM, 1983, ANAL BIOCHEM, V133, P394, DOI 10.1016/0003-2697(83)90100-8; ROWLANDS MG, 1990, BIOCHEM PHARMACOL, V40, P283, DOI 10.1016/0006-2952(90)90689-I; SANO H, 1983, EUR J BIOCHEM, V135, P181, DOI 10.1111/j.1432-1033.1983.tb07635.x; SANO H, 1980, EUR J BIOCHEM, V105, P471, DOI 10.1111/j.1432-1033.1980.tb04522.x; SAVILLE MK, 1994, BIOCHEM J, V299, P863, DOI 10.1042/bj2990863; SCHAEFFER P, 1987, BIOCHEM PHARMACOL, V36, P1989, DOI 10.1016/0006-2952(87)90498-9; Segel I.H., 1975, ENZYME KINETICS; SHI YQ, 1992, J BIOL CHEM, V267, P9547; Siegel F. L., 1990, PROTEIN METHYLATION, P33; SIMMS SA, 1991, J BIOL CHEM, V266, P12741; SONG QS, 1994, MOL CELL ENDOCRINOL, V99, P1; VOLKER C, 1991, J BIOL CHEM, V266, P21515; WEISS B, 1980, CALMODULIN CELL FUNC, P319; WRIGHT LS, 1993, PROTEIN EXPRES PURIF, V4, P417, DOI 10.1006/prep.1993.1055; WRIGHT LS, 1991, BIOCHIM BIOPHYS ACTA, V1079, P174, DOI 10.1016/0167-4838(91)90123-H; YEE WC, 1989, BIOCHEM BIOPH RES CO, V162, P483, DOI 10.1016/0006-291X(89)92023-8; ZHANG MJ, 1994, J BIOL CHEM, V269, P5099; ZIMMER M, 1987, EUR J BIOCHEM, V164, P411, DOI 10.1111/j.1432-1033.1987.tb11073.x	73	10	10	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 31	1996	271	22					12737	12743		10.1074/jbc.271.22.12737	http://dx.doi.org/10.1074/jbc.271.22.12737			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UN474	8662690	hybrid			2022-12-25	WOS:A1996UN47400009
J	Bai, RL; Pei, XF; Boye, O; Getahun, Z; Grover, S; Bekisz, J; Nguyen, NY; Brossi, A; Hamel, E				Bai, RL; Pei, XF; Boye, O; Getahun, Z; Grover, S; Bekisz, J; Nguyen, NY; Brossi, A; Hamel, E			Identification of cysteine 354 of beta-tubulin as part of the binding site for the A ring of colchicine	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							2,4-DICHLOROBENZYL THIOCYANATE; ANTIMITOTIC AGENT; TAXOL; PROTEIN; CHROMATOGRAPHY; CONFORMATIONS; SEPARATION; MUTANTS; NMR	The colchicine analog 3-chloroacetyl-3-demethylthiocolchicine (3CTC) is a competitive inhibitor of colchicine binding to tubulin, binds to tubulin at 37 degrees C, but not at 0 degrees C, and covalently reacts with beta-tubulin at 37 degrees C, but not at 0 degrees C, in a reaction inhibited by colchicine site drugs. The approximate intramolecular distance be tween the oxygen at position C-3 in 3CTC and the chlorine atom of the 3-chloroacetyl group is 3 Angstrom. Using decylagarose chromatography, we purified beta-tubulin that had reacted with 3-(chloromethyl-[C-14]carbonyl)-3-demethylthiocolchicine ([C-14]3CTC). This beta-tubulin was digested with formic acid, cyanogen bromide, endoproteinase Glu-C, or endoproteinase Lys C, and the radiolabeled peptide(s) were isolated. The sequences of these peptides indicated that as much as 90% of the covalent reaction between the [C-14]3CTC and beta-tubulin occurred at cysteine 354. This finding indicates that the C-3 oxygen atom of colchicinoids is within 3 Angstrom of the sulfur atom of the Cys-354 residue, suggests that the colchicine A ring lies between Cys-354 and Cys-239, based on the known 9 Angstrom distance between these residues, and may indicate that the tropolone C ring lies between the peptide region containing Cys-239 and the amino-terminal beta-tubulin sequence, based on the labeling pattern observed following direct photoactivation of tubulin-bound colchicine.	NCI,MOLEC PHARMACOL LAB,DIV BASIC SCI,NIH,BETHESDA,MD 20892; NIDDK,STRUCT BIOL LAB,NIH,BETHESDA,MD 20892; GEORGETOWN UNIV,DEPT CHEM,WASHINGTON,DC 20057; US FDA,CTR BIOL EVALUAT & RES,FACIL BIOTECHNOL RESOURCES,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); Georgetown University; US Food & Drug Administration (FDA)								ABRAHAM I, 1986, P NATL ACAD SCI USA, V83, P6839, DOI 10.1073/pnas.83.18.6839; BAI RL, 1989, BIOCHIM BIOPHYS ACTA, V994, P12, DOI 10.1016/0167-4838(89)90056-3; BAI RL, 1989, BIOCHEMISTRY-US, V28, P5606, DOI 10.1021/bi00439a040; BIELLMANN JF, 1976, EUR J BIOCHEM, V63, P477, DOI 10.1111/j.1432-1033.1976.tb10250.x; BOYE O, 1991, MED CHEM RES, V1, P142; BOYE O, 1992, J LABELLED COMPOUNDS, V33, P293; CABRAL F, 1980, CELL, V20, P29, DOI 10.1016/0092-8674(80)90231-7; DUBOIS J, 1993, TETRAHEDRON, V49, P6533, DOI 10.1016/S0040-4020(01)81822-6; FLOYD LJ, 1989, BIOCHEMISTRY-US, V28, P8515, DOI 10.1021/bi00447a037; GROSS E, 1961, J AM CHEM SOC, V83, P1510, DOI 10.1021/ja01467a052; GROVER S, 1992, BIOCHEM BIOPH RES CO, V187, P1350, DOI 10.1016/0006-291X(92)90451-P; GUERITTEVOEGELEIN F, 1990, ACTA CRYSTALLOGR C, V46, P781, DOI 10.1107/S0108270189009376; HAMEL E, 1984, BIOCHEMISTRY-US, V23, P4173, DOI 10.1021/bi00313a026; HASTIE SB, 1991, PHARMACOL THERAPEUT, V51, P377, DOI 10.1016/0163-7258(91)90067-V; HEWICK RM, 1981, J BIOL CHEM, V256, P7990; KEATES RAB, 1981, P NATL ACAD SCI-BIOL, V78, P5638, DOI 10.1073/pnas.78.9.5638; KRAUHS E, 1981, P NATL ACAD SCI-BIOL, V78, P4156, DOI 10.1073/pnas.78.7.4156; Landon, 1977, Methods Enzymol, V47, P145; LESSINGER L, 1978, ACTA CRYSTALLOGR B, V34, P578, DOI 10.1107/S0567740878003568; LUDUENA RF, 1991, PHARMACOL THERAPEUT, V49, P133, DOI 10.1016/0163-7258(91)90027-J; MCCARTHY AD, 1982, FEBS LETT, V147, P256, DOI 10.1016/0014-5793(82)81054-5; NOGALES E, 1995, NATURE, V375, P424, DOI 10.1038/375424a0; RAO S, 1994, J BIOL CHEM, V269, P3132; RAO S, 1992, J NATL CANCER I, V84, P785, DOI 10.1093/jnci/84.10.785; RAO S, 1995, J BIOL CHEM, V270, P20235, DOI 10.1074/jbc.270.35.20235; SCHMITT H, 1976, J MOL BIOL, V102, P743, DOI 10.1016/0022-2836(76)90289-8; SCHMITT H, 1978, EXP CELL RES, V115, P408, DOI 10.1016/0014-4827(78)90295-1; SHEIRNEISS G, 1978, CELL, V15, P639, DOI 10.1016/0092-8674(78)90032-6; SHIVANNA BD, 1993, J BIOL CHEM, V268, P127; UPPULURI S, 1993, P NATL ACAD SCI USA, V90, P11598, DOI 10.1073/pnas.90.24.11598; VANDERVELDE DG, 1993, J AM CHEM SOC, V115, P11650, DOI 10.1021/ja00077a095; WEISENBERG RC, 1968, BIOCHEMISTRY-US, V7, P4466, DOI 10.1021/bi00852a043; WILKINSON JM, 1986, PRACTICAL PROTEIN CH, P122; WILLIAMS HJ, 1993, TETRAHEDRON, V49, P6545, DOI 10.1016/S0040-4020(01)81823-8; WILLIAMS RF, 1985, J BIOL CHEM, V260, P1379; WOLFF J, 1991, P NATL ACAD SCI USA, V88, P2820, DOI 10.1073/pnas.88.7.2820; ZIMMERMAN CL, 1977, ANAL BIOCHEM, V77, P569, DOI 10.1016/0003-2697(77)90276-7	37	90	98	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 24	1996	271	21					12639	12645		10.1074/jbc.271.21.12639	http://dx.doi.org/10.1074/jbc.271.21.12639			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UL660	8647876	hybrid			2022-12-25	WOS:A1996UL66000078
J	Li, SW; Resnicoff, M; Baserga, R				Li, SW; Resnicoff, M; Baserga, R			Effect of mutations at serines 1280-1283 on the mitogenic and transforming activities of the insulin-like growth factor I receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE KINASE-ACTIVITY; SIGNAL-TRANSDUCTION; IGF-1 RECEPTOR; EXPRESSION; ACTIVATION; CELLS; TRANSPHOSPHORYLATION; PHOSPHORYLATION; OVEREXPRESSION; FIBROBLASTS	The insulin-like growth factor I receptor (IGF-IR) controls the extent of cell proliferation in a variety of cell types by at least 3 different ways: it is mitogenic, it causes transformation, and it protects cells from apoptosis. Previous reports indicated that certain domains in the C terminus of the IGF-IR transmitted a transforming signal that is additional to and separate from the mitogenic signal. We have now mutated the four serine residues at 1280-1283 of the IGF-IR, and transfected the mutant receptor into R(-) cells. Cells expressing the mutant receptor are fully responsive to IGF-I-mediated mitogenesis, but are not transformed (no colony formation in soft agar). Several downstream signal transducers are not affected by the mutation, again suggesting a separate pathway for transformation. The mutant receptor can act as a dominant negative for growth, but cannot induce apoptosis in cells with endogenous wild-type receptors.	THOMAS JEFFERSON UNIV,KIMMEL CANC CTR,PHILADELPHIA,PA 19107	Jefferson University					NIA NIH HHS [AG00378] Funding Source: Medline	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ARGETSINGER LS, 1995, J BIOL CHEM, V270, P14685, DOI 10.1074/jbc.270.24.14685; ARTEAGA CL, 1992, BREAST CANCER RES TR, V22, P101, DOI 10.1007/BF01833338; BAKER J, 1993, CELL, V75, P73, DOI 10.1016/0092-8674(93)90680-O; BALLOTTI R, 1989, EMBO J, V8, P3303, DOI 10.1002/j.1460-2075.1989.tb08491.x; BASERGA R, 1995, CANCER RES, V55, P249; Burgaud JL, 1996, EXP CELL RES, V223, P412, DOI 10.1006/excr.1996.0096; BURGAUD JL, 1995, BIOCHEM BIOPH RES CO, V214, P475, DOI 10.1006/bbrc.1995.2311; BUSCHER D, 1995, MOL CELL BIOL, V15, P466; CAI H, 1992, MOL CELL BIOL, V12, P5329, DOI 10.1128/MCB.12.12.5329; CHANTRY A, 1995, J BIOL CHEM, V270, P3068; CHRISTOFORI G, 1994, NATURE, V369, P414, DOI 10.1038/369414a0; COOK SJ, 1993, EMBO J, V12, P3475, DOI 10.1002/j.1460-2075.1993.tb06022.x; COPPOLA D, 1994, MOL CELL BIOL, V14, P4588, DOI 10.1128/MCB.14.7.4588; DAMBROSIO C, 1995, CELL GROWTH DIFFER, V6, P557; DANGELIS T, 1995, J CELL PHYSL, V164, P214; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DAVID M, 1995, SCIENCE, V269, P1721, DOI 10.1126/science.7569900; FALCO JP, 1988, ONCOGENE, V2, P573; FARIA TN, 1994, J BIOL CHEM, V269, P13922; FRATTALI AL, 1993, J BIOL CHEM, V268, P7393; FU XY, 1993, CELL, V74, P1135, DOI 10.1016/0092-8674(93)90734-8; GRONBORG M, 1993, J BIOL CHEM, V268, P23435; Hongo A, 1996, ONCOGENE, V12, P1231; IHLE JN, 1994, TRENDS BIOCHEM SCI, V19, P222, DOI 10.1016/0968-0004(94)90026-4; KALEBIC T, 1994, CANCER RES, V54, P5531; KALEKO M, 1990, MOL CELL BIOL, V10, P464, DOI 10.1128/MCB.10.2.464; KATO H, 1993, J BIOL CHEM, V268, P2655; LAMMERS R, 1990, J BIOL CHEM, V265, P16886; LAMMERS R, 1989, EMBO J, V8, P1369, DOI 10.1002/j.1460-2075.1989.tb03517.x; LANGLOIS WJ, 1995, ENDOCRINOLOGY, V136, P1978, DOI 10.1210/en.136.5.1978; LEWIS RE, 1990, J BIOL CHEM, V265, P947; LI SW, 1994, J BIOL CHEM, V269, P32558; LIU DL, 1993, J VIROL, V67, P6835, DOI 10.1128/JVI.67.11.6835-6840.1993; LIU JP, 1993, CELL, V75, P59, DOI 10.1016/S0092-8674(05)80084-4; LONG L, 1995, CANCER RES, V55, P1006; MARRERO MB, 1995, NATURE, V375, P247, DOI 10.1038/375247a0; MCCUE JL, 1991, BRIT J SURG, V78, P921, DOI 10.1002/bjs.1800780808; MEDEMA RH, 1993, CRIT REV ONCOGENESIS, V4, P615; MIURA M, 1995, CANCER RES, V55, P663; MIURA M, 1995, J BIOL CHEM, V270, P22639, DOI 10.1074/jbc.270.38.22639; MORRIONE A, 1995, J VIROL, V69, P5300, DOI 10.1128/JVI.69.9.5300-5303.1995; MULLIGAN RC, 1980, SCIENCE, V209, P1422, DOI 10.1126/science.6251549; PIETRZKOWSKI Z, 1992, MOL CELL BIOL, V12, P3883, DOI 10.1128/MCB.12.9.3883; PIETRZKOWSKI Z, 1992, CELL GROWTH DIFFER, V3, P199; PRAGER D, 1994, P NATL ACAD SCI USA, V91, P2181, DOI 10.1073/pnas.91.6.2181; RESNICOFF M, 1994, CANCER RES, V54, P2218; RESNICOFF M, 1995, CANCER RES, V55, P3739; RESNICOFF M, 1995, CANCER RES, V55, P2463; ROGLER CE, 1994, J BIOL CHEM, V269, P13779; ROSE DW, 1994, P NATL ACAD SCI USA, V91, P797, DOI 10.1073/pnas.91.2.797; SADOWSKI HB, 1993, SCIENCE, V261, P1739, DOI 10.1126/science.8397445; SAKAUE M, 1995, MOL CELL BIOL, V15, P379, DOI 10.1128/MCB.15.1.379; SCHER CD, 1979, BIOCHIM BIOPHYS ACTA, V560, P217, DOI 10.1016/0304-419X(79)90020-9; SELL C, 1994, MOL CELL BIOL, V14, P3604, DOI 10.1128/MCB.14.6.3604; SELL C, 1993, P NATL ACAD SCI USA, V90, P11217, DOI 10.1073/pnas.90.23.11217; SHAPIRO DN, 1994, J CLIN INVEST, V94, P1235, DOI 10.1172/JCI117441; SHUAL K, 1993, NATURE, V366, P580, DOI 10.1038/366580a0; SILVENNOINEN O, 1993, SCIENCE, V261, P1736, DOI 10.1126/science.8378775; STILES CD, 1979, P NATL ACAD SCI USA, V76, P1279, DOI 10.1073/pnas.76.3.1279; SURMACZ E, 1995, EXP CELL RES, V218, P370, DOI 10.1006/excr.1995.1168; TAOUIS M, 1994, J BIOL CHEM, V269, P27762; TARTAREDECKERT S, 1995, J BIOL CHEM, V270, P23456, DOI 10.1074/jbc.270.40.23456; TAVARE JM, 1993, BIOCHIM BIOPHYS ACTA, V1178, P21, DOI 10.1016/0167-4889(93)90106-Y; TROJAN J, 1993, SCIENCE, V259, P94, DOI 10.1126/science.8418502; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; ULLRICH A, 1986, EMBO J, V5, P503; WATERS SB, 1993, J BIOL CHEM, V268, P22231; WHITE MF, 1994, J BIOL CHEM, V269, P1; YAMASAKI H, 1992, J BIOL CHEM, V267, P20953; YAMAUCHI K, 1994, MOL CELL BIOL, V14, P4427, DOI 10.1128/MCB.14.7.4427	70	68	68	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 24	1996	271	21					12254	12260		10.1074/jbc.271.21.12254	http://dx.doi.org/10.1074/jbc.271.21.12254			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UL660	8647823	hybrid			2022-12-25	WOS:A1996UL66000025
J	Shin, EK; Tevosian, SG; Yee, AS				Shin, EK; Tevosian, SG; Yee, AS			The N-terminal region of E2F-1 is required for transcriptional activation of a new class of target promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETINOBLASTOMA GENE-PRODUCT; THYMIDINE KINASE GENE; HERPES-SIMPLEX VIRUS; BINDING PROTEIN; ADENOVIRUS; EXPRESSION; RB; TRANSACTIVATION; COMPLEX; P107	Because of its expression in numerous cells, the herpes simplex virus thymidine kinase promoter (HSV-TK) is one of the best characterized promoters. Using the HSV-TK promoter as a model system, we have defined a new mode of E2F-1 transcriptional activation which utilizes the N-terminal region of E2F-1, We demonstrate that E2F-1 strongly activated HSV-TK, but in the absence of consensus E2F DNA elements, Nonetheless, E2F-1 could bind to GC-rich elements, which were conclusively identified in classic studies of HSV-TK as SP-1 sites. Second, the transcriptional activation of HSV-TK required the entire E2F-1 protein, including the N-terminal 89 amino acids, In contrast, the N-terminal 89 amino acids of E2F-1 were dispensable for transcriptional activation through consensus E2F sites, Third, we demonstrated that S phase entry is not sufficient for activation of HSV-TK by E2F-1, while the activation through consensus E2F sites is strictly linked to the cell cycle. Taken together, the activation of HSV-TK by E2F-1 proceeds by a different mechanism directed in part through the N-terminal region of E2F-1 and may be uncoupled from the known cell cycle regulatory role.	TUFTS UNIV, SCH MED, DEPT BIOCHEM, BOSTON, MA 02111 USA	Tufts University					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK034928] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044634] Funding Source: NIH RePORTER; NIDDK NIH HHS [P30 DK-34928] Funding Source: Medline; NIGMS NIH HHS [GM44634] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Azizkhan Jane C., 1993, Critical Reviews in Eukaryotic Gene Expression, V3, P229; BAGCHI S, 1990, CELL, V62, P659, DOI 10.1016/0092-8674(90)90112-R; BRIGGS MR, 1986, SCIENCE, V234, P47, DOI 10.1126/science.3529394; CHELLAPPAN S, 1992, P NATL ACAD SCI USA, V89, P4549, DOI 10.1073/pnas.89.10.4549; COBRINIK D, 1993, GENE DEV, V7, P2392, DOI 10.1101/gad.7.12a.2392; COOK WJ, 1995, MOL CELL BIOL, V15, P4998; CRESS WD, 1993, MOL CELL BIOL, V13, P6314, DOI 10.1128/MCB.13.10.6314; DATTA PK, 1995, MOL CELL BIOL, V15, P5444; DEGREGORI J, 1995, MOL CELL BIOL, V15, P4215; DYNAN WS, 1983, CELL, V35, P79, DOI 10.1016/0092-8674(83)90210-6; DYNLACHT BD, 1994, GENE DEV, V8, P1772, DOI 10.1101/gad.8.15.1772; FELDMAN LT, 1982, P NATL ACAD SCI-BIOL, V79, P4952, DOI 10.1073/pnas.79.16.4952; FLEMINGTON EK, 1993, P NATL ACAD SCI USA, V90, P6914, DOI 10.1073/pnas.90.15.6914; GENETTA T, 1994, MOL CELL BIOL, V14, P6153, DOI 10.1128/MCB.14.9.6153; HELIN K, 1992, CELL, V70, P337, DOI 10.1016/0092-8674(92)90107-N; HELIN K, 1993, MOL CELL BIOL, V13, P6501, DOI 10.1128/MCB.13.10.6501; Helin Kristian, 1993, Trends in Cell Biology, V3, P43, DOI 10.1016/0962-8924(93)90150-Y; HUANG S, 1992, DNA CELL BIOL, V11, P539, DOI 10.1089/dna.1992.11.539; IMBALZANO AN, 1991, J VIROL, V65, P565, DOI 10.1128/JVI.65.2.565-574.1991; IMPERIALE MJ, 1983, CELL, V35, P127, DOI 10.1016/0092-8674(83)90215-5; JOHNSON DG, 1994, P NATL ACAD SCI USA, V91, P12823, DOI 10.1073/pnas.91.26.12823; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; JONES KA, 1985, CELL, V42, P559, DOI 10.1016/0092-8674(85)90113-8; KADONAGA JT, 1987, CELL, V51, P1079, DOI 10.1016/0092-8674(87)90594-0; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; Karlseder J, 1996, MOL CELL BIOL, V16, P1659; KIM SJ, 1992, MOL CELL BIOL, V12, P2455, DOI 10.1128/MCB.12.6.2455; KREK W, 1994, CELL, V78, P161, DOI 10.1016/0092-8674(94)90582-7; LATHANGUE NB, 1994, TRENDS BIOCHEM SCI, V19, P108, DOI 10.1016/0968-0004(94)90202-X; LEES E, 1992, GENE DEV, V6, P1874, DOI 10.1101/gad.6.10.1874; Lin SY, 1996, MOL CELL BIOL, V16, P1668; MCKNIGHT SL, 1982, CELL, V31, P355, DOI 10.1016/0092-8674(82)90129-5; NEVINS JR, 1992, SCIENCE, V258, P424; QIN XQ, 1994, P NATL ACAD SCI USA, V91, P10918, DOI 10.1073/pnas.91.23.10918; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Schilling Lynda J., 1994, Critical Reviews in Eukaryotic Gene Expression, V4, P19; SCHWARZ JK, 1993, EMBO J, V12, P1013, DOI 10.1002/j.1460-2075.1993.tb05742.x; SHAN B, 1994, MOL CELL BIOL, V14, P8166, DOI 10.1128/MCB.14.12.8166; SHIN EK, 1995, MOL CELL BIOL, V15, P2252; SHIRODKAR S, 1992, CELL, V68, P157, DOI 10.1016/0092-8674(92)90214-W; SLANSKY J, 1995, CURR TOP MICROBIOL, V208, P1; SUNG NS, 1994, MOL CELL BIOL, V14, P7144, DOI 10.1128/MCB.14.11.7144; UDVADIA AJ, 1995, P NATL ACAD SCI USA, V92, P3953, DOI 10.1073/pnas.92.9.3953; UDVADIA AJ, 1993, P NATL ACAD SCI USA, V90, P3265, DOI 10.1073/pnas.90.8.3265; WEINTRAUB H, 1990, P NATL ACAD SCI USA, V87, P5623, DOI 10.1073/pnas.87.15.5623; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602; XU M, 1994, MOL CELL BIOL, V14, P8420, DOI 10.1128/MCB.14.12.8420; YEE AS, 1987, EMBO J, V6, P2061, DOI 10.1002/j.1460-2075.1987.tb02471.x; YEE AS, 1989, MOL CELL BIOL, V9, P578, DOI 10.1128/MCB.9.2.578	49	29	29	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 24	1996	271	21					12261	12268		10.1074/jbc.271.21.12261	http://dx.doi.org/10.1074/jbc.271.21.12261			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UL660	8647824	hybrid			2022-12-25	WOS:A1996UL66000026
J	Slominski, A; Baker, J; Rosano, TG; Guisti, LW; Ermak, G; Grande, M; Gaudet, SJ				Slominski, A; Baker, J; Rosano, TG; Guisti, LW; Ermak, G; Grande, M; Gaudet, SJ			Metabolism of serotonin to N-acetylserotonin, melatonin, and 5-methoxytryptamine in hamster skin culture	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYDROXYINDOLE-O-METHYLTRANSFERASE; XENOPUS-LAEVIS; ACETYLTRANSFERASE; DEACETYLATION; MELANOGENESIS; TRACT; CELLS	Biotransformation of [H-3]serotonin by cultured hamster skin to H-3-metabolites corresponding to N-acetylserotonin (NAS), melatonin, and 5-methoxytryptamine (5-MT) was demonstrated. This process was time-dependent, with the highest production of radioactive NAS and melatonin metabolites after 3 and 5 h of incubation followed by a decrease in the rate of metabolite release into the media. Conversely, the formation of radioactive metabolite corresponding to 5-MT increased gradually during skin culture, reaching the highest level after 24 h of incubation. The production of H-3-metabolites, corresponding to NAS, melatonin, and 5-MT, was stimulated by forskolin with a maximum effect of forskolin at 10 mu M concentration. The gas chromatographic/mass spectroscopy analysis of the fraction eluting at the retention time of NAS standard material showed that it contained NAS, further confirming production and release of NAS into the media by hamster skin. Therefore, we conclude that mammalian skin can acetylate serotonin to NAS and postulate that the NAS is further metabolized by the skin to form melatonin which is subsequently transformed to 5-MT.	ALBANY MED COLL, DEPT PATHOL & LAB MED, ALBANY, NY 12208 USA; MERRIMACK COLL, DEPT BIOL, BOSTON, MA 01845 USA	Albany Medical College; Merrimack College				Slominski, Andrzej/0000-0001-8963-3995				BINKLEY S, 1975, ENDOCRINOLOGY, V96, P848, DOI 10.1210/endo-96-4-848; BORJIGIN J, 1995, NATURE, V378, P783, DOI 10.1038/378783a0; Bos JD, 1990, SKIN IMMUNE SYSTEM S; BRAMMER GL, 1994, LIFE SCI, V55, P775, DOI 10.1016/0024-3205(94)00561-3; CAHILL GM, 1989, P NATL ACAD SCI USA, V86, P1098, DOI 10.1073/pnas.86.3.1098; CHAMPION RH, 1990, TXB DERMATOLOGY; COON SL, 1995, SCIENCE, V270, P1681, DOI 10.1126/science.270.5242.1681; FINOCCHIARO LME, 1991, BIOCHEM J, V280, P727, DOI 10.1042/bj2800727; GAUDET SJ, 1993, J INVEST DERMATOL, V101, P660, DOI 10.1111/1523-1747.ep12371672; Gilbert Scott F., 1988, DEV BIOL; GRACE MS, 1991, BRAIN RES, V559, P56, DOI 10.1016/0006-8993(91)90286-5; GRACE MS, 1993, J NEUROCHEM, V60, P990, DOI 10.1111/j.1471-4159.1993.tb03246.x; Hadley M.E., 1988, ENDOCRINOLOGY; HUETHER G, 1992, LIFE SCI, V51, P945, DOI 10.1016/0024-3205(92)90402-B; KLEIN DC, 1979, BRAIN RES, V174, P245, DOI 10.1016/0006-8993(79)90848-5; KOPIN IJ, 1961, J BIOL CHEM, V236, P3072; KVEDER S, 1961, J BIOL CHEM, V236, P3214; LOGAN A, 1980, J INVEST DERMATOL, V74, P47, DOI 10.1111/1523-1747.ep12514608; MILSTONE LM, 1988, ANN NY ACAD SCI, V548, P1, DOI 10.1111/j.1749-6632.1988.tb18787.x; NAMBOODIRI MAA, 1987, METHOD ENZYMOL, V142, P583; REITER RJ, 1991, ENDOCR REV, V12, P151, DOI 10.1210/edrv-12-2-151; ROGAWSKI MA, 1979, J NEUROCHEM, V32, P1219, DOI 10.1111/j.1471-4159.1979.tb11049.x; SLOMINSKI A, 1993, J THEOR BIOL, V164, P103, DOI 10.1006/jtbi.1993.1142; Slominski A, 1994, Exp Dermatol, V3, P45, DOI 10.1111/j.1600-0625.1994.tb00265.x; SLOMINSKI A, 1993, MOL CELL ENDOCRINOL, V93, pC1, DOI 10.1016/0303-7207(93)90131-3; SLOMINSKI A, 1995, FEBS LETT, V374, P113, DOI 10.1016/0014-5793(95)01090-2; SLOMINSKI A, 1993, EXP CELL RES, V206, P189, DOI 10.1006/excr.1993.1137; SLOMINSKI A, 1988, J CELL SCI, V89, P287; SUGDEN D, 1987, METHOD ENZYMOL, V142, P590; Yu H. L., 2020, ARXIV PREPRINT ARXIV	30	101	102	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 24	1996	271	21					12281	12286		10.1074/jbc.271.21.12281	http://dx.doi.org/10.1074/jbc.271.21.12281			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UL660	8647827	hybrid			2022-12-25	WOS:A1996UL66000029
J	Communi, D; Lecocq, R; Erneux, C				Communi, D; Lecocq, R; Erneux, C			Arginine 343 and 350 are two active site residues involved in substrate binding by human type I D-myo-inositol 1,4,5-trisphosphate 5-phosphatase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							6-PHOSPHOFRUCTO-2-KINASE FRUCTOSE-2,6-BISPHOSPHATASE; HUMAN-PLATELETS; PROTEIN-KINASE; POLYPHOSPHATE-5-PHOSPHATASE; TRISPHOSPHATE; METABOLISM; LIVER; 5'-PARA-FLUOROSULFONYLBENZOYLADENOSINE; IDENTIFICATION; PHOSPHATES	The crucial role of two reactive arginyl residues within the substrate binding domain of human Type I D-myo-inositol 1,4,5-trisphosphate (Ins(1,4,5)P-3) 5-phosphatase has been investigated by chemical modification and site-directed mutagenesis. Chemical modification of the enzyme by phenylglyoxal is accompanied by irreversible inhibition of enzymic activity. Our studies demonstrate that phenylglyoxal forms an enzyme inhibitor complex and that the modification reaction is prevented in the presence of either Ins(1,4,5)P-3, D-myo-inositol 1,3,4,5-tetrakisphosphate (Ins(1,3,4,5)P-4) or 2,3-bisphosphoglycerate (2,3-BPG). Direct [H-3]Ins(1,4,5)P-3 binding to the covalently modified enzyme is dramatically reduced. The stoichiometry of labeling with C-14-labeled phenylglyoxal is shown to be 2.1 mol of phenylglyoxal incorporated per mol of enzyme. A single [C-14]phenylglyoxal-modified peptide is isolated following a-chymotrypsin proteolysis of the radiolabeled Ins(1,4,5)P-3 5-phosphatase and reverse-phase high performance liquid chromatography (HPLC). The peptide sequence (i.e. M-N-T-R-C-P-A-W-C-D-R-I-L) corresponds to amino acids 340-352 of Ins(1,4,5)P-3 5-phosphatase. An estimate of the radioactivity of the different phenylthiohydantoin amino acid derivatives shows the modified amino acids to be Arg-343 and Arg-350. Furthermore, two mutant enzymes were obtained by site directed mutagenesis of the two arginyl residues to alanine, and both mutant enzymes have identical UV circular dichroism (CD) spectra. The two mutants (i.e. R343A and R350A) show increased K-m values for Ins(1,4,5)P-3 (10- and 15-fold, respectively) resulting in a dramatic loss in enzymic activity. In conclusion, we have directly identified two reactive arginyl residues as part of the active site of Ins(1,4,5)P-3 5-phosphatase. These results point out the crucial role for substrate recognition of a 10 amino acids-long sequence segment which is conserved among the primary structure of inositol and phosphatidylinositol polyphosphate 5-phosphatases.			Communi, D (corresponding author), UNIV BRUSSELS,INST INTERDISCIPLINARY RES,CAMPUS ERASME,BLDG C,RT LENNIK 808,B-1070 BRUSSELS,BELGIUM.							ATTREE O, 1992, NATURE, V358, P239, DOI 10.1038/358239a0; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BERRIDGE MJ, 1984, NATURE, V312, P315, DOI 10.1038/312315a0; COMMUNI D, 1995, BIOCHEM J, V310, P109, DOI 10.1042/bj3100109; CONNOLLY TM, 1987, J BIOL CHEM, V262, P2146; CONNOLLY TM, 1985, J BIOL CHEM, V260, P7868; CULLEN PJ, 1995, NATURE, V376, P527, DOI 10.1038/376527a0; DESMEDT F, 1994, FEBS LETT, V347, P69, DOI 10.1016/0014-5793(94)00509-5; ERNEUX C, 1986, BIOCHEM BIOPH RES CO, V143, P351; EVANS PR, 1979, NATURE, V279, P500, DOI 10.1038/279500a0; FOSTER WB, 1981, J BIOL CHEM, V256, P882; FUKUDA M, 1994, J BIOL CHEM, V269, P29206; GIBSON TJ, 1994, TRENDS BIOCHEM SCI, V19, P349, DOI 10.1016/0968-0004(94)90108-2; HAJDU J, 1987, EMBO J, V6, P539, DOI 10.1002/j.1460-2075.1987.tb04786.x; HANSEN CA, 1986, J BIOL CHEM, V261, P8100; HIXSON CS, 1979, J BIOL CHEM, V254, P7509; Irvine Robin F., 1992, Advances in Second Messenger and Phosphoprotein Research, V26, P161; JACKSON SP, 1995, EMBO J, V14, P4490, DOI 10.1002/j.1460-2075.1995.tb00128.x; JEFFERSON AB, 1995, J BIOL CHEM, V270, P9370, DOI 10.1074/jbc.270.16.9370; KINCAID RL, 1988, METHOD ENZYMOL, V159, P627; LAXMINARAYAN KM, 1994, J BIOL CHEM, V269, P17305; LIN K, 1992, J BIOL CHEM, V267, P19163; MATZARIS M, 1994, J BIOL CHEM, V269, P3397; MITCHELL CA, 1989, J BIOL CHEM, V264, P8873; PAVELAVRANCIC M, 1994, J BIOL CHEM, V269, P14962; PETTERSON G, 1977, ANAL BIOCHEM, V83, P346; RIDER MH, 1992, EUR J BIOCHEM, V207, P967, DOI 10.1111/j.1432-1033.1992.tb17131.x; ROSKOSKI R, 1983, METHOD ENZYMOL, V99, P3; ROSS TS, 1991, J BIOL CHEM, V266, P20283; SHEARS SB, 1989, BIOCHEM J, V260, P313, DOI 10.1042/bj2600313; STEPHENS L, 1995, BIOCHEM SOC T, V23, P207, DOI 10.1042/bst0230207; STOREY DJ, 1984, NATURE, V312, P374, DOI 10.1038/312374a0; TAKAHASHI K, 1968, J BIOL CHEM, V243, P6171; VERJANS B, 1994, BIOCHEM J, V300, P85, DOI 10.1042/bj3000085; VERJANS B, 1992, EUR J BIOCHEM, V204, P1083, DOI 10.1111/j.1432-1033.1992.tb16732.x; WELLS TNC, 1994, BIOCHEMISTRY-US, V33, P5777, DOI 10.1021/bi00185a015; YAGISAWA H, 1994, J BIOL CHEM, V269, P20179; YAMAGATA K, 1993, J BIOL CHEM, V268, P20930; YU FX, 1992, J BIOL CHEM, V267, P14616; ZHANG XL, 1995, P NATL ACAD SCI USA, V92, P4853, DOI 10.1073/pnas.92.11.4853; ZHANG YP, 1993, BIOCHEM BIOPH RES CO, V190, P1080, DOI 10.1006/bbrc.1993.1159	42	34	34	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 17	1996	271	20					11676	11683		10.1074/jbc.271.20.11676	http://dx.doi.org/10.1074/jbc.271.20.11676			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UL250	8662625	hybrid			2022-12-25	WOS:A1996UL25000017
J	Jackson, JD; Petrykowska, H; Philipsen, S; Miller, W; Hardison, R				Jackson, JD; Petrykowska, H; Philipsen, S; Miller, W; Hardison, R			Role of DNA sequences outside the cores of DNase hypersensitive sites (HSs) in functions of the beta-globin locus control region - Domain opening and synergism between HS2 and HS3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOMINANT CONTROL REGION; HIGH-LEVEL EXPRESSION; HUMAN ERYTHROID-CELLS; TRANSGENIC MICE; MINIMAL REQUIREMENTS; CHROMATIN STRUCTURE; GENE-CLUSTER; ENHANCER; ORGANIZATION; CONSERVATION	The roles of each DNase hypersensitive site (HS), and the DNA sequences between them, in the activity of the locus control region of the mammalian beta-globin gene domain were examined by placing human and rabbit restriction fragments containing the cores of HS2, HS3, HS4, and HS5, along with varying amounts of flanking DNA, upstream of a hybrid epsilon-globin-luciferase reporter gene and testing for effects on expression both prior to and after integration into the chromosomes of K562 cells, a human erythroid cell line. Prior to integration, fragments containing HS2 enhanced expression to the greatest extent, and the modest enhancement by some fragments containing HS3 correlated with the presence of a well-conserved binding site for AP1/NFE2. The stronger effects of larger locus control region DNA fragments in clones of stably transfected cells indicates a role for sequences outside the HS cores after integration into the genome. The strong effect of a 1.9-kilobase Hin-dIII fragment containing HS3 after, but not prior to, integration argues for the presence of a chromatin domain opening activity. Use of a rabbit DNA fragment containing both HS2 and HS3 demonstrated a synergistic interaction between the two HSs when their natural context and spacing are preserved.	PENN STATE UNIV,DEPT BIOCHEM & MOLEC BIOL,UNIVERSITY PK,PA 16802; PENN STATE UNIV,DEPT COMP SCI & ENGN,UNIVERSITY PK,PA 16802; PENN STATE UNIV,CTR GENE REGULAT,UNIVERSITY PK,PA 16802; ERASMUS UNIV ROTTERDAM,DEPT CELL BIOL & GENET,MGC,3000 DR ROTTERDAM,NETHERLANDS	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Erasmus University Rotterdam			Hardison, Ross C/G-1142-2010	Hardison, Ross C/0000-0003-4084-7516	NIDDK NIH HHS [DK27635] Funding Source: Medline; NLM NIH HHS [LM05573, LM05110] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK027635] Funding Source: NIH RePORTER; NATIONAL LIBRARY OF MEDICINE [N01LM005573, R01LM005110] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NLM NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Library of Medicine (NLM)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL LIBRARY OF MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Library of Medicine (NLM))		Bungert J, 1995, GENE DEV, V9, P3083, DOI 10.1101/gad.9.24.3083; CAO SX, 1989, P NATL ACAD SCI USA, V86, P5306, DOI 10.1073/pnas.86.14.5306; CATERINA JJ, 1994, NUCLEIC ACIDS RES, V22, P1006, DOI 10.1093/nar/22.6.1006; CATERINA JJ, 1991, P NATL ACAD SCI USA, V88, P1626, DOI 10.1073/pnas.88.5.1626; CHUNG JH, 1993, CELL, V74, P505, DOI 10.1016/0092-8674(93)80052-G; COLLIS P, 1990, EMBO J, V9, P233, DOI 10.1002/j.1460-2075.1990.tb08100.x; ELLIS J, 1993, EMBO J, V12, P127, DOI 10.1002/j.1460-2075.1993.tb05638.x; Ellis J, 1996, EMBO J, V15, P562, DOI 10.1002/j.1460-2075.1996.tb00388.x; FORRESTER WC, 1986, P NATL ACAD SCI USA, V83, P1359, DOI 10.1073/pnas.83.5.1359; FORRESTER WC, 1990, GENE DEV, V4, P1637, DOI 10.1101/gad.4.10.1637; FRASER P, 1990, NUCLEIC ACIDS RES, V18, P3503, DOI 10.1093/nar/18.12.3503; FRASER P, 1993, GENE DEV, V7, P106, DOI 10.1101/gad.7.1.106; GROSVELD F, 1987, CELL, V51, P975, DOI 10.1016/0092-8674(87)90584-8; GROSVELD F, 1993, PHILOS T ROY SOC B, V339, P183, DOI 10.1098/rstb.1993.0015; HARDISON R, 1993, NUCLEIC ACIDS RES, V21, P1265, DOI 10.1093/nar/21.5.1265; HARDISON R, 1994, GENOMICS, V21, P344, DOI 10.1006/geno.1994.1275; HARDISON R, 1993, DNA SEQUENCE, V4, P163, DOI 10.3109/10425179309015629; HARDISON R, 1995, MOL BIOL HEMOGLOBIN, P405; HUG BA, 1992, NUCLEIC ACIDS RES, V21, P5771; JAMESPEDERSON M, 1995, J BIOL CHEM, V270, P3965, DOI 10.1074/jbc.270.8.3965; JIMENEZ G, 1992, NUCLEIC ACIDS RES, V20, P5797, DOI 10.1093/nar/20.21.5797; LAKER C, 1987, P NATL ACAD SCI USA, V84, P8458, DOI 10.1073/pnas.84.23.8458; LI QL, 1990, P NATL ACAD SCI USA, V87, P8207, DOI 10.1073/pnas.87.21.8207; LI QL, 1994, BLOOD, V84, P1399; LIU DP, 1992, P NATL ACAD SCI USA, V89, P3899, DOI 10.1073/pnas.89.9.3899; LOWREY CH, 1992, P NATL ACAD SCI USA, V89, P1143, DOI 10.1073/pnas.89.3.1143; Miller JH., 1972, EXPT MOL GENETICS; MOON AM, 1991, BLOOD, V77, P2272; MOON AM, 1990, P NATL ACAD SCI USA, V87, P7693, DOI 10.1073/pnas.87.19.7693; ONDEK B, 1988, NATURE, V333, P40, DOI 10.1038/333040a0; PHILIPSEN S, 1993, EMBO J, V12, P1077, DOI 10.1002/j.1460-2075.1993.tb05749.x; PHILIPSEN S, 1990, EMBO J, V9, P2159, DOI 10.1002/j.1460-2075.1990.tb07385.x; PRUZINA S, 1994, BBA-GENE STRUCT EXPR, V1219, P351, DOI 10.1016/0167-4781(94)90059-0; PRUZINA S, 1991, NUCLEIC ACIDS RES, V19, P1413, DOI 10.1093/nar/19.7.1413; RYAN TM, 1989, GENE DEV, V3, P314, DOI 10.1101/gad.3.3.314; TALBOT D, 1990, EMBO J, V9, P2169, DOI 10.1002/j.1460-2075.1990.tb07386.x; THOMPSON JP, 1991, J BIOL CHEM, V266, P2549; TOWNES TM, 1990, TRENDS GENET, V6, P219, DOI 10.1016/0168-9525(90)90182-6; TREPICCHIO WL, 1993, MOL CELL BIOL, V13, P7457, DOI 10.1128/MCB.13.12.7457; TUAN D, 1985, P NATL ACAD SCI USA, V82, P6384, DOI 10.1073/pnas.82.19.6384; Tuan D, 1987, DEV CONTROL GLOBIN G, P211; TUAN DYH, 1989, P NATL ACAD SCI USA, V86, P2554, DOI 10.1073/pnas.86.8.2554; WIJGERDE M, 1995, NATURE, V377, P209, DOI 10.1038/377209a0; YU Z, 1994, GENE, V139, P139	44	40	41	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 17	1996	271	20					11871	11878		10.1074/jbc.271.20.11871	http://dx.doi.org/10.1074/jbc.271.20.11871			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UL250	8662652	hybrid, Green Submitted, Green Published			2022-12-25	WOS:A1996UL25000047
J	Muller, S; Straub, A; Schroder, S; Bauer, PH; Lohse, MJ				Muller, S; Straub, A; Schroder, S; Bauer, PH; Lohse, MJ			Interactions of phosducin with defined G protein beta gamma-subunits	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADRENERGIC-RECEPTOR KINASE; LIGHT-DEPENDENT PHOSPHORYLATION; BACULOVIRUS EXPRESSION SYSTEM; HETEROTRIMERIC G-PROTEINS; FUNCTIONAL-CHARACTERIZATION; GUANINE-NUCLEOTIDES; BINDING; PURIFICATION; RHODOPSIN; CELLS	Phosducin has recently been identified as a cytosolic protein that interacts with the beta gamma-subunits of G proteins and thereby may regulate transmembrane signaling. It is expressed predominantly in the retina but also in many other tissues, which raises the question of its potential specificity for retinal versus nonretinal beta gamma-subunits. We have therefore expressed and purified different combinations of beta- and gamma-subunits from Sf9 cells and have also purified transducin-beta gamma from bovine retina and a mixture of beta gamma complexes from bovine brain. Their interactions with phosducin were determined in a variety of assays for beta gamma function: support of ADP-ribosylation of alpha(0) by pertussis toxin, enhancement of the GTPase activity of alpha(0), and enhancement of rhodopsin phosphorylation by the beta-adrenergic receptor kinase 1 (beta ARK1). There were only moderate differences in the effects of the various beta gamma complexes alone on alpha(0), but there were marked differences in their ability to support beta ARK1 catalyzed rhodopsin phosphorylation. Phosducin inhibited all beta gamma-mediated effects and showed little specificity toward specific defined beta gamma complexes with the exception of transducin-beta gamma (beta(1) gamma(1)), which was inhibited more efficiently than the other beta gamma combinations. In a direct binding assay, there was no apparent selectivity of phosducin for any beta gamma combination tested. Thus, in contrast to beta ARK1, phosducin does not appear to discriminate strongly between different G protein beta- and gamma-subunits.	UNIV WURZBURG,INST PHARMACOL,D-97078 WURZBURG,GERMANY; UNIV MUNICH,MOLEC BIOL LAB,D-82152 MARTINSRIED,GERMANY	University of Wurzburg; University of Munich			Lohse, Martin J/A-7160-2012	Lohse, Martin J/0000-0002-0599-3510				ASANO T, 1993, J BIOL CHEM, V268, P20512; BAUER PH, 1992, NATURE, V358, P73, DOI 10.1038/358073a0; BENOVIC JL, 1986, NATURE, V322, P869; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHEN JQ, 1995, SCIENCE, V268, P1166, DOI 10.1126/science.7761832; GIERSCHIK P, 1984, FEBS LETT, V172, P321, DOI 10.1016/0014-5793(84)81149-7; GRABER SG, 1992, J BIOL CHEM, V267, P1271; GRABER SG, 1992, J BIOL CHEM, V267, P13123; HAGA K, 1992, J BIOL CHEM, V267, P2222; HAUSDORFF WP, 1990, FASEB J, V4, P2881, DOI 10.1096/fasebj.4.11.2165947; HAWES BE, 1994, J BIOL CHEM, V269, P29825; HEITHIER H, 1992, EUR J BIOCHEM, V204, P1169, DOI 10.1111/j.1432-1033.1992.tb16744.x; HEKMAN M, 1987, EUR J BIOCHEM, V169, P431, DOI 10.1111/j.1432-1033.1987.tb13630.x; HEKMAN M, 1994, FEBS LETT, V343, P120, DOI 10.1016/0014-5793(94)80302-1; HIGASHIJIMA T, 1987, J BIOL CHEM, V262, P762; Iniguez-Lluhi Jorge, 1993, Trends in Cell Biology, V3, P230, DOI 10.1016/0962-8924(93)90122-H; INIGUEZLLUHI JA, 1992, J BIOL CHEM, V267, P23409; KALKBRENNER F, 1995, EMBO J, V14, P4728, DOI 10.1002/j.1460-2075.1995.tb00154.x; KISSELEV O, 1995, J BIOL CHEM, V270, P25356, DOI 10.1074/jbc.270.43.25356; KISSELEV O, 1993, J BIOL CHEM, V268, P24519; KLEUSS C, 1992, NATURE, V358, P424, DOI 10.1038/358424a0; KLEUSS C, 1991, NATURE, V353, P43, DOI 10.1038/353043a0; KLEUSS C, 1993, SCIENCE, V259, P832, DOI 10.1126/science.8094261; KOCH WJ, 1993, J BIOL CHEM, V268, P8256; LEE RH, 1987, BIOCHEMISTRY-US, V26, P3983, DOI 10.1021/bi00387a036; LEE RH, 1992, J BIOL CHEM, V267, P25104; LOHSE MJ, 1993, BIOCHIM BIOPHYS ACTA, V1179, P171, DOI 10.1016/0167-4889(93)90139-G; LOHSE MJ, 1992, J BIOL CHEM, V267, P8558; MILES MF, 1993, P NATL ACAD SCI USA, V90, P10831, DOI 10.1073/pnas.90.22.10831; MULLER S, 1993, P NATL ACAD SCI USA, V90, P10439, DOI 10.1073/pnas.90.22.10439; MULLER S, 1995, BIOCHEM SOC T, V23, P141; PITCHER JA, 1992, SCIENCE, V257, P1264, DOI 10.1126/science.1325672; RAY K, 1995, J BIOL CHEM, V270, P21765, DOI 10.1074/jbc.270.37.21765; Schroder S, 1996, P NATL ACAD SCI USA, V93, P2100, DOI 10.1073/pnas.93.5.2100; SOHLEMANN P, 1993, FEBS LETT, V324, P59, DOI 10.1016/0014-5793(93)81532-5; STERNWEIS PC, 1984, J BIOL CHEM, V259, P3806; STRYER L, 1991, J BIOL CHEM, V266, P10711; TOUHARA K, 1995, J BIOL CHEM, V270, P17000, DOI 10.1074/jbc.270.28.17000; UEDA N, 1994, J BIOL CHEM, V269, P4388; WATSON AJ, 1994, J BIOL CHEM, V269, P22150; WICKMAN KD, 1994, NATURE, V368, P255, DOI 10.1038/368255a0; WILDEN U, 1982, BIOCHEMISTRY-US, V21, P3014, DOI 10.1021/bi00541a032; XU J, 1995, P NATL ACAD SCI USA, V92, P2086, DOI 10.1073/pnas.92.6.2086; YOSHIDA T, 1994, J BIOL CHEM, V269, P24050	44	50	50	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 17	1996	271	20					11781	11786		10.1074/jbc.271.20.11781	http://dx.doi.org/10.1074/jbc.271.20.11781			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UL250	8662655	hybrid			2022-12-25	WOS:A1996UL25000033
J	Nakagawa, T; Goto, K; Kondo, H				Nakagawa, T; Goto, K; Kondo, H			Cloning, expression, and localization of 230-kDa phosphatidylinositol 4-kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIACYLGLYCEROL KINASE; INOSITOL TRISPHOSPHATE; SIGNAL TRANSDUCTION; 2ND MESSENGERS; RAT-LIVER; PROTEIN; IDENTIFICATION; PURIFICATION; 4-PHOSPHATE; VESICLES	A phosphatidylinositol (PI) 4-kinase cDNA was cloned from a rat brain cDNA library. This cDNA encoded a protein of 2041 amino acids with a calculated molecular weight of 231,317. The deduced amino acid sequence shared the identity of 52.3 and 34.4% in the presumed catalytic domain with two yeast PI 4-kinases, STT4 and PIK1, respectively, and showed 31.7% identity to p110 alpha subunit of rat PI 3-kinase in the same domain. In addition, a 3' half coding region of the present cDNA was 89.6% identical to and its deduced amino acid sequence was 98.2% identical to the sequence for PI4K alpha, a recently reported human PI 4-kinase of type II, suggesting that PI4K alpha is an alternative form of the present PI 4-kinase molecule. The present cDNA contained sequences encoding the ankyrin repeat domain, lipid kinase unique domain, pleckstrin homology domain, presumed lipid kinase/protein kinase homology domain, proline-rich region, and SH3 domain. By examining PI kinase activity in transfected COS-7 cells using the epitope tag immunoprecipitation as well as the conventional way, the product phosphatidylinositol phosphate was identified as phosphatidylinositol 4-phosphate but not phosphatidylinositol 3-phosphate. This PI 4-kinase activity was markedly enhanced in the presence of Triton X-100 but relatively insensitive to inhibition by adenosine. By epitope tag immunohistochemistry, the immunoreactivity for this PI 4-kinase molecule was largely localized in close association with the membranes of the Golgi vesicles and vacuoles. By in situ hybridization analysis, the expression of mRNA for this PI 4-kinase was evident throughout the gray matter of entire brain with higher expression intensity in fetal brain. These data imply that this novel PI 4-kinase is involved in some processes essential to neuronal differentiation and maturation in eluding the synaptogenesis and synaptic plasticity.	TOHOKU UNIV,SCH MED,DEPT ANAT,SENDAI,MIYAGI 980,JAPAN	Tohoku University								BERRIDGE MJ, 1984, BIOCHEM J, V220, P345, DOI 10.1042/bj2200345; BERRIDGE MJ, 1984, NATURE, V312, P315, DOI 10.1038/312315a0; CAMPBELL CR, 1985, J BIOL CHEM, V260, P948; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHOU PY, 1978, ANNU REV BIOCHEM, V47, P251, DOI 10.1146/annurev.bi.47.070178.001343; COCKCROFT S, 1985, BIOCHIM BIOPHYS ACTA, V845, P163, DOI 10.1016/0167-4889(85)90173-9; COLLINS CA, 1983, J BIOL CHEM, V258, P2130; DELVECCHIO RL, 1991, J BIOL CHEM, V266, P13278; EDMANN G, 1987, BIOCHEMISTRY-US, V26, P6845; ENDEMANN GC, 1991, BIOCHEM J, V273, P63, DOI 10.1042/bj2730063; FLANAGAN CA, 1993, SCIENCE, V262, P1444, DOI 10.1126/science.8248783; GOTO K, 1992, MOL BRAIN RES, V16, P75, DOI 10.1016/0169-328X(92)90196-I; GOTO K, 1993, P NATL ACAD SCI USA, V90, P7598, DOI 10.1073/pnas.90.16.7598; GRAZIANI A, 1992, BIOCHEM J, V284, P39, DOI 10.1042/bj2840039; HOKIN LE, 1985, ANNU REV BIOCHEM, V54, P205, DOI 10.1146/annurev.biochem.54.1.205; KATO H, 1989, J BIOL CHEM, V264, P3116; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI YS, 1989, BIOCHEM BIOPH RES CO, V160, P202, DOI 10.1016/0006-291X(89)91641-0; LISCOVITCH M, 1994, J BIOL CHEM, V269, P21403; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MILLER ES, 1990, BIOCHEM BIOPH RES CO, V173, P289, DOI 10.1016/S0006-291X(05)81055-1; MUSACCHIO A, 1993, TRENDS BIOCHEM SCI, V18, P343, DOI 10.1016/0968-0004(93)90071-T; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; OKAYAMA H, 1987, METHOD ENZYMOL, V154, P2; PARKER PJ, 1994, TRENDS BIOCHEM SCI, V19, P54, DOI 10.1016/0968-0004(94)90031-0; PORTER FD, 1988, J BIOL CHEM, V263, P8989; SAKANE F, 1991, BIOCHEM BIOPH RES CO, V181, P1015, DOI 10.1016/0006-291X(91)92038-L; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; STOYANOV B, 1995, SCIENCE, V269, P690, DOI 10.1126/science.7624799; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; TOOKE NE, 1984, BIOCHEM J, V219, P471, DOI 10.1042/bj2190471; TOUHARA K, 1994, J BIOL CHEM, V269, P10217; WALSH JP, 1991, P NATL ACAD SCI USA, V88, P9184, DOI 10.1073/pnas.88.20.9184; WHITMAN M, 1988, NATURE, V332, P644, DOI 10.1038/332644a0; WONG K, 1994, J BIOL CHEM, V269, P28878; YOSHIDA S, 1994, J BIOL CHEM, V269, P1166	37	95	99	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 17	1996	271	20					12088	12094		10.1074/jbc.271.20.12088	http://dx.doi.org/10.1074/jbc.271.20.12088			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UL250	8662589	hybrid			2022-12-25	WOS:A1996UL25000076
J	Mautner, J; Behrends, U; Hortnagel, K; Brielmeier, M; Hammerschmidt, W; Strobl, L; Bornkamm, GW; Polack, A				Mautner, J; Behrends, U; Hortnagel, K; Brielmeier, M; Hammerschmidt, W; Strobl, L; Bornkamm, GW; Polack, A			c-myc expression is activated by the immunoglobulin kappa-enhancers from a distance of at least 30 kb but not by elements located within 50 kb of the unaltered c-myc locus in vivo	ONCOGENE			English	Article						chromatin analysis; c-myc; gene expression; immunoglobulin enhancer; locus control	BURKITTS-LYMPHOMA CELLS; REGULATORY ELEMENTS; GENE-EXPRESSION; PROMOTER SHIFT; 1ST EXON; T-CELL; TRANSLOCATIONS; REGION; PROTOONCOGENE; TRANSCRIPTION	50 kb of contiguous DNA sequences covering the human c-myc coding region and approximately 20 kb of flanking upstream and downstream sequences were cloned onto a prokaryotic F-factor derived plasmid, which also contains a selectable marker and the plasmid origin of DNA replication oriP of Epstein Barr virus (EBV). Since these plasmids replicate extrachromosomally after stable transfection into EBV-positive B-cell lines, the gene regulation of c-myc can be analysed independent from chromosomal integration positions, Despite the presence of all known c-myc regulatory elements on these constructs, expression from the stably transfected c-myc gene was barely detectable in either cell line, Hypermethylation of these plasmids could be excluded as a mechanism for the lack of gene expression, Insertion of the immunoglobulin kappa-intron and 3' enhancers, however, activated c-myc transcription, when placed adjacent to pr separated from the c-myc promoters by as far as 30 kh, These results indicate that transcription of c-myc in vivo requires additional and still unidentified control elements located outside this 50 kb fragment, and experimentally demonstrate long range enhancer function in vivo.	GSF FORSCHUNGSZENTRUM UNWELT & GESUNDHEIT GMBH, INST KLIN MOL BIOL & TUMORGENET, D-81377 MUNICH, GERMANY; GSF FORSCHUNGSZENTRUM UNWELT & GESUNDHEIT GMBH, INST STRAHLENBIOL, D-85764 OBERSCHLEISSHEIM, GERMANY; UNIV MUNICH, ABT PADIATR GENET, D-80336 MUNICH, GERMANY	Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; University of Munich			Hammerschmidt, Wolfgang/ABG-3921-2021; Brielmeier, Markus/M-7352-2014; Strobl, Lothar J/M-7357-2014	Hammerschmidt, Wolfgang/0000-0002-4659-0427; Brielmeier, Markus/0000-0002-8715-869X; Strobl, Lothar J/0000-0001-8389-1862				BERGMAN Y, 1984, P NATL ACAD SCI-BIOL, V81, P7041, DOI 10.1073/pnas.81.22.7041; BIRD A, 1992, CELL, V70, P5, DOI 10.1016/0092-8674(92)90526-I; CANN AJ, 1988, ONCOGENE, V3, P123; CHUNG JH, 1993, CELL, V74, P505, DOI 10.1016/0092-8674(93)80052-G; DILLON N, 1993, TRENDS GENET, V9, P134, DOI 10.1016/0168-9525(93)90208-Y; EICK D, 1986, NUCLEIC ACIDS RES, V14, P8331, DOI 10.1093/nar/14.21.8331; EICK D, 1989, EMBO J, V8, P1965, DOI 10.1002/j.1460-2075.1989.tb03602.x; FEO S, 1994, ONCOGENE, V9, P955; GAZIN C, 1984, EMBO J, V3, P383, DOI 10.1002/j.1460-2075.1984.tb01816.x; HALUSKA FG, 1988, NUCLEIC ACIDS RES, V16, P2077, DOI 10.1093/nar/16.5.2077; HAY N, 1987, GENE DEV, V1, P659, DOI 10.1101/gad.1.7.659; HENGLEIN B, 1989, MOL CELL BIOL, V9, P2105, DOI 10.1128/MCB.9.5.2105; HORTNAGEL K, 1995, ONCOGENE, V10, P1393; HSIEH CL, 1994, MOL CELL BIOL, V14, P5487, DOI 10.1128/MCB.14.8.5487; JOOS S, 1992, CANCER RES, V52, P6547; JUCKER M, 1992, ONCOGENE, V7, P943; KAVATHAS P, 1980, P NATL ACAD SCI-BIOL, V77, P4251, DOI 10.1073/pnas.77.7.4251; KEMPKES B, 1995, J VIROL, V69, P231, DOI 10.1128/JVI.69.1.231-238.1995; LAVENU A, 1994, ONCOGENE, V9, P527; LAZO PA, 1990, P NATL ACAD SCI USA, V87, P170, DOI 10.1073/pnas.87.1.170; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; LIPP M, 1987, MOL CELL BIOL, V7, P1393, DOI 10.1128/MCB.7.4.1393; MAGRATH I, 1990, ADV CANCER RES, V55, P134; MARCU KB, 1992, ANNU REV BIOCHEM, V61, P809, DOI 10.1146/annurev.bi.61.070192.004113; MAUTNER J, 1995, NUCLEIC ACIDS RES, V23, P72, DOI 10.1093/nar/23.1.72; MENGLEGAW L, 1987, EMBO J, V6, P1959, DOI 10.1002/j.1460-2075.1987.tb02458.x; NISHIKURA K, 1986, MOL CELL BIOL, V6, P4093, DOI 10.1128/MCB.6.11.4093; OCONNOR M, 1989, SCIENCE, V244, P1307, DOI 10.1126/science.2660262; POLACK A, 1991, ONCOGENE, V6, P2033; POLACK A, 1993, EMBO J, V12, P3913, DOI 10.1002/j.1460-2075.1993.tb06069.x; PTASHNE M, 1986, NATURE, V322, P697, DOI 10.1038/322697a0; PULVERTA.RJ, 1965, J CLIN PATHOL, V18, P261, DOI 10.1136/jcp.18.3.261; Sambrook J, 1989, MOL CLONING LABORATO; SIEBENLIST U, 1988, MOL CELL BIOL, V8, P867, DOI 10.1128/MCB.8.2.867; SPENCER CA, 1991, ADV CANCER RES, V56, P1; STROBL LJ, 1993, ONCOGENE, V8, P1437; SUN LK, 1986, NUCLEIC ACIDS RES, V14, P4037, DOI 10.1093/nar/14.10.4037; TRAVERS AA, 1992, CELL, V69, P573, DOI 10.1016/0092-8674(92)90218-2; YATES JL, 1985, NATURE, V313, P812, DOI 10.1038/313812a0; ZEIDLER R, 1994, GENE CHROMOSOME CANC, V9, P282, DOI 10.1002/gcc.2870090408	40	25	25	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 21	1996	12	6					1299	1307						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UC067	8649832				2022-12-25	WOS:A1996UC06700015
J	Wu, HK; Heng, HHQ; Siderovski, DP; Dong, WF; Okuno, Y; Shi, XM; Tsui, LC; Minden, MD				Wu, HK; Heng, HHQ; Siderovski, DP; Dong, WF; Okuno, Y; Shi, XM; Tsui, LC; Minden, MD			Identification of a human LIM-Hox gene, hLH-2, aberrantly expressed in chronic myelogenous Leukaemia and located on 9q33-34.1	ONCOGENE			English	Article						fluorescence in situ hybridization; hematological malignancies; hLH-2; Philadelphia chromosome; reverse transcription polymerase chain reaction	T-CELL LEUKEMIA; HOMEOBOX GENE; TRANSGENIC MICE; BCR-ABL; PROTEINS; TRANSLOCATION; INDUCTION; LYMPHOMA; ELEGANS; MEMBER	We describe the isolation of human LH-2, a putative transcription factor containing two cysteine-rich regions (LIM domains) and a homeobox (Hox) DNA-binding domain. High levels of hLH-2 expression were observed in all cases of chronic myelogenous leukaemia (CML) tested, regardless of disease status. hLH-2 was mapped to chromosome 9q33-34.1, in the same region as the reciprocal translocation that creates the BCR-ABL chimera of the Philadelphia chromosome (Ph'), the hallmark of CML; hLH-2 was retained on the derivative 9 chromosome and is therefore centromeric of c-ABL. The proximity of hLH-2 to the breakpoint on chromosome 9 raises the possibility of cis-activation by the t(9;22)(q34;q11) translocation. In addition to finding hLH-2 expression in all cases of CML, expression was observed in lymphoid malignancies and myeloid cell lines, but not in primary cases of acute myelogenous leukaemia. The role of hLH-2 in the development or progression of leukaemia is not known. However, hLH-2 may prove useful as a marker of CML for monitoring residual disease.	UNIV TORONTO,PRINCESS MARGARET HOSP,ONTARIO CANC INST,DEPT MED,TORONTO,ON M5G 2M9,CANADA; UNIV TORONTO,PRINCESS MARGARET HOSP,ONTARIO CANC INST,DEPT MED BIOPHYS,TORONTO,ON M5G 2M9,CANADA; HOSP SICK CHILDREN,DEPT GENET,TORONTO,ON M5G 1X8,CANADA; HOSP SICK CHILDREN,DEPT MOLEC & MED GENET,TORONTO,ON M5G 1X8,CANADA; AMGEN INST,QUANTITAT BIOL LAB,TORONTO,ON M5G 2C1,CANADA	University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids)			Siderovski, David Peter/AAA-9603-2019	Siderovski, David Peter/0000-0002-0688-8210				BARNES JD, 1994, DEV BIOL, V161, P168, DOI 10.1006/dbio.1994.1018; BENDAVID L, 1991, VIROLOGY, V182, P382, DOI 10.1016/0042-6822(91)90686-6; BOEHM T, 1990, ONCOGENE, V5, P1103; BRADY G, 1993, METHOD ENZYMOL, V225, P611; CARLESSO N, 1994, ONCOGENE, V9, P149; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COHEN B, 1992, GENE DEV, V6, P715, DOI 10.1101/gad.6.5.715; DALEY GQ, 1990, SCIENCE, V247, P824, DOI 10.1126/science.2406902; DUBOULE D, 1989, EMBO J, V8, P1497, DOI 10.1002/j.1460-2075.1989.tb03534.x; ELEFANTY AG, 1992, MOL CELL BIOL, V12, P1755, DOI 10.1128/MCB.12.4.1755; ELEFANTY AG, 1990, EMBO J, V9, P1069, DOI 10.1002/j.1460-2075.1990.tb08212.x; FISCH P, 1992, ONCOGENE, V7, P2389; GEHRING WJ, 1987, SCIENCE, V236, P1245, DOI 10.1126/science.2884726; HATANO M, 1991, SCIENCE, V253, P79, DOI 10.1126/science.1676542; HENG HHQ, 1994, HUM MOL GENET, V3, P61, DOI 10.1093/hmg/3.1.61; KAMPS MP, 1991, GENE DEV, V5, P358, DOI 10.1101/gad.5.3.358; KARLSSON O, 1990, NATURE, V344, P879, DOI 10.1038/344879a0; KAWASAKI ES, 1988, P NATL ACAD SCI USA, V85, P5698, DOI 10.1073/pnas.85.15.5698; KELLIHER MA, 1990, P NATL ACAD SCI USA, V87, P6649, DOI 10.1073/pnas.87.17.6649; LI H, 1994, EMBO J, V13, P2876, DOI 10.1002/j.1460-2075.1994.tb06582.x; LI PM, 1991, P NATL ACAD SCI USA, V88, P9210, DOI 10.1073/pnas.88.20.9210; LU M, 1991, EMBO J, V10, P2905, DOI 10.1002/j.1460-2075.1991.tb07840.x; MAGLI MC, 1991, P NATL ACAD SCI USA, V88, P6348, DOI 10.1073/pnas.88.14.6348; MATULONIS U, 1993, EXP HEMATOL, V21, P1460; MAVILIO F, 1986, NATURE, V324, P664, DOI 10.1038/324664a0; MCGUIRE EA, 1992, MOL CELL BIOL, V12, P4186, DOI 10.1128/MCB.12.9.4186; MINDEN MD, 1979, BLOOD, V54, P186; PERKINS A, 1990, P NATL ACAD SCI USA, V87, P8393; RASSOOL F, 1990, LEUKEMIA, V4, P273; ROBERSON MS, 1994, MOL CELL BIOL, V14, P2985, DOI 10.1128/MCB.14.5.2985; ROWLEY JD, 1973, NATURE, V243, P290, DOI 10.1038/243290a0; Sambrook J., 2002, MOL CLONING LAB MANU; SHTIVELMAN E, 1985, NATURE, V315, P550, DOI 10.1038/315550a0; SIMEONE A, 1987, P NATL ACAD SCI USA, V84, P4914, DOI 10.1073/pnas.84.14.4914; TAKESHITA K, 1993, P NATL ACAD SCI USA, V90, P3535, DOI 10.1073/pnas.90.8.3535; WAY JC, 1988, CELL, V54, P5, DOI 10.1016/0092-8674(88)90174-2; WU HK, 1995, LEUKEMIA, V9, P1291; XU WM, 1994, BONE MARROW TRANSPL, V14, P299; XU Y, 1993, P NATL ACAD SCI USA, V90, P227, DOI 10.1073/pnas.90.1.227	39	42	45	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR 21	1996	12	6					1205	1212						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UC067	8649822				2022-12-25	WOS:A1996UC06700005
J	Ames, GFL; Liu, CE; Joshi, AK; Nikaido, K				Ames, GFL; Liu, CE; Joshi, AK; Nikaido, K			Liganded and unliganded receptors interact with equal affinity with the membrane complex of periplasmic permeases, a subfamily of traffic ATPases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ORNITHINE-BINDING PROTEIN; HISTIDINE PERMEASE; SALMONELLA-TYPHIMURIUM; TRANSPORT-SYSTEMS; ESCHERICHIA-COLI; CYSTIC-FIBROSIS; MULTIDRUG-RESISTANCE; BACTERIAL TRANSPORT; ACTIVE-TRANSPORT; ATP HYDROLYSIS	The histidine-binding protein, HisJ, is the soluble receptor for the periplasmic histidine permease of Salmonella typhimurium, The receptor binds the substrate in the periplasm, interacts with the membrane-bound complex, transmits a transmembrane signal to hydrolyze ATP, and releases the ligand for translocation, HisJ, like other periplasmic receptors, has two lobes that are apart in the unliganded structure (open conformation) and drawn close together in the liganded structure (closed conformation), burying deeply the ligand, Such receptors are postulated to interact with the membrane bound complex with high affinity in their liganded con formation, and, upon substrate translocation, to undergo a reduction in affinity and therefore be released, Here we show that in contrast to the current postulate, liganded and unliganded receptors have equal affinity for the membrane-bound complex, The affinity is measured both by chemical cross-linking and co-sedimentation procedures, An ATPase activity assay is also used to demonstrate the interaction of unliganded receptor with the membrane-bound complex, These findings support a new model for the transport mechanism, in which the soluble receptor functions independently of the commonly accepted high-low affinity switch.			Ames, GFL (corresponding author), UNIV CALIF BERKELEY, DEPT MOLEC & CELL BIOL, DIV BIOCHEM & MOLEC BIOL, BERKELEY, CA 94720 USA.				NIDDK NIH HHS [DK-12121] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK012121, R37DK012121] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AMES BN, 1952, J AM CHEM SOC, V74, P252; AMES GF, 1990, FEMS MICROBIOL LETT, V75, P429, DOI 10.1016/S0168-6445(05)80008-7; AMES GF, 1964, ARCH BIOCHEM BIOPHYS, V104, P1, DOI 10.1016/S0003-9861(64)80028-X; AMES GFL, 1972, J BIOL CHEM, V247, P4309; AMES GFL, 1986, ANNU REV BIOCHEM, V55, P397, DOI 10.1146/annurev.biochem.55.1.397; BISHOP L, 1989, P NATL ACAD SCI USA, V86, P6953, DOI 10.1073/pnas.86.18.6953; BOEDTKER H, 1967, BIOCHEMISTRY-US, V6, P2718, DOI 10.1021/bi00861a011; BOHL E, 1995, J THEOR BIOL, V172, P83, DOI 10.1006/jtbi.1995.0006; BRASS JM, 1986, J BACTERIOL, V165, P787, DOI 10.1128/jb.165.3.787-795.1986; BROWN EM, 1993, NATURE, V366, P575, DOI 10.1038/366575a0; CANTOR CR, 1980, BIOPHYSICAL CHEM, P943; CHIFFLET S, 1988, ANAL BIOCHEM, V168, P1, DOI 10.1016/0003-2697(88)90002-4; DAVIDSON AL, 1992, P NATL ACAD SCI USA, V89, P2360, DOI 10.1073/pnas.89.6.2360; DOIGE CA, 1993, ANNU REV MICROBIOL, V47, P291, DOI 10.1146/annurev.micro.47.1.291; EASLEY CW, 1969, BIOCHIM BIOPHYS ACTA, V175, P211, DOI 10.1016/0005-2795(69)90161-5; FERROLUZZIAMES G, 1976, P NATL ACAD SCI USA, V73, P1877, DOI 10.1073/pnas.73.6.1877; FLOCCO MM, 1994, J BIOL CHEM, V269, P8931; GHINEA N, 1989, J BIOL CHEM, V264, P4755; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; HOBOT JA, 1984, J BACTERIOL, V160, P143, DOI 10.1128/JB.160.1.143-152.1984; HOBSON AC, 1984, P NATL ACAD SCI-BIOL, V81, P7333, DOI 10.1073/pnas.81.23.7333; HUANG ZJ, 1995, SCIENCE, V267, P1169, DOI 10.1126/science.7855598; HYDE SC, 1990, NATURE, V346, P362, DOI 10.1038/346362a0; JACKSON V, 1978, CELL, V15, P945, DOI 10.1016/0092-8674(78)90278-7; KERPPOLA RE, 1991, J BIOL CHEM, V266, P9857; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MILLER DM, 1983, J BIOL CHEM, V258, P3665; NIKAIDO K, 1992, J BIOL CHEM, V267, P20706; OH BH, 1993, J BIOL CHEM, V268, P11348; OH BH, 1994, J BIOL CHEM, V269, P4135; OHARA PJ, 1993, NEURON, V11, P41, DOI 10.1016/0896-6273(93)90269-W; PETRONILLI V, 1991, J BIOL CHEM, V266, P16293; PROSSNITZ E, 1988, J BIOL CHEM, V263, P17917; PROSSNITZ E, 1989, J BIOL CHEM, V264, P5006; PROSSNITZ E, 1989, THESIS U CALIFORNIA; QUIOCHO FA, 1990, PHILOS T R SOC B, V326, P341, DOI 10.1098/rstb.1990.0016; ROTH JR, 1970, METHODS ENZYMOL    A, V17, P3; SHARFF AJ, 1992, BIOCHEMISTRY-US, V31, P10657, DOI 10.1021/bi00159a003; SHILTON BH, 1995, PROTEIN SCI, V4, P1346, DOI 10.1002/pro.5560040710; SHYAMALA V, 1991, J BIOL CHEM, V266, P18714; SILHAVY TJ, 1975, P NATL ACAD SCI USA, V72, P2120, DOI 10.1073/pnas.72.6.2120; SPEISER DM, 1991, J BACTERIOL, V173, P1444, DOI 10.1128/jb.173.4.1444-1451.1991; SPEISER DM, 1989, THESIS U CALIFORNIA; STERN MJ, 1986, THESIS U CALIFORNIA; STERNBACH Y, 1994, NEURON, V13, P1345, DOI 10.1016/0896-6273(94)90420-0; WALMSLEY AR, 1992, BIOCHEMISTRY-US, V31, P11175, DOI 10.1021/bi00160a031; WILLIS RC, 1974, J BIOL CHEM, V249, P6926; WOLF A, 1994, J BIOL CHEM, V269, P23051	48	70	70	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 14	1996	271	24					14264	14270		10.1074/jbc.271.24.14264	http://dx.doi.org/10.1074/jbc.271.24.14264			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UQ660	8662800	hybrid			2022-12-25	WOS:A1996UQ66000051
J	Missbach, M; Jagher, B; Sigg, I; Nayeri, S; Carlberg, C; Wiesenberg, I				Missbach, M; Jagher, B; Sigg, I; Nayeri, S; Carlberg, C; Wiesenberg, I			Thiazolidine diones, specific ligands of the nuclear receptor retinoid Z receptor retinoid acid receptor-related orphan receptor alpha with potent antiarthritic activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT ADJUVANT ARTHRITIS; BREAST-CANCER-CELLS; MELATONIN; CULTURE; MCF-7	Rat adjuvant arthritis is a chronic T cell-dependent autoimmune disease with many similarities to rheumatoid arthritis. We have identified a class of thiazolidine diones with high potency in suppressing chronic inflammation and joint destruction in this experimental model. The lead compound CGP 52608 (1-(3-allyl-4-oxothiazolidine-2-ylidene)-4- methylthiosemicarbazone) exhibits antiarthritic activity at dailyoral doses between 0.01 and 1 mg/kg and was shown to specifically activate the retinoid Z receptor/retinoid acid receptor-related orphan receptor alpha (RZR/ROR alpha) in low nanomolar concentrations, This receptor is a novel member of the superfamily of ligand-inducible transcription factors, and we have recently identified the pineal gland hormone melatonin as a natural ligand. Structure-activity relationship studies with 13 closely related analogues of CGP 52608 revealed a striking correlation between RZR/ROR alpha activation and antiarthritic activity. We therefore suggest that nuclear signaling via RZR/ROR alpha is a key mechanism in mediating the antiarthritic effects of these thiazolidine diones and may open a novel therapeutic approach for the treatment of rheumatoid arthritis and other autoimmune diseases. The existence of a nuclear melatonin receptor may lead to a better understanding of the immunomodulatory actions of melatonin.	CIBA GEIGY AG, PHARMA FORSCH, CH-4002 BASEL, SWITZERLAND; HOP CANTONAL UNIV GENEVA, DERMATOL CLIN, CH-1211 GENEVA 14, SWITZERLAND	Novartis; University of Geneva			Carlberg, Carsten/C-9075-2011	Carlberg, Carsten/0000-0003-2633-0684				ACUNACASTROVIEJO D, 1994, J PINEAL RES, V16, P100, DOI 10.1111/j.1600-079X.1994.tb00089.x; ARMSTRONG SM, 1993, PHARMACOL BIOCHEM BE, V46, P45, DOI 10.1016/0091-3057(93)90315-K; BECKERANDRE M, 1993, BIOCHEM BIOPH RES CO, V194, P1371, DOI 10.1006/bbrc.1993.1976; BECKERANDRE M, 1994, J BIOL CHEM, V269, P28531; BILLINGHAM MEJ, 1983, PHARMACOL THERAPEUT, V21, P389, DOI 10.1016/0163-7258(83)90062-1; BUCK J, 1993, J EXP MED, V178, P675, DOI 10.1084/jem.178.2.675; CARLBERG C, 1994, MOL ENDOCRINOL, V8, P757, DOI 10.1210/me.8.6.757; CARLBERG C, 1995, J PINEAL RES, V18, P171, DOI 10.1111/j.1600-079X.1995.tb00157.x; CARLBERG C, 1993, NATURE, V361, P657, DOI 10.1038/361657a0; CARLBERG C, 1993, BIOCHEM J, V295, P343, DOI 10.1042/bj2950343; COS S, 1991, J PINEAL RES, V10, P36, DOI 10.1111/j.1600-079X.1991.tb00007.x; DEPREUX P, 1994, J MED CHEM, V37, P3231, DOI 10.1021/jm00046a006; EBISAWA T, 1994, P NATL ACAD SCI USA, V91, P6133, DOI 10.1073/pnas.91.13.6133; FEIGE U, 1992, Patent No. 508955; GEIGER T, 1992, CLIN EXP RHEUMATOL, V10, P467; GEISSLER JF, 1990, J BIOL CHEM, V265, P22255; GIGUERE V, 1994, GENE DEV, V8, P538, DOI 10.1101/gad.8.5.538; HAGAN RM, 1995, TRENDS PHARMACOL SCI, V16, P81, DOI 10.1016/S0165-6147(00)88985-3; HILL SM, 1988, CANCER RES, V48, P6121; HIROSE T, 1994, BIOCHEM BIOPH RES CO, V205, P1976, DOI 10.1006/bbrc.1994.2902; IP MM, 1983, 13 INT C CHEM VIENN, V16, P192; JORDAN VC, 1979, EUR J CANCER, V15, P755, DOI 10.1016/0014-2964(79)90150-6; KLIEWER SA, 1995, CELL, V83, P813, DOI 10.1016/0092-8674(95)90194-9; LAUDET V, 1992, EMBO J, V11, P1003, DOI 10.1002/j.1460-2075.1992.tb05139.x; LEHMANN JM, 1995, J BIOL CHEM, V270, P12953, DOI 10.1074/jbc.270.22.12953; LEVIN AA, 1992, NATURE, V355, P359, DOI 10.1038/355359a0; LEWIS AJ, 1985, HDB INFLAMMATION, V5, P371; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MENENDEZPELAEZ A, 1993, J CELL BIOCHEM, V53, P373, DOI 10.1002/jcb.240530415; MISSBACH, 1993, Patent No. 573392; MISSBACH M, 1995, Patent No. 9514685; MORGAN PJ, 1994, NEUROCHEM INT, V24, P101, DOI 10.1016/0197-0186(94)90100-7; ORTIZ MA, 1995, MOL ENDOCRINOL, V9, P1679, DOI 10.1210/me.9.12.1679; POTHIER F, 1992, DNA CELL BIOL, V11, P83, DOI 10.1089/dna.1992.11.83; REITER RJ, 1993, EXPERIENTIA, V49, P654, DOI 10.1007/BF01923947; REPPERT SM, 1994, NEURON, V13, P1177, DOI 10.1016/0896-6273(94)90055-8; ROSEN J, 1995, J MED CHEM, V38, P4855, DOI 10.1021/jm00025a001; SCHEINMAN RI, 1995, SCIENCE, V270, P283, DOI 10.1126/science.270.5234.283; SCHIEWECK K, 1983, 13 INT C CHEM VIENN, V16, P66; SCHMIDTRUPPIN KH, 1976, ONCOLOGY, V33, P229, DOI 10.1159/000225152; SCHMIDTRUPPIN KH, 1973, EXPERIENTIA, V29, P823, DOI 10.1007/BF01946310; SCHRADER M, 1994, J BIOL CHEM, V269, P5501; SCHRADER M, 1994, J BIOL CHEM, V269, P6444; SCHRADER M, 1994, J MOL ENDOCRINOL, V12, P327, DOI 10.1677/jme.0.0120327; STEINHILBER D, 1995, J BIOL CHEM, V270, P7037, DOI 10.1074/jbc.270.13.7037; VITTE PA, 1988, J PINEAL RES, V5, P437, DOI 10.1111/j.1600-079X.1988.tb00787.x; WIESENBERG I, 1995, NUCLEIC ACIDS RES, V23, P327, DOI 10.1093/nar/23.3.327; WIESENBERG I, 1989, CLIN EXP IMMUNOL, V78, P245; Yu H. L., 2020, ARXIV PREPRINT ARXIV	49	89	95	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 7	1996	271	23					13515	13522		10.1074/jbc.271.23.13515	http://dx.doi.org/10.1074/jbc.271.23.13515			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UP385	8662835	hybrid			2022-12-25	WOS:A1996UP38500033
J	Elgawish, A; Glomb, M; Friedlander, M; Monnier, VM				Elgawish, A; Glomb, M; Friedlander, M; Monnier, VM			Involvement of hydrogen peroxide in collagen cross-linking by high glucose in vitro and in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-EPSILON-CARBOXYMETHYLLYSINE; ALDOSE REDUCTASE INHIBITION; DIABETIC RATS; LIPID-PEROXIDATION; PROTEIN GLYCATION; OXIDATIVE STRESS; OXIDASE ACTIVITY; FREE-RADICALS; TAIL TENDONS; VITAMIN-E	The Maillard reaction has been implicated in crosslinking and fluorescence formation of collagen exposed to high glucose in vitro. However, several pharmacologic agents, whose action seems unrelated to pathways of nonenzymatic glycation, have been demonstrated to prevent cross-linking in diabetes. To clarify this discrepancy, kinetic changes in glycation, glycoxidation (carboxymethyllysine, CML), and cross-linking (measured as tendon breaking time, TBT) were evaluated in rat tail tendons incubated in 5 and 30 mM glucose in vitro, and in tendons implanted in vivo into diabetic rat peritoneal cavity. In vitro, rates were found to be both O-2- and glucose-dependent. Tendon preglycation and presence of added 2 mM glycosylamine and Amadori compounds (Amadori product of glucose and propylamine) catalyzed these changes in a primarily O-2-dependent manner. In the presence of Amadori compounds, kinetic changes were dramatically increased and were preventable by addition of catalase to the medium. Tendons implanted into diabetic rat peritoneum became more rapidly glycoxidized and cross-linked when implanted at day 30 from diabetes onset (high tissue glycation) compared to day 3 (low tissue glycation) in spite of similar glycation kinetics, suggesting a mechanistic dissociation between glycation, glycoxidation, and crosslinking in diabetes. Indeed, intraperitoneal injection of catalase and other antioxidants dramatically suppressed cross-linking, fluorescence formation, and, to some extent, glycoxidation, without affecting glycation, This study confirms the role of oxidative stress in protein cross-linking by the Maillard reaction in vitro and provides the first evidence for a role of H2O2 in crosslinking in diabetes. Whereas Amadori products are a potent source of H2O2 formation in vitro, their precise contribution to H2O2 generation and the actual role of Maillard reaction products in collagen cross-linking in diabetes requires further investigation.	CASE WESTERN RESERVE UNIV, INST PATHOL, CLEVELAND, OH 44106 USA; CASE WESTERN RESERVE UNIV, SCH MED, DEPT MED, CLEVELAND, OH 44106 USA	Case Western Reserve University; Case Western Reserve University			Monnier, Vincent M/B-1371-2009		NEI NIH HHS [EY 07099] Funding Source: Medline; NIA NIH HHS [AG 05601] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY007099] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG005601] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		AHMED MU, 1986, J BIOL CHEM, V261, P4889; AOKI Y, 1992, DIABETOLOGIA, V35, P913, DOI 10.1007/BF00401418; BAKER JR, 1994, CLIN CHEM, V40, P1950; BAYNES JW, 1991, DIABETES, V40, P405, DOI 10.2337/diabetes.40.4.405; BRENNAN M, 1989, J BIOL CHEM, V264, P20947; BRENNAN M, 1989, J BIOL CHEM, V264, P20953; BROWNLEE M, 1983, J EXP MED, V158, P1739, DOI 10.1084/jem.158.5.1739; BROWNLEE M, 1986, SCIENCE, V232, P1629, DOI 10.1126/science.3487117; CHACE KV, 1991, ARCH BIOCHEM BIOPHYS, V288, P473, DOI 10.1016/0003-9861(91)90223-6; CHANG K, 1980, DIABETES, V29, P778, DOI 10.2337/diabetes.29.10.778; COHEN MP, 1991, GEN PHARMACOL, V22, P603, DOI 10.1016/0306-3623(91)90063-C; EHRENWALD E, 1994, J CLIN INVEST, V93, P1493, DOI 10.1172/JCI117127; FU MX, 1994, DIABETES, V43, P676, DOI 10.2337/diabetes.43.5.676; GLOMB MA, 1995, J BIOL CHEM, V270, P10017, DOI 10.1074/jbc.270.17.10017; HALLIWELL B, 1988, BIOCHEM PHARMACOL, V37, P569, DOI 10.1016/0006-2952(88)90126-8; HODGE JE, 1953, J AGR FOOD CHEM, V1, P928, DOI 10.1021/jf60015a004; HUNT JV, 1993, BIOCHEM J, V291, P529, DOI 10.1042/bj2910529; ILLING EKB, 1951, BIOCHEM J, V48, P637, DOI 10.1042/bj0480637; JIANG ZY, 1990, FEBS LETT, V268, P69, DOI 10.1016/0014-5793(90)80974-N; JOHNSON RN, 1983, CLIN CHIM ACTA, V127, P87, DOI 10.1016/0009-8981(83)90078-5; KARPEN CW, 1984, DIABETES, V33, P239, DOI 10.2337/diabetes.33.3.239; KAWAKISHI S, 1994, MAILLARD REACTIONS C; KOWLURU R, 1995, DIABETES, V44, pA117; KUCHINSKAS EJ, 1962, ARCH BIOCHEM BIOPHYS, V97, P370, DOI 10.1016/0003-9861(62)90090-5; LEDL F, 1990, ANGEW CHEM INT EDIT, V29, P565, DOI 10.1002/anie.199005653; MADIA AM, 1979, BIOCHIM BIOPHYS ACTA, V585, P481, DOI 10.1016/0304-4165(79)90181-8; MARTINMATEO MC, 1978, BIOMED EXPRESS, V29, P56; MICHEEL F, 1959, CHEM BER-RECL, V92, P2836, DOI 10.1002/cber.19590921127; MINOTTI G, 1987, J BIOL CHEM, V262, P1098; MONNIER VM, 1981, SCIENCE, V211, P491, DOI 10.1126/science.6779377; NAGARAJ RH, 1993, DIABETES, V42, pA240; NAMIKI M, 1975, J AGR FOOD CHEM, V23, P487, DOI 10.1021/jf60199a024; NIMNI ME, 1968, J BIOL CHEM, V243, P1457; NIMNI NE, 1966, SCIENCE, V150, P905; ODETTI P, 1994, LAB INVEST, V70, P61; ODETTI PR, 1990, DIABETES, V39, P796, DOI 10.2337/diabetes.39.7.796; PARCHMENT RE, 1990, P NATL ACAD SCI USA, V87, P4340, DOI 10.1073/pnas.87.11.4340; REISER K, 1992, FASEB J, V6, P2439, DOI 10.1096/fasebj.6.7.1348714; Resmini P., 1990, ITAL J FOOD SCI, V3, P173; RICHARD S, 1991, DIABETES, V40, P1049, DOI 10.2337/diabetes.40.8.1049; SAKURAI T, 1990, BIOCHIM BIOPHYS ACTA, V1043, P27, DOI 10.1016/0005-2760(90)90106-8; SAKURAI T, 1988, FEBS LETT, V236, P406, DOI 10.1016/0014-5793(88)80066-8; SELL DR, 1995, HDB PHYSL, P253; SMITH PR, 1992, EUR J BIOCHEM, V210, P729, DOI 10.1111/j.1432-1033.1992.tb17474.x; SOM S, 1981, METABOLISM, V30, P572, DOI 10.1016/0026-0495(81)90133-5; STADTMAN ER, 1992, SCIENCE, V257, P1220, DOI 10.1126/science.1355616; SUAREZ G, 1988, J CLIN INVEST, V82, P624, DOI 10.1172/JCI113641; WATKINS NG, 1987, J BIOL CHEM, V262, P7207; WELLSKNECHT KJ, 1995, BIOCHEMISTRY-US, V34, P3702, DOI 10.1021/bi00011a027; WELLSKNECHT MC, 1995, BIOCHEMISTRY-US, V34, P15134, DOI 10.1021/bi00046a020; WENINGER M, 1992, NEPHRON, V62, P80, DOI 10.1159/000187000; WOLFF SP, 1991, FREE RADICAL BIO MED, V10, P339, DOI 10.1016/0891-5849(91)90040-A; WOLFF SP, 1987, BIOCHEM J, V245, P243, DOI 10.1042/bj2450243; Wolff SP, 1987, DIABETIC COMPLICATIO, P167; YU PH, 1993, DIABETES, V42, P594, DOI 10.2337/diabetes.42.4.594; YUE DK, 1984, DIABETES, V33, P745, DOI 10.2337/diabetes.33.8.745; YUE DK, 1985, DIABETES, V34, P74, DOI 10.2337/diabetes.34.1.74; ZYZAK DV, 1995, ARCH BIOCHEM BIOPHYS, V316, P547, DOI 10.1006/abbi.1995.1073	58	163	170	2	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 31	1996	271	22					12964	12971		10.1074/jbc.271.22.12964	http://dx.doi.org/10.1074/jbc.271.22.12964			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UN474	8662699	hybrid			2022-12-25	WOS:A1996UN47400045
J	Hirano, M; Osada, S; Aoki, T; Hirai, S; Hosaka, M; Inoue, J; Ohno, S				Hirano, M; Osada, S; Aoki, T; Hirai, S; Hosaka, M; Inoue, J; Ohno, S			MEK kinase is involved in tumor necrosis factor alpha-induced NF-kappa B activation and degradation of I kappa B-alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ZETA-SUBSPECIES BLOCKS; PROTEIN-KINASE; TRANSCRIPTION FACTOR; GENE-EXPRESSION; PHOSPHORYLATION; INHIBITOR; ENCODES; ELEMENT; VIRUS; CELLS	Signal-dependent activation of the transcription factor NF-kappa B is dominantly regulated by degradation of I kappa B-alpha protein. However, the signaling pathways that lead to the degradation are not clear. Here we report that mitogen-activated protein kinase/extracellular signal-regulated kinase kinase (MEK) kinase, an activator of stress-activated protein kinases/jun kinase-1 (SAPKs/JNK1), is involved in such signaling pathways. The transient overexpression of MEK kinase in NIH3T3 fibroblasts activates kappa B-CAT reporter expression in a synergistic: manner with TNF alpha stimulation. In contrast, overexpression of kinase-negative MEK kinase suppresses TNF alpha-induced reporter expression. The overexpression of MEK kinase suppresses the inhibitory activity of co-transfected I kappa B-alpha on the kappa B-CAT or human immunodeficiency virus-long terminal repeat-luciferase reporter expression and causes the simultaneous disappearance of the overexpressed I kappa B-alpha. The disappearance of exogenous I kappa B-alpha by the overexpression of MER kinase is prevented by calpain inhibitor-I, an inhibitor of I kappa B-alpha degradation. These results suggest that MEK kinase is a signal mediator involved in TNF alpha-induced NF-kappa B activation and that the activation of NF-kappa B by MER kinase is regulated through the degradation of I kappa B-alpha.	YOKOHAMA CITY UNIV,SCH MED,DEPT BIOL MOLEC,KANAZAWA KU,YOKOHAMA,KANAGAWA 236,JAPAN; YOKOHAMA CITY UNIV,SCH MED,DEPT UROL,KANAZAWA KU,YOKOHAMA,KANAGAWA 236,JAPAN; UNIV TOKYO,INST MED SCI,DEPT ONCOL,MINATO KU,TOKYO 108,JAPAN	Yokohama City University; Yokohama City University; University of Tokyo			Ohno, Shigeo/B-1768-2010	Ohno, Shigeo/0000-0002-1294-5269; Osada, Shin-Ichi/0000-0001-5387-085X				BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; BEG AA, 1993, MOL CELL BIOL, V13, P3301, DOI 10.1128/MCB.13.6.3301; BROCKMAN JA, 1995, MOL CELL BIOL, V15, P2809; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; BROWN K, 1993, P NATL ACAD SCI USA, V90, P2532, DOI 10.1073/pnas.90.6.2532; CHEN Z, 1955, GENE DEV, V9, P1586; CORDLE SR, 1993, J BIOL CHEM, V268, P11803; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DEVARY Y, 1993, SCIENCE, V261, P1442, DOI 10.1126/science.8367725; DIAZMECO MT, 1994, EMBO J, V13, P2842, DOI 10.1002/j.1460-2075.1994.tb06578.x; DIAZMECO MT, 1993, MOL CELL BIOL, V13, P4770, DOI 10.1128/MCB.13.8.4770; DIDONATO JA, 1995, MOL CELL BIOL, V15, P1302; DOMINGUEZ I, 1993, MOL CELL BIOL, V13, P1290, DOI 10.1128/MCB.13.2.1290; FINCO TS, 1993, J BIOL CHEM, V268, P17676; FUJITA T, 1989, NUCLEIC ACIDS RES, V17, P3335, DOI 10.1093/nar/17.9.3335; FUJITA T, 1993, GENE DEV, V7, P1354, DOI 10.1101/gad.7.7b.1354; GENOT EM, 1995, J BIOL CHEM, V270, P9833, DOI 10.1074/jbc.270.17.9833; HASKILL S, 1991, CELL, V65, P1281, DOI 10.1016/0092-8674(91)90022-Q; HENKEL T, 1993, NATURE, V365, P182, DOI 10.1038/365182a0; Hirai S, 1996, ONCOGENE, V12, P641; HIRANO M, 1995, BIOCHEM BIOPH RES CO, V206, P429, DOI 10.1006/bbrc.1995.1059; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; LI SF, 1993, P NATL ACAD SCI USA, V90, P9247, DOI 10.1073/pnas.90.20.9247; LIN YC, 1995, P NATL ACAD SCI USA, V92, P552, DOI 10.1073/pnas.92.2.552; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; MIYAMOTO S, 1994, P NATL ACAD SCI USA, V91, P12740, DOI 10.1073/pnas.91.26.12740; NABEL G, 1987, NATURE, V326, P711, DOI 10.1038/326711a0; OHNO S, 1988, CELL, V53, P731, DOI 10.1016/0092-8674(88)90091-8; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; ROSENTHAL N, 1983, SCIENCE, V222, P749, DOI 10.1126/science.6314501; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; SUN SC, 1993, SCIENCE, V259, P1912, DOI 10.1126/science.8096091; TRAENCKNER EBM, 1995, EMBO J, V14, P2876, DOI 10.1002/j.1460-2075.1995.tb07287.x; TRAENCKNER EBM, 1994, EMBO J, V13, P5433, DOI 10.1002/j.1460-2075.1994.tb06878.x; WINSTON BW, 1995, P NATL ACAD SCI USA, V92, P1614, DOI 10.1073/pnas.92.5.1614; YAN MH, 1994, NATURE, V372, P798; YAN MH, 1994, J BIOL CHEM, V269, P19067	38	155	157	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 31	1996	271	22					13234	13238		10.1074/jbc.271.22.13234	http://dx.doi.org/10.1074/jbc.271.22.13234			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UN474	8662753	hybrid			2022-12-25	WOS:A1996UN47400084
J	Kurita, K; Honda, K; Suzuma, S; Takamatsu, H; Nakamura, K; Yamane, K				Kurita, K; Honda, K; Suzuma, S; Takamatsu, H; Nakamura, K; Yamane, K			Identification of a region of Bacillus subtilis Ffh, a homologue of mammalian SRP54 protein, that is essential for binding to small cytoplasmic RNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-RECOGNITION PARTICLE; METHIONINE-RICH DOMAIN; COLI 4.5S RNA; SITE-SPECIFIC MUTAGENESIS; ESCHERICHIA-COLI; ENDOPLASMIC-RETICULUM; NASCENT PREPROLACTIN; SACCHAROMYCES-CEREVISIAE; SEQUENCE RECOGNITION; PHENOTYPIC SELECTION	Bacillus subtilis Ffh and scRNA are homologues of mammalian SRP54 and SR9 RNA, respectively, which are components of the eukaryotic signal recognition particle (SR9). Ffh (446 amino acids) interacts with scRNA to form a stable complex in vivo. Here, we identified an RNA-binding domain of Ffh. The results obtained using a series of deletion mutants show that amino acid positions 364 to 432 in the C-terminal region of Ffh correlates with its ability to bind RNA. The amino acid sequence of this region is well conserved among members of the SRP54 protein family. This sequence contains two hydrophobic regions (h2, 364 to 391, and h3, 416 to 435), separated by the positively charged amino acid motif, (398)RRKRIAKGSG(407). Among the basic amino acid residues in this region, Arg-401 was essential for binding to scRNA, but Arg-399 and Lys-400 were not. The co-existence of Arg-398 and Lye-404 was necessary for the same affinity as wild type Ffh. The two glycine residues of the (405)GSG(407) were also essential. MH23 peptide (91 amino acids) encompassing from 356 to 446, consisting of h2-RRKRIAKGSG-h3, bound scRNA with the same affinity as wild type Ffh, whereas a 24-amino acid synthetic peptide (392)DIINASRRKRIAKGSGTSVQEVNR(415) did not. The region containing two hydrophobic segments separated by the positively charged motif is the minimal requirement of Ffh for RNA binding.	UNIV TSUKUBA,INST BIOL SCI,TSUKUBA,IBARAKI 305,JAPAN	University of Tsukuba								AEVARSSON A, 1994, EMBO J, V13, P3669, DOI 10.1002/j.1460-2075.1994.tb06676.x; AMAYA Y, 1990, J BIOCHEM-TOKYO, V107, P457, DOI 10.1093/oxfordjournals.jbchem.a123067; BERNSTEIN HD, 1989, NATURE, V340, P482, DOI 10.1038/340482a0; BURD CG, 1994, SCIENCE, V265, P615, DOI 10.1126/science.8036511; BYSTROM AS, 1983, EMBO J, V2, P899, DOI 10.1002/j.1460-2075.1983.tb01519.x; CZARNOTA GJ, 1994, J STRUCT BIOL, V113, P35, DOI 10.1006/jsbi.1994.1030; FRANKLIN AE, 1993, J BIOL CHEM, V268, P22175; HANN BC, 1989, J CELL BIOL, V109, P3223, DOI 10.1083/jcb.109.6.3223; HANN BC, 1991, CELL, V67, P131, DOI 10.1016/0092-8674(91)90577-L; HIGH S, 1991, J CELL BIOL, V113, P229, DOI 10.1083/jcb.113.2.229; HONDA K, 1993, J BACTERIOL, V175, P4885, DOI 10.1128/JB.175.15.4885-4894.1993; HOU Y, 1994, J BACTERIOL, V176, P7038, DOI 10.1128/JB.176.22.7038-7044.1994; JAEGER JA, 1989, P NATL ACAD SCI USA, V86, P7706, DOI 10.1073/pnas.86.20.7706; Johnston D.S.T., 1992, P NATL ACAD SCI USA, V89, P10979; KHARRAT A, 1995, EMBO J, V14, P3572, DOI 10.1002/j.1460-2075.1995.tb07363.x; KRIEG UC, 1986, P NATL ACAD SCI USA, V83, P8604, DOI 10.1073/pnas.83.22.8604; KROLKIEWICZ S, 1994, MOL GEN GENET, V245, P565, DOI 10.1007/BF00282219; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; KURZCHALIA TV, 1986, NATURE, V320, P634, DOI 10.1038/320634a0; LARSEN N, 1991, NUCLEIC ACIDS RES, V19, P209, DOI 10.1093/nar/19.2.209; LIFSON JD, 1988, SCIENCE, V241, P712, DOI 10.1126/science.2969619; LINDSTROM JT, 1993, PLANT MOL BIOL, V23, P1265, DOI 10.1007/BF00042359; LUIRINK J, 1992, NATURE, V359, P741, DOI 10.1038/359741a0; LUTCKE H, 1992, EMBO J, V11, P1543, DOI 10.1002/j.1460-2075.1992.tb05199.x; MEYER DI, 1982, NATURE, V297, P647, DOI 10.1038/297647a0; MOAZED D, 1988, NATURE, V334, P362, DOI 10.1038/334362a0; NAKAMURA K, 1992, J BACTERIOL, V174, P2185, DOI 10.1128/JB.174.7.2185-2192.1992; NAKAMURA K, 1994, BIOCHEM BIOPH RES CO, V199, P1394, DOI 10.1006/bbrc.1994.1385; NISHIGUCHI M, 1994, J BACTERIOL, V176, P157, DOI 10.1128/JB.176.1.157-165.1994; PORITZ MA, 1990, SCIENCE, V250, P1111, DOI 10.1126/science.1701272; RIBES V, 1990, CELL, V63, P591, DOI 10.1016/0092-8674(90)90454-M; ROMISCH K, 1989, NATURE, V340, P478, DOI 10.1038/340478a0; ROMISCH K, 1990, J CELL BIOL, V111, P1793, DOI 10.1083/jcb.111.5.1793; SAMUELSSON T, 1993, NUCLEIC ACIDS RES, V21, P847, DOI 10.1093/nar/21.4.847; SAMUELSSON T, 1992, NUCLEIC ACIDS RES, V20, P5763, DOI 10.1093/nar/20.21.5763; SELINGER D, 1994, NUCLEIC ACIDS RES, V22, P2557, DOI 10.1093/nar/22.13.2557; SELINGER D, 1993, MOL CELL BIOL, V13, P1353, DOI 10.1128/MCB.13.3.1353; SIEGEL V, 1988, P NATL ACAD SCI USA, V85, P1801, DOI 10.1073/pnas.85.6.1801; SKOLD SE, 1983, NUCLEIC ACIDS RES, V11, P4923, DOI 10.1093/nar/11.14.4923; WALTER P, 1981, J CELL BIOL, V91, P557, DOI 10.1083/jcb.91.2.557; WALTER P, 1981, J CELL BIOL, V91, P545, DOI 10.1083/jcb.91.2.545; WALTER P, 1982, NATURE, V299, P691, DOI 10.1038/299691a0; WIEDMANN M, 1987, J CELL BIOL, V104, P201, DOI 10.1083/jcb.104.2.201; WOOD H, 1992, NUCLEIC ACIDS RES, V20, P5919, DOI 10.1093/nar/20.22.5919; ZOPF D, 1993, J CELL BIOL, V120, P1113, DOI 10.1083/jcb.120.5.1113; ZOPF D, 1990, EMBO J, V9, P4511, DOI 10.1002/j.1460-2075.1990.tb07902.x	47	36	37	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 31	1996	271	22					13140	13146		10.1074/jbc.271.22.13140	http://dx.doi.org/10.1074/jbc.271.22.13140			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UN474	8662730	hybrid			2022-12-25	WOS:A1996UN47400070
J	Nielsen, KL; Holtet, TL; Etzerodt, M; Moestrup, SK; Gliemann, J; SottrupJensen, L; Thogersen, HC				Nielsen, KL; Holtet, TL; Etzerodt, M; Moestrup, SK; Gliemann, J; SottrupJensen, L; Thogersen, HC			Identification of residues in alpha-macroglobulins important for binding to the alpha(2)-macroglobulin receptor low density lipoprotein receptor-related protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-2-MACROGLOBULIN RECEPTOR; MESSENGER-RNA; LIMITED PROTEOLYSIS; MOLECULAR-CLONING; DOMAIN-STRUCTURE; HIGH-AFFINITY; HALF-CYSTINE; SEQUENCE; INHIBITOR; COMPLEXES	Variants of the receptor binding domain of both human alpha(2)-macroglobulin and the corresponding domain of hen egg white ovomacroglobulin have been expressed in Escherichia coli and refolded in vitro, Competition experiments with methylamine treated alpha(2)-macroglobulin for binding to the multifunctional alpha(2)-macroglobulin receptor identify two Lys residues (residues 1370 and 1374 in human alpha(2)-macroglobulin) spaced by three amino acid residues as crucial for receptor binding, From this result and mutational evidence from other ligands for the alpha(2)-macroglobulin receptor, a tentative sequence motif for receptor binding is proposed.	AARHUS UNIV,DEPT CHEM,GENE EXPRESS LAB,DK-8000 AARHUS C,DENMARK; AARHUS UNIV,DEPT MOLEC BIOL,DK-8000 AARHUS C,DENMARK; AARHUS UNIV,DEPT BIOCHEM MED,DK-8000 AARHUS C,DENMARK	Aarhus University; Aarhus University; Aarhus University			Nielsen, Kåre Lehmann L/A-1181-2013; Moestrup, Søren Kragh/A-1403-2014; Moestrup, Søren Kragh/AAD-1735-2019	Nielsen, Kåre Lehmann L/0000-0002-5598-4401; Moestrup, Søren Kragh/0000-0003-3862-2107; 				BARKHOLT V, 1989, ANAL BIOCHEM, V177, P318, DOI 10.1016/0003-2697(89)90059-6; BEISIEGEL U, 1989, NATURE, V341, P162, DOI 10.1038/341162a0; BEISIEGEL U, 1991, P NATL ACAD SCI USA, V88, P8342, DOI 10.1073/pnas.88.19.8342; BRACIAK TA, 1988, J BIOL CHEM, V263, P3999; CHEN WJ, 1990, J BIOL CHEM, V265, P3116; CHRISTENSEN JH, 1991, FEBS LETT, V281, P181, DOI 10.1016/0014-5793(91)80388-J; DEVRIENDT K, 1991, BIOCHIM BIOPHYS ACTA, V1088, P95, DOI 10.1016/0167-4781(91)90157-H; EGGERTSEN G, 1991, MOL BIOL MED, V8, P287; ENGHILD JJ, 1989, BIOCHEMISTRY-US, V28, P1406, DOI 10.1021/bi00429a069; FELDMAN SR, 1984, ARCH BIOCHEM BIOPHYS, V235, P267, DOI 10.1016/0003-9861(84)90275-3; GEHRING MR, 1987, J BIOL CHEM, V262, P446; HERZ J, 1990, EMBO J, V9, P1769, DOI 10.1002/j.1460-2075.1990.tb08301.x; HERZ J, 1988, EMBO J, V7, P4119, DOI 10.1002/j.1460-2075.1988.tb03306.x; HERZ J, 1991, J BIOL CHEM, V266, P21232; HOLTET TL, 1994, FEBS LETT, V344, P242, DOI 10.1016/0014-5793(94)00349-1; HUBER R, 1970, NATURWISSENSCHAFTEN, V57, P389, DOI 10.1007/BF00599976; JONES DH, 1990, NATURE, V344, P793, DOI 10.1038/344793a0; KOUNNAS MZ, 1992, J BIOL CHEM, V267, P12420; KOWAL RC, 1989, P NATL ACAD SCI USA, V86, P5810, DOI 10.1073/pnas.86.15.5810; KRISTENSEN T, 1990, FEBS LETT, V276, P151, DOI 10.1016/0014-5793(90)80530-V; MOESTRUP SK, 1995, J CLIN INVEST, V96, P1404, DOI 10.1172/JCI118176; MOESTRUP SK, 1992, CELL TISSUE RES, V269, P375, DOI 10.1007/BF00353892; MOESTRUP SK, 1991, J BIOL CHEM, V266, P14011; MOESTRUP SK, 1993, J BIOL CHEM, V268, P13691; NIELSEN KL, 1994, DNA SEQUENCE, V5, P111, DOI 10.3109/10425179409039712; NYKJAER A, 1994, J BIOL CHEM, V269, P31747; NYKJAER A, 1992, J BIOL CHEM, V267, P14543; OVERBERGH L, 1991, J BIOL CHEM, V266, P16903; RUSSELL DW, 1983, P NATL ACAD SCI-BIOL, V80, P7501, DOI 10.1073/pnas.80.24.7501; SAITO A, 1994, P NATL ACAD SCI USA, V91, P9725, DOI 10.1073/pnas.91.21.9725; SALVESEN G, 1992, FEBS LETT, V313, P198, DOI 10.1016/0014-5793(92)81443-P; SOTTRUPJENSEN L, 1993, BIOCHEM MOL BIOL INT, V30, P789; SOTTRUPJENSEN L, 1986, FEBS LETT, V205, P20, DOI 10.1016/0014-5793(86)80857-2; SOTTRUPJENSEN L, 1984, J BIOL CHEM, V259, P8318; STRICKLAND DK, 1990, J BIOL CHEM, V265, P17401; TAKAHASHI S, 1992, P NATL ACAD SCI USA, V89, P9252, DOI 10.1073/pnas.89.19.9252; THOMSEN NK, 1993, ARCH BIOCHEM BIOPHYS, V300, P327, DOI 10.1006/abbi.1993.1045; VANLEUVEN F, 1992, EUR J BIOCHEM, V210, P319; VANLEUVEN F, 1981, J BIOL CHEM, V256, P9016; VANLEUVEN F, 1986, J BIOL CHEM, V261, P1369; VANLEUVEN F, 1986, J BIOL CHEM, V261, P6933; WARSHAWSKY I, 1995, BIOCHEMISTRY-US, V34, P3404, DOI 10.1021/bi00010a032; WILLIAMS SE, 1994, J BIOL CHEM, V269, P8653; WILLIAMS SE, 1992, J BIOL CHEM, V267, P9035; WILLNOW TE, 1992, J BIOL CHEM, V267, P26172	45	81	91	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 31	1996	271	22					12909	12912		10.1074/jbc.271.22.12909	http://dx.doi.org/10.1074/jbc.271.22.12909			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UN474	8662686	hybrid			2022-12-25	WOS:A1996UN47400036
J	Beard, WA; Osheroff, WP; Prasad, R; Sawaya, MR; Jaju, M; Wood, TG; Kraut, J; Kunkel, TA; Wilson, SH				Beard, WA; Osheroff, WP; Prasad, R; Sawaya, MR; Jaju, M; Wood, TG; Kraut, J; Kunkel, TA; Wilson, SH			Enzyme-DNA interactions required for efficient nucleotide incorporation and discrimination in human DNA polymerase beta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIV-1 REVERSE-TRANSCRIPTASE; MUTAGENESIS	In the crystal structure of a substrate complex, the side chains of residues Asn(279), Tyr(271), and Arg(283) of DNA polymerase beta are within hydrogen bonding distance to the bases of the incoming deoxynucleoside 5'-triphosphate (dNTP), the terminal primer nucleotide, and the templating nucleotide, respectively (Pelletier, H., Sawaya, M., R., Kumar, A., Wilson, S. H., and Kraut, J. (1994) Science 264, 1891-1903), We have altered these side chains through individual site-directed mutagenesis, Each mutant protein was expressed in Escherichia coli and was soluble, The mutant enzymes were purified and characterized to probe their role in nucleotide discrimination and catalysis, A reversion assay was developed on a short (5 nucleotide) gapped DNA substrate containing an opal codon to assess the effect of the amino acid substitutions on fidelity, Substitution of the tyrosine at position 271 with phenylalanine or histidine did not influence catalytic efficiency (k(cat)/K-m) or fidelity, The hydrogen bonding potential between the side chain of Asn(279) and the incoming nucleotide was removed by replacing this residue with alanine or leucine, Although catalytic efficiency was reduced as much as 17-fold for these mutants, fidelity was not, In contrast, both catalytic efficiency and fidelity decreased dramatically for all mutants of Arg(283) (Ala > Leu > Lys), The fidelity and catalytic efficiency of the alanine mutant of Arg(283) decreased 160- and 5000-fold, respectively, relative to wild-type enzyme, Sequence analyses of the mutant DNA resulting from short gap filling synthesis indicated that the types of base substitution errors produced by the wild-type and R283A mutant were similar and indicated misincorporations resulting in frequent T . dGTP and A . dGTP mispairing. With R283A, a dGMP was incorporated opposite a template thymidine as often as the correct nucleotide. The x-ray crystallographic structure of the alanine mutant of Arg(283) verified the loss of the mutated side chain, Our results indicate that specific interactions between DNA polymerase beta and the template base, but not hydrogen bonding to the incoming dNTP or terminal primer nucleotide, are required for both high catalytic efficiency and nucleotide discrimination.	UNIV TEXAS, MED BRANCH, SEALY CTR MOL SCI, GALVESTON, TX 77555 USA; NIEHS, MOLEC GENET LAB, RES TRIANGLE PK, NC 27709 USA; UNIV CALIF SAN DIEGO, DEPT CHEM, LA JOLLA, CA 92093 USA	University of Texas System; University of Texas Medical Branch Galveston; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); University of California System; University of California San Diego			Kunkel, Thomas A./D-5088-2019; Wood, Thomas/B-6172-2012; Wilson, Samuel H/E-6644-2019; Wood, Thomas/GWZ-2481-2022	Kunkel, Thomas A./0000-0002-9900-1788; Wilson, Samuel H/0000-0002-1702-5293; Wood, Thomas/0000-0001-8962-8571	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES006839, P30ES006676] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM052982] Funding Source: NIH RePORTER; NIEHS NIH HHS [ES06839, ES06676] Funding Source: Medline; NIGMS NIH HHS [GM52982] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Beard WA, 1995, METHOD ENZYMOL, V262, P98; BEARD WA, 1993, BIOCHEMISTRY-US, V32, P9745, DOI 10.1021/bi00088a029; Bebenek K, 1995, METHOD ENZYMOL, V262, P217; DIANOV G, 1994, CURR BIOL, V4, P1069, DOI 10.1016/S0960-9822(00)00245-1; ECHOLS H, 1991, ANNU REV BIOCHEM, V60, P477, DOI 10.1146/annurev.biochem.60.1.477; FEIG DI, 1993, BIOCHEMISTRY-US, V32, P4466, DOI 10.1021/bi00067a040; FEIG DI, 1994, J MOL BIOL, V235, P33, DOI 10.1016/S0022-2836(05)80009-9; HAMLIN R, 1985, METHOD ENZYMOL, V114, P416; HORTON JK, 1995, NUCLEIC ACIDS RES, V23, P3810, DOI 10.1093/nar/23.19.3810; JENKINS TM, 1992, SCIENCE, V258, P475, DOI 10.1126/science.1411545; JOYCE CM, 1995, J BACTERIOL, V177, P6321, DOI 10.1128/jb.177.22.6321-6329.1995; Kennard O, 1988, STRUCTURE EXPRESSION, V2, P1; KOHLSTAEDT LA, 1992, SCIENCE, V256, P1783, DOI 10.1126/science.1377403; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KUNKEL TA, 1985, J BIOL CHEM, V260, P5787; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; KUNKEL TA, 1988, J BIOL CHEM, V263, P14784; LINN S, 1991, CELL, V66, P185, DOI 10.1016/0092-8674(91)90608-2; PELLETIER H, 1994, SCIENCE, V264, P1891, DOI 10.1126/science.7516580; PELLETIER H, 1996, IN PRESS BIOCHEMISTR; PRASAD R, 1994, J BIOL CHEM, V269, P18096; ROBERTS JD, 1988, SCIENCE, V242, P1171, DOI 10.1126/science.2460925; SAWAYA MR, 1994, SCIENCE, V264, P1930, DOI 10.1126/science.7516581; SEEMAN NC, 1976, P NATL ACAD SCI USA, V73, P804, DOI 10.1073/pnas.73.3.804; SINGHAL RK, 1993, J BIOL CHEM, V268, P15906; SINGHAL RK, 1995, J BIOL CHEM, V270, P949, DOI 10.1074/jbc.270.2.949; Sobol RW, 1996, NATURE, V379, P183, DOI 10.1038/379183a0; SWEASY JB, 1992, J BIOL CHEM, V267, P1407; WIEBAUER K, 1990, P NATL ACAD SCI USA, V87, P5842, DOI 10.1073/pnas.87.15.5842	29	191	192	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 24	1996	271	21					12141	12144		10.1074/jbc.271.21.12141	http://dx.doi.org/10.1074/jbc.271.21.12141			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UL660	8647805	hybrid			2022-12-25	WOS:A1996UL66000007
J	Chobert, MN; Grondin, G; Brouillet, A; Laperche, Y; Beaudoin, AR				Chobert, MN; Grondin, G; Brouillet, A; Laperche, Y; Beaudoin, AR			Control of gamma-glutamyl transpeptidase expression by glucocorticoids in the rat pancreas - Correlation with granule formation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TISSUE-SPECIFIC EXPRESSION; ACINAR AR42J CELLS; SINGLE COPY GENE; EXOCRINE PANCREAS; TRANSFERASE TRANSPEPTIDASE; ZYMOGEN GRANULES; MEMBRANE-PROTEIN; MESSENGER-RNAS; AMYLASE GENE; SECRETION	Glucocorticoids are known to promote the formation of zymogen granules in acinar cells of the exocrine pancreas in vivo as well as in vitro. To gain insight into the mechanism of this regulation, we studied the effects of glucocorticoids on the synthesis of two components of the secretory granule membrane, the glycoprotein 2 (GP-2) and the gamma-glutamyl transpeptidase (GGT). It was demonstrated that following adrenalectomy, degranulation of pancreatic acinar cells is accompanied by a sharp decrease in GGT and GP-2 synthesis as measured by mRNA and protein accumulation. The decline of GGT synthesis was prevented by glucocorticoid replacement therapy, whereas GP-2 synthesis could be maintained with either glucocorticoid or estradiol treatment. These in vivo observations were corroborated and extended in an in vitro study using AR42J pancreatic cells. With this cell line, it was demonstrated that dexamethasone induces the formation of zymogen granules and the accumulation of a specific GGT transcript (mRNA III) by decreasing its degradation rate. At the same time, the GP-2 mRNA level was not modified by the hormonal treatment. These data demonstrate that glucocorticoids exert a positive control on the GGT expression in pancreatic cells at a post-transcriptional level. GGT, an enzyme of the glutathione metabolism, could play a significant role in protein packaging in secretory cells.	UNIV SHERBROOKE,FAC SCI,DEPT BIOL,SHERBROOKE,PQ J1K 2R1,CANADA	University of Sherbrooke	Chobert, MN (corresponding author), HOP HENRI MONDOR,INSERM,U99,F-94010 CRETEIL,FRANCE.		Brouillet, Arthur/S-4499-2018					ALONSO S, 1986, J MOL EVOL, V23, P11, DOI 10.1007/BF02100994; ANDERSON ME, 1980, J BIOL CHEM, V255, P9530; ANTRAS J, 1991, J BIOL CHEM, V266, P1157; ARVAN P, 1987, J CELL BIOL, V104, P243, DOI 10.1083/jcb.104.2.243; Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; BATTISTINI B, 1990, LIFE SCI, V47, P2435, DOI 10.1016/0024-3205(90)90488-D; BEAUDOIN AR, 1986, ENDOCRINOLOGY, V119, P2106, DOI 10.1210/endo-119-5-2106; BEAUDOIN AR, 1993, J HISTOCHEM CYTOCHEM, V41, P225, DOI 10.1177/41.2.7678269; BEAUDOIN AR, 1992, INT REV CYTOL, V132, P177, DOI 10.1016/S0074-7696(08)62456-0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROUILLET A, 1994, J BIOL CHEM, V269, P14878; CAMERON RS, 1986, J CELL BIOL, V103, P1299, DOI 10.1083/jcb.103.4.1299; CHIN RJ, 1992, J PEDIATR GASTROENTE, V12, P243; CHOBERT MN, 1990, J BIOL CHEM, V265, P2352; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DARBOUY M, 1991, AM J PHYSIOL, V261, pC1130, DOI 10.1152/ajpcell.1991.261.6.C1130; DITTIE A, 1992, EUR J CELL BIOL, V58, P243; FUKUOKA SI, 1991, P NATL ACAD SCI USA, V88, P2898, DOI 10.1073/pnas.88.7.2898; GITHENS S, 1991, INT J PANCREATOL, V8, P97; GRIFFITH OW, 1980, J BIOL CHEM, V255, P5011; GRONDIN G, 1992, EUR J CELL BIOL, V57, P155; GROSSMAN A, 1969, ENDOCRINOLOGY, V85, P956, DOI 10.1210/endo-85-5-956; HOBBS AA, 1982, J BIOL CHEM, V257, P3598; HOOPS TC, 1991, J BIOL CHEM, V266, P4257; HWANG C, 1992, SCIENCE, V257, P1496, DOI 10.1126/science.1523409; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAFOREST L, 1992, BIOCHEM BIOPH RES CO, V184, P888, DOI 10.1016/0006-291X(92)90674-A; LAHUNA O, 1992, BIOCHEMISTRY-US, V31, P9190, DOI 10.1021/bi00153a011; LAPERCHE Y, 1986, P NATL ACAD SCI USA, V83, P937, DOI 10.1073/pnas.83.4.937; LEBEL D, 1988, BIOCHEM BIOPH RES CO, V154, P818, DOI 10.1016/0006-291X(88)90213-6; LEE PC, 1990, BIOCHIM BIOPHYS ACTA, V1049, P244, DOI 10.1016/0167-4781(90)90093-H; LOGSDON CD, 1985, J CELL BIOL, V100, P1200, DOI 10.1083/jcb.100.4.1200; LOGSDON CD, 1986, J BIOL CHEM, V261, P2096; LOGSDON CD, 1987, J BIOL CHEM, V262, P15765; LU RB, 1987, J STEROID BIOCHEM, V26, P213; LYLES MM, 1991, BIOCHEMISTRY-US, V30, P613, DOI 10.1021/bi00217a004; MACDONALD RJ, 1980, NATURE, V287, P117, DOI 10.1038/287117a0; OKAMOTO T, 1994, BIOCHEMISTRY-US, V33, P11536, DOI 10.1021/bi00204a016; ORLOWSKI M, 1963, BIOCHIM BIOPHYS ACTA, V73, P679; PAEK I, 1987, MOL CELL BIOL, V87, P12496; PAQUET MR, 1982, EUR J CELL BIOL, V28, P20; PAWLAK A, 1988, J BIOL CHEM, V263, P9913; PHILIPPE J, 1990, ENDOCRINOLOGY, V127, P1640, DOI 10.1210/endo-127-4-1640; RONZIO RA, 1978, BIOCHIM BIOPHYS ACTA, V508, P65, DOI 10.1016/0005-2736(78)90189-X; SEVIGNY J, 1995, BIOCHEM J, V312, P351, DOI 10.1042/bj3120351; SIEGRIST S, 1990, BIOCHEM J, V267, P621, DOI 10.1042/bj2670621; WITHIAMLEITCH M, 1993, BIOCHEM BIOPH RES CO, V194, P1167, DOI 10.1006/bbrc.1993.1945	47	13	13	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 24	1996	271	21					12431	12437		10.1074/jbc.271.21.12431	http://dx.doi.org/10.1074/jbc.271.21.12431			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UL660	8647848	hybrid			2022-12-25	WOS:A1996UL66000050
J	Inagaki, H; Matsushima, Y; Nakamura, K; Ohshima, M; Kadowaki, T; Kitagawa, Y				Inagaki, H; Matsushima, Y; Nakamura, K; Ohshima, M; Kadowaki, T; Kitagawa, Y			A large DNA-binding nuclear protein with RNA recognition motif and serine/arginine-rich domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERMEDIATE FILAMENT PROTEINS; MOLECULAR-CLONING; DROSOPHILA-MELANOGASTER; ATTACHMENT SITES; MATRIX PROTEINS; HELA-CELLS; SEQUENCE; CDNA; GENE; ORGANIZATION	cDNA species encoding a large DNA-binding protein (NP220) of 1978 amino acids was isolated from human cDNA libraries. Human NP220 binds to double-stranded DNA fragments by recognizing clusters of cytidines. Immunofluorescent microscopy with antiserum directed against NP220 revealed a punctate or ''speckled'' pattern and coiled body-like structures in the nucleoplasm of various human cell lines. These structures diffused in the cytoplasm during mitosis. Western blot analysis showed that NP220 is enriched in the lithium 3,5-diiodosalicylate insoluble fraction of nuclei. The domain essential for DNA binding is localized in C-terminal half of NP220. Human NP220 shares three types of domains (MH1, MH2, and MH3) with the acidic nuclear protein, matrin 3 (Belgrader, P., Dey, R., and Berezney, R. (1991) J. Biol. Chem. 266, 9893-9899). MH1 is a 48-amino acid sequence near the N terminus of both human NP220 and rat matrin 3. MH2 is a 75-amino acid sequence homologous to the RNA recognition motifs of heterogeneous nuclear RNP I and L. It is repeated three times in NP220 and twice in matrin 3. MH3 is a 60-amino acid sequence at the C terminus of both NP220 and matrin 3. NP220 has an arginine/serine rich domain commonly found in pre-mRNA splicing factors. Close to the domain essential for DNA binding, there are nine repeats of the sequence LVTVDEVIEEEDL. Thus, NP220 is a novel type of nucleoplasmic protein with multiple domains.	NAGOYA UNIV, BIOSCI CTR, CHIKUSA KU, NAGOYA, AICHI 46401, JAPAN; NAGOYA UNIV, SCH AGR SCI, GRAD PROGRAM BIOCHEM REGULAT, NAGOYA, AICHI 46401, JAPAN	Nagoya University; Nagoya University			Inagaki, Hidetoshi/J-9071-2018	Inagaki, Hidetoshi/0000-0001-7820-3420				AMREIN H, 1988, CELL, V55, P1025, DOI 10.1016/0092-8674(88)90247-4; ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0; BALL EE, 1991, NUCLEIC ACIDS RES, V19, P397, DOI 10.1093/nar/19.2.397; BELGRADER P, 1991, J BIOL CHEM, V266, P9893; BEREZNEY R, 1974, BIOCHEM BIOPH RES CO, V60, P1410, DOI 10.1016/0006-291X(74)90355-6; BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; BOGGS RT, 1987, CELL, V50, P739, DOI 10.1016/0092-8674(87)90332-1; BONIFER C, 1991, J CELL BIOCHEM, V47, P99, DOI 10.1002/jcb.240470203; BURD CG, 1994, SCIENCE, V265, P615, DOI 10.1126/science.8036511; BURD CG, 1989, P NATL ACAD SCI USA, V86, P9788, DOI 10.1073/pnas.86.24.9788; BUVOLI M, 1988, NUCLEIC ACIDS RES, V16, P3751, DOI 10.1093/nar/16.9.3751; CHOU TB, 1987, EMBO J, V6, P4095, DOI 10.1002/j.1460-2075.1987.tb02755.x; COOK PR, 1991, CELL, V66, P627, DOI 10.1016/0092-8674(91)90109-C; DICKINSON LA, 1992, CELL, V70, P631, DOI 10.1016/0092-8674(92)90432-C; Dubnau J, 1996, NATURE, V379, P694, DOI 10.1038/379694a0; Fakan Stanislav, 1994, Trends in Cell Biology, V4, P86, DOI 10.1016/0962-8924(94)90180-5; FERREIRA JA, 1994, J CELL BIOL, V126, P11, DOI 10.1083/jcb.126.1.11; FISHER DZ, 1986, P NATL ACAD SCI USA, V83, P6450, DOI 10.1073/pnas.83.17.6450; FRANGIONI JV, 1992, CELL, V68, P545, DOI 10.1016/0092-8674(92)90190-N; FREY MR, 1995, P NATL ACAD SCI USA, V92, P5915, DOI 10.1073/pnas.92.13.5915; Frohman Michael A., 1994, P14; FU XD, 1992, SCIENCE, V256, P535, DOI 10.1126/science.1373910; GASSER SM, 1989, INT REV CYTOL, V119, P57; GASSER SM, 1987, TRENDS GENET, V3, P16, DOI 10.1016/0168-9525(87)90156-9; GE H, 1991, CELL, V66, P373, DOI 10.1016/0092-8674(91)90626-A; GHETTI A, 1992, NUCLEIC ACIDS RES, V20, P3671, DOI 10.1093/nar/20.14.3671; GIL A, 1991, GENE DEV, V5, P1224, DOI 10.1101/gad.5.7.1224; HAKES DJ, 1991, P NATL ACAD SCI USA, V88, P6186, DOI 10.1073/pnas.88.14.6186; HAKES DJ, 1991, J BIOL CHEM, V266, P11131; HOGER TH, 1988, EUR J CELL BIOL, V47, P283; JACKSON DA, 1990, NUCLEIC ACIDS RES, V18, P4385, DOI 10.1093/nar/18.15.4385; KAY BK, 1990, P NATL ACAD SCI USA, V87, P1367, DOI 10.1073/pnas.87.4.1367; KOZAK M, 1984, NATURE, V308, P241, DOI 10.1038/308241a0; KRAINER AR, 1991, CELL, V66, P383, DOI 10.1016/0092-8674(91)90627-B; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LASSAR AB, 1989, CELL, V58, P823, DOI 10.1016/0092-8674(89)90935-5; LUDERUS MEE, 1992, CELL, V70, P949, DOI 10.1016/0092-8674(92)90245-8; MARUYAMA K, 1984, J BIOCHEM-TOKYO, V95, P511, DOI 10.1093/oxfordjournals.jbchem.a134633; MATERA AG, 1993, J CELL BIOL, V121, P715, DOI 10.1083/jcb.121.4.715; MATUNIS EL, 1992, J CELL BIOL, V116, P257, DOI 10.1083/jcb.116.2.257; MCKEON FD, 1986, NATURE, V319, P463, DOI 10.1038/319463a0; MIRKOVITCH J, 1984, CELL, V39, P223, DOI 10.1016/0092-8674(84)90208-3; MISKIMINS WK, 1985, P NATL ACAD SCI USA, V82, P6741, DOI 10.1073/pnas.82.20.6741; NAKAYASU H, 1991, P NATL ACAD SCI USA, V88, P10312, DOI 10.1073/pnas.88.22.10312; NEUGEBAUER KM, 1995, J CELL BIOL, V129, P899, DOI 10.1083/jcb.129.4.899; NYMAN U, 1986, J CELL BIOL, V102, P137, DOI 10.1083/jcb.102.1.137; PATTON JG, 1991, GENE DEV, V5, P1237, DOI 10.1101/gad.5.7.1237; PINOLROMA S, 1989, J CELL BIOL, V109, P2575, DOI 10.1083/jcb.109.6.2575; QUERY CC, 1989, CELL, V57, P89, DOI 10.1016/0092-8674(89)90175-X; REUTER R, 1984, EXP CELL RES, V154, P548, DOI 10.1016/0014-4827(84)90179-4; RiveraPomar R, 1996, NATURE, V379, P746, DOI 10.1038/379746a0; ROMIG H, 1992, EMBO J, V11, P3431, DOI 10.1002/j.1460-2075.1992.tb05422.x; ROTH MB, 1990, J CELL BIOL, V111, P2217, DOI 10.1083/jcb.111.6.2217; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SINGH H, 1988, CELL, V52, P415, DOI 10.1016/S0092-8674(88)80034-5; SPECTOR DL, 1993, ANNU REV CELL BIOL, V9, P265, DOI 10.1146/annurev.cellbio.9.1.265; STADEN R, 1982, NUCLEIC ACIDS RES, V10, P2951, DOI 10.1093/nar/10.9.2951; THEISSEN H, 1986, EMBO J, V5, P3209, DOI 10.1002/j.1460-2075.1986.tb04631.x; THEUNISSEN O, 1992, CELL, V71, P679, DOI 10.1016/0092-8674(92)90601-8; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TUFTY RM, 1975, SCIENCE, V187, P167, DOI 10.1126/science.1111094; VERHEIJEN R, 1988, J CELL SCI, V90, P11; VONKRIES JP, 1991, CELL, V64, P123, DOI 10.1016/0092-8674(91)90214-J; WALBERG MW, 1981, NUCLEIC ACIDS RES, V9, P5411, DOI 10.1093/nar/9.20.5411; ZAMORE PD, 1992, NATURE, V355, P609, DOI 10.1038/355609a0	65	35	37	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 24	1996	271	21					12525	12531		10.1074/jbc.271.21.12525	http://dx.doi.org/10.1074/jbc.271.21.12525			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UL660	8647861	hybrid			2022-12-25	WOS:A1996UL66000063
J	Yurchak, LK; Hardwick, JS; Amrein, K; Pierno, K; Sefton, BM				Yurchak, LK; Hardwick, JS; Amrein, K; Pierno, K; Sefton, BM			Stimulation of phosphorylation of Tyr(394) by hydrogen peroxide reactivates biologically inactive, non-membrane-bound forms of Lck	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE-PROTEIN-KINASE; T-CELL ACTIVATION; LYMPHOCYTES-T; P56LCK; P56(LCK); GENE; CD4; SRC; AUTOPHOSPHORYLATION; EXPRESSION	Lck, a lymphocyte-specific tyrosine protein kinase, is bound to cellular membranes as the result of myristoylation and palmitoylation of its amino terminus. Its activity is inhibited by phosphorylation of tyrosine 505 and stimulated by phosphorylation of tyrosine 394. The Tyr-505 --> Phe mutant of Lck (F505Lck) exhibits elevated biological activity and constitutive phosphorylation of Tyr-394 in vivo. Mutations at sites of fatty acyla tion that prevent F505Lck from associating with cellular membranes abolish the biological activity of the molecule in vivo, compromise its activity as a protein kinase in vivo and in vitro, and eliminate the phosphorylation of Tyr-394. Here, we show that exposure of cells expressing cytoplasmic or nuclear forms of F505Lck to H2O2, a general inhibitor of tyrosine protein phosphatases, restores the catalytic activity of these mutant proteins through stimulation of phosphorylation of Tyr-394. H2O2 treatment induced the phosphorylation of Tyr-394 on catalytically inactive forms of Lck regardless of cellular localization. Phosphorylation of Tyr-394 therefore need not occur by autophosphorylation. Thus, there appear to be two mechanisms through which the phosphorylation of Lck at Tyr-394 can occur. One is restricted to the plasma membrane and does not require the presence of oxidants. The other is operational in the nucleus as well as the cytosol and is responsive to oxidants.	SALK INST,MOLEC BIOL & VIROL LAB,SAN DIEGO,CA 92186; UNIV CALIF SAN DIEGO,DEPT BIOL,SAN DIEGO,CA 92037; UNIV CALIF SAN DIEGO,PROGRAM MOL PATHOL,SAN DIEGO,CA 92037	Salk Institute; University of California System; University of California San Diego; University of California System; University of California San Diego					NCI NIH HHS [CA 42350, CA 17289, CA 14195] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA042350, P30CA014195, R01CA017289] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABRAHAM N, 1990, MOL CELL BIOL, V10, P5197, DOI 10.1128/MCB.10.10.5197; ABRAHAM N, 1991, NATURE, V350, P62, DOI 10.1038/350062a0; ALLEN JM, 1992, MOL CELL BIOL, V12, P2758, DOI 10.1128/MCB.12.6.2758; AMREIN KE, 1988, P NATL ACAD SCI USA, V85, P4247, DOI 10.1073/pnas.85.12.4247; BERGMAN M, 1992, EMBO J, V11, P2919, DOI 10.1002/j.1460-2075.1992.tb05361.x; BOULET I, 1987, BIOCHEM BIOPH RES CO, V149, P56, DOI 10.1016/0006-291X(87)91604-4; BUSS JE, 1986, J VIROL, V4, P2696; CAMPBELL MA, 1990, EMBO J, V9, P2125, DOI 10.1002/j.1460-2075.1990.tb07381.x; COLLINS TL, 1993, P NATL ACAD SCI USA, V90, P11885, DOI 10.1073/pnas.90.24.11885; HARDWICK JS, 1995, P NATL ACAD SCI USA, V92, P4527, DOI 10.1073/pnas.92.10.4527; HEFFETZ D, 1990, J BIOL CHEM, V265, P2896; HUNTER T, 1980, P NATL ACAD SCI-BIOL, V77, P1311, DOI 10.1073/pnas.77.3.1311; HURLEY TR, 1989, ONCOGENE, V4, P265; KAMPS MP, 1988, ONCOGENE, V2, P305; KARNITZ L, 1992, MOL CELL BIOL, V12, P4521, DOI 10.1128/MCB.12.10.4521; KWONG J, 1995, BIOCHEM BIOPH RES CO, V207, P868, DOI 10.1006/bbrc.1995.1266; LANDAU NR, 1992, J VIROL, V66, P5110, DOI 10.1128/JVI.66.8.5110-5113.1992; LUO K, 1990, ONCOGENE, V5, P921; LUO KX, 1992, MOL CELL BIOL, V12, P4724, DOI 10.1128/MCB.12.10.4724; MARCHILDON GA, 1984, P NATL ACAD SCI-BIOL, V81, P7679, DOI 10.1073/pnas.81.24.7679; MARTH JD, 1988, MOL CELL BIOL, V8, P540, DOI 10.1128/MCB.8.2.540; MARTH JD, 1985, CELL, V43, P393, DOI 10.1016/0092-8674(85)90169-2; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; MOLINA TJ, 1992, NATURE, V357, P161, DOI 10.1038/357161a0; MULLER AJ, 1991, MOL CELL BIOL, V11, P1785, DOI 10.1128/MCB.11.4.1785; NAKAMURA K, 1993, ONCOGENE, V8, P3133; O'SHEA JJ, 1992, P NATL ACAD SCI USA, V89, P10306, DOI 10.1073/pnas.89.21.10306; PAIGE LA, 1993, J BIOL CHEM, V268, P8669; REYNOLDS AB, 1989, MOL CELL BIOL, V9, P629, DOI 10.1128/MCB.9.2.629; ROBERTS BL, 1987, CELL, V50, P465, DOI 10.1016/0092-8674(87)90500-9; RODGERS W, 1994, MOL CELL BIOL, V14, P5384, DOI 10.1128/MCB.14.8.5384; RUDD CE, 1988, P NATL ACAD SCI USA, V85, P5190, DOI 10.1073/pnas.85.14.5190; SCHIEVEN GL, 1993, MOL BIOL CELL, V4, P523, DOI 10.1091/mbc.4.5.523; SECRIST JP, 1993, J BIOL CHEM, V268, P5886; SHENOYSCARIA AM, 1993, MOL CELL BIOL, V13, P6385, DOI 10.1128/MCB.13.10.6385; SIEH M, 1993, EMBO J, V12, P315, DOI 10.1002/j.1460-2075.1993.tb05659.x; STEFANOVA I, 1991, SCIENCE, V254, P1016, DOI 10.1126/science.1719635; STRAUS DB, 1992, CELL, V70, P585, DOI 10.1016/0092-8674(92)90428-F; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VEILLETTE A, 1990, ONCOGENE, V5, P1455; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; VORONOVA AF, 1986, NATURE, V319, P682, DOI 10.1038/319682a0; YURCHAK LK, 1995, MOL CELL BIOL, V15, P6914, DOI 10.1128/mcb.15.12.6914	43	23	23	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 24	1996	271	21					12549	12554		10.1074/jbc.271.21.12549	http://dx.doi.org/10.1074/jbc.271.21.12549			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UL660	8647864	hybrid			2022-12-25	WOS:A1996UL66000066
J	Fang, SM; Burton, ZF				Fang, SM; Burton, ZF			RNA polymerase II-associated protein (RAP) 74 binds transcription factor (TF) IIB and blocks TFIIB-RAP30 binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-TFIIB; INITIATION-FACTOR; PREINITIATION COMPLEX; FUNCTIONAL DOMAINS; SUBUNIT; PURIFICATION; SELECTION; SEQUENCE; RAP30/74; CDNA	A set of deletion mutants of human RNA polymerase II-associated protein (RAP) 30, the small subunit of transcription factor IIF (TFIIF; RAP30/74), was constructed to map functional domains. Mutants were tested for accurate transcriptional activity, RAP74 binding, and TFIIB binding. Transcription assays indicate the importance of both N- and C-terminal sequences for RAP30 function. RAP74 binds to the N-terminal region of RAP30 between amino acids 1 and 98. TFIIB binds to an overlapping region of RAP30, localized to amino acids 1-176 (amino acids 27-152 comprise a minimal binding region), The C-terminal region of RAP74 (amino acids 358-517) binds directly and independently to TFIIB, Interestingly, RAP74 blocks TFIIB-RAP30 binding, both by binding TFIIB and by binding RAP30. When the TFIIF complex is intact, therefore, TFIIB TFIIF contact is maintained through RAP74. If the TFIIB-RAP30 interaction is physiologically important, the TFIIF complex must dissociate within some transcription complexes.	MICHIGAN STATE UNIV,DEPT BIOCHEM,E LANSING,MI 48824	Michigan State University								ASO T, 1992, NATURE, V355, P461, DOI 10.1038/355461a0; BAGBY S, 1995, CELL, V82, P857, DOI 10.1016/0092-8674(95)90483-2; BERROTERAN RW, 1994, MOL CELL BIOL, V14, P226, DOI 10.1128/MCB.14.1.226; BURATOWSKI S, 1993, P NATL ACAD SCI USA, V90, P5633, DOI 10.1073/pnas.90.12.5633; BURATOWSKI S, 1989, CELL, V56, P549, DOI 10.1016/0092-8674(89)90578-3; CHAMBERS RS, 1995, J BIOL CHEM, V270, P14962, DOI 10.1074/jbc.270.25.14962; CHAMBERS RS, 1994, J BIOL CHEM, V269, P26243; CHANG CH, 1993, J BIOL CHEM, V268, P20482; CONAWAY JW, 1989, J BIOL CHEM, V264, P2357; CONAWAY RC, 1991, P NATL ACAD SCI USA, V88, P6205, DOI 10.1073/pnas.88.14.6205; CORDEN JL, 1992, TRANSCRIPTIONAL REGU, P81; DAHMUS ME, 1994, TRANSCRIPTION MECHAN, P243; FINKELSTEIN A, 1992, NATURE, V355, P464, DOI 10.1038/355464a0; FLORES O, 1990, J BIOL CHEM, V265, P5629; FLORES O, 1988, J BIOL CHEM, V263, P10812; FLORES O, 1991, P NATL ACAD SCI USA, V88, P9999, DOI 10.1073/pnas.88.22.9999; GARRETT KP, 1992, J BIOL CHEM, V267, P23942; HA I, 1993, GENE DEV, V7, P1021, DOI 10.1101/gad.7.6.1021; HA L, 1991, NATURE, V352, P689; HISATAKE K, 1993, NATURE, V363, P744, DOI 10.1038/363744a0; HODO HG, 1977, BIOCHEMISTRY-US, V16, P2334, DOI 10.1021/bi00630a005; KILLEEN M, 1992, J BIOL CHEM, V267, P9463; KITAJIMA S, 1990, NUCLEIC ACIDS RES, V18, P4843, DOI 10.1093/nar/18.16.4843; KITAJIMA S, 1994, J BIOL CHEM, V269, P29970; LI Y, 1994, SCIENCE, V263, P805, DOI 10.1126/science.8303296; LUTHY R, 1990, SEQUENCE ANAL PRIMER, P61; MALDONADO E, 1990, MOL CELL BIOL, V10, P6335, DOI 10.1128/MCB.10.12.6335; MALIK S, 1991, P NATL ACAD SCI USA, V88, P9553, DOI 10.1073/pnas.88.21.9553; MALIK S, 1993, MOL CELL BIOL, V13, P6253, DOI 10.1128/MCB.13.10.6253; MARSZALEK J, 1994, J BIOL CHEM, V269, P4883; MCCRACKEN S, 1991, SCIENCE, V253, P900, DOI 10.1126/science.1652156; NIKOLOV DB, 1995, NATURE, V377, P119, DOI 10.1038/377119a0; PARVIN JD, 1993, CELL, V73, P533, DOI 10.1016/0092-8674(93)90140-L; PINTO I, 1992, CELL, V68, P977, DOI 10.1016/0092-8674(92)90040-J; PINTO I, 1994, J BIOL CHEM, V269, P30569; ROBERTS SGE, 1993, NATURE, V363, P741, DOI 10.1038/363741a0; ROBERTS SGE, 1994, NATURE, V371, P717, DOI 10.1038/371717a0; SERIZAWA H, 1994, TRANSCRIPTION MECHAN, P27; SOPTA M, 1989, NATURE, V341, P410, DOI 10.1038/341410a0; SUN Z, 1994, P NATL ACAD SCI USA, V92, P3127; TAN SY, 1994, P NATL ACAD SCI USA, V91, P9808, DOI 10.1073/pnas.91.21.9808; TAN SY, 1995, P NATL ACAD SCI USA, V92, P6042, DOI 10.1073/pnas.92.13.6042; USHEVA A, 1994, CELL, V76, P1115, DOI 10.1016/0092-8674(94)90387-5; WANG BQ, 1993, PROTEIN EXPRES PURIF, V4, P207, DOI 10.1006/prep.1993.1027; WANG BQ, 1995, J BIOL CHEM, V270, P27035, DOI 10.1074/jbc.270.45.27035; YONAHA M, 1993, NUCLEIC ACIDS RES, V21, P273, DOI 10.1093/nar/21.2.273; ZAWEL L, 1993, PROG NUCLEIC ACID RE, V44, P67, DOI 10.1016/S0079-6603(08)60217-2; ZAWEL L, 1995, ANNU REV BIOCHEM, V64, P533	48	45	45	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 17	1996	271	20					11703	11709		10.1074/jbc.271.20.11703	http://dx.doi.org/10.1074/jbc.271.20.11703			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UL250	8662660	hybrid			2022-12-25	WOS:A1996UL25000021
J	Ordentlich, A; Barak, D; Kronman, C; Ariel, N; Segall, Y; Velan, B; Shafferman, A				Ordentlich, A; Barak, D; Kronman, C; Ariel, N; Segall, Y; Velan, B; Shafferman, A			The architecture of human acetylcholinesterase active center probed by interactions with selected organophosphate inhibitors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECOMBINANT HUMAN ACETYLCHOLINESTERASE; RESIDUES; SUBSTRATE; ENZYME; CHOLINESTERASE; MUTAGENESIS; CONSTANTS; BUTYRYLCHOLINESTERASE; IDENTIFICATION; DETERMINANTS	The role of the functional architecture of human acetylcholinesterase (HuAChE) active center in facilitating reactions with organophosphorus inhibitors was examined by a combination of site-directed mutagenesis and kinetic studies of phosphorylation with organophosphates differing in size of their alkoxy substituents and in the nature of the leaving group. Replacements of residues Phe-295 and Phe-297, constituting the HuAChE acyl pocket, increase up to 80-fold the reactivity of the enzymes toward diisopropyl phosphorofluoridate, diethyl phosphorofluoridate, and p-nitrophenyl diethyl phosphate (paraoxon), indicating the role of this subsite in accommodating the phosphate alkoxy substituent. On the other hand, a decrease of up to 160-fold in reactivity was observed for enzymes carrying replacements of residues Tyr-133, Glu-202, and Glu-450, which are constituents of the hydrogen bond network in the HuAChE active center, which maintains its unique functional architecture. Replacement of residues Trp-86, Tyr-337, and Phe-338 in the alkoxy pocket affected reactivity toward diisopropyl phosphorofluoridate and paraoxon, but to a lesser extent that toward diethyl phosphorofluoridate, indicating that both the alkoxy substituent and the p-nitrophenoxy leaving group interact with this subsite. In all cases the effects on reactivity toward organophosphates, demonstrated in up to 10,000-fold differences in the values of bimolecular rate constants, were mainly a result of altered affinity of the HuAChE mutants, while the apparent first order rate constants of phosphorylation varied within a narrow range. This finding indicates that the main role of the functional architecture of HuAChE active center in phosphorylation is to facilitate the formation of enzyme-inhibitor Michaelis complexes and that this affinity, rather than the nucleophilic activity of the enzyme catalytic machinery, is a major determinant of HuAChE reactivity toward organophosphates.	ISRAEL INST BIOL RES,DEPT BIOCHEM,IL-70450 NESS ZIONA,ISRAEL; ISRAEL INST BIOL RES,DEPT ORGAN CHEM,IL-70450 NESS ZIONA,ISRAEL									Aldridge W. N., 1972, ENZYME INHIBITORS SU; ANDERSEN RA, 1977, GEN PHARMACOL, V8, P331, DOI 10.1016/0306-3623(77)90009-X; BARAK D, 1992, MULTIDISCIPLINARY APPROACHES TO CHOLINESTERASE FUNCTIONS, P195; BARAK D, 1994, J BIOL CHEM, V269, P6296; BENSCHOP HP, 1988, ACCOUNTS CHEM RES, V21, P368, DOI 10.1021/ar00154a003; BERMAN HA, 1989, J BIOL CHEM, V264, P3942; ELLMAN GL, 1961, BIOCHEM PHARMACOL, V7, P88, DOI 10.1016/0006-2952(61)90145-9; FORSBERG A, 1984, EUR J BIOCHEM, V140, P153, DOI 10.1111/j.1432-1033.1984.tb08079.x; FOURNIER D, 1992, J BIOL CHEM, V267, P14270; FRIBOULET A, 1990, BIOCHEMISTRY-US, V29, P914, DOI 10.1021/bi00456a010; GIBNEY G, 1990, P NATL ACAD SCI USA, V87, P7546, DOI 10.1073/pnas.87.19.7546; GNATT A, 1994, J NEUROCHEM, V62, P749; GOZES A, 1992, J BIOL CHEM, V267, P17640; GRAY PJ, 1989, BIOCHEM J, V257, P419, DOI 10.1042/bj2570419; GRAY PJ, 1987, TOXICOL APPL PHARM, V91, P140, DOI 10.1016/0041-008X(87)90201-8; HAREL M, 1992, P NATL ACAD SCI USA, V89, P10827, DOI 10.1073/pnas.89.22.10827; HART GJ, 1973, BIOCHEMISTRY-US, V12, P2940, DOI 10.1021/bi00739a026; HOSEA NA, 1995, BIOCHEMISTRY-US, V34, P11528, DOI 10.1021/bi00036a028; JARV J, 1984, BIOORG CHEM, V12, P259, DOI 10.1016/0045-2068(84)90010-5; KEMP JR, 1990, TOXICOL APPL PHARM, V104, P264; Kovach I M, 1991, J Enzyme Inhib, V4, P201, DOI 10.3109/14756369109035844; KRONMAN C, 1994, J BIOL CHEM, V269, P27819; KRONMAN C, 1992, GENE, V121, P295, DOI 10.1016/0378-1119(92)90134-B; LIU W, 1986, BIOCHIM BIOPHYS ACTA, V870, P185, DOI 10.1016/0167-4838(86)90220-7; LOCKRIDGE O, 1987, J BIOL CHEM, V262, P549; MAIN AR, 1976, BIOL CHOLINERGIC FUN, P269; MAIN AR, 1966, BIOCHEM J, V100, P265; MASSOULIE J, 1992, MULTIDISCIPLINARY APPROACHES TO CHOLINESTERASE FUNCTIONS, P285; ORDENTLICH A, 1995, J BIOL CHEM, V270, P2082, DOI 10.1074/jbc.270.5.2082; ORDENTLICH A, 1993, FEBS LETT, V334, P215, DOI 10.1016/0014-5793(93)81714-B; ORDENTLICH A, 1993, J BIOL CHEM, V268, P17083; QUINN DM, 1987, CHEM REV, V87, P955, DOI 10.1021/cr00081a005; RADIC Z, 1992, BIOCHEMISTRY-US, V31, P9760, DOI 10.1021/bi00155a032; RADIC Z, 1995, J BIOL CHEM, V270, P20391, DOI 10.1074/jbc.270.35.20391; RADIC Z, 1993, BIOCHEMISTRY-US, V32, P12074, DOI 10.1021/bi00096a018; Rogers D.F., 1990, MATH ELEMENTS COMPUT, P247; RYU SM, 1991, CHEM RES TOXICOL, V4, P517, DOI 10.1021/tx00023a004; SAUNDERS BC, 1948, J CHEM SOC, P695, DOI 10.1039/jr9480000695; SHAFFERMAN A, 1992, EMBO J, V11, P3561, DOI 10.1002/j.1460-2075.1992.tb05439.x; SHAFFERMAN A, 1992, J BIOL CHEM, V267, P17640; SHAFFERMAN A, 1992, MULTIDISCIPLINARY APPROACHES TO CHOLINESTERASE FUNCTIONS, P165; SHAFFERMAN A, 1993, MED DEFENSE BIOSCI R, V3, P1111; SUSSMAN JL, 1991, SCIENCE, V253, P872, DOI 10.1126/science.1678899; TAYLOR P, 1994, ANNU REV PHARMACOL, V34, P281, DOI 10.1146/annurev.pa.34.040194.001433; VELAN B, 1991, J BIOL CHEM, V266, P23977; VELAN B, 1991, CELL MOL NEUROBIOL, V11, P143, DOI 10.1007/BF00712806; VELLOM DC, 1993, BIOCHEMISTRY-US, V32, P12, DOI 10.1021/bi00052a003; WANG C, 1982, TOXICOL APPL PHARM, V66, P409, DOI 10.1016/0041-008X(82)90307-6	48	100	103	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 17	1996	271	20					11953	11962		10.1074/jbc.271.20.11953	http://dx.doi.org/10.1074/jbc.271.20.11953			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UL250	8662593	hybrid			2022-12-25	WOS:A1996UL25000058
J	Muller, BF; Paulsen, D; Deppert, W				Muller, BF; Paulsen, D; Deppert, W			Specific binding of MAR/SAR DNA-elements by mutant p53	ONCOGENE			English	Review						oncogenic function of mutant p53; MAR/SAR DNA-elements; binding of MAR/SAR DNA-elements by mutant p53	WILD-TYPE P53; SCAFFOLD-ATTACHED REGIONS; LARGE-T-ANTIGEN; CHROMOSOMAL LOOP ANCHORAGE; TUMOR SUPPRESSOR GENE; AMINO-ACID-SEQUENCE; CELL-CYCLE CONTROL; A MOUSE CELLS; SIMIAN VIRUS-40; MONOCLONAL-ANTIBODY	Inactivation of the tumor suppressor p53 by single missense point mutations characterizes a large number of human tumors, At least some mutant p53 proteins not only have lost the tumor suppressor function, but at the same time reveal a variety of dominant oncogenic properties. The molecular basis of this 'gain of function' is still unknown. In this report we describe a new biochemical activity of mutant p53, the specific high-affinity interaction with MAR/SAR DNA-elements (nuclear matrix/scaffold attachment regions). This DNA-binding activity can be distinguished from the previously reported DNA-binding activities of p53 by its specificity for mutant p53, the high binding affinity, and the domains of the mutant p53 molecule involved in MAR/SAR DNA-binding. The MAR/SAR-binding region of mutant p53 maps to a bipartite domain consisting of the mutated core region and the C-terminal 60 amino acids, carrying the unspecific DNA-binding domain and the oligomerization motif. MAR/SAR elements are considered as important regulatory elements in a variety of nuclear processes. We propose a model according to which the specific interaction of mutant p53 with MAR/SAR elements might interfere with these processes, thereby exerting pleiotropic oncogenic effects.	UNIV HAMBURG, HEINRICH PETTE INST EXPTL VIROL & IMMUNOL, D-20251 HAMBURG, GERMANY	Heinrich Pette Institute; University of Hamburg								AGOFF SN, 1993, SCIENCE, V259, P84, DOI 10.1126/science.8418500; ANDERSON JN, 1986, NUCLEIC ACIDS RES, V14, P8513, DOI 10.1093/nar/14.21.8513; BAKALKIN G, 1995, NUCLEIC ACIDS RES, V23, P362, DOI 10.1093/nar/23.3.362; BAKALKIN G, 1994, P NATL ACAD SCI USA, V91, P413, DOI 10.1073/pnas.91.1.413; BARGONETTI J, 1993, GENE DEV, V7, P2565, DOI 10.1101/gad.7.12b.2565; BARTEK J, 1990, ONCOGENE, V5, P893; BEREZNEY R, 1991, J CELL BIOCHEM, V47, P109, DOI 10.1002/jcb.240470204; BERTHOLD H, 1992, PROTEIN EXPRES PURIF, V3, P50, DOI 10.1016/1046-5928(92)90055-2; BODE J, 1988, BIOCHEMISTRY-US, V27, P4706, DOI 10.1021/bi00413a019; Bode J, 1995, INT REV CYTOL, V162A, P389; BOULIKAS T, 1992, J CELL BIOCHEM, V50, P111, DOI 10.1002/jcb.240500202; BOULIKAS T, 1994, J CELL BIOCHEM, V55, P513, DOI 10.1002/jcb.240550411; Boulikas Teni, 1994, Critical Reviews in Eukaryotic Gene Expression, V4, P117; BRAIN R, 1994, ONCOGENE, V9, P1775; CHEN PL, 1990, SCIENCE, V250, P1576, DOI 10.1126/science.2274789; CHIN KV, 1992, SCIENCE, V255, P459, DOI 10.1126/science.1346476; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; COCKERILL PN, 1987, J BIOL CHEM, V262, P5394; COCKERILL PN, 1986, CELL, V44, P273, DOI 10.1016/0092-8674(86)90761-0; COX LS, 1995, BIOESSAYS, V17, P501, DOI 10.1002/bies.950170606; DEB S, 1992, J VIROL, V66, P6164, DOI 10.1128/JVI.66.10.6164-6170.1992; DEFROMENTEL CC, 1992, GENE CHROMOSOME CANC, V4, P1; DELEO AB, 1977, J EXP MED, V146, P720, DOI 10.1084/jem.146.3.720; DEPPERT W, 1986, MOL CELL BIOL, V6, P2233, DOI 10.1128/MCB.6.6.2233; DEPPERT W, 1994, SEMIN CANCER BIOL, V5, P187; DEPPERT W, 1990, ONCOGENE, V5, P1701; DEPPERT W, 1994, INT CONGR SER, V1050, P11; DITTMER D, 1993, NAT GENET, V4, P42, DOI 10.1038/ng0593-42; ELIYAHU D, 1984, NATURE, V312, P646, DOI 10.1038/312646a0; ELIYAHU D, 1985, NATURE, V316, P158, DOI 10.1038/316158a0; ELIYAHU D, 1989, P NATL ACAD SCI USA, V86, P8763, DOI 10.1073/pnas.86.22.8763; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FOORD OS, 1991, NUCLEIC ACIDS RES, V19, P5191, DOI 10.1093/nar/19.19.5191; FRIEND S, 1994, SCIENCE, V265, P334, DOI 10.1126/science.8023155; Gai X X, 1988, Oncogene Res, V3, P377; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; GASSER SM, 1987, TRENDS GENET, V3, P16, DOI 10.1016/0168-9525(87)90156-9; GINSBERG D, 1991, MOL CELL BIOL, V11, P582, DOI 10.1128/MCB.11.1.582; GURNEY EG, 1980, J VIROL, V34, P752, DOI 10.1128/JVI.34.3.752-763.1980; HALEVY O, 1990, SCIENCE, V250, P113, DOI 10.1126/science.2218501; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HARLOW E, 1981, J VIROL, V37, P564, DOI 10.1128/JVI.37.2.564-573.1981; HERBOMEL P, 1990, NEW BIOL, V39, P937; HINDS P, 1989, J VIROL, V63, P739, DOI 10.1128/JVI.63.2.739-746.1989; HINDS PW, 1987, MOL CELL BIOL, V7, P2863, DOI 10.1128/MCB.7.8.2863; HINDS PW, 1990, CELL GROWTH DIFFER, V1, P571; HINZPETER M, 1986, VIROLOGY, V148, P159, DOI 10.1016/0042-6822(86)90411-3; HIROMI Y, 1985, CELL, V43, P603, DOI 10.1016/0092-8674(85)90232-6; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HOMBERGER HP, 1989, CHROMOSOMA, V98, P99, DOI 10.1007/BF00291044; HUPP TR, 1994, CURR BIOL, V4, P865, DOI 10.1016/S0960-9822(00)00195-0; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; JAYARAMAN L, 1995, CELL, V81, P1021, DOI 10.1016/S0092-8674(05)80007-8; JENKINS JR, 1985, NATURE, V317, P816, DOI 10.1038/317816a0; JENKINS JR, 1984, NATURE, V312, P651, DOI 10.1038/312651a0; JENKINS JR, 1988, J VIROL, V62, P3903, DOI 10.1128/JVI.62.10.3903-3906.1988; KACZMAREK L, 1986, EXP CELL RES, V162, P268, DOI 10.1016/0014-4827(86)90445-3; KERN SE, 1991, ONCOGENE, V6, P131; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; KIESER A, 1994, ONCOGENE, V9, P963; KLEHR D, 1991, BIOCHEMISTRY-US, V30, P1264, DOI 10.1021/bi00219a015; LANE DP, 1983, CELL BIOL INT REP, V7, P513, DOI 10.1016/0309-1651(83)90154-6; LEE S, 1995, CELL, V81, P1013, DOI 10.1016/S0092-8674(05)80006-6; LEGROS Y, 1994, ONCOGENE, V9, P3689; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; MAH DCW, 1993, J CELL SCI, V105, P807; MERCER WE, 1990, P NATL ACAD SCI USA, V87, P6166, DOI 10.1073/pnas.87.16.6166; MERRIL CR, 1981, SCIENCE, V211, P1437, DOI 10.1126/science.6162199; MICHALOVITZ D, 1991, J CELL BIOCHEM, V45, P22, DOI 10.1002/jcb.240450108; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MIELKE C, 1990, BIOCHEMISTRY-US, V29, P7475, DOI 10.1021/bi00484a017; MILNER J, 1991, CELL, V65, P765, DOI 10.1016/0092-8674(91)90384-B; MILNER J, 1991, MOL CELL BIOL, V11, P12, DOI 10.1128/MCB.11.1.12; MILNER J, 1987, ONCOGENE, V1, P453; MOSNER J, 1995, EMBO J, V14, P4442, DOI 10.1002/j.1460-2075.1995.tb00123.x; MULLIGAN LM, 1990, P NATL ACAD SCI USA, V87, P5863, DOI 10.1073/pnas.87.15.5863; OBEROSLER P, 1993, EMBO J, V12, P2389, DOI 10.1002/j.1460-2075.1993.tb05893.x; PARADA LF, 1984, NATURE, V312, P649, DOI 10.1038/312649a0; PAVLETICH NP, 1993, GENE DEV, V7, P2556, DOI 10.1101/gad.7.12b.2556; PENNICA D, 1984, VIROLOGY, V134, P477, DOI 10.1016/0042-6822(84)90316-7; PHIVAN L, 1988, EMBO J, V7, P655, DOI 10.1002/j.1460-2075.1988.tb02860.x; PHIVAN L, 1990, MOL CELL BIOL, V10, P2302, DOI 10.1128/MCB.10.5.2302; PHIVAN L, 1990, PROG MOL SUBCELL BIO, V11, P1; POHL J, 1988, MOL CELL BIOL, V8, P2078, DOI 10.1128/MCB.8.5.2078; POLACK A, 1991, ONCOGENE, V6, P2033; POLJAK L, 1994, NUCLEIC ACIDS RES, V22, P4386, DOI 10.1093/nar/22.21.4386; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; Reed Michael, 1993, Gene Expression, V3, P95; ROVINSKI B, 1988, ONCOGENE, V2, P445; SCHARER E, 1992, NUCLEIC ACIDS RES, V20, P1539, DOI 10.1093/nar/20.7.1539; SCHMIEG FI, 1993, ONCOGENE, V8, P2043; SCHWYZER M, 1977, C INSERM, V69, P63; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; SHAULIAN E, 1992, MOL CELL BIOL, V12, P5581, DOI 10.1128/MCB.12.12.5581; SHAULIAN E, 1993, EMBO J, V12, P2789, DOI 10.1002/j.1460-2075.1993.tb05940.x; SHAULSKY G, 1991, CANCER RES, V51, P5232; SOUSSI T, 1994, INT J CANCER, V57, P1, DOI 10.1002/ijc.2910570102; STEINMEYER K, 1990, ONCOGENE, V5, P1691; STEINMEYER K, 1988, ONCOGENE, V3, P501; STENGER JE, 1994, EMBO J, V13, P6011, DOI 10.1002/j.1460-2075.1994.tb06947.x; STEPHEN CW, 1992, J MOL BIOL, V225, P577, DOI 10.1016/0022-2836(92)90386-X; STIEF A, 1989, NATURE, V341, P343, DOI 10.1038/341343a0; STURZBECHER HW, 1987, ONCOGENE, V1, P201; STURZBECHER HW, 1992, ONCOGENE, V7, P1513; TARUNINA M, 1993, ONCOGENE, V8, P3165; VOGELSTEIN B, 1990, NATURE, V348, P681, DOI 10.1038/348681a0; VONKRIES JP, 1991, CELL, V64, P123, DOI 10.1016/0092-8674(91)90214-J; VONKRIES JP, 1990, NUCLEIC ACIDS RES, V18, P3881; WANG Y, 1993, GENE DEV, V7, P2575, DOI 10.1101/gad.7.12b.2575; WEIDT G, 1994, J IMMUNOL, V153, P2554; WEISSKER SN, 1992, ONCOGENE, V7, P1921; WOLF D, 1985, MOL CELL BIOL, V5, P127, DOI 10.1128/MCB.5.1.127; YEWDELL JW, 1986, J VIROL, V59, P444, DOI 10.1128/JVI.59.2.444-452.1986; ZAKUTHOURI R, 1983, NATURE, V306, P594, DOI 10.1038/306594a0; ZAMBETTI GP, 1993, FASEB J, V7, P855, DOI 10.1096/fasebj.7.10.8344485; ZASTAWNY RL, 1993, ONCOGENE, V8, P1529; ZERRAHN J, 1992, ONCOGENE, V7, P1371; ZHIVOTOVSKY B, 1994, FEBS LETT, V351, P150, DOI 10.1016/0014-5793(94)00827-2; ZHIVOTOVSKY B, 1994, INT ARCH ALLERGY IMM, V105, P333, DOI 10.1159/000236778; ZHIVOTOVSKY B, 1994, BIOCHEM BIOPH RES CO, V202, P120, DOI 10.1006/bbrc.1994.1901	121	53	53	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 2	1996	12	9					1941	1952						12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UK498	8649855				2022-12-25	WOS:A1996UK49800013
J	Chan, AML; Takai, S; Yamada, K; Miki, T				Chan, AML; Takai, S; Yamada, K; Miki, T			Isolation of a novel oncogene, NET1, from neuroepithelioma cells by expression cDNA cloning	ONCOGENE			English	Article						oncogene; expression cloning; neuroepithelioma; GEF; RAS; RHO	INSITU HYBRIDIZATION; GENE-PRODUCT; CDC24; BCR; PROTEINS; SYSTEM; CYCLE; VAV; RAS; DNA	We generated a cDNA expression library from a human neuroepithelioma cell line for detection of novel oncogenes by focus formation assay in NIH3T3 cells. A morphologically unique focus was identified upon transfection and the transforming plasmid was isolated. The transforming gene, designated NET1, encoded a predicted protein species of 54 kDa containing the Dbl-Homology (DH) motif. This motif is also present in other growth regulatory molecules including Bcr, Cdc24, Vav, Ras-Grf, Ect2, Ost, Tim and Tiam1, which have been implicated as regulators of small GTP-binding proteins. NIH3T3 cells transfected with NET1 expression plasmid showed altered growth properties in vitro and were tumorigenic when injected into nude mice. In addition, a 2.5 kb cDNA was isolated from a normal human cDNA library which represented the NET1 proto-oncogene contained a 5' extended open reading frame. The fact that the proto-oncogene failed to induce transformation in NIH3T3 cells suggested that the original NET1 oncogene was activated by 5'-truncation. The 3.0 and 2.4 kilobasepair (kb) transcripts of the NET1 gene was ubiquitously expressed in all tissues examined. Using fluorescence in situ hybridization, we localized the NET1 gene to the short arm of human chromosome 10 at band p15.	NCI, CELLULAR & MOLEC BIOL LAB, BETHESDA, MD 20892 USA; INT MED CTR JAPAN, RES INST, DEPT GENET, SHINJUKU KU, TOKYO 162, JAPAN	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Center for Global Health & Medicine - Japan			Chan, Andrew Man-Lok/J-9497-2013; Chan, Andrew/AAC-1145-2020	Chan, Andrew Man-Lok/0000-0001-9923-5464; Chan, Andrew/0000-0001-9923-5464				ADAMS JM, 1992, ONCOGENE, V7, P611; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BONFINI L, 1992, SCIENCE, V255, P603, DOI 10.1126/science.1736363; CHAN AML, 1994, P NATL ACAD SCI USA, V91, P7558, DOI 10.1073/pnas.91.16.7558; CHAN AML, 1994, ONCOGENE, V9, P1057; DALEY GQ, 1991, ADV CANCER RES, V57, P151; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; DIEKMANN D, 1991, NATURE, V351, P400, DOI 10.1038/351400a0; FARNSWORTH CL, 1995, NATURE, V376, P524, DOI 10.1038/376524a0; GIBSON TJ, 1994, TRENDS BIOCHEM SCI, V19, P349, DOI 10.1016/0968-0004(94)90108-2; HABETS GGM, 1994, CELL, V77, P537, DOI 10.1016/0092-8674(94)90216-X; HART MJ, 1994, J BIOL CHEM, V269, P62; HART MJ, 1991, NATURE, V354, P311, DOI 10.1038/354311a0; HIU RG, 1995, NATURE, V374, P457; HORII Y, 1994, EMBO J, V13, P4776, DOI 10.1002/j.1460-2075.1994.tb06803.x; KATZAV S, 1989, EMBO J, V8, P2283, DOI 10.1002/j.1460-2075.1989.tb08354.x; LOWY DR, 1993, ANNU REV BIOCHEM, V62, P851, DOI 10.1146/annurev.bi.62.070193.004223; MICHIELS F, 1995, NATURE, V375, P338, DOI 10.1038/375338a0; MIKI T, 1993, NATURE, V362, P462, DOI 10.1038/362462a0; MIKI T, 1989, GENE, V83, P137, DOI 10.1016/0378-1119(89)90411-3; MIKI T, 1991, P NATL ACAD SCI USA, V88, P5167, DOI 10.1073/pnas.88.12.5167; MIKI T, 1992, P NATL ACAD SCI USA, V89, P246, DOI 10.1073/pnas.89.1.246; MIKI T, 1991, SCIENCE, V251, P72, DOI 10.1126/science.1846048; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; PRENDERGAST GC, 1995, ONCOGENE, V10, P2289; QUILLIAM LA, 1995, BIOESSAYS, V17, P395, DOI 10.1002/bies.950170507; RON D, 1991, NEW BIOL, V3, P372; SHIH C, 1979, P NATL ACAD SCI USA, V76, P5714, DOI 10.1073/pnas.76.11.5714; SLOAT BF, 1981, J CELL BIOL, V89, P395, DOI 10.1083/jcb.89.3.395; SOLOMON E, 1991, SCIENCE, V254, P1153, DOI 10.1126/science.1957167; TAKAHASHI E, 1990, HUM GENET, V86, P14; TAKAI S, 1993, CYTOGENET CELL GENET, V63, P59, DOI 10.1159/000133503; VIEGASPEQUIGNOT E, 1978, ANN GENET-PARIS, V21, P122; WIGLER M, 1977, CELL, V11, P223, DOI 10.1016/0092-8674(77)90333-6	35	76	82	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 21	1996	12	6					1259	1266						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UC067	8649828				2022-12-25	WOS:A1996UC06700011
J	Nikitin, AY; Jin, JJ; Papewalis, J; Prokopenko, SN; Pozharisski, KM; Winterhager, E; FleskenNikitin, A; Rajewsky, MF				Nikitin, AY; Jin, JJ; Papewalis, J; Prokopenko, SN; Pozharisski, KM; Winterhager, E; FleskenNikitin, A; Rajewsky, MF			Wild type neu transgene counteracts mutant homologue in malignant transformation of rat Schwann cells	ONCOGENE			English	Article						neu (erbB-2); rat schwannomas; ethylnitrosourea; gene dosage; transgenic rats	GROWTH-FACTOR RECEPTOR; TYROSINE KINASE-ACTIVITY; NERVOUS-SYSTEM; NEOPLASTIC TRANSFORMATION; C-ERBB-2 RECEPTOR; PERIPHERAL MYELIN; PROTO-ONCOGENE; HUMAN-BREAST; GENE; EXPRESSION	Mutational activation of the neu (erbB-2) receptor protein tyrosine kinase gene appears to be the triggering event in the process of oncogenesis induced by N-ethyl-N-nitrosourea (EtNU) in immature Schwann cells of the rat peripheral nervous system. Subsequent loss of the wild-type neu allele may represent a critical secondary step towards malignancy. Developmentally-regulated expression of a wild-type rat neu transgene (neu cDNA under the control of the rat P-o promotor) in the Schwann cells of transgenic BDIX and Sprague-Dawley rats exposed to EtNU on postnatal day 1 results in a lower incidence of early atypical proliferates in the trigeminal nerve. Furthermore, re-introduction of the wild-type neu gene into homozygous neu mutant schwannoma cells counteracts the expression of the tumorigenic phenotype. The suppressive action of the wild-type gene over its mutationally activated oncogenic homologue underlines the critical function of the neu gene in the control of differentiation in the Schwann cell lineage, and provides evidence for the responsiveness of cellular phenotypes towards quantitative shifts in the dosage of wild-type vs mutant signal transducing molecules.	UNIV ESSEN GESAMTHSCH,SCH MED,INST CELL BIOL CANC RES,D-45122 ESSEN,GERMANY; UNIV ESSEN GESAMTHSCH,SCH MED,INST ANAT,D-45122 ESSEN,GERMANY; NN PETROV ONCOL RES INST,PATHOL LAB,ST PETERSBURG 189646,RUSSIA	University of Duisburg Essen; University of Duisburg Essen; N.N. Petrov Research Institute of Oncology				Flesken-Nikitin, Andrea/0000-0003-3017-1399				BACUS SS, 1993, CANCER RES, V53, P5251; BARGMANN CI, 1988, P NATL ACAD SCI USA, V85, P5394, DOI 10.1073/pnas.85.15.5394; BARGMANN CI, 1986, CELL, V45, P549; BISHOP JM, 1991, CELL, V64, P235, DOI 10.1016/0092-8674(91)90636-D; CARRAWAY KL, 1994, CELL, V78, P5, DOI 10.1016/0092-8674(94)90564-9; CHAZIN VR, 1992, ONCOGENE, V7, P1859; CHEN PL, 1990, SCIENCE, V250, P1576, DOI 10.1126/science.2274789; COHEN JA, 1992, J NEUROSCI RES, V31, P622, DOI 10.1002/jnr.490310406; DATI C, 1990, ONCOGENE, V5, P1001; DIFIORE PP, 1987, SCIENCE, V237, P178, DOI 10.1126/science.2885917; DIMARCO E, 1990, MOL CELL BIOL, V10, P3247, DOI 10.1128/MCB.10.6.3247; DOBASHI K, 1989, DNA-J MOLEC CELL BIO, V8, P723, DOI 10.1089/dna.1989.8.723; DOUGALL WC, 1994, ONCOGENE, V9, P2103; DRUCKREY H, 1971, ARZNEI-FORSCHUNG, V21, P1274; EPSTEIN RJ, 1992, P NATL ACAD SCI USA, V89, P10435, DOI 10.1073/pnas.89.21.10435; FINNEY RE, 1993, SCIENCE, V260, P1524, DOI 10.1126/science.8502998; GURDON JB, 1992, CELL, V68, P185, DOI 10.1016/0092-8674(92)90465-O; HAYES C, 1992, J NEUROSCI RES, V31, P175, DOI 10.1002/jnr.490310123; HOGAN B, 1986, MANIPULATING MOUSE E; HOLMES WE, 1992, SCIENCE, V256, P1205, DOI 10.1126/science.256.5060.1205; JIN JJ, 1993, CELL GROWTH DIFFER, V4, P227; KIYOKAWA N, 1995, P NATL ACAD SCI USA, V92, P1092, DOI 10.1073/pnas.92.4.1092; KOKAI Y, 1989, CELL, V58, P287, DOI 10.1016/0092-8674(89)90843-X; LAERUM OD, 1975, J NATL CANCER I, V55, P1177, DOI 10.1093/jnci/55.5.1177; LEMKE G, 1988, NEURON, V1, P73, DOI 10.1016/0896-6273(88)90211-5; LEMKE G, 1985, CELL, V40, P501, DOI 10.1016/0092-8674(85)90198-9; LOFTS FJ, 1993, ONCOGENE, V8, P2813; LOTTI LV, 1992, EXP CELL RES, V202, P274, DOI 10.1016/0014-4827(92)90075-J; MARCHIONNI MA, 1993, NATURE, V362, P312, DOI 10.1038/362312a0; MARTE BM, 1995, ONCOGENE, V10, P167; MESSERLE K, 1994, MOL CELL ENDOCRINOL, V105, P1, DOI 10.1016/0303-7207(94)90029-9; MESSING A, 1992, NEURON, V8, P507, DOI 10.1016/0896-6273(92)90279-M; MORGAN L, 1991, J CELL BIOL, V112, P457, DOI 10.1083/jcb.112.3.457; MORRISSEY TK, 1995, P NATL ACAD SCI USA, V92, P1431, DOI 10.1073/pnas.92.5.1431; NIKITIN AY, 1993, VIRCHOWS ARCH B, V64, P151, DOI 10.1007/BF02915108; NIKITIN AY, 1991, P NATL ACAD SCI USA, V88, P9939, DOI 10.1073/pnas.88.22.9939; NIKITIN AY, 1991, DIFFERENTIATION, V48, P33, DOI 10.1111/j.1432-0436.1991.tb00240.x; PELES E, 1992, CELL, V69, P205, DOI 10.1016/0092-8674(92)90131-U; PENG WW, 1982, SCIENCE, V215, P1102, DOI 10.1126/science.7063842; PERANTONI AO, 1987, P NATL ACAD SCI USA, V84, P6317, DOI 10.1073/pnas.84.17.6317; PINKASKRAMARSKI R, 1994, P NATL ACAD SCI USA, V91, P9387, DOI 10.1073/pnas.91.20.9387; SAMANTA A, 1994, P NATL ACAD SCI USA, V91, P1711, DOI 10.1073/pnas.91.5.1711; Sambrook J, 1989, MOL CLONING LABORATO; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SCHUBERT D, 1974, NATURE, V249, P224, DOI 10.1038/249224a0; SHAH NM, 1994, CELL, V77, P349, DOI 10.1016/0092-8674(94)90150-3; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SPORN MB, 1988, NATURE, V332, P217, DOI 10.1038/332217a0; STERN DF, 1986, MOL CELL BIOL, V6, P1729, DOI 10.1128/MCB.6.5.1729; SUEN TS, 1990, MOL CELL BIOL, V10, P6303; SWENBERG JA, 1975, J NATL CANCER I, V55, P147, DOI 10.1093/jnci/55.1.147; TAVERNA D, 1991, CELL GROWTH DIFFER, V2, P145; WEINBERG R, 1993, NEURON, V11, P191, DOI 10.1016/0896-6273(93)90177-S; WEINER DB, 1989, NATURE, V339, P230, DOI 10.1038/339230a0; WINTERHAGER E, 1991, EUR J CELL BIOL, V55, P133; YAMAMOTO T, 1986, NATURE, V319, P230, DOI 10.1038/319230a0	56	20	20	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR 21	1996	12	6					1309	1317						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UC067	8649833				2022-12-25	WOS:A1996UC06700016
J	Chen, J; Nachabah, A; Scherer, C; Ganju, P; Reith, A; Bronson, R; Ruley, HE				Chen, J; Nachabah, A; Scherer, C; Ganju, P; Reith, A; Bronson, R; Ruley, HE			Germ-line inactivation of the murine Eck receptor tyrosine kinase by gene trap retroviral insertion	ONCOGENE			English	Article						Eck deficient mice; gene trap retrovirus; insertional mutagenesis; node	EMBRYONIC STEM-CELLS; RETINOIC ACID; SIGNAL TRANSDUCTION; PROTO-ONCOGENE; LACZ REPORTER; W-LOCUS; EXPRESSION; HINDBRAIN; DISRUPTION; MICE	The present study characterized a mutation in the Eck receptor tyrosine kinase gene induced by the U3 beta geo gene trap retrovirus. The mutation (eck(i)) was identified during an in vitro screen for proviruses that disrupt developmentally regulated genes in cultured ES cells. The germ-line eck(i) fusion gene was expressed in blastocyst and later restricted to the primitive streak, node and to regions of the hindbrain in 6.5-10.5 day embryos. This is identical to the pattern of Eck gene expression as determined by either in situ hybridization or immunostaining, suggesting that expression of the Eck promoter was not affected by provirus integration. The provirus inserted approximately 8 kb upstream of the 5' end of the published cDNA sequence, and 1.8 kb downstream of an alternatively spliced 5' exon. The eck(i) allele is essentially a null mutation since mutant mice are severely deficient for Eck protein as determined by Western blot analysis and irt vitro kinase assays. Nevertheless, mice homozygous for the mutation did not exhibit any discernable phenotype. These results suggest that other members of the Eph family of receptor tyrosine kinases can functionally compensate for loss of Eck.	MIT, DEPT BIOL, CAMBRIDGE, MA 02139 USA; LUDWIG INST CANC RES, LONDON W1P 8BT, ENGLAND; TUFTS UNIV, SCH MED, HUMAN NUTR RES CTR, BOSTON, MA 02111 USA	Massachusetts Institute of Technology (MIT); Ludwig Institute for Cancer Research; Tufts University	Chen, J (corresponding author), VANDERBILT UNIV, MED CTR, SCH MED, DEPT MICROBIOL & IMMUNOL, NASHVILLE, TN 37232 USA.			Chen, Jin/0000-0002-5557-2079	NIGMS NIH HHS [R01GM84688, 1 F32 GM17003-01] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM017003] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AIBA A, 1994, CELL, V79, P365, DOI 10.1016/0092-8674(94)90204-6; AIBA A, 1994, CELL, V79, P377, DOI 10.1016/0092-8674(94)90204-6; ANDRES AC, 1994, ONCOGENE, V9, P1461; BARTLEY TD, 1994, NATURE, V368, P558, DOI 10.1038/368558a0; BECKER N, 1994, MECH DEVELOP, V47, P3, DOI 10.1016/0925-4773(94)90091-4; BECKMANN MP, 1994, EMBO J, V13, P3757, DOI 10.1002/j.1460-2075.1994.tb06685.x; BOURTCHULADZE R, 1994, CELL, V79, P59, DOI 10.1016/0092-8674(94)90400-6; BOYLAN JF, 1995, MOL CELL BIOL, V15, P843; BRAUN T, 1992, CELL, V71, P369, DOI 10.1016/0092-8674(92)90507-9; BUCKLER AJ, 1991, P NATL ACAD SCI USA, V88, P4005, DOI 10.1073/pnas.88.9.4005; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CHABOT B, 1988, NATURE, V335, P88, DOI 10.1038/335088a0; CHEN J, 1994, METH MOL G, V4, P123; CHENG HJ, 1994, CELL, V79, P157, DOI 10.1016/0092-8674(94)90408-1; COLON FL, 1991, DEVELOPMENT, V111, P969; DAVIS S, 1994, SCIENCE, V266, P816, DOI 10.1126/science.7973638; DEGREGORI J, 1994, GENE DEV, V8, P265, DOI 10.1101/gad.8.3.265; FANTL WJ, 1993, ANNU REV BIOCHEM, V62, P453, DOI 10.1146/annurev.bi.62.070193.002321; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GANJU P, 1994, ONCOGENE, V9, P1613; GEISSLER EN, 1988, CELL, V55, P185, DOI 10.1016/0092-8674(88)90020-7; GILARDIHEBENSTREIT P, 1992, ONCOGENE, V7, P2499; HAFEN E, 1991, DEVELOPMENT S, V112, P123; HEMPSTEAD BL, 1992, NEURON, V9, P883, DOI 10.1016/0896-6273(92)90241-5; HENKEMEYER M, 1994, ONCOGENE, V9, P1001; Hogan B, 1994, MANIPULATING MOUSE E; HOSLER BA, 1989, MOL CELL BIOL, V9, P5623, DOI 10.1128/MCB.9.12.5623; JOYNER AL, 1991, S POSTIMPLANTATION D, P277; KLEIN R, 1992, NEURON, V8, P947, DOI 10.1016/0896-6273(92)90209-V; KURATANI SC, 1993, DEVELOPMENT, V117, P105; LEMOUELLIC H, 1990, P NATL ACAD SCI USA, V87, P4712, DOI 10.1073/pnas.87.12.4712; LEMOUELLIC H, 1992, CELL, V69, P251, DOI 10.1016/0092-8674(92)90406-3; LHOTAK V, 1991, MOL CELL BIOL, V11, P2496, DOI 10.1128/MCB.11.5.2496; LI E, 1993, P NATL ACAD SCI USA, V90, P1590, DOI 10.1073/pnas.90.4.1590; LINDBERG RA, 1990, MOL CELL BIOL, V10, P6316, DOI 10.1128/MCB.10.12.6316; LOEB DM, 1991, CELL, V66, P861; LUMSDEN A, 1991, DEVELOPMENT, V113, P1281; MAISONPIERRE PC, 1993, ONCOGENE, V8, P3277; MANSOUR SL, 1990, P NATL ACAD SCI USA, V87, P7688, DOI 10.1073/pnas.87.19.7688; NIETO MA, 1992, DEVELOPMENT, V116, P1137; NODEN DM, 1988, DEVELOPMENT, V103, P121; PANDEY A, 1995, SCIENCE, V268, P567, DOI 10.1126/science.7536959; PAWSON T, 1990, TRENDS GENET, V6, P350, DOI 10.1016/0168-9525(90)90276-C; REDDY S, 1992, P NATL ACAD SCI USA, V89, P6721, DOI 10.1073/pnas.89.15.6721; REITH AD, 1991, GENOME ANAL, V3, P105; Robertson E. J., 1987, TERATOCARCINOMAS EMB; ROGERS MB, 1991, DEVELOPMENT, V113, P815; RUBIN GM, 1991, TRENDS GENET, V7, P372, DOI 10.1016/0168-9525(91)90258-R; RUDNICKI MA, 1992, CELL, V71, P383, DOI 10.1016/0092-8674(92)90508-A; RUDNICKI MA, 1993, CELL, V75, P1351, DOI 10.1016/0092-8674(93)90621-V; RUIZ JC, 1994, MECH DEVELOP, V46, P87; Sambrook J., 2002, MOL CLONING LAB MANU; SCHNEIDERMAUNOURY S, 1993, CELL, V75, P1199, DOI 10.1016/0092-8674(93)90329-O; SERBEDZIJA GN, 1992, DEVELOPMENT, V116, P297; SKARNES WC, 1992, GENE DEV, V6, P903, DOI 10.1101/gad.6.6.903; STERNBERG PW, 1991, TRENDS GENET, V7, P336; VONMELCHNER H, 1992, GENE DEV, V6, P919, DOI 10.1101/gad.6.6.919; ZHOU XL, 1993, NATURE, V361, P543, DOI 10.1038/361543a0	58	64	67	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 7	1996	12	5					979	988						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UA884	8649815				2022-12-25	WOS:A1996UA88400005
J	Hazen, SA; Waheed, A; Sly, WS; LaNoue, KF; Lynch, CJ				Hazen, SA; Waheed, A; Sly, WS; LaNoue, KF; Lynch, CJ			Differentiation-dependent expression of CA V and the role of carbonic anhydrase isozymes in pyruvate carboxylation in adipocytes	FASEB JOURNAL			English	Article						lipogenesis; pyruvate carboxylase; carbon fixation; trifluormethanesulfonamide; obesity	FATTY-ACID SYNTHESIS; GLUCOSE SYNTHESIS; RODENT TISSUES; UREA SYNTHESIS; ZUCKER RATS; INHIBITION; METABOLISM; LIVER; HEPATOCYTES; OBESITY	The incorporation of radioactivity from C-14-labeled compounds into metabolic intermediates and total lipids was examined in 3T3 adipocytes. The heterocyclic sulfonamide carbonic anhydrase inhibitor (SCAI) 6-ethoxyzolamide (ETZ) caused a decrease (42 +/- 7% of control, IC50 = 2.2 +/- 1.1 x 10(-7) M) in the incorporation of [C-14]bicarbonate into several Krebs cycle intermediates in 3T3-F442A adipocytes. This decrease in pyruvate carboxylase-mediated [C-14] carbon fixation was associated with a reduction in fluorometrically determined [citrate] and [malate]. The ability of ETZ to decrease both the incorporation of radioactivity into and the concentrations of Krebs cycle intermediates was not of sufficient magnitude to lower [ATP], but was associated with a decrease in de novo lipogenesis from [C-14]glucose, De novo lipogenesis was also inhibited to a similar extent by trifluormethanesulfonamide, an aliphatic SCAI, which suggests that the effects are mediated by carbonic anhydrase, ETZ did not inhibit de novo lipogenesis from [C-14]glutamine (12.38 +/- 1.068 nmol/mg protein, ETZ; 12.5 +/- 0.846 nmol/mg protein, DMSO). This suggests that ETZ inhibition of lipogenesis involves an inhibitory effect on pyruvate carboxylase as opposed to acetyl CoA carboxylase, because the incorporation of glutamine into lipids does not involve pyruvate carboxylase. Decreased de novo Lipogenesis was also observed by incubating cultures in media that contained 1 mM bicarbonate (atmosphere:100% humidified air) rather than 25 mM bicarbonate (atmosphere:95% humidified air/5% CO2). This suggests that exogenous CO2/bicarbonate may be required to sustain maximal rates of de novo lipogenesis. Because these results implied that CA V, the mitochondrial isoform of carbonic anhydrase, might be present in adipocytes, CA V levels were measured by immunoblotting, Mitochondrial preparations of adipocytes and liver were found to contain similar concentrations of CA V. Unlike adipocyte CA III, CA V concentrations were not significantly different in lean and obese Zucker rats, However, CA V levels were ninefold higher in differentiated 3T3-FP42A adipocytes compared to undifferentiated adipoblasts. Our data indicate that CA V is relatively abundant in adipocyte mitochondria and exhibits differentiation-dependent expression like pyruvate carboxylase and the cytosolic isozymes CA II and CA III. The possible roles of CA II and CA V in pyruvate carboxylation are discussed.	PENN STATE UNIV,MILTON S HERSHEY MED CTR,DEPT CELLULAR & MOLEC PHYSIOL,COLL MED,HERSHEY,PA 17033; PENN STATE UNIV,CHILDRENS HOSP,HERSHEY,PA 17033; ST LOUIS UNIV,HLTH SCI CTR,EDWARD A DOISY DEPT BIOCHEM & MOLEC BIOL,ST LOUIS,MO 63104	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; Saint Louis University			Lynch, Christopher J./E-6875-2010; Wahhed, Abdul/AAA-3099-2020	Lynch, Christopher J./0000-0003-2453-5838; 	NHLBI NIH HHS [HL49244] Funding Source: Medline; NIDDK NIH HHS [DK43402] Funding Source: Medline; NIGMS NIH HHS [GM34182] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL049244, R01HL049244] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK043402] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM034182, R01GM034182] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BERGMEYER HU, 1974, METHODS ENZYMATIC AN; BODE AM, 1994, J BIOL CHEM, V269, P7879; BRAY GA, 1972, J CLIN INVEST, V51, P537, DOI 10.1172/JCI106842; CAO TP, 1978, LIFE SCI, V22, P2067, DOI 10.1016/0024-3205(78)90449-6; CORNELIUS P, 1994, ANNU REV NUTR, V14, P99, DOI 10.1146/annurev.nu.14.070194.000531; COULSON RA, 1984, ANN NY ACAD SCI, V429, P505, DOI 10.1111/j.1749-6632.1984.tb12379.x; DJIAN P, 1985, J CELL PHYSIOL, V124, P554, DOI 10.1002/jcp.1041240327; Dodgson S.J., 1991, CARBONIC ANHYDRASES, P3; DODGSON SJ, 1984, ANN NY ACAD SCI, V429, P516, DOI 10.1111/j.1749-6632.1984.tb12380.x; DODGSON SJ, 1991, BIOCHEM CELL BIOL, V69, P761, DOI 10.1139/o91-116; DODGSON SJ, 1989, AM J PHYSIOL, V257, pE791, DOI 10.1152/ajpendo.1989.257.6.E791; DODGSON SJ, 1986, ARCH BIOCHEM BIOPHYS, V251, P198, DOI 10.1016/0003-9861(86)90066-4; DODGSON SJ, 1986, J APPL PHYSIOL, V60, P646, DOI 10.1152/jappl.1986.60.2.646; DODGSON SJ, 1991, CARBONIC ANHYDRASES, P297; DOLE VP, 1960, J BIOL CHEM, V235, P2595; GLENN KC, 1992, ENDOCRINOLOGY, V131, P1115, DOI 10.1210/en.131.3.1115; HALL TJ, 1991, CALCIFIED TISSUE INT, V49, P328, DOI 10.1007/BF02556255; HAUSSINGER D, 1986, BIOCHEM PHARMACOL, V35, P3317, DOI 10.1016/0006-2952(86)90429-6; HAZEN SA, 1995, J LIPID RES, V36, P868; HECK RW, 1994, J BIOL CHEM, V269, P24742; HERBERT JD, 1984, ANN NY ACAD SCI, V429, P525, DOI 10.1111/j.1749-6632.1984.tb12381.x; Khalifah R. G., 1991, CARBONIC ANHYDRASES, P49, DOI DOI 10.1007/978-1-4899-0750-9_4; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LONGMUIR IS, 1966, NATURE, V209, P393, DOI 10.1038/209393a0; LOWENSTEIN JM, 1971, COMPREHENSIVE BIOCH, P31; LYNCH CJ, 1993, AM J PHYSIOL, V265, pC234, DOI 10.1152/ajpcell.1993.265.1.C234; LYNCH CJ, 1993, AM J PHYSIOL, V264, pE621, DOI 10.1152/ajpendo.1993.264.4.E621; LYNCH CJ, 1995, BIOCHEM J, V310, P197, DOI 10.1042/bj3100197; LYNCH CJ, 1992, AM J PHYSIOL, V262, pE608, DOI 10.1152/ajpendo.1992.262.5.E608; MACKALL JC, 1977, BIOCHEM BIOPH RES CO, V79, P720, DOI 10.1016/0006-291X(77)91171-8; MAREN TH, 1983, ANNU REV PHARMACOL, V23, P439, DOI 10.1146/annurev.pa.23.040183.002255; MAREN TH, 1980, HISTOCHEM J, V12, P183, DOI 10.1007/BF01024548; MAREN TH, 1993, J BIOL CHEM, V268, P26233; METCALFE HK, 1985, BIOCHEM SOC T, V13, P255, DOI 10.1042/bst0130255; NAGAO Y, 1993, P NATL ACAD SCI USA, V90, P7623, DOI 10.1073/pnas.90.16.7623; NAGAO Y, 1994, P NATL ACAD SCI USA, V91, P10330, DOI 10.1073/pnas.91.22.10330; RAMANADHAM M, 1984, ANN NY ACAD SCI, V429, P49; RUBIO V, 1986, BIOSCIENCE REP, V6, P335, DOI 10.1007/BF01116420; SCHNEIDER WC, 1950, J BIOL CHEM, V183, P123; SPENCER IM, 1988, BIOCHEM SOC T, V16, P973, DOI 10.1042/bst0160973; SPENCER IM, 1994, ISOZYME B, V27, P42; SPICER SS, 1990, AM J ANAT, V187, P55, DOI 10.1002/aja.1001870107; SPICER SS, 1979, J HISTOCHEM CYTOCHEM, V27, P820, DOI 10.1177/27.4.109495; STANTON LW, 1991, MOL ENDOCRINOL, V5, P860, DOI 10.1210/mend-5-6-860; STUDENT AK, 1980, J BIOL CHEM, V255, P4745; VANNUCCI SJ, 1989, AM J PHYSIOL, V257, pE871, DOI 10.1152/ajpendo.1989.257.6.E871; WAHEED A, 1992, J BIOL CHEM, V267, P3308; WILLIAMSON JR, 1969, METHOD ENZYMOL, V13, P435	48	61	64	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	MAR	1996	10	4					481	490		10.1096/fasebj.10.4.8647347	http://dx.doi.org/10.1096/fasebj.10.4.8647347			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	UE557	8647347				2022-12-25	WOS:A1996UE55700012
J	Chang, CL; Strahler, JR; Thoraval, DH; Qian, MG; Hinderer, R; Hanash, SM				Chang, CL; Strahler, JR; Thoraval, DH; Qian, MG; Hinderer, R; Hanash, SM			A nucleoside diphosphate kinase A (nm23-H1) serine 120->glycine substitution in advanced stage neuroblastoma affects enzyme stability and alters protein-protein interaction	ONCOGENE			English	Article						NDP kinase; nm23-H1; neuroblastoma	REDUCED EXPRESSION; TUMOR-METASTASIS; MYXOCOCCUS-XANTHUS; ESCHERICHIA-COLI; MESSENGER-RNA; GENE-PRODUCT; DROSOPHILA; CARCINOMA; CELLS; AUTOPHOSPHORYLATION	A high level of nucleoside diphosphate kinase A (NDPK A/nm23-H1) in neuroblastoma is associated with advanced stage disease. We have also found a serine 120-->glycine substitution in NDPK A and/or amplification of the nm23-H1 gene in advanced stage neuroblastomas. Serine 120, a highly conserved residue, is located in proximity to histidine 118 which forms a phosphorylated intermediate essential for NDPK activity. The effect of Ser120-->Gly substitution on the biochemical properties of NDPK A was investigated. Phosphate-transferase activity was lower in the recombinant mutant NDPK A and in the immunoprecipitated complex consisting of NDPK A and NDPK B prepared from a neuroblastoma tumor containing the mutation, relative to the wild-type. There was a significant decrease in the enzyme stability toward urea- or temperature-induced denaturation for the recombinant mutant NDPK A and in an immunoprecipitate from a tumor containing the mutation. Recombinant NDPK A containing the Ser120-->Gly mutation exhibited reduced hexameric and increased dimeric oligomerization relative to the wild-type. Moreover a 28 kDa cellular protein was detected, that co-precipitated with the mutant but not wild-type NDPK A. The altered properties of the mutant protein may have relevance to a role for NDPK A in neuroblastoma progression.	UNIV MICHIGAN, DEPT CHEM, ANN ARBOR, MI 48109 USA	University of Michigan System; University of Michigan	Chang, CL (corresponding author), UNIV MICHIGAN, DEPT PEDIAT, ANN ARBOR, MI 48109 USA.		Chang, Christina/B-9650-2009		NCI NIH HHS [CA32146, CA26803] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA032146, P01CA026803] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Agarwal R P, 1978, Methods Enzymol, V51, P376; AGARWAL RP, 1971, J BIOL CHEM, V246, P2258; AYHAN A, 1993, VIRCHOWS ARCH B, V63, P213, DOI 10.1007/BF02899264; BIGGS J, 1988, GENE DEV, V2, P1333, DOI 10.1101/gad.2.10.1333; BIGGS J, 1990, CELL, V63, P933, DOI 10.1016/0092-8674(90)90496-2; BOMINAAR AA, 1994, FEBS LETT, V353, P5, DOI 10.1016/0014-5793(94)00997-X; CHANG CL, 1994, NATURE, V370, P335, DOI 10.1038/370335a0; CRAIG WS, 1988, METHOD ENZYMOL, V156, P333; DEAROLF C, 1988, DEV BIOL, V129, P139; DUMAS C, 1992, EMBO J, V11, P3203, DOI 10.1002/j.1460-2075.1992.tb05397.x; ENGEL M, 1993, INT J CANCER, V55, P375, DOI 10.1002/ijc.2910550306; FLORENES VA, 1992, CANCER RES, V52, P6088; GARCES E, 1969, BIOCHEMISTRY-US, V8, P633, DOI 10.1021/bi00830a026; GILLES AM, 1991, J BIOL CHEM, V266, P8784; HAILAT N, 1991, J CLIN INVEST, V88, P341, DOI 10.1172/JCI115299; HAMA H, 1991, GENE, V105, P31, DOI 10.1016/0378-1119(91)90510-I; HEMMERICH S, 1992, BIOCHEMISTRY-US, V31, P4580, DOI 10.1021/bi00134a007; KIMURA N, 1988, J BIOL CHEM, V263, P4647; KIMURA N, 1990, J BIOL CHEM, V265, P15744; KODERA Y, 1994, CANCER, V73, P259, DOI 10.1002/1097-0142(19940115)73:2<259::AID-CNCR2820730205>3.0.CO;2-V; KOYAMA K, 1984, J BIOCHEM-TOKYO, V95, P925, DOI 10.1093/oxfordjournals.jbchem.a134720; LACOMBE ML, 1990, J BIOL CHEM, V265, P10012; LASCU I, 1992, J BIOL CHEM, V267, P12775; LEONE A, 1993, ONCOGENE, V8, P2325; LEONE A, 1993, ONCOGENE, V8, P855; LEONE A, 1991, CANCER RES, V51, P2490; MACDONALD NJ, 1993, J BIOL CHEM, V268, P25780; MORERA S, 1994, BIOCHEMISTRY-US, V33, P459, DOI 10.1021/bi00168a010; MUNOZDORADO J, 1993, J BACTERIOL, V175, P1176; MUNOZDORADO J, 1990, J BIOL CHEM, V265, P2702; NAKAMORI S, 1993, INT J PANCREATOL, V14, P125; NAKAYAMA H, 1993, JPN J CANCER RES, V84, P184, DOI 10.1111/j.1349-7006.1993.tb02853.x; NAKAYAMA T, 1992, J NATL CANCER I, V84, P1349, DOI 10.1093/jnci/84.17.1349; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; OKABEKADO J, 1992, BIOCHEM BIOPH RES CO, V182, P987, DOI 10.1016/0006-291X(92)91829-F; Parks R.E., 1973, ENZYMES, V8, P307, DOI [10.1016/S1874-6047(08)60069-4, DOI 10.1016/S1874-6047(08)60069-4]; POSTEL EH, 1993, SCIENCE, V261, P478, DOI 10.1126/science.8392752; ROSENGARD AM, 1989, NATURE, V342, P177, DOI 10.1038/342177a0; SCHWAB M, 1990, Critical Reviews in Oncogenesis, V2, P35; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; STAHL JA, 1991, CANCER RES, V51, P445; STEEG PS, 1988, J NATL CANCER I, V80, P200, DOI 10.1093/jnci/80.3.200; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TEPPER AD, 1994, J BIOL CHEM, V269, P32175; TIMMONS L, 1993, DEV BIOL, V158, P364, DOI 10.1006/dbio.1993.1195; TOKUNAGA Y, 1993, INT J CANCER, V55, P66, DOI 10.1002/ijc.2910550113; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; URANO T, 1993, ONCOGENE, V8, P1371; URANO T, 1992, FEBS LETT, V309, P358, DOI 10.1016/0014-5793(92)80807-S; ZHOU M, 1993, BRIT J CANCER, V68, P385, DOI 10.1038/bjc.1993.345; ZINYK DL, 1993, NAT GENET, V4, P195, DOI 10.1038/ng0693-195	52	50	53	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 1	1996	12	3					659	667						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TV597	8637723				2022-12-25	WOS:A1996TV59700023
J	VanDam, AM; DeVries, HE; Kuiper, J; Zijlstra, FJ; DeBoer, AG; Tilders, FJH; Berkenbosch, F				VanDam, AM; DeVries, HE; Kuiper, J; Zijlstra, FJ; DeBoer, AG; Tilders, FJH; Berkenbosch, F			Interleukin-1 receptors on rat brain endothelial cells: A role in neuroimmune interaction?	FASEB JOURNAL			English	Article						endothelium; brain; prostaglandin	HIGH-AFFINITY; MESSENGER-RNA; T-CELLS; NEURONAL LOCALIZATION; ENDOGENOUS PYROGEN; MOUSE-BRAIN; B-CELLS; BINDING; FEVER; PROSTAGLANDIN-E(2)	Inflammation following an infection induces a range of nonspecific symptoms of sickness in animals and humans. The cytokine interleukin-l (IL-1) mediates many of the brain-mediated symptoms of sickness. Binding sites for IL-1 have been found in mouse brain, but not in the brains of rats, This raises questions as to the involvement of these neuronally localized IL-1 binding sites in the induction of sickness symptoms. Based on observations of IL-1 receptor mRNA in close vicinity to the vasculature in the mouse and rat brain, we studied the possibility that endothelial cells in the rat brain exhibit IL-1 receptors to transduce information to the brain. Ligand binding studies reveal that cultured endothelial cells of adult rat brain exhibit specific binding sites for rat IL-1 beta. Polymerase chain reaction experiments demonstrated that mRNA of the type I but not that of the type II IL-1 receptor is present in rat brain endothelial cells. Incubation of these endothelial cells with recombinant rat IL-1 beta showed a dose-dependent increase in interleukin-6, prostaglandin E(2), and prostacyclin secretion. Intravenous administration of rat IL-1 beta to adult rats enhanced prostaglandin E(2) immnnoreactivity in endothelial cells of the brain microvasculature. These results indicate that functional type I IL-1 receptors are present on endothelial cells of adult rat brain, We postulate that circulating IL-1 can be translated by brain endothelial cells into other signals such as interleukin-6 or prostaglandins that have access to the brain and induce sickness symptoms.	LEIDEN UNIV,SYLVIUS LAB,LEIDEN AMSTERDAM CTR DRUG RES,DIV PHARMACOL,LEIDEN,NETHERLANDS; LEIDEN UNIV,DIV BIOPHARMACEUT,LEIDEN,NETHERLANDS; ERASMUS UNIV ROTTERDAM,DEPT PHARMACOL,3000 DR ROTTERDAM,NETHERLANDS	Leiden University; Leiden University - Excl LUMC; Leiden University; Leiden University - Excl LUMC; Erasmus University Rotterdam	VanDam, AM (corresponding author), FREE UNIV AMSTERDAM,FAC MED,DEPT PHARMACOL,NEUROSCI RES INST,VAN BOECHORSTSTRAAT 7,1081 BT AMSTERDAM,NETHERLANDS.							AARDEN LA, 1987, EUR J IMMUNOL, V17, P1411, DOI 10.1002/eji.1830171004; AKAHOSHI T, 1988, J EXP MED, V167, P924, DOI 10.1084/jem.167.3.924; BAN E, 1991, NEUROSCIENCE, V43, P21, DOI 10.1016/0306-4522(91)90412-H; BERKENBOSCH F, 1987, SCIENCE, V238, P524, DOI 10.1126/science.2443979; BERKENBOSCH F, 1992, STRESS : NEUROENDOCRINE AND MOLECULAR APPROACHES, VOLS 1 AND 2, P623; BORASCHI D, 1991, BLOOD, V78, P1262; BRISTULF J, 1994, EUR CYTOKINE NETW, V5, P319; CANNON JG, 1990, J INFECT DIS, V161, P79, DOI 10.1093/infdis/161.1.79; CHANCE WT, 1991, BRAIN RES, V568, P261, DOI 10.1016/0006-8993(91)91406-Q; CHIZZONITE R, 1989, P NATL ACAD SCI USA, V86, P8029, DOI 10.1073/pnas.86.20.8029; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COCEANI F, 1986, YALE J BIOL MED, V59, P169; COCEANI F, 1992, CAN J PHYSIOL PHARM, V70, P1590, DOI 10.1139/y92-228; COLOTTA F, 1993, SCIENCE, V261, P472, DOI 10.1126/science.8332913; CRESTANI F, 1991, BRAIN RES, V542, P330, DOI 10.1016/0006-8993(91)91587-Q; CUNNINGHAM ET, 1992, J NEUROSCI, V12, P1101; DERIJK R, 1992, AM J PHYSIOL, V263, pE1092; DUBIUS JM, 1988, ENDOCRINOLOGY, V123, P2175; FARRAR WL, 1987, J IMMUNOL, V139, P459; GIULIAN D, 1985, SCIENCE, V228, P497, DOI 10.1126/science.3872478; GOTTSCHALL PE, 1991, AM J PHYSIOL, V261, pE362, DOI 10.1152/ajpendo.1991.261.3.E362; GRANOWITZ EV, 1991, J BIOL CHEM, V266, P14147; HAOUR FG, 1990, PROG NEUROENDOCRINIM, V3, P196; HART RP, 1993, J NEUROIMMUNOL, V44, P49, DOI 10.1016/0165-5728(93)90267-3; KATSUKI H, 1990, EUR J PHARMACOL, V181, P323, DOI 10.1016/0014-2999(90)90099-R; KATSUURA G, 1988, BIOCHEM BIOPH RES CO, V156, P61, DOI 10.1016/S0006-291X(88)80805-2; KENT S, 1992, TRENDS PHARMACOL SCI, V13, P24, DOI 10.1016/0165-6147(92)90012-U; KLUGER MJ, 1991, PHYSIOL REV, V71, P93, DOI 10.1152/physrev.1991.71.1.93; KRUEGER JM, 1984, AM J PHYSIOL, V246, pR994, DOI 10.1152/ajpregu.1984.246.6.R994; LEE SC, 1993, J IMMUNOL, V150, P2659; LOWENTHAL JW, 1986, J EXP MED, V164, P1060, DOI 10.1084/jem.164.4.1060; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MATSUMURA K, 1992, BRAIN RES, V581, P292, DOI 10.1016/0006-8993(92)90720-T; MCMAHAN CJ, 1991, EMBO J, V10, P2821, DOI 10.1002/j.1460-2075.1991.tb07831.x; NAVARRA P, 1991, ENDOCRINOLOGY, V128, P37, DOI 10.1210/endo-128-1-37; PONTE P, 1984, NUCLEIC ACIDS RES, V12, P1687, DOI 10.1093/nar/12.3.1687; RISAU W, 1990, J CELL BIOL, V110, P1757, DOI 10.1083/jcb.110.5.1757; RIVIER C, 1991, ENDOCRINOLOGY, V129, P384, DOI 10.1210/endo-129-1-384; RIVIER C, 1989, ENDOCRINOLOGY, V124, P2105, DOI 10.1210/endo-124-5-2105; ROTHWELL NJ, 1991, CAN J PHYSIOL PHARM, V69, P1465, DOI 10.1139/y91-219; SCAPIGLIATI G, 1989, FEBS LETT, V243, P394, DOI 10.1016/0014-5793(89)80169-3; SCHOBITZ B, 1993, EUR J NEUROSCI, V5, P1426, DOI 10.1111/j.1460-9568.1993.tb00210.x; SIMS JE, 1993, P NATL ACAD SCI USA, V90, P6155, DOI 10.1073/pnas.90.13.6155; SIMS JE, 1989, P NATL ACAD SCI USA, V86, P8946, DOI 10.1073/pnas.86.22.8946; SIRKO S, 1989, AM J PHYSIOL, V256, pR616, DOI 10.1152/ajpregu.1989.256.3.R616; TAKAO T, 1990, ENDOCRINOLOGY, V127, P3070, DOI 10.1210/endo-127-6-3070; TAKAO T, 1993, BRAIN RES, V623, P172, DOI 10.1016/0006-8993(93)90026-J; TORRE D, 1994, CLIN INFECT DIS, V18, P194, DOI 10.1093/clinids/18.2.194; VANDAM AM, 1993, BRAIN RES, V613, P331, DOI 10.1016/0006-8993(93)90922-A; VANDAM AM, 1995, NEUROSCIENCE, V65, P815, DOI 10.1016/0306-4522(94)00549-K; WELLER M, 1991, J NEUROL SCI, V104, P215, DOI 10.1016/0022-510X(91)90313-V; Wong Ma-Li, 1994, Neuroimmunomodulation, V1, P110, DOI 10.1159/000097143; ZIJLSTRA FJ, 1992, EUR J CLIN INVEST, V22, P301, DOI 10.1111/j.1365-2362.1992.tb01466.x	53	112	113	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	FEB	1996	10	2					351	356		10.1096/fasebj.10.2.8641570	http://dx.doi.org/10.1096/fasebj.10.2.8641570			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	TY962	8641570				2022-12-25	WOS:A1996TY96200021
J	Jain, N; Mahendran, R; Philp, R; Guy, GR; Tan, YH; Cao, X				Jain, N; Mahendran, R; Philp, R; Guy, GR; Tan, YH; Cao, X			Casein kinase II associates with Egr-1 and acts as a negative modulator of its DNA binding and transcription activities in NIH 3T3 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUTATHIONE-S-TRANSFERASE; TUMOR SUPPRESSOR PROTEIN; SERUM RESPONSE FACTOR; GENE-PRODUCT; ESCHERICHIA-COLI; GROWTH; PHOSPHORYLATION; EXPRESSION; DIFFERENTIATION; SUBUNIT	Although the activation domains within early growth response gene protein 1 (Egr-1) have been mapped, little is known of the kinases which phosphorylate Egr-1 and how phosphorylation correlates with the transcriptional activity of Egr-1. In this study we report that casein kinase II (CKII) co-immunoprecipitates with Egr-1 from NIH 3T3 cell lysates. The association of Egr-1 and CKII requires the C terminus of Egr-1 and CKII phosphorylates Egr-1 in vitro. The in vitro phosphorylation of Egr-1 by CKII and that induced by serum in vivo was compared by examining the CNBr-digested fragments of the phosphorylated Egr-1, CKII strongly phosphorylates fragments 7 and 10 which cover part of the activation/nuclear localization and DNA binding domains of Egr-1. CKII also phosphorylates, albeit weakly, fragments 5 and 8 which cover part of activation domain and the entire repression domain of Egr-1, respectively. Strong phosphorylation on fragment 10 as well as fragment 5 was also observed in Egr-1 immunoprecipitated from serum-induced, P-32-labeled cells. CKII phosphorylation of Egr-1 resulted in a decrease of its DNA binding as well as its transcriptional activities.	NATL UNIV SINGAPORE, INST MOLEC & CELL BIOL, SIGNAL TRANSDUCT LAB, SINGAPORE 119260, SINGAPORE	Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB); National University of Singapore			Mahendran, Ratha/B-3827-2012					BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; CAO XM, 1990, MOL CELL BIOL, V10, P1931, DOI 10.1128/MCB.10.5.1931; CAO XM, 1993, J BIOL CHEM, V268, P16949; CAO XM, 1992, J BIOL CHEM, V267, P12991; CARDENAS ME, 1993, J CELL SCI, V104, P533; CHRISTY B, 1989, P NATL ACAD SCI USA, V86, P8737, DOI 10.1073/pnas.86.22.8737; CHRISTY BA, 1988, P NATL ACAD SCI USA, V85, P7857, DOI 10.1073/pnas.85.21.7857; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DOHROWOLSKA G, 1991, BIOCHIM BIOPHYS ACTA, V1129, P139; FILHOL O, 1992, J BIOL CHEM, V267, P20577; GASHLER AL, 1993, MOL CELL BIOL, V13, P4556, DOI 10.1128/MCB.13.8.4556; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; HELLERHARRISON RA, 1991, J BIOL CHEM, V266, P14435; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; HUANG RP, 1994, BIOCHEM BIOPH RES CO, V200, P1271, DOI 10.1006/bbrc.1994.1588; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; JIN YJ, 1993, P NATL ACAD SCI USA, V90, P7769, DOI 10.1073/pnas.90.16.7769; KAMPS MP, 1991, METHOD ENZYMOL, V201, P21; KIKKAWA U, 1992, MOL CELL BIOL, V12, P5711, DOI 10.1128/MCB.12.12.5711; KUENZEL EA, 1985, P NATL ACAD SCI USA, V82, P737, DOI 10.1073/pnas.82.3.737; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEMAIRE P, 1988, P NATL ACAD SCI USA, V85, P4691, DOI 10.1073/pnas.85.13.4691; LIM RW, 1987, ONCOGENE, V1, P263; LIN AN, 1992, CELL, V70, P777, DOI 10.1016/0092-8674(92)90311-Y; LUDEMANN R, 1993, J BIOL CHEM, V268, P17413; LUSCHER B, 1994, EUR J BIOCHEM, V220, P521, DOI 10.1111/j.1432-1033.1994.tb18651.x; LUSCHER B, 1990, NATURE, V344, P517, DOI 10.1038/344517a0; MADDEN SL, 1991, SCIENCE, V253, P1550, DOI 10.1126/science.1654597; MANAK JR, 1993, ONCOGENE, V8, P703; MANAK JR, 1990, GENE DEV, V4, P955, DOI 10.1101/gad.4.6.955; MEEK DW, 1990, EMBO J, V9, P3253, DOI 10.1002/j.1460-2075.1990.tb07524.x; MEGGIO F, 1994, CELL MOL BIOL RES, V40, P401; MILBRANDT J, 1987, SCIENCE, V238, P797, DOI 10.1126/science.3672127; NGUYEN HQ, 1993, CELL, V72, P197, DOI 10.1016/0092-8674(93)90660-I; RUDNICKI MA, 1990, DEV BIOL, V138, P348, DOI 10.1016/0012-1606(90)90202-T; RUSSO MW, 1993, MOL CELL BIOL, V13, P6858, DOI 10.1128/MCB.13.11.6858; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STIGARE J, 1993, MOL CELL BIOCHEM, V129, P77, DOI 10.1007/BF00926578; SUKHATME VP, 1990, J AM SOC NEPHROL, V1, P859; SUKHATME VP, 1988, CELL, V53, P37, DOI 10.1016/0092-8674(88)90485-0; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WATT PM, 1994, BIOCHEM J, V303, P681, DOI 10.1042/bj3030681	44	43	45	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 7	1996	271	23					13530	13536		10.1074/jbc.271.23.13530	http://dx.doi.org/10.1074/jbc.271.23.13530			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UP385	8662759	hybrid			2022-12-25	WOS:A1996UP38500035
J	Mechling, DE; Gambee, JE; Morris, NP; Sakai, LY; Keene, DR; Mayne, R; Bachinger, HP				Mechling, DE; Gambee, JE; Morris, NP; Sakai, LY; Keene, DR; Mayne, R; Bachinger, HP			Type IX collagen NC1 domain peptides can trimerize in vitro without forming a triple helix	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONSTRUCTION; MUTATIONS; XII	Synthetic peptides of the three chains of type IX collagen consisting of the carboxyl-terminal end of the COL1 domain and the complete NC1 domain were characterized by circular dichroism spectroscopy and analyzed for their ability to assemble into trimers, In vitro association and oxidation result in disulfide-linked oligomers as shown by molecular sieve chromatography and SDS-polyacrylamide electrophoresis, Whereas the individual peptides show a tendency to self-associate, when an equimolar amount of the three peptides was oxidized, a heterotrimer of the three chains was observed, This heterotrimer is recognized by a monoclonal antibody against the disulfide-linked NC1 domain of chicken type IX collagen, indicating the correct formation of the disulfide bonds, Circular dichroism measurements show that under the association conditions used, a triple helix does not form between the chains, These results indicate that these peptides contain all the necessary information for chain selection and assembly.	SHRINERS HOSP CRIPPLED CHILDRENS,PORTLAND,OR 97201; OREGON HLTH SCI UNIV,DEPT BIOCHEM & MOLEC BIOL,PORTLAND,OR 97201; UNIV ALABAMA,DEPT CELL BIOL,BIRMINGHAM,AL 35294	Oregon Health & Science University; University of Alabama System; University of Alabama Birmingham					NEI NIH HHS [EY09908] Funding Source: Medline; NIAMS NIH HHS [AR30481] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY009908] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R37AR030481, R01AR030481] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BACHINGER HP, 1993, AM J MED GENET, V45, P152, DOI 10.1002/ajmg.1320450204; BREWTON RG, 1995, GENOMICS, V30, P329, DOI 10.1006/geno.1995.9870; BREWTON RG, 1992, EUR J BIOCHEM, V205, P443, DOI 10.1111/j.1432-1033.1992.tb16798.x; BREWTON RG, 1994, EXTRACELLULAR MATRIX, P129; COMPTON LA, 1987, J BIOL CHEM, V262, P13039; DOEGE KJ, 1986, J BIOL CHEM, V261, P8924; ELIMA K, 1992, BIOCHIM BIOPHYS ACTA, V1130, P78, DOI 10.1016/0167-4781(92)90465-C; ENGEL J, 1991, ANNU REV BIOPHYS BIO, V20, P137, DOI 10.1146/annurev.biophys.20.1.137; EYRE DR, 1995, J RHEUMATOL, V22, P82; FASSLER R, 1994, P NATL ACAD SCI USA, V91, P5070, DOI 10.1073/pnas.91.11.5070; FESSLER JH, 1978, ANNU REV BIOCHEM, V47, P129, DOI 10.1146/annurev.bi.47.070178.001021; HEIDEMANN E, 1982, ADV POLYM SCI, V43, P143; HWANG C, 1992, SCIENCE, V257, P1496, DOI 10.1126/science.1523409; LABOURDETTE L, 1993, FEBS LETT, V320, P211, DOI 10.1016/0014-5793(93)80588-L; LAMBERT N, 1983, BIOCHEM J, V213, P213; LEES JF, 1994, J BIOL CHEM, V269, P24354; LOZANO G, 1985, P NATL ACAD SCI USA, V82, P4050, DOI 10.1073/pnas.82.12.4050; MAZZORANA M, 1993, J BIOL CHEM, V268, P3029; MIDDLETON RB, 1993, BIOCHEM J, V296, P511, DOI 10.1042/bj2960511; MORRIS NP, 1987, J BIOL CHEM, V262, P11345; MURAGAKI Y, 1990, EUR J BIOCHEM, V192, P703, DOI 10.1111/j.1432-1033.1990.tb19279.x; NINOMIYA Y, 1985, BIOCHEMISTRY-US, V24, P4223, DOI 10.1021/bi00336a061; Prockop D.J., 1976, BIOCH COLLAGENS, P163; RIES A, 1995, J BIOL CHEM, V270, P23790, DOI 10.1074/jbc.270.40.23790; SAKAI LY, 1994, METHOD ENZYMOL, V245, P29; SAKAI LY, 1986, J CELL BIOL, V103, P2499, DOI 10.1083/jcb.103.6.2499; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHMID FX, 1993, ADV PROTEIN CHEM, V44, P25, DOI 10.1016/S0065-3233(08)60563-X; SHAW LM, 1991, TRENDS BIOCHEM SCI, V16, P191, DOI 10.1016/0968-0004(91)90074-6; STEINMANN B, 1991, J BIOL CHEM, V266, P1299; WATT SL, 1992, J BIOL CHEM, V267, P20093	31	29	31	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 7	1996	271	23					13781	13785		10.1074/jbc.271.23.13781	http://dx.doi.org/10.1074/jbc.271.23.13781			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UP385	8662808	hybrid			2022-12-25	WOS:A1996UP38500072
J	Altucci, L; Addeo, R; Cicatiello, L; Dauvois, S; Parker, MG; Truss, M; Beato, M; Sica, V; Bresciani, F; Weisz, A				Altucci, L; Addeo, R; Cicatiello, L; Dauvois, S; Parker, MG; Truss, M; Beato, M; Sica, V; Bresciani, F; Weisz, A			17 beta-Estradiol induces cyclin D-1 gene transcription, p36(D1)-p34(cdk4) complex activation and p105(Rb) phosphorylation during mitogenic stimulation of G(1)-arrested human breast cancer	ONCOGENE			English	Article						estrogen; breast cancer; cell cycle; cyclins; HMG-CoA reductase; retinoblastoma protein	MYC ONCOGENE EXPRESSION; CELL-CYCLE; RETINOBLASTOMA PROTEIN; NUCLEAR-PROTEIN; GROWTH-FACTOR; OVEREXPRESSION; PROGRESSION; FIBROBLASTS; INHIBITION; LOVASTATIN	MCF-7 human breast cancer cells express functional estrogen receptor and grow in response to estrogen stimulation. G(1)-synchronized MCF-7 cells, made quiescent by exposure to the HMG-CoA reductase inhibitor Simvastatin in estrogen-free medium, readily resume cell cycle progression up-on stimulation with 17 beta-estradiol (E(2)), even under conditions where polypeptide growth factor-triggered signal transduction pathways are inhibited by the continuous presence of Simvastatin in the culture medium. Under these conditions, cyclin D-1 gene transcription is transiently induced within the first 1-9 h of stimulation, as shown by the accumulation of cyclin D-1 mRNA and protein (p36(D1)) in the cell and by enhanced expression of stably transfected D-1 promoter-luciferase hybrid genes. Estrogen-induced p36(D1) associates readily with p32(cdk2) and p34(cdk4), but not with p31(cdk5) which is however abundantly expressed in these cells. Only p36(D1)-p34(cdk4) complexes are activated by E(2), as detected in cell extracts by immunoprecipitation with anti-D-1 antibodies followed by assessment of phosphotransferase activity toward the retinoblastoma (Rb) gene product and by analysis of p105(Rb) phosphorylation in vivo, An estrogen-responsive regulatory region has been mapped within the first 944 bp upstream of the transcriptional startsite of the human D-1 gene. Sequence analysis of this DNA region reveals that the cis-acting elements responsive to estrogen are likely to be different in this case from the canonical EREs.	UNIV NAPLES 2, FAC MED & CHIRURG, IST PATOL GEN & ONCOL, I-80138 NAPLES, ITALY; IMPERIAL CANC RES FUND, MOLEC ENDOCRINOL LAB, LONDON WC2A 3PX, ENGLAND; UNIV MARBURG, INST MOLEK BIOL & TUMORFORSCH, D-35037 MARBURG, GERMANY	Universita della Campania Vanvitelli; Cancer Research UK; Philipps University Marburg			Altucci, Lucia/S-8031-2019; Weisz, Alessandro/A-1317-2014; Beato, Miguel/B-5564-2015	Weisz, Alessandro/0000-0003-0455-2083; Beato, Miguel/0000-0002-2878-2222; altucci, lucia/0000-0002-7312-5387				ADDEO R, 1996, IN PRESS BIOCH BIOPH; AJCHENBAUM F, 1993, J BIOL CHEM, V268, P4113; BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812; BATES S, 1994, ONCOGENE, V9, P71; BODRUG SE, 1994, EMBO J, V13, P2124, DOI 10.1002/j.1460-2075.1994.tb06488.x; Bonapace IM, 1996, ONCOGENE, V12, P753; BUCKLEY MF, 1993, ONCOGENE, V8, P2127; CEPKO CL, 1984, CELL, V37, P1053, DOI 10.1016/0092-8674(84)90440-9; DAKSIS JI, 1994, ONCOGENE, V9, P3635; DOWDY SF, 1993, CELL, V73, P499, DOI 10.1016/0092-8674(93)90137-F; DOYLE A, 1994, CELL TISSUE CULTURE; DUBIK D, 1987, CANCER RES, V47, P6517; DUBIK D, 1992, ONCOGENE, V7, P1587; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; EWEN ME, 1993, CELL, V74, P1009, DOI 10.1016/0092-8674(93)90723-4; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; FILMUS J, 1994, ONCOGENE, V9, P3627; GRANA X, 1995, ONCOGENE, V11, P211; HALL FL, 1993, ONCOGENE, V8, P1377; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; Harlow E., 1988, ANTIBODIES LAB MANUA; HATAKEYAMA M, 1994, GENE DEV, V8, P1759, DOI 10.1101/gad.8.15.1759; HERBER B, 1994, ONCOGENE, V9, P1295; HINDS PW, 1994, P NATL ACAD SCI USA, V91, P709, DOI 10.1073/pnas.91.2.709; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; HUI Z, 1993, MOL BIOL CELL, V4, P897, DOI 10.1091/mbc.4.9.897; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; JAKOBISIAK M, 1991, P NATL ACAD SCI USA, V88, P3628, DOI 10.1073/pnas.88.9.3628; JANSENDURR P, 1993, P NATL ACAD SCI USA, V90, P3685, DOI 10.1073/pnas.90.8.3685; JIANG W, 1993, ONCOGENE, V8, P3447; KEYOMARSI K, 1993, P NATL ACAD SCI USA, V90, P1112, DOI 10.1073/pnas.90.3.1112; KEYOMARSI K, 1991, CANCER RES, V51, P3602; LAMMIE GA, 1991, CANCER CELL-MON REV, V3, P413; LANDERS J P, 1992, Critical Reviews in Eukaryotic Gene Expression, V2, P19; LIU JJ, 1995, MOL CELL BIOL, V15, P3654; LOVEC H, 1994, EMBO J, V13, P3487, DOI 10.1002/j.1460-2075.1994.tb06655.x; LUKAS J, 1995, ONCOGENE, V10, P2125; MALTESE WA, 1990, FASEB J, V4, P3319, DOI 10.1096/fasebj.4.15.2123808; MASIAKOWSKI P, 1982, NUCLEIC ACIDS RES, V10, P7895, DOI 10.1093/nar/10.24.7895; MATSUOKA M, 1994, MOL CELL BIOL, V14, P7265, DOI 10.1128/MCB.14.11.7265; MATSUSHIME H, 1992, CELL, V71, P323, DOI 10.1016/0092-8674(92)90360-O; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; MEYERSON M, 1994, MOL CELL BIOL, V14, P2077, DOI 10.1128/MCB.14.3.2077; MOTOKURA T, 1991, NATURE, V350, P512, DOI 10.1038/350512a0; MULLER H, 1994, P NATL ACAD SCI USA, V91, P2945, DOI 10.1073/pnas.91.8.2945; MUSGROVE EA, 1993, MOL CELL BIOL, V13, P3577, DOI 10.1128/MCB.13.6.3577; PHILIPP A, 1994, MOL CELL BIOL, V14, P4032, DOI 10.1128/MCB.14.6.4032; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; RESTNITZKY D, 1994, MOL CELL BIOL, V14, P1669; ROSENBERG CL, 1991, P NATL ACAD SCI USA, V88, P9638, DOI 10.1073/pnas.88.21.9638; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SEWING A, 1993, J CELL SCI, V104, P545; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SICINSKI P, 1995, CELL, V82, P621, DOI 10.1016/0092-8674(95)90034-9; SUKOVICH DA, 1994, MOL CELL BIOL, V14, P7134, DOI 10.1128/MCB.14.11.7134; TAM SW, 1994, ONCOGENE, V9, P2663; VEDECKIS WV, 1992, P SOC EXP BIOL MED, V199, P1; VINCENT TS, 1991, BIOCHEM BIOPH RES CO, V180, P1284, DOI 10.1016/S0006-291X(05)81334-8; WATTS CKW, 1994, BREAST CANCER RES TR, V31, P95, DOI 10.1007/BF00689680; WEISZ A, 1993, CRIT REV ONCOGENESIS, V4, P361; WEISZ A, 1990, MOL ENDOCRINOL, V4, P1041, DOI 10.1210/mend-4-7-1041; WITHERS DA, 1991, MOL CELL BIOL, V11, P4846, DOI 10.1128/MCB.11.10.4846; WON KA, 1992, P NATL ACAD SCI USA, V89, P9910, DOI 10.1073/pnas.89.20.9910; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0	68	312	316	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 6	1996	12	11					2315	2324						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UQ220	8649771				2022-12-25	WOS:A1996UQ22000008
J	Couvineau, A; RouyerFessard, C; Maoret, JJ; Gaudin, P; Nicole, P; Laburthe, M				Couvineau, A; RouyerFessard, C; Maoret, JJ; Gaudin, P; Nicole, P; Laburthe, M			Vasoactive intestinal peptide (VIP)(1) receptor - Three nonadjacent amino acids are responsible for species selectivity with respect to recognition of peptide histidine isoleucineamide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENYLATE-CYCLASE; VIP RECEPTORS; TISSUE DISTRIBUTION; RAT; PHI; POLYPEPTIDE; SECRETIN; LIVER; GRF	Vasoactive intestinal peptide (VIP)(1) receptors in rats and humans recognize peptide histidine isoleucineamide (PHI) with high and low affinity, respectively. We took advantage of this phenotypic difference to identify the domain responsible for the selective recognition of PHI by rat and human receptors which display >80% sequence identity. After transfection of human and rat receptors in COS cells, the ratio of IC50 for PHI/IC50 for VIP (referred to as P/V) in inhibiting I-125-VIP binding was shown to be >1,000 and <40, respectively. Construction of eight rat/human receptor chimerae by overlap polymerase chain reaction and determination of their P/V ratios demonstrated that the critical domain for PHI recognition is present within a sequence comprising part of the first extracellular loop and third transmembrane domain. This domain contains three different amino acids numbered according to human and rat sequences, respectively, e.g. Gln(207) (human) versus His(208) (rat), Gly(211) versus Ala(212) and Met(219) versus Val(220). Site-directed mutagenesis introducing individual, double, or triple mutations in a chimeric construct revealed that all three amino acids were involved in the recognition of PHI. Triple mutations were then introduced in the wild type receptors i.e. Q207H, G211A, M219V human VIP1 receptor and H208Q, A212G, V220M rat VIP1 receptor, resulting in a complete change in their phenotype from human to rat and from rat to human, respectively. The results demonstrate that three nonadjacent amino acids are responsible for the selective recognition of PHI by human and rat VIP1 receptors.			Couvineau, A (corresponding author), UNIV PARIS 07, FAC MED XAVIER BICHAT, INSERM, U410, UNIT RECH NEUROENDOCRINOL & BIOL CELLUL DIGEST, F-75870 PARIS 18, FRANCE.		couvineau, alain/T-3466-2019; LABURTHE, Marc/C-1875-2012; couvineau, alain/G-3641-2013	couvineau, alain/0000-0003-2912-5168; couvineau, alain/0000-0003-2912-5168				BATAILLE D, 1980, FEBS LETT, V114, P240, DOI 10.1016/0014-5793(80)81124-0; BrõndÚn CI., 1991, INTRO PROTEIN STRUCT; CAO YJ, 1995, BIOCHEM BIOPH RES CO, V212, P673, DOI 10.1006/bbrc.1995.2021; Couvineau A, 1996, BIOCHEMISTRY-US, V35, P1745, DOI 10.1021/bi952022h; COUVINEAU A, 1990, J BIOL CHEM, V265, P13386; COUVINEAU A, 1994, BIOCHEM BIOPH RES CO, V200, P769, DOI 10.1006/bbrc.1994.1517; COUVINEAU A, 1986, J BIOL CHEM, V261, P4482; COUVINEAU A, 1995, BIOCHEM BIOPH RES CO, V206, P246, DOI 10.1006/bbrc.1995.1034; FAHRENKRUG J, 1989, HDB PHYSL GASTROINTE, V2, P611; GAUDIN P, 1995, BIOCHEM BIOPH RES CO, V211, P901, DOI 10.1006/bbrc.1995.1897; HASHIMOTO H, 1993, NEURON, V11, P333, DOI 10.1016/0896-6273(93)90188-W; HOLTMANN MH, 1995, J BIOL CHEM, V270, P14394, DOI 10.1074/jbc.270.24.14394; Horton MR, 1991, DIRECTED MUTAGENESIS, P217; ISHIHARA T, 1992, NEURON, V8, P811, DOI 10.1016/0896-6273(92)90101-I; LABURTHE M, 1987, J BIOL CHEM, V262, P10180; LABURTHE M, 1983, FEBS LETT, V159, P89, DOI 10.1016/0014-5793(83)80422-0; LABURTHE M, 1985, LIFE SCI, V36, P991, DOI 10.1016/0024-3205(85)90396-0; LABURTHE M, 1986, MOL PHARMACOL, V29, P23; LABURTHE M, 1988, ANN NY ACAD SCI, V527, P296; LABURTHE M, 1993, HDB EXPT PHARM, V106, P133; LUTZ EM, 1993, FEBS LETT, V334, P3, DOI 10.1016/0014-5793(93)81668-P; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; SEGRE GV, 1993, TRENDS ENDOCRIN MET, V4, P309, DOI 10.1016/1043-2760(93)90071-L; SREEDHARAN SP, 1995, P NATL ACAD SCI USA, V92, P2939, DOI 10.1073/pnas.92.7.2939; SVOBODA M, 1994, BIOCHEM BIOPH RES CO, V205, P1617, DOI 10.1006/bbrc.1994.2852; SVOBODA M, 1995, INT SOC NEUR SAT S V; VILARDAGA JP, 1995, BIOCHEM BIOPH RES CO, V211, P885, DOI 10.1006/bbrc.1995.1895; Voisin T, 1996, J BIOL CHEM, V271, P574, DOI 10.1074/jbc.271.1.574	28	66	66	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 31	1996	271	22					12795	12800		10.1074/jbc.271.22.12795	http://dx.doi.org/10.1074/jbc.271.22.12795			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UN474	8662697	hybrid			2022-12-25	WOS:A1996UN47400018
J	Hemmann, U; Gerhartz, C; Heesel, B; Sasse, J; Kurapkat, G; Grotzinger, J; Wollmer, A; Zhong, Z; Darnell, JE; Graeve, L; Heinrich, PC; Horn, F				Hemmann, U; Gerhartz, C; Heesel, B; Sasse, J; Kurapkat, G; Grotzinger, J; Wollmer, A; Zhong, Z; Darnell, JE; Graeve, L; Heinrich, PC; Horn, F			Differential activation of acute phase response factor/Stat3 and Stat1 via the cytoplasmic domain of the interleukin 6 signal transducer gp130 .2. Src homology SH2 domains define the specificity of STAT factor activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE KINASE; TRANSCRIPTION FACTOR; INTERFERON-GAMMA; BINDING; PHOSPHORYLATION; ASSOCIATION; ALPHA/BETA; EXPRESSION; RECEPTOR; PATHWAY	Distinct yet overlapping sets of STAT transcription factors are activated by different cytokines. One example is the differential activation of acute phase response factor (APRF, also called Stat3) and Stat1 by interleukin 6 and interferon-gamma. Interleukin 6 activates both factors while, at least in human cells, interferon-gamma recruits only Stat1. Stat1 activation by interferon-gamma is mediated through a cytosolic tyrosine motif, Y440, of the interferon-gamma receptor. In an accompanying paper (Gerhartz, C., Heesel, B., Sasse, J., Hemmann, U., Landgraf, C., Schneider-Mergener, J., Horn, F., Heinrich, P. C., and Graeve, L. (1996) J. Biol. Chem. 271, 12991-12998), we demonstrated that two tyrosine motifs within the cytoplasmic part of the interleukin 6 signal transducer gp130 specifically mediate APRF activation while two others can recruit both APRF and Stat1. By expressing a series of Stat1/APRF domain swap mutants in COS-7 cells, we now determined which domains of Stat1 and APRF are involved in the specific recognition of phosphotyrosine motifs. Our data demonstrate that the SH2 domain is the sole determinant of specific STAT factor recruitment. Furthermore, the SH2 domain of Stat1 is able to recognize two unrelated types of phosphotyrosine motifs, one represented by the interferon-gamma receptor Y440DKPH peptide, and the other by two gp130 YXPQ motifs. By molecular modeling, we propose three dimensional model structures of the Stat1 and APRF SH2 domains which allow us to explain the different binding preferences of these factors and to predict amino acids crucial for specific peptide recognition.	RHEIN WESTFAL TH AACHEN,INST BIOCHEM,D-52057 AACHEN,GERMANY; ROCKEFELLER UNIV,MOLEC CELL BIOL LAB,NEW YORK,NY 10021	RWTH Aachen University; Rockefeller University								AKIRA S, 1994, CELL, V77, P63, DOI 10.1016/0092-8674(94)90235-6; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; BAZAN JF, 1990, IMMUNOL TODAY, V11, P350, DOI 10.1016/0167-5699(90)90139-Z; BOOKER GW, 1992, NATURE, V358, P684, DOI 10.1038/358684a0; CALDENHOVEN E, 1994, J BIOL CHEM, V269, P21146; CAMPBELL GS, 1995, J BIOL CHEM, V270, P3974, DOI 10.1074/jbc.270.8.3974; COFFER P, 1995, ONCOGENE, V10, P985; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DITTRICH E, 1994, J BIOL CHEM, V269, P19014; FU XY, 1992, CELL, V70, P323, DOI 10.1016/0092-8674(92)90106-M; FUJII H, 1995, P NATL ACAD SCI USA, V92, P5482, DOI 10.1073/pnas.92.12.5482; Gerhartz C, 1996, J BIOL CHEM, V271, P12991, DOI 10.1074/jbc.271.22.12991; GREENLUND AC, 1994, EMBO J, V13, P1591, DOI 10.1002/j.1460-2075.1994.tb06422.x; GREENLUND AC, 1995, IMMUNITY, V2, P677, DOI 10.1016/1074-7613(95)90012-8; GUSCHIN D, 1995, EMBO J, V14, P1421, DOI 10.1002/j.1460-2075.1995.tb07128.x; HEIM MH, 1995, SCIENCE, V267, P1347, DOI 10.1126/science.7871432; HEMMI S, 1994, CELL, V76, P803, DOI 10.1016/0092-8674(94)90355-7; HIBI M, 1990, CELL, V63, P1149, DOI 10.1016/0092-8674(90)90411-7; HORVATH CM, 1995, GENE DEV, V9, P984, DOI 10.1101/gad.9.8.984; HOU JZ, 1994, SCIENCE, V265, P1701, DOI 10.1126/science.8085155; LEE CH, 1994, STRUCTURE, V2, P423, DOI 10.1016/S0969-2126(00)00044-7; LEUNG S, 1995, MOL CELL BIOL, V15, P1312; LITTICKEN C, 1994, SCIENCE, V263, P89; MAYER BJ, 1992, MOL CELL BIOL, V12, P609, DOI 10.1128/MCB.12.2.609; MULLER M, 1993, NATURE, V366, P129, DOI 10.1038/366129a0; MURAKAMI M, 1993, SCIENCE, V260, P1808, DOI 10.1126/science.8511589; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; OVERDUIN M, 1992, CELL, V70, P697, DOI 10.1016/0092-8674(92)90437-H; PASCAL SM, 1994, CELL, V77, P461, DOI 10.1016/0092-8674(94)90160-0; SCHINDLER C, 1992, P NATL ACAD SCI USA, V89, P7836, DOI 10.1073/pnas.89.16.7836; SCHINDLER C, 1992, SCIENCE, V257, P809, DOI 10.1126/science.1496401; SEIDEL HM, 1995, P NATL ACAD SCI USA, V92, P3041, DOI 10.1073/pnas.92.7.3041; SHUAI K, 1994, CELL, V76, P821, DOI 10.1016/0092-8674(94)90357-3; SHUAI K, 1993, SCIENCE, V261, P1744, DOI 10.1126/science.7690989; SOH J, 1994, CELL, V76, P793, DOI 10.1016/0092-8674(94)90354-9; STAHL N, 1994, SCIENCE, V263, P92, DOI 10.1126/science.8272873; STAHL N, 1995, SCIENCE, V267, P1349, DOI 10.1126/science.7871433; TAGA T, 1989, CELL, V58, P573, DOI 10.1016/0092-8674(89)90438-8; VELAZQUEZ L, 1992, CELL, V70, P313, DOI 10.1016/0092-8674(92)90105-L; VRIEND G, 1990, J MOL GRAPHICS, V8, P52, DOI 10.1016/0263-7855(90)80070-V; WAGNER BJ, 1990, EMBO J, V9, P4477, DOI 10.1002/j.1460-2075.1990.tb07898.x; WAKAO H, 1995, EMBO J, V14, P2527, DOI 10.1002/j.1460-2075.1995.tb07250.x; WAKSMAN G, 1993, CELL, V72, P779, DOI 10.1016/0092-8674(93)90405-F; WAKSMAN G, 1992, NATURE, V358, P646, DOI 10.1038/358646a0; WANG YD, 1995, J BIOL CHEM, V270, P7021, DOI 10.1074/jbc.270.13.7021; WATLING D, 1993, NATURE, V366, P166, DOI 10.1038/366166a0; WEGENKA UM, 1994, MOL CELL BIOL, V14, P3186, DOI 10.1128/MCB.14.5.3186; WEGENKA UM, 1993, MOL CELL BIOL, V13, P276, DOI 10.1128/MCB.13.1.276; YAMASAKI K, 1988, SCIENCE, V241, P825, DOI 10.1126/science.3136546; YUAN JP, 1994, MOL CELL BIOL, V14, P1657, DOI 10.1128/MCB.14.3.1657; ZHANG XK, 1995, SCIENCE, V267, P1990, DOI 10.1126/science.7701321; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422; Ziemiecki Andrew, 1994, Trends in Cell Biology, V4, P207, DOI 10.1016/0962-8924(94)90143-0; ZVELEBIL MJJM, 1995, PROTEIN ENG, V8, P527, DOI 10.1093/protein/8.6.527	56	143	146	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 31	1996	271	22					12999	13007		10.1074/jbc.271.22.12999	http://dx.doi.org/10.1074/jbc.271.22.12999			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UN474	8662795	hybrid			2022-12-25	WOS:A1996UN47400050
J	Ishizuka, T; Oshiba, A; Sakata, N; Terada, N; Johnson, GL; Gelfand, EW				Ishizuka, T; Oshiba, A; Sakata, N; Terada, N; Johnson, GL; Gelfand, EW			Aggregation of the Fc epsilon RI on mast cells stimulates c-Jun amino-terminal kinase activity - A response inhibited by Wortmannin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AFFINITY IGE RECEPTOR; PROTEIN-KINASE; TYROSINE PHOSPHORYLATION; ANTIGEN RECEPTOR; PHOSPHATIDYLINOSITOL 3-KINASE; SIGNAL TRANSDUCTION; ACTIVATION DOMAIN; TRANSFECTED CELLS; RBL-2H3 CELLS; MAP KINASE	Aggregation of the high-affinity Fc receptors for immunoglobulin E (IgE) (Fc epsilon RI) on the surface of mast cells initiates intracellular signal transduction pathways including the tyrosine phosphorylation of cellular proteins, phosphoinositide hydrolysis, an increase in intracellular calcium, and protein kinase C activation. These signals are believed to be involved in the exocytic release of inflammatory mediators such as vasoactive amines, cytokines, and lipid metabolites. However, the downstream consequences of these early activation events are not well defined. One exception is the activation of the extracellular signal-regulated kinases/mitogen-activated protein kinases. One member of the mitogen-activated protein kinase superfamily, designated c-Jun amino-terminal kinase (JNK), has been recently identified. JNK is activated following dual phosphorylation at a Thr-Pro-Tyr motif in response to diverse stimuli including tumor necrosis factor-alpha, heat shock, or ultraviolet irradiation. We found that JNK was strongly activated by antigen cross-linking in a mouse mast cell line passively sensitized with ovalbumin-specific IgE. Anti-mouse IgE antibody also activated JNK. MEK kinase 1 (MEKK1) which activates the JNK activator, JNK kinase (JNKK), was similarly activated by antigen stimulation. JNK but not p42(erk2) activation induced by antigen was significantly inhibited in the presence of wortmannin, a known inhibitor of phosphatidylinositol 3-kinase. These results indicate that in response to the aggregation of Fc epsilon RI on mast cells, phosphatidylinositol 3-kinase activation is involved in the stimulation of the MEKK1, JNKK, JNK pathway.	NATL JEWISH CTR IMMUNOL & RESP MED,DEPT PEDIAT,DIV BASIC SCI,DENVER,CO 80206; NATL JEWISH CTR IMMUNOL & RESP MED,PROGRAM MOL SIGNAL TRANSDUCT,DENVER,CO 80206	National Jewish Health; National Jewish Health					NIAID NIH HHS [AI HL-36577] Funding Source: Medline; NIDDK NIH HHS [DK-37871] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK037871] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALVAREZ E, 1991, J BIOL CHEM, V266, P15277; ANDERSON NG, 1990, NATURE, V343, P651, DOI 10.1038/343651a0; ARCARO A, 1993, BIOCHEM J, V296, P297, DOI 10.1042/bj2960297; BEAVEN MA, 1984, J BIOL CHEM, V259, P7137; BENHAMOU M, 1990, P NATL ACAD SCI USA, V87, P5327, DOI 10.1073/pnas.87.14.5327; BLANK U, 1989, NATURE, V337, P187, DOI 10.1038/337187a0; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; COOK SJ, 1993, SCIENCE, V262, P1069, DOI 10.1126/science.7694367; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; EISEMAN E, 1992, NATURE, V355, P78; GALLI SJ, 1993, NEW ENGL J MED, V328, P257; GALLI SJ, 1982, J CELL BIOL, V95, P435, DOI 10.1083/jcb.95.2.435; GOTTSCHALK LR, 1993, J EXP MED, V178, P1681, DOI 10.1084/jem.178.5.1681; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; HUTCHCROFT JE, 1992, P NATL ACAD SCI USA, V89, P9107, DOI 10.1073/pnas.89.19.9107; HUTCHINSON LE, 1995, J BIOL CHEM, V270, P16333, DOI 10.1074/jbc.270.27.16333; KAWAKAMI T, 1992, J IMMUNOL, V148, P3513; KAWAKAMI Y, 1994, MOL CELL BIOL, V14, P5108, DOI 10.1128/MCB.14.8.5108; KAYE RE, 1992, P NATL ACAD SCI USA, V89, P8542, DOI 10.1073/pnas.89.18.8542; KIMURA K, 1994, J BIOL CHEM, V269, P18961; KOTANI K, 1994, EMBO J, V13, P2313, DOI 10.1002/j.1460-2075.1994.tb06515.x; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LANGECARTER CA, 1994, SCIENCE, V265, P1458, DOI 10.1126/science.8073291; LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; MUKHOPADHYAY NK, 1992, J BIOL CHEM, V267, P3325; NABEL G, 1981, NATURE, V291, P332, DOI 10.1038/291332a0; NINOMIYA N, 1994, J BIOL CHEM, V269, P22732; OFFERMANNS S, 1994, J IMMUNOL, V152, P250; OKADA T, 1994, J BIOL CHEM, V269, P3563; OKADA T, 1994, J BIOL CHEM, V269, P3568; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; Oshiba A, 1996, J CLIN INVEST, V97, P1398, DOI 10.1172/JCI118560; OZAWA K, 1993, J BIOL CHEM, V268, P1749; PAOLINI R, 1991, NATURE, V353, P855, DOI 10.1038/353855a0; PLAUT M, 1989, NATURE, V339, P64, DOI 10.1038/339064a0; RA C, 1989, J BIOL CHEM, V264, P15323; RAZIN E, 1983, J EXP MED, V157, P189, DOI 10.1084/jem.157.1.189; RETH M, 1989, NATURE, V338, P383, DOI 10.1038/338383b0; ROONEY JW, 1995, IMMUNITY, V2, P473, DOI 10.1016/1074-7613(95)90028-4; Sakata N, 1995, J BIOL CHEM, V270, P30823, DOI 10.1074/jbc.270.51.30823; SAMELSON LE, 1992, J BIOL CHEM, V267, P24913; SANTINI F, 1993, J BIOL CHEM, V268, P22716; SHIUE L, 1995, MOL CELL BIOL, V15, P272, DOI 10.1128/MCB.15.1.272; SU B, 1994, CELL, V77, P727, DOI 10.1016/0092-8674(94)90056-6; TOLIAS KF, 1995, J BIOL CHEM, V270, P17656, DOI 10.1074/jbc.270.30.17656; WEISS A, 1993, CELL, V73, P209, DOI 10.1016/0092-8674(93)90221-B; WHITE KN, 1988, J IMMUNOL, V141, P942; WODNARFILIPOWICZ A, 1989, NATURE, V339, P150, DOI 10.1038/339150a0; YANO H, 1993, J BIOL CHEM, V268, P25846	52	70	70	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 31	1996	271	22					12762	12766		10.1074/jbc.271.22.12762	http://dx.doi.org/10.1074/jbc.271.22.12762			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UN474	8662803	hybrid			2022-12-25	WOS:A1996UN47400013
J	Pansegrau, W; Lanka, E				Pansegrau, W; Lanka, E			Mechanisms of initiation and termination reactions in conjugative DNA processing - Independence of tight substrate binding and catalytic activity of relaxase (TraI) of IncP alpha plasmid RP4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFER ORIGIN; BACTERIAL CONJUGATION; SEQUENCE MOTIFS; STRAND TRANSFER; NICK REGIONS; PROTEIN; SITE; MOBILIZATION; REPLICATION; CLEAVAGE	The relaxase (TraI) of plasmid RP4 (IncP alpha) plays a key role in initiation and termination of transfer DNA replication during conjugative transmission of the plasmid. TraI functions as a DNA strand transferase that cleaves a unique phosphodiester bond at nic of the transfer origin. The cleavage reaction consists in a reversible transesterification that leads to transfer of the 5' phosphoryl at nic to the hydroxyl group of TraI Tyr-22. Hence, cleavage results in the covalent attachment of TraI to the 5' terminus of the plasmid strand destined for transfer. To investigate the protein's ability to function in a ''second cleavage'' reaction proposed to terminate rolling circle mode transfer DNA replication, single-stranded oligonucleotides containing the nic region were immobilized at their 3' ends on magnetic beads and cleaved by TraI. The resulting covalent TraI-oligonucleotide adducts were active in the joining reaction but unable to cleave oligonucleotides containing an intact nic region, indicating that second cleavage probably requires a TraI dimer, since a monomer is insufficient. The covalently attached oligonucleotide determines the affinity of the relaxase for the 3' terminus of the T-strand. To further the biochemical characterization of TraI-catalyzed reactions, me used specific TraI mutants, showing that amino acid residues in each relaxase motif are involved in substrate binding. To uncouple substrate binding and cleaving-joining we applied partially biotinylated TraI mutant proteins that were immobilized to magnetic beads. Using this approach we could demonstrate that tight DNA substrate binding and cleaving-joining are independent processes. Enhanced topoisomerase activity of some TraI mutants was correlated with low specific substrate binding affinity in conjunction with high cleaving-joining activity.	MAX PLANCK INST MOLEC GENET, D-14195 BERLIN, GERMANY	Max Planck Society								BALZER D, 1994, J BACTERIOL, V176, P4285, DOI 10.1128/jb.176.14.4285-4295.1994; BHATTACHARJEE M, 1992, J BACTERIOL, V174, P6659, DOI 10.1128/JB.174.20.6659-6665.1992; CRONAN JE, 1990, J BIOL CHEM, V265, P10327; ERICKSON MJ, 1993, MOL MICROBIOL, V7, P289, DOI 10.1111/j.1365-2958.1993.tb01120.x; FURSTE JP, 1989, P NATL ACAD SCI USA, V86, P1771, DOI 10.1073/pnas.86.6.1771; GAO Q, 1994, MOL MICROBIOL, V11, P449, DOI 10.1111/j.1365-2958.1994.tb00326.x; HANAI R, 1993, J BIOL CHEM, V268, P23830; ILYINA TV, 1992, NUCLEIC ACIDS RES, V20, P3279, DOI 10.1093/nar/20.13.3279; JOHNSTON RF, 1990, ELECTROPHORESIS, V11, P355, DOI 10.1002/elps.1150110503; KORNBERG A, 1992, DNA REPLICATION, P553; LANKA E, 1995, ANNU REV BIOCHEM, V64, P141, DOI 10.1146/annurev.bi.64.070195.001041; LESSL M, 1993, J BACTERIOL, V175, P6415, DOI 10.1128/jb.175.20.6415-6425.1993; MEYER R, 1989, J BACTERIOL, V171, P799, DOI 10.1128/jb.171.2.799-806.1989; PANSEGRAU W, 1994, J BIOL CHEM, V269, P2782; PANSEGRAU W, 1990, J BIOL CHEM, V265, P10637; PANSEGRAU W, 1994, J MOL BIOL, V239, P623, DOI 10.1006/jmbi.1994.1404; Pansegrau W, 1996, PROG NUCLEIC ACID RE, V54, P197, DOI 10.1016/S0079-6603(08)60364-5; PANSEGRAU W, 1993, P NATL ACAD SCI USA, V90, P2925, DOI 10.1073/pnas.90.7.2925; PANSEGRAU W, 1990, P NATL ACAD SCI USA, V87, P6555, DOI 10.1073/pnas.87.17.6555; PANSEGRAU W, 1991, NUCLEIC ACIDS RES, V19, P3455, DOI 10.1093/nar/19.12.3455; PANSEGRAU W, 1991, THESIS FREIE U BERLI; RAO XM, 1994, J BACTERIOL, V176, P5958, DOI 10.1128/jb.176.19.5958-5961.1994; RASOOLY A, 1994, EMBO J, V13, P5245, DOI 10.1002/j.1460-2075.1994.tb06856.x; RASOOLY A, 1994, J BACTERIOL, V176, P2450, DOI 10.1128/JB.176.8.2450-2453.1994; Sambrook, 1989, MOL CLONING LAB MANU, P68; SCHERZINGER E, 1993, EUR J BIOCHEM, V217, P929, DOI 10.1111/j.1432-1033.1993.tb18323.x; THOMAS CD, 1990, J BIOL CHEM, V265, P5519; VANMANSFELD ADM, 1986, NUCLEIC ACIDS RES, V14, P4229, DOI 10.1093/nar/14.10.4229; WATERS VL, 1992, J BACTERIOL, V174, P6666, DOI 10.1128/JB.174.20.6666-6673.1992; WATERS VL, 1991, P NATL ACAD SCI USA, V88, P1456, DOI 10.1073/pnas.88.4.1456; Wilkins B, 1993, BACTERIAL CONJUGATIO, P105; ZIEGELIN G, 1989, J BIOL CHEM, V264, P11989; ZIEGELIN G, 1992, J BIOL CHEM, V267, P17279	33	54	54	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 31	1996	271	22					13068	13076		10.1074/jbc.271.22.13068	http://dx.doi.org/10.1074/jbc.271.22.13068			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UN474	8662726				2022-12-25	WOS:A1996UN47400060
J	Agarwal, C; Chandraratna, RAS; Johnson, AT; Rorke, EA; Eckert, RL				Agarwal, C; Chandraratna, RAS; Johnson, AT; Rorke, EA; Eckert, RL			AGN193109 is a highly effective antagonist of retinoid action in human ectocervical epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THERAPEUTIC ANTICANCER AGENTS; KERATIN GENE-EXPRESSION; ACID RECEPTOR; VITAMIN-A; IDENTIFICATION; CARCINOMA; IMMORTALIZATION; DIFFERENTIATION; CLONING; FAMILY	Retinoids are important physiological agents that regulate epithelial cell differentiation and proliferation. The importance of these agents in regulating growth, development, and differentiation has led to a search for new retinoid agonists and antagonists. In the present manuscript we show that AGN193109, a retinoid analog, is an efficient antagonist of retinoid action in human cervical epithelial cells. Treatment of ECE16-1 cells with natural or synthetic retinoids reduces cytokeratin K5, K6, K14, K16, and K17 levels, increases cytokeratin K7, K8, and K19 levels, increases retinoic acid receptor-beta (RAR beta) mRNA levels, suppresses proliferation, and alters cell morphology. Co-treatment with AGN193109 prevents these responses. Half-maximal and maximal antagonism is observed at a molar ratio of AGN193109: retinoid agonist of 1:1 and 10:1, respectively. When administered alone AGN193109 has no agonist activity. Thus, AGN193109, which binds to RAR alpha, RAR beta, and RAR gamma with K-d values = 2, 2, and 3 nM, respectively, but is unable to bind to the retinoid X receptors, is a highly active antagonist of retinoid action in ECE16-1 cells.	CASE WESTERN RESERVE UNIV,SCH MED,DEPT PHYSIOL & BIOPHYS,CLEVELAND,OH 44106; CASE WESTERN RESERVE UNIV,SCH MED,DEPT DERMATOL,CLEVELAND,OH 44106; CASE WESTERN RESERVE UNIV,SCH MED,DEPT REPROD BIOL,CLEVELAND,OH 44106; CASE WESTERN RESERVE UNIV,SCH MED,DEPT BIOCHEM,CLEVELAND,OH 44106; CASE WESTERN RESERVE UNIV,SCH MED,DEPT ENVIRONM HLTH SCI,CLEVELAND,OH 44106; ALLERGAN PHARMACEUT INC,DEPT CHEM,RETINOID RES,IRVINE,CA 92713; ALLERGAN PHARMACEUT INC,DEPT BIOL,IRVINE,CA 92713	Case Western Reserve University; Case Western Reserve University; Case Western Reserve University; Case Western Reserve University; Case Western Reserve University; AbbVie; Allergan; AbbVie; Allergan					NIAMS NIH HHS [AR39750] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P30AR039750] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		AGARWAL C, 1994, CANCER RES, V54, P2108; Agarwal C, 1996, CELL GROWTH DIFFER, V7, P521; AGARWAL C, 1991, CANCER RES, V51, P3982; AGARWAL C, 1993, DIFFERENTIATION, V52, P185, DOI 10.1111/j.1432-0436.1993.tb00629.x; APFEL C, 1992, P NATL ACAD SCI USA, V89, P7129, DOI 10.1073/pnas.89.15.7129; BEARD RL, 1995, J MED CHEM, V38, P2820, DOI 10.1021/jm00015a004; BENBROOK D, 1988, NATURE, V333, P669, DOI 10.1038/333669a0; BOEDTKER H, 1971, BIOCHIM BIOPHYS ACTA, V240, P448, DOI 10.1016/0005-2787(71)90539-9; BRAND N, 1988, NATURE, V332, P850, DOI 10.1038/332850a0; CHANDRARATNA RAS, 1995, BIOORG MED CHEM LETT, V5, P523, DOI 10.1016/0960-894X(95)00065-2; CHOO CK, 1995, CARCINOGENESIS, V16, P375, DOI 10.1093/carcin/16.2.375; ECKERT RL, 1984, P NATL ACAD SCI-BIOL, V81, P4321, DOI 10.1073/pnas.81.14.4321; EYROLLES L, 1994, J MED CHEM, V37, P1508, DOI 10.1021/jm00036a017; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; GIGUERE V, 1994, ENDOCR REV, V15, P61, DOI 10.1210/er.15.1.61; GIGUERE V, 1990, METHOD ENZYMOL, V189, P223; GIGUERE V, 1987, NATURE, V330, P624, DOI 10.1038/330624a0; GILFIX BM, 1985, J BIOL CHEM, V260, P4026; GORODESKI GI, 1990, ENDOCRINOLOGY, V126, P399, DOI 10.1210/endo-126-1-399; GORODESKI GI, 1989, DIFFERENTIATION, V42, P75, DOI 10.1111/j.1432-0436.1989.tb00609.x; GUDAS LJ, 1994, J BIOL CHEM, V269, P15399; HEMBREE JR, 1994, CANCER RES, V54, P3160; HEYMAN RA, 1992, CELL, V68, P397, DOI 10.1016/0092-8674(92)90479-V; ISHIKAWA T, 1990, MOL ENDOCRINOL, V4, P837, DOI 10.1210/mend-4-6-837; JOHNSON AT, 1995, J MED CHEM, V38, P4764, DOI 10.1021/jm00024a003; KANEKO S, 1991, MED CHEM RES, V1, P220; KRUST A, 1989, P NATL ACAD SCI USA, V86, P5310, DOI 10.1073/pnas.86.14.5310; LIPPMAN SM, 1993, J NATL CANCER I, V85, P499, DOI 10.1093/jnci/85.6.499; LIPPMAN SM, 1987, CANCER TREAT REP, V71, P391; LIPPMAN SM, 1987, CANCER TREAT REP, V71, P493; LOELIGER P, 1980, EUR J MED CHEM, V15, P9; MANGELSDORF DJ, 1992, GENE DEV, V6, P329, DOI 10.1101/gad.6.3.329; NAGPAL S, 1995, J BIOL CHEM, V270, P923, DOI 10.1074/jbc.270.2.923; PETKOVICH M, 1987, NATURE, V330, P444, DOI 10.1038/330444a0; RIBOT TE, 1994, J AM ACAD DERMATOL, V30, P581; SIZEMORE N, 1993, CANCER RES, V53, P4511; SIZEMORE N, 1993, DIFFERENTIATION, V54, P219, DOI 10.1111/j.1432-0436.1993.tb01603.x; STRICKLAND S, 1983, CANCER RES, V43, P5268; TSO JY, 1985, NUCLEIC ACIDS RES, V13, P2485, DOI 10.1093/nar/13.7.2485; VANLEYEN SA, 1994, J CELL PHYSL, V160, P265; WEINSTEIN GD, 1993, J INVEST DERMATOL, V100, P544; YOSHIMURA H, 1995, J MED CHEM, V38, P3163, DOI 10.1021/jm00016a020; ZELENT A, 1989, NATURE, V339, P714, DOI 10.1038/339714a0	43	67	71	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 24	1996	271	21					12209	12212		10.1074/jbc.271.21.12209	http://dx.doi.org/10.1074/jbc.271.21.12209			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UL660	8647816	hybrid			2022-12-25	WOS:A1996UL66000018
J	Traxler, B; Murphy, C				Traxler, B; Murphy, C			Insertion of the polytopic membrane protein MalF is dependent on the bacterial secretion machinery	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; ENDOPLASMIC-RETICULUM; CYTOPLASMIC MEMBRANE; PLASMA-MEMBRANE; MUTANTS; EXPORT; TRANSLOCATION; COMPONENT	We examined the dependence of protein export and membrane protein insertion on SecE and SecA, two components of the secretion (Sec) apparatus of Escherichia coli. The magnitude of the secretion defect observed for signal sequence-containing proteins in cells depleted of SecE is larger and more general than that in many temperature- or cold-sensitive Sec mutants. In addition, we show that the proper insertion of the polytopic MalF protein (synthesized without a signal sequence) into the cytoplasmic membrane is also SecE-dependent. In contrast to an earlier study (McGovern, K., and Beckwith, J. (1991) J. Biol. Chem. 266, 20870-20876), the membrane insertion of MalF also is inhibited by treatment of cells with sodium azide, a potent inhibitor of SecA. Therefore, our data strongly suggest that the cytoplasmic membrane insertion of MalF is dependent on the same cellular machinery as is involved in the export of signal sequence-containing proteins. We propose that the mechanism of export from the cytoplasm is related for both signal sequence-containing and cytoplasmic membrane proteins, but hydrophobic membrane proteins such as MalF may have a higher affinity for the Sec apparatus.	HARVARD UNIV,SCH MED,DEPT MICROBIOL & MOLEC GENET,BOSTON,MA 02115	Harvard University; Harvard Medical School	Traxler, B (corresponding author), UNIV WASHINGTON,DEPT MICROBIOL,BOX 35742,SEATTLE,WA 98195, USA.							AKIYAMA Y, 1989, J BIOL CHEM, V264, P437; BOYD D, 1987, P NATL ACAD SCI USA, V84, P8525, DOI 10.1073/pnas.84.23.8525; GEBERT JF, 1988, J BIOL CHEM, V263, P16652; GREEN N, 1992, J CELL BIOL, V116, P597, DOI 10.1083/jcb.116.3.597; JANDER G, 1996, IN PRESS J BACT, V178; MCGOVERN K, 1991, J BIOL CHEM, V266, P20870; MURPHY CK, 1994, P NATL ACAD SCI USA, V91, P2557, DOI 10.1073/pnas.91.7.2557; OLIVER DB, 1990, P NATL ACAD SCI USA, V87, P8227, DOI 10.1073/pnas.87.21.8227; POGLIANO JA, 1994, EMBO J, V13, P554, DOI 10.1002/j.1460-2075.1994.tb06293.x; POGLIANO KJ, 1993, GENETICS, V133, P763; RUSCH SL, 1994, J CELL BIOCHEM, V55, P209, DOI 10.1002/jcb.240550208; SAAF A, 1995, MOL MEMBR BIOL, V12, P209, DOI 10.3109/09687689509027509; SCHATZ PJ, 1991, EMBO J, V10, P1749, DOI 10.1002/j.1460-2075.1991.tb07699.x; SCHATZ PJ, 1990, ANNU REV GENET, V24, P215, DOI 10.1146/annurev.ge.24.120190.001243; SELIGMAN L, 1994, J BIOL CHEM, V269, P19888; STIRLING CJ, 1992, MOL BIOL CELL, V3, P129, DOI 10.1091/mbc.3.2.129; TRAXLER B, 1992, P NATL ACAD SCI USA, V89, P10852, DOI 10.1073/pnas.89.22.10852; TRAXLER B, 1992, J BIOL CHEM, V267, P5339; VONHEIJNE G, 1994, FEBS LETT, V346, P69, DOI 10.1016/0014-5793(94)00296-7; WERNER PK, 1992, J BIOL CHEM, V267, P24523; WHITLEY P, 1994, EMBO J, V13, P4653, DOI 10.1002/j.1460-2075.1994.tb06788.x; WICKNER W, 1991, ANNU REV BIOCHEM, V60, P101, DOI 10.1146/annurev.bi.60.070191.000533; WOLFE PB, 1985, J BIOL CHEM, V260, P1836	23	91	91	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 24	1996	271	21					12394	12400		10.1074/jbc.271.21.12394	http://dx.doi.org/10.1074/jbc.271.21.12394			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UL660	8647843	hybrid			2022-12-25	WOS:A1996UL66000045
J	Udagawa, T; McIntyre, BW				Udagawa, T; McIntyre, BW			ADP-ribosylation of the G protein Rho inhibits integrin regulation of tumor cell growth	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTP-BINDING-PROTEIN; PHOSPHATIDYLINOSITOL 4,5-BISPHOSPHATE; EXTRACELLULAR-MATRIX; ADHESION; FIBRONECTIN; EXPRESSION; GENE; CARCINOMA; CYCLE; LINE	Using a gastric derived tumor line, we investigated the involvement of beta 1 integrin and Rho in cell growth regulation in response to collagen. The addition of C3 exoenzyme from Clostridium botulinum to specifically ribosylate and inhibit the function of the rho gene products inhibited cellular proliferation in a dose-dependent fashion. C3 exoenzyme exhibited broad cytostatic activity toward a number of tumor lines and induced G(0)/G(1), accumulation, cyclin A inhibition, and pronounced alterations in cell morphology. Integrin-mediated adhesion to collagen led to the expression of the cyclin A gene whose expression could be blocked using anti-beta 1 integrin monoclonal antibodies. Phospholipid levels were induced upon beta 1 integrin-mediated adhesion to collagen, and the phospholipid induction was inhibited by either antibodies to beta 1 integrin or pretreatment of cells with C3 exoenzyme. Significant reduction in phospholipid levels correlated with proliferation for a panel of tumor lines deprived of adhesion to substrate. These results implicate a novel role for integrins and Rho in the regulation of tumor growth in response to matrix.	UNIV TEXAS, MD ANDERSON CANC CTR, DEPT IMMUNOL, HOUSTON, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center					PHS HHS [62596] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ADAMS JC, 1993, DEVELOPMENT, V117, P1183; ADES EW, 1992, J INVEST DERMATOL, V99, P683, DOI 10.1111/1523-1747.ep12613748; ALBELDA SM, 1990, FASEB J, V4, P2868, DOI 10.1096/fasebj.4.11.2199285; AVRAHAM H, 1989, MOL CELL BIOL, V9, P2058, DOI 10.1128/MCB.9.5.2058; BAUER JS, 1993, J CELL BIOL, V122, P209, DOI 10.1083/jcb.122.1.209; BEDNARCZYK JL, 1993, J CELL BIOCHEM, V51, P465, DOI 10.1002/jcb.2400510412; BERRIDGE MJ, 1987, BIOCHIM BIOPHYS ACTA, V907, P33, DOI 10.1016/0304-419X(87)90017-5; CHONG LD, 1994, CELL, V79, P507, DOI 10.1016/0092-8674(94)90259-3; CHUN JS, 1993, MOL BIOL CELL, V4, P271; DAVIS LS, 1990, J IMMUNOL, V145, P785; FOLKMAN J, 1978, NATURE, V273, P345, DOI 10.1038/273345a0; FUKAMI K, 1992, NATURE, V359, P150, DOI 10.1038/359150a0; GOLDMANN WH, 1992, BIOCHEMISTRY-US, V31, P7665, DOI 10.1021/bi00148a030; GUADAGNO TM, 1993, SCIENCE, V262, P1572, DOI 10.1126/science.8248807; GUADAGNO TM, 1991, J CELL BIOL, V115, P1419, DOI 10.1083/jcb.115.5.1419; GUINEBAULT C, 1995, J CELL BIOL, V129, P831, DOI 10.1083/jcb.129.3.831; HART MJ, 1994, J BIOL CHEM, V269, P62; HARTWELL L, 1992, CELL, V71, P543, DOI 10.1016/0092-8674(92)90586-2; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; HELSETH E, 1990, APMIS, V98, P996, DOI 10.1111/j.1699-0463.1990.tb05026.x; HUANG MN, 1990, BIOTECHNIQUES, V9, P710; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; JANMEY PA, 1987, NATURE, V325, P362, DOI 10.1038/325362a0; Jones Peter Lloyd, 1993, Critical Reviews in Eukaryotic Gene Expression, V3, P137; JUST I, 1992, J BIOL CHEM, V267, P10274; KAPRONBRAS C, 1993, J BIOL CHEM, V268, P20701; Karpatkin S, 1988, Prog Clin Biol Res, V283, P585; KLEINMAN HK, 1981, J CELL BIOL, V88, P473, DOI 10.1083/jcb.88.3.473; KORNBERG L, 1992, J BIOL CHEM, V267, P23439; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LASSING I, 1985, NATURE, V314, P472, DOI 10.1038/314472a0; LEONARD D, 1992, J BIOL CHEM, V267, P22860; MANIATIS T, 1982, MOL CLONING LABORATO, pA3; MATSUYAMA T, 1989, J EXP MED, V170, P1133, DOI 10.1084/jem.170.4.1133; MCNAMEE HP, 1993, J CELL BIOL, V121, P673, DOI 10.1083/jcb.121.3.673; MENARD L, 1992, EUR J BIOCHEM, V206, P537, DOI 10.1111/j.1432-1033.1992.tb16957.x; MOHR C, 1992, FEBS LETT, V297, P95, DOI 10.1016/0014-5793(92)80335-E; OTSUKA H, 1976, J CELL PHYSIOL, V87, P213, DOI 10.1002/jcp.1040870209; PATERSON HF, 1990, J CELL BIOL, V111, P1001, DOI 10.1083/jcb.111.3.1001; PERONA R, 1993, ONCOGENE, V8, P1285; PIGNATELLI M, 1988, P NATL ACAD SCI USA, V85, P5561, DOI 10.1073/pnas.85.15.5561; POPOFF M, 1990, NUCLEIC ACIDS RES, V18, P1291, DOI 10.1093/nar/18.5.1291; POTTEN CS, 1994, GROWTH FACTORS, V10, P53, DOI 10.3109/08977199409019603; QUILLIAM LA, 1989, FEBS LETT, V247, P221, DOI 10.1016/0014-5793(89)81339-0; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; RUGGIERO M, 1989, ONCOGENE, V4, P767; RUOSLAHTI E, 1989, CANCER CELL-MON REV, V1, P119; SAUTER G, 1994, INT J CANCER, V57, P508, DOI 10.1002/ijc.2910570412; SCHWARTZ MA, 1991, P NATL ACAD SCI USA, V88, P7849, DOI 10.1073/pnas.88.17.7849; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; UDAGAWA T, 1995, CLIN EXP METASTAS, V13, P427, DOI 10.1007/BF00118182; WANG J, 1990, NATURE, V343, P555, DOI 10.1038/343555a0; YUE X, 1991, CELL, V65, P691, DOI 10.1016/0092-8674(91)90100-D	54	39	39	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 24	1996	271	21					12542	12548		10.1074/jbc.271.21.12542	http://dx.doi.org/10.1074/jbc.271.21.12542			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UL660	8647863	hybrid			2022-12-25	WOS:A1996UL66000065
J	Watanabe, S; Itoh, T; Arai, K				Watanabe, S; Itoh, T; Arai, K			JAK2 is essential for activation of c-fos and c-myc promoters and cell proliferation through the human granulocyte-macrophage colony-stimulating factor receptor in BA/F3 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE KINASE; GAMMA SIGNAL-TRANSDUCTION; INTERFERON-ALPHA/BETA; INTERLEUKIN-3; PHOSPHORYLATION; PATHWAY; FAMILY; LINES	Interleukin-3 (IL-3) or granulocyte-macrophage colony-stimulating factor (GM-CSF) is known to activate JAK2 in various cells, but the role of JAK2 in IL-3 or GM-CSF receptor signal transduction is largely unknown. We have now examined the role of JAK2 in GM-CSF-induced signaling events in BA/F3 cells. In BA/F3 cells expressing hGMR, activation of JAK2 by hGM-CSF requires the box1 region of hGMR beta. Dominant negative JAK2 (Delta JAK2), which lacked the kinase domain suppressed mIL-3- or hGM-CSF-induced c-fos promoter activation as well as c-myc promoter activation/cell proliferation, thereby suggesting that JAK2 is involved in the signaling of both pathways. Further analyses of the role of JAK2 in c-fos gene activation in BA/F3 cells expressing hGMR revealed that Delta JAK2 inhibited hGM-CSF-induced phosphorylation of Shc and protein tyrosine phosphatase 1D. Within hGMR beta, the several tyrosine residues which exist are related to activation of Shc or protein tyrosine phosphatase 1D, and are phosphorylated in response to hGM-CSF stimulation. In addition, we observed that Delta JAK2 inhibited hGM-CSF-induced phosphorylation of hGMR beta. Taken together, our results suggest that JAK2 activated by the box1 region of hGMR mediates hGM-CSF-induced c-fos promoter activation through phosphorylation of hGMR.	UNIV TOKYO,INST MED SCI,DEPT MED & DEV BIOL,MINATO KU,TOKYO 108,JAPAN	University of Tokyo			Itoh, Tohru/GYQ-8698-2022	Itoh, Tohru/0000-0002-6579-1638				ARAI K, 1990, ANNU REV BIOCHEM, V59, P783, DOI 10.1146/annurev.biochem.59.1.783; AZAM M, 1995, EMBO J, V14, P1402, DOI 10.1002/j.1460-2075.1995.tb07126.x; BRIZZI MF, 1994, J BIOL CHEM, V269, P31680; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; FU XY, 1993, CELL, V74, P1135, DOI 10.1016/0092-8674(93)90734-8; FUKUMOTO Y, 1990, J BIOL CHEM, V265, P774; HANAZONO Y, 1993, EMBO J, V12, P1641, DOI 10.1002/j.1460-2075.1993.tb05809.x; HIRT B, 1967, J MOL BIOL, V26, P365, DOI 10.1016/0022-2836(67)90307-5; IHLE JN, 1994, TRENDS BIOCHEM SCI, V19, P222, DOI 10.1016/0968-0004(94)90026-4; Isfort RJ, 1990, GROWTH FACTORS, V2, P213, DOI 10.3109/08977199009071507; Itoh T, 1996, J BIOL CHEM, V271, P7587, DOI 10.1074/jbc.271.13.7587; JOHNSTON JA, 1994, NATURE, V370, P151, DOI 10.1038/370151a0; KANAKURA Y, 1990, BLOOD, V76, P706; KOBAYASHI N, 1993, P NATL ACAD SCI USA, V90, P4201, DOI 10.1073/pnas.90.9.4201; LI W, 1994, MOL CELL BIOL, V14, P509, DOI 10.1128/MCB.14.1.509; LUO H, 1995, EMBO J, V14, P1412, DOI 10.1002/j.1460-2075.1995.tb07127.x; Maniatis T., 1982, MOL CLONING; MINAMI Y, 1993, EMBO J, V12, P759, DOI 10.1002/j.1460-2075.1993.tb05710.x; MIYAJIMA A, 1992, ANNU REV IMMUNOL, V10, P295, DOI 10.1146/annurev.immunol.10.1.295; MIYAJIMA A, 1993, BLOOD, V82, P1960; MIYAJIMA A, 1987, GENE, V58, P273, DOI 10.1016/0378-1119(87)90382-9; MORLA AO, 1988, MOL CELL BIOL, V8, P2214, DOI 10.1128/MCB.8.5.2214; MUI ALF, 1995, EMBO J, V14, P1166, DOI 10.1002/j.1460-2075.1995.tb07100.x; MULLER M, 1993, NATURE, V366, P129, DOI 10.1038/366129a0; MURAKAMI M, 1991, P NATL ACAD SCI USA, V88, P11349, DOI 10.1073/pnas.88.24.11349; MURATA Y, 1990, BIOCHEM BIOPH RES CO, V173, P1102, DOI 10.1016/S0006-291X(05)80899-X; NARAZAKI M, 1994, P NATL ACAD SCI USA, V91, P2285, DOI 10.1073/pnas.91.6.2285; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; QUELLE FW, 1994, MOL CELL BIOL, V14, P4335, DOI 10.1128/MCB.14.7.4335; QUELLE FW, 1995, MOL CELL BIOL, V15, P3336; RAO P, 1995, J BIOL CHEM, V270, P6886, DOI 10.1074/jbc.270.12.6886; SILVENNOINEN O, 1993, P NATL ACAD SCI USA, V90, P8429, DOI 10.1073/pnas.90.18.8429; TANIGUCHI T, 1995, SCIENCE, V268, P251, DOI 10.1126/science.7716517; TANIGUCHI T, 1993, CELL, V73, P5, DOI 10.1016/0092-8674(93)90152-G; TANNER JW, 1995, J BIOL CHEM, V270, P6523, DOI 10.1074/jbc.270.12.6523; TORIGOE T, 1992, BLOOD, V80, P617; VELAZQUEZ L, 1992, CELL, V70, P313, DOI 10.1016/0092-8674(92)90105-L; VOGEL W, 1993, SCIENCE, V259, P1611, DOI 10.1126/science.7681217; WAKAO H, 1994, EMBO J, V13, P2182, DOI 10.1002/j.1460-2075.1994.tb06495.x; WANG Y, 1994, MOL BIOL CELL, V5, P819, DOI 10.1091/mbc.5.7.819; WATANABE S, 1995, MOL BIOL CELL, V6, P627, DOI 10.1091/mbc.6.6.627; WATANABE S, 1993, MOL CELL BIOL, V13, P1440, DOI 10.1128/MCB.13.3.1440; WATANABE S, 1993, MOL BIOL CELL, V4, P983, DOI 10.1091/mbc.4.10.983; WATANABE S, 1995, J BIOL CHEM, V270, P9615, DOI 10.1074/jbc.270.16.9615; WATLING D, 1993, NATURE, V366, P166, DOI 10.1038/366166a0; WEGENKA UM, 1994, MOL CELL BIOL, V14, P3186, DOI 10.1128/MCB.14.5.3186; WELHAM MJ, 1994, J BIOL CHEM, V269, P23764; WITTHUHN BA, 1994, NATURE, V370, P153, DOI 10.1038/370153a0; WITTHUHN BA, 1993, CELL, V74, P227, DOI 10.1016/0092-8674(93)90414-L; ZHUANG HM, 1994, J BIOL CHEM, V269, P21411	50	110	112	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 24	1996	271	21					12681	12686		10.1074/jbc.271.21.12681	http://dx.doi.org/10.1074/jbc.271.21.12681			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UL660	8647882	hybrid			2022-12-25	WOS:A1996UL66000084
J	Dawson, SJ; Morris, PJ; Latchman, DS				Dawson, SJ; Morris, PJ; Latchman, DS			A single amino acid change converts an inhibitory transcription factor into an activator	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOMAIN PROTEIN; HOMEO DOMAIN; CELL-LINES; NEURONS; DIFFERENTIATION; ELEMENTS; DISTINCT	The closely related POU family transcription factors Brn-3a and Brn-3b differ in their functional activity with Brn-3a activating several target promoters, which are repressed by Brn-3b. Brn-3b also prevents promoter activation by Brn-3a. Here we have altered a single isoleucine residue in the POU homeodomain of Brn-3b to the valine residue found at the equivalent position in Brn-3a. This change not only abolishes the ability of Brn-3b to repress basal and Brn-3a-stimulated promoter activity but also converts it to an activator of similar potency to Brn-3a. Hence a single amino acid difference determines the difference between an activator and a repressor in the Brn-3 family.	UCL, SCH MED, MED MOLEC BIOL UNIT, DEPT MOLEC PATHOL, LONDON W1P 6DB, ENGLAND	University of London; University College London; UCL Medical School				Dawson, Sally/0000-0002-4421-2043				ABKEN H, 1992, NUCLEIC ACIDS RES, V20, P3527, DOI 10.1093/nar/20.13.3527; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BudhramMahadeo V, 1996, J BIOL CHEM, V271, P9108, DOI 10.1074/jbc.271.15.9108; BUDHRAMMAHADEO V, 1995, J BIOL CHEM, V270, P2853, DOI 10.1074/jbc.270.6.2853; BUDHRAMMAHADEO V, 1994, NUCLEIC ACIDS RES, V22, P3092, DOI 10.1093/nar/22.15.3092; Dawson SJ, 1996, BIOCHEM J, V314, P439, DOI 10.1042/bj3140439; DESAI C, 1988, NATURE, V336, P638, DOI 10.1038/336638a0; FEDTSOVA NG, 1995, MECH DEVELOP, V53, P291, DOI 10.1016/0925-4773(95)00435-1; FINNEY M, 1988, CELL, V55, P757, DOI 10.1016/0092-8674(88)90132-8; GERRERO MR, 1993, P NATL ACAD SCI USA, V90, P10841, DOI 10.1073/pnas.90.22.10841; GORMAN C, 1985, DNA CLONING PRACTICA, V2, P143; KLEMM JD, 1994, CELL, V77, P21, DOI 10.1016/0092-8674(94)90231-3; LAI JS, 1992, GENE DEV, V6, P2058, DOI 10.1101/gad.6.11.2058; LILLYCROP KA, 1992, NUCLEIC ACIDS RES, V20, P5093, DOI 10.1093/nar/20.19.5093; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MACPHERSON I, 1962, VIROLOGY, V16, P147, DOI 10.1016/0042-6822(62)90290-8; MORRIS PJ, 1994, MOL CELL BIOL, V14, P6907, DOI 10.1128/MCB.14.10.6907; NINKINA NN, 1993, NUCLEIC ACIDS RES, V21, P3175, DOI 10.1093/nar/21.14.3175; POMERANTZ JL, 1992, GENE DEV, V6, P2047, DOI 10.1101/gad.6.11.2047; SUBURO AM, 1992, NEUROSCIENCE, V46, P881, DOI 10.1016/0306-4522(92)90191-4; THEIL T, 1993, NUCLEIC ACIDS RES, V21, P5921, DOI 10.1093/nar/21.25.5921; THEIL T, 1994, CYTOGENET CELL GENET, V66, P267, DOI 10.1159/000133709; TURNER EE, 1994, NEURON, V12, P205, DOI 10.1016/0896-6273(94)90164-3; VERRIJZER CP, 1993, BIOCHIM BIOPHYS ACTA, V1173, P1, DOI 10.1016/0167-4781(93)90237-8; Wegner M, 1993, CURR OPIN CELL BIOL, V5, P488, DOI 10.1016/0955-0674(93)90015-I; WOOD JN, 1990, P ROY SOC B-BIOL SCI, V241, P187, DOI 10.1098/rspb.1990.0084; XI H, 1989, NATURE, V340, P35, DOI 10.1038/340035a0	27	29	30	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 17	1996	271	20					11631	11633		10.1074/jbc.271.20.11631	http://dx.doi.org/10.1074/jbc.271.20.11631			3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UL250	8662774	hybrid			2022-12-25	WOS:A1996UL25000010
J	Genazzani, AA; Empson, RM; Galione, A				Genazzani, AA; Empson, RM; Galione, A			Unique inactivation properties of NAADP-sensitive Ca2+ release	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIC-ADP-RIBOSE; INDUCED CALCIUM-RELEASE; SEA-URCHIN EGGS; INOSITOL TRISPHOSPHATE; FERTILIZATION; RECEPTORS; STORES	Ca2+ mobilization from intracellular stores constitutes an important mechanism for generating cytoplasmic Ca2+ signals. Inositol trisphosphate (InsP(3)) and ryanodine receptors are the two families of intracellular Ca2+ release channels that have been identified, which may be regulated by separate intracellular messengers, InsP(3) and cyclic adenosine 5'-diphosphate ribose, respectively. A third molecule, nicotinic acid adenine dinucleotide phosphate (NAADP), has recently been recognized as a potent Ca2+ releasing agent in sea urchin eggs and microsomes. We now report that non-releasing concentrations of NAADP fully and irreversibly inactivate the NAADP-sensitive Ca2+ release mechanism. This phenomenon occurred both in intact sea urchin eggs and in homogenates and is not shared by either InsP(3) or cyclic adenosine 5'-diphosphate ribose, The novel properties of this Ca2+ release mechanism, giving a one-shot Ca2+ release, may be suited to irreversible cellular events.			Genazzani, AA (corresponding author), UNIV OXFORD,DEPT PHARMACOL,S PARKS RD,OXFORD OX1 3QT,ENGLAND.		Galione, Antony/E-5884-2011; Genazzani, Armando/AAI-8280-2020	Galione, Antony/0000-0002-4132-7646; Genazzani, Armando/0000-0003-1923-7430; Empson, Ruth/0000-0002-0415-6083				Aarhus R, 1995, J BIOL CHEM, V270, P30327, DOI 10.1074/jbc.270.51.30327; BOOTMAN M, 1994, CURR BIOL, V4, P169, DOI 10.1016/S0960-9822(94)00041-2; BOYD ND, 1987, J PHYSIOL-LONDON, V389, P45, DOI 10.1113/jphysiol.1987.sp016646; CHINI EN, 1995, J BIOL CHEM, V270, P3216, DOI 10.1074/jbc.270.7.3216; CHINI EN, 1995, BIOCHEM BIOPH RES CO, V209, P167, DOI 10.1006/bbrc.1995.1485; CLAPPER DL, 1985, J BIOL CHEM, V260, P3947; CLAPPER DL, 1987, J BIOL CHEM, V262, P9561; DARGIE PJ, 1990, CELL REGUL, V1, P279, DOI 10.1091/mbc.1.3.279; EHRLICH BE, 1994, TRENDS PHARMACOL SCI, V15, P145, DOI 10.1016/0165-6147(94)90074-4; FINCH EA, 1991, SCIENCE, V252, P443, DOI 10.1126/science.2017683; GALIONE A, 1993, SCIENCE, V261, P348, DOI 10.1126/science.8392748; GALIONE A, 1991, SCIENCE, V253, P1143, DOI 10.1126/science.1909457; GENAZZANI AA, 1996, BIOCHEM J, V315, P715; HAJNOCZKY G, 1994, NATURE, V370, P474, DOI 10.1038/370474a0; LEE HC, 1995, J BIOL CHEM, V270, P2152, DOI 10.1074/jbc.270.5.2152; LEE HC, 1993, SCIENCE, V261, P352, DOI 10.1126/science.8392749; OEKEN HJ, 1986, EUR J BIOCHEM, V156, P661, DOI 10.1111/j.1432-1033.1986.tb09629.x; PerezTerzic CM, 1995, BIOCHEM J, V312, P955, DOI 10.1042/bj3120955; POENIE M, 1990, CELL CALCIUM, V11, P85, DOI 10.1016/0143-4160(90)90062-Y; ROSALES C, 1992, J BIOL CHEM, V267, P1443; SPEDDING M, 1992, PHARMACOL REV, V44, P363; WALSETH TF, 1993, BIOCHIM BIOPHYS ACTA, V1178, P235, DOI 10.1016/0167-4889(93)90199-Y	23	146	147	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 17	1996	271	20					11599	11602		10.1074/jbc.271.20.11599	http://dx.doi.org/10.1074/jbc.271.20.11599			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UL250	8662773	hybrid			2022-12-25	WOS:A1996UL25000002
J	Karim, S; Habib, A; LevyToledano, S; Maclouf, J				Karim, S; Habib, A; LevyToledano, S; Maclouf, J			Cyclooxygenases-1 and -2 of endothelial cells utilize exogenous or endogenous arachidonic acid for transcellular production of thromboxane	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROSTAGLANDIN ENDOPEROXIDES; HUMAN-PLATELETS; INDUCIBLE CYCLOOXYGENASE; MESSENGER-RNA; SYNTHASE; EXPRESSION; INHIBITION; ASPIRIN; PROTEINS	The presence of prostaglandin (PG) H-2 in the supernatant of human umbilical vein endothelial cells (HUVEC) stimulated by thrombin restores the capacity of aspirin-treated platelets to generate thromboxane (TX) B-2. Induction of cyclooxygenase-2 (Cox-2) by interleukin (IL)-1 alpha or a phorbol ester increases this formation. HUVEC treated with aspirin lost their capacity to generate PGs but recovery occurred after 3 or 6-h induction of Cox-2 with phorbol ester or IL-1 alpha. Enzyme activity of the newly synthesized Cox-2 in aspirin-treated cells, evaluated after immunoprecipitation, was similar to untreated cells but after 18 h of cell stimulation only 50-60% recovery of Cox-1 was observed. The use of SC58125, a selective Cox-2 inhibitor, confirmed these findings in intact cells. Cyclooxygenase activity was related to the amount of Cox proteins present in the cells, but after induction of Cox-25, contribution of the latter to PG production was 6-8-fold that of Cox-1 . Aspirin-treated or untreated cells were incubated in the absence or presence of SC58125 and stimulated by thrombin, the ionophore A23187, or exogenous arachidonic acid. The production of endogenous (6-keto-PGF(1 alpha), PGE(2), PGF(2 alpha)) versus transcellular (TXB(2)) metabolites was independent of the inducer, the source of arachidonic acid and the Cox isozyme. However, in acetylsalicylic acid-treated cells, after 6-h stimulation with IL 1 alpha, newly synthesized Cox-2 produced less TXB(2) than 6-keto-PGF-(1 alpha) compared to untreated cells. At later times (>18 h), there was no metabolic difference between the cells. These studies suggest that in HUVEC, Cox compartmentalization occurring after short-term activation may selectively affect transcellular metabolism, but not constitutive production, of PGs.	HOP LARIBOISIERE,INSERM,U348,INST FEDERAT RECH BIOL CIRCULAT LARIBOISIERE,F-75475 PARIS,FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Lariboisiere-Fernand-Widal - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite			Habib, Aida/H-8647-2019	Habib, Aida/0000-0001-6027-0043				BUNTING S, 1976, PROSTAG OTH LIPID M, V12, P897, DOI 10.1016/0090-6980(76)90125-8; BURCH JW, 1978, J CLIN INVEST, V61, P314, DOI 10.1172/JCI108941; CREMINON C, 1995, BBA-LIPID LIPID MET, V1254, P333, DOI 10.1016/0005-2760(94)00196-6; CREMINON C, 1995, BBA-LIPID LIPID MET, V1254, P341, DOI 10.1016/0005-2760(94)00197-7; DEWITT D, 1995, CELL, V83, P345, DOI 10.1016/0092-8674(95)90109-4; FITZPATRICK FA, 1978, NATURE, V273, P302, DOI 10.1038/273302a0; GORMAN RR, 1983, PROSTAGLANDINS, V26, P325, DOI 10.1016/0090-6980(83)90099-0; HABIB A, 1992, ARCH BIOCHEM BIOPHYS, V298, P544, DOI 10.1016/0003-9861(92)90448-6; HABIB A, 1993, J BIOL CHEM, V268, P23448; HLA T, 1992, P NATL ACAD SCI USA, V89, P7384, DOI 10.1073/pnas.89.16.7384; JAFFE EA, 1973, J CLIN INVEST, V52, P2745, DOI 10.1172/JCI107470; JONES DA, 1993, J BIOL CHEM, V268, P9049; KAWATA R, 1995, J IMMUNOL, V155, P818; KOPP E, 1994, SCIENCE, V265, P956, DOI 10.1126/science.8052854; KUJUBU DA, 1991, J BIOL CHEM, V266, P12866; KULMACZ RJ, 1995, J BIOL CHEM, V270, P24019, DOI 10.1074/jbc.270.41.24019; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE SH, 1992, J BIOL CHEM, V267, P25934; MACLOUF J, 1980, EUR J BIOCHEM, V109, P561, DOI 10.1111/j.1432-1033.1980.tb04828.x; MARCUS AJ, 1993, J LIPID RES, V34, P2017; MARCUS AJ, 1980, J CLIN INVEST, V66, P979, DOI 10.1172/JCI109967; MORITA I, 1995, J BIOL CHEM, V270, P10902, DOI 10.1074/jbc.270.18.10902; MURAKAMI M, 1994, J BIOL CHEM, V269, P22269; PATSCHEKE H, 1981, HAEMOSTASIS, V10, P14; PRADELLES P, 1985, ANAL CHEM, V57, P1170, DOI 10.1021/ac00284a003; Reddy ST, 1996, J BIOL CHEM, V271, P186, DOI 10.1074/jbc.271.1.186; REDDY ST, 1994, J BIOL CHEM, V269, P15473; SCHAFER AI, 1984, J CLIN INVEST, V73, P1105, DOI 10.1172/JCI111296; SEIBERT K, 1994, P NATL ACAD SCI USA, V91, P12013, DOI 10.1073/pnas.91.25.12013; SMITH JB, 1971, NATURE-NEW BIOL, V231, P235, DOI 10.1038/newbio231235a0; SMITH WL, 1992, AM J PHYSIOL, V263, pF181; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WU KK, 1991, P NATL ACAD SCI USA, V88, P2384, DOI 10.1073/pnas.88.6.2384; XIE WL, 1991, P NATL ACAD SCI USA, V88, P2692, DOI 10.1073/pnas.88.7.2692; ZYGLEWSKA T, 1992, BIOCHIM BIOPHYS ACTA, V1131, P78, DOI 10.1016/0167-4781(92)90101-5	35	117	122	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 17	1996	271	20					12042	12048		10.1074/jbc.271.20.12042	http://dx.doi.org/10.1074/jbc.271.20.12042			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UL250	8662657	hybrid			2022-12-25	WOS:A1996UL25000069
J	Rohde, LH; Julian, J; Babaknia, A; Carson, DD				Rohde, LH; Julian, J; Babaknia, A; Carson, DD			Cell surface expression of HIP, a novel heparin/heparan sulfate-binding protein, of human uterine epithelial cells and cell lines	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPARIN HEPARAN-SULFATE; MOUSE EMBRYOS; PROTEOGLYCANS; GLYCOSAMINOGLYCANS; ELECTROPHORESIS; ATTACHMENT; RESOLUTION; CLEAVAGE; ADHESION; RL95	Previous studies established that uterine epithelial cells and cell lines express cell surface heparin/heparan sulfate (HP/HS)-binding proteins (Wilson, O., Jacobs, A. L., Stewart, S., and Carson, D. D. (1990) J. Cell. Physiol. 143, 60-67; Raboudi, N., Julian, J., Rohde, L. H., and Carson, D. D. (1992) J. Biol. Chem. 267, 11930-11939). The accompanying paper (Liu, S., Smith, S. E., Julian, J., Rohde, L. H., Karin, N. J., and Carson, D. D. (1996) J. Biol. Chem. 271, 11817-11823) describes the cloning of a full-length cDNA corresponding to a candidate cell surface HP/HS interacting protein, HIP, expressed by a variety of human epithelia. A synthetic peptide was synthesized corresponding to an amino acid sequence predicted from the cDNA sequence and used to prepare a rabbit polyclonal antibody. This antibody reacted with a protein with an apparent M(r) of 24,000 by SDS-polyacrylamide gel electrophoresis that was highly enriched in the 100,000 x g particulate fraction of RL95 cells. This molecular weight is similar to that of the protein expressed by 3T3 cells transfected with HIP cDNA. HIP was solubilized from this particulate fraction with NaCl concentrations greater than or equal to 0.8 M demonstrating a peripheral association consistent with the lack of a membrane spanning domain in the predicted cDNA sequence. HIP was not released by heparinase digestion suggesting that the association is not via membrane-bound HS proteoglycans. NaCl solubilized HIP bound to heparin-agarose in physiological saline and eluted with NaCl concentrations of 0.75 M and above. Furthermore, incubation of I-125-HP With transblots of the NaCl solubilized HIP preparations separated by two-dimensional gel electrophoresis demonstrated direct binding of HP to HIP. Indirect immunofluorescence studies demonstrated that HIP is expressed on the surfaces of intact RL95 cells. Binding of HIP antibodies to RL95 cell surfaces at 4 degrees C was saturable and blocked by preincubation with the peptide antigen. Single cell suspensions of RL95 cells formed large aggregates when incubated with antibodies directed against HIP but not irrelevant antibodies. Finally, indirect immunofluorescence studies demonstrate that HIP is expressed in both lumenal and glandular epithelium of normal human endometrium throughout the menstrual cycle. In addition, HIP expression increases in the predecidual cells of post ovulatory day 13-15 stroma. Collectively, these data indicate that HIP is a membrane-associated HP-binding protein expressed on the surface of normal human uterine epithelia and uterine epithelial cell lines.	UNIV TEXAS,MD ANDERSON CANCER CTR,DEPT BIOCHEM & MOLEC BIOL,HOUSTON,TX 77030; WOMENS HLTH INST CALIF,COSTA MESA,CA 92626	University of Texas System; UTMD Anderson Cancer Center					EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD025235, R37HD025235] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [P30CA016672] Funding Source: NIH RePORTER; NCI NIH HHS [CA-16672] Funding Source: Medline; NICHD NIH HHS [HD25235] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BISWAS C, 1988, J CELL PHYSIOL, V136, P147, DOI 10.1002/jcp.1041360119; CARSON DD, 1993, DEV BIOL, V155, P97, DOI 10.1006/dbio.1993.1010; CHANG CD, 1978, INT J PEPT PROT RES, V11, P246; COLE GJ, 1986, J CELL BIOL, V102, P403, DOI 10.1083/jcb.102.2.403; DAS SK, 1994, DEVELOPMENT, V120, P1071; DZIADEK M, 1985, EMBO J, V4, P905, DOI 10.1002/j.1460-2075.1985.tb03717.x; FARACH MC, 1988, BIOL REPROD, V39, P443, DOI 10.1095/biolreprod39.2.443; FARACH MC, 1987, DEV BIOL, V123, P401, DOI 10.1016/0012-1606(87)90398-8; FRANSSON LA, 1987, TRENDS BIOCHEM SCI, V12, P406, DOI 10.1016/0968-0004(87)90197-6; GALLAGHER JT, 1986, BIOCHEM J, V236, P313, DOI 10.1042/bj2360313; HASSELL JR, 1986, ANNU REV BIOCHEM, V55, P539, DOI 10.1146/annurev.bi.55.070186.002543; HOOK M, 1984, ANNU REV BIOCHEM, V53, P847; JALKANEN M, 1987, MED BIOL, V65, P41; JULIAN JA, 1994, DEVELOPMENT, V120, P661; KISALUS LL, 1987, ANAT RECORD, V218, P402, DOI 10.1002/ar.1092180408; KJELLEN L, 1980, J BIOL CHEM, V255, P407; KOHNKEGODT B, 1991, BIOCHEMISTRY-US, V30, P55, DOI 10.1021/bi00215a009; KURAMOTO H, 1972, Acta Obstetrica et Gynaecologica Japonica (English Edition), V19, P47; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANKES W, 1988, BIOCHEM J, V251, P831, DOI 10.1042/bj2510831; Liu SC, 1996, J BIOL CHEM, V271, P11817, DOI 10.1074/jbc.271.20.11817; MARKWELL MAK, 1982, ANAL BIOCHEM, V125, P427, DOI 10.1016/0003-2697(82)90025-2; NOYES RW, 1950, FERTIL STERIL, V1, P3, DOI 10.1016/s0015-0282(16)30062-0; OFARRELL PZ, 1977, CELL, V12, P1133, DOI 10.1016/0092-8674(77)90176-3; POOLE AR, 1986, BIOCHEM J, V236, P1; PORZIO MA, 1977, BIOCHIM BIOPHYS ACTA, V490, P27, DOI 10.1016/0005-2795(77)90102-7; RABOUDI N, 1992, J BIOL CHEM, V267, P11930; REDINI F, 1989, BIOCHIM BIOPHYS ACTA, V991, P359, DOI 10.1016/0304-4165(89)90129-3; ROHDE LH, 1993, J CELL PHYSIOL, V155, P185, DOI 10.1002/jcp.1041550124; SURVEYOR GA, 1995, ENDOCRINOLOGY, V136, P3639, DOI 10.1210/en.136.8.3639; TEMPLETON DM, 1992, CRIT REV CL LAB SCI, V29, P141, DOI 10.3109/10408369209114599; WATT SM, 1993, BLOOD, V82, P2649; WILSON O, 1990, J CELL PHYSIOL, V143, P60, DOI 10.1002/jcp.1041430108; WRAY W, 1981, ANAL BIOCHEM, V118, P197, DOI 10.1016/0003-2697(81)90179-2; YANAGISHITA M, 1992, J BIOL CHEM, V267, P9451	35	52	53	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 17	1996	271	20					11824	11830		10.1074/jbc.271.20.11824	http://dx.doi.org/10.1074/jbc.271.20.11824			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UL250	8662617	hybrid			2022-12-25	WOS:A1996UL25000040
J	Simmons, WW; Closs, EI; Cunningham, JM; Smith, TW; Kelly, RA				Simmons, WW; Closs, EI; Cunningham, JM; Smith, TW; Kelly, RA			Cytokines and insulin induce cationic amino acid transporter (CAT) expression in cardiac myocytes Regulation of L-arginine transport and no production by CAT-1, CAT-2A, and CAT-2B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE SYNTHASE; VASCULAR SMOOTH-MUSCLE; NECROSIS-FACTOR-ALPHA; ECOTROPIC RETROVIRUS RECEPTOR; HUMAN ENDOTHELIAL-CELLS; CULTURED ANIMAL-CELLS; MESSENGER-RNA; MOLECULAR-CLONING; RELAXING FACTOR; RAT-LIVER	Cytokine-dependent production of nitric oxide (NO) by rat cardiac myocytes is a consequence of increased expression of the inducible isoform of nitric oxide synthase (iNOS or NOS2) and, in the presence of insulin, depresses the contractile function of these cells in vivo and in vitro. Experiments reported here show that L-lysine, a competitive antagonist of L-arginine uptake, suppressed NO production (detected as nitrite accumulation) by interleukin (IL)-1 beta and interferon (IFN) gamma-pretreated cardiac myocytes by 70%, demonstrating that NO production is dependent on L-arginine uptake, Cardiac myocytes constitutively exhibit a high affinity L-arginine transport system (K-m = 125 mu M; V-max = 44 pmol/2 x 10(5) cells/min), Following a 24-h exposure to IL-1 beta and IFN gamma, arginine uptake increases (V-max = 167 pmol/2 x 10(5) cells/min) and a second low affinity L-arginine transporter activity appears (K-m = 1.2 mM). To examine the molecular basis for these cytokine-induced changes in arginine transport, we examined expression of three related arginine transporters previously identified in other cell types, mRNA for the high affinity cationic amino acid transporter-1 (CAT-1) is expressed in resting myocytes and steady-state levels increase by 10-fold following exposure to IL-1 beta and IFN gamma. Only cytokine-pretreated myocytes expressed a second high-affinity L-arginine transporter, CAT-2B, as well as a low-affinity L-arginine transporter, CAT-2A. In addition, insulin, which potentiated cytokine-dependent NO production independent of any change in NOS activity, increased myocyte L-arginine uptake by 2-fold and steady-state levels of CAT-1, but not CAT-2A or CAT-2B mRNA Thus, NO production by cardiac myocytes exposed to IL-1 beta plus IFN gamma appears to be dependent on the coinduction of CAT-1, CAT-2A, and CAT-2B, while insulin independently augments L-arginine transport through CAT-1.	BRIGHAM & WOMENS HOSP,DEPT MED,DIV CARDIOVASC,BOSTON,MA 02115; BRIGHAM & WOMENS HOSP,HOWARD HUGHES MED INST,DEPT MED,BOSTON,MA 02115; BRIGHAM & WOMENS HOSP,DEPT MED,DIV HEMATOL ONCOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,BOSTON,MA 02115	Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Howard Hughes Medical Institute; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School			Closs, Ellen/ABD-5217-2020	Closs, Ellen/0000-0002-9505-2289	NCI NIH HHS [CA61246] Funding Source: Medline; NHLBI NIH HHS [R37-HL36141] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA061246] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL036141] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALBRITTON LM, 1989, CELL, V57, P659, DOI 10.1016/0092-8674(89)90134-7; ALTMAN P, 1967, BLOOD OTHER BODY FLU, P75; Ausubel FM, 1987, CURRENT PROTOCOLS MO, V1-5; BALLIGAND JL, 1993, J CLIN INVEST, V91, P2314, DOI 10.1172/JCI116461; BALLIGAND JL, 1993, P NATL ACAD SCI USA, V90, P347, DOI 10.1073/pnas.90.1.347; BALLIGAND JL, 1994, J BIOL CHEM, V269, P27580; BALLIGAND JL, 1995, J BIOL CHEM, V270, P14582, DOI 10.1074/jbc.270.24.14582; BEASLEY D, 1991, J CLIN INVEST, V87, P602, DOI 10.1172/JCI115036; BERGER HJ, 1994, AM J PHYSIOL, V266, pH341, DOI 10.1152/ajpheart.1994.266.1.H341; BOGLE RG, 1992, BIOCHEM J, V284, P15, DOI 10.1042/bj2840015; BRADY AJB, 1993, AM J PHYSIOL, V265, pH176, DOI 10.1152/ajpheart.1993.265.1.H176; BRADY AJB, 1992, AM J PHYSIOL, V263, pH1963, DOI 10.1152/ajpheart.1992.263.6.H1963; BUNE AJ, 1995, FEBS LETT, V366, P127, DOI 10.1016/0014-5793(95)00495-U; BUSSOLATI O, 1993, AM J PHYSIOL, V265, pC1006, DOI 10.1152/ajpcell.1993.265.4.C1006; CHEATHAM B, 1994, MOL CELL BIOL, V14, P4902, DOI 10.1128/MCB.14.7.4902; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLOSS EI, 1993, J BIOL CHEM, V268, P20796; CLOSS EI, 1993, J BIOL CHEM, V268, P7538; DIETRICK J, 1988, Current Surgery, V45, P189; DURANTE W, 1995, AM J PHYSIOL-HEART C, V268, pH1158; ELLINGSEN O, 1993, AM J PHYSIOL, V265, pH747, DOI 10.1152/ajpheart.1993.265.2.H747; FEINSTEIN R, 1993, J BIOL CHEM, V268, P26055; FINKEL MS, 1992, SCIENCE, V257, P387, DOI 10.1126/science.1631560; FLOYD JC, 1966, J CLIN INVEST, V45, P1487, DOI 10.1172/JCI105456; GAZZOLA GC, 1981, ANAL BIOCHEM, V115, P368, DOI 10.1016/0003-2697(81)90019-1; GRANGER DL, 1990, J CLIN INVEST, V85, P264, DOI 10.1172/JCI114422; GREEN LC, 1982, ANAL BIOCHEM, V126, P131, DOI 10.1016/0003-2697(82)90118-X; GREENE B, 1993, AM J PHYSIOL, V264, pL351, DOI 10.1152/ajplung.1993.264.4.L351; GROCOTTMASON R, 1994, AM J PHYSIOL, V266, pH1699, DOI 10.1152/ajpheart.1994.266.5.H1699; GROCOTTMASON R, 1994, AM J PHYSIOL-HEART C, V267, pH1804, DOI 10.1152/ajpheart.1994.267.5.H1804; GROSS SS, 1992, J BIOL CHEM, V267, P25722; HATAKEYAMA K, 1991, J BIOL CHEM, V266, P765; HATTORI Y, 1994, J BIOL CHEM, V269, P9405; HATTORI Y, 1993, BIOCHEM BIOPH RES CO, V195, P435, DOI 10.1006/bbrc.1993.2062; HECKER M, 1990, P NATL ACAD SCI USA, V87, P8612, DOI 10.1073/pnas.87.21.8612; HEVEL JM, 1991, J BIOL CHEM, V266, P22789; HOTAMISLIGIL GS, 1993, SCIENCE, V259, P87, DOI 10.1126/science.7678183; HOTAMISLIGIL GS, 1994, P NATL ACAD SCI USA, V91, P4854, DOI 10.1073/pnas.91.11.4854; HUSSON A, 1986, ENDOCRINOLOGY, V119, P1171, DOI 10.1210/endo-119-3-1171; IYENGAR R, 1987, P NATL ACAD SCI USA, V84, P6369, DOI 10.1073/pnas.84.18.6369; KANAI F, 1993, BIOCHEM BIOPH RES CO, V195, P762, DOI 10.1006/bbrc.1993.2111; KAVANAUGH MP, 1994, J BIOL CHEM, V269, P15445; KAVANAUGH MP, 1993, BIOCHEMISTRY-US, V32, P5781, DOI 10.1021/bi00073a009; KAWAMOTO S, 1986, BIOCHEM BIOPH RES CO, V136, P955, DOI 10.1016/0006-291X(86)90425-0; KILBERG MS, 1993, ANNU REV NUTR, V13, P137, DOI 10.1146/annurev.nu.13.070193.001033; KIM JW, 1991, NATURE, V352, P725, DOI 10.1038/352725a0; KIMBALL SR, 1994, ANNU REV PHYSIOL, V56, P321, DOI 10.1146/annurev.ph.56.030194.001541; LAMBERT MA, 1986, MOL CELL BIOL, V6, P1722, DOI 10.1128/MCB.6.5.1722; LANG CH, 1992, ENDOCRINOLOGY, V130, P43, DOI 10.1210/en.130.1.43; LING PR, 1994, METABOLISM, V43, P279, DOI 10.1016/0026-0495(94)90093-0; LOW BC, 1993, J CELL PHYSIOL, V156, P626, DOI 10.1002/jcp.1041560323; LUSCHER TF, 1993, CIRCULATION, V87, P1746, DOI 10.1161/01.CIR.87.5.1746; LYONS CR, 1992, J BIOL CHEM, V267, P6370; MACLEOD CL, 1990, MOL CELL BIOL, V10, P3663, DOI 10.1128/MCB.10.7.3663; MAYER B, 1989, BIOCHEM BIOPH RES CO, V164, P678, DOI 10.1016/0006-291X(89)91513-1; MCGIVAN JD, 1994, BIOCHEM J, V299, P321, DOI 10.1042/bj2990321; MORRIS SM, 1989, ARCH BIOCHEM BIOPHYS, V273, P230, DOI 10.1016/0003-9861(89)90183-5; MORRIS SM, 1992, ANNU REV NUTR, V12, P81, DOI 10.1146/annurev.nu.12.070192.000501; NATHAN C, 1994, CELL, V78, P915, DOI 10.1016/0092-8674(94)90266-6; NATHAN C, 1994, J BIOL CHEM, V269, P13725; NICHOL CA, 1985, ANNU REV BIOCHEM, V54, P729, DOI 10.1146/annurev.biochem.54.1.729; NUSSLER AK, 1994, J BIOL CHEM, V269, P1257; PLUMB JA, 1989, CANCER RES, V49, P4435; ROBERTS AB, 1992, MOL ENDOCRINOL, V6, P1921, DOI 10.1210/me.6.11.1921; SCHERRER U, 1994, J CLIN INVEST, V94, P2511, DOI 10.1172/JCI117621; SCHMIDT HHHW, 1992, SCIENCE, V255, P721, DOI 10.1126/science.1371193; SCHOTT CA, 1993, BRIT J PHARMACOL, V108, P38, DOI 10.1111/j.1476-5381.1993.tb13436.x; SCHULZ R, 1992, BRIT J PHARMACOL, V105, P575, DOI 10.1111/j.1476-5381.1992.tb09021.x; SCOTTBURDEN T, 1993, BIOCHEM BIOPH RES CO, V196, P1261, DOI 10.1006/bbrc.1993.2388; Singh K, 1996, J BIOL CHEM, V271, P1111, DOI 10.1074/jbc.271.2.1111; SPRINGHORN JP, 1992, J BIOL CHEM, V267, P14360; SPRINGHORN JP, 1989, BIOCHEM J, V258, P73, DOI 10.1042/bj2580073; STEINBERG HO, 1994, J CLIN INVEST, V94, P1172, DOI 10.1172/JCI117433; STEPHENS JM, 1991, J BIOL CHEM, V266, P21839; UNGUREANULONGROIS D, 1995, CIRC RES, V77, P486, DOI 10.1161/01.RES.77.3.486; WANG H, 1991, NATURE, V352, P729, DOI 10.1038/352729a0; WELLS RG, 1992, J BIOL CHEM, V267, P15285; WELLS RG, 1992, P NATL ACAD SCI USA, V89, P5596, DOI 10.1073/pnas.89.12.5596; WERNERFELMAYER G, 1993, J BIOL CHEM, V268, P1842; WHITE MF, 1982, J BIOL CHEM, V257, P4450; WHITE MF, 1982, J BIOL CHEM, V257, P4443; WOODARD MH, 1994, AM J PHYSIOL, V266, pE817, DOI 10.1152/ajpendo.1994.266.5.E817; WU GY, 1992, BIOCHEM J, V281, P45, DOI 10.1042/bj2810045; WU JY, 1994, J VIROL, V68, P1615, DOI 10.1128/JVI.68.3.1615-1623.1994; XIE QW, 1992, SCIENCE, V256, P225, DOI 10.1126/science.1373522; YOUNG LH, 1992, CIRC RES, V71, P393, DOI 10.1161/01.RES.71.2.393; ZENNI GC, 1992, CIRC SHOCK, V37, P198	87	148	150	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 17	1996	271	20					11694	11702		10.1074/jbc.271.20.11694	http://dx.doi.org/10.1074/jbc.271.20.11694			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UL250	8662674	hybrid			2022-12-25	WOS:A1996UL25000020
J	Westphal, V; Marcusson, EG; Winther, JR; Emr, SD; vandenHazel, H				Westphal, V; Marcusson, EG; Winther, JR; Emr, SD; vandenHazel, H			Multiple pathways for vacuolar sorting of yeast proteinase A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBOXYPEPTIDASE-Y; PROPEPTIDE; MUTANT; GENE; SACCHAROMYCES; HYDROLASES	The sorting of the yeast proteases proteinase A and carboxypeptidase Y to the vacuole is a saturable, receptor-mediated process. Information sufficient for vacuolar sorting of the normally secreted protein invertase has in fusion constructs previously been found to reside in the propeptide of proteinase A. We found that sorting of such a hybrid protein is dependent on the vacuolar protein sorting receptor Vps10p. This was unexpected, as strains disrupted for VPS10 sort more than 85% of the proteinase A to the vacuole. Consistent with a role for Vps10p in sorting of proteinase A, we found that 1) overproduction of Vps10p suppressed the missorting phenotype associated with overproduction of proteinase A, 2) overproduction of proteinase A induced missorting of carboxypeptidase Y, 3) vacuolar sorting of proteinase A in a Delta vps10 strain was readily saturated by modest overproduction of proteinase A, and 4) Vps10p and proteinase A interact directly and specifically as shown by chemical cross-linking. Interestingly, overexpression of two telomere-linked VPS10 homologues, VTH1 and VTH2 suppressed the missorting phenotypes of a Delta vps10 strain. However, disruption of the VTH1 and VTH2 genes did not affect the sorting of proteinase A. We conclude that proteinase A utilizes at least two mechanisms for sorting, a Vps10p-dependent path and a Vth1p/Vth2p/Vps10p-independent path.	CARLSBERG LAB, DEPT YEAST GENET, DK-2500 COPENHAGEN, DENMARK; UNIV CALIF SAN DIEGO, SCH MED, DIV CELLULAR & MOLEC MED, LA JOLLA, CA 92093 USA; UNIV CALIF SAN DIEGO, SCH MED, HUGHES MED INST, LA JOLLA, CA 92093 USA	University of California System; University of California San Diego; University of California System; University of California San Diego			Winther, Jakob R./K-4451-2014	Winther, Jakob R./0000-0001-6995-9154; Marcusson, Eric/0000-0002-0504-8674	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032703] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM32703] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BANKAITIS VA, 1986, P NATL ACAD SCI USA, V83, P9075, DOI 10.1073/pnas.83.23.9075; CARLSON M, 1985, MOL CELL BIOL, V5, P2894, DOI 10.1128/MCB.5.11.2894; CHRISTIANSON TW, 1992, GENE, V110, P119, DOI 10.1016/0378-1119(92)90454-W; GRAHAM TR, 1991, J CELL BIOL, V114, P207, DOI 10.1083/jcb.114.2.207; HORAZDOVSKY BF, 1995, CURR OPIN CELL BIOL, V7, P544, DOI 10.1016/0955-0674(95)80012-3; JOHNSON LM, 1987, CELL, V48, P875, DOI 10.1016/0092-8674(87)90084-5; KLIONSKY DJ, 1988, MOL CELL BIOL, V8, P2105, DOI 10.1128/MCB.8.5.2105; MARCUSSON EG, 1994, CELL, V77, P579, DOI 10.1016/0092-8674(94)90219-4; PARAVICINI G, 1992, MOL BIOL CELL, V3, P415, DOI 10.1091/mbc.3.4.415; ROBINSON JS, 1988, MOL CELL BIOL, V8, P4936, DOI 10.1128/MCB.8.11.4936; ROGGENTIN P, 1989, GLYCOCONJUGATE J, V6, P349, DOI 10.1007/BF01047853; ROTHMAN JH, 1986, P NATL ACAD SCI USA, V83, P3248, DOI 10.1073/pnas.83.10.3248; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; STEVENS TH, 1986, J CELL BIOL, V102, P1551, DOI 10.1083/jcb.102.5.1551; VALLS LA, 1990, J CELL BIOL, V111, P361, DOI 10.1083/jcb.111.2.361; VALLS LA, 1987, CELL, V48, P887, DOI 10.1016/0092-8674(87)90085-7; VANDENHAZEL HB, 1992, EUR J BIOCHEM, V207, P277; VANDENHAZEL HB, 1993, J BIOL CHEM, V268, P18002; VANDENHAZEL HB, 1995, J BIOL CHEM, V270, P8602, DOI 10.1074/jbc.270.15.8602; vanVoorst F, 1996, J BIOL CHEM, V271, P841, DOI 10.1074/jbc.271.2.841; VIDA TA, 1993, J CELL BIOL, V121, P1245, DOI 10.1083/jcb.121.6.1245; WINSTON F, 1983, METHOD ENZYMOL, V101, P211; WINTHER JR, 1991, EUR J BIOCHEM, V197, P681, DOI 10.1111/j.1432-1033.1991.tb15959.x	23	52	56	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 17	1996	271	20					11865	11870		10.1074/jbc.271.20.11865	http://dx.doi.org/10.1074/jbc.271.20.11865			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UL250	8662642	hybrid			2022-12-25	WOS:A1996UL25000046
J	Parks, GD				Parks, GD			Differential effects of changes in the length of a signal anchor domain on membrane insertion, subunit assembly, and intracellular transport of a type II integral membrane protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INFLUENZA-VIRUS NEURAMINIDASE; HEMAGGLUTININ-NEURAMINIDASE; ENDOPLASMIC-RETICULUM; SIMIAN VIRUS-5; TRANSMEMBRANE PROTEINS; GOLGI RETENTION; CELL-SURFACE; SEQUENCE; GLYCOPROTEIN; RECEPTOR	The length requirement for a functional uncleaved signal/anchor (S/A) domain of the paramyxovirus hemagglutinin-neuraminidase (HN) type II glycoprotein was analyzed. HN mutants with progressive NH2-terminal S/A deletions or insertions were expressed in HeLa cells, and the membrane targeting, folding, tetramer assembly, and intracellular transport of the proteins were examined. Changing the length of the S/A by two residues resulted in HN mutants that displayed aberrant endoplasmic reticulum (ER) membrane targeting or translocation. This phenotype did not simply reflect upper or lower limitations on the size of a functional S/A, because normal signaling was restored by further alterations involving three or four residues. Likewise, ER-to-Golgi transport of mutants containing deletions of one or two S/A residues was delayed (similar to 30% of WT) or blocked, but transport was restored for a mutant with a total of three deleted residues. HN mutants with S/A insertions of three or four Leu residues differed from wild-type HN by having heterogeneous Golgi-specific carbohydrate modifications. Differences in ER-to-Golgi transport of the mutants did not strictly correlate with defects in either native folding of the ectodomain or the assembly of two dimers into a tetramer. Together, these data suggest that efficient entry into and exit from the ER are sensitive to changes in the HN S/A that may reflect alterations to a structural requirement along one side of an alpha-helix.			Parks, GD (corresponding author), WAKE FOREST UNIV, BOWMAN GRAY SCH MED, DEPT MICROBIOL & IMMUNOL, MED CTR, MED CTR BLVD, WINSTON SALEM, NC 27157 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI034329] Funding Source: NIH RePORTER; NIAID NIH HHS [AI34329] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ADAMS GA, 1985, CELL, V41, P1007, DOI 10.1016/S0092-8674(85)80081-7; ASHFORD DA, 1993, J BIOL CHEM, V268, P3260; BOS TJ, 1984, P NATL ACAD SCI-BIOL, V81, P2327, DOI 10.1073/pnas.81.8.2327; BRETSCHER MS, 1993, SCIENCE, V261, P1280, DOI 10.1126/science.8362242; BROWN DJ, 1988, J VIROL, V62, P3824, DOI 10.1128/JVI.62.10.3824-3831.1988; CASANOVA JE, 1991, CELL, V66, P65, DOI 10.1016/0092-8674(91)90139-P; DEBER CM, 1993, P NATL ACAD SCI USA, V90, P11648, DOI 10.1073/pnas.90.24.11648; DOMS RW, 1993, VIROLOGY, V193, P545, DOI 10.1006/viro.1993.1164; ENGLEMAN DM, 1986, ANN REV BIOPHYS CHEM, V15, P321; FUERST TR, 1986, P NATL ACAD SCI USA, V83, P8122, DOI 10.1073/pnas.83.21.8122; HAMMOND C, 1995, CURR OPIN CELL BIOL, V7, P523, DOI 10.1016/0955-0674(95)80009-3; HARTMANN E, 1989, P NATL ACAD SCI USA, V86, P5786, DOI 10.1073/pnas.86.15.5786; HIEBERT SW, 1985, J VIROL, V54, P1; HOGUE BG, 1994, J GEN VIROL, V75, P1015, DOI 10.1099/0022-1317-75-5-1015; HUBBARD SC, 1988, J BIOL CHEM, V263, P19303; IZARD JW, 1994, MOL MICROBIOL, V13, P765, DOI 10.1111/j.1365-2958.1994.tb00469.x; LAMB RA, 1978, VIROLOGY, V91, P60, DOI 10.1016/0042-6822(78)90355-0; LAMB RA, 1976, VIROLOGY, V74, P504, DOI 10.1016/0042-6822(76)90356-1; LANKFORD SP, 1993, J BIOL CHEM, V268, P4814; LAZAROVITS J, 1990, J BIOL CHEM, V265, P4760; LEMMON MA, 1992, BIOCHEMISTRY-US, V31, P12719, DOI 10.1021/bi00166a002; LEWIS BA, 1983, J MOL BIOL, V166, P203, DOI 10.1016/S0022-2836(83)80006-0; LIPP J, 1986, CELL, V46, P1103, DOI 10.1016/0092-8674(86)90710-5; Machamer CE, 1993, CURR OPIN CELL BIOL, V5, P606, DOI 10.1016/0955-0674(93)90129-E; MADDON PJ, 1985, CELL, V42, P93, DOI 10.1016/S0092-8674(85)80105-7; MASIBAY AS, 1993, J BIOL CHEM, V268, P9908; MCGINNES L, 1993, VIROLOGY, V196, P101, DOI 10.1006/viro.1993.1458; MOURITSEN OG, 1984, BIOPHYS J, V46, P141, DOI 10.1016/S0006-3495(84)84007-2; MUNRO S, 1991, EMBO J, V10, P3577, DOI 10.1002/j.1460-2075.1991.tb04924.x; NAYAK DP, 1989, ANNU REV MICROBIOL, V43, P465, DOI 10.1146/annurev.mi.43.100189.002341; NG DTW, 1989, J CELL BIOL, V109, P3273, DOI 10.1083/jcb.109.6.3273; NG DTW, 1990, MOL CELL BIOL, V10, P1989, DOI 10.1128/MCB.10.5.1989; NILSSON T, 1989, CELL, V58, P707, DOI 10.1016/0092-8674(89)90105-0; PARKS GD, 1993, J BIOL CHEM, V268, P19101; PARKS GD, 1990, VIROLOGY, V178, P498, DOI 10.1016/0042-6822(90)90347-T; PARKS GD, 1990, J VIROL, V64, P3605, DOI 10.1128/JVI.64.8.3605-3616.1990; PARKS GD, 1995, VIROLOGY, V213, P263, DOI 10.1006/viro.1995.1569; PARKS GD, 1994, J VIROL, V68, P4862, DOI 10.1128/JVI.68.8.4862-4872.1994; PATERSON RG, 1990, J CELL BIOL, V110, P999, DOI 10.1083/jcb.110.4.999; PAULSON JC, 1989, J BIOL CHEM, V264, P17615; PELHAM HRB, 1989, ANNU REV CELL BIOL, V5, P1, DOI 10.1146/annurev.cb.05.110189.000245; RANDALL RE, 1987, J GEN VIROL, V68, P2769, DOI 10.1099/0022-1317-68-11-2769; REES DC, 1989, ANNU REV BIOCHEM, V58, P607; SAKAGUCHI T, 1989, VIROLOGY, V169, P260, DOI 10.1016/0042-6822(89)90151-7; SHELNESS GS, 1993, J BIOL CHEM, V268, P5201; SPIESS M, 1987, EMBO J, V6, P2683, DOI 10.1002/j.1460-2075.1987.tb02560.x; SPIESS M, 1986, CELL, V44, P177, DOI 10.1016/0092-8674(86)90496-4; STECK T L, 1973, Journal of Supramolecular Structure, V1, P220, DOI 10.1002/jss.400010307; VONHEIJNE G, 1988, BIOCHIM BIOPHYS ACTA, V947, P307, DOI 10.1016/0304-4157(88)90013-5; WALTER P, 1986, ANNU REV CELL BIOL, V2, P499, DOI 10.1146/annurev.cellbio.2.1.499; WILLIAMS MA, 1988, MOL CELL BIOL, V8, P1186, DOI 10.1128/MCB.8.3.1186; ZERIAL M, 1987, CELL, V48, P147, DOI 10.1016/0092-8674(87)90365-5	52	9	10	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 22	1996	271	12					7187	7195		10.1074/jbc.271.12.7187	http://dx.doi.org/10.1074/jbc.271.12.7187			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UB157	8636156	hybrid			2022-12-25	WOS:A1996UB15700091
J	vanGrunsven, LA; Billon, N; Savatier, P; Thomas, A; Urdiales, JL; Rudkin, BB				vanGrunsven, LA; Billon, N; Savatier, P; Thomas, A; Urdiales, JL; Rudkin, BB			Effect of nerve growth factor on the expression of cell cycle regulatory proteins in PC12 cells: Dissection of the neurotrophic response from the anti-mitogenic response	ONCOGENE			English	Article						NGF; PC12; cyclin D1; p21(Cip1)/WAFI; cell cycle; differentiation	AFFINITY NGF RECEPTOR; PHEOCHROMOCYTOMA CELLS; DIFFERENTIATION; KINASE; LINE; PHOSPHORYLATION; ENCODES; CDC2; RAS	PC12 cells treated with nerve growth factor (NGF) undergo a G1 block and differentiate. Expression of selected cell cycle regulatory proteins was studied under culture conditions which permit observation of differentiation response independently from a mitogenic or anti-mitogenic response. The expression of all cell cycle regulatory proteins studied is modulated by NGF addition to exponentially-growing cultures in the presence of serum. While levels of most of these proteins decrease, accumulation of cyclin D1 and the cyclin-dependent kinase inhibitor p21(Cip1/WAF1) is observed. Cyclin D1-associated kinase activity is inhibited, correlating with an increase in p21 protein. PC12 cells, synchronized by serum starvation, undergo morphological and functional differentiation in the presence of NGF. Neither cyclin D1 nor p21 are present in such cultures, nor is their expression upregulated by NGF, indicating that they are not required for this process. Removal of serum from differentiated PC12 cells results in loss of these proteins, but has no effect on differentiation or the nonproliferative state in presence of NGF, Together, the results indicate that cyclin D1 and p21 are not necessary for differentiation per se, nor are they required for maintenance of the differentiated state in the absence of serum.	ECOLE NORMALE SUPER LYON,DIFFERENTIAT & CELL CYCLE GRP,F-69364 LYON 07,FRANCE; ECOLE NORMALE SUPER LYON,CNRS,UMR 49,VIRAL ONCOGENESIS & CELLULAR DIFFERENTIAT GRP,F-69364 LYON 07,FRANCE	Ecole Normale Superieure de Lyon (ENS de LYON); Centre National de la Recherche Scientifique (CNRS); Ecole Normale Superieure de Lyon (ENS de LYON)			SAVATIER, Pierre/J-4663-2014; Urdiales, José Luis/K-1125-2014; van Grunsven, Leo/E-5839-2010	Urdiales, José Luis/0000-0002-2519-9293; van Grunsven, Leo/0000-0002-0990-7034; RUDKIN, Brian B./0000-0003-3700-1982				ALLEN JM, 1984, NEUROSCI LETT, V46, P291, DOI 10.1016/0304-3940(84)90114-9; BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812; BARBACID M, 1994, J NEUROBIOL, V25, P1386, DOI 10.1002/neu.480251107; Barde Y A, 1994, Prog Clin Biol Res, V390, P45; BOCCHINI V, 1969, P NATL ACAD SCI USA, V64, P787, DOI 10.1073/pnas.64.2.787; BRIZUELA L, 1987, EMBO J, V6, P3507, DOI 10.1002/j.1460-2075.1987.tb02676.x; BUCHKOVICH KJ, 1994, MOL BIOL CELL, V5, P1225, DOI 10.1091/mbc.5.11.1225; CHAO MV, 1994, J NEUROBIOL, V25, P1373, DOI 10.1002/neu.480251106; CURRAN T, 1985, SCIENCE, V229, P1265, DOI 10.1126/science.4035354; DRAETTA G, 1989, CELL, V56, P829, DOI 10.1016/0092-8674(89)90687-9; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELLEDGE SJ, 1994, CURR OPIN CELL BIOL, V6, P847, DOI 10.1016/0955-0674(94)90055-8; FEINSTEIN SC, 1985, P NATL ACAD SCI USA, V82, P5761, DOI 10.1073/pnas.82.17.5761; FESQUET D, 1993, EMBO J, V12, P3111, DOI 10.1002/j.1460-2075.1993.tb05980.x; FISHER RP, 1994, CELL, V78, P713, DOI 10.1016/0092-8674(94)90535-5; FRODIN M, 1994, J BIOL CHEM, V269, P6207; FUJITA K, 1989, ENVIRON HEALTH PERSP, V80, P127, DOI 10.2307/3430738; GREENE LA, 1983, J CELL BIOL, V96, P76, DOI 10.1083/jcb.96.1.76; GREENE LA, 1978, J CELL BIOL, V78, P747, DOI 10.1083/jcb.78.3.747; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; HALEVY O, 1995, SCIENCE, V267, P1018, DOI 10.1126/science.7863327; Helin Kristian, 1993, Trends in Cell Biology, V3, P43, DOI 10.1016/0962-8924(93)90150-Y; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; JIANG HP, 1995, ONCOGENE, V10, P1855; JOHNSON D, 1986, CELL, V47, P545, DOI 10.1016/0092-8674(86)90619-7; KALMAN D, 1993, MOL BIOL CELL, V4, P353, DOI 10.1091/mbc.4.4.353; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; KAPLAN DR, 1991, NATURE, V350, P158, DOI 10.1038/350158a0; KAPLAN DR, 1991, SCIENCE, V252, P4554; KIM SJ, 1994, J BIOL CHEM, V269, P3739; KLEIN R, 1991, CELL, V65, P189, DOI 10.1016/0092-8674(91)90419-Y; LEE KF, 1992, CELL, V69, P737, DOI 10.1016/0092-8674(92)90286-L; LEE MH, 1995, GENE DEV, V9, P639, DOI 10.1101/gad.9.6.639; LEW J, 1994, NATURE, V371, P423, DOI 10.1038/371423a0; LI Y, 1994, ONCOGENE, V9, P2261; LUKAS J, 1994, J CELL BIOL, V125, P625, DOI 10.1083/jcb.125.3.625; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MATSUOKA S, 1995, GENE DEV, V9, P650, DOI 10.1101/gad.9.6.650; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2006; MISSERO C, 1995, P NATL ACAD SCI USA, V92, P5451, DOI 10.1073/pnas.92.12.5451; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; NODA M, 1985, NATURE, V318, P73, DOI 10.1038/318073a0; PARKER SB, 1995, SCIENCE, V267, P1024, DOI 10.1126/science.7863329; PETER M, 1994, CELL, V79, P181, DOI 10.1016/0092-8674(94)90186-4; RABIZADEH S, 1993, SCIENCE, V261, P345, DOI 10.1126/science.8332899; RADEKE MJ, 1987, NATURE, V325, P593, DOI 10.1038/325593a0; RUDKIN BB, 1989, EMBO J, V8, P3319, DOI 10.1002/j.1460-2075.1989.tb08493.x; SAVATIER P, 1994, ONCOGENE, V9, P809; SCHUBERT D, 1977, P NATL ACAD SCI USA, V74, P2579, DOI 10.1073/pnas.74.6.2579; SEDMAK JJ, 1977, ANAL BIOCHEM, V79, P544, DOI 10.1016/0003-2697(77)90428-6; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SIMPSON DL, 1991, J NEUROSCI RES, V28, P486, DOI 10.1002/jnr.490280405; SKAPEK SX, 1995, SCIENCE, V267, P1022, DOI 10.1126/science.7863328; STEINMAN RA, 1994, ONCOGENE, V9, P3389; TAMARU T, 1994, NEUROSCI LETT, V168, P229, DOI 10.1016/0304-3940(94)90457-X; TRAVERSE S, 1994, CURR BIOL, V4, P694, DOI 10.1016/S0960-9822(00)00154-8; TSAI LH, 1994, NATURE, V371, P419, DOI 10.1038/371419a0; vanGrunsven LA, 1996, ONCOGENE, V12, P855; WOOD KW, 1993, P NATL ACAD SCI USA, V90, P5016, DOI 10.1073/pnas.90.11.5016; WU BY, 1989, J BIOL CHEM, V264, P9000; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H; YAN G, 1992, J NEUROSCI, V15, P6200; ZHANG H, 1994, GENE DEV, V8, P1750, DOI 10.1101/gad.8.15.1750	64	60	60	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR 21	1996	12	6					1347	1356						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UC067	8649837				2022-12-25	WOS:A1996UC06700020
J	DeLaAsuncion, JG; Millan, A; Pla, R; Bruseghini, L; Esteras, A; Pallardo, FV; Sastre, J; Vina, J				DeLaAsuncion, JG; Millan, A; Pla, R; Bruseghini, L; Esteras, A; Pallardo, FV; Sastre, J; Vina, J			Mitochondrial glutathione oxidation correlates with age-associated oxidative damage to mitochondrial DNA	FASEB JOURNAL			English	Article						free radicals; aging; oxidative stress; vitamins; antioxidants	PERFORMANCE LIQUID-CHROMATOGRAPHY; ASCORBIC-ACID; ANTIOXIDANTS; BLOOD	Mitochondria may be primary targets of free radical damage associated with aging. We have found that mitochondrial glutathione is markedly oxidized with aging in rats and mice. The oxidized to reduced glutathione ratio rises with aging in the liver, kidney, and brain. The magnitude of these changes is much higher than that previously found in whole cells of any species previously studied. In the liver, this ratio (expressing GSSG as a percent of GSH) changed from 0.77 +/- 0.19% (n=5) in young rats to 2.47 +/- 1.25% (n=5) in old ones, i.e., 320% of the controls. In the brain and kidney, values for old rats were, respectively, 600 and 540% higher than those of young rats. A marked oxidation of mitochondrial glutathione also occurred in mice. Aging also caused an increase in 8-oxo-7,8-dihydro-2'-dexoyguanosine levels in mtDNA in rats and mice. Oral antioxidant administration protected against both glutathione oxidation and mtDNA damage in rats and mice. Finally, we have found a direct relationship between mtDNA damage and mitochondrial glutathione oxidation. This occurs both in rats (r=0.95) and in mice (r=0.98). This relationship, which has been observed for the first time in these studies, underscores the role of glutathione in the protection against free radical damage that occurs upon aging.	UNIV VALENCIA, DEPT FISIOL, FAC MED, VALENCIA, SPAIN	University of Valencia			Vina, Jose/AAB-3069-2021; Pallardo, Federico V./T-1156-2017	Vina, Jose/0000-0001-9709-0089; Pallardo, Federico V./0000-0003-3715-1980				AMES BN, 1993, P NATL ACAD SCI USA, V90, P7915, DOI 10.1073/pnas.90.17.7915; ASENSI M, 1994, ANAL BIOCHEM, V217, P323, DOI 10.1006/abio.1994.1126; BRIGELIUS R, 1983, BIOCHEM PHARMACOL, V32, P2529, DOI 10.1016/0006-2952(83)90014-X; CUTLER RG, 1991, AM J CLIN NUTR, V53, pS373, DOI 10.1093/ajcn/53.1.373S; FRAGA CG, 1991, P NATL ACAD SCI USA, V88, P11003, DOI 10.1073/pnas.88.24.11003; GOHIL K, 1988, J APPL PHYSIOL, V64, P115, DOI 10.1152/jappl.1988.64.1.115; HARMAN D, 1956, J GERONTOL, V11, P298, DOI 10.1093/geronj/11.3.298; KASAI H, 1984, NUCLEIC ACIDS RES, V12, P2137, DOI 10.1093/nar/12.4.2137; LATORRE A, 1986, P NATL ACAD SCI USA, V83, P8649, DOI 10.1073/pnas.83.22.8649; LOFT S, 1994, FASEB J, V8, P534, DOI 10.1096/fasebj.8.8.8181672; LOPEZTORRES M, 1993, MECH AGEING DEV, V70, P177, DOI 10.1016/0047-6374(93)90047-U; MEDVEDEV ZA, 1990, BIOL REV, V65, P375, DOI 10.1111/j.1469-185X.1990.tb01428.x; MEREDITH MJ, 1982, J BIOL CHEM, V257, P3747; MILLS BJ, 1990, ANAL BIOCHEM, V184, P263, DOI 10.1016/0003-2697(90)90678-3; MIQUEL J, 1980, EXP GERONTOL, V15, P575, DOI 10.1016/0531-5565(80)90010-8; MIQUEL J, 1979, EXP GERONTOL, V14, P279, DOI 10.1016/0531-5565(79)90039-1; OSHINO N, 1977, BIOCHEM J, V162, P509, DOI 10.1042/bj1620509; REED DJ, 1980, ANAL BIOCHEM, V106, P55, DOI 10.1016/0003-2697(80)90118-9; RICHIE JP, 1994, FASEB J, V8, P1302, DOI 10.1096/fasebj.8.15.8001743; RICHTER C, 1988, P NATL ACAD SCI USA, V85, P6465, DOI 10.1073/pnas.85.17.6465; RICKWOOD DW, 1987, MITOCHONDRIA PRACTIC, P4; SHIGENAGA MK, 1994, P NATL ACAD SCI USA, V91, P10771, DOI 10.1073/pnas.91.23.10771; SHIGENAGA MK, 1990, METHOD ENZYMOL, V186, P521; SIES H, 1986, ANGEW CHEM INT EDIT, V25, P1058, DOI 10.1002/anie.198610581; SOHAL RS, 1994, FREE RADICAL BIO MED, V16, P621, DOI 10.1016/0891-5849(94)90062-0; TIMIRAS PS, 1988, PHYSL BASIS AGING GE, P1; VINA J, 1995, METHOD ENZYMOL, V251, P237, DOI 10.1016/0076-6879(95)51126-1; Vina J., 1990, GLUTATHIONE METABOLI; VINA J, 1992, FREE RADICALS AGING, P136; WAHLLANDER A, 1979, FEBS LETT, V97, P138, DOI 10.1016/0014-5793(79)80069-1; Weber H U, 1982, Arch Gerontol Geriatr, V1, P299, DOI 10.1016/0167-4943(82)90030-9; WLODEK L, 1993, BIOCHEM PHARMACOL, V46, P1917, DOI 10.1016/0006-2952(93)90632-7	32	211	220	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	1996	10	2					333	338		10.1096/fasebj.10.2.8641567	http://dx.doi.org/10.1096/fasebj.10.2.8641567			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	TY962	8641567				2022-12-25	WOS:A1996TY96200018
J	Mazzanti, M; Assandri, R; Ferroni, A; Difrancesco, D				Mazzanti, M; Assandri, R; Ferroni, A; Difrancesco, D			Cytoskeletal control of rectification and expression of four substates in cardiac inward rectifier K+ channels	FASEB JOURNAL			English	Article						inward rectification; K channels; patch-clamp; calcium ions	GUINEA-PIG HEART; RECTIFYING POTASSIUM CHANNELS; VENTRICULAR CELLS; BLOCK; ACTIN; CYTOCHALASIN; MICROTUBULES; CONDUCTANCE; PHALLOIDIN; FILAMENTS	Cardiac inward rectifiers may have a three-barrel channel structure, based on evidence for three substates in single-channel recordings. However, some reports indicate four substates, a feature more compatible with the four-subunit structure for which there is evidence in cloned voltage-activated K+ channels. Here we show that although the fourth is easily missed, inward rectifier channels have four substates whose expression is controlled by intracellular Ca2+ ions. Fourth substate openings also appear after rectification loss in intracellular divalent cation-free solution. We find that this process is accelerated by cytochalasin, a microfilament disrupter. Cytochalasin also abolishes Ca2+, but not Mg2+, -induced rectification by restoring fourth substate openings. Thus, cytoskeletal elements control Ca2+-dependent substate expression and rectification in native inwardly rectifying K+ channels.-Mazzanti, M., Assandri, R., Ferroni, A., DiFrancesco, D. Cytoskeletal control of rectification and expression of four substrates in cardiac inward rectifier K+ channels.	UNIV MILAN,DIPARTIMENTO FISIOL & BIOCHIM GEN,I-20133 MILAN,ITALY	University of Milan			DiFrancesco, Dario/G-8408-2017; Mazzanti, Michele/A-8941-2011	DiFrancesco, Dario/0000-0002-7322-1790; Mazzanti, Michele/0000-0002-1819-3811				ALDRICH R, 1993, NATURE, V362, P107, DOI 10.1038/362107a0; BLACK MM, 1982, J CELL BIOL, V95, P379, DOI 10.1083/jcb.95.2.379; COOPER JA, 1987, J CELL BIOL, V105, P1473, DOI 10.1083/jcb.105.4.1473; FAKLER B, 1994, FEBS LETT, V356, P199, DOI 10.1016/0014-5793(94)01258-X; FICKER E, 1994, SCIENCE, V266, P1068, DOI 10.1126/science.7973666; FUKUDA J, 1981, NATURE, V294, P82, DOI 10.1038/294082a0; GALLI A, 1994, BIOPHYS J, V67, P2296, DOI 10.1016/S0006-3495(94)80715-5; HO K, 1993, NATURE, V362, P31, DOI 10.1038/362031a0; JAN LY, 1994, NATURE, V371, P119, DOI 10.1038/371119a0; JOHNSON BD, 1993, NEURON, V10, P797, DOI 10.1016/0896-6273(93)90196-X; KUBO Y, 1993, NATURE, V362, P127, DOI 10.1038/362127a0; LETURNEAU PC, 1987, CELL MOTIL CYTOSKEL, V8, P193; LOPATIN AN, 1994, NATURE, V372, P366, DOI 10.1038/372366a0; MACKINNON R, 1991, NATURE, V350, P232, DOI 10.1038/350232a0; MATSUDA H, 1987, NATURE, V325, P156, DOI 10.1038/325156a0; MATSUDA H, 1989, J PHYSIOL-LONDON, V413, P139, DOI 10.1113/jphysiol.1989.sp017646; MATSUDA H, 1988, J PHYSIOL-LONDON, V397, P237, DOI 10.1113/jphysiol.1988.sp016998; MATSUDA H, 1993, J PHYSIOL-LONDON, V470, P295, DOI 10.1113/jphysiol.1993.sp019859; MATSUMOTO G, 1984, J MEMBRANE BIOL, V77, P77; MAZZANTI M, 1989, PFLUG ARCH EUR J PHY, V413, P322, DOI 10.1007/BF00583549; ROSENMUND C, 1993, NEURON, V10, P805, DOI 10.1016/0896-6273(93)90197-Y; SAKMANN B, 1984, J PHYSIOL-LONDON, V347, P641, DOI 10.1113/jphysiol.1984.sp015088; SAMPATH P, 1991, BIOCHEMISTRY-US, V30, P1973, DOI 10.1021/bi00221a034; STANFIELD PR, 1994, J PHYSIOL-LONDON, V475, P1; VANDENBERG CA, 1987, P NATL ACAD SCI USA, V84, P2560, DOI 10.1073/pnas.84.8.2560; WIBLE BA, 1994, NATURE, V371, P246, DOI 10.1038/371246a0	26	37	39	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	FEB	1996	10	2					357	361		10.1096/fasebj.10.2.8641571	http://dx.doi.org/10.1096/fasebj.10.2.8641571			5	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	TY962	8641571				2022-12-25	WOS:A1996TY96200022
J	Kawamura, M; Yamashita, T; Segawa, K; Kaneuchi, M; Shindoh, M; Fujinaga, K				Kawamura, M; Yamashita, T; Segawa, K; Kaneuchi, M; Shindoh, M; Fujinaga, K			The 273rd codon mutants of p53 show growth modulation activities not correlated with p53-specific transactivation activity	ONCOGENE			English	Article						p53 tumor suppressor gene; codon 273; missense mutant; transactivation; ras-collaborative transformation	WILD-TYPE P53; CELL-CYCLE CONTROL; TRANSCRIPTIONAL ACTIVITY; BINDING-SITE; DNA-BINDING; SUPPRESSOR; MUTATIONS; PROTEIN; GENE; ANTIGEN	Cancer-related mutations of the p53 tumor suppressor gene are clustered in the four so-called 'hot spots', codons 175, 248, 273 and 281/282, By using recombination PCR in vitro mutagenesis, we introduced point mutations into the codon 273 of wild-type (wt) p53 (pC53-SN3) from Arg to His (pC53-273H [273H]), Asp (273D),Pro (273P), Lys (273K), Leu (273L) or Thr (273T), and compared their biological and biochemical activities with wt p53 and cancer-derived 175H, 248W and 273H/309S, Among them, 273H/309S, 273H and 273D as well as wt p53 transactivated the chloramphenicol acetyltransferase (CAT) gene placed downstream of the p53 binding consensus, while none of the other mutants including 273L did, Transcriptions from human c-fos and rat PCNA promoters were suppressed by wt p53 and 273D, while they were enhanced variously by all other mutants in Saos-2 and/or NIH3T3 cells. On the other hand, growth of human squamous carcinoma cell lines measured by the plating efficiency of G418-resistant colonies was enhanced by transfection of 175H, 248W, 273H/309S and 273P, while suppressed by not only wt p53, 273D and 273H but also 273L, Thus, 273H/309S enhanced cell growth in spite of its p53-specific transactivation activity, while 273L suppressed cell growth in spite of its complete loss of the p53-specific transactivation, We concluded that the sequence-specific transactivation of p53 is not always correlated with its growth inhibitory activity.	SAPPORO MED UNIV,SCH MED,CANC RES INST,DEPT MOLEC BIOL,CHUO KU,SAPPORO,HOKKAIDO 060,JAPAN; KEIO UNIV,SCH MED,DEPT MICROBIOL,SHINJUKU KU,TOKYO 160,JAPAN	Sapporo Medical University; Keio University			Shindoh, Masanobu/A-4799-2012	Shindoh, Masanobu/0000-0002-7782-5823				BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BARGONETTI J, 1993, GENE DEV, V7, P2565, DOI 10.1101/gad.7.12b.2565; CHEN JY, 1993, ONCOGENE, V8, P2159; CROOK T, 1994, CELL, V79, P817, DOI 10.1016/0092-8674(94)90071-X; DEB S, 1992, J VIROL, V66, P6164, DOI 10.1128/JVI.66.10.6164-6170.1992; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; DITTMER D, 1993, NAT GENET, V4, P42, DOI 10.1038/ng0593-42; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELIYAHU D, 1989, P NATL ACAD SCI USA, V86, P8763, DOI 10.1073/pnas.86.22.8763; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HALAZONETIS TD, 1993, EMBO J, V12, P1021, DOI 10.1002/j.1460-2075.1993.tb05743.x; HARPER JW, 1993, CELL, V75, P805; HINDS PW, 1990, CELL GROWTH DIFFER, V1, P571; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; IWABUCHI K, 1994, P NATL ACAD SCI USA, V91, P6098, DOI 10.1073/pnas.91.13.6098; JONES DH, 1991, BIOTECHNIQUES, V10, P62; KANDA T, 1994, MOL CELL BIOL, V14, P2651, DOI 10.1128/MCB.14.4.2651; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KEMP CJ, 1993, CELL, V74, P813, DOI 10.1016/0092-8674(93)90461-X; KERN SE, 1991, ONCOGENE, V6, P131; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LEVINE AJ, 1994, BRIT J CANCER, V69, P409, DOI 10.1038/bjc.1994.76; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LI CY, 1995, J BIOL CHEM, V270, P4971, DOI 10.1074/jbc.270.10.4971; LIN D, 1992, P NATL ACAD SCI USA, V89, P9210, DOI 10.1073/pnas.89.19.9210; MARTINEZ J, 1991, GENE DEV, V5, P151, DOI 10.1101/gad.5.2.151; MERCER WE, 1990, P NATL ACAD SCI USA, V87, P6166, DOI 10.1073/pnas.87.16.6166; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; OHASHI Y, 1992, BIOCHIM BIOPHYS ACTA, V1130, P175, DOI 10.1016/0167-4781(92)90525-5; ORY K, 1994, EMBO J, V13, P3496, DOI 10.1002/j.1460-2075.1994.tb06656.x; PAVLETICH NP, 1993, GENE DEV, V7, P2556, DOI 10.1101/gad.7.12b.2556; PIETENPOL JA, 1994, P NATL ACAD SCI USA, V91, P1998, DOI 10.1073/pnas.91.6.1998; RAYCROFT L, 1991, MOL CELL BIOL, V11, P6067, DOI 10.1128/MCB.11.12.6067; RYAN JJ, 1993, MOL CELL BIOL, V13, P711, DOI 10.1128/MCB.13.1.711; SAKAI E, 1992, ONCOGENE, V7, P927; SEGAWA K, 1993, ONCOGENE, V8, P543; SHAW P, 1992, P NATL ACAD SCI USA, V89, P4495, DOI 10.1073/pnas.89.10.4495; SHIH C, 1982, CELL, V29, P161, DOI 10.1016/0092-8674(82)90100-3; SLINGERLAND JM, 1993, EMBO J, V12, P1029, DOI 10.1002/j.1460-2075.1993.tb05744.x; UNGER T, 1992, EMBO J, V11, P1383, DOI 10.1002/j.1460-2075.1992.tb05183.x; van der Eb A J, 1980, Methods Enzymol, V65, P826; WANG Y, 1993, GENE DEV, V7, P2575, DOI 10.1101/gad.7.12b.2575; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; YAMASHITA T, 1993, ONCOGENE, V8, P2433; YAMASHITA T, 1986, Tumor Research, V21, P67; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; YONISHROUACH E, 1993, MOL CELL BIOL, V13, P1415, DOI 10.1128/MCB.13.3.1415; ZAKUTHOURI R, 1985, EMBO J, V4, P1251, DOI 10.1002/j.1460-2075.1985.tb03768.x; ZHANG W, 1993, ONCOGENE, V8, P2555	58	34	35	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN 6	1996	12	11					2361	2367						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UQ220	8649776				2022-12-25	WOS:A1996UQ22000013
J	Varley, JM; McGown, G; Thorncroft, M; Cochrane, S; Morrison, P; Woll, P; Kelsey, AM; Mitchell, ELD; Boyle, J; Birch, JM; Evans, DGR				Varley, JM; McGown, G; Thorncroft, M; Cochrane, S; Morrison, P; Woll, P; Kelsey, AM; Mitchell, ELD; Boyle, J; Birch, JM; Evans, DGR			A previously undescribed mutation within the tetramerisation domain of TP53 in a family with Li-Fraumeni syndrome	ONCOGENE			English	Article						TP53; Li-Fraumeni; codon 344; tetramerisation domain	NORMAL KIDNEY TISSUE; BREAST-CANCER; P53 MUTATIONS; GERM; CHROMOSOME; GENE	We report details of a family with classic Li-Fraumeni syndrome in which there is a mutation in codon 344 of the tumour suppressor gene TP53, Codon 344 is a key residue within the tetramerisation domain, and the amino acid substitution of a proline for a leucine is predicted to have profound implications for tetramerisation and potentially DNA binding, This is the first report of a mutation at this residue in either sporadic tumours or in the germline and the first report of a germline mutation within the tetramerisation domain, The family does not appear to be remarkable in the spectrum of tumours, and there is loss of the wild-type allele in a leiomyosarcoma from the proband. A cell line has been established from the tumour of the proband and cytogenetic and molecular studies carried out, providing an extensive analysis in this family.	CITY HOSP,DEPT CLIN GENET,NOTTINGHAM NG5 1PB,ENGLAND; QUEENS MED CTR,DEPT MED ONCOL,NOTTINGHAM NG7 2UH,ENGLAND; ROYAL MANCHESTER CHILDRENS HOSP,PAEDIAT & FAMILIAL CANC RES GRP,CRC,MANCHESTER M27 4HA,LANCS,ENGLAND; ROYAL MANCHESTER CHILDRENS HOSP,DEPT HISTOPATHOL,MANCHESTER M27 4HA,LANCS,ENGLAND	University of Nottingham; University of Nottingham; Royal Manchester Children's Hospital; Royal Manchester Children's Hospital	Varley, JM (corresponding author), PATERSON INST CANC RES,DEPT CANC GENET,CRC,WILMSLOW RD,MANCHESTER M20 9BX,LANCS,ENGLAND.		Evans, D Gareth/AAB-4308-2022	Evans, D Gareth/0000-0002-8482-5784; Woll, Penella/0000-0002-1118-0831				BIRCH JM, 1994, BRIT J CANCER, V70, P1176, DOI 10.1038/bjc.1994.468; BIRCH JM, 1990, J PATHOL, V161, P1, DOI 10.1002/path.1711610102; BIRCH JM, 1994, EUR J CANCER, V30A, P1935, DOI 10.1016/0959-8049(94)00383-G; BORRESEN AL, 1992, CANCER RES, V52, P3234; CHEN PC, 1995, CANCER GENET CYTOGEN, V82, P106, DOI 10.1016/0165-4608(94)00213-U; CLORE GM, 1994, SCIENCE, V265, P386, DOI 10.1126/science.8023159; DILLER L, 1995, J CLIN INVEST, V95, P1606, DOI 10.1172/JCI117834; ELFVING P, 1990, CYTOGENET CELL GENET, V53, P123, DOI 10.1159/000132910; EMANUEL A, 1992, GENE CHROMOSOME CANC, V4, P75, DOI 10.1002/gcc.2870040110; FREBOURG T, 1995, AM J HUM GENET, V56, P608; HOGGARD N, 1995, CHROMOSOME RES, V3, P137, DOI 10.1007/BF00710677; HOLLSTEIN M, 1994, NUCLEIC ACIDS RES, V22, P3551; ISHIOKA C, 1995, ONCOGENE, V10, P1485; JEFFREY PD, 1995, SCIENCE, V267, P1498, DOI 10.1126/science.7878469; KYRITSIS AP, 1994, JNCI-J NATL CANCER I, V86, P344, DOI 10.1093/jnci/86.5.344; LI FP, 1988, CANCER RES, V48, P5358; LI FP, 1969, ANN INTERN MED, V71, P747, DOI 10.7326/0003-4819-71-4-747; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; MCINTYRE JF, 1994, J CLIN ONCOL, V12, P925, DOI 10.1200/JCO.1994.12.5.925; SAMESHIMA Y, 1992, J NATL CANCER I, V84, P703, DOI 10.1093/jnci/84.9.703; SHISEKI M, 1993, CANCER LETT, V73, P51, DOI 10.1016/0304-3835(93)90187-E; SIDRANSKY D, 1992, CANCER RES, V52, P2984; SRIVASTAVA S, 1990, NATURE, V348, P747, DOI 10.1038/348747a0; VARLEY JM, 1995, J MED GENET, V32, P946; WAGNER J, 1994, JNCI-J NATL CANCER I, V86, P1707, DOI 10.1093/jnci/86.22.1707	25	48	48	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN 6	1996	12	11					2437	2442						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UQ220	8649785				2022-12-25	WOS:A1996UQ22000022
J	Dzeja, PP; Zeleznikar, RJ; Goldberg, ND				Dzeja, PP; Zeleznikar, RJ; Goldberg, ND			Suppression of creatine kinase-catalyzed Phosphotransfer results in increased phosphoryl transfer by adenylate kinase in intact skeletal muscle	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENERGY-TRANSPORT; ADENOSINE-TRIPHOSPHATE; COMPARTMENTATION; METABOLISM; PHOSPHATE; ATP; KINETICS; HEART; SHUTTLE; CELLS	The kinetics of creatine kinase (CK) and adenylate kinase (AK) activities were monitored in intact diaphragm muscle by O-18 phosphoryl oxygen exchange to assess whether these two phosphotransferases provide an interrelated function integral to high energy phosphoryl metabolism. This possibility was examined by quantitating the net rates of CK- and AK-catalyzed phosphoryl transfer in comparison to the total cellular ATP metabolic rate when CK activity in the intact diaphragm muscle was progressively inhibited by 2,4-dinitrofluorobenzene. In noncontracting muscle from untreated rats, net rates of CK- and AK-catalyzed phosphotransfer were equivalent to 88 and 7%, respectively, of the total ATP metabolic rate. These results were compared with reported (31)p NMR analyses of total creatine phosphate flux to estimate that each creatine phosphate molecule produced undergoes about 50 unidirectional CK-catalyzed phosphotransfers in transit to an ATP consumption site in the intact muscles. Graded inhibition by 2,4-dinitrofluorobenzene of intracellular CK activity by up to 98% resulted in a progressive shift in phosphotransferase catalysis from the CK to the AK system; the sum of the net rates of phosphoryl transfer by combining the increasing AK and decreasing CK activities continued to approximate the total cellular ATP metabolic rate. These results indicate that in diaphragm muscle CK and AK operate as interrelated cellular high energy phosphoryl transfer systems through which the majority of newly generated ATP is processed prior to its utilization.	UNIV MINNESOTA, SCH MED,DEPT BIOCHEM, MINNEAPOLIS, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM028818] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM28818] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BESSMAN SP, 1981, SCIENCE, V211, P448, DOI 10.1126/science.6450446; BESSMAN SP, 1985, ANNU REV BIOCHEM, V54, P831, DOI 10.1146/annurev.bi.54.070185.004151; BESSMAN SP, 1966, BIOCHEM BIOPH RES CO, V8, P361; BITTL JA, 1987, BIOCHEMISTRY-US, V26, P6083, DOI 10.1021/bi00393a021; CHANCE B, 1957, NATURE, V179, P1235, DOI 10.1038/1791235a0; DAWIS SM, 1989, BIOPHYS J, V55, P79, DOI 10.1016/S0006-3495(89)82782-1; DZEJA P, 1985, BIOCHEM INT, V10, P259; GADIAN DG, 1981, BIOCHEM J, V194, P215, DOI 10.1042/bj1940215; GOLDBETER A, 1976, PROG THEOR BIOL, V4, P65; HOCHACHAKA PW, 1994, MUSCLES MOL METABOLI; JACOBUS WE, 1985, BIOCHEM BIOPH RES CO, V133, P1035, DOI 10.1016/0006-291X(85)91240-9; JACOBUS WE, 1985, ANNU REV PHYSIOL, V47, P707; KINGSLEYHICKMAN PB, 1987, BIOCHEMISTRY-US, V26, P7501, DOI 10.1021/bi00397a045; KRAUSE SM, 1992, J BIOL CHEM, V267, P2480; Lowry O. H., 1972, FLEXIBLE SYSTEM ENZY, P146; MAINWOOD GW, 1982, CAN J PHYSIOL PHARM, V60, P98, DOI 10.1139/y82-016; MEYER RA, 1984, AM J PHYSIOL, V246, pC365, DOI 10.1152/ajpcell.1984.246.5.C365; MITCHELL P, 1991, BIOSCIENCE REP, V11, P297, DOI 10.1007/BF01130212; MOERLAND TS, 1994, AM J PHYSIOL, V267, pC127, DOI 10.1152/ajpcell.1994.267.1.C127; NAGLE S, 1970, KLIN WOCHENSCHR, V48, P332, DOI 10.1007/BF01484859; REICH JG, 1981, ENERGY METABOLISM CE, P95; SAKS VA, 1974, CIRC RES, V35, P138; SAKS VA, 1994, MOL CELL BIOCHEM, V133, P155, DOI 10.1007/BF01267954; SAVABI F, 1986, BIOCHEM MED METAB B, V35, P227, DOI 10.1016/0885-4505(86)90078-2; SHOUBRIDGE EA, 1985, BIOCHIM BIOPHYS ACTA, V847, P25, DOI 10.1016/0167-4889(85)90148-X; STUCKI JW, 1980, EUR J BIOCHEM, V109, P257, DOI 10.1111/j.1432-1033.1980.tb04791.x; TOMBES RM, 1985, CELL, V41, P325, DOI 10.1016/0092-8674(85)90085-6; VANDEURSEN J, 1993, CELL, V74, P621, DOI 10.1016/0092-8674(93)90510-W; WALLIMANN T, 1992, BIOCHEM J, V281, P21, DOI 10.1042/bj2810021; WEGMANN G, 1992, J MUSCLE RES CELL M, V13, P420, DOI 10.1007/BF01738037; ZAHLER R, 1987, BIOPHYS J, V51, P883, DOI 10.1016/S0006-3495(87)83416-1; ZELEZNIKAR RJ, 1990, J BIOL CHEM, V265, P300; ZELEZNIKAR RJ, 1991, J BIOL CHEM, V266, P15110; ZELEZNIKAR RJ, 1995, J BIOL CHEM, V270, P7311, DOI 10.1074/jbc.270.13.7311	34	78	78	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 31	1996	271	22					12847	12851		10.1074/jbc.271.22.12847	http://dx.doi.org/10.1074/jbc.271.22.12847			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UN474	8662747	hybrid			2022-12-25	WOS:A1996UN47400026
J	Wu, YY; Bradshaw, RA				Wu, YY; Bradshaw, RA			Synergistic induction of neurite outgrowth by nerve growth factor or epidermal growth factor and interleukin-6 in PC12 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHEOCHROMOCYTOMA CELLS; GAP-43; GENE	Native PC12 cells respond differentially to nerve growth factor (NGF) but not interkeukin-6 (IL-6); PC12-E2 cells, a stable variant, respond to both stimuli (and more rapidly to NGF). Neither responds to epidermal growth factor (EGF), NGF primarily induces the RAS/extracellular signal-regulated kinase (ERK) pathway and IL-6 activates a JAK (Janus tyrosine kinase)/STAT (signal transducers and activators of transcription) response. EGF also stimulates RAS/ERK but in a transient manner. When either cell type is treated with combinations of NGF, EGF, and IL-6, at concentrations that produce modest or no response, a substantial augmentation of neurite outgrowth is observed. With PC12-E2 cells, a subthreshold concentration of IL-6 increases NGF response by similar to-3-fold after 1-2 days; the increase with EGF is more pronounced. Native PC12 cells show even greater synergistic effects with NGF and IL-6. The most dramatic effect was observed with low levels of EGF, where IL-6 increased the percentage of responsive cells from zero to similar to 60% after 3 days. In addition, two neural specific transcripts, GAP-43 and SCG-10, are synergistically increased by the combinations of growth factors. Importantly, IL-6 does not enhance ERK phosphorylation in the presence of either NGF or EGF. In contrast, NGF and EGF, in the presence or absence of IL-6, cause mobility shifts of Stat3 that are consistent with serine phosphorylations. Although these modifications do not lead to activation and translocation by themselves, in the presence of the tyrosine phosphorylation induced by IL-6, they may play a role in the synergistic responses. These observations suggest a differentially regulated two-stage mechanism for the differentiative response of PC12 cells to NGF.	UNIV CALIF IRVINE,COLL MED,DEPT BIOL CHEM,IRVINE,CA 92717	University of California System; University of California Irvine			Bradshaw, Ralph A/K-1515-2013		NIA NIH HHS [AG09735] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R01AG009735] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ALTIN JG, 1991, J BIOL CHEM, V266, P5401; BASI GS, 1987, CELL, V49, P785, DOI 10.1016/0092-8674(87)90616-7; BOULTON TG, 1995, P NATL ACAD SCI USA, V92, P6915, DOI 10.1073/pnas.92.15.6915; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; Decker SJ, 1995, J BIOL CHEM, V270, P30841, DOI 10.1074/jbc.270.52.30841; DOBASHI Y, 1995, J BIOL CHEM, V270, P23031, DOI 10.1074/jbc.270.39.23031; FANTL WJ, 1993, ANNU REV BIOCHEM, V62, P453, DOI 10.1146/annurev.bi.62.070193.002321; FEDEROFF HJ, 1988, J BIOL CHEM, V263, P19290; Glass David J., 1993, Trends in Cell Biology, V3, P262, DOI 10.1016/0962-8924(93)90054-5; GLOWACKA D, 1990, J NEUROSCI RES, V25, P453, DOI 10.1002/jnr.490250403; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; Greene LA., 1982, ADV CELL NEUROBIOL, V3, P373, DOI [10.1016/B978-0-12-008303-9.50016-5, DOI 10.1016/B978-0-12-008303-9.50016-5]; GUSCHIN D, 1995, EMBO J, V14, P1421, DOI 10.1002/j.1460-2075.1995.tb07128.x; HONDERMARCK H, 1994, P NATL ACAD SCI USA, V91, P9377, DOI 10.1073/pnas.91.20.9377; HOPKINS SJ, 1995, TRENDS NEUROSCI, V18, P83; IHLE JN, 1995, NATURE, V377, P591, DOI 10.1038/377591a0; IHLE JN, 1995, ANNU REV IMMUNOL, V13, P369, DOI 10.1146/annurev.iy.13.040195.002101; Ihle JN, 1996, CELL, V84, P331, DOI 10.1016/S0092-8674(00)81277-5; Leaman DW, 1996, MOL CELL BIOL, V16, P369; LOTAN M, 1994, FASEB J, V8, P1026, DOI 10.1096/fasebj.8.13.7926367; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MITSUMOTO H, 1994, SCIENCE, V265, P1107, DOI 10.1126/science.8066451; MURPHY PG, 1995, J NEUROSCI, V15, P5130; PANG L, 1995, J BIOL CHEM, V270, P13585, DOI 10.1074/jbc.270.23.13585; PENG X, 1995, NEURON, V15, P3395; RAFFIONI S, 1995, J BIOL CHEM, V270, P7568, DOI 10.1074/jbc.270.13.7568; ROTHWELL NJ, 1995, TRENDS NEUROSCI, V18, P130, DOI 10.1016/0166-2236(95)93890-A; SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201; STAHL N, 1994, SCIENCE, V263, P92, DOI 10.1126/science.8272873; STAHL N, 1993, CELL, V74, P587, DOI 10.1016/0092-8674(93)90506-L; STEIN R, 1988, DEV BIOL, V127, P316, DOI 10.1016/0012-1606(88)90318-1; TENG KK, 1995, J BIOL CHEM, V270, P20677, DOI 10.1074/jbc.270.35.20677; VAILLANCOURT RR, 1995, MOL CELL BIOL, V15, P3644; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; WILDER RL, 1995, ANNU REV IMMUNOL, V13, P307; WU YY, 1995, J CELL PHYSIOL, V164, P522, DOI 10.1002/jcp.1041640310; WU YY, 1993, J CELL BIOL, V121, P409, DOI 10.1083/jcb.121.2.409; Wu YY, 1996, J BIOL CHEM, V271, P13023, DOI 10.1074/jbc.271.22.13023; YAN GZ, 1995, J NEUROSCI, V15, P6200; ZHANG XK, 1995, SCIENCE, V267, P1990, DOI 10.1126/science.7701321	41	69	74	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 31	1996	271	22					13033	13039		10.1074/jbc.271.22.13033	http://dx.doi.org/10.1074/jbc.271.22.13033			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UN474	8662831	hybrid			2022-12-25	WOS:A1996UN47400055
J	Ahn, T; Kim, HM				Ahn, T; Kim, HM			Differential effect of precursor ribose binding protein of Escherichia coli and its signal peptide on the SecA penetration of lipid bilayer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INNER MEMBRANES; APOCYTOCHROME-C; MODEL MEMBRANES; PHOSPHOLIPIDS; TRANSLOCATION; EXPORT; ATP; DOMAINS; PHOSPHATIDYLGLYCEROL; INTERACTS	Digestion of vesicle-bound SecA by trypsin entrapped within the vesicles showed that refolding precursor ribose-binding protein (pRBP) of Escherichia coli retards the lipid bilayer penetration by SecA while the signal peptide enhances it. This discrepancy was found to be due to reduced SecA binding to the vesicles in the presence of the pRBP while the signal peptide induced a tight binding. Studies on the binding of 1-anilino-8-naphthalene sulfonate (ANS) to SecA indicated that SecA assumes more closed conformation upon interaction with pRBP and signal peptide induces more open structure of SecA. Kinetic studies of ANS binding to SecA upon dilution of unfolded pRBP with SecA solution showed an initial fast ANS binding, which was followed by a slow release of ANS. This suggests that first the signal peptide portion of the pRBP binds with the SecA making its structure more open and then the subsequent binding of the mature domain makes the SecA structure more compact. The pRBP enhanced the digestion of SecA added to the E. coli inverted vesicles, suggesting an inhibition of SecA penetration while the signal peptide had an opposite effect, agreeing with the results from the model systems above. When the pRBP and ATP were present together, however, the penetration of SecA increased dramatically underlining the importance of the SecY/E complex for the membrane insertion of SecA.	KOREA ADV INST SCI & TECHNOL, DEPT BIOL SCI, TAEJON 305701, SOUTH KOREA	Korea Advanced Institute of Science & Technology (KAIST)								AHN T, 1994, BIOCHEM BIOPH RES CO, V203, P326, DOI 10.1006/bbrc.1994.2185; AKITA M, 1990, J BIOL CHEM, V265, P8164; ALTMAN E, 1990, J BIOL CHEM, V265, P18148; BIEKER KL, 1990, J BIOENERG BIOMEMBR, V22, P291, DOI 10.1007/BF00763169; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BREUKINK E, 1992, BIOCHEMISTRY-US, V31, P1119, DOI 10.1021/bi00119a021; CABELLI RJ, 1991, J BIOL CHEM, V266, P24420; CHANG CN, 1978, P NATL ACAD SCI USA, V75, P361, DOI 10.1073/pnas.75.1.361; Chi SW, 1995, BIOPHYS J, V69, P2703, DOI 10.1016/S0006-3495(95)80141-4; CSERMELY P, 1993, J BIOL CHEM, V268, P1901; CUNNINGHAM K, 1989, EMBO J, V8, P955, DOI 10.1002/j.1460-2075.1989.tb03457.x; DEVRIJE T, 1988, NATURE, V334, P173, DOI 10.1038/334173a0; DUMONT ME, 1984, J BIOL CHEM, V259, P4147; ECONOMOU A, 1994, CELL, V78, P835, DOI 10.1016/S0092-8674(94)90582-7; EFTINK MR, 1981, ANAL BIOCHEM, V114, P199, DOI 10.1016/0003-2697(81)90474-7; JOLY JC, 1993, EMBO J, V12, P255, DOI 10.1002/j.1460-2075.1993.tb05651.x; KAWASAKI H, 1989, FEBS LETT, V242, P431, DOI 10.1016/0014-5793(89)80516-2; KIM JH, 1992, J BACTERIOL, V174, P5219, DOI 10.1128/JB.174.16.5219-5227.1992; KIM YJ, 1994, CELL, V78, P845; KUSTERS R, 1991, J BIOL CHEM, V266, P8659; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LILL R, 1990, CELL, V60, P271, DOI 10.1016/0092-8674(90)90742-W; LILL R, 1989, EMBO J, V8, P961, DOI 10.1002/j.1460-2075.1989.tb03458.x; MARKWELL MAK, 1978, BIOCHEMISTRY-US, V17, P4807, DOI 10.1021/bi00615a031; MITCHELL C, 1993, MOL MICROBIOL, V10, P483, DOI 10.1111/j.1365-2958.1993.tb00921.x; PALLEROS DR, 1992, J BIOL CHEM, V267, P5279; PARK SH, 1988, SCIENCE, V239, P1033, DOI 10.1126/science.3278378; PHILLIPS GJ, 1992, NATURE, V359, P744, DOI 10.1038/359744a0; RANDALL LL, 1985, EMBO J, V4, P1875; RIETVELD A, 1986, J BIOL CHEM, V261, P3846; ROMISCH K, 1989, NATURE, V340, P478, DOI 10.1038/340478a0; SHINKAI A, 1991, J BIOL CHEM, V266, P5827; SIMON SM, 1992, CELL, V69, P677, DOI 10.1016/0092-8674(92)90231-Z; SZOKA F, 1978, P NATL ACAD SCI USA, V75, P4194, DOI 10.1073/pnas.75.9.4194; TESCHKE CM, 1991, J BIOL CHEM, V266, P11789; ULBRANDT ND, 1992, J BIOL CHEM, V267, P15184; VASKOVSKY VE, 1975, J CHROMATOGR, V114, P129, DOI 10.1016/S0021-9673(00)85249-8; WOLIN SL, 1994, CELL, V77, P787, DOI 10.1016/0092-8674(94)90124-4; YI GS, 1994, BIOPHYS J, V66, P1604, DOI 10.1016/S0006-3495(94)80952-X	39	22	22	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 24	1996	271	21					12372	12379		10.1074/jbc.271.21.12372	http://dx.doi.org/10.1074/jbc.271.21.12372			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UL660	8647840	hybrid			2022-12-25	WOS:A1996UL66000042
J	Siegers, K; Heinzmann, S; Entian, KD				Siegers, K; Heinzmann, S; Entian, KD			Biosynthesis of lantibiotic nisin - Posttranslational modification of its prepeptide occurs at a multimeric membrane-associated lanthionine synthetase complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STRUCTURAL GENE ISOLATION; LACTOCOCCUS-LACTIS; PROTEIN; EXPRESSION; EPIDERMIN; SUBTILIN; PRECURSOR; SEQUENCE; CLONING; SYSTEM	The lantibiotic nisin of Lactococcus lactis is matured from a ribosomally synthesized prepeptide by posttranslational modification. Genetic and biochemical evidence suggests that genes nisB and nisC of the nisin gene cluster encode proteins necessary for prenisin modification. Inactivation of both genes resulted in complete loss of nisin production. The preparation of membrane vesicles revealed that NisB and NisC are attached to the cellular membrane, and co-immunoprecipitation experiments showed that they are associated with each other. By using the yeast two-hybrid system, which is a highly sensitive method to unravel protein-protein interactions, we could show that the nisin prepeptide physically interacts with the NisC protein, suggesting that NisC contains a binding site for prenisin. This was also confirmed by co-immunoprecipitation of the NisC protein and the NisA prepeptide by antibodies directed against the leader sequence of the nisin prepeptide. The two-hybrid analysis also confirmed the interaction between NisB and NisC as well as the interaction between NisC and the NisT ABC transporter. A minor interaction was also indicated between prenisin and the NisB protein. Furthermore, the two-hybrid investigations also revealed that at least two molecules of NisC and two molecules of NisT are part of the modification and transport complex. Our results suggest that lantibiotic maturation and secretion occur at a membrane associated multimeric lanthionine synthetase complex consisting of proteins NisB, NisC, and the ABC transporter molecules NisT.	UNIV FRANKFURT, INST MICROBIOL, D-60439 FRANKFURT, GERMANY	Goethe University Frankfurt			Entian, Karl-Dieter/D-3080-2011					ALLGAIER H, 1986, EUR J BIOCHEM, V160, P9, DOI 10.1111/j.1432-1033.1986.tb09933.x; AUGUSTIN J, 1992, EUR J BIOCHEM, V204, P1149, DOI 10.1111/j.1432-1033.1992.tb16740.x; BANERJEE S, 1988, J BIOL CHEM, V263, P9508; BENZ R, 1991, NISIN NOVEL LANTIBIO; BIRNBOIM HC, 1979, NUCLEIC ACIDS RES, V7, P1513; BLIGHT MA, 1990, MOL MICROBIOL, V4, P873, DOI 10.1111/j.1365-2958.1990.tb00660.x; BUCHMAN GW, 1988, J BIOL CHEM, V263, P16260; Chevalier RJ, 1957, ANN TECHNOL AGR, V2, P117; CHIEN CT, 1991, P NATL ACAD SCI USA, V88, P9578, DOI 10.1073/pnas.88.21.9578; DEVOS WM, 1995, MOL MICROBIOL, V17, P427, DOI 10.1111/j.1365-2958.1995.mmi_17030427.x; DODD HM, 1990, J GEN MICROBIOL, V136, P555, DOI 10.1099/00221287-136-3-555; ENGELKE G, 1992, APPL ENVIRON MICROB, V58, P3730, DOI 10.1128/AEM.58.11.3730-3743.1992; ENGELKE G, 1994, APPL ENVIRON MICROB, V60, P816; Entian KD, 1996, ANTON LEEUW INT J G, V69, P109, DOI 10.1007/BF00399416; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; GASSON MJ, 1983, J BACTERIOL, V154, P1; GILMORE MS, 1994, J BACTERIOL, V176, P7335, DOI 10.1128/JB.176.23.7335-7344.1994; GUARENTE L, 1983, METHOD ENZYMOL, V101, P181; HIGGINS CF, 1995, CELL, V82, P693, DOI 10.1016/0092-8674(95)90465-4; HOLO H, 1989, APPL ENVIRON MICROB, V55, P3119, DOI 10.1128/AEM.55.12.3119-3123.1989; HORINOUCHI S, 1980, P NATL ACAD SCI-BIOL, V77, P7079, DOI 10.1073/pnas.77.12.7079; HURST A, 1981, ADV APPL MICROBIOL, V27, P263; INGRAM LC, 1969, BIOCHIM BIOPHYS ACTA, V184, P216, DOI 10.1016/0304-4165(69)90121-4; KALETTA C, 1989, J BACTERIOL, V171, P1597, DOI 10.1128/jb.171.3.1597-1601.1989; KALETTA C, 1989, ARCH MICROBIOL, V152, P16, DOI 10.1007/BF00447005; KALETTA C, 1991, NISIN NOVEL LANTIBIO; KLEBE RJ, 1983, GENE, V25, P333, DOI 10.1016/0378-1119(83)90238-X; KLEIN C, 1992, APPL ENVIRON MICROB, V58, P132, DOI 10.1128/AEM.58.1.132-142.1992; KLEIN C, 1993, APPL ENVIRON MICROB, V59, P296, DOI 10.1128/AEM.59.1.296-303.1993; KLEIN C, 1994, APPL ENVIRON MICROB, V60, P2793, DOI 10.1128/AEM.60.8.2793-2801.1994; KOERNER TJ, 1991, METHOD ENZYMOL, V194, P477; KUIPERS OP, 1993, EUR J BIOCHEM, V216, P281, DOI 10.1111/j.1432-1033.1993.tb18143.x; MEYER C, 1995, EUR J BIOCHEM, V232, P478, DOI 10.1111/j.1432-1033.1995.tb20834.x; NIEDERACHER D, 1987, MOL GEN GENET, V206, P505, DOI 10.1007/BF00428892; OTTO R, 1982, J BACTERIOL, V149, P733, DOI 10.1128/JB.149.2.733-738.1982; RINCE A, 1994, APPL ENVIRON MICROB, V60, P1652, DOI 10.1128/AEM.60.5.1652-1657.1994; SAHL HG, 1995, EUR J BIOCHEM, V230, P827, DOI 10.1111/j.1432-1033.1995.tb20627.x; SAHL HG, 1985, J BACTERIOL, V162, P833, DOI 10.1128/JB.162.2.833-836.1985; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SCHAGGER H, 1994, ANAL BIOCHEM, V217, P220, DOI 10.1006/abio.1994.1112; SCHNELL N, 1992, EUR J BIOCHEM, V204, P57, DOI 10.1111/j.1432-1033.1992.tb16605.x; SCHNELL N, 1989, FEMS MICROBIOL LETT, V58, P263, DOI 10.1016/0378-1097(89)90050-5; SCHNELL N, 1988, NATURE, V333, P276, DOI 10.1038/333276a0; SCHNELL N, 1991, NISIN NOVEL LANTIBIO; SCHULLER F, 1989, EUR J BIOCHEM, V182, P181, DOI 10.1111/j.1432-1033.1989.tb14815.x; SIEGERS K, 1995, APPL ENVIRON MICROB, V61, P1082, DOI 10.1128/AEM.61.3.1082-1089.1995; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; TAUTZ D, 1983, ANAL BIOCHEM, V132, P503; VANDERMEER JR, 1993, J BACTERIOL, V175, P2578, DOI 10.1128/JB.175.9.2578-2588.1993; WEIL HP, 1990, EUR J BIOCHEM, V194, P217, DOI 10.1111/j.1432-1033.1990.tb19446.x; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	51	109	112	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 24	1996	271	21					12294	12301		10.1074/jbc.271.21.12294	http://dx.doi.org/10.1074/jbc.271.21.12294			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UL660	8647829	hybrid			2022-12-25	WOS:A1996UL66000031
J	vanderSpek, JC; Sutherland, JA; Ratnarathorn, M; Howland, K; Ciardelli, TL; Murphy, JR				vanderSpek, JC; Sutherland, JA; Ratnarathorn, M; Howland, K; Ciardelli, TL; Murphy, JR			DAB(389) interleukin-2 receptor binding domain mutations - Cytotoxic probes for studies of ligand-receptor interactions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN KINASE-C; FUSION PROTEIN; TARGET-CELLS; EFFICIENT DELIVERY; FRAGMENT-A; TOXIN; CYTOSOL; CHAIN; PHOSPHORYLATION; PROLIFERATION	Site-directed mutagenesis was used to generate point mutations in the diphtheria toxin-related fusion protein, DAB(389) interleukin-2 (IL-2). Thr-439, in the IL-2 receptor binding domain of the fusion toxin, was changed to a Pro residue. The resultant fusion toxin, DAB(389) IL-2(T439P), was 300-fold less cytotoxic than wild type DAB(389) IL-2, partially as the result of a 100-fold decrease in binding affinity for the high affinity form of the IL-2 receptor. However, DAB(389) IL-2(T439P) stimulated DNA synthesis to a greater extent than expected. Studies of intoxication kinetics indicated that the increased stimulation might result from an increased contact time between the mutated IL-2 receptor binding domain and the receptor, perhaps due to a decreased internalization rate. Another mutant, DAB(389) IL-2(Q514D), in which a Gln residue at position 514 was changed to an Asp, was 2000-fold less cytotoxic than wild type DAB(389) IL-2. This mutant had a 50-fold decrease in binding affinity, did not stimulate DNA synthesis and also had a reduced rate of intoxication. Gln-514 appears to play a role in receptor binding and activation, whereas Thr-439 appears to be involved with receptor binding and signaling internalization of the fusion toxin-receptor complex.	BOSTON UNIV,MED CTR,DEPT MED,BOSTON,MA 02118; DARTMOUTH COLL,SCH MED,DEPT PHARMACOL & TOXICOL,HANOVER,NH 03755; VET ADM MED CTR,WHITE RIVER JCT,VT 05001	Boston University; Dartmouth College; US Department of Veterans Affairs; Veterans Health Administration (VHA)	vanderSpek, JC (corresponding author), BOSTON UNIV,MED CTR,EVANS MEM DEPT CLIN RES,BOSTON,MA 02118, USA.				NCI NIH HHS [CA-60934] Funding Source: Medline; NIGMS NIH HHS [R01 GM 52858-01] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA060934] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052858] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AUSUBEL FM, 1991, CURRENT PROTOCOL S15, V1; BACHA P, 1988, J EXP MED, V167, P612, DOI 10.1084/jem.167.2.612; BECKNER SK, 1987, BIOCHEM BIOPH RES CO, V145, P176, DOI 10.1016/0006-291X(87)91303-9; BERNDT WG, 1994, BIOCHEMISTRY-US, V33, P6571, DOI 10.1021/bi00187a026; BERNDT WG, 1992, INTERLEUKIN, V2, P12; BUCHLI P, 1993, ARCH BIOCHEM BIOPHYS, V207, P411; CHANG DZ, 1995, MOL PHARMACOL, V47, P206; COLLINS L, 1988, P NATL ACAD SCI USA, V85, P7709, DOI 10.1073/pnas.85.20.7709; FARRAR WL, 1985, NATURE, V315, P233, DOI 10.1038/315233a0; GILLIS S, 1978, J IMMUNOL, V120, P2027; ISHII T, 1988, J IMMUNOL, V141, P174; LANDGRAF BE, 1992, J BIOL CHEM, V267, P18511; MANIATIS T, 1982, MOL CLONING LABORATO, P90; MILLS GB, 1985, J BIOL CHEM, V260, P2500; RAYHEL EJ, 1988, BIOCHEM J, V249, P333, DOI 10.1042/bj2490333; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SUAVE K, 1991, P NATL ACAD SCI USA, V88, P4636; TAKESHITA T, 1992, SCIENCE, V257, P379, DOI 10.1126/science.1631559; VANDERSPEK JC, 1993, J BIOL CHEM, V268, P12077; WANG HM, 1987, J EXP MED, V166, P1055, DOI 10.1084/jem.166.4.1055; WATERS CA, 1990, EUR J IMMUNOL, V20, P785, DOI 10.1002/eji.1830200412; WILLIAMS DP, 1990, J BIOL CHEM, V265, P11885; WILLIAMS DP, 1987, PROTEIN ENG, V1, P493, DOI 10.1093/protein/1.6.493; WILLIAMS DP, 1990, J BIOL CHEM, V265, P20673; ZURAWSKI SM, 1992, EMBO J, V11, P3905, DOI 10.1002/j.1460-2075.1992.tb05483.x	25	12	13	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 24	1996	271	21					12145	12149		10.1074/jbc.271.21.12145	http://dx.doi.org/10.1074/jbc.271.21.12145			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UL660	8647806	hybrid			2022-12-25	WOS:A1996UL66000008
J	Vihinen, T; Maatta, A; Jaakkola, P; Auvinen, P; Jalkanen, M				Vihinen, T; Maatta, A; Jaakkola, P; Auvinen, P; Jalkanen, M			Functional characterization of mouse syndecan-1 promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SECRETORY GRANULE PROTEOGLYCANS; FIBROBLAST GROWTH-FACTOR; CELL-SURFACE PROTEOGLYCAN; REDUCTASE GENE PROMOTER; BOX-BINDING-PROTEINS; HEPARAN-SULFATE; PEPTIDE CORE; TRANSIENT EXPRESSION; EPITHELIAL-CELLS; LESS PROMOTER	The members of the syndecan family are temporally and spatially expressed heparan sulfate proteoglycans of various tissues, where they mediate extracellular influences on cell morphology and behavior. Functional characterization of the mouse syndecan-1 promoter was carried out in order to elucidate the mechanisms involved in the maintenance of the high transcription levels of syndecan-1 gene in various epithelia. For that 9.5 kilobase pairs of the upstream region of mouse syndecan-1 gene were cloned, sequenced, and used to prepare chimaeric constructs with a reporter gene followed by transient or stable transfections into NMuMG epithelial and 3T3 fibroblastic cells. In NMuMG cells, cultured either in the presence or absence of serum, the 2.5-kilobase pair promoter region resulted in the constitutive transcription activity, whereas in 3T3 cells the serum depletion decreased the promoter activity significantly. Deletion of the upstream sequences to -437 base pairs relative to the translation initiation site had little effect on this promoter activity. Further deletion to -365 base pairs removed three GT boxes and slightly increased the promoter activity, whereas the deletion of the next two GC boxes (to -326 base pair) reduced the promoter activity dramatically. All of the GC or GT box sequences bound the same set of Sp1-like nuclear proteins in gel shift assays. Nuclear protein binding was also demonstrated around both of the most intense transcription initiation sites. Mutation of these regions separately resulted in total loss of transcription initiation from the deleted site and decreased the promoter activity in relation to the intensity of the abolished start site. This indicates that the transcription initiation of the syndecan-1 gene is directed through initiator-like elements directly overlapping the start sites, as shown for several TATA-less housekeeping and growth regulated genes. We assume that the constitutive high level gene expression in epithelial cells is achieved by the proximal promoter, which is controlled by members of Sp1 transcription factor family.	TURKU CTR BIOTECHNOL,FIN-20521 TURKU,FINLAND; TURKU UNIV,DEPT BIOCHEM MED,FIN-20520 TURKU,FINLAND	University of Turku			Auvinen, Petri/D-5044-2009; Jaakkola, Panu M/B-4355-2012; Auvinen, Petri/AAP-8117-2021	Auvinen, Petri/0000-0002-3947-4778; Maatta, Arto/0000-0003-3759-1310; Jaakkola, Panu/0000-0002-2365-4985				Ausubel F.M., 1993, CURRENT PROTOCOLS MO; AVRAHAM S, 1992, J BIOL CHEM, V267, P610; AVRAHAM S, 1989, J BIOL CHEM, V264, P16719; AZIZKHAN JC, 1986, BIOCHEMISTRY-US, V25, P6228, DOI 10.1021/bi00368a059; BACIU PC, 1994, J BIOL CHEM, V269, P696; BECKER PB, 1986, NATURE, V324, P686, DOI 10.1038/324686a0; BERNFIELD M, 1992, ANNU REV CELL BIOL, V8, P365, DOI 10.1146/annurev.cb.08.110192.002053; BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; BLAKE MC, 1990, MOL CELL BIOL, V10, P6632, DOI 10.1128/MCB.10.12.6632; BRAUKER JH, 1991, DEV BIOL, V147, P285, DOI 10.1016/0012-1606(91)90286-C; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHEN XR, 1992, ONCOGENE, V7, P1805; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COHEN IR, 1993, P NATL ACAD SCI USA, V90, P10404, DOI 10.1073/pnas.90.21.10404; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; DANESCH U, 1987, EMBO J, V6, P625, DOI 10.1002/j.1460-2075.1987.tb04800.x; DYNAN WS, 1983, CELL, V35, P79, DOI 10.1016/0092-8674(83)90210-6; ELENIUS K, 1994, J CELL SCI, V107, P2975; ELENIUS K, 1991, J CELL BIOL, V114, P585, DOI 10.1083/jcb.114.3.585; FISHER LW, 1991, J BIOL CHEM, V266, P14371; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; GIDONI D, 1985, SCIENCE, V230, P511, DOI 10.1126/science.2996137; HAGEN G, 1992, NUCLEIC ACIDS RES, V20, P5519, DOI 10.1093/nar/20.21.5519; HAGEN G, 1994, EMBO J, V13, P3843, DOI 10.1002/j.1460-2075.1994.tb06695.x; HINKES MT, 1993, J BIOL CHEM, V268, P11440; INAGAKI Y, 1994, J BIOL CHEM, V269, P14828; INKI P, 1994, BRIT J CANCER, V70, P319, DOI 10.1038/bjc.1994.300; INKI P, 1991, AM J PATHOL, V139, P1333; INKI P, 1992, LAB INVEST, V66, P314; JALKANEN M, 1993, TRENDS GLYCOSCI GLYC, V5, P107; JAVAHERY R, 1994, MOL CELL BIOL, V14, P116, DOI 10.1128/MCB.14.1.116; KIM CW, 1994, MOL BIOL CELL, V5, P797, DOI 10.1091/mbc.5.7.797; KINGSLEY C, 1992, MOL CELL BIOL, V12, P4251, DOI 10.1128/MCB.12.10.4251; KRISHNAN V, 1994, J BIOL CHEM, V269, P15912; LEGGETT RW, 1995, J BIOL CHEM, V270, P25879, DOI 10.1074/jbc.270.43.25879; LEPPA S, 1992, P NATL ACAD SCI USA, V89, P932, DOI 10.1073/pnas.89.3.932; LEPPA S, 1991, CELL REGUL, V2, P1; LI R, 1991, CELL, V65, P493, DOI 10.1016/0092-8674(91)90467-D; MALI M, 1993, J BIOL CHEM, V268, P24215; MAUVIEL A, 1995, J BIOL CHEM, V270, P11692, DOI 10.1074/jbc.270.19.11692; Maxam A M, 1980, Methods Enzymol, V65, P499; MIETTINEN HM, 1994, MOL BIOL CELL, V5, P1325, DOI 10.1091/mbc.5.12.1325; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; MYERS RM, 1986, SCIENCE, V232, P613, DOI 10.1126/science.3457470; NASO MF, 1994, J BIOL CHEM, V269, P32999; NICODEMUS CF, 1990, J BIOL CHEM, V265, P5889; PUGH BF, 1991, GENE DEV, V5, P1935, DOI 10.1101/gad.5.11.1935; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; RAPRAEGER A, 1985, J BIOL CHEM, V260, P1046; RAPRAEGER AC, 1991, SCIENCE, V252, P1705, DOI 10.1126/science.1646484; RIDLEY RC, 1993, BLOOD, V81, P767; SAFFER JD, 1991, MOL CELL BIOL, V11, P2189, DOI 10.1128/MCB.11.4.2189; SALMIVIRTA M, 1992, J BIOL CHEM, V267, P17606; SALMIVIRTA M, 1995, EXPERIENTIA, V51, P863, DOI 10.1007/BF01921737; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SANTRA M, 1994, J BIOL CHEM, V269, P579; SAUNDERS S, 1989, J CELL BIOL, V108, P1547, DOI 10.1083/jcb.108.4.1547; SCHLESSINGER J, 1995, CELL, V83, P357, DOI 10.1016/0092-8674(95)90112-4; SCHULE R, 1988, NATURE, V332, P87, DOI 10.1038/332087a0; SKERKA C, 1995, J BIOL CHEM, V270, P22500, DOI 10.1074/jbc.270.38.22500; SOLURSH M, 1990, DEV BIOL, V140, P83, DOI 10.1016/0012-1606(90)90055-N; STRAHLE U, 1988, EMBO J, V7, P3389, DOI 10.1002/j.1460-2075.1988.tb03212.x; SWICK AG, 1989, NUCLEIC ACIDS RES, V17, P9291, DOI 10.1093/nar/17.22.9291; VAINIO S, 1991, DEV BIOL, V147, P322, DOI 10.1016/0012-1606(91)90290-J; VAINIO S, 1992, DEV BIOL, V152, P221, DOI 10.1016/0012-1606(92)90130-9; VIHINEN T, 1993, J BIOL CHEM, V268, P17261; VOGEL A, 1978, P NATL ACAD SCI USA, V75, P2810, DOI 10.1073/pnas.75.6.2810; WATANABE H, 1995, BIOCHEM J, V308, P433, DOI 10.1042/bj3080433; WU RL, 1994, J BIOL CHEM, V269, P28450; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W	70	36	37	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 24	1996	271	21					12532	12541		10.1074/jbc.271.21.12532	http://dx.doi.org/10.1074/jbc.271.21.12532			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UL660	8647862	hybrid			2022-12-25	WOS:A1996UL66000064
J	Andoniou, CE; Thien, CBF; Langdon, WY				Andoniou, CE; Thien, CBF; Langdon, WY			The two major sites of cbl tyrosine phosphorylation in abl-transformed cells select the crkL SH2 domain	ONCOGENE			English	Article						tyrosine kinase; cbl oncogene; cell transformation; crk adaptor	CHRONIC MYELOGENOUS LEUKEMIA; V-CBL; PROTEIN; ONCOGENE; TRUNCATION; RETROVIRUS; GENE; RAS	We recently found that the 120-kD protein product of the c-cbl oncogene is tyrosine phosphorylated in tumor cells generated by bcr-abl or v-abl and that p120(cbl) will associate with these proteins bl vivo, We also found an oncogenic form of cbl protein in the 70Z/3 pre-B cell lymphoma which exhibits deregulated tyrosine phosphorylation. These findings have led us to broaden our study of cbl's involvement in abl-mediated tumorigenesis. Here we show by immunodepletion that cbl is the major 120-kD tyrosine phosphorylated protein in cells which express activated forms of the abl oncogene. We also demonstrate that tyrosine phosphorylation of p120(cbl) in bcr-abl transformed cells does not alter its subcellular localization. In addition we show that the oncogenic 70Z/3 form of cbl exhibits enhanced tyrosine phosphorylation in v-abl infected cells and that cbl is heavily tyrosine phosphorylated in hemopoietic cells transformed by v-src. Finally this study identifies two sites that are essential for the tyrosine phosphorylation of cbl in abl-transformed cells. These sites conform to the preferred abl kinase substrate sequence of YXXP and we show that following phosphorylation they mediate an association with the crkL SH2 domain.	UNIV WESTERN AUSTRALIA, QUEEN ELIZABETH II MED CTR, DEPT PATHOL, NEDLANDS, WA 6009, AUSTRALIA	University of Western Australia			Andoniou, Christopher/B-6296-2013; Thien, Christine/GQP-0424-2022	Andoniou, Christopher/0000-0003-0566-3180; Thien, Christine/0000-0003-3884-5546				AFAR DEH, 1994, SCIENCE, V264, P424, DOI 10.1126/science.8153630; ANDONIOU CE, 1994, EMBO J, V13, P4515, DOI 10.1002/j.1460-2075.1994.tb06773.x; BLAKE TJ, 1992, ONCOGENE, V7, P757; BLAKE TJ, 1991, ONCOGENE, V6, P653; BLAKE TJ, 1993, EMBO J, V12, P2017, DOI 10.1002/j.1460-2075.1993.tb05851.x; BOWTELL DDL, 1995, ONCOGENE, V11, P1561; CORTEZ D, 1995, MOL CELL BIOL, V15, P5531; CORY GOC, 1995, J EXP MED, V182, P611, DOI 10.1084/jem.182.2.611; DALEY GQ, 1988, P NATL ACAD SCI USA, V85, P9312, DOI 10.1073/pnas.85.23.9312; DEJONG R, 1995, J BIOL CHEM, V270, P21468, DOI 10.1074/jbc.270.37.21468; DONOVAN JA, 1994, J BIOL CHEM, V269, P22921; FUKAZAWA T, 1995, J BIOL CHEM, V270, P19141, DOI 10.1074/jbc.270.32.19141; GALISTEO ML, 1995, J BIOL CHEM, V270, P20242, DOI 10.1074/jbc.270.35.20242; GOGA A, 1995, CELL, V82, P981, DOI 10.1016/0092-8674(95)90277-5; HOLMES KL, 1986, J EXP MED, V164, P443, DOI 10.1084/jem.164.2.443; JOHNSON GR, 1989, EMBO J, V8, P441, DOI 10.1002/j.1460-2075.1989.tb03396.x; JONGEWARD GD, 1995, GENETICS, V139, P1553; KONOPKA JB, 1984, CELL, V37, P1035, DOI 10.1016/0092-8674(84)90438-0; LANGDON WY, 1989, P NATL ACAD SCI USA, V86, P1168, DOI 10.1073/pnas.86.4.1168; MANDANAS RA, 1993, BLOOD, V82, P1838; MANN KP, 1987, J VIROL, V61, P2100, DOI 10.1128/JVI.61.7.2100-2108.1987; MARCILLA A, 1995, J BIOL CHEM, V270, P9115, DOI 10.1074/jbc.270.16.9115; MEISNER H, 1995, J BIOL CHEM, V270, P25332, DOI 10.1074/jbc.270.43.25332; MEISNER H, 1995, MOL CELL BIOL, V15, P3571; MUSHINSKI JF, 1994, ONCOGENE, V9, P2489; ODAI H, 1995, J BIOL CHEM, V270, P10800, DOI 10.1074/jbc.270.18.10800; PENDERGAST AM, 1993, CELL, V75, P175, DOI 10.1016/S0092-8674(05)80094-7; PUIL L, 1994, EMBO J, V13, P764, DOI 10.1002/j.1460-2075.1994.tb06319.x; REN RB, 1994, GENE DEV, V8, P783, DOI 10.1101/gad.8.7.783; RIVEROLEZCANO OM, 1994, J BIOL CHEM, V269, P17363; SAWYERS CL, 1995, J EXP MED, V181, P307, DOI 10.1084/jem.181.1.307; SAWYERS CL, 1992, CELL, V70, P901, DOI 10.1016/0092-8674(92)90241-4; SAWYERS CL, 1992, CANCER SURV, V15, P37; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SONGYANG Z, 1995, NATURE, V373, P536, DOI 10.1038/373536a0; TANAKA S, 1995, J BIOL CHEM, V270, P14347, DOI 10.1074/jbc.270.24.14347; TENHOEVE J, 1993, ONCOGENE, V8, P2469; VARTICOVSKI L, 1991, MOL CELL BIOL, V11, P1107, DOI 10.1128/MCB.11.2.1107; Wang Y, 1996, J BIOL CHEM, V271, P17, DOI 10.1074/jbc.271.1.17; WILSON IA, 1984, CELL, V37, P767, DOI 10.1016/0092-8674(84)90412-4; YOON CH, 1995, SCIENCE, V269, P1102, DOI 10.1126/science.7652556; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	42	107	108	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 2	1996	12	9					1981	1989						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UK498	8649859				2022-12-25	WOS:A1996UK49800017
J	Yao, XB; Cheng, L; Forte, JG				Yao, XB; Cheng, L; Forte, JG			Biochemical characterization of ezrin-actin interaction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GASTRIC PARIETAL-CELLS; BETA-ACTIN; 80-KDA PHOSPHOPROTEIN; APICAL MICROVILLI; MEMBRANE; PURIFICATION; PROFILIN; PROTEINS; POLYMERIZATION; LOCALIZATION	The highly related actin isoforms are thought to have different functions. We recently demonstrated a polarized distribution of actin isoforms in gastric parietal cells and association of gastric ezrin with the cytoplasmic beta-actin isoform (Yao, X., Chaponnier, C., Gabbiani, G., and Forte, J. G. (1995) Mol. Biol. Cell. 6, 541-557). Here we used ultrastructural immunocytochemistry to verify that beta-actin is located within canalicular microvilli and the apical cortex of parietal cells, similar to the localization reported for ezrin. Furthermore, we tested whether ezrin binds preferentially to cytoplasmic beta-actin compared with the skeletal muscle alpha-actin isoform. Purified cytoplasmic beta-actin (from erythrocytes) and skeletal alpha-actin were assembled with gastric ezrin. Co-sedimentation experiments showed that gastric ezrin selectively co-pelleted with the beta-actin isoform and only very poorly with alpha-actin. Binding of erythrocytic beta-actin to ezrin is saturable with a molar ratio of similar to 1:10 (ezrin: actin) and a dissociation constant similar to 4.6 x 10(-8) M. In addition, ezrin promoted pyrene-labeled actin assembly, with predominant effects on filament elongation and a distinct preference for beta-actin compared with alpha-actin. Given these isoform-selective associations, we speculate that actin isoforms might segregate into different functional domains and exert specificity by interacting with isoform-orientated binding proteins.	UNIV CALIF BERKELEY, DEPT MOLEC & CELL BIOL, BERKELEY, CA 94720 USA	University of California System; University of California Berkeley			Yao, Xuebiao/P-5771-2014					ATTRI AK, 1991, J BIOL CHEM, V266, P6815; BERRYMAN M, 1993, J CELL SCI, V105, P1025; BRETSCHER A, 1983, J CELL BIOL, V97, P425, DOI 10.1083/jcb.97.2.425; BRETSCHER A, 1989, J CELL BIOL, V108, P921, DOI 10.1083/jcb.108.3.921; BRETSCHER A, 1986, METHOD ENZYMOL, V134, P24; COOPER JA, 1983, J MUSCLE RES CELL M, V4, P253, DOI 10.1007/BF00712034; EDMONDS BT, 1995, J BIOL CHEM, V270, P15222, DOI 10.1074/jbc.270.25.15222; FUNAYAMA N, 1991, J CELL BIOL, V115, P1039, DOI 10.1083/jcb.115.4.1039; GARY R, 1993, P NATL ACAD SCI USA, V90, P10846, DOI 10.1073/pnas.90.22.10846; GARY R, 1995, MOL BIOL CELL, V6, P1061, DOI 10.1091/mbc.6.8.1061; HANZEL D, 1991, EMBO J, V10, P2363, DOI 10.1002/j.1460-2075.1991.tb07775.x; HANZEL DK, 1989, AM J PHYSIOL, V256, pG1082, DOI 10.1152/ajpgi.1989.256.6.G1082; HENRY MD, 1995, J CELL BIOL, V129, P1007, DOI 10.1083/jcb.129.4.1007; HILL MA, 1993, J CELL BIOL, V122, P825, DOI 10.1083/jcb.122.4.825; HOOCK TC, 1991, J CELL BIOL, V112, P653, DOI 10.1083/jcb.112.4.653; HUG C, 1992, J CELL BIOL, V116, P923, DOI 10.1083/jcb.116.4.923; KOUYAMA T, 1981, EUR J BIOCHEM, V114, P33; KOUYAMA T, 1980, EUR J BIOCHEM, V105, P279, DOI 10.1111/j.1432-1033.1980.tb04499.x; LARSSON H, 1988, BIOCHIM BIOPHYS ACTA, V953, P95, DOI 10.1016/0167-4838(88)90013-1; MARTIN M, 1995, J CELL BIOL, V128, P1081, DOI 10.1083/jcb.128.6.1081; MOON AL, 1993, J CELL BIOL, V120, P421, DOI 10.1083/jcb.120.2.421; NORTH AJ, 1994, J CELL SCI, V107, P445; OGIHARA S, 1995, MOL BIOL CELL, V6, P2155; PARDEE JD, 1982, METHOD CELL BIOL, V24, P271; PESTONJAMASP K, 1995, MOL BIOL CELL, V6, P247, DOI 10.1091/mbc.6.3.247; PUSZKIN S, 1978, BIOCHIM BIOPHYS ACTA, V513, P205, DOI 10.1016/0005-2736(78)90174-8; ROZYCKI M, 1991, METHOD ENZYMOL, V196, P100; ROZYCKI MD, 1994, CURR OPIN CELL BIOL, V6, P87, DOI 10.1016/0955-0674(94)90121-X; SCHUTT CE, 1993, NATURE, V365, P810, DOI 10.1038/365810a0; SHUSTER CB, 1995, J CELL BIOL, V128, P837, DOI 10.1083/jcb.128.5.837; TURUNEN O, 1994, J CELL BIOL, V126, P1445, DOI 10.1083/jcb.126.6.1445; URUSHIDANI T, 1989, AM J PHYSIOL, V256, pG1070, DOI 10.1152/ajpgi.1989.256.6.G1070; VANDEKERCKHOVE J, 1978, J MOL BIOL, V126, P783, DOI 10.1016/0022-2836(78)90020-7; YAO XB, 1993, AM J PHYSIOL, V265, pC36, DOI 10.1152/ajpcell.1993.265.1.C36; YAO XB, 1995, MOL BIOL CELL, V6, P541, DOI 10.1091/mbc.6.5.541; YONEMURA S, 1993, J CELL BIOL, V120, P437, DOI 10.1083/jcb.120.2.437	36	105	105	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 22	1996	271	12					7224	7229		10.1074/jbc.271.12.7224	http://dx.doi.org/10.1074/jbc.271.12.7224			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UB157	8636161	hybrid			2022-12-25	WOS:A1996UB15700096
J	Guerrero, C; Rojas, JM; Chedid, M; Esteban, LM; Zimonjic, DB; Popescu, NC; deMora, JF; Santos, E				Guerrero, C; Rojas, JM; Chedid, M; Esteban, LM; Zimonjic, DB; Popescu, NC; deMora, JF; Santos, E			Expression of alternative forms of Ras exchange factors GRF and SOS1 in different human tissues and cell lines	ONCOGENE			English	Article						Ras; hGRF; hSOS1; expression; alternative splicing	NUCLEOTIDE-RELEASING FACTOR; RECEPTOR TYROSINE KINASES; SACCHAROMYCES-CEREVISIAE; DROSOPHILA SON; SEVENLESS GENE; IDENTIFICATION; HOMOLOGS; PROTEINS; GRB2; CDNAS	DNA probes and antibodies specific for different coding regions of human SOS1 and GRF genes were used to screen expression of these genes in a variety of adult and fetal human tissues and cell lines. Despite previous reports of the exclusive expression of hGRF RNA in brain, we also observed expression of this gene in various other tissues including lung and pancreas, as web as several tumor cell lines. At least three different hGRF mRNA transcripts were observed depending on the probe used, with the larger transcripts being detected by probes corresponding to the 5' end of the gene while smaller transcripts were detected by probes corresponding to the 3' end. Expression of hSOS1-related transcripts was more ubiquitous and homogeneous than with hGRF, with similar levels of specific transcripts being detected in most tissues and cell lines tested. Three to five different transcripts were detected in human tissues when using probes for the 5' end and middle regions of this gene, whereas only two were detected with probes corresponding to the 3' end. Screening of multiple human tumor cell lines showed ubiquitous expression of three specific transcripts, although the level and ratio of each of these transcripts varied widely among individual cell lines. Consistent with the variety of transcripts detected, several protein forms were also identified in Western immunoblots with antisera raised against specific domains of hSOS1 and human Ras-GRF gene products. Fluorescence in situ chromosomal hybridization suggested that, in both cases, the multiple forms arise from single chromosomal loci. The heterogeneity of hGRF and hSOS1 gene products detected (which appear to retain in most cases a functional catalytic domain), suggests that differentially expressed, alternatively spliced hSOS1 and hGRF forms may contribute to fine regulation of Ras activation in different tissues or at different stages of development.	NCI, DBS, CELLULAR & MOLEC BIOL LAB, NATL INST HLTH, BETHESDA, MD 20892 USA; NCI, DBS, BIOL LAB, NATL INST HLTH, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			Rojas, José M/D-3718-2018; Rojas, José M./AAA-3354-2021; de Mora, Jaime Font/H-6304-2015; Zimonjic, Drazen/AAX-7513-2020; Guerrero, Carmen/F-1776-2010; de Mora, Jaime Font/AAK-7591-2021	Rojas, José M/0000-0002-5383-3482; Rojas, José M./0000-0002-7547-2825; de Mora, Jaime Font/0000-0002-6816-2095; Guerrero, Carmen/0000-0002-8747-6831; de Mora, Jaime Font/0000-0002-6816-2095				BEALL JA, 1986, J IMMUNOL METHODS, V86, P217, DOI 10.1016/0022-1759(86)90456-4; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BOWTELL D, 1992, P NATL ACAD SCI USA, V89, P6511, DOI 10.1073/pnas.89.14.6511; CEN H, 1992, EMBO J, V11, P4007, DOI 10.1002/j.1460-2075.1992.tb05494.x; CEN H, 1993, MOL CELL BIOL, V13, P7718, DOI 10.1128/MCB.13.12.7718; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; CHARDIN P, 1994, CYTOGENET CELL GENET, V66, P68, DOI 10.1159/000133667; CHEN LP, 1993, DEV GENET, V14, P339, DOI 10.1002/dvg.1020140503; DALY RJ, 1994, ONCOGENE, V9, P2723; DOWNWARD J, 1994, FEBS LETT, V338, P113, DOI 10.1016/0014-5793(94)80346-3; FATH I, 1993, NUCLEIC ACIDS RES, V21, P4398, DOI 10.1093/nar/21.18.4398; FEIG LA, 1994, CURR OPIN CELL BIOL, V6, P204, DOI 10.1016/0955-0674(94)90137-6; FENG SB, 1994, SCIENCE, V266, P1241, DOI 10.1126/science.7526465; FERRARI C, 1994, EXP CELL RES, V210, P353, DOI 10.1006/excr.1994.1048; KARLOVICH CA, 1995, SCIENCE, V268, P576, DOI 10.1126/science.7725106; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LIM WA, 1994, NATURE, V372, P375, DOI 10.1038/372375a0; LOWY DR, 1993, ANNU REV BIOCHEM, V62, P851, DOI 10.1146/annurev.bi.62.070193.004223; MARTEGANI E, 1992, EMBO J, V11, P2151, DOI 10.1002/j.1460-2075.1992.tb05274.x; MUSACCHIO A, 1993, TRENDS BIOCHEM SCI, V18, P343, DOI 10.1016/0968-0004(93)90071-T; MUSACCHIO A, 1994, TRENDS BIOCHEM SCI, V19, P349; POPESCU N, 1994, GENOMICS, V20, P333, DOI 10.1006/geno.1994.1182; SCHLESSINGER J, 1993, TRENDS BIOCHEM SCI, V18, P273, DOI 10.1016/0968-0004(93)90031-H; SCHWEIGHOFFER F, 1993, ONCOGENE, V8, P1477; SHOU C, 1992, NATURE, V358, P351, DOI 10.1038/358351a0; SHOU CC, 1995, ONCOGENE, V10, P1887; SKOLNIK EY, 1993, SCIENCE, V260, P1953, DOI 10.1126/science.8316835; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; TANAKA S, 1994, P NATL ACAD SCI USA, V91, P3443, DOI 10.1073/pnas.91.8.3443; WEBB GC, 1993, GENOMICS, V18, P14, DOI 10.1006/geno.1993.1421; WEI W, 1992, P NATL ACAD SCI USA, V89, P7100, DOI 10.1073/pnas.89.15.7100; WEI W, 1994, GENE, V151, P279, DOI 10.1016/0378-1119(94)90671-8; ZIMONJIC DB, 1994, CYTOGENET CELL GENET, V65, P184, DOI 10.1159/000133628; ZIMONJIC DB, 1995, CANCER GENET CYTOGEN, V80, P100, DOI 10.1016/0165-4608(94)00161-4	34	48	49	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 7	1996	12	5					1097	1107						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UA884	8649802				2022-12-25	WOS:A1996UA88400019
J	Evans, MK; Chin, KV; Gottesman, MM; Bohr, VA				Evans, MK; Chin, KV; Gottesman, MM; Bohr, VA			Gene-specific DNA repair and steady state transcription of the MDR1 gene in human tumor cell lines	ONCOGENE			English	Article						DNA repair; drug resistance; tumor cells	COMPLEMENTATION GROUP-C; STRAND-SPECIFIC REPAIR; KB CARCINOMA-CELLS; PYRIMIDINE DIMERS; DEFECTIVE REPAIR; COUPLING FACTOR; ACTIVE GENE; RESISTANT; AMPLIFICATION; FIBROBLASTS	We have explored the relationship between DNA repair and transcription in vivo, A gene-specific repair assay has been employed to study removal of ultraviolet light-induced cyclobutane pyrimidine diners in the MDR1 gene at different levels of MDR1 mRNA expression, The parental human adenocarcinoma cell line, KB-3-1, has very low levels of MDR1 mRNA expression, but its multidrug resistant derivatives KB-8-5 and KB-C1 have 42-fold and 3800-fold increases in MDR1 mRNA expression, respectively, In the KB-3-1 cell line that has a low level of MDR1 mRNA expression, we find a low level of MDR1 gene-specific repair and inefficient repair of the transcribed strand of the gene, In the KB-8-5 cell line that has a modest increase in MDR1 mRNA expression, we find only a minor increase in dimer repair in the MDR1 gene, Here, the repair in the transcribed strand is not significantly higher than that in the KB-3-1 cell line, However, in the KB-C1 derivative, where there is a 3800-fold increase in the level of MDR1 mRNA expression, we find a substantial increase in the level of dimer repair in the MDR1 gene, In addition, the MDR1 transcribed strand repair is markedly more efficient than the repair in the nontranscribed strand, Our data suggest that the rate of transcription in the MDR1 gene must be substantially increased before there is any measurable effect on DNA repair, Repair in the housekeeping gene, dihydrofolate reductase (DHFR), was similar in all three tumor cell lines, Repair in its transcribed strand was markedly lower than previously reported in normal human fibroblasts, We suspect that these human HeLa-derived tumor cell lines have deficient gene-specific DNA repair, This may be an important aspect of their malignant phenotype.	NIA,MOLEC GENET LAB,NIH,BALTIMORE,MD 21224; UNIV MED & DENT NEW JERSEY,ROBERT WOOD JOHNSON MED SCH,CANC INST NEW JERSEY,PISCATAWAY,NJ 08854; NCI,CELL BIOL LAB,NIH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers Cancer Institute of New Jersey; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			Evans, Michele Kim/AAE-4776-2019; Bohr, Vilhelm/AAP-5931-2020; Chin, Khew-Voon/F-2670-2013	Evans, Michele/0000-0002-8546-2831				AKIYAMA SI, 1985, SOMAT CELL MOLEC GEN, V11, P117, DOI 10.1007/BF01534700; ARRAND JE, 1982, NUCLEIC ACIDS RES, V10, P1547, DOI 10.1093/nar/10.5.1547; BEECHAM EJ, 1994, MOL CELL BIOL, V14, P1204, DOI 10.1128/MCB.14.2.1204; BEECHAM EJ, 1991, MOL CELL BIOL, V11, P3095, DOI 10.1128/MCB.11.6.3095; BOHR VA, 1985, CELL, V40, P359, DOI 10.1016/0092-8674(85)90150-3; BOHR VA, 1988, DNA REPAIR LABORATOR, P347; DAY RS, 1980, NATURE, V288, P724, DOI 10.1038/288724a0; DRAPKIN R, 1994, NATURE, V368, P769, DOI 10.1038/368769a0; EVANS MK, 1993, CANCER RES, V53, P5377; EVANS MK, 1993, J BIOL CHEM, V268, P4839; EVANS MK, 1994, MUTAT RES, V314, P221, DOI 10.1016/0921-8777(94)90067-1; FOJO AT, 1985, P NATL ACAD SCI USA, V82, P7661, DOI 10.1073/pnas.82.22.7661; GOTTESMAN MM, 1993, ANNU REV BIOCHEM, V62, P385, DOI 10.1146/annurev.bi.62.070193.002125; JI J, 1995, P AM ASOCATION CANCE, V36, P550; KANTOR GJ, 1990, MUTAT RES, V235, P171, DOI 10.1016/0921-8777(90)90071-C; LARMINAT F, 1995, ONCOGENE, V10, P1639; MADHANI HD, 1986, CELL, V45, P417, DOI 10.1016/0092-8674(86)90327-2; MAYNE LV, 1984, MUTAT RES, V131, P187, DOI 10.1016/0167-8817(84)90023-3; MELLON I, 1986, P NATL ACAD SCI USA, V83, P8878, DOI 10.1073/pnas.83.23.8878; MELON I, 1987, CELL, V51, P241; MELON I, 1989, NATURE, V342, P95; MULLENDERS LHF, 1988, NUCLEIC ACIDS RES, V16, P10602; OKUMOTO DS, 1987, NUCLEIC ACIDS RES, V15, P10021, DOI 10.1093/nar/15.23.10021; PARSHAD R, 1984, CANCER RES, V44, P5577; PARSONS R, 1993, CELL, V75, P1227, DOI 10.1016/0092-8674(93)90331-J; PASTAN I, 1987, NEW ENGL J MED, V316, P1388; RAINBOW AJ, 1989, CARCINOGENESIS, V10, P1073, DOI 10.1093/carcin/10.6.1073; SANFORD KK, 1992, CARCINOGENESIS, V13, P1137, DOI 10.1093/carcin/13.7.1137; SANFORD KK, 1985, ENHANCED G2 CHROMOSO, P811; SCHAEFFER L, 1993, SCIENCE, V260, P58, DOI 10.1126/science.8465201; SCHOENLEIN PV, 1992, MOL BIOL CELL, V3, P507, DOI 10.1091/mbc.3.5.507; SELBY CP, 1991, P NATL ACAD SCI USA, V88, P8232, DOI 10.1073/pnas.88.18.8232; SELBY CP, 1993, SCIENCE, V260, P53, DOI 10.1126/science.8465200; SELBY CP, 1991, P NATL ACAD SCI USA, V88, P11574, DOI 10.1073/pnas.88.24.11574; SHEN D, 1986, J BIOL CHEM, V216, P7762; SHEN DW, 1986, SCIENCE, V232, P643, DOI 10.1126/science.3457471; Smerdon MJ, 1991, CURR OPIN CELL BIOL, V3, P422, DOI 10.1016/0955-0674(91)90069-B; THIEBAUT F, 1993, FEBS LETT, V319, P133, DOI 10.1016/0014-5793(93)80052-V; VANVUUREN AJ, 1994, EMBO J, V13, P1645, DOI 10.1002/j.1460-2075.1994.tb06428.x; VENEMA J, 1990, NUCLEIC ACIDS RES, V18, P443, DOI 10.1093/nar/18.3.443; VENEMA J, 1991, MOL CELL BIOL, V11, P4128, DOI 10.1128/MCB.11.8.4128; YAROSH DB, 1985, MUTAT RES, V145, P1, DOI 10.1016/0167-8817(85)90034-3	42	10	10	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB 1	1996	12	3					651	658						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TV597	8637722				2022-12-25	WOS:A1996TV59700022
J	Hirai, S; Izawa, M; Osada, S; Spyrou, G; Ohno, S				Hirai, S; Izawa, M; Osada, S; Spyrou, G; Ohno, S			Activation of the JNK pathway by distantly related protein kinases, MEKK and MUK	ONCOGENE			English	Article						ERK; Jun; MAP kinase; Raf; SAPK	C-JUN; MAP KINASE; TRANSCRIPTIONAL ACTIVATION; DOMAIN; ONCOGENE; PHOSPHORYLATION; IDENTIFICATION; AP-1; RAF; FOS	JNK/SAPKs are identified as new members of the MAPK family; they phosphorylate c-Jun protein in response to several cellular stimuli including ultraviolet irradiation, TNF and osmotic shock. We have identified a protein kinase, MUK, as an activator of the JNK-pathway, whose kinase domain shows significant homology to MAPKKK-related proteins such as c-Raf and MEKK. The over-expression of MUK or MEK kinase (MEKK) in NIH3T3 or COS1 cells results in the activation of JNK1 and the accumulation of a hyper-phosphorylated form of c-Jun. While MEKK also activates the ERK pathway, MUK is a rather selective activator of the JNK pathway, On the other hand, c-Raf activates the JNK pathway only slightly despite its remarkable ability to activate the ERK pathway. Even though we originally identified MUK as a MAPKKK-related protein kinase, a greater similarity to mixed lineage kinase (MLK) is found not only in the catalytic domain but also in the 'leucine-zipper'-like motifs located at the C-terminal side of the catalytic domain. The structural divergence between MUK and MEKK reveals the multiplicity of signaling pathways that activate JNK/SAPKs.	KAROLINSKA INST, MED NOBEL INST BIOCHEM, DEPT MED BIOCHEM & BIOPHYS, S-17177 STOCKHOLM, SWEDEN	Karolinska Institutet	Hirai, S (corresponding author), YOKOHAMA CITY UNIV, SCH MED, DEPT MOLEC BIOL, KANAZAWA KU, 3-9 FUKU URA, YOKOHAMA, KANAGAWA 236, JAPAN.		Ohno, Shigeo/B-1768-2010	Ohno, Shigeo/0000-0002-1294-5269; Osada, Shin-Ichi/0000-0001-5387-085X				ADLER V, 1994, J BIOL CHEM, V269, P11186; ADLER V, 1992, P NATL ACAD SCI USA, V89, P5341, DOI 10.1073/pnas.89.12.5341; ANGEL P, 1988, CELL, V55, P875, DOI 10.1016/0092-8674(88)90143-2; BINETRUY B, 1991, NATURE, V351, P122, DOI 10.1038/351122a0; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; BONNER TI, 1986, NUCLEIC ACIDS RES, V14, P1009, DOI 10.1093/nar/14.2.1009; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; DAUM G, 1994, TRENDS BIOCHEM SCI, V19, P474, DOI 10.1016/0968-0004(94)90133-3; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; DIAMOND MI, 1990, SCIENCE, V249, P1266, DOI 10.1126/science.2119054; DORROW DS, 1993, EUR J BIOCHEM, V213, P701; EROE K, 1994, ONCOGENE, V9, P935; GALCHEVAGARGOVA Z, 1994, SCIENCE, V265, P806, DOI 10.1126/science.8047888; GALLO KA, 1994, J BIOL CHEM, V269, P15092; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; HIRAI S, 1994, EMBO J, V13, P2331, DOI 10.1002/j.1460-2075.1994.tb06517.x; HIRAI SI, 1990, ONCOGENE, V5, P39; HOLZMAN LB, 1994, J BIOL CHEM, V269, P30808; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; ING YL, 1994, ONCOGENE, V9, P1745; JANKNECHT R, 1993, EMBO J, V12, P5097, DOI 10.1002/j.1460-2075.1993.tb06204.x; KATOH M, 1995, ONCOGENE, V10, P1447; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LAMPH WW, 1988, NATURE, V334, P629, DOI 10.1038/334629a0; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LANGECARTER CA, 1994, SCIENCE, V265, P1458, DOI 10.1126/science.8073291; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; LIN AN, 1995, SCIENCE, V268, P286, DOI 10.1126/science.7716521; LIVINGSTONE C, 1995, EMBO J, V14, P1785, DOI 10.1002/j.1460-2075.1995.tb07167.x; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MATSUDA S, 1995, J BIOL CHEM, V270, P12781, DOI 10.1074/jbc.270.21.12781; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; MORIGUCHI T, 1995, J BIOL CHEM, V270, P12969, DOI 10.1074/jbc.270.22.12969; POSADA J, 1993, MOL CELL BIOL, V13, P2546, DOI 10.1128/MCB.13.4.2546; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; REDDY UR, 1994, BIOCHEM BIOPH RES CO, V202, P613, DOI 10.1006/bbrc.1994.1972; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; RYSECK RP, 1988, NATURE, V334, P535, DOI 10.1038/334535a0; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; STEIN B, 1993, EMBO J, V12, P3879, DOI 10.1002/j.1460-2075.1993.tb06066.x; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; VANDAM H, 1995, EMBO J, V14, P1798, DOI 10.1002/j.1460-2075.1995.tb07168.x; WARNE PH, 1993, NATURE, V364, P352, DOI 10.1038/364352a0; YAN MH, 1994, NATURE, V372, P798; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0	51	126	131	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 1	1996	12	3					641	650						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TV597	8637721				2022-12-25	WOS:A1996TV59700021
J	Guimaraes, MJ; Bazan, JF; Castagnola, J; Diaz, S; Copeland, NG; Gilbert, DJ; Jenkins, NA; Varki, A; Zlotnik, A				Guimaraes, MJ; Bazan, JF; Castagnola, J; Diaz, S; Copeland, NG; Gilbert, DJ; Jenkins, NA; Varki, A; Zlotnik, A			Molecular cloning and characterization of lysosomal sialic acid O-acetylesterase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DE-ORTHO-ACETYLATION; INFLUENZA-C VIRUS; COLONY-STIMULATING FACTOR; RAT-LIVER; CELL; GROWTH; IDENTIFICATION; PROLIFERATION; PURIFICATION; LYMPHOCYTES	O-Acetylation and de-O-acetylation of sialic acids have been implicated in the regulation of a variety of biological phenomena, including endogenous lectin recognition, tumor antigenicity, virus binding, and complement activation. Applying a strategy designed to identify genes preferentially expressed in active sites of embryonic hematopoiesis, we isolated a novel cDNA from the pluripotent hematopoietic cell line FDCP-mixA4 whose open reading frame contained sequences homologous to peptide fragments of a lysosomal sialic acid O-acetylesterase (Use) previously purified from rat liver, but with no evident similarity to endoplasmic reticulum-derived acetylesterases. The expressed Lse protein exhibits sialic-acid O-acetylesterase activity that is not attributable to a typical serine esterase active site, Lse expression is spatially and temporally restricted during embryogenesis, and its mRNA levels correlate with differences in O-acetylesterase activity described in adult tissues and blood cell. types, Using interspecific backcross analysis, we further mapped the Ise gene to the central region of mouse chromosome 9, This constitutes the first report on the molecular cloning of a sialic acid specific O-acetylesterase in vertebrates and suggests novel roles for the 9-O-acetyl modification of sialic acids during the development and differentiation of mammalian organisms.	UNIV CALIF SAN DIEGO, CTR CANC, GLYCOBIOL PROGRAM, LA JOLLA, CA 92093 USA; NCI, FREDERICK CANC RES & DEV CTR, ABL BASIC RES PROGRAM, FREDERICK, MD 21702 USA	University of California System; University of California San Diego; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick	Guimaraes, MJ (corresponding author), DNAX RES INST MOLEC & CELLULAR BIOL INC, 901 CALIF AVE, PALO ALTO, CA 94304 USA.		Zlotnik, Albert/C-3791-2011; Bazan, J. Fernando/B-4562-2010	Guimaraes, M. Jorge/0000-0002-1588-7391	NCI NIH HHS [N01-CO-4600] Funding Source: Medline; NIGMS NIH HHS [R01GM32373] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032373] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTSCHUL SF, 1994, NAT GENET, V6, P119, DOI 10.1038/ng0294-119; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; ARNOLD LW, 1983, J IMMUNOL, V131, P2064; BAUER SR, 1986, J IMMUNOL, V136, P4695; Bazan JF, 1996, PROTEINS, V24, P1; BENSON DA, 1994, NUCLEIC ACIDS RES, V22, P3441, DOI 10.1093/nar/22.17.3441; BOGUSKI MS, 1995, TRENDS BIOCHEM SCI, V20, P295, DOI 10.1016/S0968-0004(00)89051-9; Bork P, 1996, METHOD ENZYMOL, V266, P162; BORK P, 1994, CURR OPIN STRUC BIOL, V4, P393, DOI 10.1016/S0959-440X(94)90109-0; BOURETTE RP, 1993, BLOOD, V81, P2511; BRANDEN CI, 1980, Q REV BIOPHYS, V13, P317, DOI 10.1017/S0033583500001712; BRENNER S, 1988, NATURE, V334, P528, DOI 10.1038/334528a0; BUTOR C, 1993, J BIOL CHEM, V268, P10207; BUTOR C, 1995, J CELL SCI, V108, P2213; CHERESH DA, 1984, SCIENCE, V225, P844, DOI 10.1126/science.6206564; COPELAND NG, 1991, TRENDS GENET, V7, P113, DOI 10.1016/0168-9525(91)90455-Y; DEIBEL MR, 1988, LYMPHOKINE RES, V7, P469; DIAZ S, 1989, J BIOL CHEM, V264, P19416; EVERSON MP, 1989, BLOOD, V74, P1472; FORD AM, 1992, BLOOD, V79, P1962, DOI 10.1182/blood.V79.8.1962.bloodjournal7981962; FUJINO E, 1995, J BACTERIOL, V177, P5169, DOI 10.1128/jb.177.17.5169-5175.1995; Green EL, 1981, GENETICS PROBABILITY, P77; GUIMARAES MJ, 1995, DEVELOPMENT, V121, P3335; GUIMARAES MJ, 1995, NUCLEIC ACIDS RES, V23, P1832, DOI 10.1093/nar/23.10.1832; HANSEN JE, 1995, BIOCHEM J, V308, P801, DOI 10.1042/bj3080801; HAYES BK, 1989, J BIOL CHEM, V264, P19443; HERRLER G, 1985, EMBO J, V4, P1503, DOI 10.1002/j.1460-2075.1985.tb03809.x; HERRLER G, 1991, ADV VIRUS RES, V40, P213; HIGA HH, 1989, J BIOL CHEM, V264, P19435; HOPP TP, 1988, BIO-TECHNOL, V6, P1204, DOI 10.1038/nbt1088-1204; HUNT P, 1987, CELL, V48, P997, DOI 10.1016/0092-8674(87)90708-2; KAMERLING JP, 1982, BIOCHIM BIOPHYS ACTA, V714, P351, DOI 10.1016/0304-4165(82)90344-0; KIM KJ, 1986, IMMUNOLOGY, V59, P15; KNIEP B, 1995, J BIOL CHEM, V270, P30173; KORNFELD S, 1992, ANNU REV BIOCHEM, V61, P307, DOI 10.1146/annurev.bi.61.070192.001515; LAWSON DM, 1994, BIOCHEMISTRY-US, V33, P9382, DOI 10.1021/bi00198a003; LEDERER JA, 1994, J IMMUNOL, V152, P77; MACNEIL I, 1993, J IMMUNOL, V151, P6913; MARKS PA, 1978, ANNU REV BIOCHEM, V47, P419, DOI 10.1146/annurev.bi.47.070178.002223; OLLIS DL, 1992, PROTEIN ENG, V5, P197, DOI 10.1093/protein/5.3.197; RENNICK D, 1989, J IMMUNOL, V142, P161; ROST B, 1996, IN PRESS ANN REV BIO, V25; ROTH J, 1993, HISTOCHEM J, V25, P687; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SCHAUER R, 1991, Glycobiology, V1, P449, DOI 10.1093/glycob/1.5.449; SCHAUER R, 1989, J BIOCHEM-TOKYO, V106, P143, DOI 10.1093/oxfordjournals.jbchem.a122804; SCHAUER R, 1988, BIOCHIMIE, V70, P1511, DOI 10.1016/0300-9084(88)90288-X; Schauer R., 1982, CELL BIOL MONOGRAPHS, V10; SJOBERG ER, 1994, J CELL BIOL, V126, P549, DOI 10.1083/jcb.126.2.549; UNDEM BJ, 1990, J BIOL CHEM, V265, P6750; VALLETTE F, 1989, NUCLEIC ACIDS RES, V17, P723, DOI 10.1093/nar/17.2.723; VARKI A, 1980, J EXP MED, V152, P532, DOI 10.1084/jem.152.3.532; VARKI A, 1991, CELL, V65, P65, DOI 10.1016/0092-8674(91)90408-Q; VARKI A, 1992, GLYCOBIOLOGY, V2, P25, DOI 10.1093/glycob/2.1.25; VARKI A, 1993, GLYCOBIOLOGY, V3, P97, DOI 10.1093/glycob/3.2.97; VLASAK R, 1989, J VIROL, V63, P2056, DOI 10.1128/JVI.63.5.2056-2062.1989; VLASAK R, 1988, P NATL ACAD SCI USA, V85, P4526, DOI 10.1073/pnas.85.12.4526; WATSON J, 1979, J EXP MED, V150, P1510, DOI 10.1084/jem.150.6.1510; WEST AH, 1995, J MOL BIOL, V250, P276, DOI 10.1006/jmbi.1995.0376; WILKIE TM, 1993, GENOMICS, V18, P175, DOI 10.1006/geno.1993.1452; WORLEY KC, 1995, GENOME RES, V5, P173, DOI 10.1101/gr.5.2.173; ZIMMER G, 1994, GLYCOBIOLOGY, V4, P343, DOI 10.1093/glycob/4.3.343; ZVELEBIL MJJM, 1988, PROTEIN ENG, V2, P127, DOI 10.1093/protein/2.2.127	63	23	25	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 7	1996	271	23					13697	13705		10.1074/jbc.271.23.13697	http://dx.doi.org/10.1074/jbc.271.23.13697			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UP385	8662838				2022-12-25	WOS:A1996UP38500061
J	Kilbey, A; Black, EJ; Unlu, M; Gillespie, DAF				Kilbey, A; Black, EJ; Unlu, M; Gillespie, DAF			The v-Jun oncoprotein replaces p39 c-Jun as the predominant AP-1 constituent in ASV17-transformed fibroblasts: Implications for SAPK/JNK-mediated signal transduction	ONCOGENE			English	Article						v-Jun; AP-1; transformation; SAPK/JNK	CHICKEN-EMBRYO FIBROBLASTS; DNA-BINDING ACTIVITY; TRANSCRIPTIONAL ACTIVATION; MOUSE FIBROBLASTS; G0-TO-G1 TRANSITION; LEUCINE ZIPPER; FOS PROTEINS; TRANSFORMATION; DOMAIN; INVITRO	We have investigated the expression of Jun family proteins and composition of AP-I in chicken embryo fibroblasts before and after transformation by the v-Jun oncoprotein of ASV17, We show that p39 c-Jun is the predominant Jun family protein expressed in normal fibroblasts, and that heterodimers of c-Jun and Fos-related partners (Fra's) account for the majority of the AP-1 DNA binding activity, Unexpectedly, because ASV17-transformed fibroblasts do not express p39 c-Jun, v-Jun replaces c-Jun as the predominant AP-1 constituent in association with similar or identical Fra's, This substitution has little effect on the overall level of TRE-specific DNA binding activity, however it results in a profound reduction in TRE-dependent component of AP-1; whilst agonists of SAPK/JNK kinases trigger transient N-terminal phosphorylation of c-Jun in normal fibroblasts, no corresponding modification of v-Jun occurs in ASV17-transformed cells. Because SAPK/JNK-mediated phosphorylation is thought to regulate c-Jun transcriptional activity and thereby cellular gene expression in response to extracellular signals, we propose that subversion of this signal transduction process by v-Jun is likely to contribute to oncogenesis by ASV17.	BEATSON INST CANC RES,CANC RES CAMPAIGN BEATSON LABS,GLASGOW G61 1BD,LANARK,SCOTLAND	Beatson Institute			Gillespie, David/R-4771-2019	Gillespie, David/0000-0002-6338-0544				Abate C, 1990, Semin Cancer Biol, V1, P19; ABATE C, 1990, SCIENCE, V249, P1157, DOI 10.1126/science.2118682; ANGEL P, 1987, MOL CELL BIOL, V7, P2256, DOI 10.1128/MCB.7.6.2256; BAICHWAL VR, 1990, CELL, V63, P815, DOI 10.1016/0092-8674(90)90147-7; BINETRUY B, 1991, NATURE, V351, P122, DOI 10.1038/351122a0; BLACK EJ, 1994, ONCOGENE, V9, P2363; BLACK EJ, 1991, ONCOGENE, V6, P1949; BOHMANN D, 1989, CELL, V59, P709, DOI 10.1016/0092-8674(89)90017-2; BOHMANN D, 1994, CELL, V78, P973, DOI 10.1016/0092-8674(94)90273-9; BOS TJ, 1990, GENE DEV, V4, P1677, DOI 10.1101/gad.4.10.1677; CANO E, 1995, TRENDS BIOCHEM SCI, V20, P117, DOI 10.1016/S0968-0004(00)88978-1; CATLING AD, 1993, ONCOGENE, V8, P1875; CROUCH DH, 1990, ONCOGENE, V5, P683; DAI TN, 1995, ONCOGENE, V10, P849; DEAN DC, 1989, MOL CELL BIOL, V9, P1489; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; FRAME MC, 1991, ONCOGENE, V6, P205; GOLDSTONE SD, 1994, ONCOGENE, V9, P2305; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HAAS S, 1995, CARCINOGENESIS, V16, P985, DOI 10.1093/carcin/16.5.985; HADMAN M, 1993, ONCOGENE, V8, P1895; HAVARSTEIN LS, 1992, P NATL ACAD SCI USA, V89, P618, DOI 10.1073/pnas.89.2.618; HAWKER KL, 1993, J VIROL, V67, P5487, DOI 10.1128/JVI.67.9.5487-5495.1993; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; HILBERG F, 1993, NATURE, V365, P179, DOI 10.1038/365179a0; JOHNSON RS, 1993, GENE DEV, V7, P1309, DOI 10.1101/gad.7.7b.1309; KARIN MJ, BIOL CHEM, V270, P16483; KATAOKA K, 1994, MOL CELL BIOL, V14, P700, DOI 10.1128/MCB.14.1.700; KOVARY K, 1992, MOL CELL BIOL, V12, P5015, DOI 10.1128/MCB.12.11.5015; KOVARY K, 1991, MOL CELL BIOL, V11, P4466, DOI 10.1128/MCB.11.9.4466; KOVARY K, 1991, MOL CELL BIOL, V11, P2451, DOI 10.1128/MCB.11.5.2451; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LANDSCHULZ WH, 1988, GENE DEV, V2, P786, DOI 10.1101/gad.2.7.786; LAROCCA SA, 1994, ONCOGENE, V9, P3499; LIN AN, 1992, CELL, V70, P777, DOI 10.1016/0092-8674(92)90311-Y; MAKI Y, 1987, P NATL ACAD SCI USA, V84, P2848, DOI 10.1073/pnas.84.9.2848; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MASOOD K, 1993, J NEUROCHEM, V61, P160, DOI 10.1111/j.1471-4159.1993.tb03551.x; MATRISIAN LM, 1986, MOL CELL BIOL, V6, P1679, DOI 10.1128/MCB.6.5.1679; MINDEN A, 1994, MOL CELL BIOL, V14, P6683, DOI 10.1128/MCB.14.10.6683; MORGAN IM, 1993, ONCOGENE, V8, P1135; MORGAN IM, 1992, ONCOGENE, V7, P1119; NISHIMURA T, 1988, ONCOGENE, V3, P659; PFARR CM, 1994, CELL, V76, P747, DOI 10.1016/0092-8674(94)90513-4; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; RYSECK RP, 1988, NATURE, V334, P535, DOI 10.1038/334535a0; SCHUTTE J, 1989, P NATL ACAD SCI USA, V86, P2257, DOI 10.1073/pnas.86.7.2257; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; SMEAL T, 1994, EMBO J, V13, P6006, DOI 10.1002/j.1460-2075.1994.tb06946.x; SUZUKI T, 1994, J VIROL, V68, P3527, DOI 10.1128/JVI.68.6.3527-3535.1994; SUZUKI T, 1991, JPN J CANCER RES, V82, P58, DOI 10.1111/j.1349-7006.1991.tb01746.x; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9; VANDAM H, 1995, EMBO J, V14, P1798, DOI 10.1002/j.1460-2075.1995.tb07168.x; VOSATKA RJ, 1989, J CELL PHYSIOL, V138, P493, DOI 10.1002/jcp.1041380308	54	32	32	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN 6	1996	12	11					2409	2418						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UQ220	8649782				2022-12-25	WOS:A1996UQ22000019
J	Damaj, BB; McColl, SR; Mahana, W; Crouch, MF; Naccache, PH				Damaj, BB; McColl, SR; Mahana, W; Crouch, MF; Naccache, PH			Physical association of G(i2)alpha with interleukin-8 receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEUTROPHIL-ACTIVATING PEPTIDE-2; G-PROTEIN; CHEMOTACTIC CYTOKINES; GENE-EXPRESSION; HIGH-AFFINITY; GRO-ALPHA; FIBROBLASTS; BINDING; CELLS; LEUKOCYTES	Interleukin-8 (IL-8), one of the major mediators of the inflammatory response, belongs to a family of chemokines that includes NAP-2 (neutrophil-activating peptide-2) and Gro-alpha and whose biological activities are directed to a great extent toward neutrophils. Two distinct receptors have been described with overlapping, but not identical, binding affinities for IL-8, NAP-2, and Gro-alpha. This study was designed to examine the intracellular pathways activated upon the occupation of each of the IL-8 receptors (IL-8R). The formation of a physical coupling between IL-8 receptors and the alpha-subunit of heterotrimeric G proteins was tested in neutrophils by examining the presence of the former in anti-G alpha immune precipitates. The addition of IL-8 to a suspension of human neutrophils led to a time-dependent detection of IL-8 in anti-G(i2)alpha (raised against amino acids 159-168 (LERIAQSDYI) of G(i2)alpha) and anti-G(t) alpha (raised against the COOH-terminal 10 amino acids (KENLKDCGLF) of G(t) alpha), but not anti-G(q), immunoprecipitates. Similar results were obtained in human 293 cells stably transfected with IL-8RA or IL-8RB. The peptide derived from the COOH-terminal sequence of G(t) inhibited the co-immunoprecipitation of IL-8R and G(i) observed in response to the anti-G(t) alpha and anti-G(i2)alpha antibodies. On the other hand, the G(i2)alpha peptide only inhibited the immunoprecipitation induced by the anti-G(i2)alpha antibody. Peptides derived from G(i1)alpha or G(i3)alpha had no effect in this assay. The introduction of the anti-G(i2)alpha or anti-(t) alpha antibodies or their neutralizing peptides, but not the G(i1)alpha or G(i3)alpha peptides, into 293 IL-8RA or 293 IL-8RB cells completely blocked the calcium responses obtained upon stimulation with IL-8. These results demonstrate that the occupation of either type of IL-8 receptor leads to a physical coupling to the alpha-subunit of G(i2). In addition, the use of the subunit-specific peptides identified two functionally important but distinct regions of G(i) alpha, one involved in receptor/G(i) alpha interaction (KENLKDCGLF) and the other mediating downstream signal transmission (LERIAQSDYI). Finally, the results of this study also validate the use of the transfected 293 cell line as a model for the study of the signal transduction pathway(s) initiated by IL-8.	CHU LAVAL,CTR RECH RHUMATOL & IMMUNOL,CTR RECH,ST FOY,PQ G1V 4G2,CANADA; UNIV LAVAL,FAC MED,DEPT MED,ST FOY,PQ G1V 4G2,CANADA; UNIV ADELAIDE,DEPT MICROBIOL & IMMUNOL,ADELAIDE,SA 5001,AUSTRALIA; NIAID,IMMUNOGENET LAB,NIH,ROCKVILLE,MD 20852; AUSTRALIAN NATL UNIV,JOHN CURTIN SCH MED RES,DIV NEUROSCI,CANBERRA,ACT 2601,AUSTRALIA	Laval University; Laval University; University of Adelaide; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Australian National University; John Curtin School of Medical Research								BAGGIOLINI M, 1994, ADV IMMUNOL, V55, P97; BAGGIOLINI M, 1989, J CLIN INVEST, V84, P1045, DOI 10.1172/JCI114265; BAGGIOLINI M, 1993, CLIN INVESTIGATOR, V71, P812; BAGGIOLINI M, 1992, FEBS LETT, V307, P97, DOI 10.1016/0014-5793(92)80909-Z; BIGNOLD LP, 1992, INT ARCH ALLERGY IMM, V97, P350, DOI 10.1159/000236144; CASSATELLA MA, 1993, BIOCHEM BIOPH RES CO, V190, P660, DOI 10.1006/bbrc.1993.1099; CERRETTI DP, 1993, MOL IMMUNOL, V30, P359; CLARKLEWIS I, 1991, J BIOL CHEM, V266, P23128; CROUCH MF, 1993, CELL SIGNAL, V5, P41, DOI 10.1016/0898-6568(93)90006-8; CROUCH MF, 1991, FASEB J, V5, P200, DOI 10.1096/fasebj.5.2.1900794; DJEU JY, 1990, J IMMUNOL, V144, P2205; FAUCHER N, 1987, J CELL PHYSIOL, V132, P483, DOI 10.1002/jcp.1041320310; GEISER T, 1993, J BIOL CHEM, V268, P15419; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HEBERT CA, 1993, CANCER INVEST, V11, P743, DOI 10.3109/07357909309046949; HEBERT CA, 1993, J BIOL CHEM, V268, P18549; JESAITIS AJ, 1993, EUR J HAEMATOL, V51, P288; KASLOW HR, 1992, FASEB J, V6, P2684, DOI 10.1096/fasebj.6.9.1612292; KATZ A, 1992, NATURE, V360, P686, DOI 10.1038/360686a0; LEE J, 1992, J BIOL CHEM, V267, P16283; LHEUREUX G, 1994, BLOOD, V85, P522; LIU JH, 1992, J INFECT DIS, V166, P1089; LOETSCHER P, 1994, FEBS LETT, V341, P187, DOI 10.1016/0014-5793(94)80454-0; MCCOLL SR, 1993, J IMMUNOL, V150, P4550; MICHEL G, 1992, FEBS LETT, V305, P241, DOI 10.1016/0014-5793(92)80677-9; MUELLER SG, 1994, J BIOL CHEM, V269, P1973; ODAKE H, 1993, EXP MOL PATHOL, V58, P14, DOI 10.1006/exmp.1993.1002; PETERSEN F, 1994, J IMMUNOL, V152, P2467; RATHANASWAMI P, 1993, ARTHRITIS RHEUM, V36, P1295, DOI 10.1002/art.1780360914; ROLLET E, 1994, J IMMUNOL, V153, P353; ROLLINS TE, 1991, P NATL ACAD SCI USA, V88, P971, DOI 10.1073/pnas.88.3.971; SANDER B, 1991, IMMUNOL REV, V119, P65, DOI 10.1111/j.1600-065X.1991.tb00578.x; SCHREIBER RE, 1993, J LEUKOCYTE BIOL, V53, P470, DOI 10.1002/jlb.53.4.470; SCHUMACHER C, 1992, P NATL ACAD SCI USA, V89, P10542, DOI 10.1073/pnas.89.21.10542; SMITH RJ, 1992, J LEUKOCYTE BIOL, V52, P17, DOI 10.1002/jlb.52.1.17; STICHERLING M, 1993, J INVEST DERMATOL, V101, P573, DOI 10.1111/1523-1747.ep12366023; STRIETER RM, 1994, J LAB CLIN MED, V123, P183; STRIETER RM, 1992, AM J PATHOL, V141, P397; TORTI M, 1992, BIOCHEM BIOPH RES CO, V186, P440, DOI 10.1016/S0006-291X(05)80827-7; TSIEN RY, 1982, J CELL BIOL, V94, P3325; UI M, 1984, TRENDS PHARMACOL SCI, V4, P272; WU DQ, 1993, SCIENCE, V261, P101, DOI 10.1126/science.8316840; YE RD, 1993, J IMMUNOL, V150, P1383	43	66	70	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 31	1996	271	22					12783	12789		10.1074/jbc.271.22.12783	http://dx.doi.org/10.1074/jbc.271.22.12783			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UN474	8662698	hybrid			2022-12-25	WOS:A1996UN47400016
J	Eason, MG; Liggett, SB				Eason, MG; Liggett, SB			Chimeric mutagenesis of putative G-protein coupling domains of the alpha(2A)-adrenergic receptor - Localization of two redundant and fully competent G(1) coupling domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-ADRENERGIC-RECEPTOR; HUMAN ALPHA-2-ADRENERGIC RECEPTOR; HUMAN BETA-2-ADRENERGIC RECEPTOR; 3RD INTRACELLULAR LOOP; HAMSTER OVARY CELLS; ALPHA(2)-ADRENERGIC RECEPTOR; ADENYLATE-CYCLASE; CYTOPLASMIC DOMAINS; AMINO-ACIDS; EXPRESSION	We have investigated potential G(i) and G(s) coupling domains within the intracellular regions of the alpha(2A)AR subtype using a series of nine chimeric mutations. The second intracellular loop (ICL2, amino acids 133-149) and the amino- and carboxyl-terminal regions of the third intracellular loop (ICL3, amino acids 218-235 and 355-371, respectively) of the cloned human alpha(2A)AR were substituted with the analogous sequence from either the G(s)-coupled beta(2)AR or the G(i)-coupled serotonin type 1A receptor (5-HT(1A)R). Mutant and wild type alpha(2A)AR were stably expressed in Chinese hamster ovary cells and functional coupling of each receptor to G(i) and G(s) was assessed in membrane adenylyl cyclase assays. Substitution of 5-HT(1A)R sequence into ICL2 ablated coupling to G(s) but not to G(i), whereas substitution of beta(2)AR sequence significantly depressed coupling to G(i) but not to G(s). Thus, the ICL2 of the alpha(2A)AR contains elements essential for both signaling pathways. Substitution of either the amino- or carboxyl-terminal. segments of ICL3 with 5-HT(1A)R sequence ablated agonist stimulation of adenylyl cyclase activity (without affecting inhibition), suggesting that both domains are necessary for alpha(2A)AR coupling to G(s). In contrast, individual substitution of beta(2)AR sequence into ICL3 amino or carboxyl termini had no appreciable effect on G(i) coupling. Concomitant substitution of beta(2)AR sequence into both regions substantially impaired G(i) coupling, implying that each is capable of independently supporting functional coupling. Substitution of 5-HT(1A)R at either locus had no effect on G(i) coupling. Thus, for G(s) coupling, these two domains within ICL3 are both required for functional coupling. However, for G(i) coupling, the alpha(2A)AR appears to have two distinct regions within ICL3 that are capable of supporting G(i) coupling independently. There has been no previous elucidation of a receptor having redundant, fully competent domains for coupling to a single class of G-protein. Such duplicity of functional domains within alpha(2)AR may suggest strong evolutionary pressure to maintain G(i) coupling.	UNIV CINCINNATI,COLL MED,DEPT PULM MED,CINCINNATI,OH 45267; UNIV CINCINNATI,COLL MED,DEPT MOLEC GENET,CINCINNATI,OH 45267; UNIV CINCINNATI,COLL MED,DEPT PHARMACOL,CINCINNATI,OH 45267	University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati			liggett, stephen b/E-7453-2012	Liggett, Stephen B./0000-0002-0128-3669	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL053436, P01HL041496] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL53436, HL41496] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BERKOWITZ DE, 1994, ANESTHESIOLOGY, V81, P1235, DOI 10.1097/00000542-199411000-00018; CHABRE O, 1994, J BIOL CHEM, V269, P5730; CHEUNG AH, 1992, MOL PHARMACOL, V41, P1061; CHEUNG AH, 1991, FEBS LETT, V279, P277, DOI 10.1016/0014-5793(91)80167-2; CHEUNG AH, 1990, MOL PHARMACOL, V37, P775; COTECCHIA S, 1990, J BIOL CHEM, V265, P63; CULLEN BR, 1987, METHOD ENZYMOL, V152, P684; DALMAN HM, 1991, J BIOL CHEM, V266, P11025; DELEAN A, 1981, MOL PHARMACOL, V21, P5; DUMAN RS, 1986, J NEUROCHEM, V47, P800; DUZIC E, 1992, J BIOL CHEM, V267, P24045; EASON MG, 1993, MOL PHARMACOL, V44, P70; EASON MG, 1992, J BIOL CHEM, V267, P15795; EASON MG, 1995, J BIOL CHEM, V270, P24753, DOI 10.1074/jbc.270.42.24753; EASON MG, 1994, MOL PHARMACOL, V45, P696; FEDERMAN AD, 1992, NATURE, V356, P159, DOI 10.1038/356159a0; FRASER CM, 1989, J BIOL CHEM, V264, P11754; GUAN XM, 1995, MOL PHARMACOL, V48, P492; HAUSDORFF WP, 1990, J BIOL CHEM, V265, P1388; HAUSDORFF WP, 1989, J BIOL CHEM, V264, P12657; IKEZU T, 1992, FEBS LETT, V311, P29, DOI 10.1016/0014-5793(92)81359-T; JANSSON CC, 1994, EUR J PHARM-MOLEC PH, V266, P165, DOI 10.1016/0922-4106(94)90106-6; JONES SB, 1991, MOL PHARMACOL, V39, P239; KOBILKA BK, 1988, SCIENCE, V240, P1310, DOI 10.1126/science.2836950; KOBILKA BK, 1987, SCIENCE, V238, P650, DOI 10.1126/science.2823383; KOSUGI S, 1994, MOL ENDOCRINOL, V8, P498, DOI 10.1210/me.8.4.498; KOSUGI S, 1994, FEBS LETT, V356, P291, DOI 10.1016/0014-5793(94)01286-5; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; KUROSE H, 1994, J BIOL CHEM, V269, P10093; LECHLEITER J, 1990, EMBO J, V9, P4381, DOI 10.1002/j.1460-2075.1990.tb07888.x; LEEUWEN DH, 1995, MOL PHARMACOL, V48, P344; LIGGETT SB, 1992, J BIOL CHEM, V267, P4740; LIGGETT SB, 1991, J BIOL CHEM, V266, P4816; LIMBIRD LE, 1985, RECEPTORS, V2, P281; LOMASNEY JW, 1991, BIOCHIM BIOPHYS ACTA, V1095, P127, DOI 10.1016/0167-4889(91)90075-9; LOMASNEY JW, 1990, P NATL ACAD SCI USA, V87, P5094, DOI 10.1073/pnas.87.13.5094; ODOWD BF, 1988, J BIOL CHEM, V263, P15985; OKAMOTO T, 1992, J BIOL CHEM, V267, P8342; PEPPERL DJ, 1993, MOL PHARMACOL, V44, P802; RAYMOND JR, 1993, BIOCHEMISTRY-US, V32, P11064, DOI 10.1021/bi00092a016; REGAN JW, 1988, P NATL ACAD SCI USA, V85, P6301, DOI 10.1073/pnas.85.17.6301; SALOMON Y, 1974, ANAL BIOCHEM, V58, P541, DOI 10.1016/0003-2697(74)90222-X; SCHEININ M, 1994, MOL BRAIN RES, V21, P133, DOI 10.1016/0169-328X(94)90386-7; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; ULLRICH S, 1984, J BIOL CHEM, V259, P4111; WESS J, 1990, MOL PHARMACOL, V38, P517; WONG SKF, 1990, J BIOL CHEM, V265, P6219; YAMADA M, 1994, MOL PHARMACOL, V46, P470; ZENG DW, 1991, MOL BRAIN RES, V10, P219, DOI 10.1016/0169-328X(91)90064-5	49	79	83	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 31	1996	271	22					12826	12832		10.1074/jbc.271.22.12826	http://dx.doi.org/10.1074/jbc.271.22.12826			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UN474	8662784	hybrid			2022-12-25	WOS:A1996UN47400023
J	Fixman, ED; Fournier, TM; Kamikura, DM; Naujokas, MA; Park, M				Fixman, ED; Fournier, TM; Kamikura, DM; Naujokas, MA; Park, M			Pathways downstream of Shc and Grb2 are required for cell transformation by the Tpr-Met oncoprotein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPATOCYTE GROWTH-FACTOR; PROTEIN-TYROSINE KINASE; PAPILLARY THYROID CARCINOMAS; SCATTER FACTOR-RECEPTOR; SIGNAL TRANSDUCTION; NUCLEOTIDE EXCHANGE; ADAPTER PROTEIN; ACTIVATION; ONCOGENE; GENE	The Tpr-Met oncoprotein, which is a member of a family of tyrosine kinase oncoproteins generated following genomic rearrangement, consists of the catalytic kinase domain of the hepatocyte growth factor/scatter factor receptor tyrosine kinase (Met) fused downstream from sequences encoded by the tpr gene. We have previously demonstrated that a single tyrosine residue in the carboxyl terminus, Tyr(489), is highly phosphorylated and is essential for efficient transformation of Fr3T3 fibroblasts by Tpr-Met and for the association of Tpr-Met with the Grb2 adaptor protein and phosphatidylinositol 3'-kinase. We show here that Tyr(489) is also required for association of Tpr-Met with phospholipase C gamma and the tyrosine phosphatase, SHPTP2/Syp. To distinguish which of these substrates are required for cell transformation by the Tpr-Met oncoprotein, we generated a novel Tpr-Met mutant that selectively fails to associate with the Grb2 adaptor protein. Utilizing this mutant, together with additional Tpr-Met mutants containing Tyr to Phe substitutions, we have demonstrated that transformation of Fr3T3 fibroblasts by the Tpr-Met oncoprotein is dependent upon pathways downstream of Shc and Grb2 and that pathways downstream of phosphatidylinositol 3'-kinase, phospholipase G gamma, and SHPTP2/Syp are insufficient for transformation.	MCGILL UNIV, MOLEC ONCOL GRP, ROYAL VICTORIA HOSP, DEPT MED, MONTREAL, PQ H3A 1A1, CANADA; MCGILL UNIV, MOLEC ONCOL GRP, ROYAL VICTORIA HOSP, DEPT ONCOL, MONTREAL, PQ H3A 1A1, CANADA; MCGILL UNIV, MOLEC ONCOL GRP, ROYAL VICTORIA HOSP, DEPT BIOCHEM, MONTREAL, PQ H3A 1A1, CANADA	McGill University; Royal Victoria Hospital; McGill University; Royal Victoria Hospital; McGill University; Royal Victoria Hospital								ABRAHAM N, 1990, MOL CELL BIOL, V10, P5197, DOI 10.1128/MCB.10.10.5197; BASU T, 1994, ONCOGENE, V9, P3483; BATZER AG, 1995, MOL CELL BIOL, V15, P4403; BONGARZONE I, 1993, MOL CELL BIOL, V13, P358, DOI 10.1128/MCB.13.1.358; BORRELLO MG, 1994, ONCOGENE, V9, P1661; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; CLARK SG, 1992, NATURE, V356, P340, DOI 10.1038/356340a0; COOPER CS, 1984, NATURE, V311, P29, DOI 10.1038/311029a0; CROWE AJ, 1994, ONCOGENE, V9, P537; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; FIXMAN ED, 1995, ONCOGENE, V10, P237; FLETTO DL, 1993, HEPATOCYTE GROWTH FA, P108; GIGUERE V, 1994, GENE DEV, V8, P538, DOI 10.1101/gad.8.5.538; GILMAN MZ, 1986, MOL CELL BIOL, V6, P4305, DOI 10.1128/MCB.6.12.4305; GOTOH N, 1994, P NATL ACAD SCI USA, V91, P167, DOI 10.1073/pnas.91.1.167; GRAZIANI A, 1991, J BIOL CHEM, V266, P22087; GRECO A, 1992, ONCOGENE, V7, P237; GRIECO M, 1990, CELL, V60, P557, DOI 10.1016/0092-8674(90)90659-3; HALABAN R, 1992, ONCOGENE, V7, P2195; HUFF JL, 1993, P NATL ACAD SCI USA, V90, P6140, DOI 10.1073/pnas.90.13.6140; ISHIZAKA Y, 1992, ONCOGENE, V7, P1441; Kamikura DM, 1996, BIOCHEMISTRY-US, V35, P1010, DOI 10.1021/bi9514065; KAVANAUGH WM, 1995, SCIENCE, V268, P1177, DOI 10.1126/science.7539155; LANDAU NR, 1992, J VIROL, V66, P5110, DOI 10.1128/JVI.66.8.5110-5113.1992; LANZI C, 1992, ONCOGENE, V7, P2189; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LI NX, 1994, ONCOGENE, V9, P3457; LOWY DR, 1993, ANNU REV BIOCHEM, V62, P851, DOI 10.1146/annurev.bi.62.070193.004223; MARTINZANCA D, 1986, NATURE, V319, P743, DOI 10.1038/319743a0; MATSUMOTO K, 1994, J BIOL CHEM, V269, P31807; MCGLADE J, 1992, P NATL ACAD SCI USA, V89, P8869, DOI 10.1073/pnas.89.19.8869; MEDEMA RH, 1991, MOL CELL BIOL, V11, P5963, DOI 10.1128/MCB.11.12.5963; MEYER S, 1994, MOL CELL BIOL, V14, P3253, DOI 10.1128/MCB.14.5.3253; NALDINI L, 1991, EMBO J, V10, P2867, DOI 10.1002/j.1460-2075.1991.tb07836.x; OKANO Y, 1993, BIOCHEM BIOPH RES CO, V190, P842, DOI 10.1006/bbrc.1993.1125; OKUTANI T, 1994, J BIOL CHEM, V269, P31310; OLIVIER JP, 1993, CELL, V73, P179, DOI 10.1016/0092-8674(93)90170-U; OUWENS DM, 1994, J BIOL CHEM, V269, P33116; PARK M, 1986, CELL, V45, P895, DOI 10.1016/0092-8674(86)90564-7; PELICCI G, 1995, ONCOGENE, V10, P1631; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; PONZETTO C, 1994, CELL, V77, P261, DOI 10.1016/0092-8674(94)90318-2; PRIGENT SA, 1994, EMBO J, V13, P2831, DOI 10.1002/j.1460-2075.1994.tb06577.x; PUIL L, 1994, EMBO J, V13, P764, DOI 10.1002/j.1460-2075.1994.tb06319.x; RODRIGUES CA, 1994, CURR OPIN GENET DEV, V4, P15, DOI 10.1016/0959-437X(94)90086-8; RODRIGUES GA, 1993, MOL CELL BIOL, V13, P6711, DOI 10.1128/MCB.13.11.6711; RODRIGUES GA, 1991, MOL CELL BIOL, V11, P2962, DOI 10.1128/MCB.11.6.2962; RONSIN C, 1993, ONCOGENE, V8, P1195; ROYAL I, 1995, J BIOL CHEM, V270, P27780, DOI 10.1074/jbc.270.46.27780; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; SALCINI AE, 1994, ONCOGENE, V9, P2827; SIMON MA, 1993, CELL, V73, P169, DOI 10.1016/0092-8674(93)90169-Q; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; TAKAHASHI M, 1985, CELL, V42, P581, DOI 10.1016/0092-8674(85)90115-1; VANDERGEER P, 1995, CURR BIOL, V5, P404, DOI 10.1016/S0960-9822(95)00081-9; WHITMAN M, 1985, NATURE, V315, P239, DOI 10.1038/315239a0; YOKOTE K, 1994, J BIOL CHEM, V269, P15337; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E; ZHU H, 1994, J BIOL CHEM, V269, P29943	63	109	111	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 31	1996	271	22					13116	13122		10.1074/jbc.271.22.13116	http://dx.doi.org/10.1074/jbc.271.22.13116			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UN474	8662733	hybrid			2022-12-25	WOS:A1996UN47400066
J	Logan, HM; Cathala, N; Grignon, C; Davidian, JC				Logan, HM; Cathala, N; Grignon, C; Davidian, JC			Cloning of a cDNA encoded by a member of the Arabidopsis thaliana ATP sulfurylase multigene family - Expression studies in yeast and in relation to plant sulfur nutrition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ASSIMILATORY SULFATE REDUCTION; SACCHAROMYCES-CEREVISIAE; PISUM-SATIVUM; ACTIVATION; METABOLISM; PROTEIN; GENE; TRANSFORMATION; PURIFICATION; LOCALIZATION	An Arabidopsis thaliana ATP sulfurylase cDNA (ASA1), encoding a putative chloroplastic isoform, has been cloned by functional complementation of a Saccharomyces cerevisiae (met3) ATP sulfurylase mutant which also has a poor sulfate transport capacity. Homologous complementation of the yeast mutant with the ATP sulfurylase gene restores both ATP sulfurylase function and sulfate transport. Heterologous complementation restores only ATP sulfurylase function as demonstrated by low [S-35]sulfate influx measurements and selenate resistance. A structural relationship between ATP sulfurylase and sulfate membrane transporters in yeast is proposed. The sequence of ASA1 is homologous to deduced plant and animal ATP sulfurylase sequences. Analyses indicate a potential tyrosine phosphorylation site which is unique to higher eukaryote sequences, ASA1 is specified by a single copy gene that is part of a multigene family in A. thaliana. At least two ASA1 copies are found in Brassica napus plants. ASA1 transcripts were found in all organs examined, with the highest transcript abundance and ATP sulfurylase activity in leaves or cotyledons. Absence of sulfate from culture media transiently increased B. napus transcript abundance, indicating that initially, the response to sulfate deprivation is transcriptionally regulated.	ECOLE NATL SUPER AGRON MONTIPELLIER,LAB BIOCHIM & PHYSIOL VEGETALES,INST NATL RECH AGRON,CNRS,F-34060 MONTPELLIER,FRANCE	Centre National de la Recherche Scientifique (CNRS); INRAE; Institut Agro; Montpellier SupAgro			North, Helen/AAD-4964-2020	North, Helen/0000-0002-5749-2603				ALI N, 1994, J BIOL CHEM, V269, P31626; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Ames B. N., 1966, METHOD ENZYMOL, P115, DOI DOI 10.1016/0076-6879(66)08014-5; Ausubel F.M., 1993, CURRENT PROTOCOLS MO; BAIROCH A, 1994, NUCLEIC ACIDS RES, V22, P3583; BELL CI, 1995, J EXP BOT, V46, P73, DOI 10.1093/jxb/46.1.73; BOEKE JD, 1984, MOL GEN GENET, V197, P345, DOI 10.1007/BF00330984; BRETON A, 1977, J BACTERIOL, V132, P224, DOI 10.1128/JB.132.1.224-232.1977; BRUNOLD C, 1989, PLANTA, V179, P228, DOI 10.1007/BF00393693; BRUNOLD C, 1987, PHYSIOL PLANTARUM, V70, P168, DOI 10.1111/j.1399-3054.1987.tb06127.x; CHEREST H, 1985, GENE, V34, P269; CHEREST H, 1987, MOL GEN GENET, V210, P307, DOI 10.1007/BF00325699; CHEREST H, 1992, GENETICS, V130, P51; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CRABEEL M, 1981, P NATL ACAD SCI-BIOL, V78, P5026, DOI 10.1073/pnas.78.8.5026; DEAN C, 1986, NUCLEIC ACIDS RES, V14, P2229, DOI 10.1093/nar/14.5.2229; Dellaporta SL, 1983, PLANT MOL BIOL REP, V1, P19, DOI DOI 10.1007/BF02712670; DEVITO PC, 1964, J BACTERIOL, V88, P1341, DOI 10.1128/JB.88.5.1341-1348.1964; DOMONEY C, 1987, PLANTA, V170, P562, DOI 10.1007/BF00402992; FOSTER BA, 1994, J BIOL CHEM, V269, P19777; GAVEL Y, 1990, FEBS LETT, V261, P455, DOI 10.1016/0014-5793(90)80614-O; GISH W, 1993, NAT GENET, V3, P266, DOI 10.1038/ng0393-266; HAWKESFORD MJ, 1993, PLANTA, V190, P297, DOI 10.1007/BF00196957; HERSCHBACH C, 1994, J EXP BOT, V45, P1069, DOI 10.1093/jxb/45.8.1069; HINNEN A, 1978, P NATL ACAD SCI USA, V75, P1929, DOI 10.1073/pnas.75.4.1929; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; KEEGSTRA K, 1989, ANNU REV PLANT PHYS, V40, P471, DOI 10.1146/annurev.pp.40.060189.002351; KLONUS D, 1994, PLANT J, V6, P105, DOI 10.1046/j.1365-313X.1994.6010105.x; KLONUS D, 1995, PLANT PHYSIOL, V107, P653, DOI 10.1104/pp.107.2.653; LASKEY RA, 1975, EUR J BIOCHEM, V56, P335, DOI 10.1111/j.1432-1033.1975.tb02238.x; LAUE BE, 1994, J BACTERIOL, V176, P3723, DOI 10.1128/JB.176.12.3723-3729.1994; LEUSTEK T, 1994, PLANT PHYSIOL, V105, P897, DOI 10.1104/pp.105.3.897; LEYH TS, 1992, J BIOL CHEM, V267, P10405; LEYH TS, 1993, CRIT REV BIOCHEM MOL, V28, P515, DOI 10.3109/10409239309085137; LI H, 1995, J BIOL CHEM, V270, P29453, DOI 10.1074/jbc.270.49.29453; LUNN JE, 1990, PLANT PHYSIOL, V94, P1345, DOI 10.1104/pp.94.3.1345; LYLE S, 1994, BIOCHEMISTRY-US, V33, P5920, DOI 10.1021/bi00185a032; MINET M, 1992, PLANT J, V2, P417; MURILLO M, 1995, ARCH BIOCHEM BIOPHYS, V323, P195, DOI 10.1006/abbi.1995.0026; Nagahara U, 1935, JPN J BOT, V7, P389; NEWMAN T, 1994, PLANT PHYSIOL, V106, P1241, DOI 10.1104/pp.106.4.1241; OSSLUND T, 1982, PLANT PHYSIOL, V70, P39, DOI 10.1104/pp.70.1.39; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; RASBAND WS, 1995, MICROBEAM ANAL, V4, P137; RENNENBERG H, 1990, SULFUR NUTRITION AND SULFUR ASSIMILATION IN HIGHER PLANTS, P53; RENOSTO F, 1990, J BIOL CHEM, V265, P10300; RENOSTO F, 1993, ARCH BIOCHEM BIOPHYS, V307, P272, DOI 10.1006/abbi.1993.1590; ROSENTHAL E, 1995, GENE, V165, P243, DOI 10.1016/0378-1119(95)00450-K; RUFFET ML, 1994, PLANT PHYSIOL, V104, P597, DOI 10.1104/pp.104.2.597; SAITO K, 1995, J BIOL CHEM, V270, P16321, DOI 10.1074/jbc.270.27.16321; SCHMIDT A, 1992, ANNU REV PLANT PHYS, V43, P325, DOI 10.1146/annurev.pp.43.060192.001545; SCHWEDOCK J, 1989, Molecular Plant-Microbe Interactions, V2, P181, DOI 10.1094/MPMI-2-181; SMITH FW, 1995, P NATL ACAD SCI USA, V92, P9373, DOI 10.1073/pnas.92.20.9373; SUZUKI K, 1995, PLANT CELL, V7, P639, DOI 10.1105/tpc.7.5.639; THOMAS D, 1989, MOL CELL BIOL, V9, P3292, DOI 10.1128/MCB.9.8.3292; THOMAS D, 1992, MOL CELL BIOL, V12, P1719, DOI 10.1128/MCB.12.4.1719; VONARB C, 1986, PHYSIOL PLANTARUM, V67, P81, DOI 10.1111/j.1399-3054.1986.tb01266.x; YU M, 1989, ARCH BIOCHEM BIOPHYS, V269, P156, DOI 10.1016/0003-9861(89)90096-9	58	75	82	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 24	1996	271	21					12227	12233		10.1074/jbc.271.21.12227	http://dx.doi.org/10.1074/jbc.271.21.12227			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UL660	8647819	hybrid, Green Published			2022-12-25	WOS:A1996UL66000021
J	Vallett, SM; Sanchez, HB; Rosenfeld, JM; Osborne, TF				Vallett, SM; Sanchez, HB; Rosenfeld, JM; Osborne, TF			A direct role for sterol regulatory element binding protein in activation of 3-hydroxy-3-methylglutaryl coenzyme A reductase gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIPOPROTEIN RECEPTOR PROMOTER; A REDUCTASE; SEQUENCE; IDENTIFICATION; REPRESSION; REGION	In earlier studies the DNA site required for sterol regulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase was shown to be distinct from the classic sterol regulatory element (SRE-1) of the low density lipoprotein receptor gene (Osborne, T. F. (1991) J. Biol. Chem. 266, 13947-13951), However, oxysterol-resistant cells that continuously overproduce one of the sterol regulatory element binding proteins in the nucleus result in high unregulated expression of both genes (Yang, J., Brown, M. S., Ho, Y. K., and Goldstein, J. L. (1995) J. Biol, Chem. 270, 12152-12161) suggesting a direct role for the SREBPs in the activation of the reductase gene, In the present studies we demonstrate that SREBP-1 binds to two adjacent sites within the previously identified sterol regulatory element of the reductase gene even though there is only limited homology with the SRE-1 of the receptor. We also show that SREBP-1 specifically activates the reductase promoter in transient DNA transfection studies in HepG2 cells and that mutations which eliminate sterol regulation and SREBP-1 binding also abolish transient activation by SREBP-1, Although specific, the magnitude of the activation observed is considerably lower than for the low density lipoprotein (LDL) receptor analyzed in parallel, suggesting there is an additional protein required for activation of the reductase promoter that is limiting in the transient assay, SREBP also binds to two additional sites in the reductase promoter which probably play an auxiliary role in expression. When the DNA sequence within the sites are aligned with each other and with the LDL receptor SRE-1, a consensus half-site is revealed 5'-PyCAPy-3'. The LDL receptor element contains two half-sites oriented as a direct repeat spaced by one nucleotide. The SREBP proteins are special members of the basic-helix-loop-helix-zipper (bHLHZip) family of DNA binding proteins since they bind the classic palindromic E-box site as well as the direct repeat SRE-1 element. The SREBP binding sites in both the reductase and those recently identified in other sterol regulated promoters appear to contain a half-site with considerable divergence in the flanking residues, Here we also show that a 22-amino acid domain located immediately adjacent to the basic domain of the bHLHZip region is required for SREBP to efficiently recognize divergent sites in the reductase and 3-hydroxy-3-methylglutaryl-CoA synthase promoters but, interestingly, this domain is not required for efficient binding to the LDL direct repeat SRE-1 or to a palindromic high-affinity E-box element.	UNIV CALIF IRVINE,DEPT MOLEC BIOL & BIOCHEM,IRVINE,CA 92717	University of California System; University of California Irvine					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL048044] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL48044] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BLACKWELL TK, 1993, MOL CELL BIOL, V13, P5216, DOI 10.1128/MCB.13.9.5216; BRENOWITZ M, 1993, FOOTPRINTING TECHNIQ, P1; BRIGGS MR, 1993, J BIOL CHEM, V268, P14490; DAWSON PA, 1988, J BIOL CHEM, V263, P3372; Ericsson J, 1996, P NATL ACAD SCI USA, V93, P945, DOI 10.1073/pnas.93.2.945; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; HUA XX, 1995, J BIOL CHEM, V270, P29422, DOI 10.1074/jbc.270.49.29422; KIM JB, 1995, MOL CELL BIOL, V15, P2582; Lopez JM, 1996, P NATL ACAD SCI USA, V93, P1049, DOI 10.1073/pnas.93.3.1049; LUSKEY KL, 1987, MOL CELL BIOL, V7, P1881, DOI 10.1128/MCB.7.5.1881; Maxam A M, 1980, Methods Enzymol, V65, P499; METHERALL JE, 1989, J BIOL CHEM, V264, P15634; MURRE C, 1994, BBA-GENE STRUCT EXPR, V1218, P129, DOI 10.1016/0167-4781(94)90001-9; OSBORNE TF, 1988, J BIOL CHEM, V263, P3380; OSBORNE TF, 1991, J BIOL CHEM, V266, P13947; OSBORNE TF, 1992, J BIOL CHEM, V267, P18973; Osborne TF, 1995, CRIT REV EUKAR GENE, V5, P317, DOI 10.1615/CritRevEukarGeneExpr.v5.i3-4.50; Sambrook J, 1989, MOL CLONING LABORATO, P545; SANCHEZ HB, 1995, J BIOL CHEM, V270, P1161, DOI 10.1074/jbc.270.3.1161; SATO R, 1994, J BIOL CHEM, V269, P17267; SHENG ZQ, 1995, P NATL ACAD SCI USA, V92, P935, DOI 10.1073/pnas.92.4.935; SMITH JR, 1990, J BIOL CHEM, V265, P2306; SMITH JR, 1988, J BIOL CHEM, V263, P18480; SMITH JR, 1990, THESIS U TEXAS DALLA; SUDHOF TC, 1987, J BIOL CHEM, V262, P10773; WANG XD, 1993, J BIOL CHEM, V268, P14497; WANG XD, 1994, CELL, V77, P53, DOI 10.1016/0092-8674(94)90234-8; YANG JX, 1994, GENE DEV, V8, P1910, DOI 10.1101/gad.8.16.1910; YANG JX, 1995, J BIOL CHEM, V270, P12152, DOI 10.1074/jbc.270.20.12152; Yokoyama C., 1993, CELL, V75, P185	30	195	202	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 24	1996	271	21					12247	12253		10.1074/jbc.271.21.12247	http://dx.doi.org/10.1074/jbc.271.21.12247			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UL660	8647822	hybrid			2022-12-25	WOS:A1996UL66000024
J	Boisrame, A; Beckerich, JM; Gaillardin, C				Boisrame, A; Beckerich, JM; Gaillardin, C			Sls1p, an endoplasmic reticulum component, is involved in the protein translocation process in the yeast Yarrowia lipolytica	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL RECOGNITION PARTICLE; ALKALINE EXTRACELLULAR PROTEASE; SACCHAROMYCES-CEREVISIAE; SCHIZOSACCHAROMYCES-POMBE; ESCHERICHIA-COLI; GENE; SECRETION; POLYPEPTIDES; HOMOLOG; RNA	Signal recognition particle-dependent targeting of secretory proteins to the endoplasmic reticulum membrane is predominant in the yeast Yarrowia lipolytica. A conditional lethal mutant of the SCR2-encoded 7S RNA provided the first in vivo evidence for involvement of this particle in cotranslational translocation (He, F., Beckerich, J. M., and Gaillardin, C. M. (1992) J. Biol. Chem. 267, 1932-1937), In order to identify partners of 7S RNA or signal recognition particle in their function, we selected synthetic lethal mutations with the 7S RNA mutation (sls), The SLS1 gene, cloned by complementation of the sls1 mutant growth defect, encodes a 426-amino acid polypeptide containing a NH2-terminal signal peptide and a COOH-terminal endoplasmic reticulum (ER) retention motif, The SLS1 gene product behaves as a lumenal protein of the ER. Sls1p was sedimented with membrane-rich organelles and was resistant to protease degradation without prior membrane solubilization. Immunofluorescence microscopy showed a typical endoplasmic reticulum perinuclear staining. Co-immunoprecipitation revealed that Sls1p resides close to the major translocation apparatus component, Sec61p. Deletion of the SLS1 gene led to a temperature-sensitive growth phenotype. Synthesis of several secretory proteins was shown to be specifically reduced in Delta sls1 cells, We propose that Sls1p acts in the preprotein translocation process, interacting directly with translocating polypeptides to facilitate their transfer and/or help their folding in the ER.			Boisrame, A (corresponding author), INRA,LAB GENET MOL & CELLULAIRE,INST NATL AGRONOM,CTR GRIGNON,CNRS,F-78850 THIVERVAL GRIGNON,FRANCE.							BROWN JD, 1994, EMBO J, V13, P4390, DOI 10.1002/j.1460-2075.1994.tb06759.x; DESHAIES RJ, 1988, NATURE, V332, P800, DOI 10.1038/332800a0; DORNER AJ, 1992, EMBO J, V11, P1563, DOI 10.1002/j.1460-2075.1992.tb05201.x; ESNAULT Y, 1993, EMBO J, V12, P4083, DOI 10.1002/j.1460-2075.1993.tb06092.x; FABRE E, 1992, J BIOL CHEM, V267, P15049; FELICI F, 1989, MOL CELL BIOL, V9, P3260, DOI 10.1128/MCB.9.8.3260; GORLICH D, 1992, CELL, V71, P489, DOI 10.1016/0092-8674(92)90517-G; HANN BC, 1989, J CELL BIOL, V109, P3223, DOI 10.1083/jcb.109.6.3223; HARTMANN E, 1994, NATURE, V367, P654, DOI 10.1038/367654a0; HE F, 1990, CURR GENET, V17, P289, DOI 10.1007/BF00314874; HE F, 1992, J BIOL CHEM, V267, P1932; KAISER CA, 1990, CELL, V61, P723, DOI 10.1016/0092-8674(90)90483-U; LEWIS MJ, 1990, CELL, V61, P1359, DOI 10.1016/0092-8674(90)90699-F; MATOBA S, 1988, MOL CELL BIOL, V8, P4904, DOI 10.1128/MCB.8.11.4904; MUNRO S, 1987, CELL, V48, P899, DOI 10.1016/0092-8674(87)90086-9; NICCHITTA CV, 1993, CELL, V73, P989, DOI 10.1016/0092-8674(93)90276-V; PIDOUX AL, 1992, EMBO J, V11, P1583, DOI 10.1002/j.1460-2075.1992.tb05203.x; RANDALL LL, 1986, CELL, V46, P921, DOI 10.1016/0092-8674(86)90074-7; ROSE MD, 1989, CELL, V57, P1211, DOI 10.1016/0092-8674(89)90058-5; ROTHBLATT JA, 1989, J CELL BIOL, V109, P2641, DOI 10.1083/jcb.109.6.2641; ROTHBLATT JA, 1986, EMBO J, V5, P1031; SCIDMORE MA, 1993, MOL BIOL CELL, V4, P1145, DOI 10.1091/mbc.4.11.1145; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STIRLING CJ, 1992, NATURE, V356, P534, DOI 10.1038/356534a0; VONHEIJNE G, 1985, J MOL BIOL, V184, P99, DOI 10.1016/0022-2836(85)90046-4; WALTER P, 1980, P NATL ACAD SCI-BIOL, V77, P7112, DOI 10.1073/pnas.77.12.7112; WALTER P, 1983, CELL, V34, P525, DOI 10.1016/0092-8674(83)90385-9; WIEDMANN B, 1994, NATURE, V370, P434, DOI 10.1038/370434a0; XUAN JW, 1988, CURR GENET, V14, P15, DOI 10.1007/BF00405848; YAVER DS, 1992, J CELL BIOL, V116, P605, DOI 10.1083/jcb.116.3.605	30	37	48	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 17	1996	271	20					11668	11675		10.1074/jbc.271.20.11668	http://dx.doi.org/10.1074/jbc.271.20.11668			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UL250	8662639	Green Published, hybrid			2022-12-25	WOS:A1996UL25000016
J	Cheng, M; Zhen, E; Robinson, MJ; Ebert, D; Goldsmith, E; Cobb, MH				Cheng, M; Zhen, E; Robinson, MJ; Ebert, D; Goldsmith, E; Cobb, MH			Characterization of a protein kinase that phosphorylates serine 189 of the mitogen-activated protein kinase homolog ERK3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAP KINASE; GROWTH-FACTOR; CATALYTIC SUBUNIT; CRYSTAL-STRUCTURE; IDENTIFICATION; INSULIN; PATHWAY; INVITRO; CELLS	A novel protein kinase activity present in nuclear and cytosolic extracts has been identified and partially purified as a consequence of its tight binding to and phosphorylation of the extracellular signal-regulated protein kinase (ERK) 3. This novel protein kinase is inactivated by treatment with phosphoprotein phosphatase 2A. The ERK3 protein kinase was immunologically distinct from mitogen-activated protein (MAP) kinase/ERK kinases (MEK) 1 and 2 which phosphorylate the ERK3-related MAP kinases ERK1 and ERK2. This ERK3 kinase phosphorylated a single site on ERK3, Ser(189), comparable to Thr(183), one of the two activating phospho rylation sites of ERK2. To test the specificity of the ERK3 kinase, mutants of ERK3 and ERK2 were made in which the phosphorylated residues were exchanged. The double mutant S189T,G191Y ERK3, in which the phosphorylated residues from ERK2 replaced the comparable residues in ERK3, was phosphorylated by the ERK3 kinase but only on threonine. The ERK3 kinase did not phosphorylate ERK2 or ERK2 mutants. These findings indicate that although the ERK3 kinase is highly specific for ERK3, it does not recognize tyrosine, a feature that distinguishes it from MEKs that phosphorylate other ERK/MAP kinase family members.	UNIV TEXAS,SW MED CTR,DEPT PHARMACOL,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,DEPT BIOCHEM,DALLAS,TX 75235	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas				Cobb, Melanie/0000-0003-0833-5473	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK034128, R37DK034128] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK34128] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AHN NG, 1991, J BIOL CHEM, V266, P4220; ANDERSON NG, 1990, NATURE, V343, P651, DOI 10.1038/343651a0; BLUMER KJ, 1994, TRENDS BIOCHEM SCI, V19, P236, DOI 10.1016/0968-0004(94)90147-3; BOULTON TG, 1991, CELL REGUL, V2, P357, DOI 10.1091/mbc.2.5.357; BOULTON TG, 1990, SCIENCE, V249, P64, DOI 10.1126/science.2164259; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; CHEN RH, 1992, MOL CELL BIOL, V12, P915, DOI 10.1128/MCB.12.3.915; Cheng M, 1996, J BIOL CHEM, V271, P8951, DOI 10.1074/jbc.271.15.8951; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; CREWS CM, 1992, SCIENCE, V258, P478, DOI 10.1126/science.1411546; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DEBONDT HL, 1993, NATURE, V363, P595, DOI 10.1038/363595a0; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; ENGLISH JM, 1995, J BIOL CHEM, V270, P28897, DOI 10.1074/jbc.270.48.28897; HERSKOWITZ I, 1995, CELL, V80, P187, DOI 10.1016/0092-8674(95)90402-6; KIKKAWA U, 1983, METHOD ENZYMOL, V99, P288; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; LEVIN DE, 1993, J NIH RES, V5, P49; MUMBY MC, 1985, J BIOL CHEM, V260, P3763; NEIMAN AM, 1993, MOL BIOL CELL, V4, P107, DOI 10.1091/mbc.4.1.107; PAYNE DM, 1991, EMBO J, V10, P885, DOI 10.1002/j.1460-2075.1991.tb08021.x; ROBBINS DJ, 1992, MOL BIOL CELL, V3, P299, DOI 10.1091/mbc.3.3.299; ROBBINS DJ, 1993, J BIOL CHEM, V268, P5097; ROBBINS DJ, 1994, ADV CANCER RES, V63, P93, DOI 10.1016/S0065-230X(08)60399-1; SEGER R, 1992, J BIOL CHEM, V267, P14373; SONTAG E, 1993, CELL, V75, P887, DOI 10.1016/0092-8674(93)90533-V; WU J, 1992, BIOCHEM J, V285, P701, DOI 10.1042/bj2850701; WU J, 1993, MOL CELL BIOL, V13, P4539, DOI 10.1128/MCB.13.8.4539; XU RM, 1995, EMBO J, V14, P1015, DOI 10.1002/j.1460-2075.1995.tb07082.x; XU SC, 1995, P NATL ACAD SCI USA, V92, P6808, DOI 10.1073/pnas.92.15.6808; ZHANG FM, 1994, NATURE, V367, P704, DOI 10.1038/367704a0; ZHANG JD, 1995, STRUCTURE, V3, P299, DOI 10.1016/S0969-2126(01)00160-5; ZHENG CF, 1994, J BIOL CHEM, V269, P19947; ZHENG CF, 1993, J BIOL CHEM, V268, P11435	34	37	37	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 17	1996	271	20					12057	12062		10.1074/jbc.271.20.12057	http://dx.doi.org/10.1074/jbc.271.20.12057			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UL250	8662649	hybrid			2022-12-25	WOS:A1996UL25000071
J	Fisher, MD; Frost, SC				Fisher, MD; Frost, SC			Translocation of GLUT1 does not account for elevated glucose transport in glucose-deprived 3T3-L1 adipocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA; MURINE FIBROBLASTS; INSULIN; PROTEIN; EXPRESSION; CELLS; DEPRIVATION; STARVATION; HEPG2	Glucose deprivation increases the rate of glucose transport in 3T3-L1 adipocytes in a protein synthesis-dependent fashion. To determine if translocation of either GLUT1 or GLUT4 is responsible for this phenomenon, we adapted existing fractionation procedures toward isolating 3T3-L1 adipocyte membranes. By Western blot analysis of equal protein, GLUT1 was distributed between plasma membranes, high density ''microsomal'' membranes, and low density ''microsomal'' membranes isolated from control cells. GLUT4 comigrated with high density and low density membranes. Glucose deprivation for 12 h did not alter the distribution of either GLUT1 or GLUT4, despite an 8-10-fold increase in glucose transport activity in intact cells, Importantly, increased transport activity was retained in plasma membrane vesicles isolated from glucose-deprived cells. These data show for the first time that the increase in transport activity associated with glucose deprivation does not result from the translocation of either of the glucose transporters known to exist in 3T3-L1 adipocytes. As GLUT4 is excluded from the plasma membrane, these data provide evidence for activation of GLUT1.	UNIV FLORIDA,COLL MED,DEPT BIOCHEM & MOLEC BIOL,GAINESVILLE,FL 32610	State University System of Florida; University of Florida					NIDDK NIH HHS [DK 45035] Funding Source: Medline	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BALCH WE, 1985, ARCH BIOCHEM BIOPHYS, V240, P413, DOI 10.1016/0003-9861(85)90046-3; CALDERHEAD DM, 1990, J BIOL CHEM, V265, P13800; HASPEL HC, 1986, J BIOL CHEM, V261, P6778; JAMES DE, 1993, J CELL SCI, V104, P607; KITZMAN HH, 1993, J BIOL CHEM, V268, P1320; KLIP A, 1994, FASEB J, V8, P43, DOI 10.1096/fasebj.8.1.8299889; KOZKA IJ, 1991, J BIOL CHEM, V266, P11726; MARKWELL MAK, 1978, ANAL BIOCHEM, V87, P206, DOI 10.1016/0003-2697(78)90586-9; MAYOR P, 1992, DIABETES, V41, P274, DOI 10.2337/diabetes.41.3.274; ORTIZ PA, 1992, BIOCHEMISTRY-US, V31, P5386, DOI 10.1021/bi00138a021; REED BC, 1990, ARCH BIOCHEM BIOPHYS, V279, P261, DOI 10.1016/0003-9861(90)90490-P; SIMPSON IA, 1983, BIOCHIM BIOPHYS ACTA, V763, P393, DOI 10.1016/0167-4889(83)90101-5; TORDJMAN KM, 1990, BIOCHEM J, V271, P201, DOI 10.1042/bj2710201; VANPUTTEN JPM, 1985, J BIOL CHEM, V260, P7996; WALKER PS, 1988, J BIOL CHEM, V263, P15594; WALKER PS, 1990, J BIOL CHEM, V265, P1516; WEBER TM, 1988, RECEPTOR BIOCH METHO, P171; YAMADA K, 1983, J BIOL CHEM, V258, P9786; YANG J, 1992, J BIOL CHEM, V267, P10393	19	35	35	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 17	1996	271	20					11806	11809		10.1074/jbc.271.20.11806	http://dx.doi.org/10.1074/jbc.271.20.11806			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UL250	8662621	hybrid			2022-12-25	WOS:A1996UL25000037
J	He, WM; Craparo, A; Zhu, YY; ONeill, TJ; Wang, LM; Pierce, JH; Gustafson, TA				He, WM; Craparo, A; Zhu, YY; ONeill, TJ; Wang, LM; Pierce, JH; Gustafson, TA			Interaction of insulin receptor substrate-2 (IRS-2) with the insulin and insulin-like growth factor I receptors - Evidence for two distinct phosphotyrosine-dependent interaction domains within IRS-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL TRANSDUCTION; HEMATOPOIETIC-CELLS; PROTEIN; SHC; PHOSPHORYLATION; SITES; ACIDS	Insulin receptor substrate 2 (IRS-2) has recently been shown to be a substrate of the insulin receptor (IR), In this study we utilize the yeast two-hybrid system and assays of in vitro interaction to demonstrate that IRS-2 interacts directly with the IR and the insulin-like growth factor I receptor, We show that, like IRS-1, the region of IRS-2 that contains the putative phosphotyrosine binding and SAIN elements (188-591) is sufficient for receptor interaction and that this interaction is dependent upon the NPX(p)Y (where (p)Y is phosphotyrosine) motifs within the juxtamembrane domains of the receptors, In addition to this amino-terminal NPX(p)Y-binding domain, an additional domain of strong interaction was identified in the central region of IRS-2 and was localized between amino acids 591 and 733, This interaction was found to be dependent upon receptor phosphorylation but was NPX(p)Y-independent, This region does not appear to have either an SH2 or a phosphotyrosine binding domain, Both of the interactions could also be demonstrated in vitro using IRS-2 glutathione S-transferase fusion proteins, We conclude that IRS-2, unlike IRS-1, can interact with tyrosine phosphorylated receptors such as the IR and insulin-like growth factor I receptor via multiple independent binding motifs, Our findings suggest the existence of a previously unidentified phosphotyrosine dependent binding domain within the central region of IRS-2.	UNIV MARYLAND,SCH MED,DEPT PHYSIOL,BALTIMORE,MD 21201; UNIV MARYLAND,SCH MED,PROGRAM MOLEC & CELLULAR BIOL,BALTIMORE,MD 21201; NCI,CELLULAR & MOLEC BIOL LAB,NIH,BETHESDA,MD 20892	University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK044093] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008181] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK44093] Funding Source: Medline; NIGMS NIH HHS [GM08181] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARAKI E, 1994, NATURE, V372, P186, DOI 10.1038/372186a0; Ausubel F.M., 1993, CURRENT PROTOCOLS MO; BACKER JM, 1993, J BIOL CHEM, V268, P8204; BECKER AB, 1990, ANNU REV MED, V41, P99; BLAIKIE P, 1994, J BIOL CHEM, V269, P32031; BREEDEN L, 1985, COLD SPRING HARB SYM, V50, P643, DOI 10.1101/SQB.1985.050.01.078; CHUANG LM, 1993, P NATL ACAD SCI USA, V90, P5172, DOI 10.1073/pnas.90.11.5172; CRAPARO A, 1995, J BIOL CHEM, V270, P15639, DOI 10.1074/jbc.270.26.15639; EBINA Y, 1985, CELL, V40, P747, DOI 10.1016/0092-8674(85)90334-4; GIORGETTI S, 1994, EUR J BIOCHEM, V223, P195, DOI 10.1111/j.1432-1033.1994.tb18983.x; GOLEMIS EA, 1992, MOL CELL BIOL, V12, P3006, DOI 10.1128/MCB.12.7.3006; GUSTAFSON TA, 1995, MOL CELL BIOL, V15, P2500; GUTHRIE C, 1992, METHOD ENZYMOL, V194, P1; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; HARA K, 1994, P NATL ACAD SCI USA, V91, P7415, DOI 10.1073/pnas.91.16.7415; HE WM, 1995, J BIOL CHEM, V270, P23258, DOI 10.1074/jbc.270.40.23258; KAHN CR, 1993, RECENT PROG HORM RES, V48, P291; KAVANAUGH WM, 1994, SCIENCE, V266, P1862, DOI 10.1126/science.7527937; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; Miller J.H., 1972, EXPT MOL GENETICS; OKADA T, 1994, J BIOL CHEM, V269, P3568; ONEILL TJ, 1994, MOL CELL BIOL, V14, P6433, DOI 10.1128/MCB.14.10.6433; PATTI ME, 1995, J BIOL CHEM, V270, P24670, DOI 10.1074/jbc.270.42.24670; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; PRONK GJ, 1994, MOL CELL BIOL, V14, P1575, DOI 10.1128/MCB.14.3.1575; PRONK GJ, 1993, J BIOL CHEM, V268, P5748; PRUETT W, 1995, MOL CELL BIOL, V15, P1778; QUON MJ, 1994, J BIOL CHEM, V269, P27920; RON D, 1992, BIOTECHNIQUES, V13, P866; ROSE DW, 1994, P NATL ACAD SCI USA, V91, P797, DOI 10.1073/pnas.91.2.797; SASAOKA T, 1994, J BIOL CHEM, V269, P10734; SCHIESTL RH, 1989, CURR GENET, V16, P339, DOI 10.1007/BF00340712; SKOLNIK EY, 1993, EMBO J, V12, P1929, DOI 10.1002/j.1460-2075.1993.tb05842.x; SUN XJ, 1995, NATURE, V377, P173, DOI 10.1038/377173a0; SUN XJ, 1993, MOL CELL BIOL, V13, P7418, DOI 10.1128/MCB.13.12.7418; TAMEMOTO H, 1994, NATURE, V372, P182, DOI 10.1038/372182a0; ULLRICH A, 1985, NATURE, V313, P756, DOI 10.1038/313756a0; WANG LM, 1992, EMBO J, V11, P4899, DOI 10.1002/j.1460-2075.1992.tb05596.x; WANG LM, 1993, SCIENCE, V261, P1591, DOI 10.1126/science.8372354; WANG LM, 1993, P NATL ACAD SCI USA, V90, P4032, DOI 10.1073/pnas.90.9.4032; WHITE MF, 1994, J BIOL CHEM, V269, P1; WOLF G, 1995, J BIOL CHEM, V270, P27407, DOI 10.1074/jbc.270.46.27407; YONEZAWA K, 1994, J BIOL CHEM, V269, P4634; ZERVOS AS, 1993, CELL, V72, P223, DOI 10.1016/0092-8674(93)90662-A; ZHANG B, 1991, J BIOL CHEM, V266, P990	45	125	126	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 17	1996	271	20					11641	11645		10.1074/jbc.271.20.11641	http://dx.doi.org/10.1074/jbc.271.20.11641			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UL250	8662806	hybrid			2022-12-25	WOS:A1996UL25000012
J	Li, CH; Ramjeesingh, M; Bear, CE				Li, CH; Ramjeesingh, M; Bear, CE			Purified cystic fibrosis transmembrane conductance regulator (CFTR) does not function as an ATP channel	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHLORIDE CHANNEL; CELL-LINE; RECONSTITUTION; PROTEINS; CAMP	The gene mutated in cystic fibrosis codes for the cystic fibrosis transmembrane conductance regulator (CFTR). Previously, we provided definitive evidence that CFTR functions as a phosphorylation-regulated chloride channel in our planar lipid bilayer studies of the purified, reconstituted protein. Recent patch-clamp studies have lead to the suggestion that CFTR may also be capable of conducting ATP or inducing this function in neighboring channels. In the present study, we assessed the ATP channel activity of purified CFTR and found that the purified protein does not function as an ATP channel in planar bilayer studies of single channel activity nor in ATP flux measurements in proteoliposomes. Hence, CFTR does not possess intrinsic ATP channel activity and its putative role in cellular ATP transport may be indirect.	UNIV TORONTO,HOSP SICK CHILDREN,RES INST,DIV CELL BIOL,TORONTO,ON M5G 1X8,CANADA; UNIV TORONTO,DEPT PHYSIOL,TORONTO,ON M5G 1X8,CANADA	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto								ANDERSON MP, 1991, SCIENCE, V253, P202, DOI 10.1126/science.1712984; BEAR CE, 1992, CELL, V68, P809, DOI 10.1016/0092-8674(92)90155-6; BEAR CE, 1992, AM J PHYSIOL, V262, pC251, DOI 10.1152/ajpcell.1992.262.1.C251; EGAN M, 1992, NATURE, V358, P581, DOI 10.1038/358581a0; GABRIEL SE, 1993, NATURE, V363, P263, DOI 10.1038/363263a0; GARTY H, 1983, J BIOL CHEM, V258, P3094; GOLDBERG AFX, 1991, J MEMBRANE BIOL, V124, P199, DOI 10.1007/BF01994354; Grygorczyk R., 1996, Biophysical Journal, V70, pA71; KARTNER N, 1991, CELL, V64, P681, DOI 10.1016/0092-8674(91)90498-N; KNOWLES MR, 1991, NEW ENGL J MED, V325, P533, DOI 10.1056/NEJM199108223250802; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; REISIN IL, 1994, J BIOL CHEM, V269, P20584; SCHWIEBERT EM, 1995, CELL, V81, P1063, DOI 10.1016/S0092-8674(05)80011-X; SEIBERT FS, 1995, J BIOL CHEM, V270, P2158, DOI 10.1074/jbc.270.5.2158; STUTTS MJ, 1995, SCIENCE, V269, P847, DOI 10.1126/science.7543698; STUTTS MJ, 1994, AM J PHYSIOL-CELL PH, V267, pC1442, DOI 10.1152/ajpcell.1994.267.5.C1442; TABCHARANI JA, 1990, FEBS LETT, V270, P157, DOI 10.1016/0014-5793(90)81257-O; TABCHARANI JA, 1993, NATURE, V366, P79, DOI 10.1038/366079a0; Welsh MJ, 1995, METABOLIC MOL BASES, V3, P3799; WOODBURY DJ, 1990, BIOPHYS J, V58, P833, DOI 10.1016/S0006-3495(90)82429-2	20	96	98	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 17	1996	271	20					11623	11626		10.1074/jbc.271.20.11623	http://dx.doi.org/10.1074/jbc.271.20.11623			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UL250	8662751	hybrid			2022-12-25	WOS:A1996UL25000008
J	OBryan, JP; Martin, CB; Songyang, Z; Cantley, LC; Der, CJ				OBryan, JP; Martin, CB; Songyang, Z; Cantley, LC; Der, CJ			Binding specificity and mutational analysis of the phosphotyrosine binding domain of the brain-specific adaptor protein ShcC	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SH2 DOMAIN	She proteins (hereafter referred to as ShcA) represent major substrates of tyrosine phosphorylation by a wide variety of growth factors and cytokines, We have recently described a novel ShcA-like protein, ShcC, which like ShcA contains an NH2-terminal phosphotyrosine binding domain (PTB), a central effector region (CH1) and a COOH-terminal Src homology 2 domain (SH2). Both the SH2 and PTB domains of ShcC bind a similar profile of proteins as the comparable regions of ShcA. In an effort to define the functional differences or similarities between ShcA and ShcC, we have further characterized the PTB domain of ShcC. Using a degenerate phosphopeptide library screen, we show that the PTB domain of ShcC preferentially binds the sequence His-hydrophobic-Asn/hydrophobic-Asn-Pro-Ser/Thr-Tyr(P). This sequence is similar to the binding site for the ShcA PTB domain, suggesting that these two proteins may have overlapping specificities. In addition, random mutagenesis of the ShcC PTB domain has identified several amino acids important for PTB function (Gly(32), Glu(63), Ala(136), Gly(139), and Asp(140)). Mutation of these amino acids dramatically reduces the affinity of the ShcC PTB domain for the activated epidermal growth factor receptor in vitro.	HARVARD UNIV, SCH MED, BOSTON, MA 02115 USA; BETH ISRAEL HOSP, DEPT MED, BOSTON, MA 02115 USA	Harvard University; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center	OBryan, JP (corresponding author), UNIV N CAROLINA, DEPT PHARMACOL, CB 7365, CHAPEL HILL, NC 27599 USA.		Cantley, Lewis C/D-1800-2014	Cantley, Lewis C/0000-0002-1298-7653; Der, Channing/0000-0002-7751-2747; O'Bryan, John/0000-0001-5386-1080	NCI NIH HHS [CA42978, CA55008, CA63071] Funding Source: Medline; NIGMS NIH HHS [R01 GM056203] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA055008, R01CA063071, R01CA042978] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM056203] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BATZER AG, 1995, MOL CELL BIOL, V15, P4403; BATZER AG, 1994, MOL CELL BIOL, V14, P5192, DOI 10.1128/MCB.14.8.5192; BLAIKIE P, 1994, J BIOL CHEM, V269, P32031; BORK P, 1995, CELL, V80, P693, DOI 10.1016/0092-8674(95)90347-X; CAMPBELL KS, 1994, P NATL ACAD SCI USA, V91, P6344, DOI 10.1073/pnas.91.14.6344; DILWORTH SM, 1994, NATURE, V367, P87, DOI 10.1038/367087a0; FEIG LA, 1987, MOL ENDOCRINOL, V1, P127, DOI 10.1210/mend-1-2-127; Fridell YWC, 1996, MOL CELL BIOL, V16, P135; GOTOH N, 1994, P NATL ACAD SCI USA, V91, P167, DOI 10.1073/pnas.91.1.167; GUSTAFSON TA, 1995, MOL CELL BIOL, V15, P2500; KAVANAUGH WM, 1995, SCIENCE, V268, P1177, DOI 10.1126/science.7539155; KAVANAUGH WM, 1994, SCIENCE, V266, P1862, DOI 10.1126/science.7527937; LI NX, 1994, ONCOGENE, V9, P3457; MARENGERE LEM, 1992, J BIOL CHEM, V267, P22779; OBryan JP, 1996, P NATL ACAD SCI USA, V93, P2729, DOI 10.1073/pnas.93.7.2729; OKABAYASHI Y, 1994, J BIOL CHEM, V269, P18674; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; QUILLIAM LA, 1994, MOL CELL BIOL, V14, P1113, DOI 10.1128/MCB.14.2.1113; RAMEH LE, 1995, CELL, V83, P821, DOI 10.1016/0092-8674(95)90195-7; SOLER C, 1994, ONCOGENE, V9, P2207; SONGYANG Z, 1995, J BIOL CHEM, V270, P14863, DOI 10.1074/jbc.270.25.14863; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; vanderGeer P, 1996, P NATL ACAD SCI USA, V93, P963, DOI 10.1073/pnas.93.3.963; WAKSMAN G, 1993, CELL, V72, P779, DOI 10.1016/0092-8674(93)90405-F; WOLF G, 1995, J BIOL CHEM, V270, P27407, DOI 10.1074/jbc.270.46.27407; Yajnik V, 1996, J BIOL CHEM, V271, P1813, DOI 10.1074/jbc.271.4.1813; ZHOU MM, 1995, P NATL ACAD SCI USA, V92, P7784, DOI 10.1073/pnas.92.17.7784; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	29	18	18	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 17	1996	271	20					11787	11791		10.1074/jbc.271.20.11787	http://dx.doi.org/10.1074/jbc.271.20.11787			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UL250	8662772	hybrid			2022-12-25	WOS:A1996UL25000034
J	Moggs, JG; Yarema, KJ; Essigmann, JM; Wood, RD				Moggs, JG; Yarema, KJ; Essigmann, JM; Wood, RD			Analysis of incision sites produced by human cell extracts and purified proteins during nucleotide excision repair of a 1,3-intrastrand d(GpTpG)-cisplatin adduct	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA; NUCLEASE; BINDING; CIS-DIAMMINEDICHLOROPLATINUM(II)	Nucleotide excision repair by mammalian enzymes removes DNA damage as part of similar to 30-mer oligonucleotides by incising phosphodiester bonds on either side of a lesion, We analyzed this dual incision reaction at a single 1,3-intrastrand d(GpTpG)-cisplatin cross-link in a closed circular duplex DNA substrate. Incisions were formed in the DNA with human cell extracts in which DNA repair synthesis was inhibited. The nicks were mapped by restriction fragment end labeling and primer extension analysis. Principal sites of cleavage were identified at the 9th phosphodiester bond 3' to the lesion and at the 16th phosphodiester bond 5' to the lesion. The predominant product was found to be a 26-mer platinated oligonucleotide by hybridization to a P-32-labeled complementary DNA probe. Oligonucleotides were formed at the same rate as the 3' cleavage, suggesting that both incisions are made in a near-synchronous manner. There was, however, a low frequency of 5' incisions in the absence of 3' cleavage. The dual incision reaction was reconstituted using the purified mammalian proteins XPA, RPA, XPC, TFIIH, XPG, and a fraction containing ERCC1-XPF and IF7. All of these components were required in order to observe any cleavage.	MIT,DEPT CHEM,CAMBRIDGE,MA 02139; IMPERIAL CANC RES FUND,CLARE HALL LABS,S MIMMS EN6 3LD,HERTS,ENGLAND	Massachusetts Institute of Technology (MIT)			Wood, Richard D/M-6319-2018	Wood, Richard D/0000-0002-9495-6892	NCI NIH HHS [CA52127] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R35CA052127] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABOUSSEKHRA A, 1995, CELL, V80, P859, DOI 10.1016/0092-8674(95)90289-9; ANIN MF, 1990, NUCLEIC ACIDS RES, V18, P4395, DOI 10.1093/nar/18.15.4395; BARDWELL AJ, 1994, SCIENCE, V265, P2082, DOI 10.1126/science.8091230; BARONE F, 1995, PHOTOCHEM PHOTOBIOL, V61, P61, DOI 10.1111/j.1751-1097.1995.tb09243.x; BELLON SF, 1991, BIOCHEMISTRY-US, V30, P8026, DOI 10.1021/bi00246a021; CALSOU P, 1994, NUCLEIC ACIDS RES, V22, P4937, DOI 10.1093/nar/22.23.4937; CALVERT H, 1993, PHARMACOKINETICS CAN, V17, P189; COMESS KM, 1992, BIOCHEMISTRY-US, V31, P3975, DOI 10.1021/bi00131a013; COVERLEY D, 1992, NUCLEIC ACIDS RES, V20, P3873, DOI 10.1093/nar/20.15.3873; DAVIES AA, 1995, J BIOL CHEM, V270, P24638, DOI 10.1074/jbc.270.42.24638; DRAPKIN R, 1994, NATURE, V368, P769, DOI 10.1038/368769a0; HABRAKEN Y, 1994, J BIOL CHEM, V269, P31342; HE ZG, 1995, NATURE, V374, P566, DOI 10.1038/374566a0; HUANG JC, 1994, P NATL ACAD SCI USA, V91, P10394, DOI 10.1073/pnas.91.22.10394; HUANG JC, 1992, P NATL ACAD SCI USA, V89, P3664, DOI 10.1073/pnas.89.8.3664; HUANG JC, 1994, P NATL ACAD SCI USA, V91, P12213, DOI 10.1073/pnas.91.25.12213; JONES CJ, 1993, BIOCHEMISTRY-US, V32, P12096, DOI 10.1021/bi00096a021; KIM JK, 1995, EUR J BIOCHEM, V228, P849, DOI 10.1111/j.1432-1033.1995.0849m.x; LI L, 1994, P NATL ACAD SCI USA, V91, P5012, DOI 10.1073/pnas.91.11.5012; LI L, 1995, MOL CELL BIOL, V15, P5396; MASUTANI C, 1994, EMBO J, V13, P1831, DOI 10.1002/j.1460-2075.1994.tb06452.x; MATSUDA T, 1995, J BIOL CHEM, V270, P4152, DOI 10.1074/jbc.270.8.4152; MATSUNAGA T, 1995, J BIOL CHEM, V270, P20862, DOI 10.1074/jbc.270.35.20862; MU D, 1995, J BIOL CHEM, V270, P2415, DOI 10.1074/jbc.270.6.2415; NAGAI A, 1995, BIOCHEM BIOPH RES CO, V211, P960, DOI 10.1006/bbrc.1995.1905; ODONOVAN A, 1994, J BIOL CHEM, V269, P15965; ODONOVAN A, 1994, NATURE, V371, P432, DOI 10.1038/371432a0; Oliver Timothy, 1993, Current Opinion in Oncology, V5, P559, DOI 10.1097/00001622-199305000-00018; PARK CH, 1995, J BIOL CHEM, V270, P4896, DOI 10.1074/jbc.270.9.4896; Patel D. J., 1992, CURR OPIN STRUC BIOL, V2, P345; RAMPINO NJ, 1994, P NATL ACAD SCI USA, V91, P10977, DOI 10.1073/pnas.91.23.10977; SAMBROOK J, 1989, MOL CLONING LABORATO, P421; SCHAEFFER L, 1994, EMBO J, V13, P2388, DOI 10.1002/j.1460-2075.1994.tb06522.x; SHIVJI MKK, 1994, CURR BIOL, V4, P1062, DOI 10.1016/S0960-9822(00)00244-X; SHIVJI MKK, 1994, J BIOL CHEM, V269, P22749; SHIVJI MKK, 1992, CELL, V69, P367, DOI 10.1016/0092-8674(92)90416-A; SHIVJI MKK, 1995, BIOCHEMISTRY-US, V34, P5011, DOI 10.1021/bi00015a012; SVEJSTRUP JQ, 1995, CELL, V80, P21, DOI 10.1016/0092-8674(95)90447-6; SVOBODA DL, 1993, J BIOL CHEM, V268, P1931; SZYMKOWSKI DE, 1992, P NATL ACAD SCI USA, V89, P10772, DOI 10.1073/pnas.89.22.10772; VANGARDEREN CJ, 1994, EUR J BIOCHEM, V225, P1169; VANHOUTEN B, 1993, BIOESSAYS, V15, P51, DOI 10.1002/bies.950150108; VISSE R, 1994, BIOCHEMISTRY-US, V33, P1804, DOI 10.1021/bi00173a025; WANG TSF, 1991, ANNU REV BIOCHEM, V60, P513, DOI 10.1146/annurev.biochem.60.1.513; WOOD RD, 1993, COLD SPRING HARB SYM, V58, P625, DOI 10.1101/SQB.1993.058.01.069; Wood Richard D., 1995, Methods (Orlando), V7, P163, DOI 10.1006/meth.1995.1022; ZOU Y, 1994, BIOCHEMISTRY-US, V33, P5404, DOI 10.1021/bi00184a007	47	175	178	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 22	1996	271	12					7177	7186		10.1074/jbc.271.12.7177	http://dx.doi.org/10.1074/jbc.271.12.7177			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UB157	8636155	hybrid			2022-12-25	WOS:A1996UB15700090
J	Santos, J; Perez de Castro, I; Herranz, M; Pellicer, A; FernandezPiqueras, J				Santos, J; Perez de Castro, I; Herranz, M; Pellicer, A; FernandezPiqueras, J			Allelic losses on chromosome 4 suggest the existence of a candidate tumor suppressor gene region of about 0.6 cM in gamma-radiation-induced mouse primary thymic lymphomas	ONCOGENE			English	Article						mouse thymic lymphomas; gamma-radiation; microsatellites; loss of heterozygosity; chromosome 4; tumour suppressor genes	HOMOZYGOUS DELETIONS; N-METHYLNITROSOUREA; GENOME; ONCOGENES; RAS; MICROSATELLITES; HETEROZYGOSITY; CARCINOGENESIS; ABNORMALITIES; IRRADIATION	Mouse chromosome 4 was investigated to assess the involvement of tumor suppressor genes in primary thymic lymphomas induced by gamma-irradiation. PCR analysis using microsatellite DNA polymorphic markers was performed in F1 animals generated from a cross between the strains C57BL/6J and RF/J. Microsatellite markers were selected with focus on chromosome 4 around the region containing the interferon alpha gene cluster (D4Mit17, D4Wsm1, D4Mit9, and D4Mit205 and a more distal region (D4Mit12, D4Mit54, and D4Mit13). Allelic losses were detected in 21/47 (44.7%) gamma-radiation-induced thymic lymphomas, Analysis of markers located on six other chromosomes as well as on the proximal region of chromosome 4 illustrates the specificity of the occurrences of LOH appearing on the former markers. This analysis clearly suggests the existence of a candidate tumor suppressor gene region on mouse chromosome 4 of about 0.6 cM between the markers D4Wsm1 and D4Mit9 (TLSR1, Thymic Lymphoma Suppressor Region 1). In addition, another more distal region centered at the marker D4Mit58 could be also exist (TLSR2), In most tumors, allelic losses on these chromosome regions involved the paternal RF/J allele (19 of 20).	UNIV AUTONOMA MADRID, FAC CIENCIAS, DEPT BIOL, LAB GENET MOLEC HUMANA, E-28049 MADRID, SPAIN; NYU, MED CTR, DEPT PATHOL, NEW YORK, NY 10016 USA; NYU, MED CTR, KAPLAN CANC CTR, NEW YORK, NY 10016 USA	Autonomous University of Madrid; New York University; New York University			Santos, Javier/ABF-5755-2021; MARTINEZ, ANTONIO PELLICER/C-4832-2015; de Castro, Ignacio Pérez/A-6260-2012	Santos, Javier/0000-0002-4168-6251; de Castro, Ignacio Pérez/0000-0002-8822-8274				ABBOTT CM, 1994, MAMM GENOME, V5, pS51; ABBOTT CM, 1992, MAMM GENOME, V3, pS55, DOI 10.1007/BF00648422; AITMAN TJ, 1991, MAMM GENOME, V1, P206, DOI 10.1007/BF00352326; ALLEN ND, 1990, CELL, V61, P853, DOI 10.1016/0092-8674(90)90195-K; BARDI G, 1993, CANCER RES, V53, P1895; BIECHE I, 1994, CANCER RES, V54, P4274; BRATHWAITE O, 1992, CANCER RES, V52, P3791; CAIRNS P, 1994, CANCER RES, V54, P1422; CALDAS C, 1994, NAT GENET, V8, P27, DOI 10.1038/ng0994-27; CHENG JQ, 1994, CANCER RES, V54, P5547; CHENG JQ, 1993, CANCER RES, V53, P4761; CHENG NC, 1995, ONCOGENE, V10, P291; CORNALL RJ, 1991, GENOMICS, V10, P874, DOI 10.1016/0888-7543(91)90175-E; DIAMOND LE, 1988, MOL CELL BIOL, V8, P2233, DOI 10.1128/MCB.8.5.2233; DIAZ MO, 1988, P NATL ACAD SCI USA, V85, P5259, DOI 10.1073/pnas.85.14.5259; DIETRICH W, 1992, GENETICS, V131, P423; DIETRICH WF, 1993, CELL, V75, P631, DOI 10.1016/0092-8674(93)90484-8; DIETRICH WF, 1994, NAT GENET, V7, P220, DOI 10.1038/ng0694supp-220; ENGLER P, 1991, CELL, V65, P939, DOI 10.1016/0092-8674(91)90546-B; FONG CT, 1992, CANCER RES, V52, P1780; FOREJT J, 1992, CELL, V70, P443, DOI 10.1016/0092-8674(92)90168-C; FOUNTAIN JW, 1992, P NATL ACAD SCI USA, V89, P10557, DOI 10.1073/pnas.89.21.10557; GUAN KL, 1994, GENE DEV, V8, P2939, DOI 10.1101/gad.8.24.2939; GUERRERO I, 1987, MUTAT RES, V185, P293, DOI 10.1016/0165-1110(87)90021-2; GUERRERO I, 1984, P NATL ACAD SCI-BIOL, V81, P202, DOI 10.1073/pnas.81.1.202; HARRIS LJ, 1982, P NATL ACAD SCI-BIOL, V79, P4175, DOI 10.1073/pnas.79.13.4175; HEARNE CM, 1991, MAMM GENOME, V1, P273, DOI 10.1007/BF00352339; HEBERT J, 1994, BLOOD, V84, P4038, DOI 10.1182/blood.V84.12.4038.bloodjournal84124038; HEGI ME, 1994, CANCER RES, V54, P6257; HERZOG CR, 1994, CANCER RES, V54, P4007; HUSSUSSIAN CJ, 1994, NAT GENET, V8, P15, DOI 10.1038/ng0994-15; JEN J, 1994, CANCER RES, V54, P6353; KAMB A, 1994, NAT GENET, V8, P22, DOI 10.1038/ng0994-22; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; KEEN AJ, 1994, ONCOGENE, V9, P2083; KEMP CJ, 1993, CANCER RES, V53, P6022; KLINGER HP, 1982, CYTOGENET CELL GENET, V32, P68, DOI 10.1159/000131688; KNOWLES MA, 1993, ONCOGENE, V8, P1357; LEVINE AJ, 1993, ANNU REV BIOCHEM, V62, P623, DOI 10.1146/annurev.bi.62.070193.003203; LO KW, 1995, CANCER RES, V55, P2039; LOVE JM, 1990, NUCLEIC ACIDS RES, V18, P4123, DOI 10.1093/nar/18.14.4123; MCMORROW LE, 1988, LEUKEMIA, V2, P115; MIYASAKA K, 1995, MOL CARCINOGEN, V13, P37, DOI 10.1002/mc.2940130107; MORI T, 1994, CANCER RES, V54, P3396; NEWCOMB EW, 1988, CANCER RES, V48, P5514; NEWCOMB EW, 1989, ANTICANCER RES, V9, P1407; NISHIMORI H, 1994, INT J CANCER, V59, P108, DOI 10.1002/ijc.2910590120; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; OBRIEN SJ, 1993, NAT GENET, V3, P103, DOI 10.1038/ng0293-103; OKAMOTO A, 1995, CANCER RES, V55, P1448; OLOPADE OI, 1993, CANCER RES, V53, P2410; OLOPADE OI, 1992, CANCER RES, V52, P2523; OTSUKI T, 1995, CANCER RES, V55, P1436; QUELLE DE, 1995, ONCOGENE, V11, P635; SAEZ GT, 1994, MOL CARCINOGEN, V9, P40, DOI 10.1002/mc.2940090108; SANTOS J, 1995, CYTOGENET CELL GENET, V71, P223, DOI 10.1159/000134114; SAPIENZA C, 1989, DEVELOPMENT, V107, P165; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SIMON D, 1991, ONCOGENE, V6, P765; SOKOVA OI, 1992, CANCER GENET CYTOGEN, V58, P24, DOI 10.1016/0165-4608(92)90128-U; SPRUCK CH, 1994, NATURE, V370, P183, DOI 10.1038/370183a0; SREEKANTAIAH C, 1993, AM J PATHOL, V142, P293; SUGAWARA O, 1990, SCIENCE, V247, P707, DOI 10.1126/science.2300822; VANDERRIET P, 1994, CANCER RES, V54, P1156; WISEMAN RW, 1994, P NATL ACAD SCI USA, V91, P3759, DOI 10.1073/pnas.91.9.3759	65	55	55	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB 1	1996	12	3					669	676						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TV597	8637724				2022-12-25	WOS:A1996TV59700024
J	Varlamov, O; Leiter, EH; Fricker, L				Varlamov, O; Leiter, EH; Fricker, L			Induced and spontaneous mutations at Ser(202) of carboxypeptidase E - Effect on enzyme expression, activity, and intracellular routing	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEUROPEPTIDE-PROCESSING ENZYME; MOLECULAR-CLONING; SEQUENCE-ANALYSIS; CRYSTAL-STRUCTURE; ATT-20 CELLS; CDNA; IDENTIFICATION; PURIFICATION; DEGRADATION; RESOLUTION	Carboxypeptidase E (CPE) is involved in peptide processing in the brain and various neuroendocrine tissues. In mice homozygous for the Cpe(fat) mutation, the virtual absence of CPE activity in islets of Langerhans and pituitary was associated with a missense mutation effecting a Ser(202) to Pro shift (Naggert, J. K., Fricker, L. D., Varlamov, O., Nishina, P. M., Rouille, Y., Steiner, D. F., Carroll, R. J., Paigen, B. J., and Leiter, E. H. (1995) Not. Genet. 10, 135-142). To examine the importance of Ser(202) in CPE function, several mutations in this position were generated (pro(202), Ala(202), Gly(202), and Phe(202)). When the mutant proteins were expressed in a Baculovirus system, both Phe(202) and Pro(202)CPE were enzymatically inactive, were unable to bind to a substrate affinity column, and were not secreted from Sf9 cells. In contrast, Ala(202)CPE or Gly(202)CPE exhibited enzymatic properties similar to those of wild-type CPE and were secreted from Sf9 cells. When expressed in AtT-20 cells, a mouse pituitary-derived cell line, CPE with pro(202) and Phe(202) were not secreted. Pulse-chase analysis with [S-35]Met indicated that Pro(202)CPE Wag degraded in AtT-20 cells within several hours. This degradative process was blocked by incubation at 15 degrees C but not by brefeldin A or by lysoso-motrophic drugs. Pulse-chase analysis using dispersed pituitary cells from C57BLKS/Lt-Cpe(fat)/Cpe(fat) mutant mice shows similar results; Pro(202)-CPE produced in these cells was not secreted but rather was degraded within 5 h. Immunofluorescence analysis of epitope-tagged CPE revealed Ser(202)CPE to be present primarily in secretory vesicles, whereas pro(202)CPE was localized to the endoplasmic reticulum and not the secretory vesicle-like structures. These results support the previous finding that Cpe(fat)/Cpe(fat) mice are defective in CPE activity because of the point mutation producing the Ser(202) to Pro substitution. Furthermore, these results are consistent with a model that Ser(202) is important for the intracellular folding of CPE.	ALBERT EINSTEIN COLL MED,DEPT MOLEC PHARMACOL,BRONX,NY 10461; JACKSON LAB,BAR HARBOR,ME 04609	Yeshiva University; Albert Einstein College of Medicine; Jackson Laboratory					NATIONAL INSTITUTE ON DRUG ABUSE [R01DA004494, K02DA000194] Funding Source: NIH RePORTER; NIDA NIH HHS [DA-00194, DA-04494] Funding Source: Medline	NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA))		ADELI K, 1994, J BIOL CHEM, V269, P9166; [Anonymous], 1995, METH NEUROSCI; Bennett HPJ, 1991, PEPTIDE BIOSYNTHESIS, P111; BRADSHAW RA, 1969, P NATL ACAD SCI USA, V63, P1389, DOI 10.1073/pnas.63.4.1389; CLAUSER E, 1988, J BIOL CHEM, V263, P17837; DAVIDSON HW, 1987, BIOCHEM J, V245, P575, DOI 10.1042/bj2450575; EATON DL, 1991, J BIOL CHEM, V266, P21833; FRICKER LD, 1986, NATURE, V323, P461, DOI 10.1038/323461a0; FRICKER LD, 1990, J BIOL CHEM, V265, P2476; FRICKER LD, 1983, J BIOL CHEM, V258, P950; FRICKER LD, 1988, ANNU REV PHYSIOL, V50, P309, DOI 10.1146/annurev.ph.50.030188.001521; FRICKER LD, 1993, J NEUROCHEM, V61, P1404, DOI 10.1111/j.1471-4159.1993.tb13634.x; FRICKER LD, 1989, MOL ENDOCRINOL, V3, P666, DOI 10.1210/mend-3-4-666; FRICKER LD, 1991, PEPTIDE BIOSYNTHESIS, P199; GARDNER AM, 1993, J BIOL CHEM, V268, P25940; GEBHARD W, 1989, EUR J BIOCHEM, V178, P603, DOI 10.1111/j.1432-1033.1989.tb14488.x; HAMMOND C, 1994, J CELL BIOL, V126, P41, DOI 10.1083/jcb.126.1.41; HE GP, 1995, NATURE, V378, P92, DOI 10.1038/378092a0; HORNBY PJ, 1993, NEUROENDOCRINOLOGY, V58, P555, DOI 10.1159/000126590; HOSAKA M, 1991, J BIOL CHEM, V266, P12127; KUROKI K, 1995, J BIOL CHEM, V270, P15022, DOI 10.1074/jbc.270.25.15022; LIPPINCOTTSCHWARTZ J, 1988, CELL, V54, P209, DOI 10.1016/0092-8674(88)90553-3; MANSER E, 1990, BIOCHEM J, V267, P517, DOI 10.1042/bj2670517; MITRA A, 1994, J BIOL CHEM, V269, P19876; NAGGERT JK, 1995, NAT GENET, V10, P135, DOI 10.1038/ng0695-135; REES DC, 1983, J MOL BIOL, V168, P367, DOI 10.1016/S0022-2836(83)80024-2; REYNOLDS DS, 1989, P NATL ACAD SCI USA, V86, P9480, DOI 10.1073/pnas.86.23.9480; ROTH WW, 1991, MOL CELL ENDOCRINOL, V78, P171, DOI 10.1016/0303-7207(91)90120-H; Sambrook J., 2002, MOL CLONING LAB MANU; SCHAFER MKH, 1993, J NEUROSCI, V13, P1258; SCHMID MF, 1976, J MOL BIOL, V103, P175, DOI 10.1016/0022-2836(76)90058-9; SEIDAH NG, 1990, DNA CELL BIOL, V9, P415, DOI 10.1089/dna.1990.9.415; SETTLE SH, 1995, P NATL ACAD SCI USA, V92, P9470, DOI 10.1073/pnas.92.21.9470; SMEEKENS SP, 1990, J BIOL CHEM, V265, P2997; SONG LX, 1995, J BIOL CHEM, V270, P7963, DOI 10.1074/jbc.270.14.7963; SONG LX, 1995, J BIOL CHEM, V270, P25007, DOI 10.1074/jbc.270.42.25007; SONG LX, 1995, J NEUROCHEM, V65, P444; TAN FL, 1989, J BIOL CHEM, V264, P13165; TEPLYAKOV A, 1992, EUR J BIOCHEM, V208, P281, DOI 10.1111/j.1432-1033.1992.tb17184.x; TITANI K, 1975, P NATL ACAD SCI USA, V72, P1666, DOI 10.1073/pnas.72.5.1666; Varlamov O, 1996, J BIOL CHEM, V271, P6077, DOI 10.1074/jbc.271.11.6077; YAMASHITA Y, 1994, J VIROL, V68, P7933, DOI 10.1128/JVI.68.12.7933-7943.1994; YUN HY, 1995, J BIOL CHEM, V270, P15412, DOI 10.1074/jbc.270.25.15412; ZHENG M, 1994, J NEUROSCI, V14, P4656; ZHU X, 1996, IN PRESS P NATL ACAD	45	81	83	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 14	1996	271	24					13981	13986		10.1074/jbc.271.24.13981	http://dx.doi.org/10.1074/jbc.271.24.13981			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UQ660	8662840	hybrid			2022-12-25	WOS:A1996UQ66000011
J	McKenzie, FR; Pouyssegur, J				McKenzie, FR; Pouyssegur, J			cAMP-mediated growth inhibition in fibroblasts is not mediated via mitogen-activated protein (MAP) kinase (ERK) inhibition - cAMP-dependent protein kinase induces a temporal shift in growth factor-stimulated MAP kinases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIC-AMP; HAMSTER FIBROBLASTS; SIGNAL-TRANSDUCTION; DNA-SYNTHESIS; PHOSPHORYLATION; PATHWAY; RAF; CELLS; PROLIFERATION; P42(MAPK)	Growth factors stimulate fibroblast cell division by activating the recently identified mitogen-activated protein kinase (MAP kinase) signaling cascade. In contrast to our previous work (Kahan, K., Seuwen, K., 13369-13375), several reports have suggested that an elevation in intracellular cAMP blocks cell proliferation by attenuating MAP kinase activation. Hence we re-examined the effect of a long term increase in intracellular cAMP and therefore cAMP-dependent protein kinase (PKA) activation on the MAP kinase cascade in CCL39 fibroblasts. The concomitant addition of cAMP-elevating agents prostaglandin E, (PGE(1)) and IBMX did not inhibit the mitogen-mediated activation of p44 MAP kinase. However, a 5-min PGE(1)/IBMX pretreatment abolished the MAP kinase response, in a manner correlating with the extent of PKA activity. This inhibition was temporal in nature, and while modifying the time course of growth factor-mediated p44 MAP kinase, activation did not diminish the magnitude of the response. Thus the major peak of MAP kinase activity normally present 5 min after alpha-thrombin addition was now evident at 10 min in the presence of PGE(1)/IBMX. CCL39 cell proliferation could reflect either a reduction in the number of cells entering the cell cycle or a delay in the time required to go through the cycle. Bromodeoxyuridine labeling experiments revealed that the cAMP-mediated inhibition of DNA synthesis in CCL39 cell was not due to a delay in S phase entry, but was due to a reduction in the number of cells entering S phase. Thus we conclude that although PKA activation may slightly modify the time course of MAP kinase activation in response to mitogens in CCL39 cells, the PKA-mediated inhibition of cell division occurs through modulation of an intracellular target, distinct from the p42/p44 MAP kinase cascade.			McKenzie, FR (corresponding author), CTR BIOCHIM,CNRS,PARC VALROSE,F-06108 NICE,FRANCE.							ALALAWI N, 1995, MOL CELL BIOL, V15, P1162; BARLAT I, 1995, ONCOGENE, V11, P1309; Berra E, 1995, EMBO J, V14, P6157, DOI 10.1002/j.1460-2075.1995.tb00306.x; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; BRONDELLO JM, 1995, ONCOGENE, V10, P1895; BRUGGEMANN A, 1993, NATURE, V365, P445, DOI 10.1038/365445a0; BRUNET A, 1994, ONCOGENE, V9, P3379; BURGERING BMT, 1993, EMBO J, V12, P4211, DOI 10.1002/j.1460-2075.1993.tb06105.x; BURGERING BMT, 1995, TRENDS BIOCHEM SCI, V20, P18, DOI 10.1016/S0968-0004(00)88944-6; BURK RR, 1968, NATURE, V219, P1272, DOI 10.1038/2191272a0; CANO E, 1995, TRENDS BIOCHEM SCI, V20, P117, DOI 10.1016/S0968-0004(00)88978-1; CHEN JH, 1994, SCIENCE, V263, P1278, DOI 10.1126/science.8122111; COHEN P, 1992, TRENDS BIOCHEM SCI, V17, P408, DOI 10.1016/0968-0004(92)90010-7; COOK SJ, 1993, SCIENCE, V262, P1069, DOI 10.1126/science.7694367; CREWS CM, 1992, CELL GROWTH DIFFER, V3, P135; DENT P, 1995, SCIENCE, V268, P1902, DOI 10.1126/science.7604263; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DIFRANCESCO D, 1991, NATURE, V351, P145, DOI 10.1038/351145a0; DUMONT JE, 1989, TRENDS BIOCHEM SCI, V14, P67, DOI 10.1016/0968-0004(89)90046-7; FANTL WJ, 1994, NATURE, V371, P612, DOI 10.1038/371612a0; FAURE M, 1994, J BIOL CHEM, V269, P7851; FREED E, 1994, SCIENCE, V265, P1713, DOI 10.1126/science.8085158; FRODIN M, 1994, J BIOL CHEM, V269, P6207; FU H, 1994, SCIENCE, V266, P126, DOI 10.1126/science.7939632; GRAVES LM, 1993, P NATL ACAD SCI USA, V90, P10300, DOI 10.1073/pnas.90.21.10300; GUY HR, 1991, SCIENCE, V254, P730, DOI 10.1126/science.1658932; HAFNER S, 1994, MOL CELL BIOL, V14, P6696; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; HAYSTEAD CMM, 1994, J BIOL CHEM, V269, P12804; HORDIJK PL, 1994, J BIOL CHEM, V269, P3534; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; IRIE K, 1994, SCIENCE, V265, P1716, DOI 10.1126/science.8085159; ITOH T, 1993, P NATL ACAD SCI USA, V90, P975, DOI 10.1073/pnas.90.3.975; JAISWAL RK, 1994, MOL CELL BIOL, V14, P6944, DOI 10.1128/MCB.14.10.6944; KAHAN C, 1992, J BIOL CHEM, V267, P13369; KUPPERMAN E, 1993, MOL CELL BIOL, V13, P4477, DOI 10.1128/MCB.13.8.4477; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LAMY F, 1993, J BIOL CHEM, V268, P8398; LANGECARTER CA, 1994, SCIENCE, V265, P1458, DOI 10.1126/science.8073291; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; LENORMAND P, 1993, J CELL BIOL, V122, P1079, DOI 10.1083/jcb.122.5.1079; LOEVERS SJ, 1994, NATURE, V369, P411; MAGNALDO I, 1989, FEBS LETT, V245, P65, DOI 10.1016/0014-5793(89)80193-0; MARAIS R, 1995, EMBO J, V14, P3136, DOI 10.1002/j.1460-2075.1995.tb07316.x; MOODIE SA, 1994, TRENDS GENET, V10, P44, DOI 10.1016/0168-9525(94)90147-3; MORRISON DK, 1993, J BIOL CHEM, V268, P17309; NAKAMURA T, 1987, NATURE, V325, P442, DOI 10.1038/325442a0; NISHIDA E, 1993, TRENDS BIOCHEM SCI, V18, P128, DOI 10.1016/0968-0004(93)90019-J; PAGES G, 1993, P NATL ACAD SCI USA, V90, P8319, DOI 10.1073/pnas.90.18.8319; PAGES G, 1994, EMBO J, V13, P3003, DOI 10.1002/j.1460-2075.1994.tb06599.x; PASTAN IH, 1975, ANNU REV BIOCHEM, V44, P491, DOI 10.1146/annurev.bi.44.070175.002423; PERALDI P, 1995, FEBS LETT, V357, P290, DOI 10.1016/0014-5793(94)01376-C; PIPER RC, 1993, J BIOL CHEM, V268, P16557; REUTER CWM, 1995, J BIOL CHEM, V270, P7644, DOI 10.1074/jbc.270.13.7644; ROGERS KV, 1990, P NATL ACAD SCI USA, V87, P8975, DOI 10.1073/pnas.87.22.8975; ROSKOSKI R, 1983, METHOD ENZYMOL, V99, P3; SAUNIER B, 1995, J BIOL CHEM, V270, P3693, DOI 10.1074/jbc.270.8.3693; SEUWEN K, 1990, J BIOL CHEM, V265, P22292; SEVETSON BR, 1993, P NATL ACAD SCI USA, V90, P10305, DOI 10.1073/pnas.90.21.10305; SUTHERLAND EW, 1957, J AM CHEM SOC, V79, P3608, DOI 10.1021/ja01570a087; VAILLANCOURT RR, 1994, MOL CELL BIOL, V14, P6522, DOI 10.1128/MCB.14.10.6522; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WALSH DA, 1990, CRC CRIT REV BIOCH, P43; WANG YZ, 1992, BIOCHEM J, V287, P589, DOI 10.1042/bj2870589; WU J, 1993, SCIENCE, V262, P1065, DOI 10.1126/science.7694366; ZHENG CF, 1994, BIOCHEMISTRY-US, V33, P5595, DOI 10.1021/bi00184a031; ZHONG Y, 1995, NATURE, V375, P588, DOI 10.1038/375588a0	68	92	92	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 7	1996	271	23					13476	13483		10.1074/jbc.271.23.13476	http://dx.doi.org/10.1074/jbc.271.23.13476			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UP385	8662790				2022-12-25	WOS:A1996UP38500028
J	Pinkus, R; Weiner, LM; Daniel, V				Pinkus, R; Weiner, LM; Daniel, V			Role of oxidants and antioxidants in the induction of AP-1, NF-kappa B, and glutathione S-transferase gene expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YA-SUBUNIT GENE; ELECTROPHILE-RESPONSIVE ELEMENT; INDUCIBLE EXPRESSION; TRANSCRIPTION FACTOR; BUTYLATED HYDROXYANISOLE; SUPEROXIDE-DISMUTASE; RADICAL FORMATION; INTACT-CELLS; ACTIVATION; JUN	Transcription factors AP-1 and NF-kappa B have been implicated in the inducible expression of a variety of genes in response to oxidative stress. Recently, based on the observation that butylated hydroxyanisole (BHA) and pyrrolidine dithiocarbamate (PDTC) induce AP-1 binding activity and AP-1-dependent gene expression and assuming that these compounds exert an antioxidant effect, it was claimed that AP-1 is an antioxidant-responsive factor. To determine whether AP-1 can be responsive to both oxidant and antioxidant, we examined the nature of BHA and PDTC inducing activity. Using EPR spectroscopy to detect semiquinone radicals, we demonstrate the autoxidation of BHA metabolite tert-butylhydroquinone (TBHQ) to tert-butylquinone. The kinetics of TBHQ-mediated generations of (OH)-O-. radicals were monitored in intact hepatoma HepG2 cells by EPR spin trapping technique. Exogenous catalase inhibited the rate and amount of (OH)-O-. radical formation and the induction of AP-1-mediated glutathione S-transferase (GST) Ya gene expression by BHA and TBHQ, thus indicating the intermediate formation of H2O2 in the metabolism of these chemicals. Furthermore, we show that the induction of AP-1 and NF-kappa B activities and GST Ya gene expression by BHA and TBHQ is due to a pro-oxidant activity, since this induction was inhibited by thiol compounds N-acetyl cysteine and GSH. The present findings do not support the notion that the induction of AP-1 by BHA, TBHQ, or PDTC is an antioxidant response and demonstrate that both AP-1 and NF-kappa B activities are induced by oxygen radicals.	WEIZMANN INST SCI, DEPT BIOCHEM, IL-76100 REHOVOT, ISRAEL; WEIZMANN INST SCI, DEPT ORGAN CHEM, IL-76100 REHOVOT, ISRAEL	Weizmann Institute of Science; Weizmann Institute of Science			Lev, Weiner/GZK-4484-2022					ADCOCK IM, 1994, BIOCHEM BIOPH RES CO, V199, P1518, DOI 10.1006/bbrc.1994.1403; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; ASHWORTH P, 1975, MOL PHYS, V30, P313, DOI 10.1080/00268977500101961; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; BELLOMO G, 1990, METHOD ENZYMOL, V186, P627; BERGELSON S, 1994, ONCOGENE, V9, P565; BERGELSON S, 1994, CANCER RES, V54, P36; BOYNE AF, 1972, ANAL BIOCHEM, V46, P639, DOI 10.1016/0003-2697(72)90335-1; BUETTNER GR, 1987, FREE RADICAL BIO MED, V3, P259, DOI 10.1016/S0891-5849(87)80033-3; BUETTNER GR, 1990, METHOD ENZYMOL, V186, P127; CERUTTI PA, 1985, SCIENCE, V227, P375, DOI 10.1126/science.2981433; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DANIEL V, 1993, CRIT REV BIOCHEM MOL, V28, P173, DOI 10.3109/10409239309086794; DANIEL V, 1989, DNA-J MOLEC CELL BIO, V8, P399, DOI 10.1089/dna.1.1989.8.399; DANIEL V, 1993, STRUCTURE FUNCTION G, P129; DENEKE SM, 1979, J PHARMACOL EXP THER, V208, P377; DEVARY Y, 1991, MOL CELL BIOL, V11, P2804, DOI 10.1128/MCB.11.5.2804; DIKALOV SI, 1992, BIOCHEMISTRY-US, V31, P8947, DOI 10.1021/bi00152a034; FORMAN HJ, 1980, J PHARMACOL EXP THER, V212, P452; FRIDOVICH I, 1978, SCIENCE, V201, P875, DOI 10.1126/science.210504; FRILING RS, 1990, P NATL ACAD SCI USA, V87, P6258, DOI 10.1073/pnas.87.16.6258; FRILING RS, 1992, P NATL ACAD SCI USA, V89, P668, DOI 10.1073/pnas.89.2.668; GOLDSTEIN BD, 1979, BIOCHEM PHARMACOL, V28, P27, DOI 10.1016/0006-2952(79)90265-X; GRIFFITH OW, 1980, ANAL BIOCHEM, V106, P207, DOI 10.1016/0003-2697(80)90139-6; ISRAEL N, 1992, J IMMUNOL, V149, P3386; KAHL R, 1989, TOXICOLOGY, V59, P179, DOI 10.1016/0300-483X(89)90056-5; KHRAMTSOV VV, 1989, ANAL BIOCHEM, V182, P58, DOI 10.1016/0003-2697(89)90718-5; LAUTIER D, 1992, CARCINOGENESIS, V13, P227, DOI 10.1093/carcin/13.2.227; MEISTER A, 1991, PHARMACOL THERAPEUT, V51, P155, DOI 10.1016/0163-7258(91)90076-X; MEYER M, 1993, EMBO J, V12, P2005, DOI 10.1002/j.1460-2075.1993.tb05850.x; MIHM S, 1991, AIDS, V5, P497, DOI 10.1097/00002030-199105000-00004; MORGAN JI, 1991, ANNU REV NEUROSCI, V14, P421, DOI 10.1146/annurev.ne.14.030191.002225; MORIMOTO K, 1991, CARCINOGENESIS, V12, P703, DOI 10.1093/carcin/12.4.703; NGUYEN T, 1994, J BIOL CHEM, V269, P13656; NOBEL CSI, 1995, J BIOL CHEM, V270, P26202, DOI 10.1074/jbc.270.44.26202; OLLINGER K, 1990, CHEM-BIOL INTERACT, V73, P53, DOI 10.1016/0009-2797(90)90108-Y; PEDERSEN JA, 1985, CRC HDB EPR SPECTRA, P69; PINKUS R, 1993, BIOCHEM J, V290, P637, DOI 10.1042/bj2900637; PINKUS R, 1995, BIOCHEMISTRY-US, V34, P81, DOI 10.1021/bi00001a010; POWIS G, 1989, FREE RADICAL BIO MED, V6, P63, DOI 10.1016/0891-5849(89)90162-7; PUGA A, 1992, DNA CELL BIOL, V11, P269, DOI 10.1089/dna.1992.11.269; SCHENK H, 1994, P NATL ACAD SCI USA, V91, P1672, DOI 10.1073/pnas.91.5.1672; SCHILDERMAN PAEL, 1993, CARCINOGENESIS, V14, P347, DOI 10.1093/carcin/14.3.347; SCHMIDT KN, 1995, CHEM BIOL, V2, P13, DOI 10.1016/1074-5521(95)90076-4; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; SCHRECK R, 1992, J EXP MED, V175, P1181, DOI 10.1084/jem.175.5.1181; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SCHULZEOSTHOFF K, 1993, EMBO J, V12, P3095, DOI 10.1002/j.1460-2075.1993.tb05978.x; SHERMAN ML, 1990, P NATL ACAD SCI USA, V87, P5663, DOI 10.1073/pnas.87.15.5663; SHI MM, 1994, J BIOL CHEM, V269, P26512; Sies, 1991, OXIDATIVE STRESS OXI, P245; SIES H, 1991, AM J MED, V91, pS31, DOI 10.1016/0002-9343(91)90281-2; STAAL FJT, 1990, P NATL ACAD SCI USA, V87, P9943, DOI 10.1073/pnas.87.24.9943; STEENKEN S, 1979, J PHYS CHEM-US, V83, P595, DOI 10.1021/j100468a008; TAYLOR KL, 1987, BIOCHEM PHARMACOL, V36, P141, DOI 10.1016/0006-2952(87)90391-1; WEINER LM, 1994, METHOD ENZYMOL, V233, P92; WEINER LM, 1995, METHOD ENZYMOL, V251, P87, DOI 10.1016/0076-6879(95)51113-X; WILFORD JH, 1985, J ELECTROANAL CHEM, V190, P271, DOI 10.1016/0022-0728(85)80094-2; YOSHIOKA K, 1995, P NATL ACAD SCI USA, V92, P4972, DOI 10.1073/pnas.92.11.4972; ZIEGLER DM, 1991, OXIDATIVE STRESS OXI, P85	60	425	434	2	23	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 7	1996	271	23					13422	13429		10.1074/jbc.271.23.13422	http://dx.doi.org/10.1074/jbc.271.23.13422			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UP385	8662787				2022-12-25	WOS:A1996UP38500020
J	Yoshida, H; Kinoshita, K; Ashida, M				Yoshida, H; Kinoshita, K; Ashida, M			Purification of a peptidoglycan recognition protein from hemolymph of the silkworm, Bombyx mori	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROPHENOLOXIDASE ACTIVATING SYSTEM; BACTERIAL-CELL WALLS; MURAMYL PEPTIDES; BINDING-PROTEIN; FREE IMMUNITY; AMINO-ACID; PLASMA; BETA-1,3-GLUCAN; LECTIN; LARVAE	A method was developed far obtaining a homogeneous silkworm hemolymph protein (peptidoglycan recognition protein, PGRP) which has affinity for peptidoglycan and the ability to trigger the prophenoloxidase cascade upon its binding to peptidoglycan. The purified PGRP had a molecular mass of about 19 kDa and is composed of a single polypeptide with an isoelectric point of 6.5. It bound to peptidoglycan in the absence of divalent cation, whereas its binding to beta 1,3-glucan and chitin was not detected. N-Acetyl-D-glucosaminyl-(beta 1-4)-N-acetylmuramyl-L-alanyl-D-isoglutamine did not inhibit purified PGRP to bind Insoluble peptidoglycan, but fragmented soluble peptidoglycan did. PGRP seemed to require peptidoglycan as a possible ligand to keep its glycan portion consisting of at least two or more of the repeating unit. PGRP did not have any detectable lysozyme activity, and its amino acid composition and amino-terminal sequence of 20 amino acid residues were shown to be different from those of silkworm lysozyme, PGRP seems to be a hitherto unknown protein. In the absence of PGRP, the prophenoloxidase cascade in the plasma fraction of hemolymph could not be triggered by peptidoglycan, indicating that some type of activity, capable of activating the cascade, is generated upon their binding. However, the exact nature of this activity is not yet known. The purified PGRP bound to peptidoglycan did not hydrolyze significantly any of the 26 commercially available peptidyl-7-amino-4-methylcoumarins, substrates for various proteases.	HOKKAIDO UNIV, INST LOW TEMP SCI, SAPPORO, HOKKAIDO 060, JAPAN	Hokkaido University								AMANAI K, 1990, COMP BIOCHEM PHYS B, V97, P471, DOI 10.1016/0305-0491(90)90146-K; ARAKI Y, 1972, J BIOL CHEM, V247, P6312; ASHIDA M, 1983, BIOCHEM BIOPH RES CO, V113, P562, DOI 10.1016/0006-291X(83)91762-X; ASHIDA M, 1994, INSECT BIOCHEM MOLEC, V24, P1037, DOI 10.1016/0965-1748(94)90141-4; Ashida M., 1990, P239; ASHIDA M, 1995, P NATL ACAD SCI USA, V92, P10698, DOI 10.1073/pnas.92.23.10698; ASHIDA M, 1981, INSECT BIOCHEM, V11, P57, DOI 10.1016/0020-1790(81)90041-X; ASHIDA M, 1988, INSECT BIOCHEM, V18, P11, DOI 10.1016/0020-1790(88)90031-5; BOMAN HG, 1991, EUR J BIOCHEM, V201, P23, DOI 10.1111/j.1432-1033.1991.tb16252.x; BOMAN HG, 1981, TRENDS BIOCHEM SCI, V6, P306, DOI 10.1146/annurev.mi.41.100187.000535; CERENIUS L, 1994, J BIOL CHEM, V269, P29462; DUNN PE, 1994, ANN NY ACAD SCI, V712, P117, DOI 10.1111/j.1749-6632.1994.tb33567.x; DUNN PE, 1986, ANNU REV ENTOMOL, V31, P321, DOI 10.1146/annurev.en.31.010186.001541; DUVIC B, 1990, J BIOL CHEM, V265, P9327; DZIARSKI R, 1994, J BIOL CHEM, V269, P2100; DZIARSKI R, 1991, J BIOL CHEM, V266, P4719; DZIARSKI R, 1994, J BIOL CHEM, V269, P20431; ENGSTROM A, 1985, EMBO J, V4, P2119, DOI 10.1002/j.1460-2075.1985.tb03901.x; HEWICK RM, 1981, J BIOL CHEM, V256, P7990; IKETANI M, 1993, INSECT BIOCHEM MOLEC, V23, P913, DOI 10.1016/0965-1748(93)90108-5; JANEWAY CA, 1989, COLD SPRING HARB SYM, V54, P1; JOHANSSON MW, 1989, PARASITOL TODAY, V5, P171, DOI 10.1016/0169-4758(89)90139-7; JOMORI T, 1991, J BIOL CHEM, V266, P13318; KIJIMOTOOCHIAI S, 1985, ANAL BIOCHEM, V147, P222, DOI 10.1016/0003-2697(85)90031-4; KOJIMA K, 1979, ANAL BIOCHEM, V100, P43, DOI 10.1016/0003-2697(79)90106-4; KOMANO H, 1985, DEV COMP IMMUNOL, V9, P31, DOI 10.1016/0145-305X(85)90057-6; KOTANI E, 1995, BBA-GENE STRUCT EXPR, V1260, P245, DOI 10.1016/0167-4781(94)00202-E; KOTANI S, 1986, FASEB J, V45, P2534; Lackie A.M., 1988, Advances in Insect Physiology, V21, P85, DOI 10.1016/S0065-2806(08)60123-X; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUNT MR, 1960, BIOCHIM BIOPHYS ACTA, V44, P371, DOI 10.1016/0006-3002(60)91581-X; MUTA T, 1991, J BIOL CHEM, V266, P6554; NAPPI AJ, 1993, PIGM CELL RES, V6, P117, DOI 10.1111/j.1600-0749.1993.tb00590.x; OCHIAI M, 1988, J BIOL CHEM, V263, P12056; PENDLAND JC, 1986, DEV COMP IMMUNOL, V10, P477, DOI 10.1016/0145-305X(86)90169-2; RATCLIFFE NA, 1984, SCIENCE, V226, P557, DOI 10.1126/science.226.4674.557; SAMAKOVLIS C, 1992, BIOCHEM BIOPH RES CO, V188, P1169, DOI 10.1016/0006-291X(92)91354-S; SCHMIDT O, 1993, DEV COMP IMMUNOL, V17, P195, DOI 10.1016/0145-305X(93)90038-R; SILVERMAN DHS, 1986, J IMMUNOL, V136, P2195; SIMPSON RJ, 1976, J BIOL CHEM, V251, P1936; SODERHALL K, 1988, INSECT BIOCHEM, V18, P323, DOI 10.1016/0020-1790(88)90045-5; SUN SC, 1990, SCIENCE, V250, P1729, DOI 10.1126/science.2270488; TAKLE GB, 1986, J CELL SCI, V85, P85; ULEVITCH RJ, 1993, ADV IMMUNOL, V53, P267, DOI 10.1016/S0065-2776(08)60502-7; VASTA GR, 1994, ANN NY ACAD SCI, V712, P55, DOI 10.1111/j.1749-6632.1994.tb33562.x; Vey A., 1986, P89; Wrigley C.W., 1971, METHOD ENZYMOL, V22, P559; YOSHIDA H, 1986, BIOCHEM BIOPH RES CO, V141, P1177, DOI 10.1016/S0006-291X(86)80168-1; YOSHIDA H, 1986, INSECT BIOCHEM, V16, P539, DOI 10.1016/0020-1790(86)90031-4; YPHANTIS DA, 1964, BIOCHEMISTRY-US, V3, P297, DOI 10.1021/bi00891a003	51	384	424	2	36	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 7	1996	271	23					13854	13860		10.1074/jbc.271.23.13854	http://dx.doi.org/10.1074/jbc.271.23.13854			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UP385	8662762	hybrid			2022-12-25	WOS:A1996UP38500082
J	Yoshimura, M; Ihara, Y; Matsuzawa, Y; Taniguchi, N				Yoshimura, M; Ihara, Y; Matsuzawa, Y; Taniguchi, N			Aberrant glycosylation of E-cadherin enhances cell-cell binding to suppress metastasis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UDP-N-ACETYLGLUCOSAMINE; OLIGOSACCHARIDES; PURIFICATION; EXPRESSION; CDNA	Introduction of the beta 1-4 N-acetylglucosaminyltransferase (GnT-III) gene was reported to suppress metastasis in highly metastatic B16-hm murine melanoma cells (Yoshimura, M., Nishikawa, A., Ihara, Y., Taniguchi, S., and Taniguchi, N. (1995) Proc, Natl. Acad, Sci. U. S. A. 92, 8754-8758), In this study, the effect of GnT-III gene transfer on E-cadherin was studied, since E-cadherin acts as a suppressor of metastasis. E-cadherin expression at cell-cell contacts of B16-hm cells expressing high GnT-III activity was greater than controls without affecting transcription, Lectin blotting showed that E-cadherin from GnT-III transfectants was glycosylated by ectopically expressed GnT-III, The glycosylated E-cadherin exhibited the delayed turnover and the decreased release from cell surface, as compared with the native E-cadherin, resulting in the elevated expression at the cell-cell border of GnT-III transfectants. Furthermore, cell-cell aggregation was enhanced in GnT-III transfectants, indicating that the glycosylated E-cadherin is biologically functional, These results suggest that the glycosylated E-cadherin contributes to the suppression of metastasis by the introduction of GnT-III gene into melanoma cells.	OSAKA UNIV,SCH MED,DEPT BIOCHEM,SUITA,OSAKA 565,JAPAN; OSAKA UNIV,SCH MED,DEPT INTERNAL MED 2,SUITA,OSAKA 565,JAPAN	Osaka University; Osaka University			Taniguchi, Naoyuki/A-7086-2016; Taniguchi, Naoyuki/I-4182-2014	Taniguchi, Naoyuki/0000-0001-5889-5968				CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DEMETRIOU M, 1995, J CELL BIOL, V130, P383, DOI 10.1083/jcb.130.2.383; DENNIS JW, 1987, SCIENCE, V236, P582, DOI 10.1126/science.2953071; DWEK RA, 1995, SCIENCE, V269, P1234, DOI 10.1126/science.7652569; FERNANDES B, 1991, CANCER RES, V51, P718; FUJII S, 1990, J BIOL CHEM, V265, P6009; GU JG, 1993, J BIOCHEM, V113, P614, DOI 10.1093/oxfordjournals.jbchem.a124091; HART IR, 1992, LANCET, V339, P1453, DOI 10.1016/0140-6736(92)92039-I; JIANG WG, 1995, CANCER RES, V55, P5043; MIYOSHI E, 1995, J BIOL CHEM, V270, P28311; NAGAFUCHI A, 1987, NATURE, V329, P341, DOI 10.1038/329341a0; NISHIKAWA A, 1992, J BIOL CHEM, V267, P18199; ODA T, 1994, P NATL ACAD SCI USA, V91, P1858, DOI 10.1073/pnas.91.5.1858; SAITOH O, 1992, J BIOL CHEM, V267, P5700; SCHACHTER H, 1986, BIOCHEM CELL BIOL, V64, P163, DOI 10.1139/o86-026; SCHEIFFELE P, 1995, NATURE, V378, P96, DOI 10.1038/378096a0; Takeichi M, 1993, CURR OPIN CELL BIOL, V5, P806, DOI 10.1016/0955-0674(93)90029-P; TANIGUCHI N, 1995, GLYCOCONJUGATE J, V12, P733, DOI 10.1007/BF00731232; WYSS DF, 1995, SCIENCE, V269, P1273, DOI 10.1126/science.7544493; YAMASHITA K, 1983, J BIOL CHEM, V258, P4753; YOSHIMURA M, 1995, P NATL ACAD SCI USA, V92, P8754, DOI 10.1073/pnas.92.19.8754; YOUSEFI S, 1991, J BIOL CHEM, V266, P1772	22	173	177	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 7	1996	271	23					13811	13815		10.1074/jbc.271.23.13811	http://dx.doi.org/10.1074/jbc.271.23.13811			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UP385	8662832				2022-12-25	WOS:A1996UP38500076
J	Mahajan, MA; Park, ST; Sun, XH				Mahajan, MA; Park, ST; Sun, XH			Association of a novel GTP binding protein, DRG, with TAL oncogenic proteins	ONCOGENE			English	Article						T cell leukemia; helix-loop-helix protein; GTP-binding protein; erythroid differentiation	LOOP-HELIX PROTEINS; T-CELL LEUKEMIA; ACUTE LYMPHOBLASTIC-LEUKEMIA; DNA-BINDING; ENHANCER-BINDING; GENE SCL; EXPRESSION; MOTIF; TRANSLOCATION; TRANSCRIPTION	TAL1 is a basic helix-loop-helix (bHLH) protein involved in hematopoietic development. In T cell acute lymphoblastic leukemic cells, TAL1 is aberrantly overexpressed and is thought to contribute to oncogenesis. To identify proteins that interact with TAL1 in mediating leukemogenesis, we used TAL1 as a bait in a two-hybrid interaction screen, and isolated a cDNA clone that encodes a unique GTP binding protein, DRG. The interaction between DRG and TAL1 was confirmed both in vitro and in vivo, DRG was also shown to bind in vitro to two TAL1-related proteins, TAL2 and Lyl1. Mutational analyses showed that the HLH domain of TAL1 was necessary and sufficient for its interaction with the C-terminus of DRG. Furthermore, while DRG and E47 compete to interact with TAL1, TAL1 binds to DRG and E47 in a mutually exclusive manner. In rat embryonic fibroblast transformation assays, DRG stimulated the cotransforming activity of c-myc and I as. Based on these results, DRG appears to be a potential target for TAL-like oncoproteins.	NYU, MED CTR, DEPT CELL BIOL, NEW YORK, NY 10016 USA	New York University				Mahajan, Muktar/0000-0003-1024-6808	NIAID NIH HHS [AI-33597] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI033597, R01AI033597] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		APLAN PD, 1990, SCIENCE, V250, P1426, DOI 10.1126/science.2255914; AUSUBAL FM, 1994, CURRENT PROTOCOLS MO; BEGLEY CG, 1989, P NATL ACAD SCI USA, V86, P10128, DOI 10.1073/pnas.86.24.10128; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BERNARD O, 1992, J EXP MED, V176, P919, DOI 10.1084/jem.176.4.919; BOURNE HR, 1991, NATURE, V349, P118; BROWN L, 1990, EMBO J, V9, P3343, DOI 10.1002/j.1460-2075.1990.tb07535.x; CARROLL AJ, 1990, BLOOD, V76, P1220; CHEN Q, 1990, EMBO J, V9, P415, DOI 10.1002/j.1460-2075.1990.tb08126.x; CHENG JT, 1993, ONCOGENE, V8, P677; CONDORELLI G, 1995, BLOOD, V86, P164, DOI 10.1182/blood.V86.1.164.bloodjournal861164; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; GOLDFARB AN, 1994, LEUKEMIA LYMPHOMA, V12, P157, DOI 10.3109/10428199409059586; GOLDFARB AN, 1992, BLOOD, V80, P2858; GREEN AR, 1991, ONCOGENE, V6, P475; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; HENTHORN P, 1990, SCIENCE, V247, P467, DOI 10.1126/science.2105528; HSU HL, 1994, P NATL ACAD SCI USA, V91, P5947, DOI 10.1073/pnas.91.13.5947; HSU HL, 1991, MOL CELL BIOL, V11, P3037, DOI 10.1128/MCB.11.6.3037; HSU HL, 1994, MOL CELL BIOL, V14, P1256, DOI 10.1128/MCB.14.2.1256; KADESCH T, 1992, IMMUNOL TODAY, V13, P31, DOI 10.1016/0167-5699(92)90201-H; KORSMEYER SJ, 1992, ANNU REV IMMUNOL, V10, P785, DOI 10.1146/annurev.immunol.10.1.785; KUMAR S, 1993, INT J DEV BIOL, V37, P539; MELLENTIN JD, 1989, CELL, V58, P77, DOI 10.1016/0092-8674(89)90404-2; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; ORKIN SH, 1995, J BIOL CHEM, V270, P4955, DOI 10.1074/jbc.270.10.4955; PRENDERGAST GC, 1992, GENE DEV, V6, P2426; RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0; SANCHEZGARCIA I, 1994, P NATL ACAD SCI USA, V91, P7869, DOI 10.1073/pnas.91.17.7869; SAZUKA T, 1992, BIOCHEM BIOPH RES CO, V189, P371, DOI 10.1016/0006-291X(92)91568-B; SAZUKA T, 1992, BIOCHEM BIOPH RES CO, V189, P363, DOI 10.1016/0006-291X(92)91567-A; SHIVDASANI RA, 1995, NATURE, V373, P432, DOI 10.1038/373432a0; SUN XH, 1991, MOL CELL BIOL, V11, P5603, DOI 10.1128/MCB.11.11.5603; VISVADER J, 1991, ONCOGENE, V6, P187; VORONOVA A, 1990, P NATL ACAD SCI USA, V87, P4722, DOI 10.1073/pnas.87.12.4722; VORONOVA AF, 1994, P NATL ACAD SCI USA, V91, P5952, DOI 10.1073/pnas.91.13.5952; WADMAN I, 1994, EMBO J, V13, P4831, DOI 10.1002/j.1460-2075.1994.tb06809.x; WEINTRAUB H, 1991, SCIENCE, V251, P761, DOI 10.1126/science.1846704; XIA Y, 1991, P NATL ACAD SCI USA, V88, P11416, DOI 10.1073/pnas.88.24.11416	39	52	52	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN 6	1996	12	11					2343	2350						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UQ220	8649774				2022-12-25	WOS:A1996UQ22000011
J	Feng, XH; Derynck, R				Feng, XH; Derynck, R			Ligand-independent activation of transforming growth factor (TGF) beta signaling pathways by heteromeric cytoplasmic domains of TGF-beta receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERINE THREONINE KINASE; II RECEPTOR; ACTIVIN RECEPTOR; EXPRESSION CLONING; IDENTIFICATION; COMPLEX	Transforming growth factor beta (TGF-beta) transduces signals through two related serine/threonine kinase receptors, the type I and type II receptors, which have the ability to interact with each other. In the heteromeric complex, the type II receptor is the primary determinant of ligand binding and phosphorylates the cytoplasmic domain of the type I receptor. Using a chimeric receptor strategy, we and others have shown previously that a functional TGF-beta receptor complex requires heteromerization of both extracellular and intracellular domains of type I and type II receptors. In the current study, we show that overexpression of two receptors carrying a heteromeric combination of cytoplasmic domains resulted in ligand-independent responses, fur ther supporting the functional requirement of the two heterologous cytoplasmic domains in TGF-beta signaling. Furthermore, coexpression of only the cytoplasmic domains of both the type I and II receptors or tethering the type II to the type I cytoplasmic domain activated TGF-beta responses in a ligand-independent manner. In cotransfected COS-1 cells, both cytoplasmic domains are associated with each other. Our results indicate that the cytoplasmic domains of the type I and type II TGF-beta receptors physically and functionally interact with each other in the heteromeric complex.	UNIV CALIF SAN FRANCISCO,DEPT GROWTH & DEV,PROGRAM CELL & DEV BIOL,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT ANAT,PROGRAM CELL & DEV BIOL,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco					NCI NIH HHS [CA63101] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA063101] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ATTISANO L, 1992, CELL, V68, P97, DOI 10.1016/0092-8674(92)90209-U; ATTISANO L, 1993, CELL, V75, P671, DOI 10.1016/0092-8674(93)90488-C; BASSING CH, 1994, J BIOL CHEM, V269, P14861; CHEN F, 1995, P NATL ACAD SCI USA, V92, P1565, DOI 10.1073/pnas.92.5.1565; CHEN RH, 1995, J BIOL CHEM, V270, P12235, DOI 10.1074/jbc.270.20.12235; CHEN RH, 1994, J BIOL CHEM, V269, P22868; DERYNCK R, 1994, TRENDS BIOCHEM SCI, V19, P548, DOI 10.1016/0968-0004(94)90059-0; Derynck R, 1994, CYTOKINE HDB, P319; EBNER R, 1993, SCIENCE, V262, P900, DOI 10.1126/science.8235612; EBNER R, 1993, SCIENCE, V260, P1344, DOI 10.1126/science.8388127; FENG XH, 1995, J BIOL CHEM, V270, P24237, DOI 10.1074/jbc.270.41.24237; FRANZEN P, 1993, CELL, V75, P681, DOI 10.1016/0092-8674(93)90489-D; HE WW, 1993, DEV DYNAM, V196, P133, DOI 10.1002/aja.1001960207; HENIS YI, 1994, J CELL BIOL, V126, P139, DOI 10.1083/jcb.126.1.139; KEETON MR, 1991, J BIOL CHEM, V266, P23048; KINGSLEY DM, 1994, GENE DEV, V8, P133, DOI 10.1101/gad.8.2.133; LILLIEN L, 1995, NATURE, V377, P158, DOI 10.1038/377158a0; LIN HY, 1992, CELL, V68, P775, DOI 10.1016/0092-8674(92)90152-3; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; MATHEWS LS, 1992, SCIENCE, V255, P1702, DOI 10.1126/science.1313188; MATHEWS LS, 1991, CELL, V65, P973, DOI 10.1016/0092-8674(91)90549-E; MIETTINEN PJ, 1994, J CELL BIOL, V127, P2021, DOI 10.1083/jcb.127.6.2021; NEUHOLD LA, 1993, CELL, V74, P1033, DOI 10.1016/0092-8674(93)90725-6; OKADOME T, 1994, J BIOL CHEM, V269, P30753; RODRIGUEZ C, 1995, J BIOL CHEM, V270, P15919, DOI 10.1074/jbc.270.27.15919; TENDIJKE P, 1994, SCIENCE, V264, P101, DOI 10.1126/science.8140412; TENDIJKE P, 1994, J BIOL CHEM, V269, P16985; TENDIJKE P, 1993, ONCOGENE, V8, P2879; VELU TJ, 1989, J CELL BIOCHEM, V39, P153, DOI 10.1002/jcb.240390207; VENTURA F, 1994, EMBO J, V13, P5581, DOI 10.1002/j.1460-2075.1994.tb06895.x; VIVIEN D, 1995, J BIOL CHEM, V270, P7134, DOI 10.1074/jbc.270.13.7134; WIESER R, 1995, EMBO J, V14, P2199, DOI 10.1002/j.1460-2075.1995.tb07214.x; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0; YAMASHITA H, 1994, J BIOL CHEM, V269, P20172	35	90	94	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 31	1996	271	22					13123	13129		10.1074/jbc.271.22.13123	http://dx.doi.org/10.1074/jbc.271.22.13123			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UN474	8662796	hybrid			2022-12-25	WOS:A1996UN47400067
J	Feng, GS; Ouyang, YB; Hu, DP; Shi, ZQ; Gentz, R; Ni, JA				Feng, GS; Ouyang, YB; Hu, DP; Shi, ZQ; Gentz, R; Ni, JA			Grap is a novel SH3-SH2-SH3 adaptor protein that couples tyrosine kinases to the Ras pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GUANINE-NUCLEOTIDE EXCHANGE; EPIDERMAL GROWTH-FACTOR; SIGNALING GENE SEM-5; SH3 DOMAINS; GRB2; SOS; TRANSDUCTION; ACTIVATION; RECEPTOR; ASSOCIATION	A human cytoplasmic signaling protein has been cloned that possesses the same structural arrangement of SH3-SH2-SH3 domains as Grb2, This protein is designated Grap for Grb2-related adaptor protein, The single 2.3-kilobase (kb) grap transcript was expressed predominantly in thymus and spleen, while the ubiquitously expressed grb2 gene produced two mRNA species of 3.8 and 1.5 kb, Grap and Grb2 consist of 217 amino acids and share 59% amino acid sequence identity, with highest homology in the N-terminal SH3 domain. The GrapSH2 domain interacts with ligand-activated receptors for stem cell factor (c-kit) and erythropoietin (EpoR). Grap also forms a stable complex with the Bcr-Abl oncoprotein via its SH2 domain in K562 cells, Furthermore, Grap is associated with a Ras guanine nucleotide exchange factor mSos1, primarily through its N-terminal SH3 domain, These results show that a family of Grb2-like proteins exist and couple signals from receptor and cytoplasmic tyrosine kinases to the Ras signaling pathway.	HUMAN GENOME SCI INC, ROCKVILLE, MD 20850 USA	GlaxoSmithKline; Human Genome Sciences Inc	Feng, GS (corresponding author), INDIANA UNIV, SCH MED,DEPT BIOCHEM & MOLEC BIOL, WALTHER ONCOL CTR,975 W WALNUT ST, RM 501, INDIANAPOLIS, IN 46202 USA.							ADAMS MD, 1992, NATURE, V355, P632, DOI 10.1038/355632a0; ADAMS MD, 1995, NATURE, V377, P3; ADAMS MD, 1991, SCIENCE, V252, P1651, DOI 10.1126/science.2047873; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; CLARK SG, 1992, NATURE, V356, P340, DOI 10.1038/356340a0; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; FENG GS, 1994, ONCOGENE, V9, P1545; FENG GS, 1993, SCIENCE, V259, P1607, DOI 10.1126/science.8096088; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; LI W, 1994, MOL CELL BIOL, V14, P509, DOI 10.1128/MCB.14.1.509; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MARENGERE LEM, 1994, NATURE, V369, P502, DOI 10.1038/369502a0; MCCORMICK F, 1993, NATURE, V363, P15, DOI 10.1038/363015a0; OLIVIER JP, 1993, CELL, V73, P179, DOI 10.1016/0092-8674(93)90170-U; Panchamoorthy G, 1996, J BIOL CHEM, V271, P3187, DOI 10.1074/jbc.271.6.3187; PAWSON T, 1993, DEV GENET, V14, P333, DOI 10.1002/dvg.1020140502; PENDERGAST AM, 1993, CELL, V75, P175, DOI 10.1016/S0092-8674(05)80094-7; PUIL L, 1994, EMBO J, V13, P764, DOI 10.1002/j.1460-2075.1994.tb06319.x; RAABE T, 1995, EMBO J, V14, P2509, DOI 10.1002/j.1460-2075.1995.tb07248.x; REIF K, 1994, J BIOL CHEM, V269, P14081; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; SIMON MA, 1993, CELL, V73, P169, DOI 10.1016/0092-8674(93)90169-Q; STERN MJ, 1993, MOL BIOL CELL, V4, P1175, DOI 10.1091/mbc.4.11.1175; SUEN KL, 1993, MOL CELL BIOL, V13, P5500, DOI 10.1128/MCB.13.9.5500; TAUCHI T, 1994, J BIOL CHEM, V269, P15381; WANG J, 1995, J BIOL CHEM, V270, P12774, DOI 10.1074/jbc.270.21.12774; YANG B, 1995, J BIOL CHEM, V270, P11711, DOI 10.1074/jbc.270.20.11711; YE ZS, 1994, P NATL ACAD SCI USA, V91, P12629, DOI 10.1073/pnas.91.26.12629; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	30	108	110	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 24	1996	271	21					12129	12132		10.1074/jbc.271.21.12129	http://dx.doi.org/10.1074/jbc.271.21.12129			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UL660	8647802	hybrid			2022-12-25	WOS:A1996UL66000004
J	Kozasa, T; Gilman, AG				Kozasa, T; Gilman, AG			Protein kinase C phosphorylates G(12 alpha) and inhibits its interaction with G(beta gamma)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REGULATORY COMPONENT; ADENYLATE-CYCLASE; BINDING; G-ALPHA-12; ALPHA; SITE; SPECIFICITY; SUBUNITS; CELLS; GI2	Of nine G protein alpha subunits examined, only alpha(12) and alpha(z) served as substrates for phosphorylation by various iso forms of protein kinase C in vitro. A close homolog of alpha(12), alpha(13), was not phosphorylated. Exposure of NIH 3T3 cells that stably express alpha(12) to phorbol 12-myristate 13-acetate also resulted in phosphorylation of the protein. Phosphorylation in vitro occurred near the amino terminus (probably Ser(38)), and approximately 1 mol of phosphate was incorporated per mol of alpha(12). Although G protein heterotrimers containing either alpha(12) or alpha(z) were poor substrates for phosphorylation, the isolated a subunits were phosphorylated equally well in their GDP- or GTP gamma S bound forms. The guanine nucleotide binding properties of purified alpha(12) and alpha(z) were unaltered by phosphorylation, as was the capacity of alpha(z) to inhibit type V adenylyl cyclase. However, phosphorylation of either protein greatly reduced its affinity for G protein beta gamma subunits, consistent with the newly determined crystal structure of a G protein heterotrimer. We suggest that protein kinase C regulates alpha(12)- and alpha(z)-mediated signaling pathways by preventing their association with beta gamma.	UNIV TEXAS, SW MED CTR, DEPT PHARMACOL, DALLAS, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas					NIGMS NIH HHS [GM34497] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034497, R37GM034497] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARFORD D, 1989, NATURE, V340, P609, DOI 10.1038/340609a0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUSHFIELD M, 1990, BIOCHEM J, V268, P449, DOI 10.1042/bj2680449; CHAN AML, 1993, MOL CELL BIOL, V13, P762, DOI 10.1128/MCB.13.2.762; COLEMAN DE, 1994, SCIENCE, V265, P1405, DOI 10.1126/science.8073283; DANIELISSAKANI S, 1989, J BIOL CHEM, V264, P20240; DHANASEKARAN N, 1994, J BIOL CHEM, V269, P11802; FIELDS TA, 1995, J BIOL CHEM, V270, P23119, DOI 10.1074/jbc.270.39.23119; FUJISE A, 1994, J BIOL CHEM, V269, P31642; HEPLER JR, 1992, TRENDS BIOCHEM SCI, V17, P383, DOI 10.1016/0968-0004(92)90005-T; INIGUEZLLUHI JA, 1992, J BIOL CHEM, V267, P23409; JACOBOWITZ O, 1994, P NATL ACAD SCI USA, V91, P10630, DOI 10.1073/pnas.91.22.10630; JIANG HP, 1993, FEBS LETT, V330, P319, DOI 10.1016/0014-5793(93)80896-3; KATADA T, 1985, EUR J BIOCHEM, V151, P431, DOI 10.1111/j.1432-1033.1985.tb09120.x; KAWABE J, 1994, J BIOL CHEM, V269, P16554; KAZIRO Y, 1991, ANNU REV BIOCHEM, V60, P349, DOI 10.1146/annurev.bi.60.070191.002025; KOZASA T, 1995, J BIOL CHEM, V270, P1734, DOI 10.1074/jbc.270.4.1734; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOUNSBURY KM, 1993, J BIOL CHEM, V268, P3494; LYNCH CJ, 1985, J BIOL CHEM, V260, P2844; MIXON MB, 1995, SCIENCE, V270, P954, DOI 10.1126/science.270.5238.954; NEER EJ, 1995, CELL, V80, P249, DOI 10.1016/0092-8674(95)90407-7; NORTHUP JK, 1982, J BIOL CHEM, V257, P1416; ORELLANA SA, 1985, J BIOL CHEM, V260, P5236; PEARSON RB, 1991, METHOD ENZYMOL, V200, P62; SCHAFFNE.W, 1973, ANAL BIOCHEM, V56, P502, DOI 10.1016/0003-2697(73)90217-0; SINGER WD, 1994, J BIOL CHEM, V269, P19796; STRATHMANN MP, 1991, P NATL ACAD SCI USA, V88, P5582, DOI 10.1073/pnas.88.13.5582; TAKANO K, 1995, NEURON, V14, P999, DOI 10.1016/0896-6273(95)90338-0; VOYNOYASENETSKAYA T, 1994, J BIOL CHEM, V269, P4721; VOYNOYASENETSKAYA TA, 1994, ONCOGENE, V9, P2559; WALL MA, 1995, CELL, V83, P1047, DOI 10.1016/0092-8674(95)90220-1; WRAY W, 1981, ANAL BIOCHEM, V118, P197, DOI 10.1016/0003-2697(81)90179-2; YASUDA I, 1990, BIOCHEM BIOPH RES CO, V166, P1220, DOI 10.1016/0006-291X(90)90996-Z	34	78	81	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 24	1996	271	21					12562	12567		10.1074/jbc.271.21.12562	http://dx.doi.org/10.1074/jbc.271.21.12562			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UL660	8647866	hybrid			2022-12-25	WOS:A1996UL66000068
J	Missiaen, L; DeSmedt, H; Parys, JB; Sienaert, I; Vanlingen, S; Casteels, R				Missiaen, L; DeSmedt, H; Parys, JB; Sienaert, I; Vanlingen, S; Casteels, R			Threshold for inositol 1,4,5-trisphosphate action	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CELLS; LUMINAL CA2+ INCREASES; CALCIUM RELEASE; CYTOSOLIC CA2+; RECEPTOR; HEPATOCYTES; TRISPHOSPHATE; AFFINITY; STORES; SENSITIVITY	We developed a unidirectional Ca-45(2+) efflux technique in which 60 cumulative doses of inositol 1,4,5-trisphosphate (InsP(3)), each lasting 6 s, were subsequently added to permeabilized A7r5 cells. This technique allowed an accurate determination of the threshold for InsP(3) action, which was around 32 nM InsP(3) under control conditions. The InsP(3)-induced Ca2+ release was characterized by an initial rapid phase, after which the normalized rate progressively decreased. The slowing of the release was associated with a shift of the threshold to higher InsP(3) concentrations. Stimulatory concentrations of thimerosal (10 mu M) shifted the threshold to 4.5 nM InsP(3) and increased both the cooperativity and the max imal normalized rate of Ca2+ release. This low threshold was maintained when the thimerosal concentration was increased to inhibitory levels (100 mu M) but then the effects on the cooperativity and on the normalized rate of Ca2+ release disappeared. Oxidized glutathione (5 mM) was much less effective in stimulating the release and did not have an effect on the threshold or on the cooperativity. ATP (5 mM) stimulated the release despite a shift in threshold toward higher InsP(3) concentrations. Luminal Ca2+ did not affect the threshold for InsP(3) action but stimulated the normalized release at each InsP(3) concentration. The inhibitory effect of 10 mu M free cytosolic Ca2+ was associated with a shift in threshold to higher InsP(3) concentrations and a decreased cooperativity of the release process. We conclude that this novel technique of accurately measuring the threshold for InsP(3) action under various experimental conditions has allowed us to refine the analysis of the kinetic parameters involved in the regulation of the InsP(3) receptor.			Missiaen, L (corresponding author), KATHOLIEKE UNIV LEUVEN, FYSIOL LAB, CAMPUS GASTHUISBERG, HERESTR 49, B-3000 LOUVAIN, BELGIUM.			Parys, Jan/0000-0002-3591-4967				BERRIDGE MJ, 1994, BIOCHEM J, V302, P545, DOI 10.1042/bj3020545; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BEZPROZVANNY I, 1993, NEURON, V10, P1175, DOI 10.1016/0896-6273(93)90065-Y; BEZPROZVANNY I, 1991, NATURE, V351, P751, DOI 10.1038/351751a0; BIRD GS, 1993, J BIOL CHEM, V268, P17917; BOOTMAN MD, 1992, J BIOL CHEM, V267, P25113; BOOTMAN MD, 1995, BIOCHEM J, V306, P445, DOI 10.1042/bj3060445; CAMACHO P, 1995, CELL, V82, P765, DOI 10.1016/0092-8674(95)90473-5; COMBETTES L, 1993, CELL CALCIUM, V14, P279, DOI 10.1016/0143-4160(93)90049-C; DESMEDT H, 1994, J BIOL CHEM, V269, P21691; FINCH EA, 1991, SCIENCE, V252, P443, DOI 10.1126/science.2017683; GAMBERUCCI A, 1995, CELL CALCIUM, V17, P431, DOI 10.1016/0143-4160(95)90089-6; GUILLEMETTE G, 1987, P NATL ACAD SCI USA, V84, P8195, DOI 10.1073/pnas.84.23.8195; HAJNOCZKY G, 1994, NATURE, V370, P474, DOI 10.1038/370474a0; HILLY M, 1993, J BIOL CHEM, V268, P16488; HIROSE K, 1994, NATURE, V372, P791; HIROTA J, 1995, J BIOL CHEM, V270, P19046, DOI 10.1074/jbc.270.32.19046; HIROTA J, 1995, FEBS LETT, V368, P248, DOI 10.1016/0014-5793(95)00659-W; HORNE JH, 1995, BIOCHEMISTRY-US, V34, P12738, DOI 10.1021/bi00039a033; IINO M, 1991, J GEN PHYSIOL, V98, P681, DOI 10.1085/jgp.98.4.681; IINO M, 1992, NATURE, V360, P76, DOI 10.1038/360076a0; IINO M, 1990, J GEN PHYSIOL, V95, P1103, DOI 10.1085/jgp.95.6.1103; JOSEPH SK, 1995, J BIOL CHEM, V270, P3588, DOI 10.1074/jbc.270.8.3588; KAPLIN AI, 1994, J BIOL CHEM, V269, P28972; LIPINSKY D, 1993, PFLUG ARCH EUR J PHY, V425, P140, DOI 10.1007/BF00374514; MAEDA N, 1991, J BIOL CHEM, V266, P1109; MARSHALL ICB, 1993, J BIOL CHEM, V268, P13214; MEZNA M, 1995, NATURE, V376, P300, DOI 10.1038/376300a0; MISSIAEN L, 1994, J BIOL CHEM, V269, P7238; MISSIAEN L, 1992, J BIOL CHEM, V267, P22961; MISSIAEN L, 1991, NATURE, V352, P241, DOI 10.1038/352241a0; MISSIAEN L, 1992, J PHYSIOL-LONDON, V455, P623, DOI 10.1113/jphysiol.1992.sp019319; MISSIAEN L, 1994, BIOCHEM J, V300, P81, DOI 10.1042/bj3000081; MISSIAEN L, 1992, NATURE, V357, P599, DOI 10.1038/357599a0; NUNN DL, 1992, MOL PHARMACOL, V41, P115; OLDERSHAW KA, 1993, BIOCHEM J, V292, P631, DOI 10.1042/bj2920631; PARYS JB, 1995, BIOCHEM BIOPH RES CO, V209, P451, DOI 10.1006/bbrc.1995.1523; PARYS JB, 1992, J BIOL CHEM, V267, P18776; PARYS JB, 1993, PFLUG ARCH EUR J PHY, V424, P516, DOI 10.1007/BF00374916; PARYS JB, 1993, J BIOL CHEM, V268, P25206; Patel S, 1995, BIOCHEM J, V312, P789, DOI 10.1042/bj3120789; POITRAS M, 1993, J BIOL CHEM, V268, P24078; RENARD DC, 1992, BIOCHEM J, V284, P507, DOI 10.1042/bj2840507; RENARDROONEY DC, 1995, BIOCHEM J, V310, P185, DOI 10.1042/bj3100185; Schrenzel J, 1995, BIOPHYS J, V69, P2378, DOI 10.1016/S0006-3495(95)80107-4; SUGIYAMA T, 1995, AM J PHYSIOL-CELL PH, V269, pC813, DOI 10.1152/ajpcell.1995.269.3.C813; TORTORICI G, 1994, J BIOL CHEM, V269, P29621; WANG SSH, 1995, J GEN PHYSIOL, V105, P149, DOI 10.1085/jgp.105.1.149	48	41	41	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 24	1996	271	21					12287	12293		10.1074/jbc.271.21.12287	http://dx.doi.org/10.1074/jbc.271.21.12287			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UL660	8647828	hybrid			2022-12-25	WOS:A1996UL66000030
J	Huber, A; Sander, P; Paulsen, R				Huber, A; Sander, P; Paulsen, R			Phosphorylation of the InaD gene product, a photoreceptor membrane protein required for recovery of visual excitation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KINASE-C; DROSOPHILA PHOTORECEPTORS; EXTRACELLULAR CALCIUM; LIGHT ADAPTATION; GATED CHANNEL; PHOTOTRANSDUCTION; RHODOPSIN; ARRESTIN; OPSIN; MELANOGASTER	In an approach directed to isolate and characterize key proteins of the transduction cascade in photoreceptors using the phosphoinositide signaling pathway, we have isolated the Calliphora homolog of the Drosophila InaD gene product, which in Drosophila InaD mutants causes slow deactivation of the light response. By screening a retinal cDNA library with antibodies directed against photoreceptor membrane proteins, we have isolated a cDNA coding for an amino acid sequence of 665 residues (M(r) = 73,349). The sequence displays 65.3% identity (77.3% similarity) with the Drosophila InaD gene product. Probing Western blots with monospecific antibodies directed against peptides comprising amino acids 272-542 (anti-InaD-(272-542)) or amino acids 643-655 (anti-InaD-(643-655)) of the InaD gene product revealed that the Calliphora InaD protein is specifically associated with the signal-transducing rhabdomeral photoreceptor membrane from which it can be extracted by high salt buffer containing 1.5 M NaCl. As five out of eight consensus sequences for protein kinase C phosphorylation reside within stretches of 10-16 amino acids that are identical in the Drosophila and Calliphora InaD protein, the InaD gene product is likely to be a target of protein kinase C, Phosphorylation studies with isolated rhabdomeral photoreceptor membranes followed by InaD immunoprecipitation revealed that the InaD protein is a phosphoprotein. In vitro phosphorylation is, at least to some extent, Ca2+-dependent and activated by phorbol 12-myristate 13-acetate, The inaC-encoded eye-specific form of a protein kinase C (eye-PKC) is co-precipitated by antibodies specific for the InaD protein from detergent extracts of rhabdomeral photoreceptor membranes, suggesting that the InaD protein and eye-PKC are interacting in these membranes. Co-precipitating with the InaD protein and eye-PKC are two other key components of the transduction pathway, namely the trp protein, which is proposed to form a Ca2+ channel, and the norpA-encoded phospholipase C, the primary target enzyme of the transduction pathway, It is proposed that the rise of the intracellular Ca2+ concentration upon visual excitation initiates the phosphorylation of the InaD protein by eye-PKC and thereby modulates its function in the control of the light response.			Huber, A (corresponding author), UNIV KARLSRUHE, INST ZOOL 1, KAISERSTR 12, POSTFACH 6980, D-76128 KARLSRUHE, GERMANY.		Huber, Armin/GYU-6322-2022	Huber, Armin/0000-0003-3977-089X				BENTROP J, 1986, EUR J BIOCHEM, V161, P61, DOI 10.1111/j.1432-1033.1986.tb10124.x; BLOOMQUIST BT, 1988, CELL, V54, P723, DOI 10.1016/S0092-8674(88)80017-5; BYK T, 1993, P NATL ACAD SCI USA, V90, P1907, DOI 10.1073/pnas.90.5.1907; CAVENER DR, 1987, NUCLEIC ACIDS RES, V15, P1353, DOI 10.1093/nar/15.4.1353; DOLPH PJ, 1994, NATURE, V370, P59, DOI 10.1038/370059a0; FABIATO A, 1988, METHOD ENZYMOL, V157, P378; GREENE NM, 1995, J BIOL CHEM, V270, P6710, DOI 10.1074/jbc.270.12.6710; HARDIE RC, 1991, P ROY SOC B-BIOL SCI, V245, P203, DOI 10.1098/rspb.1991.0110; HARDIE RC, 1993, TRENDS NEUROSCI, V16, P371, DOI 10.1016/0166-2236(93)90095-4; HARDIE RC, 1992, NEURON, V8, P643, DOI 10.1016/0896-6273(92)90086-S; Harlow E., 1988, ANTIBODIES LAB MANUA; HUBER A, 1990, J BIOL CHEM, V265, P17906; HYDE DR, 1990, P NATL ACAD SCI USA, V87, P1008, DOI 10.1073/pnas.87.3.1008; KAUPP UB, 1989, NATURE, V342, P762, DOI 10.1038/342762a0; KELLEHER DJ, 1986, J BIOL CHEM, V261, P4749; KOMORI N, 1994, INSECT BIOCHEM MOLEC, V24, P607, DOI 10.1016/0965-1748(94)90097-3; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LUDWIG J, 1990, FEBS LETT, V270, P24, DOI 10.1016/0014-5793(90)81226-E; MATSUMOTO H, 1982, SCIENCE, V217, P839, DOI 10.1126/science.7100927; MATSUMOTO H, 1994, NEURON, V12, P997, DOI 10.1016/0896-6273(94)90309-3; MATSUMOTO H, 1984, SCIENCE, V223, P184, DOI 10.1126/science.6419348; MCKAY RR, 1994, J NEUROGENET, V9, P177, DOI 10.3109/01677069409167278; MOJET MH, 1993, J COMP PHYSIOL A, V173, P335, DOI 10.1007/BF00212698; MONTELL C, 1989, NEURON, V2, P1313, DOI 10.1016/0896-6273(89)90069-X; NEWTON AC, 1993, J BIOL CHEM, V268, P18181; OTOUSA JE, 1985, CELL, V40, P839, DOI 10.1016/0092-8674(85)90343-5; Pak W.L., 1979, P67; PAULSEN R, 1984, J COMP PHYSIOL, V155, P47, DOI 10.1007/BF00610930; PAULSEN R, 1984, J COMP PHYSIOL, V155, P39, DOI 10.1007/BF00610929; PERETZ A, 1994, J GEN PHYSIOL, V104, P1057, DOI 10.1085/jgp.104.6.1057; PICHER J, 1992, BIOCHEMISTRY-US, V31, P3193; PLANGGER A, 1994, J BIOL CHEM, V269, P26969; RANGANATHAN R, 1991, NATURE, V354, P230, DOI 10.1038/354230a0; Sambrook J., 1989, MOL COLONING LAB MAN, V2nd; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SANDLER C, 1991, J COMP PHYSIOL A, V169, P299; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHAEFFER E, 1989, CELL, V57, P403, DOI 10.1016/0092-8674(89)90915-X; SHIEH BH, 1995, NEURON, V14, P201, DOI 10.1016/0896-6273(95)90255-4; SMITH DP, 1991, SCIENCE, V254, P1478, DOI 10.1126/science.1962207; WES PD, 1995, P NATL ACAD SCI USA, V92, P9652, DOI 10.1073/pnas.92.21.9652; WONG F, 1989, NEURON, V3, P81, DOI 10.1016/0896-6273(89)90117-7; YAMADA T, 1990, SCIENCE, V248, P483, DOI 10.1126/science.2158671; ZHU LQ, 1993, J BIOL CHEM, V268, P15994; ZUKER CS, 1985, CELL, V40, P851, DOI 10.1016/0092-8674(85)90344-7	47	69	69	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 17	1996	271	20					11710	11717		10.1074/jbc.271.20.11710	http://dx.doi.org/10.1074/jbc.271.20.11710			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UL250	8662634	hybrid			2022-12-25	WOS:A1996UL25000022
J	Tremethick, DJ; Hyman, L				Tremethick, DJ; Hyman, L			High mobility group proteins 14 and 17 can prevent the close packing of nucleosomes by increasing the strength of protein contacts in the linker DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							XENOPUS-LAEVIS OOCYTES; CHROMATIN STRUCTURE; CORE PARTICLE; INVITRO; BINDING; TRANSCRIPTION; DOMAIN	High mobility group (HMG) proteins 14 and 17 are abundant chromatin-associated proteins found in all higher eukaryotic nuclei. This observation demonstrates that HMGs 14 and 17 must have an important and universal function with regard to the structure and function of chromatin. What this function is, including how they interact with a nucleosomal array in vivo, is not known. Recently, we have demonstrated that HMGs 14 and 17 can organize nucleosomes into a regular array and increase the repeat length from 145 to about 160-165 base pairs in vitro. In addition, they can increase the apparent repeat length of chromatin deficient in histones H2A/H2B from 125 to approximately 145 base pairs. Importantly, this template was transcriptionally active. In this study, we report five new observations that begin to address the mechanism by which HMGs 14 and 17 space nucleosomal particles. First, we demonstrate that both human placenta HMG 14 and HMG 17 can space nucleosomes to produce a chromatin template with a repeat length around 160 base pairs. This result further highlights the similarity between these proteins in terms of protein structure and perhaps function. Second, we show that digestion of HMG containing chromatin with micrococcal nuclease produces DNA fragments that were approximately 10 and 20 base pairs longer than nucleosome core-particle DNA. This suggests that HMG 14 or HMG 17 can protect, directly or indirectly, at least an additional 10 base pairs of linker DNA from micrococcal digestion. However, this HMG-containing particle does not produce a strong kinetic block, and further digestion results in the eventual accumulation of DNA fragments 145 base pairs in length. Third, by comparing the full-length protein with different domains, we demonstrate that the acidic carboxyl-terminal domain is absolutely required for nucleosome spacing; neither the nucleosome binding domain of HMG 14 or HMG 17 nor the amino-terminal domain plus the nucleosome binding domain of HMG 14 could space nucleosomes. Fourth, we demonstrate that extensive micrococcal nuclease digestion of chromatin deficient in histones H2A/H2B led to the accumulation of DNA fragments about 110 base pairs in length, which is presumably the length of DNA associated with a nucleosomal particle deficient in one H2A/H2B dimer. Incorporation of either HMG 14 or HMG 17 into this chromatin results in the disappearance of this band and increase in the accumulation of fragments around 140-150 base pairs in length. Finally, in contrast to spacing of complete nucleosomes, we find that the nucleosome binding domain of HMG 17 (but not the nucleosome binding of HMG 14) is the only domain required for spacing of H2A/H2B-deficient chromatin.			Tremethick, DJ (corresponding author), AUSTRALIAN NATL UNIV,JOHN CURTIN SCH MED RES,POB 334,CANBERRA,ACT 2601,AUSTRALIA.			Tremethick, David/0000-0001-5274-8078				ADAMS CC, 1995, MOL CELL BIOL, V15, P1405; ALFONSO PJ, 1994, J MOL BIOL, V236, P189, DOI 10.1006/jmbi.1994.1128; BARRATT MJ, 1994, EMBO J, V13, P4524, DOI 10.1002/j.1460-2075.1994.tb06774.x; BLANK TA, 1995, J MOL BIOL, V252, P305, DOI 10.1006/jmbi.1995.0498; BRAWLEY JV, 1992, BIOCHEMISTRY-US, V31, P364, DOI 10.1021/bi00117a008; BUSTIN M, 1990, BIOCHIM BIOPHYS ACTA, V1049, P231, DOI 10.1016/0167-4781(90)90092-G; COOK GR, 1989, J BIOL CHEM, V264, P1799; CRIPPA MP, 1992, J MOL BIOL, V228, P442, DOI 10.1016/0022-2836(92)90833-6; DREW HR, 1993, J MOL BIOL, V230, P824, DOI 10.1006/jmbi.1993.1204; EINICK L, 1985, EXP CELL RES, V156, P295; FOLETTA VC, 1994, ONCOGENE, V9, P3305; GODDE JS, 1992, J MOL BIOL, V226, P1009, DOI 10.1016/0022-2836(92)91049-U; GONZALEZ PJ, 1990, J BIOL CHEM, V265, P8225; GRUNSTEIN M, 1990, TRENDS GENET, V6, P395, DOI 10.1016/0168-9525(90)90299-L; HAYES JJ, 1994, P NATL ACAD SCI USA, V91, P7817, DOI 10.1073/pnas.91.16.7817; LU Q, 1994, J CELL BIOCHEM, V55, P83, DOI 10.1002/jcb.240550110; Owen-Hughes Thomas, 1994, Critical Reviews in Eukaryotic Gene Expression, V4, P403; PARANJAPE SM, 1995, GENE DEV, V9, P1978, DOI 10.1101/gad.9.16.1978; PRUSS D, 1993, BIOCHEMISTRY-US, V32, P6810, DOI 10.1021/bi00078a002; SASI R, 1982, J BIOL CHEM, V257, P1448; SCHWARZ PM, 1994, J BIOL CHEM, V269, P15041; SEALE RL, 1983, BIOCHEMISTRY-US, V22, P5008, DOI 10.1021/bi00290a020; SHIMAMURA A, 1988, MOL CELL BIOL, V8, P4257, DOI 10.1128/MCB.8.10.4257; STEIN A, 1988, J MOL BIOL, V203, P1029, DOI 10.1016/0022-2836(88)90127-1; THOMAS JO, 1976, FEBS LETT, V66, P274, DOI 10.1016/0014-5793(76)80521-2; TREMETHICK DJ, 1994, J BIOL CHEM, V269, P28436; TREMETHICK DJ, 1992, J BIOL CHEM, V267, P15041; TREMETHICK DJ, 1993, J BIOL CHEM, V268, P11389; TRIESCHMANN L, 1995, EMBO J, V14, P1478, DOI 10.1002/j.1460-2075.1995.tb07134.x; van Holde KE., 1989, SPRINGER SERIES MOL; WALTER PP, 1995, MOL CELL BIOL, V15, P6178; WEISCHET WO, 1979, NUCLEIC ACIDS RES, V6, P1843, DOI 10.1093/nar/6.5.1843; WOLFFE A P, 1990, New Biologist, V2, P211; WORKMAN JL, 1993, TRENDS BIOCHEM SCI, V18, P90, DOI 10.1016/0968-0004(93)90160-O; ZUCKER K, 1990, J BIOL CHEM, V265, P14487	35	27	33	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 17	1996	271	20					12009	12016		10.1074/jbc.271.20.12009	http://dx.doi.org/10.1074/jbc.271.20.12009			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UL250	8662614	hybrid			2022-12-25	WOS:A1996UL25000065
J	Chang, ZY; Primm, TP; Jakana, J; Lee, IH; Serysheva, I; Chiu, W; Gilbert, HF; Quiocho, FA				Chang, ZY; Primm, TP; Jakana, J; Lee, IH; Serysheva, I; Chiu, W; Gilbert, HF; Quiocho, FA			Mycobacterium tuberculosis 16-kDa antigen (Hsp16.3) functions as an oligomeric structure in vitro to suppress thermal aggregation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEINS; CRYO-ELECTRON MICROSCOPY; ALPHA-CRYSTALLIN; MOLECULAR-WEIGHT; MONOCLONAL-ANTIBODIES; FAMILY; EXPRESSION; IDENTIFICATION; CHAPERONES; LEPRAE	Tuberculosis continues to be a major disease threatening millions of lives worldwide. Several antigens of Mycobacferium tuberculosis, identified by monoclonal antibodies, have been cloned and are being exploited in the development of improved vaccines and diagnostic reagents. We have expressed and purified the 18-kDa antigen, an immunodominant antigen with serodiagnostic value, which has been previously cloned and shown to share low sequence homology with the alpha-crystallin-related small heat shock protein family. Sedimentation equilibrium analytical ultracentrifugation and dynamic light scattering demonstrate the formation of a specific oligomer, 149 +/- 8 kDa, consisting of approximately nine monomers. In 4 M urea, a smaller oligomer of 47 +/- 6 kDa (or trimer) is produced. Analysis by electron cryomicroscopy reveals a triangular shaped oligomeric structure arising from the presence of three subparticles or globules. Taken together, the data suggest an antigen complex structure of a trimer of trimers. This antigen, independent of ATP addition, effectively suppresses the thermal aggregation of citrate synthase at 40 degrees C, indicating that it can function as a molecular chaperone in vitro. A complex between the antigen and heat-denatured citrate synthase can be detected and isolated using high performance Liquid chromatography. We propose to rename the 16-kDa antigen Hsp16.3 to be consistent with other members of the small heat shock protein family.	BAYLOR COLL MED, HOWARD HUGHES MED INST, HOUSTON, TX 77030 USA; BAYLOR COLL MED, VERNA & MARRS MCLEAN DEPT BIOCHEM, HOUSTON, TX 77030 USA; BAYLOR COLL MED, DEPT MOLEC PHYSIOL & BIOPHYS, HOUSTON, TX 77030 USA	Baylor College of Medicine; Howard Hughes Medical Institute; Baylor College of Medicine; Baylor College of Medicine					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM040379] Funding Source: NIH RePORTER; NCRR NIH HHS [RR02250] Funding Source: Medline; NIGMS NIH HHS [GM 40379] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABOUZEID C, 1988, J GEN MICROBIOL, V134, P531; ALLEN SP, 1992, J BACTERIOL, V174, P6938, DOI 10.1128/JB.174.21.6938-6947.1992; ARRIGO AP, 1988, MOL CELL BIOL, V8, P5059, DOI 10.1128/MCB.8.12.5059; Arrigo AP, 1994, BIOL HEAT SHOCK PROT, P335; Ausubel FM, 1992, CURRENT PROTOCOLS MO; AVILASAKAR AJ, 1994, J MOL BIOL, V239, P689, DOI 10.1006/jmbi.1994.1406; BEHLKE J, 1991, FEBS LETT, V288, P119, DOI 10.1016/0014-5793(91)81016-2; BLOOM BR, 1992, SCIENCE, V257, P1055, DOI 10.1126/science.257.5073.1055; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHANG ZY, 1994, J BIOL CHEM, V269, P1956; COATES ARM, 1981, LANCET, V2, P167; COLLIER NC, 1986, J CELL BIOL, V103, P1495, DOI 10.1083/jcb.103.4.1495; DEJONG WW, 1993, MOL BIOL EVOL, V10, P103; DUBOCHET J, 1988, Q REV BIOPHYS, V21, P129, DOI 10.1017/S0033583500004297; ENGERS HD, 1986, INFECT IMMUN, V51, P718; HANSEN JC, 1994, BIOCHEMISTRY-US, V33, P13155, DOI 10.1021/bi00249a001; HOCKERTZ MK, 1991, FEBS LETT, V280, P375, DOI 10.1016/0014-5793(91)80335-Z; HORWITZ J, 1992, P NATL ACAD SCI USA, V89, P10449, DOI 10.1073/pnas.89.21.10449; IVANYI J, 1988, BRIT MED BULL, V44, P635, DOI 10.1093/oxfordjournals.bmb.a072273; JACKETT PS, 1988, J CLIN MICROBIOL, V26, P2313, DOI 10.1128/JCM.26.11.2313-2318.1988; JAKOB U, 1993, J BIOL CHEM, V268, P1517; JAKOB U, 1994, TRENDS BIOCHEM SCI, V19, P205, DOI 10.1016/0968-0004(94)90023-X; JAKOB U, 1995, J BIOL CHEM, V270, P7288, DOI 10.1074/jbc.270.13.7288; KATO K, 1994, J BIOL CHEM, V269, P11274; KINGSTON AE, 1987, INFECT IMMUN, V55, P3149, DOI 10.1128/IAI.55.12.3149-3154.1987; KONG TH, 1993, P NATL ACAD SCI USA, V90, P2608, DOI 10.1073/pnas.90.7.2608; LAMB FI, 1990, J IMMUNOL, V144, P1922; LAUE TM, 1990, METHOD ENZYMOL, V182, P566; LEE BY, 1992, INFECT IMMUN, V60, P2066, DOI 10.1128/IAI.60.5.2066-2074.1992; LEE GJ, 1995, J BIOL CHEM, V270, P10432, DOI 10.1074/jbc.270.18.10432; MERCK KB, 1992, BIOCHIM BIOPHYS ACTA, V1130, P267, DOI 10.1016/0167-4781(92)90439-7; MERCK KB, 1993, J BIOL CHEM, V268, P1046; NERLAND AH, 1988, J BACTERIOL, V170, P5919, DOI 10.1128/jb.170.12.5919-5921.1988; NOWAK R, 1995, SCIENCE, V267, P1763, DOI 10.1126/science.7892595; SASS HJ, 1989, J MOL BIOL, V209, P171, DOI 10.1016/0022-2836(89)90180-0; SCHONINGH R, 1990, J CLIN MICROBIOL, V28, P708; SINGH M, 1970, J BIOL CHEM, V245, P4636; SRERE PA, 1963, ACTA CHEM SCAND, V17, pS129; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; VANHEEL M, 1981, ULTRAMICROSCOPY, V6, P187, DOI 10.1016/0304-3991(81)90059-0; VANHEEL M, 1989, OPTIK, V82, P114; vanHeel M, 1996, J STRUCT BIOL, V116, P17, DOI 10.1006/jsbi.1996.0004; VERBON A, 1990, J GEN MICROBIOL, V136, P955, DOI 10.1099/00221287-136-5-955; VERBON A, 1992, J BACTERIOL, V174, P1352, DOI 10.1128/jb.174.4.1352-1359.1992; VERSTIJNEN CPHJ, 1989, RES MICROBIOL, V140, P653, DOI 10.1016/0923-2508(89)90197-6; YOUNG D, 1990, MOL BIOL MYCOBACTERI, P1; YOUNG DB, 1991, INFECT IMMUN, V59, P3086, DOI 10.1128/IAI.59.9.3086-3093.1991	47	200	212	8	25	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 22	1996	271	12					7218	7223		10.1074/jbc.271.12.7218	http://dx.doi.org/10.1074/jbc.271.12.7218			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UB157	8636160	hybrid			2022-12-25	WOS:A1996UB15700095
J	Hongo, A; DAmbrosio, C; Miura, M; Morrione, A; Baserga, R				Hongo, A; DAmbrosio, C; Miura, M; Morrione, A; Baserga, R			Mutational analysis of the mitogenic and transforming activities of the insulin-like growth factor I receptor	ONCOGENE			English	Article						IGF-1 receptor; transformation; growth; mutation	SIGNAL-TRANSDUCTION; TYROSINE KINASE; HEMATOPOIETIC-CELLS; RAS; TRANSPHOSPHORYLATION; PHOSPHORYLATION; OVEREXPRESSION; EXPRESSION; MECHANISM; IGF-1	The type 1 insulin-like growth factor receptor (IGF-IR) plays an important role in mitogenesis and transformation. It has been previously shown that mitogenic signaling and transforming activity of the IGF-IR can be dissociated: a receptor truncated at residue 1229 (C-terminus) is fully mitogenic, in terms of its response to IGF-I, but cannot transform 3T3-like cells that are devoid of endogenous IGF-IRs (R(-) cells). We have extended our mutational analysis of the C-terminus of the human IGF-IR, by stably transfecting several mutant receptors into R(-) cells, and testing the resulting cell lines for IGF-I-mediated mitogenic response and formation of colonies in soft agar. The results indicate that the transforming domain of the IGF-IR can be localized between residues 1245 and 1310, these sequences being not required for mitogenic signaling. Within these residues, there are at least two areas that contribute to the transforming activity of the receptor.	THOMAS JEFFERSON UNIV,JEFFERSON CANC CTR,PHILADELPHIA,PA 19107	Jefferson University					NIGMS NIH HHS [GM 33684] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARTEAGA CL, 1992, BREAST CANCER RES TR, V22, P101, DOI 10.1007/BF01833338; BAKER J, 1993, CELL, V75, P73, DOI 10.1016/0092-8674(93)90680-O; BALLOTTI R, 1989, EMBO J, V8, P3303, DOI 10.1002/j.1460-2075.1989.tb08491.x; BASERGA R, 1995, CANCER RES, V55, P249; BASERGA R, 1994, CELL, V79, P927, DOI 10.1016/0092-8674(94)90023-X; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; BURGAUD JL, 1995, BIOCHEM BIOPH RES CO, V214, P475, DOI 10.1006/bbrc.1995.2311; BUSCHER D, 1995, MOL CELL BIOL, V15, P466; CAI H, 1992, MOL CELL BIOL, V12, P5329, DOI 10.1128/MCB.12.12.5329; CHANTRY A, 1995, J BIOL CHEM, V270, P3068; CHRISTOFORI G, 1994, NATURE, V369, P414, DOI 10.1038/369414a0; COPPOLA D, 1994, MOL CELL BIOL, V14, P4588, DOI 10.1128/MCB.14.7.4588; CREWS CM, 1993, CELL, V74, P215, DOI 10.1016/0092-8674(93)90411-I; DAMBROSIO C, 1995, CELL GROWTH DIFFER, V6, P557; DEANGELIS T, 1995, J CELL PHYSIOL, V164, P214, DOI 10.1002/jcp.1041640126; DELALUNA S, 1988, GENE, V62, P121; FALCO JP, 1988, ONCOGENE, V2, P573; FARIA TN, 1994, J BIOL CHEM, V269, P13922; FRATTALI AL, 1993, J BIOL CHEM, V268, P7393; GRONBORG M, 1993, J BIOL CHEM, V268, P23435; HARRINGTON EA, 1994, EMBO J, V13, P3286, DOI 10.1002/j.1460-2075.1994.tb06630.x; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; KALEBIC T, 1994, CANCER RES, V54, P5531; KALEKO M, 1990, MOL CELL BIOL, V10, P464, DOI 10.1128/MCB.10.2.464; KATO H, 1993, J BIOL CHEM, V268, P2655; LAMMERS R, 1990, J BIOL CHEM, V265, P16886; LANGLOIS WJ, 1995, ENDOCRINOLOGY, V136, P1978, DOI 10.1210/en.136.5.1978; LI SW, 1994, J BIOL CHEM, V269, P32558; LIU DL, 1993, J VIROL, V67, P6835, DOI 10.1128/JVI.67.11.6835-6840.1993; LIU JP, 1993, CELL, V75, P59, DOI 10.1016/S0092-8674(05)80084-4; LONG L, 1995, CANCER RES, V55, P1006; MCCORMICK F, 1993, NATURE, V363, P15, DOI 10.1038/363015a0; MCCUE JL, 1991, BRIT J SURG, V78, P921, DOI 10.1002/bjs.1800780808; MEDEMA RH, 1993, CRIT REV ONCOGENESIS, V4, P615; MIURA M, 1995, CANCER RES, V55, P663; MIURA M, 1995, J BIOL CHEM, V270, P22639, DOI 10.1074/jbc.270.38.22639; MIURA M, 1994, CANCER RES, V54, P2472; MORRIONE A, 1995, J VIROL, V69, P5300, DOI 10.1128/JVI.69.9.5300-5303.1995; MYERS MG, 1993, ENDOCRINOLOGY, V132, P1421, DOI 10.1210/en.132.4.1421; PIETRZKOWSKI Z, 1992, CELL GROWTH DIFFER, V3, P199; PRAGER D, 1994, P NATL ACAD SCI USA, V91, P2181, DOI 10.1073/pnas.91.6.2181; RESNICOFF M, 1994, CANCER RES, V54, P2218; RESNICOFF M, 1994, CANCER RES, V54, P4848; RESNICOFF M, 1995, CANCER RES, V55, P3739; RESNICOFF M, 1995, CANCER RES, V55, P2463; RODRIGUEZTARDUCHY G, 1992, J IMMUNOL, V149, P535; ROGLER CE, 1994, J BIOL CHEM, V269, P13779; ROSE DW, 1994, P NATL ACAD SCI USA, V91, P797, DOI 10.1073/pnas.91.2.797; SAKAUE M, 1995, MOL CELL BIOL, V15, P379, DOI 10.1128/MCB.15.1.379; SCHER CD, 1979, BIOCHIM BIOPHYS ACTA, V560, P217, DOI 10.1016/0304-419X(79)90020-9; SELL C, 1995, CANCER RES, V55, P303; SELL C, 1994, MOL CELL BIOL, V14, P3604, DOI 10.1128/MCB.14.6.3604; SELL C, 1993, P NATL ACAD SCI USA, V90, P11217, DOI 10.1073/pnas.90.23.11217; SHAPIRO DN, 1994, J CLIN INVEST, V94, P1235, DOI 10.1172/JCI117441; SILVENNOINEN O, 1993, SCIENCE, V261, P1736, DOI 10.1126/science.8378775; STILES CD, 1979, P NATL ACAD SCI USA, V76, P1279, DOI 10.1073/pnas.76.3.1279; SURMACZ E, 1995, EXP CELL RES, V218, P370, DOI 10.1006/excr.1995.1168; TAOUIS M, 1994, J BIOL CHEM, V269, P27762; TROJAN J, 1993, SCIENCE, V259, P94, DOI 10.1126/science.8418502; ULLRICH A, 1986, EMBO J, V5, P2503, DOI 10.1002/j.1460-2075.1986.tb04528.x; WATERS SB, 1993, J BIOL CHEM, V268, P22231; WHITE MF, 1994, J BIOL CHEM, V269, P1; YAMAUCHI K, 1994, MOL CELL BIOL, V14, P4427, DOI 10.1128/MCB.14.7.4427	63	104	105	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR 21	1996	12	6					1231	1238						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UC067	8649825				2022-12-25	WOS:A1996UC06700008
J	Kim, S; Brown, PH; Birrer, MJ				Kim, S; Brown, PH; Birrer, MJ			The inhibitory activity of a transdominant c-jun mutant fused to the ligand binding domain of the estrogen receptor	ONCOGENE			English	Article						transcription factor; jun; fos; AP-1; dominant negative mutant; estrogen receptor	FUSION PROTEIN; TRANSCRIPTIONAL ACTIVATION; EMBRYO FIBROBLASTS; GENE FAMILY; TRANSFORMATION; CELLS; DIFFERENTIATION; ONCOPROTEIN; SUPPRESSION; EXPRESSION	Tam-67 is an amino-terminal deletion mutant of c-Jun (Delta 3-122) lacking most of the c-Jun transactivation domain, which has been shown previously to function in a transdominant fashion to inhibit c-Jun-induced transactivation and cellular transformation. In order to create a ligand-dependent dominant negative repressor of AP-1, we have constructed a fusion of the TAM-67 gene with the ligand binding domain of the estrogen receptor. Fusion of TAM-67 with the ligand binding domain of the estrogen receptor produced a 68 kD protein (TAM-67ER) which was immunoprecipitated by c-Jun-specific and estrogen receptor-specific antisera and shown by gel retardation assay to bind oligonucleotides containing an AP-1 sequence. Cotransfection of TAM-67ER and an AP-1-dependent reporter construct into rat embryo cells demonstrated ligand specific inhibition of AP-1 transactivation. In the absence of hormone, TAM-67ER produced complete inhibition of cJun-induced AP-1 transactivation. This inhibition was relieved by treatment with estradiol but not by treatment with tamoxifen. In addition, TAM-67ER inhibited activated c-Ha-ras- or c- raf-induced transformation of NTH3T3 cells. However, this inhibition of transformation was not relieved by the addition of estrogen. Thus, TAM-67ER inhibits transactivation in a ligand-dependent manner, but inhibits transformation in a ligand-independent manner. The results suggest that the ligand-dependent transactivation domain of the estrogen receptor (TAF-2) can substitute for the cJun transactivation domain absent in TAM-67 to stimulate transactivation. However, TAF-2 cannot substitute for the missing c-Jun transactivation domain to induce cellular transformation.	NCI,DIV CLIN SCI,BIOMARKERS & PREVENT RES BRANCH,ROCKVILLE,MD 20850; UNIFORMED SERV UNIV HLTH SCI,BETHESDA,MD 20814	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Uniformed Services University of the Health Sciences - USA								ALANI R, 1991, MOL CELL BIOL, V11, P6286, DOI 10.1128/MCB.11.12.6286; ANGEL P, 1988, NATURE, V332, P166, DOI 10.1038/332166a0; BEEKMAN JM, 1993, MOL ENDOCRINOL, V7, P1266, DOI 10.1210/me.7.10.1266; BIRRER MJ, 1988, MOL CELL BIOL, V8, P2668, DOI 10.1128/MCB.8.6.2668; BOEHMELT G, 1992, EMBO J, V11, P4641, DOI 10.1002/j.1460-2075.1992.tb05566.x; BOS TJ, 1990, GENE DEV, V4, P1677, DOI 10.1101/gad.4.10.1677; BROWN PH, 1994, ONCOGENE, V9, P791; BROWN PH, 1993, ONCOGENE, V8, P877; BURK O, 1991, EMBO J, V10, P3713, DOI 10.1002/j.1460-2075.1991.tb04939.x; CLEVELAND JL, 1994, ONCOGENE, V9, P2217; COHEN DR, 1988, MOL CELL BIOL, V8, P2063, DOI 10.1128/MCB.8.5.2063; DAVENPORT EA, 1988, ANTICANCER RES, V8, P959; DOMANN FE, 1994, CELL GROWTH DIFFER, V5, P9; DONG ZG, 1994, P NATL ACAD SCI USA, V91, P609, DOI 10.1073/pnas.91.2.609; DOSAKAAKITA H, 1991, ONCOGENE, V6, P371; EILERS M, 1989, NATURE, V340, P66, DOI 10.1038/340066a0; FRANCIS MK, 1995, J BIOL CHEM, V270, P11502, DOI 10.1074/jbc.270.19.11502; FRANZA BR, 1988, SCIENCE, V239, P1150, DOI 10.1126/science.2964084; GILBERT DM, 1993, MOL CELL BIOL, V13, P462, DOI 10.1128/MCB.13.1.462; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; MATSUI M, 1990, ONCOGENE, V5, P249; MATTIONI T, 1994, METHOD CELL BIOL, V43, P335; PICARD D, 1988, CELL, V54, P1073, DOI 10.1016/0092-8674(88)90122-5; Picard Didier, 1993, Trends in Cell Biology, V3, P278, DOI 10.1016/0962-8924(93)90057-8; RAPP UR, 1994, ONCOGENE, V9, P3493; REESE JC, 1992, MOL CELL BIOL, V12, P4531, DOI 10.1128/MCB.12.10.4531; REICHMANN E, 1992, CELL, V71, P1103, DOI 10.1016/S0092-8674(05)80060-1; RYDER K, 1989, P NATL ACAD SCI USA, V86, P1500, DOI 10.1073/pnas.86.5.1500; SCHUERMANN M, 1993, ONCOGENE, V8, P2781; SUPERTIFURGA G, 1991, P NATL ACAD SCI USA, V88, P5114, DOI 10.1073/pnas.88.12.5114; SZABO E, 1991, CELL GROWTH DIFFER, V2, P475; TOMMASINO M, 1994, J VIROL, V68, P2206; TROPPMAIR J, 1994, J BIOL CHEM, V269, P7030; WEBSTER NJG, 1988, CELL, V54, P199, DOI 10.1016/0092-8674(88)90552-1; ZERIAL M, 1989, EMBO J, V8, P805, DOI 10.1002/j.1460-2075.1989.tb03441.x	35	9	9	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR 7	1996	12	5					1043	1053						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UA884	8649795				2022-12-25	WOS:A1996UA88400012
J	Kazmierczak, B; Rosigkeit, J; Wanschura, S; MeyerBolte, K; VandeVen, WJM; Kayser, K; Krieghoff, B; Kastendiek, H; Bartnitzke, S; Bullerdiek, J				Kazmierczak, B; Rosigkeit, J; Wanschura, S; MeyerBolte, K; VandeVen, WJM; Kayser, K; Krieghoff, B; Kastendiek, H; Bartnitzke, S; Bullerdiek, J			HMGI-C rearrangements as the molecular basis for the majority of pulmonary chondroid hamartomas: A survey of 30 tumors	ONCOGENE			English	Article						chondroid hamartomas of the lung, 12q14-15; HMGI-C gene	DNA-BINDING DOMAIN; INSITU HYBRIDIZATION; PROTEIN	Pulmonary chondroid hamartomas (PCH) are benign tumors of the lung characterized by a more or less high degree of mesenchymal metaplasia, In our series we investigated 30 PCH by a combination of cytogenetic and molecular methods, 18 tumors (60%) had cytogenetically detectable aberrations involving either 12q14-15 or 6p21 with a clear predominance of chromosomal abnormalities involving 12q14-15 (15 tumors), As in subgroups of pleomorphic adenomas of the salivary glands, leiomyomas of the uterus, and lipomas with 12q14-15 abnormalities the HMGI-C gene is frequently rearranged we tested PCH with either 12q14-15 abnormalities or normal karyotype by FISH and 3' RACE experiments for rearrangements of HMGI-C, Rearrangements were found in all cases with chromosomal 12q14-15 abnormalities and further six cases with an apparently normal karyotype, By the combination of cytogenetics with molecular techniques the percentage of cases with intragenic rearrangements of HMGI-C or rearrangements of its immediate surrounding was thus increased to 70% (21/30 cases), Considering all types of aberrations within this series 80% (24/30) of all PCH were aberrant, This is the first report on a combined molecular and cytogenetic analysis of a large series of pulmonary chondroid hamartomas indicating that rearrangements of HMGI-C, a member of the high mobility group protein gene family, are the;leading molecular events in the genesis of PCH.	UNIV BREMEN,CTR HUMAN GENET & GENET COUNSELLING,ZHG,D-28359 BREMEN,GERMANY; CATHOLIC UNIV LEUVEN,CTR HUMAN GENET,B-3000 LOUVAIN,BELGIUM; LVA BODEN,HOSP PULM DIS,DEPT PATHOL,D-69126 HEIDELBERG,GERMANY; URBAN HOSP ST GEORGE,DEPT PATHOL,D-04129 LEIPZIG,GERMANY; PUBL HOSP HARBURG,DEPT PATHOL,D-21041 HAMBURG,GERMANY	University of Bremen; KU Leuven								ASHAR HR, 1995, CELL, V82, P57; BERLINGIERI MT, 1995, MOL CELL BIOL, V15, P1545; BULLERDIEK J, 1987, CYTOGENET CELL GENET, V45, P187, DOI 10.1159/000132452; DALCIN P, 1993, GENE CHROMOSOME CANC, V8, P131; FLETCHER AJ, 1995, GENE CHROMOSOME CANC, V12, P220; FLETCHER JA, 1992, CANCER RES, V52, P6224; FLETCHER JA, 1991, AM J PATHOL, V138, P1199; JOHANSSON M, 1992, CANCER GENET CYTOGEN, V60, P219, DOI 10.1016/0165-4608(92)90026-5; JOHANSSON M, 1993, BRIT J CANCER, V67, P1236, DOI 10.1038/bjc.1993.231; KAZMIERCZAK B, 1995, CANCER RES, V55, P2497; KAZMIERCZAK B, 1995, AM J PATHOL, V147, P580; KIEVITS T, 1990, CYTOGENET CELL GENET, V53, P134, DOI 10.1159/000132913; KOOLS PFJ, 1995, CANCER GENET CYTOGEN, V79, P1, DOI 10.1016/0165-4608(94)00137-Z; Koss MN, 1990, SURGICAL PATHOLOGY L, P418; MANFIOLETTI G, 1991, NUCLEIC ACIDS RES, V19, P6793, DOI 10.1093/nar/19.24.6793; PATEL UA, 1994, BIOCHEM BIOPH RES CO, V201, P63, DOI 10.1006/bbrc.1994.1669; REEVES R, 1990, J BIOL CHEM, V265, P8573; REEVES R, 1991, P NATL ACAD SCI USA, V88, P1671, DOI 10.1073/pnas.88.5.1671; ROMMEL B, 1988, CYTOMETRY, V9, P504, DOI 10.1002/cyto.990090517; SCHOENMAKERS EFPM, 1994, GENE CHROMOSOME CANC, V11, P106, DOI 10.1002/gcc.2870110207; SCHOENMAKERS EFPM, 1994, GENOMICS, V20, P210, DOI 10.1006/geno.1994.1155; SCHOENMAKERS EFPM, 1995, NAT GENET, V10, P436, DOI 10.1038/ng0895-436; THANOS D, 1992, CELL, V71, P777, DOI 10.1016/0092-8674(92)90554-P; VANDEVEN WJM, 1995, GENE CHROMOSOME CANC, V12, P296	24	115	116	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB 1	1996	12	3					515	521						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TV597	8637707				2022-12-25	WOS:A1996TV59700007
J	Mari, B; Guerin, S; Far, DF; Breitmayer, JP; Belhacene, N; Peyron, JF; Rossi, B; Auberger, P				Mari, B; Guerin, S; Far, DF; Breitmayer, JP; Belhacene, N; Peyron, JF; Rossi, B; Auberger, P			Thrombin and trypsin-induced Ca2+ mobilization in human T cell lines through interaction with different protease-activated receptors	FASEB JOURNAL			English	Article						thrombin receptor; protease-activated receptor 2; T leukemic cell lines	STIMULATE PHOSPHOINOSITIDE HYDROLYSIS; PHOSPHOLIPASE-C; ALPHA-THROMBIN; RESPONSES; PEPTIDES; MECHANISM; CYCLASE; AGONIST	This study was conducted to determine whether serine proteinases may induce [Ca2+](i) mobilization in different hematopoietic cell lines and to analyze their mechanisms of action. We show that in addition to thrombin and thrombin receptor agonist peptide (TRP, SFLLRN), trypsin induced [Ca2+](i) mobilization in a highly thrombin-sensitive Jurkat T cell clone. Thrombin, TRP, and trypsin were found to induce [Ca2+](i) release in three different Jurkat T cell clones differing in the level of T cell receptor expression. Similar results were obtained with a prothymocytic leukemic cell line, MPB.ALL, although these cells were much more responsive to trypsin than to thrombin and TRP. Other cell types such as THP1, a myelomonocytic cell line, or CEM, a CD4(+) positive leukemic cell line, were unresponsive to thrombin, TRP, and trypsin. The effect of trypsin was mimicked by SLIGRL, a peptide corresponding to the cleaved amino-terminal sequence of the recently characterized murine trypsin-activated receptor (PAR2). At suboptimal concentrations, the effects of SFLLRN and SLIGRL were additive, whereas saturating doses of peptides did not further increase [Ca2+](i) mobilization in Jurkat T cells, indicating that both peptides were able to mobilize the same pool of calcium. Northern blot analysis of mRNAs from different leukemic cell lines indicated a remarkable correlation between PAR2 expression in different cell lines and SLIGRL or trypsin responses in the same cells. The expression of the ''trypsin receptor'' was also confirmed by polymerase chain reaction analysis. Moreover, a 24 h treatment of Jurkat cells by an anti-CDS monoclonal antibody, a condition known to down-regulate thrombin receptor expression, induced loss of thrombin and TRP responses but only partially affected trypsin stimulation of [Ca2+](i) release. Finally, after a first stimulation with either thrombin or trypsin, Jurkat cells were still able to respond to trypsin or thrombin, respectively, demonstrating that thrombin and trypsin essentially activated their own receptors. Our data provided evidence that 1) the human T leukemic cell line Jurkat and other T cell lines express at least two different functional protease-activated receptors, the thrombin receptor and a highly sensitive trypsin receptor, likely the human counterpart of the murine PAR2, and 2) at variance with the commonly accepted model, trypsin exerts most of its effect in T leukemic cell lines by thrombin receptor-independent mechanisms.	FAC MED NICE,INSERM,U364,F-06107 NICE 02,FRANCE; FAC MED NICE,INSERM,U343,F-06107 NICE 02,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur			Jean-Francois, Peyron/AAA-9496-2022; AUBERGER, Patrick/G-1491-2013; Mari, Bernard P/F-8960-2013; Mari, Bernard/Q-5832-2019; Mari, Bernard P/D-7445-2015; Mari, Bernard P/GVS-3100-2022; Peyron, Jean-Francois/M-5682-2016	Jean-Francois, Peyron/0000-0001-6113-916X; AUBERGER, Patrick/0000-0002-2481-8275; Mari, Bernard P/0000-0002-0422-9182; Mari, Bernard/0000-0002-0422-9182; Mari, Bernard P/0000-0002-0422-9182; Mari, Bernard P/0000-0002-0422-9182; Peyron, Jean-Francois/0000-0001-6113-916X				AUBERGER P, 1989, J IMMUNOL, V142, P289; BRASS LF, 1991, J BIOL CHEM, V266, P958; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HUNG DT, 1992, J BIOL CHEM, V267, P20831; JAKOBS KH, 1988, BIOCHEM J, V249, P639, DOI 10.1042/bj2490639; JAKOBS KH, 1988, EUR J BIOCHEM, V172, P255, DOI 10.1111/j.1432-1033.1988.tb13881.x; JONES LG, 1989, MOL PHARMACOL, V36, P142; LAZAROWSKI ER, 1990, ARCH BIOCHEM BIOPHYS, V276, P265, DOI 10.1016/0003-9861(90)90037-Y; MARI B, 1992, EMBO J, V11, P3875, DOI 10.1002/j.1460-2075.1992.tb05480.x; MARI B, 1994, J BIOL CHEM, V269, P8517; MCNAMARA CA, 1993, J CLIN INVEST, V91, P94, DOI 10.1172/JCI116206; NYSTEDT S, 1994, P NATL ACAD SCI USA, V91, P9208, DOI 10.1073/pnas.91.20.9208; RABINOVITCH PS, 1986, J IMMUNOL, V137, P952; RASMUSSEN UB, 1991, FEBS LETT, V288, P123, DOI 10.1016/0014-5793(91)81017-3; RUGGIERO M, 1985, BIOCHEM BIOPH RES CO, V131, P1198, DOI 10.1016/0006-291X(85)90218-9; SCARBOROUGH RM, 1992, J BIOL CHEM, V267, P13146; SELAK MA, 1994, BIOCHEM J, V297, P269, DOI 10.1042/bj2970269; SUIDAN HS, 1994, P NATL ACAD SCI USA, V91, P8112, DOI 10.1073/pnas.91.17.8112; TORDAI A, 1993, J IMMUNOL, V150, P4876; VASSALLO RR, 1992, J BIOL CHEM, V267, P6081; VOURETCRAVIARI V, 1993, BIOCHEM J, V289, P209, DOI 10.1042/bj2890209; VOURETCRAVIARI V, 1992, MOL BIOL CELL, V3, P95, DOI 10.1091/mbc.3.1.95; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V; VU TKH, 1991, NATURE, V353, P674, DOI 10.1038/353674a0	26	71	71	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	FEB	1996	10	2					309	316		10.1096/fasebj.10.2.8641564	http://dx.doi.org/10.1096/fasebj.10.2.8641564			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	TY962	8641564				2022-12-25	WOS:A1996TY96200015
J	Homma, K; Matsushita, T; Natori, S				Homma, K; Matsushita, T; Natori, S			Purification, characterization, and cDNA cloning of a novel growth factor from the conditioned medium of NIH-Sape-4, an embryonic cell line of Sarcophaga peregrina (flesh fly)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DROSOPHILA EGF RECEPTOR; FACTOR-BETA FAMILY; GENE; PROTEIN; HOMOLOG; ESTABLISHMENT; POLARITY; PATTERN; DPP; RNA	A growth factor from the conditioned medium of NIH-Sape-4, an embryonic cell line of the flesh fly, was purified to homogeneity. This growth factor, termed IDGF, stimulated the proliferation of NIH-Sape-4 cells in an autocrine manner; it was a homodimer of a protein with a molecular mass of 52 kDa, and its specific activity was comparable with those of mammalian growth factors, Immunoblotting experiments revealed that unfertilized mature eggs of the flesh fly contained this growth factor, a certain level of which was maintained throughout embryonic development, Analysis of cDNA for this growth factor showed that this factor is a novel protein consisting of 553 amino acid residues, No significant sequence similarity was found between this factor and other proteins except atrial gland granule-specific antigen of Aplysia californica.	UNIV TOKYO,FAC PHARMACEUT SCI,BUNKYO KU,TOKYO 113,JAPAN	University of Tokyo								AHMED SA, 1994, J IMMUNOL METHODS, V170, P211, DOI 10.1016/0022-1759(94)90396-4; BRAND AH, 1994, GENE DEV, V8, P629, DOI 10.1101/gad.8.5.629; BRUMMEL TJ, 1994, CELL, V78, P251, DOI 10.1016/0092-8674(94)90295-X; FAIRBANKS G, 1971, BIOCHEMISTRY-US, V10, P2606, DOI 10.1021/bi00789a030; FERGUSON EL, 1992, CELL, V71, P451, DOI 10.1016/0092-8674(92)90514-D; GOODE S, 1992, DEVELOPMENT, V116, P177; HEBERLEIN U, 1993, CELL, V75, P913, DOI 10.1016/0092-8674(93)90535-X; HELDIN CH, 1981, BIOCHEM J, V193, P907, DOI 10.1042/bj1930907; HENIKOFF S, 1987, METHOD ENZYMOL, V155, P156; HOMMA K, 1994, J BIOL CHEM, V269, P15258; KOMANO H, 1991, FEBS LETT, V289, P167, DOI 10.1016/0014-5793(91)81061-C; KOMANO H, 1987, BIOCHEM J, V248, P217, DOI 10.1042/bj2480217; KURAMA T, 1995, EUR J BIOCHEM, V228, P229, DOI 10.1111/j.1432-1033.1995.tb20254.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEMKE GE, 1984, J NEUROSCI, V4, P75; LIVNEH E, 1985, CELL, V40, P599, DOI 10.1016/0092-8674(85)90208-9; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MCCAULEY R, 1973, MOL CELL BIOCHEM, V1, P73, DOI 10.1007/BF01659940; MITSUHAS.J, 1964, CONTRIB BOYCE THOMPS, V22, P435; NAKANISHIMATSUI M, 1995, EUR J BIOCHEM, V230, P396, DOI 10.1111/j.1432-1033.1995.0396h.x; NELLEN D, 1994, CELL, V78, P225, DOI 10.1016/0092-8674(94)90293-3; NEUMANSILBERBERG FS, 1993, CELL, V75, P165, DOI 10.1016/S0092-8674(05)80093-5; PADGETT RW, 1987, NATURE, V325, P81, DOI 10.1038/325081a0; PAGE B, 1993, INT J ONCOL, V3, P473; PANGANIBAN GEF, 1990, MOL CELL BIOL, V10, P2669, DOI 10.1128/MCB.10.6.2669; PENTON A, 1994, CELL, V78, P239, DOI 10.1016/0092-8674(94)90294-1; RAZ E, 1993, GENE DEV, V7, P1937, DOI 10.1101/gad.7.10.1937; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SGARAMELLA V, 1972, J MOL BIOL, V72, P427, DOI 10.1016/0022-2836(72)90155-6; SOSSIN WS, 1989, J BIOL CHEM, V264, P16933; STAEHLINGHAMPTON K, 1994, NATURE, V372, P783; TAKAHASHI M, 1980, DEV GROWTH DIFFER, V22, P11; THOMAS KA, 1984, P NATL ACAD SCI-BIOL, V81, P357, DOI 10.1073/pnas.81.2.357; XIE T, 1994, SCIENCE, V263, P1756, DOI 10.1126/science.8134837	34	56	58	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 7	1996	271	23					13770	13775		10.1074/jbc.271.23.13770	http://dx.doi.org/10.1074/jbc.271.23.13770			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UP385	8662793	hybrid			2022-12-25	WOS:A1996UP38500070
J	Li, WL; Park, JW; Nuijens, A; Sliwkowski, MX; Keller, GA				Li, WL; Park, JW; Nuijens, A; Sliwkowski, MX; Keller, GA			Heregulin is rapidly translocated to the nucleus and its transport is correlated with c-myc induction in breast cancer cells	ONCOGENE			English	Article						heregulin; ErbB2/HER2/neu; growth factor internalization; nuclear transport; c-myc	EPIDERMAL GROWTH-FACTOR; LOCALIZATION; ACTIVATION; RECEPTORS; PROTEINS	Heregulins (neuregulins) are a family of proteins known to interact and activate the receptor tyrosine kinases ErbB2 in association with ErbB3 or ErbB4. Using immunofluorescence microscopy, electron microscopy autoradiography, and SDS-PAGE analysis of nuclear fractions, we show that the heregulin-beta 1(1-244) isoform is rapidly internalized and translocated to the nucleus of SK-BR-3 breast cancer cells as an intact molecule. Heregulin-beta 1(1-244) treatment up-regulated expression of c-myc mRNA and protein, which was also observed to undergo its own translocation from the cytosol to the nucleus. c-myc thus appears to be a cellular target gene of HRG beta 1(1-244) and its induction may be related to the nuclear translocation of heregulin.	GENENTECH INC,S SAN FRANCISCO,CA 94080	Roche Holding; Genentech								BENBARUCH N, 1994, P SOC EXP BIOL MED, V206, P221; CARPENTER G, 1987, ANNU REV BIOCHEM, V56, P881, DOI 10.1146/annurev.biochem.56.1.881; DINGWALL C, 1986, ANNU REV CELL BIOL, V2, P367, DOI 10.1146/annurev.cellbio.2.1.367; EVAN GI, 1993, CURR OPIN GENET DEV, V3, P44, DOI 10.1016/S0959-437X(05)80339-9; GARCIA G, 1987, CANCER RES, V49, P6675; HARRIS JR, 1992, NEW ENGL J MED, V327, P473, DOI 10.1056/NEJM199208133270706; HOLMES WE, 1992, SCIENCE, V256, P1205, DOI 10.1126/science.256.5060.1205; HYNES NE, 1994, BBA-REV CANCER, V1198, P165, DOI 10.1016/0304-419X(94)90012-4; JOHNSON GR, 1992, J CELL BIOL, V118, P741, DOI 10.1083/jcb.118.3.741; KELLY K, 1986, ANNU REV IMMUNOL, V4, P317, DOI 10.1146/annurev.immunol.4.1.317; KIMURA H, 1993, P NATL ACAD SCI USA, V90, P2165, DOI 10.1073/pnas.90.6.2165; KLEMPNAUER KH, 1984, CELL, V37, P537, DOI 10.1016/0092-8674(84)90384-2; KRAUS MH, 1993, P NATL ACAD SCI USA, V90, P2900, DOI 10.1073/pnas.90.7.2900; PEITRAS RJ, 1995, ONCOGENE, V10, P2435; PLOWMAN GD, 1993, P NATL ACAD SCI USA, V90, P1746, DOI 10.1073/pnas.90.5.1746; ROUX P, 1990, CELL, V63, P341, DOI 10.1016/0092-8674(90)90167-D; SARUP JC, 1991, GROWTH REGULAT, V1, P72; SHIBUYA H, 1992, CELL, V70, P57, DOI 10.1016/0092-8674(92)90533-I; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; WAKAMATSU Y, 1993, NEURON, V10, P1, DOI 10.1016/0896-6273(93)90236-K	20	56	60	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN 6	1996	12	11					2473	2477						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UQ220	8649790				2022-12-25	WOS:A1996UQ22000027
J	Cassell, M; Tobacman, LS				Cassell, M; Tobacman, LS			Opposite effects of myosin subfragment 1 on binding of cardiac troponin and tropomyosin to the thin filament	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUSCLE-CONTRACTION; COOPERATIVE BINDING; F-ACTIN; HEAVY-MEROMYOSIN; COMPLEX; MOLECULES	To better understand the regulation of striated muscle contraction, the effects of myosin subfragment 1 (S-1) on the actin binding of cardiac troponin and tropomyosin were investigated, Troponin's affinity for actin-tropomyosin was 4-fold stronger in the absence than in the presence of myosin S-1. CaCl2 had no effect on troponin binding to the thin filament in the presence of myosin S-1, The binding curve was weakly cooperative, implying interactions between adjacent troponin molecules, Myosin S-1 increased (40-200-fold) the affinity of tropomyosin for the thin filament, an effect opposite to the effect of myosin on troponin, This effect was highly cooperative and occurred in the presence of ADP or in the absence of nucleotide; Myosin altered the effect of ionic conditions on tropomyosin-actin binding, consistent with tropomyosin binding to a different site on F-actin in the presence of myosin. The results indicate that troponin-tropomyosin and strongly binding myosin crossbridges do not compete for an F-actin binding site, Although repositioning of troponin-tropomyosin on the actin filament may be sterically required for tight myosin-actin binding, a myosin-induced conformational change in actin provides a better explanation for the complex effects of myosin on thin filament assembly.	UNIV IOWA,DEPT INTERNAL MED,IOWA CITY,IA 52246; UNIV IOWA,DEPT BIOCHEM,IOWA CITY,IA 52246	University of Iowa; University of Iowa								BUTTERS CA, 1993, J BIOL CHEM, V268, P15565; CHALOVICH JM, 1992, PHARMACOL THERAPEUT, V55, P95, DOI 10.1016/0163-7258(92)90013-P; DAHIYA R, 1994, J BIOL CHEM, V269, P29457; EATON BL, 1976, SCIENCE, V192, P1337, DOI 10.1126/science.131972; EBASHI S, 1969, Quarterly Reviews of Biophysics, V2, P351; FISHER D, 1995, J BIOL CHEM, V270, P25455, DOI 10.1074/jbc.270.43.25455; Geeves M A, 1995, Biophys J, V68, p194S; GREENE LE, 1980, P NATL ACAD SCI-BIOL, V77, P2616, DOI 10.1073/pnas.77.5.2616; GREENE LE, 1981, BIOCHEMISTRY-US, V20, P2120, DOI 10.1021/bi00511a008; Haselgrove J. C., 1972, COLD SPRING HARB SYM, V37, P341; HILL LE, 1992, J BIOL CHEM, V267, P16106; Hill T. L., 1985, COOPERATIVITY THEORY; HOLMES KC, 1995, BIOPHYS J, V68, pS2; Huxley H. E., 1972, COLD SPRING HARB SYM, V37, P361; Huynh Q, 1996, BIOPHYS J, V70, P1447, DOI 10.1016/S0006-3495(96)79704-7; JONTES JD, 1995, NATURE, V378, P751, DOI 10.1038/378751a0; LEAVIS PC, 1984, CRC CR REV BIOCH MOL, V16, P235, DOI 10.3109/10409238409108717; LORENZ M, 1995, J MOL BIOL, V246, P108, DOI 10.1006/jmbi.1994.0070; MCGHEE JD, 1974, J MOL BIOL, V86, P469, DOI 10.1016/0022-2836(74)90031-X; MEHEGAN JP, 1991, J BIOL CHEM, V266, P966; NAGASHIMA H, 1982, J MOL BIOL, V155, P409, DOI 10.1016/0022-2836(82)90479-X; PARRY DAD, 1973, J MOL BIOL, V75, P33, DOI 10.1016/0022-2836(73)90527-5; RAYMENT I, 1993, SCIENCE, V261, P58, DOI 10.1126/science.8316858; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; SZCZESNA D, 1989, BIOL CHEM H-S, V370, P399, DOI 10.1515/bchm3.1989.370.1.399; TOBACMAN LS, 1986, BIOCHEMISTRY-US, V25, P798, DOI 10.1021/bi00352a010; TOBACMAN LS, 1987, J BIOL CHEM, V262, P4059; Tobacman LS, 1996, ANNU REV PHYSIOL, V58, P447, DOI 10.1146/annurev.physiol.58.1.447; TOBACMAN LS, 1990, J BIOL CHEM, V265, P931; TRYBUS KM, 1980, P NATL ACAD SCI-BIOL, V77, P7209, DOI 10.1073/pnas.77.12.7209; WEEDS AG, 1975, NATURE, V257, P54, DOI 10.1038/257054a0; WHITTAKER M, 1995, NATURE, V378, P748, DOI 10.1038/378748a0; WILLADSEN KA, 1992, J BIOL CHEM, V267, P23746; WILLIAMS DL, 1983, BIOCHEMISTRY-US, V22, P2770, DOI 10.1021/bi00280a027; YANG YZ, 1979, J BIOL CHEM, V254, P2084	35	48	48	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 31	1996	271	22					12867	12872		10.1074/jbc.271.22.12867	http://dx.doi.org/10.1074/jbc.271.22.12867			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UN474	8662810	hybrid			2022-12-25	WOS:A1996UN47400029
J	Joseph, DE; Paul, CC; Baumann, MA; GomezCambronero, J				Joseph, DE; Paul, CC; Baumann, MA; GomezCambronero, J			S6 kinase p90(rsk) in granulocyte-macrophage colony-stimulating factor-stimulated proliferative and mature hematopoietic cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RIBOSOMAL-PROTEIN S6; TYROSINE PHOSPHORYLATION; HUMAN-NEUTROPHILS; MAP KINASE; RAPID PHOSPHORYLATION; SWISS 3T3-CELLS; GM-CSF; ACTIVATION; INTERLEUKIN-3; EXPRESSION	The ribosomal S6 kinase p90(rsk) was studied in mature and proliferating hemopoietic cells in response to the human cytokine granulocyte-macrophage colony-stimulating factor (GM-CSF). In neutrophils, GM-CSF induced time-dependent electrophoretic mobility shifts in immunoreactive p90(rsk) Although these shifts suggested changes in the phosphorylation status of the molecule, a kinase assay with whole cell lysates detected minimal (1.5-fold) increments in enzymatic activity. Only immunoprecipitation followed by immune complex kinase assay or in-gel kinase assay performed against the RSK substrate RRLSSLRA evidenced an increase in p90(rsk) activity (SR-fold). p90(rsk) was also detected in the GMCSF-dependent erythroleukemia cell line TF-1. Normally cultured, cytokine-supplemented cells did not respond to further GM-CSF stimulation. However, the activity of p90(rsk) in cytokine-starved cells increased dramatically in response to short term CRI-CSF challenge. This effect was readily observable in total cell lysates (6.6-fold increase over controls) and was paralleled by changes in mitogen-activated protein kinase activity (a substrate of p90(rsk)). Thus, p90(rsk) is present in mature hemopoietic cells, but the extent of the enzymatic response to GM-CSF is significantly lower than that seen in proliferative cells.	WRIGHT STATE UNIV,SCH MED,DEPT PHYSIOL,DAYTON,OH 45435; WRIGHT STATE UNIV,SCH MED,DEPT BIOPHYS,DAYTON,OH 45435; WRIGHT STATE UNIV,SCH MED,DEPT MED,DAYTON,OH 45435; VET AFFAIRS MED CTR,RES SERV,DAYTON,OH 45428	University System of Ohio; Wright State University Dayton; University System of Ohio; Wright State University Dayton; University System of Ohio; Wright State University Dayton; US Department of Veterans Affairs; Veterans Health Administration (VHA); Case Western Reserve University; Louis Stokes Cleveland Veterans Affairs Medical Center				Gomez-Cambronero, Julian/0000-0002-7581-9227				AHN NG, 1990, J BIOL CHEM, V265, P11487; AHN NG, 1990, J BIOL CHEM, V265, P11495; ALCORTA DA, 1989, MOL CELL BIOL, V9, P3850, DOI 10.1128/MCB.9.9.3850; BAXTER GT, 1992, BIOCHEMISTRY-US, V31, P10950, DOI 10.1021/bi00160a002; BERKOW RL, 1989, BIOCHIM BIOPHYS ACTA, V997, P292, DOI 10.1016/0167-4838(89)90200-8; BLENIS J, 1986, EMBO J, V5, P3441, DOI 10.1002/j.1460-2075.1986.tb04667.x; CALVO V, 1992, EUR J IMMUNOL, V22, P457, DOI 10.1002/eji.1830220225; CANNISTRA SA, 1988, SEMIN HEMATOL, V25, P173; CARROLL MP, 1990, J BIOL CHEM, V265, P19812; CLARK SC, 1987, SCIENCE, V236, P1229, DOI 10.1126/science.3296190; COLOTTA F, 1987, J EXP MED, V165, P1224, DOI 10.1084/jem.165.4.1224; COREY S, 1993, EMBO J, V12, P2681, DOI 10.1002/j.1460-2075.1993.tb05929.x; DENT P, 1990, NATURE, V348, P302, DOI 10.1038/348302a0; ENGLISH D, 1974, J IMMUNOL METHODS, V5, P249, DOI 10.1016/0022-1759(74)90109-4; ERIKSON E, 1986, J BIOL CHEM, V261, P350; ERIKSON RL, 1991, J BIOL CHEM, V266, P6007; GEARING DP, 1989, EMBO J, V8, P3667, DOI 10.1002/j.1460-2075.1989.tb08541.x; GOLDE DW, 1988, INFLAMMATION BASIC P, P253; GOMEZCAMBRONERO J, 1995, J INTERF CYTOK RES, V15, P877, DOI 10.1089/jir.1995.15.877; GOMEZCAMBRONERO J, 1991, J BIOL CHEM, V266, P6240; GOMEZCAMBRONERO J, 1991, ADV EXP MED BIOL, V314, P35; GOMEZCAMBRONERO J, 1992, P NATL ACAD SCI USA, V89, P7551, DOI 10.1073/pnas.89.16.7551; GRINSTEIN S, 1992, J BIOL CHEM, V267, P18122; HANAZONO Y, 1993, EMBO J, V12, P1641, DOI 10.1002/j.1460-2075.1993.tb05809.x; HUANG CK, 1990, BIOCHEM J, V269, P431, DOI 10.1042/bj2690431; HUANG CK, 1994, J LEUKOCYTE BIOL, V55, P430, DOI 10.1002/jlb.55.4.430; JOHNSON GM, 1995, J LEUKOCYTE BIOL, V57, P692, DOI 10.1002/jlb.57.4.692; KAMESHITA I, 1989, ANAL BIOCHEM, V183, P139, DOI 10.1016/0003-2697(89)90181-4; KANAKURA Y, 1991, BLOOD, V77, P243; KITAMURA T, 1989, J CELL PHYSIOL, V140, P323, DOI 10.1002/jcp.1041400219; KYRIAKIS JM, 1990, J BIOL CHEM, V265, P17355; MCCOLL SR, 1989, BLOOD, V73, P588; METCALF D, 1985, SCIENCE, V229, P16, DOI 10.1126/science.2990035; NACCACHE PH, 1990, BLOOD, V76, P2098; NASMITH PE, 1989, BIOCHEM J, V257, P893, DOI 10.1042/bj2570893; OKUDA K, 1992, BLOOD, V79, P2880; PELECH S, 1986, P NATL ACAD SCI USA, V383, P5968; RAINES MA, 1992, BLOOD, V79, P3350; RAY LB, 1988, J BIOL CHEM, V263, P12721; STURGILL TW, 1988, NATURE, V334, P715, DOI 10.1038/334715a0; STURGILL TW, 1991, BIOCHIM BIOPHYS ACTA, V1092, P350, DOI 10.1016/S0167-4889(97)90012-4; SWEET LJ, 1990, MOL CELL BIOL, V10, P2413, DOI 10.1128/MCB.10.5.2413; THOMAS G, 1992, CELL, V68, P3, DOI 10.1016/0092-8674(92)90199-M; THOMPSON HL, 1993, BIOCHEM J, V290, P483, DOI 10.1042/bj2900483; TORRES M, 1993, J IMMUNOL, V150, P1563; WOOL IG, 1979, ANNU REV BIOCHEM, V48, P719, DOI 10.1146/annurev.bi.48.070179.003443	46	28	28	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 31	1996	271	22					13088	13093		10.1074/jbc.271.22.13088	http://dx.doi.org/10.1074/jbc.271.22.13088			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UN474	8662788	hybrid			2022-12-25	WOS:A1996UN47400062
J	Kaberdin, VR; Chao, YH; Sue, LC				Kaberdin, VR; Chao, YH; Sue, LC			RNase E cleaves at multiple sites in bubble regions of RNA I stem loops yielding products that dissociate differentially from the enzyme	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; MESSENGER-RNA; ANTISENSE RNAI; COPY NUMBER; GENE; DEGRADATION; REPLICATION; PLASMIDS; PCNB; INVIVO	Earlier work has shown that RNase E cleaves RNAI, the antisense repressor of replication of ColE1-type plasmids, producing pRNAI(-5), whose further decay is mediated by the poly(A)-dependent activity of polynucleotide phosphorylase and other 3' to 5' exonucleases. Using a poly(A) polymerase-deficient strain to impede exonucleolytic decay, we show that RNAI is additionally cleaved by RNase E at multiple sites, generating a series of decay intermediates that are differentially retained by the RNA binding domain (RBD) of RNase E. Primer extension analysis of RNAI decay intermediates and RNase T-1 mapping of the cleavage products of RNAI generated in vitro by affinity-purified RNase E showed that RNase E can cleave internucleotide bonds in the bubble regions of duplex RNA segments and in single-stranded regions. Chemical in situ probing of a complex formed between RNAI and the RBD indicates that binding to the RBD destabilizes RNAI secondary structure. Our results suggest a model in which a series of sequential RNase E-mediated cleavages occurring at multiple sites of RNAI, some of which may be made more accessible to RNase E by the destabilizing effects of its RBD, generate RNA fragments that are further degraded by poly(A)-dependent 3' to 5' exonucleases.	ACAD SINICA, INST MOL BIOL, TAIPEI 11529, TAIWAN	Academia Sinica - Taiwan			Kaberdin, Vladimir/C-3870-2017; Lin-Chao, Sue/AAZ-8246-2021; Lin-Chao, Sue/AGI-2030-2022	Kaberdin, Vladimir/0000-0002-7166-5136; Lin-Chao, Sue/0000-0002-8415-9304; Lin-Chao, Sue/0000-0002-8415-9304				ALIFANO P, 1994, GENE DEV, V8, P3021, DOI 10.1101/gad.8.24.3021; BELASCO JG, 1988, GENE, V72, P15, DOI 10.1016/0378-1119(88)90123-0; CARPOUSIS AJ, 1989, MOL GEN GENET, V219, P39, DOI 10.1007/BF00261155; CARPOUSIS AJ, 1994, CELL, V76, P889, DOI 10.1016/0092-8674(94)90363-8; COHEN SN, 1995, CELL, V80, P829, DOI 10.1016/0092-8674(95)90284-8; GOLDBLUM K, 1981, J BACTERIOL, V146, P128, DOI 10.1128/JB.146.1.128-132.1981; HAJNSDORF E, 1994, EMBO J, V13, P3368, DOI 10.1002/j.1460-2075.1994.tb06639.x; HAJNSDORF E, 1994, J MOL BIOL, V239, P439, DOI 10.1006/jmbi.1994.1387; HAJNSDORF E, 1995, P NATL ACAD SCI USA, V92, P3973, DOI 10.1073/pnas.92.9.3973; HE L, 1993, MOL MICROBIOL, V9, P1131, DOI 10.1111/j.1365-2958.1993.tb01243.x; HELMERCITTERICH M, 1988, EMBO J, V7, P557, DOI 10.1002/j.1460-2075.1988.tb02845.x; KUWANO M, 1977, MOL GEN GENET, V154, P279, DOI 10.1007/BF00571283; Lin-Chao S, 1992, MOL MICROBIOL, V6, P3385, DOI 10.1111/j.1365-2958.1992.tb02206.x; LINCHAO S, 1994, J BIOL CHEM, V269, P10797; LINCHAO S, 1991, CELL, V65, P1233, DOI 10.1016/0092-8674(91)90018-T; LINCHAO S, 1986, MOL GEN GENET, V203, P143, DOI 10.1007/BF00330395; LOPILATO J, 1986, MOL GEN GENET, V205, P285, DOI 10.1007/BF00430440; MACKIE GA, 1991, J BACTERIOL, V173, P2488, DOI 10.1128/jb.173.8.2488-2497.1991; MCDOWALL KJ, 1995, NATURE, V374, P287, DOI 10.1038/374287a0; MCDOWALL KJ, 1994, J BIOL CHEM, V269, P10790; McDowall KJ, 1996, J MOL BIOL, V255, P349, DOI 10.1006/jmbi.1996.0027; MICZAK A, 1991, MOL MICROBIOL, V5, P1801, DOI 10.1111/j.1365-2958.1991.tb01929.x; Miczak A, 1996, P NATL ACAD SCI USA, V93, P3865, DOI 10.1073/pnas.93.9.3865; OHARA EB, 1995, P NATL ACAD SCI USA, V92, P1807, DOI 10.1073/pnas.92.6.1807; PAPAVASSILIOU AG, 1993, ANAL BIOCHEM, V214, P331, DOI 10.1006/abio.1993.1498; PY B, 1994, MOL MICROBIOL, V14, P717, DOI 10.1111/j.1365-2958.1994.tb01309.x; Sambrook J, 1989, MOL CLONNING LAB MAN; SOHLBERG B, 1993, P NATL ACAD SCI USA, V90, P277, DOI 10.1073/pnas.90.1.277; TAMM J, 1983, NUCLEIC ACIDS RES, V11, P6381, DOI 10.1093/nar/11.18.6381; TOMCSANYI T, 1985, J MOL BIOL, V185, P713, DOI 10.1016/0022-2836(85)90056-7; XU FF, 1995, NATURE, V374, P180, DOI 10.1038/374180a0; XU FF, 1993, P NATL ACAD SCI USA, V90, P6756, DOI 10.1073/pnas.90.14.6756	32	37	37	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 31	1996	271	22					13103	13109		10.1074/jbc.271.22.13103	http://dx.doi.org/10.1074/jbc.271.22.13103			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UN474	8662734	hybrid			2022-12-25	WOS:A1996UN47400064
J	Qian, WJ; Zhu, SH; Sobolev, AY; Wek, RC				Qian, WJ; Zhu, SH; Sobolev, AY; Wek, RC			Expression of vaccinia virus K3L protein in yeast inhibits eukaryotic initiation factor-2 kinase GCN2 and the general amino acid control pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFER-RNA-SYNTHETASES; SACCHAROMYCES-CEREVISIAE; ALPHA-SUBUNIT; FACTOR-II; TRANSLATION INITIATION; EIF-2-ALPHA KINASE; PHOSPHORYLATION; IDENTIFICATION; INTERFERON; ACTIVATION	Phosphorylation of the alpha subunit of eukaryotic initiation factor-2 (eIF-2) is a well characterized mechanism regulating protein synthesis. Viral and cellular proteins have been identified that regulate the activity of the eIF-2 alpha kinases. The regulatory protein, K3L, from vaccinia virus is homologous to the amino terminus of eIF-2 alpha and is thought to inhibit the activity of the double-stranded RNA-dependent kinase suppressing the antiviral mechanism mediated by this kinase. We investigated whether K3L can inhibit the activity of the yeast eIF-2 alpha kinase GCN2. Expression of K3L protein in yeast reduced the level of eIF-2 alpha phosphorylation by GCN2 and blocked the stimulation of the general amino acid control pathway in response to starvation conditions. Accompanying in vitro studies showed that recombinant K3L protein reduced GCN2 autophosphorylation and phosphorylation elF-2 alpha. In agreement with the hypothesis that K3L inhibits eIF-2 alpha kinases by functioning as a pseudosubstrate, we observed that K3L directly interacted with the kinase catalytic domain of GCN2. Together, these results indicate that K3L is a specific inhibitor of eIF-2 alpha kinases from mammals and yeast and suggest that the kinases contain common structural features important for recognition of their substrate eIF-2 alpha.	INDIANA UNIV,SCH MED,DEPT BIOCHEM & MOLEC BIOL,INDIANAPOLIS,IN 46202	Indiana University System; Indiana University-Purdue University Indianapolis					NIGMS NIH HHS [GM49164] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049164, R29GM049164] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALANI E, 1987, GENETICS, V116, P541, DOI 10.1534/genetics.112.541.test; BARBER GN, 1995, J BIOL CHEM, V270, P17423, DOI 10.1074/jbc.270.29.17423; BEATTIE E, 1991, VIROLOGY, V183, P419, DOI 10.1016/0042-6822(91)90158-8; CARROLL K, 1993, J BIOL CHEM, V268, P12837; Cesareni G, 1987, GENETIC ENG PRINCIPL, V9, P135, DOI DOI 10.1007/978-1-4684-5377-5_9; CHEN JJ, 1995, TRENDS BIOCHEM SCI, V20, P105, DOI 10.1016/S0968-0004(00)88975-6; CHEN JJ, 1991, P NATL ACAD SCI USA, V88, P7729, DOI 10.1073/pnas.88.17.7729; CIGAN AM, 1989, P NATL ACAD SCI USA, V86, P2784, DOI 10.1073/pnas.86.8.2784; CLEMENS MJ, 1994, BIOCHIMIE, V76, P770, DOI 10.1016/0300-9084(94)90081-7; COSENTINO GP, 1995, P NATL ACAD SCI USA, V92, P9445, DOI 10.1073/pnas.92.21.9445; DAVIES MV, 1992, J VIROL, V66, P1943, DOI 10.1128/JVI.66.4.1943-1950.1992; DEALDANA CRV, 1993, P NATL ACAD SCI USA, V90, P7215; DEVER TE, 1992, CELL, V68, P585, DOI 10.1016/0092-8674(92)90193-G; ERNST H, 1987, J BIOL CHEM, V262, P1206; FENG L, 1994, MOL CELL BIOL, V14, P5139, DOI 10.1128/MCB.14.8.5139; HADFIELD C, 1986, GENE, V45, P149, DOI 10.1016/0378-1119(86)90249-0; HANNIG EM, 1990, GENETICS, V126, P546; HERSHEY JWB, 1991, ANNU REV BIOCHEM, V60, P717, DOI 10.1146/annurev.bi.60.070191.003441; HINNEBUSCH AG, 1994, TRENDS BIOCHEM SCI, V19, P409, DOI 10.1016/0968-0004(94)90089-2; HINNEBUSCH AG, 1988, MICROBIOL REV, V52, P248, DOI 10.1128/MMBR.52.2.248-273.1988; HINNEBUSCH AG, 1993, TRANSLATIONAL REGULA, V2, P87; Jackson RJ, 1991, TRANSLATION EUKARYOT, P193; JAGUS R, 1994, BIOCHIMIE, V76, P779, DOI 10.1016/0300-9084(94)90082-5; Kaiser C. S., 1994, METHODS YEAST GENETI, P207; KOROMILAS AE, 1992, SCIENCE, V257, P1685, DOI 10.1126/science.1382315; LUCCHINI G, 1984, MOL CELL BIOL, V4, P1326, DOI 10.1128/MCB.4.7.1326; MASSUNG RF, 1993, VIROLOGY, V197, P511, DOI 10.1006/viro.1993.1625; MERRICK WC, 1992, MICROBIOL REV, V56, P291, DOI 10.1128/MMBR.56.2.291-315.1992; MEURS EF, 1993, P NATL ACAD SCI USA, V90, P232, DOI 10.1073/pnas.90.1.232; Moore DD, 1995, GLOB MOB SURV; PROUD CG, 1991, EUR J BIOCHEM, V195, P771, DOI 10.1111/j.1432-1033.1991.tb15765.x; PROUD CG, 1995, TRENDS BIOCHEM SCI, V20, P217; RAMIREZ M, 1992, MOL CELL BIOL, V12, P5801, DOI 10.1128/MCB.12.12.5801; RAMIREZ M, 1991, MOL CELL BIOL, V11, P3027, DOI 10.1128/MCB.11.6.3027; SAMUEL CE, 1993, J BIOL CHEM, V268, P7603; VANDENHEUVEL J, 1995, BBA-GENE STRUCT EXPR, V1261, P337, DOI 10.1016/0167-4781(95)00026-D; WEK RC, 1994, TRENDS BIOCHEM SCI, V19, P491, DOI 10.1016/0968-0004(94)90136-8; WEK RC, 1989, P NATL ACAD SCI USA, V86, P4579, DOI 10.1073/pnas.86.12.4579; WEK RC, 1990, MOL CELL BIOL, V10, P2820, DOI 10.1128/MCB.10.6.2820; WEK SA, 1995, MOL CELL BIOL, V15, P4497; YOON H, 1992, MOL MICROBIOL, V6, P1413, DOI 10.1111/j.1365-2958.1992.tb00861.x	41	16	16	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 31	1996	271	22					13202	13207		10.1074/jbc.271.22.13202	http://dx.doi.org/10.1074/jbc.271.22.13202			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UN474	8662715				2022-12-25	WOS:A1996UN47400079
J	Aumais, JP; Lee, HS; DeGannes, C; Horsford, J; White, JH				Aumais, JP; Lee, HS; DeGannes, C; Horsford, J; White, JH			Function of directly repeated half-sites as response elements for steroid hormone receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING DOMAIN; HUMAN ESTROGEN-RECEPTOR; RETINOIC ACID RECEPTORS; GLUCOCORTICOID RECEPTOR; THYROID-HORMONE; NUCLEAR RECEPTORS; AMINO-ACIDS; GENE-EXPRESSION; FAR UPSTREAM; X-RECEPTOR	The mouse mammary tumor virus promoter has been shown to be inducible by glucocorticoids and progesterone. Although steroid hormone receptors bind with high affinity to palindromic response elements, the hormone-responsive region of the mouse mammary tumor virus promoter contains a pair of directly repeated half-sites that are important for hormone inducibility. Recent experiments have also indicated that direct repeats can function as estrogen response elements. Here, we have investigated DNA binding by steroid receptors to direct repeats and provide evidence using gel retardation assays, methylation interference, and gene transfer experiments that direct repeats of TGTTCT or RGGTCA motifs function as response elements for glucocorticoid (GR) or estrogen receptors (ER), respectively, by binding receptor homodimers. Specific GR- or ER-DNA complexes were observed on direct repeats with different spacings between half-sites, indicating that binding of steroid receptors to direct repeats is more flexible than binding to palindromic elements. This flexibility was further emphasized by the observation that the GR could also bind to everted repeats of TGTTCT motifs separated by 9 base pairs. The isolated DNA binding domains of the GR and ER bound cooperatively to palindromes, but no evidence was observed for cooperative binding to direct repeats. Under similar conditions the DNA binding domains of retinoid receptors retinoid X receptor and retinoic acid receptor bound to direct repeats cooperatively as heterodimers. Similarly, ER derivative HE15, which lacks a functional ligand binding domain, bound palindromic response elements but failed to bind direct repeats. These results indicate that the dimerization domain in the ligand binding domain is essential for binding of steroid receptors to direct re peats and that the dimerization domain in the D-box of the DNA binding domain is not functional under these conditions. Moreover, the results suggest that steroid receptor DNA binding domains may lack dimerization domains outside the D-box, which would function in binding to direct repeats, in contrast to receptors for retinoids and thyroid hormone. A comparison of the mechanisms of binding of steroid receptors and retinoid and thyroid hormone receptors to direct repeats is presented.	MCGILL UNIV,DEPT PHYSIOL,MONTREAL,PQ H3G 1Y6,CANADA	McGill University			white, john h/N-9782-2013	white, john h/0000-0002-4785-2687				ALI S, 1993, HYBRIDOMA, V12, P391, DOI 10.1089/hyb.1993.12.391; BERRY M, 1989, P NATL ACAD SCI USA, V86, P1218, DOI 10.1073/pnas.86.4.1218; BURCH JBE, 1988, MOL CELL BIOL, V8, P1123, DOI 10.1128/MCB.8.3.1123; CAIRNS W, 1991, J BIOL CHEM, V266, P11221; CHALEPAKIS G, 1988, CELL, V53, P371, DOI 10.1016/0092-8674(88)90157-2; CHANG TC, 1992, MOL ENDOCRINOL, V6, P346, DOI 10.1210/me.6.3.346; CHESKIS B, 1994, MOL CELL BIOL, V14, P3329, DOI 10.1128/MCB.14.5.3329; DAHLMANWRIGHT K, 1991, J BIOL CHEM, V266, P3107; DAHLMANWRIGHT K, 1990, J BIOL CHEM, V265, P14030; DANA SL, 1994, MOL ENDOCRINOL, V8, P1193, DOI 10.1210/me.8.9.1193; DANIELSEN M, 1989, CELL, V57, P1131, DOI 10.1016/0092-8674(89)90050-0; DETHE H, 1990, NATURE, V343, P177, DOI 10.1038/343177a0; DURAND B, 1992, CELL, V71, P73, DOI 10.1016/0092-8674(92)90267-G; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; EVANS RM, 1988, CELL, V52, P1, DOI 10.1016/0092-8674(88)90522-3; FAWELL SE, 1990, CELL, V60, P953, DOI 10.1016/0092-8674(90)90343-D; FORMAN B M, 1990, New Biologist, V2, P587; GIGUERE V, 1994, ENDOCR REV, V15, P61, DOI 10.1210/er.15.1.61; GREEN S, 1986, NATURE, V320, P134, DOI 10.1038/320134a0; GREEN S, 1988, TRENDS GENET, V4, P309, DOI 10.1016/0168-9525(88)90108-4; GRONEMEYER H, 1991, ANNU REV GENET, V25, P89, DOI 10.1146/annurev.ge.25.120191.000513; HARD T, 1990, SCIENCE, V249, P157, DOI 10.1126/science.2115209; HENDRICKSON W, 1985, P NATL ACAD SCI USA, V82, P3129, DOI 10.1073/pnas.82.10.3129; JANTZEN HM, 1987, CELL, V49, P29, DOI 10.1016/0092-8674(87)90752-5; KATO S, 1995, MOL CELL BIOL, V15, P5858; KATO S, 1992, CELL, V68, P731, DOI 10.1016/0092-8674(92)90148-6; KLEINHITPASS L, 1986, CELL, V46, P1053, DOI 10.1016/0092-8674(86)90705-1; KLIEWER SA, 1992, NATURE, V355, P446, DOI 10.1038/355446a0; Kraus WL, 1995, P NATL ACAD SCI USA, V92, P12314, DOI 10.1073/pnas.92.26.12314; KRUST A, 1986, EMBO J, V5, P891, DOI 10.1002/j.1460-2075.1986.tb04300.x; KUMAR V, 1987, CELL, V51, P941, DOI 10.1016/0092-8674(87)90581-2; KUMAR V, 1988, CELL, V55, P145, DOI 10.1016/0092-8674(88)90017-7; KUROKAWA R, 1993, GENE DEV, V7, P1423, DOI 10.1101/gad.7.7b.1423; LANGLEY E, 1995, J BIOL CHEM, V270, P29983; LEES JA, 1990, MOL CELL BIOL, V10, P5529, DOI 10.1128/MCB.10.10.5529; LEID M, 1992, CELL, V68, P377, DOI 10.1016/0092-8674(92)90478-U; LUISI BF, 1991, NATURE, V352, P497, DOI 10.1038/352497a0; MADER S, 1993, NUCLEIC ACIDS RES, V21, P1125, DOI 10.1093/nar/21.5.1125; MADER S, 1993, EMBO J, V12, P5029, DOI 10.1002/j.1460-2075.1993.tb06196.x; MADER S, 1989, NATURE, V338, P271, DOI 10.1038/338271a0; MADER S, 1993, P NATL ACAD SCI USA, V90, P5603, DOI 10.1073/pnas.90.12.5603; MADER S, 1993, J BIOL CHEM, V268, P591; Nawaz Zafar, 1992, Gene Expression, V2, P39; NORDEEN SK, 1990, MOL ENDOCRINOL, V4, P1866, DOI 10.1210/mend-4-12-1866; PAYVAR F, 1983, CELL, V35, P381, DOI 10.1016/0092-8674(83)90171-X; PERLMANN T, 1993, GENE DEV, V7, P1411, DOI 10.1101/gad.7.7b.1411; PREDKI PF, 1994, MOL ENDOCRINOL, V8, P31, DOI 10.1210/me.8.1.31; RICHARD S, 1990, J BIOL CHEM, V265, P6098; SALOMONSSON M, 1994, J STEROID BIOCHEM, V48, P447, DOI 10.1016/0960-0760(94)90192-9; SAVOURET JF, 1991, EMBO J, V10, P1875, DOI 10.1002/j.1460-2075.1991.tb07713.x; SCHWABE JWR, 1990, NATURE, V348, P458, DOI 10.1038/348458a0; SLATER EP, 1990, MOL ENDOCRINOL, V4, P604, DOI 10.1210/mend-4-4-604; TINI M, 1994, MOL ENDOCRINOL, V8, P1494, DOI 10.1210/me.8.11.1494; TORA L, 1989, CELL, V59, P477, DOI 10.1016/0092-8674(89)90031-7; TORA L, 1989, EMBO J, V8, P1986; TURKASPA R, 1988, VIROLOGY, V167, P630, DOI 10.1016/0042-6822(88)90127-4; UMESONO K, 1988, NATURE, V336, P262, DOI 10.1038/336262a0; UMESONO K, 1989, CELL, V57, P1139, DOI 10.1016/0092-8674(89)90051-2; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; WAHLI W, 1991, FASEB J, V5, P2243, DOI 10.1096/fasebj.5.9.1860615; WEISZ A, 1990, NUCLEIC ACIDS RES, V18, P5097, DOI 10.1093/nar/18.17.5097; WRANGE O, 1989, J BIOL CHEM, V264, P5253; YU VC, 1991, CELL, V67, P1251, DOI 10.1016/0092-8674(91)90301-E; ZECHEL C, 1994, EMBO J, V13, P1425, DOI 10.1002/j.1460-2075.1994.tb06396.x; ZECHEL C, 1994, EMBO J, V13, P1414, DOI 10.1002/j.1460-2075.1994.tb06395.x; ZHANG XK, 1992, NATURE, V358, P587, DOI 10.1038/358587a0; ZHANG XK, 1992, NATURE, V355, P441, DOI 10.1038/355441a0	68	66	67	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 24	1996	271	21					12568	12577		10.1074/jbc.271.21.12568	http://dx.doi.org/10.1074/jbc.271.21.12568			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UL660	8647867	hybrid			2022-12-25	WOS:A1996UL66000069
J	Bossard, MJ; Tomaszek, TA; Thompson, SK; Amegadzie, BY; Hanning, CR; Jones, C; Kurdyla, JT; McNulty, DE; Drake, FH; Gowen, M; Levy, MA				Bossard, MJ; Tomaszek, TA; Thompson, SK; Amegadzie, BY; Hanning, CR; Jones, C; Kurdyla, JT; McNulty, DE; Drake, FH; Gowen, M; Levy, MA			Proteolytic activity of human osteoclast cathepsin K - Expression, purification, activation, and substrate identification	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYSTEINE-PROTEINASES; BONE-RESORPTION; ESCHERICHIA-COLI; PAPAIN PRECURSOR; INSECT CELLS; INHIBITORS; SECRETION; SEQUENCE; PEPTIDE; ENZYME	Human cathepsin K is a recently identified protein with high primary sequence homology to members of the papain cysteine protease superfamily including cathepsins S, L, and B and is selectively expressed in osteoclasts (Drake, F. H., Dodds, R., James, I., Conner, J., Debouck, C., Richardson, S., Lee, E., Rieman, D., Barth low, R., Hastings, G., and Gowen, M. (1996) J. Biol. Chem. 271, 12511-12516). To characterize its catalytic properties, cathepsin K has been expressed in baculovirus-infected SF21 cells and the soluble recombinant protein isolated from growth media was purified. Purified protein includes an inhibitory pro-leader sequence common to this family of protease. Conditions for enzyme activation upon removal of the pro sequence have been identified. Fluorogenic peptides have been identified as substrates for mature cathepsin K, In addition, two protein components of bone matrix, collagen and osteonectin, have been shown to be substrates of the activated protease. Cathepsin K is inhibited by E-64 and leupeptin, but not by pepstatin, EDTA, phenylmethylsulfonyl fluoride, or phenanthroline, consistent with its classification within the cysteine protease class. Leupeptin has been characterized as a slow binding inhibitor of cathepsin K (k(obs)/[I] = 273,000 M(-1) s(-1)). Cathepsin K may represent the elusive protease implicated in degradation of protein matrix during bone resorption and represents a novel molecular target in treatment of disease states associated with excessive bone loss such as osteoporosis.	SMITHKLINE BEECHAM PHARMACEUT,DEPT MED CHEM,KING OF PRUSSIA,PA 19406; SMITHKLINE BEECHAM PHARMACEUT,DEPT GENE EXPRESS SCI,KING OF PRUSSIA,PA 19406; SMITHKLINE BEECHAM PHARMACEUT,DEPT PROT BIOCHEM,KING OF PRUSSIA,PA 19406; SMITHKLINE BEECHAM PHARMACEUT,DEPT CELLULAR BIOCHEM,KING OF PRUSSIA,PA 19406	GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline								AMEGADZIE BY, 1995, CELL BIOL INT, V19, P477, DOI 10.1006/cbir.1995.1091; AMEGADZIE BY, 1992, J VIROL, V66, P3003, DOI 10.1128/JVI.66.5.3003-3010.1992; Baron Roland, 1993, P3; BLISSARD GW, 1990, ANNU REV ENTOMOL, V35, P127, DOI 10.1146/annurev.en.35.010190.001015; BROMME D, 1993, J BIOL CHEM, V268, P4832; BROMME D, 1995, BIOL CHEM H-S, V376, P379, DOI 10.1515/bchm3.1995.376.6.379; BROMME D, 1989, BIOCHEM J, V264, P475; BROMMED, 1996, J BIOL CHEM, V271, P2126; CLELAND WW, 1979, ADV ENZYMOL, V29, P1; COHEN LW, 1990, GENE, V88, P263, DOI 10.1016/0378-1119(90)90041-O; DELAISSE JM, 1980, BIOCHEM J, V192, P365, DOI 10.1042/bj1920365; DELAISSE JM, 1987, BONE, V8, P305, DOI 10.1016/8756-3282(87)90007-X; DELAISSE JM, 1984, BIOCHEM BIOPH RES CO, V125, P441, DOI 10.1016/0006-291X(84)90560-6; Drake FH, 1996, J BIOL CHEM, V271, P12511, DOI 10.1074/jbc.271.21.12511; EAKIN AE, 1992, J BIOL CHEM, V267, P7411; HASNAIN S, 1992, J BIOL CHEM, V267, P4713; HILL PA, 1994, J CELL BIOCHEM, V56, P118, DOI 10.1002/jcb.240560116; INAOKA T, 1995, BIOCHEM BIOPH RES CO, V206, P89, DOI 10.1006/bbrc.1995.1013; LERNER UH, 1992, J BONE MINER RES, V7, P433; Li Y. P., 1994, Molecular Biology of the Cell, V5, p335A; MORRISON JF, 1988, ADV ENZYMOL RAMB, V61, P201; PALMER JT, 1995, J MED CHEM, V38, P3193, DOI 10.1021/jm00017a002; RAWLINGS ND, 1992, BIOL CHEM H-S, V373, P1211, DOI 10.1515/bchm3.1992.373.2.1211; SHI GP, 1995, FEBS LETT, V357, P129, DOI 10.1016/0014-5793(94)01349-6; SUMMERS MD, 1987, TEX AGR EXP STN B, V1555; TAYLOR MAJ, 1992, PROTEIN ENG, V5, P455, DOI 10.1093/protein/5.5.455; Termine John D., 1993, P21; TESSIER DC, 1991, GENE, V98, P177, DOI 10.1016/0378-1119(91)90171-7; TEZUKA K, 1994, J BIOL CHEM, V269, P1106; VELASCO G, 1994, J BIOL CHEM, V269, P27136; VERNET T, 1991, J BIOL CHEM, V266, P21451; VERNET T, 1990, J BIOL CHEM, V265, P16661; WIEDERANDERS B, 1992, J BIOL CHEM, V267, P13708	33	429	447	0	22	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 24	1996	271	21					12517	12524		10.1074/jbc.271.21.12517	http://dx.doi.org/10.1074/jbc.271.21.12517			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UL660	8647860	hybrid			2022-12-25	WOS:A1996UL66000062
J	Grab, B; Miles, AJ; Furcht, LT; Fields, GB				Grab, B; Miles, AJ; Furcht, LT; Fields, GB			Promotion of fibroblast adhesion by triple-helical peptide models of type I collagen-derived sequences	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLATELET-REACTIVE SITES; MELANOMA CELL-ADHESION; BINDING-SITE; IDENTIFICATION; ATTACHMENT; RECOGNITION; FIBRONECTIN; INTEGRINS; RECEPTOR; CHAIN	The dissection of the activities mediated by type I collagen requires an approach by which the influence of triple-helical conformation can be evaluated. The alpha(1) beta(1) and alpha(2) beta(1) integrin binding sites within type I collagen are dependent upon triple-helical conformation and contained within residues 124-822 from alpha 1(I). Seven alpha 1(I)-derived triple-helical peptides (THPs) were synthesized based on charge clustering (alpha 1(I)256-270, alpha 1(I)385-396, alpha 1(I)406-417, alpha 1(I)415-423, alpha 1(I)448-456, alpha 1(I)496-507, and alpha 1(I)526-537). Three additional THPs were synthesized (alpha 1(I)85-96, alpha 1(I)433-441, and alpha 1(I)772-786) based on previously described or proposed activities (Kleinman, H. K., McGoodwin, E. B., Martin, G. R., Klebe, R. J., Fietzek, P. P., and Wooley, D. E. (1978) J. Biol. Chem. 253, 5642-5646; Staatz, W. D., Fok, K. F., Zutter, M. M., Adams, S. P., Rodriguez, B. A., and Santoro, S. A. (1991) J. Biol. Chem. 266, 7363-7367; San Antonio, J. D., Lander, A. D., Karnovsky, M. J., and Slayter, H. S. (1994) J. Cell Biol. 125, 1179-1188). Of the ten THPs, alpha 1(I)772-786 THP had the greatest activity, with half-maximal normal dermal fibroblast adhesion occurring at a peptide concentration of 1.6 mu M. Triple-helicity was essential for activity of this sequence, as the non-triple-helical peptide analog (alpha 1(I)772-786 SSP) exhibited considerably lower levels of cell adhesion promotion even at peptide concentrations as high as 100 mu M. Within the sequence itself, residues 784-786 (Gly-Leu-Hyp) were important for cellular recognition, as the alpha 1(I)772-783 THP had greatly reduced cell adhesion activity compared with alpha 1(I)772-786 THP. Preliminary studies indicate that the beta(1) integrin subunit mediates fibroblast adhesion to alpha 1(I)772-786 THP. The identification of fibroblast integrin binding sites within type I collagen may have important implications for understanding collagen metabolism.	UNIV MINNESOTA,DEPT LAB MED & PATHOL,MINNEAPOLIS,MN 55455; UNIV MINNESOTA,DEPT BIOCHEM,MINNEAPOLIS,MN 55455; UNIV MINNESOTA,CTR BIOMED ENGN,MINNEAPOLIS,MN 55455	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities					NCI NIH HHS [CA 63671] Funding Source: Medline; NIAMS NIH HHS [AR 01929] Funding Source: Medline; PHS HHS [KD 44494] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA063671] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [K04AR001929] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		AIMES RT, 1995, J BIOL CHEM, V270, P5872, DOI 10.1074/jbc.270.11.5872; AUMAILLEY M, 1986, J CELL BIOL, V103, P1569, DOI 10.1083/jcb.103.4.1569; BAUMGARTNER HR, 1977, THROMB HAEMOSTASIS, V37, P1; BERMAN A, 1993, BIOCHEM BIOPH RES CO, V194, P351, DOI 10.1006/bbrc.1993.1827; BHATNAGAR RS, 1992, FASEB J, V6, pA288; BOEDTKER H, 1956, J AM CHEM SOC, V78, P4267, DOI 10.1021/ja01598a024; CAMERON JD, 1991, INVEST OPHTH VIS SCI, V32, P2766; CHELBERG MK, 1990, J CELL BIOL, V111, P261, DOI 10.1083/jcb.111.1.261; COLLER BS, 1989, BLOOD, V74, P182; DAVIS GE, 1992, BIOCHEM BIOPH RES CO, V182, P1025, DOI 10.1016/0006-291X(92)91834-D; DOLZ R, 1986, BIOPOLYMERS, V25, P1069, DOI 10.1002/bip.360250607; DZAMBA BJ, 1993, J CELL BIOL, V121, P1165, DOI 10.1083/jcb.121.5.1165; ELICES MJ, 1989, P NATL ACAD SCI USA, V86, P9906, DOI 10.1073/pnas.86.24.9906; FIELDS C G, 1991, Peptide Research, V4, P95; Fields C G, 1994, Methods Mol Biol, V35, P29; FIELDS CG, 1993, PEPTIDE RES, V6, P39; FIELDS CG, 1995, ANAL BIOCHEM, V231, P57, DOI 10.1006/abio.1995.1503; FIELDS CG, 1993, J BIOL CHEM, V268, P14153; FIELDS CG, 1993, BIOPOLYMERS, V33, P1695, DOI 10.1002/bip.360331107; FIELDS CG, 1992, ANAL BIOCHEM, V203, P245, DOI 10.1016/0003-2697(92)90309-U; Fields G. B., 1992, SYNTHETIC PEPTIDES U, P77; FIELDS GB, 1991, J THEOR BIOL, V153, P585, DOI 10.1016/S0022-5193(05)80157-2; Fields GB, 1995, CONNECT TISSUE RES, V31, P235, DOI 10.3109/03008209509010815; FITZSIMMONS CM, 1986, THROMB HAEMOSTASIS, V56, P95; GAUSEPOHL H, 1992, PEPTIDE RES, V5, P315; GRAB B, 1996, PEPTIDES CHEM STRUCT, P603; GULLBERG D, 1992, EMBO J, V11, P3865, DOI 10.1002/j.1460-2075.1992.tb05479.x; HAWIGER J, 1987, HUM PATHOL, V18, P111, DOI 10.1016/S0046-8177(87)80330-1; HEIDEMANN E, 1982, ADV POLYM SCI, V43, P143; KERN A, 1993, EUR J BIOCHEM, V215, P151, DOI 10.1111/j.1432-1033.1993.tb18017.x; KING DS, 1990, INT J PEPT PROT RES, V36, P255; KLEINMAN HK, 1978, J BIOL CHEM, V253, P5642; KNOWLES GC, 1991, J CELL SCI, V98, P551; KOSEKI N, 1994, CELL ADHES COMMUN, V1, P355, DOI 10.3109/15419069409097266; Kuhn K, 1994, Trends Cell Biol, V4, P256, DOI 10.1016/0962-8924(94)90124-4; LABHARD ME, 1990, MATRIX, V10, P124, DOI 10.1016/S0934-8832(11)80178-2; LI SW, 1995, MATRIX BIOL, V14, P593, DOI 10.1016/S0945-053X(05)80009-5; MILES AJ, 1994, J BIOL CHEM, V269, P30939; MILES AJ, 1995, J BIOL CHEM, V270, P29047, DOI 10.1074/jbc.270.49.29047; MORTON LF, 1994, BIOCHEM J, V299, P791, DOI 10.1042/bj2990791; MORTON LF, 1995, BIOCHEM J, V306, P337, DOI 10.1042/bj3060337; NIEUWENHUIS HK, 1985, NATURE, V318, P470, DOI 10.1038/318470a0; NORRIS WD, 1990, J CELL SCI, V95, P255; PERRIS R, 1993, J CELL SCI, V106, P1357; PFAFF M, 1993, EXP CELL RES, V206, P167, DOI 10.1006/excr.1993.1134; POLANOWSKAGRABOWSKA R, 1993, BIOCHEM J, V296, P543, DOI 10.1042/bj2960543; QIAN JJ, 1992, FASEB J, V7, pA1306; RAO GHR, 1994, J BIOL CHEM, V269, P13899; RIIKONEN T, 1995, J BIOL CHEM, V270, P13548, DOI 10.1074/jbc.270.22.13548; RUBIN K, 1981, CELL, V24, P463, DOI 10.1016/0092-8674(81)90337-8; RUGGIERO F, 1994, EXP CELL RES, V206, P167; SAELMAN EUM, 1993, BLOOD, V82, P3029; SANANTONIO JD, 1994, J CELL BIOL, V125, P1179, DOI 10.1083/jcb.125.5.1179; SANTORO SA, 1986, CELL, V46, P913, DOI 10.1016/0092-8674(86)90073-5; SCHARFFETTERKOCHANEK K, 1992, J INVEST DERMATOL, V98, P3, DOI 10.1111/1523-1747.ep12493266; SODEK J, 1988, BIOL MECH TOOTH ERUP, V2, P303; STAATZ WD, 1990, J BIOL CHEM, V265, P4778; STAATZ WD, 1991, J BIOL CHEM, V266, P7363; TROMP G, 1988, BIOCHEM J, V253, P919, DOI 10.1042/bj2530919; TUCKWELL DS, 1994, J CELL SCI, V107, P993; VANDENBERG P, 1991, J CELL BIOL, V113, P1475, DOI 10.1083/jcb.113.6.1475; VANDERZEE E, 1995, J CELL SCI, V108, P3307; WAYNER EA, 1987, J CELL BIOL, V105, P1873, DOI 10.1083/jcb.105.4.1873; WERB Z, 1974, J EXP MED, V140, P1482, DOI 10.1084/jem.140.6.1482; WILKE MS, 1990, J INVEST DERMATOL, V95, P264, DOI 10.1111/1523-1747.ep12484883; WINKLER J R, 1991, Journal of Cell Biology, V115, p442A; ZIJENAH LS, 1990, THROMB RES, V59, P553, DOI 10.1016/0049-3848(90)90415-9	67	80	89	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 24	1996	271	21					12234	12240		10.1074/jbc.271.21.12234	http://dx.doi.org/10.1074/jbc.271.21.12234			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UL660	8647820	hybrid			2022-12-25	WOS:A1996UL66000022
J	Muhlebach, SM; Wirz, T; Brandle, U; Perriard, JC				Muhlebach, SM; Wirz, T; Brandle, U; Perriard, JC			Evolution of the creatine kinases - The chicken acidic type mitochondrial creatine kinase gene as the first nonmammalian gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMPLETE NUCLEOTIDE-SEQUENCE; MESSENGER-RNA; STRUCTURAL CHARACTERIZATION; MOLECULAR-CLONING; MUSCLE; BRAIN; ISOENZYMES; PROTEIN; TISSUE; CDNA	In both mammals and birds, the creatine kinase (CK) family consists of four types of genes: cytosolic brain type (B-CK); cytosolic muscle type (M-CK); mitochondrial ubiquitous, acidic type (Mi(a)-CK); and mitochondrial sarcomeric, basic type (Mi(b)-CK). We report here the cloning of the chicken Mi(a)-CK cDNA and its gene. Amino acid sequences of the mature chicken Mi-CK proteins show about 90% identity to the homologous mammalian isoforms. The leader peptides, however, which are isoenzyme-specifically conserved among the mammalian Mi-CKs, are quite different in the chicken with amino acid identity values compared with the mammalian leader peptides of 38.5-51.3%. The chicken Mi(a)-CK gene spans about 7.6 kilobases and contains 9 exons. The region around exon 1 shows a peculiar base composition, with more than 80% GC, and has the characteristics of a CpG island. The upstream sequences lack TATA or CCAAT boxes and display further properties of housekeeping genes. Several transcription factor binding sites known from mammalian Mi-CK genes are absent from the chicken gene. Although the promoter structure suggests a ubiquitous range of expression, analysis of Mi(a)-CK transcripts in chicken tissues shows a restricted pattern and therefore does not fulfill all criteria of a housekeeping enzyme.	SWISS FED INST TECHNOL,INST CELL BIOL,CH-8093 ZURICH,SWITZERLAND	ETH Zurich								BENFIELD PA, 1988, GENE, V63, P227, DOI 10.1016/0378-1119(88)90527-6; CHENG JM, 1994, CIRCULATION, V90, P634; CHIDA K, 1990, BIOCHEM BIOPH RES CO, V173, P251; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; DAGERLIND A, 1992, HISTOCHEMISTRY, V98, P39, DOI 10.1007/BF00716936; DAOUK GH, 1988, J BIOL CHEM, V263, P2442; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DEVEREUX JP, 1991, GCG SOFTWARE PACKAGE; DYNAN WS, 1986, TRENDS GENET, V2, P196, DOI 10.1016/0168-9525(86)90226-X; ELLINGTON WR, 1989, J EXP BIOL, V143, P177; EPPENBERGER HM, 1967, J BIOL CHEM, V242, P204; FAISST S, 1992, NUCLEIC ACIDS RES, V20, P3, DOI 10.1093/nar/20.1.3; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; Frohman M.A., 1990, PCR PROTOCOLS GUIDE, P28; GARDINERGARDEN M, 1987, J MOL BIOL, V196, P261, DOI 10.1016/0022-2836(87)90689-9; GROSS M, 1994, PROTEIN SCI, V3, P1058, DOI 10.1002/pro.5560030708; HAAS RC, 1990, J BIOL CHEM, V265, P6921; HAAS RC, 1989, J BIOL CHEM, V264, P2890; HARTL FU, 1989, BIOCHIM BIOPHYS ACTA, V988, P1, DOI 10.1016/0304-4157(89)90002-6; HEMMER W, 1993, FEBS LETT, V327, P35, DOI 10.1016/0014-5793(93)81034-W; HOSSLE JP, 1986, NUCLEIC ACIDS RES, V14, P1449, DOI 10.1093/nar/14.3.1449; HOSSLE JP, 1988, BIOCHEM BIOPH RES CO, V151, P408, DOI 10.1016/0006-291X(88)90608-0; ISHIDA Y, 1991, FEBS LETT, V283, P37, DOI 10.1016/0014-5793(91)80548-H; KADONAGA JT, 1986, TRENDS BIOCHEM SCI, V11, P20, DOI 10.1016/0968-0004(86)90226-4; KLEIN SC, 1991, J BIOL CHEM, V266, P18058; KWIATKOWSKI RW, 1985, DEV BIOL, V112, P84, DOI 10.1016/0012-1606(85)90121-6; KWIATKOWSKI RW, 1984, NUCLEIC ACIDS RES, V12, P6925, DOI 10.1093/nar/12.18.6925; LABBE S, 1991, NUCLEIC ACIDS RES, V19, P4225, DOI 10.1093/nar/19.15.4225; LYONS GE, 1991, DEVELOPMENT, V113, P1017; MARIMAN E C M, 1987, Genomics, V1, P126, DOI 10.1016/0888-7543(87)90004-8; MARIMAN ECM, 1989, NUCLEIC ACIDS RES, V17, P6385, DOI 10.1093/nar/17.15.6385; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; MUHLEBACH SM, 1994, MOL CELL BIOCHEM, V133, P245, DOI 10.1007/BF01267958; ORDAHL CP, 1984, J BIOL CHEM, V259, P5224; PAYNE RM, 1991, BIOCHIM BIOPHYS ACTA, V1089, P352, DOI 10.1016/0167-4781(91)90176-M; PERRIARD JC, 1989, CELLULAR MOL BIOL MU, P545; QUEST AFG, 1990, FEBS LETT, V262, P299, DOI 10.1016/0014-5793(90)80214-4; QUEST AFG, 1990, FEBS LETT, V269, P457, DOI 10.1016/0014-5793(90)81215-A; RATTO A, 1989, EUR J BIOCHEM, V186, P195, DOI 10.1111/j.1432-1033.1989.tb15195.x; ROSENBERG UB, 1981, EUR J BIOCHEM, V116, P87, DOI 10.1111/j.1432-1033.1981.tb05304.x; ROSSI AM, 1990, J BIOL CHEM, V265, P5258; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; Sambrook J., 2002, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SASSOON DA, 1988, DEVELOPMENT, V104, P155; SCHAFER BW, 1988, J CELL BIOL, V106, P1161, DOI 10.1083/jcb.106.4.1161; SCHLEGEL J, 1988, J BIOL CHEM, V263, P16963; SCHOWALTER DB, 1989, ANAL BIOCHEM, V177, P90, DOI 10.1016/0003-2697(89)90019-5; SOLDATI T, 1990, J BIOL CHEM, V265, P4498; SOM T, 1982, MOL GEN GENET, V187, P375, DOI 10.1007/BF00332615; STEEGHS K, 1995, DNA CELL BIOL, V14, P539, DOI 10.1089/dna.1995.14.539; SUKOVICH DA, 1994, MOL CELL BIOL, V14, P7134, DOI 10.1128/MCB.14.11.7134; SUZUKI H, 1990, J BIOL CHEM, V265, P8159; SUZUKI JC, 1994, ISOZYMES, V237, P358; TOMBES RM, 1987, J BIOL CHEM, V262, P16011; WALLIMANN T, 1992, BIOCHEM J, V281, P21, DOI 10.1042/bj2810021; Wallimann T, 1985, Cell Muscle Motil, V6, P239; WATTS DC, 1971, BIOCH EVOLUTION ORIG, P150; WIRZ T, 1990, J BIOL CHEM, V265, P11656; WYSS M, 1990, J BIOL CHEM, V265, P15900; WYSS M, 1992, BIOCHIM BIOPHYS ACTA, V1102, P119, DOI 10.1016/0167-4838(92)90506-9; XU Y, 1994, COMPUT APPL BIOSCI, V10, P613	63	20	22	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 17	1996	271	20					11920	11929		10.1074/jbc.271.20.11920	http://dx.doi.org/10.1074/jbc.271.20.11920			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UL250	8662608	hybrid			2022-12-25	WOS:A1996UL25000054
J	Rowland, O; Segall, J				Rowland, O; Segall, J			Interaction of wild-type and truncated forms of transcription factor IIIA from Saccharomyces cerevisiae with the 5 S RNA gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERNAL CONTROL REGION; INDIVIDUAL ZINC FINGERS; DNA-BINDING DOMAIN; RIBOSOMAL-RNA; FACTOR-TFIIIA; CRYSTAL-STRUCTURE; FUNCTIONAL DOMAINS; FACTOR COMPLEXES; XENOPUS TFIIIA; 5S-RNA GENE	Transcription factor (TF) IIIA, which contains nine zinc finger motifs, binds to the internal control region of the 5 S RNA gene as the first step in the assembly of a multifactor complex that promotes accurate initiation of transcription by RNA polymerase III. We have monitored the interaction of wild-type and truncated forms of yeast TFIIIA with the 5 S RNA gene. The DNase I footprints obtained with full-length TFIIIA and a polypeptide containing the amino-terminal five zinc fingers (TF5) were indistinguishable, extending from nucleotides +64 to +99 of the 5 S RNA gene. This suggests that fingers 6 through 9 of yeast TFIIIA are not in tight association with DNA. The DNase I footprint obtained with a polypeptide containing the amino-terminal four zinc fingers (TF4) was 14 base pairs shorter than that of TF5, extending from nucleotides +78 to +99 on the nontranscribed strand and from nucleotides +79 to +98 on the transcribed strand of the 5 S RNA gene. Protection provided by a polypeptide containing the first three zinc fingers (TF3) was similar to that provided by TF4, with the exception that protection on the nontranscribed strand ended at nucleotide +80, rather than nucleotide +78. Methylation protection analysis indicated that finger 5 makes major groove contacts with guanines +73 and +74. The amino-terminal four zinc fingers make contacts that span the internal control region, which extends from nucleotides +81 to +94 of the 5 S RNA gene, with finger 4 appearing to contact guanine +82. Measurements of the apparent K-d values of the TFIIIA DNA complexes indicated that the amino-terminal three zinc fingers of TFIIIA have a binding energy that is similar to that of the full-length protein.	UNIV TORONTO,DEPT BIOCHEM,TORONTO,ON M5S 1A8,CANADA; UNIV TORONTO,DEPT MOLEC & MED GENET,TORONTO,ON M5S 1A8,CANADA	University of Toronto; University of Toronto			Rowland, Owen/ABH-2744-2021	Rowland, Owen/0000-0002-2752-2584				ARAKAWA H, 1995, CYTOGENET CELL GENET, V70, P235, DOI 10.1159/000134041; ARCHAMBAULT J, 1992, J BIOL CHEM, V267, P3282; BERG JM, 1990, ANNU REV BIOPHYS BIO, V19, P405; BIEKER JJ, 1984, J BIOL CHEM, V259, P6158; BOGENHAGEN DF, 1993, MOL CELL BIOL, V13, P5149, DOI 10.1128/MCB.13.9.5149; BOGENHAGEN DF, 1985, J BIOL CHEM, V260, P6466; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAUN BR, 1992, J MOL BIOL, V228, P1063, DOI 10.1016/0022-2836(92)90315-B; BRAUN BR, 1989, P NATL ACAD SCI USA, V86, P2530, DOI 10.1073/pnas.86.8.2530; BRAUN BR, 1992, J BIOL CHEM, V267, P22562; BROWN RS, 1985, FEBS LETT, V186, P271, DOI 10.1016/0014-5793(85)80723-7; CHALLICE JM, 1989, J BIOL CHEM, V264, P20060; CHOO Y, 1993, NUCLEIC ACIDS RES, V21, P3341, DOI 10.1093/nar/21.15.3341; CHRISTENSEN JH, 1991, FEBS LETT, V281, P181, DOI 10.1016/0014-5793(91)80388-J; CHURCHILL MEA, 1990, P NATL ACAD SCI USA, V87, P5528, DOI 10.1073/pnas.87.14.5528; CLEMENS KR, 1992, P NATL ACAD SCI USA, V89, P10822, DOI 10.1073/pnas.89.22.10822; CLEMENS KR, 1994, J MOL BIOL, V244, P23, DOI 10.1006/jmbi.1994.1701; DARBY MK, 1992, MOL CELL BIOL, V12, P3155, DOI 10.1128/MCB.12.7.3155; DELRIO S, 1993, J MOL BIOL, V233, P567, DOI 10.1006/jmbi.1993.1536; DELRIO S, 1991, NUCLEIC ACIDS RES, V19, P6197; DREW PD, 1995, GENE, V159, P215, DOI 10.1016/0378-1119(95)00145-V; ENGELKE DR, 1980, CELL, V19, P717, DOI 10.1016/S0092-8674(80)80048-1; FAIRALL L, 1992, NUCLEIC ACIDS RES, V20, P4727, DOI 10.1093/nar/20.18.4727; FAIRALL L, 1993, NATURE, V366, P483, DOI 10.1038/366483a0; FAIRALL L, 1986, J MOL BIOL, V192, P577, DOI 10.1016/0022-2836(86)90278-0; GABRIELSEN OS, 1991, TRENDS BIOCHEM SCI, V16, P412, DOI 10.1016/0968-0004(91)90166-S; Geiduschek E.P., 1992, TRANSCRIPTIONAL REGU, P247; GINSBERG AM, 1984, CELL, V39, P479, DOI 10.1016/0092-8674(84)90455-0; HANAS JS, 1983, P NATL ACAD SCI-BIOL, V80, P2142, DOI 10.1073/pnas.80.8.2142; HANSEN PK, 1993, J MOL BIOL, V233, P191, DOI 10.1006/jmbi.1993.1499; HAYES JJ, 1992, J MOL BIOL, V227, P407, DOI 10.1016/0022-2836(92)90897-S; HAYES JJ, 1992, BIOCHEMISTRY-US, V31, P11600, DOI 10.1021/bi00161a045; KASSAVETIS GA, 1990, CELL, V60, P235, DOI 10.1016/0092-8674(90)90739-2; KASSAVETIS GA, 1995, P NATL ACAD SCI USA, V92, P9786, DOI 10.1073/pnas.92.21.9786; KOCHOYAN M, 1991, BIOCHEMISTRY-US, V30, P3371, DOI 10.1021/bi00228a004; LAGNA G, 1994, MOL CELL BIOL, V14, P3053, DOI 10.1128/MCB.14.5.3053; LEE MS, 1989, SCIENCE, V245, P635, DOI 10.1126/science.2503871; LEE Y, 1995, NUCLEIC ACIDS RES, V23, P634, DOI 10.1093/nar/23.4.634; LETOILE ND, 1994, P NATL ACAD SCI USA, V91, P1652, DOI 10.1073/pnas.91.5.1652; LIAO XB, 1992, J MOL BIOL, V223, P857, DOI 10.1016/0022-2836(92)90248-I; Maxam A M, 1980, Methods Enzymol, V65, P499; MILLER J, 1985, EMBO J, V4, P1609, DOI 10.1002/j.1460-2075.1985.tb03825.x; MILNE CA, 1993, J BIOL CHEM, V268, P11364; MOOREFIELD B, 1994, J BIOL CHEM, V269, P20857; OLSON MV, 1981, NATURE, V291, P464, DOI 10.1038/291464a0; OTTONELLO S, 1994, BIOCHEM BIOPH RES CO, V203, P1217, DOI 10.1006/bbrc.1994.2312; PARRAGA G, 1988, SCIENCE, V241, P1489, DOI 10.1126/science.3047872; PAVLETICH NP, 1993, SCIENCE, V261, P1701, DOI 10.1126/science.8378770; PAVLETICH NP, 1991, SCIENCE, V252, P809, DOI 10.1126/science.2028256; PIELER T, 1993, TRENDS BIOCHEM SCI, V18, P226, DOI 10.1016/0968-0004(93)90194-R; PIELER T, 1985, EMBO J, V4, P3751, DOI 10.1002/j.1460-2075.1985.tb04144.x; PIELER T, 1987, CELL, V48, P91, DOI 10.1016/0092-8674(87)90359-X; ROMANIUK PJ, 1990, J BIOL CHEM, V265, P17593; SAKONJU S, 1981, CELL, V23, P665, DOI 10.1016/0092-8674(81)90429-3; SAKONJU S, 1982, CELL, V31, P395, DOI 10.1016/0092-8674(82)90133-7; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEIFART KH, 1989, J BIOL CHEM, V264, P1702; SINN E, 1995, GENE DEV, V9, P675, DOI 10.1101/gad.9.6.675; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TAYLOR MJ, 1985, J BIOL CHEM, V260, P4531; THEUNISSEN O, 1992, CELL, V71, P679, DOI 10.1016/0092-8674(92)90601-8; VELDHOEN N, 1994, BIOCHEMISTRY-US, V33, P7568, DOI 10.1021/bi00190a009; VRANA KE, 1988, MOL CELL BIOL, V8, P1684, DOI 10.1128/MCB.8.4.1684; WANG CK, 1989, J BIOL CHEM, V264, P1092; WHITE RJ, 1994, RNA POLYMERASE 3 TRA; WOYCHIK NA, 1992, P NATL ACAD SCI USA, V89, P3999, DOI 10.1073/pnas.89.9.3999; YOU QM, 1991, BIOCHEMISTRY-US, V30, P2495, DOI 10.1021/bi00223a028; ZANG WQ, 1995, BIOCHEMISTRY-US, V34, P15545, DOI 10.1021/bi00047a021	68	12	12	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 17	1996	271	20					12103	12110		10.1074/jbc.271.20.12103	http://dx.doi.org/10.1074/jbc.271.20.12103			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UL250	8662611	hybrid			2022-12-25	WOS:A1996UL25000078
J	Tetsuka, T; Baier, LD; Morrison, AR				Tetsuka, T; Baier, LD; Morrison, AR			Antioxidants inhibit interleukin-1-induced cyclooxygenase and nitric-oxide synthase expression in rat mesangial cells - Evidence for post-transcriptional regulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR KAPPA-B; OXIDATION-REDUCTION; PHORBOL ESTER; ACTIVATION; GENE; PHOSPHORYLATION; PROMOTER; RNA	Glomerular mesangial cells produce reactive oxygen intermediates when stimulated by interleukin-1 (IL-1) or turner necrosis factor. Recent observations suggest that reactive oxygen intermediates may play a role in IL-1 and tumor necrosis factor signaling and may upregulate gene expression. We therefore evaluated the effects of antioxidants on IL-1 beta-induced cyclooxygenase-2 (Cox-2) and inducible nitric-oxide synthase (iNOS) expression in rat mesangial cells, The oxidant scavenger, pyrrolidine dithiocarbamate (PDTC), inhibited iNOS expression at the transcriptional level, since PDTC abolished iNOS mRNA accumulation. In contrast, PDTC inhibited Cox-a expression at the post-transcriptional level, since PDTC did not affect IL-1 beta-induced Cox-2 mRNA levels but inhibited Cox-2 protein expression and prostaglandin E(2) production. Another antioxidant, rotenone, which inhibits reactive oxygen intermediate production by inhibiting the mitochondrial electron transport system, did not inhibit IL-1 beta-induced iNOS and Cox-2 mRNA expression but inhibited iNOS and Cox-2 protein expression, suggesting a post-transcriptional target for the inhibition of iNOS and Cox-2 expression induced by IL-1 beta. These results suggest that not only transcriptional regulation but also post-transcriptional mechanisms are involved in redox-sensitive inhibition of cytokine induced Cox-2 and iNOS expression. These results suggest a novel approach for intervention in cytokine-mediated inflammatory processes.	WASHINGTON UNIV,SCH MED,DEPT MED,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT MOLEC BIOL & PHARMACOL,ST LOUIS,MO 63110	Washington University (WUSTL); Washington University (WUSTL)					NIDDK NIH HHS [DK 38111] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK038111] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABATE C, 1990, SCIENCE, V249, P1157, DOI 10.1126/science.2118682; DEVARY Y, 1991, MOL CELL BIOL, V11, P2804, DOI 10.1128/MCB.11.5.2804; DINARELLO CA, 1994, FASEB J, V8, P1314, DOI 10.1096/fasebj.8.15.8001745; HENTZE MW, 1989, SCIENCE, V244, P357, DOI 10.1126/science.2711187; JAGUS R, 1981, J BIOL CHEM, V256, P1324; KUJUBU DA, 1991, J BIOL CHEM, V266, P12866; LYONS CR, 1992, J BIOL CHEM, V267, P6370; MALTER JS, 1991, J BIOL CHEM, V266, P3167; RADEKE HH, 1990, KIDNEY INT, V37, P767, DOI 10.1038/ki.1990.44; ROVIN BH, 1995, KIDNEY INT, V48, P1263, DOI 10.1038/ki.1995.410; RZYMKIEWICZ D, 1994, AM J PHYSIOL, V266, pF39, DOI 10.1152/ajprenal.1994.266.1.F39; SCHRECK R, 1992, FREE RADICAL RES COM, V17, P221, DOI 10.3109/10715769209079515; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; SCHRECK R, 1992, J EXP MED, V175, P1181, DOI 10.1084/jem.175.5.1181; SCHULZEOSTHOFF K, 1993, EMBO J, V12, P3095, DOI 10.1002/j.1460-2075.1993.tb05978.x; SRIVASTAVA SK, 1994, AM J PHYSIOL, V267, pF504, DOI 10.1152/ajprenal.1994.267.3.F504; TETSUKA T, 1994, P NATL ACAD SCI USA, V91, P12168, DOI 10.1073/pnas.91.25.12168; TETSUKA T, 1995, AM J PHYSIOL-CELL PH, V269, pC55, DOI 10.1152/ajpcell.1995.269.1.C55; XIE QW, 1993, J EXP MED, V177, P1779, DOI 10.1084/jem.177.6.1779	19	98	98	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 17	1996	271	20					11689	11693		10.1074/jbc.271.20.11689	http://dx.doi.org/10.1074/jbc.271.20.11689			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UL250	8662662	hybrid			2022-12-25	WOS:A1996UL25000019
J	Lenahan, MK; Ozer, HL				Lenahan, MK; Ozer, HL			Induction of c-myc mediated apoptosis in SV40-transformed rat fibroblasts	ONCOGENE			English	Article						apoptosis; p53; T antigen; c-myc; fibroblasts; SV40	WILD-TYPE P53; LARGE-T-ANTIGEN; SIMIAN VIRUS-40; CELLULAR SENESCENCE; GENE; IMMORTALIZATION; TRANSFORMATION; TEMPERATURE; EXPRESSION; PROTEIN	The ability of SV40 T antigen to block apoptosis was investigated in Rat1-A fibroblasts expressing an estrogen-dependent c-myc construct, mycER (filers ed al., 1989). These RatmycER cells undergo apoptosis upon activation of c-myc by estradiol under conditions of serum deprivation. Under such conditions SV40-transfected derivatives of RatmycER undergo apoptosis as evidenced by rapid cell death, characteristic morphological changes and DNA fragmentation in a manner indistinguishable from the parental cell line, indicating that T antigen is not able to protect against myc-induced apoptosis. In as much as it had been reported that myc-mediated apoptosis involves wild-type p53 in other systems and T antigen is known to bind and inhibit p53 function, we examined these two polypeptides under different experimental conditions. In all cases, the great majority of the p53 in the SV40 transfectants was found to be in complexes with T antigen. Furthermore, the residual p53 in the uncomplexed state was not sufficient to transactivate an endogenous promoter, WAF1/p21. These data indicate that the failure of T antigen to block apoptosis cannot be attributed to defective function of T antigen and suggest that myc-mediated apoptosis may involve a p53-independent pathway in these cells.	UNIV MED & DENT NEW JERSEY,NEW JERSEY MED SCH,DEPT MICROBIOL & MOLEC GENET,NEWARK,NJ 07103; UNIV MED & DENT NEW JERSEY,GRAD SCH BIOMED SCI,DEPT MICROBIOL & MOLEC GENET,NEWARK,NJ 07103	Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick; Rutgers State University Medical Center					NATIONAL INSTITUTE ON AGING [P01AG000378, R01AG004821] Funding Source: NIH RePORTER; NIA NIH HHS [AG00378, AG04821] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; CHOWDARY DR, 1994, MOL CELL BIOL, V14, P1997, DOI 10.1128/MCB.14.3.1997; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; DHANARAJ SN, 1996, IN PRESS EXP CELL RE; EILERS M, 1989, NATURE, V340, P66, DOI 10.1038/340066a0; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELLIS RE, 1991, ANN REV CELL BIOL, V7, P633; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; GINSBERG D, 1991, P NATL ACAD SCI USA, V88, P9979, DOI 10.1073/pnas.88.22.9979; HARLOW E, 1985, J VIROL, V55, P533, DOI 10.1128/JVI.55.3.533-546.1985; HAYASHI M, 1990, MUTAT RES, V245, P245, DOI 10.1016/0165-7992(90)90153-B; HERMEKING H, 1994, SCIENCE, V265, P2091, DOI 10.1126/science.8091232; HIRT B, 1967, J MOL BIOL, V26, P365, DOI 10.1016/0022-2836(67)90307-5; HORIKOSHI N, 1995, MOL CELL BIOL, V15, P227, DOI 10.1128/MCB.15.1.227; HSU B, 1995, ONCOGENE, V11, P175; HUBBARDSMITH K, 1992, MOL CELL BIOL, V12, P2273, DOI 10.1128/MCB.12.5.2273; IMAI Y, 1994, INT J ONCOL, V5, P945; JAT PS, 1989, MOL CELL BIOL, V9, P1672, DOI 10.1128/MCB.9.4.1672; JIANG D, 1993, ONCOGENE, V8, P2805; LI QT, 1995, J BIOL CHEM, V270, P15777, DOI 10.1074/jbc.270.26.15777; LIEBERMANN DA, 1995, ONCOGENE, V11, P199; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; MCCARTHY SA, 1994, P NATL ACAD SCI USA, V91, P3979, DOI 10.1073/pnas.91.9.3979; MIETZ JA, 1992, EMBO J, V11, P5013, DOI 10.1002/j.1460-2075.1992.tb05608.x; MIYASHITA T, 1994, ONCOGENE, V9, P1799; MIYASHITA T, 1994, CANCER RES, V54, P3131; MORGENBESSER SD, 1994, NATURE, V371, P72, DOI 10.1038/371072a0; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; OZER HL, 1996, IN PRESS EXP GERONTO; PARKER SB, 1995, SCIENCE, V267, P1024, DOI 10.1126/science.7863329; RADNA RL, 1989, MOL CELL BIOL, V9, P3093, DOI 10.1128/MCB.9.7.3093; RESNICKSILVERMAN L, 1991, J VIROL, V65, P2845, DOI 10.1128/JVI.65.6.2845-2852.1991; SABBATINI P, 1995, MOL CELL BIOL, V15, P1060; SEKIGUCHI T, 1995, EXP CELL RES, V218, P490, DOI 10.1006/excr.1995.1183; SHAW P, 1992, P NATL ACAD SCI USA, V89, P4495, DOI 10.1073/pnas.89.10.4495; SHAY JW, 1991, EXP CELL RES, V196, P33, DOI 10.1016/0014-4827(91)90453-2; SMALL MB, 1982, NATURE, V296, P671, DOI 10.1038/296671a0; SYMONDS H, 1994, CELL, V78, P703, DOI 10.1016/0092-8674(94)90534-7; TIEMANN F, 1995, J VIROL, V69, P6115, DOI 10.1128/JVI.69.10.6115-6121.1995; TIEMANN F, 1994, J VIROL, V68, P2869, DOI 10.1128/JVI.68.5.2869-2878.1994; WAGNER AJ, 1994, GENE DEV, V8, P2817, DOI 10.1101/gad.8.23.2817; WAGNER AJ, 1993, MOL CELL BIOL, V13, P2432, DOI 10.1128/MCB.13.4.2432; WHITE E, 1984, J VIROL, V52, P410, DOI 10.1128/JVI.52.2.410-419.1984; WRIGHT WE, 1989, MOL CELL BIOL, V9, P3088, DOI 10.1128/MCB.9.7.3088; Wyllie A H, 1980, Int Rev Cytol, V68, P251; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; YANAI N, 1994, EXP CELL RES, V211, P296, DOI 10.1006/excr.1994.1090; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; ZAMBETTI GP, 1992, GENE DEV, V6, P1143, DOI 10.1101/gad.6.7.1143; ZHENG DQ, 1994, ONCOGENE, V9, P3345	51	33	33	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY 2	1996	12	9					1847	1854						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UK498	8649844				2022-12-25	WOS:A1996UK49800002
J	Salzet, M; Bulet, P; Weber, WM; Clauss, W; VergerBocquet, M; Malecha, J				Salzet, M; Bulet, P; Weber, WM; Clauss, W; VergerBocquet, M; Malecha, J			Structural characterization of a novel neuropeptide from the central nervous system of the leech Erpobdella octoculata - The leech osmoregulator factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THEROMYZON-TESSULATUM OFM; SEX SEGMENTAL GANGLIA; SUPRAESOPHAGEAL GANGLION; YOLK PROTEIN; OXYTOCIN; NEURONS; IDENTIFICATION; VITELLOGENIN; SUBSTANCE; PEPTIDE	Purification of a material immunoreactive to an antiserum against the C-terminal part of the oxytocin (Pro-Leu-Gly-amide) and present in the central nervous system of the Pharyngobdellid leech Erpobdella octoculata was performed by reversed-phase high performance liquid chromatography combined with both enzyme-linked immunosorbent and dot immunobinding assays for oxytocin. The amino acid sequence of the purified peptide (Ile-Pro-Glu-Pro-Tyr-Val-Trp-Asp) was established by Edman degradation and confirmed be electrospray mass spectrometry measurement. When injected in leeches, purified or synthetic peptides exert an antidiuretic effect, the most effective ranged between 10 pmol and 1 nmol. They provoked an uptake of water 1-2 h post-injection. Furthermore, electrophysiological experiments conducted in the leech Hirudo medicinalis revealed an inhibition of the potency of Na+ conductances of leech skin by this peptide. Immunocytochemical studies with an antiserum against synthetic oxytocin-like molecule provided the cytological basis for existence of a neuropeptide, since large amounts of immunoreactive neurons were detected ih the central nervous systems of E. octoculata. The purified molecule is both different to peptides of the oxytocin/vasopressin family and is a novel neuropeptide in the animal kingdom, It was named the leech osmoregulator factor (LORF). An identification of the proteins immunoreactive to an antiserum against oxytocin performed at the level of both central nervous systems extracts and in vitro central nervous system-translated RNA products indicated that in the two cases, a single protein was detected. These proteins with a molecular masses of, respectively, similar to 34 kDa (homodimer of 17 kDa) for the central nervous systems extracts and similar to 19 kDa for in vitro central nervous system-translated RNA products were not recognized by the antiserum against MSEL- and VLDV-neurophysin (proteins associated to oxytocin and vasopressin), confirming that LORF did not belong to the oxytocin/vasopressin family.	INST BIOL MOLEC & CELLULAIRE, UPR 9022 CNRS, F-67084 STRASBOURG, FRANCE; UNIV GIESSEN, INST TIERPHYSIOL, D-35392 GIESSEN, GERMANY	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Justus Liebig University Giessen	Salzet, M (corresponding author), UNIV SCI & TECH LILLE FLANDRES ARTOIS, GRP NEUROENDOCRINOL, LAB PHYLOGENIE MOLEC ANNELIDES, F-59655 VILLENEUVE DASCQ, FRANCE.		BULET, Philippe/C-8557-2014; Salzet, Michel/A-7675-2011	BULET, Philippe/0000-0001-9016-265X; Salzet, Michel/0000-0003-4318-0817				Acher R., 1985, P1147; BAERT JL, 1991, EUR J BIOCHEM, V201, P191, DOI 10.1111/j.1432-1033.1991.tb16273.x; BAERT JL, 1992, EUR J BIOCHEM, V209, P563, DOI 10.1111/j.1432-1033.1992.tb17321.x; COCHRAN WG, 1977, SAMPLING TECHNIQUES, P251; CZECHOWICZ K, 1968, Zoologica Poloniae, V18, P81; DEWITH ND, 1992, NEUROREPORT, V3, P612, DOI 10.1097/00001756-199207000-00017; HAGADORN IRVINE REY, 1958, J MORPH, V102, P55, DOI 10.1002/jmor.1051020104; KLIPPENSTEIN GL, 1976, BIOCHEMISTRY-US, V15, P1128, DOI 10.1021/bi00650a027; KULKARNI GK, 1978, HYDROBIOLOGIA, V59, P197, DOI 10.1007/BF00036498; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MALECHA J, 1989, CAN J ZOOL, V67, P636, DOI 10.1139/z89-091; MALECHA J, 1983, GEN COMP ENDOCR, V49, P344, DOI 10.1016/0016-6480(83)90198-3; MALECHA J, 1989, CR ACAD SCI III-VIE, V309, P127; Muller K. J., 1981, NEUROBIOLOGY LEECH, P320; ORCHARD I, 1980, J NEUROBIOL, V11, P229, DOI 10.1002/neu.480110302; ROSCA D. I., 1958, STUD CERCETARI BIOL [CLUJ], V9, P113; SALZET M, 1993, EUR J BIOCHEM, V217, P897, DOI 10.1111/j.1432-1033.1993.tb18319.x; SALZET M, 1994, EUR J BIOCHEM, V221, P269, DOI 10.1111/j.1432-1033.1994.tb18738.x; SALZET M, 1993, COMP BIOCHEM PHYS A, V104, P75, DOI 10.1016/0300-9629(93)90011-R; SALZET M, 1993, BRAIN RES, V601, P173, DOI 10.1016/0006-8993(93)91708-Z; SALZET M, 1992, COMP BIOCHEM PHYS C, V102, P483, DOI 10.1016/0742-8413(92)90147-Y; SALZET M, 1995, J BIOL CHEM, V270, P1575, DOI 10.1074/jbc.270.4.1575; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Sawyer R. T, 1986, LEECH BIOL BEHAV, V1; TRAMU G, 1983, NEUROENDOCRINOLOGY, V37, P467, DOI 10.1159/000123595; VERGERBOCQUET M, 1992, CAN J ZOOL, V70, P856, DOI 10.1139/z92-122; WEBER WM, 1995, AM J PHYSIOL-REG I, V268, pR605, DOI 10.1152/ajpregu.1995.268.3.R605; WEBER WM, 1993, J COMP PHYSIOL B, V163, P153	28	16	16	0	1	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 22	1996	271	12					7237	7243		10.1074/jbc.271.12.7237	http://dx.doi.org/10.1074/jbc.271.12.7237			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UB157	8636163	hybrid			2022-12-25	WOS:A1996UB15700098
J	Carver, RS; Sliwkowski, MX; Sitaric, S; Russell, WE				Carver, RS; Sliwkowski, MX; Sitaric, S; Russell, WE			Insulin regulates heregulin binding and ErbB3 expression in rat hepatocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; FACTOR-ALPHA; DNA-SYNTHESIS; LIVER-REGENERATION; PRIMARY CULTURES; FACTOR-BETA; LIGAND; DIFFERENTIATION; RECEPTOR; CELLS	The heregulin-ErbB system of ligands and receptors are newly described epidermal growth factor (EGF) and EGF receptor-related proteins that regulate growth, differentiation, and gene expression in numerous cell types, This study describes a receptor for heregulin beta-1 (HRG beta 1) on cultured rat hepatocytes and an inhibitory influence of insulin on HRG beta 1 binding. HRG beta 1 (30 nM) stimulated DNA synthesis 2-fold and was not augmented by insulin as is the case with EGF receptor ligands, A labeled peptide corresponding to the EGF domain of HRG beta 1 bound to a single population of 19,600 +/- 1,800 binding sites/cell with a K-d of 360 +/- 22 PM. Cross-linking experiments showed binding of HRG beta 1 to ErbB3 but not ErbB2 or ErbB4. HRG beta 1 induced phosphorylation of ErbB3 and decreased ErbB3 protein levels, suggesting that HRG beta 1 activates signaling through the ErbB3 receptor and influences receptor trafficking, Following plating, [I-125]HRG beta 1 binding and ErbB3 protein levels increased 8- and 3-fold, respectively, over the first 12 h in culture, These increases required de novo protein synthesis and were inhibited with 50 nM insulin resulting in 3500 binding sites with a K-d of 265 PM. These data suggest that the heregulin-ErbB system can regulate liver functions and may be linked to the metabolic and nutritional status of the animal.	VANDERBILT UNIV, DEPT PEDIAT, NASHVILLE, TN 37232 USA; VANDERBILT UNIV, DEPT CELL BIOL, NASHVILLE, TN 37232 USA; VANDERBILT CANC CTR, NASHVILLE, TN 37232 USA; GENENTECH INC, DEPT PROT CHEM, SAN FRANCISCO, CA 94080 USA	Vanderbilt University; Vanderbilt University; Vanderbilt University; Roche Holding; Genentech			Russell, William/A-7307-2009		NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK044557] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK44557] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALIMANDI M, 1995, ONCOGENE, V10, P1813; BACUS SS, 1993, CANCER RES, V53, P5251; BACUS SS, 1992, CELL GROWTH DIFFER, V3, P401; Bucher N L, 1975, Adv Enzyme Regul, V13, P281; BUCHER NLR, 1975, P NATL ACAD SCI USA, V72, P1157, DOI 10.1073/pnas.72.3.1157; BUCHER NLR, 1990, LIVER BILIARY DIS, P258; CARRAWAY KL, 1994, J BIOL CHEM, V269, P14303; CARRAWAY KL, 1994, CELL, V78, P5, DOI 10.1016/0092-8674(94)90564-9; DONG Z, 1995, NEURON, V15, P585, DOI 10.1016/0896-6273(95)90147-7; DUNN WA, 1984, J CELL BIOL, V98, P2148, DOI 10.1083/jcb.98.6.2148; EARP HS, 1995, BREAST CANCER RES TR, V35, P115, DOI 10.1007/BF00694752; EVARTS RP, 1992, MOL CARCINOGEN, V5, P25, DOI 10.1002/mc.2940050107; FALLS DL, 1993, CELL, V72, P801, DOI 10.1016/0092-8674(93)90407-H; Fausto N, 1991, Prog Growth Factor Res, V3, P219, DOI 10.1016/0955-2235(91)90008-R; GEBHARDT R, 1988, SCAND J GASTROENTERO, V23, P8, DOI 10.3109/00365528809095909; GRAUSPORTA D, 1995, MOL CELL BIOL, V15, P1182; GUY PM, 1994, P NATL ACAD SCI USA, V91, P8132, DOI 10.1073/pnas.91.17.8132; HELMAN A, 1984, AM J PHYSIOL, V246, pE544, DOI 10.1152/ajpendo.1984.246.6.E544; HOLMES WE, 1992, SCIENCE, V256, P1205, DOI 10.1126/science.256.5060.1205; HUNTER WM, 1962, NATURE, V194, P495, DOI 10.1038/194495a0; HYNES NE, 1994, BBA-REV CANCER, V1198, P165, DOI 10.1016/0304-419X(94)90012-4; KREAMER BL, 1986, IN VITRO CELL DEV B, V22, P201; LEVI ADO, 1995, J NEUROSCI, V15, P1329; MARCHIONNI MA, 1993, NATURE, V362, P312, DOI 10.1038/362312a0; MARTE BM, 1995, ONCOGENE, V10, P167; MCGOWAN JA, 1981, J CELL PHYSIOL, V108, P353, DOI 10.1002/jcp.1041080309; MEAD JE, 1989, P NATL ACAD SCI USA, V86, P1558, DOI 10.1073/pnas.86.5.1558; MICHALOPOULOS GK, 1994, J GASTROENTEROL, V29, P23; MORIARITY DM, 1980, ARCH BIOCHEM BIOPHYS, V203, P506, DOI 10.1016/0003-9861(80)90208-8; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; PELES E, 1993, BIOESSAYS, V15, P815, DOI 10.1002/bies.950151207; PELES E, 1992, CELL, V69, P205, DOI 10.1016/0092-8674(92)90131-U; PIETRAS RJ, 1995, ONCOGENE, V10, P2435; PINKASKRAMARSKI R, 1994, P NATL ACAD SCI USA, V91, P9387, DOI 10.1073/pnas.91.20.9387; RAM TG, 1995, J CELL PHYSIOL, V163, P589, DOI 10.1002/jcp.1041630320; RANA B, 1994, MOL CELL BIOL, V14, P5858, DOI 10.1128/MCB.14.9.5858; RICHARDS GM, 1974, ANAL BIOCHEM, V57, P369, DOI 10.1016/0003-2697(74)90091-8; RICHMAN RA, 1976, P NATL ACAD SCI USA, V73, P3589, DOI 10.1073/pnas.73.10.3589; RIESE DJ, 1995, MOL CELL BIOL, V15, P5770; RUSSELL WE, 1993, ENDOCRINOLOGY, V133, P1731, DOI 10.1210/en.133.4.1731; RUSSELL WE, 1988, J CELL PHYSIOL, V135, P253, DOI 10.1002/jcp.1041350212; RUSSELL WE, 1994, REGULATION LIVER GRO, P11; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SHAH NM, 1994, CELL, V77, P349, DOI 10.1016/0092-8674(94)90150-3; SHIOTA K, 1986, BIOCHEM INT, V13, P893; SHOYAB M, 1989, SCIENCE, V243, P1074, DOI 10.1126/science.2466334; SLIWKOWSKI MX, 1994, J BIOL CHEM, V269, P14661; SOLTOFF SP, 1994, MOL CELL BIOL, V14, P3550, DOI 10.1128/MCB.14.6.3550; STROMBLAD S, 1993, EXP CELL RES, V204, P321, DOI 10.1006/excr.1993.1039; TZAHAR E, 1994, J BIOL CHEM, V269, P25226; WALLASCH C, 1995, EMBO J, V14, P4267, DOI 10.1002/j.1460-2075.1995.tb00101.x; WEBBER EM, 1993, HEPATOLOGY, V18, P1422, DOI 10.1016/0270-9139(93)90234-E; WEN DZ, 1992, CELL, V69, P559, DOI 10.1016/0092-8674(92)90456-M	53	38	38	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 7	1996	271	23					13491	13496		10.1074/jbc.271.23.13491	http://dx.doi.org/10.1074/jbc.271.23.13491			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UP385	8662847	hybrid			2022-12-25	WOS:A1996UP38500030
J	Durrer, P; Galli, C; Hoenke, S; Corti, C; Gluck, R; Vorherr, T; Brunner, J				Durrer, P; Galli, C; Hoenke, S; Corti, C; Gluck, R; Vorherr, T; Brunner, J			H+-induced membrane insertion of influenza virus hemagglutinin involves the HA2 amino-terminal fusion peptide but not the coiled coil region	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SODIUM DODECYL-SULFATE; POLYACRYLAMIDE-GEL-ELECTROPHORESIS; CONFORMATIONAL CHANGE; PROTEINS; GLYCOPROTEIN; ECTODOMAIN; SUBUNIT	Fusion of influenza virus with target membranes is induced by acid and involves complex changes in the viral envelope protein hemagglutinin (HA), In a first, kinetically distinct step, the HA polypeptide chain 2 (HA2) is inserted into the target membrane bilayer, Using hydrophobic photolabeling with the phospholipid analogue 1-O-hexadecanoyl-2-O-[9-[[[2-[I-125] iodo-4-(trifluoromethyl-3H-diazirin-3-yl)benzyl] oxy]carbonyl]nonanoyl]-sn-glycero-3-phosphocholine, we identified the segment within HA2 that interacts with the membrane. The sole part of the HA2 ectodomain that was labeled with the membrane-restricted reagent is the NH2-terminal fusion peptide (residues 1-22). No labeling occurred within the long coiled coil region generated during the acid induced conformational transition (Bullough, P. A., Hughson, F. M., Skehel, J. J., and Wiley, D. C. (1994) Nature 371, 37-43). These data strongly suggest that the coiled coil region of HA2 does not insert into the lipid bilayer, This conclusion is at variance with the recent suggestion (Yu, Y. G., King, D. S., and Shin, Y.-K. (1994) Science 266, 274-276) that the coiled coil of HA may splay apart and insert into the target membrane, providing a mechanism by which the viral and the target membrane may come in close apposition.	ETH ZENTRUM,BIOCHEM LAB 2,CH-8092 ZURICH,SWITZERLAND; SWISS SERUM & VACCINE INST,POB 2707,CH-3021 BERN,SWITZERLAND; HOFFMANN LA ROCHE AG,CH-4002 BASEL,SWITZERLAND	Swiss Federal Institutes of Technology Domain; ETH Zurich; Roche Holding								BALL EH, 1986, ANAL BIOCHEM, V155, P23, DOI 10.1016/0003-2697(86)90218-6; BRUNNER J, 1991, BIOCHEMISTRY-US, V30, P2432, DOI 10.1021/bi00223a019; BULLOUGH PA, 1994, NATURE, V371, P37, DOI 10.1038/371037a0; CARR CM, 1993, CELL, V73, P823, DOI 10.1016/0092-8674(93)90260-W; DURRER P, 1995, J BIOL CHEM, V270, P17575, DOI 10.1074/jbc.270.29.17575; GAUDIN Y, 1995, J GEN VIROL, V76, P1541, DOI 10.1099/0022-1317-76-7-1541; GERHARD W, 1976, J EXP MED, V144, P985, DOI 10.1084/jem.144.4.985; HARTER C, 1989, J BIOL CHEM, V264, P6459; HARTER C, 1988, BIOCHEMISTRY-US, V27, P1856, DOI 10.1021/bi00406a010; HOPE MJ, 1985, BIOCHIM BIOPHYS ACTA, V812, P55, DOI 10.1016/0005-2736(85)90521-8; HUGHSON FM, 1995, CURR BIOL, V5, P265, DOI 10.1016/S0960-9822(95)00057-1; KONIGSBERG WH, 1983, METHOD ENZYMOL, V91, P254; LAURIERE M, 1993, ANAL BIOCHEM, V212, P206, DOI 10.1006/abio.1993.1313; Ohnishi Shun-Ichi, 1988, Curr Top Membr Transp, V32, P257, DOI 10.1016/S0070-2161(08)60137-9; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; STEGMANN T, 1989, ANNU REV BIOPHYS BIO, V18, P187, DOI 10.1146/annurev.bb.18.060189.001155; STEGMANN T, 1991, J BIOL CHEM, V266, P18404; TATULIAN SA, 1995, EMBO J, V14, P5514, DOI 10.1002/j.1460-2075.1995.tb00238.x; TSURUDOME M, 1992, J BIOL CHEM, V267, P20225; WEBER T, 1994, J BIOL CHEM, V269, P18353; WEBER T, 1995, J AM CHEM SOC, V117, P3084, DOI 10.1021/ja00116a013; WHARTON SA, 1995, EMBO J, V14, P240, DOI 10.1002/j.1460-2075.1995.tb06997.x; WHITE JM, 1992, SCIENCE, V258, P917, DOI 10.1126/science.1439803; WILEY DC, 1987, ANNU REV BIOCHEM, V56, P365, DOI 10.1146/annurev.bi.56.070187.002053; WILSON IA, 1981, NATURE, V289, P366, DOI 10.1038/289366a0; YU YG, 1994, SCIENCE, V266, P274, DOI 10.1126/science.7939662; ZIMMERBERG J, 1993, ANNU REV BIOPH BIOM, V22, P433, DOI 10.1146/annurev.bb.22.060193.002245	28	166	172	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 7	1996	271	23					13417	13421		10.1074/jbc.271.23.13417	http://dx.doi.org/10.1074/jbc.271.23.13417			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UP385	8662770	hybrid			2022-12-25	WOS:A1996UP38500019
J	Guy, HI; Evans, DR				Guy, HI; Evans, DR			Function of the major synthetase subdomains of carbamyl-phosphate synthetase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIFUNCTIONAL PROTEIN CAD; INITIATES PYRIMIDINE BIOSYNTHESIS; ATP-BINDING-SITES; CARBONIC-PHOSPHORIC ANHYDRIDE; COOH-TERMINAL DOMAIN; ESCHERICHIA-COLI; ASPARTATE-TRANSCARBAMYLASE; REVERSIBLE DISSOCIATION; LARGE SUBUNIT; NUCLEOTIDE-SEQUENCE	The amidotransferase domain (GLNase) of mammalian carbamyl-phosphate synthetase II hydrolyzes glutamine and transfers ammonia to the synthetase domain where carbamyl phosphate is formed in a three-step reaction sequence. The synthetase domain consists of two homologous subdomains, CPS.A and CPS.B. Recent studies suggest that CPS.A catalyzes the initial ATP dependent-activation of bicarbonate, whereas CPS.B uses a second ATP to form carbamyl phosphate. To establish the function of these substructural elements, we have cloned and expressed the mammalian protein and its subdomains in Escherichia coli. Recombinant CPSase (GLNase-CPS.A-CPS.B) was found to br fully functional. Two other proteins were made; the first consisted of only GLNase and CPS.A, whereas the second lacked CPS.A and had the GLNase domain fused directly to CPS.B. Remarkably, both proteins catalyzed the entire series of reactions involved in glutamine-dependent carbamyl phosphate synthesis. The stoichiometry, like that of the native enzyme, was 2 mol of ATP utilized per mol of carbamyl phosphate formed. GLN-CPS.B is allosterically regulated, whereas GLN-CPS.A was insensitive to effectors, a result consistent with evidence showing that allosteric effectors bind to CPS.B. These properties are not peculiar to the mammalian protein, because the separately cloned CPS.A subdomain of the E. coli enzyme was also found to catalyze carbamyl phosphate synthesis. Gel filtration chromatography and chemical cross-linking studies showed that these molecules are dimers, a structural organization that may be a prerequisite for the overall reaction. Thus, the homologous CPS.A and CPS.B subdomains are functionally equivalent, although in the native enzyme they may have different functions resulting from their juxtaposition relative to the other components in the complex.	WAYNE STATE UNIV, SCH MED, DEPT BIOCHEM & MOLEC BIOL, DETROIT, MI 48201 USA	Wayne State University					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047399] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM47399] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ACKERS GK, 1964, BIOCHEMISTRY-US, V3, P723, DOI 10.1021/bi00893a021; ALONSO E, 1995, EUR J BIOCHEM, V229, P377, DOI 10.1111/j.1432-1033.1995.tb20478.x; ANDERSON PM, 1965, BIOCHEMISTRY-US, V4, P2803, DOI 10.1021/bi00888a034; ANDERSON PM, 1966, BIOCHEMISTRY-US, V5, P3157, DOI 10.1021/bi00874a012; ANDERSON PM, 1986, BIOCHEMISTRY-US, V25, P5576, DOI 10.1021/bi00367a035; ANDERSON PM, 1968, BIOCHEM BIOPH RES CO, V32, P928, DOI 10.1016/0006-291X(68)90116-2; ANDERSON PM, 1995, NITROGEN METABOLISM, P33; BAUR H, 1989, EUR J BIOCHEM, V179, P53, DOI 10.1111/j.1432-1033.1989.tb14520.x; BEIN K, 1991, J BIOL CHEM, V266, P3791; BOETTCHER BR, 1980, J BIOL CHEM, V255, P7129; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRITTON HG, 1979, EUR J BIOCHEM, V102, P521, DOI 10.1111/j.1432-1033.1979.tb04268.x; CERVERA J, 1993, J BIOL CHEM, V268, P12504; CLIMENT I, 1986, ARCH BIOCHEM BIOPHYS, V251, P465, DOI 10.1016/0003-9861(86)90353-X; COLEMAN PF, 1977, J BIOL CHEM, V252, P6379; FAURE M, 1989, EUR J BIOCHEM, V179, P345, DOI 10.1111/j.1432-1033.1989.tb14560.x; FOLEY R, 1971, BIOCHEMISTRY-US, V10, P4562, DOI 10.1021/bi00800a034; FREUND JN, 1987, J MOL BIOL, V193, P1, DOI 10.1016/0022-2836(87)90621-8; GUILLOU F, 1992, BIOCHEMISTRY-US, V31, P1656, DOI 10.1021/bi00121a012; GUILLOU F, 1989, P NATL ACAD SCI USA, V86, P8304, DOI 10.1073/pnas.86.21.8304; GUY HI, 1994, J BIOL CHEM, V269, P23808; Hanahan D., 1985, DNA CLONING PRACTICA, V1, P109; HONG J, 1994, J MOL BIOL, V243, P131, DOI 10.1006/jmbi.1994.1638; HONG J, 1995, J BIOL CHEM, V270, P14130, DOI 10.1074/jbc.270.23.14130; KANAZAWA H, 1982, BIOCHEM BIOPH RES CO, V105, P1257, DOI 10.1016/0006-291X(82)90922-6; KIM H, 1991, BIOCHEMISTRY-US, V30, P10322, DOI 10.1021/bi00106a033; KIM HS, 1992, J BIOL CHEM, V267, P7177; KNOWLES JR, 1989, ANNU REV BIOCHEM, V58, P195, DOI 10.1146/annurev.bi.58.070189.001211; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE L, 1985, P NATL ACAD SCI USA, V82, P6802, DOI 10.1073/pnas.82.20.6802; LIM F, 1988, J BIOL CHEM, V263, P11493; LIU X, 1994, J BIOL CHEM, V269, P27747; LUSTY CJ, 1983, J BIOL CHEM, V258, P4466; MALLY MI, 1980, J BIOL CHEM, V255, P1372; MALLY MI, 1981, P NATL ACAD SCI-BIOL, V78, P6647, DOI 10.1073/pnas.78.11.6647; Maniatis T., 1982, MOL CLONING; MARSHALL M, 1961, J BIOL CHEM, V236, P2229; MARSHALL M, 1985, ARCH BIOCHEM BIOPHYS, V241, P200, DOI 10.1016/0003-9861(85)90376-5; MEEK TD, 1987, BIOCHEMISTRY-US, V26, P2584, DOI 10.1021/bi00383a026; MEISTER A, 1989, ADV ENZYMOL RAMB, V62, P315; METZENBERG RL, 1957, J BIOL CHEM, V229, P1019; MORI M, 1975, BIOCHEMISTRY-US, V14, P2622, DOI 10.1021/bi00683a010; NOWLAN SF, 1985, J BIOL CHEM, V260, P4712; NYUNOYA H, 1983, P NATL ACAD SCI-BIOL, V80, P4629, DOI 10.1073/pnas.80.15.4629; NYUNOYA H, 1985, J BIOL CHEM, V260, P9346; POLAKIS SE, 1972, J BIOL CHEM, V247, P1335; POST LE, 1990, J BIOL CHEM, V265, P7742; POTTER MD, 1992, J BIOL CHEM, V267, P2023; POWERS SG, 1983, J BIOL CHEM, V258, P7545; POWERS SG, 1980, J BIOL CHEM, V255, P1554; POWERS SG, 1976, P NATL ACAD SCI USA, V73, P3020, DOI 10.1073/pnas.73.9.3020; POWERS SG, 1977, J BIOL CHEM, V252, P3558; POWERS SG, 1978, J BIOL CHEM, V253, P1258; POWERS SG, 1978, J BIOL CHEM, V253, P800; POWERSLEE SG, 1987, J BIOL CHEM, V262, P9052; QUINN CL, 1991, J BIOL CHEM, V266, P9113; RAUSHEL FM, 1992, BIOORG MED CHEM LETT, V2, P319, DOI 10.1016/S0960-894X(01)80209-2; RAUSHEL FM, 1979, BIOCHEMISTRY-US, V18, P3424, DOI 10.1021/bi00582a033; RAUSHEL FM, 1980, BIOCHEMISTRY-US, V19, P3170, DOI 10.1021/bi00555a009; RAUSHEL FM, 1978, BIOCHEMISTRY-US, V17, P5587, DOI 10.1021/bi00619a001; RODRIGUEZAPARICIO LB, 1989, BIOCHEMISTRY-US, V28, P3070, DOI 10.1021/bi00433a050; RUBINO SD, 1987, J BIOL CHEM, V262, P4382; RUBIO V, 1991, BIOCHEMISTRY-US, V30, P1068, DOI 10.1021/bi00218a027; RUBIO V, 1979, EUR J BIOCHEM, V93, P245, DOI 10.1111/j.1432-1033.1979.tb12817.x; SHIGESADA K, 1985, MOL CELL BIOL, V5, P1735, DOI 10.1128/MCB.5.7.1735; SHOAF WT, 1973, BIOCHEMISTRY-US, V12, P4039, DOI 10.1021/bi00745a004; SIMMER JP, 1990, J BIOL CHEM, V265, P10395; SOUCIET JL, 1989, GENE, V79, P59, DOI 10.1016/0378-1119(89)90092-9; TAKAI T, 1988, J BIOL CHEM, V263, P2651; TROTTA PP, 1971, P NATL ACAD SCI USA, V68, P2599, DOI 10.1073/pnas.68.10.2599; TROTTA PP, 1974, J BIOL CHEM, V249, P482; TROTTA PP, 1974, J BIOL CHEM, V249, P492; WIMMER MJ, 1979, J BIOL CHEM, V254, P1854	73	33	34	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 7	1996	271	23					13762	13769		10.1074/jbc.271.23.13762	http://dx.doi.org/10.1074/jbc.271.23.13762			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UP385	8662713	hybrid			2022-12-25	WOS:A1996UP38500069
J	Hirako, Y; Usukura, J; Nishizawa, Y; Owaribe, K				Hirako, Y; Usukura, J; Nishizawa, Y; Owaribe, K			Demonstration of the molecular shape of BP180, a 180-kDa bullous pemphigoid antigen and its potential for trimer formation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BASEMENT-MEMBRANE ADHESION; IMMUNOELECTRON MICROSCOPY; INTEGRIN ALPHA-6-BETA-4; ANCHORING FILAMENTS; EPITHELIAL-CELLS; HEMIDESMOSOMES; COMPONENT; PROTEINS; AUTOANTIBODIES; EXPRESSION	The 180-kDa bullous pemphigoid antigen (BP180) is a hemidesmosomal transmembrane glycoprotein comprising interrupted collagen domains in its extracellular part, BP180 is also termed type XVII collagen, But the question of whether it actually takes a collagen-like triple helical conformation in. vivo has remained unanswered, Using a monoclonal antibody, we found that a sub-population of BP180 localizes at the lateral surfaces of corneal basal cells and cultured cells, in addition to the basal surface, This subpopulation of BP180 could be solubilized by 0.5% Triton X-100 and, among examined cell lines, was found to be most abundant in BMGE+H, a bovine mammary gland epithelial cell line, The Triton soluble fraction of BMGE+H cells was used for characterization, On sucrose gradient centrifugation, the soluble BP180 demonstrated a value of approximately 7 S, and chemical cross-linking experiments revealed a trimer form, The calculated frictional ratio, f/f(0) = 2.8, suggests an asymmetric configuration, For further characterization, we purified the soluble BP180 by immunoaffinity column chromatography using an anti-BP180 monoclonal antibody, Rotary shadowing images of the purified BP180 showed a quaver-like molecule consisting of a globular head, a central rod, and a flexible tail, With regard to the primary structure and species comparisons, the central rod, 60-70 nm in length, probably corresponds to the largest collagenous region, forming a collagen-like triple helix, in human form, The globular head and the flexible tail seem to correspond to the cytoplasmic and the interrupted collagenous region, respectively, of the extracellular portions, In conclusion, the present demonstration of the entire configuration of BP180, with a collagen-like trimer in its extracellular part, suggests that BP180 is one of the major components of anchoring filaments.	NAGOYA UNIV, SCH SCI, DEPT BIOL MOLEC, CHIKUSA KU, NAGOYA, AICHI 46401, JAPAN; NAGOYA UNIV, SCH MED, DEPT ANAT, CHIKUSA KU, NAGOYA, AICHI 46401, JAPAN	Nagoya University; Nagoya University	Hirako, Y (corresponding author), NAGOYA UNIV, GRAD SCH HUMAN INFORMAT, UNIT BIOSYST, CHIKUSA KU, NAGOYA, AICHI 46401, JAPAN.			Usukura, Jiro/0000-0003-2286-5403				AMAGAI M, 1990, J INVEST DERMATOL, V95, P252, DOI 10.1111/1523-1747.ep12484863; BERNARD P, 1990, J INVEST DERMATOL, V94, P630, DOI 10.1111/1523-1747.ep12876206; DOMLOGEHULTSCH N, 1992, J CLIN INVEST, V90, P1628, DOI 10.1172/JCI116033; ELLISON J, 1984, J CELL SCI, V72, P163; Garrod DR, 1993, CURR OPIN CELL BIOL, V5, P30, DOI 10.1016/S0955-0674(05)80005-5; GIUDICE GJ, 1992, J INVEST DERMATOL, V99, P243, DOI 10.1111/1523-1747.ep12616580; GUO LF, 1995, CELL, V81, P233, DOI 10.1016/0092-8674(95)90333-X; HIEDA Y, 1992, J CELL BIOL, V116, P1497, DOI 10.1083/jcb.116.6.1497; HOPKINSON SB, 1992, J INVEST DERMATOL, V99, P264, DOI 10.1111/1523-1747.ep12616615; HOPKINSON SB, 1995, J CELL BIOL, V130, P117, DOI 10.1083/jcb.130.1.117; JONES JCR, 1994, EXP CELL RES, V213, P1, DOI 10.1006/excr.1994.1166; JONES JCR, 1991, CELL REGUL, V2, P427, DOI 10.1091/mbc.2.6.427; JONKMAN MF, 1995, J CLIN INVEST, V95, P1345, DOI 10.1172/JCI117785; KATZ SI, 1984, CIBA F SYMP, V108, P243; KITAJIMA Y, 1988, CANCER RES, V48, P964; KITAJIMA Y, 1992, EXP CELL RES, V203, P17, DOI 10.1016/0014-4827(92)90034-6; Kitajima Y, 1995, EPITHELIAL CELL BIOL, V4, P70; KITAJIMA Y, 1994, JOURNAL OF DERMATOLOGY, VOL 21, NO 11, NOVEMBER 1994, P838, DOI 10.1111/j.1346-8138.1994.tb03299.x; KLATTE DH, 1989, J CELL BIOL, V109, P3377, DOI 10.1083/jcb.109.6.3377; KURPAKUS MA, 1991, J CELL BIOL, V115, P1737, DOI 10.1083/jcb.115.6.1737; LABIB RS, 1986, J IMMUNOL, V136, P1231; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE EC, 1992, J CELL BIOL, V117, P671, DOI 10.1083/jcb.117.3.671; LI KH, 1993, J BIOL CHEM, V268, P8825; LIU Z, 1993, J CLIN INVEST, V92, P2480, DOI 10.1172/JCI116856; MARINKOVICH MP, 1993, LAB INVEST, V69, P295; MCGRATH JA, 1995, NAT GENET, V11, P83, DOI 10.1038/ng0995-83; NIESSEN CM, 1994, EXP CELL RES, V211, P360, DOI 10.1006/excr.1994.1099; NISHIZAWA Y, 1993, J BIOCHEM-TOKYO, V113, P493, DOI 10.1093/oxfordjournals.jbchem.a124072; OWARIBE K, 1991, EXP CELL RES, V192, P622, DOI 10.1016/0014-4827(91)90084-8; ROUSSELLE P, 1991, J CELL BIOL, V114, P567, DOI 10.1083/jcb.114.3.567; SAWAMURA D, 1991, J BIOL CHEM, V266, P17784; SCHMID E, 1983, J CELL BIOL, V96, P37, DOI 10.1083/jcb.96.1.37; SONNENBERG A, 1991, J CELL BIOL, V113, P907, DOI 10.1083/jcb.113.4.907; SPINARDI L, 1995, J CELL BIOL, V129, P473, DOI 10.1083/jcb.129.2.473; STANLEY JR, 1988, J CLIN INVEST, V82, P1864, DOI 10.1172/JCI113803; STANLEY JR, 1993, ADV IMMUNOL, V53, P291, DOI 10.1016/S0065-2776(08)60503-9; STEPP MA, 1990, P NATL ACAD SCI USA, V87, P8970, DOI 10.1073/pnas.87.22.8970; UEMATSU J, 1994, J BIOCHEM-TOKYO, V115, P469, DOI 10.1093/oxfordjournals.jbchem.a124361; VERRANDO P, 1987, EXP CELL RES, V170, P116, DOI 10.1016/0014-4827(87)90121-2	40	110	111	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 7	1996	271	23					13739	13745		10.1074/jbc.271.23.13739	http://dx.doi.org/10.1074/jbc.271.23.13739			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UP385	8662839				2022-12-25	WOS:A1996UP38500066
J	Huang, LX; Scrutton, NS; Hille, R				Huang, LX; Scrutton, NS; Hille, R			Reaction of the C30A mutant of trimethylamine dehydrogenase with diethylmethylamine	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTRAMOLECULAR ELECTRON-TRANSFER; COVALENTLY BOUND COENZYME; DIMETHYLAMINE DEHYDROGENASE; BACTERIUM W3A1; FLAVOPROTEIN; IDENTIFICATION; SUBSTRATE; FLAVINS	The role played by the 6-S-cysteinyl-FMN bond of trimethylamine dehydrogenase in the reductive half-reaction of the enzyme has been studied by following the reaction of the slow substrate diethylmethylamine with a C30A mutant of the enzyme lacking the covalent flavin attachment to the polypeptide. Removal of the 6-S-cysteinyl-FMN bond diminishes the limiting rate for the first of the three observed kinetic phases of the reaction by a factor of 6, but has no effect on the rate constants for the two subsequent kinetic phases. The flavin in the C30A-enzyme recovered from the reaction of the C30A enzyme with excess substrate is found to have been converted to the 6-hydroxy derivative, rendering the enzyme inactive, The noncovalently bound FMN of the C30A mutant enzyme is also converted to 6-hydroxy-FMN and rendered inactive upon reduction with excess trimethylamine, but not by reduction with dithionite, even at high pH or in the presence of the effector tetramethylammonium chloride, These results suggest that one significant role of the 6-S-cysteinyl-FMN bond is to prevent the inactivation of the enzyme during catalysis. A reaction mechanism is proposed whereby OH- attacks C-6 of a flavin-substrate covalent adduct in the course of steady-state turnover to form 6-hydroxy-FMN.	OHIO STATE UNIV,DEPT MED BIOCHEM,COLUMBUS,OH 43210; UNIV LEICESTER,DEPT BIOCHEM,LEICESTER LE1 7RH,LEICS,ENGLAND	University System of Ohio; Ohio State University; University of Leicester								BELLAMY HD, 1989, J BIOL CHEM, V264, P11887; Bevington P. R., 1969, DATA REDUCTION ERROR, P235; DUPLESSIS ER, 1994, BIOCHEM MOL BIOL INT, V32, P195; HILL CL, 1977, P NATL ACAD SCI USA, V74, P547, DOI 10.1073/pnas.74.2.547; HUANG L, 1995, J BIOL CHEM, V270, P23956; KASPRZAK AA, 1983, BIOCHEM J, V211, P535, DOI 10.1042/bj2110535; KENNEY WC, 1978, FEBS LETT, V85, P137, DOI 10.1016/0014-5793(78)81265-4; LEHMAN TC, 1990, BIOCHEMISTRY-US, V29, P10594, DOI 10.1021/bi00499a004; LEHMAN TC, 1990, ANAL BIOCHEM, V186, P280, DOI 10.1016/0003-2697(90)90080-S; LIM LW, 1988, J BIOL CHEM, V263, P3075; LIM LW, 1982, J MOL BIOL, V162, P869, DOI 10.1016/0022-2836(82)90551-4; LIM LW, 1986, J BIOL CHEM, V261, P5140; MASSEY V, 1986, BIOCHEMISTRY-US, V25, P8103, DOI 10.1021/bi00372a046; MASSEY V, 1991, J BIOL CHEM, V266, P8281; Massey V., 1970, PYRIDINE NUCLEOTIDE, P393; Massey V, 1980, BIOCHEM SOC T, V8, P246, DOI 10.1042/bst0080246; MAYHEW SG, 1974, EUR J BIOCHEM, V44, P579, DOI 10.1111/j.1432-1033.1974.tb03515.x; NAGY J, 1979, J BIOL CHEM, V254, P2684; PACKMAN LC, 1995, J BIOL CHEM, V270, P13186, DOI 10.1074/jbc.270.22.13186; ROHLFS RJ, 1994, J BIOL CHEM, V269, P30869; ROHLFS RJ, 1995, J BIOL CHEM, V270, P22196, DOI 10.1074/jbc.270.38.22196; ROHLFS RJ, 1991, J BIOL CHEM, V266, P15244; SCHOLLNHAMMER G, 1974, EUR J BIOCHEM, V44, P561, DOI 10.1111/j.1432-1033.1974.tb03514.x; SCRUTTON NS, 1994, J BIOL CHEM, V269, P13942; SINGER TP, 1980, FLAVINS FLAVOPROTEIN, P277; STEENKAMP DJ, 1982, BIOCHEM J, V207, P241, DOI 10.1042/bj2070241; STEENKAMP DJ, 1978, BIOCHEM J, V169, P361, DOI 10.1042/bj1690361; STEENKAMP DJ, 1978, J BIOL CHEM, V253, P4086; STEENKAMP DJ, 1978, J BIOL CHEM, V253, P2818; STEENKAMP DJ, 1978, MECHANISMS OXIDIZING, P127; STRICKLAND S, 1975, J BIOL CHEM, V250, P4048	31	15	15	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 7	1996	271	23					13401	13406		10.1074/jbc.271.23.13401	http://dx.doi.org/10.1074/jbc.271.23.13401			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UP385	8662829	hybrid			2022-12-25	WOS:A1996UP38500017
J	Turchi, JJ; Henkels, K				Turchi, JJ; Henkels, K			Human Ku autoantigen binds cisplatin-damaged DNA but fails to stimulate human DNA-activated protein kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTICANCER DRUG CIS-DIAMMINEDICHLOROPLATINUM(II); OVARIAN-CANCER; HUMAN P53; SITE; PHOSPHORYLATION; SENSITIVITY; REQUIREMENT; RESISTANCE; INHIBITION; MECHANISM	We have identified a series of proteins based on an affinity for cisplatin-damaged DNA, One protein termed DRP-1 has been purified to homogeneity and was isolated as two distinct complexes, The first complex is a heterodimer of 83- and 68-kDa subunits, while the second complex is a heterotrimer of 350-, 83-, and 68-kDa subunits in a 1:1:1 ratio, The 83- and 68-kDa subunits in each complex are identical, The 83-kDa subunit of DRP-1 was identified as the p80 subunit of Ku autoantigen by N-terminal protein sequence analysis and reactivity with a monoclonal antibody directed against human Ku p80 subunit. The 68-kDa subunit of DRP-1 crossreacted with monoclonal antisera raised against the Ku autoantigen p70 subunit, The 350-kDa subunit was identified as DNA-PKcs, the catalytic subunit of the human DNA-activated protein kinase, DNA-PK, DRP-1/Ku DNA binding was assessed in mobility shift assays and competition binding assays using cisplatin-damaged DNA, Results indicate that DNA binding was essentially unaffected by cisplatin-DNA adducts in the presence or absence of DNA-PKcs, DNA-PK activity was only stimulated with undamaged DNA, despite the ability of Ku to bind to cisplatin-damaged DNA. The lack of DNA-PR stimulation by cisplatin-damaged DNA correlated with the extent of cisplatin-DNA adduct formation, These results demonstrate that Ku can bind cisplatin-damaged DNA but fails to activate DNA-PR, These results are discussed with respect to the repair of cisplatin-DNA adducts and the role of DNA-PK in coordinating DNA repair processes.			Turchi, JJ (corresponding author), WRIGHT STATE UNIV, DEPT BIOCHEM & MOLEC BIOL, SCH MED, 3640 COLONEL GLENN HIGHWAY, DAYTON, OH 45435 USA.		Turchi, John J/B-5807-2015	Turchi, John J/0000-0001-5375-2992	NATIONAL CANCER INSTITUTE [R29CA064374] Funding Source: NIH RePORTER; NCI NIH HHS [CA64374] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Anderson Carl W., 1992, Critical Reviews in Eukaryotic Gene Expression, V2, P283; ANDERSON CW, 1993, TRENDS BIOCHEM SCI, V18, P433, DOI 10.1016/0968-0004(93)90144-C; BELLON SF, 1990, BIOPHYS CHEM, V35, P179, DOI 10.1016/0301-4622(90)80007-T; BELLON SF, 1991, BIOCHEMISTRY-US, V30, P8026, DOI 10.1021/bi00246a021; BOUBNOV NV, 1995, P NATL ACAD SCI USA, V92, P890, DOI 10.1073/pnas.92.3.890; BROWN SJ, 1993, SCIENCE, V261, P603, DOI 10.1126/science.8342024; BRUHN SL, 1992, P NATL ACAD SCI USA, V89, P2307, DOI 10.1073/pnas.89.6.2307; BRUSH GS, 1994, P NATL ACAD SCI USA, V91, P12520, DOI 10.1073/pnas.91.26.12520; CARTY MP, 1994, EMBO J, V13, P2114, DOI 10.1002/j.1460-2075.1994.tb06487.x; CHU G, 1994, J BIOL CHEM, V269, P787; CLUGSTON CK, 1992, CANCER RES, V52, P6375; COMESS KM, 1992, BIOCHEMISTRY-US, V31, P3975, DOI 10.1021/bi00131a013; COVERLEY D, 1991, NATURE, V349, P538, DOI 10.1038/349538a0; DEMARCQ C, 1994, CELL GROWTH DIFFER, V5, P983; DVIR A, 1992, P NATL ACAD SCI USA, V89, P11920, DOI 10.1073/pnas.89.24.11920; EVANS DL, 1994, CANCER RES, V54, P1596; FALZON M, 1993, J BIOL CHEM, V268, P10546; FINNIE NJ, 1995, P NATL ACAD SCI USA, V92, P320, DOI 10.1073/pnas.92.1.320; FISCELLA M, 1993, ONCOGENE, V8, P1519; GOTTLIEB TM, 1993, CELL, V72, P131, DOI 10.1016/0092-8674(93)90057-W; HARTLEY KO, 1995, CELL, V82, P849, DOI 10.1016/0092-8674(95)90482-4; HUANG HF, 1995, SCIENCE, V270, P1842, DOI 10.1126/science.270.5243.1842; HUANG L, 1993, BIOCHEMISTRY-US, V32, P841, DOI 10.1021/bi00054a015; HUGHES EN, 1992, J BIOL CHEM, V267, P13520; IIJIMA S, 1992, EUR J BIOCHEM, V206, P595, DOI 10.1111/j.1432-1033.1992.tb16964.x; JOHNSON SW, 1994, BIOCHEM PHARMACOL, V47, P689, DOI 10.1016/0006-2952(94)90132-5; JONES SL, 1994, INT J CANCER, V59, P388, DOI 10.1002/ijc.2910590317; JONES SL, 1994, BIOCHEM PHARMACOL, V48, P1662, DOI 10.1016/0006-2952(94)90213-5; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEESMILLER SP, 1992, MOL CELL BIOL, V12, P5041, DOI 10.1128/MCB.12.11.5041; MASUDA H, 1988, CANCER RES, V48, P5713; MOROZOV VE, 1994, J BIOL CHEM, V269, P16664; MORRISSEY JH, 1981, ANAL BIOCHEM, V117, P307, DOI 10.1016/0003-2697(81)90783-1; ORMEROD MG, 1994, BRIT J CANCER, V69, P93, DOI 10.1038/bjc.1994.14; ORMEROD MG, 1994, EXP CELL RES, V211, P231, DOI 10.1006/excr.1994.1082; PAILLARD S, 1991, NUCLEIC ACIDS RES, V19, P5619, DOI 10.1093/nar/19.20.5619; PAN ZQ, 1994, P NATL ACAD SCI USA, V91, P8343, DOI 10.1073/pnas.91.18.8343; PAN ZQ, 1995, P NATL ACAD SCI USA, V92, P4636, DOI 10.1073/pnas.92.10.4636; PENEFSKY HS, 1977, J BIOL CHEM, V252, P2891; PEREZ RP, 1993, CANCER, V71, P1571, DOI 10.1002/cncr.2820710424; PIL PM, 1992, SCIENCE, V256, P234, DOI 10.1126/science.1566071; RATHMELL WK, 1994, P NATL ACAD SCI USA, V91, P7623, DOI 10.1073/pnas.91.16.7623; Sambrook J., 2002, MOL CLONING LAB MANU; SIBGHATULLAH, 1989, NUCLEIC ACIDS RES, V17, P4471, DOI 10.1093/nar/17.12.4471; SMIDER V, 1994, SCIENCE, V266, P288, DOI 10.1126/science.7939667; SUWA A, 1994, P NATL ACAD SCI USA, V91, P6904, DOI 10.1073/pnas.91.15.6904; TAKAHARA PM, 1995, NATURE, V377, P649, DOI 10.1038/377649a0; Turchi JJ, 1996, BIOCHEMISTRY-US, V35, P2992, DOI 10.1021/bi951843j; USHAY HM, 1981, BIOCHEMISTRY-US, V20, P3744, DOI 10.1021/bi00516a012; WANG JS, 1993, MOL BIOL REP, V18, P15, DOI 10.1007/BF01006891; WANG JS, 1994, FEBS LETT, V351, P219, DOI 10.1016/0014-5793(94)00863-9; YANG DZ, 1995, BIOCHEMISTRY-US, V34, P12912, DOI 10.1021/bi00039a054	52	51	53	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 7	1996	271	23					13861	13867		10.1074/jbc.271.23.13861	http://dx.doi.org/10.1074/jbc.271.23.13861			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UP385	8662830	hybrid			2022-12-25	WOS:A1996UP38500083
J	Demetriou, M; Binkert, C; Sukhu, B; Tenenbaum, HC; Dennis, JW				Demetriou, M; Binkert, C; Sukhu, B; Tenenbaum, HC; Dennis, JW			Fetuin/alpha 2-HS glycoprotein is a transforming growth factor-beta type II receptor mimic and cytokine antagonist	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-2 HS-GLYCOPROTEIN; TGF-BETA; HUMAN ALPHA-2-HS-GLYCOPROTEIN; SERUM CONCENTRATION; NEGATIVE REGULATION; BONE-FORMATION; BOVINE FETUIN; EXPRESSION; PROTEIN; KINASE	The serum glycoprotein fetuin is expressed during embryogenesis in multiple tissues including limb buds and has been shown to promote bone remodeling and stimulate cell proliferation in vitro. In this report, we demonstrate that fetuin antagonizes the antiproliferative action of transforming growth factor-beta 1 (TGF-beta 1) in cell cultures. Surface plasmon resonance measurements show that fetuin binds directly to TGF beta 1 and TGF-beta 2 and with greater affinity to the TGF-beta-related bone morphogenetic proteins (BMP-2, BMP-4, and BMP-6). In a competitive enzyme-linked immunosorbent assay, fetuin blocked binding of TGF-beta 1 to the extracellular domain of TGF-beta receptor type II (T beta RII), one of the primary TGF-beta-binding receptors. A comparison of fetuin and T beta RII shows homology in an 18-19-amino acid sequence, which we have designated TGF-beta receptor II homology 1 domain (TRH1). Since the TRH1 sequence is known to form a disulfide loop in fetuin, cyclized TRH1 peptides from both fetuin and T beta RII were chemically synthesized and tested for cytokine binding activity. Cyclized TRH1 peptide from T beta RII bound to TGF-beta 1 with greater affinity than to BMP-2, while the cyclized TRH1 peptide from fetuin bound preferentially to BMP-2. Finally, fetuin or neutralizing anti-TGF-beta antibodies blocked osteogenesis and deposition of calcium-containing matrix in cultures of dexamethasone-treated rat bone marrow cells. In summary, these experiments define the TRH1 peptide loop as a cytokine-binding domain in both T beta RII and fetuin and suggest that fetuin is a natural antagonist of TGF-beta and BMP activities.	MT SINAI HOSP,SAMUEL LUNENFELD RES INST,TORONTO,ON M5G 1X5,CANADA; UNIV TORONTO,DEPT MED GENET,TORONTO,ON M5S 1A8,CANADA; UNIV TORONTO,FAC DENT,MRC,PERIODONTAL PHYSIOL GRP,TORONTO,ON M5S 1A8,CANADA	University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto; University of Toronto			Dennis, James/E-7268-2013					AKHOUNDI C, 1994, J BIOL CHEM, V269, P15925; ASHTON BA, 1980, CLIN SCI, V58, P435, DOI 10.1042/cs0580435; ATTISANO L, 1993, CELL, V75, P671, DOI 10.1016/0092-8674(93)90488-C; BORDER WA, 1992, J CLIN INVEST, V90, P1, DOI 10.1172/JCI115821; BORDER WA, 1992, NATURE, V360, P361, DOI 10.1038/360361a0; BROWN WM, 1992, EUR J BIOCHEM, V205, P321, DOI 10.1111/j.1432-1033.1992.tb16783.x; CAYATTE AJ, 1990, J BIOL CHEM, V265, P5883; CENTRELLA M, 1995, MOL CELL BIOL, V15, P3273; CHEN RH, 1994, J BIOL CHEM, V269, P22868; CHOU PY, 1978, ANNU REV BIOCHEM, V47, P251, DOI 10.1146/annurev.bi.47.070178.001343; COLCLASURE GC, 1988, J CLIN ENDOCR METAB, V66, P187, DOI 10.1210/jcem-66-1-187; DAMERON KM, 1994, SCIENCE, V265, P1582, DOI 10.1126/science.7521539; DICKSON IR, 1975, NATURE, V256, P430, DOI 10.1038/256430a0; DICKSON IR, 1983, CALCIFIED TISSUE INT, V35, P16, DOI 10.1007/BF02405000; DZIEGIELEWSKA KM, 1990, J BIOL CHEM, V265, P4354; EBNER R, 1993, SCIENCE, V260, P1344, DOI 10.1126/science.8388127; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; GENG Y, 1993, P NATL ACAD SCI USA, V90, P10315, DOI 10.1073/pnas.90.21.10315; HENIS YI, 1994, J CELL BIOL, V126, P139, DOI 10.1083/jcb.126.1.139; HILDEBRAND A, 1994, BIOCHEM J, V302, P527, DOI 10.1042/bj3020527; JONES CM, 1991, DEVELOPMENT, V111, P531; KELLERMANN J, 1989, J BIOL CHEM, V264, P14121; KINGSLEY DM, 1994, GENE DEV, V8, P133, DOI 10.1101/gad.8.2.133; KINGSLEY DM, 1992, CELL, V71, P399, DOI 10.1016/0092-8674(92)90510-J; KOFF A, 1993, SCIENCE, V260, P536, DOI 10.1126/science.8475385; LEBRETON JP, 1979, J CLIN INVEST, V64, P1118, DOI 10.1172/JCI109551; LEE CC, 1987, P NATL ACAD SCI USA, V84, P4403, DOI 10.1073/pnas.84.13.4403; LEVINE JH, 1993, AM J PATHOL, V143, P368; LIN HY, 1992, CELL, V68, P775, DOI 10.1016/0092-8674(92)90152-3; LIN HY, 1995, J BIOL CHEM, V270, P2747, DOI 10.1074/jbc.270.6.2747; LIU F, 1995, MOL CELL BIOL, V15, P3479; LOPEZCASILLAS F, 1994, J CELL BIOL, V124, P557, DOI 10.1083/jcb.124.4.557; LOPEZCASILLAS F, 1993, CELL, V73, P1435, DOI 10.1016/0092-8674(93)90368-Z; LYONS KM, 1990, DEVELOPMENT, V109, P833; LYONS KM, 1989, GENE DEV, V3, P1657, DOI 10.1101/gad.3.11.1657; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; MATZUK MM, 1995, NATURE, V374, P360, DOI 10.1038/374360a0; NAKAMURA T, 1990, SCIENCE, V247, P836, DOI 10.1126/science.2106159; NIE ZT, 1992, AM J PHYSIOL, V263, pC551, DOI 10.1152/ajpcell.1992.263.3.C551; OCONNORMCCORT MD, 1994, ANN NY ACAD SCI, V766, P300; OCONNORMCCOURT MD, 1987, J BIOL CHEM, V262, P14090; OSHANNESSY DJ, 1994, METHOD ENZYMOL, V240, P323; OURSLER MJ, 1993, ENDOCRINOLOGY, V133, P2187, DOI 10.1210/en.133.5.2187; Pedersen KO, 1944, NATURE, V154, P575, DOI 10.1038/154575a0; PUCK TT, 1968, P NATL ACAD SCI USA, V59, P192, DOI 10.1073/pnas.59.1.192; RAUTH G, 1992, EUR J BIOCHEM, V204, P523, DOI 10.1111/j.1432-1033.1992.tb16663.x; ROSEN V, 1992, TRENDS GENET, V8, P97, DOI 10.1016/0168-9525(92)90063-A; SCHNEYER AL, 1994, ENDOCRINOLOGY, V135, P667, DOI 10.1210/en.135.2.667; SCHUSTER SC, 1993, NATURE, V365, P343, DOI 10.1038/365343a0; SHAH M, 1992, LANCET, V339, P213, DOI 10.1016/0140-6736(92)90009-R; TRIFFITT JT, 1976, NATURE, V262, P226, DOI 10.1038/262226a0; VANDERMERWE PA, 1994, TRENDS BIOCHEM SCI, V19, P354; VANVLASSELAER P, 1994, J CELL BIOL, V124, P569, DOI 10.1083/jcb.124.4.569; WAKEFIELD LM, 1995, CLIN CANCER RES, V1, P129; WOLF YG, 1994, J CLIN INVEST, V93, P1172, DOI 10.1172/JCI117070; WOZNEY JM, 1988, SCIENCE, V242, P1528, DOI 10.1126/science.3201241; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0; YAMAGUCHI Y, 1990, NATURE, V346, P281, DOI 10.1038/346281a0; YAMASHITA H, 1995, J CELL BIOL, V130, P217, DOI 10.1083/jcb.130.1.217; YANG F, 1991, BONE, V12, P7, DOI 10.1016/8756-3282(91)90048-N; YANG FM, 1992, BIOCHIM BIOPHYS ACTA, V1130, P149, DOI 10.1016/0167-4781(92)90522-2	61	226	253	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 31	1996	271	22					12755	12761		10.1074/jbc.271.22.12755	http://dx.doi.org/10.1074/jbc.271.22.12755			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UN474	8662721	hybrid			2022-12-25	WOS:A1996UN47400012
J	Morrison, P; Saltiel, AR; Rosner, MR				Morrison, P; Saltiel, AR; Rosner, MR			Role of mitogen-activated protein kinase kinase in regulation of the epidermal growth factor receptor by protein kinase C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGAND-INDUCED INTERNALIZATION; SIGNAL TRANSDUCTION; PHOSPHORYLATION; THREONINE-654; PHOSPHATASE; BINDING; MUTANTS; SITES	The epidermal growth factor receptor (EGFR) is regulated by at least two mechanisms involving protein kinase C (PKC), inhibition of EGF binding and inhibition of EGF-stimulated tyrosine kinase activity. In this study we investigated whether mitogen-activated protein kinase (MAPK) mediates the inhibitory effects of PKC on EGFR binding or kinase activity by pretreating NIH3T3 and Chinese hamster ovary cells expressing the EGFR with PD98059, an inhibitor of MAPK/extracellular signal-regulated kinase kinase (MEK). We also determined whether substitution of cysteine for threonine at residue 669, the site of MAPK phosphorylation of the EGFR, alters the inhibition of kinase activity by PKC. The results indicate that 1) PKC down-regulates EGFR tyrosine kinase activity by an MEK-dependent mechanism presumably involving MAPK; 2) the inhibition by PKC is not a direct result of phosphorylation of the EGFR by PKC or MAPK; 3) activation of MAPK is not sufficient to regulate EGFR kinase activity; and 4) PKC-mediated down-regulation of EGF binding and EGFR kinase activity occur by different mechanisms. These data are consistent with a model for regulation of the EGFR by other receptors whereby their activation of PKC, in conjunction with MAPK, results in the phosphorylation of a protein(s) that modulates EGFR kinase activity.	UNIV CHICAGO,BEN MAY INST,CHICAGO,IL 60637; UNIV CHICAGO,DEPT PHARMACOL & PHYSIOL SCI,CHICAGO,IL 60637; UNIV CHICAGO,DEPT MOLEC GENET & CELL BIOL,CHICAGO,IL 60637; WARNER LAMBERT PARKE DAVIS,DIV PHARMACEUT RES,DEPT SIGNAL TRANSDUCT,ANN ARBOR,MI 48105	University of Chicago; University of Chicago; University of Chicago; Pfizer			Saltiel, Alan/L-3632-2019	Saltiel, Alan/0000-0002-9726-9828	NCI NIH HHS [CA35541] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA035541] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; CASTAGNINO P, 1995, ONCOGENE, V10, P723; CHAO TSO, 1992, J BIOL CHEM, V267, P19876; COCHET C, 1991, J BIOL CHEM, V266, P637; COUNTAWAY JL, 1990, J BIOL CHEM, V265, P3407; DECKER SJ, 1990, J BIOL CHEM, V265, P7009; DOWNWARD J, 1985, J BIOL CHEM, V260, P14358; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; FELDER S, 1992, J CELL BIOL, V117, P203, DOI 10.1083/jcb.117.1.203; FOWLER KJ, 1995, P NATL ACAD SCI USA, V92, P1465, DOI 10.1073/pnas.92.5.1465; FRIEDMAN B, 1989, P NATL ACAD SCI USA, V86, P812, DOI 10.1073/pnas.86.3.812; GRISWOLDPRENNER I, 1993, J BIOL CHEM, V268, P27489; HEISERMANN GJ, 1990, J BIOL CHEM, V265, P12820; HONEGGER A, 1988, EMBO J, V7, P3053, DOI 10.1002/j.1460-2075.1988.tb03170.x; LUND KA, 1990, J BIOL CHEM, V265, P20517; MATTHEWS RJ, 1992, MOL CELL BIOL, V12, P2396, DOI 10.1128/MCB.12.5.2396; MOOLENAAR WH, 1988, EMBO J, V7, P707, DOI 10.1002/j.1460-2075.1988.tb02866.x; MORRISON P, 1993, J BIOL CHEM, V268, P15536; PANG L, 1995, J BIOL CHEM, V270, P13585, DOI 10.1074/jbc.270.23.13585; Sambrook J., 2002, MOL CLONING LAB MANU; SUN H, 1995, P NATL ACAD SCI USA, V92, P2229, DOI 10.1073/pnas.92.6.2229; TAKISHIMA K, 1991, P NATL ACAD SCI USA, V88, P2520, DOI 10.1073/pnas.88.6.2520; TOMIC S, 1995, J BIOL CHEM, V270, P21277, DOI 10.1074/jbc.270.36.21277; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VOGEL W, 1993, SCIENCE, V259, P1611, DOI 10.1126/science.7681217; WALTON KM, 1993, ANNU REV BIOCHEM, V62, P101; WATTENBERG EV, 1989, J BIOL CHEM, V264, P14668; ZHAO ZH, 1994, P NATL ACAD SCI USA, V91, P5007, DOI 10.1073/pnas.91.11.5007	28	48	48	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 31	1996	271	22					12891	12896		10.1074/jbc.271.22.12891	http://dx.doi.org/10.1074/jbc.271.22.12891			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UN474	8662819	hybrid			2022-12-25	WOS:A1996UN47400033
J	Shibata, T; Fujii, Y; Nakamura, Y; Nakamura, K; Yamane, K				Shibata, T; Fujii, Y; Nakamura, Y; Nakamura, K; Yamane, K			Identification of protein synthesis elongation factor G as a 4.5 S RNA-binding protein in Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-RECOGNITION PARTICLE; ENDOPLASMIC-RETICULUM MEMBRANE; SMALL CYTOPLASMIC RNA; SECONDARY STRUCTURE; 23S RNA; NASCENT PREPROLACTIN; SEQUENCE RECOGNITION; BACILLUS-SUBTILIS; GENETIC SELECTION; SRP-RNA	Escherichia coli 4.5 S RNA is metabolically stable and abundant. It consists of 114 nucleotides, and it is structurally homologous to domain TV of mammalian signal recognition particle (SRP) RNA. In this study, we found two 4.5 S RNA-binding proteins in cell extracts by means of a gel mobility shift assay. One protein was identified as Ffh, which has been characterized as 4.5 S RNA-binding protein. The other protein was separated from Ffh by two consecutive column chromatographic elutions and by monitoring the 4.5 S RNA binding activity. After the second chromatography, a dominant protein with an approximate molecular weight of 78,000 was associated with 4.5 S RNA binding activity. A sequence of the NH2-terminal 19 residues of the 78-kDa protein was completely identical to that of the protein elongation factor G (EF-G) of E. coli, and further it cross-reacted with antiserum against E. coli EF-G. The results obtained using a synthetic oligo RNA corresponding to the 23 S rRNA defining the EF-G binding site indicated that 4.5 S RNA and 23 S rRNA are competitive in 4.5 S RNA binding and that a decanucleotide sequence conserved between them serves as a binding site for EF-G. Conservation of the SRP RNA binding activity of EF-G from Bacillus sabtilis suggests that the binding of EF-G to SRP RNA is essential for its function.	UNIV TSUKUBA,INST BIOL SCI,IBARAKI,OSAKA 305,JAPAN	University of Tsukuba								AEVARSSON A, 1994, EMBO J, V13, P3669, DOI 10.1002/j.1460-2075.1994.tb06676.x; BERNSTEIN HD, 1989, NATURE, V340, P482, DOI 10.1038/340482a0; BOTHWELL ALM, 1976, J BIOL CHEM, V251, P7709; BOURGAIZE DB, 1987, NATURE, V325, P281, DOI 10.1038/325281a0; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BROWN S, 1989, J MOL BIOL, V209, P79, DOI 10.1016/0022-2836(89)90171-X; BROWN S, 1991, NEW BIOL, V3, P430; BROWN S, 1984, J MOL BIOL, V178, P533, DOI 10.1016/0022-2836(84)90237-7; BROWN S, 1989, J BACTERIOL, V171, P6517, DOI 10.1128/jb.171.12.6517-6520.1989; BROWN S, 1987, CELL, V49, P825, DOI 10.1016/0092-8674(87)90620-9; CZWORKOWSKI J, 1994, EMBO J, V13, P3661, DOI 10.1002/j.1460-2075.1994.tb06675.x; GILMORE R, 1993, CELL, V75, P589, DOI 10.1016/0092-8674(93)90476-7; HOU Y, 1994, J BACTERIOL, V176, P7038, DOI 10.1128/JB.176.22.7038-7044.1994; HSU LM, 1984, J MOL BIOL, V178, P509, DOI 10.1016/0022-2836(84)90236-5; JENSEN CG, 1994, J BACTERIOL, V176, P7148, DOI 10.1128/JB.176.23.7148-7154.1994; KAZIRO Y, 1978, BIOCHIM BIOPHYS ACTA, V505, P95, DOI 10.1016/0304-4173(78)90009-5; KAZIRO Y, 1969, COLD SPRING HARB SYM, V34, P385, DOI 10.1101/SQB.1969.034.01.045; KRIEG UC, 1986, P NATL ACAD SCI USA, V83, P8604, DOI 10.1073/pnas.83.22.8604; KURZCHALIA TV, 1986, NATURE, V320, P634, DOI 10.1038/320634a0; LARSEN N, 1991, NUCLEIC ACIDS RES, V19, P209, DOI 10.1093/nar/19.2.209; LILJAS A, 1990, RIBOSOME, P309; LUIRINK J, 1992, NATURE, V359, P741, DOI 10.1038/359741a0; LUIRINK J, 1994, EMBO J, V13, P2289, DOI 10.1002/j.1460-2075.1994.tb06511.x; MILLAN MJ, 1975, EUR J BIOCHEM, V57, P431; MILLER JD, 1994, NATURE, V367, P657, DOI 10.1038/367657a0; MOAZED D, 1988, NATURE, V334, P362, DOI 10.1038/334362a0; NAKAMURA K, 1992, J BACTERIOL, V174, P2185, DOI 10.1128/JB.174.7.2185-2192.1992; NAKAMURA K, 1992, NUCLEIC ACIDS RES, V20, P5227, DOI 10.1093/nar/20.19.5227; NAKAMURA K, 1995, MICROBIOL-SGM, V141, P2965, DOI 10.1099/13500872-141-11-2965; NIERHAUS KH, 1992, BIOCHIMIE, V74, P403, DOI 10.1016/0300-9084(92)90118-X; NISHIGUCHI M, 1994, J BACTERIOL, V176, P157, DOI 10.1128/JB.176.1.157-165.1994; NUNNARI J, 1992, Current Opinion in Cell Biology, V4, P573, DOI 10.1016/0955-0674(92)90074-M; PHILLIPS GJ, 1992, NATURE, V359, P744, DOI 10.1038/359744a0; PORITZ MA, 1988, CELL, V55, P4, DOI 10.1016/0092-8674(88)90003-7; PORITZ MA, 1990, SCIENCE, V250, P1111, DOI 10.1126/science.1701272; RAPOPORT TA, 1992, SCIENCE, V258, P931, DOI 10.1126/science.1332192; RAPOPORT TA, 1991, FASEB J, V5, P2792, DOI 10.1096/fasebj.5.13.1916103; RIBES V, 1990, CELL, V63, P591, DOI 10.1016/0092-8674(90)90454-M; ROMISCH K, 1989, NATURE, V340, P478, DOI 10.1038/340478a0; SAMUELSSON T, 1993, NUCLEIC ACIDS RES, V21, P847, DOI 10.1093/nar/21.4.847; SIMONEAU P, 1992, J BACTERIOL, V174, P627, DOI 10.1128/jb.174.2.627-629.1992; SKOLD SE, 1983, NUCLEIC ACIDS RES, V11, P4923, DOI 10.1093/nar/11.14.4923; SPIRIN AS, 1985, PROG NUCLEIC ACID RE, V32, P75, DOI 10.1016/S0079-6603(08)60346-3; STRUCK JCR, 1990, EUR J BIOCHEM, V192, P17, DOI 10.1111/j.1432-1033.1990.tb19189.x; STRUCK JCR, 1988, NUCLEIC ACIDS RES, V16, P7740, DOI 10.1093/nar/16.15.7740; STRUCK JCR, 1990, J BACTERIOL, V172, P1284, DOI 10.1128/jb.172.3.1284-1288.1990; STRUCK JCR, 1988, NUCLEIC ACIDS RES, V16, P2719, DOI 10.1093/nar/16.6.2719; WALTER P, 1986, ANNU REV CELL BIOL, V2, P499, DOI 10.1146/annurev.cellbio.2.1.499; WALTER P, 1982, NATURE, V299, P691, DOI 10.1038/299691a0; WOLIN SL, 1994, CELL, V77, P787, DOI 10.1016/0092-8674(94)90124-4	50	26	26	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 31	1996	271	22					13162	13168		10.1074/jbc.271.22.13162	http://dx.doi.org/10.1074/jbc.271.22.13162			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UN474	8662727	hybrid			2022-12-25	WOS:A1996UN47400073
J	Wainwright, G; Webster, SG; Wilkinson, MC; Chung, JS; Rees, HH				Wainwright, G; Webster, SG; Wilkinson, MC; Chung, JS; Rees, HH			Structure and significance of mandibular organ-inhibiting hormone in the crab, Cancer pagurus - Involvement in multihormonal regulation of growth and reproduction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; METHYL FARNESOATE; HOMARUS-AMERICANUS; CARCINUS-MAENAS; CRUSTACEAN REPRODUCTION; PROCAMBARUS-CLARKII; JUVENILE-HORMONE; LOBSTER; INVITRO; HEMOLYMPH	Current evidence indicates that methyl farnesoate is the crustacean equivalent of the juvenile hormones of insects. This putative hormone is produced by the mandibular organs and is negatively regulated by a neuropeptide produced and secreted by the X-organ-sinus gland complex of the eyestalk. To identify this neuropeptide, a bioassay was developed which measures the inhibition of methyl farnesoate synthesis by mandibular organs exposed to fractionated sinus gland extracts from the crab, Cancer pagurus. Two neuropeptides, named mandibular organ-inhibiting hormones (MOIH-1 and -2) repressed methyl farnesoate synthesis. MOIH-1 was fully sequenced by automated Edman degradation of endoproteinase-derived fragments and further characterized by mass spectrometry. This peptide consisted of 78 residues (M(r) 9235.6), with unblocked termini and three intrachain disulfide bridges. MOIH-2 appeared to be almost identical to MOIH-1 with the exception of a Gin for Lys substitution at position 33. Comparison with previously sequenced crustacean neuropeptides shows that these MOIHs are members of the ever expanding crustacean hyperglycemic hormone family, with significant sequence similarity to molt inhibiting hormones (MIHs). It is possible that these two structurally similar peptides (MIH, MOIH) may control mutually exclusive physiological phenomena (somatic and gonadal growth), suggesting a complex hormonal integration of these processes in crustaceans.	UNIV WALES,SCH BIOL SCI,BANGOR LL57 2UW,GWYNEDD,WALES; UNIV LIVERPOOL,DEPT BIOCHEM,LIVERPOOL L69 3BX,MERSEYSIDE,ENGLAND	Bangor University; University of Liverpool			Chung, J.Sook/D-3832-2012	Chung, J.Sook/0000-0002-9318-304X				BAZIN F, 1976, CR ACAD SCI D NAT, V282, P739; BORST DW, 1987, INSECT BIOCHEM, V17, P1123, DOI 10.1016/0020-1790(87)90133-8; BORST DW, 1994, BIOL BULL, V186, P9, DOI 10.2307/1542032; BORST DW, 1974, STEROIDS, V24, P637, DOI 10.1016/0039-128X(74)90017-8; BORST DW, 1990, RECENT ADV COMP ARTH, P35; BRODY MD, 1989, INVERTEBR REPROD DEV, V16, P141, DOI 10.1080/07924259.1989.9672070; CHANG ES, 1990, BIOCHEM BIOPH RES CO, V171, P818, DOI 10.1016/0006-291X(90)91219-I; Chung JS, 1996, NEUROPEPTIDES, V30, P95, DOI 10.1016/S0143-4179(96)90061-X; DEKLEIJN DPV, 1994, FEBS LETT, V353, P255, DOI 10.1016/0014-5793(94)01055-2; DING Q, 1991, INSECT BIOCHEM, V21, P285, DOI 10.1016/0020-1790(91)90018-A; HINSCH GW, 1981, INT J INVER REP DEV, V3, P237; HINSCH GW, 1980, T AM MICROSC SOC, V99, P317, DOI 10.2307/3226007; HORN DHS, 1976, J INSECT PHYSIOL, V22, P901, DOI 10.1016/0022-1910(76)90263-8; KING LE, 1995, INSECT BIOCHEM MOLEC, V25, P495, DOI 10.1016/0965-1748(94)00089-H; Koeppe J.K., 1985, P165; LANDAU M, 1989, INVERTEBR REPROD DEV, V16, P165, DOI 10.1080/07924259.1989.9672073; LAUFER H, 1994, INSECT NEUROCHEMISTRY AND NEUROPHYSIOLOGY 1993, P203; Laufer H., 1988, Invertebrate Endocrinology, V2, P305; LAUFER H, 1993, AM ZOOL, V33, P365; LAUFER H, 1987, SCIENCE, V235, P202, DOI 10.1126/science.235.4785.202; LAUFER H, 1987, INSECT BIOCHEM, V17, P1129, DOI 10.1016/0020-1790(87)90134-X; Laufes H., 1986, Advances in Invertebrate Reproduction, V4, P135; LEE KJ, 1995, BIOCHEM BIOPH RES CO, V209, P1126, DOI 10.1006/bbrc.1995.1614; LI H, 1991, GEN COMP ENDOCR, V81, P335, DOI 10.1016/0016-6480(91)90159-4; MEUSY JJ, 1988, ZOOL SCI, V5, P217; PRESTWICH GD, 1990, GEN COMP ENDOCR, V80, P232, DOI 10.1016/0016-6480(90)90168-L; RIDDIFORD LM, 1994, ADV INSECT PHYSIOL, V24, P213, DOI 10.1016/S0065-2806(08)60084-3; SAGI A, 1991, COMP BIOCHEM PHYS B, V99, P879, DOI 10.1016/0305-0491(91)90157-9; SEVALA VL, 1989, EXPERIENTIA, V45, P355, DOI 10.1007/BF01957476; SOYEZ D, 1987, J EXP ZOOL, V244, P479, DOI 10.1002/jez.1402440314; SOYEZ D, 1991, NEUROPEPTIDES, V20, P25, DOI 10.1016/0143-4179(91)90036-I; STAY B, 1994, ADV INSECT PHYSL, V25, P268; Sun Piera S., 1994, Molecular Marine Biology and Biotechnology, V3, P1; TAKETOMI Y, 1989, CELL BIOL INT REP, V9, P1069; TAMONE SL, 1993, GEN COMP ENDOCR, V89, P425, DOI 10.1006/gcen.1993.1050; TOBE SS, 1994, PERSPECTIVES IN COMPARATIVE ENDOCRINOLOGY, P12; TSUKIMURA B, 1992, GEN COMP ENDOCR, V86, P297, DOI 10.1016/0016-6480(92)90114-Y; WAINWRIGHT G, 1995, THESIS U LIVERPOOL; WEBSTER SG, 1986, GEN COMP ENDOCR, V61, P237, DOI 10.1016/0016-6480(86)90201-7; WEBSTER SG, 1991, P ROY SOC B-BIOL SCI, V244, P247, DOI 10.1098/rspb.1991.0078; WEBSTER SG, 1986, J COMP PHYSIOL B, V156, P617, DOI 10.1007/BF00692738; WEBSTER SG, 1996, MARINE BIOL PORT ERI; WYATT GR, 1994, PERSPECTIVES IN COMPARATIVE ENDOCRINOLOGY, P202; YUDIN AI, 1980, BIOL BULL, V159, P760, DOI 10.2307/1540840	44	136	144	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 31	1996	271	22					12749	12754		10.1074/jbc.271.22.12749	http://dx.doi.org/10.1074/jbc.271.22.12749			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UN474	8662685	hybrid			2022-12-25	WOS:A1996UN47400011
J	Zera, EM; Molloy, DP; Angleson, JK; Lamture, JB; Wensel, TG; Malinski, JA				Zera, EM; Molloy, DP; Angleson, JK; Lamture, JB; Wensel, TG; Malinski, JA			Low affinity interactions of GDP beta S and ribose- or phosphoryl-substituted GTP analogues with the heterotrimeric G protein, transducin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OUTER SEGMENT MEMBRANES; H-RAS P21; CGMP PHOSPHODIESTERASE ACTIVATION; ELONGATION-FACTOR-TU; GUANINE-NUCLEOTIDES; GUANOSINE 5'-O-(2-THIODIPHOSPHATE); BOVINE TRANSDUCIN; CRYSTAL-STRUCTURE; ESCHERICHIA-COLI; GAMMA-SUBUNITS	We have examined the effects of three commonly used classes of guanine nucleotide analogues on the retinal G protein, transducin (G(t)), and found them to be quite different from those that might be expected from results with other GTP-binding proteins, The most surprising results were with guanosine 5'-O-(2-thiodiphosphate) (GDP beta S); rather than inhibiting activation of G(t), GDP beta S addition activated G(t) as a result of a trace contaminant, Even when the contaminant levels were reduced 5-fold by chromatography, its effects dominated those of GDP beta S, which binds G(t) at least 1500-fold more weakly than guanosine 5'-O-(3-thiotriphosphate) (GTP gamma S). The affinity of G(t) for GDP was found to be at least 300-fold weaker than for GTP gamma S, while the affinities of GTP and GTP gamma S were similar. Ribose-modified GTP analogues, including 2'(3')-O-(N-methylanthraniloyl) GTP (mant-GTP), 2'(3')-O-[(2-aminoethyl)carbamyl] GTP (edGTP), and adducts of fluorescein 5-isothiocyanate and rhodamine B-isothiocyanate with edGTP, interacted extremely weakly, if at all, with the GTP binding site of the alpha subunit of G(t). They were neither effective activators of G(t) nor effective inhibitors of activation by GTP or GTP gamma S. A gamma-phosphoryl-modified analogue, an adduct of GTP gamma S and (5-(2(iodoacetyl)aminoethyl)amino)naphthalene-1-sulfonic acid (dnsGTP), also activated G(t) weakly, if at all, and did not inhibit its activation, The exclusion of these analogues points to the highly restrictive and specific nature of the GTP binding site of G(t), in contrast to those of numerous other GTP-binding proteins which are potently activated or inhibited by these analogues.	BAYLOR COLL MED,DEPT BIOCHEM,HOUSTON,TX 77030	Baylor College of Medicine				Wensel, Theodore/0000-0003-3518-9352	NEI NIH HHS [EY07981, EY07001] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY007981] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ANGLESON JK, 1993, NEURON, V11, P939, DOI 10.1016/0896-6273(93)90123-9; CASHEL M, 1969, J CHROMATOGR, V40, P103, DOI 10.1016/S0021-9673(01)96624-5; CREMO CR, 1990, BIOCHEMISTRY-US, V29, P3309, DOI 10.1021/bi00465a023; ECCLESTON JF, 1991, BIOCHEM SOC T, V19, P432, DOI 10.1042/bst0190432; ECKSTEIN F, 1979, J BIOL CHEM, V254, P9829; FAWZI AB, 1990, BIOCHEMISTRY-US, V29, P3804, DOI 10.1021/bi00467a030; FIELDS TA, 1994, BIOCHEMISTRY-US, V33, P6877, DOI 10.1021/bi00188a017; HAZLETT TL, 1993, BIOCHEMISTRY-US, V32, P13575, DOI 10.1021/bi00212a025; HINGORANI VN, 1989, BIOCHEMISTRY-US, V28, P7424, DOI 10.1021/bi00444a041; HIRATSUKA T, 1983, BIOCHIM BIOPHYS ACTA, V742, P496, DOI 10.1016/0167-4838(83)90267-4; JOHN J, 1990, BIOCHEMISTRY-US, V29, P6058, DOI 10.1021/bi00477a025; KAHLERT M, 1990, J BIOL CHEM, V265, P18928; KALBITZER HR, 1990, EUR J BIOCHEM, V188, P355, DOI 10.1111/j.1432-1033.1990.tb15411.x; KELLEHER DJ, 1986, MOL PHARMACOL, V30, P603; KJELDGAARD M, 1992, J MOL BIOL, V223, P721, DOI 10.1016/0022-2836(92)90986-T; KUTUZOV M, 1994, EUR J BIOCHEM, V220, P963, DOI 10.1111/j.1432-1033.1994.tb18700.x; LACOUR TFM, 1985, EMBO J, V4, P2385, DOI 10.1002/j.1460-2075.1985.tb03943.x; LAMB TD, 1988, J PHYSIOL-LONDON, V407, P463, DOI 10.1113/jphysiol.1988.sp017426; LAMBRIGHT DG, 1994, NATURE, V369, P621, DOI 10.1038/369621a0; LOGSDON N, 1992, ANAL BIOCHEM, V205, P36, DOI 10.1016/0003-2697(92)90575-R; MALINSKI JA, 1992, BIOCHEMISTRY-US, V31, P9502, DOI 10.1021/bi00154a024; Malinski JA, 1996, J BIOL CHEM, V271, P12919, DOI 10.1074/jbc.271.22.12919; Means GE, 1971, CHEM MODIFICATION PR, P217; MILLS J S, 1991, Biophysical Journal, V59, p348A; MILLS JS, 1993, BIOPHYS J, V64, pA383; MOLLOY DP, 1990, THESIS NATL I MED RE; MOORE KJM, 1993, BIOCHEMISTRY-US, V32, P7451, DOI 10.1021/bi00080a016; NOEL JP, 1993, NATURE, V366, P654, DOI 10.1038/366654a0; PAI EF, 1990, EMBO J, V9, P2351, DOI 10.1002/j.1460-2075.1990.tb07409.x; PANICO J, 1990, J BIOL CHEM, V265, P18922; PAPERMASTER DS, 1974, BIOCHEMISTRY-US, V13, P2438, DOI 10.1021/bi00708a031; PARIS S, 1990, J BIOL CHEM, V265, P11567; PFEUFFER T, 1977, J BIOL CHEM, V252, P7224; RAMDAS L, 1991, BIOCHEMISTRY-US, V30, P11637, DOI 10.1021/bi00114a005; REMMERS AE, 1994, J BIOL CHEM, V269, P13771; RENSLAND H, 1991, BIOCHEMISTRY-US, V30, P11181, DOI 10.1021/bi00110a023; SATHER WA, 1987, P NATL ACAD SCI USA, V84, P9290, DOI 10.1073/pnas.84.24.9290; WATSON BS, 1995, BIOCHEMISTRY-US, V34, P7904, DOI 10.1021/bi00024a015; WIELAND T, 1991, EUR J BIOCHEM, V196, P707, DOI 10.1111/j.1432-1033.1991.tb15869.x; WIELAND T, 1992, J BIOL CHEM, V267, P20791; WIELAND T, 1990, J BIOL CHEM, V265, P20791; YAMANAKA G, 1985, BIOCHEMISTRY-US, V24, P8094, DOI 10.1021/bi00348a039	42	18	18	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 31	1996	271	22					12925	12931		10.1074/jbc.271.22.12925	http://dx.doi.org/10.1074/jbc.271.22.12925			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UN474	8662741	hybrid			2022-12-25	WOS:A1996UN47400039
J	Hahn, H; Christiansen, J; Wicking, C; Zaphiropoulos, PG; Chidambaram, A; Gerrard, B; Vorechovsky, I; Bale, AE; Toftgard, R; Dean, M; Wainwright, B				Hahn, H; Christiansen, J; Wicking, C; Zaphiropoulos, PG; Chidambaram, A; Gerrard, B; Vorechovsky, I; Bale, AE; Toftgard, R; Dean, M; Wainwright, B			A mammalian patched homolog is expressed in target tissues of sonic hedgehog and maps to a region associated with developmental abnormalities	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FLOOR PLATE; PROTEIN; GENE; NOTOCHORD	Drosophila patched is a segment polarity gene required for the correct patterning of larval segments and imaginal discs during fly development and has a close functional relationship with hedgehog. We have isolated a complete human PATCHED cDNA sequence, which encodes a putative protein of 1296 amino acids, and displays 39% identity and 60% similarity to the Drosophila PATCHED protein, Hydropathy analysis suggests that human PATCHED is an integral membrane protein with a pattern of hydrophobic and hydrophilic stretches nearly identical to that of Drosophila patched, In the developing mouse embryo, patched is initially detected within the ventral neural tube and later in the somites and limb buds, Expression in the limb buds is restricted to the posterior ectoderm surrounding the zone of polarizing activity, The results show that patched is expressed in target tissues of sonic hedgehog, a murine homolog of Drosophila hedgehog suggesting that patched/hedgehog interactions have been conserved during evolution. Human PATCHED maps to human chromosome 9q22.3, the candidate region for the nevoid basal cell carcinoma syndrome. Patched expression is compatible with the congenital defects observed in the nevoid basal cell carcinoma syndrome.	NCI,FREDERICK CANC RES & DEV CTR,VIRAL CARCINOGENESIS LAB,HUMAN GENET SECT,FREDERICK,MD 21702; NCI,FREDERICK CANC RES & DEV CTR,INTRAMURAL RES SUPPORT PROGRAM,SCI APPLICAT INT CORP,FREDERICK,MD 21702; UNIV QUEENSLAND,CTR CELLULAR & MOLEC BIOL,BRISBANE,QLD 4072,AUSTRALIA; CTR NUTR & TOXICOL,KAROLINSKA INST,DEPT BIOSCI,S-17157 HUDDINGE,SWEDEN; YALE UNIV,SCH MED,DEPT GENET,NEW HAVEN,CT 06520	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; University of Queensland; Karolinska Institutet; Yale University			Dean, Michael/R-7501-2019; Dean, Michael C/G-8172-2012; Wicking, Carol/J-1814-2014	Dean, Michael C/0000-0003-2234-0631; Wicking, Carol/0000-0002-7225-3803; Wainwright, Brandon/0000-0003-0406-2092; Zaphiropoulos, Peter/0000-0003-4298-3861; Christiansen, Jeff/0000-0002-8146-1225				BALE AE, 1994, J INVEST DERMATOL, V103, pS126, DOI 10.1111/1523-1747.ep12399438; BASLER K, 1994, NATURE, V368, P208, DOI 10.1038/368208a0; CAPDEVILA J, 1994, EMBO J, V13, P71, DOI 10.1002/j.1460-2075.1994.tb06236.x; CHRISTIANSEN JH, 1995, MECH DEVELOP, V51, P341, DOI 10.1016/0925-4773(95)00383-5; FARNDON PA, 1994, GENOMICS, V23, P486, DOI 10.1006/geno.1994.1528; Goodrich LV, 1996, GENE DEV, V10, P301, DOI 10.1101/gad.10.3.301; GORLIN RJ, 1987, MEDICINE, V66, P98, DOI 10.1097/00005792-198703000-00002; HOOPER JE, 1989, CELL, V59, P751, DOI 10.1016/0092-8674(89)90021-4; INGHAM PW, 1991, NATURE, V353, P184, DOI 10.1038/353184a0; JESSELL TM, 1992, HARVEY LECT, V86, P87; JOHNSON RL, 1995, CELL, V81, P313, DOI 10.1016/0092-8674(95)90381-X; JOHNSON RL, 1994, CELL, V79, P1165, DOI 10.1016/0092-8674(94)90008-6; KOZAK M, 1991, J BIOL CHEM, V266, P19867; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Levanat S, 1996, NAT GENET, V12, P85, DOI 10.1038/ng0196-85; NAKANO Y, 1989, NATURE, V341, P508, DOI 10.1038/341508a0; PERICAKVANCE MA, 1995, ANN HUM GENET, V59, P347, DOI 10.1111/j.1469-1809.1995.tb00756.x; POURQUIE O, 1993, P NATL ACAD SCI USA, V90, P5242, DOI 10.1073/pnas.90.11.5242; POVEY S, 1994, ANN HUM GENET, V58, P177, DOI 10.1111/j.1469-1809.1994.tb01887.x; RIDDLE RD, 1993, CELL, V75, P1401, DOI 10.1016/0092-8674(93)90626-2; ROELINK H, 1995, CELL, V81, P445, DOI 10.1016/0092-8674(95)90397-6; ROELINK H, 1994, CELL, V76, P761, DOI 10.1016/0092-8674(94)90514-2; ROWE LB, 1994, MAMM GENOME, V5, P253, DOI 10.1007/BF00389540; VORECHOVSKY I, 1994, GENOMICS, V21, P517, DOI 10.1006/geno.1994.1310; YAMADA T, 1993, CELL, V73, P673, DOI 10.1016/0092-8674(93)90248-O	25	175	189	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 24	1996	271	21					12125	12128		10.1074/jbc.271.21.12125	http://dx.doi.org/10.1074/jbc.271.21.12125			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UL660	8647801	hybrid			2022-12-25	WOS:A1996UL66000003
J	Mysliwiec, T; Perego, R; Kruh, GD				Mysliwiec, T; Perego, R; Kruh, GD			Analysis of chimeric Gag-Arg/Abl molecules indicates a distinct negative regulatory role for the Arg C-terminal domain	ONCOGENE			English	Article						tyrosine kinase; Arg/Abl chimera; transforming activity	MURINE LEUKEMIA-VIRUS; ABL TYROSINE KINASE; CHRONIC MYELOGENOUS LEUKEMIA; ONCOGENIC ACTIVATION; TRANSFORMING ABILITY; GENE-PRODUCT; PROTEIN; BINDING; CELLS; BCR	Arg and c-Abl represent the mammalian member of the Abelson family of nonreceptor protein tyrosine kinases. The two proteins are composed of SH2, SH3, kinase and C-terminal domains, To examine Arg structure-function relationships we analysed a Gag-Arg fusion protein, analogous to the oncogenic Gag-Abl fusion protein of Abelson Murine Leukaemia Virus and found that in contrast to Gag-Abl, it lacked transforming activity, Three observations indicated that the difference in the transforming activity was mediated by the distinct Arg and Abl C-terminal domains, (1) The analysis of chimeric Gag-Arg/Abl molecules revealed that the Arg C-terminal domain completely abrogated Gag-Abl transforming activity and that the Abl C-terminus conferred transforming activity to Gag-Arg, Substitutions of SH2 and kinase domains did not affect activity, (2) Alterations in the Arg C-terminus were observed in spontaneous foci that developed in transfections of two nontransforming chimera. (3) An engineered Gag-Arg molecule containing a truncation of almost the entire C-terminal domain, including three SH3 domain-binding sites, was oncogenic, whereas a slightly smaller truncation that deleted two of three SH3 domain-binding sites, lacked transforming activity, These observations indicate that the C-terminal domain regulates Arg biological activity in a manner distinct from c-Abl and suggest that this effect may be mediated in part by SH3 domain-binding sites.	FOX CHASE CANC CTR,DEPT MED ONCOL,PHILADELPHIA,PA 19111; UNIV MILAN,INST GEN PATHOL,MILAN,ITALY; CNR,CTR RES CELL PATHOL,MILAN,ITALY	Fox Chase Cancer Center; University of Milan; Consiglio Nazionale delle Ricerche (CNR)					NATIONAL CANCER INSTITUTE [R55CA057273, P30CA006927, R01CA057273, F32CA060453] Funding Source: NIH RePORTER; NCI NIH HHS [CA-60453, CA06927, CA-57273] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AUSUBEL FM, 1994, CURRENT PROTOCOLS MO, V2; BEN-NERIAH Y, 1986, CELL, V44, P577, DOI 10.1016/0092-8674(86)90267-9; BOLEN J, 1993, ONCOGENE, V3, P2025; CICCHETTI P, 1992, SCIENCE, V257, P803, DOI 10.1126/science.1379745; CLARK SS, 1987, SCIENCE, V235, P85, DOI 10.1126/science.3541203; DALEY GQ, 1988, P NATL ACAD SCI USA, V85, P9312, DOI 10.1073/pnas.85.23.9312; DIFIORE PP, 1987, SCIENCE, V237, P178, DOI 10.1126/science.2885917; DIKSTEIN R, 1992, CELL, V69, P751, DOI 10.1016/0092-8674(92)90287-M; FELLER SM, 1994, TRENDS BIOCHEM SCI, V19, P453, DOI 10.1016/0968-0004(94)90129-5; FELLER SM, 1994, EMBO J, V13, P2341, DOI 10.1002/j.1460-2075.1994.tb06518.x; FRANZ WM, 1989, EMBO J, V8, P137, DOI 10.1002/j.1460-2075.1989.tb03358.x; GOFF SP, 1982, J VIROL, V41, P271, DOI 10.1128/JVI.41.1.271-285.1982; GOGA A, 1993, MOL CELL BIOL, V13, P4967, DOI 10.1128/MCB.13.8.4967; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; JACKSON P, 1989, EMBO J, V8, P449, DOI 10.1002/j.1460-2075.1989.tb03397.x; JACKSON PK, 1993, ONCOGENE, V8, P1943; KIPREOS ET, 1990, SCIENCE, V248, P217, DOI 10.1126/science.2183353; KIPREOS ET, 1992, SCIENCE, V256, P382, DOI 10.1126/science.256.5055.382; KONOPKA JB, 1984, CELL, V37, P1035, DOI 10.1016/0092-8674(84)90438-0; KONOPKA JB, 1985, MOL CELL BIOL, V5, P3116, DOI 10.1128/MCB.5.11.3116; KRUH GD, 1986, SCIENCE, V234, P1545, DOI 10.1126/science.3787260; KRUH GD, 1990, P NATL ACAD SCI USA, V87, P5802, DOI 10.1073/pnas.87.15.5802; LUGO TG, 1990, SCIENCE, V237, P532; MCWHIRTER JR, 1991, MOL CELL BIOL, V11, P1553, DOI 10.1128/MCB.11.3.1553; MULLER AJ, 1991, MOL CELL BIOL, V11, P1785, DOI 10.1128/MCB.11.4.1785; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; PENDERGAST AM, 1991, P NATL ACAD SCI USA, V88, P5927, DOI 10.1073/pnas.88.13.5927; PEREGO R, 1991, ONCOGENE, V6, P1899; PRYWES R, 1983, CELL, V34, P569, DOI 10.1016/0092-8674(83)90389-6; REICHMAN CT, 1992, CELL GROWTH DIFFER, V3, P451; REN RB, 1994, GENE DEV, V8, P783, DOI 10.1101/gad.8.7.783; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; RENSHAW MW, 1992, EMBO J, V11, P3941, DOI 10.1002/j.1460-2075.1992.tb05488.x; ROSENBERG N, 1975, P NATL ACAD SCI USA, V72, P1932, DOI 10.1073/pnas.72.5.1932; SAWYERS CL, 1994, CELL, V77, P121, DOI 10.1016/0092-8674(94)90240-2; SCHER CD, 1975, NATURE, V253, P729, DOI 10.1038/253729a0; SHIELDS A, 1979, CELL, V18, P955, DOI 10.1016/0092-8674(79)90208-3; SHORE SK, 1990, P NATL ACAD SCI USA, V87, P6502, DOI 10.1073/pnas.87.17.6502; SHTIVELMAN E, 1985, NATURE, V315, P550, DOI 10.1038/315550a0; SRINIVASAN A, 1981, P NATL ACAD SCI-BIOL, V78, P2077, DOI 10.1073/pnas.78.4.2077; SRINIVASAN A, 1982, P NATL ACAD SCI-BIOL, V79, P5508, DOI 10.1073/pnas.79.18.5508; VANETTEN RA, 1989, CELL, V58, P669, DOI 10.1016/0092-8674(89)90102-5; VANETTEN RA, 1994, J CELL BIOL, V124, P325, DOI 10.1083/jcb.124.3.325; WITTE ON, 1980, NATURE, V283, P826, DOI 10.1038/283826a0; ZIEGLER SF, 1981, CELL, V27, P477, DOI 10.1016/0092-8674(81)90389-5	46	19	19	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB 1	1996	12	3					631	640						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TV597	8637720				2022-12-25	WOS:A1996TV59700020
J	Wu, SJ; Pena, A; Korcz, A; Soprano, DR; Soprano, KJ				Wu, SJ; Pena, A; Korcz, A; Soprano, DR; Soprano, KJ			Overexpression of Mxi1 inhibits the induction of the human ornithine decarboxylase gene by the Myc/Max protein complex	ONCOGENE			English	Article						Mxi1; ODC; c-myc/max; cell growth; cell cycle	C-MYC; MESSENGER-RNA; GROWTH ARREST; DNA-BINDING; TRANSCRIPTIONAL ACTIVATION; CELL-TRANSFORMATION; SENSITIVE METHOD; MAMMALIAN-CELLS; MOUSE KIDNEY; EXPRESSION	We have previously shown that the Myc/Max protein complex plays a role in the growth-associated expression of the human ornithine decarboxylase gene. Mxi1 and Mad, novel Max-associated proteins have been identified and shown to form heterodimers with Max which bind efficiently to the Myc/Max consensus recognition sequence, CACGTG, in vitro. However, formation of Max/Mxi1 or Max/Mad heterodimers results in a reduction in Myc/Max dependent transcriptional activation of reporter plasmid constructs containing the consensus element. In light of the evidence that ODC is transcriptionally regulated in vitro and in vivo by the Myc/Max protein complex and the potential role of Mxi1 and Mad as antagonists of Myc transactivation activity, we set out to determine if one of these Max associated proteins, Mxi1, could affect the regulation of ODC expression by Myc/Max and if this regulation was correlated to growth status, Our results show that overexpression of Mxi1 does in fact inhibit ODC gene expression in a dose-dependent manner both in vivo and in vitro. In addition, evidence is presented which shows that levels of Mxi1 are up-regulated during long term quiescence and down-regulated following growth stimulation by serum. These results suggest that alterations in the levels of Max-associated proteins such as Mxi1 can modulate critical levels of functional Myc/Max protein complexes. This can alter transcriptional transactivation of Myc-regulated targets and as a consequence affect levels of genes essential for initiation and/or maintenance of growth.	TEMPLE UNIV,SCH MED,DEPT MICROBIOL & IMMUNOL,PHILADELPHIA,PA 19140; TEMPLE UNIV,SCH MED,DEPT BIOCHEM,PHILADELPHIA,PA 19140; TEMPLE UNIV,SCH MED,FELS INST CANC RES & MOLEC BIOL,PHILADELPHIA,PA 19140	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University				Korcz, Aleksandra/0000-0002-9501-3343	NCI NIH HHS [CA 56309, CA 64945] Funding Source: Medline; NIDDK NIH HHS [DK 49045] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA064945, P01CA056309] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK049045] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABRAHAMSEN MS, 1990, MOL CELL BIOL, V10, P5525, DOI 10.1128/MCB.10.10.5525; ALBAROSA R, 1995, HUM GENET, V95, P709; AUGENLICHT LH, 1974, EXP CELL RES, V89, P255, DOI 10.1016/0014-4827(74)90789-7; AUVINEN M, 1992, NATURE, V360, P355, DOI 10.1038/360355a0; AYER DE, 1995, CELL, V80, P767, DOI 10.1016/0092-8674(95)90355-0; AYER DE, 1993, CELL, V72, P211, DOI 10.1016/0092-8674(93)90661-9; AYER DE, 1993, GENE DEV, V7, P2110, DOI 10.1101/gad.7.11.2110; BELLOFERNANDEZ C, 1993, P NATL ACAD SCI USA, V90, P7804, DOI 10.1073/pnas.90.16.7804; BERGER FG, 1984, J BIOL CHEM, V259, P7941; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CARTER R, 1991, ONCOGENE, V6, P229; COSENZA SC, 1988, J BIOL CHEM, V263, P12751; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; EUSTICE DC, 1991, BIOTECHNIQUES, V11, P739; FORNACE AJ, 1989, MOL CELL BIOL, V9, P4196, DOI 10.1128/MCB.9.10.4196; HALAZONETIS TD, 1991, P NATL ACAD SCI USA, V88, P6162, DOI 10.1073/pnas.88.14.6162; HOLTTA E, 1993, J CELL BIOL, V122, P903, DOI 10.1083/jcb.122.4.903; HOLTTA E, 1988, J BIOL CHEM, V263, P4500; KAHANA C, 1984, P NATL ACAD SCI-BIOL, V81, P3645, DOI 10.1073/pnas.81.12.3645; KATZ A, 1987, MOL CELL BIOL, V7, P2641, DOI 10.1128/MCB.7.7.2641; KONTULA KK, 1984, P NATL ACAD SCI-BIOL, V81, P731, DOI 10.1073/pnas.81.3.731; LAHOZ EG, 1994, P NATL ACAD SCI USA, V91, P5503, DOI 10.1073/pnas.91.12.5503; LARSSON LG, 1994, ONCOGENE, V9, P1247; LORD KA, 1990, ONCOGENE, V5, P387; LU L, 1991, BIOCHEM J, V277, P671, DOI 10.1042/bj2770671; MANZELLA JM, 1991, J BIOL CHEM, V266, P2383; MANZELLA JM, 1990, J BIOL CHEM, V265, P11817; MCCONLOGUE L, 1984, P NATL ACAD SCI-BIOL, V81, P540, DOI 10.1073/pnas.81.2.540; MOONSLEHNER K, 1991, MOL CELL BIOL, V11, P886; MOSHIER JA, 1993, CANCER RES, V53, P2618; OWEN TA, 1987, J BIOL CHEM, V262, P15111; PEGG AE, 1986, BIOCHEM J, V234, P249, DOI 10.1042/bj2340249; PEGG AE, 1988, CANCER RES, V48, P759; PENA A, 1995, J CELL PHYSIOL, V162, P234, DOI 10.1002/jcp.1041620209; PENA A, 1993, J BIOL CHEM, V268, P27277; PRENDERGAST GC, 1991, CELL, V65, P395, DOI 10.1016/0092-8674(91)90457-A; RAPPOLEE DA, 1989, J CELL BIOCHEM, V39, P1, DOI 10.1002/jcb.240390102; REDDY CD, 1992, ONCOGENE, V7, P2085; SCHNEIDER C, 1988, CELL, V54, P787, DOI 10.1016/S0092-8674(88)91065-3; SCHREIBERAGUS N, 1995, CELL, V80, P777, DOI 10.1016/0092-8674(95)90356-9; SEED B, 1988, GENE, V67, P271, DOI 10.1016/0378-1119(88)90403-9; SETH A, 1986, GENE, V42, P49, DOI 10.1016/0378-1119(86)90149-6; SISTONEN L, 1989, J CELL BIOL, V109, P1911, DOI 10.1083/jcb.109.5.1911; SISTONEN L, 1989, EMBO J, V8, P815, DOI 10.1002/j.1460-2075.1989.tb03442.x; SISTONEN L, 1987, EXP CELL RES, V168, P518, DOI 10.1016/0014-4827(87)90024-3; SOPRANO KJ, 1987, MOL CELL BIOCHEM, V75, P61, DOI 10.1007/BF00231609; SOPRANO KJ, 1994, J CELL BIOCHEM, V54, P405, DOI 10.1002/jcb.240540407; TABOR CW, 1984, ANNU REV BIOCHEM, V53, P749, DOI 10.1146/annurev.bi.53.070184.003533; THOMAS P, 1980, P NATL ACAD SCI USA, V77, P54201; WAGNER AJ, 1993, CELL GROWTH DIFFER, V4, P879; WETTERS TV, 1989, MOL CELL BIOL, V9, P5484, DOI 10.1128/MCB.9.12.5484; WETTERS TV, 1989, NUCLEIC ACIDS RES, V17, P9843, DOI 10.1093/nar/17.23.9843; ZERVOS AS, 1993, CELL, V72, P223, DOI 10.1016/0092-8674(93)90662-A	54	44	44	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB 1	1996	12	3					621	629						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TV597	8637719				2022-12-25	WOS:A1996TV59700019
J	Desaubry, L; Shoshani, N; Johnson, RA				Desaubry, L; Shoshani, N; Johnson, RA			Inhibition of adenylyl cyclase by a family of newly synthesized adenine nucleoside 3'-polyphosphates	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-MEDIATED INHIBITION; BETA-GAMMA-SUBUNITS; CYCLIC-AMP; GUANOSINE TETRAPHOSPHATE; ESCHERICHIA-COLI; ADENOSINE; BRAIN; ACID; 2',5'-DIDEOXYADENOSINE; REQUIREMENTS	The synthesis of a number of adenine nucleoside 3'-polyphosphates has been devised via a phosphotriester approach that combines the method of alkoxide activation with the use of 2,2,2-tribromoethyl phosphoromorpholinochloridate as a phosphorylating agent, The family of compounds included 3'ADP, 3'ATP, 2'-deoxy-3'ADP, 2'-deoxy-3'ATP, 2',5'-dideoxy-3'ADP, and 2',5'-dideoxy-3'ATP. Potency as inhibitors of adenylyl cyclases followed the order: 3'-mono- < 3'-di- < 3'-triphosphate and adenosine (Ado) < 2'-d-Ado < 2',5'-dd-Ado derivatives, with 2',5'-dideoxy-3'ATP exhibiting an IC50 of similar to 40 nM. This order was maintained with purified and recombinant forms of the type I enzyme, The nucleoside 3'-phosphates caused noncompetitive inhibition of the type I adenylyl cyclase from bovine brain, consistent with inhibition via the P-site, Inhibition was not due to hydrolytic products because this was minimal and inhibition kinetics by inorganic polyphosphates were inconsistent with those caused by the nucleoside 3'-polyphosphates. Only 3'ATP underwent cation-catalyzed, nonenzymatic hydrolysis, with the primary product being 2':3'-cAMP. Because 3'-ADP and 3'-ATP are naturally occurring, this class of compounds may physiologically regulate adenylyl cyclases and possibly other enzymes, mediating responses that include a reduction in 3':5'-cAMP levels and consequent reductions in protein kinase A-activated pathways.	SUNY STONY BROOK, HLTH SCI CTR, DEPT PHYSIOL & BIOPHYS, STONY BROOK, NY 11794 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook			Desaubry, Laurent G/R-5446-2017	Desaubry, Laurent G/0000-0002-1192-2970	NIDDK NIH HHS [DK38828] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK038828] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BEAVO JA, 1995, PHYSIOL REV, V75, P725, DOI 10.1152/physrev.1995.75.4.725; BENNETT GN, 1976, BIOCHEMISTRY-US, V15, P4623, DOI 10.1021/bi00666a012; BUSHFIELD M, 1990, MOL PHARMACOL, V38, P848; CASHEL M, 1969, J BIOL CHEM, V244, P3133; CASHEL M, 1996, ESCHERICHIA COLI S T; CHARUBALA R, 1981, HETEROCYCLES, V15, P761; CHASHEL M, 1969, NATURE, V221, P838, DOI 10.1038/221838a0; CLAUS TH, 1982, MOL CELL ENDOCRINOL, V26, P269, DOI 10.1016/0303-7207(82)90116-2; COOK PN, 1995, BIOCHEM PHARMACOL, V49, P1043, DOI 10.1016/0006-2952(95)98499-Y; DENHARTOG JAJ, 1981, RECL TRAV CHIM PAY B, V100, P317; DESAUBRY L, 1995, NUCLEOS NUCLEOT, V14, P1453, DOI 10.1080/15257779508010705; Desaubry L, 1996, J BIOL CHEM, V271, P2380, DOI 10.1074/jbc.271.5.2380; DESOUZA NJ, 1993, J ETHNOPHARMACOL, V38, P177, DOI 10.1016/0378-8741(93)90014-V; DILLINGHAM MA, 1985, J MEMBRANE BIOL, V88, P277, DOI 10.1007/BF01871091; FAIN JN, 1972, J BIOL CHEM, V247, P6866; FLORIO VA, 1983, MOL PHARMACOL, V24, P195; FRANCIS SH, 1994, ANNU REV PHYSIOL, V56, P237, DOI 10.1146/annurev.ph.56.030194.001321; GARBERS DL, 1975, J BIOL CHEM, V250, P8449; GARTNER R, 1985, MOL CELL ENDOCRINOL, V42, P145, DOI 10.1016/0303-7207(85)90102-9; GREGA DS, 1987, J NEUROSCI, V7, P700; HAMEL E, 1975, BIOCHEMISTRY-US, V14, P5055, DOI 10.1021/bi00694a004; HASELTINE WA, 1973, P NATL ACAD SCI USA, V70, P1564, DOI 10.1073/pnas.70.5.1564; HASLAM RJ, 1972, LIFE SCI 2-BIOCH GEN, V11, P1143, DOI 10.1016/0024-3205(72)90269-X; HASLAM RJ, 1978, BIOCHEM J, V176, P83, DOI 10.1042/bj1760083; JOHNSON RA, 1977, ARCH BIOCHEM BIOPHYS, V183, P216, DOI 10.1016/0003-9861(77)90435-0; JOHNSON RA, 1980, J BIOL CHEM, V255, P8252; JOHNSON RA, 1989, MOL PHARMACOL, V35, P681; JOHNSON RA, 1990, J BIOL CHEM, V265, P11595; JOHNSON RA, 1979, J BIOL CHEM, V254, P1094; JOHNSON RA, 1977, RECEPTORS HORMONE AC, V1, P549; JOHNSON RA, 1994, CAN J PHYSL PHARM S1, V72, P511; JOHNSON RW, 1990, BEHAVIORAL ASPECTS A, P43; JOSSE J, 1965, BIOCHEMISTRY-US, V4, P2825, DOI 10.1021/bi00888a037; KOESLING D, 1991, FASEB J, V5, P2785, DOI 10.1096/fasebj.5.13.1680765; KOZARICH JW, 1975, BIOCHEMISTRY-US, V14, P981, DOI 10.1021/bi00676a017; KRUPINSKI J, 1989, SCIENCE, V244, P1558, DOI 10.1126/science.2472670; LONDOS C, 1977, P NATL ACAD SCI USA, V74, P5482, DOI 10.1073/pnas.74.12.5482; MCKENZIE SG, 1973, CAN J PHYSIOL PHARM, V51, P190, DOI 10.1139/y73-027; MITCHEL REJ, 1967, CAN J BIOCHEM CELL B, V45, P89, DOI 10.1139/o67-010; PFEUFFER E, 1985, EMBO J, V4, P3675, DOI 10.1002/j.1460-2075.1985.tb04134.x; REID IR, 1990, AM J PHYSIOL, V258, pE708, DOI 10.1152/ajpendo.1990.258.4.E708; RHAESE HJ, 1976, EUR J BIOCHEM, V64, P205, DOI 10.1111/j.1432-1033.1976.tb10289.x; RHAESE HJ, 1975, FEBS LETT, V53, P113, DOI 10.1016/0014-5793(75)80696-X; RHAESE HJ, 1974, FEBS LETT, V44, P87, DOI 10.1016/0014-5793(74)80312-1; SCHATTENKERK C, 1985, NUCLEIC ACIDS RES, V13, P3635, DOI 10.1093/nar/13.10.3635; SCHATTENKERK C, 1983, NUCLEIC ACIDS RES, V11, P7545, DOI 10.1093/nar/11.21.7545; SEGAL IH, 1975, ENZYME KINETICS, P125; SIMONCSITS A, 1974, BIOCHIM BIOPHYS ACTA, V340, P509, DOI 10.1016/0005-2787(74)90071-9; STUBNER D, 1989, FEBS LETT, V248, P155, DOI 10.1016/0014-5793(89)80452-1; SY J, 1973, P NATL ACAD SCI USA, V70, P306, DOI 10.1073/pnas.70.2.306; SY J, 1973, P NATL ACAD SCI USA, V70, P2145, DOI 10.1073/pnas.70.7.2145; TANG WJ, 1995, BIOCHEMISTRY-US, V34, P14563, DOI 10.1021/bi00044a035; TANG WJ, 1995, SCIENCE, V268, P1769, DOI 10.1126/science.7792604; TANG WJ, 1991, SCIENCE, V254, P1500, DOI 10.1126/science.1962211; TANG WJ, 1991, J BIOL CHEM, V266, P8595; TAUSSIG R, 1993, J BIOL CHEM, V268, P9; TI GS, 1982, J AM CHEM SOC, V104, P1316, DOI 10.1021/ja00369a029; UCHIYAMA M, 1993, J ORG CHEM, V58, P373, DOI 10.1021/jo00054a020; VANBOOM JH, 1977, NUCLEIC ACIDS RES, V4, P1047, DOI 10.1093/nar/4.4.1047; VANBOOM JH, 1975, TETRAHEDRON LETT, P2779; WEINRYB I, 1974, BIOCHIM BIOPHYS ACTA, V334, P218, DOI 10.1016/0005-2744(74)90165-X; WILSON DK, 1993, P NATL ACAD SCI USA, V90, P9847, DOI 10.1073/pnas.90.21.9847; WOLFF J, 1981, ADV CYCL NUCL RES<D>, V14, P199; YEUNG SMH, 1990, J BIOL CHEM, V265, P16745	64	48	51	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 14	1996	271	24					14028	14034		10.1074/jbc.271.24.14028	http://dx.doi.org/10.1074/jbc.271.24.14028			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UQ660	8662735	hybrid			2022-12-25	WOS:A1996UQ66000017
J	Obin, MS; JahngenHodge, J; Nowell, T; Taylor, A				Obin, MS; JahngenHodge, J; Nowell, T; Taylor, A			Ubiquitinylation and ubiquitin-dependent proteolysis in vertebrate photoreceptors (rod outer segments) - Evidence for ubiquitinylation of G(t) and rhodopsin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBOXYL-TERMINAL HYDROLASE; RETINITIS-PIGMENTOSA; PROTEIN BREAKDOWN; SYSTEM; PURIFICATION; DEGRADATION; RESOLUTION; PATHWAY; CHAINS; PHOTOTRANSDUCTION	In corroboration of the hypothesized regulation of phototransduction proteins by the ubiquitin-dependent pathway, we identified free ubiquitin (8 kDa) and ubiquitin-protein conjugates (50 to >200 kDa; pi 5.3-6.8 by two-dimensional electrophoresis) in bovine rod outer segments (ROS). A 38-kDa ubiquitinylated protein and transducin (G(t)) were eluted together from light-adapted ROS membranes with GTP. When ROS were dark-adapted, this 38-kDa ubiquitinylated species and G, were readily solubilized in buffer lacking GTP, These data are consistent with ubiquitinylation of G(t) and corroborate previous cell-free experiments identifying G(t) as a substrate for ubiquitin-dependent proteolysis (Obin, M. S,, Nowell, T,, and Taylor, A. (1994) Biochem. Biophys. Res, Commun. 200, 1169-1176). Evidence for ubiquitinylation of rhodopsin (36 kDa), the (photo)receptor coupled to G(t), included (i) the presence in ROS membranes ''stripped'' of peripheral membrane proteins of numerous ubiquitin-protein conjugates, including two whose masses (44 and 50 kDa) are consistent with mono- and diubiquitinylated rhodopsin; (ii) catalysis by permeabilized ROS of I-125-labeled ubiquitin-protein conjugates whose masses (42, 50, and 58 kDa) suggest a ''ladder'' of mono-, di-, and triubiquitinylated rhodopsin; (iii) parallel mobility shifts on SDS-polyacrylamide gels of rhodopsin and these I-125-labeled ubiquitin-protein conjugates; and (iv) generation of enhanced levels of I-125-labeled ubiquitin-protein conjugates when stripped, detergent-solubilized ROS membranes (95% rhodopsin) were incubated with reticulocyte lysate. A functional ubiquitin-dependent pathway in ROS is demonstrated by the presence of (i) the ubiquitin-activating enzyme (El); (ii) four ubiquitin carrier proteins (E2(14K), E2(20K), E2(25K), and E2(35K)) and pronounced activity of E2(14K), an enzyme required for ''N-end rule'' proteolysis; (iii) ATP-dependent 26 S proteasome activity that rapidly degrades high mass I-125-labeled ubiquitin-ROS protein conjugates; and (iv) distinct ubiquitin C-terminal isopeptidase/hydrolase activities, including potent ubiquitin-aldehyde-insensitive activity directed at high mass ubiquitinylated moieties, Considered together, the data support a novel role for the ubiquitin-dependent pathway in the regulation of mammalian phototransduction protein levels and/or activities and provide the first identification of a non-calpain proteolytic system in photoreceptors.	TUFTS UNIV, USDA, JMHNRCA, LAB NUTR & VIS RES, BOSTON, MA 02111 USA	Tufts University; United States Department of Agriculture (USDA)					PHS HHS [8566] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		AZARIAN SM, 1995, J BIOL CHEM, V270, P24375, DOI 10.1074/jbc.270.41.24375; BIZZI A, 1991, BRAIN RES, V548, P292, DOI 10.1016/0006-8993(91)91135-N; Bok D., 1979, RETINAL PIGMENT EPIT, P148; BONFANTI L, 1992, J COMP NEUROL, V322, P35, DOI 10.1002/cne.903220104; CHABRE M, 1989, EUR J BIOCHEM, V179, P255, DOI 10.1111/j.1432-1033.1989.tb14549.x; CHEN ZJ, 1990, J BIOL CHEM, V265, P21835; CIECHANOVER A, 1978, BIOCHEM BIOPH RES CO, V81, P1100, DOI 10.1016/0006-291X(78)91249-4; CIECHANOVER A, 1994, FASEB J, V8, P182, DOI 10.1096/fasebj.8.2.8119489; DRYJA TP, 1991, P NATL ACAD SCI USA, V88, P9370, DOI 10.1073/pnas.88.20.9370; DUBIEL W, 1993, FEBS LETT, V323, P276, DOI 10.1016/0014-5793(93)81356-5; DUNTEN RL, 1989, J BIOL CHEM, V264, P16739; FAIN GL, 1993, EXP EYE RES, V57, P335, DOI 10.1006/exer.1993.1132; FARBER DB, 1988, EXP EYE RES, V46, P363, DOI 10.1016/S0014-4835(88)80026-5; FEENEY L, 1973, INVEST OPHTH VISUAL, V12, P635; FINLEY D, 1991, ANNU REV CELL BIOL, V7, P25, DOI 10.1146/annurev.cb.07.110191.000325; GONDA DK, 1989, J BIOL CHEM, V264, P16700; HAAS AL, 1995, J BIOL CHEM, V270, P9407, DOI 10.1074/jbc.270.16.9407; HAAS AL, 1988, J BIOL CHEM, V263, P13258; HAAS AL, 1988, UBIQUITIN, P173; HADARI T, 1992, J BIOL CHEM, V267, P719; HALDEMAN MT, 1995, J BIOL CHEM, V270, P9507, DOI 10.1074/jbc.270.16.9507; HARA S, 1983, EXP EYE RES, V36, P799, DOI 10.1016/0014-4835(83)90034-9; HARGRAVE PA, 1992, FASEB J, V6, P2323, DOI 10.1096/fasebj.6.6.1544542; HARGRAVE PA, 1994, REGULATION CELLULAR, P25; HERSHKO A, 1980, P NATL ACAD SCI-BIOL, V77, P1783, DOI 10.1073/pnas.77.4.1783; HERSHKO A, 1983, J BIOL CHEM, V258, P8206; HERSHKO A, 1987, P NATL ACAD SCI USA, V84, P1829, DOI 10.1073/pnas.84.7.1829; HERSHKO A, 1992, ANNU REV BIOCHEM, V61, P761, DOI 10.1146/annurev.bi.61.070192.003553; HOU D, 1994, J BIOL CHEM, V269, P14244; HOUGH R, 1986, J BIOL CHEM, V261, P2391; HUANG HV, 1973, FEBS LETT, V37, P285, DOI 10.1016/0014-5793(73)80479-X; HUANG LL, 1995, EXP EYE RES, V61, P45, DOI 10.1016/S0014-4835(95)80057-3; JOHNSTON NL, 1991, BIOCHEMISTRY-US, V30, P7514, DOI 10.1021/bi00244a021; KAWAMURA S, 1993, J BIOL CHEM, V268, P14579; KLEMPERER NS, 1989, BIOCHEMISTRY-US, V28, P6035, DOI 10.1021/bi00440a047; KOCH KW, 1988, NATURE, V334, P64, DOI 10.1038/334064a0; KOLESNIKOV SS, 1995, NATURE, V376, P85, DOI 10.1038/376085a0; KOLLING R, 1994, EMBO J, V13, P3261, DOI 10.1002/j.1460-2075.1994.tb06627.x; KORNITZER D, 1994, EMBO J, V13, P6021, DOI 10.1002/j.1460-2075.1994.tb06948.x; Koutalos Y, 1993, Curr Opin Neurobiol, V3, P513, DOI 10.1016/0959-4388(93)90049-5; KUHN H, 1980, NATURE, V283, P587, DOI 10.1038/283587a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE RH, 1992, J BIOL CHEM, V267, P25104; LOETSCHER P, 1991, J BIOL CHEM, V266, P11213; MA CP, 1994, J BIOL CHEM, V269, P3539; MADURA K, 1994, SCIENCE, V265, P1454, DOI 10.1126/science.8073290; MCLAUGHLIN ME, 1993, NAT GENET, V4, P130, DOI 10.1038/ng0693-130; MOLDAY RS, 1983, BIOCHEMISTRY-US, V22, P653, DOI 10.1021/bi00272a020; MOLDAY RS, 1987, INVEST OPHTH VIS SCI, V28, P50; MOLDAY RS, 1993, METH NEUROSCI, V15, P131; MURA CV, 1993, CURR EYE RES, V12, P1081, DOI 10.3109/02713689309033506; NAASH M, 1991, J NEUROSCI RES, V30, P433, DOI 10.1002/jnr.490300220; NAASH M, 1990, THESIS BAYLOR COLL M; NAASH M, 1991, INVEST OPHTHALMOL  S, V31, P293; OBIN M, 1995, CURR EYE RES, V14, P751, DOI 10.3109/02713689508995796; OBIN M, 1994, BIOCHEM BIOPH RES CO, V200, P1169, DOI 10.1006/bbrc.1994.1574; OFARRELL PZ, 1977, CELL, V12, P1133, DOI 10.1016/0092-8674(77)90176-3; PAPERMASTER DS, 1995, INVEST OPHTH VIS SCI, V36, P977; PETERS JM, 1994, TRENDS BIOCHEM SCI, V19, P377, DOI 10.1016/0968-0004(94)90115-5; PICKART CM, 1985, J BIOL CHEM, V260, P1573; PORTERACAILLIAU C, 1994, P NATL ACAD SCI USA, V91, P974, DOI 10.1073/pnas.91.3.974; RECHSTEINER M, 1991, CELL, V66, P615, DOI 10.1016/0092-8674(91)90104-7; RECHSTEINER M, 1993, J BIOL CHEM, V268, P6065; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; Rose I. A., 1988, UBIQUITIN, P135; SALESSE C, 1984, ANAL BIOCHEM, V142, P258, DOI 10.1016/0003-2697(84)90462-7; SEMPLEROWLAND SL, 1991, ELECTROPHORESIS, V12, P307, DOI 10.1002/elps.1150120414; SHANG F, 1995, BIOCHEM J, V307, P297, DOI 10.1042/bj3070297; SHANKLIN J, 1987, P NATL ACAD SCI USA, V84, P359, DOI 10.1073/pnas.84.2.359; STRADER CD, 1995, FASEB J, V9, P745, DOI 10.1096/fasebj.9.9.7601339; SUNG CH, 1993, J BIOL CHEM, V268, P26645; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9; VANNOCKER S, 1993, J BIOL CHEM, V268, P24766; WEISS ER, 1994, BIOCHEMISTRY-US, V33, P7587, DOI 10.1021/bi00190a011; WIEBEL FF, 1992, NATURE, V359, P73, DOI 10.1038/359073a0; WILKINSON KD, 1989, SCIENCE, V246, P670, DOI 10.1126/science.2530630; WING SS, 1995, BIOCHEM J, V305, P125, DOI 10.1042/bj3050125; WITT PL, 1987, BIOCHEMISTRY-US, V26, P1769, DOI 10.1021/bi00380a040; WOO SK, 1995, J BIOL CHEM, V270, P18766, DOI 10.1074/jbc.270.32.18766; YARFITZ S, 1994, J BIOL CHEM, V269, P14329	80	73	73	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 14	1996	271	24					14473	14484		10.1074/jbc.271.24.14473	http://dx.doi.org/10.1074/jbc.271.24.14473			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UQ660	8662797	hybrid			2022-12-25	WOS:A1996UQ66000079
J	Faiman, GA; Levy, R; Anglister, J; Horovitz, A				Faiman, GA; Levy, R; Anglister, J; Horovitz, A			Contribution of arginine residues in the RP135 peptide derived from the V3 loop of gp120 to its interaction with the Fv fragment of the 0.5 beta HIV-1 neutralizing antibody	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; MONOCLONAL-ANTIBODY; ESCHERICHIA-COLI; PROTEIN; EXPRESSION; ANTIGEN; COOPERATIVITY; CHIMPANZEES; DETERMINANT; SEQUENCE	The construction, expression, and purification of an active Fv fragment of the 0.5 beta monoclonal human immunodeficiency virus type 1 (HIV-1) neutralizing antibody is reported, The interaction between the Fv fragment and the RP135 peptide derived from the V3 loop of gp120 from HIV-1(IIIB) was studied by varying the salt concentration and by mutating arginine residues in the peptide, The mutations R4A, R8A and R11A (which correspond to residues 311, 315, and 318 in gp120 of HIV-1(IIIB)) reduce the binding free energy by 0.22 (+/- 0.20), 4.32 (+/- 0.16), and 1.58 (+/- 0.17) kcal mol(-1), respectively. The salt-dependent components of their contributions to binding are 0.02 (+/- 0.22), -0.55 (+/- 0.18), and -0.97 (+/- 0.19) kcal mol(-1), respectively. The magnitudes of the mutational effects and the extent of shielding by 1 M NaCl suggest that Arg-8 is involved in a buried salt bridge in the peptide-Fv fragment complex, whereas Arg-11 is involved in a more solvent-exposed electrostatic interaction.	WEIZMANN INST SCI, DEPT BIOL STRUCT, IL-76100 REHOVOT, ISRAEL	Weizmann Institute of Science								ANDERSON DE, 1990, BIOCHEMISTRY-US, V29, P2403, DOI 10.1021/bi00461a025; BETTER M, 1988, SCIENCE, V240, P1041, DOI 10.1126/science.3285471; BIRD RE, 1988, SCIENCE, V242, P423, DOI 10.1126/science.3140379; EMINI EA, 1992, NATURE, V355, P728, DOI 10.1038/355728a0; GHIARA JB, 1994, SCIENCE, V264, P82, DOI 10.1126/science.7511253; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; GOUDSMIT J, 1988, P NATL ACAD SCI USA, V85, P4478, DOI 10.1073/pnas.85.12.4478; HOROVITZ A, 1990, J MOL BIOL, V214, P613, DOI 10.1016/0022-2836(90)90275-Q; HOROVITZ A, 1990, J MOL BIOL, V216, P1031, DOI 10.1016/S0022-2836(99)80018-7; HUSTON JS, 1988, P NATL ACAD SCI USA, V85, P5879, DOI 10.1073/pnas.85.16.5879; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAROSA GJ, 1990, SCIENCE, V249, P932, DOI 10.1126/science.2392685; MARASCO WA, 1993, P NATL ACAD SCI USA, V90, P7889, DOI 10.1073/pnas.90.16.7889; MATSUSHITA S, 1988, J VIROL, V62, P2107, DOI 10.1128/JVI.62.6.2107-2114.1988; MATSUSHITA S, 1992, AIDS RES HUM RETROV, V8, P1107, DOI 10.1089/aid.1992.8.1107; MEAD DA, 1986, PROTEIN ENG, V1, P67, DOI 10.1093/protein/1.1.67; NOVOTNY J, 1992, PROG BIOPHYS MOL BIO, V58, P203, DOI 10.1016/0079-6107(92)90006-R; OKADA T, 1994, AIDS RES HUM RETROV, V10, P803, DOI 10.1089/aid.1994.10.803; ORLANDI R, 1989, P NATL ACAD SCI USA, V86, P3833, DOI 10.1073/pnas.86.10.3833; PALKER TJ, 1988, P NATL ACAD SCI USA, V85, P1932, DOI 10.1073/pnas.85.6.1932; RIECHMANN L, 1991, FEBS LETT, V287, P185, DOI 10.1016/0014-5793(91)80047-7; RIECHMANN L, 1988, J MOL BIOL, V203, P825, DOI 10.1016/0022-2836(88)90214-8; RINI JM, 1993, P NATL ACAD SCI USA, V90, P6325, DOI 10.1073/pnas.90.13.6325; SAYERS JR, 1988, NUCLEIC ACIDS RES, V16, P791, DOI 10.1093/nar/16.3.791; SKERRA A, 1993, CURR OPIN IMMUNOL, V5, P256, DOI 10.1016/0952-7915(93)90014-J; SKERRA A, 1988, SCIENCE, V240, P1038, DOI 10.1126/science.3285470; SKINNER MA, 1988, AIDS RES HUM RETROV, V4, P187, DOI 10.1089/aid.1988.4.187; SNYDER SL, 1975, ANAL BIOCHEM, V64, P284, DOI 10.1016/0003-2697(75)90431-5; WINTER G, 1991, NATURE, V349, P293, DOI 10.1038/349293a0; ZVI A, 1992, BIOCHEMISTRY-US, V31, P6972, DOI 10.1021/bi00145a015; ZVI A, 1995, EUR J BIOCHEM, V229, P178, DOI 10.1111/j.1432-1033.1995.tb20453.x	31	16	16	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 7	1996	271	23					13829	13833		10.1074/jbc.271.23.13829	http://dx.doi.org/10.1074/jbc.271.23.13829			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UP385	8662780	hybrid			2022-12-25	WOS:A1996UP38500079
J	Kukimoto, M; Nishiyama, M; Tanokura, M; Adman, ET; Horinouchi, S				Kukimoto, M; Nishiyama, M; Tanokura, M; Adman, ET; Horinouchi, S			Studies on protein-protein interaction between copper-containing nitrite reductase and pseudoazurin from Alcaligenes faecalis S-6	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; ACHROMOBACTER-CYCLOCLASTES; PSEUDOMONAS-AUREOFACIENS; ESCHERICHIA-COLI; STRAIN S-6; SITE; PURIFICATION; MUTAGENESIS; RESOLUTION; CENTERS	Site-directed mutagenesis of a copper-containing nitrite reductase (NIR) from Alcaligenes faecalis S-6 was carried out to identify the amino acid residues involved in interaction with its redox partner, pseudoazurin, in which four positively charged residues were previously shown to be important in the interaction, Ten negatively charged residues located on the surface of NIR were replaced independently by alanine or serine, All the altered NIRs showed CHI spectra and optical spectra identical to those of wild-type NIR, suggesting that all the replacements caused no gross change in the overall structure or in the environment of type 1 copper site, Kinetic analysis of electron transfer between pseudoazurin and altered NIRs revealed that the replacement of Glu-118, Glu-197, Asp-201, Glu-204, or Asp-205 by Ala caused. a significant increase in the K-m value for pseudoazurin compared with that of wild-type NIR. Furthermore, the simultaneous replacement of three of these residues (Glu-118, Glu-197, and Asp-201) caused a further increase in the K-m value. These results suggested that time negatively charged residues are involved in electrostatic interaction with pseudoazurin, Kinetic analyses of the altered NIRs (E118A, E197A, or D201A) with altered pseudoazurins (K10A, K57A, or K77A) implicate specific pairs of the charged residues that are involved in electrostatic interaction between NIR and pseudoazurin.	UNIV TOKYO,BIOTECHNOL RES CTR,BUNKYO KU,TOKYO 113,JAPAN; UNIV TOKYO,DEPT BIOTECHNOL,BUNKYO KU,TOKYO 113,JAPAN; UNIV WASHINGTON,DEPT BIOL STRUCT,SEATTLE,WA 98195	University of Tokyo; University of Tokyo; University of Washington; University of Washington Seattle			Kukimoto-Niino, Mutsuko/C-6704-2017	Kukimoto-Niino, Mutsuko/0000-0002-4178-1611; Nishiyama, Makoto/0000-0001-8143-8052; Tanokura, Masaru/0000-0001-5072-2480	NIGMS NIH HHS [GM31770] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031770] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAHAM ZHL, 1993, BIOCHEM J, V295, P587, DOI 10.1042/bj2950587; ADMAN ET, 1989, J BIOL CHEM, V264, P87; BAKER EN, 1988, J MOL BIOL, V203, P1071, DOI 10.1016/0022-2836(88)90129-5; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Cleland W W, 1979, Methods Enzymol, V63, P103; DEREGE PJF, 1995, SCIENCE, V269, P1409, DOI 10.1126/science.7660123; DODD FE, 1995, BIOCHEMISTRY-US, V34, P10180, DOI 10.1021/bi00032a011; FENDERSON FF, 1991, BIOCHEMISTRY-US, V30, P7180, DOI 10.1021/bi00243a020; GLOCKNER AB, 1993, ARCH MICROBIOL, V160, P18; GODDEN JW, 1991, SCIENCE, V253, P438, DOI 10.1126/science.1862344; HORMEL S, 1986, FEBS LETT, V197, P301, DOI 10.1016/0014-5793(86)80346-5; IWASAKI H, 1972, J BIOCHEM, V71, P645; IWASAKI Y, 1992, ELECTROANAL, V4, P771, DOI 10.1002/elan.1140040806; IWATA S, 1995, NATURE, V376, P660, DOI 10.1038/376660a0; KAKUTANI T, 1981, J BIOCHEM-TOKYO, V89, P463, DOI 10.1093/oxfordjournals.jbchem.a133221; KAKUTANI T, 1981, AGR BIOL CHEM TOKYO, V45, P23, DOI 10.1080/00021369.1981.10864492; KAKUTANI T, 1981, J BIOCHEM, V89, P453, DOI 10.1093/oxfordjournals.jbchem.a133220; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KUKIMOTO M, 1995, PROTEIN ENG, V8, P153, DOI 10.1093/protein/8.2.153; KUKIMOTO M, 1994, BIOCHEMISTRY-US, V33, P5246, DOI 10.1021/bi00183a030; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIBBY E, 1992, BIOCHEM BIOPH RES CO, V187, P1529, DOI 10.1016/0006-291X(92)90476-2; LIU MY, 1986, J BACTERIOL, V166, P604, DOI 10.1128/jb.166.2.604-608.1986; MESSING J, 1982, GENE, V19, P269, DOI 10.1016/0378-1119(82)90016-6; NISHIYAMA M, 1993, J GEN MICROBIOL, V139, P725, DOI 10.1099/00221287-139-4-725; NISHIYAMA M, 1992, PROTEIN ENG, V5, P177, DOI 10.1093/protein/5.2.177; NORGARD MV, 1978, GENE AMST, V3, P379; PETRATOS K, 1987, FEBS LETT, V218, P209, DOI 10.1016/0014-5793(87)81048-7; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; YAMAMOTO K, 1987, J BACTERIOL, V169, P5648, DOI 10.1128/jb.169.12.5648-5652.1987; ZUMFT WG, 1987, EUR J BIOCHEM, V168, P301, DOI 10.1111/j.1432-1033.1987.tb13421.x	32	52	52	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 7	1996	271	23					13680	13683		10.1074/jbc.271.23.13680	http://dx.doi.org/10.1074/jbc.271.23.13680			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UP385	8662745	hybrid			2022-12-25	WOS:A1996UP38500058
J	Lokuta, MA; Maher, J; Noe, KH; Pitha, PM; Shin, ML; Shin, HS				Lokuta, MA; Maher, J; Noe, KH; Pitha, PM; Shin, ML; Shin, HS			Mechanisms of murine RANTES chemokine gene induction by Newcastle disease virus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INFLAMMATORY PROTEIN 1-ALPHA; TRANSCRIPTION FACTOR; CYTOKINE RANTES; CHROMOSOMAL-PROTEINS; INTERFERON; ACTIVATION; EXPRESSION; CELLS; DNA; IDENTIFICATION	We have previously defined the lipopolysaccharide (LPS)-responsive element (LRE) in the promoters of murine RANTES (regulated on activation normal T-cell expressed) (MuRantes) and murine IP-10/crg-2, chemokines which have potent chemotactic properties for inflammatory cells including monocytes and T lymphocytes. In the present work, we studied the transcriptional mechanism of MuRantes gene induction by virus and compared it with that of LPS in an effort to understand the host responses to virus and bacterial toxins at the molecular level, MuRantes mRNA expression is induced by Newcastle disease virus (NDV) and LPS in the RAW 264.7 macrophage cell line and peritoneal macrophages of LPS-responsive C3HeB/FeJ mice. Tn LPS-hyporesponsive C3H/HeJ mice, only NDV induces this chemokine gene, indicating that the pathways of transcriptional activation by NDV and LPS are not identical. Using a transient transfection assay, the minimal virus-responsive element (VRE) was localized between nt -175 and -116. The VRE contains previously defined LRE motif 1 (TCAYRCTT) and motif 3 ((T/A)GRTT-TCA(G/C)TTT), which were shown to also be important for initiation of transcription by virus. NDV-stimulated nuclear extracts were tested for trans activating factors able to bind the VRE, The chromosomal protein HMG-I(C) was shown to bind the 3'-A-T-rich domains of the VRE, and the presence of HMG-I(C) was demonstrated in the VRE-protein complex formed with nuclear extracts from NDV-stimulated, but not unstimulated cells. These findings demonstrate the role of HMG-I(C) in activation of MuRantes promoter by NDV.	UNIV MARYLAND,SCH MED,DEPT PATHOL,BALTIMORE,MD 21201; JOHNS HOPKINS UNIV,SCH MED,DEPT MOLEC BIOL & GENET,BALTIMORE,MD 21205	University System of Maryland; University of Maryland Baltimore; Johns Hopkins University					NCI NIH HHS [R01 CA1411320] Funding Source: Medline; NIAID NIH HHS [R01 AI19622] Funding Source: Medline; NINDS NIH HHS [R01 NS 15662] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA014113] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI019622] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS015662] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ABDELHAFIZ HAM, 1993, ONCOGENE, V8, P1161; AU WC, 1992, NUCLEIC ACIDS RES, V20, P2877, DOI 10.1093/nar/20.11.2877; AZNAR C, 1990, Cytokine, V2, P259, DOI 10.1016/1043-4666(90)90026-P; BUSTIN M, 1990, BIOCHIM BIOPHYS ACTA, V1049, P231, DOI 10.1016/0167-4781(90)90092-G; CHATTON B, 1993, MOL CELL BIOL, V13, P561, DOI 10.1128/MCB.13.1.561; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; Drysdale B E, 1986, Methods Enzymol, V132, P549; DU W, 1993, CELL, V74, P887, DOI 10.1016/0092-8674(93)90468-6; EINCK L, 1985, EXP CELL RES, V156, P295, DOI 10.1016/0014-4827(85)90539-7; ELTON TS, 1987, BIOCHEM BIOPH RES CO, V143, P260, DOI 10.1016/0006-291X(87)90659-0; Fisher SN, 1995, BRAIN BEHAV IMMUN, V9, P331, DOI 10.1006/brbi.1995.1031; FISHER SN, 1994, J IMMUNOL, V153, P3210; Galinski M.S., 1991, PARAMYXOVIRUSES, P41; GIANCOTTI V, 1991, EUR J BIOCHEM, V198, P211, DOI 10.1111/j.1432-1033.1991.tb16003.x; GIESE K, 1992, CELL, V69, P185, DOI 10.1016/0092-8674(92)90129-Z; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRILLI M, 1993, INT REV CYTOL, V143, P1; HIDAKA H, 1984, BIOCHEMISTRY-US, V23, P5036, DOI 10.1021/bi00316a032; LAMB P, 1991, TRENDS BIOCHEM SCI, V16, P417, DOI 10.1016/0968-0004(91)90167-T; LIEBERMAN AP, 1989, P NATL ACAD SCI USA, V86, P6348, DOI 10.1073/pnas.86.16.6348; Liou HC, 1993, CURR OPIN CELL BIOL, V5, P477, DOI 10.1016/0955-0674(93)90014-H; LIU F, 1990, CELL, V61, P1217, DOI 10.1016/0092-8674(90)90686-9; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MANFIOLETTI G, 1991, NUCLEIC ACIDS RES, V19, P6793, DOI 10.1093/nar/19.24.6793; MARFAINGKOKA A, 1995, J IMMUNOL, V154, P1870; MEURER R, 1993, J EXP MED, V178, P1913, DOI 10.1084/jem.178.6.1913; Nagai Y, 1989, Prog Vet Microbiol Immunol, V5, P16; NELSON PJ, 1993, J IMMUNOL, V151, P2601; OHNO S, 1983, NUCLEIC ACIDS RES, V11, P5403, DOI 10.1093/nar/11.16.5403; RAJ NBK, 1991, J BIOL CHEM, V266, P11360; RATHANASWAMI P, 1993, J BIOL CHEM, V268, P5834; ROSENSTREICH DL, 1985, CELLULAR BIOL ENDOTO, P82; ROT A, 1992, J EXP MED, V176, P1489, DOI 10.1084/jem.176.6.1489; ROULSTON A, 1993, J VIROL, V67, P5235, DOI 10.1128/JVI.67.9.5235-5246.1993; RUS HG, 1992, J IMMUNOL, V148, P928; Sambrook J., 2002, MOL CLONING LAB MANU; SCHALL TJ, 1990, NATURE, V347, P669, DOI 10.1038/347669a0; SHIN HS, 1994, MOL CELL BIOL, V14, P2914, DOI 10.1128/MCB.14.5.2914; SHIN ML, 1993, NEUROBIOLOGY CYTOK B, P16; STARR DB, 1991, CELL, V67, P1231, DOI 10.1016/0092-8674(91)90299-E; STEIN B, 1993, EMBO J, V12, P3879, DOI 10.1002/j.1460-2075.1993.tb06066.x; TANAKA N, 1992, ADV IMMUNOL, V52, P263, DOI 10.1016/S0065-2776(08)60877-9; TANIGUCHI T, 1988, ANNU REV IMMUNOL, V6, P439, DOI 10.1146/annurev.iy.06.040188.002255; THANOS D, 1992, CELL, V71, P777, DOI 10.1016/0092-8674(92)90554-P; VANDAM H, 1993, EMBO J, V12, P479, DOI 10.1002/j.1460-2075.1993.tb05680.x; VANGURI P, 1994, J IMMUNOL, V152, P1411; VANGURI P, 1990, J BIOL CHEM, V265, P15049; WOLF G, 1993, KIDNEY INT, V44, P795, DOI 10.1038/ki.1993.314; ZAWATZKY R, 1991, PATHOBIOLOGY, V59, P232, DOI 10.1159/000163652	49	32	32	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 7	1996	271	23					13731	13738		10.1074/jbc.271.23.13731	http://dx.doi.org/10.1074/jbc.271.23.13731			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UP385	8662857	hybrid			2022-12-25	WOS:A1996UP38500065
J	MacDonald, RJ; SouthardSmith, EM; Kroon, E				MacDonald, RJ; SouthardSmith, EM; Kroon, E			Disparate tissue-specific expression of members of the tissue kallikrein multigene family of the rat	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; GENE FAMILY; MESSENGER-RNA; SUBMAXILLARY-GLAND; MOLECULAR-BIOLOGY; SUBMANDIBULAR-GLAND; NUCLEOTIDE-SEQUENCE; SERINE PROTEASE; CHAIN-REACTION; KININ SYSTEM	To understand the regulatory diversity of the rat Family of linked kallikrein genes, we have assayed the expression of family members in 20 major organs. Reverse transcription-polymerase chain reaction analysis using primers and hybridization probes specific for each of the 10 expressed kallikrein genes showed that no two family members share the same organ-specific pattern of expression. The only common site of expression for all 10 known active genes is the submandibular gland. The presence of the mRNA for at least one family member is detected in 19 of these 20 organs (liver excepted), from as few as three organs to as many as 18 for individual family members. For individual genes there can be more than a 10(5)-fold variation in mRNA levels among organs, from a limit of detection of slightly less than 1 mRNA molecule/10 cells to more than 10,000 mRNA molecules/cell. Despite high sequence conservation and close linkage, the members of this family are expressed in very different and complex patterns. A gradient of diversity of expression corresponds to the order of the genes within the kallikrein family locus.			MacDonald, RJ (corresponding author), UNIV TEXAS,SW MED CTR,DEPT BIOCHEM,MOL IMMUNOL CTR,6000 HARRY HINES BLVD,DALLAS,TX 75235, USA.		Southard-Smith, Michelle/C-3488-2012; Kroon, Erna/V-5444-2019; MacDonald, Ray/AAA-1290-2022	KROON, EVERT/0000-0002-4069-3644; Southard-Smith, E Michelle/0000-0003-4718-5869	NIGMS NIH HHS [GM08203, GM31689] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM031689] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ASHLEY PL, 1985, BIOCHEMISTRY-US, V24, P4512, DOI 10.1021/bi00338a005; ASHLEY PL, 1985, BIOCHEMISTRY-US, V24, P4520, DOI 10.1021/bi00338a006; BERG T, 1992, J HISTOCHEM CYTOCHEM, V40, P83, DOI 10.1177/40.1.1309555; BERG T, 1992, RECENT PROGR KININS, V1, P19; BRADY JM, 1990, ARCH BIOCHEM BIOPHYS, V278, P342, DOI 10.1016/0003-9861(90)90269-5; BRADY JM, 1989, BIOCHEMISTRY-US, V28, P5203, DOI 10.1021/bi00438a043; CARRETERO OA, 1993, J HYPERTENS, V11, P693, DOI 10.1097/00004872-199307000-00002; CHAO J, 1983, J BIOL CHEM, V258, P5173; CHAPDELAINE P, 1984, J ANDROL, V5, P206; CHEN YP, 1988, BIOCHEMISTRY-US, V27, P7189, DOI 10.1021/bi00419a005; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CLEMENTS JA, 1988, J BIOL CHEM, V263, P16132; CLEMENTS JA, 1989, J NEUROENDOCRINOL, V1, P199; CLEMENTS JA, 1989, ENDOCR REV, V10, P393, DOI 10.1210/edrv-10-4-393; CLEMENTS JA, 1990, J BIOL CHEM, V265, P1077; CROSSLEY M, 1993, CURR OPIN GENET DEV, V3, P232, DOI 10.1016/0959-437X(93)90028-N; DOVER G, 1982, NATURE, V299, P111, DOI 10.1038/299111a0; DOVER GA, 1986, PHILOS T R SOC B, V312, P275, DOI 10.1098/rstb.1986.0007; DOVER GA, 1982, NATURE, V289, P111; DUNBAR JC, 1987, BIOCHEMISTRY-US, V26, P3471, DOI 10.1021/bi00386a034; ELMOUJAHED A, 1990, FEBS LETT, V265, P137, DOI 10.1016/0014-5793(90)80903-V; EVANS BA, 1987, J BIOL CHEM, V262, P8027; FIEDLER F, 1979, HDB EXPT PHARMACOLOG, V25, P103; FULLER PJ, 1988, MOL CELL ENDOCRINOL, V60, P225, DOI 10.1016/0303-7207(88)90182-7; FULLER PJ, 1989, BIOCHEM J, V264, P133, DOI 10.1042/bj2640133; GERALD WL, 1986, BIOCHIM BIOPHYS ACTA, V866, P1, DOI 10.1016/0167-4781(86)90093-X; GRISE C, 1981, CAN J BIOCHEM CELL B, V59, P250, DOI 10.1139/o81-034; GUBITS RM, 1984, J BIOL CHEM, V259, P2803; GUTMAN N, 1991, EUR J BIOCHEM, V197, P425, DOI 10.1111/j.1432-1033.1991.tb15928.x; HIBNER BL, 1988, DEV BIOL, V125, P423, DOI 10.1016/0012-1606(88)90223-0; INOUE H, 1989, J BIOCHEM-TOKYO, V105, P834, DOI 10.1093/oxfordjournals.jbchem.a122754; KAFATOS FC, 1987, ADV GENET, V24, P223, DOI 10.1016/S0065-2660(08)60009-7; KEDES LH, 1979, ANNU REV BIOCHEM, V48, P837, DOI 10.1146/annurev.bi.48.070179.004201; LILJA H, 1985, J CLIN INVEST, V76, P1899, DOI 10.1172/JCI112185; MA J, 1992, BIOCHEMISTRY-US, V31, P10922, DOI 10.1021/bi00159a036; MACDONALD RJ, 1988, BIOCHEM J, V253, P313, DOI 10.1042/bj2530313; MACDONALD RJ, 1987, METHOD ENZYMOL, V152, P219; MASON AJ, 1983, NATURE, V303, P300, DOI 10.1038/303300a0; MULLIS KB, 1987, METHOD ENZYMOL, V155, P335; MURRAY V, 1989, NUCLEIC ACIDS RES, V17, P8889, DOI 10.1093/nar/17.21.8889; NOLLY H, 1993, HYPERTENSION, V21, P911, DOI 10.1161/01.HYP.21.6.911; NUDEL U, 1983, NUCLEIC ACIDS RES, V11, P1759, DOI 10.1093/nar/11.6.1759; PRITCHETT DB, 1987, P NATL ACAD SCI USA, V84, P5545, DOI 10.1073/pnas.84.16.5545; PROBER JM, 1987, SCIENCE, V238, P336, DOI 10.1126/science.2443975; SAED GM, 1990, CIRC RES, V67, P510, DOI 10.1161/01.RES.67.2.510; SAED GM, 1992, HYPERTENSION, V19, P262; SCICLI AG, 1993, J HYPERTENS, V11, P775, DOI 10.1097/00004872-199308000-00002; SOUTHARDSMITH M, 1994, GENOMICS, V22, P404, DOI 10.1006/geno.1994.1402; SOUTHARDSMITH M, 1992, DNA CELL BIOL, V11, P345; SPOEREL NA, 1989, J MOL BIOL, V209, P1, DOI 10.1016/0022-2836(89)90166-6; SWIFT GH, 1982, P NATL ACAD SCI-BIOL, V79, P7263, DOI 10.1073/pnas.79.23.7263; VANLEEUWEN BH, 1986, J BIOL CHEM, V261, P5529; VERES G, 1987, SCIENCE, V237, P415, DOI 10.1126/science.3603027; WINES DR, 1989, J BIOL CHEM, V264, P7653; WINES DR, 1991, J MOL EVOL, V32, P476, DOI 10.1007/BF02102650; WINES DR, 1989, THESIS U TEXAS SW ME; YAMAGUCHI T, 1991, J BIOL CHEM, V266, P5011	57	40	42	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 7	1996	271	23					13684	13690		10.1074/jbc.271.23.13684	http://dx.doi.org/10.1074/jbc.271.23.13684			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UP385	8662704	hybrid			2022-12-25	WOS:A1996UP38500059
J	Molz, L; Chen, YW; Hirano, M; Williams, LT				Molz, L; Chen, YW; Hirano, M; Williams, LT			Cpk is a novel class of Drosophila PtdIns 3-kinase containing a C2 domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; GROWTH-FACTOR RECEPTORS; PHOSPHATIDYLINOSITOL 3-KINASE; SH2 DOMAINS; SACCHAROMYCES-CEREVISIAE; ACTIVATED NEUTROPHILS; BOVINE BRAIN; BINDING; COMPLEX; SUBUNIT	We report the identification of a novel class of phosphatidylinositol (PtdIns) 3-kinases whose members contain C-terminal C2 domains. We have isolated Drosophila and murine genes (termed cpk and cpk-m respectively) by polymerase chain reaction amplification of cDNA libraries with degenerate primers corresponding to conserved regions of PtdIns kinases. The amino acid sequences of Cpk and Cpk-m are most similar to that of p110, a family of PtdIns 3-kinases that mediates the responses of cells to mitogenic stimuli. The Cpk and Cpk-m sequences are similar to a large, central region of p110, but differ from p110 at their N and C termini. The N termini of the Cpk proteins do not contain any recognizable protein motif, while the C termini contain ''C2 domains,'' a feature unique among PtdIns kinases. Cpk has an intrinsic PtdIns kinase activity and can phosphorylate PtdIns and PtdIns-4-P, but not PtdIns(4,5)P-2, at the D3 position of the inositol ring. Cpk is the first PtdIns 3-kinase identified with this particular substrate specificity, We have identified two potential Cpk-binding proteins, p90 and p190, and have determined that both Cpk and p190 may be tyrosine phosphorylated. This finding suggests that Cpk function may be regulated by tyrosine kinases.	UNIV CALIF SAN FRANCISCO,CARDIOVASC RES INST,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DAIICHI RES CTR,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco								AUGER KR, 1989, CELL, V57, P167, DOI 10.1016/0092-8674(89)90182-7; BROWN NH, 1988, J MOL BIOL, V203, P425, DOI 10.1016/0022-2836(88)90010-1; CARPENTER CL, 1990, BIOCHEMISTRY-US, V29, P11147, DOI 10.1021/bi00503a001; CARPENTER CL, 1990, J BIOL CHEM, V265, P19704; DHAND R, 1994, EMBO J, V13, P522, DOI 10.1002/j.1460-2075.1994.tb06290.x; FLANAGAN CA, 1993, SCIENCE, V262, P1444, DOI 10.1126/science.8248783; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; FRY MJ, 1992, BIOCHEM J, V288, P383, DOI 10.1042/bj2880383; GEPPERT M, 1991, J BIOL CHEM, V266, P13548; Harlow E., 1988, ANTIBODIES LAB MANUA; Herman Paul K., 1992, Trends in Cell Biology, V2, P363, DOI 10.1016/0962-8924(92)90048-R; HERMAN PK, 1990, MOL CELL BIOL, V10, P6742, DOI 10.1128/MCB.10.12.6742; HILES ID, 1992, CELL, V70, P419, DOI 10.1016/0092-8674(92)90166-A; HOLT KH, 1994, MOL CELL BIOL, V14, P42, DOI 10.1128/MCB.14.1.42; HU P, 1993, MOL CELL BIOL, V13, P7677, DOI 10.1128/MCB.13.12.7677; HU P, 1992, MOL CELL BIOL, V12, P981, DOI 10.1128/MCB.12.3.981; HU QJ, 1995, SCIENCE, V268, P100, DOI 10.1126/science.7701328; JESSUS C, 1992, CELL, V68, P323, DOI 10.1016/0092-8674(92)90473-P; KAPELLER R, 1994, BIOESSAYS, V16, P565, DOI 10.1002/bies.950160810; KAPLAN DR, 1987, CELL, V50, P1021, DOI 10.1016/0092-8674(87)90168-1; KLIPPEL A, 1992, MOL CELL BIOL, V12, P1451, DOI 10.1128/MCB.12.4.1451; KLIPPEL A, 1994, MOL CELL BIOL, V14, P2675, DOI 10.1128/MCB.14.4.2675; KUNZ J, 1993, CELL, V73, P585, DOI 10.1016/0092-8674(93)90144-F; LISCOVITCH M, 1994, CELL, V77, P329, DOI 10.1016/0092-8674(94)90148-1; Macdougall LK, 1995, CURR BIOL, V5, P1404, DOI 10.1016/S0960-9822(95)00278-8; MATTHIAS P, 1989, NUCLEIC ACIDS RES, V17, P6418, DOI 10.1093/nar/17.15.6418; MCGLADE CJ, 1992, MOL CELL BIOL, V12, P991, DOI 10.1128/MCB.12.3.991; MOCHLYROSEN D, 1995, SCIENCE, V268, P247, DOI 10.1126/science.7716516; MORGAN SJ, 1990, EUR J BIOCHEM, V191, P761, DOI 10.1111/j.1432-1033.1990.tb19185.x; NAKANISHI H, 1993, J BIOL CHEM, V268, P13; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PERIN MS, 1990, NATURE, V345, P260, DOI 10.1038/345260a0; REEDIJK M, 1992, EMBO J, V11, P1365, DOI 10.1002/j.1460-2075.1992.tb05181.x; Sambrook J., 2002, MOL CLONING LAB MANU; SCHAEFFER E, 1989, CELL, V57, P403, DOI 10.1016/0092-8674(89)90915-X; SCHU PV, 1993, SCIENCE, V260, P88, DOI 10.1126/science.8385367; SHIBASAKI F, 1991, J BIOL CHEM, V266, P8108; SHIRATAKI H, 1993, MOL CELL BIOL, V13, P2061, DOI 10.1128/MCB.13.4.2061; STACK JH, 1993, EMBO J, V12, P2195, DOI 10.1002/j.1460-2075.1993.tb05867.x; STEPHENS LR, 1993, BIOCHIM BIOPHYS ACTA, V1179, P27, DOI 10.1016/0167-4889(93)90072-W; STEPHENS LR, 1991, NATURE, V351, P33, DOI 10.1038/351033a0; STOYANOV B, 1995, SCIENCE, V269, P690, DOI 10.1126/science.7624799; TOKER A, 1994, J BIOL CHEM, V269, P32358; TRAYNORKAPLAN AE, 1988, NATURE, V334, P353, DOI 10.1038/334353a0; TRAYNORKAPLAN AE, 1989, J BIOL CHEM, V264, P15668; TYERS M, 1992, EMBO J, V11, P1773, DOI 10.1002/j.1460-2075.1992.tb05229.x; VOLINIA S, 1994, GENOMICS, V24, P472, DOI 10.1006/geno.1994.1655; VOLINIA S, 1995, EMBO J, V14, P3339, DOI 10.1002/j.1460-2075.1995.tb07340.x; WALSH JP, 1991, P NATL ACAD SCI USA, V88, P9184, DOI 10.1073/pnas.88.20.9184; WHITMAN M, 1988, NATURE, V332, P644, DOI 10.1038/332644a0; WOSCHOLSKI R, 1994, FEBS LETT, V342, P109, DOI 10.1016/0014-5793(94)80482-6; YOAKIM M, 1992, J VIROL, V66, P5485, DOI 10.1128/JVI.66.9.5485-5491.1992; YONEZAWA K, 1992, J BIOL CHEM, V267, P25958; ZHANG JZ, 1994, CELL, V78, P751, DOI 10.1016/S0092-8674(94)90442-1; ZHOU KM, 1995, MOL CELL BIOL, V15, P5645	56	55	64	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 7	1996	271	23					13892	13899		10.1074/jbc.271.23.13892	http://dx.doi.org/10.1074/jbc.271.23.13892			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UP385	8662856	hybrid			2022-12-25	WOS:A1996UP38500088
J	Chen, L; Qi, H; Korenberg, J; Garrow, TA; Choi, YJ; Shane, B				Chen, L; Qi, H; Korenberg, J; Garrow, TA; Choi, YJ; Shane, B			Purification and properties of human cytosolic folylpoly-gamma-glutamate synthetase and organization, localization, and differential splicing of its gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ONE-CARBON METABOLISM; HAMSTER OVARY CELLS; MAMMALIAN-CELLS; FOLYLPOLY(GAMMA-GLUTAMATE) SYNTHETASE; BIOCHEMICAL-CHARACTERIZATION; CHROMOSOMAL LOCALIZATION; SUBSTRATE-SPECIFICITY; INSITU HYBRIDIZATION; INVITRO METABOLISM; FOLATE METABOLISM	Human cytosolic folylpolyglutamate synthetase (FPGS) was expressed in Escherichia coli and purified to homo geneity. Tetrahydrofolate and dihydrofolate were the most effective substrates, while 5-substituted folates were poor substrates. Most pteroyldiglutamates were better substrates than monoglutamates. The human FPGS gene spans 12 kilobases and contains 15 exons and 14 introns. A single FPGS gene was located to chromosome region 9q34.1. Four exon 1 variants were identified, each of which was spliced to exon 2. The exon 1 variant corresponding to the isolated cDNA contains two ATG codons and multiple transcription start sites in this region generates mitochondrial and cytosolic FPGS (Freemantle, S. J., Taylor, S. M., Krystal, G., and Moran, R. G. (1995) J. Biol. Chem. 270, 9579-9584). Exons 1B and 1C, generated by alternate splicing in intron 1, and exon 1A, which is 5' to exon 1 and may encode an additional mitochondrial isoform, are preceded by a number of potential promoter sites. Chinese hamster ovary cell transfectants expressing FPGS activity in the mitochondria contained normal mitochondrial and low cytosolic folylpolyglutamate pools. Mitochondrial FPGS activity is required for mitochondrial folate accumulation, while cytosolic FPGS activity is needed for establishment of normal cytosolic folate pools. The reconstructed FPGS gene restored normal cytosolic and mitochondrial folate metabolism in hamster cells.	UNIV CALIF BERKELEY, DEPT NUTR SCI, BERKELEY, CA 94720 USA; UNIV CALIF LOS ANGELES, CEDARS SINAI MED CTR, DEPT PEDIAT, MED BIRTH DEFECTS CTR, LOS ANGELES, CA 90048 USA	University of California System; University of California Berkeley; Cedars Sinai Medical Center; University of California System; University of California Los Angeles					NCI NIH HHS [CA-41991] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA041991] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		APTE AN, 1993, BIOTECHNIQUES, V15, P890; AUSUBEL FM, 1999, SHORT PROTOCOLS MOL; BARREDO J, 1992, MOL PHARMACOL, V42, P687; BEARDSLEY GP, 1989, J BIOL CHEM, V264, P328; BLAKLEY RL, 1969, BIOCH FOLIC ACID REL, P92; BOGNAR AL, 1983, J BIOL CHEM, V258, P2574; BOGNAR AL, 1987, J BIOL CHEM, V262, P12337; BOLANOWSKA WE, 1990, ARCH BIOCHEM BIOPHYS, V281, P198, DOI 10.1016/0003-9861(90)90432-X; CHABNER BA, 1985, J CLIN INVEST, V76, P907, DOI 10.1172/JCI112088; CICHOWICZ DJ, 1987, BIOCHEMISTRY-US, V26, P504, DOI 10.1021/bi00376a024; CICHOWICZ DJ, 1987, BIOCHEMISTRY-US, V26, P513, DOI 10.1021/bi00376a025; CLARKE L, 1987, ARCH BIOCHEM BIOPHYS, V256, P585, DOI 10.1016/0003-9861(87)90616-3; COLL RJ, 1991, BIOCHEM PHARMACOL, V42, P833, DOI 10.1016/0006-2952(91)90043-5; COOK JD, 1987, BIOCHEMISTRY-US, V26, P530, DOI 10.1021/bi00376a027; DEBOERHA, 1986, MAXIMIZING GENE EXPR, P225; EGAN MG, 1995, J BIOL CHEM, V270, P5462, DOI 10.1074/jbc.270.10.5462; FOO SK, 1982, J BIOL CHEM, V257, P13587; FORT DW, 1993, BRIT J HAEMATOL, V84, P595, DOI 10.1111/j.1365-2141.1993.tb03133.x; FREEMANTLE SJ, 1995, J BIOL CHEM, V270, P9579, DOI 10.1074/jbc.270.16.9579; GARROW TA, 1992, P NATL ACAD SCI USA, V89, P9151, DOI 10.1073/pnas.89.19.9151; GARROW TA, 1993, J BIOL CHEM, V268, P11910; GEORGE S, 1987, BIOCHEMISTRY-US, V26, P522, DOI 10.1021/bi00376a026; HAGAN RL, 1991, BIOCHEM PHARMACOL, V41, P781, DOI 10.1016/0006-2952(91)90081-F; HANLON MH, 1990, CANCER RES, V50, P3207; JONES C, 1980, CYTOGENET CELL GENET, V28, P181, DOI 10.1159/000131529; KADESCH T, 1993, CELL GROWTH DIFFER, V4, P49; KELLEY JL, 1990, J MED CHEM, V33, P561, DOI 10.1021/jm00164a014; KIM JS, 1994, J BIOL CHEM, V269, P9714; KIM JS, 1993, J BIOL CHEM, V268, P21680; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LENZ HJ, 1994, ONCOL RES, V6, P329; LI WW, 1992, CANCER RES, V52, P3908; LIN BF, 1993, J BIOL CHEM, V268, P21674; LIN BF, 1994, J BIOL CHEM, V269, P9705; LOWE KE, 1993, J BIOL CHEM, V268, P21665; MAGENIS RE, 1985, HUM GENET, V69, P300, DOI 10.1007/BF00291645; MCBURNEY MW, 1974, CELL, V2, P173, DOI 10.1016/0092-8674(74)90091-9; MCCLOSKEY DE, 1991, J BIOL CHEM, V266, P6181; MCGUIRE JJ, 1980, J BIOL CHEM, V255, P5776; MCGUIRE JJ, 1984, FOLATES PTERINS, V1, P135; MCGUIRE JJ, 1991, J CELL PHARM, V2, P317; MORAN RG, 1985, MOL PHARMACOL, V27, P156; MORAN RG, 1984, BIOCHEMISTRY-US, V23, P4580, DOI 10.1021/bi00315a011; NAKAMAYE KL, 1986, NUCLEIC ACIDS RES, V14, P9679, DOI 10.1093/nar/14.24.9679; OSBORNE CB, 1993, J BIOL CHEM, V268, P21657; PADGETT RA, 1986, ANNU REV BIOCHEM, V55, P1119, DOI 10.1146/annurev.bi.55.070186.005351; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; PIZZORNO G, 1995, CANCER RES, V55, P566; PIZZORNO G, 1989, CANCER RES, V49, P5275; PRISTUPA ZB, 1984, CAN J BIOCHEM CELL B, V62, P495, DOI 10.1139/o84-067; RUMBERGER BG, 1990, CANCER RES, V50, P4639; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SANTORO C, 1988, NATURE, V334, P218, DOI 10.1038/334218a0; SHANE B, 1980, J BIOL CHEM, V255, P5655; SHANE B, 1989, VITAM HORM, V45, P263; SIROTNAK FM, 1988, BIOCHEM PHARMACOL, V37, P4239, DOI 10.1016/0006-2952(88)90122-0; STOVER P, 1993, ADV EXP MED BIOL, V338, P723; SUSSMAN DJ, 1986, SOMAT CELL MOLEC GEN, V12, P531, DOI 10.1007/BF01671939; TAYLOR RT, 1977, ARCH BIOCHEM BIOPHYS, V181, P331, DOI 10.1016/0003-9861(77)90512-4; VONHEIJNE G, 1986, EMBO J, V5, P1335, DOI 10.1002/j.1460-2075.1986.tb04364.x; WANG FS, 1993, CANCER RES, V53, P3677; WHITEHEAD VM, 1990, BLOOD, V76, P44; ZABEL BU, 1983, P NATL ACAD SCI-BIOL, V80, P6932, DOI 10.1073/pnas.80.22.6932; ZHANG ZG, 1991, CANCER RES, V51, P3476	65	74	76	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 31	1996	271	22					13077	13087		10.1074/jbc.271.22.13077	http://dx.doi.org/10.1074/jbc.271.22.13077			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UN474	8662720	hybrid			2022-12-25	WOS:A1996UN47400061
J	Li, JX; Zhu, ZX; Bao, ZH				Li, JX; Zhu, ZX; Bao, ZH			Role of MacMARCKS in integrin-dependent macrophage spreading and tyrosine phosphorylation of paxillin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; MEDIATED PHAGOCYTOSIS; HUMAN-NEUTROPHILS; HUMAN-MONOCYTES; CELL-ADHESION; ACTIVATION; MARCKS; FIBROBLASTS; MODULATION; MECHANISMS	The cellular function of the MARCKS family of protein kinase C substrates is unknown, In this report, we present evidence that indicates a role for MacMARCKS, a member of the MARCKS family, in the integrin-dependent signal transduction pathways in macrophages, Using a dominant negative mutant of MacMARCKS, we showed that MacMARCKS participates in several integrirm-dependent macrophage functions, including the phorbol ester-stimulated macrophage spreading, a process involving multiple integrins, The dominant negative mutant also blocks macrophage spreading on immune complex-coated surfaces, a process again requiring beta(2) integrin, More direct evidence of the role of MacMARCKS in the integrin-dependent pathway is the ablation of macrophage binding to complement iC3b-coated sheep erythrocytes by MacMARCKS mutant, suggesting an effect of this mutant on the avidity of complement receptor 3, a member of the beta(2) integrin family, To further evaluate the possible mechanism of MacMARCKS function, the integrin-dependent tyrosine phosphorylation of paxillin was examined, Concomitant with the inhibition of macrophage spreading and rosette formation, MacMARCKS mutant also inhibits integrin-dependent tyrosine phosphorylation of paxillin, Furthermore, immunofluorescent microscopy data showed that MacMARCKS and paxillin colocalize in the membrane ruffles at the leading edge of the spreading cells, providing a potential site and opportunity for MacMARCKS to participate in the regulation of integrin-dependent tyrosine phosphorylation of paxillin, Together, these data strongly suggest that MacMARCKS plays a role in integrin-dependent signal transduction pathways in macrophages.			Li, JX (corresponding author), UNIV TENNESSEE,COLL MED,DEPT MICROBIOL & IMMUNOL,858 MADISON AVE,MEMPHIS,TN 38163, USA.							ANDERSON DC, 1987, ANNU REV MED, V38, P175, DOI 10.1146/annurev.med.38.1.175; BIRGE RB, 1993, MOL CELL BIOL, V13, P4648, DOI 10.1128/MCB.13.8.4648; BLACKSHEAR PJ, 1992, J BIOL CHEM, V267, P13540; BROWN EJ, 1988, J CLIN INVEST, V81, P365, DOI 10.1172/JCI113328; BUYON JP, 1988, J IMMUNOL, V140, P3156; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; DANILOV YN, 1989, J CELL BIOL, V108, P1925, DOI 10.1083/jcb.108.5.1925; DUSTIN ML, 1989, NATURE, V341, P619, DOI 10.1038/341619a0; FUORTES M, 1994, J CELL BIOL, V127, P1477, DOI 10.1083/jcb.127.5.1477; GRAHAM IL, 1993, J CELL BIOL, V120, P1509, DOI 10.1083/jcb.120.6.1509; GRAHAM IL, 1994, J CELL BIOL, V127, P1139, DOI 10.1083/jcb.127.4.1139; GREENBERG S, 1994, J BIOL CHEM, V269, P3897; GRESHAM HD, 1991, J CLIN INVEST, V88, P588, DOI 10.1172/JCI115343; HARTWIG JH, 1992, NATURE, V356, P618, DOI 10.1038/356618a0; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; KIM JY, 1994, BIOPHYS J, V67, P227, DOI 10.1016/S0006-3495(94)80473-4; LI JX, 1992, CELL, V70, P791, DOI 10.1016/0092-8674(92)90312-Z; LIPFERT L, 1992, J CELL BIOL, V119, P905, DOI 10.1083/jcb.119.4.905; MINOGUCHI K, 1994, MOL IMMUNOL, V31, P519; MIYAMOTO S, 1995, SCIENCE, V267, P883, DOI 10.1126/science.7846531; NATHAN C, 1989, J CELL BIOL, V109, P1341, DOI 10.1083/jcb.109.3.1341; PETTY HR, 1989, BIOCHIM BIOPHYS ACTA, V1012, P284, DOI 10.1016/0167-4889(89)90110-9; PHAIREWASHINGTON L, 1980, J CELL BIOL, V86, P634, DOI 10.1083/jcb.86.2.634; PHILLIPS WD, 1991, SCIENCE, V251, P568, DOI 10.1126/science.1703661; RICHTER J, 1990, P NATL ACAD SCI USA, V87, P9472, DOI 10.1073/pnas.87.23.9472; ROSALES C, 1995, J LEUKOCYTE BIOL, V57, P189, DOI 10.1002/jlb.57.2.189; SCHALLER MD, 1994, CURR OPIN CELL BIOL, V6, P705, DOI 10.1016/0955-0674(94)90097-3; SHAW LM, 1990, J CELL BIOL, V110, P2167, DOI 10.1083/jcb.110.6.2167; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; TURNER CE, 1990, J CELL BIOL, V111, P1059, DOI 10.1083/jcb.111.3.1059; TURNER CE, 1994, J CELL SCI, V107, P1583; TURNER CE, 1994, BIOESSAYS, V16, P47, DOI 10.1002/bies.950160107; UMEKAGE T, 1991, FEBS LETT, V286, P147, DOI 10.1016/0014-5793(91)80961-2; VUORI K, 1993, J BIOL CHEM, V268, P21459; WALLIS WJ, 1986, BLOOD, V67, P1007; WALLIS WJ, 1985, J IMMUNOL, V135, P2323; WENG ZG, 1993, J BIOL CHEM, V268, P14956; WOODS A, 1992, J CELL SCI, V101, P277; Wright S D, 1986, Methods Enzymol, V132, P204; WRIGHT SD, 1982, J EXP MED, V156, P1149, DOI 10.1084/jem.156.4.1149; YAMADA KM, 1995, CURR OPIN CELL BIOL, V7, P681, DOI 10.1016/0955-0674(95)80110-3; ZHELEZNYAK A, 1992, J BIOL CHEM, V267, P12042; ZHU ZX, 1995, J BIOL CHEM, V270, P17652, DOI 10.1074/jbc.270.30.17652	43	45	46	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 31	1996	271	22					12985	12990		10.1074/jbc.271.22.12985	http://dx.doi.org/10.1074/jbc.271.22.12985			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UN474	8662782	hybrid			2022-12-25	WOS:A1996UN47400048
J	Malcolm, KC; Elliott, CM; Exton, JH				Malcolm, KC; Elliott, CM; Exton, JH			Evidence for Rho-mediated agonist stimulation of phospholipase D in Rat1 fibroblasts - Effects of Clostridium botulinum C3 exoenzyme	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTP-BINDING PROTEIN; SWISS 3T3 CELLS; ADP-RIBOSYLATION; LYSOPHOSPHATIDIC-ACID; GENE-PRODUCT; PHOSPHATIDYLCHOLINE HYDROLYSIS; SIGNALING PATHWAYS; KINASE-C; ACTIVATION; MEMBRANE	Small GTP-binding proteins of the Rho family are implicated in the in vitro regulation of phosphatidylcholine hydrolysis by phospholipase D (PLD), However, their role in agonist-stimulated PLD activity in whole cells is not clear. The ribosyltransferase C3 from Clostridium botulinum modifies Rho proteins and inhibits their function. When introduced into rat1 fibroblasts by scrape-loading, C3 inhibited PLD activity stimulated by lysophosphatidic acid (LPA), endothelin-1, or phorbol ester. Neither the time course nor agonist dose response for LPA-stimulated PLD activity was altered in C3-treated cells. In contrast to the effects of C3 on PLD activity, agonist-stimulated phosphatidylinositol-phospholipase C activity was not altered in C3-treated cells, Surprisingly, C3 treatment led to a decrease in the amount of RhoA protein, indicating that the loss of PLD activity in response to agonist was partly due to the loss of Rho proteins. As described previously, C3 treatment led to the inhibition of LPA-stimulated actin filament formation. However, disruption of actin filaments with cytochalasin D caused only a minor inhibition of LPA-stimulated PLD activity. Interestingly, stimulation of cells with LPA caused a rapid enrichment of RhoA in the particulate fraction of cell lysates. These data support an in vivo role for RhoA in agonist-stimulated PLD activity that is separate from its role in actin fiber formation.	VANDERBILT UNIV,SCH MED,HOWARD HUGHES MED INST,NASHVILLE,TN 37232; VANDERBILT UNIV,SCH MED,DEPT MOLEC PHYSIOL & BIOPHYS,NASHVILLE,TN 37232; VANDERBILT UNIV,SCH MED,DEPT PHARMACOL,NASHVILLE,TN 37232	Howard Hughes Medical Institute; Vanderbilt University; Vanderbilt University; Vanderbilt University								AKTORIES K, 1995, METHOD ENZYMOL, V256, P184; Amano M, 1996, SCIENCE, V271, P648, DOI 10.1126/science.271.5249.648; AVRAHAM H, 1989, MOL CELL BIOL, V9, P2058, DOI 10.1128/MCB.9.5.2058; BALBOA MA, 1995, J BIOL CHEM, V270, P29843; BERRIDGE MJ, 1983, BIOCHEM J, V212, P473, DOI 10.1042/bj2120473; BILLAH MM, 1990, BIOCHEM J, V269, P281, DOI 10.1042/bj2690281; BOCCKINO SB, 1987, J BIOL CHEM, V262, P15309; BOKOCH GM, 1994, J BIOL CHEM, V269, P31674; BOWMAN EP, 1993, J BIOL CHEM, V268, P21509; BROWN HA, 1993, CELL, V75, P1137, DOI 10.1016/0092-8674(93)90323-I; COCKCROFT S, 1994, SCIENCE, V263, P523, DOI 10.1126/science.8290961; CONRICODE KM, 1992, J BIOL CHEM, V267, P7199; DILLON ST, 1995, INFECT IMMUN, V63, P1421, DOI 10.1128/IAI.63.4.1421-1426.1995; DUBYAK GR, 1993, BIOCHEM J, V292, P121, DOI 10.1042/bj2920121; EXTON JH, 1994, BBA-LIPID LIPID MET, V1212, P26, DOI 10.1016/0005-2760(94)90186-4; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; HORDIJK PL, 1994, J BIOL CHEM, V269, P645; HOULE MG, 1995, J BIOL CHEM, V270, P22795, DOI 10.1074/jbc.270.39.22795; INOUE H, 1995, BIOCHEM BIOPH RES CO, V210, P542, DOI 10.1006/bbrc.1995.1694; JIANG H, 1995, NATURE, V378, P409, DOI 10.1038/378409a0; KUMAGAI N, 1993, J BIOL CHEM, V268, P24535; KUMAGAI N, 1995, FEBS LETT, V366, P11, DOI 10.1016/0014-5793(95)00478-R; KURIBARA H, 1995, J BIOL CHEM, V270, P25667, DOI 10.1074/jbc.270.43.25667; KWAK JY, 1995, J BIOL CHEM, V270, P27093, DOI 10.1074/jbc.270.45.27093; LAMBETH JD, 1995, J BIOL CHEM, V270, P2431, DOI 10.1074/jbc.270.6.2431; LEONARD D, 1992, J BIOL CHEM, V267, P22860; LEUNG T, 1995, J BIOL CHEM, V270, P29051, DOI 10.1074/jbc.270.49.29051; MACNULTY EE, 1992, J BIOL CHEM, V267, P2149; MALCOLM KC, 1994, J BIOL CHEM, V269, P25951; MARTIN TW, 1989, J BIOL CHEM, V264, P8847; MCNEIL PL, 1984, J CELL BIOL, V98, P1556, DOI 10.1083/jcb.98.4.1556; MORII N, 1992, J BIOL CHEM, V267, P20921; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; OHGUCHI K, 1995, BIOCHEM BIOPH RES CO, V211, P306, DOI 10.1006/bbrc.1995.1811; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; OLSON SC, 1991, J BIOL CHEM, V266, P17236; PLEVIN R, 1991, BIOCHEM J, V280, P609, DOI 10.1042/bj2800609; PRICE BD, 1989, J BIOL CHEM, V264, P16638; QIAN Z, 1989, J BIOL CHEM, V264, P21720; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; RODEN RBS, 1993, CELL GROWTH DIFFER, V4, P957; Schmidt M, 1996, J BIOL CHEM, V271, P2422, DOI 10.1074/jbc.271.5.2422; SIDDIQI AR, 1995, J BIOL CHEM, V270, P8466, DOI 10.1074/jbc.270.15.8466; SINGER WD, 1995, J BIOL CHEM, V270, P14944, DOI 10.1074/jbc.270.25.14944; VANCORVEN EJ, 1989, CELL, V59, P45, DOI 10.1016/0092-8674(89)90868-4; VANDERBEND RL, 1992, BIOCHEM J, V285, P235, DOI 10.1042/bj2850235; Watanabe G, 1996, SCIENCE, V271, P645, DOI 10.1126/science.271.5249.645; YAMAMOTO M, 1993, ONCOGENE, V8, P1449; YEO EJ, 1995, J BIOL CHEM, V270, P3980, DOI 10.1074/jbc.270.8.3980; ZHANG J, 1993, J BIOL CHEM, V268, P22251	51	136	136	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 31	1996	271	22					13135	13139		10.1074/jbc.271.22.13135	http://dx.doi.org/10.1074/jbc.271.22.13135			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UN474	8662844	hybrid			2022-12-25	WOS:A1996UN47400069
J	Ward, PP; Zhou, X; Conneely, OM				Ward, PP; Zhou, X; Conneely, OM			Cooperative interactions between the amino- and carboxyl-terminal lobes contribute to the unique iron-binding stability of lactoferrin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-SERUM TRANSFERRIN; MESSENGER-RNA; LACTOTRANSFERRIN; SEQUENCE; RELEASE; INVIVO; MILK; IDENTIFICATION; MEMBRANE; FRAGMENT	Lactoferrin is a member of the transferrin family of iron-binding proteins. Several functions have been ascribed to lactoferrin, including regulation of iron homeostasis, antibacterial properties, and regulation of myelopoiesis. However, the structural features of lactoferrin that are required for most of these functions are unknown. Previously, we reported the development of an efficient fungal expression system to produce recombinant human lactoferrin. The availability of this production system demonstrated the feasibility of producing mutant lactoferrins to address the structure/function relationship of the protein. In the present study, we used a site-directed mutagenesis approach to address the contribution of the bilobal structure of lactoferrin to its unique iron-binding stability. Like transferrin, lactoferrin consists of two repeated iron-binding lobes that bind one iron atom each. However, unlike transferrin, lactoferrin retains iron over a broad pH range, a key property that contributes to the unique iron-binding functions of the protein. Using mutants that selectively ablate the iron-binding function in either lobe, we demonstrate differential iron-binding stability of the amino- and carboxyl-terminal iron-binding lobes of lactoferrin. Further, we show that the unique iron-binding stability of the protein is imparted primarily by the carboxyl-terminal domain which functions cooperatively to stabilize iron-binding to the amino-terminal domain of lactoferrin.	BAYLOR COLL MED,DEPT CELL BIOL,HOUSTON,TX 77030	Baylor College of Medicine								AISEN P, 1980, ANNU REV BIOCHEM, V49, P357, DOI 10.1146/annurev.bi.49.070180.002041; ANDERSON BF, 1989, J MOL BIOL, V209, P711, DOI 10.1016/0022-2836(89)90602-5; ARNOLD RR, 1977, SCIENCE, V197, P263, DOI 10.1126/science.327545; BAKER EN, 1992, J INORG BIOCHEM, V47, P147, DOI 10.1016/0162-0134(92)84061-Q; BELLAMY W, 1992, BIOCHIM BIOPHYS ACTA, V1121, P130, DOI 10.1016/0167-4838(92)90346-F; BROXMEYER HE, 1987, BLOOD CELLS, V13, P31; COX TM, 1979, BIOCHIM BIOPHYS ACTA, V558, P129; CROUCH SPM, 1992, BLOOD, V80, P235; DAY CL, 1992, J BIOL CHEM, V267, P13857; ELLISON RT, 1988, INFECT IMMUN, V56, P2774, DOI 10.1128/IAI.56.11.2774-2781.1988; FRANSSON GB, 1980, J PEDIATR-US, V96, P380, DOI 10.1016/S0022-3476(80)80676-7; GATIGNOL A, 1987, MOL GEN GENET, V207, P342, DOI 10.1007/BF00331599; GISLASON J, 1995, J PEDIATR GASTR NUTR, V21, P37, DOI 10.1097/00005176-199507000-00006; HASHIZUME S, 1983, BIOCHIM BIOPHYS ACTA, V763, P377, DOI 10.1016/0167-4889(83)90099-X; HENNART PF, 1991, AM J CLIN NUTR, V53, P32, DOI 10.1093/ajcn/53.1.32; HU WL, 1988, BIOCHEM J, V249, P435, DOI 10.1042/bj2490435; IYER S, 1993, EUR J CLIN NUTR, V47, P232; JELTSCH JM, 1982, EUR J BIOCHEM, V122, P291, DOI 10.1111/j.1432-1033.1982.tb05879.x; LINDLEY PF, 1988, BIOCHEMISTRY-US, V27, P5804; LINEBACKZINS J, 1980, J BIOL CHEM, V255, P708; MACGILLIVRAY RTA, 1983, J BIOL CHEM, V258, P3543; MACHNICKI M, 1993, INT J EXP PATHOL, V74, P433; MASSON PL, 1968, EUR J BIOCHEM, V6, P579, DOI 10.1111/j.1432-1033.1968.tb00484.x; MASSON PL, 1971, COMP BIOCHEM PHYSIOL, V39, P119, DOI 10.1016/0305-0491(71)90258-6; MASSON PL, 1966, CLIN CHIM ACTA, V14, P735, DOI 10.1016/0009-8981(66)90004-0; MASSON PL, 1969, J EXP MED, V130, P643, DOI 10.1084/jem.130.3.643; MAZURIER J, 1980, BIOCHIM BIOPHYS ACTA, V629, P399, DOI 10.1016/0304-4165(80)90112-9; METZBOUTIGUE MH, 1984, EUR J BIOCHEM, V145, P659, DOI 10.1111/j.1432-1033.1984.tb08607.x; MIKOGAMI T, 1994, AM J PHYSIOL, V267, pG1; NICHOLS BL, 1987, PEDIATR RES, V21, P563, DOI 10.1203/00006450-198706000-00011; ORAM JD, 1968, BIOCHIM BIOPHYS ACTA, V170, P351, DOI 10.1016/0304-4165(68)90015-9; PENTECOST BT, 1987, J BIOL CHEM, V262, P10134; REJMAN JJ, 1994, INT J BIOCHEM, V26, P201, DOI 10.1016/0020-711X(94)90146-5; ROSE TM, 1986, P NATL ACAD SCI USA, V83, P1261, DOI 10.1073/pnas.83.5.1261; SAWATZKI G, 1989, BLOOD CELLS, V15, P371; SHIMAZAKI K, 1993, J DAIRY SCI, V76, P946, DOI 10.3168/jds.S0022-0302(93)77421-4; VILJA P, 1985, J IMMUNOL METHODS, V76, P73, DOI 10.1016/0022-1759(85)90482-X; WARD PP, 1995, BIO-TECHNOL, V13, P498, DOI 10.1038/nbt0595-498; WILLIAMS J, 1982, TRENDS BIOCHEM SCI, V7, P394, DOI 10.1016/0968-0004(82)90183-9; YAMAUCHI K, 1993, INFECT IMMUN, V61, P719, DOI 10.1128/IAI.61.2.719-728.1993; YU LC, 1993, BIOCHEM J, V296, P107, DOI 10.1042/bj2960107; ZACALI JR, 1979, BLOOD, V54, P951; ZAGULSKI T, 1989, BRIT J EXP PATHOL, V70, P697	43	50	53	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 31	1996	271	22					12790	12794		10.1074/jbc.271.22.12790	http://dx.doi.org/10.1074/jbc.271.22.12790			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UN474	8662718	hybrid			2022-12-25	WOS:A1996UN47400017
J	Stover, DR; Furet, P; Lydon, NB				Stover, DR; Furet, P; Lydon, NB			Modulation of the SH2 binding specificity and kinase activity of Src by tyrosine phosphorylation within its SH2 domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR; C-SRC; PDGF RECEPTOR; PP60C-SRC; FAMILY; AUTOPHOSPHORYLATION; ASSOCIATION; PP60(C-SRC); PROTEINS; PRODUCT	The Src family of kinases are held in an inactive state by interaction of their SH2 domain with a C-terminal phosphotyrosine. Dephosphorylation of this site can reactivate Src; however, recent evidence suggests that activation can also occur without dephosphorylation. In this study, platelet-derived growth factor receptor phosphorylation of Src on Tyr-213 specifically blocked binding of its SH2 domain to a phosphopeptide corresponding to the C-terminal regulatory sequence, while binding to other sequences, such as the platelet-derived growth factor receptor or a peptide from the epidermal growth factor receptor, was unaffected. Consequently, Src was activated over 50-fold. This is the first demonstration of regulation of a SH2 domain specificity by post-translational modification and is likely to be a general mechanism for regulation of all Src-like kinases.			Stover, DR (corresponding author), CIBA GEIGY LTD, DIV PHARMACEUT RES, K125308, CH-4002 BASEL, SWITZERLAND.							BUCHDUNGER E, 1995, P NATL ACAD SCI USA, V92, P2558, DOI 10.1073/pnas.92.7.2558; BURNS CM, 1994, J BIOL CHEM, V269, P13594; CHANG JH, 1993, ONCOGENE, V8, P959; Cooper J.A, 1990, PEPT PROT PHOSPH, P85; COOPER JA, 1986, SCIENCE, V231, P1431, DOI 10.1126/science.2420005; COOPER JA, 1986, MOL CELL BIOL, V6, P4467, DOI 10.1128/MCB.6.12.4467; COURTNEIDGE SA, 1993, EMBO J, V12, P943, DOI 10.1002/j.1460-2075.1993.tb05735.x; COUTURE C, 1994, MOL CELL BIOL, V14, P5249, DOI 10.1128/MCB.14.8.5249; GOULD KL, 1988, MOL CELL BIOL, V8, P3345, DOI 10.1128/MCB.8.8.3345; HUNTER T, 1980, P NATL ACAD SCI-BIOL, V77, P1311, DOI 10.1073/pnas.77.3.1311; HUNTER T, 1995, 5 INT C HORM CANC QU, P25; KAPLAN KB, 1994, EMBO J, V13, P4745, DOI 10.1002/j.1460-2075.1994.tb06800.x; KAZLAUSKAS A, 1989, CELL, V58, P1121, DOI 10.1016/0092-8674(89)90510-2; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; LUTTRELL DK, 1994, P NATL ACAD SCI USA, V91, P83, DOI 10.1073/pnas.91.1.83; LUTTRELL DK, 1988, MOL CELL BIOL, V8, P497, DOI 10.1128/MCB.8.1.497; LYDON NB, 1992, BIOCHEM J, V287, P985, DOI 10.1042/bj2870985; MORI S, 1993, EMBO J, V12, P2257, DOI 10.1002/j.1460-2075.1993.tb05879.x; PAWSON T, 1988, ONCOGENE, V3, P491; RALSTON R, 1985, P NATL ACAD SCI USA, V82, P7845, DOI 10.1073/pnas.82.23.7845; RUSSELL RB, 1992, FEBS LETT, V304, P15, DOI 10.1016/0014-5793(92)80579-6; SOULA M, 1993, J BIOL CHEM, V268, P27420; STOVER DR, 1995, J BIOL CHEM, V270, P15591, DOI 10.1074/jbc.270.26.15591; STOVER DR, 1994, J BIOL CHEM, V269, P26885; STOVER DR, 1993, TECHNIQUES PROTEIN C, V4, P193; SUGIMOTO S, 1994, J BIOL CHEM, V269, P13614; SUPERTIFURGA G, 1995, FEBS LETT, V369, P62, DOI 10.1016/0014-5793(95)00636-N; TAYLOR SJ, 1993, CURR OPIN GENET DEV, V3, P26, DOI 10.1016/S0959-437X(05)80337-5; WAKSMAN G, 1993, CELL, V72, P779, DOI 10.1016/0092-8674(93)90405-F; WAKSMAN G, 1992, NATURE, V358, P646, DOI 10.1038/358646a0; WALKER F, 1993, J BIOL CHEM, V268, P19552; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	32	79	79	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 24	1996	271	21					12481	12487		10.1074/jbc.271.21.12481	http://dx.doi.org/10.1074/jbc.271.21.12481			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UL660	8647855	hybrid			2022-12-25	WOS:A1996UL66000057
J	Benmerah, A; Begue, B; DautryVarsat, A; CerfBensussan, N				Benmerah, A; Begue, B; DautryVarsat, A; CerfBensussan, N			The ear of alpha-adaptin interacts with the COOH-terminal domain of the Eps15 protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CLATHRIN-COATED VESICLES; PLASMA-MEMBRANE; CLONING; AP-2; COMPONENTS; COMPLEXES; SUBUNIT; BINDING; CHAINS; GOLGI	The role of Eps15 in clathrin-mediated endocytosis is supported by two observations. First, it interacts specifically and constitutively with the plasma membrane adaptor AP-2. Second, its NH2 terminus shows significant homology to the NH2 terminus of yeast End3p, necessary for endocytosis of Lu-factor. To gain further insight into the role of Eps15-AP-2 association, we have now delineated their sites of interactions. AP-2 binds to a domain of 72 amino acids (767-739) present in the COOH terminus of Fps15. This domain contains 4 of the 15 DPF repeats characteristic of the COOH-terminal domain of Eps15 and shares no homology with known proteins, including the related Fps15r protein. Precipitation of proteolytic fragments of AP-2 with Eps15-derived fusion proteins containing the binding site for AP-2 showed that Eps15 binds specifically to a 40-kDa fragment corresponding to the ear of alpha-adaptin, a result confirmed by precipitation of Eps15 by alpha-adaptin-derived fusion proteins. Our data indicate that this specific part of AP-2 binds to a cellular component and provide the tools for investigating the function(s) of the association between AP-2 and Eps15.	HOP NECKER ENFANTS MALAD,INSERM,U429,F-75743 PARIS 15,FRANCE; INST PASTEUR,CNRS,URA 1960,UNITE BIOL INTERACT CELLULAIRES,F-75724 PARIS 15,FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris			Begue, Bernadette/I-2744-2017; benmerah, alexandre/H-3742-2017; Cerf-Bensussan, nadine/H-9505-2017	Begue, Bernadette/0000-0002-1228-9978; benmerah, alexandre/0000-0003-0188-8016; Cerf-Bensussan, nadine/0000-0003-0665-1245				AHLE S, 1989, J BIOL CHEM, V264, P20089; BECK KA, 1991, J BIOL CHEM, V266, P4442; BECK KA, 1991, J BIOL CHEM, V266, P4437; BENEDETTI H, 1994, MOL BIOL CELL, V5, P1023, DOI 10.1091/mbc.5.9.1023; Benmerah A, 1995, J CELL BIOL, V131, P1831, DOI 10.1083/jcb.131.6.1831; BRODSKY FM, 1988, SCIENCE, V242, P1396, DOI 10.1126/science.2904698; CHANG MP, 1993, EMBO J, V12, P2169, DOI 10.1002/j.1460-2075.1993.tb05865.x; FAZIOLI F, 1993, MOL CELL BIOL, V13, P5814, DOI 10.1128/MCB.13.9.5814; GALLUSSER A, 1993, EMBO J, V12, P5237, DOI 10.1002/j.1460-2075.1993.tb06219.x; GOODMAN OB, 1995, J BIOL CHEM, V270, P23768, DOI 10.1074/jbc.270.40.23768; KEEN JH, 1990, ANNU REV BIOCHEM, V59, P415, DOI 10.1146/annurev.biochem.59.1.415; KIRCHHAUSEN T, 1991, J BIOL CHEM, V266, P11153; KIRCHHAUSEN T, 1989, P NATL ACAD SCI USA, V86, P2612, DOI 10.1073/pnas.86.8.2612; LINDNER R, 1992, J BIOL CHEM, V267, P16567; NATKE IS, 1992, CELL, V68, P899; OHNO H, 1995, SCIENCE, V269, P1872, DOI 10.1126/science.7569928; PAGE LJ, 1995, J CELL BIOL, V131, P619, DOI 10.1083/jcb.131.3.619; PONNAMBALAM S, 1990, J BIOL CHEM, V265, P4814; ROBINSON M S, 1992, Trends in Cell Biology, V2, P293, DOI 10.1016/0962-8924(92)90118-7; ROBINSON MS, 1993, J CELL BIOL, V123, P67, DOI 10.1083/jcb.123.1.67; ROBINSON MS, 1989, J CELL BIOL, V108, P833, DOI 10.1083/jcb.108.3.833; ROBINSON MS, 1987, J CELL BIOL, V104, P887, DOI 10.1083/jcb.104.4.887; ROBINSON MS, 1990, J CELL BIOL, V111, P2319, DOI 10.1083/jcb.111.6.2319; SCHRODER S, 1991, J BIOL CHEM, V266, P7910; SCHUMACHER C, 1995, J BIOL CHEM, V270, P15341, DOI 10.1074/jbc.270.25.15341; SORKIN A, 1995, J BIOL CHEM, V270, P619, DOI 10.1074/jbc.270.2.619; THURIEAU C, 1988, DNA-J MOLEC CELL BIO, V7, P663, DOI 10.1089/dna.1988.7.663; WONG WT, 1994, ONCOGENE, V9, P1591; WONG WT, 1995, P NATL ACAD SCI USA, V92, P9530, DOI 10.1073/pnas.92.21.9530	29	166	169	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 17	1996	271	20					12111	12116		10.1074/jbc.271.20.12111	http://dx.doi.org/10.1074/jbc.271.20.12111			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UL250	8662627	hybrid			2022-12-25	WOS:A1996UL25000079
J	Jin, DJ				Jin, DJ			A mutant RNA polymerase reveals a kinetic mechanism for the switch between nonproductive stuttering synthesis and productive initiation during promoter clearance	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PSEUDO-TEMPLATED TRANSCRIPTION; ESCHERICHIA-COLI; RIFAMPICIN-RESISTANT; TRANSCRIBING COMPLEX; PYRBI OPERON; BETA-SUBUNIT; INHIBITION; MUTATIONS; INVITRO; ELONGATION	During transcription initiation from galP2, one of the two promoters of the Escherichia coli galactose operon with an initially transcribed sequence of pppAUUUC, RNA polymerase (RNAP) is known to engage nonproductive stuttering synthesis, which is sensitive to the concentration of UTP. This study examines the effect of this nonproductive synthesis on promoter clearance and determines other parameters that might affect stuttering synthesis by analyzing a mutant RNAP, RpoB3449, that has altered its function at this process at galP2, RpoB3449 has dramatically diminished stuttering synthesis, and consequently, it has increased the rate of productive initiation due to its enhanced rate of promoter clearance of galP2 compared with wild-type RNAP. Thus, a direct linkage between promoter clearance and productive transcription is demonstrated. The mechanism by which the mutant RNAP has altered the switch between nonproductive stuttering synthesis and productive initiation during promoter clearance is studied. Apparently, RpoB3449 has increased its efficiency in incorporating CTP at the +5 position of the galP2 transcript leading to its reduced stuttering synthesis, indicating that the rate of an RNAP incorporating the CTP after a stretch of uridine residues is important for promoter clearance at galP2. Because RpoB3449 demonstrates ''wild-type'' stuttering synthesis at the mutant galP2 promoter, which contains the 6 residue at the +5 position, it indicates that the mutant RNAP has altered in binding CTP at this context, Further experiments indicate that it is the +5 position per se of the galP2 sequence rather than a particular nucleotide at that position that is critical in determining the switch between the two alternate pathways during transcription initiation, A checkpoint model for the switch between nonproductive and productive initiations during promoter clearance is discussed.			Jin, DJ (corresponding author), NCI,MOLEC BIOL LAB,NIH,BLDG 37,RM 2E14,9000 ROCKVILLE PIKE,BETHESDA,MD 20892, USA.							BUJARD H, 1986, RNA POLYMERASE REGUL, P95; CARPOUSIS AJ, 1980, BIOCHEMISTRY-US, V19, P3245, DOI 10.1021/bi00555a023; CHAMBERLIN MJ, 1994, HARVEY LECTURES 88, P1; CHOY HE, 1992, P NATL ACAD SCI USA, V89, P11264, DOI 10.1073/pnas.89.23.11264; DONAHUE JP, 1990, J BIOL CHEM, V265, P19091; GULLAND U, 1992, GENE, V114, P97, DOI 10.1016/0378-1119(92)90713-Y; GUO HC, 1990, BIOCHEMISTRY-US, V29, P10702, DOI 10.1021/bi00499a019; HAGER DA, 1990, BIOCHEMISTRY-US, V29, P7890, DOI 10.1021/bi00486a016; HARLEY CB, 1988, NUCLEIC ACIDS RES, V16, P7269, DOI 10.1093/nar/16.15.7269; Hawley D. K., 1982, PROMOTERS STRUCTURE, P54; HSU LM, 1995, P NATL ACAD SCI USA, V92, P11588, DOI 10.1073/pnas.92.25.11588; JACQUES JP, 1991, GENE DEV, V5, P707, DOI 10.1101/gad.5.5.707; JACQUES JP, 1990, GENE DEV, V4, P1801, DOI 10.1101/gad.4.10.1801; JIN DJ, 1988, J MOL BIOL, V202, P245, DOI 10.1016/0022-2836(88)90455-X; JIN DJ, 1991, J BIOL CHEM, V266, P14478; JIN DJ, 1992, P NATL ACAD SCI USA, V89, P1453, DOI 10.1073/pnas.89.4.1453; JIN DJ, 1994, J BIOL CHEM, V269, P17221; JIN DJ, 1988, J MOL BIOL, V202, P45, DOI 10.1016/0022-2836(88)90517-7; JIN DJ, 1994, J MOL BIOL, V236, P72, DOI 10.1006/jmbi.1994.1119; JIN DJ, 1988, J MOL BIOL, V204, P247, DOI 10.1016/0022-2836(88)90573-6; KAMMERER W, 1986, EMBO J, V5, P2995, DOI 10.1002/j.1460-2075.1986.tb04597.x; KASHLEV M, 1990, SCIENCE, V248, P1006, DOI 10.1126/science.1693014; LEE JY, 1991, P NATL ACAD SCI USA, V88, P6018, DOI 10.1073/pnas.88.14.6018; LEE JY, 1991, CELL, V66, P793, DOI 10.1016/0092-8674(91)90122-F; LIU CG, 1989, J BACTERIOL, V171, P3337, DOI 10.1128/jb.171.6.3337-3342.1989; LIU CG, 1994, GENE DEV, V8, P2904, DOI 10.1101/gad.8.23.2904; MARTIN FH, 1980, NUCLEIC ACIDS RES, V8, P2259; MCCLURE WR, 1985, ANNU REV BIOCHEM, V54, P171, DOI 10.1146/annurev.bi.54.070185.001131; MCCLURE WR, 1978, J BIOL CHEM, V253, P8949; MCDOWELL JC, 1994, SCIENCE, V266, P822, DOI 10.1126/science.7526463; MENENDEZ M, 1987, EMBO J, V6, P4227, DOI 10.1002/j.1460-2075.1987.tb02771.x; MUNSON LM, 1981, BIOCHEMISTRY-US, V20, P2081, DOI 10.1021/bi00511a003; MUSSO RE, 1977, CELL, V12, P847, DOI 10.1016/0092-8674(77)90283-5; MUSTAEV A, 1994, P NATL ACAD SCI USA, V91, P12036, DOI 10.1073/pnas.91.25.12036; SCHULZ W, 1981, NUCLEIC ACIDS RES, V9, P6889, DOI 10.1093/nar/9.24.6889; SEVERINOV K, 1993, J BIOL CHEM, V268, P14820; VONHIPPEL PH, 1984, ANNU REV BIOCHEM, V53, P389, DOI 10.1146/annurev.bi.53.070184.002133; XIONG XF, 1993, J MOL BIOL, V231, P569, DOI 10.1006/jmbi.1993.1310; ZHOU YN, 1995, J MOL BIOL, V253, P414, DOI 10.1006/jmbi.1995.0563	39	18	20	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 17	1996	271	20					11659	11667						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UL250	8662641				2022-12-25	WOS:A1996UL25000015
J	Li, X; Galanakis, D; Gabriel, DA				Li, X; Galanakis, D; Gabriel, DA			Transient intermediates in the thrombin activation of fibrinogen - Evidence for only the desAA species	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							B-BETA CHAIN; POLYMERIZATION SITES; LIGHT-SCATTERING; CALCIUM-BINDING; LOCALIZATION; CONVERSION; OLIGOMERS; KINETICS; SEGMENTS; CLEAVAGE	The structure of a fibrin gel depends on the nature of the fibrinogen activation products produced by thrombin and the physical condition under which assembly occurs. Two different structures of the intermediate fibrin protofibril have been proposed, the production of which requires different extents of fibrinopeptide A (FpA) cleavage from fibrinogen. The fibrin activation intermediates must be stable since time is required for the intermediates to diffuse to growing protofibrils. The classic Hall-Slayter model requires cleavage of both FpAs to form a desAA intermediate. The Hunziker model requires cleavage of only one FpA to form an AdesA intermediate. Electrophoretic quasi elastic light scattering has been used to show the time dependent production of the relevant fibrinogen activation intermediates that includes desAA but not AdesA.	UNIV N CAROLINA, SCH MED, DIV HEMATOL ONCOL, CHAPEL HILL, NC 27599 USA; UNIV N CAROLINA, SCH MED, CTR THROMBOSIS & HEMOSTASIS, CHAPEL HILL, NC 27599 USA; SUNY STONY BROOK, DEPT PATHOL, STONY BROOK, NY 11794 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook								ALKJAERSIG N, 1983, BIOCHEM J, V213, P75, DOI 10.1042/bj2130075; BAILEY K, 1951, NATURE, V167, P233, DOI 10.1038/167233a0; BALE MD, 1982, BIOPOLYMERS, V21, P2265, DOI 10.1002/bip.360211113; BERNE B. J., 1976, DYNAMIC LIGHT SCATTE; BLOMBACK B, 1978, NATURE, V275, P501, DOI 10.1038/275501a0; BUDZYNSKI AZ, 1983, ANN NY ACAD SCI, V408, P301, DOI 10.1111/j.1749-6632.1983.tb23253.x; CARR ME, 1989, BIOCHEMISTRY-US, V28, P1384, DOI 10.1021/bi00429a066; CARR ME, 1986, BIOCHEM J, V239, P513, DOI 10.1042/bj2390513; DIETLER G, 1986, BIOPOLYMERS, V25, P905, DOI 10.1002/bip.360250511; Doolittle R F, 1973, Adv Protein Chem, V27, P1, DOI 10.1016/S0065-3233(08)60446-5; ENDRES GF, 1966, BIOCHEMISTRY-US, V5, P1561, DOI 10.1021/bi00869a016; ENDRES GF, 1972, ARCH BIOCHEM BIOPHYS, V153, P266, DOI 10.1016/0003-9861(72)90445-6; FERRY JD, 1952, P NATL ACAD SCI USA, V38, P566, DOI 10.1073/pnas.38.7.566; FERRY JD, 1947, J AM CHEM SOC, V69, P388, DOI 10.1021/ja01194a066; GALANAKIS DK, 1987, BIOCHEMISTRY-US, V26, P2389, DOI 10.1021/bi00382a046; HALL CE, 1959, J BIOPHYS BIOCHEM CY, V5, P11, DOI 10.1083/jcb.5.1.11; HANTGAN RR, 1979, J BIOL CHEM, V254, P1272; HENSCHEN A, 1990, ADV EXP MED BIOL, V281, P49; HERMANS J, 1979, P NATL ACAD SCI USA, V76, P1189, DOI 10.1073/pnas.76.3.1189; HIGGINS DL, 1983, J BIOL CHEM, V258, P9276; HUNZIKER EB, 1990, J BIOL CHEM, V265, P7455; JANMEY PA, 1983, BIOCHEMISTRY-US, V22, P4336, DOI 10.1021/bi00287a026; JANMEY PA, 1982, BIOPOLYMERS, V21, P2253, DOI 10.1002/bip.360211112; JANMEY PA, 1983, BIOPOLYMERS, P2017; JOHNSON CS, 1981, SPECTROSCOPY BIOCH, V2, P177; Johnson Jr C. S., 1995, LASER LIGHT SCATTERI; LAUDANO AP, 1978, P NATL ACAD SCI USA, V75, P3085, DOI 10.1073/pnas.75.7.3085; LAUDANO AP, 1980, BIOCHEMISTRY-US, V19, P1013, DOI 10.1021/bi00546a028; LAURENT TC, 1958, ACTA CHEM SCAND, V12, P1875, DOI 10.3891/acta.chem.scand.12-1875; NIEUWENHUIZEN W, 1982, BIOCHIM BIOPHYS ACTA, V707, P190, DOI 10.1016/0167-4838(82)90349-1; OLEXA SA, 1980, P NATL ACAD SCI-BIOL, V77, P1374, DOI 10.1073/pnas.77.3.1374; OLEXA SA, 1981, J BIOL CHEM, V256, P3544; PANDYA BV, 1985, J BIOL CHEM, V260, P2994; SCHERAGA HA, 1957, ADV PROTEIN CHEM, V12, P1, DOI 10.1016/S0065-3233(08)60115-1; SHAINOFF JR, 1970, THROMB DIATH HAEMO, V39, P203; SHIMIZU A, 1986, P NATL ACAD SCI USA, V83, P591, DOI 10.1073/pnas.83.3.591; SMITH GF, 1980, BIOCHEM J, V185, P1; VARADI A, 1986, BIOCHEMISTRY-US, V25, P519, DOI 10.1021/bi00351a001; Ware B. R., 1974, Advances in Colloid and Interface Science, V4, P1, DOI 10.1016/0001-8686(74)80001-1; WARE BR, 1971, CHEM PHYS LETT, V12, P81, DOI 10.1016/0009-2614(71)80621-8; WEISEL JW, 1993, J MOL BIOL, V232, P285, DOI 10.1006/jmbi.1993.1382; WILF J, 1986, BIOCHEMISTRY-US, V25, P3124, DOI 10.1021/bi00359a009	42	9	12	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 17	1996	271	20					11767	11771		10.1074/jbc.271.20.11767	http://dx.doi.org/10.1074/jbc.271.20.11767			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UL250	8662661	hybrid			2022-12-25	WOS:A1996UL25000031
J	Mok, SC; Chan, WY; Wong, KK; Muto, MG; Berkowitz, RS				Mok, SC; Chan, WY; Wong, KK; Muto, MG; Berkowitz, RS			SPARC, an extracellular matrix protein with tumor-suppressing activity in human ovarian epithelial cells	ONCOGENE			English	Article						ovarian cancer; SPARC; tumor suppressor; RNA fingerprinting	MESSENGER-RNA; INSITU HYBRIDIZATION; ENDOTHELIAL-CELLS; OSTEONECTIN; EXPRESSION; GLYCOPROTEIN; GENE; SEQUENCES; SECRETION; TISSUES	SPARC, also termed osteonectin, BM-40 and 43K protein, is an acidic, cysteine-rich component of the extracellular matrix that has been shown to be directly regulated by progesterone and dexamethasone and indirectly by cytokines. By RNA fingerprinting technique, we cloned a SPARC homolog from the normal human ovarian surface epithelial (HOSE) cells and demonstrated that it is expressed at high levels in the normal HOSE cells but at much lower levels in ovarian carcinoma cells in vitro and in vivo. Subsequently, we transfected the full length SPARC cDNA into an ovarian carcinoma cell line SKOV3 and showed that it reduced the growth rate of the cancer cell line in culture and reduced the cell's ability to induce tumours in nude mice. These results suggest that SPARC may play an important role in growth and and differentiation of the HOSE cells and support the hypothesis that SPARC functions as a tumor suppressor.	PACIFIC NW LAB, RICHLAND, WA 99352 USA; CHINESE UNIV HONG KONG, DEPT ANAT, SHA TIN, HONG KONG	United States Department of Energy (DOE); Pacific Northwest National Laboratory; Chinese University of Hong Kong	Mok, SC (corresponding author), HARVARD UNIV, BRIGHAM & WOMENS HOSP, SCH MED, LAB GYNECOL ONCOL, DEPT OBSTET GYNECOL & REPROD BIOL, BOSTON, MA 02115 USA.		Chan, Wood Yee/R-6692-2018; Wong, K.-k./AAA-6589-2020	Chan, Wood Yee/0000-0002-7114-1463; Wong, K.-k./0000-0002-0375-6669	NATIONAL CANCER INSTITUTE [R01CA063381] Funding Source: NIH RePORTER; NCI NIH HHS [CA63381] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BELLAHCENE A, 1995, AM J PATHOL, V146, P95; BOLANDER ME, 1988, P NATL ACAD SCI USA, V85, P1919; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DOMENICUCCI C, 1988, BIOCHEM J, V253, P139, DOI 10.1042/bj2530139; DZIADEK M, 1986, EUR J BIOCHEM, V161, P455, DOI 10.1111/j.1432-1033.1986.tb10466.x; ENGEL J, 1987, BIOCHEMISTRY-US, V26, P6958, DOI 10.1021/bi00396a015; HOLLAND PWH, 1987, J CELL BIOL, V105, P473, DOI 10.1083/jcb.105.1.473; HOWE CC, 1990, EXP CELL RES, V188, P185, DOI 10.1016/0014-4827(90)90158-7; LANE TF, 1990, J CELL BIOL, V111, P3065, DOI 10.1083/jcb.111.6.3065; LANKAT-BUTTGEREIT B, 1991, Journal of Dermatological Science, V2, P300, DOI 10.1016/0923-1811(91)90054-2; LEE SW, 1991, P NATL ACAD SCI USA, V88, P2825, DOI 10.1073/pnas.88.7.2825; MASON IJ, 1986, EMBO J, V5, P1465, DOI 10.1002/j.1460-2075.1986.tb04383.x; MASON IJ, 1986, EMBO J, V5, P1831, DOI 10.1002/j.1460-2075.1986.tb04434.x; MOK CH, 1992, CANCER RES, V52, P5119; MOK SC, 1994, GYNECOL ONCOL, V52, P247, DOI 10.1006/gyno.1994.1040; MUNDLOS S, 1992, J HISTOCHEM CYTOCHEM, V40, P283, DOI 10.1177/40.2.1552170; MURANO S, 1991, MOL CELL BIOL, V11, P3905, DOI 10.1128/MCB.11.8.3905; NERI M, 1992, EUR J BIOCHEM, V205, P569, DOI 10.1111/j.1432-1033.1992.tb16814.x; NG KW, 1989, MOL ENDOCRINOL, V3, P2079, DOI 10.1210/mend-3-12-2079; NOMURA S, 1989, J BIOL CHEM, V264, P12201; NOMURA S, 1988, J CELL BIOL, V106, P441, DOI 10.1083/jcb.106.2.441; PIVER MS, 1992, GYNECOL ONCOL, P250; REED MJ, 1993, J HISTOCHEM CYTOCHEM, V41, P1467, DOI 10.1177/41.10.8245406; SAGE EH, 1992, BIOCHEM CELL BIOL, V70, P579, DOI 10.1139/o92-089; SAGE H, 1986, J CELL PHYSIOL, V127, P373, DOI 10.1002/jcp.1041270305; SAGE H, 1989, J HISTOCHEM CYTOCHEM, V37, P819, DOI 10.1177/37.6.2723400; SAGE H, 1984, J BIOL CHEM, V259, P3993; SUN LZ, 1994, J BIOL CHEM, V269, P26449; TERMINE JD, 1981, CELL, V26, P99, DOI 10.1016/0092-8674(81)90037-4; TSAO SW, 1995, EXP CELL RES, V218, P499, DOI 10.1006/excr.1995.1184; VILLARREAL XC, 1989, BIOCHEMISTRY-US, V28, P6483, DOI 10.1021/bi00441a049	31	124	130	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY 2	1996	12	9					1895	1901						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UK498	8649850				2022-12-25	WOS:A1996UK49800008
J	Biggs, PJ; Chapman, P; Lakhani, SR; Burn, J; Stratton, MR				Biggs, PJ; Chapman, P; Lakhani, SR; Burn, J; Stratton, MR			The cylindromatosis gene (cyld1) on chromosome 16q may be the only tumour suppressor gene involved in the development of cylindromas	ONCOGENE			English	Article						cylindroma; cylindromatosis; tumour suppressor gene	BASAL-CELL ADENOMA; TURBAN TUMOR; PAROTID-GLAND; DERMAL CYLINDROMAS; RETINOBLASTOMA; PATIENT; CANCER	Hereditary cylindromatosis is a rare autosomal dominant disease characterised by the development of multiple benign neoplasms of the skin, We recently localised the gene responsible for this disease (cyld1) to chromosome 16q12-q13 and provided evidence that it is a tumour suppressor gene (Biggs et al., 1995). We have now examined polymorphic markers on every chromosome, some of which are close to known tumour suppressor genes, in 25 tumours from 4 individuals with familial cylindromatosis, No loss of heterozygosity (LOH) was detected other than at loci on chromosome 16q. This observation suggests that the cyld1 gene may be the only tumour suppressor gene implicated in the development of cylindromas. We have also demonstrated LOH using markers on chromosome 16q in 8/14 (57%) sporadic cylindromas, indicating that the cyld1 gene is likely to be involved in the genesis of both familial and sporadic cylindromas.	INST CANC RES,HADDOW LABS,MOLEC CARCINOGENESIS SECT,SUTTON SM2 5NG,SURREY,ENGLAND; UNIV NEWCASTLE,DIV HUMAN GENET,NEWCASTLE TYNE NE2 4AA,TYNE & WEAR,ENGLAND; ROYAL MARSDEN NHS TRUST,DEPT HISTOPATHOL,SUTTON SM2 5PT,SURREY,ENGLAND	University of London; Institute of Cancer Research - UK; Newcastle University - UK; Royal Marsden NHS Foundation Trust			Lakhani, Sunil R/I-1970-2018; Biggs, Patrick Jon/H-3355-2014	Lakhani, Sunil R/0000-0003-4067-2760; Biggs, Patrick Jon/0000-0002-0285-4101; Burn, John/0000-0002-9823-2322				ABENOZA P, 1990, NEOPLASMS ECCRINE DI, P253; ALAWI MH, 1982, BRIT J PLAST SURG, V35, P167, DOI 10.1016/0007-1226(82)90157-6; AUTIOHARMAINEN H, 1988, CANCER-AM CANCER SOC, V61, P161, DOI 10.1002/1097-0142(19880101)61:1<161::AID-CNCR2820610127>3.0.CO;2-1; BIGGS PJ, 1995, IN PRESS NATURE GENE; CAVENEE WK, 1985, SCIENCE, V228, P501, DOI 10.1126/science.3983638; COLLINS N, 1995, ONCOGENE, V10, P1673; DEVILEE P, 1994, BBA-REV CANCER, V1198, P113, DOI 10.1016/0304-419X(94)90009-4; FABIAN RL, 1981, HEAD NECK SURG, V4, P165, DOI 10.1002/hed.2890040214; FERRANDIZ C, 1985, J CUTAN PATHOL, V12, P72, DOI 10.1111/j.1600-0560.1985.tb00432.x; FREEDMAN AM, 1989, ANN PLAS SURG, V22, P50, DOI 10.1097/00000637-198901000-00010; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; Harper P S, 1971, Birth Defects Orig Artic Ser, V7, P338; HYMA BA, 1988, ARCH PATHOL LAB MED, V112, P209; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; KNUDSON AG, 1993, P NATL ACAD SCI USA, V90, P10914, DOI 10.1073/pnas.90.23.10914; Lever W. F., 1990, HISTOPATHOLOGY SKIN; PINGITORE R, 1984, TUMORI, V70, P385, DOI 10.1177/030089168407000415; REINGOLD IM, 1977, CANCER, V40, P1702, DOI 10.1002/1097-0142(197710)40:4<1702::AID-CNCR2820400446>3.0.CO;2-A; SATO S, 1994, CANCER RES, V54, P5652; SMITH SA, 1992, NAT GENET, V2, P128, DOI 10.1038/ng1092-128; STRATTON MR, 1995, J PATHOL, V175, P195, DOI 10.1002/path.1711750207; VERNON HJ, 1988, J AM ACAD DERMATOL, V19, P397, DOI 10.1016/S0190-9622(88)70186-3; VOGELSTEIN B, 1989, SCIENCE, V244, P207, DOI 10.1126/science.2565047	23	54	54	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR 21	1996	12	6					1375	1377						3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UC067	8649842				2022-12-25	WOS:A1996UC06700025
J	Kondo, M; Matsuoka, S; Uchida, K; Osada, H; Nagatake, M; Takagi, K; Harper, JW; Takahashi, T; Elledge, SJ; Takahashi, T				Kondo, M; Matsuoka, S; Uchida, K; Osada, H; Nagatake, M; Takagi, K; Harper, JW; Takahashi, T; Elledge, SJ; Takahashi, T			Selective maternal-allele loss in human lung cancers of the maternally expressed p57(KIP2) gene at 11p15.5	ONCOGENE			English	Article						lung cancer; genomic imprinting; allele loss; p57(KIP2); cyclin dependent kinase inhibitor	SPORADIC WILMS-TUMOR; CHROMOSOME-11; HETEROZYGOSITY; P53; ABNORMALITIES; SUPPRESSION	Genomic imprinting at 11p15 is suggested to play a role in certain pediatric tumors such as Wilms' tumor, based on the findings of selective maternal loss of this chromosomal region, Although the allele loss at 11p15 is also frequent in a number of cancers of adults including lung, breast, and bladder cancers, possible involvement of genomic imprinting in these tumors has not been investigated extensively, p57(KIP2), a newly described member of the p21 cyclin-dependent kinase (CDK) inhibitor family which is thought to negatively regulate the cell cylce at the G(1) checkpoint, has been mapped to 11p15, In the present study, we searched for somatic p57(KIP2) mutations in lung cancer, but failed to find such alterations, Interestingly, however, we found that the p57(KIP2) gene is imprinted with maternal expression and that the maternal alleles had been selectively lost in 11 of 13 (85%) lung cancer cases carrying 11p15 deletions, this being a significant bias (P=0.01), These data provide the first evidence that genomic imprinting may play a role in the oncogenesis of not only rare pediatric tumors but also this common cancer of adults, suggesting that the imprinted p57(KIP2) CDK inhibitor gene is a potential target for maternally biased 11p15 deletions.	AICHI CANC CTR,RES INST,LAB ULTRASTRUCT RES,CHIKUSA KU,NAGOYA,AICHI 464,JAPAN; AICHI CANC CTR,RES INST,IMMUNOL LAB,CHIKUSA KU,NAGOYA,AICHI 464,JAPAN; BAYLOR COLL MED,VERNA & MARRS MCLEAN DEPT BIOCHEM,HOUSTON,TX 77030; BAYLOR COLL MED,DEPT HUMAN & MOL GENET,HOUSTON,TX 77030; NAGOYA UNIV,SCH MED,DEPT INTERNAL MED 2,SHOWA KU,NAGOYA,AICHI 466,JAPAN	Aichi Cancer Center; Aichi Cancer Center; Baylor College of Medicine; Baylor College of Medicine; Nagoya University			Osada, Hiroyuki/AAY-6254-2020; Takahashi, Takashi/I-7262-2014; Kondo, Masashi/I-7378-2014	Takahashi, Takashi/0000-0003-0615-7001; Harper, Jeffrey/0000-0002-6944-7236				DOWDY SF, 1991, SCIENCE, V254, P293, DOI 10.1126/science.1656527; EFSTRATIADIS A, 1994, CURR OPIN GENET DEV, V4, P265, DOI 10.1016/S0959-437X(05)80054-1; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; HARBOUR JW, 1988, SCIENCE, V241, P353, DOI 10.1126/science.2838909; HARPER JW, 1993, CELL, V75, P805; HATADA I, 1995, NAT GENET, V11, P204, DOI 10.1038/ng1095-204; HIBI K, 1994, ONCOGENE, V9, P611; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; KOI M, 1993, SCIENCE, V260, P361, DOI 10.1126/science.8469989; KONDO M, 1995, ONCOGENE, V10, P1193; KONDO M, 1994, ONCOGENE, V9, P3063; LEE MH, 1995, GENE DEV, V9, P639, DOI 10.1101/gad.9.6.639; MANNENS M, 1988, HUM GENET, V81, P41, DOI 10.1007/BF00283727; MATSUOKA S, 1995, GENE DEV, V9, P650, DOI 10.1101/gad.9.6.650; MOUTLON T, 1994, NAT GENET, V7, P440; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; OKAMOTO A, 1994, P NATL ACAD SCI USA, V91, P11045, DOI 10.1073/pnas.91.23.11045; PAL N, 1990, ONCOGENE, V5, P1665; RAZIN A, 1994, CELL, V77, P473, DOI 10.1016/0092-8674(94)90208-9; REEVE AE, 1989, MOL CELL BIOL, V9, P1799, DOI 10.1128/MCB.9.4.1799; SCHROEDER WT, 1987, AM J HUM GENET, V40, P413; SEIZINGER BR, 1991, CYTOGENET CELL GENET, V58, P1080, DOI 10.1159/000133722; SHIRAISHI M, 1987, JPN J CANCER RES, V78, P1302; STEENMAN MJC, 1994, NAT GENET, V7, P433, DOI 10.1038/ng0794-433; SURANI MA, 1993, NATURE, V366, P302, DOI 10.1038/366302a0; SUZUKI H, 1994, NAT GENET, V6, P332, DOI 10.1038/ng0494-332; TAKAHASHI T, 1989, SCIENCE, V246, P491, DOI 10.1126/science.2554494; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; WADEY RB, 1990, ONCOGENE, V5, P901; WASHIMI O, 1995, CANCER RES, V55, P514; WESTON A, 1989, P NATL ACAD SCI USA, V86, P5099, DOI 10.1073/pnas.86.13.5099	31	113	126	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR 21	1996	12	6					1365	1368						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UC067	8649840				2022-12-25	WOS:A1996UC06700023
J	Zubiaur, M; Forman, LW; Stice, LL; Faller, DV				Zubiaur, M; Forman, LW; Stice, LL; Faller, DV			A role for activated p21(ras) in inhibition regulation of platelet-derived growth factor (PDGF) type-beta receptor activation	ONCOGENE			English	Article						Ras; signal transduction; tyrosine phosphorylation; EGF; grb-2; syp	SH2-CONTAINING PHOSPHOTYROSINE PHOSPHATASE; PROTEIN-TYROSINE KINASES; PHOSPHOLIPASE-C-GAMMA; EJ-RAS ONCOGENE; SIGNAL TRANSDUCTION; CDNA CLONING; TRANSFORMED CELLS; PHOSPHORYLATION; EXPRESSION; BINDING	Ligand-stimulated Platelet-Derived Growth Factor [PDGF] type-beta receptor autophosphorylation, and tyrosine phosphorylation of receptor-associated signalling proteins, is blocked in cells expressing activated Ras genes. A factor present in membrane fractions of v-ras-expressing fibroblasts (Kbalb cells) dominantly inhibits the autophosphorylation of the PDGF type-beta receptor. Purification of this factor, via ion exchange, reveals that the inhibitor can be physically separated from the PDGF type-beta receptor, with reconstitution of PDGF type-beta receptor kinase activity in response to ligand binding. The inhibitor exhibited specificity for the PDGF type-beta receptor, and consistently co-purified with activated p21(ras), with Syp/PTP-2, and with Grb2. Neutralization of the p21(ras) protein from the Kbalb cell membranes by p21(ras)-specific monoclonal antibodies, however, completely removed the inhibition of PDGF type-beta receptor, rendering the PDGF type-beta receptor molecule capable of autophosphorylation in response to ligand. These results indicate that activated p21(ras) either interacts directly with the PDGF type-beta receptor to inhibit autokinase activity, or complexes with different molecules such as Syp and/or Grb2 at the cell membrane to act on another effector which then inhibits PDGF type-beta receptor function.	BOSTON UNIV,SCH MED,CTR CANC RES,BOSTON,MA 02118; BOSTON UNIV,SCH MED,DEPT MED,BOSTON,MA 02118; BOSTON UNIV,SCH MED,DEPT BIOCHEM,BOSTON,MA 02118; BOSTON UNIV,SCH MED,DEPT PEDIAT,BOSTON,MA 02118; BOSTON UNIV,SCH MED,DEPT MICROBIOL,BOSTON,MA 02118; BOSTON UNIV,SCH MED,DEPT PATHOL & LAB MED,BOSTON,MA 02118	Boston University; Boston University; Boston University; Boston University; Boston University; Boston University			Zubiaur, Mercedes/AAC-5792-2021; Zubiaur, Mercedes/K-9390-2014	Zubiaur, Mercedes/0000-0002-4127-3027; Zubiaur, Mercedes/0000-0002-4127-3027				BALTENSPERGER K, 1993, SCIENCE, V260, P1950, DOI 10.1126/science.8391166; BENJAMIN CW, 1988, P NATL ACAD SCI USA, V85, P4345, DOI 10.1073/pnas.85.12.4345; BENJAMIN CW, 1987, P NATL ACAD SCI USA, V84, P546, DOI 10.1073/pnas.84.2.546; BENNETT AM, 1994, P NATL ACAD SCI USA, V91, P7335, DOI 10.1073/pnas.91.15.7335; BOWENPOPE DF, 1989, J BIOL CHEM, V264, P2502; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; CAI H, 1990, MOL CELL BIOL, V10, P5314, DOI 10.1128/MCB.10.10.5314; CLAESSONWELSH L, 1989, P NATL ACAD SCI USA, V86, P4917, DOI 10.1073/pnas.86.13.4917; CLAESSONWELSH L, 1988, MOL CELL BIOL, V8, P3476, DOI 10.1128/MCB.8.8.3476; COHEN S, 1980, J BIOL CHEM, V255, P4834; DOWNING JR, 1991, ONCOGENE, V6, P607; EGAN SE, 1993, NATURE, V363, P15; ESCOBEDO JA, 1991, CELL, V65, P75, DOI 10.1016/0092-8674(91)90409-R; FENG GS, 1993, SCIENCE, V259, P1607, DOI 10.1126/science.8096088; FERAMISCO JR, 1985, NATURE, V314, P639, DOI 10.1038/314639a0; FURTH ME, 1982, J VIROL, V43, P294, DOI 10.1128/JVI.43.1.294-304.1982; HELDIN CH, 1989, J BIOL CHEM, V264, P8905; HUNTER T, 1989, CELL, V58, P1013, DOI 10.1016/0092-8674(89)90496-0; KANNER SB, 1991, MOL CELL BIOL, V11, P713, DOI 10.1128/MCB.11.2.713; KUMJIAN DA, 1989, P NATL ACAD SCI USA, V86, P8232, DOI 10.1073/pnas.86.21.8232; LECHLEIDER RJ, 1993, J BIOL CHEM, V268, P21478; LI W, 1994, MOL CELL BIOL, V14, P509, DOI 10.1128/MCB.14.1.509; LIN AH, 1988, MOL CELL BIOL, V18, P5052; LOWE PN, 1991, J BIOL CHEM, V266, P1672; MATSUI T, 1989, SCIENCE, V243, P800, DOI 10.1126/science.2536956; MEDEMA RH, 1991, J BIOL CHEM, V266, P21186; MEISENHELDER J, 1989, CELL, V57, P1109, DOI 10.1016/0092-8674(89)90048-2; MILARSKI KL, 1994, J BIOL CHEM, V269, P21239; MORRISON DK, 1989, CELL, V58, P649, DOI 10.1016/0092-8674(89)90100-1; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; MUNDSCHAU LJ, 1994, J BIOL CHEM, V269, P16137; PARRIES G, 1987, P NATL ACAD SCI USA, V84, P2648, DOI 10.1073/pnas.84.9.2648; QUINONES MA, 1991, J BIOL CHEM, V266, P14055; RAKE JB, 1991, J BIOL CHEM, V266, P5348; RAVICHANDRAN KS, 1995, MOL CELL BIOL, V15, P593; SASAOKA T, 1994, J BIOL CHEM, V269, P10734; SEIFERT RA, 1989, J BIOL CHEM, V264, P8771; SIGAL IS, 1986, P NATL ACAD SCI USA, V83, P4725, DOI 10.1073/pnas.83.13.4725; SUN H, 1994, TRENDS BIOCHEM SCI, V19, P480, DOI 10.1016/0968-0004(94)90134-1; TOMASKA L, 1993, BIOCHEM J, V293, P215, DOI 10.1042/bj2930215; TONKS NK, 1989, TRENDS BIOCHEM SCI, V14, P497, DOI 10.1016/0968-0004(89)90184-9; VOGEL W, 1993, SCIENCE, V259, P1611, DOI 10.1126/science.7681217; WAHL MI, 1989, MOL CELL BIOL, V9, P2934, DOI 10.1128/MCB.9.7.2934; WATERS SB, 1995, J BIOL CHEM, V270, P20883, DOI 10.1074/jbc.270.36.20883; WILLIAMS LT, 1989, SCIENCE, V243, P1564, DOI 10.1126/science.2538922; WU J, 1993, SCIENCE, V262, P1065, DOI 10.1126/science.7694366; XIAO S, 1994, J BIOL CHEM, V269, P21244; YARDEN Y, 1986, NATURE, V323, P226, DOI 10.1038/323226a0; ZULLO JN, 1988, MOL CELL BIOL, V8, P5080, DOI 10.1128/MCB.8.12.5080	49	9	9	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR 21	1996	12	6					1213	1222						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UC067	8649823				2022-12-25	WOS:A1996UC06700006
J	Zhang, GQ; Humphries, EH				Zhang, GQ; Humphries, EH			v-rel and c-rel induce a membrane protein, p75, on avian hematopoietic cells	ONCOGENE			English	Article						rel oncogene; p75; ectopic expression	NF-KAPPA-B; VIRUS STRAIN-T; RETICULOENDOTHELIOSIS VIRUS; TRANSCRIPTIONAL ACTIVATOR; ONCOGENIC TRANSFORMATION; GENE-EXPRESSION; LYMPHOID-CELLS; LINES; IDENTIFICATION; REPRESSION	v-rel-induced neoplasias are thought to be caused by the aberrant expression of cellular genes. Using a monoclonal antibody we detected a 75 kDa-protein (p75) on vrel-transformed chicken hematopoietic cells. This protein is normally expressed only on a certain type of non-T, non-B cells in the chicken caecal tonsils. Overexpression of v-rel in two B-cell lines and in splenic cells induced the expression of p75. In contrast, overexpression of c-rel in these cells resulted in variable expression of p75. These data indicated that p75 is ectopically expressed on v-rel-transformed hematopoietic cells and that it responds differently to v-rel and c-rel induction.	W VIRGINIA UNIV,HLTH SCI CTR,MARY BABB RANDOLPH CANC CTR,MORGANTOWN,WV 26506; W VIRGINIA UNIV,HLTH SCI CTR,DEPT MICROBIOL & IMMUNOL,MORGANTOWN,WV 26506	West Virginia University; West Virginia University					NATIONAL CANCER INSTITUTE [R01CA041450] Funding Source: NIH RePORTER; NCI NIH HHS [CA41450] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AKIYAMA Y, 1974, BIKEN J, V17, P105; BABA TW, 1985, VIROLOGY, V144, P139, DOI 10.1016/0042-6822(85)90312-5; BALLARD DW, 1990, CELL, V63, P803, DOI 10.1016/0092-8674(90)90146-6; BALLARD DW, 1992, P NATL ACAD SCI USA, V89, P1875, DOI 10.1073/pnas.89.5.1875; BARTH CF, 1988, J EXP MED, V167, P89, DOI 10.1084/jem.167.1.89; BARTH CF, 1988, MOL CELL BIOL, V8, P5358, DOI 10.1128/MCB.8.12.5358; BARTH CF, 1990, J VIROL, V64, P6054, DOI 10.1128/JVI.64.12.6054-6062.1990; BOEHMELT G, 1992, EMBO J, V11, P4641, DOI 10.1002/j.1460-2075.1992.tb05566.x; BOSE HR, 1992, BIOCHIM BIOPHYS ACTA, V1114, P1, DOI 10.1016/0304-419X(92)90002-G; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHEN CH, 1988, EUR J IMMUNOL, V18, P539, DOI 10.1002/eji.1830180408; CHEN CLH, 1986, J EXP MED, V164, P375, DOI 10.1084/jem.164.1.375; DAVIS N, 1990, J VIROL, V64, P584, DOI 10.1128/JVI.64.2.584-591.1990; GELINAS C, 1988, ONCOGENE, V3, P349; GILMORE TD, 1990, CELL, V62, P841, DOI 10.1016/0092-8674(90)90257-F; GRILLI M, 1993, INT REV CYTOL, V143, P1; HANNINK M, 1989, MOL CELL BIOL, V9, P4323, DOI 10.1128/MCB.9.10.4323; HANNINK M, 1991, Critical Reviews in Oncogenesis, V2, P293; Harlow E., 1988, ANTIBODIES LAB MANUA; HOELZER JD, 1980, VIROLOGY, V100, P462, DOI 10.1016/0042-6822(80)90536-X; HRDLICKOVA R, 1994, J VIROL, V68, P2371; HUFFNAGLE GB, 1989, HYBRIDOMA, V8, P589, DOI 10.1089/hyb.1989.8.589; HUMPHRIES EH, 1992, CURRENT TOPIC MICROB, V18, P475; KAMENS J, 1990, MOL CELL BIOL, V10, P2840, DOI 10.1128/MCB.10.6.2840; LEWIS RB, 1981, CELL, V25, P421, DOI 10.1016/0092-8674(81)90060-X; MOSCOVICI C, 1982, EXPRESSION DIFFERENT, P435; NAZERIAN K, 1982, J GEN VIROL, V58, P351, DOI 10.1099/0022-1317-58-2-351; NEHYBA J, 1994, J VIROL, V68, P2039, DOI 10.1128/JVI.68.4.2039-2050.1994; OKAZAKI W, 1980, AVIAN PATHOL, V9, P311, DOI 10.1080/03079458008418416; OLSON LD, 1967, AM J VET RES, V28, P1501; RICHARDSON PM, 1991, J VIROL, V65, P3122, DOI 10.1128/JVI.65.6.3122-3130.1991; WALKER WH, 1992, J VIROL, V66, P5018, DOI 10.1128/JVI.66.8.5018-5029.1992; WILHELMSEN KC, 1984, J VIROL, V52, P172, DOI 10.1128/JVI.52.1.172-182.1984; ZHANG GQ, 1995, MOL CELL BIOL, V15, P1806	34	7	7	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR 7	1996	12	5					1153	1157						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UA884	8649808				2022-12-25	WOS:A1996UA88400025
J	Shi, H; Severs, NJ; Robenek, H				Shi, H; Severs, NJ; Robenek, H			Effects of calcium on the migration and recruitment of macrophages and macrophage-derived foam cells	FASEB JOURNAL			English	Article						macrophage foam cell; atherosclerosis; lipoprotein; isradipine; Boyden chamber	LOW-DENSITY-LIPOPROTEIN; MOUSE PERITONEAL-MACROPHAGES; FAMILIAL HYPERCHOLESTEROLEMIA; CHANNEL BLOCKERS; ATHEROSCLEROSIS; ANTAGONISTS; ATHEROGENESIS; PATHOGENESIS; DEGRADATION; MECHANISMS	Calcium is thought to play an important role in the genesis of atherosclerotic lesions, but the precise mechanisms involved are unclear, In the present investigation, we have used in vitro systems to investigate the effects of calcium on one key aspect of lesion development: the migration of macrophages and macrophage/foam cells, Using agarose plate migration assays, the migratory characteristics of macrophages exposed to 1) no lipoprotein, 2) low density lipoprotein (LDL), 3) acetylated low density lipoprotein (acLDL), and) oxidized low density lipoprotein were examined. The most marked stimulatory effect on macrophage mobility was observed when freshly isolated cells were exposed to acLDL during the migration assay. High levels of exogenous calcium were found to suppress the stimulatory effect of acLDL on migration, As the responses of macrophages exposed to a uniform concentration of agents in the surrounding medium may differ from chemotactic responses to a concentration gradient, the migration of macrophages, with and without preexposure to acLDL or LDL, was studied using microchemotaxis Boyden chambers, Under these conditions, calcium acted as a highly potent chemoattractant, especially to cells that had been preincubated with acLDL. These results suggest how elevated external calcium concentration leads initially to macrophage recruitment, and subsequently to foam cell aggregation and lipid core formation, in association with calcification, in the developing atherosclerotic plaque.	UNIV MUNSTER,DEPT CELL BIOL & ULTRASTRUCT RES,INST ARTERIOSCLEROSIS RES,D-48149 MUNSTER,GERMANY; ROYAL BROMPTON HOSP,NATL HEART & LUNG INST,UNIV LONDON IMPERIAL COLL SCI TECHNOL & MED,LONDON SW3 6LY,ENGLAND	University of Munster; Imperial College London; Royal Brompton Hospital								BASU SK, 1976, P NATL ACAD SCI USA, V73, P3178, DOI 10.1073/pnas.73.9.3178; BERNINI F, 1991, J CARDIOVASC PHARM, V18, pS42; Blumenthal Herman T., 1944, AMER JOUR PATH, V20, P665; BORN GVR, 1991, CALCIUM ANTAGONISM A, P1; Campbell A.K, 1983, INTRACELLULAR CALCIU; CHARO IF, 1994, P NATL ACAD SCI USA, V91, P2752, DOI 10.1073/pnas.91.7.2752; CONRAD DJ, 1992, P NATL ACAD SCI USA, V89, P217, DOI 10.1073/pnas.89.1.217; DAUGHERTY A, 1987, BRIT J PHARMACOL, V91, P113, DOI 10.1111/j.1476-5381.1987.tb08989.x; DUSHKIN MI, 1991, BIOCHEMISTRY-MOSCOW+, V56, P551; FALK E, 1992, CIRCULATION, V86, P30; FISHER M, 1991, CEREBROVAS BRAIN MET, V3, P114; FITZPATRICK LA, 1994, J CLIN INVEST, V94, P1597, DOI 10.1172/JCI117501; FLECKENSTEIN A, 1986, AM J CARDIOL, V57, pD1, DOI 10.1016/0002-9149(86)90798-8; FLECKENSTEIN A, 1983, CIRC RES, V52, P3; FLECKENSTEINGRUN G, 1991, ANN MED, V23, P589, DOI 10.3109/07853899109150522; GERRITY RG, 1981, AM J PATHOL, V103, P191; GERRITY RG, 1981, AM J PATHOL, V103, P181; HABIB JB, 1986, CIRC RES, V58, P305, DOI 10.1161/01.RES.58.2.305; HANDLEY DA, 1986, AM J PATHOL, V124, P88; HARA S, 1992, ARTERIOSCLER THROMB, V12, P593, DOI 10.1161/01.ATV.12.5.593; HENRIKSEN T, 1983, ARTERIOSCLEROSIS, V3, P149, DOI 10.1161/01.ATV.3.2.149; HENRY PD, 1991, J CARDIOVASC PHARM, V18, pS6, DOI 10.1097/00005344-199106181-00003; HENRY PD, 1990, ARTERIOSCLEROSIS, V10, P963, DOI 10.1161/01.ATV.10.6.963; HO YK, 1980, J LIPID RES, V21, P391; KITA T, 1987, P NATL ACAD SCI USA, V84, P5928, DOI 10.1073/pnas.84.16.5928; KODAMA T, 1990, NATURE, V343, P531, DOI 10.1038/343531a0; LICHTLEN PR, 1990, CARDIOVASC DRUG THER, V4, P1017; MALAYEV A, 1995, J MEMBRANE BIOL, V146, P101; Meyer W W, 1971, Monatsschr Kinderheilkd, V119, P298; NAYLER W, 1991, 2 GENERATION CALCIUM; NAYLER WG, 1992, J HUM HYPERTENS, V6, pS19; NAYLER WG, 1992, J CARDIOVASC PHARM, V19, pS17, DOI 10.1097/00005344-199219002-00005; NOMOTO A, 1987, ATHEROSCLEROSIS, V64, P255, DOI 10.1016/0021-9150(87)90253-X; OBRIEN ER, 1994, ARTERIOSCLER THROMB, V14, P1648, DOI 10.1161/01.ATV.14.10.1648; PALINSKI W, 1989, P NATL ACAD SCI USA, V86, P1372, DOI 10.1073/pnas.86.4.1372; PARTHASARATHY S, 1992, ANNU REV MED, V43, P219, DOI 10.1146/annurev.me.43.020192.001251; PATAKI M, 1992, ARTERIOSCLER THROMB, V12, P936, DOI 10.1161/01.ATV.12.8.936; PAULETTO P, 1992, J CARDIOVASC PHARM, V19, pS8, DOI 10.1097/00005344-199219002-00004; ROBENEK H, 1988, ARTERIOSCLEROSIS, V8, P57, DOI 10.1161/01.ATV.8.1.57; ROBENEK H, 1985, EUR J CELL BIOL, V39, P77; ROHRER L, 1990, NATURE, V343, P570, DOI 10.1038/343570a0; ROSS R, 1995, ANNU REV PHYSIOL, V57, P791, DOI 10.1146/annurev.ph.57.030195.004043; ROSS R, 1993, TRANSPLANT P, V25, P2041; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; SARIG S, 1994, LAB INVEST, V71, P782; SCHMID K, 1980, ATHEROSCLEROSIS, V37, P199, DOI 10.1016/0021-9150(80)90005-2; SCHMITZ G, 1985, EMBO J, V4, P613, DOI 10.1002/j.1460-2075.1985.tb03674.x; SCHMITZ G, 1991, ATHEROSCLEROSIS, V88, P109, DOI 10.1016/0021-9150(91)90074-D; SCHMITZ G, 1988, ARTERIOSCLEROSIS, V8, P45; SCHUH J, 1978, P NATL ACAD SCI USA, V75, P3173, DOI 10.1073/pnas.75.7.3173; SCHWARTZ CJ, 1992, CIRCULATION, V86, P117; SHANAHAN CM, 1994, J CLIN INVEST, V93, P2393, DOI 10.1172/JCI117246; STEINBRECHER UP, 1984, P NATL ACAD SCI-BIOL, V81, P3883, DOI 10.1073/pnas.81.12.3883; TAKEO S, 1989, ATHEROSCLEROSIS, V77, P175, DOI 10.1016/0021-9150(89)90079-8; TRIGGLE DJ, 1991, CALCIUM ANTAGONISM A, P27; WALERS D, 1992, CIRCULATION S, V86, P111; WEISSER B, 1992, ARTERIOSCLER THROMB, V12, P231, DOI 10.1161/01.ATV.12.2.231; WISSLER RW, 1992, ARCH PATHOL LAB MED, V116, P1281; WITTEMAN JCM, 1990, AM J CARDIOL, V66, P1060, DOI 10.1016/0002-9149(90)90505-U; WITZTUM JL, 1991, ADV EXP MED BIOL, V285, P353	60	14	14	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	MAR	1996	10	4					491	501		10.1096/fasebj.10.4.8647348	http://dx.doi.org/10.1096/fasebj.10.4.8647348			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	UE557	8647348				2022-12-25	WOS:A1996UE55700013
J	Rao, VN; Shao, NS; Ahmad, M; Reddy, ESP				Rao, VN; Shao, NS; Ahmad, M; Reddy, ESP			Antisense RNA to the putative tumor suppressor gene BRCA1 transforms mouse fibroblasts	ONCOGENE			English	Article						BRCA1 proteins; antisense RNA; tumor suppressor; breast and ovarian cancers	FAMILIAL BREAST; OVARIAN-CANCER; CHROMOSOME; REGION	Recently, BRCA1, a familial breast and ovarian cancer susceptible gene has been cloned and shown to be either lost or mutated in families with breast and ovarian cancers, BRCA1 has been postulated to encode a tumor suppressor, a protein that acts as a negative regulator of tumor growth, We have characterized the BRCA1 gene products by Western blot and immunoprecipitation analysis in mouse and tumor cells. Multiple BRCA1 polypeptides of approximately 225, 185, 160, 145, 100, 52 and 38 kD were identified in these cells, BRCA1 proteins were found to be localized mainly in the nucleus of normal Rat1 cells and human breast cancer cells, Tn order to understand the role of BRCA1 in cell transformation, we have established a stable NIH3T3 cell line expressing BRCA1 antisense RNA. The inhibition of expression of endogenous BRCA1 protein was detected in NIH3T3 transfectants by Western blot analysis, The antisense BRCA1 expressing NIH3T3 cells showed accelerated growth rate, anchorage independent growth and tumorigenicity in nude mice unlike the parental and sense transfectants, These results provide the first direct biological evidence for the possible function of BRCA1 as a tumor suppressor gene.			Rao, VN (corresponding author), THOMAS JEFFERSON UNIV, JEFFERSON CANC INST, DEPT MICROBIOL & IMMUNOL, 233 S 10TH ST, PHILADELPHIA, PA 19107 USA.				NATIONAL CANCER INSTITUTE [P01CA050507, R01CA057322, R01CA057157] Funding Source: NIH RePORTER; NCI NIH HHS [CA 57322, CA 57157, CA 50507] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		CLAUS EB, 1991, AM J HUM GENET, V48, P232; EASTON DF, 1993, AM J HUM GENET, V52, P678; FUTREAL PA, 1994, SCIENCE, V266, P120, DOI 10.1126/science.7939630; HOSKING L, 1995, NAT GENET, V9, P343, DOI 10.1038/ng0495-343; ISZAT JG, 1984, CELL, V36, P1007; KELSELL DP, 1993, HUM MOL GENET, V2, P1823; LOVELAND BE, 1992, BIOCHEM INT, V27, P501; MERAJVER SD, 1995, NAT GENET, V9, P439, DOI 10.1038/ng0495-439; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; RAO VN, 1989, SCIENCE, V244, P66, DOI 10.1126/science.2539641; RAO VN, 1993, CANCER RES, V53, P215; SMITH HS, 1993, J CELL BIOCHEM, P144; SMITH SA, 1992, NAT GENET, V2, P128, DOI 10.1038/ng1092-128; TAKAHASHI H, 1995, CANCER RES, V55, P2998; THOMPSON ME, 1995, NAT GENET, V9, P444, DOI 10.1038/ng0495-444	15	99	101	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 1	1996	12	3					523	528						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TV597	8637708				2022-12-25	WOS:A1996TV59700008
J	Soprano, DR; Chen, LX; Wu, S; Donigan, AM; Borghaei, RC; Soprano, KJ				Soprano, DR; Chen, LX; Wu, S; Donigan, AM; Borghaei, RC; Soprano, KJ			Overexpression of both RAR and RXR restores AP-1 repression in ovarian adenocarcinoma cells resistant to retinoic acid-dependent growth inhibition	ONCOGENE			English	Article						retinoic acid receptor; retinoic acid resistance; ovarian carcinoma cells; AP-1 antagonism	RECEPTOR-ALPHA; X RECEPTOR; EXPRESSION; LINES; CARCINOMA; COMPLEX; GAMMA; BETA; MICE; GENE	Retinoids including retinoic acid (RA) have been demonstrated to be effective growth inhibitors of a number of human cancer cell lines including ovarian adenocarcinoma cells, To begin to determine the mechanism of action by which RA inhibits the growth of ovarian carcinoma cells, we have examined AP-1 activity in two representative cell lines: CaOV-3 a RA-sensitive cell line and SK-OV-3 a RA-resistant cell line, AP-1 activity was found to be inhibited by 50% upon RA treatment of the RA-sensitive cells while there was no change in AP-1 activity following RA treatment of the RA-resistant cells, Maximal inhibition of AP-1 activity could be achieved in the RA-resistant SK-OV-3 cells by overexpression of any one of the three retinoic acid receptor (RAR) subtypes in conjunction with retinoid X receptor (RXR) alpha. This inhibition of AP-1 activity was nearly comparable to that of the RA-sensitive cells, A similar change in AP-1 complex formation in vitro has also been observed, These results suggest that one mechanism by which RA inhibits growth of RA-sensitive ovarian carcinoma cells is by repressing AP-1 activity, Moreover, in the RA-resistant cells the RAR/RXR signalling pathway leading to inhibition of AP-1 activity is impaired however overexpression of one of the RAR subtypes along with RXR alpha is sufficient to restore this pathway.	TEMPLE UNIV,SCH MED,FELS INST CANC RES & MOLEC BIOL,PHILADELPHIA,PA 19140; TEMPLE UNIV,SCH MED,DEPT BIOCHEM,PHILADELPHIA,PA 19140; TEMPLE UNIV,SCH MED,DEPT IMMUNOL & MICROBIOL,PHILADELPHIA,PA 19140	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University				Borghaei, Ruth/0000-0003-4206-0231	NATIONAL CANCER INSTITUTE [R01CA064945] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK044517, R01DK049045] Funding Source: NIH RePORTER; NCI NIH HHS [CA 64945] Funding Source: Medline; NIDDK NIH HHS [DK44517, DK 49045] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; Baserga R, 1969, AUTORADIOGRAPHY TECH; CALIARO MJ, 1994, INT J CANCER, V56, P743, DOI 10.1002/ijc.2910560522; CARTER R, 1991, ONCOGENE, V6, P229; CHEN JY, 1995, EMBO J, V14, P1187, DOI 10.1002/j.1460-2075.1995.tb07102.x; EUSTICE DC, 1991, BIOTECHNIQUES, V11, P739; FANJUL A, 1994, NATURE, V372, P107, DOI 10.1038/372107a0; GRUNT TW, 1991, J CELL SCI, V100, P657; HARANT H, 1993, BRIT J CANCER, V68, P530, DOI 10.1038/bjc.1993.381; HEYMAN RA, 1992, CELL, V68, P397, DOI 10.1016/0092-8674(92)90479-V; Hong Waun Ki, 1994, P597; HONG WK, 1990, NEW ENGL J MED, V323, P795, DOI 10.1056/NEJM199009203231205; HUANG ME, 1988, BLOOD, V72, P567, DOI 10.1182/blood.V72.2.567.567; LANGDON SP, 1988, CANCER RES, V48, P6161; LEVIN AA, 1992, NATURE, V355, P359, DOI 10.1038/355359a0; LI E, 1993, P NATL ACAD SCI USA, V90, P1590, DOI 10.1073/pnas.90.4.1590; LOHNES D, 1993, CELL, V73, P643, DOI 10.1016/0092-8674(93)90246-M; LUFKIN T, 1993, P NATL ACAD SCI USA, V90, P7225, DOI 10.1073/pnas.90.15.7225; Mangelsdorf David J., 1994, P319; MARTH C, 1989, ANTICANCER RES, V9, P461; MENDELSOHN C, 1994, DEVELOPMENT, V120, P2723; NAGPAL S, 1995, J BIOL CHEM, V270, P923, DOI 10.1074/jbc.270.2.923; ORTH K, 1994, P NATL ACAD SCI USA, V91, P9495, DOI 10.1073/pnas.91.20.9495; OWEN TA, 1987, J BIOL CHEM, V262, P15111; PAN LY, 1992, NUCLEIC ACIDS RES, V20, P3105, DOI 10.1093/nar/20.12.3105; PAN LY, 1995, J CELL BIOCHEM, V57, P575, DOI 10.1002/jcb.240570402; PENA A, 1993, J BIOL CHEM, V268, P27277; PFAHL M, 1993, ENDOCR REV, V14, P651, DOI 10.1210/er.14.5.651; SALBERT G, 1993, MOL ENDOCRINOL, V7, P1347, DOI 10.1210/me.7.10.1347; SCHULE R, 1991, P NATL ACAD SCI USA, V88, P6092, DOI 10.1073/pnas.88.14.6092; SEED B, 1988, GENE, V67, P271, DOI 10.1016/0378-1119(88)90403-9; SMITH MA, 1992, J CLIN ONCOL, V10, P839, DOI 10.1200/JCO.1992.10.5.839	32	36	36	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB 1	1996	12	3					577	584						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TV597	8637715				2022-12-25	WOS:A1996TV59700015
J	Hsu, MH; Chirala, SS; Wakil, SJ				Hsu, MH; Chirala, SS; Wakil, SJ			Human fatty-acid synthase gene - Evidence for the presence of two promoters and their functional interaction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA; TRANSCRIPTIONAL INTERFERENCE; MOLECULAR-CLONING; LIVER; EXPRESSION; ENZYME; TERMINATION; SEQUENCES; REGION	We have isolated and sequenced a genomic clone coding for the first three exons and the 5'-flanking region of the human fatty-acid synthase gene, The translation initiation site, ATG, is located in exon II. Primer extension and S1 nuclease analyses showed the presence of three transcription initiation (Ti) sites: Ti I, Ti II, and Ti III, The Ti I site is mapped to the beginning of the untranslated exon I and preceded by a promoter with recognizable TATA and CAAT boxes. The Ti II and Ti III sites are located in intron I, at 60 and 49 nucleotides upstream of the translation initiation site ATG in exon II , respectively, These two Ti sites are preceded by four putative Sp1 boxes, but lack TATA and CAAT boxes, Analysis of luciferase reporter gene expression in transient transfection assays confirmed the existence of two promoters, A 200-base pair 5'-flanking region, which has strong promoter activity comparable with that of the CMV promoter, is considered human fatty-acid synthase promoter I. In a wild-type human fatty-acid synthase-luciferase construct, in which promoter I and intron I are present in their natural configuration, the reporter gene activity is only 1% of that of promoter I. Deletion analysis showed the existence of promoter II, which is located in intron I immediately upstream of the Ti II site. The strength of promoter II is approximately 1/15th of that of promoter I in transient transfection assays, Further analysis of reporter gene constructs showed that promoter II inhibited the reporter gene activity of the wildtype construct that contained promoter I and intron I and that the spatial separation of the two promoters is important for this inhibition, A model is proposed based on the possibility that the assembly of transcription complexes on promoter HP creates a ''roadblock'' and reduces the overall expression of the fatty-acid synthase gene by interfering with the progression of transcription from promoter I.	BAYLOR COLL MED, VERNA & MARRS MCLEAN DEPT BIOCHEM, HOUSTON, TX 77030 USA	Baylor College of Medicine					NIGMS NIH HHS [GM-19091] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMY CM, 1990, BIOCHEM J, V271, P675, DOI 10.1042/bj2710675; AMY CM, 1992, P NATL ACAD SCI USA, V89, P1105, DOI 10.1073/pnas.89.3.1105; BACK DW, 1986, J BIOL CHEM, V261, P4190; Beck K F, 1992, DNA Seq, V2, P359, DOI 10.3109/10425179209020817; BEELMAN CA, 1995, CELL, V81, P179, DOI 10.1016/0092-8674(95)90326-7; BENNETT MK, 1995, J BIOL CHEM, V270, P25578, DOI 10.1074/jbc.270.43.25578; BERK AJ, 1977, CELL, V12, P721, DOI 10.1016/0092-8674(77)90272-0; BRIGGS MR, 1986, SCIENCE, V234, P47, DOI 10.1126/science.3529394; CHALBOS D, 1991, J BIOL CHEM, V266, P8220; CHIRALA SS, 1992, P NATL ACAD SCI USA, V89, P10232, DOI 10.1073/pnas.89.21.10232; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CULLEN BR, 1984, NATURE, V307, P241, DOI 10.1038/307241a0; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; GOODRIDGE AG, 1984, ARCH BIOCHEM BIOPHYS, V230, P82, DOI 10.1016/0003-9861(84)90088-2; HA J, 1994, EUR J BIOCHEM, V219, P297, DOI 10.1111/j.1432-1033.1994.tb19941.x; HILLGARTNER F, 1995, PHYSIOL REV, V75, P47, DOI 10.1152/physrev.1995.75.1.47; HOFFMANN GE, 1980, BIOCHIM BIOPHYS ACTA, V620, P151, DOI 10.1016/0005-2760(80)90194-0; HUNT CR, 1986, P NATL ACAD SCI USA, V83, P3786, DOI 10.1073/pnas.83.11.3786; IRITANI N, 1992, J NUTR, V122, P28, DOI 10.1093/jn/122.1.28; IRNIGER S, 1992, NUCLEIC ACIDS RES, V20, P4733, DOI 10.1093/nar/20.18.4733; JAYAKUMAR A, 1995, P NATL ACAD SCI USA, V92, P8695, DOI 10.1073/pnas.92.19.8695; JAYAKUMAR A, 1994, GENOMICS, V23, P420, DOI 10.1006/geno.1994.1518; KAMEDA K, 1995, MOL CELL BIOCHEM, V144, P105, DOI 10.1007/BF00944388; KAMEDA K, 1991, J BIOL CHEM, V266, P419; KASTURI R, 1988, BIOCHEMISTRY-US, V27, P7778, DOI 10.1021/bi00420a029; LOPEZCASILLAS F, 1989, J BIOL CHEM, V264, P7176; Maniatis T., 1982, MOL CLONING; Miller JH, 1972, EXPT MOL GENETICS, P403; MOHAMED AH, 1988, J BIOL CHEM, V263, P12315; MONACO L, 1994, J BIOL CHEM, V269, P347; MORRIS SM, 1982, J BIOL CHEM, V257, P3225; MOUSTAID N, 1991, J BIOL CHEM, V266, P18550; MOUSTAID N, 1994, J BIOL CHEM, V269, P5629; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; PONCZ M, 1982, P NATL ACAD SCI-BIOL, V79, P4298, DOI 10.1073/pnas.79.14.4298; PROUDFOOT NJ, 1986, NATURE, V322, P562, DOI 10.1038/322562a0; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEMENKOVICH CF, 1993, J BIOL CHEM, V268, P6961; SHRAGO E, 1969, J BIOL CHEM, V244, P2761; Soncini M, 1995, J BIOL CHEM, V270, P30339, DOI 10.1074/jbc.270.51.30339; STAPLETON SR, 1990, J BIOL CHEM, V265, P18442; TAE HJ, 1994, J BIOL CHEM, V269, P10475; TOWLE HC, 1995, J BIOL CHEM, V270, P23235, DOI 10.1074/jbc.270.40.23235; WAKIL SJ, 1983, ANNU REV BIOCHEM, V52, P537, DOI 10.1146/annurev.bi.52.070183.002541; WAKIL SJ, 1989, BIOCHEMISTRY-US, V28, P4523, DOI 10.1021/bi00437a001; WANG D, 1995, J BIOL CHEM, V270, P28716, DOI 10.1074/jbc.270.48.28716; WOLF SS, 1994, BIOCHEM BIOPH RES CO, V203, P943, DOI 10.1006/bbrc.1994.2273; ZELEWSKI M, 1990, COMP BIOCHEM PHYS B, V95, P469, DOI 10.1016/0305-0491(90)90004-D	48	43	44	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 7	1996	271	23					13584	13592		10.1074/jbc.271.23.13584	http://dx.doi.org/10.1074/jbc.271.23.13584			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UP385	8662758	hybrid			2022-12-25	WOS:A1996UP38500044
J	Duprez, E; Lillehaug, JR; Gaub, MP; Lanotte, M				Duprez, E; Lillehaug, JR; Gaub, MP; Lanotte, M			Differential changes of retinoid-X-receptor (RXR alpha) and its RAR alpha and PML-RAR alpha partners induced by retinoic acid and cAMP distinguish maturation sensitive and resistant t(15;17) promyelocytic leukemia NB4 cells	ONCOGENE			English	Article						acute promyelocytic leukemia; retinoic acid; nuclear receptor superfamily; transcription factors; differentiation; NB4 cells	TRANSLOCATION; PROTEIN; EXPRESSION; GENE; LINE; RNA; BREAKPOINT; EXTRACTION; LOCUS	The expression of retinoid receptors (RXR alpha, RAR alpha and the chimeric form PML-RAR alpha) was analysed both at the mRNA and protein level in the maturation sensitive NB4 and resistant NB4-R1 cell lines of t(15;17) promyelocytic leukemia (APL), All-trans RA and cAMP which show synergistic activity in inducing maturation of NB4 cells and maturation triggering of the RA 'primed' NB4-R1 resistant cells, distinctly modulate RXR alpha, RAR alpha and PML-RAR alpha mRNA. In the NB4 and NB4-R1 cells, RXR alpha mRNA was downregulated by RA, but only in RA-primed NB4-R1 cells a release from RXR alpha mRNA downregulation was obtained by cAMP treatment, RXR alpha protein (53 kDa) was decreased to the western-blot detection limit (97.5%) by RA in NB4 cells, but in NB4-R1 cells although it was frankly decreased (85%), the signal for RXR alpha protein remained very significant, More importantly, while cAMP slightly upregulated RXR alpha protein in RA-treated NB4 cells, it caused an increase of RXR alpha protein in RA-treated NB4-R1 cells bringing RXR alpha to the initial control level, RXR alpha partners in heterodimers (PML-RAR alpha, RAR alpha) were also analysed, In contrast to RXR alpha, RAR alpha and PML-RAR alpha mRNA were not modulated by RA and/or cAMP, while significant changes were observed at the protein levels, A putatively phosphorylated form of RAR alpha (52 kDa) during maturation of NB4 cells, but was in resistant NB4-R1 cells, Conversely, while PML-RAR alpha remained stable during RA-induced NB4 maturation, RA treatment which failed to induce maturation of NB4-R1 cells significantly down-regulated the chimeric receptor (120 kDa), These likely results from translational and post-translational regulation, This work reveals complex pattern of subtle changes at the protein level distinguishing RA-sensitive and RA-resistant cells, Our data show that the RA-cAMP synergistic effect on NB4 cell maturation and cooperation in triggering maturation of RA-primed NB4-R1 cells operate changes in the RXR/ PML-RAR alpha ratio which are both favouring RXR alpha. In both cell lines, variations of PML-RAR alpha and RXR alpha may result in a decrease in the formation of the PML-RAR alpha/RXR alpha heterodimers which are supposed involved in the block of maturation, This may prove crucial to embark cells on maturation.	HOP ST LOUIS,CTR G HAYEM,INSERM U301,F-75010 PARIS,FRANCE; IGBMC,INSERM U184,F-67404 ILLKIRCH GRAFFENS,FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm)			duprez, estelle a/R-2357-2016					ALCALAY M, 1991, P NATL ACAD SCI USA, V88, P1977, DOI 10.1073/pnas.88.5.1977; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; ASCOLI CA, 1991, J CELL BIOL, V112, P785, DOI 10.1083/jcb.112.5.785; BAIN G, 1994, BIOCHEM BIOPH RES CO, V200, P1252, DOI 10.1006/bbrc.1994.1585; BORDEN K, 1985, EMBO J, V14, P1532; BORROW J, 1990, SCIENCE, V249, P1577, DOI 10.1126/science.2218500; BRUEL A, 1995, LEUKEMIA, V9, P1173; CHEN A, 1994, BLOOD, V84, P2122, DOI 10.1182/blood.V84.7.2122.bloodjournal8472122; CHEN Z, 1990, LEUKEMIA, V5, P288; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DERMIME S, 1993, BLOOD, V82, P1573; DETHE H, 1991, CELL, V66, P675, DOI 10.1016/0092-8674(91)90113-D; DETHE H, 1990, NATURE, V347, P558, DOI 10.1038/347558a0; DIGMAN JDL, 1983, NUCLEIC ACIDS RES, V11, P1495; Duprez E, 1996, ONCOGENE, V12, P2451; DUPREZ E, 1992, LEUKEMIA, V6, P1281; DYCK JA, 1994, CELL, V76, P333, DOI 10.1016/0092-8674(94)90340-9; EVERETT RD, 1994, EMBO J, V13, P5062, DOI 10.1002/j.1460-2075.1994.tb06835.x; FAGIOLI M, 1992, ONCOGENE, V7, P1083; GAUB MP, 1992, EXP CELL RES, V201, P335, DOI 10.1016/0014-4827(92)90282-D; GIANNI M, 1995, BLOOD, V85, P3619, DOI 10.1182/blood.V85.12.3619.bloodjournal85123619; GIGUERE V, 1994, ENDOCR REV, V15, P61, DOI 10.1210/er.15.1.61; GLASS CK, 1994, ENDOCR REV, V15, P391, DOI 10.1210/er.15.3.391; GODDARD AD, 1991, SCIENCE, V254, P1371, DOI 10.1126/science.1720570; GREEN S, 1993, NATURE, V361, P590, DOI 10.1038/361590a0; GRIGNANI F, 1993, CELL, V74, P423, DOI 10.1016/0092-8674(93)80044-F; Gudas Lorraine J., 1994, P443; HEYMAN RA, 1992, CELL, V68, P397, DOI 10.1016/0092-8674(92)90479-V; HUANG ME, 1988, BLOOD, V72, P567, DOI 10.1182/blood.V72.2.567.567; HUGGENVIK JI, 1993, MOL ENDOCRINOL, V7, P543, DOI 10.1210/me.7.4.543; KAKIZUKA A, 1991, CELL, V66, P653; Kastner P., 1994, Vitamin A in health and disease., P189; KASTNER P, 1992, EMBO J, V11, P629, DOI 10.1002/j.1460-2075.1992.tb05095.x; KIZAKI M, 1993, BLOOD, V82, P3592; KOKEN MHM, 1994, EMBO J, V13, P1073, DOI 10.1002/j.1460-2075.1994.tb06356.x; LANOTTE M, 1991, BLOOD, V77, P1080; LAVAU C, 1994, LEUKEMIA, V8, P1615; LEID M, 1992, TRENDS BIOCHEM SCI, V17, P427, DOI 10.1016/0968-0004(92)90014-Z; LEVIN AA, 1992, NATURE, V355, P359, DOI 10.1038/355359a0; LONGO L, 1990, J EXP MED, V172, P1571, DOI 10.1084/jem.172.6.1571; Mangelsdorf David J., 1994, P319; MU ZM, 1994, MOL CELL BIOL, V14, P6858, DOI 10.1128/MCB.14.10.6858; MUINDI J, 1992, BLOOD, V79, P299; OLSON IL, 1982, CANCER RES, V42, P3922; PEMRICK SM, 1994, LEUKEMIA, V8, P1797; PEREZ A, 1993, EMBO J, V12, P3171, DOI 10.1002/j.1460-2075.1993.tb05986.x; ROCHETTEEGLY C, 1994, BIOCHEM BIOPH RES CO, V204, P525, DOI 10.1006/bbrc.1994.2491; ROWLEY JD, 1977, LANCET, V1, P549; RUCHAUD S, 1994, P NATL ACAD SCI USA, V91, P8428, DOI 10.1073/pnas.91.18.8428; WAN YJY, 1994, EXP CELL RES, V210, P56, DOI 10.1006/excr.1994.1009; WARRELL RP, 1993, BLOOD, V82, P1949, DOI 10.1182/blood.V82.7.1949.bloodjournal8271949; WEIS K, 1994, CELL, V76, P345, DOI 10.1016/0092-8674(94)90341-7; ZHANG XK, 1992, NATURE, V358, P587, DOI 10.1038/358587a0	53	43	43	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN 6	1996	12	11					2443	2450						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UQ220	8649786				2022-12-25	WOS:A1996UQ22000023
J	Massimi, P; Pim, D; Storey, A; Banks, L				Massimi, P; Pim, D; Storey, A; Banks, L			HPV-16 E7 and adenovirus E1a complex formation with TATA box binding protein is enhanced by casein kinase II phosphorylation	ONCOGENE			English	Article						CKII; HPV; E7; TBP	HUMAN PAPILLOMAVIRUS TYPE-16; RETINOBLASTOMA GENE-PRODUCT; TRANSCRIPTION FACTOR; HUMAN KERATINOCYTES; ACTIVATION DOMAIN; MOUSE CELLS; CYCLIN-A; EJ-RAS; TRANSFORMATION; TRANSACTIVATION	The major transforming protein of HPV-16 is encoded by the E7 gene. This has been shown to cooperate with EJ-ras in the immortalisation of primary rodent cells and with the viral E6 gene in the immortalisation of primary human keratinocytes. HPV-16 E7 protein has been shown to bind to a number of cellular proteins involved in the control of cell growth; including pRB, p107 and cyclin A, Loss of pRb or p107 binding results in the loss of transforming activity. In this paper we demonstrate that HPV-16 E7 can also complex with the core component of TFIID, the TATA Box Binding Protein (TBP). This interaction is partly dependent upon phosphorylation of the E7 protein by cellular casein kinase II (CKII), since phosphorylation of E7 by CKII increases the affinity with which E7 binds TBP. Similar results are also obtained with the Adenovirus Ela protein, indicating a conservation of function between these two viral oncoproteins. Mutation of the CKII site to two acidic amino acids significantly increases the affinity of E7 for TBP, indicating that the incorporation of two negative charges at this region of E7 is important in regulating the interaction with TBP.	INT CTR GENET ENGN & BIOTECHNOL, I-34012 TRIESTE, ITALY; ROYAL LONDON HOSP, DEPT EXPTL DERMATOL, LONDON, ENGLAND	International Center for Genetic Engineering & Biotechnology (ICGEB); Barts Health NHS Trust; Royal London Hospital				Storey, Alan/0000-0003-2001-9772				ANDROPHY EJ, 1987, EMBO J, V6, P989, DOI 10.1002/j.1460-2075.1987.tb04849.x; BANDARA LR, 1991, NATURE, V352, P249, DOI 10.1038/352249a0; BANKS L, 1988, VIROLOGY, V165, P326, DOI 10.1016/0042-6822(88)90695-2; BANKS L, 1990, ONCOGENE, V5, P1383; BANKS L, 1987, J GEN VIROL, V68, P1351, DOI 10.1099/0022-1317-68-5-1351; BARBOSA MS, 1990, EMBO J, V9, P153, DOI 10.1002/j.1460-2075.1990.tb08091.x; CROOK T, 1989, EMBO J, V8, P513, DOI 10.1002/j.1460-2075.1989.tb03405.x; DAVIES R, 1993, J VIROL, V67, P2521, DOI 10.1128/JVI.67.5.2521-2528.1993; DEMERS GW, 1994, P NATL ACAD SCI USA, V91, P4382, DOI 10.1073/pnas.91.10.4382; DOEBERITZ MV, 1988, CANCER RES, V48, P3780; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; EDMONDS C, 1989, J VIROL, V63, P2650, DOI 10.1128/JVI.63.6.2650-2656.1989; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FIRZLAFF JM, 1991, P NATL ACAD SCI USA, V88, P5187, DOI 10.1073/pnas.88.12.5187; HALBERT CL, 1991, J VIROL, V65, P473, DOI 10.1128/JVI.65.1.473-478.1991; HARPER JW, 1993, CELL, V75, P805; HAWLEYNELSON P, 1989, EMBO J, V8, P3905, DOI 10.1002/j.1460-2075.1989.tb08570.x; HOPPESEYLER F, 1993, J VIROL, V67, P3111, DOI 10.1128/JVI.67.6.3111-3117.1993; HORIKOSHI N, 1991, P NATL ACAD SCI USA, V88, P5124, DOI 10.1073/pnas.88.12.5124; HUDSON JB, 1990, J VIROL, V64, P519, DOI 10.1128/JVI.64.2.519-526.1990; IMAI Y, 1991, J VIROL, V65, P4966, DOI 10.1128/JVI.65.9.4966-4972.1991; KERR LD, 1993, NATURE, V336, P646; LEE WS, 1991, CELL, V67, P365, DOI 10.1016/0092-8674(91)90188-5; LIEBERMAN PM, 1991, GENE DEV, V5, P2441, DOI 10.1101/gad.5.12b.2441; METZ R, 1994, MOL CELL BIOL, V14, P6021, DOI 10.1128/MCB.14.9.6021; MUNGER K, 1989, J VIROL, V63, P4417; PHELPS WC, 1991, J VIROL, V65, P6922, DOI 10.1128/JVI.65.12.6922-6930.1991; PHELPS WC, 1988, CELL, V53, P539, DOI 10.1016/0092-8674(88)90570-3; PIM D, 1994, ONCOGENE, V9, P1869; SLEBOS RJC, 1994, P NATL ACAD SCI USA, V91, P5320, DOI 10.1073/pnas.91.12.5320; SMOTKIN D, 1986, P NATL ACAD SCI USA, V83, P4680, DOI 10.1073/pnas.83.13.4680; STOREY A, 1990, J GEN VIROL, V71, P965, DOI 10.1099/0022-1317-71-4-965; STOREY A, 1988, EMBO J, V7, P1815, DOI 10.1002/j.1460-2075.1988.tb03013.x; STOREY A, 1993, ONCOGENE, V8, P919; STOREY A, 1995, J GEN VIROL, V76, P819, DOI 10.1099/0022-1317-76-4-819; STRINGER KF, 1990, NATURE, V345, P783, DOI 10.1038/345783a0; TOMMASINO M, 1993, ONCOGENE, V8, P195; VOUSDEN KH, 1993, ONCOGENE, V8, P1697; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; ZAWEL L, 1992, Current Opinion in Cell Biology, V4, P488, DOI 10.1016/0955-0674(92)90016-6; zur Hausen H, 1987, PAPILLOMAVIRUSES, P245	41	74	78	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 6	1996	12	11					2325	2330						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UQ220	8649772				2022-12-25	WOS:A1996UQ22000009
J	Rojas, JM; Coque, JJR; Guerrero, C; Aroca, P; deMora, JF; delaCruz, X; Lorenzi, MV; Esteban, LM; Santos, E				Rojas, JM; Coque, JJR; Guerrero, C; Aroca, P; deMora, JF; delaCruz, X; Lorenzi, MV; Esteban, LM; Santos, E			A 15 amino acid stretch close to the Grb2-binding domain defines two differentially expressed hSos1 isoforms with markedly different Grb2 binding affinity and biological activity	ONCOGENE			English	Article						hSos1; isoforms; Ras activation; Grb2 binding; differential expression	RECEPTOR TYROSINE KINASES; GUANINE-NUCLEOTIDE EXCHANGE; GROWTH-FACTOR RECEPTORS; SIGNAL TRANSDUCTION; SEVENLESS GENE; SH3 DOMAINS; RAS; PROTEIN; CELLS; IDENTIFICATION	We compared structure, expression and functional properties of two hSos1 cDNA isoforms (IsfI and Isf II) isolated, respectively, from human fetal brain and adult skeletal muscle libraries, IsfI and IsfII nucleotide sequences differ only by the presence in IsfII of an in-frame 45 bp insertion located near the first proline-rich motif required for Grb2 binding, Some human tissues express only one isoform whereas others express different proportions of both in fetal and adult stages, In vitro binding assays and in vivo functional studies showed that IsfII exhibits significantly higher Grb2 binding affinity and biological activity than IsfI, These results suggest that functionally different hSos1 isoforms, with differential tissue expression and distribution, play important regulatory roles in the mechanisms controlling Ras activation in different tissues and/or developmental stages.	NCI, CELLULAR & MOLEC BIOL LAB, BETHESDA, MD 20892 USA; NCI, MOLEC BIOL LAB, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			Aroca, Pilar/P-2141-2017; Rojas, José M/D-3718-2018; de Mora, Jaime Font/H-6304-2015; Guerrero, Carmen/F-1776-2010; Coque, Juan Jose Rubio/AAV-2049-2021; Rojas, José M./AAA-3354-2021; de Mora, Jaime Font/AAK-7591-2021	Aroca, Pilar/0000-0002-7557-6931; Rojas, José M/0000-0002-5383-3482; de Mora, Jaime Font/0000-0002-6816-2095; Guerrero, Carmen/0000-0002-8747-6831; Coque, Juan Jose Rubio/0000-0001-8221-7817; Rojas, José M./0000-0002-7547-2825; de Mora, Jaime Font/0000-0002-6816-2095; De la Cruz Montserrat, Fco. Xavier/0000-0002-9738-8472				ADHUBEI AA, 1993, J MOL BIOL, V229, P472; ANDO A, 1994, EMBO J, V13, P3033, DOI 10.1002/j.1460-2075.1994.tb06602.x; ARONHEIM A, 1994, CELL, V78, P949, DOI 10.1016/0092-8674(94)90271-2; BALTENSPERGER K, 1993, SCIENCE, V260, P1950, DOI 10.1126/science.8391166; BENITO M, 1991, SCIENCE, V253, P565, DOI 10.1126/science.1857988; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BONFINI L, 1992, SCIENCE, V255, P603, DOI 10.1126/science.1736363; BOWTELL D, 1992, P NATL ACAD SCI USA, V89, P6511, DOI 10.1073/pnas.89.14.6511; BRUGGE J, 1987, GENE DEV, V1, P287, DOI 10.1101/gad.1.3.287; CHAN AML, 1991, SCIENCE, V254, P1382, DOI 10.1126/science.1720571; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; CHRISTY B, 1989, MOL CELL BIOL, V9, P4889, DOI 10.1128/MCB.9.11.4889; CHU CS, 1991, EMBO J, V10, P1355, DOI 10.1002/j.1460-2075.1991.tb07655.x; CUSSAC D, 1994, EMBO J, V13, P4011, DOI 10.1002/j.1460-2075.1994.tb06717.x; DALTON S, 1992, CELL, V68, P597, DOI 10.1016/0092-8674(92)90194-H; DIFIORE PP, 1987, SCIENCE, V237, P178, DOI 10.1126/science.2885917; DIKIC I, 1994, CURR BIOL, V4, P702, DOI 10.1016/S0960-9822(00)00155-X; DOWNWARD J, 1994, FEBS LETT, V338, P113, DOI 10.1016/0014-5793(94)80346-3; EGAN SE, 1993, NATURE, V365, P781, DOI 10.1038/365781a0; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; FATH I, 1994, SCIENCE, V264, P971, DOI 10.1126/science.8178156; FEIG LA, 1994, CURR OPIN CELL BIOL, V6, P204, DOI 10.1016/0955-0674(94)90137-6; FENG SB, 1994, SCIENCE, V266, P1241, DOI 10.1126/science.7526465; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; Gilliland G., 1990, PCR PROTOCOLS GUIDE, P60; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; HALL A, 1994, SCIENCE, V264, P1413, DOI 10.1126/science.8197454; HERTOG J, 1994, EMBO J, V13, P3020; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; LEGRAIN P, 1993, GENE DEV, V7, P1390, DOI 10.1101/gad.7.7b.1390; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LIM WA, 1994, NATURE, V372, P375, DOI 10.1038/372375a0; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MARTINEZ R, 1987, SCIENCE, V237, P411, DOI 10.1126/science.2440106; MIKI T, 1992, P NATL ACAD SCI USA, V89, P246, DOI 10.1073/pnas.89.1.246; NISHI T, 1991, ONCOGENE, V6, P1555; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; QUILLIAM LA, 1994, P NATL ACAD SCI USA, V91, P8512, DOI 10.1073/pnas.91.18.8512; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; ROST B, 1994, PROTEINS, V20, P216, DOI 10.1002/prot.340200303; ROST B, 1993, J MOL BIOL, V232, P584, DOI 10.1006/jmbi.1993.1413; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; SANTOS E, 1982, NATURE, V298, P343, DOI 10.1038/298343a0; SASAOKA T, 1994, J BIOL CHEM, V269, P10734; SCHLESSINGER J, 1993, TRENDS BIOCHEM SCI, V18, P273, DOI 10.1016/0968-0004(93)90031-H; SKOLNIK EY, 1993, EMBO J, V12, P1929, DOI 10.1002/j.1460-2075.1993.tb05842.x; SKOLNIK EY, 1993, SCIENCE, V260, P1953, DOI 10.1126/science.8316835; SLEIGH MJ, 1986, ANAL BIOCHEM, V156, P251, DOI 10.1016/0003-2697(86)90180-6; SUEN KL, 1993, MOL CELL BIOL, V13, P5500, DOI 10.1128/MCB.13.9.5500; TANAKA S, 1994, P NATL ACAD SCI USA, V91, P3443, DOI 10.1073/pnas.91.8.3443; TAUCHI T, 1994, J BIOL CHEM, V269, P25206; TRAVERSE S, 1994, CURR BIOL, V4, P694, DOI 10.1016/S0960-9822(00)00154-8; WIGLER M, 1977, CELL, V11, P223, DOI 10.1016/0092-8674(77)90333-6; YU HT, 1994, CELL, V76, P933, DOI 10.1016/0092-8674(94)90367-0	58	10	11	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 6	1996	12	11					2291	2300						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UQ220	8649768				2022-12-25	WOS:A1996UQ22000005
J	Chun, JS; Ha, MJ; Jacobson, BS				Chun, JS; Ha, MJ; Jacobson, BS			Differential translocation of protein kinase C epsilon during HeLa cell adhesion to a gelatin substratum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXTRACELLULAR-MATRIX; ARACHIDONIC-ACID; TYROSINE PHOSPHORYLATION; SIGNAL TRANSDUCTION; PLASMA-MEMBRANE; ACTIVATION; RECEPTOR; CYTOSKELETON; FIBRONECTIN; INTEGRINS	The spreading of HeLa cells, following attachment to a collagen or gelatin substratum, requires the activation of protein kinase C (PKC). Membrane-bound PKC was previously shown to be activated during cell attachment and in response to the activation of a series of lipid second messengers turned on by the ligation of beta 1-integrin collagen receptors. HeLa cells express the alpha, gamma, epsilon, zeta, lambda, and iota isozymes of PKC as determined by Western blotting with specific antibodies. Only PKC epsilon redistributed from the cytosol to the membrane during cell adhesion. Most of the PKC epsilon in cells that were in suspension was in the cytosolic fraction. During cell attachment to a gelatin matrix, all of the PKC epsilon moved out of the cytosol, with most going to the membrane fraction. After the cells became fully spread, PKC epsilon began to reappear in the cytosol. Translocation of PKC epsilon was not observed during the adhesion of cells to culture dishes where cells nonspecifically attach but do not spread, The conventional PKC alpha and -gamma isozymes were translocated from the cytosol to the membrane only when phorbol ester was present at a concentration that increases the rate and extent of cell spreading. Under normal conditions, i.e. in the absence of phorbol ester, PKC epsilon appears to be the PKC isozyme responsible for the regulation of HeLa cell adhesion to the extracellular matrix.	UNIV MASSACHUSETTS,DEPT BIOCHEM & MOLEC BIOL,AMHERST,MA 01003; KYUNGPOOK NATL UNIV,DEPT BIOL,TAEGU 702701,SOUTH KOREA; AJOU UNIV,INST MED SCI,MED GENET LAB,SUWON 441749,SOUTH KOREA; UNIV MASSACHUSETTS,DEPT BIOCHEM & MOLEC BIOL,AMHERST,MA 01003	University of Massachusetts System; University of Massachusetts Amherst; Kyungpook National University; Ajou University; University of Massachusetts System; University of Massachusetts Amherst					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM029127] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-29127] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALBELDA SM, 1990, FASEB J, V4, P2868, DOI 10.1096/fasebj.4.11.2199285; AUER KL, 1995, MOL BIOL CELL, V6, P1305, DOI 10.1091/mbc.6.10.1305; BURRIDGE K, 1988, ANNU REV CELL BIOL, V4, P487, DOI 10.1146/annurev.cb.04.110188.002415; CHEN QM, 1994, J BIOL CHEM, V269, P26602; CHUN JS, 1993, MOL BIOL CELL, V4, P271; CHUN JS, 1992, MOL BIOL CELL, V3, P481, DOI 10.1091/mbc.3.5.481; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; CYBULSKY AV, 1993, AM J PHYSIOL, V264, pC323, DOI 10.1152/ajpcell.1993.264.2.C323; DANILOV YN, 1989, J CELL BIOL, V108, P1925, DOI 10.1083/jcb.108.5.1925; FRAZIER WA, 1984, CELL MEMBR METH REV, V2, P1; GOODNIGHT J, 1994, ADV CANCER RES, V64, P159, DOI 10.1016/S0065-230X(08)60838-6; GROSSI IM, 1989, CANCER RES, V49, P1029; HEIDENREICH KA, 1990, J BIOL CHEM, V265, P15076; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; JULIANO RL, 1993, J CELL BIOL, V120, P577, DOI 10.1083/jcb.120.3.577; KAPRONBRAS C, 1993, J BIOL CHEM, V268, P20701; KORNBERG LJ, 1991, P NATL ACAD SCI USA, V88, P8392, DOI 10.1073/pnas.88.19.8392; LU ML, 1992, J CELL SCI, V101, P873; MCNAMEE HP, 1993, J CELL BIOL, V121, P673, DOI 10.1083/jcb.121.3.673; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; OHMICHI M, 1993, BIOCHEM J, V295, P767, DOI 10.1042/bj2950767; PATTON WF, 1989, J CELL SCI, V92, P85; SCHLAEPFER DD, 1994, NATURE, V372, P786; SCHWARTZ MA, 1993, J CELL BIOL, V120, P1003, DOI 10.1083/jcb.120.4.1003; SHAW LM, 1990, J CELL BIOL, V110, P2167, DOI 10.1083/jcb.110.6.2167; VUORI K, 1993, J BIOL CHEM, V268, P21459; ZHU XY, 1995, MOL BIOL CELL, V6, P273, DOI 10.1091/mbc.6.3.273	27	82	84	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 31	1996	271	22					13008	13012		10.1074/jbc.271.22.13008	http://dx.doi.org/10.1074/jbc.271.22.13008			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UN474	8662811	hybrid			2022-12-25	WOS:A1996UN47400051
J	Gardella, TJ; Luck, MD; Fan, MH; Lee, CW				Gardella, TJ; Luck, MD; Fan, MH; Lee, CW			Transmembrane residues of the parathyroid hormone (PTH)/PTH-related peptide receptor that specifically affect binding and signaling by agonist ligands	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VASOACTIVE-INTESTINAL-PEPTIDE; BETA-ADRENERGIC-RECEPTOR; TERNARY COMPLEX MODEL; EXPRESSION CLONING; MOLECULAR-CLONING; IDENTIFICATION; POLYPEPTIDE; CAMP	Polar residues within the transmembrane domains (TMs) of G protein-coupled receptors have been implicated to be important determinants of receptor function. We have identified mutations at two polar sites in the TM regions of the rat parathyroid hormone (PTH)/PTH-related peptide receptor, Arg-233 in TM 2 and Gln-451 in TM 7, that caused 17-200-fold reductions in the binding affinity of the agonist peptide PTH-(1-34) without affecting the binding affinity of the antagonist/partial agonist PTH-(3-34). When mutations at the TM 2 and TM 7 sites were combined, binding affinity for PTH-(1-34) was restored to nearly that of the wild type receptor. The double mutant receptors, however, were completely defective in signaling cAMP or inositol phosphate production in response to PTH-(1-34) agonist ligand. The results demonstrate that Arg-233 and Gln-451 have important roles in determining agonist binding affinity and transmembrane signaling. Furthermore, the finding that residues in TM 2 and TM 7 are functionally linked suggests that the TM domain topology of the PTH/PTH-related peptide receptor may resemble that of receptors in the rhodopsin/beta-adrenergic receptor family, for which structural and mutagenesis data suggest interactions between TMs 2 and 7.	HARVARD UNIV, SCH MED, BOSTON, MA 02114 USA	Harvard University; Harvard Medical School	Gardella, TJ (corresponding author), MASSACHUSETTS GEN HOSP, DEPT MED, ENDOCRINE UNIT, BOSTON, MA 02114 USA.							ABOUSAMRA AB, 1992, P NATL ACAD SCI USA, V89, P2732, DOI 10.1073/pnas.89.7.2732; BALDWIN JM, 1993, EMBO J, V12, P1693, DOI 10.1002/j.1460-2075.1993.tb05814.x; BERRIDGE MJ, 1983, BIOCHEM J, V212, P473, DOI 10.1042/bj2120473; BUGGY JJ, 1995, J BIOL CHEM, V270, P7474, DOI 10.1074/jbc.270.13.7474; CHEN RP, 1993, P NATL ACAD SCI USA, V90, P8967, DOI 10.1073/pnas.90.19.8967; DELEAN A, 1980, J BIOL CHEM, V255, P7108; GARDELLA TJ, 1994, ENDOCRINOLOGY, V135, P1186, DOI 10.1210/en.135.3.1186; GOLTZMANN D, 1975, J BIOL CHEM, V250, P3199; HOLTMANN MH, 1995, J BIOL CHEM, V270, P14394, DOI 10.1074/jbc.270.24.14394; HUANG RRC, 1994, BIOCHEMISTRY-US, V33, P3007, DOI 10.1021/bi00176a033; HUNYADY L, 1995, J BIOL CHEM, V270, P9702, DOI 10.1074/jbc.270.17.9702; IIDAKLEIN A, 1995, J BIOL CHEM, V270, P8458, DOI 10.1074/jbc.270.15.8458; ISHIHARA T, 1992, NEURON, V8, P811, DOI 10.1016/0896-6273(92)90101-I; ISHIHARA T, 1991, EMBO J, V10, P1635, DOI 10.1002/j.1460-2075.1991.tb07686.x; JELINEK LJ, 1993, SCIENCE, V259, P1614, DOI 10.1126/science.8384375; JI IH, 1991, J BIOL CHEM, V266, P14953; JUPPNER H, 1991, SCIENCE, V254, P1024, DOI 10.1126/science.1658941; JUPPNER H, 1994, ENDOCRINOLOGY, V134, P879, DOI 10.1210/en.134.2.879; KOLODZIEJ PA, 1991, METHOD ENZYMOL, V194, P508; KRYSTEK SR, 1994, J BIOL CHEM, V269, P12383; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LEE CW, 1995, MOL ENDOCRINOL, V9, P1269, DOI 10.1210/me.9.10.1269; LEE CW, 1994, ENDOCRINOLOGY, V135, P1488, DOI 10.1210/en.135.4.1488; LEE JA, 1994, P NATL ACAD SCI USA, V91, P7164, DOI 10.1073/pnas.91.15.7164; LIN HY, 1991, SCIENCE, V254, P1022, DOI 10.1126/science.1658940; LUTZ EM, 1993, FEBS LETT, V334, P3, DOI 10.1016/0014-5793(93)81668-P; MAYO KE, 1992, MOL ENDOCRINOL, V6, P1734, DOI 10.1210/me.6.10.1734; Mizobe T, 1996, J BIOL CHEM, V271, P2387, DOI 10.1074/jbc.271.5.2387; REAGAN JD, 1994, J BIOL CHEM, V269, P9; ROSENKILDE MM, 1994, J BIOL CHEM, V269, P28160; ROST B, 1995, PROTEIN SCI, V4, P521; SAMAMA P, 1993, J BIOL CHEM, V268, P4625; SCHERTLER G, 1995, NATURE, V362, P770; SEALFON S, 1995, MOL PHARMACOL, V270, P16683; SEED B, 1987, P NATL ACAD SCI USA, V84, P3365, DOI 10.1073/pnas.84.10.3365; SPENGLER D, 1993, NATURE, V365, P170, DOI 10.1038/365170a0; STRADER CD, 1991, J BIOL CHEM, V266, P5; STRADER CD, 1987, P NATL ACAD SCI USA, V84, P4384, DOI 10.1073/pnas.84.13.4384; STROOP S, 1994, BIOCHEMISTRY-US, V34, P1050; SURYANARAYANA S, 1992, J BIOL CHEM, V267, P21991; THORENS B, 1992, P NATL ACAD SCI USA, V89, P8641, DOI 10.1073/pnas.89.18.8641; USDIN TB, 1993, ENDOCRINOLOGY, V133, P2861, DOI 10.1210/en.133.6.2861; ZHOU W, 1994, MOL PHARMACOL, V45, P165	44	72	82	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 31	1996	271	22					12820	12825		10.1074/jbc.271.22.12820	http://dx.doi.org/10.1074/jbc.271.22.12820			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UN474	8662729	hybrid			2022-12-25	WOS:A1996UN47400022
J	Malinski, JA; Zera, EM; Angleson, JK; Wensel, TG				Malinski, JA; Zera, EM; Angleson, JK; Wensel, TG			High affinity interactions of GTP gamma S with the heterotrimeric G protein, transducin - Evidence at high and low protein concentrations	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OUTER SEGMENT MEMBRANES; CGMP PHOSPHODIESTERASE ACTIVATION; BINDING REGULATORY PROTEINS; BOVINE CEREBRAL-CORTEX; VISUAL EXCITATION; ADENYLATE-CYCLASE; CRYSTAL-STRUCTURE; RETINAL RODS; NUCLEOTIDE; RHODOPSIN	A well known difference in nucleotide binding characteristics between heterotrimeric G proteins and small GTP binding proteins of the Ras superfamily is that the former bind GTP or guanosine 5'-O-(3-thiotriphosphate) (GTP gamma S) with a much lower affinity (K-d similar to 10(-8)-10(-7) M) than the latter (K-d similar to 10(-11)-10(-10) M). We report here that the alpha subunit of the heterotrimeric G protein transducin (G(t)) binds GTP gamma S with an affinity comparable to that of Ras. High affinity binding was suggested by GTP gamma S titrations of rod outer segment samples with G(t) concentrations in the range of 7 nM to 300 nM; the results were more consistent with a dissociation constant for GTP gamma S in the subnanomolar range, than with one in the 10(-8)-10(-7) M range typically reported for heterotrimeric G proteins. Equilibrium binding experiments with G protein concentrations in the subnanomolar to nanomolar range confirmed this conclusion and revealed a dissociation constant of 50 pM, Thus, transducin's affinity for GTP gamma S, and by inference, for GTP, appears to be approximately three orders of magnitude higher than previously reported. These results raise the possibility that some results obtained with high concentrations of nucleotide analogues may be due to minute traces of contaminants such as GTP, GTP gamma S, or GTP alpha S, that have high affinities for G(t alpha).	BAYLOR COLL MED,DEPT BIOCHEM,HOUSTON,TX 77030	Baylor College of Medicine				Wensel, Theodore/0000-0003-3518-9352	NEI NIH HHS [EY07001, EY07981] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY007981] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ANGLESON JK, 1993, NEURON, V11, P939, DOI 10.1016/0896-6273(93)90123-9; ANGLESON JK, 1994, J BIOL CHEM, V269, P16290; ARSHAVSKY VY, 1994, J BIOL CHEM, V269, P19882; ASANO T, 1984, BIOCHEMISTRY-US, V23, P5460, DOI 10.1021/bi00318a013; BENNETT N, 1985, J BIOL CHEM, V260, P4156; BEVINGTON PR, 1969, DATA REDUCTION ERROR, P237; FUKADA Y, 1994, J BIOL CHEM, V269, P5163; GOODY RS, 1991, TRENDS BIOCHEM SCI, V16, P327, DOI 10.1016/0968-0004(91)90134-H; HAMM HE, 1986, BIOCHEMISTRY-US, V25, P4512, DOI 10.1021/bi00364a010; HECK M, 1993, BIOCHEMISTRY-US, V32, P8220, DOI 10.1021/bi00083a024; HUFF RM, 1985, J BIOL CHEM, V260, P864; HUFF RM, 1986, J BIOL CHEM, V261, P1105; KAHLERT M, 1991, BIOPHYS J, V59, P375, DOI 10.1016/S0006-3495(91)82231-7; KELLEHER DJ, 1986, MOL PHARMACOL, V30, P603; KUHN H, 1980, NATURE, V283, P587, DOI 10.1038/283587a0; KUTUZOV M, 1994, EUR J BIOCHEM, V220, P963, DOI 10.1111/j.1432-1033.1994.tb18700.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MALINSKI JA, 1992, BIOCHEMISTRY-US, V31, P9502, DOI 10.1021/bi00154a024; MALINSKI JA, 1993, CELL MOTIL CYTOSKEL, V24, P304; MARQUARDT DW, 1963, J SOC IND APPL MATH, V11, P431, DOI 10.1137/0111030; MITTAL R, 1994, BIOCHEMISTRY-US, V33, P10178, DOI 10.1021/bi00199a046; NOEL JP, 1993, NATURE, V366, P654, DOI 10.1038/366654a0; NORTHUP JK, 1982, J BIOL CHEM, V257, P1416; OTTOBRUC A, 1993, BIOCHEMISTRY-US, V32, P8636, DOI 10.1021/bi00084a035; OTTOBRUC A, 1994, BIOCHEMISTRY-US, V33, P15215, DOI 10.1021/bi00255a001; PAI EF, 1990, EMBO J, V9, P2351, DOI 10.1002/j.1460-2075.1990.tb07409.x; PAPERMASTER DS, 1974, BIOCHEMISTRY-US, V13, P2438, DOI 10.1021/bi00708a031; PUGH EN, 1993, BIOCHIM BIOPHYS ACTA, V1141, P111, DOI 10.1016/0005-2728(93)90038-H; RAMDAS L, 1991, BIOCHEMISTRY-US, V30, P11637, DOI 10.1021/bi00114a005; ROBINSON WE, 1979, NATURE, V280, P398, DOI 10.1038/280398a0; STRYER L, 1991, J BIOL CHEM, V266, P10711; VUONG TM, 1984, NATURE, V311, P659, DOI 10.1038/311659a0; WENSEL TG, 1990, BIOCHEMISTRY-US, V29, P2155, DOI 10.1021/bi00460a028; WESSLINGRESNICK M, 1987, BIOCHEMISTRY-US, V26, P4316, DOI 10.1021/bi00388a020; WIELAND T, 1991, EUR J BIOCHEM, V196, P707, DOI 10.1111/j.1432-1033.1991.tb15869.x; WIELAND T, 1992, J BIOL CHEM, V267, P20791; YAMANAKA G, 1985, BIOCHEMISTRY-US, V24, P8094, DOI 10.1021/bi00348a039; YOSHIDA T, 1994, J BIOL CHEM, V269, P24050; Zera EM, 1996, J BIOL CHEM, V271, P12925, DOI 10.1074/jbc.271.22.12925	39	21	22	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 31	1996	271	22					12919	12924		10.1074/jbc.271.22.12919	http://dx.doi.org/10.1074/jbc.271.22.12919			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UN474	8662740	hybrid			2022-12-25	WOS:A1996UN47400038
J	Schwarz, D; Kisselev, P; Wessel, R; Jueptner, O; Schmid, RD				Schwarz, D; Kisselev, P; Wessel, R; Jueptner, O; Schmid, RD			alpha-Branched 1,2-diacyl phosphatidylcholines as effectors of activity of cytochrome P450SCC (CYP11A1) - Modeling the structure of the fatty acyl chain region of cardiolipln	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PURIFIED CYTOCHROME-P-450SCC; PHOSPHOLIPID-VESICLES; CHOLESTEROL; P-450SCC; MEMBRANE; CLEAVAGE; MITOCHONDRIA; ACTIVATION; BEHAVIOR; BINDING	Cardiolipin has been shown to be the most effective activator of cholesterol side chain cleavage activity of cytochrome P450SCC, and evidence has been provided for a lipid effector site on the enzyme. Results suggested the headgroup of cardiolipin as major determinant of lipid interaction with P450SCC (Lambeth, J. D. (1981) J. Biol. Chem. 258, 4757-4762). The role of unsaturation is contradictory and open to question (Igarashi, Y. and Kimura, T. (1986) Biochemistry 25, 6461-6466). We synthesized phosphatidylcholines with fully saturated branched fatty acyl chains substituted in the 2-positions of the main chains and studied the influence of these lipids on the activity and other properties of P450SCC in vesicle-reconstituted systems. These saturated branched lipids, with regard to the fatty acyl moiety in molecular shape similar to cardiolipin but with the headgroup of phosphatidylcholines retained, showed a stimulatory efficiency higher than any other phospholipid and at least comparable to cardiolipin. Activation is sensitive to the acyl chain structure and composition. Results suggest that the shape of the molecule at least partially plays an important role in the process of stimulation of the activity of P450SCC. Because binding of cholesterol was increased by the branched lipids monitored optically by the fraction of P450SCC in the high spin form, it was concluded that these lipids, like cardiolipin and other lipids, exert their effects by regulating the binding of cholesterol to P450SCC. These data suggest that polymorphic lipids such as branched phosphatidylcholines and cardiolipin might influence P450SCC function by maintenance of the membrane curvature at a value optimal for activity.	BYELARUSSIAN ACAD SCI, INST BIOORGAN CHEM, MINSK 220141, BELARUS; UNIV STUTTGART, INST TECH BIOCHEM, D-70569 STUTTGART, GERMANY	National Academy of Sciences of Belarus (NASB); Institute of Bioorganic Chemistry of the National Academy of Sciences of Belarus; University of Stuttgart	Schwarz, D (corresponding author), MAX DELBRUCK CTR MOLEC MED, ROBERT ROESSLE STR 10, D-13125 BERLIN, GERMANY.							AMES BN, 1960, J BIOL CHEM, V235, P769; BREZESINSKI G, 1987, CHEM PHYS LIPIDS, V43, P257, DOI 10.1016/0009-3084(87)90022-3; CHASHCHIN VL, 1984, BIOCHIM BIOPHYS ACTA, V787, P27, DOI 10.1016/0167-4838(84)90104-3; CHENG B, 1983, LIPIDS, V18, P577, DOI 10.1007/BF02534665; Cullis P, 1983, CONCEPTS MEMBRANE ST, P39; DHARIWAL MS, 1989, BIOCHEMISTRY-US, V28, P8397, DOI 10.1021/bi00447a019; EPAND RM, 1991, CHEM PHYS LIPIDS, V57, P75, DOI 10.1016/0009-3084(91)90051-C; GRUNER SM, 1985, ANNU REV BIOPHYS BIO, V14, P211, DOI 10.1146/annurev.biophys.14.1.211; HANUKOGLU I, 1981, J BIOL CHEM, V256, P4329, DOI 10.1016/S0021-9258(19)69437-8; HERMETTER A, 1981, CHEM PHYS LIPIDS, V28, P111, DOI 10.1016/0009-3084(81)90039-6; HESS HH, 1975, ANAL BIOCHEM, V63, P607, DOI 10.1016/0003-2697(75)90388-7; HUANG CH, 1969, BIOCHEMISTRY-US, V8, P344, DOI 10.1021/bi00829a048; HUI SW, 1989, P NATL ACAD SCI USA, V86, P5825, DOI 10.1073/pnas.86.15.5825; IGARASHI Y, 1986, BIOCHEMISTRY-US, V25, P6461, DOI 10.1021/bi00369a018; KOWLURU RA, 1983, J BIOL CHEM, V258, P8053; LAMBETH JD, 1981, J BIOL CHEM, V256, P4757; LAMBETH JD, 1980, J BIOL CHEM, V255, P8282; LAMBETH JD, 1982, J BIOL CHEM, V257, P1876; LAMBETH JD, 1990, FRONTIERS BIOTRANSFO, V3, P58; LEWIS RNAH, 1994, BIOPHYS J, V66, P1088, DOI 10.1016/S0006-3495(94)80890-2; OMURA T, 1964, J BIOL CHEM, V239, P2370; PEMBER SO, 1983, J BIOL CHEM, V258, P3198; RUCKPAUL K, 1993, HDB EXPT PHARM CYTOC, V105, P581; RUCKPAUL K, 1984, CYTOCHROME P450 STRU; RURUP J, 1994, CHEM PHYS LIPIDS, V72, P175, DOI 10.1016/0009-3084(94)90100-7; SCHMIDT W, 1983, J MEMBRANE BIOL, V76, P73, DOI 10.1007/BF01871454; SCHWARZ D, 1993, BIOCHEM BIOPH RES CO, V195, P889, DOI 10.1006/bbrc.1993.2128; SCHWARZ D, 1994, J STRUCT BIOL, V113, P207, DOI 10.1006/jsbi.1994.1055; SEYBERT DW, 1990, ARCH BIOCHEM BIOPHYS, V279, P188, DOI 10.1016/0003-9861(90)90480-M; SEYBERT DW, 1979, J BIOL CHEM, V254, P2088; USANOV S A, 1987, Biokhimiya, V52, P110; WARNER TG, 1977, J LIPID RES, V18, P548; YAMAKURA F, 1981, BIOCHIM BIOPHYS ACTA, V649, P343, DOI 10.1016/0005-2736(81)90424-7	33	18	18	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 31	1996	271	22					12840	12846		10.1074/jbc.271.22.12840	http://dx.doi.org/10.1074/jbc.271.22.12840			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UN474	8662703	hybrid			2022-12-25	WOS:A1996UN47400025
J	Yamin, TT; Ayala, JM; Miller, DK				Yamin, TT; Ayala, JM; Miller, DK			Activation of the native 45-kDa precursor form of interleukin-1-converting enzyme	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERLEUKIN-1-BETA-CONVERTING ENZYME; SEQUENCE; PROTEASE	Active interleukin-1 beta-converting enzyme (ICE) is composed of 20- and 10-kDa polypeptides (p20 and p10) derived from the processing of a cytosolic 45-kDa precursor protein (p45). The cleavage and activation of the native p45 ICE precursor have been characterized by use of specific inhibitors and antibodies recognizing various regions of ICE, The processing of p45 in vitro in THP.1 monocytic cell cytoplasmic extracts is inhibited only by protease inhibitors that inhibit ICE and not by inhibitors of other protease classes. The addition of L-742,395, a biotinylated irreversible ICE inhibitor, to these extracts labels only p45 and simultaneously inhibits p45 processing, demonstrating that the p45 has catalytic activity. Following a cleavage of p45 at a site that becomes the COOH terminus of p20, a more active intermediate is formed which migrates on SDS-polyacrylamide gel electrophoresis with an molecular mass of 35 kDa (ED(50) of similar to 0.1 mu M L-742,395 labeling versus 5 mu M for p45), This new more active ICE form serves both as an intermediate enzyme to cleave p45 as well as a substrate for the formation of the final active ICE (ED(50) of 1 nM L-742,395 labeling of p20 and for p22, an NH2-terminally extended form of p20), While initial cleavage of p45 can be found at the sites corresponding to both the NH2 termini of p22 and p20, these fragments cannot be labeled by L-742,395 and are hence inactive, p45 is not processed at the site corresponding to the NH2 terminus of the p10. Less than 50% of the p45 is cleaved down to active p20 or p22 ICE as determined by band shift on SDS-polyacrylamide gel electrophoresis of the biotinylated fragments, indicating that the in vitro activation is highly inefficient. The ICE fragmentation occurs by an intermolecular process and is highly dilution sensitive. Cleavage of p45 by exogenous p20/p10 ICE differs from that of the endogenous p45 cleavage activity in that the p20/p10 activity is more salt sensitive, and it produces a different pattern of cleavage fragments, principally 35- and 12-kDa fragments, These results indicate that the nature of the ICE activity changes as p45 is processed down to the p20/p10 form of the enzyme.	MERCK RES LABS,DEPT INFLAMMAT RES,RAHWAY,NJ 07065	Merck & Company								ALNEMRI ES, 1995, J BIOL CHEM, V270, P4312, DOI 10.1074/jbc.270.9.4312; AURON PE, 1984, P NATL ACAD SCI-BIOL, V81, P7907, DOI 10.1073/pnas.81.24.7907; AYALA JM, 1994, J IMMUNOL, V153, P2592; BLACK RA, 1989, FEBS LETT, V247, P386, DOI 10.1016/0014-5793(89)81376-6; CAMERON P, 1985, J EXP MED, V162, P790, DOI 10.1084/jem.162.3.790; CASANO FJ, 1994, GENOMICS, V20, P474, DOI 10.1006/geno.1994.1203; CERRETTI DP, 1994, GENOMICS, V20, P468, DOI 10.1006/geno.1994.1202; DINARELLO CA, 1991, BLOOD, V77, P1627; Duan HJ, 1996, J BIOL CHEM, V271, P1621, DOI 10.1074/jbc.271.3.1621; FERNANDESALNEMRI T, 1995, CANCER RES, V55, P6045; FERNANDESALNEMRI T, 1994, J BIOL CHEM, V269, P30761; FLETCHER DS, 1995, J INTERF CYTOK RES, V15, P243, DOI 10.1089/jir.1995.15.243; HORVITZ HR, 1995, J CELL BIOCH B, V19, P261; HOWARD AD, 1995, J IMMUNOL, V154, P2321; KOSTURA MJ, 1989, P NATL ACAD SCI USA, V86, P5227, DOI 10.1073/pnas.86.14.5227; KUIDA K, 1995, SCIENCE, V267, P2000, DOI 10.1126/science.7535475; KUMAR S, 1994, GENE DEV, V8, P1613, DOI 10.1101/gad.8.14.1613; LI P, 1995, CELL, V80, P401, DOI 10.1016/0092-8674(95)90490-5; MARCH CJ, 1985, NATURE, V315, P641, DOI 10.1038/315641a0; MILLER BE, 1995, J IMMUNOL, V154, P1331; MILLER DK, 1993, J BIOL CHEM, V268, P18062; MUNDAY NA, 1995, J BIOL CHEM, V270, P15870, DOI 10.1074/jbc.270.26.15870; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; RAMAGE P, 1995, J BIOL CHEM, V270, P9378, DOI 10.1074/jbc.270.16.9378; ROLANDO AM, 1994, J CELL BIOCHEM, V18, P147; THORNBERRY NA, 1992, NATURE, V356, P768, DOI 10.1038/356768a0; THORNBERRY NA, 1994, BIOCHEMISTRY-US, V33, P3934, DOI 10.1021/bi00179a020; THORNBERRY NA, 1994, METHOD ENZYMOL, V244, P615; WALKER NPC, 1994, CELL, V78, P343, DOI 10.1016/0092-8674(94)90303-4; WANG L, 1994, CELL, V78, P739, DOI 10.1016/S0092-8674(94)90422-7; WANG XM, 1994, GENE, V145, P273; WILSON KP, 1994, NATURE, V370, P270, DOI 10.1038/370270a0; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9	33	152	156	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 31	1996	271	22					13273	13282		10.1074/jbc.271.22.13273	http://dx.doi.org/10.1074/jbc.271.22.13273			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UN474	8662843	hybrid			2022-12-25	WOS:A1996UN47400090
J	Kang, YJ; Chen, Y; Epstein, PN				Kang, YJ; Chen, Y; Epstein, PN			Suppression of cardiotoxicity by overexpression of catalase in the heart of transgenic mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIPID-PEROXIDATION; ANTHRACYCLINE CARDIOTOXICITY; DOXORUBICIN ADRIAMYCIN; GLUTATHIONE-PEROXIDASE; HYDROGEN-PEROXIDE; OXIDATIVE STRESS; N-ACETYLCYSTEINE; FREE-RADICALS; RAT-HEART; TOXICITY	Weak antioxidant capacity, particularly low catalase activity in the heart, may be a factor responsible for the high sensitivity of this organ to doxorubicin-induced oxidative damage. To test this hypothesis, a heart-specific promoter was used to drive the expression of murine catalase cDNA in transgenic mice. Fifteen healthy transgenic mouse lines were produced. Cardiac catalase activity was constitutively overexpressed in both atrium and ventricle, ranging from 2- to 630-fold higher than normal. This enzyme activity was not altered in liver, kidneys, lungs, and skeletal muscles. Other antioxidant components, including glutathione, glutathione peroxidase, glutathione reductase, metallothionein, and superoxide dismutase, were not altered in the catalase-overexpressing heart. Mice (7 weeks old) from several transgenic lines and from nontransgenic controls were treated intraperitoneally with doxorubicin at a single dose of 20 mg/kg and sacrificed on the 4th day after treatment. As compared to normal controls, transgenic lines expressing catalase activity 60- or 100-fold higher than normal exhibited a significant resistance to doxorubicin induced cardiac lipid peroxidation, elevation of serum creatine phosphokinase, and functional changes in the isolated atrium. Interestingly, 200-fold or greater elevation of catalase activity did not provide protection. The results provide direct evidence for the role of catalase in doxorubicin cardiotoxic responses.			Kang, YJ (corresponding author), UNIV N DAKOTA, SCH MED, DEPT PHARMACOL & TOXICOL, POB 9037, GRAND FORKS, ND 58202 USA.			Epstein, Paul/0000-0002-7006-8954	NATIONAL CANCER INSTITUTE [R15CA063752, R29CA068125] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK044519] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AEBI H, 1984, METHOD ENZYMOL, V105, P121; AMSTAD P, 1991, BIOCHEMISTRY-US, V30, P9305, DOI 10.1021/bi00102a024; BACHUR NR, 1978, CANCER RES, V38, P1745; BOCHERENSGADIENT SA, 1992, J CARDIOVASC PHARM, V19, P770; BUZDAR AU, 1985, CANCER, V55, P2761, DOI 10.1002/1097-0142(19850615)55:12<2761::AID-CNCR2820551206>3.0.CO;2-P; CARLBERG I, 1985, METHOD ENZYMOL, V113, P484; CHEN Y, 1994, FREE RADICAL BIO MED, V17, P529, DOI 10.1016/0891-5849(94)90092-2; DEJONG J, 1990, RES COMMUN CHEM PATH, V68, P275; DEMANT EJF, 1984, EUR J BIOCHEM, V142, P571, DOI 10.1111/j.1432-1033.1984.tb08324.x; DOROSHOW JH, 1980, J CLIN INVEST, V65, P128, DOI 10.1172/JCI109642; EATON DL, 1991, METHOD ENZYMOL, V205, P83; ESTERBAUER H, 1990, METHOD ENZYMOL, V186, P407; FERRANS VJ, 1978, CANCER TREAT REP, V62, P955; FLOHE L, 1984, METHOD ENZYMOL, V105, P114; FURUTA S, 1990, J BIOCHEM, V107, P708, DOI 10.1093/oxfordjournals.jbchem.a123113; GIANNI L, 1992, CANC TREATMENT HEART, P9; GULICK J, 1991, J BIOL CHEM, V266, P9180; HERMANSEN K, 1990, PHARMACOL TOXICOL, V66, P299, DOI 10.1111/j.1600-0773.1990.tb00751.x; HIDA H, 1995, BIOL TRACE ELEM RES, V47, P111, DOI 10.1007/BF02790107; HOGAN B, 1986, MANIPULATING MOUSE E; Ishikawa T., 1986, TARGET ORGAN TOXICIT, P129; JANERO DR, 1990, FREE RADICAL BIO MED, V9, P515, DOI 10.1016/0891-5849(90)90131-2; JONES DP, 1978, J BIOL CHEM, V253, P6031; JULICHER RHM, 1985, RES COMMUN CHEM PATH, V47, P35; KALYANARAMAN B, 1984, BIOCHIM BIOPHYS ACTA, V799, P270, DOI 10.1016/0304-4165(84)90270-8; KEIZER HG, 1990, PHARMACOL THERAPEUT, V47, P219, DOI 10.1016/0163-7258(90)90088-J; KIRSHENBAUM LA, 1993, AM J PHYSIOL, V265, pH484, DOI 10.1152/ajpheart.1993.265.2.H484; KOJIMA S, 1993, J PHARMACOL EXP THER, V266, P1699; LEE V, 1991, AM J PHYSIOL, V261, pH989, DOI 10.1152/ajpheart.1991.261.4.H989; LOMEDICO P, 1979, CELL, V18, P545, DOI 10.1016/0092-8674(79)90071-0; MAO GD, 1993, J BIOL CHEM, V268, P416; MYERS C, 1983, SEMIN ONCOL, V10, P53; MYERS CE, 1977, SCIENCE, V197, P165, DOI 10.1126/science.877547; NEBOT C, 1993, ANAL BIOCHEM, V214, P442, DOI 10.1006/abio.1993.1521; ODOM AL, 1992, BIOCHEM PHARMACOL, V43, P831, DOI 10.1016/0006-2952(92)90250-M; OLIVER LT, 1963, J LAB CLIN MED, V62, P159; OLSON RD, 1981, LIFE SCI, V29, P1393, DOI 10.1016/0024-3205(81)90001-1; ORR WC, 1994, SCIENCE, V263, P1128, DOI 10.1126/science.8108730; POWELL SR, 1988, TOXICOL APPL PHARM, V96, P175, DOI 10.1016/0041-008X(88)90078-6; PRITSOS CR, 1992, BIOCHEM PHARMACOL, V44, P839, DOI 10.1016/0006-2952(92)90427-K; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SPERANZA MJ, 1993, J BIOL CHEM, V268, P19039; TAKETO M, 1991, P NATL ACAD SCI USA, V88, P2065, DOI 10.1073/pnas.88.6.2065; THAYER WS, 1986, FEBS LETT, V202, P137, DOI 10.1016/0014-5793(86)80664-0; TIETZE F, 1969, ANAL BIOCHEM, V27, P502, DOI 10.1016/0003-2697(69)90064-5; UNVERFERTH DV, 1985, AM J CARDIOL, V56, P157, DOI 10.1016/0002-9149(85)90585-5; VANACKER SABE, 1993, CANCER RES, V53, P4603; VONHOFF DD, 1979, ANN INTERN MED, V91, P710, DOI 10.7326/0003-4819-91-5-710; WILLIS EH, 1990, BIOTECHNIQUES, V9, P92	49	256	260	1	11	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 24	1996	271	21					12610	12616		10.1074/jbc.271.21.12610	http://dx.doi.org/10.1074/jbc.271.21.12610			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UL660	8647872	hybrid			2022-12-25	WOS:A1996UL66000074
J	Sheikh, H; Isacke, CM				Sheikh, H; Isacke, CM			A di-hydrophobic Leu-Val motif regulates the basolateral localization of CD44 in polarized Madin-Darby canine kidney epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYMERIC IMMUNOGLOBULIN RECEPTOR; MDCK CELLS; CYTOPLASMIC DOMAIN; PLASMA-MEMBRANE; HOMING RECEPTOR; SORTING SIGNAL; PHOSPHORYLATION; GLYCOPROTEIN; REQUIRES; DISTINCT	Both in vivo and in vitro the distribution of the resident plasma membrane adhesion protein, CD44, is restricted to the basolateral domain of polarized epithelial cells, suggesting a role in interepithelial interactions. To determine how this localization might be regulated, a range of CD44 cytoplasmic domain mutations were generated and a minimal 5 amino acid sequence, His(330)-Leu-Val-Asn-Lys(334), was identified which when deleted results in expression of CD44 on the apical microvillal membrane, Further mutagenesis throughout this regions pinpointed a critical di-hydrophobic motif, Leu(331)/Val(332), The ability of wild type but not mutant CD44 cytoplasmic domains to redirect an apically targeted protein, placental alkaline phosphatase, to the basolateral plasma membrane demonstrates that this sequence can function as a dominant localization signal. This His(330)-Lys(334) sequence is spatially separate from other CD44 regulatory elements and as discussed here, a comparison with known basolateral sorting sequences identified in other transmembrane proteins suggests that a distinct mechanism operates to retain resident plasma membrane proteins in their correct plasma membrane subdomains.			Sheikh, H (corresponding author), UNIV LONDON IMPERIAL COLL SCI TECHNOL & MED,DEPT BIOL,PRINCE CONSORT RD,LONDON SW7 2BB,ENGLAND.			Isacke, Clare/0000-0002-9222-3345				ALHO AM, 1989, J CELL BIOL, V108, P1557, DOI 10.1083/jcb.108.4.1557; AROETI B, 1993, J CELL BIOL, V123, P1149, DOI 10.1083/jcb.123.5.1149; BERGER J, 1988, J BIOL CHEM, V263, P10016; BRETSCHER MS, 1980, P NATL ACAD SCI-BIOL, V77, P4156, DOI 10.1073/pnas.77.7.4156; BROWN DA, 1989, SCIENCE, V245, P1499, DOI 10.1126/science.2571189; CASANOVA JE, 1990, SCIENCE, V248, P742, DOI 10.1126/science.2110383; CASANOVA JE, 1991, CELL, V66, P65, DOI 10.1016/0092-8674(91)90139-P; DARGEMONT C, 1993, EMBO J, V12, P1713, DOI 10.1002/j.1460-2075.1993.tb05816.x; GEFFEN I, 1993, J BIOL CHEM, V268, P20772; HAGGERTY JG, 1992, J INVEST DERMATOL, V99, P374, DOI 10.1111/1523-1747.ep12616087; HUDSON DL, 1995, J CELL SCI, V108, P1959; HUNZIKER W, 1991, CELL, V66, P907, DOI 10.1016/0092-8674(91)90437-4; HUNZIKER W, 1994, EMBO J, V13, P2963, DOI 10.1002/j.1460-2075.1994.tb06594.x; ISACKE CM, 1994, J CELL SCI, V107, P2353; ISHIHARA A, 1988, J CELL BIOL, V106, P329, DOI 10.1083/jcb.106.2.329; JACOBSON K, 1984, J CELL BIOL, V99, P1624, DOI 10.1083/jcb.99.5.1624; JACOBSON K, 1984, J CELL BIOL, V99, P1613, DOI 10.1083/jcb.99.5.1613; LEBIVIC A, 1991, J CELL BIOL, V115, P607, DOI 10.1083/jcb.115.3.607; LESLEY J, 1990, EXP CELL RES, V187, P224, DOI 10.1016/0014-4827(90)90085-O; LESLEY J, 1993, ADV IMMUNOL, V54, P271, DOI 10.1016/S0065-2776(08)60537-4; LIAO HX, 1993, J IMMUNOL, V151, P6490; LOKESHWAR VB, 1994, J CELL BIOL, V126, P1099, DOI 10.1083/jcb.126.4.1099; MATTER K, 1994, CURR OPIN CELL BIOL, V6, P545, DOI 10.1016/0955-0674(94)90075-2; MATTER K, 1994, J CELL BIOL, V126, P991, DOI 10.1083/jcb.126.4.991; MATTER K, 1992, CELL, V71, P741, DOI 10.1016/0092-8674(92)90551-M; MILDE KF, 1994, IMMUNOGENETICS, V40, P437; MILLAN JL, 1986, J BIOL CHEM, V261, P3112; MILSTONE LM, 1994, J CELL SCI, V107, P3183; MONLAUZEUR L, 1995, J BIOL CHEM, V270, P12219, DOI 10.1074/jbc.270.20.12219; MOSTOV K, 1992, J CELL BIOL, V116, P577, DOI 10.1083/jcb.116.3.577; MOSTOV KE, 1995, BIOESSAYS, V17, P129, DOI 10.1002/bies.950170208; NEAME SJ, 1995, J CELL SCI, V108, P3127; NEAME SJ, 1993, J CELL BIOL, V121, P1299, DOI 10.1083/jcb.121.6.1299; NEAME SJ, 1992, EMBO J, V11, P4733, DOI 10.1002/j.1460-2075.1992.tb05578.x; PERSCHL A, 1995, EUR J IMMUNOL, V25, P495, DOI 10.1002/eji.1830250228; PERSCHL A, 1995, J CELL SCI, V108, P1033; PRILL V, 1993, EMBO J, V12, P2181, DOI 10.1002/j.1460-2075.1993.tb05866.x; PURE E, 1995, J EXP MED, V181, P55, DOI 10.1084/jem.181.1.55; RODRIGUEZBOULAN E, 1989, SCIENCE, V245, P718, DOI 10.1126/science.2672330; Sandoval Ignacio V., 1994, Trends in Cell Biology, V4, P292, DOI 10.1016/0962-8924(94)90220-8; SANDOVAL IV, 1994, J BIOL CHEM, V269, P6622; SCREATON GR, 1993, J BIOL CHEM, V268, P12235; SCREATON GR, 1992, P NATL ACAD SCI USA, V89, P12160, DOI 10.1073/pnas.89.24.12160; SHERMAN L, 1994, CURR OPIN CELL BIOL, V6, P726, DOI 10.1016/0955-0674(94)90100-7; SHIN JY, 1991, J BIOL CHEM, V266, P10658; SIMONS K, 1990, CELL, V62, P207, DOI 10.1016/0092-8674(90)90357-K; SIMONS K, 1985, ANNU REV CELL BIOL, V1, P243, DOI 10.1146/annurev.cb.01.110185.001331; STAMENKOVIC I, 1989, CELL, V56, P1057, DOI 10.1016/0092-8674(89)90638-7; THOMAS DC, 1994, J BIOL CHEM, V269, P15732; THOMAS DC, 1993, J BIOL CHEM, V268, P3313; UFF CR, 1995, EUR J IMMUNOL, V25, P1883, DOI 10.1002/eji.1830250714; VAUX D, 1992, Trends in Cell Biology, V2, P189, DOI 10.1016/0962-8924(92)90232-C; WANG C, 1992, HISTOCHEMISTRY, V98, P105, DOI 10.1007/BF00717001	53	58	59	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 24	1996	271	21					12185	12190		10.1074/jbc.271.21.12185	http://dx.doi.org/10.1074/jbc.271.21.12185			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UL660	8647812	hybrid			2022-12-25	WOS:A1996UL66000014
J	VanderMolen, MA; Rubin, CT; McLeod, KJ; McCauley, LK; Donahue, HJ				VanderMolen, MA; Rubin, CT; McLeod, KJ; McCauley, LK; Donahue, HJ			Gap junctional intercellular communication contributes to hormonal responsiveness in osteoblastic networks	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTRACELLULAR FREE CALCIUM; PARATHYROID-HORMONE; BONE-CELLS; ALKALINE-PHOSPHATASE; PROTEIN CONNEXIN-43; COMMON RECEPTOR; OSTEO-SARCOMA; ROS 17/2.8; EXPRESSION; DENSITY	To evaluate whether intercellular coupling via connexin43 gap junction channels modulates hormonal responsiveness of cells in contact, we have created osteoblastic cell lines deficient in connexin43. Osteoblastic ROS 17/2.8 cells were transfected with a plasmid containing an antisense cDNA construct to rat connexin43. Control transfection did not alter cell-to-cell coupling nor connexin43 mRNA or protein expression relative to nontransfected ROS 17/2.8 cells. In contrast, stable transfection with an antisense connexin43 cDNA resulted in two clones, RCx4 and RCx16, which displayed significant decreases in connexin43 mRNA and protein expression and were dramatically deficient in cell-to-cell coupling. Phenotypically, all transfectants retained osteoblastic characteristics. However,cells rendered connexin43-deficient through antisense transfection displayed a dramatic attenuation in the cAMP response to parathyroid hormone, Alterations in hormonal responses were not due to changes in parathyroid hormone receptor number or binding kinetics nor to alterations in adenylyl cyclase activity. These results indicate that gap junctions may be required for mediating hormonal signals. Furthermore, these experiments support a regulatory role for connexin43-mediated intercellular communication in the modulation of hormonal responses within elaborately networked bone cells.	PENN STATE UNIV,COLL MED,MUSCULOSKELETAL RES LAB,DEPT ORTHOPAED & REHABIL,HERSHEY,PA 17033; SUNY STONY BROOK,MUSCULOSKELETAL RES LAB,DEPT ORTHOPED,STONY BROOK,NY 11794; UNIV MICHIGAN,SCH DENT,ANN ARBOR,MI 48109; PENN STATE UNIV,COLL MED,DEPT CELLULAR & MOLEC PHYSIOL,HERSHEY,PA 17033	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; University of Michigan System; University of Michigan; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health					NIA NIH HHS [AG10199, AG13087] Funding Source: Medline; NIEHS NIH HHS [ES06287] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES006287] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R29AG010199, R01AG013087] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ABOUSAMRA AB, 1992, P NATL ACAD SCI USA, V89, P2732, DOI 10.1073/pnas.89.7.2732; ABOUSAMRA AB, 1989, ENDOCRINOLOGY, V125, P2215, DOI 10.1210/endo-125-4-2215; BASTIAANSE EML, 1993, J MEMBRANE BIOL, V136, P135, DOI 10.1007/BF02505758; BOS MP, 1991, J CELL PHYSIOL, V147, P87, DOI 10.1002/jcp.1041470112; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWN MEA, 1993, BONE, V14, P473, DOI 10.1016/8756-3282(93)90182-A; CHIBA H, 1994, CELL STRUCT FUNCT, V19, P173, DOI 10.1247/csf.19.173; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHRIST GJ, 1993, J PHARMACOL EXP THER, V266, P1054; CIVITELLI R, 1993, J CLIN INVEST, V91, P1888, DOI 10.1172/JCI116406; CIVITELLI R, 1992, ENDOCRINOLOGY, V130, P2392, DOI 10.1210/en.130.4.2392; COELHO CND, 1991, DEV BIOL, V144, P47, DOI 10.1016/0012-1606(91)90477-K; DEALY CN, 1994, DEV DYNAM, V199, P156, DOI 10.1002/aja.1001990208; DEMAY M, 1985, AM J PHYSIOL, V249, pE437, DOI 10.1152/ajpendo.1985.249.5.E437; DEMOTZ S, 1990, SCIENCE, V249, P1028, DOI 10.1126/science.2118680; DONAHUE HJ, 1988, J BIOL CHEM, V263, P13522; DONAHUE HJ, 1995, J BONE MINER RES, V10, P881; DONAHUE HJ, 1992, BONE MINER S1, V17, P123; EGAN JJ, 1991, J CELL BIOCHEM, V45, P93, DOI 10.1002/jcb.240450116; EGRISE D, 1992, BONE, V13, P355, DOI 10.1016/8756-3282(92)90451-2; Fedotov V P, 1993, Biull Eksp Biol Med, V116, P619; FISHMAN GI, 1990, J CELL BIOL, V111, P589, DOI 10.1083/jcb.111.2.589; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; GREEN CR, 1994, DEV BIOL, V161, P12, DOI 10.1006/dbio.1994.1002; HARDING CV, 1990, NATURE, V346, P574, DOI 10.1038/346574a0; JEANSONNE BG, 1979, J DENT RES, V58, P1415, DOI 10.1177/00220345790580042101; JONES SJ, 1993, ANAT EMBRYOL, V187, P343; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEHRACH H, 1978, P NATL ACAD SCI USA, V75, P5417, DOI 10.1073/pnas.75.11.5417; MAJESKA RJ, 1985, ENDOCRINOLOGY, V116, P170, DOI 10.1210/endo-116-1-170; MAJESKA RJ, 1980, ENDOCRINOLOGY, V107, P1494, DOI 10.1210/endo-107-5-1494; Martinez Arias Alfonso, 1994, Trends in Genetics, V10, P219; MCCAULEY LK, 1994, MOL CELL ENDOCRINOL, V101, P331, DOI 10.1016/0303-7207(94)90250-X; MCLEOD KJ, 1993, J BONE MINER RES, V8, P977, DOI 10.1002/jbmr.5650080811; MODROWSKI D, 1993, CELL TISSUE RES, V271, P499, DOI 10.1007/BF02913733; MUNARISILEM Y, 1995, J CLIN INVEST, V95, P1429, DOI 10.1172/JCI117813; ORLOFF JJ, 1989, ENDOCR REV, V10, P476, DOI 10.1210/edrv-10-4-476; PECK WA, 1981, CALCIFIED TISSUE INT, V33, P409, DOI 10.1007/BF02409464; RODAN GA, 1984, ADV BONE MINERAL RES, V2, P240; SAEZ JC, 1993, ADV SEC MESS PHOSPH, V27, P163; SAEZ JC, 1990, IN VITRO TOXICOL, V3, P69; SCHILLER PC, 1992, MOL ENDOCRINOL, V6, P1433, DOI 10.1210/me.6.9.1433; SCHIRRMACHER K, 1992, CALCIFIED TISSUE INT, V51, P285, DOI 10.1007/BF00334489; STAUFFER PL, 1993, J BIOL CHEM, V268, P19769; STEHLE JH, 1993, NATURE, V365, P314, DOI 10.1038/365314a0; STEINBERG TH, 1994, EMBO J, V13, P744, DOI 10.1002/j.1460-2075.1994.tb06316.x; VANDERPLAS A, 1988, BONE, V9, P107, DOI 10.1016/8756-3282(88)90111-1; WEINREB M, 1990, J BONE MINER RES, V5, P831; WOLBURG H, 1995, INT REV CYTOL, V157, P315, DOI 10.1016/S0074-7696(08)62161-0; WONG GL, 1992, J BONE MINER RES, V7, P701; XIA SL, 1992, BIOCHEM BIOPH RES CO, V186, P1212, DOI 10.1016/S0006-291X(05)81535-9; YAMAGUCHI DT, 1994, J BONE MINER RES, V9, P791; YAMAMOTO T, 1990, BRAIN RES, V508, P313, DOI 10.1016/0006-8993(90)90415-8; YANCEY SB, 1992, DEVELOPMENT, V114, P203; ZIMMERMANN B, 1984, J ANAT, V138, P351	55	95	96	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 24	1996	271	21					12165	12171		10.1074/jbc.271.21.12165	http://dx.doi.org/10.1074/jbc.271.21.12165			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UL660	8647809	hybrid			2022-12-25	WOS:A1996UL66000011
J	vanNocker, S; Walker, JM; Vierstra, RD				vanNocker, S; Walker, JM; Vierstra, RD			The Arabidopsis thaliana UBC7/13/14 genes encode a family of multiubiquitin chain-forming E2 enzymes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UBIQUITIN-CONJUGATING ENZYMES; ESCHERICHIA-COLI; EXPRESSION; YEAST; PROTEINS; INVIVO; LOCALIZATION; DEGRADATION	Covalent modification of proteins by attachment of multiubiquitin chains serves as an essential signal for selective protein degradation in eukaryotes. The specificity of ubiquitin-protein conjugation is controlled in part by a diverse group of ubiquitin-conjugating enzymes (E2s or UBCs), We have previously reported that the product of the wheat TaUBC7 gene recognizes ubiquitin as a substrate for ubiquitination in vitro, catalyzing the condensation of free ubiquitin into multiubiquitin chains linked via lysine 48 (van Nocker, S., and Vierstra, R. D. (1991) Proc. Natl. Acad. Sci. U. S. A. 88, 10297-10301), Based on this activity, this E2 may play a central role in the ubiquitin proteolytic pathway by assembling chains in vivo. Here, we describe the cloning and characterization of a three-member gene family from Arabidopsis thaliana (designated AtUBC7/13/14) encoding structural homologs of TaUBC7. Like TaUBC7, recombinant AtUBC7/13/14 proteins formed multiubiquitin chains in vitro. AtUBC7/13/14 mRNAs were found in all tissues examined, and unlike related UBCs from yeast, the levels of mRNA were not elevated by heat stress or cadmium exposure, Transgenic Arabidopsis were engineered to express increased levels of active AtUBC7, for the first time altering the level of an E2 in a higher eukaryote, Plants expressing high levels of AtUBC7 exhibited no phenotypic abnormalities and were not noticeably enriched in multiubiquitinated conjugates. These findings indicate that the in vivo synthesis of multiubiquitin chains is not rate-limited by the abundance of AtUBC7 and/or involves other, yet undefined components.	UNIV WISCONSIN,DEPT HORT,MADISON,WI 53706	University of Wisconsin System; University of Wisconsin Madison								BAILLY V, 1994, GENE DEV, V8, P811, DOI 10.1101/gad.8.7.811; BARTLING D, 1993, PLANT MOL BIOL, V23, P387, DOI 10.1007/BF00029013; BEERS EP, 1992, J BIOL CHEM, V267, P15432; BENFEY PN, 1990, EMBO J, V9, P1677, DOI 10.1002/j.1460-2075.1990.tb08291.x; CALLIS J, 1990, J BIOL CHEM, V265, P12486; CHAU V, 1989, SCIENCE, V243, P1576, DOI 10.1126/science.2538923; CHEN P, 1993, CELL, V74, P357, DOI 10.1016/0092-8674(93)90426-Q; CHEN ZJ, 1990, J BIOL CHEM, V265, P21835; CHEN ZJ, 1991, J BIOL CHEM, V266, P15698; CIECHANOVER A, 1994, CELL, V79, P13, DOI 10.1016/0092-8674(94)90396-4; COOK WJ, 1993, BIOCHEMISTRY-US, V32, P13809, DOI 10.1021/bi00213a009; DEAN C, 1986, NUCLEIC ACIDS RES, V14, P2229, DOI 10.1093/nar/14.5.2229; DEVERAUX Q, 1994, J BIOL CHEM, V269, P7059; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GENSCHIK P, 1994, MOL GEN GENET, V244, P548, DOI 10.1007/BF00583906; GIROD PA, 1993, PLANT J, V3, P545, DOI 10.1046/j.1365-313X.1993.03040545.x; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; GOEBL MG, 1988, SCIENCE, V241, P1331, DOI 10.1126/science.2842867; HATFIELD PM, 1990, J BIOL CHEM, V265, P15813; HERSHKO A, 1992, ANNU REV BIOCHEM, V61, P761, DOI 10.1146/annurev.bi.61.070192.003553; HOCHSTRASSER M, 1991, P NATL ACAD SCI USA, V88, P4606, DOI 10.1073/pnas.88.11.4606; JABBEN M, 1989, J BIOL CHEM, V264, P4998; JEFFERSON RA, 1987, EMBO J, V6, P3901; Jensen JP, 1995, J BIOL CHEM, V270, P30408, DOI 10.1074/jbc.270.51.30408; JUNGMANN J, 1993, NATURE, V361, P369, DOI 10.1038/361369a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MADURA K, 1994, SCIENCE, V265, P1454, DOI 10.1126/science.8073290; MATZKE MA, 1995, PLANT PHYSIOL, V107, P579; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; ROSENBERG AH, 1987, GENE, V56, P125, DOI 10.1016/0378-1119(87)90165-X; Sambrook J., 2002, MOL CLONING LAB MANU	32	25	32	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 24	1996	271	21					12150	12158		10.1074/jbc.271.21.12150	http://dx.doi.org/10.1074/jbc.271.21.12150			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UL660	8647807	hybrid			2022-12-25	WOS:A1996UL66000009
J	Yamakita, Y; Ono, S; Matsumura, F; Yamashiro, S				Yamakita, Y; Ono, S; Matsumura, F; Yamashiro, S			Phosphorylation of human fascin inhibits its actin binding and bundling activities	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NONMUSCLE CALDESMON; CULTURED-CELLS; PROTEIN; LOCALIZATION; TROPOMYOSIN; ACTIVATION; KINASE	Human fascin is an actin-bundling protein that is thought to be involved in the assembly of actin filament bundles present in microspikes as well as in membrane ruffles and stress fibers. We have found that human fascin is phosphorylated in vivo upon treatment with 12-O-tetradecanoylphorbol-13-acetate, a tumor promoter. The in vivo phosphorylation is gradually increased from 0.13 to 0.30 mol/mol during 2 h of treatment, concomitant with the disappearance of human fascin from stress fibers, membrane ruffles, and microspikes. Human fascin can also be phosphorylated in vitro by protein kinase C at the same sites as observed in vivo as judged by phosphopeptide mapping. The extent of phosphorylation depends on pH: the stoichiometries are 0.05, 0.38, and 0.6 mol of phosphate/mol of protein at pH 7.0, 6.0, and 5.0, respectively. Phosphorylation greatly reduces actin binding of human fascin, while lowering the pH to 6.0 alone does not affect fascin-actin binding. With the incorporation of 0.25 mol of phosphate/mol of protein, the actin binding affinity is reduced from 6.7 x 10(6) to 1.5 x 10(6) m(-1). The actin bundling activity is also decreased. These results suggest that phosphorylation of fascin plays a role in actin reorganization after treatment with 12-O-tetradecanoylphorbol-13-acetate.			Yamakita, Y (corresponding author), RUTGERS STATE UNIV, DEPT MOLEC BIOL & BIOCHEM, PISCATAWAY, NJ 08855 USA.		Ono, Shoichiro/A-6475-2015; Yamakita, Yoshihiko/A-3003-2016	Ono, Shoichiro/0000-0002-4763-0398; Matsumura, Fumio/0000-0002-8204-153X; Yamashiro, Shigeko/0000-0001-7207-9406	NATIONAL CANCER INSTITUTE [R37CA042742] Funding Source: NIH RePORTER; NCI NIH HHS [R37 CA42742] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRYAN J, 1993, P NATL ACAD SCI USA, V90, P9115, DOI 10.1073/pnas.90.19.9115; CANT K, 1994, J CELL BIOL, V125, P369, DOI 10.1083/jcb.125.2.369; CASSIDY P, 1979, J BIOL CHEM, V254, P1148; DUH FM, 1994, DNA CELL BIOL, V13, P821, DOI 10.1089/dna.1994.13.821; EDWARDS RA, 1995, J BIOL CHEM, V270, P10764, DOI 10.1074/jbc.270.18.10764; GOODNIGHT J, 1995, J BIOL CHEM, V270, P9991, DOI 10.1074/jbc.270.17.9991; HOAR PE, 1979, SCIENCE, V204, P503, DOI 10.1126/science.432654; ISHIKAWA R, 1989, J BIOL CHEM, V264, P7490; KANE RE, 1976, J CELL BIOL, V71, P704, DOI 10.1083/jcb.71.3.704; MAHOWALD AP, 1980, GENET BIOL DROSOPHIL, P141; MOSIALOS G, 1994, J VIROL, V68, P7320, DOI 10.1128/JVI.68.11.7320-7328.1994; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; OTTO JJ, 1979, CELL, V17, P285, DOI 10.1016/0092-8674(79)90154-5; PATTERSON J, 1991, GENETICS, V129, P1073; POODRY CA, 1980, GENET BIOL DROSOPHIL, P443; SCHLIWA M, 1984, J CELL BIOL, V99, P1045, DOI 10.1083/jcb.99.3.1045; YAMAKITA Y, 1994, J CELL BIOL, V124, P129, DOI 10.1083/jcb.124.1.129; YAMASHIRO S, 1991, NATURE, V349, P169, DOI 10.1038/349169a0; YAMASHIRO S, 1994, ADV EXP MED BIOL, V358, P113; YAMASHIROMATSUMURA S, 1986, J CELL BIOL, V103, P631, DOI 10.1083/jcb.103.2.631; YAMASHIROMATSUMURA S, 1985, J BIOL CHEM, V260, P5087	22	110	112	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 24	1996	271	21					12632	12638		10.1074/jbc.271.21.12632	http://dx.doi.org/10.1074/jbc.271.21.12632			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UL660	8647875	hybrid			2022-12-25	WOS:A1996UL66000077
J	Dolis, D; deKroon, IPM; deKruijff, B				Dolis, D; deKroon, IPM; deKruijff, B			Transmembrane movement of phosphatidylcholine in mitochondrial outer membrane vesicles	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER MITOCHONDRIA; PHOSPHOLIPID ASYMMETRY; TRANSFER PROTEIN; TRANSLOCATION	One of the steps in the import of phosphatidylcholine (PC) in mitochondria is transmembrane movement across the outer membrane, This process was investigated in vitro using isolated mitochondrial outer membrane vesicles (OMV) from rat liver. C-14-Labeled PC was introduced into the OMV from small unilamellar vesicles by a PC-specific transfer protein (PCTP). The membrane topology of the newly introduced PC was determined from its accessibility to phospholipase A(2). Under conditions where the OMV stay intact, externally added phospholipase A(2) is able to hydrolyze up to 50% of both the introduced [C-14]PC and the endogenous PC. Pool size calculations showed that close to 100% of the PC in the OMV can be exchanged by PCTP. A back-exchange experiment revealed that the introduction of the labeled PC is reversible. The results demonstrate that newly introduced PC molecules readily equilibrate over both leaflets of the OMV membrane. The kinetics of the PCTP-mediated exchange process indicate that the t(1/2) of the transmembrane movement at 30 degrees C is 2 min or less.	UNIV UTRECHT,CTR BIOMEMBRANES & LIPID ENZYMOL,DEPT BIOCHEM MEMBRANES,INST BIOMEMBRANES,3584 CH UTRECHT,NETHERLANDS	Utrecht University			de Kroon, Anton I/O-4119-2016	de Kroon, Anton/0000-0003-1209-756X				AKEROYD R, 1981, EUR J BIOCHEM, V114, P385, DOI 10.1111/j.1432-1033.1981.tb05158.x; ANCE DE, 1991, BIOCH LIPIDS LIPOPRO, P205; ARDAIL D, 1993, J BIOL CHEM, V268, P25985; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BLOK MC, 1971, BIOCHIM BIOPHYS ACTA, V233, P61, DOI 10.1016/0005-2736(71)90358-0; DAUM G, 1985, BIOCHIM BIOPHYS ACTA, V822, P1, DOI 10.1016/0304-4157(85)90002-4; Fiske CH, 1925, J BIOL CHEM, V66, P375; GAIGG B, 1995, BBA-BIOMEMBRANES, V1234, P214, DOI 10.1016/0005-2736(94)00287-Y; HERRMANN A, 1990, BIOCHEMISTRY-US, V29, P2023, DOI 10.1021/bi00460a010; HOVIUS R, 1990, BIOCHIM BIOPHYS ACTA, V1021, P217, DOI 10.1016/0005-2736(90)90036-N; HOVIUS R, 1993, FEBS LETT, V330, P71, DOI 10.1016/0014-5793(93)80922-H; Huijbregts RPH, 1996, BBA-BIOMEMBRANES, V1280, P41, DOI 10.1016/0005-2736(95)00272-3; JOHNSON LW, 1975, BIOCHIM BIOPHYS ACTA, V375, P176, DOI 10.1016/0005-2736(75)90187-X; MAYER A, 1993, J CELL BIOL, V121, P1233, DOI 10.1083/jcb.121.6.1233; NICOLAY K, 1990, BIOCHIM BIOPHYS ACTA, V1025, P49, DOI 10.1016/0005-2736(90)90189-U; Nieuwenhuizen W, 1974, Methods Enzymol, V32, P147; ROSE HG, 1965, J LIPID RES, V6, P428; ROTHMAN JE, 1976, BIOCHEMISTRY-US, V15, P2361, DOI 10.1021/bi00656a018; ROUSSELET A, 1976, BIOCHIM BIOPHYS ACTA, V426, P372, DOI 10.1016/0005-2736(76)90383-7; SCHMIDT B, 1984, EUR J BIOCHEM, V144, P581, DOI 10.1111/j.1432-1033.1984.tb08505.x; SHIAO YJ, 1995, J BIOL CHEM, V270, P11190, DOI 10.1074/jbc.270.19.11190; SPERKAGOTTLIEB CDM, 1988, BIOCHIM BIOPHYS ACTA, V946, P227, DOI 10.1016/0005-2736(88)90397-5; TROTTER PJ, 1994, BBA-LIPID LIPID MET, V1213, P241, DOI 10.1016/0005-2760(94)00073-5; VAN MEER G, 1980, EUR J BIOCHEM, V103, P283; VANCE JE, 1990, J BIOL CHEM, V265, P7248; VANDENBESSELAAR AMHP, 1978, BIOCHIM BIOPHYS ACTA, V510, P242, DOI 10.1016/0005-2736(78)90024-X; VOELKER DR, 1993, J BIOL CHEM, V268, P7069; WESTERMAN J, 1983, METHOD ENZYMOL, V98, P581; WIRTZ KWA, 1991, ANNU REV BIOCHEM, V60, P73, DOI 10.1146/annurev.biochem.60.1.73; WOJTCZAK L, 1969, BIOCHIM BIOPHYS ACTA, V193, P64, DOI 10.1016/0005-2736(69)90059-5; YAFFE MP, 1983, BIOCHEMISTRY-US, V22, P1497, DOI 10.1021/bi00275a026	31	21	21	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 17	1996	271	20					11879	11883		10.1074/jbc.271.20.11879	http://dx.doi.org/10.1074/jbc.271.20.11879			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UL250	8662651	hybrid			2022-12-25	WOS:A1996UL25000048
J	Mutskov, VJ; Russanova, VR; Dimitrov, SI; Pashev, IG				Mutskov, VJ; Russanova, VR; Dimitrov, SI; Pashev, IG			Histones associated with non-nucleosomal rat ribosomal genes are acetylated while those bound to nucleosome-organized gene copies are not	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTIONALLY ACTIVE CHROMATIN; RNA GENES; XENOPUS-LAEVIS; DROSOPHILA-MELANOGASTER; PSORALEN-CROSSLINKING; NUCLEOLAR CHROMATIN; LASER IRRADIATION; DNA CROSSLINKING; CELL-CYCLE; EXPRESSION	Acetylation of histones bound to rat rRNA genes has been studied relative to their organization in chromatin, either as canonical nucleosomes, containing the inactive copies, or as anucleosomal nonrepeating structures, corresponding to the transcribed genes (Conconi, A., Widmer, R. M., Koller, T., and Sogo, J. M. (1989) Cell 57, 753-761). Nuclei from butyrate-treated rat tumor cells were irradiated with a UV laser to cross-link proteins to DNA, and the purified covalent complexes were immunofractionated by an antibody that specifically recognized the acetylated histones. Upon probing with sequences coding for mature rat 28 S RNA, DNA of the antibody-bound complexes was 5-20-fold enriched relative to the total rat DNA. Since the laser cross-links histones to DNA in both active and inactive genes, one cannot distinguish which one of them, or both, are bound to acetylated histones. Alternatively, purified mononucleosomes were immunofractionated, but DNA from the antibody bound monosomes was not enriched in coding rDNA. Taken together, these results suggest that nucleosome organized rRNA genes are bound to nonmodified histones and that the acetylated histones are associated with the active, anucleosomal gene copies.	BULGARIAN ACAD SCI, INST MOLEC BIOL, BU-1113 SOFIA, BULGARIA	Bulgarian Academy of Sciences			dimitrov, stefan/M-7697-2013	dimitrov, stefan/0000-0002-1326-3630				AMERO SA, 1988, J BIOL CHEM, V263, P10734; ANGELOV D, 1988, NUCLEIC ACIDS RES, V16, P4525, DOI 10.1093/nar/16.10.4525; BELIKOV SV, 1990, FEBS LETT, V273, P205, DOI 10.1016/0014-5793(90)81085-3; BONNER WM, 1980, EUR J BIOCHEM, V109, P17, DOI 10.1111/j.1432-1033.1980.tb04762.x; BRAGA EA, 1985, GENE, V36, P249, DOI 10.1016/0378-1119(85)90180-5; BRAUNSTEIN M, 1993, GENE DEV, V7, P592, DOI 10.1101/gad.7.4.592; CLAYTON AL, 1993, FEBS LETT, V336, P23, DOI 10.1016/0014-5793(93)81601-U; COLAVITOSHEPANSKI M, 1983, J BIOL CHEM, V258, P5944; CONCONI A, 1989, CELL, V57, P753, DOI 10.1016/0092-8674(89)90790-3; CONCONI A, 1984, J MOL BIOL, V178, P920, DOI 10.1016/0022-2836(84)90319-X; CSORDAS A, 1990, BIOCHEM J, V265, P23, DOI 10.1042/bj2650023; CULOTTA V, 1988, CELL, V52, P585, DOI 10.1016/0092-8674(88)90471-0; DAMMANN R, 1993, NUCLEIC ACIDS RES, V21, P2331, DOI 10.1093/nar/21.10.2331; DIMITROV SI, 1990, NUCLEIC ACIDS RES, V18, P6393, DOI 10.1093/nar/18.21.6393; DIMITROV SI, 1987, EMBO J, V6, P2387, DOI 10.1002/j.1460-2075.1987.tb02516.x; DIMITROV SI, 1992, EUR J BIOCHEM, V204, P977, DOI 10.1111/j.1432-1033.1992.tb16719.x; DURRIN LK, 1991, CELL, V65, P1023, DOI 10.1016/0092-8674(91)90554-C; FELSENFELD G, 1992, NATURE, V355, P219, DOI 10.1038/355219a0; HAAF T, 1991, EXP CELL RES, V193, P78, DOI 10.1016/0014-4827(91)90540-B; HEBBES TR, 1992, NUCLEIC ACIDS RES, V20, P1017, DOI 10.1093/nar/20.5.1017; HEBBES TR, 1988, EMBO J, V7, P1395, DOI 10.1002/j.1460-2075.1988.tb02956.x; JEPPESEN P, 1993, CELL, V74, P281, DOI 10.1016/0092-8674(93)90419-Q; JOHNSON EM, 1987, J BIOL CHEM, V262, P6943; JUDELSON HS, 1982, MOL CELL BIOL, V2, P211, DOI 10.1128/MCB.2.3.211; LABHART P, 1982, CELL, V28, P279, DOI 10.1016/0092-8674(82)90346-4; LEE DY, 1993, CELL, V72, P73, DOI 10.1016/0092-8674(93)90051-Q; LOIDL P, 1992, CELL BIOL INT REP, V16, P1177, DOI 10.1016/S0309-1651(05)80045-1; LUCCHINI R, 1992, MOL CELL BIOL, V12, P4288, DOI 10.1128/MCB.12.10.4288; MEGEE PC, 1990, SCIENCE, V247, P841, DOI 10.1126/science.2106160; NESS PJ, 1983, J MOL BIOL, V166, P361, DOI 10.1016/S0022-2836(83)80090-4; ONEILL LP, 1995, EMBO J, V14, P3946, DOI 10.1002/j.1460-2075.1995.tb00066.x; PASHEV IG, 1991, TRENDS BIOCHEM SCI, V16, P323, DOI 10.1016/0968-0004(91)90133-G; PASHEV IG, 1983, EUR J BIOCHEM, V133, P379, DOI 10.1111/j.1432-1033.1983.tb07473.x; PRIOR CP, 1983, CELL, V34, P1033, DOI 10.1016/0092-8674(83)90561-5; REEVES R, 1976, SCIENCE, V194, P529, DOI 10.1126/science.973136; RIGGS MG, 1977, NATURE, V268, P462, DOI 10.1038/268462a0; SCHEER U, 1984, J CELL BIOL, V99, P672, DOI 10.1083/jcb.99.2.672; SOGO JM, 1984, J MOL BIOL, V178, P897, DOI 10.1016/0022-2836(84)90318-8; SPADAFORA C, 1984, NUCLEIC ACIDS RES, V12, P2691, DOI 10.1093/nar/12.6.2691; STEFANOVSKY VY, 1989, BIOCHEM BIOPH RES CO, V164, P304, DOI 10.1016/0006-291X(89)91718-X; TAZI J, 1990, CELL, V60, P909, DOI 10.1016/0092-8674(90)90339-G; TSANEV R, 1993, REPLICATION TRANSCRI, P137; TURNER BM, 1992, CELL, V69, P375, DOI 10.1016/0092-8674(92)90417-B; TURNER BM, 1989, EUR J BIOCHEM, V179, P131, DOI 10.1111/j.1432-1033.1989.tb14530.x; TURNER BM, 1991, J CELL SCI, V99, P13; UDVARDY A, 1984, J MOL BIOL, V175, P113, DOI 10.1016/0022-2836(84)90470-4	46	30	32	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 17	1996	271	20					11852	11857		10.1074/jbc.271.20.11852	http://dx.doi.org/10.1074/jbc.271.20.11852			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UL250	8662629	hybrid			2022-12-25	WOS:A1996UL25000044
J	Negrete, HO; Rivers, RL; Gough, AH; Colombini, M; Zeidel, ML				Negrete, HO; Rivers, RL; Gough, AH; Colombini, M; Zeidel, ML			Individual leaflets of a membrane bilayer can independently regulate permeability	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NONELECTROLYTE PERMEABILITIES; WATER PERMEABILITY; LIPID-MEMBRANES; CELL-MEMBRANE; MDCK CELLS; CHOLESTEROL; MONOLAYERS; TRANSPORT; KIDNEY; DOMAIN	Water rapidly crosses most membranes, but only slowly crosses apical membranes of barrier epithelia such as bladder and kidney collecting duct, a feature essential to barrier function. How apical membrane structure reduces permeabilities remains unclear, Cell plasma membranes contain two leaflets of distinct lipid composition; the role of this bilayer asymmetry in membrane permeability is unclear, To determine how asymmetry of leaflet composition affects membrane permeability, effects on bilayer permeation of reducing single leaflet permeability were determined using two approaches: formation of asymmetric bilayers in an Ussing chamber, with only one of two leaflets containing cholesterol sulfate, and stabilization of the external leaflet of unilamellar vesicles with praeseodymium (Pr3+). In both systems, permeability measurements showed that each leaflet acts as an independent resistor of water permeation, These results show that a single bilayer leaflet can act as the barrier to permeation and provide direct evidence that segregation of lipids to create a low permeability exofacial leaflet may act to reduce the permeability of barrier epithelial apical membranes.	UNIV PITTSBURGH,MED CTR,LAB EPITHELIAL CELL BIOL,RENAL ELECTROLYTE DIV,PITTSBURGH,PA 15213; CARNEGIE MELLON UNIV,CTR LIGHT MICROSCOPE IMAGING & BIOTECHNOL,PITTSBURGH,PA 15213; CARNEGIE MELLON UNIV,DEPT BIOL SCI,PITTSBURGH,PA 15213; UNIV MARYLAND,DEPT ZOOL,COLLEGE PK,MD 20742	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Carnegie Mellon University; Carnegie Mellon University; University System of Maryland; University of Maryland College Park			Gough, Albert/K-2490-2019; Colombini, Marco/A-1540-2014	Gough, Albert/0000-0001-6456-0195; 				COLOMBINI M, 1987, METHOD ENZYMOL, V148, P465; FETTIPLACE R, 1980, PHYSIOL REV, V60, P510, DOI 10.1152/physrev.1980.60.2.510; GENZ A, 1986, EUR BIOPHYS J BIOPHY, V13, P323, DOI 10.1007/BF00265668; GROSSMAN EB, 1992, AM J PHYSIOL, V262, pC1109, DOI 10.1152/ajpcell.1992.262.5.C1109; HOLZ R, 1970, J GEN PHYSIOL, V56, P125, DOI 10.1085/jgp.56.1.125; HUNT GR, 1978, BIOCHIM BIOPHYS ACTA, V507, P242, DOI 10.1016/0005-2736(78)90420-0; KIKERI D, 1989, NATURE, V339, P478, DOI 10.1038/339478a0; LANDE MB, 1994, AM J PHYSIOL, V267, pC367, DOI 10.1152/ajpcell.1994.267.2.C367; LANDE MB, 1995, J GEN PHYSIOL, V106, P67, DOI 10.1085/jgp.106.1.67; LANGE Y, 1984, BIOCHIM BIOPHYS ACTA, V769, P551, DOI 10.1016/0005-2736(84)90053-1; LANGE Y, 1989, J BIOL CHEM, V264, P3786; LEGRIMELLEC C, 1992, KIDNEY INT, V42, P825, DOI 10.1038/ki.1992.357; MONTAL M, 1981, Q REV BIOPHYS, V14, P1, DOI 10.1017/S0033583500002079; MONTAL M, 1972, P NATL ACAD SCI USA, V69, P3561, DOI 10.1073/pnas.69.12.3561; PRENNER E, 1993, ARCH BIOCHEM BIOPHYS, V305, P473, DOI 10.1006/abbi.1993.1449; PRIVER NA, 1993, BIOCHEMISTRY-US, V32, P2459, DOI 10.1021/bi00061a002; RODRIGUEZA WV, 1995, BIOCHEMISTRY-US, V34, P6208, DOI 10.1021/bi00018a025; SCHMIDT CF, 1978, NATURE, V271, P775, DOI 10.1038/271775a0; SILLERUD LO, 1982, BIOCHEMISTRY-US, V21, P1756, DOI 10.1021/bi00537a009; SIMONS K, 1988, BIOCHEMISTRY-US, V27, P6197, DOI 10.1021/bi00417a001; STRANGE K, 1987, J MEMBRANE BIOL, V96, P27, DOI 10.1007/BF01869332; VAN MEER G, 1987, J CELL BIOL, V105, P1623, DOI 10.1083/jcb.105.4.1623; VAN MEER G, 1986, EMBO J, V5, P1455, DOI 10.1002/j.1460-2075.1986.tb04382.x; VAN MEER G, 1982, EMBO J, V1, P847, DOI 10.1002/j.1460-2075.1982.tb01258.x; ZACHOWSKI A, 1989, NATURE, V340, P75, DOI 10.1038/340075a0; ZACHOWSKI A, 1989, COMMENTS MOL CELL BI, V6, P63; ZEIDEL ML, 1993, SEMIN NEPHROL, V13, P155; ZEIDEL ML, 1995, KIDNEY, P516	28	48	48	0	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 17	1996	271	20					11627	11630		10.1074/jbc.271.20.11627	http://dx.doi.org/10.1074/jbc.271.20.11627			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UL250	8662821	hybrid			2022-12-25	WOS:A1996UL25000009
J	Xia, Y; Buja, LM; McMillin, JB				Xia, Y; Buja, LM; McMillin, JB			Change in expression of heart carnitine palmitoyltransferase I isoforms with electrical stimulation of cultured rat neonatal cardiac myocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYNTHASE GAMMA-SUBUNIT; MYOSIN HEAVY-CHAIN; MALONYL-COA; GENE-EXPRESSION; SKELETAL-MUSCLE; HYPERTROPHY; GROWTH; LIVER; CDNA; ADAPTATION	Electrical stimulation of neonatal rat cardiac myocytes in culture produces increases in myocyte size (hypertrophy) and organization of actin into myofibrillar arrays. The maturation of the cells is associated with enhanced contractile parameters and cellular calcium content. The numbers and intensity of cellular mitochondrial profiles increase, as measured by scanning laser confocal microscopy. Consistent with the hypertrophic response is increased cellular content of beta-myosin heavy chain and cytochrome oxidase subunit Va messages, as well as increases in cytochrome oxidase activity in the stimulated cardiac myocytes. Myocyte contractile capacity is associated with increased expression of the muscle carnitine palmitoyltransferase (CPT-I) isoform as measured by Northern analysis, immunoblotting, and altered sensitivity of CPT-I activity to malonyl-CoA in the stimulated cells. The data suggest that a switch from the liver isoform of CPT-I, prominent in the neonatal rat heart, to the muscle CPT-I which predominates in adult rat heart, takes place in the neonatal cardiac myocytes over the same time period as the hypertrophic-mediated changes in myofibrillar assembly and increased contractile activity.	UNIV TEXAS, HLTH SCI CTR, SCH MED, DEPT PATHOL & LAB MED, HOUSTON, TX 77030 USA	University of Texas System; University of Texas Health Science Center Houston				Buja, Louis Maximilian/0000-0001-8386-7029	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL038863] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01-HL-38863] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AWAN MM, 1993, BIOCHEM J, V295, P61, DOI 10.1042/bj2950061; BATTINI R, 1987, J BIOL CHEM, V262, P4355; BOOTH FW, 1991, PHYSIOL REV, V71, P541, DOI 10.1152/physrev.1991.71.2.541; BREVET A, 1976, SCIENCE, V193, P1152, DOI 10.1126/science.959833; BROWN NF, 1995, J BIOL CHEM, V270, P8952, DOI 10.1074/jbc.270.15.8952; CHIEN KR, 1991, FASEB J, V5, P3037, DOI 10.1096/fasebj.5.15.1835945; COOK GA, 1987, J BIOL CHEM, V262, P2050; DECLERCQ PE, 1987, J BIOL CHEM, V262, P9812; DONOHUE TJ, 1994, CIRCULATION, V89, P799, DOI 10.1161/01.CIR.89.2.799; Esser V, 1996, J BIOL CHEM, V271, P6972, DOI 10.1074/jbc.271.12.6972; ESSER V, 1993, J BIOL CHEM, V268, P5817; EVANS MJ, 1989, J BIOL CHEM, V264, P14361; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; HAENDLER B, 1987, EMBO J, V6, P947, DOI 10.1002/j.1460-2075.1987.tb04843.x; HENNIG B, 1975, EUR J BIOCHEM, V55, P167, DOI 10.1111/j.1432-1033.1975.tb02149.x; HILENSKI LL, 1991, CELL TISSUE RES, V264, P577, DOI 10.1007/BF00319047; HOULDSWORTH J, 1988, P NATL ACAD SCI USA, V85, P377, DOI 10.1073/pnas.85.2.377; HUDSON EK, 1996, IN PRESS AM J PHYSL; IZQUIERDO JM, 1995, J BIOL CHEM, V270, P10342, DOI 10.1074/jbc.270.17.10342; KELLY K, 1983, CELL, V35, P603, DOI 10.1016/0092-8674(83)90092-2; KERNER J, 1994, J BIOL CHEM, V269, P8209; KOLODZIEJ MP, 1992, BIOCHEM J, V282, P415, DOI 10.1042/bj2820415; KOMURO I, 1990, J BIOL CHEM, V265, P3595; KRAFT R, 1989, NUCLEIC ACIDS RES, V17, P7529, DOI 10.1093/nar/17.18.7529; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MATSUDA C, 1993, J BIOL CHEM, V268, P24950; MATSUDA C, 1993, FEBS LETT, V325, P281, DOI 10.1016/0014-5793(93)81089-I; MATSUDA C, 1994, BIOCHEM BIOPH RES CO, V200, P671, DOI 10.1006/bbrc.1994.1503; MCDONOUGH PM, 1992, J BIOL CHEM, V267, P11665; MCDONOUGH PM, 1994, J BIOL CHEM, V269, P9466; MCGARRY JD, 1989, DIABETES METAB REV, V5, P271, DOI 10.1002/dmr.5610050305; MCMILLIN JB, 1994, ARCH BIOCHEM BIOPHYS, V312, P375, DOI 10.1006/abbi.1994.1322; MCMILLIN JB, 1993, METHODS TOXICOL, V2, P301; MERLE PL, 1995, J BIOL CHEM, V270, P17361, DOI 10.1074/jbc.270.29.17361; MILLS SE, 1983, BIOCHEM J, V214, P83, DOI 10.1042/bj2140083; ROGERS TB, 1990, J BIOL CHEM, V265, P4302; SCHNEIDER MD, 1991, MOL BIOL MED, V8, P167; SEDAN RS, 1996, J BIOL CHEM, V271, P2112; SIMPSON P, 1983, J CLIN INVEST, V72, P732, DOI 10.1172/JCI111023; SOTTOCASA GL, 1967, J CELL BIOL, V32, P415, DOI 10.1083/jcb.32.2.415; WASPE LE, 1990, J CLIN INVEST, V85, P1206, DOI 10.1172/JCI114554; WEIS BC, 1994, J BIOL CHEM, V269, P26443; WEIS BC, 1994, J BIOL CHEM, V269, P18712; WHITAKER JE, 1991, BIOCHEM BIOPH RES CO, V175, P387, DOI 10.1016/0006-291X(91)91576-X; WILLIAMS RS, 1987, J BIOL CHEM, V262, P2764; YAMAZAKI N, 1995, FEBS LETT, V363, P41, DOI 10.1016/0014-5793(95)00277-G	46	37	37	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 17	1996	271	20					12082	12087		10.1074/jbc.271.20.12082	http://dx.doi.org/10.1074/jbc.271.20.12082			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UL250	8662650	hybrid			2022-12-25	WOS:A1996UL25000075
J	Das, R; Reddy, EP; Chatterjee, D; Andrews, DW				Das, R; Reddy, EP; Chatterjee, D; Andrews, DW			Identification of a novel Bcl-2 related gene, BRAG-1, in human glioma	ONCOGENE			English	Article						apoptosis; Bcl-2; BRAG-1; glioma	APOPTOTIC CELL-DEATH; RNA; PROTEIN	Programmed cell death (apoptosis) plays a major role in embryogenesis, in mature organ homeostasis and in many disease states including cancer. Apoptosis occurs as an orderly cell-intrinsic suicide program regulated by a family of genes related to Bcl-2. Here, we describe the cloning and molecular characterization of a gene homologous to Bcl-2 from a human glioma. This gene named BRAG-1 (for brain-related apoptosis gene) has an open reading frame that encodes for a protein of 31 kDa sharing significant sequence homology with the Bcl-2 family of genes in the BH1 and BH2 regions. Northern blot analyses revealed that BRAG-1 is expressed in human gliomas as a 1.8 kb message. This gene, interestingly, was found to be expressed predominantly in normal human brain as a 4.5 kb transcript which is different in size from the message found in tumor tissues. These results suggest that BRAG-1 may be rearranged in human gliomas leading to its over-expression as a truncated transcript. Utilizing a bacterial expression vector, we produced BRAG-1 protein which was found to cross-react with a Bcl-2 monoclonal antibody, further suggesting structural and immunological similarity to Bcl-2.	THOMAS JEFFERSON UNIV HOSP, WILLS NEUROSENSORY INST, DEPT NEUROSURG, NEUROONCOL LAB, PHILADELPHIA, PA 19107 USA; THOMAS JEFFERSON UNIV HOSP, JEFFERSON CANC INST, PHILADELPHIA, PA 19140 USA; TEMPLE UNIV, HLTH SCI CTR, SCH MED, FELS INST CANC RES & MOLEC BIOL, PHILADELPHIA, PA 19140 USA	Jefferson University; Jefferson University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University			Reddy, E. Premkumar/F-6233-2011		NATIONAL CANCER INSTITUTE [K11CA001514] Funding Source: NIH RePORTER; NCI NIH HHS [NIHK11-CA01514] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALDERSON LM, 1995, CANCER RES, V55, P999; ANDREWS AT, 1986, MONOGRAPHS PHYSICAL; ARENDS MJ, 1991, INT REV EXP PATHOL, V32, P223; AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; BARTON GJ, 1993, PROTEIN ENG, V6, P37, DOI 10.1093/protein/6.1.37; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; CHITTENDEN T, 1995, NATURE, V374, P733, DOI 10.1038/374733a0; CHOI SS, 1995, ONCOGENE, V11, P1693; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CORY S, 1995, ANNU REV IMMUNOL, V13, P513, DOI 10.1146/annurev.iy.13.040195.002501; FARROW SN, 1995, NATURE, V374, P731, DOI 10.1038/374731a0; FARWELL J, 1984, NEW ENGL J MED, V311, P749, DOI 10.1056/NEJM198409203111201; HENGARTNER MO, 1994, CELL, V76, P665, DOI 10.1016/0092-8674(94)90506-1; HOCKENBERY DM, 1991, P NATL ACAD SCI USA, V88, P6961, DOI 10.1073/pnas.88.16.6961; KIEFER MC, 1995, NATURE, V374, P736, DOI 10.1038/374736a0; KRIEG PA, 1984, NUCLEIC ACIDS RES, V12, P7057, DOI 10.1093/nar/12.18.7057; LEGRICE SFJ, 1990, EUR J BIOCHEM, V187, P307, DOI 10.1111/j.1432-1033.1990.tb15306.x; LIN EY, 1993, J IMMUNOL, V151, P1979; MALONE M, 1986, CANCER, V57, P1979, DOI 10.1002/1097-0142(19860515)57:10<1979::AID-CNCR2820571016>3.0.CO;2-R; Maniatis T., 1982, MOL CLONING; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; RICCIARDI RP, 1977, P NATL ACAD SCI USA, V74, P5461; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; TSUJIMOTO Y, 1986, P NATL ACAD SCI USA, V83, P5214, DOI 10.1073/pnas.83.14.5214; VEIS DJ, 1993, CELL, V75, P229, DOI 10.1016/0092-8674(93)80065-M; Wyllie A H, 1980, Int Rev Cytol, V68, P251; YOUNG RA, 1983, P NATL ACAD SCI-BIOL, V80, P1194, DOI 10.1073/pnas.80.5.1194	28	24	26	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 7	1996	12	5					947	951						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UA884	8649811				2022-12-25	WOS:A1996UA88400001
J	Shin, KH; Tannyhill, RJ; Liu, X; Park, NH				Shin, KH; Tannyhill, RJ; Liu, X; Park, NH			Oncogenic transformation of HPV-immortalized human oral keratinocytes is associated with the genetic instability of cells	ONCOGENE			English	Article						genetic stability; oral cancer; p53; HPV; carcinogenesis	WILD-TYPE P53; HUMAN PAPILLOMAVIRUS TYPE-16; SIMPLEX VIRUS TYPE-1; DNA-DAMAGING AGENTS; SHUTTLE VECTOR; GROWTH ARREST; MUTAGENESIS; MUTATIONS; IRRADIATION; INDUCTION	HPV-immortalized human oral keratinocytes can convert to tumorigenic cells when exposed to N-methyl-N-nitro-N-nitrosoguanidine (MNNG), but normal human oral keratinocytes cannot transform with a similar exposure. The different responses of these cells could be due to different genetic stability of cells. In as much as genetic stability is determined by cell cycle control and of repair of damaged DNA, we studied the effect of MNNG exposure upon cell cycle progression, expression of p53, WAF1/CIP1 and gadd45, and the mutation frequency of a shuttle vector pS189 in normal human oral keratinocytes, in HPV-immortalized oral keratinocytes, and in an oral cancer cell line expressing mutant p53. Normal cells demonstrated transient cell cycle arrest after exposure to MNNG, but the other tested cells did not. While MNNG exposure significantly increased the levels of intranuclear wt p53 protein and the expression of WAF1/CIP1 and gadd45 genes in normal cells, it did not alter them in the immortalized and cancer cells. The mutation frequency of pS189 plasmid was significantly lower in normal cells than in the other tested cells. These data indicate that malignant conversion of HPV-immortalized oral keratinocytes may, in part, be associated with the cells' genetic instability. The genetic instability may be due to cells' (1) inability to accumulate intranuclear wt p53 to a threshold level at which p53 upregulates the transcription of WAF1/CIP1 and gadd45, resulting in the loss of cell cycle control and (2) inefficient repair of DNA damage caused by genotoxic agents.	UNIV CALIF LOS ANGELES, SCH DENT, DENT RES INST, LOS ANGELES, CA 90095 USA; UNIV CALIF LOS ANGELES, JONSSON COMPREHENS CANC CTR, LOS ANGELES, CA 90095 USA	University of California System; University of California Los Angeles; UCLA Jonsson Comprehensive Cancer Center; University of California System; University of California Los Angeles			Tannyhill, R. John/AAE-7432-2019	Tannyhill, R. John/0000-0003-3172-0345	NIDCR NIH HHS [K15 DE00371, R01 DE 10049, DE11229] Funding Source: Medline; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE010049, R01DE011229, K15DE000371] Funding Source: NIH RePORTER	NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		AGOFF SN, 1993, SCIENCE, V259, P84, DOI 10.1126/science.8418500; BAEK JH, 1994, INT J ONCOL, V5, P1023; BAKALKIN G, 1995, NUCLEIC ACIDS RES, V23, P362, DOI 10.1093/nar/23.3.362; BAKALKIN G, 1994, P NATL ACAD SCI USA, V91, P413, DOI 10.1073/pnas.91.1.413; BREDBERG A, 1986, P NATL ACAD SCI USA, V83, P8273, DOI 10.1073/pnas.83.21.8273; BURNS PA, 1987, J MOL BIOL, V194, P385, DOI 10.1016/0022-2836(87)90668-1; CANMAN CE, 1994, CANCER RES, V54, P5054; CHIN KV, 1992, SCIENCE, V255, P459, DOI 10.1126/science.1346476; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FORNACE AJ, 1989, MOL CELL BIOL, V9, P4196, DOI 10.1128/MCB.9.10.4196; FUKUSHIMA A, 1994, GENOMICS, V22, P127, DOI 10.1006/geno.1994.1353; GUJULUVA CN, 1994, ONCOGENE, V9, P1819; HARPER JW, 1993, CELL, V75, P805; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HWANG CBC, 1991, VIROLOGY, V181, P620, DOI 10.1016/0042-6822(91)90895-I; JAYARAMAN L, 1995, CELL, V81, P1021, DOI 10.1016/S0092-8674(05)80007-8; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; KESSIS TD, 1993, MOL CELL BIOL, V13, P4242; KIM MS, 1993, ANTICANCER RES, V13, P1405; KIM S, 1986, MUTAT RES, V173, P141, DOI 10.1016/0165-7992(86)90092-8; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LI SL, 1992, ORAL ONCOL, V28B, P129, DOI 10.1016/0964-1955(92)90041-X; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; MERCER WE, 1984, MOL CELL BIOL, V4, P276, DOI 10.1128/MCB.4.2.276; OKUBO K, 1992, NAT GENET, V2, P173, DOI 10.1038/ng1192-173; PARK NH, 1991, CARCINOGENESIS, V12, P1627, DOI 10.1093/carcin/12.9.1627; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SEIDMAN M, 1989, MUTAT RES, V220, P55, DOI 10.1016/0165-1110(89)90010-9; SEIDMAN MM, 1987, P NATL ACAD SCI USA, V84, P4944, DOI 10.1073/pnas.84.14.4944; SHAULSKY G, 1991, P NATL ACAD SCI USA, V88, P8982, DOI 10.1073/pnas.88.20.8982; SHAW P, 1992, P NATL ACAD SCI USA, V89, P4495, DOI 10.1073/pnas.89.10.4495; SHILLITOE EJ, 1993, VIRUS RES, V27, P239, DOI 10.1016/0168-1702(93)90036-M; SHIN KH, 1994, MOL CARCINOGEN, V9, P76, DOI 10.1002/mc.2940090205; SMITH ML, 1994, SCIENCE, V266, P1376, DOI 10.1126/science.7973727; STARY A, 1992, MUTAT RES, V272, P101, DOI 10.1016/0165-1161(92)90038-N; SUN XG, 1995, MOL CELL BIOL, V15, P4489; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; WEINERT TA, 1988, SCIENCE, V241, P317, DOI 10.1126/science.3291120; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; WU L, 1995, MOL CELL BIOL, V15, P497, DOI 10.1128/MCB.15.1.497; YEUNG MC, 1993, BIOTECHNIQUES, V15, P381; ZHAN QM, 1993, MOL CELL BIOL, V13, P4242, DOI 10.1128/MCB.13.7.4242	43	29	30	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 7	1996	12	5					1089	1096						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UA884	8649801				2022-12-25	WOS:A1996UA88400018
J	Kochetkova, M; Shannon, MF				Kochetkova, M; Shannon, MF			DNA triplex formation selectively inhibits granulocyte-macrophage colony-stimulating factor gene expression in human T cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACUTE MYELOID-LEUKEMIA; HELIX FORMATION; GM-CSF; FORMING-OLIGONUCLEOTIDES; BINDING-PROTEINS; AUTOCRINE GROWTH; TRANSCRIPTION; SEQUENCE; RECOGNITION; PROMOTERS	Granulocyte-macrophage colony-stimulating factor (GM-CSF) is a hemopoietic growth factor that is expressed in activated T cells, fibroblasts, macrophages, and endothelial cells. Although GM-CSF does not appear to be essential for normal hemopoiesis, overexpression of GM-CSF has been implicated in the pathogenesis of some diseases such as myeloid leukemia and chronic inflammation, An NF-kappa B/Rel binding site within the GMCSF promoter, termed the kappa B element appears to be important for controlling expression in reporter gene assays in response to a number of stimuli in T cells, We investigated oligonucleotide-directed triple helix formation across this regulatory sequence as a potential tool to inhibit GM-CSF gene transcription. A 15-base oligonucleotide, GM3, was targeted to a purine-rich region in the GM-CSF proximal promoter, which overlaps the kappa B element. Gel mobility shift assays and DNase I footprinting demonstrated that GM3 formed a sequence-specific collinear tripler with its double-stranded DNA target, Tripler formation by GM3 blocked recombinant and nuclear NF-kappa B proteins binding to the GM-CSF element. GM3 also caused selective inhibition of the human T-cell lymphotrophic virus-1 Tax transactivator-induced luciferase activity from a reporter construct driven by the GM-CSF promoter in Jurkat T cells, Finally, GM3 greatly reduced the concentration of endogenous GM-CSF mRNA induced by different stimuli in Jurkat T cells but did not affect interleukin 3 mRNA levels in the same cells. We conclude that the kappa B element in the GM-CSF promoter plays a central role in the transcriptional activation of the endogenous GM-CSF gene, Colinear tripler formation acts as a selective transcriptional repressor of the GM-CSF gene and may have potential therapeutic application in cases of undesirable overexpression of this protein.	INST MED & VET SCI, DIV HUMAN IMMUNOL, HANSON CTR CANC RES, ADELAIDE, SA 5000, AUSTRALIA	Institute Medical & Veterinary Science Australia				Kochetkova, Marina/0000-0002-0599-7378				Akhtar S, 1992, Trends Cell Biol, V2, P139, DOI 10.1016/0962-8924(92)90100-2; BEAL PA, 1991, SCIENCE, V251, P1360, DOI 10.1126/science.2003222; BUDEL LM, 1989, BLOOD, V74, P565; CHENG AJ, 1994, NUCLEIC ACIDS RES, V22, P4742, DOI 10.1093/nar/22.22.4742; COCKERILL PN, 1993, P NATL ACAD SCI USA, V90, P2466, DOI 10.1073/pnas.90.6.2466; COCKERILL PN, 1995, MOL CELL BIOL, V15, P2071; DURLAND RH, 1991, BIOCHEMISTRY-US, V30, P9246, DOI 10.1021/bi00102a017; ESTROV Z, 1992, EXP HEMATOL, V20, P558; FREEDMAN MH, 1992, BRIT J HAEMATOL, V80, P40, DOI 10.1111/j.1365-2141.1992.tb06398.x; GASSON JC, 1991, BLOOD, V77, P1131, DOI 10.1182/blood.V77.6.1131.1131; GOODALL GJ, 1989, CELL, V58, P473, DOI 10.1016/0092-8674(89)90428-5; GRIGORIEV M, 1993, P NATL ACAD SCI USA, V90, P3501, DOI 10.1073/pnas.90.8.3501; GRIGORIEV M, 1992, J BIOL CHEM, V267, P3389; GUSCHLBAUER W, 1990, J BIOMOL STRUCT DYN, V8, P491, DOI 10.1080/07391102.1990.10507825; HELENE C, 1991, ANTI-CANCER DRUG DES, V6, P569; HENDERSON B, 1992, TRENDS PHARMACOL SCI, V13, P145, DOI 10.1016/0165-6147(92)90052-8; HERCUS TR, 1994, P NATL ACAD SCI USA, V91, P5838, DOI 10.1073/pnas.91.13.5838; HIMES SR, 1993, ONCOGENE, V8, P3189; HOLT JT, 1988, MOL CELL BIOL, V8, P963, DOI 10.1128/MCB.8.2.963; JENKINS F, 1995, J IMMUNOL, V155, P1240; JMASUDA ES, 1994, BIOCHEM BIOPH RES CO, V205, P1518; KATO M, 1992, LYMPHOKINE CYTOK RES, V11, P287; LAPIDOT T, 1994, NATURE, V367, P645, DOI 10.1038/367645a0; LEDOAN T, 1987, NUCLEIC ACIDS RES, V15, P8643, DOI 10.1093/nar/15.21.8643; MAHER LJ, 1992, BIOCHEMISTRY-US, V31, P7587, DOI 10.1021/bi00148a021; MAHER LJ, 1989, SCIENCE, V245, P725, DOI 10.1126/science.2549631; Maxam A M, 1980, Methods Enzymol, V65, P499; MAYFIELD C, 1994, J BIOL CHEM, V269, P18232; MAYFIELD C, 1994, NUCLEIC ACIDS RES, V22, P1909, DOI 10.1093/nar/22.10.1909; MCSHAN WM, 1992, J BIOL CHEM, V267, P5712; MERGNY JL, 1991, BIOCHEMISTRY-US, V30, P9791, DOI 10.1021/bi00104a031; METCALF D, 1986, BLOOD, V67, P257; MIYATAKE S, 1988, NUCLEIC ACIDS RES, V16, P6547, DOI 10.1093/nar/16.14.6547; MOSER HE, 1987, SCIENCE, V238, P645, DOI 10.1126/science.3118463; NICOLA NA, 1989, ANNU REV BIOCHEM, V58, P45; NICOLA NA, 1993, BLOOD, V82, P1724, DOI 10.1182/blood.V82.6.1724.bloodjournal8261724; OLIVAS WM, 1995, BIOCHEMISTRY-US, V34, P278, DOI 10.1021/bi00001a034; ORSON FM, 1991, NUCLEIC ACIDS RES, V19, P3435, DOI 10.1093/nar/19.12.3435; PEBUSQUE MJ, 1988, EXP HEMATOL, V16, P360; POSTEL EH, 1991, P NATL ACAD SCI USA, V88, P8227, DOI 10.1073/pnas.88.18.8227; POVSIC TJ, 1989, J AM CHEM SOC, V111, P3059, DOI 10.1021/ja00190a047; REILLY IAG, 1989, BRIT J HAEMATOL, V72, P363, DOI 10.1111/j.1365-2141.1989.tb07717.x; ROY C, 1994, EUR J BIOCHEM, V220, P493, DOI 10.1111/j.1432-1033.1994.tb18648.x; RUSSELL NH, 1992, BLOOD REV, V6, P149, DOI 10.1016/0268-960X(92)90026-M; SAMADASHWILY GM, 1994, GENE, V149, P127, DOI 10.1016/0378-1119(94)90421-9; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SHANNON MF, 1995, J LEUKOCYTE BIOL, V57, P767, DOI 10.1002/jlb.57.5.767; SMITH MR, 1990, GENE DEV, V4, P1875, DOI 10.1101/gad.4.11.1875; STROBEL SA, 1991, NATURE, V350, P172, DOI 10.1038/350172a0; STULL RA, 1995, PHARM RES-DORDR, V12, P465, DOI 10.1023/A:1016281324761; SUN JS, 1991, CR ACAD SCI III-VIE, V313, P585; THOMAS TJ, 1995, NUCLEIC ACIDS RES, V23, P3594, DOI 10.1093/nar/23.17.3594; TU GC, 1995, J BIOL CHEM, V270, P28402; VELLENGA E, 1987, EXP HEMATOL, V15, P652; WANO Y, 1988, P NATL ACAD SCI USA, V85, P9733, DOI 10.1073/pnas.85.24.9733; WILLIAMSON DJ, 1988, CLIN EXP IMMUNOL, V72, P67; WILSON WD, 1993, BIOCHEMISTRY-US, V32, P10614, DOI 10.1021/bi00091a011; WOOD KV, 1991, BIOLUMINESCENCE AND CHEMILUMINESCENCE, P543; YOUNG DC, 1986, BLOOD, V68, P1178	59	33	35	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 14	1996	271	24					14438	14444		10.1074/jbc.271.24.14438	http://dx.doi.org/10.1074/jbc.271.24.14438			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UQ660	8662666	hybrid			2022-12-25	WOS:A1996UQ66000074
J	Cook, JR; Cleary, CM; Mariano, TM; Izotova, L; Pestka, S				Cook, JR; Cleary, CM; Mariano, TM; Izotova, L; Pestka, S			Differential responsiveness of a splice variant of the human type I interferon receptor to interferons	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEUKOCYTE INTERFERONS; GAMMA RECEPTOR; HUMAN-CELLS; BINDING; ALPHA; RECOMBINANT; GENE; PURIFICATION; EXPRESSION; CLONING	Chinese hamster ovary cells containing the yeast artificial chromosome F136C5 (alpha YAC) respond to all type I human interferons including IFN-alpha A, IFN-beta, and IFN-omega. The alpha YAC contains at least two genes encoding interferon-alpha receptor (IFN-alpha R) chains that are required for response to type I human interferons: Hu-IFN-alpha R1 and Hu-IFN-alpha R2. Ne previously isolated a splice variant of the Hu-IFN-alpha R1 chain designated Hu-IFN-alpha R1s. Chinese hamster ovary cells containing a disrupted alpha YAC, which contains a deletion in the human IFNAR1 gene, were transfected with expression vectors for the Hu IFN-alpha R1 and Hu-IFN-alpha R1s chains, With these cells, two type I interferons have been identified which can interact with the splice valiant (Hu-IFN-alpha R1s) and with the Hu IFN-alpha R1 chains: Hu-IFN-alpha A and IFN-omega. Two other type I interferons, Hu-IFN-alpha B2 and Hu-IFN-alpha F, are capable of signaling through the Hu-IFN-alpha R1 chain only and cannot utilize the splice variant Hu-IFN-alpha R1s. Hu-IFN-alpha R1 and Hu-IFN-alpha R1s differ in that the latter is missing a single subdomain of the receptor extracellular domain encoded by exons 4 and 5 of the IFNAR1 gene. These results therefore indicate that different type I interferons require different subdomains of the Hu-IFN-alpha R1 receptor chain, and that the splice variant chain (Hu-IFN-alpha R1s) is functional.	UNIV MED & DENT NEW JERSEY,ROBERT WOOD JOHNSON MED SCH,DEPT MOLEC GENET & MICROBIOL,PISCATAWAY,NJ 08854	Rutgers State University New Brunswick; Rutgers State University Medical Center					NATIONAL CANCER INSTITUTE [R01CA046465, R01CA052363] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI036450] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA52363, R01 CA46465] Funding Source: Medline; NIAID NIH HHS [R01 AI/GM36450] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BAZAN JF, 1990, CELL, V61, P753, DOI 10.1016/0092-8674(90)90182-E; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; Cleary Cathleen M., 1992, Journal of Interferon Research, V12, pS220; CLEARY CM, 1994, J BIOL CHEM, V269, P18747; CLEARY CM, 1995, THESIS RUTGERS U PIS; COOK JR, 1994, J BIOL CHEM, V269, P7013; COOK JR, 1993, GENET ANAL-BIOMOL E, V10, P109, DOI 10.1016/1050-3862(93)90033-F; COOK JR, 1992, P NATL ACAD SCI USA, V89, P11317, DOI 10.1073/pnas.89.23.11317; EMANUEL SL, 1995, GENE, V155, P167, DOI 10.1016/0378-1119(94)00852-J; EMANUEL SL, 1995, THESIS U MED DENT NE; EMANUEL SL, 1995, PHARM TECHNOL, V19, P22; EVINGER M, 1981, ARCH BIOCHEM BIOPHYS, V210, P319, DOI 10.1016/0003-9861(81)90195-8; Familletti P C, 1981, Methods Enzymol, V78, P387; FISH EN, 1983, BIOCHEM BIOPH RES CO, V112, P537, DOI 10.1016/0006-291X(83)91498-5; FLORES I, 1991, J BIOL CHEM, V266, P19875; JUNG V, 1991, THESIS RUTGERS U PIS; LANGER JA, 1986, METHOD ENZYMOL, V119, P305; LANGER JA, 1990, SOMAT CELL MOLEC GEN, V16, P321; LI BL, 1989, P NATL ACAD SCI USA, V86, P558, DOI 10.1073/pnas.86.2.558; LUTFALLA G, 1993, GENOMICS, V16, P366, DOI 10.1006/geno.1993.1199; LUTFALLA G, 1992, J BIOL CHEM, V267, P2802; MANIATIS T, 1982, MOL CLONING LABORATO, P63; MARIANO TM, 1992, INTERFERON PRINCIPLE, P129; MIKI T, 1991, P NATL ACAD SCI USA, V88, P5167, DOI 10.1073/pnas.88.12.5167; MIKI T, 1992, P NATL ACAD SCI USA, V89, P246, DOI 10.1073/pnas.89.1.246; MOSCHERA JA, 1986, METHOD ENZYMOL, V119, P177; NOVICK D, 1994, CELL, V77, P391, DOI 10.1016/0092-8674(94)90154-6; ORTALDO JR, 1984, P NATL ACAD SCI-BIOL, V81, P4926, DOI 10.1073/pnas.81.15.4926; PESTKA S, 1986, METHOD ENZYMOL, V119, P3; REHBERG E, 1982, J BIOL CHEM, V257, P1497; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SOH J, 1993, P NATL ACAD SCI USA, V90, P8737, DOI 10.1073/pnas.90.18.8737; SOH J, 1994, CELL, V76, P793, DOI 10.1016/0092-8674(94)90354-9; SOH JM, 1994, J BIOL CHEM, V269, P18102; SOMMER B, 1991, CELL, V67, P11, DOI 10.1016/0092-8674(91)90568-J; STAEHELIN T, 1981, J BIOL CHEM, V256, P9750; UZE G, 1990, CELL, V60, P225, DOI 10.1016/0092-8674(90)90738-Z; WANG PY, 1994, J INTERFERON RES, V14, P41, DOI 10.1089/jir.1994.14.41; WERNER S, 1992, MOL CELL BIOL, V12, P82, DOI 10.1128/MCB.12.1.82	39	59	66	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 7	1996	271	23					13448	13453		10.1074/jbc.271.23.13448	http://dx.doi.org/10.1074/jbc.271.23.13448			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UP385	8662801	hybrid			2022-12-25	WOS:A1996UP38500024
J	Nemoto, Y; Terajima, M; Shoji, W; Obinata, M				Nemoto, Y; Terajima, M; Shoji, W; Obinata, M			Regulatory function of delta/YY-1 on the locus control region-like sequence of mouse glycophorin gene in erythroleukemia cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOMINANT CONTROL REGION; DNA-BINDING; TRANSCRIPTION FACTOR; HEMATOPOIETIC-CELLS; PUTATIVE ONCOGENE; FINGER PROTEIN; POLYMERASE-II; ENHANCER; EXPRESSION; ELEMENTS	The far upstream region (-1.2-0.9 kilobase pairs) of the mouse glycophorin gene contains the locus control region (LCR)-like region, which acts as an erythroid-specific enhancer dependent on chromosomal integration in murine erythroleukemia (MEL) cells. In the present study, we demonstrated that this region binds six nuclear factors, The binding of GATA-1 to corresponding sites did not show any change before or after induction with dimethyl sulfoxide, but the binding of Spi-1/PU.1 and an unidentified factor called glycophorin regulatory element binding factor (GRBF) showed a change during induction. While binding activity of Spi-1/PU.1 dropped soon after induction, the GRBF activity increased after induction when expression of the glycophorin gene began, After identification of the consensus binding site of GRBF, we cloned cDNA for that factor by Southwestern method, and it was Identified as a previously reported transcription factor, delta, a murine form of YY-1 which is a versatile transcription factor, Mutation analysis in the delta/YY-1 binding site within the LCR-like region indicated that delta/YY-1 acts as a regulatory protein in combination with the E-box-binding protein that binds to the neighboring sequence.	TOHOKU UNIV,INST DEV AGING & CANC,DEPT CELL BIOL,AOBA KU,SENDAI,MIYAGI 98077,JAPAN	Tohoku University			Watanabe, Mamoru/AHE-0489-2022					ANDREWS NC, 1993, NATURE, V362, P722, DOI 10.1038/362722a0; BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; BRUCE AH, 1992, NUCLEIC ACIDS RES, V20, P5771; CHANG JC, 1992, P NATL ACAD SCI USA, V89, P3107, DOI 10.1073/pnas.89.7.3107; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; EVANS T, 1989, CELL, V58, P877, DOI 10.1016/0092-8674(89)90940-9; FLANAGAN JR, 1992, MOL CELL BIOL, V12, P38, DOI 10.1128/MCB.12.1.38; FRASER P, 1990, NUCLEIC ACIDS RES, V18, P3503, DOI 10.1093/nar/18.12.3503; FRIEND C, 1971, P NATL ACAD SCI USA, V68, P378; GALAS DJ, 1978, NUCLEIC ACIDS RES, V5, P3157, DOI 10.1093/nar/5.9.3157; GALSON DL, 1993, MOL CELL BIOL, V13, P2929, DOI 10.1128/MCB.13.5.2929; GOEBL MG, 1990, CELL, V61, P1165, DOI 10.1016/0092-8674(90)90676-6; GREGOR PD, 1990, GENE DEV, V4, P1730, DOI 10.1101/gad.4.10.1730; HARIHARAN N, 1991, P NATL ACAD SCI USA, V88, P9799, DOI 10.1073/pnas.88.21.9799; JARMAN AP, 1991, MOL CELL BIOL, V11, P679; KILIANG L, 1990, P NATL ACAD SCI USA, V87, P8207; KLEMENZ M, 1990, CELL, V60, P113; KUME TU, 1988, J MOL BIOL, V202, P779, DOI 10.1016/0022-2836(88)90558-X; MARTIN DIK, 1990, GENE DEV, V4, P1886, DOI 10.1101/gad.4.11.1886; MATSUI Y, 1989, GENE, V77, P325, DOI 10.1016/0378-1119(89)90080-2; MEIER VS, 1994, MOL CELL BIOL, V14, P128, DOI 10.1128/MCB.14.1.128; MIGNOTTE V, 1989, P NATL ACAD SCI USA, V86, P6548, DOI 10.1073/pnas.86.17.6548; MOREAUGACHELIN F, 1989, ONCOGENE, V4, P1449; MOREAUGACHELIN F, 1988, NATURE, V331, P277, DOI 10.1038/331277a0; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; NEY PA, 1990, GENE DEV, V4, P993, DOI 10.1101/gad.4.6.993; ORKIN SH, 1992, BLOOD, V80, P575; PANDEL MD, 1992, NUCLEIC ACIDS RES, V20, P237; PARK K, 1991, P NATL ACAD SCI USA, V88, P9804, DOI 10.1073/pnas.88.21.9804; PRENDERGAST GC, 1991, SCIENCE, V251, P186, DOI 10.1126/science.1987636; REITMAN M, 1988, P NATL ACAD SCI USA, V85, P6267, DOI 10.1073/pnas.85.17.6267; RIGGS KJ, 1993, MOL CELL BIOL, V13, P7487, DOI 10.1128/MCB.13.12.7487; SATYAMOORTHY K, 1993, MOL CELL BIOL, V13, P6621, DOI 10.1128/MCB.13.11.6621; SHI Y, 1991, CELL, V67, P377, DOI 10.1016/0092-8674(91)90189-6; SHOJI W, 1993, JPN J CANCER RES, V84, P885, DOI 10.1111/j.1349-7006.1993.tb02062.x; SHRIVASTAVA A, 1993, SCIENCE, V262, P889; SIGH H, 1986, NATURE, V19, P154; TALBOT D, 1990, EMBO J, V9, P2169, DOI 10.1002/j.1460-2075.1990.tb07386.x; TALBOT D, 1991, EMBO J, V10, P1391, DOI 10.1002/j.1460-2075.1991.tb07659.x; TERAJIMA M, 1995, J BIOCHEM-TOKYO, V118, P593, DOI 10.1093/oxfordjournals.jbchem.a124951; TERAJIMA M, 1994, J BIOCHEM-TOKYO, V116, P1105, DOI 10.1093/oxfordjournals.jbchem.a124634; TUAN DYH, 1989, P NATL ACAD SCI USA, V86, P2554, DOI 10.1073/pnas.86.8.2554; VINSON CR, 1988, GENE DEV, V2, P801, DOI 10.1101/gad.2.7.801	43	7	7	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 7	1996	271	23					13542	13548		10.1074/jbc.271.23.13542	http://dx.doi.org/10.1074/jbc.271.23.13542			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UP385	8662744	hybrid			2022-12-25	WOS:A1996UP38500037
J	Rockow, S; Tang, JP; Xiong, W; Li, W				Rockow, S; Tang, JP; Xiong, W; Li, W			Nck inhibits NGF and basic FGF induced PC12 cell differentiation via mitogen-activated protein kinase-independent pathway	ONCOGENE			English	Article						receptor tyrosine kinases; src-homology domains; adapter molecules; signal transduction	NERVE GROWTH-FACTOR; PHEOCHROMOCYTOMA CELLS; SIGNAL-TRANSDUCTION; FACTOR RECEPTOR; SH3 DOMAINS; MAP KINASE; SRC; PHOSPHOTYROSINE; PHOSPHORYLATION; TYROSINE	Proto-oncogene Nck, an adapter molecule containing three SH3 and one SH2 domains, binds to cell surface receptors and mediate mitogenic effects in the cells. Overexpression of Nck caused cell transformation in vitro and tumor formation in the nude mice. The mechanism of this action by Nck, however, remained unclear. Rat adrenal pheochromocytoma cell line PC12 provides a useful system for studying growth factor-regulated cell proliferation and differentiation. Serum and epidermal growth factor (EGF) stimulate proliferation, whereas nerve growth factor (NGF) and basic fibroblast growth factor (bFGF) cause growth arrest and sympathetic neurite outgrowth in these cells. To study the function of Nck, we generated stable clones of PC12 cells overexpressing the human Nck. We report here that the overexpressed Nck caused continued proliferation of PC12 cells even in the presence of NGF and blocked both the NGF- and bFGF-induced neurite outgrowth. Anti-sense but not sense oligonucleotides to the human Nck resumed the NGF-induced differentiation, indicating the specific inhibitory effect of Nck. Interestingly, Nck did not interfere with the kinetics of NGF- and EGF-stimulated protein tyrosine phosphorylation and the mitogen-activated protein kinase (MAPK) activation, suggesting that Nck inhibited the induced PC12 cell differentiation via a MAPK-independent mechanism. This study has provided a useful system for further understanding the function of Nck.	UNIV CHICAGO, BEN MAY INST, CHICAGO, IL 60637 USA; UNIV CHICAGO, DEPT PHARMACOL & PHYSIOL SCI, CHICAGO, IL 60637 USA	University of Chicago; University of Chicago					NCI NIH HHS [CA65567] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA065567] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CHAO MV, 1992, CELL, V68, P995, DOI 10.1016/0092-8674(92)90068-N; CHOU MM, 1992, MOL CELL BIOL, V12, P5834, DOI 10.1128/MCB.12.12.5834; CHOU MM, 1995, J BIOL CHEM, V270, P7359, DOI 10.1074/jbc.270.13.7359; CICCHETTI P, 1992, SCIENCE, V257, P803, DOI 10.1126/science.1379745; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; COHEN P, 1992, BIOCHEM SOC T, V20, P671, DOI 10.1042/bst0200671; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; DARCANGELO G, 1993, MOL CELL BIOL, V13, P3146, DOI 10.1128/MCB.13.6.3146; DERRY JMJ, 1994, CELL, V78, P635, DOI 10.1016/0092-8674(94)90528-2; FELLER SM, 1994, TRENDS BIOCHEM SCI, V19, P453, DOI 10.1016/0968-0004(94)90129-5; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; GUERRERO I, 1986, J CELL PHYSIOL, V129, P71, DOI 10.1002/jcp.1041290111; HU QJ, 1995, MOL CELL BIOL, V15, P1169; KAPLAN DR, 1994, J NEUROBIOL, V25, P1404, DOI 10.1002/neu.480251108; KIRSCHMEIER PT, 1988, DNA-J MOLEC CELL BIO, V7, P219, DOI 10.1089/dna.1988.7.219; KWAN SP, 1995, P NATL ACAD SCI USA, V92, P4706, DOI 10.1073/pnas.92.10.4706; LEE CH, 1993, P NATL ACAD SCI USA, V90, P11713, DOI 10.1073/pnas.90.24.11713; LEHMANN JM, 1990, NUCLEIC ACIDS RES, V18, P1048, DOI 10.1093/nar/18.4.1048; LI W, 1992, MOL CELL BIOL, V12, P5824, DOI 10.1128/MCB.12.12.5824; LI W, 1994, MOL CELL BIOL, V14, P509, DOI 10.1128/MCB.14.1.509; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MATSUDA M, 1992, J VIROL, V66, P115, DOI 10.1128/JVI.66.1.115-121.1992; MATUOKA K, 1992, P NATL ACAD SCI USA, V89, P9015, DOI 10.1073/pnas.89.19.9015; MAYER BJ, 1990, J VIROL, V64, P3581, DOI 10.1128/JVI.64.8.3581-3589.1990; MEISENHELDER J, 1992, MOL CELL BIOL, V12, P5843, DOI 10.1128/MCB.12.12.5843; NISHIMURA R, 1993, MOL CELL BIOL, V13, P6889, DOI 10.1128/MCB.13.11.6889; NODA M, 1985, NATURE, V318, P73, DOI 10.1038/318073a0; PARK D, 1992, MOL CELL BIOL, V12, P5816, DOI 10.1128/MCB.12.12.5816; PAWSON T, 1993, CURR BIOL, V3, P343; PAWSON T, 1995, NATURE, V373, P575; RABIN SJ, 1993, MOL CELL BIOL, V13, P2203, DOI 10.1128/MCB.13.4.2203; REN RB, 1994, GENE DEV, V8, P783, DOI 10.1101/gad.8.7.783; RIVEROLEZCANO OM, 1995, MOL CELL BIOL, V15, P5725; RIVEROLEZCANO OM, 1994, J BIOL CHEM, V269, P17363; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; STEPHENS RM, 1994, NEURON, V12, P691, DOI 10.1016/0896-6273(94)90223-2; TANAKA M, 1995, MOL CELL BIOL, V15, P6829; THOMAS SM, 1992, CELL, V68, P1030; TRAVERSE S, 1992, BIOCHEM J, V288, P351, DOI 10.1042/bj2880351; WOOD KW, 1993, P NATL ACAD SCI USA, V90, P5016, DOI 10.1073/pnas.90.11.5016; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O	42	34	34	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN 6	1996	12	11					2351	2359						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UQ220	8649775				2022-12-25	WOS:A1996UQ22000012
J	Ajiro, K; Yoda, K; Utsumi, K; Nishikawa, Y				Ajiro, K; Yoda, K; Utsumi, K; Nishikawa, Y			Alteration of cell cycle-dependent histone phosphorylations by okadaic acid - Induction of mitosis-specific H3 phosphorylation and chromatin condensation in mammalian interphase cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PREMATURE CHROMOSOME CONDENSATION; PROTEIN PHOSPHATASE INHIBITOR; CHINESE-HAMSTER CELLS; TUMOR PROMOTER; M-PHASE; KINASE; H1; STARFISH; P34CDC2; OOCYTE	Effects of okadaic acid (OA), a protein phosphatase inhibitor, on chromatin structure and phosphorylation of histones were examined using HeLa and N18 cells. The chromatin condensation in HeLa cells was mild and resemble prometaphase nuclei, while the condensation in N18 cells was extensive and chromatin became a compact body, H2A in HeLa cells was extensively and consistently phosphorylated at the same site throughout the cell cycle, and H3 was demonstrated to be phosphorylated at the mitosis-specific site Ser(10). In contrast, H1 phosphorylation was rapidly decreased in most sites within 3 h. The reduction of H1 phosphorylation was accompanied by a quantitative change in the set of H1 phosphopeptides. During the early phase of the OA treatment, H1 phosphorylation was transiently elevated in tandem, whereas H3 phosphorylation reached a maximum somewhat later, The results suggest that mitosis-specific events (cdc2/H1 kinase activation, H1 super-phosphorylation, mitosis-specific H3 phosphorylation and chromatin condensation) induced by OA are sequentially associated, The changes appear to reflect a molecular mechanism similar to that operating in normal mitosis.	AICHI CANC CTR, RES INST, CELL BIOL LAB, LAB ULTRASTRUCT RES, NAGOYA, AICHI 464, JAPAN; NAGOYA UNIV, FAC SCI, INST MOLEC BIOL, NAGOYA, AICHI 464, JAPAN	Aichi Cancer Center; Nagoya University	Ajiro, K (corresponding author), AICHI CANC CTR, RES INST, CELL BIOL LAB, CHIKUSA KU, NAGOYA, AICHI 464, JAPAN.							AGOSTINIS P, 1990, EUR J BIOCHEM, V189, P235, DOI 10.1111/j.1432-1033.1990.tb15482.x; AJIRO K, 1985, J BIOL CHEM, V260, P5379; AJIRO K, 1983, J BIOL CHEM, V258, P4534; AJIRO K, 1981, BIOCHEMISTRY-US, V20, P1445, DOI 10.1021/bi00509a007; AJIRO K, 1981, BIOCHEMISTRY-US, V20, P1454, DOI 10.1021/bi00509a008; BALHORN R, 1972, BIOCHEMISTRY-US, V11, P1094, DOI 10.1021/bi00756a023; BIALOJAN C, 1988, BIOCHEM J, V256, P283, DOI 10.1042/bj2560283; BRADBURY EM, 1974, NATURE, V247, P257, DOI 10.1038/247257a0; COHEN P, 1989, ANNU REV BIOCHEM, V58, P453, DOI 10.1146/annurev.bi.58.070189.002321; COHEN P, 1990, TRENDS BIOCHEM SCI, V15, P98, DOI 10.1016/0968-0004(90)90192-E; DASSO M, 1994, P NATL ACAD SCI USA, V91, P12477, DOI 10.1073/pnas.91.26.12477; DOLBY TW, 1979, BIOCHEMISTRY-US, V18, P1333, DOI 10.1021/bi00574a033; GLIKSMAN NR, 1992, J CELL BIOL, V119, P1271, DOI 10.1083/jcb.119.5.1271; GURLEY LR, 1975, J BIOL CHEM, V250, P3936; GURLEY LR, 1978, EUR J BIOCHEM, V84, P1, DOI 10.1111/j.1432-1033.1978.tb12135.x; HANKS SK, 1983, EXP CELL RES, V148, P293, DOI 10.1016/0014-4827(83)90153-2; HAYSTEAD TAJ, 1989, NATURE, V337, P78, DOI 10.1038/337078a0; KIGUCHI K, 1994, CELL GROWTH DIFFER, V5, P995; KING RW, 1994, CELL, V79, P563, DOI 10.1016/0092-8674(94)90542-8; KINOSHITA N, 1991, COLD SH Q B, V56, P621; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAKE RS, 1972, BIOCHEMISTRY-US, V11, P4817, DOI 10.1021/bi00775a027; LEWIN B, 1990, CELL, V61, P743, DOI 10.1016/0092-8674(90)90181-D; MEIJER L, 1991, EMBO J, V10, P1545, DOI 10.1002/j.1460-2075.1991.tb07674.x; NEANT I, 1988, EXP CELL RES, V176, P68, DOI 10.1016/0014-4827(88)90121-8; Nigg E A, 1990, Adv Cancer Res, V55, P271, DOI 10.1016/S0065-230X(08)60471-6; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; OHSUMI K, 1993, SCIENCE, V262, P2033, DOI 10.1126/science.8266099; PAULSON JR, 1994, J CELL SCI, V107, P267; PAULSON JR, 1982, J BIOL CHEM, V257, P6064; PICARD A, 1989, J CELL BIOL, V109, P3347, DOI 10.1083/jcb.109.6.3347; RIEBER MS, 1992, CANCER RES, V52, P6397; RIME H, 1990, DEV BIOL, V141, P115, DOI 10.1016/0012-1606(90)90106-S; SCHONTHAL A, 1993, ONCOGENE, V8, P433; SCHONTHAL A, 1992, NEW BIOL, V4, P16; SHEN XT, 1995, CELL, V82, P47, DOI 10.1016/0092-8674(95)90051-9; SHIBATA K, 1993, J BIOL CHEM, V268, P18431; SHIBATA K, 1990, EUR J BIOCHEM, V192, P87, DOI 10.1111/j.1432-1033.1990.tb19199.x; SOLA MM, 1991, BIOCHIM BIOPHYS ACTA, V1094, P211, DOI 10.1016/0167-4889(91)90011-L; STEINMANN KE, 1991, P NATL ACAD SCI USA, V88, P6843, DOI 10.1073/pnas.88.15.6843; SUGANUMA M, 1988, P NATL ACAD SCI USA, V85, P1768, DOI 10.1073/pnas.85.6.1768; SZOLLOSI MS, 1993, J CELL SCI, V104, P861; THNG JPH, 1994, J BIOL CHEM, V269, P9568; van Holde K.E., 1988, CHROMATIN; YAMASHITA K, 1990, EMBO J, V9, P4331, DOI 10.1002/j.1460-2075.1990.tb07882.x; ZHENG B, 1991, J BIOL CHEM, V266, P10031; Zweidler A, 1978, Methods Cell Biol, V17, P223, DOI 10.1016/S0091-679X(08)61145-0	48	126	128	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 31	1996	271	22					13197	13201		10.1074/jbc.271.22.13197	http://dx.doi.org/10.1074/jbc.271.22.13197			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UN474	8662672	hybrid			2022-12-25	WOS:A1996UN47400078
J	Herwald, H; Dedio, J; Kellner, R; Loos, M; MullerEsterl, W				Herwald, H; Dedio, J; Kellner, R; Loos, M; MullerEsterl, W			Isolation and characterization of the kininogen-binding protein p33 from endothelial cells - Identity with the gC1q receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-WEIGHT KININOGEN; EXPRESSION; PLATELETS; PREKALLIKREIN; ACTIVATION; PLASMA; SITE; BRADYKININ; KALLIKREIN; CLEAVAGE	Kininogens, the precursor proteins of the vasoactive kinins, bind specifically, reversibly, and saturably to platelets, neutrophils, and endothelial cells. Two domains of the kininogens expose major cell binding sites: domain D3 that is shared by H- and L-kininogen and domain D5(H) that is exclusively present in H-kininogen. Previously we have mapped the kininogen cell binding sites to 27 residues of D3 (''LDC27'') and 20 residues of D5(H) (''HKH20''), respectively (Herwald, H., Hasan, A. A. K., Godovae-Zimmermann, J., Schmaier, A. H., and Muller-Esterl, W. (1995) J. Biol. Chem. 270, 14634-14642; Hasan, A. A. K., Cines, D. B., Herwald, H., Schmaier, A. H., and Muller-Esterl, W. (1995) J. Biol. Chen. 270, 19256-19261). The corresponding kininogen acceptor site(s) exposed by the cell surfaces are still poorly defined. Using a non-ionic detergent, Nonidet P-40, we have been able to solubilize kininogen binding sites from an endothelial cell line, EA.hy926, in their functionally active form. Affinity chromatography of the solubilized kininogen binding sites on HKH20, a synthetic peptide representing the D5(H) cell binding site, allowed us to isolate a 33-kDa protein (''p33'') that binds specifically and reversibly to H-kininogen with a K-D (apparent dissociation constant) of 9 +/- 2 nM. Preparative SDS electrophoresis followed by NH2-terminal amino acid sequence analysis identified the kininogen-binding protein p33 as the gC1q receptor (''gC1qR''), an extrinsic membrane protein that interacts with the globular domains of the complement component C1q. The purified p33 binds C1q with moderate affinity, K-D = 240 +/- 10 nM. Recombinant expression of the corresponding cDNA in Escherichia coli demonstrated that p33 binds H-kininogen, but not L-kininogen. Peptide HKH20 but not peptide LDC27 inhibited binding of H-kininogen to the recombinant p33 in a concentration-dependent manner, indicating that H-kininogen binds to p33 via domain D5(H). Recombinant p33 efficiently inhibited the binding of H-kininogen to EA.hy926 cells. Factor XII, but not prekallikrein, competed with H-kininogen binding to p33. These findings suggest that an endothelial binding protein mediates the assembly of critical components of the kinin-generating pathway on the surface of endothelial cells, thereby linking the early events of kinin formation and complement activation.	UNIV MAINZ, INST PHYSIOL CHEM & PATHOBIOCHEM, D-55099 MAINZ, GERMANY; UNIV MAINZ, INST MED MICROBIOL & HYG, D-55099 MAINZ, GERMANY	Johannes Gutenberg University of Mainz; Johannes Gutenberg University of Mainz			Herwald, Heiko/AAN-3708-2021	Herwald, Heiko/0000-0002-8111-2842				ABDALLA S, 1993, J BIOL CHEM, V268, P17277; BERRETTINI M, 1992, J BIOL CHEM, V267, P19833; BHOOLA KD, 1992, PHARMACOL REV, V44, P1; CHAIKEN I, 1992, ANAL BIOCHEM, V201, P197, DOI 10.1016/0003-2697(92)90329-6; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; EDGELL CJ, 1983, P NATL ACAD SCI-BIOL, V80, P3734, DOI 10.1073/pnas.80.12.3734; EGGLETON P, 1994, BLOOD, V84, P1640; FRAKER PJ, 1978, BIOCHEM BIOPH RES CO, V80, P849, DOI 10.1016/0006-291X(78)91322-0; GHEBREHIWET B, 1995, J IMMUNOL, V155, P2614; GHEBREHIWET B, 1981, J EXP MED, V153, P665, DOI 10.1084/jem.153.3.665; GHEBREHIWET B, 1994, J EXP MED, V179, P1809, DOI 10.1084/jem.179.6.1809; GREENGARD JS, 1992, METHOD ENZYMOL, V215, P369; GREENGARD JS, 1984, BIOCHEMISTRY-US, V23, P6863, DOI 10.1021/bi00321a090; HASAN AAK, 1994, J BIOL CHEM, V269, P31822; HASAN AAK, 1995, J BIOL CHEM, V270, P19256, DOI 10.1074/jbc.270.33.19256; HENDERSON LM, 1994, BLOOD, V84, P474; HERWALD H, 1995, J BIOL CHEM, V270, P14634; JAFFE EA, 1973, J CLIN INVEST, V52, P2745, DOI 10.1172/JCI107470; JIANG YP, 1992, J BIOL CHEM, V267, P3712; KYHSEANDERSEN J, 1984, J BIOCHEM BIOPH METH, V10, P203, DOI 10.1016/0165-022X(84)90040-X; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MANDLE RJ, 1976, P NATL ACAD SCI USA, V73, P4179, DOI 10.1073/pnas.73.11.4179; MELONI FJ, 1992, BLOOD, V79, P1233; MELONI FJ, 1991, J BIOL CHEM, V266, P6786; MULLERESTERL W, 1988, METHOD ENZYMOL, V163, P240; MULLERESTERL W, 1986, TRENDS BIOCHEM SCI, V11, P336, DOI 10.1016/0968-0004(86)90293-8; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; NISHIKAWA K, 1992, BLOOD, V80, P1980; PEERSCHKE EIB, 1994, J IMMUNOL, V152, P5896; REDDIGARI SR, 1993, J BIOL CHEM, V268, P11982; SALVESEN G, 1986, BIOCHEM J, V234, P429, DOI 10.1042/bj2340429; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SCHMAIER AH, 1988, J BIOL CHEM, V263, P16327; STEMMER F, 1984, J IMMUNOL METHODS, V74, P9, DOI 10.1016/0022-1759(84)90361-2; Stewart J.M., 1980, BRADYKININ KALLIDIN, P227; TAIT JF, 1987, J BIOL CHEM, V262, P11651; VANIWAARDEN F, 1988, J BIOL CHEM, V263, P4698; VANIWAARDEN F, 1988, BLOOD, V71, P1268; VOGEL R, 1990, J BIOL CHEM, V265, P12494; WACHTFOGEL YT, 1994, J BIOL CHEM, V269, P19307; ZINI JM, 1993, BLOOD, V81, P2936	41	200	209	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 31	1996	271	22					13040	13047		10.1074/jbc.271.22.13040	http://dx.doi.org/10.1074/jbc.271.22.13040			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UN474	8662673				2022-12-25	WOS:A1996UN47400056
J	Hofhaus, G; Johns, DR; Hurko, O; Attardi, G; Chomyn, A				Hofhaus, G; Johns, DR; Hurko, O; Attardi, G; Chomyn, A			Respiration and growth defects in transmitochondrial cell lines carrying the 11778 mutation associated with Leber's hereditary optic neuropathy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C OXIDASE; COMPLEX-I; NADH DEHYDROGENASE; MITOCHONDRIAL NADH; HUMAN MTDNA; HELA-CELLS; LACKING; GENE; NEURORETINOPATHY; FIBROBLASTS	Mitochondrial DNA from two genetically unrelated patients carrying the mutation at position 11778 that causes Leber's hereditary optic neuropathy has been transferred with mitochondria into human mtDNA-less rho(0)206 cells. As analyzed in several transmitochondrial cell lines thus obtained, the mutation, which is in the gene encoding subunit ND4 of the respiratory chain NADH dehydrogenase (ND), did not affect the synthesis, size, or stability of ND4, nor its incorporation into the enzyme complex, However, NADH dehydrogenase-dependent respiration, as measured in digitonin-permeabilized cells, was specifically decreased by approximately 40% in cells carrying the mutation, This decrease, which was significant at the 99.99% confidence level, was correlated with a significantly reduced ability of the mutant cells to grow in a medium containing galactose instead of glucose, indicating a clear impairment in their oxidative phosphorylation capacity. On the contrary, no decrease in rotenone-sensitive NADH dehydrogenase activity, using a water-soluble ubiquinone analogue as electron acceptor, was detected in disrupted mitochondrial membranes. This is the first cellular model exhibiting in a foreign nuclear background mitochondrial DNA-linked biochemical defects underlying the optic neuropathy phenotype.	CALTECH, DIV BIOL, PASADENA, CA 91125 USA; HARVARD UNIV, BETH ISRAEL HOSP, SCH MED, DEPT NEUROL, BOSTON, MA 02215 USA; JOHNS HOPKINS UNIV, SCH MED, DEPT NEUROL, BALTIMORE, MD 21206 USA	California Institute of Technology; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Johns Hopkins University					NATIONAL EYE INSTITUTE [R01EY010864] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR038231] Funding Source: NIH RePORTER; NEI NIH HHS [EY 10864] Funding Source: Medline; NIAMS NIH HHS [AR NS 38231] Funding Source: Medline; NIGMS NIH HHS [GM 11726] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ATTARDI B, 1969, J MOL BIOL, V44, P47, DOI 10.1016/0022-2836(69)90404-5; BENECKE R, 1992, ANN NEUROL, V32, P683, DOI 10.1002/ana.410320512; BONNER WM, 1974, EUR J BIOCHEM, V46, P83, DOI 10.1111/j.1432-1033.1974.tb03599.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWN MD, 1992, GENETICS, V130, P163; BU XD, 1991, P NATL ACAD SCI USA, V88, P8198, DOI 10.1073/pnas.88.18.8198; CHOMYN A, 1994, AM J HUM GENET, V54, P966; Chomyn A, 1996, Methods Enzymol, V264, P197, DOI 10.1016/S0076-6879(96)64020-8; CHOMYN A, 1986, SCIENCE, V234, P614, DOI 10.1126/science.3764430; CHOMYN A, 1991, MOL CELL BIOL, V11, P2236, DOI 10.1128/MCB.11.4.2236; CHU EHY, 1972, P NATL ACAD SCI USA, V69, P3459, DOI 10.1073/pnas.69.11.3459; CLEETER MWJ, 1985, BIOCHEM J, V227, P467, DOI 10.1042/bj2270467; DAY CE, 1982, SOMAT CELL GENET, V8, P691, DOI 10.1007/BF01543012; DONNELLY M, 1976, J CELL PHYSIOL, V89, P39, DOI 10.1002/jcp.1040890105; ESPOSTI MD, 1994, FEBS LETT, V352, P375, DOI 10.1016/0014-5793(94)00971-6; ESTORNELL E, 1993, FEBS LETT, V332, P127, DOI 10.1016/0014-5793(93)80498-J; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GRANGER DL, 1982, J CELL BIOL, V95, P527, DOI 10.1083/jcb.95.2.527; GUAN MX, 1996, IN PRESS HUM MOL GEN; HARDING AE, 1995, AM J HUM GENET, V57, P77; HAYASHI JI, 1991, P NATL ACAD SCI USA, V88, P10614, DOI 10.1073/pnas.88.23.10614; Hofhaus G, 1996, Methods Enzymol, V264, P476, DOI 10.1016/S0076-6879(96)64043-9; HOFHAUS G, 1993, EMBO J, V12, P3043, DOI 10.1002/j.1460-2075.1993.tb05973.x; HOWELL N, 1991, AM J HUM GENET, V48, P935; HOWELL N, 1991, AM J HUM GENET, V49, P939; HUOPONEN K, 1991, AM J HUM GENET, V48, P1147; JOHNS DR, 1993, AM J HUM GENET, V53, P916; JOHNS DR, 1992, BIOCHEM BIOPH RES CO, V187, P1551, DOI 10.1016/0006-291X(92)90479-5; JOHNS DR, 1991, BIOCHEM BIOPH RES CO, V181, P1358, DOI 10.1016/0006-291X(91)92088-2; JUN AS, 1994, P NATL ACAD SCI USA, V91, P6206, DOI 10.1073/pnas.91.13.6206; KING MP, 1989, SCIENCE, V246, P500, DOI 10.1126/science.2814477; LARSSON NG, 1991, ANN NEUROL, V30, P701, DOI 10.1002/ana.410300511; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAJANDER A, 1991, FEBS LETT, V292, P289, DOI 10.1016/0014-5793(91)80886-8; MARIOTTINI P, 1986, J BIOL CHEM, V261, P3355; MASON TL, 1973, J BIOL CHEM, V248, P1346; NEWMAN NJ, 1993, ARCH NEUROL-CHICAGO, V50, P540, DOI 10.1001/archneur.1993.00540050082021; REITZER LJ, 1979, J BIOL CHEM, V254, P2669; ROBINSON BH, 1992, BIOCHEM MED METAB B, V48, P122, DOI 10.1016/0885-4505(92)90056-5; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; STORRIE B, 1972, J MOL BIOL, V71, P177, DOI 10.1016/0022-2836(72)90345-2; SUMEGI B, 1984, J BIOL CHEM, V259, P5040; VERGANI L, 1995, BIOCHEM BIOPH RES CO, V210, P880, DOI 10.1006/bbrc.1995.1740; WALLACE DC, 1994, P NATL ACAD SCI USA, V91, P8739, DOI 10.1073/pnas.91.19.8739; WALLACE DC, 1988, SCIENCE, V242, P1427, DOI 10.1126/science.3201231; YONEDA M, 1992, P NATL ACAD SCI USA, V89, P11164, DOI 10.1073/pnas.89.23.11164	46	131	136	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 31	1996	271	22					13155	13161		10.1074/jbc.271.22.13155	http://dx.doi.org/10.1074/jbc.271.22.13155			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UN474	8662757	Green Accepted, hybrid			2022-12-25	WOS:A1996UN47400072
J	Neddermann, P; Gallinari, P; Lettieri, T; Schmid, D; Truong, O; Hsuan, JJ; Wiebauer, K; Jiricny, J				Neddermann, P; Gallinari, P; Lettieri, T; Schmid, D; Truong, O; Hsuan, JJ; Wiebauer, K; Jiricny, J			Cloning and expression of human G/T mismatch-specific thymine-DNA glycosylase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOSINE METHYLATION; NUCLEAR EXTRACTS; MAMMALIAN-CELLS; G.T MISPAIRS; POLYMERASE; DEAMINATION; PROTEINS; INVITRO	Hydrolytic deamination of 5-methylcytosine leads to the formation of G/T mismatches. We have shown previously that these G/T mispairs are corrected to G/C pairs by a mismatch-specific thymine-DNA glycosylase, TDG, which we subsequently purified from human cells. Here we describe the cloning of the human cDNA encoding TDG. We have identified two distinct cDNA species that differ by 100 nucleotides at the 3'-untranslated region. These cDNAs contain a 410-amino acid open reading frame that encodes a 46-kDa polypeptide. The G/T glycosylase, expressed both in vitro and in Escherichia coli, migrated in denaturing polyacrylamide gels with an apparent size of 60 kDa. The substrate specificity of the recombinant protein corresponded to that of the cellular enzyme, and polyclonal antisera raised against the recombinant protein neutralized both activities. We therefore conclude that the cDNA described below encodes human TDG. Data base searches identified a serendipitously cloned mouse cDNA sequence that could be shown to encode the murine TDG homologue. No common amino acid sequence motifs between the G/T-specific enzyme and other DNA glycosylases could be found, suggesting that TDG belongs to a new class of base-excision repair enzymes.	IST RIC BIOL MOLEC P ANGELETTI, DEPT BIOCHEM, I-00040 POMEZIA, ITALY; LUDWIG INST CANC RES, LONDON W1P 8BT, ENGLAND; UCL, DEPT BIOCHEM & MOLEC BIOL, LONDON WC1E 6BT, ENGLAND	Ludwig Institute for Cancer Research; University of London; University College London			Hsuan, Justin/C-8825-2009; Gallinari, Paola/ABE-8238-2021	Hsuan, Justin/0000-0001-6083-7564; Lettieri, Teresa/0000-0002-3363-9666				[Anonymous], 1982, MOL CLONING LAB MANU; BROWN TC, 1987, CELL, V50, P945, DOI 10.1016/0092-8674(87)90521-6; BROWN TC, 1988, CELL, V54, P705, DOI 10.1016/S0092-8674(88)80015-1; CHEVRAY PM, 1992, P NATL ACAD SCI USA, V89, P5789, DOI 10.1073/pnas.89.13.5789; DIANOV G, 1994, CURR BIOL, V4, P1069, DOI 10.1016/S0960-9822(00)00245-1; DUNCAN BK, 1980, NATURE, V287, P560, DOI 10.1038/287560a0; EHRLICH M, 1986, BIOSCIENCE REP, V6, P387, DOI 10.1007/BF01116426; FRIEDBERG EC, 1995, DNA REPAIR MUTAGENES, P108; GREENBLATT MS, 1994, CANCER RES, V54, P4855; GRIFFIN S, 1994, BIOCHEMISTRY-US, V33, P4787, DOI 10.1021/bi00182a006; GRIFFIN S, 1993, BIOCHEMISTRY-US, V32, P13032, DOI 10.1021/bi00211a012; Harlow E., 1988, ANTIBODIES LAB MANUA; HERGERSBERG M, 1991, EXPERIENTIA, V47, P1171, DOI 10.1007/BF01918381; KARRAN P, 1994, BIOESSAYS, V16, P833, DOI 10.1002/bies.950161110; KAWASAKI H, 1990, ANAL BIOCHEM, V186, P264, DOI 10.1016/0003-2697(90)90077-M; LINDAHL T, 1982, ANNU REV BIOCHEM, V51, P61, DOI 10.1146/annurev.bi.51.070182.000425; LINGNER J, 1991, NATURE, V354, P496, DOI 10.1038/354496a0; NEDDERMANN P, 1993, J BIOL CHEM, V268, P21218; NEDDERMANN P, 1994, P NATL ACAD SCI USA, V91, P1642, DOI 10.1073/pnas.91.5.1642; SAPARBAEV M, 1994, P NATL ACAD SCI USA, V91, P5873, DOI 10.1073/pnas.91.13.5873; SEEBERG E, 1995, TRENDS BIOCHEM SCI, V20, P391, DOI 10.1016/S0968-0004(00)89086-6; SHEETS MD, 1990, NUCLEIC ACIDS RES, V18, P5799, DOI 10.1093/nar/18.19.5799; SIBGHATULLAH, 1995, BIOCHEMISTRY-US, V34, P6869, DOI 10.1021/bi00020a034; SIBGHATULLAH, 1992, BIOCHEMISTRY-US, V31, P7998, DOI 10.1021/bi00149a034; SIBGHATULLAH, 1993, NUCLEIC ACIDS RES, V21, P1281, DOI 10.1093/nar/21.5.1281; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TOTTY NF, 1992, PROTEIN SCI, V1, P1215, DOI 10.1002/pro.5560010914; WIEBAUER K, 1990, P NATL ACAD SCI USA, V87, P5842, DOI 10.1073/pnas.87.15.5842; WIEBAUER K, 1989, NATURE, V339, P234, DOI 10.1038/339234a0; ZARBL H, 1985, NATURE, V315, P382, DOI 10.1038/315382a0	30	233	248	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 31	1996	271	22					12767	12774		10.1074/jbc.271.22.12767	http://dx.doi.org/10.1074/jbc.271.22.12767			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UN474	8662714	hybrid			2022-12-25	WOS:A1996UN47400014
J	Ceresa, BP; Pessin, JE				Ceresa, BP; Pessin, JE			Insulin stimulates the serine phosphorylation of the signal transducer and activator of transcription (STAT3) isoform	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE PHOSPHORYLATION; INTERFERON-ALPHA; GROWTH-FACTOR; GAMMA; INDUCTION; PROTEINS	Insulin stimulation of Chinese hamster ovary cells expressing the human insulin receptor and differentiated 3T3L1 adipocytes resulted in a time-dependent reduction in the SDS polyacrylamide gel electrophoretic mobility of STATS. The decreased STAT3 mobility initially occurred by 2 min and was quantitative by 5 min. In addition, the change in STAT3 mobility was concentration-dependent and was detectable at 0.3 nM insulin with maximal effect between 1 and 3 nM. Although both these cell types also express the STAT1 alpha, STAT1 beta, STAT5, and STAT6 isoforms, only STAT3 was observed to undergo an insulin dependent reduction in mobility. Immunoprecipitation of STAT1 and STAT3 from P-32-labeled cells demonstrated that only STAT3 was phosphorylated in response to insulin whereas phosphoamino acid analysis indicated that this phosphorylation event occurred exclusively on serine residues. Furthermore, treatment of cell extracts with alkaline phosphatase reversed the insulin-stimulated decrease in STAT3 mobility. Together, these data demonstrate that insulin is a specific activator of STAT3 serine phosphorylation without affecting the other STAT isoforms.	UNIV IOWA,DEPT PHYSIOL & BIOPHYS,IOWA CITY,IA 52242	University of Iowa					NIDDK NIH HHS [DK25295, DK33823] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK033823, P30DK025295, R01DK033823] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARGETSINGER LS, 1993, CELL, V74, P237, DOI 10.1016/0092-8674(93)90415-M; BHAT GJ, 1995, J BIOL CHEM, V270, P19059, DOI 10.1074/jbc.270.32.19059; BOULTON TG, 1994, J BIOL CHEM, V269, P11648; BOULTON TG, 1995, P NATL ACAD SCI USA, V92, P6915, DOI 10.1073/pnas.92.15.6915; CRESSMAN DE, 1995, HEPATOLOGY, V21, P1443, DOI 10.1016/0270-9139(95)90068-3; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DAVID M, 1995, SCIENCE, V269, P1721, DOI 10.1126/science.7569900; DECKER T, 1991, EMBO J, V10, P927, DOI 10.1002/j.1460-2075.1991.tb08026.x; DEVRIESSMITS AMM, 1992, NATURE, V357, P602, DOI 10.1038/357602a0; EILERS A, 1995, MOL CELL BIOL, V15, P3579; FU XY, 1992, CELL, V70, P323, DOI 10.1016/0092-8674(92)90106-M; IHLE JN, 1995, TRENDS GENET, V11, P69, DOI 10.1016/S0168-9525(00)89000-9; IHLE JN, 1994, TRENDS BIOCHEM SCI, V19, P222, DOI 10.1016/0968-0004(94)90026-4; KANETY H, 1995, J BIOL CHEM, V270, P23780, DOI 10.1074/jbc.270.40.23780; LEBRUN JJ, 1994, J BIOL CHEM, V269, P14021; LEVY DE, 1988, GENE DEV, V2, P383, DOI 10.1101/gad.2.4.383; LEW DJ, 1991, MOL CELL BIOL, V11, P182, DOI 10.1128/MCB.11.1.182; LIU XW, 1995, P NATL ACAD SCI USA, V92, P8831, DOI 10.1073/pnas.92.19.8831; LUTTICKEN C, 1995, FEBS LETT, V360, P137, DOI 10.1016/0014-5793(95)00076-L; QURESHI SA, 1995, P NATL ACAD SCI USA, V92, P3829, DOI 10.1073/pnas.92.9.3829; RUFFJAMISON S, 1993, SCIENCE, V261, P1733, DOI 10.1126/science.8378774; SADOWSKI HB, 1993, SCIENCE, V261, P1739, DOI 10.1126/science.8397445; SAKAI I, 1995, J BIOL CHEM, V270, P18420, DOI 10.1074/jbc.270.31.18420; SCHAEFER TS, 1995, P NATL ACAD SCI USA, V92, P9097, DOI 10.1073/pnas.92.20.9097; SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201; SCHINDLER C, 1992, P NATL ACAD SCI USA, V89, P7836, DOI 10.1073/pnas.89.16.7836; SCHINDLER C, 1992, SCIENCE, V257, P809, DOI 10.1126/science.1496401; SHUAI K, 1993, SCIENCE, V261, P1744, DOI 10.1126/science.7690989; SILVENNOINEN O, 1993, SCIENCE, V261, P1736, DOI 10.1126/science.8378775; TIAN SS, 1994, BLOOD, V84, P1760; WATERS SB, 1995, MOL CELL BIOL, V15, P2791; WATERS SB, 1995, J BIOL CHEM, V270, P20883, DOI 10.1074/jbc.270.36.20883; WELHAM MJ, 1995, J BIOL CHEM, V270, P12286, DOI 10.1074/jbc.270.20.12286; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; ZHANG XK, 1995, SCIENCE, V267, P1990, DOI 10.1126/science.7701321; ZHONG Z, 1994, P NATL ACAD SCI USA, V91, P4806, DOI 10.1073/pnas.91.11.4806	36	64	64	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 24	1996	271	21					12121	12124		10.1074/jbc.271.21.12121	http://dx.doi.org/10.1074/jbc.271.21.12121			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UL660	8647800	hybrid			2022-12-25	WOS:A1996UL66000002
J	Daly, RJ; Sanderson, GM; Janes, PW; Sutherland, RL				Daly, RJ; Sanderson, GM; Janes, PW; Sutherland, RL			Cloning and characterization of GRB14, a novel member of the GRB7 gene family	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR TYROSINE KINASES; EPIDERMAL GROWTH-FACTOR; HUMAN-BREAST-CANCER; EXPRESSION CLONING; SH3 DOMAIN; PROTEIN; PURIFICATION; POLYPEPTIDES; CELLS; IDENTIFICATION	Screening of a human breast epithelial cell cDNA library with the tyrosine-phosphorylated C terminus of the epidermal growth factor receptor identified a novel member of the GRB7 gene family, designated GRB14. In addition to a pleckstrin homology domain-containing central region homologous to the Caenorhabditis elegans protein F10E9.6/mig 10 and a C-terminal Src homology 2 (SH2) domain, a conserved N-terminal motif, P(S/A)IPNPFPEL, can now be included as a hallmark of this family. GRB14 mRNA was expressed at high levels in the liver, kidney, pancreas, testis, ovary, heart, and skeletal muscle. Anti-Grb14 antibodies recognized a protein of approximately 58 kDa in a restricted range of human cell lines. Among those of breast cancer origin, GRB14 expression strongly correlated with estrogen receptor positivity, and differential expression was also observed among human prostate cancer cell lines. A GST-Grb14 SH2 domain fusion protein exhibited strong binding to activated platelet-derived growth factor (PDGF) receptors (PDGFRs) in vitro, but association between Grb14 and beta-PDGFRs could not be detected in vivo. In serum-starved cells, Grb14 was phosphorylated on serine residues, which increased with PDGF, but not EGF, treatment. Grb14 is therefore a target for a PDGF-regulated serine kinase, an interaction that does not require PDGFR-Grb14 association.			Daly, RJ (corresponding author), ST VINCENTS HOSP, GARVAN INST MED RES, DIV CANC BIOL, DARLINGHURST, NSW 2010, AUSTRALIA.		Daly, Roger J/C-8179-2009; Sutherland, Robert L/A-8378-2008	Daly, Roger/0000-0002-5739-8027				ALEXANDER IE, 1989, MOL ENDOCRINOL, V3, P1377, DOI 10.1210/mend-3-9-1377; BLAIKIE P, 1994, J BIOL CHEM, V269, P32031; BUCKLEY MF, 1993, ONCOGENE, V8, P2127; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CONNOLLY JM, 1989, PROSTATE, V15, P177, DOI 10.1002/pros.2990150211; DALY RJ, 1995, BREAST CANCER RES TR, V34, P85, DOI 10.1007/BF00666495; DATTA K, 1995, MOL CELL BIOL, V15, P2304; DICKSON RB, 1988, BREAST CANCER CELLUL, P119; DOWNING AK, 1994, CURR BIOL, V4, P884, DOI 10.1016/S0960-9822(00)00197-4; FERGUSON KM, 1994, CELL, V79, P199, DOI 10.1016/0092-8674(94)90190-2; FERGUSON KM, 1995, CELL, V83, P1037, DOI 10.1016/0092-8674(95)90219-8; GIBSON TJ, 1994, TRENDS BIOCHEM SCI, V19, P349, DOI 10.1016/0968-0004(94)90108-2; HARLAN JE, 1994, NATURE, V371, P168, DOI 10.1038/371168a0; HONEGGER AM, 1987, CELL, V51, P199, DOI 10.1016/0092-8674(87)90147-4; HOPP TP, 1988, BIO-TECHNOL, V6, P1204, DOI 10.1038/nbt1088-1204; JANES PW, 1994, ONCOGENE, V9, P3601; KAMPS MP, 1991, METHOD ENZYMOL, V201, P21; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; LAMMERS R, 1993, J BIOL CHEM, V268, P22456; LEE CH, 1994, STRUCTURE, V2, P423, DOI 10.1016/S0969-2126(00)00044-7; LEE J, 1989, EMBO J, V8, P167, DOI 10.1002/j.1460-2075.1989.tb03361.x; LEMMON MA, 1995, P NATL ACAD SCI USA, V92, P10472, DOI 10.1073/pnas.92.23.10472; LI W, 1992, MOL CELL BIOL, V12, P5824, DOI 10.1128/MCB.12.12.5824; LIU F, 1995, P NATL ACAD SCI USA, V92, P10287, DOI 10.1073/pnas.92.22.10287; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MACIAS MJ, 1994, NATURE, V369, P675, DOI 10.1038/369675a0; MANSER J, 1990, DEV GENET, V11, P49, DOI 10.1002/dvg.1020110107; MARGOLIS B, 1992, P NATL ACAD SCI USA, V89, P8894, DOI 10.1073/pnas.89.19.8894; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; OOI J, 1995, ONCOGENE, V10, P1621; PANDEY A, 1995, J BIOL CHEM, V270, P21461, DOI 10.1074/jbc.270.37.21461; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SKOLNIK EY, 1991, CELL, V65, P83, DOI 10.1016/0092-8674(91)90410-Z; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SMITH DE, 1984, J CELL BIOL, V99, P20, DOI 10.1083/jcb.99.1.20; STEIN D, 1994, EMBO J, V13, P1331, DOI 10.1002/j.1460-2075.1994.tb06386.x; TOUHARA K, 1994, J BIOL CHEM, V269, P10217; TRAHEY M, 1988, SCIENCE, V242, P1697, DOI 10.1126/science.3201259; YAO L, 1994, P NATL ACAD SCI USA, V91, P9175, DOI 10.1073/pnas.91.19.9175; YOON HS, 1994, NATURE, V369, P672, DOI 10.1038/369672a0; YU HT, 1994, CELL, V76, P933, DOI 10.1016/0092-8674(94)90367-0	44	112	118	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 24	1996	271	21					12502	12510		10.1074/jbc.271.21.12502	http://dx.doi.org/10.1074/jbc.271.21.12502			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UL660	8647858	hybrid			2022-12-25	WOS:A1996UL66000060
J	Levkowitz, G; Klapper, LN; Tzahar, E; Freywald, A; Sela, M; Yarden, Y				Levkowitz, G; Klapper, LN; Tzahar, E; Freywald, A; Sela, M; Yarden, Y			Coupling of the c-Cbl protooncogene product to ErbB-1/EGF-receptor but not to other ErbB proteins	ONCOGENE			English	Article						tyrosine kinase; growth factor; signal transduction; Neu differentiation factor	GROWTH-FACTOR RECEPTOR; TYROSINE PHOSPHORYLATION; PHOSPHOLIPASE-C; EGF RECEPTOR; V-CBL; NEU RECEPTOR; SH2 DOMAINS; BINDING; KINASE; GENE	The ErbB family of transmembrane tyrosine kinases includes the receptor for EGF (ErbB-1), two receptors for NDF/heregulin (ErbB-3 and ErbB-4) and an orphan receptor (ErbB-2). In order to examine the possibility that distinct signal transduction pathways are coupled to each ErbB protein, we examined the interaction of individual ligand-stimulated receptors with the c-Cbl protein, a protooncogene-encoded signaling molecule previously identified in hematopoietic cells. We report that c-Cbl undergoes rapid and sustained phosphorylation on tyrosine residues upon stimulation of fibroblast and epithelial cell lines with ligands of ErbB-1. By contrast, activation of either ErbB-3 or ErbB-4 by NDF did not affect tyrosine phosphorylation of c-Cbl. Likewise, activation of a chimeric ligand-stimulatable ErbB-2 by a heterologous ligand was ineffective. Despite rapidity of the EGF effect, we observed no association of c-Cbl with activated ErbB-1, implying that the interaction is indirect. Our in vitro experiments suggest that a candidate mediator of the interaction is the Grb-2/Ash adaptor protein, which is constitutively bound to c-Cbl. These results indicate that different ErbB proteins can couple to distinct signaling pathways, and therefore their physiological functions are probably non-redundant.	WEIZMANN INST SCI,DEPT CHEM IMMUNOL,IL-76100 REHOVOT,ISRAEL	Weizmann Institute of Science			Levkowitz, Gil/AAB-9441-2019; YARDEN, YOSEF/K-1467-2012	Levkowitz, Gil/0000-0002-3896-1881; 	NATIONAL CANCER INSTITUTE [R01CA051712] Funding Source: NIH RePORTER; NCI NIH HHS [CA51712] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDERSON D, 1990, SCIENCE, V250, P979, DOI 10.1126/science.2173144; ANDONIOU CE, 1994, EMBO J, V13, P4515, DOI 10.1002/j.1460-2075.1994.tb06773.x; AROIAN RV, 1994, EMBO J, V13, P360, DOI 10.1002/j.1460-2075.1994.tb06269.x; AROIAN RV, 1990, NATURE, V348, P693, DOI 10.1038/348693a0; BATEWELL DDL, 1995, ONCOGENE, V11, P1561; BENLEVY R, 1994, EMBO J, V13, P3302, DOI 10.1002/j.1460-2075.1994.tb06632.x; BENLEVY R, 1992, J BIOL CHEM, V267, P17304; BLAKE TJ, 1991, ONCOGENE, V6, P653; BLAKE TJ, 1993, EMBO J, V12, P2017, DOI 10.1002/j.1460-2075.1993.tb05851.x; BRUNNER D, 1994, CELL, V76, P875, DOI 10.1016/0092-8674(94)90362-X; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; CARRAWAY KL, 1994, J BIOL CHEM, V269, P14303; CARRAWAY KL, 1994, CELL, V78, P5, DOI 10.1016/0092-8674(94)90564-9; CULOUSCOU JM, 1995, J BIOL CHEM, V270, P12857, DOI 10.1074/jbc.270.21.12857; DONOVAN JA, 1994, J BIOL CHEM, V269, P22921; EAGAN SE, 1993, NATURE, V363, P45; FAJARDO JE, 1993, MOL CELL BIOL, V13, P7295, DOI 10.1128/MCB.13.12.7295; FANTL WJ, 1993, ANNU REV BIOCHEM, V62, P453, DOI 10.1146/annurev.bi.62.070193.002321; FAZIOLI F, 1991, MOL CELL BIOL, V11, P2040, DOI 10.1128/MCB.11.4.2040; FAZIOLI F, 1993, EMBO J, V12, P3799, DOI 10.1002/j.1460-2075.1993.tb06058.x; FEDI P, 1994, MOL CELL BIOL, V14, P492, DOI 10.1128/MCB.14.1.492; FU XY, 1993, CELL, V74, P1135, DOI 10.1016/0092-8674(93)90734-8; GALISTEO ML, 1995, J BIOL CHEM, V270, P20242, DOI 10.1074/jbc.270.35.20242; GOLDMAN R, 1990, BIOCHEMISTRY-US, V29, P11024, DOI 10.1021/bi00502a002; GRAUSPORTA D, 1995, MOL CELL BIOL, V15, P1182; HILL RJ, 1992, NATURE, V358, P470, DOI 10.1038/358470a0; HSU JC, 1994, GENE DEV, V8, P2176, DOI 10.1101/gad.8.18.2176; KEANE MM, 1995, ONCOGENE, V10, P2367; LANGDON WY, 1989, P NATL ACAD SCI USA, V86, P1168, DOI 10.1073/pnas.86.4.1168; LEE J, 1989, EMBO J, V8, P167, DOI 10.1002/j.1460-2075.1989.tb03361.x; LEHVASLAIHO H, 1989, EMBO J, V8, P159, DOI 10.1002/j.1460-2075.1989.tb03360.x; LI W, 1992, MOL CELL BIOL, V12, P5824, DOI 10.1128/MCB.12.12.5824; LI W, 1994, MOL CELL BIOL, V14, P509, DOI 10.1128/MCB.14.1.509; LIVNEH E, 1985, CELL, V40, P599, DOI 10.1016/0092-8674(85)90208-9; LUTTRELL DK, 1994, P NATL ACAD SCI USA, V91, P83, DOI 10.1073/pnas.91.1.83; MARCILLA A, 1995, J BIOL CHEM, V270, P9115, DOI 10.1074/jbc.270.16.9115; MARGOLIS B, 1992, P NATL ACAD SCI USA, V89, P8894, DOI 10.1073/pnas.89.19.8894; MEISENHELDER J, 1992, MOL CELL BIOL, V12, P5843, DOI 10.1128/MCB.12.12.5843; MEISNER H, 1995, J BIOL CHEM, V270, P25332, DOI 10.1074/jbc.270.43.25332; MEISNER H, 1995, MOL CELL BIOL, V15, P3571; MUTHUSWAMY SK, 1994, MOL CELL BIOL, V14, P735, DOI 10.1128/MCB.14.1.735; ODAI H, 1995, J BIOL CHEM, V270, P10800, DOI 10.1074/jbc.270.18.10800; PARK D, 1992, MOL CELL BIOL, V12, P5816, DOI 10.1128/MCB.12.12.5816; PELES E, 1991, EMBO J, V10, P2077, DOI 10.1002/j.1460-2075.1991.tb07739.x; PELES E, 1992, J BIOL CHEM, V267, P12266; PELES E, 1993, BIOESSAYS, V15, P815, DOI 10.1002/bies.950151207; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; PLOWMAN GD, 1993, NATURE, V366, P473, DOI 10.1038/366473a0; PRIGENT SA, 1994, EMBO J, V13, P2831, DOI 10.1002/j.1460-2075.1994.tb06577.x; RIVEROLEZCANO OM, 1994, J BIOL CHEM, V269, P17363; ROTIN D, 1992, EMBO J, V11, P559, DOI 10.1002/j.1460-2075.1992.tb05087.x; RUTLEDGE BJ, 1992, GENE DEV, V6, P1503, DOI 10.1101/gad.6.8.1503; SEGATTO O, 1993, ONCOGENE, V8, P2105; SOLTOFF SP, 1994, MOL CELL BIOL, V14, P3550, DOI 10.1128/MCB.14.6.3550; STEIN D, 1994, EMBO J, V13, P1331, DOI 10.1002/j.1460-2075.1994.tb06386.x; TZAHAR E, 1994, J BIOL CHEM, V269, P25226; VEGA QC, 1992, MOL CELL BIOL, V12, P128, DOI 10.1128/MCB.12.1.128; VOGEL W, 1993, SCIENCE, V259, P1611, DOI 10.1126/science.7681217; WADA T, 1990, CELL, V61, P1339, DOI 10.1016/0092-8674(90)90697-D; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303; YOON CH, 1995, SCIENCE, V269, P1102, DOI 10.1126/science.7652556	61	139	142	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR 7	1996	12	5					1117	1125						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UA884	8649804				2022-12-25	WOS:A1996UA88400021
J	Albright, CD; Liu, R; Bethea, TC; DaCosta, KA; Salganik, RI; Zeisel, SH				Albright, CD; Liu, R; Bethea, TC; DaCosta, KA; Salganik, RI; Zeisel, SH			Choline deficiency induces apoptosis in SV40-immortalized CWSV-1 rat hepatocytes in culture	FASEB JOURNAL			English	Article						p53; hepatocytes; PCNA expression; cell proliferation	TRANSFORMING GROWTH FACTOR-BETA-1; CELL NUCLEAR ANTIGEN; DEVOID DIET; SIMIAN VIRUS-40; T-ANTIGEN; LIVER; DNA; DEATH; INDUCTION; INVITRO	Immortalized CWSV-1 rat hepatocytes, in which p53 protein is inactivated by SV40 large T antigen, had increased numbers of cells with strand breaks in genomic DNA (terminal dUTP end labeling) when grown in 0 mu M choline (67-73% of cells) than when grown in 70 mu M choline (2-3% of cells). Internucleosomal fragmentation of DNA (DNA ladders) was detected in cells grown with 5 mu M and 0 mu M choline for 72 h, Cells treated with 8 or 5 mu M choline for 72 h detached from the substrate in high numbers (58% of choline deficient cells vs, 1.4% of choline sufficient cells detached) exhibited a high incidence of apoptosis (apoptotic bodies were seen in 55-75% of cells; 67-73% had DNA strand breaks), and an absence of mitosis and proliferating cell nuclear antigen (PCNA) expression, Cells undergoing DNA fragmentation had functioning mitochondria, At 24 h, cells grown in 0 or 5 mu M choline synthesized DNA more rapidly than those grown in 70 mu M choline. By 72 h, the cells grown in 0 or 5 mu M choline were forming DNA much more slowly than control cells (assessed by thymidine incorporation, PCNA expression, and mitotic index), Western blot analysis showed that p53 in the nucleus of cells was detected in direct association with SV40 T-antigen, and was therefore likely to be inactive. We conclude that choline deficiency kills CWSV-1 hepatocytes in culture by inducing apoptosis via what may be a p53-independent process, and that this process begins in viable cells before they detach from the culture dish.	UNIV N CAROLINA,DEPT NUTR,CHAPEL HILL,NC 27599	University of North Carolina; University of North Carolina Chapel Hill								ABANOBI SE, 1982, CANCER RES, V42, P412; ALBRIGHT CD, 1990, CELL BIOL TOXICOL, V6, P379, DOI 10.1007/BF00120804; ALBRIGHT CD, 1991, J TISSUE CULTURE MET, V13, P5; ARENDS MJ, 1990, AM J PATHOL, V136, P593; BIES J, 1995, CANCER RES, V55, P501; BRAVO R, 1987, J CELL BIOL, V105, P1549, DOI 10.1083/jcb.105.4.1549; CHANDAR N, 1987, CARCINOGENESIS, V8, P669, DOI 10.1093/carcin/8.5.669; CHANDAR N, 1988, CARCINOGENESIS, V9, P259, DOI 10.1093/carcin/9.2.259; DONALDSON RW, 1992, P NATL ACAD SCI USA, V89, P8477, DOI 10.1073/pnas.89.18.8477; ELDEIRY WS, 1994, CANCER RES, V54, P1169; GEHRING H, 1991, BIOCHEM BIOPH RES CO, V177, P259, DOI 10.1016/0006-291X(91)91976-J; GERSCHENSON LE, 1992, FASEB J, V6, P2450, DOI 10.1096/fasebj.6.7.1563596; GHOSHAL AK, 1984, CARCINOGENESIS, V5, P1367, DOI 10.1093/carcin/5.10.1367; GHOSHAL AK, 1983, AM J PATHOL, V113, P309; GIAMBARRESI LI, 1982, BRIT J CANCER, V46, P825, DOI 10.1038/bjc.1982.278; GRASLKRAUPP B, 1995, HEPATOLOGY, V21, P1465, DOI 10.1016/0270-9139(95)90071-3; GRASLKRAUPP B, 1994, P NATL ACAD SCI USA, V91, P9995, DOI 10.1073/pnas.91.21.9995; JAMES SJ, 1994, CANCER RES, V54, P5508; LANE DP, 1994, PHILOS T ROY SOC B, V345, P277, DOI 10.1098/rstb.1994.0106; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LIN JK, 1992, CANCER RES, V52, P385; LOMBARDI B, 1971, FED PROC, V30, P139; MARTIKAINEN P, 1991, CANCER RES, V51, P4693; MCCARTHY SA, 1994, P NATL ACAD SCI USA, V91, P3979, DOI 10.1073/pnas.91.9.3979; MIETZ JA, 1992, EMBO J, V11, P5013, DOI 10.1002/j.1460-2075.1992.tb05608.x; MURGIA M, 1992, J BIOL CHEM, V267, P10939; NOSSERI C, 1994, EXP CELL RES, V212, P367, DOI 10.1006/excr.1994.1156; OBERHAMMER F, 1991, CANCER RES, V51, P2478; OBERHAMMER FA, 1992, P NATL ACAD SCI USA, V89, P5408, DOI 10.1073/pnas.89.12.5408; ROBBINS SL, 1984, PATHOLOGIC BASIS DIS, P1; RUSHMORE TH, 1986, CARCINOGENESIS, V7, P1677, DOI 10.1093/carcin/7.10.1677; SHINOMIYA N, 1994, EXP CELL RES, V210, P236, DOI 10.1006/excr.1994.1035; SLATER TF, 1963, BIOCHIM BIOPHYS ACTA, V77, P383, DOI 10.1016/0006-3002(63)90513-4; TAN CK, 1986, J BIOL CHEM, V261, P2310; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; UEDA N, 1994, J LAB CLIN MED, V124, P169; *US DEPT HHS, 1988, DHHS PUBL; WASEEM NH, 1990, J CELL SCI, V96, P121; WEISENTHAL LM, 1983, CANCER RES, V43, P258; WIJSMAN JH, 1993, J HISTOCHEM CYTOCHEM, V41, P7, DOI 10.1177/41.1.7678025; WILSON RB, 1973, EXP MOL PATHOL, V18, P357, DOI 10.1016/0014-4800(73)90031-2; WOODWORTH C, 1986, CANCER RES, V46, P4018; WOODWORTH CD, 1987, MOL CELL BIOL, V7, P3740, DOI 10.1128/MCB.7.10.3740; WOODWORTH CD, 1988, MOL CELL BIOL, V8, P4492, DOI 10.1128/MCB.8.10.4492; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0; WYLLIE AH, 1987, INT REV CYTOL S, V17, P755; YAO ZM, 1988, J BIOL CHEM, V263, P2998; YAO ZM, 1989, J BIOL CHEM, V264, P11373; YOKOYAMA S, 1985, CANCER RES, V45, P2834; ZEISEL SH, 1993, FASEB J, V7, P551, DOI 10.1096/fasebj.7.6.8472893; ZEISEL SH, 1994, ANNU REV NUTR, V14, P269, DOI 10.1146/annurev.nu.14.070194.001413; ZEISEL SH, 1990, J NUTR BIOCH, P132	52	91	95	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	MAR	1996	10	4					510	516		10.1096/fasebj.10.4.8647350	http://dx.doi.org/10.1096/fasebj.10.4.8647350			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	UE557	8647350	Green Submitted			2022-12-25	WOS:A1996UE55700015
J	Fowler, GJS; Hunter, CN				Fowler, GJS; Hunter, CN			The synthesis and assembly of functional high and low light LH2 antenna complexes from Rhodopseudomonas palustris in Rhodobacter sphaeroides	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HARVESTING COMPLEX; MUTAGENESIS; ACIDOPHILA; BACTERIA; GENOME; GENES	PHotosynthetic bacteria respond to lowered light intensity by increasing the level of the peripheral light-harvesting (LH2) complex. Several species possess an additional mechanism, responding to variations in light conditions by making different types of LH2 complex. However, the study of these complexes in isolation and in the native membrane environment has not been possible. Therefore two LH2 gene pairs from Rhodopseudomonas palustris, associated, respectively, with high light (pucBa(a)) and low light (pucBA(d)) growth conditions, were expressed in Rhodobacter sphaeroides. The high light LH2 complex PucBA(n) was synthesized at appreciable levels in R. sphaeroides, and near-infrared absorption bands at similar to 800-855 nm, and was able to transfer energy efficiently to the native LH1 complex. In contrast, the low light complex PucBA(d) was found at comparatively low levels, had absorption bands at similar to 797-830 nm, and did not transfer energy to the native LH1 complex efficiently. these observations are discussed in the light of site-directed studies on the R. sphaeroids LH2 complex, and the recently elucidated Rhodopseudomonas acidophila 10050 LH2 structure. Potentially important residues for energy transfer between LH2 and LH1 complexes are identified, as well between LH2 and LH1 complexes are identified, as well as some of the factors that influence stability and assembly of LH2 complexes, such as the N-terminal sequences of their protein sub-units and their carotenoid binding sites.	UNIV SHEFFIELD, DEPT MOLEC BIOL & BIOTECHNOL, KREBS INST, SHEFFIELD S10 2TN, S YORKSHIRE, ENGLAND	University of Sheffield	Fowler, GJS (corresponding author), UNIV SHEFFIELD, DEPT MOLEC BIOL & BIOTECHNOL, ROBERT HILL INST PHOTOSYNTH, SHEFFIELD S10 2TN, S YORKSHIRE, ENGLAND.			Fowler, Gregory/0000-0002-0420-7661				AAGAARD J, 1972, PHOTOCHEM PHOTOBIOL, V15, P209, DOI 10.1111/j.1751-1097.1972.tb06240.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRUNISHOLZ RA, 1992, J PHOTOCH PHOTOBIO B, V15, P113, DOI 10.1016/1011-1344(92)87010-7; Cogdell R., 1993, PHOTOSYNTHETIC REACT, V1, P23; COGDELL RJ, 1983, BIOCHIM BIOPHYS ACTA, V722, P427, DOI 10.1016/0005-2728(83)90058-0; ELDER DJE, 1993, FEMS MICROBIOL LETT, V111, P23; EVANS MB, 1989, THESIS U GLASGOW; FOWLER GJS, 1992, NATURE, V355, P848, DOI 10.1038/355848a0; FOWLER GJS, 1994, BIOCHEM J, V299, P695, DOI 10.1042/bj2990695; FOWLER GJS, 1995, J BIOL CHEM, V270, P23875, DOI 10.1074/jbc.270.40.23875; GARDINER AT, 1993, PHOTOSYNTH RES, V38, P159, DOI 10.1007/BF00146415; GIBSON LCD, 1992, MOL MICROBIOL, V6, P3171, DOI 10.1111/j.1365-2958.1992.tb01773.x; Hawthornthwaite-Lawless A. M., 1991, CHLOROPHYLLS, P493; Hess S, 1995, P NATL ACAD SCI USA, V92, P12333, DOI 10.1073/pnas.92.26.12333; HESS S, 1994, BIOCHEMISTRY-US, V33, P8300, DOI 10.1021/bi00193a017; Hunter C. N., 1995, ANOXYGENIC PHOTOSYNT, V2, P473, DOI DOI 10.1007/0-306-47954-0_22; HUNTER CN, 1988, J GEN MICROBIOL, V134, P1471; HUNTER CN, 1994, J BACTERIOL, V176, P3693; JONES MR, 1992, MOL MICROBIOL, V6, P1173, DOI 10.1111/j.1365-2958.1992.tb01556.x; LANG HP, 1994, BIOCHEM J, V298, P197, DOI 10.1042/bj2980197; MCDERMOTT G, 1995, NATURE, V374, P517, DOI 10.1038/374517a0; OLSEN JD, 1994, P NATL ACAD SCI USA, V91, P7124, DOI 10.1073/pnas.91.15.7124; PAPIZ MZ, 1989, J MOL BIOL, V209, P833, DOI 10.1016/0022-2836(89)90612-8; SIMON R, 1983, BIO-TECHNOL, V1, P784, DOI 10.1038/nbt1183-784; TADROS MH, 1990, FEMS SYMP, V53, P181; TADROS MH, 1993, EUR J BIOCHEM, V217, P867, DOI 10.1111/j.1432-1033.1993.tb18315.x; TADROS MH, 1989, EMBO J, V8, P1303, DOI 10.1002/j.1460-2075.1989.tb03509.x; VANGRONDELLE R, 1994, BBA-BIOENERGETICS, V1187, P1, DOI 10.1016/0005-2728(94)90166-X; VANMOURIK F, 1992, BIOCHIM BIOPHYS ACTA, V1140, P85, DOI 10.1016/0005-2728(92)90023-U	29	13	15	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 7	1996	271	23					13356	13361		10.1074/jbc.271.23.13356	http://dx.doi.org/10.1074/jbc.271.23.13356			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UP385	8662765	hybrid			2022-12-25	WOS:A1996UP38500011
J	Duprez, E; Lillehaug, JR; Naoe, T; Lanotte, M				Duprez, E; Lillehaug, JR; Naoe, T; Lanotte, M			cAMP signalling is decisive for recovery of nuclear bodies (PODs) during maturation of RA-resistant t(15;17) promyelocytic leukemia NB4 cells expressing PML-RAR alpha	ONCOGENE			English	Article						acute promyelocytic leukemia; cAMP; NB4; retinoic acid; nuclear receptors; transcription factors; nuclear bodies; differentiation	ACID RECEPTOR-ALPHA; RETINOIC ACID; TRANSLOCATION; PROTEIN; EXTRACTION; ISOFORMS; GENES; LINE	We analysed the expression of retinoid receptors and PML in relation to the morphology of PML-containing nuclear bodies (PODs) in maturation sensitive (NB4) and resistant subclones (NB4-R1 and R2) of the promyelocytic NB4 cell line, The basal level of RAR alpha, RXR alpha and PML mRNA and protein were roughly the same in the three cell lines, While NB4 and NB4-R1 cells express comparable amounts of PML-RAR alpha mRNA and 120 kDa protein, NB4-R2 cells despite normal mRNA levels the 120 kDa protein was not detectable, In NB4-R2 cells however, two novel PML-related entities of 65 kDa and 85 kDa were detected with a anti-PML antibody, in addition to the two PML isoforms of 78 and 97 kDa found in any NB4 cells, Despite the 120 kDa PML-RAR alpha defect, NB4-R2 cells show micropunctuated nuclear bodies typical of APL cells, Contrasting with NS4 cells, neither NB4-R1 cells which express PML-RAR alpha, nor NB4-R2 cells lacking the 120 kDa PML-RAR alpha reorganised nuclear bodies (PODs) in response to RA, Importantly, in RA-primed NB4-R1 cells, a secondary event triggered by cAMP restored PODs, concomitant to maturation, This indicates that the recovery of nuclear bodies in APL is dissociated from the early action of RA in cell maturation, Finally, the key finding of this work is that cAMP signalling ultimately determines the recovery of nuclear bodies associated to cell maturation.	HOP ST LOUIS,CTR G HAYEN,INSERM U301,F-75010 PARIS,FRANCE; NAGOYA UNIV,SCH MED,NAGOYA,AICHI 466,JAPAN	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Nagoya University			Naoe, Tomoki/I-1888-2012; duprez, estelle a/R-2357-2016					ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; ASCOLI CA, 1991, J CELL BIOL, V112, P785, DOI 10.1083/jcb.112.5.785; BORDEN KLB, 1995, EMBO J, V14, P1532, DOI 10.1002/j.1460-2075.1995.tb07139.x; BORROW J, 1990, SCIENCE, V249, P1577, DOI 10.1126/science.2218500; BRUEL A, 1995, LEUKEMIA, V9, P1173; CHANG KS, 1995, BLOOD, V85, P3646, DOI 10.1182/blood.V85.12.3646.bloodjournal85123646; CHEN A, 1994, BLOOD, V84, P2122, DOI 10.1182/blood.V84.7.2122.bloodjournal8472122; CHEN Z, 1990, LEUKEMIA, V5, P288; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DERMIME S, 1993, BLOOD, V82, P1573; DETHE H, 1991, CELL, V66, P675, DOI 10.1016/0092-8674(91)90113-D; DETHE H, 1990, NATURE, V347, P558, DOI 10.1038/347558a0; DIGMAN JDL, 1983, NUCLEIC ACIDS RES, V11, P1495; Duprez E, 1996, ONCOGENE, V12, P2443; DUPREZ E, 1992, LEUKEMIA, V6, P1281; DYCK JA, 1994, CELL, V76, P333, DOI 10.1016/0092-8674(94)90340-9; FAGIOLI M, 1992, ONCOGENE, V7, P1083; FOULKES NS, 1991, CELL, V64, P739, DOI 10.1016/0092-8674(91)90503-Q; GAUB MP, 1992, EXP CELL RES, V201, P335, DOI 10.1016/0014-4827(92)90282-D; GIANNI M, 1995, BLOOD, V85, P3619, DOI 10.1182/blood.V85.12.3619.bloodjournal85123619; HUANG ME, 1988, BLOOD, V72, P567, DOI 10.1182/blood.V72.2.567.567; HUGGENVIK JI, 1993, MOL ENDOCRINOL, V7, P543, DOI 10.1210/me.7.4.543; KAKIZUKA A, 1991, CELL, V66, P653; KASTNER P, 1992, EMBO J, V11, P629, DOI 10.1002/j.1460-2075.1992.tb05095.x; KOKEN MHM, 1994, EMBO J, V13, P1073, DOI 10.1002/j.1460-2075.1994.tb06356.x; LANOTTE M, 1991, BLOOD, V77, P1082; LAVAU C, 1994, LEUKEMIA, V8, P1615; LEROY P, 1991, EMBO J, V10, P59, DOI 10.1002/j.1460-2075.1991.tb07921.x; MANGELSDORF DJ, 1992, GENE DEV, V6, P329, DOI 10.1101/gad.6.3.329; Maniatis T, 1989, DECONTAMINATION DILU; MONTMINY MR, 1990, TRENDS NEUROSCI, V13, P184, DOI 10.1016/0166-2236(90)90045-C; MU ZM, 1994, MOL CELL BIOL, V14, P6858, DOI 10.1128/MCB.14.10.6858; OLSON IL, 1982, CANCER RES, V42, P3922; ROCHETTEEGLY C, 1994, BIOCHEM BIOPH RES CO, V204, P525, DOI 10.1006/bbrc.1994.2491; ROWLEY JD, 1977, LANCET, V1, P549; RUCHAUD S, 1994, P NATL ACAD SCI USA, V91, P8428, DOI 10.1073/pnas.91.18.8428; WEIS K, 1994, CELL, V76, P345, DOI 10.1016/0092-8674(94)90341-7; ZHU J, 1995, LEUKEMIA, V9, P302	38	40	40	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN 6	1996	12	11					2451	2459						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UQ220	8649787				2022-12-25	WOS:A1996UQ22000024
J	Lippuner, V; Cyert, MS; Gasser, CS				Lippuner, V; Cyert, MS; Gasser, CS			Two classes of plant cDNA clones differentially complement yeast calcineurin mutants and increase salt tolerance of wild-type yeast	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; ARABIDOPSIS-THALIANA; PHOSPHOPROTEIN PHOSPHATASES; IMPORTANT DETERMINANT; TRANSGENIC TOBACCO; SEQUENCE-ANALYSIS; PROTEIN-KINASE; ZINC FINGERS; GENES; EXPRESSION	The salt-sensitive phenotype of yeast cells deficient in the phosphoprotein phosphatase, calcineurin, was used to identify genes from the higher plant Arabidopsis thaliana that complement this phenotype, cDNA clones corresponding to two different sequences, designated STO (salt tolerance) and STZ (salt tolerance zinc finger), were found to increased tolerance of calcineurin mutants and of wild-type yeast to both Li+ and Na+ ions, STZ is related to Cys(2)/His(2)-type zinc-finger proteins found in higher plants, and STO is similar to the Arabidopsis CONSTANS protein in regions that may also be zinc fingers, Although neither protein has sequence similarity to any protein phosphatase, STO was able to at least partially compensate for all tested additional phenotypic effects of calcineurin deficiency, and STZ compensated for a subset of these effects, Salt tolerance produced by STZ appeared to be partially dependent on ENA1/PMR2, a P-type ATPase required for Li+ and Na+ efflux in yeast, whereas the effect of STO on salt tolerance was independent of ENA1/PMR2, STZ and STO were found to be expressed in Arabidopsis roots and leaves, whereas only STO message was detectable in flowers. An apparent increase in the level of STZ mRNA was observed in response NaCl exposure in Arabidopsis seedlings, but the level of STO mRNA was not altered by this treatment.	UNIV CALIF DAVIS,SECT MOL & CELLULAR BIOL,DIV BIOL SCI,DAVIS,CA 95616; STANFORD UNIV,DEPT BIOL SCI,STANFORD,CA 94305	University of California System; University of California Davis; Stanford University				Gasser, Charles/0000-0001-5735-8175; Cyert, Martha/0000-0003-3825-7437	NIGMS NIH HHS [GM-48729] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM048729] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALANI E, 1987, GENETICS, V116, P541, DOI 10.1534/genetics.112.541.test; ARMSTRONG DL, 1989, TRENDS NEUROSCI, V12, P117, DOI 10.1016/0166-2236(89)90168-9; BERG JM, 1990, ANNU REV BIOPHYS BIO, V19, P405; BIERER BE, 1994, LYMPHOCYTE ACTIVATIO, P128; BOEKE JD, 1984, MOL GEN GENET, V197, P345, DOI 10.1007/BF00330984; BORSTPAUWELS GWFH, 1981, BIOCHIM BIOPHYS ACTA, V650, P88, DOI 10.1016/0304-4157(81)90002-2; BREUDER T, 1994, P NATL ACAD SCI USA, V91, P5372, DOI 10.1073/pnas.91.12.5372; CALLIS J, 1990, J BIOL CHEM, V265, P12486; CHEN TC, 1995, J BIOL CHEM, V270, P7750, DOI 10.1074/jbc.270.13.7750; CROUSE GF, 1983, METHOD ENZYMOL, V101, P78; CUNNINGHAM KW, 1994, J CELL BIOL, V124, P351, DOI 10.1083/jcb.124.3.351; CYERT MS, 1992, MOL CELL BIOL, V12, P3460, DOI 10.1128/MCB.12.8.3460; CYERT MS, 1991, P NATL ACAD SCI USA, V88, P7376, DOI 10.1073/pnas.88.16.7376; Dellaporta SL, 1983, PLANT MOL BIOL REP, V1, P19, DOI DOI 10.1007/BF02712670; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; ELBLE R, 1992, BIOTECHNIQUES, V13, P18; ELLEDGE SJ, 1991, P NATL ACAD SCI USA, V88, P1731, DOI 10.1073/pnas.88.5.1731; EVANS RM, 1988, CELL, V52, P1, DOI 10.1016/0092-8674(88)90522-3; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FERRANDO A, 1995, MOL CELL BIOL, V15, P5470; GABER RF, 1988, MOL CELL BIOL, V8, P2848, DOI 10.1128/MCB.8.7.2848; GARCIADEBLAS B, 1993, MOL GEN GENET, V236, P363, DOI 10.1007/BF00277134; GASSER CS, 1988, J BIOL CHEM, V263, P4280; GAXIOLA R, 1992, EMBO J, V11, P3157, DOI 10.1002/j.1460-2075.1992.tb05392.x; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; GLASER HU, 1993, EMBO J, V12, P3105, DOI 10.1002/j.1460-2075.1993.tb05979.x; HARO R, 1991, FEBS LETT, V291, P189, DOI 10.1016/0014-5793(91)81280-L; HOFFMAN CS, 1993, CURRENT PROTOCOLS MO; Innis MA, 1990, PCR PROTOCOLS GUIDE, P3; JACOBS GH, 1992, EMBO J, V11, P4507, DOI 10.1002/j.1460-2075.1992.tb05552.x; KINCAID R, 1993, ADV SEC MESS PHOSPH, V27, P1; KISHOR PBK, 1995, PLANT PHYSIOL, V108, P1387, DOI 10.1104/pp.108.4.1387; KLEE CB, 1988, ADV ENZYMOL RAMB, V61, P149; KRANZ AR, 1987, ARABIDOPSIS INFORMAT, V24; LEHLE FR, 1992, PHYSIOL PLANTARUM, V84, P223, DOI 10.1111/j.1399-3054.1992.tb04657.x; LIEBERMAN DN, 1994, NATURE, V369, P235, DOI 10.1038/369235a0; LIPPUNER V, 1994, J BIOL CHEM, V269, P7863; LIU Y, 1991, MOL GEN GENET, V227, P52, DOI 10.1007/BF00260706; LUAN S, 1993, P NATL ACAD SCI USA, V90, P2202, DOI 10.1073/pnas.90.6.2202; MENDOZA I, 1994, J BIOL CHEM, V269, P8792; MUMBY MC, 1993, PHYSIOL REV, V73, P673, DOI 10.1152/physrev.1993.73.4.673; MURGUIA JR, 1995, SCIENCE, V267, P232; MURPHY BJ, 1993, J BIOL CHEM, V268, P27355; NAKAMURA T, 1993, EMBO J, V12, P4063, DOI 10.1002/j.1460-2075.1993.tb06090.x; PAVIETICH NP, 1991, SCIENCE, V252, P809; POSAS F, 1995, J BIOL CHEM, V270, P13036, DOI 10.1074/jbc.270.22.13036; PUTTERILL J, 1995, CELL, V80, P847, DOI 10.1016/0092-8674(95)90288-0; Quintero FJ, 1996, PLANT CELL, V8, P529, DOI 10.1105/tpc.8.3.529; ROBINSON LC, 1992, P NATL ACAD SCI USA, V89, P28, DOI 10.1073/pnas.89.1.28; ROCHESTER DE, 1986, EMBO J, V5, P451, DOI 10.1002/j.1460-2075.1986.tb04233.x; RUDOLPH HK, 1989, CELL, V58, P133, DOI 10.1016/0092-8674(89)90410-8; SAKAMOTO A, 1993, EUR J BIOCHEM, V217, P1049, DOI 10.1111/j.1432-1033.1993.tb18336.x; SANCHEZGARCIA I, 1994, TRENDS GENET, V10, P315, DOI 10.1016/0168-9525(94)90034-5; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SERRANO R, 1994, CRIT REV PLANT SCI, V13, P121, DOI 10.1080/713608057; Sherman F., 1986, METHODS YEAST GENETI; SIKORSKI RS, 1989, GENETICS, V122, P19; SKALA J, 1991, YEAST, V7, P651, DOI 10.1002/yea.320070614; TAKATSUJI H, 1992, EMBO J, V11, P241, DOI 10.1002/j.1460-2075.1992.tb05047.x; TAKATSUJI H, 1994, PLANT CELL, V6, P947, DOI 10.1105/tpc.6.7.947; TANIDA I, 1995, J BIOL CHEM, V270, P10113, DOI 10.1074/jbc.270.17.10113; TARCZYNSKI MC, 1993, SCIENCE, V259, P508, DOI 10.1126/science.259.5094.508; VALVEKENS D, 1988, P NATL ACAD SCI USA, V85, P5536, DOI 10.1073/pnas.85.15.5536; VIEIRA J, 1987, METHOD ENZYMOL, V153, P3	64	152	207	2	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 31	1996	271	22					12859	12866		10.1074/jbc.271.22.12859	http://dx.doi.org/10.1074/jbc.271.22.12859			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UN474	8662738	hybrid			2022-12-25	WOS:A1996UN47400028
J	Sato, K; Aoto, M; Mori, K; Akasofu, S; Tokmakov, AA; Sahara, S; Fukami, Y				Sato, K; Aoto, M; Mori, K; Akasofu, S; Tokmakov, AA; Sahara, S; Fukami, Y			Purification and characterization of a Src-related p57 protein-tyrosine kinase from Xenopus oocytes - Isolation of an inactive form of the enzyme and its activation and translocation upon fertilization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR RECEPTOR; CELL-DIVISION; GENE-PRODUCT; PHOSPHORYLATION; EXPRESSION; VIRUS; SEQUENCE; LAEVIS; IDENTIFICATION; PP60SRC	In the previous study (Fukami, Y., Sate, K.-I., Ikeda, H., Kamisango, K., Koizumi, K., and Matsuno, T. (1993) J. Biol. Chem. 268, 1132-1140), we found that an antibody termed anti-pepY antibody causes a severalfold activation of bovine brain c-Src. The anti-pepY antibody was raised against a synthetic peptide corresponding to residues 410-428 of chicken c-Src, one of the most conserved regions among the Src family protein-tyrosine kinases. In this study, we have used this antibody as an in vitro activator and purified a c-Src-related protein-tyrosine kinase from the particulate fraction of Xenopus laevis oocytes. A synthetic peptide corresponding to residues 7-26 of fission yeast Cdc2 was used as substrate. Immunoreactivity toward the antibody was also monitored during the purification. The purified kinase displayed a single polypeptide of 57 kDa on SDS-gel electrophoresis and showed a specific activity of 2.37 and 20.1 nmol/min/mg protein in the absence and the presence of the anti-pepY antibody, respectively. The purified enzyme underwent autophosphorylation and phosphorylated actin and the Cdc2 peptide exclusively on tyrosine residues. Specific antibodies against c-Src, Fyn, c-Yes, c-Fgr, Lck, Lyn, Hck, and Blk proteins did not recognize the p57 Xenopus tyrosine kinase. The kinase activity of the Xenopus enzyme was not affected by oocyte maturation but was found to be elevated severalfold upon fertilization. Fertilization also caused a translocation of the activated enzyme from the particulate fraction to the cytosolic fraction. The activation and translocation was observed within 1 min after fertilization. These results suggest a possible involvement of the p57 Xenopus tyrosine kinase in the signal transduction of fertilization.	KOBE UNIV,GRAD SCH SCI & TECHNOL,NADA KU,KOBE 657,JAPAN	Kobe University	Sato, K (corresponding author), KOBE UNIV,BIOSIGNAL RES CTR,MOLEC BIOL LAB,NADA KU,KOBE 657,JAPAN.		SATO, Kan/G-1076-2013					ABASSI YA, 1994, DEV BIOL, V164, P430, DOI 10.1006/dbio.1994.1213; AZUMA K, 1991, J BIOL CHEM, V266, P4831; BARTH LG, 1959, J EMBRYOL EXP MORPH, V7, P210; BISHOP JM, 1983, ANNU REV BIOCHEM, V52, P301, DOI 10.1146/annurev.bi.52.070183.001505; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CASNELLIE JE, 1984, P NATL ACAD SCI-BIOL, V81, P6676, DOI 10.1073/pnas.81.21.6676; CIAPA B, 1991, FEBS LETT, V295, P167, DOI 10.1016/0014-5793(91)81410-A; COOPER JA, 1990, PEPTIDES PROTEIN PHO, P86; FEDER D, 1990, J BIOL CHEM, V265, P8205; FELLER SM, 1992, BIOCHEMISTRY-US, V31, P3044, DOI 10.1021/bi00127a003; FOLTZ KR, 1993, SCIENCE, V259, P1421, DOI 10.1126/science.8383878; FUKAMI Y, 1985, P NATL ACAD SCI USA, V82, P321, DOI 10.1073/pnas.82.2.321; FUKAMI Y, 1993, J BIOL CHEM, V268, P1132; FUKAMI Y, 1986, P NATL ACAD SCI USA, V83, P4190, DOI 10.1073/pnas.83.12.4190; GOULD KL, 1989, NATURE, V342, P39, DOI 10.1038/342039a0; HAINAUT P, 1991, BIOCHEM J, V273, P673, DOI 10.1042/bj2730673; HARLOW E, 1988, ANTIBODIES LAB MANUA, P522; HEDRICK JL, 1991, METHOD CELL BIOL, V36, P231; HESKETH R, 1994, ONCOGENE HDB, P448; HINDLEY J, 1984, GENE, V31, P129, DOI 10.1016/0378-1119(84)90203-8; HUNTER T, 1980, P NATL ACAD SCI-BIOL, V77, P1311, DOI 10.1073/pnas.77.3.1311; HUNTER T, 1986, ENZYMES, V17, P191; ISLAM N, 1994, DNA CELL BIOL, V13, P719, DOI 10.1089/dna.1994.13.719; JONES SD, 1993, DEV GENET, V14, P185, DOI 10.1002/dvg.1020140305; JOVE R, 1987, ANNU REV CELL BIOL, V3, P31, DOI 10.1146/annurev.cellbio.3.1.31; KINSEY WH, 1995, BIOCHEM BIOPH RES CO, V208, P204, DOI 10.1006/bbrc.1995.1324; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LITWIN CME, 1991, J BIOL CHEM, V266, P2557; MALLER JL, 1990, BIOCHEMISTRY-US, V29, P3157, DOI 10.1021/bi00465a001; MOORE KL, 1994, DEV BIOL, V164, P444, DOI 10.1006/dbio.1994.1214; MOORE KL, 1995, DEV BIOL, V168, P1, DOI 10.1006/dbio.1995.1056; MUSCI TJ, 1990, P NATL ACAD SCI USA, V87, P8365, DOI 10.1073/pnas.87.21.8365; MUSTELIN T, 1993, TRENDS BIOCHEM SCI, V18, P215, DOI 10.1016/0968-0004(93)90192-P; OAKLEY BR, 1980, ANAL BIOCHEM, V105, P361, DOI 10.1016/0003-2697(80)90470-4; PEAUCELLIER G, 1988, J BIOL CHEM, V263, P13806; PEAUCELLIER G, 1993, DEV GROWTH DIFFER, V35, P199; SATO K, 1990, BIOCHEM BIOPH RES CO, V171, P1152, DOI 10.1016/0006-291X(90)90805-W; SATO KI, 1995, BIOCHEM BIOPH RES CO, V210, P844, DOI 10.1006/bbrc.1995.1735; SCHARTL M, 1984, DEV BIOL, V105, P415, DOI 10.1016/0012-1606(84)90298-7; SPIVACK JG, 1984, MOL CELL BIOL, V4, P1631, DOI 10.1128/MCB.4.8.1631; STEELE RE, 1989, J BIOL CHEM, V264, P10649; STEELE RE, 1990, ONCOGENE, V5, P369; STEELE RE, 1989, ONCOGENE RES, V1, P223; TAKEYA T, 1983, CELL, V32, P881, DOI 10.1016/0092-8674(83)90073-9; UNGER TF, 1992, MOL CELL BIOL, V12, P5485, DOI 10.1128/MCB.12.12.5485; WATTS JD, 1992, J BIOL CHEM, V267, P901; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303	47	68	68	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 31	1996	271	22					13250	13257		10.1074/jbc.271.22.13250	http://dx.doi.org/10.1074/jbc.271.22.13250			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UN474	8662722	hybrid			2022-12-25	WOS:A1996UN47400087
J	Nicholson, B; McGivan, JD				Nicholson, B; McGivan, JD			Induction of high affinity glutamate transport activity by amino acid deprivation in renal epithelial cells does not involve an increase in the amount of transporter protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYSTEM-A ACTIVITY; LINE NBL-1; RAT-BRAIN; EXPRESSION; LEADS	In renal epithelial cells amino acid deprivation in duces an increase in L-Asp transport with a doubling of the V-max and no change in K-m (4.5 mu M) in a cycloheximide-sensitive process. The induction of sodium-dependent L-aspartate transport was inhibited by single amino acids that are metabolized to produce glutamate but not by those that do not produce glutamate. The transaminase inhibitor aminooxyacetate in glutamine free medium caused a decrease in cell glutamate content and an induction of glutamate transport. In complete medium aminooxyacetate neither decreased cell glutamate nor increased transport activity. These results are consistent with a triggering of induction of transport by low intracellular glutamate concentrations. High affinity glutamate transport in these cells is mediated by the excitatory amino acid carrier 1 (EAAC1) gene product. Western blotting using antibodies to the C-terminal region of EAAC1 showed that there is no increase in the amount of EAAC1 protein on prolonged incubation in amino acid-free medium. Conversely, the induction of high affinity glutamate transport by hyperosmotic shock was accompanied by an increase in EAAC1 protein. It is proposed that low glutamate levels lead to the induction of a putative protein that activates the EAAC1 transporter. A model illustrating such a mechanism is described.			Nicholson, B (corresponding author), UNIV BRISTOL,SCH MED SCI,DEPT BIOCHEM,BRISTOL BS8 1TD,AVON,ENGLAND.				Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ARRIZA JL, 1994, J NEUROSCI, V14, P5559; Bernt E., 1963, METHOD ENZYMAT AN, P384; BOUVIER M, 1992, NATURE, V360, P471, DOI 10.1038/360471a0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CALVO JM, 1994, MICROBIOL REV, V58, P466, DOI 10.1128/MMBR.58.3.466-490.1994; DALLASTA V, 1983, J BIOL CHEM, V258, P6371; DOYLE FA, 1992, BIOCHIM BIOPHYS ACTA, V1104, P55, DOI 10.1016/0005-2736(92)90131-5; FAIRMAN WA, 1995, NATURE, V375, P599, DOI 10.1038/375599a0; FELIPE A, 1992, BIOCHEM J, V284, P577, DOI 10.1042/bj2840577; FERRERMARTINEZ A, 1995, BIOCHEM J, V310, P689, DOI 10.1042/bj3100689; INOUE K, 1995, MOL BRAIN RES, V28, P343, DOI 10.1016/0169-328X(94)00244-9; KANAI Y, 1992, NATURE, V360, P467, DOI 10.1038/360467a0; KILBERG MS, 1985, CURR TOP CELL REGUL, V25, P133; LEE AS, 1987, TRENDS BIOCHEM SCI, V12, P20, DOI 10.1016/0968-0004(87)90011-9; MCGIVAN JD, 1994, BIOCHEM J, V299, P321, DOI 10.1042/bj2990321; MOFFETT J, 1984, MOL CELL BIOL, V4, P799, DOI 10.1128/MCB.4.4.799; NANDAN D, 1990, BIOCHEM CELL BIOL, V68, P1057, DOI 10.1139/o90-156; PEEKHAUS N, 1995, J BACTERIOL, V177, P5140, DOI 10.1128/jb.177.17.5140-5147.1995; PINES G, 1992, NATURE, V360, P464, DOI 10.1038/360464a0; PLAKIDOUDYMOCK S, 1993, BIOCHEM J, V295, P749, DOI 10.1042/bj2950749; ROTHSTEIN JD, 1994, NEURON, V13, P713, DOI 10.1016/0896-6273(94)90038-8; SOLER C, 1993, BIOCHEM J, V289, P653, DOI 10.1042/bj2890653; STORCK T, 1992, P NATL ACAD SCI USA, V89, P10955, DOI 10.1073/pnas.89.22.10955	23	28	30	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 24	1996	271	21					12159	12164		10.1074/jbc.271.21.12159	http://dx.doi.org/10.1074/jbc.271.21.12159			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UL660	8647808	hybrid			2022-12-25	WOS:A1996UL66000010
J	Pratt, JC; Weiss, M; Sieff, CA; Shoelson, SE; Burakoff, SJ; Ravichandran, KS				Pratt, JC; Weiss, M; Sieff, CA; Shoelson, SE; Burakoff, SJ; Ravichandran, KS			Evidence for a physical association between the Shc-PTB domain and the beta(c) chain of the granulocyte-macrophage colony-stimulating factor receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION; ACTIVATION; PROTEIN; INTERLEUKIN-3; REQUIRES; SUBUNIT	Granulocyte-macrophage colony-stimulating factor (GM-CSF) regulates the growth and function of several myeloid cell types at different stages of maturation. The effects of GM-CSF are mediated through a high affinity receptor that is composed of two chains: a unique, ligand-specific alpha chain and a beta common chain (beta(c)) that is also a component of the receptors for interleukin 3 (IL-3) and IL-5, beta(c) plays an essential role in the transduction of extracellular signals to the nucleus through its recruitment of secondary messengers, Several downstream signaling events induced by GM CSF stimulation have been described, including activation of tyrosine kinases and tyrosine phosphorylation of cellular proteins (including beta(c)) and activation of the Ras/mitogen-activated protein kinase and the JAK/STAT pathways, A region within the beta(c) cytoplasmic tail (amino acids 517-763) has been reported to be necessary for tyrosine phosphorylation of the adapter protein, Shc, and for the subsequent GM-CSF-induced activation of Ras, In this paper, we describe a physical association between the tyrosine phosphorylated GM-CSF receptor (GMR)-beta(c) chain and Shc in vivo. Using a series of cytoplasmic truncation mutants of beta(c) and various mutant Shc proteins, we demonstrate that the N-terminal phosphotyrosine-binding (PTB) domain of Shc binds to a short region of beta(c) (amino acids 549-656) that contains Tyr(577). Addition of a specific phosphopeptide encoding amino acids surrounding this tyrosine inhibited the interaction between beta(c) and Shc. Moreover, mutation of a key residue within the phosphotyrosine binding pocket of the Shc-PTB domain abrogated its association with beta(c). These observations provide an explanation for the previously described requirement for Tyr(577) of beta(c) for GM-CSF-induced tyrosine phosphorylation of She and have implications for Ras activation through the GM-CSF, IL-3, and IL-5 receptors.	HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DIV PEDIAT ONCOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT PEDIAT,BOSTON,MA 02115; UNIV MUNICH,CHILDRENS HOSP,DEPT PEDIAT,D-80337 MUNICH,GERMANY; HARVARD UNIV,SCH MED,JOSLIN DIABET CTR,BOSTON,MA 02115	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School; University of Munich; Harvard University; Harvard Medical School; Joslin Diabetes Center, Inc.			Ravichandran, Kattur Soundarapandian/AAG-7319-2019	Ravichandran, Kattur Soundarapandian/0000-0003-2397-461X	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI017258] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-17258] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BATZER AG, 1995, MOL CELL BIOL, V15, P4403; BATZER AG, 1994, MOL CELL BIOL, V14, P5192, DOI 10.1128/MCB.14.8.5192; BLAIKIE P, 1994, J BIOL CHEM, V269, P32031; CONSCIENCE JF, 1986, EMBO J, V5, P317, DOI 10.1002/j.1460-2075.1986.tb04215.x; DIKIC I, 1995, J BIOL CHEM, V270, P15125, DOI 10.1074/jbc.270.25.15125; DORSCH M, 1994, BIOCHEM BIOPH RES CO, V200, P562, DOI 10.1006/bbrc.1994.1485; DURONIO V, 1992, P NATL ACAD SCI USA, V89, P1587, DOI 10.1073/pnas.89.5.1587; Durstin M., 1995, Blood, V86, p257A; EVANS GA, 1995, J BIOL CHEM, V270, P28858, DOI 10.1074/jbc.270.48.28858; INHORN RC, 1995, P NATL ACAD SCI USA, V92, P8665, DOI 10.1073/pnas.92.19.8665; KAVANAUGH WM, 1994, SCIENCE, V266, P1862, DOI 10.1126/science.7527937; MIYAJIMA A, 1993, BLOOD, V82, P1960; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; QUELLE FW, 1994, MOL CELL BIOL, V14, P4335, DOI 10.1128/MCB.14.7.4335; RAVICHANDRAN KS, 1995, MOL CELL BIOL, V15, P593; RAVICHANDRAN KS, 1993, SCIENCE, V262, P902, DOI 10.1126/science.8235613; RAVICHANDRAN KS, 1996, IN PRESS P NATL ACAD; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; SATO N, 1993, EMBO J, V12, P4181, DOI 10.1002/j.1460-2075.1993.tb06102.x; SATOH T, 1991, P NATL ACAD SCI USA, V88, P3314, DOI 10.1073/pnas.88.8.3314; TANAKA M, 1995, MOL CELL BIOL, V15, P6829; TRUB T, 1995, J BIOL CHEM, V270, P18205; VANDERGEER P, 1995, CURR BIOL, V5, P404, DOI 10.1016/S0960-9822(95)00081-9; VANDERGEER P, 1995, TRENDS BIOCHEM SCI, V20, P277, DOI 10.1016/S0968-0004(00)89043-X; Watanabe S., 1995, Blood, V86, p153A; WEISS M, 1993, BLOOD, V82, P3298; WOLF G, 1995, J BIOL CHEM, V270, P27407, DOI 10.1074/jbc.270.46.27407; YOKOTE K, 1994, J BIOL CHEM, V269, P15337; ZHOU MM, 1995, NATURE, V378, P584, DOI 10.1038/378584a0; ZHOU S, 1995, J BIOL CHEM, V270, P14863; ZHUANG HM, 1994, J BIOL CHEM, V269, P21411	32	72	73	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 24	1996	271	21					12137	12140		10.1074/jbc.271.21.12137	http://dx.doi.org/10.1074/jbc.271.21.12137			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UL660	8647804	hybrid			2022-12-25	WOS:A1996UL66000006
J	Bose, S; Feix, J; Seetharam, S; Seetharam, B				Bose, S; Feix, J; Seetharam, S; Seetharam, B			Dimerization of transcobalamin II receptor - Requirement of a structurally ordered lipid bilayer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SARCOPLASMIC-RETICULUM; BASOLATERAL MEMBRANES; PROTEIN INTERACTIONS; HUMAN-PLACENTA; BRUSH-BORDER; CHOLESTEROL; MODEL; BACTERIORHODOPSIN; PHOSPHOLIPIDS; THICKNESS	Transcobalamin II receptor (TC II-R) exists as a monomer and a dimer of molecular masses of 62 and 124 kDa in the microsomal and plasma membranes, respectively, and in vitro, pure TC II-R monomer dimerizes upon insertion into egg PC/cholesterol (molar ratio, 4:1) liposomes (Bose, S., Seetharam, S., and Seetharam, B. (1995) J. Biol. Chem. 270, 8152-8157 and Bose, S., Seetharam, S., Hammond, T., and Seetharam, B. (1995) Biochem. J. 310, 923-929). The current studies were carried out to define the mechanism of TC II-R dimerization. Both the mature TC II-R (62 kDa) and the enzymatically deglycosylated TC II-R (45-47 kDa) demonstrated optimal association and formed dimers of molecular masses of 95 and 124 kDa, respectively, at 22 degrees C when bound to egg PC vesicles containing at least 10 mol % of cholesterol, Mature TC II-R dimerized upon insertion into synthetic phosphatidylcholine vesicles of different fatty acyl chain length (dimyristoyl, dipalmitoyl, and disteroyl phosphatidylcholine) in the absence or the presence of cholesterol at temperatures below or above their transition temperatures, respectively, Dimerization of TC II-R also occurred with vesicles prepared using lipid extract from the plasma but not microsomal membranes, Cholesterol depletion of native intestinal plasma membranes or its enrichment in the microsomal membranes resulted in the in situ conversion of the 124-kDa dimer to the 62-kDa monomer or of the monomer into the dimer form, respectively, Treatment of plasma membranes with phospholipase A(2) resulted in the conversion of the dimer form of the receptor to the monomer form and spin label studies using 1-palmitoyl, 12 doxylsteroyl phosphatidylcholine revealed that interactions of TC II-R with PC vesicles increased order around the probe, Based on these results we suggest that dimerization of TC II-R is mediated by its interactions with a rigid more ordered lipid bilayer membrane, is regulated in plasma membranes by cholesterol levels, and is independent of glycosylation-mediated folding.	MED COLL WISCONSIN,DEPT BIOCHEM,MACC FUND CTR,MILWAUKEE,WI 53226; MED COLL WISCONSIN,DEPT BIOPHYS,MACC FUND CTR,MILWAUKEE,WI 53226; MED COLL WISCONSIN,DEPT MED,MACC FUND CTR,MILWAUKEE,WI 53226; VET ADM MED CTR,MILWAUKEE,WI 53226	Medical College of Wisconsin; Medical College of Wisconsin; Medical College of Wisconsin; US Department of Veterans Affairs; Veterans Health Administration (VHA)				, Santanu/0000-0002-5501-3293	NIDDK NIH HHS [NIDDK-26638] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK026638] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Barlett G.R., 1959, J BIOL CHEM, V234, P466; Bose S, 1996, J BIOL CHEM, V271, P4195; BOSE S, 1995, BIOCHEM J, V310, P923, DOI 10.1042/bj3100923; BOSE S, 1995, J BIOL CHEM, V270, P8152, DOI 10.1074/jbc.270.14.8152; BUSH SF, 1980, BIOCHEMISTRY-US, V19, P4429, DOI 10.1021/bi00560a008; CARLBERG K, 1994, MOL BIOL CELL, V5, P81, DOI 10.1091/mbc.5.1.81; CHAPELLE S, 1983, BIOCHIM BIOPHYS ACTA, V753, P269, DOI 10.1016/0005-2760(83)90017-6; CHAPMAN D, 1975, Q REV BIOPHYS, V8, P185, DOI 10.1017/S0033583500001797; CHAPMAN D, 1979, FEBS LETT, V98, P211, DOI 10.1016/0014-5793(79)80186-6; CORTIJO M, 1982, J MOL BIOL, V157, P597, DOI 10.1016/0022-2836(82)90501-0; COURCHAINE AJ, 1959, CLIN CHEM, V5, P609; CRIADO M, 1984, J BIOL CHEM, V259, P9188; EAST JM, 1984, J BIOL CHEM, V259, P8070; ENGELMAN DM, 1980, P NATL ACAD SCI-BIOL, V77, P5894, DOI 10.1073/pnas.77.10.5894; FONG TM, 1986, BIOCHEMISTRY-US, V25, P830, DOI 10.1021/bi00352a015; GENNIS RB, 1989, BIOMEMBRANES MOL STR, P73; HUANG CH, 1977, LIPIDS, V12, P348, DOI 10.1007/BF02533637; HURWITZ DR, 1991, J BIOL CHEM, V266, P22035; IPSEN JH, 1990, BIOPHYS J, V57, P405, DOI 10.1016/S0006-3495(90)82557-1; JOHANNSSON A, 1981, J BIOL CHEM, V256, P1643; KINNUNEN PKJ, 1991, CHEM PHYS LIPIDS, V57, P375, DOI 10.1016/0009-3084(91)90087-R; LADBROOK.BD, 1968, BIOCHIM BIOPHYS ACTA, V150, P333, DOI 10.1016/0005-2736(68)90132-6; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LINDEMANS J, 1986, SCAND J CLIN LAB INV, V46, P223, DOI 10.3109/00365518609083663; LOW MG, 1980, BIOCHEMISTRY-US, V19, P3913, DOI 10.1021/bi00558a004; MABREY S, 1978, BIOCHEMISTRY-US, V17, P2464, DOI 10.1021/bi00605a034; MOLITORIS BA, 1985, J MEMBRANE BIOL, V83, P207, DOI 10.1007/BF01868695; MOURITSEN OG, 1993, ANNU REV BIOPH BIOM, V22, P145, DOI 10.1146/annurev.bb.22.060193.001045; MOURITSEN OG, 1984, BIOPHYS J, V46, P141, DOI 10.1016/S0006-3495(84)84007-2; NEXO E, 1980, BIOCHIM BIOPHYS ACTA, V628, P190, DOI 10.1016/0304-4165(80)90366-9; OLDFIELD E, 1972, FEBS LETT, V23, P285, DOI 10.1016/0014-5793(72)80300-4; QUADROS EV, 1986, J BIOL CHEM, V261, P5455; SACKMANN E, 1984, BIOL MEMBRANES, V0005, P00105; SANDERMANN H, 1978, BIOCHIM BIOPHYS ACTA, V515, P209, DOI 10.1016/0304-4157(78)90015-1; SEARMARK T, 1987, J MOL ENDOCRINOL, V4, P51; SELIGMAN PA, 1978, J BIOL CHEM, V253, P1766; SHIMSHICK EJ, 1973, BIOCHEMISTRY-US, V12, P2351, DOI 10.1021/bi00736a026; VIST MR, 1990, BIOCHEMISTRY-US, V29, P451, DOI 10.1021/bi00454a021; WALTERS JRF, 1986, GASTROENTEROLOGY, V91, P34, DOI 10.1016/0016-5085(86)90435-X; WORCESTER DL, 1976, J MOL BIOL, V100, P359, DOI 10.1016/S0022-2836(76)80068-X; YOUNGDAHLTURNER P, 1978, J CLIN INVEST, V61, P133, DOI 10.1172/JCI108911	41	27	28	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 17	1996	271	20					11718	11725		10.1074/jbc.271.20.11718	http://dx.doi.org/10.1074/jbc.271.20.11718			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UL250	8662615	hybrid			2022-12-25	WOS:A1996UL25000023
J	Bunting, KD; Townsend, AJ				Bunting, KD; Townsend, AJ			De novo expression of transfected human class 1 aldehyde dehydrogenase (ALDH) causes resistance to oxazaphosphorine anti-cancer alkylating agents in hamster V79 cell lines - Elevated class 1 ALDH activity is closely correlated with reduction in DNA interstrand cross-linking and lethality	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEMATOPOIETIC PROGENITOR CELLS; CYCLOPHOSPHAMIDE; IDENTIFICATION; OXIDATION; ALDOPHOSPHAMIDE; ACROLEIN; 4-HYDROPEROXYCYCLOPHOSPHAMIDE; RETINALDEHYDE; METABOLISM; CATALYZE	Human class 1 aldehyde dehydrogenase (hALDH-1) can oxidize aldophosphamide, a key aldehyde intermediate in the activation pathway of cyclophosphamide and other oxazaphosphorine (GAP) anti-cancer alkylating agents. Overexpression of class 1 ALDH (ALDH-1) has been observed in cells selected for survival in the presence of OAPs. We used transfection to induce de novo expression of human ALDH-1 in V79/SD1 Chinese hamster cells to clearly quantitate the role of hALDH-1 expression in OAF resistance. Messenger RNA levels correlated well with hALDH-1 protein levels and enzyme activities (1.5-13.6 milliunits/mg with propionaldehyde/NAD(+) substrate, compared to < 1 milliunit/mg in controls) in individual clonal transfectant lines, and slot blot analysis confirmed the presence of the transfected cDNA. Expressed ALDH activity was closely correlated (r = 0.99) with resistance to mafosfamide, up to 21-fold relative to controls. Transfectants were cross-resistant to other OAPs but not to phosphoramide mustard, ifosfamide mustard, melphalan, or acrolein. Resistance was completely reversed by pretreatment with 25 mu m diethylaminobenzaldehyde, a potent ALDH inhibitor. Alkaline elution studies showed that expression of ALDH-1 reduced the number of DNA cross-links commensurate with mafosfamide resistance, and this reduction in cross-links was fully reversed by the inhibitor. Thus, overexpression of human class 1 ALDH alone is sufficient to confer GAP-specific drug resistance.	WAKE FOREST UNIV,BOWMAN GRAY SCH MED,DEPT BIOCHEM,CTR COMPREHENS CANC,WINSTON SALEM,NC 27157	Wake Forest University; Wake Forest Baptist Medical Center					NATIONAL CANCER INSTITUTE [P30CA012197] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR004869] Funding Source: NIH RePORTER; NCI NIH HHS [CA-12197] Funding Source: Medline; NCRR NIH HHS [RR-04869] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		ADAMS JD, 1993, FREE RADICAL BIO MED, V15, P187, DOI 10.1016/0891-5849(93)90058-3; BROCK N, 1982, THERAPIEWOCHE, V32, P4975; BUNTING KD, 1994, J BIOL CHEM, V269, P23197; Bunting KD, 1996, J BIOL CHEM, V271, P11891, DOI 10.1074/jbc.271.20.11891; CESARONE CF, 1979, ANAL BIOCHEM, V100, P188, DOI 10.1016/0003-2697(79)90131-3; CHANG TKH, 1993, CANCER RES, V53, P5629; COLVIN M, 1990, CANCER CHEMOTHERAPY, P276; COX PJ, 1979, BIOCHEM PHARMACOL, V28, P2045, DOI 10.1016/0006-2952(79)90222-3; DE GC, 1994, EUR J CANCER, V30, P2137; DEJONG JL, 1988, NUCLEIC ACIDS RES, V16, P8541, DOI 10.1093/nar/16.17.8541; DOCKHAM PA, 1992, BIOCHEM PHARMACOL, V43, P2453, DOI 10.1016/0006-2952(92)90326-E; GORMAN C, 1983, SCIENCE, V221, P551, DOI 10.1126/science.6306768; HILL DL, 1972, CANCER RES, V32, P658; HILTON J, 1984, CANCER RES, V44, P5156; KANO T, 1987, CANCER RES, V47, P5626; KASTAN MB, 1990, BLOOD, V75, P1947; KOHN FR, 1985, BIOCHEM PHARMACOL, V34, P3465, DOI 10.1016/0006-2952(85)90719-1; KOZAK M, 1994, BIOCHIMIE, V76, P815, DOI 10.1016/0300-9084(94)90182-1; LEE MO, 1991, BIOCHEM PHARMACOL, V42, P1279, DOI 10.1016/0006-2952(91)90266-8; LINDAHL R, 1992, CRIT REV BIOCHEM MOL, V27, P283, DOI 10.3109/10409239209082565; LINDAHL R, 1991, BIOCHEM PHARMACOL, V41, P1583, DOI 10.1016/0006-2952(91)90157-Z; MANTHEY CL, 1988, BIOCHEM PHARMACOL, V37, P2781, DOI 10.1016/0006-2952(88)90041-X; MANTHEY CL, 1990, CANCER RES, V50, P4991; MITCHELL DY, 1988, DRUG METAB DISPOS, V16, P37; MOREB J, 1992, CANCER RES, V52, P1770; NIEMEYER U, 1989, PROGR CLIN BIOCH MED, V9, P35; PASLEAU F, 1985, GENE, V38, P227, DOI 10.1016/0378-1119(85)90221-5; REKHA GK, 1994, BIOCHEM PHARMACOL, V48, P1943, DOI 10.1016/0006-2952(94)90593-2; RUSSO J, 1989, ENZYMOLOGY MOL BIOL, V2; SAHOVIC EA, 1988, CANCER RES, V48, P1223; SLADEK N, 1995, P AM ASSOC CANC RES, V35, P325; SLADEK NE, 1991, ADV EXP MED BIOL, V284, P97; SLADEK NE, 1988, PHARMACOL THERAPEUT, V37, P301, DOI 10.1016/0163-7258(88)90004-6; SLADEK NE, 1989, DRUG METAB REV, V20, P697, DOI 10.3109/03602538909103572; SREERAMA L, 1993, BIOCHEM PHARMACOL, V45, P2487, DOI 10.1016/0006-2952(93)90231-K; SREERAMA L, 1994, CANCER RES, V54, P2176; SREERAMA L, 1995, BIOCHEM PHARMACOL, V49, P669, DOI 10.1016/0006-2952(94)00503-E; SREERAMA L, 1993, ADV EXP MED BIOL, V328, P99; TOWNSEND AJ, 1992, MOL PHARMACOL, V41, P230; ZHENG CF, 1993, ALCOHOL CLIN EXP RES, V17, P828, DOI 10.1111/j.1530-0277.1993.tb00849.x	40	55	55	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 17	1996	271	20					11884	11890		10.1074/jbc.271.20.11884	http://dx.doi.org/10.1074/jbc.271.20.11884			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UL250	8662658	hybrid			2022-12-25	WOS:A1996UL25000049
J	Mineo, C; James, GL; Smart, EJ; Anderson, RGW				Mineo, C; James, GL; Smart, EJ; Anderson, RGW			Localization of epidermal growth factor-stimulated Ras/Raf-1 interaction to Caveolae membrane	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR-MEDIATED ENDOCYTOSIS; MA104 CELLS; DEPENDENT ACTIVATION; NUCLEOTIDE EXCHANGE; SIGNAL TRANSDUCTION; RAS; PROTEINS; FOLATE; KINASE; GRB2	An essential step in the epidermal growth factor (EGF)-dependent activation of MAP kinase is the recruitment of Raf-1 to the plasma membrane. Here we present evidence that caveolae are the membrane site where Raf-1 is recruited. Caveolae fractions prepared from normal Rat-1 cells grown in the absence of serum were highly enriched in both EGF receptors and Ras. Thirty seconds after EGF was added to these cells Raf-1 began to appear in caveolae but not in non caveolae membrane fractions. The maximum concentration was reached at 3 min followed by a decline over the next 60 min. During this time EGF receptors disappeared from the caveolae fraction while the concentration of Ras remained constant. The Raf-1 in this fraction was able to phosphorylate MAP kinase kinase, whereas cytoplasmic Raf-1 in the same cell was inactive. Elevation of cellular cAMP blocked the recruitment of Raf-1 to caveolae. Overexpression of Ha-Ras(V12) caused the recruitment of Raf-1 to caveolae independently of EGF stimulation, and this was blocked by the farnesyltransferase inhibitor BZA-5B. Finally, prenylation appeared to be required for localization of Ras to caveolae.	UNIV TEXAS, SW MED CTR, DEPT CELL BIOL, DALLAS, TX 75235 USA; UNIV TEXAS, SW MED CTR, DEPT NEUROSCI & MOL GENET, DALLAS, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas					NHLBI NIH HHS [HL 20948] Funding Source: Medline; NIGMS NIH HHS [GM 43169, GM 15631] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL020948] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM043169, F32GM015631] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AITKEN A, 1995, J BIOL CHEM, V270, P5706, DOI 10.1074/jbc.270.11.5706; ARONHEIM A, 1994, CELL, V78, P949, DOI 10.1016/0092-8674(94)90271-2; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P799; BELLOT F, 1990, J CELL BIOL, V110, P491, DOI 10.1083/jcb.110.2.491; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; BRTVA TR, 1995, J BIOL CHEM, V270, P9809, DOI 10.1074/jbc.270.17.9809; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; CARPENTER G, 1987, ANNU REV BIOCHEM, V56, P881, DOI 10.1146/annurev.biochem.56.1.881; CHANG WJ, 1992, J CELL BIOL, V118, P63, DOI 10.1083/jcb.118.1.63; CHANG WJ, 1994, J CELL BIOL, V126, P127, DOI 10.1083/jcb.126.1.127; COCHET C, 1988, J BIOL CHEM, V263, P3290; COOK SJ, 1993, SCIENCE, V262, P1069, DOI 10.1126/science.7694367; DAVIS RJ, 1988, J BIOL CHEM, V263, P5373; DENT P, 1994, P NATL ACAD SCI USA, V91, P9544, DOI 10.1073/pnas.91.20.9544; DUPREE P, 1993, EMBO J, V12, P1597, DOI 10.1002/j.1460-2075.1993.tb05804.x; ENHENEGOUWEN PMP, 1989, J CELL BIOCHEM, V39, P455; GADELLA TWJ, 1995, J CELL BIOL, V129, P1543, DOI 10.1083/jcb.129.6.1543; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; GOLDSTEIN JL, 1985, ANNU REV CELL BIOL, V1, P1, DOI 10.1146/annurev.cb.01.110185.000245; IRIE K, 1994, SCIENCE, V265, P1716, DOI 10.1126/science.8085159; JAMES GL, 1993, SCIENCE, V260, P1937, DOI 10.1126/science.8316834; JAMES GL, 1994, J BIOL CHEM, V269, P27705; KAMEN BA, 1989, J CLIN INVEST, V84, P1379, DOI 10.1172/JCI114310; KAMEN BA, 1986, P NATL ACAD SCI USA, V83, P5983, DOI 10.1073/pnas.83.16.5983; KAMEN BA, 1988, J BIOL CHEM, V263, P13602; KAMEN BA, 1991, J CLIN INVEST, V87, P1442, DOI 10.1172/JCI115150; KHOSRAVIFAR R, 1994, CANCER METAST REV, V13, P67, DOI 10.1007/BF00690419; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; Lisanti Michael P., 1994, Trends in Cell Biology, V4, P231, DOI 10.1016/0962-8924(94)90114-7; LISANTI MP, 1994, J CELL BIOL, V126, P111, DOI 10.1083/jcb.126.1.111; LIU P, 1994, J BIOL CHEM, V91, P11728; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; NISHIDA E, 1993, TRENDS BIOCHEM SCI, V18, P128, DOI 10.1016/0968-0004(93)90019-J; PALADE GE, 1953, J APPL PHYS, V24, P1424; PETERS KR, 1985, J CELL BIOL, V101, P2233, DOI 10.1083/jcb.101.6.2233; PUMIGLIA K, 1995, MOL CELL BIOL, V15, P398, DOI 10.1128/MCB.15.1.398; RAPOSO G, 1989, EUR J CELL BIOL, V50, P340; RITTER TE, 1995, P NATL ACAD SCI USA, V92, P3824, DOI 10.1073/pnas.92.9.3824; ROETTGER BF, 1995, J CELL BIOL, V128, P1029, DOI 10.1083/jcb.128.6.1029; ROTHBERG KG, 1992, CELL, V68, P673, DOI 10.1016/0092-8674(92)90143-Z; ROTHBERG KG, 1990, J CELL BIOL, V110, P637, DOI 10.1083/jcb.110.3.637; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; SARGIACOMO M, 1993, J CELL BIOL, V122, P789, DOI 10.1083/jcb.122.4.789; SATOH T, 1992, J BIOL CHEM, V267, P24149; SHENOYSCARIA AM, 1994, J CELL BIOL, V126, P353, DOI 10.1083/jcb.126.2.353; SMART EJ, 1995, P NATL ACAD SCI USA, V92, P10104, DOI 10.1073/pnas.92.22.10104; SMART EJ, 1995, J CELL BIOL, V131, P929, DOI 10.1083/jcb.131.4.929; SMART EJ, 1994, J CELL BIOL, V124, P307, DOI 10.1083/jcb.124.3.307; SMITH RM, 1990, ENDOCRINOLOGY, V126, P1551, DOI 10.1210/endo-126-3-1551; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WU J, 1993, SCIENCE, V262, P1065, DOI 10.1126/science.7694366; YAMADA E, 1955, J BIOPHYS BIOCHEM CY, V1, P445, DOI 10.1083/jcb.1.5.445; YARDEN Y, 1987, BIOCHEMISTRY-US, V26, P1443, DOI 10.1021/bi00379a035; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0	58	395	396	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 17	1996	271	20					11930	11935		10.1074/jbc.271.20.11930	http://dx.doi.org/10.1074/jbc.271.20.11930			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UL250	8662667	hybrid			2022-12-25	WOS:A1996UL25000055
J	Novak, S; Hiesberger, T; Schneider, WJ; Nimpf, J				Novak, S; Hiesberger, T; Schneider, WJ; Nimpf, J			A new low density lipoprotein receptor homologue with 8 ligand binding repeats in brain of chicken and mouse	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							APOLIPOPROTEIN-E; LDL-RECEPTOR; DIFFERENT PROTEINS; OOCYTE RECEPTOR; MESSENGER-RNAS; SPECIFICITY; GENE; EXPRESSION; SEQUENCES; DISEASE	The blood-brain barrier necessitates disparate macromolecular transport systems in the brain and central nervous system. We now report the discovery of a new member of the low density lipoprotein receptor (LDLR) family whose expression is highly restricted to the brain. The full-length cDNA specifying the chicken receptor (open reading frame, 2754 base pairs) as well as a cDNA for the major portion of its murine homologue have been obtained, The novel receptor shows the greatest similarity to the group of LDLR relatives with 8 ligand binding repeats, in chicken termed LR8 and in mammals, very low density lipoprotein receptors. Thus, in addition to 8 tandemly arranged ligand binding repeats, the five-domain receptor contains an O-linked sugar region and the internalization signal, Phe-Asp-Asn-Pro-Val-Tyr, typical for all LDLR gene family members, In chicken, the 6.5-kb receptor transcript is present at high levels in brain and at much lower levels in extraoocytic cells of the ovary; in mouse, the same transcript of 6.5 kb was detected in brain, but not in heart (the major site of very low density lipoprotein receptor expression), lung, liver, kidney, and ovary. An antibody directed against the predicted carboxyl terminus of the avian receptor detected a 130-kDa protein in brain extracts. The apparent size of the immunoreactive protein is compatible with extensive glycosylation of the 894-residue mature form of the receptor. The presence of this novel receptor in brain of a bird and a rodent suggests an important and evolutionary conserved function.	BIOCTR,DEPT MOLEC GENET,A-1030 VIENNA,AUSTRIA; UNIV VIENNA,A-1030 VIENNA,AUSTRIA	University of Vienna				Nimpf, Johannes/0000-0002-9273-3492				BARAKAT HA, 1985, J LIPID RES, V26, P1252; BEISIEGEL U, 1981, J BIOL CHEM, V256, P1923; BU GJ, 1995, EMBO J, V14, P2269, DOI 10.1002/j.1460-2075.1995.tb07221.x; BUJO H, 1995, J BIOL CHEM, V270, P23546, DOI 10.1074/jbc.270.40.23546; BUJO H, 1994, EMBO J, V13, P5165, DOI 10.1002/j.1460-2075.1994.tb06847.x; CHEN WJ, 1990, J BIOL CHEM, V265, P3116; DAWSON PA, 1986, J BIOL CHEM, V261, P5681; ELHAMMER AP, 1993, J BIOL CHEM, V268, P10029; FARQUHAR MG, 1995, J AM SOC NEPHROL, V6, P35; FERRARI S, 1987, GENE, V60, P39, DOI 10.1016/0378-1119(87)90211-3; GAFVELS ME, 1994, ENDOCRINOLOGY, V135, P387, DOI 10.1210/en.135.1.387; HAYASHI K, 1989, J BIOL CHEM, V264, P3131; HEIJNE GV, 1983, EUR J BIOCHEM, V133, P17; HERMIER D, 1985, BIOCHIM BIOPHYS ACTA, V836, P105, DOI 10.1016/0005-2760(85)90226-7; HERZ J, 1993, CELL, V73, P428, DOI 10.1016/0092-8674(93)90130-I; HERZ J, 1992, CELL, V71, P411, DOI 10.1016/0092-8674(92)90511-A; HERZ J, 1988, EMBO J, V7, P4119, DOI 10.1002/j.1460-2075.1988.tb03306.x; HERZ J, 1991, J BIOL CHEM, V266, P21232; HIESBERGER T, 1995, J BIOL CHEM, V270, P18219, DOI 10.1074/jbc.270.31.18219; HODITS RA, 1995, J BIOL CHEM, V270, P24078, DOI 10.1074/jbc.270.41.24078; JACOBSEN L, 1995, J BIOL CHEM, V270, P6468, DOI 10.1074/jbc.270.12.6468; Jingami Hisato, 1995, Current Opinion in Lipidology, V6, P104, DOI 10.1097/00041433-199504000-00008; JOKINEN EV, 1994, J BIOL CHEM, V269, P26411; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KRIEGER M, 1994, ANNU REV BIOCHEM, V63, P601, DOI 10.1146/annurev.bi.63.070194.003125; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEBLANC AC, 1989, J CELL BIOL, V109, P1245, DOI 10.1083/jcb.109.3.1245; NIMPF J, 1988, J LIPID RES, V29, P657; NIMPF J, 1994, J BIOL CHEM, V269, P212; PITAS RE, 1987, BIOCHIM BIOPHYS ACTA, V917, P148, DOI 10.1016/0005-2760(87)90295-5; REBECK GW, 1993, NEURON, V11, P575; RUSSELL DW, 1989, J BIOL CHEM, V264, P21682; SAITO A, 1994, P NATL ACAD SCI USA, V91, P9725, DOI 10.1073/pnas.91.21.9725; SCHMECHEL DE, 1993, P NATL ACAD SCI USA, V90, P9649, DOI 10.1073/pnas.90.20.9649; SCHNEIDER WJ, 1989, BIOCHIM BIOPHYS ACTA, V988, P303, DOI 10.1016/0304-4157(89)90023-3; Schneider Wolfgang J., 1993, Current Opinion in Lipidology, V4, P205, DOI 10.1097/00041433-199306000-00005; STEVENS PW, 1987, MOL CELL BIOL, V7, P1751, DOI 10.1128/MCB.7.5.1751; STEYRER E, 1990, J BIOL CHEM, V265, P19575; STIFANI S, 1991, J BIOL CHEM, V266, P19079; STRICKLAND DK, 1995, FASEB J, V9, P890, DOI 10.1096/fasebj.9.10.7615159; SUDHOF TC, 1985, SCIENCE, V228, P815, DOI 10.1126/science.2988123; TAKAHASHI S, 1992, P NATL ACAD SCI USA, V89, P9252, DOI 10.1073/pnas.89.19.9252; Weisgraber Karl H., 1994, Current Opinion in Lipidology, V5, P110, DOI 10.1097/00041433-199404000-00007; WILLNOW TE, 1996, IN PRESS EMBO J; YAMAMOTO T, 1984, CELL, V39, P27, DOI 10.1016/0092-8674(84)90188-0	45	92	95	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 17	1996	271	20					11732	11736		10.1074/jbc.271.20.11732	http://dx.doi.org/10.1074/jbc.271.20.11732			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UL250	8662771	hybrid			2022-12-25	WOS:A1996UL25000025
J	Sapru, MK; Gao, JP; Walke, W; Burmeister, M; Goldman, D				Sapru, MK; Gao, JP; Walke, W; Burmeister, M; Goldman, D			Cloning and characterization of a novel transcriptional repressor of the nicotinic acetylcholine receptor delta-subunit gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUSCLE ELECTRICAL-ACTIVITY; IMMEDIATE EARLY GENE; DNA-BINDING; Y-BOX; MYOGENIC FACTORS; EXPRESSION; PROTEINS; ENHANCER; PROMOTER; MOTIF	We have identified a negative cis-acting regulatory element in the nicotinic acetylcholine receptor delta-subunit gene's promoter. This element resides within a previously identified 47-base pair activity dependent enhancer. Proteins that bind this region of DNA were cloned from a lambda gt11 innervated muscle expression library. Two cDNAs (MY1 and MY1a) were isolated that encode members of the Y-box family of transcription factors. MY1/1a RNAs are expressed at relatively high levels in heart, skeletal muscle, testis, glia, and specific regions of the central nervous system, MY1/1a are nuclear proteins that bind specifically to the coding strand of the 47-base pair enhancer and suppress delta-promoter activity in a sequence-specific manner. These results suggest a novel mechanism of repression by MY1/1a, which may contribute to the low level expression of the delta- subunit gene in innervated muscle. Finally, the gene encoding MY1/1a, Yb2, maps to the mid-distal region of mouse chromosome 6.	UNIV MICHIGAN,MENTAL HLTH RES INST,ANN ARBOR,MI 48109; UNIV MICHIGAN,DEPT BIOL CHEM,ANN ARBOR,MI 48109; UNIV MICHIGAN,DEPT PSYCHIAT & HUMAN GENET,ANN ARBOR,MI 48109	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan			Burmeister, Margit/A-3157-2013	Burmeister, Margit/0000-0002-1914-2434				BEECHEY CV, 1992, MOUSE GENOME, V90, P670; BERBERICH C, 1993, EUR J BIOCHEM, V216, P395, DOI 10.1111/j.1432-1033.1993.tb18157.x; BESSEREAU JL, 1994, P NATL ACAD SCI USA, V91, P1304, DOI 10.1073/pnas.91.4.1304; BESSEREAU JL, 1993, EMBO J, V12, P443, DOI 10.1002/j.1460-2075.1993.tb05676.x; BOSHART M, 1985, CELL, V41, P521, DOI 10.1016/S0092-8674(85)80025-8; BOUVET P, 1994, CELL, V77, P931, DOI 10.1016/0092-8674(94)90141-4; BOUVET P, 1995, J BIOL CHEM, V270, P28297; BRASIER AR, 1989, BIOTECHNIQUES, V7, P1116; CHAHINE KG, 1993, J BIOL CHEM, V268, P2893; CHAHINE KG, 1992, DEVELOPMENT, V115, P213; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DIDIER DK, 1988, P NATL ACAD SCI USA, V85, P7322, DOI 10.1073/pnas.85.19.7322; DIETRICH WF, 1994, NAT GENET, V7, P220, DOI 10.1038/ng0694supp-220; ELLIOTT RW, 1994, MAMM GENOME, V5, pS79; EVANS S, 1987, J BIOL CHEM, V262, P4911; EVDOKIMOVA VM, 1995, J BIOL CHEM, V270, P3186, DOI 10.1074/jbc.270.7.3186; FABER M, 1990, J BIOL CHEM, V265, P22243; GILMOUR BP, 1991, J BIOL CHEM, V266, P19871; GILMOUR BP, 1995, DEV BIOL, V168, P416, DOI 10.1006/dbio.1995.1091; GOLDMAN D, 1991, NEURON, V7, P649, DOI 10.1016/0896-6273(91)90377-C; HALL ZW, 1993, CELL, V72, P99, DOI 10.1016/S0092-8674(05)80031-5; HASAN S, 1994, J BIOL CHEM, V269, P25042; HASTY P, 1993, NATURE, V364, P501, DOI 10.1038/364501a0; HORWITZ EM, 1994, J BIOL CHEM, V269, P14130; ITO K, 1994, NUCLEIC ACIDS RES, V22, P2036, DOI 10.1093/nar/22.11.2036; KHOURY G, 1983, CELL, V33, P313, DOI 10.1016/0092-8674(83)90410-5; KOLLURI R, 1992, NUCLEIC ACIDS RES, V20, P111, DOI 10.1093/nar/20.1.111; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANDSMAN D, 1992, NUCLEIC ACIDS RES, V20, P2861, DOI 10.1093/nar/20.11.2861; LOCK LF, 1994, GENOMICS, V20, P354, DOI 10.1006/geno.1994.1188; MACDONALD GH, 1995, J BIOL CHEM, V270, P3527, DOI 10.1074/jbc.270.8.3527; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MERLIE JP, 1994, J BIOL CHEM, V269, P2461; NEUMANN JR, 1987, BIOTECHNIQUES, V5, P444; OZER J, 1990, J BIOL CHEM, V265, P22143; PRODY CA, 1991, J BIOL CHEM, V266, P22588; ROWE LB, 1994, MAMM GENOME, V5, P253, DOI 10.1007/BF00389540; SACCOMANNO CF, 1992, BIOTECHNIQUES, V13, P847; SAKURA H, 1988, GENE, V73, P499; SAMBROOK J, 1989, MOL CLONING LABORATO, P122; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SPITKOVSKY DD, 1992, NUCLEIC ACIDS RES, V20, P797, DOI 10.1093/nar/20.4.797; SU CT, 1995, FEBS LETT, V366, P131, DOI 10.1016/0014-5793(95)00496-V; TAFURI SR, 1993, J BIOL CHEM, V268, P12213; TAFURI SR, 1992, NEW BIOL, V4, P349; TANG JC, 1994, DEVELOPMENT, V120, P1799; THOMSEN DR, 1984, P NATL ACAD SCI-BIOL, V81, P659, DOI 10.1073/pnas.81.3.659; TING JPY, 1994, J EXP MED, V179, P1605, DOI 10.1084/jem.179.5.1605; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VINSON CR, 1988, GENE DEV, V2, P801, DOI 10.1101/gad.2.7.801; WALKE W, 1994, J BIOL CHEM, V269, P19447; WOLFF JA, 1991, BIOTECHNIQUES, V11, P474; WOLFFE AP, 1992, NEW BIOL, V4, P290	53	19	20	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 22	1996	271	12					7203	7211		10.1074/jbc.271.12.7203	http://dx.doi.org/10.1074/jbc.271.12.7203			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UB157	8636158	hybrid			2022-12-25	WOS:A1996UB15700093
J	CorbalanGarcia, S; Degenhardt, KR; BarSagi, D				CorbalanGarcia, S; Degenhardt, KR; BarSagi, D			Insulin-induced dissociation of Sos from Grb2 does not contribute to the down regulation of Ras activation	ONCOGENE			English	Article						Sos; Grb2; ras; insulin; MAP kinase	GUANINE-NUCLEOTIDE EXCHANGE; RECEPTOR TYROSINE KINASES; EPIDERMAL GROWTH-FACTOR; DEPENDENT ACTIVATION; POLYACRYLAMIDE GELS; PROTEIN; INHIBITION; P21RAS; BINDS; CAMP	Activation of Ras by a number of receptor tyrosine kinases is mediated by the guanine nucleotide exchange factor Sos. This activation is thought to occur as a result of the recruitment to the plasma membrane of a complex consisting of Sos and the adaptor molecule Grb2. Growth factor stimulation has been shown to induce the rapid phosphorylation of Sos on serine and threonine residues. In rat L6 cells, insulin-induced Sos phosphorylation is accompanied by a partial dissociation of the Grb2-Sos complex. In this study we have investigated the relationship between Sos phosphorylation and Grb2 association. To this end, we have utilized cAMP because it has been demonstrated that elevation of cytoplasmic levels of cAMP inhibits growth factor-induced Sos phosphorylation. We show that in rat L6 cells, cAMP treatment prevents both the insulin-stimulated Sos phosphorylation and Grb2 dissociation. However, cAMP treatment has no effect on the duration of insulin-induced Ras activation. These results suggest that the kinetics of Ras activation are independent of the phosphorylation-induced dissociation of Sos from Grb2.	SUNY STONY BROOK, DEPT MOLEC GENET & MICROBIOL, STONY BROOK, NY 11794 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook			Corbalan-Garcia, Senena/C-6477-2009	Corbalan-Garcia, Senena/0000-0003-1840-5578; Bar-Sagi, Dafna/0000-0003-2597-8948	NCI NIH HHS [CA55360] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA055360, R01CA055360] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARONHEIM A, 1994, CELL, V78, P949, DOI 10.1016/0092-8674(94)90271-2; BLATTLER DP, 1972, J CHROMATOGR, V64, P147, DOI 10.1016/S0021-9673(00)92958-3; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BUDAY L, 1993, MOL CELL BIOL, V13, P1903, DOI 10.1128/MCB.13.3.1903; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; BUDAY L, 1995, CELL, V11, P1327; BURGERING BMT, 1993, EMBO J, V12, P4211, DOI 10.1002/j.1460-2075.1993.tb06105.x; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; CHERNIACK AD, 1994, J BIOL CHEM, V269, P4717; CHERNIACK AD, 1995, J BIOL CHEM, V270, P1485, DOI 10.1074/jbc.270.4.1485; COOK SJ, 1993, SCIENCE, V262, P1069, DOI 10.1126/science.7694367; DOWNWARD J, 1992, BIOESSAYS, V14, P177, DOI 10.1002/bies.950140308; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; KARLOVICH CA, 1995, SCIENCE, V268, P576, DOI 10.1126/science.7725106; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MCCOLLAM L, 1995, J BIOL CHEM, V270, P15954, DOI 10.1074/jbc.270.27.15954; MEDEMA RH, 1993, MOL CELL BIOL, V13, P155, DOI 10.1128/MCB.13.1.155; OLIVIER JP, 1993, CELL, V73, P179, DOI 10.1016/0092-8674(93)90170-U; ROZAKISADCOCK M, 1995, ONCOGENE, V11, P1417; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; SCHLESSINGER J, 1994, COLD SPRING HARB SYM, V59, P173, DOI 10.1101/SQB.1994.059.01.021; SHIBUYA EK, 1992, P NATL ACAD SCI USA, V89, P9831, DOI 10.1073/pnas.89.20.9831; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WANG W, 1995, NAT GENET, V10, P294, DOI 10.1038/ng0795-294; WATERS SB, 1995, MOL CELL BIOL, V15, P2791; WU J, 1993, SCIENCE, V262, P1065, DOI 10.1126/science.7694366	28	18	18	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 7	1996	12	5					1063	1068						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UA884	8649797				2022-12-25	WOS:A1996UA88400014
J	Skiba, PJ; Zha, XH; Maxfield, FR; Schissel, SL; Tabas, I				Skiba, PJ; Zha, XH; Maxfield, FR; Schissel, SL; Tabas, I			The distal pathway of lipoprotein-induced cholesterol esterification, but not sphingomyelinase-induced cholesterol esterification, is energy-dependent	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; MOUSE PERITONEAL-MACROPHAGES; ACYL COENZYME-A; COATED PIT FORMATION; HAMSTER OVARY CELLS; PLASMA-MEMBRANE SPHINGOMYELIN; RECEPTOR-MEDIATED ENDOCYTOSIS; INTRACELLULAR-TRANSPORT; CULTURED FIBROBLASTS; POTASSIUM-DEPLETION	The stimulation of the intracellular cholesterol esterification pathway by atherogenic lipoproteins in macrophages is a key step in the development of atheroma foam cells. The esterification pathway can also be stimulated by hydrolysis of cell-surface sphingomyelin by the enzyme sphingomyelinase (SMase). In both cases, intracellular cholesterol transport to the cholesterol esterifying enzyme, acyl-CoA:cholesterol O-acyltransferase (ACAT), is thought to be critical, although the mechanism of cholesterol transport is not known. In this report, we explore two fundamental properties of the cholesterol esterification pathway, namely its dependence on energy and the effect of other treatments that block membrane vesicle trafficking. After the atherogenic lipoprotein, beta-very low density lipoprotein (beta-VLDL), was internalized by macrophages and hydrolyzed in lysosomes, the cells were depleted of energy by treatment with sodium azide and 2-deoxyglucose or by permeabilization. Under these conditions, which allowed equal beta-VLDL-cholesteryl ester hydrolysis, cholesterol esterification was markedly decreased in the energy-depleted cells. This effect was not due to blockage of lysosomal cholesterol export. IN the permeabilized cell system, energy repletion restored beta-VLDL-induced, but not SMase-induced, cholesterol esterification in Chinese hamster ovary cells. Similar experiments were carried out using N-ethylmaleimide, low potassium medium, or inhibitors of phosphatidylinositol 3-kinase, each of which blocks intracellular membrane vesicle trafficking. These treatments also inhibited beta-VLDL-induced, but not SMase-induced, cholesterol esterification. Finally, we show here that SMase treatment of cells leads to an increase in plasma membrane vesiculation that is relatively resistant to energy depletion. In summary, the stimulation of cholesterol esterification by lipoproteins, but not by SMase, is energy-dependent, N-ethylmaleimide-sensitive, and blocked by both low potassium and phosphatidylinositol 3-kinase inhibitors. The affected step or steps are distal to cholesterol export form lysosomes and not due to direct inhibition of the ACAT enzyme. Thus, the mechanisms, involved in lipoprotein-induced versus SMase-induced cholesterol esterification are different, perhaps due to the involvement of energy-dependent vesicular cholesterol transport in the lipoprotein pathway and a novel, energy-independent vesicular transport mechanism in the SMase pathway.	COLUMBIA UNIV COLL PHYS & SURG, DEPT MED, NEW YORK, NY 10032 USA; COLUMBIA UNIV COLL PHYS & SURG, DEPT ANAT & CELL BIOL, NEW YORK, NY 10032 USA; COLUMBIA UNIV COLL PHYS & SURG, DEPT PATHOL, NEW YORK, NY 10032 USA; COLUMBIA UNIV COLL PHYS & SURG, DEPT PHYSIOL, NEW YORK, NY 10032 USA	Columbia University; Columbia University; Columbia University; Columbia University			Maxfield, Fred/M-6747-2019; Maxfield, Fred/A-1718-2011	Maxfield, Fred/0000-0003-4396-8866; 	NHLBI NIH HHS [HL-21006, HL-39703] Funding Source: Medline; NIDDK NIH HHS [DK-27083] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL039703, P50HL021006] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK027083, R37DK027083] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AHNERTHILGER G, 1989, METHOD CELL BIOL, V31, P63; ARCARO A, 1993, BIOCHEM J, V296, P297, DOI 10.1042/bj2960297; BLANCHETTEMACKIE EJ, 1988, P NATL ACAD SCI USA, V85, P8022, DOI 10.1073/pnas.85.21.8022; BRASAEMLE DL, 1990, J LIPID RES, V31, P103; BROWN MS, 1983, ANNU REV BIOCHEM, V52, P223, DOI 10.1146/annurev.bi.52.070183.001255; CARPENTIER JL, 1989, J CELL PHYSIOL, V138, P519, DOI 10.1002/jcp.1041380311; CHANG CCY, 1995, J BIOL CHEM, V270, P29532; CHANG CCY, 1986, BIOCHEMISTRY-US, V25, P1693, DOI 10.1021/bi00355a038; CHATTERJEE S, 1994, J BIOL CHEM, V269, P879; DUNN WA, 1980, J BIOL CHEM, V255, P5971; FUGLER L, 1985, J BIOL CHEM, V260, P4098; FURUCHI T, 1993, J BIOL CHEM, V268, P27345; FUSTER V, 1992, NEW ENGL J MED, V326, P242, DOI 10.1056/NEJM199201233260406; GERRITY RG, 1981, AM J PATHOL, V103, P181; GODAY Y, 1995, J CELL BIOL, V112, P823; GOLDSTEIN JL, 1983, METHOD ENZYMOL, V98, P241; GUPTA AK, 1991, J LIPID RES, V32, P125; HANNUN YA, 1989, SCIENCE, V243, P500, DOI 10.1126/science.2643164; HANSEN SH, 1993, J CELL BIOL, V121, P61, DOI 10.1083/jcb.121.1.61; HARMALA AS, 1993, BIOCHIM BIOPHYS ACTA, V1210, P97, DOI 10.1016/0005-2760(93)90054-D; HARMALA AS, 1994, BBA-LIPID LIPID MET, V1211, P317, DOI 10.1016/0005-2760(94)90156-2; KAPLAN MR, 1985, J CELL BIOL, V101, P446, DOI 10.1083/jcb.101.2.446; KAWAGUCHI A, 1981, J BIOCHEM-TOKYO, V89, P337, DOI 10.1093/oxfordjournals.jbchem.a133207; KOLESNICK RN, 1991, PROG LIPID RES, V30, P1, DOI 10.1016/0163-7827(91)90005-P; LABARCA C, 1980, ANAL BIOCHEM, V102, P344, DOI 10.1016/0003-2697(80)90165-7; LANGE Y, 1995, J LIPID RES, V36, P1092; LANGE Y, 1993, J BIOL CHEM, V268, P13838; LANGE Y, 1994, J BIOL CHEM, V269, P3411; LANGE Y, 1979, BIOCHIM BIOPHYS ACTA, V556, P388, DOI 10.1016/0005-2736(79)90127-5; LARKIN JM, 1983, CELL, V33, P273, DOI 10.1016/0092-8674(83)90356-2; LENHARD JM, 1992, J BIOL CHEM, V267, P1896; LI GP, 1995, P NATL ACAD SCI USA, V92, P10207, DOI 10.1073/pnas.92.22.10207; Libby Peter, 1993, Current Opinion in Lipidology, V4, P355, DOI 10.1097/00041433-199310000-00003; LIN HC, 1991, J CELL BIOL, V114, P881, DOI 10.1083/jcb.114.5.881; LISCUM L, 1992, J LIPID RES, V33, P1239; LISCUM L, 1990, BIOCHIM BIOPHYS ACTA, V1045, P40, DOI 10.1016/0005-2760(90)90201-8; LISCUM L, 1989, J BIOL CHEM, V264, P11796; MYERS JN, 1993, J CELL BIOL, V123, P1389, DOI 10.1083/jcb.123.6.1389; NAGAWA Y, 1979, BIOCHIM BIOPHYS ACTA, V553, P307; ODA H, 1995, J BIOL CHEM, V270, P15242, DOI 10.1074/jbc.270.25.15242; PODBILEWICZ B, 1990, EMBO J, V9, P3477, DOI 10.1002/j.1460-2075.1990.tb07556.x; PORN MI, 1995, BIOCHEM J, V308, P269; RODMAN J, 1994, ANN NY ACAD SCI, V733, P203, DOI 10.1111/j.1749-6632.1994.tb17270.x; ROSS AC, 1984, J BIOL CHEM, V259, P815; SARRIA AJ, 1992, J BIOL CHEM, V267, P19455; SCHAFFNER T, 1980, AM J PATHOL, V100, P57; SCHISSEL SL, 1995, BIOCHEMISTRY-US, V34, P10463, DOI 10.1021/bi00033a019; SCHMID SL, 1991, J CELL BIOL, V114, P869, DOI 10.1083/jcb.114.5.869; Skoufias DA, 1993, CURR OPIN CELL BIOL, V5, P95, DOI 10.1016/S0955-0674(05)80014-6; SLOTTE JP, 1988, BIOCHEM J, V250, P653, DOI 10.1042/bj2500653; SMITH JD, 1995, P NATL ACAD SCI USA, V92, P8264, DOI 10.1073/pnas.92.18.8264; STEVENS VL, 1986, BIOCHEMISTRY-US, V25, P4287, DOI 10.1021/bi00363a017; TABAS I, 1991, J CELL BIOL, V115, P1547, DOI 10.1083/jcb.115.6.1547; TABAS I, 1987, J BIOL CHEM, V262, P12175; TABAS I, 1988, J BIOL CHEM, V263, P1266; TABAS I, 1990, J CELL BIOL, V111, P929, DOI 10.1083/jcb.111.3.929; TABAS I, 1994, J BIOL CHEM, V269, P22547; TABAS I, 1995, CURR OPIN LIPIDOL, V6, P260, DOI 10.1097/00041433-199510000-00004; van Meer G, 1993, CURR OPIN CELL BIOL, V5, P661, DOI 10.1016/0955-0674(93)90137-F; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; WANG HX, 1994, CIRCULATION, V90, P351; WATTENBERG BW, 1983, J BIOL CHEM, V258, P2284; WHITEHEART SW, 1994, J CELL BIOL, V126, P945, DOI 10.1083/jcb.126.4.945; WIEGMANN K, 1994, CELL, V78, P1005, DOI 10.1016/0092-8674(94)90275-5	65	51	52	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 7	1996	271	23					13392	13400		10.1074/jbc.271.23.13392	http://dx.doi.org/10.1074/jbc.271.23.13392			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UP385	8662777				2022-12-25	WOS:A1996UP38500016
J	Ito, M; Komori, H				Ito, M; Komori, H			Homeostasis of cell-surface glycosphingolipid content in B16 melanoma cells - Evidence revealed by an endoglycoceramidase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CERAMIDE-GLYCANASE; PLASMA-MEMBRANE; SPHINGOSINE; OLIGOSACCHARIDE; SPHINGOMYELIN; PROLIFERATION; PURIFICATION; HYDROLYSIS; ACTIVATOR; PATHWAY	This paper describes the homeostasis of glycosphingolipid (GSL) on the cell surface as revealed for the first time by an application of endoglycoceramidase (EGCase) capable of hydrolyzing the linkage between the oligosaccharide and the ceramide of various GSLs. When cell-surface GSLs of B16 melanoma cells were hydrolyzed by the action of EGCase, the synthesis of GSLs was found to increase transiently, possibly due to the activation of UDP-glucose:ceramide glucosyltransferase. As a result, the cell-surface GSL content was restored quickly to exactly the same level found without the EGCase treatment, if EGCase was removed from the cell culture. Treatment of erythrocytes with EGCase was found to increase the ceramide content of the plasma membrane. Surprisingly, however, in B16 cells the increase of membrane ceramide by EGCase caused the suppression of de novo ceramide production, resulting in maintenance of the ceramide content of B16 cells at the same level even after EGCase treatment. The signal for homeostatic regulation could be the ceramide released by the action of EGCase, since C-2-ceramide was found to mimic in part the action of EGCase; it suppressed de novo production of ceramide and was directly converted to GSL, NeuAc alpha 2,3Gal beta 1,4Glc beta 1,1 N-acetylsphingosine (C-2-ceramide GM(3)). Our finding demonstrates a novel form of homeostatic regulation coupled to the GSL-synthesizing system in mammalian cells for maintaining the contents of both cell-surface GSLs and free ceramide. Since many opportunistic pathogens were found to produce EGCase extracellularly, this restoration mechanism could also be present as a defense mechanism against microbial EGCase.	MITSUBISHI KASEI INST LIFE SCI,MACHIDA,TOKYO 194,JAPAN		Ito, M (corresponding author), KYUSHU UNIV,FAC AGR,MARINE BIOCHEM LAB,HIGASHI KU,6-10-1 HAKOZAKI,FUKUOKA 812,JAPAN.			ito, Makoto/0000-0003-3159-7818				ASIDA H, 1992, EUR J BIOCHEM, V205, P729; BASU M, 1995, GLYCOCONJUGATE J, V12, P439; BASU S, 1990, INDIAN J BIOCHEM BIO, V27, P386; BASU SS, 1994, ANAL BIOCHEM, V222, P270, DOI 10.1006/abio.1994.1484; CHEN CS, 1995, J BIOL CHEM, V270, P13291, DOI 10.1074/jbc.270.22.13291; DRESSLER KA, 1990, J BIOL CHEM, V265, P14917; HAKOMORI S, 1985, CANCER RES, V45, P2405; HAKOMORI SI, 1981, ANNU REV BIOCHEM, V50, P733, DOI 10.1146/annurev.bi.50.070181.003505; HANNUN YA, 1994, J BIOL CHEM, V269, P3125; HIRABAYASHI Y, 1985, J BIOL CHEM, V260, P3328; IGARASHI Y, 1990, J BIOL CHEM, V265, P5385; ITO M, 1991, J BIOL CHEM, V266, P7919; ITO M, 1986, J BIOL CHEM, V261, P14278; ITO M, 1989, J BIOL CHEM, V264, P9510; ITO M, 1993, EUR J BIOCHEM, V218, P645, DOI 10.1111/j.1432-1033.1993.tb18418.x; ITO M, 1993, EUR J BIOCHEM, V218, P637, DOI 10.1111/j.1432-1033.1993.tb18417.x; ITO M, 1991, J BIOCHEM-TOKYO, V110, P328, DOI 10.1093/oxfordjournals.jbchem.a123580; JAYADEV S, 1995, J BIOL CHEM, V270, P2047, DOI 10.1074/jbc.270.5.2047; JI L, 1995, FEBS LETT, V358, P211, DOI 10.1016/0014-5793(94)01428-4; JI L, 1995, GLYCOBIOLOGY, V5, P343, DOI 10.1093/glycob/5.3.343; KOK JW, 1989, P NATL ACAD SCI USA, V86, P9896, DOI 10.1073/pnas.86.24.9896; KOMORI H, 1995, FEBS LETT, V374, P299, DOI 10.1016/0014-5793(95)01137-4; KOVAL M, 1989, J CELL BIOL, V108, P2169, DOI 10.1083/jcb.108.6.2169; LI SC, 1986, BIOCHEM BIOPH RES CO, V141, P346, DOI 10.1016/S0006-291X(86)80375-8; LI YT, 1987, BIOCHEM BIOPH RES CO, V149, P167, DOI 10.1016/0006-291X(87)91619-6; MIKAWA T, 1987, MITSUBISHI CHEM R D, V1, P34; MURAMOTO K, 1994, BIOCHEM BIOPH RES CO, V202, P398, DOI 10.1006/bbrc.1994.1941; OBEID LM, 1993, SCIENCE, V259, P1769, DOI 10.1126/science.8456305; OKAZAKI T, 1990, J BIOL CHEM, V265, P15823; OLIVERA A, 1993, NATURE, V365, P557, DOI 10.1038/365557a0; RADIN NS, 1991, TRENDS GLYCOSCI GLYC, V3, P200; SLIFE CW, 1989, J BIOL CHEM, V264, P10371; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; STRUM JC, 1995, J BIOL CHEM, V270, P13541, DOI 10.1074/jbc.270.22.13541; YAGER JA, 1991, VET MICROBIOL, V28, P363, DOI 10.1016/0378-1135(91)90071-M; ZHANG H, 1990, J BIOL CHEM, V265, P76	36	26	26	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 24	1996	271	21					12655	12660		10.1074/jbc.271.21.12655	http://dx.doi.org/10.1074/jbc.271.21.12655			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UL660	8647878	hybrid			2022-12-25	WOS:A1996UL66000080
J	Maas, S; Melcher, T; Herb, A; Seeburg, PH; Keller, W; Krause, S; Higuchi, M; OConnell, MA				Maas, S; Melcher, T; Herb, A; Seeburg, PH; Keller, W; Krause, S; Higuchi, M; OConnell, MA			Structural requirements for RNA editing in glutamate receptor pre-mRNAs by recombinant double-stranded RNA adenosine deaminase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHANNELS; CELLS	Pre-mRNAs for brain expressed ionotropic glutamate receptor subunits undergo RNA editing by site-specific adenosine deamination, which alters codons for molecular determinants of channel function. This nuclear process requires double-stranded RNA structures formed by exonic and intronic sequences in the pre-mRNA and is likely to be catalyzed by an adenosine deaminase that recognizes these structures as a substrate, DRADA, a double-stranded RNA adenosine deaminase, is a candidate enzyme for L-glutamate-activated receptor channel (GluR) pre-mRNA editing. We show here that DRADA indeed edits GluR pre-mRNAs, but that it displays selectivity for certain editing sites, Recombinantly expressed DRADA, both in its full-length form and in an N-terminally truncated version, edited the Q/R site in GluR6 pre-mRNA and the R/G site but not the Q/R site of GluR-B pre-mRNA, This substrate selectivity correlated with the base pairing status and sequence environment of the editing-targeted adenosines. The Q/R site of GluR-B pre-mRNA was edited by an activity partially purified from HeLa cells and thus differently structured editing sites in GluR pre-mRNAs appear to be substrates for different enzymatic activities.	UNIV HEIDELBERG,CTR MOLEC BIOL,LAB MOL NEUROENDOCRINOL,D-69120 HEIDELBERG,GERMANY; UNIV BASEL,DEPT CELL BIOL,BIOZENTRUM,CH-4056 BASEL,SWITZERLAND	Ruprecht Karls University Heidelberg; University of Basel			OConnell, Mary Anne/G-4740-2015; Krause, Sabine/AAJ-1163-2020; O'Connell, Mary Anne/U-7693-2019	OConnell, Mary Anne/0000-0003-3844-6174; Krause, Sabine/0000-0002-3141-886X; O'Connell, Mary Anne/0000-0003-3844-6174				BASS BL, 1995, CURR BIOL, V5, P598, DOI 10.1016/S0960-9822(95)00119-9; BASS BL, 1987, CELL, V48, P607, DOI 10.1016/0092-8674(87)90239-X; BERNARD A, 1994, J NEUROCHEM, V62, P2057, DOI 10.1046/j.1471-4159.1994.62052057.x; BRUSA R, 1995, SCIENCE, V270, P1677, DOI 10.1126/science.270.5242.1677; BYCROFT M, 1995, EMBO J, V14, P3563, DOI 10.1002/j.1460-2075.1995.tb07362.x; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Dabiri GA, 1996, EMBO J, V15, P34, DOI 10.1002/j.1460-2075.1996.tb00331.x; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; GEIGER JRP, 1995, NEURON, V15, P193, DOI 10.1016/0896-6273(95)90076-4; Herb A, 1996, P NATL ACAD SCI USA, V93, P1875, DOI 10.1073/pnas.93.5.1875; HERSCHLAG D, 1995, J BIOL CHEM, V270, P20871, DOI 10.1074/jbc.270.36.20871; HIGUCHI M, 1993, CELL, V75, P1361, DOI 10.1016/0092-8674(93)90622-W; HOLLMANN M, 1994, ANNU REV NEUROSCI, V17, P31, DOI 10.1146/annurev.ne.17.030194.000335; HOUGH RF, 1994, J BIOL CHEM, V269, P9933; JONAS P, 1995, NEURON, V15, P987, DOI 10.1016/0896-6273(95)90087-X; KHARRAT A, 1995, EMBO J, V14, P3572, DOI 10.1002/j.1460-2075.1995.tb07363.x; Kim U, 1993, Semin Cell Biol, V4, P285, DOI 10.1006/scel.1993.1034; KIM U, 1994, J BIOL CHEM, V269, P13480; KIM U, 1994, P NATL ACAD SCI USA, V91, P11457, DOI 10.1073/pnas.91.24.11457; KOHLER M, 1993, NEURON, V10, P491, DOI 10.1016/0896-6273(93)90336-P; LAI F, 1995, J BIOL CHEM, V270, P17098, DOI 10.1074/jbc.270.29.17098; LOMELI H, 1994, SCIENCE, V266, P1709, DOI 10.1126/science.7992055; MELCHER T, 1995, J BIOL CHEM, V270, P8566, DOI 10.1074/jbc.270.15.8566; Melcher T, 1996, NATURE, V379, P460, DOI 10.1038/379460a0; OCONNELL MA, 1994, P NATL ACAD SCI USA, V91, P10596, DOI 10.1073/pnas.91.22.10596; OCONNELL MA, 1995, MOL CELL BIOL, V15, P1389; PASCHEN W, 1994, J NEUROCHEM, V63, P1596, DOI 10.1046/j.1471-4159.1994.63051596.x; POLSON AG, 1994, EMBO J, V13, P5701, DOI 10.1002/j.1460-2075.1994.tb06908.x; RUETER SM, 1995, SCIENCE, V267, P1491, DOI 10.1126/science.7878468; SACCOMANNO L, 1994, MOL CELL BIOL, V14, P5425, DOI 10.1128/MCB.14.8.5425; SCHALL TJ, 1990, CELL, V61, P361, DOI 10.1016/0092-8674(90)90816-W; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SCOTT J, 1995, CELL, V81, P833, DOI 10.1016/0092-8674(95)90002-0; Seeburg PH, 1996, J NEUROCHEM, V66, P1; SHARMEEN L, 1991, P NATL ACAD SCI USA, V88, P8096, DOI 10.1073/pnas.88.18.8096; SOMMER B, 1991, CELL, V67, P11, DOI 10.1016/0092-8674(91)90568-J; WAGNER RW, 1990, MOL CELL BIOL, V10, P5586, DOI 10.1128/MCB.10.10.5586; WEEKS KM, 1993, SCIENCE, V261, P1574, DOI 10.1126/science.7690496; YANG JH, 1995, NATURE, V374, P77, DOI 10.1038/374077a0	39	117	120	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 24	1996	271	21					12221	12226		10.1074/jbc.271.21.12221	http://dx.doi.org/10.1074/jbc.271.21.12221			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UL660	8647818	hybrid			2022-12-25	WOS:A1996UL66000020
J	Williams, JP; Blair, HC; McKenna, MA; Jordan, SE; McDonald, JM				Williams, JP; Blair, HC; McKenna, MA; Jordan, SE; McDonald, JM			Regulation of avian osteoclastic H+-ATPase and bone resorption by tamoxifen and calmodulin antagonists - Effects independent of steroid receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BREAST-CANCER; ESTROGEN-RECEPTOR; PHOSPHODIESTERASE; CELLS; ANTIESTROGENS; MEMBRANE; WOMEN; ACID	We used highly purified avian osteoclasts and isolated membranes from osteoclasts to study effects of tamoxifen, 4-hydroxytamoxifen, calmodulin antagonists, estrogen, diethylstilbestrol, and the anti-estrogen ICI 182780 on cellular degradation of H-3-labeled bone in vitro and on membrane HCl transport. Bone resorption was reversibly inhibited by tamoxifen, 4-hydroxytamoxifen, and trifluoperazine with IC50 values of similar to 1 mu M. Diethylstilbestrol and 17-beta-estradiol had no effects on bone resorption at receptor-saturating concentrations, while ICI 182780 inhibited bone resorption at concentrations greater than 1 mu M. At these concentrations ICI 182780, like tamoxifen, inhibits calmodulin stimulated cyclic nucleotide phosphodiesterase activity. Membrane HCl transport, assessed by ATP-dependent acridine orange uptake, was unaffected by 17-beta-estradiol and diethylstilbestrol at concentrations up to 10 mu M, while ICI 182780 inhibited HCl transport at concentrations greater than 1 mu M. In contrast HCl transport was inhibited by tamoxifen, 4-hydroxytamoxifen, and the calmodulin antagonists, trifluoperazine and calmidazolium, with IC50 values of 0.25-1.5 mu M. These results suggested the presence of a membrane-associated non steroid receptor for tamoxifen in osteoclasts. Tamoxifen binding studies demonstrated saturable binding in the osteoclast particulate fraction, but not in the nuclear or cytosolic fractions. Membranes enriched in ruffled border by differential centrifugation following nitrogen cavitation showed binding consistent with one site, K-d similar to 1 mu M. Our findings indicate that tamoxifen inhibits osteoclastic HCl transport by binding membrane-associated target(s), probably similar or related to calmodulin antagonist targets. Further, effects of estrogens or highly specific anti-estrogens on bone turnover do not support the hypothesis of a direct effect on osteoclasts by these compounds in this species.	UNIV ALABAMA,DEPT PATHOL,BIRMINGHAM,AL 35294; VET AFFAIRS MED CTR,LAB SERV,BIRMINGHAM,AL 35294	University of Alabama System; University of Alabama Birmingham; US Department of Veterans Affairs; Veterans Health Administration (VHA)					NIAMS NIH HHS [AR43225] Funding Source: Medline; NIA NIH HHS [AG12951] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR043225] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG012951] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ALVAREZ JI, 1991, ENDOCRINOLOGY, V128, P2324, DOI 10.1210/endo-128-5-2324; BEKKER PJ, 1990, J BONE MINER RES, V5, P557; BLAIR HC, 1989, SCIENCE, V245, P855, DOI 10.1126/science.2528207; BLAIR HC, 1986, J CELL BIOL, V102, P1164, DOI 10.1083/jcb.102.4.1164; BLAIR HC, 1991, AM J PHYSIOL, V260, pC1315, DOI 10.1152/ajpcell.1991.260.6.C1315; BLAIR HC, 1993, CLIN ORTHOP RELAT R, V294, P7; BOUHOUTE A, 1995, BIOCHEM BIOPH RES CO, V208, P748, DOI 10.1006/bbrc.1995.1401; BOUHOUTE A, 1992, BIOCHEM BIOPH RES CO, V184, P1432, DOI 10.1016/S0006-291X(05)80043-9; BOUHOUTE A, 1994, BIOCHEM PHARMACOL, V47, P748, DOI 10.1016/0006-2952(94)90140-6; BRUBAKER KD, 1994, BIOCHEM BIOPH RES CO, V200, P899, DOI 10.1006/bbrc.1994.1535; CARANO A, 1993, AM J PHYSIOL, V264, pC694, DOI 10.1152/ajpcell.1993.264.3.C694; CARR BR, 1992, WILLIAMS TXB ENDOCRI, P733; DAUVOIS S, 1993, J CELL SCI, V106, P1377; FANIDI A, 1989, ENDOCRINOLOGY, V125, P1187, DOI 10.1210/endo-125-3-1187; JOHNSON JD, 1987, ANAL BIOCHEM, V162, P291, DOI 10.1016/0003-2697(87)90039-X; LAM HYP, 1984, BIOCHEM BIOPH RES CO, V118, P27, DOI 10.1016/0006-291X(84)91062-3; LERNER LJ, 1990, CANCER RES, V50, P4177; LIPPMAN SM, 1993, CANCER, V72, P984, DOI 10.1002/1097-0142(19930801)72:3+<984::AID-CNCR2820721306>3.0.CO;2-0; LISKOVA M, 1976, CALC TISS RES, V22, P207; LOVE RR, 1992, NEW ENGL J MED, V326, P852, DOI 10.1056/NEJM199203263261302; LYMAN SD, 1985, BIOCHEM PHARMACOL, V34, P2221, DOI 10.1016/0006-2952(85)90425-3; MANOLAGAS SC, 1995, NEW ENGL J MED, V332, P305, DOI 10.1056/NEJM199502023320506; MIYAUCHI A, 1991, J BIOL CHEM, V266, P20369; OURSLER MJ, 1991, P NATL ACAD SCI USA, V88, P6613, DOI 10.1073/pnas.88.15.6613; OURSLER MJ, 1985, J CELL BIOL, V100, P1592, DOI 10.1083/jcb.100.5.1592; PASSERI G, 1993, ENDOCRINOLOGY, V133, P822, DOI 10.1210/en.133.2.822; RADDING W, 1994, J CELL PHYSIOL, V160, P17, DOI 10.1002/jcp.1041600104; SILVER IA, 1988, EXP CELL RES, V175, P266, DOI 10.1016/0014-4827(88)90191-7; TOBIAS JH, 1991, ACTA ENDOCRINOL-COP, V124, P121, DOI 10.1530/acta.0.1240121; TURNER RT, 1988, ENDOCRINOLOGY, V122, P1146, DOI 10.1210/endo-122-3-1146; VEIGL ML, 1989, PHARMACOL THERAPEUT, V44, P181, DOI 10.1016/0163-7258(89)90066-1; WILLIAMS JP, 1994, ARCH BIOCHEM BIOPHYS, V315, P119, DOI 10.1006/abbi.1994.1479; WRIGHT CDP, 1994, J BONE MINER RES, V9, P153; WRIGHT CDP, 1993, BRIT MED J, V306, P429, DOI 10.1136/bmj.306.6875.429-a	34	40	40	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 24	1996	271	21					12488	12495		10.1074/jbc.271.21.12488	http://dx.doi.org/10.1074/jbc.271.21.12488			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UL660	8647856	hybrid			2022-12-25	WOS:A1996UL66000058
J	Bunting, KD; Townsend, AJ				Bunting, KD; Townsend, AJ			Protection by transfected rat or human class 3 aldehyde dehydrogenases against the cytotoxic effects of oxazaphosphorine alkylating agents in hamster V79 cell lines - Demonstration of aldophosphamide metabolism by the human cytosolic class 3 isozyme	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESISTANT L1210 CELLS; CYCLOPHOSPHAMIDE; IDENTIFICATION; EXPRESSION; OXIDATION; RETINALDEHYDE; LEUKEMIA; CATALYZE; ACID; CDNA	Expression of class 3 aldehyde dehydrogenase (ALDH-3) has been associated with acquired or inherent resistance to oxazaphosphorine (OAP) antineoplastic alkylating agents (e.g. cyclophosphamide). We previously demonstrated that expression of transfected rat ALDH-3 can confer GAP-specific resistance in human MCF-7 cells (Bunting, K. D., Lindahl, R., and Townsend, A. J. (1994) J. Biol. Chem. 269, 23197-23203). However, the aldophosphamide intermediate inactivated by human class 1 ALDH (hALDH-1) has not proven to be a good substrate for the purified hALDH-3. We have examined the ability of transfected human or rat ALDH-3 to confer OAF resistance in V79/SD1 cells, Clones expressing elevated human (386-5938 milliunits/mg) or rat (4-597 milliunits/mg, benzaldehyde/NADP(+) substrate) ALDH-3 activity were 1.3- to 12-fold resistant to mafosfamide relative to control cells (<1 milliunit/mg). Resistance was correlated with hALDH-3 activity, and was reversed by pretreatment with the ALDH inhibitor diethylaminobenzaldehyde. Transfectants were cross resistant to 4-hydroperoxycyclophosphamide and 4-hydroperoxyifosfamide but not to phosphoramide mustard, ifosfamide mustard, melphalan, or acrolein. DNA interstrand cross-links were reduced commensurately with the fold resistance to mafosfamide in the highest activity clone. A key finding was the detection of a metabolite, most likely carboxyphosphamide, that is formed only by cytosols from cells expressing either class 3 or class 1 ALDH.	WAKE FOREST UNIV,BOWMAN GRAY SCH MED,DEPT BIOCHEM,CTR COMPREHENS CANC,WINSTON SALEM,NC 27157	Wake Forest University; Wake Forest Baptist Medical Center					NATIONAL CANCER INSTITUTE [P30CA012197] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR004869] Funding Source: NIH RePORTER; NCI NIH HHS [CA-12197] Funding Source: Medline; NCRR NIH HHS [RR-04869] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		BUNTING KD, 1994, J BIOL CHEM, V269, P23197; Bunting KD, 1996, J BIOL CHEM, V271, P11884, DOI 10.1074/jbc.271.20.11884; DOCKHAM PA, 1992, BIOCHEM PHARMACOL, V43, P2453, DOI 10.1016/0006-2952(92)90326-E; DOEHMER J, 1988, P NATL ACAD SCI USA, V85, P5769, DOI 10.1073/pnas.85.16.5769; HADIDI AHFA, 1988, J CHROMATOGR-BIOMED, V427, P121, DOI 10.1016/0378-4347(88)80110-5; HILL DL, 1972, CANCER RES, V32, P658; HILTON J, 1984, BIOCHEM PHARMACOL, V33, P1867, DOI 10.1016/0006-2952(84)90541-0; HILTON J, 1984, CANCER RES, V44, P5156; HSU LC, 1992, J BIOL CHEM, V267, P3030; KOELLING TM, 1990, BLOOD, V76, P1209; KOZAK M, 1991, J BIOL CHEM, V266, P19867; LEE MO, 1991, BIOCHEM PHARMACOL, V42, P1279, DOI 10.1016/0006-2952(91)90266-8; LIN KH, 1986, IN VITRO CELL DEV B, V22, P263; LINDAHL R, 1976, BIOCHIM BIOPHYS ACTA, V452, P345, DOI 10.1016/0005-2744(76)90184-4; MANTHEY CL, 1988, BIOCHEM PHARMACOL, V37, P2781, DOI 10.1016/0006-2952(88)90041-X; REKHA GK, 1994, BIOCHEM PHARMACOL, V48, P1943, DOI 10.1016/0006-2952(94)90593-2; RUSSO JE, 1988, CANCER RES, V48, P2963; SHINE J, 1974, Proceedings of the National Academy of Sciences of the United States of America, V71, P1342, DOI 10.1073/pnas.71.4.1342; SLADEK N, 1995, P AM ASSOC CANC RES, V35, P325; SLADEK NE, 1991, ADV EXP MED BIOL, V284, P97; SLADEK NE, 1988, PHARMACOL THERAPEUT, V37, P301, DOI 10.1016/0163-7258(88)90004-6; SREERAMA L, 1994, BIOCHEM PHARMACOL, V48, P617, DOI 10.1016/0006-2952(94)90294-1; SREERAMA L, 1993, BIOCHEM PHARMACOL, V45, P2487, DOI 10.1016/0006-2952(93)90231-K; SREERAMA L, 1994, CANCER RES, V54, P2176; SREERAMA L, 1995, BIOCHEM PHARMACOL, V49, P669, DOI 10.1016/0006-2952(94)00503-E; SREERAMA L, 1993, ADV EXP MED BIOL, V328, P99; TOWNSEND AJ, 1992, MOL PHARMACOL, V41, P230; VONEITZEN U, 1994, CANCER LETT, V76, P45, DOI 10.1016/0304-3835(94)90132-5	28	48	49	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 17	1996	271	20					11891	11896		10.1074/jbc.271.20.11891	http://dx.doi.org/10.1074/jbc.271.20.11891			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UL250	8662659	hybrid			2022-12-25	WOS:A1996UL25000050
J	Liang, YX; Robinson, DF; Dennig, J; Suske, G; Fahl, WE				Liang, YX; Robinson, DF; Dennig, J; Suske, G; Fahl, WE			Transcriptional regulation of the SIS/PDGF-B gene in human osteosarcoma cells by the Sp family of transcription factors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIMIAN SARCOMA-VIRUS; GROWTH-FACTOR PDGF; RNA POLYMERASE-II; V-SIS; CELLULAR-TRANSFORMATION; IDENTIFICATION; EXPRESSION; COEXPRESSION; ACTIVATION; RECEPTORS	Expression of PDGF-B, the gene encoding the platelet-derived growth factor B chain, has been implicated as a participant in an autocrine growth loop in the human osteosarcoma cell line U2-OS. In previous work, we identified a primary site in the PDGF-B promoter, the SIS proximal element (SPE), which is critical for transcription of the PDGF-B gene in U2-OS cells. We also identified Spl as one of the SPE-binding proteins in U2-OS nuclear extracts. In the present work, we have identified another SPE-binding protein to be Sp3. Gel mobility shift assays showed that both Spl and Sp3 require the CACCC motif within the SPE for binding. In vitro transcription assays showed that Sp1 or/and Sp3 is necessary for transcription of the PDGF-B gene. Cotransfection experiments functionally demonstrated that Sp1 and Sp3 can independently or additively activate the PDGF-B promoter through the SPE as well as a synthetic promoter. However, the CACCC motif within the SPE is not the only site within the minimal PDGF-B promoter through which Sp1/Sp3 acts; additional nested deletion analyses showed that multiple cis-acting elements within the minimal promoter are required for full level transcription of the PDGF-B gene in U2-OS cells.	UNIV WISCONSIN,MCARDLE LAB CANC RES,MADISON,WI 53706; UNIV MARBURG,INST MOLEK BIOL & TUMORFORSCH,D-35037 MARBURG,GERMANY	University of Wisconsin System; University of Wisconsin Madison; Philipps University Marburg				Suske, Guntram/0000-0002-4807-0513				ANTONIADES HN, 1991, BAILLIERE CLIN ENDOC, V5, P595, DOI 10.1016/S0950-351X(10)80005-9; BEJCEK BE, 1989, SCIENCE, V245, P1496, DOI 10.1126/science.2551043; BEJCEK BE, 1992, J BIOL CHEM, V267, P3289; BETSHOLTZ C, 1984, CELL, V39, P447, DOI 10.1016/0092-8674(84)90452-5; BURATOWSKI S, 1995, SCIENCE, V270, P1773, DOI 10.1126/science.270.5243.1773; CHI TH, 1995, NATURE, V377, P254, DOI 10.1038/377254a0; CLAESSONWELSH L, 1994, J BIOL CHEM, V269, P32023; CLARKE MF, 1984, NATURE, V308, P464, DOI 10.1038/308464a0; DENNIG J, 1995, J BIOL CHEM, V270, P12737, DOI 10.1074/jbc.270.21.12737; DEUEL TF, 1982, J CLIN INVEST, V69, P1046, DOI 10.1172/JCI110509; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DOOLITTLE RF, 1983, SCIENCE, V221, P275, DOI 10.1126/science.6304883; EVA A, 1982, NATURE, V295, P116, DOI 10.1038/295116a0; FARNHAM PJ, 1991, GENE EXPRESSION, V1, P137; GAZIT A, 1984, CELL, V39, P89, DOI 10.1016/0092-8674(84)90194-6; GRAVES DT, 1984, SCIENCE, V226, P972, DOI 10.1126/science.6209798; HAGEN G, 1994, EMBO J, V13, P3843, DOI 10.1002/j.1460-2075.1994.tb06695.x; HAGEN G, 1992, NUCLEIC ACIDS RES, V20, P5591; JIN HM, 1993, P NATL ACAD SCI USA, V90, P7563, DOI 10.1073/pnas.90.16.7563; JIN HM, 1994, J BIOL CHEM, V269, P28648; JOHNSSON A, 1982, BIOCHEM BIOPH RES CO, V104, P66, DOI 10.1016/0006-291X(82)91941-6; KHACHIGIAN LM, 1994, J BIOL CHEM, V269, P22647; KINGSLEY C, 1992, MOL CELL BIOL, V12, P4251, DOI 10.1128/MCB.12.10.4251; MAJELLO B, 1995, ONCOGENE, V10, P1841; MAJELLO B, 1994, NUCLEIC ACIDS RES, V22, P4914, DOI 10.1093/nar/22.23.4914; MAXWELL M, 1990, J CLIN INVEST, V86, P131, DOI 10.1172/JCI114675; PERES R, 1987, CANCER RES, V47, P3425; RESNICK N, 1993, P NATL ACAD SCI USA, V90, P4591, DOI 10.1073/pnas.90.10.4591; ROBBINS KC, 1982, SCIENCE, V218, P1131, DOI 10.1126/science.6293053; SAUER F, 1995, SCIENCE, V270, P1783, DOI 10.1126/science.270.5243.1783; SAUER F, 1995, SCIENCE, V270, P18255; SHAMAH SM, 1993, MOL CELL BIOL, V13, P7203, DOI 10.1128/MCB.13.12.7203; Sherf BA, 1994, PROMEGA NOTES, V49, P14; STEVENS CW, 1988, MOL CELL BIOL, V8, P2089, DOI 10.1128/MCB.8.5.2089; WATERFIELD MD, 1983, NATURE, V304, P35, DOI 10.1038/304035a0	35	90	92	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 17	1996	271	20					11792	11797		10.1074/jbc.271.20.11792	http://dx.doi.org/10.1074/jbc.271.20.11792			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UL250	8662647	hybrid			2022-12-25	WOS:A1996UL25000035
J	Shiio, Y; Sawada, JI; Handa, H; Yamamoto, T; Inoue, JI				Shiio, Y; Sawada, JI; Handa, H; Yamamoto, T; Inoue, JI			Activation of the retinoblastoma gene expression by Bcl-3: Implication for muscle cell differentiation	ONCOGENE			English	Article						Bcl-3; E4TF1; GABP; muscle differentiation; Rb	NF-KAPPA-B; CANDIDATE PROTOONCOGENE BCL-3; EMBRYONAL CARCINOMA-CELLS; BETA INTERFERON GENE; NEGATIVE REGULATION; DNA-BINDING; ONCOPROTEIN BCL-3; MOLECULAR-CLONING; PROMOTER REGION; C-MYC	The retinoblastoma (Rb) protein is a master regulator of cell cycle. Accumulating evidence suggests that elevation of Rb expression is a key event in differentiation of various cell types. However the mechanism of regulation of Rb expression is poorly understood. Here we report that the candidate oncoprotein Bcl-3, previously characterized as a member of the I kappa B family, activates transcription of the Rb gene, whose promoter has no typical kappa B sites. A target element for Bcl-3 that matches the consensus for the E4TF1/GABP transcription factor was identified. Bcl-3 was shown to promote tetramer formation of E4TF1. During muscle cell differentiation, increased bcl-3 expression was observed before the induction of the Rb mRNA. Transient expression of Bcl-3 in myoblasts was shown to induce expression of the endogenous Rb. Furthermore, expression of the antisense bcl-3 RNA in myoblasts suppressed induction of Rb and myogenic differentiation. These results suggest that Bcl-3 is an upstream regulator of Rb expression during differentiation of muscle cells.	UNIV TOKYO,INST MED SCI,DEPT ONCOL,MINATO KU,TOKYO 108,JAPAN; TOKYO INST TECHNOL,FAC BIOSCI & BIOTECHNOL,MIDORI KU,YOKOHAMA,KANAGAWA 227,JAPAN	University of Tokyo; Tokyo Institute of Technology								BERNARDS R, 1989, P NATL ACAD SCI USA, V86, P6474, DOI 10.1073/pnas.86.17.6474; BHATIA K, 1991, ONCOGENE, V6, P1569; BISSONNETTE RP, 1992, NATURE, V359, P552, DOI 10.1038/359552a0; BOLWIG GM, 1992, NUCLEIC ACIDS RES, V20, P6555, DOI 10.1093/nar/20.24.6555; BOURS V, 1993, CELL, V72, P729, DOI 10.1016/0092-8674(93)90401-B; BROWN TA, 1992, GENE DEV, V6, P2502, DOI 10.1101/gad.6.12b.2502; CLARKE AR, 1992, NATURE, V359, P328, DOI 10.1038/359328a0; COPPOLA JA, 1990, ONCOGENE, V5, P1731; DUPRIEZ VJ, 1993, P NATL ACAD SCI USA, V90, P8224, DOI 10.1073/pnas.90.17.8224; ENDO T, 1992, J BIOCHEM-TOKYO, V112, P427, DOI 10.1093/oxfordjournals.jbchem.a123916; FRANZOSO G, 1992, NATURE, V359, P339, DOI 10.1038/359339a0; FUJITA T, 1993, GENE DEV, V7, P1354, DOI 10.1101/gad.7.7b.1354; FURUKAWA Y, 1990, P NATL ACAD SCI USA, V87, P2770, DOI 10.1073/pnas.87.7.2770; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GU W, 1993, CELL, V72, P309, DOI 10.1016/0092-8674(93)90110-C; HAASKOGAN DA, 1995, EMBO J, V14, P461, DOI 10.1002/j.1460-2075.1995.tb07022.x; HALEVY O, 1995, SCIENCE, V267, P1018, DOI 10.1126/science.7863327; HATADA EN, 1992, P NATL ACAD SCI USA, V89, P2489, DOI 10.1073/pnas.89.6.2489; HAUPT Y, 1995, ONCOGENE, V10, P1563; HONG FD, 1989, P NATL ACAD SCI USA, V86, P5502, DOI 10.1073/pnas.86.14.5502; INOUE J, 1993, ONCOGENE, V8, P2067; ISHIDA T, 1993, BIOCHEM BIOPH RES CO, V191, P831, DOI 10.1006/bbrc.1993.1292; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; KANEIISHII C, 1989, NUCLEIC ACIDS RES, V17, P1521, DOI 10.1093/nar/17.4.1521; KERR LD, 1992, GENE DEV, V6, P2352, DOI 10.1101/gad.6.12a.2352; LEE EYHP, 1992, NATURE, V359, P288, DOI 10.1038/359288a0; MIYAZAKI J, 1986, P NATL ACAD SCI USA, V83, P9537, DOI 10.1073/pnas.83.24.9537; MOSCA JD, 1986, MOL CELL BIOL, V6, P2279, DOI 10.1128/MCB.6.6.2279; NOLAN GP, 1993, MOL CELL BIOL, V13, P3557, DOI 10.1128/MCB.13.6.3557; OHNO H, 1990, CELL, V60, P991, DOI 10.1016/0092-8674(90)90347-H; QIN XQ, 1994, P NATL ACAD SCI USA, V91, P10918, DOI 10.1073/pnas.91.23.10918; RICHON VM, 1992, CELL GROWTH DIFFER, V3, P413; ROBBINS PD, 1990, NATURE, V346, P668, DOI 10.1038/346668a0; SAKAI T, 1991, NATURE, V353, P83, DOI 10.1038/353083a0; SAWADA J, 1994, EMBO J, V13, P1396, DOI 10.1002/j.1460-2075.1994.tb06393.x; SCHNEIDER JW, 1994, SCIENCE, V264, P1467, DOI 10.1126/science.8197461; SHIIO Y, 1992, P NATL ACAD SCI USA, V89, P5206, DOI 10.1073/pnas.89.12.5206; SHIROKI K, 1988, J VIROL, V62, P325, DOI 10.1128/JVI.62.1.325-330.1988; SLACK RS, 1993, ONCOGENE, V8, P1585; THOMPSON CC, 1991, SCIENCE, V253, P762, DOI 10.1126/science.1876833; THOMPSON JE, 1995, CELL, V80, P573, DOI 10.1016/0092-8674(95)90511-1; TRIEZENBERG SJ, 1988, GENE DEV, V2, P730, DOI 10.1101/gad.2.6.730; TSUBATA T, 1993, NATURE, V364, P645, DOI 10.1038/364645a0; UCHIUMI F, 1992, MOL CELL BIOL, V12, P3784, DOI 10.1128/MCB.12.9.3784; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; VIRBASIUS JV, 1993, GENE DEV, V7, P380, DOI 10.1101/gad.7.3.380; WATANABE H, 1993, MOL CELL BIOL, V13, P1385, DOI 10.1128/MCB.13.3.1385; WATANABE H, 1988, MOL CELL BIOL, V8, P1290, DOI 10.1128/MCB.8.3.1290; WEINBERG RA, 1991, SCIENCE, V254, P1138, DOI 10.1126/science.1659741; WULCZYN FG, 1992, NATURE, V358, P597, DOI 10.1038/358597a0; ZACKSENHAUS E, 1993, ONCOGENE, V8, P2343; ZHANG Q, 1994, MOL CELL BIOL, V14, P3915, DOI 10.1128/MCB.14.6.3915	52	12	13	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY 2	1996	12	9					1837	1845						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UK498	8649843				2022-12-25	WOS:A1996UK49800001
J	Trapasso, F; Martelli, ML; Battaglia, C; Angotti, E; Mele, E; Stella, A; Samarut, J; Avvedimento, VE; Fusco, A				Trapasso, F; Martelli, ML; Battaglia, C; Angotti, E; Mele, E; Stella, A; Samarut, J; Avvedimento, VE; Fusco, A			The v-erbA oncogene selectively inhibits iodide uptake in rat thyroid cells	ONCOGENE			English	Article						v-erbA; thyroid; differentiation; uptake; rat cells	AVIAN ERYTHROBLASTOSIS VIRUS; MURINE SARCOMA-VIRUS; HORMONE RECEPTOR; RETINOIC ACID; EPITHELIAL-CELLS; MESSENGER-RNA; MAMMALIAN-CELLS; GENE-EXPRESSION; BINDING DOMAIN; TRANSFORMATION	v-erbA is the oncogenic form of the c-erbA protooncogene, which encodes the receptor for thyroid hormones. The expression of the v-erbA oncogene in thyroid differentiated cells, PC Cl 3, inhibits iodide uptake and thyrotropin-dependent growth, whereas it has no effect on the expression of the other thyroid specific markers, i.e. thyroglobulin, thyroperoxidase and thyrotropin receptor. The activity of transcription factor AP-1, evaluated by a specific DNA binding assay and by transcription of AP-induced promoter (TRE) is enhanced in PC v-erbA cells, v-erbA mutants in the DNA binding domain do not affect the iodide uptake of thyroid cells nor AP-1 activity. We suggest that this transcriptional activation mediates the selective effects of v-erbA on the expression of thyroid specific markers.	UNIV REGGIO CALABRIA,FAC MED & CHIRURG CATANZARO,DIPARTIMENTO MED SPERIMENTALE & CLIN,I-88100 CATANZARO,ITALY; ECOLE NORMALE SUPER LYON,LAB BIOL MOL & CELLULAIRE,CNRS,UMR49,INRA,F-69364 LYON 7,FRANCE	Magna Graecia University of Catanzaro; Universita Mediterranea di Reggio Calabria; Centre National de la Recherche Scientifique (CNRS); Ecole Normale Superieure de Lyon (ENS de LYON); INRAE			Samarut, Jacques/AAD-2587-2019	Fusco, Alfredo/0000-0003-3332-5197				AKAMIZU T, 1990, P NATL ACAD SCI USA, V87, P5677, DOI 10.1073/pnas.87.15.5677; ALCALAY M, 1991, P NATL ACAD SCI USA, V88, P1977, DOI 10.1073/pnas.88.5.1977; ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; BARLOW C, 1994, EMBO J, V13, P4241, DOI 10.1002/j.1460-2075.1994.tb06744.x; BATTAGLIA C, 1993, CELL GROWTH DIFFER, V4, P185; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BERGERS G, 1995, MOL CELL BIOL, V15, P3748; BERLINGIERI MT, 1992, ONCOGENE, V8, P249; BERLINGIERI MT, 1988, MOL CELL BIOL, V8, P226; BISHOP JM, 1991, CELL, V64, P235, DOI 10.1016/0092-8674(91)90636-D; BONDE BG, 1991, J VIROL, V65, P2037, DOI 10.1128/JVI.65.4.2037-2046.1991; COLLETTA G, 1983, MOL CELL BIOL, V3, P2099, DOI 10.1128/MCB.3.11.2099; DEJEAN A, 1986, NATURE, V322, P70, DOI 10.1038/322070a0; DESBOIS C, 1991, CELL, V67, P731, DOI 10.1016/0092-8674(91)90068-A; DETHE H, 1990, NATURE, V347, P558, DOI 10.1038/347558a0; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; DILAURO R, 1982, GENE, V19, P117, DOI 10.1016/0378-1119(82)90196-2; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; FRIED M, 1981, NUCLEIC ACIDS RES, V9, P6505, DOI 10.1093/nar/9.23.6505; FUSCO A, 1982, CANCER RES, V42, P618; FUSCO A, 1987, MOL CELL BIOL, V7, P3365, DOI 10.1128/MCB.7.9.3365; FUSCO A, 1983, J VIROL, V56, P284; GALLO A, 1992, GENE DEV, V6, P1621, DOI 10.1101/gad.6.9.1621; GANDRILLON O, 1989, CELL, V58, P115, DOI 10.1016/0092-8674(89)90408-X; GANDRILLON O, 1987, CELL, V49, P687, DOI 10.1016/0092-8674(87)90545-9; GANDRILLON O, 1995, INT J ONCOL, V6, P215; GLASS CK, 1990, BIOCHIM BIOPHYS ACTA, V1032, P157, DOI 10.1016/0304-419X(90)90002-I; GORMAN C, 1983, SCIENCE, V221, P551, DOI 10.1126/science.6306768; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRAF T, 1983, CELL, V34, P7, DOI 10.1016/0092-8674(83)90130-7; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HALL BL, 1992, CELL GROWTH DIFFER, V3, P207; KAHN P, 1986, CELL, V45, P349, DOI 10.1016/0092-8674(86)90320-X; LOMBARDI A, 1988, ENDOCRINOLOGY, V123, P1544, DOI 10.1210/endo-123-3-1544; MACPHERSON I, 1964, VIROLOGY, V23, P291, DOI 10.1016/0042-6822(64)90301-0; Mangelsdorf David J., 1994, P319; MATTEI MG, 1988, HUM GENET, V80, P189, DOI 10.1007/BF00702867; MUNOZ A, 1988, EMBO J, V7, P155, DOI 10.1002/j.1460-2075.1988.tb02795.x; MURRAY MB, 1988, J BIOL CHEM, V263, P12770; PEREZ P, 1993, J BIOL CHEM, V268, P23538; PRIVALSKY ML, 1988, MOL CELL BIOL, V8, P4510, DOI 10.1128/MCB.8.10.4510; PRIVALSKY ML, 1990, CELL, V63, P1277, DOI 10.1016/0092-8674(90)90423-C; SANTORO M, 1990, ONCOGENE, V5, P1595; SANTORO M, 1993, CELL GROWTH DIFFER, V4, P77; SAP J, 1986, NATURE, V324, P635, DOI 10.1038/324635a0; SEVERNE Y, 1988, EMBO J, V7, P2503, DOI 10.1002/j.1460-2075.1988.tb03097.x; SHARIF M, 1991, CELL, V66, P885, DOI 10.1016/0092-8674(91)90435-2; TOKUNAGA K, 1986, NUCLEIC ACIDS RES, V14, P2829; ULLRICH A, 1984, NATURE, V309, P418, DOI 10.1038/309418a0; WEINBERGER C, 1986, NATURE, V324, P641, DOI 10.1038/324641a0; WU C, 1985, NATURE, V317, P84, DOI 10.1038/317084a0; ZARRILLI R, 1990, MOL ENDOCRINOL, V4, P39, DOI 10.1210/mend-4-1-39; [No title captured]	56	11	11	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY 2	1996	12	9					1879	1888						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UK498	8649848				2022-12-25	WOS:A1996UK49800006
J	Sheff, D; Lowe, M; Kreis, TE; Mellman, I				Sheff, D; Lowe, M; Kreis, TE; Mellman, I			Biochemical heterogeneity and phosphorylation of coatomer subunits	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADP-RIBOSYLATION FACTOR; GTP-BINDING PROTEIN; BETA-COP; GOLGI MEMBRANES; ENDOPLASMIC-RETICULUM; COATED VESICLES; BREFELDIN-A; KINASE-C; TRANSPORT; COMPLEX	The coat protomer complex I (COPI) family of coat proteins are involved in the assembly of membrane-associated coats thought to mediate vesicular transport between the endoplasmic reticulum and the Golgi complex, between adjacent Golgi cisternae, and possibly in the endocytic pathway. We investigated whether this heterogeneity in the sites of COPI action might be reflected in biochemical heterogeneity of one or more COPI subunits. A simplified method was devised to purify the cytosolic COPI precursor complex, coatomer, from rat liver cytosol, The individual subunits were analyzed by high resolution two dimensional gel electrophoresis and mass spectroscopic analysis of tryptic peptides. Considerable charge heterogeneity was observed, particularly for the beta-COP and delta-COP subunits. The multiple species detected, however, did not appear to reflect the presence of distinct translation products but rather a significant degree of protein phosphorylation. The observed pI of beta-COP was sensitive to alkaline phosphatase digestion. Moreover, isolation of coatomer from metabolically labeled tissue culture cells demonstrated directly that both beta-COP and delta-COP, but no other coatomer subunits, were serine-phosphorylated. COPI phosphorylation may regulate coatomer assembly, membrane recruitment, or the specificity of coatomer-organelle interaction.	YALE UNIV,SCH MED,DEPT CELL BIOL,NEW HAVEN,CT 06520; UNIV GENEVA,DEPT CELL BIOL,CH-1211 GENEVA 4,SWITZERLAND	Yale University; University of Geneva			Sheff, David/A-1269-2007; Mellman, Ira/ABG-5896-2020		NIGMS NIH HHS [GM29765, F32GM16339] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM016339, R01GM029765] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLAN VJ, 1986, J CELL BIOL, V103, P2229, DOI 10.1083/jcb.103.6.2229; ARIDOR M, 1995, J CELL BIOL, V131, P875, DOI 10.1083/jcb.131.4.875; BARLOWE C, 1994, CELL, V77, P895, DOI 10.1016/0092-8674(94)90138-4; CARDONE MH, 1994, J CELL BIOL, V124, P717, DOI 10.1083/jcb.124.5.717; CELIS JE, 1993, ELECTROPHORESIS, V14, pU1091, DOI 10.1002/elps.11501401178; COSSON P, 1994, SCIENCE, V263, P1629, DOI 10.1126/science.8128252; DEMATTEIS MA, 1993, NATURE, V364, P818, DOI 10.1038/364818a0; DONALDSON JG, 1992, NATURE, V360, P350, DOI 10.1038/360350a0; DONALDSON JG, 1992, P NATL ACAD SCI USA, V89, P6408, DOI 10.1073/pnas.89.14.6408; DUDEN R, 1991, CELL, V64, P649, DOI 10.1016/0092-8674(91)90248-W; DUDEN R, 1994, J BIOL CHEM, V269, P24486; FABBRI M, 1994, J BIOL CHEM, V269, P26848; FLEISCHER B, 1994, J BIOL CHEM, V269, P17826; GRIFFITHS G, 1996, IN PRESS J CELL SCI; GUO Q, 1994, J CELL BIOL, V125, P1213, DOI 10.1083/jcb.125.6.1213; HARAKUGE S, 1994, J CELL BIOL, V124, P883, DOI 10.1083/jcb.124.6.883; HOSOBUCHI M, 1992, NATURE, V360, P603, DOI 10.1038/360603a0; KREIS TE, 1996, IN PRESS ANN REV CEL; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEHEL C, 1995, P NATL ACAD SCI USA, V92, P1406, DOI 10.1073/pnas.92.5.1406; LOWE M, 1995, J BIOL CHEM, V270, P3164; MATTER K, 1994, CURR OPIN CELL BIOL, V6, P545, DOI 10.1016/0955-0674(94)90075-2; MOCHLYROSEN D, 1991, P NATL ACAD SCI USA, V88, P3997, DOI 10.1073/pnas.88.9.3997; MOCHLYROSEN D, 1991, J BIOL CHEM, V266, P14866; MOSS J, 1995, J BIOL CHEM, V270, P12327, DOI 10.1074/jbc.270.21.12327; OPRINS A, 1993, J CELL BIOL, V121, P49, DOI 10.1083/jcb.121.1.49; ORCI L, 1993, NATURE, V362, P648, DOI 10.1038/362648a0; ORCI L, 1993, NATURE, V364, P732, DOI 10.1038/364732a0; PAPPIN DJC, 1993, CURR BIOL, V3, P327, DOI 10.1016/0960-9822(93)90195-T; PEPPERKOK R, 1993, CELL, V74, P71, DOI 10.1016/0092-8674(93)90295-2; PETER F, 1993, J CELL BIOL, V122, P1155, DOI 10.1083/jcb.122.6.1155; PIMPLIKAR SW, 1994, J CELL BIOL, V125, P1025, DOI 10.1083/jcb.125.5.1025; ROBINSON MS, 1994, CURR OPIN CELL BIOL, V6, P538, DOI 10.1016/0955-0674(94)90074-4; ROBINSON MS, 1992, CELL, V69, P129, DOI 10.1016/0092-8674(92)90124-U; ROTHMAN JE, 1992, NATURE, V355, P409, DOI 10.1038/355409a0; SERAFINI T, 1991, CELL, V67, P239, DOI 10.1016/0092-8674(91)90176-Y; STENBECK G, 1993, EMBO J, V12, P2841, DOI 10.1002/j.1460-2075.1993.tb05945.x; VANDERSLUIJS P, 1992, EMBO J, V11, P4379, DOI 10.1002/j.1460-2075.1992.tb05538.x; WATERS MG, 1992, METHOD ENZYMOL, V219, P331; WATERS MG, 1991, NATURE, V349, P248, DOI 10.1038/349248a0; WHITNEY JA, 1995, CELL, V83, P703	41	35	36	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 22	1996	271	12					7230	7236		10.1074/jbc.271.12.7230	http://dx.doi.org/10.1074/jbc.271.12.7230			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UB157	8636162				2022-12-25	WOS:A1996UB15700097
J	Liu, XS; Kim, CN; Pohl, J; Wang, XD				Liu, XS; Kim, CN; Pohl, J; Wang, XD			Purification and characterization of an interleukin-1 beta-converting enzyme family protease that activates cysteine protease P32 (CPP32)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEUCINE ZIPPER PROTEIN; TRANSCRIPTION; INHIBITION	CPP32, a member of the interleukin-1 beta-converting enzyme (ICE) family of cysteine proteases, cleaves poly(ADP ribose) polymerase and sterol regulatory element binding proteins during apoptosis, CPP32 normally exists in the cytosol as a 32-kDa inactive precursor and only becomes activated when cells are undergoing apoptosis, The activation is a proteolytic event that generates a p20/p11 heterodimer. We report here the identification, purification, and characterization of a hamster CPP32-activating protease (CAP) that cleaves and activates CPP32. The biochemical properties of CAP suggest that it is another member of the ICE family of proteases, Purified CAP consists of two prominent polypeptides of 19 and 13 kDa. Protein sequencing revealed that CAP is derived from the hamster homolog of Mch2 alpha, a member of the ICE family recently identified based on the sequence conservation among the ICE family members, CAP activity is inhibited by CrmA, a cowpox virus protein that prevents host cell apoptosis, CAP itself is also activated through proteolytic cleavage. These data are consistent with the idea that the activation of the ICE family of proteases during apoptosis proceeds through a cascade of proteolytic events.	EMORY UNIV,SCH MED,WINSHIP CANC CTR,MICROCHEM FACIL,ATLANTA,GA 30322; EMORY UNIV,SCH MED,WINSHIP CANC CTR,DEPT BIOCHEM,ATLANTA,GA 30322	Emory University; Emory University				Wang, Xiaodong/0000-0001-9885-356X				BENNETT MK, 1995, J BIOL CHEM, V270, P25578, DOI 10.1074/jbc.270.43.25578; BOUDREAU N, 1995, SCIENCE, V267, P891, DOI 10.1126/science.7531366; BUMP NJ, 1995, SCIENCE, V269, P1885, DOI 10.1126/science.7569933; Duan HJ, 1996, J BIOL CHEM, V271, P1621, DOI 10.1074/jbc.271.3.1621; FERNANDESALNEMRI T, 1995, CANCER RES, V55, P6045; FERNANDESALNEMRI T, 1995, CANCER RES, V55, P2737; FERNANDESALNEMRI T, 1994, J BIOL CHEM, V269, P30761; GAGLIARDINI V, 1994, SCIENCE, V263, P826, DOI 10.1126/science.8303301; HUA XX, 1993, P NATL ACAD SCI USA, V90, P11603, DOI 10.1073/pnas.90.24.11603; KAMON R, 1994, CELL, V78, P343; KIM JB, 1995, MOL CELL BIOL, V15, P2582; KUIDA K, 1995, SCIENCE, V267, P2000, DOI 10.1126/science.7535475; LI P, 1995, CELL, V80, P401, DOI 10.1016/0092-8674(95)90490-5; Lippke JA, 1996, J BIOL CHEM, V271, P1825, DOI 10.1074/jbc.271.4.1825; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; RAY CA, 1992, CELL, V69, P597, DOI 10.1016/0092-8674(92)90223-Y; SHI L, 1992, J EXP MED, V176, P521; TANAKA Y, 1984, J BIOL CHEM, V259, P6579; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; TEWARI M, 1995, J BIOL CHEM, V270, P22705, DOI 10.1074/jbc.270.39.22705; TEWARI M, 1995, J BIOL CHEM, V270, P3255, DOI 10.1074/jbc.270.7.3255; THORNBERRY NA, 1992, NATURE, V356, P768, DOI 10.1038/356768a0; THORNBERRY NA, 1995, PROTEIN SCI, V4, P3; Wang XD, 1996, EMBO J, V15, P1012, DOI 10.1002/j.1460-2075.1996.tb00438.x; WANG XD, 1995, J BIOL CHEM, V270, P18044, DOI 10.1074/jbc.270.30.18044; WANG XD, 1994, CELL, V77, P53, DOI 10.1016/0092-8674(94)90234-8; WILSON KP, 1994, NATURE, V370, P270, DOI 10.1038/370270a0; XUE D, 1995, NATURE, V377, P248, DOI 10.1038/377248a0; YOKOYAMA C, 1993, CELL, V75, P187, DOI 10.1016/S0092-8674(05)80095-9	29	87	93	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 7	1996	271	23					13371	13376		10.1074/jbc.271.23.13371	http://dx.doi.org/10.1074/jbc.271.23.13371			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UP385	8662833	hybrid			2022-12-25	WOS:A1996UP38500013
J	Momand, J; Zambetti, GP				Momand, J; Zambetti, GP			Analysis of the proportion of p53 bound to mdm-2 in cells with defined growth characteristics	ONCOGENE			English	Article						cell cycle; immortalized; post-translational; tumorigenic	GENE-EXPRESSION; 3T3 CELLS; PROTEIN; DNA; PHOSPHORYLATION; TRANSFORMATION; ONCOGENE; PRODUCT; COMPLEX; FORMS	A critical parameter affecting cell growth properties is the relative levels of the p53 tumor suppressor protein and the mdm-2 oncoprotein. Because mdm-2 overexpression is observed in several types of human cancers and its physical association with p53 appears essential for down-regulating p53 activity the proportion of p53 bound to mdm-2 was examined in four types of cells with divergent growth properties: (1) Growth arrested cells (Al) expressing high levels of wild-type p53 activity; (2) Tumorigenic cells (3T3DM) expressing high levels of mdm-2; (3) Immortalized non tumorigenic cells (Swiss3T3 and Balb/c3T3); and (4) Normal murine fibroblasts. In Al cells, greater than 78% of the p53 was not bound to mdm-2, demonstrating that excess free p53 is available for cell cycle arrest. In 3T3DM cells 100% of the p53 was bound to mdm-2 and these cells were unable to support p53-mediated transactivation, a p53 function essential for cell growth inhibition, In Swiss3T3 cells 75% of the p53 was bound to mdm-2. In Balb/c3T3 cells and normal cells no detectable mdm-2 was bound to p53. Since free p53 was detected in several of these cell lines the possibility that mdm-2 is completely titrated by p53 was investigated. However, free mdm-2 was present in all these cells. Phosphorylation of p53 does not appear to control complex formation since the free and the mdm-2-bound form of p53 from Al cells had identical phosphorylation maps. These data suggest that a high proportion of p53 bound to mdm-2 is observed in some cells with a more transformed phenotype and that p53-mdm-2 complex formation is controlled by a posttranslational event other than p53 phosphorylation.	ST JUDE CHILDRENS RES HOSP, DEPT BIOCHEM, MEMPHIS, TN 38101 USA	St Jude Children's Research Hospital	Momand, J (corresponding author), CITY HOPE NATL MED CTR, DEPT CELL & TUMOR BIOL, 1500 E DUARTE RD, DUARTE, CA 91010 USA.		Zambetti, Gerard/N-8093-2018; Momand, Jamil/F-8154-2012	Zambetti, Gerard/0000-0002-0929-5007; 	NCI NIH HHS [5 P30CA 21765] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA021765] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; BARAK Y, 1994, GENE DEV, V8, P1739, DOI 10.1101/gad.8.15.1739; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; CAHILLYSNYDER L, 1987, SOMAT CELL MOLEC GEN, V13, P235, DOI 10.1007/BF01535205; CHEN CY, 1994, P NATL ACAD SCI USA, V91, P2684, DOI 10.1073/pnas.91.7.2684; CHEN JD, 1993, MOL CELL BIOL, V13, P4107, DOI 10.1128/MCB.13.7.4107; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; CLARKE CF, 1988, MOL CELL BIOL, V8, P1206, DOI 10.1128/MCB.8.3.1206; CORDONCARDO C, 1994, CANCER RES, V54, P794; CROOK T, 1994, CELL, V79, P817, DOI 10.1016/0092-8674(94)90071-X; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FAKHARZADEH SS, 1991, EMBO J, V10, P1565, DOI 10.1002/j.1460-2075.1991.tb07676.x; FINLAY CA, 1988, MOL CELL BIOL, V8, P531, DOI 10.1128/MCB.8.2.531; FINLAY CA, 1993, MOL CELL BIOL, V13, P301, DOI 10.1128/MCB.13.1.301; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GREENBLATT MS, 1994, CANCER RES, V54, P4855; GRUDAS JM, 1995, CLIN CANCER RES, V1, P71; HAINES DS, 1994, MOL CELL BIOL, V14, P1171, DOI 10.1128/MCB.14.2.1171; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HARPER JW, 1993, CELL, V75, P805; HARVEY DM, 1991, GENE DEV, V5, P2375, DOI 10.1101/gad.5.12b.2375; HINDS PW, 1990, CELL GROWTH DIFFER, V1, P571; JONES SN, 1995, NATURE, V378, P206, DOI 10.1038/378206a0; KASTAN MB, 1991, CANCER RES, V51, P6304; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; LEVINE AJ, 1994, BRIT J CANCER, V69, P409, DOI 10.1038/bjc.1994.76; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LU H, 1995, P NATL ACAD SCI USA, V92, P5154, DOI 10.1073/pnas.92.11.5154; LUNA RMD, 1995, NATURE, V378, P203; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; MARECHAL V, 1994, MOL CELL BIOL, V14, P7414, DOI 10.1128/MCB.14.11.7414; MARSTON NJ, 1994, ONCOGENE, V9, P2707; MARTIN K, 1995, NATURE, V375, P691, DOI 10.1038/375691a0; MARTINEZ J, 1991, GENE DEV, V5, P151, DOI 10.1101/gad.5.2.151; MEEK DW, 1988, MOL CELL BIOL, V8, P461, DOI 10.1128/MCB.8.1.461; MELTZER PS, 1994, J NATL CANCER I, V86, P1265, DOI 10.1093/jnci/86.17.1265; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; MONTALVO EA, 1991, J VIROL, V65, P3647, DOI 10.1128/JVI.65.7.3647-3655.1991; MOSNER J, 1994, ONCOGENE, V9, P3321; NELSON WG, 1994, MOL CELL BIOL, V14, P1815, DOI 10.1128/MCB.14.3.1815; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; OLSON DC, 1993, ONCOGENE, V8, P2353; PERRY ME, 1993, P NATL ACAD SCI USA, V90, P11623, DOI 10.1073/pnas.90.24.11623; PICKSLEY SM, 1992, ONCOGENE, V7, P1649; PICKSLEY SM, 1994, ONCOGENE, V9, P2523; RITTLING SR, 1992, ONCOGENE, V7, P935; SAMAD A, 1986, P NATL ACAD SCI USA, V83, P897, DOI 10.1073/pnas.83.4.897; SMITH ML, 1994, SCIENCE, V266, P1376, DOI 10.1126/science.7973727; TAN TH, 1986, J VIROL, V59, P574, DOI 10.1128/JVI.59.3.574-583.1986; THUT CJ, 1995, SCIENCE, V267, P100, DOI 10.1126/science.7809597; TODARO GJ, 1963, J CELL BIOL, V17, P299, DOI 10.1083/jcb.17.2.299; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WANG Y, 1992, P NATL ACAD SCI USA, V89, P4231, DOI 10.1073/pnas.89.10.4231; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; XIAO ZX, 1995, NATURE, V375, P694, DOI 10.1038/375694a0; YEW PR, 1992, NATURE, V357, P82, DOI 10.1038/357082a0; YEWDELL JW, 1986, J VIROL, V59, P444, DOI 10.1128/JVI.59.2.444-452.1986; ZAMBETTI GP, 1992, GENE DEV, V6, P1143, DOI 10.1101/gad.6.7.1143	61	30	30	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 6	1996	12	11					2279	2289						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UQ220	8649767				2022-12-25	WOS:A1996UQ22000004
J	Gingras, D; White, D; Garin, J; Multigner, L; Job, D; Cosson, J; Huitorel, P; Zingg, H; Dumas, F; Gagnon, C				Gingras, D; White, D; Garin, J; Multigner, L; Job, D; Cosson, J; Huitorel, P; Zingg, H; Dumas, F; Gagnon, C			Purification, cloning, and sequence analysis of a M(r)=30,000 protein from sea urchin axonemes that is important for sperm motility - Relationship of the protein to a dynein light chain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHLAMYDOMONAS-REINHARDTII; FLAGELLAR MICROTUBULES; MONOCLONAL-ANTIBODIES; MUTANTS; TUBULIN; ARMS	We have generated a series of monoclonal antibodies against axonemal proteins from sea urchin spermatozoa in order to identify novel proteins involved in the regulation of flagellar motility. The monoclonal antibody D405-14 inhibited the motility of demembranated-reactivated sperm models at low concentrations and recognized a single polypeptide of 33 kDa (p33) on immuno blots of sea urchin axonemal proteins. Fractionation of the axonemes with high salt solutions, heat, and detergent resulted in the selective extraction of p33 into a 0.6 M NaCl-soluble and a 0.5% sodium lauryl sarcosinate (Sarkosyl)-soluble form. Both forms of p33 were purified to apparent homogeneity by immunoaffinity chromatography on monoclonal antibody D405-14-Sepharose. We have also isolated and sequenced a full-length cDNA clone encoding the 33-kDa protein. The sequence predicts a polypeptide of 260 amino acids having a mass of 29,730 Da and an isoelectric point of 9.3. Sequence comparison indicates that p33 is 66% identical (74% similar) to the p28 light chain of axonemal inner dynein arm of Chlamydomonas reinhardtii. Taken together, these results suggest that we have identified a p28 light chain homolog in sea urchin sperm axoneme and that this protein may play a dynamic rob in flagellar motility.	MCGILL UNIV, ROYAL VICTORIA HOSP, UROL RES LAB, MONTREAL, PQ H3A 1A1, CANADA; CEA GRENOBLE, DEPT BIOL MOLEC & STRUCT, F-38054 GRENOBLE 9, FRANCE; UNIV PARIS 06, OBSERV OCEANOL, STN MARINE, URA 671 CNRS, F-06230 VILLEFRANCHE SUR MER, FRANCE; MCGILL UNIV, FAC MED, MONTREAL, PQ, CANADA; BIOTECHNOL RES INST, MONTREAL, PQ H4P 2R2, CANADA	McGill University; Royal Victoria Hospital; CEA; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Sorbonne Universite; McGill University; National Research Council Canada			Zingg, Hans/GPS-9984-2022; Multigner, Luc/AAA-6214-2020; Multigner, Luc/I-2926-2015	Multigner, Luc/0000-0003-3205-8568; Multigner, Luc/0000-0003-3205-8568				ADAMS GMW, 1981, J CELL BIOL, V91, P69, DOI 10.1083/jcb.91.1.69; ADESSIC, 1995, J CELL SCI, V108, P3331; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; ASAI DJ, 1982, CELL MOTIL CYTOSKEL, V2, P599, DOI 10.1002/cm.970020608; ASAI DJ, 1980, J CELL BIOL, V87, P114, DOI 10.1083/jcb.87.1.114; BARKALOW K, 1994, J CELL BIOL, V126, P727, DOI 10.1083/jcb.126.3.727; CURRY AM, 1993, CELL MOTIL CYTOSKEL, V24, P224, DOI 10.1002/cm.970240403; GAGNON C, 1994, MOL BIOL CELL, V5, P1051, DOI 10.1091/mbc.5.9.1051; GIBBONS BH, 1976, J CELL BIOL, V71, P823, DOI 10.1083/jcb.71.3.823; GIBBONS IR, 1981, J CELL BIOL, V91, pS107, DOI 10.1083/jcb.91.3.107s; GOUT I, 1993, CELL, V75, P25, DOI 10.1016/0092-8674(93)90676-H; HARROW E, 1988, ANTIBODIES LAB MANUA, P511; HUANG B, 1979, J BIOL CHEM, V254, P3091; KING SM, 1985, P NATL ACAD SCI USA, V82, P4717, DOI 10.1073/pnas.82.14.4717; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEDIZET M, 1995, MOL BIOL CELL, V6, P713, DOI 10.1091/mbc.6.6.713; LEDIZET M, 1995, MOL BIOL CELL, V6, P697, DOI 10.1091/mbc.6.6.697; MULTIGNER L, 1992, NATURE, V360, P33, DOI 10.1038/360033a0; MURRAY JM, 1991, INT REV CYTOL, V125, P47, DOI 10.1016/S0074-7696(08)61216-4; OBAR RA, 1990, NATURE, V347, P256, DOI 10.1038/347256a0; OKUNO M, 1981, J CELL BIOL, V91, P689, DOI 10.1083/jcb.91.3.689; PIPERNO G, 1977, P NATL ACAD SCI USA, V74, P1600, DOI 10.1073/pnas.74.4.1600; PIPERNO G, 1992, J CELL BIOL, V118, P1455, DOI 10.1083/jcb.118.6.1455; PIPERNO G, 1981, J CELL BIOL, V88, P73, DOI 10.1083/jcb.88.1.73; PORTER ME, 1989, ANNU REV CELL BIOL, V5, P119; Sale W.S., 1989, CELL MOVEMENT, P89; STEPHENS R E, 1970, Journal of Molecular Biology, V47, P353, DOI 10.1016/0022-2836(70)90307-4; TIJSSEN P, 1985, PRACTICE THEORY ENZY, P329; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WILLIAMS BD, 1986, J CELL BIOL, V101, P2085; WITMAN G B, 1992, Current Opinion in Cell Biology, V4, P74	31	25	26	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 31	1996	271	22					12807	12813		10.1074/jbc.271.22.12807	http://dx.doi.org/10.1074/jbc.271.22.12807			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UN474	8662724	hybrid			2022-12-25	WOS:A1996UN47400020
J	Lee, JY; Hannun, YA; Obeid, LM				Lee, JY; Hannun, YA; Obeid, LM			Ceramide inactivates cellular protein kinase C alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECROSIS-FACTOR-ALPHA; RETINOBLASTOMA PROTEIN; SPHINGOMYELIN TURNOVER; INHIBITION; ACTIVATION; INVITRO; CELLS; DIFFERENTIATION; PHOSPHORYLATION; IDENTIFICATION	Ceramide mediates the effects of extracellular agents on cellular growth, differentiation and apoptosis, In this study, we explored the mechanisms by which ceramide induces its cellular effects, In Molt-4 cells, phorbol 12-myristate 13-acetate (PMA) induced retinoblastoma gene product (Rb) phosphorylation, and ceramide inhibited this effect, suggesting an inhibitory effect of ceramide on the protein kinase C (PKC) pathway, the primary target of PMA. Molt-4 cells contained primarily PKC alpha and beta(II) isoforms of PKC, To determine the effects of ceramide on PKC, we developed an immunoprecipitation assay for PKC alpha activity. Exposure of Molt-4 cells to C-6-ceramide resulted in a concentration and time-dependent inhibition of immunoprecipitated protein kinase C alpha (PKC alpha). Initial inhibition was observed as early as 4.5 h after treatment of cells with C-6-ceramide, and the activity was completely lost by 13 h, Inhibition of PKC alpha activity was seen at concentrations of ceramide as low as 5 mu M with maximal effects occurring at a concentration of 15 mu M. Both C-2 and C-6-ceramide were inhibitory, but C-2 and C-6 dihydroceramides were not, Ceramide did not directly inhibit PKC alpha in vitro or modulate the levels of PKC alpha protein, suggesting that ceramide acted indirectly, Moreover, ceramide did not inhibit PMA-induced translocation of PKC alpha. Taken together, these results suggested that ceramide caused inactivation of PKC alpha. Since PKC requires phosphorylation for activity, we determined the effects of ceramide on phosphorylation of PKC alpha. C-6-ceramide inhibited basal and PMA-induced phosphorylation of PKC alpha. In addition, okadaic acid, a potent phosphatase inhibitor, slightly stimulated PKC activity and blocked the effects of ceramide on PKC alpha inhibition. These results demonstrate that ceramide causes inhibition/inactivation of PKC alpha and suggest these effects of ceramide may be mediated by a protein phosphatase.	DUKE UNIV,MED CTR,DEPT MED,DIV GERIATR,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT CELL BIOL,DURHAM,NC 27710; VET ADM MED CTR,CTR GERIATR RES EDUC & CLIN,DURHAM,NC 27710	Duke University; Duke University; Geriatric Research Education & Clinical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA)				obeid, lina/0000-0002-0734-0847	NIA NIH HHS [K08AG00520, 5T32 AG00029] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [T32AG000029, K08AG000520] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BELL RM, 1991, J BIOL CHEM, V266, P4661; BORNER C, 1989, J BIOL CHEM, V264, P13902; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CARROLL MP, 1994, J BIOL CHEM, V269, P1249; CAZAUBON S, 1994, BIOCHEM J, V301, P443, DOI 10.1042/bj3010443; CAZAUBON SM, 1993, J BIOL CHEM, V268, P17559; CHAO R, 1992, J BIOL CHEM, V267, P23459; DBAIBO GS, 1995, P NATL ACAD SCI USA, V92, P1347, DOI 10.1073/pnas.92.5.1347; DOBROWSKY RT, 1993, J BIOL CHEM, V268, P15523; DOBROWSKY RT, 1992, J BIOL CHEM, V267, P5048; DRESSLER KA, 1992, SCIENCE, V255, P1715, DOI 10.1126/science.1313189; DUTIL EM, 1994, J BIOL CHEM, V269, P29359; HAIMOVITZFRIEDMAN A, 1994, J EXP MED, V180, P525, DOI 10.1084/jem.180.2.525; HANNUN YA, 1986, J BIOL CHEM, V261, P2604; JARVIS WD, 1994, P NATL ACAD SCI USA, V91, P73, DOI 10.1073/pnas.91.1.73; JAYADEV S, 1995, J BIOL CHEM, V270, P2047, DOI 10.1074/jbc.270.5.2047; JONES MJ, 1995, J BIOL CHEM, V270, P5007, DOI 10.1074/jbc.270.10.5007; KIM MY, 1991, J BIOL CHEM, V266, P484; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAIHO M, 1990, CELL, V62, P175, DOI 10.1016/0092-8674(90)90251-9; LAW B, 1995, J BIOL CHEM, V270, P12808, DOI 10.1074/jbc.270.21.12808; MAY WS, 1994, J BIOL CHEM, V269, P26865; MCCONKEY DJ, 1989, J BIOL CHEM, V264, P13399; MERRILL AH, 1989, BIOCHEMISTRY-US, V28, P3138, DOI 10.1021/bi00434a004; NEWTON AC, 1993, ANNU REV BIOPH BIOM, V22, P1, DOI 10.1146/annurev.bb.22.060193.000245; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; OBEID LM, 1993, SCIENCE, V259, P1769, DOI 10.1126/science.8456305; OKAZAKI T, 1989, J BIOL CHEM, V264, P19076; ORR JW, 1994, J BIOL CHEM, V269, P27715; RAJOTTE D, 1992, J BIOL CHEM, V267, P9980; RESNITZKY D, 1992, P NATL ACAD SCI USA, V89, P402, DOI 10.1073/pnas.89.1.402; TOMEI LD, 1988, BIOCHEM BIOPH RES CO, V155, P324, DOI 10.1016/S0006-291X(88)81088-X; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Venable ME, 1995, J BIOL CHEM, V270, P30701, DOI 10.1074/jbc.270.51.30701; WETSEL WC, 1992, J CELL BIOL, V117, P121, DOI 10.1083/jcb.117.1.121; WOLFF RA, 1994, J BIOL CHEM, V269, P19605	36	236	241	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 31	1996	271	22					13169	13174		10.1074/jbc.271.22.13169	http://dx.doi.org/10.1074/jbc.271.22.13169			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UN474	8662781	hybrid			2022-12-25	WOS:A1996UN47400074
J	Vasilyeva, E; Forgac, M				Vasilyeva, E; Forgac, M			3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate inhibits activity of the vacuolar (H+)-ATPase from bovine brain clathrin-coated vesicles by modification of a rapidly exchangeable, noncatalytic nucleotide binding site on the B subunit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSLOCATING ADENOSINE-TRIPHOSPHATASE; BEEF-HEART F1-ATPASE; H+-ATPASE; PROTON PUMP; SACCHAROMYCES-CEREVISIAE; CATALYTIC SUBUNIT; ESCHERICHIA-COLI; CDNA SEQUENCE; ALPHA-SUBUNIT; V-ATPASES	It was previously observed that the B subunit of the tonoplast V-ATPase is modified by the photoactivated nucleotide analog 3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate (BzATP) (Manolson, M. F., Rea, P. A., and Poole, R. J. (1985) J. Biol. Chem. 260, 12273-12279). We have further characterized the nucleotide binding sites on the V-ATPase and the interaction between BzATP and the B subunit. We observe that the V-ATPase isolated from bovine clathrin coated vesicles possesses approximately 1 mol of endogenous, tightly bound ATP/mol of V-ATPase complex. BzATP is not a substrate for the V-ATPase, but does act as a noncovalent inhibitor in the absence of irradiation changing the kinetic characteristics of ATP hydrolysis. Irradiation of the V-ATPase in the presence of [H-3]BzATP results primarily in modification of the 58-kDa B subunit, with complete inhibition of V-ATPase activity occurring upon modification of one B subunit per V-ATPase complex. Inhibition occurs as the result of modification of a rapidly (t(1/2) < 2 min) exchangeable site, and yet this site does not correspond to a catalytic site, as indicated by the effects of cysteine-modifying reagents which react with Cys(254) located at the catalytic sites on the A subunit. Thus, the noncatalytic nucleotide binding site modified by BzATP appears to be rapidly exchangeable. The site of [H-3]BzATP modification of the B subunit was localized to the region Ile(164) to Gln(171), which from the x-ray crystal structure of the homologous F-ATPase alpha subunit, is within 10 Angstrom of the ribose ring of ATP bound to the noncatalytic nucleotide binding site. Thus, despite the absence of a glycine-rich loop region in the B subunit, these data are consistent with a similar overall folding pattern for the V-ATPase B subunit and the F-ATPase alpha subunit.	TUFTS UNIV, SCH MED, DEPT CELLULAR & MOLEC PHYSIOL, BOSTON, MA 02111 USA	Tufts University					NIGMS NIH HHS [R01 GM034478, GM34478] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM034478, R01GM034478] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; ACKERMAN SH, 1987, J BIOL CHEM, V262, P13765; ANRAKU Y, 1992, J BIOENERG BIOMEMBR, V24, P395, DOI 10.1007/BF00762532; ARAI H, 1987, BIOCHEMISTRY-US, V26, P6632, DOI 10.1021/bi00395a011; ARAI H, 1989, BIOCHEMISTRY-US, V28, P3075, DOI 10.1021/bi00433a051; ARAI H, 1988, J BIOL CHEM, V263, P8796; BAR-ZVI D, 1992, Journal of Biological Chemistry, V267, P11029; BOWMAN BJ, 1988, J BIOL CHEM, V263, P14002; BOWMAN BJ, 1992, J BIOENERG BIOMEMBR, V24, P361, DOI 10.1007/BF00762529; BOWMAN EJ, 1988, J BIOL CHEM, V263, P13994; BOYER PD, 1993, BIOCHIM BIOPHYS ACTA, V1140, P215, DOI 10.1016/0005-2728(93)90063-L; CHATTERJEE D, 1992, P NATL ACAD SCI USA, V89, P6257, DOI 10.1073/pnas.89.14.6257; CROSS RL, 1982, J BIOL CHEM, V257, P2874; FENG Y, 1992, J BIOL CHEM, V267, P5817; FENG Y, 1992, J BIOL CHEM, V267, P19769; FENG Y, 1994, J BIOL CHEM, V269, P13224; FLING SP, 1986, ANAL BIOCHEM, V155, P83, DOI 10.1016/0003-2697(86)90228-9; FORGAC M, 1983, P NATL ACAD SCI-BIOL, V80, P1300, DOI 10.1073/pnas.80.5.1300; FORGAC M, 1992, J BIOENERG BIOMEMBR, V24, P341, DOI 10.1007/BF00762527; FORGAC M, 1989, PHYSIOL REV, V69, P765, DOI 10.1152/physrev.1989.69.3.765; FUTAI M, 1992, J BIOENERG BIOMEMBR, V24, P463, DOI 10.1007/BF00762363; GARRETT NE, 1975, J BIOL CHEM, V250, P6640; GLUCK SL, 1992, J BIOENERG BIOMEMBR, V24, P351, DOI 10.1007/BF00762528; HARRIS D A, 1973, Biochimica et Biophysica Acta, V314, P149, DOI 10.1016/0005-2728(73)90130-8; HARRIS DA, 1978, BIOCHIM BIOPHYS ACTA, V463, P245, DOI 10.1016/0304-4173(78)90002-2; HIRATA R, 1990, J BIOL CHEM, V265, P6726; HYNDMAN DJ, 1994, J BIOL CHEM, V269, P28871; JAULT JM, 1994, J BIOL CHEM, V269, P319; JOUNOUCHI M, 1993, J BIOCHEM-TOKYO, V114, P171, DOI 10.1093/oxfordjournals.jbchem.a124150; KAMBOURIS NG, 1985, P NATL ACAD SCI USA, V82, P1950, DOI 10.1073/pnas.82.7.1950; KANE PM, 1992, J BIOENERG BIOMEMBR, V24, P383, DOI 10.1007/BF00762531; KASHO VN, 1989, P NATL ACAD SCI USA, V86, P8708, DOI 10.1073/pnas.86.22.8708; KIBAK H, 1992, J BIOENERG BIOMEMBR, V24, P415, DOI 10.1007/BF00762534; KIRONDE FAS, 1987, J BIOL CHEM, V262, P3488; LEIMGRUBER RM, 1976, J BIOL CHEM, V251, P7103; Liu Q, 1996, J BIOL CHEM, V271, P2018, DOI 10.1074/jbc.271.4.2018; LIU Q, 1994, J BIOL CHEM, V269, P31592; MAEDA M, 1976, BIOCHEM BIOPH RES CO, V70, P228, DOI 10.1016/0006-291X(76)91132-3; MAGGIO MB, 1987, J BIOL CHEM, V262, P8981; MANOLSON MF, 1985, J BIOL CHEM, V260, P2273; MANOLSON MF, 1988, J BIOL CHEM, V263, P17987; MARTINEZZAGUILAN R, 1993, AM J PHYSIOL, V265, pC1015, DOI 10.1152/ajpcell.1993.265.4.C1015; MILGROM YM, 1993, J BIOL CHEM, V268, P23179; MYERS M, 1993, J BIOL CHEM, V268, P9184; NELSON H, 1989, J BIOL CHEM, V264, P1775; NELSON N, 1992, J BIOENERG BIOMEMBR, V24, P407, DOI 10.1007/BF00762533; PEDERSEN PL, 1993, J BIOL CHEM, V268, P9937; PENEFSKY HS, 1991, ADV ENZYMOL RELAT AR, V64, P173; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; PUOPOLO K, 1992, J BIOL CHEM, V267, P3696; PUOPOLO K, 1991, J BIOL CHEM, V266, P24564; ROSING J, 1972, BIOCHIM BIOPHYS ACTA, V267, P275, DOI 10.1016/0005-2728(72)90116-8; SENIOR AE, 1990, ANNU REV BIOPHYS BIO, V19, P7; SWALLOW CJ, 1990, J BIOL CHEM, V265, P7645; SZE H, 1992, J BIOENERG BIOMEMBR, V24, P371, DOI 10.1007/BF00762530; UCHIDA E, 1988, J BIOL CHEM, V263, P45; WALKER JE, 1985, J MOL BIOL, V184, P677, DOI 10.1016/0022-2836(85)90313-4; WEBER J, 1994, J BIOL CHEM, V269, P11261; WILLIAMS N, 1982, J BIOL CHEM, V257, P2834; ZHANG JM, 1995, J BIOL CHEM, V270, P15494, DOI 10.1074/jbc.270.26.15494; ZIMNIAK L, 1988, J BIOL CHEM, V263, P9102	61	37	37	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 31	1996	271	22					12775	12782		10.1074/jbc.271.22.12775	http://dx.doi.org/10.1074/jbc.271.22.12775			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UN474	8662754	hybrid			2022-12-25	WOS:A1996UN47400015
J	Meng, HP; Leddy, JJ; Frank, J; Holland, P; Tuana, BS				Meng, HP; Leddy, JJ; Frank, J; Holland, P; Tuana, BS			The association of cardiac dystrophin with myofibrils/Z-disc regions in cardiac muscle suggests a novel role in the contractile apparatus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DUCHENNE MUSCULAR-DYSTROPHY; SKELETAL-MUSCLE; GLYCOPROTEIN COMPLEX; DILATED CARDIOMYOPATHY; EXCHANGE PROTEIN; HEART-MUSCLE; SARCOLEMMA; LOCALIZATION; MEMBRANE; HAMSTERS	Dystrophin serves a variety of roles at the cell membrane through its associations, and defects in the dystrophin gene can give rise to muscular dystrophy and genetic cardiomyopathy. We investigated localization of cardiac dystrophin to determine potential intracellular sites of association. Subcellular fractionation revealed that while the majority of dystrophin was associated with the sarcolemma, about 35% of the 427-kDa form of dystrophin was present in the myofibrils. The dystrophin homolog utrophin was detectable only in the sarcolemmal membrane and was absent from the myofibrils as were other sarcolemmal glycoproteins such as adhalin and the sodium-calcium exchanger. Extraction of myofibrils with KCl and detergents could not solubilize dystrophin. Dystrophin could only be dissociated from the myofibrillar protein complex in 5 M urea followed by sucrose density gradient centrifugation where it co-fractionated with one of two distinctly sedimenting peaks of actin. Immunoelectron microscopy of intracellular regions of cardiac muscle revealed a selective labeling of Z-discs by dystrophin antibodies. In the genetically determined cardiomyopathic hamster, strain CHF 147, the time course of development of cardiac insufficiency correlated with an overall 75% loss of myofibrillar dystrophin. These findings collectively show that a significant pool of the 427-kDa form of cardiac dystrophin was specifically associated with the contractile apparatus at the Z-discs, and its loss correlated with progression to cardiac insufficiency in genetic cardiomyopathy. The loss of distinct cellular pools of dystrophin may contribute to the tissue specific pathophysiology in muscular dystrophy.	UNIV OTTAWA, DEPT PHARMACOL, OTTAWA, ON K1H 8M5, CANADA; UNIV CALIF LOS ANGELES, SCH MED, DEPT PHYSIOL & MED, LOS ANGELES, CA 90024 USA; MCGILL UNIV, MONTREAL NEUROL INST, MONTREAL, PQ H3A 2B4, CANADA	University of Ottawa; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; McGill University								AHN AH, 1993, NAT GENET, V3, P283, DOI 10.1038/ng0493-283; ARAHATA K, 1988, NATURE, V333, P861, DOI 10.1038/333861a0; BELCASTRO AN, 1991, MOL CELL BIOCHEM, V103, P113; BONILLA E, 1988, CELL, V54, P447, DOI 10.1016/0092-8674(88)90065-7; BRENMAN JE, 1995, CELL, V82, P743, DOI 10.1016/0092-8674(95)90471-9; CAMPANELLI JT, 1994, CELL, V77, P663, DOI 10.1016/0092-8674(94)90051-5; CAMPBELL KP, 1989, NATURE, V338, P259, DOI 10.1038/338259a0; ERVASTI JM, 1991, J BIOL CHEM, V266, P9161; FRANK JS, 1994, AM J PHYSIOL-CELL PH, V267, pC1707, DOI 10.1152/ajpcell.1994.267.6.C1707; FRANK JS, 1992, J CELL BIOL, V117, P337, DOI 10.1083/jcb.117.2.337; GEE SH, 1994, CELL, V77, P675, DOI 10.1016/0092-8674(94)90052-3; HEMMINGS L, 1992, J CELL BIOL, V116, P1369, DOI 10.1083/jcb.116.6.1369; Herman IM, 1993, CURR OPIN CELL BIOL, V5, P48, DOI 10.1016/S0955-0674(05)80007-9; HOFFMAN EP, 1987, CELL, V51, P919, DOI 10.1016/0092-8674(87)90579-4; HOFFMAN EP, 1987, NATURE, V330, P754, DOI 10.1038/330754a0; HUNTER EG, 1984, CAN J PHYSIOL PHARM, V62, P1423, DOI 10.1139/y84-236; IBRAGHIMOVBESKROVNAYA O, 1992, NATURE, V355, P696, DOI 10.1038/355696a0; IWATA Y, 1993, BIOCHEM BIOPH RES CO, V190, P589, DOI 10.1006/bbrc.1993.1089; JASMIN G, 1982, MUSCLE NERVE, V5, P20, DOI 10.1002/mus.880050105; KARPATI G, 1993, J NEUROPATH EXP NEUR, V52, P119, DOI 10.1097/00005072-199303000-00004; KLIETSCH R, 1993, CIRC RES, V72, P349, DOI 10.1161/01.RES.72.2.349; KOENIG M, 1988, CELL, V53, P219, DOI 10.1016/0092-8674(88)90383-2; LEVINE BA, 1990, FEBS LETT, V263, P159, DOI 10.1016/0014-5793(90)80728-2; LI K, 1993, CARDIOVASC RES, V27, P968, DOI 10.1093/cvr/27.6.968; MAN NT, 1991, J CELL BIOL, V115, P1695; MATSUMURA K, 1992, NATURE, V359, P320, DOI 10.1038/359320a0; MENKE A, 1991, NATURE, V349, P69, DOI 10.1038/349069a0; MESSINA DA, 1994, J MOL CELL CARDIOL, V26, P937, DOI 10.1006/jmcc.1994.1111; MUNTONI F, 1993, NEW ENGL J MED, V329, P921, DOI 10.1056/NEJM199309233291304; NIGRO G, 1990, INT J CARDIOL, V26, P271, DOI 10.1016/0167-5273(90)90082-G; NIGRO G, 1994, NEUROMUSCULAR DISORD, V4, P371, DOI 10.1016/0960-8966(94)90073-6; OHLENDIECK K, 1991, J CELL BIOL, V112, P135, DOI 10.1083/jcb.112.1.135; PERENNEC J, 1992, BASIC RES CARDIOL, V87, P54, DOI 10.1007/BF00795390; PERI V, 1994, MOL CELL BIOCHEM, V130, P57, DOI 10.1007/BF01084268; PERI V, 1992, THESIS U OTTAWA; PHILIPSON KD, 1988, BIOCHIM BIOPHYS ACTA, V945, P298, DOI 10.1016/0005-2736(88)90492-0; PONS F, 1994, CIRCULATION, V90, P369, DOI 10.1161/01.CIR.90.1.369; ROBERDS SL, 1993, J BIOL CHEM, V268, P11496; ROBERDS SL, 1994, CELL, V78, P625, DOI 10.1016/0092-8674(94)90527-4; SALVIATI G, 1989, BIOCHEM J, V258, P837, DOI 10.1042/bj2580837; SATO O, 1992, J BIOCHEM-TOKYO, V112, P631, DOI 10.1093/oxfordjournals.jbchem.a123951; SCHAPER J, 1991, CIRCULATION, V83, P504, DOI 10.1161/01.CIR.83.2.504; SEILER S, 1988, METHOD ENZYMOL, V157, P26; SOLE MJ, 1988, AM J CARDIOL, V62, pG20; TUANA BS, 1987, MOL CELL BIOCHEM, V76, P173; WATKINS SC, 1988, NATURE, V333, P863, DOI 10.1038/333863a0; WAY M, 1992, FEBS LETT, V301, P243, DOI 10.1016/0014-5793(92)80249-G; XU H, 1994, NAT GENET, V8, P297, DOI 10.1038/ng1194-297; YOSHIDA K, 1993, MUSCLE NERVE, V16, P1161, DOI 10.1002/mus.880161104; YOSHIDA M, 1990, J BIOCHEM-TOKYO, V108, P748, DOI 10.1093/oxfordjournals.jbchem.a123276; ZUBRZYCKAGAARN EF, 1988, NATURE, V333, P466, DOI 10.1038/333466a0	51	40	40	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 24	1996	271	21					12364	12371		10.1074/jbc.271.21.12364	http://dx.doi.org/10.1074/jbc.271.21.12364			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UL660	8647839	hybrid			2022-12-25	WOS:A1996UL66000041
J	Unzai, S; Hori, H; Miyazaki, G; Shibayama, N; Morimoto, H				Unzai, S; Hori, H; Miyazaki, G; Shibayama, N; Morimoto, H			Oxygen equilibrium properties of chromium(III)-iron(II) hybrid hemoglobins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR MAGNETIC-RESONANCE; ELECTRON-PARAMAGNETIC RESONANCE; STATE HUMAN-HEMOGLOBIN; PROTOPORPHYRIN-IX; VALENCY HYBRIDS; LIGHT-ABSORPTION; LIGATION STATES; CARBON-MONOXIDE; LIGAND-BINDING; KINETICS	Cr(III)-Fe(II) hybrid hemoglobins, alpha(2)(Cr)beta(2)(Fe) and alpha(2)(Fe)beta(2)(Cr), in which hemes in either the alpha- or beta-subunits were substituted with chromium(III) protoporphyrin IX (Cr(III)PPIX), were prepared and characterized by oxygen equilibrium measurements. Because Cr(III)PPM binds neither oxygen molecules nor carbon monoxide, the oxygen equilibrium properties of Fe(II) subunits within these hybrids can be analyzed by a two-step oxygen equilibrium scheme. The oxygen equilibrium constants for both hybrids at the second oxygenation step agree with those for human adult hemoglobin at the last oxygenation step (at pH 6.5-8.4 with and without inositol hexaphosphate at 25 degrees C). The similarity between the effects of the Cr(III)PPM and each subunits' oxyheme on the oxygen equilibrium properties of the counterpart Fe(II) subunits within hemoglobin indicate the utility of Cr(III)PPM as a model for a permanently oxygenated heme within the hemoglobin molecule. We found that Cr(III)-Fe(II) hybrid hemoglobins have several advantages over cyanomet valency hybrid hemoglobins, which have been frequently used as a model system for partially oxygenated hemoglobins. In contrast to cyanomet heme, Cr(III)PPM within hemoglobin is not subject to reduction with dithionite or enzymatic reduction systems. Therefore, we could obtain more accurate and reasonable oxygen equilibrium curves of Cr(III)-Fe(II) hybrids in the presence of an enzymatic reduction system, and we could obtain single crystals of deoxy-alpha(2)(Cr)beta(2)(Fe) when grown in low salt solution in the presence of polyethylene glycol 1000 and 50 mM dithionite.	JICHI MED SCH,DEPT PHYS,MINAMI KAWACHI,TOCHIGI 32904,JAPAN	Jichi Medical University	Unzai, S (corresponding author), OSAKA UNIV,FAC ENGN SCI,DEPT BIOPHYS ENGN,TOYONAKA,OSAKA 560,JAPAN.			Shibayama, Naoya/0000-0002-2208-1126				ACKERS GK, 1992, SCIENCE, V255, P54, DOI 10.1126/science.1553532; ALSTON K, 1984, HEMOGLOBIN, V8, P47, DOI 10.3109/03630268408996960; BANERJEE R, 1973, J MOL BIOL, V73, P455, DOI 10.1016/0022-2836(73)90093-4; BANERJEE R, 1969, J MOL BIOL, V42, P351, DOI 10.1016/0022-2836(69)90048-5; BRANTLEY RE, 1993, J BIOL CHEM, V268, P6995; BRUNORI M, 1970, J MOL BIOL, V49, P461, DOI 10.1016/0022-2836(70)90257-3; BUCHLER JW, 1975, PORPHYRINS METALLOPO, P191; CASSOLY R, 1972, J BIOL CHEM, V247, P7332; CASSOLY R, 1971, BIOCHEM BIOPH RES CO, V44, P1015, DOI 10.1016/S0006-291X(71)80187-0; DAUGHERTY MA, 1994, BIOCHEMISTRY-US, V33, P10345, DOI 10.1021/bi00200a015; DEATHERAGE JF, 1976, J MOL BIOL, V104, P687, DOI 10.1016/0022-2836(76)90129-7; DOYLE ML, 1992, BIOCHEMISTRY-US, V31, P11182, DOI 10.1021/bi00160a032; EARLEY JE, 1965, TRANSITION METAL CHE, V1, P34; FIECHTNER MD, 1980, BIOCHEM BIOPH RES CO, V92, P277, DOI 10.1016/0006-291X(80)91549-1; FRONTICELLI C, 1993, BIOCHEMISTRY-US, V32, P1235, DOI 10.1021/bi00056a006; FUJII M, 1993, J BIOL CHEM, V268, P15386; HAYASHI A, 1973, BIOCHIM BIOPHYS ACTA, V310, P309, DOI 10.1016/0005-2795(73)90110-4; HOARD JL, 1971, SCIENCE, V174, P1295, DOI 10.1126/science.174.4016.1295; HORI H, 1991, BIOCHIM BIOPHYS ACTA, V1077, P392, DOI 10.1016/0167-4838(91)90556-F; IMAI K, 1977, J MOL BIOL, V109, P83, DOI 10.1016/S0022-2836(77)80047-8; IMAI K, 1970, Biochimica et Biophysica Acta, V200, P189, DOI 10.1016/0005-2795(70)90163-7; Imai K, 1981, Methods Enzymol, V76, P470; Imai K, 1981, Methods Enzymol, V76, P438; KILMARTIN JV, 1971, BIOCHEM J, V124, P31, DOI 10.1042/bj1240031; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUISI B, 1990, J MOL BIOL, V214, P7, DOI 10.1016/0022-2836(90)90139-D; LUISI B, 1989, J MOL BIOL, V206, P723, DOI 10.1016/0022-2836(89)90579-2; LYNCH RE, 1976, J BIOL CHEM, V251, P1015; MAEDA T, 1972, BIOCHEMISTRY-US, V11, P3685, DOI 10.1021/bi00770a004; MATHEWS AJ, 1989, J BIOL CHEM, V264, P16573; MIURA S, 1982, BIOCHEMISTRY-US, V21, P6280, DOI 10.1021/bi00267a037; MUKERJI I, 1994, BIOCHEMISTRY-US, V33, P13132, DOI 10.1021/bi00248a024; NAGAI K, 1977, J MOL BIOL, V111, P41, DOI 10.1016/S0022-2836(77)80130-7; OGAWA S, 1972, J MOL BIOL, V70, P315, DOI 10.1016/0022-2836(72)90542-6; OGAWA S, 1971, BIOCHEM BIOPH RES CO, V42, P9, DOI 10.1016/0006-291X(71)90354-8; PERRELLA M, 1994, BIOCHEMISTRY-US, V33, P10358, DOI 10.1021/bi00200a016; PERUTZ MF, 1990, ANNU REV PHYSIOL, V52, P1; PHILO JS, 1990, J BIOL CHEM, V265, P139; SCHEIDT WR, 1981, CHEM REV, V81, P543, DOI 10.1021/cr00046a002; SCHEIDT WR, 1977, ACCOUNTS CHEM RES, V10, P339, DOI 10.1021/ar50117a005; SHAANAN B, 1983, J MOL BIOL, V171, P31, DOI 10.1016/S0022-2836(83)80313-1; SHIBAYAMA N, 1993, BIOCHEMISTRY-US, V32, P8792, DOI 10.1021/bi00085a009; SHIBAYAMA N, 1986, J MOL BIOL, V192, P331, DOI 10.1016/0022-2836(86)90368-2; SHIBAYAMA N, 1986, J MOL BIOL, V192, P323, DOI 10.1016/0022-2836(86)90367-0; SHIBAYAMA N, 1995, BIOCHEMISTRY-US, V34, P4773, DOI 10.1021/bi00014a035; SHIBAYAMA N, 1987, BIOCHEMISTRY-US, V26, P2194, DOI 10.1021/bi00382a019; SHIBAYAMA N, 1991, BIOCHEMISTRY-US, V30, P8158, DOI 10.1021/bi00247a010; SMITH FR, 1985, P NATL ACAD SCI USA, V82, P5347, DOI 10.1073/pnas.82.16.5347; SUMMERVILLE DA, 1977, J AM CHEM SOC, V99, P8195, DOI 10.1021/ja00467a012; SZABO A, 1975, BIOCHEMISTRY-US, V14, P931, DOI 10.1021/bi00676a009; VANDEGRIFF KD, 1991, J BIOL CHEM, V266, P17049; WARD KB, 1975, J MOL BIOL, V98, P161, DOI 10.1016/S0022-2836(75)80107-0; WATERMAN MR, 1970, J BIOL CHEM, V245, P5847; WINTERBOURN CC, 1976, BIOCHEM J, V155, P493, DOI 10.1042/bj1550493	54	16	16	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 24	1996	271	21					12451	12456		10.1074/jbc.271.21.12451	http://dx.doi.org/10.1074/jbc.271.21.12451			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UL660	8647851	hybrid			2022-12-25	WOS:A1996UL66000053
J	Chitnis, VP; Jung, YS; Albee, L; Golbeck, JH; Chitnis, PR				Chitnis, VP; Jung, YS; Albee, L; Golbeck, JH; Chitnis, PR			Mutational analysis of photosystem I polypeptides - Role of PsaD and the Lysyl 106 residue in the reductase activity of photosystem I	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHEMICAL CROSS-LINKING; SUBUNIT; PROTEIN; FERREDOXIN; BINDING; GENE; SPINACH; IDENTIFICATION; BIOTINYLATION; PLASTOCYANIN	The ADC4 mutant of the cyanobacterium Synechocystis sp. PCC 6803 was studied to determine the structural and functional consequences of the absence of PsaD in photosystem I. Isolated ADC4 membranes were shown to be deficient in ferredoxin-mediated NADP(+) reduction, even though charge separation between P700 and F-A/F-B occurred with high efficiency. Unlike the wild type, F-B became preferentially photoreduced when ADC4 membranes were illuminated at 15 K, and the EPR line shapes were relatively broad. Membrane fragments oriented in two dimensions on thin mylar films showed that the g tensor axes of F-A(-) and F-B(-) were identical in the ADC4 and wild type strains, implying that PsaC is oriented similarly on the reaction center. PsaC and the F-A/F-B iron-sulfur clusters are lost more readily from the ADC4 membranes after treatment with Triton X-100 or chaotropic agents, implying a stabilizing role for PsaD. The specific role of Lys(106) of PsaD, which can be crosslinked to Glu(93) of ferredoxin (Lelong et al. (1994) J. Biol. Chem. 269, 10034-10039), was probed by site-directed mutagenesis. Chemical cross-linking and protease treatment experiments did not reveal any drastic alterations in the conformation of the mutant PsaD proteins. The EPR spectra of F-A and F-B in membranes of the Lys(106) mutants were similar to those of the wild type. Membranes of all Lys(106) mutants showed wild type rates of flavodoxin reduction and flavodoxin-mediated NADP(+) reduction, but had 10-54% decrease in the ferredoxin-mediated NADP(+) reduction rates. This implies that Lys(106) is a dispensable component of the docking site on the reducing side of photosystem I and an ionic interaction between Lys(106) of PsaD and Glu(93) of ferredoxin is not essential for electron transfer to ferredoxin. These results demonstrate that PsaD serves distinct roles in modulating the EPR spectral characteristics of F-A and F-B in stabilizing PsaC on the reaction center, and in facilitating ferredoxin-mediated NADP(+) photoreduction on the reducing side of photosystem I.	KANSAS STATE UNIV,DIV BIOL,MANHATTAN,KS 66506; UNIV NEBRASKA,DEPT BIOCHEM,LINCOLN,NE 68588	Kansas State University; University of Nebraska System; University of Nebraska Lincoln								ADMAN ET, 1973, J BIOL CHEM, V248, P3987; ARNON DI, 1949, PLANT PHYSIOL, V24, P1, DOI 10.1104/pp.24.1.1; BAYER EA, 1990, METHOD ENZYMOL, V184, P138; BEARDEN AJ, 1972, BIOCHIM BIOPHYS ACTA, V283, P456, DOI 10.1016/0005-2728(72)90262-9; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHITNIS PR, 1995, PHOTOSYNTH RES, V44, P23, DOI 10.1007/BF00018294; CHITNIS VP, 1993, FEBS LETT, V336, P330, DOI 10.1016/0014-5793(93)80831-E; CHITNIS VP, 1993, J BIOL CHEM, V268, P11678; DUNN PPJ, 1988, PLANT MOL BIOL, V11, P311, DOI 10.1007/BF00027388; FRANKEL LK, 1992, BIOCHEMISTRY-US, V31, P11059, DOI 10.1021/bi00160a015; GOLBECK JH, 1994, MOL BIOL CYANOBACTER, P179; HAVARRO JA, 1995, ARCH BIOCHEM BIOPHYS, V321, P229; HERVAS M, 1992, PHOTOCHEM PHOTOBIOL, V56, P319, DOI 10.1111/j.1751-1097.1992.tb02166.x; Higuchi R., 1989, PCR TECHNOLOGY, P61; HIPPLER M, 1989, FEBS LETT, V250, P280, DOI 10.1016/0014-5793(89)80738-0; Jung YS, 1995, PHOTOSYNTH RES, V46, P249, DOI 10.1007/BF00020437; LELONG C, 1994, J BIOL CHEM, V269, P10034; LI N, 1991, BIOCHEMISTRY-US, V30, P7863, DOI 10.1021/bi00245a028; MERATI G, 1987, FEBS LETT, V215, P37, DOI 10.1016/0014-5793(87)80109-6; OHOKA H, 1988, J BIOCHEM-TOKYO, V103, P962, DOI 10.1093/oxfordjournals.jbchem.a122394; ROUSSEAU F, 1993, EMBO J, V12, P1755, DOI 10.1002/j.1460-2075.1993.tb05823.x; SETIF PQY, 1994, BIOCHEMISTRY-US, V33, P8495, DOI 10.1021/bi00194a014; SONOIKE K, 1993, BIOCHIM BIOPHYS ACTA, V1141, P52, DOI 10.1016/0005-2728(93)90188-L; VIEIRA J, 1982, GENE, V19, P259, DOI 10.1016/0378-1119(82)90015-4; WEBER N, 1993, BIOCHIM BIOPHYS ACTA, V1143, P204, DOI 10.1016/0005-2728(93)90144-5; WYNN RM, 1988, BIOCHEMISTRY-US, V27, P5863, DOI 10.1021/bi00416a007; WYNN RM, 1989, BIOCHEMISTRY-US, V28, P5554, DOI 10.1021/bi00439a032; XU Q, 1994, PLANT PHYSIOL, V106, P1057, DOI 10.1104/pp.106.3.1057; XU Q, 1994, J BIOL CHEM, V269, P21512; XU Q, 1995, J BIOL CHEM, V270, P16243, DOI 10.1074/jbc.270.27.16243; XU Q, 1994, PLANT MOL BIOL, V2624, P294; XU QA, 1994, J BIOL CHEM, V269, P3205; XU QA, 1994, PLANT PHYSIOL, V106, P617, DOI 10.1104/pp.106.2.617; YU L, 1993, PLANT PHYSIOL, V103, P171, DOI 10.1104/pp.103.1.171; ZHAO J, 1993, MOL MICROBIOL, V9, P183, DOI 10.1111/j.1365-2958.1993.tb01680.x; ZILBER AL, 1988, PLANT PHYSIOL, V88, P810, DOI 10.1104/pp.88.3.810	36	45	50	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 17	1996	271	20					11772	11780		10.1074/jbc.271.20.11772	http://dx.doi.org/10.1074/jbc.271.20.11772			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UL250	8662633	hybrid			2022-12-25	WOS:A1996UL25000032
J	Gora, M; Grzybowska, E; Rytka, J; LabbeBois, R				Gora, M; Grzybowska, E; Rytka, J; LabbeBois, R			Probing the active-site residues in Saccharomyces cerevisiae ferrochelatase by directed mutagenesis - In vivo and in vitro analyses	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOVINE FERROCHELATASE; MOLECULAR-CLONING; YEAST; GENE; SEQUENCE; DISRUPTION; EXPRESSION; VECTORS; MUTANT	Ferrochelatase is a mitochondrial inner membrane-bound enzyme that catalyzes the insertion of ferrous iron into protoporphyrin, the terminal step in protoheme biosynthesis. The functional/structural roles of 10 invariant amino acid residues were investigated by site-directed mutagenesis in the yeast Saccharomyces cerevisiae ferrochelatase. The mutant enzymes were expressed in a yeast strain lacking the ferrochelatase gene HEM15 and in Escherichia coli. The kinetic parameters of the mutant enzymes were determined for the enzymes associated with the yeast membranes and the enzymes in the bacterial soluble fraction, They were compared with the in vivo functioning of the mutant enzymes. The main conclusions are the following, Glu-314 is critical for catalysis, and we suggest that it is the base responsible for abstracting the N-pyrrole proton(s). His-235 is essential for metal binding, Asp-246 and Tyr-248 are also involved in metal binding in a synergistic manner. The K-m for protoporphyrin was also increased in the H235L, D246A, and Y248L mutants, suggesting that the binding sites of the two substrates are not independent of each other. The R87A, Y95L, Q111E, Q273E, W282L, and F308A mutants had 1.2-2-fold increased V-m and 4-10-fold increased K-m values for protoporphyrin, but the amount of heme made in vivo was 10-100% of the normal value. These mutations probably affected the geometry of the active center, resulting in improper positioning of protoporphyrin.	UNIV PARIS 07,INST JACQUES MONOD,LAB BIOCHIM PORPHYRINES,F-75251 PARIS,FRANCE; POLISH ACAD SCI,INST BIOCHEM & BIOPHYS,PL-02106 WARSAW,POLAND	UDICE-French Research Universities; Universite Paris Cite; Polish Academy of Sciences; Institute of Biochemistry & Biophysics - Polish Academy of Sciences			Gora, Monika/AAB-9577-2020; Grzybowska, Ewa/F-2711-2013	Gora, Monika/0000-0002-8554-663X; 				ABBAS A, 1993, J BIOL CHEM, V268, P8541; BERBEN G, 1991, YEAST, V7, P475, DOI 10.1002/yea.320070506; BONNEAUD N, 1991, YEAST, V7, P609, DOI 10.1002/yea.320070609; BRENNER DA, 1991, P NATL ACAD SCI USA, V88, P849, DOI 10.1073/pnas.88.3.849; CAMADRO JM, 1988, J BIOL CHEM, V263, P11675; CAMADRO JM, 1982, BIOCHIM BIOPHYS ACTA, V707, P280, DOI 10.1016/0167-4838(82)90362-4; Dailey H. A., 1990, BIOSYNTHESIS HEME CH, P123; DAILEY HA, 1994, J BIOL CHEM, V269, P390; DAILEY HA, 1986, J BIOL CHEM, V261, P7902; DAILEY HA, 1994, BIOCHEMISTRY-US, V33, P403, DOI 10.1021/bi00168a003; DAILEY HA, 1985, BIOCHEMISTRY-US, V24, P1287, DOI 10.1021/bi00327a003; DAILEY HA, 1984, J BIOL CHEM, V259, P2711; FERREIRA GC, 1994, J BIOL CHEM, V269, P7062; FERREIRA GC, 1994, J BIOL CHEM, V269, P4396; FERREIRA GC, 1995, J BIOENERG BIOMEMBR, V27, P221, DOI 10.1007/BF02110037; FRANCO R, 1995, J BIOL CHEM, V270, P26352, DOI 10.1074/jbc.270.44.26352; FRUSTACI JM, 1992, J BACTERIOL, V174, P4223, DOI 10.1128/JB.174.13.4223-4229.1992; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; GORA M, 1996, IN PRESS BIOCHIMIE P; HANSSON M, 1992, J BACTERIOL, V174, P8081, DOI 10.1128/JB.174.24.8081-8093.1992; Hansson M, 1995, PROTEINS, V23, P607, DOI 10.1002/prot.340230419; HANSSON M, 1994, EUR J BIOCHEM, V220, P201, DOI 10.1111/j.1432-1033.1994.tb18615.x; KENDALL DA, 1988, J BIOL CHEM, V263, P7261; KOHNO H, 1994, BBA-PROTEIN STRUCT M, V1209, P95, DOI 10.1016/0167-4838(94)90142-2; Labbe-Bois Rosine, 1994, V11, P413; LABBEBOIS R, 1977, MOL GEN GENET, V156, P177, DOI 10.1007/BF00283490; LABBEBOIS R, 1990, J BIOL CHEM, V265, P7278; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lavallee DK, 1988, MECH PRINCIPLES ENZY, P279; MIYAMOTO K, 1991, J MOL BIOL, V219, P393, DOI 10.1016/0022-2836(91)90180-E; MIYAMOTO K, 1994, PLANT PHYSIOL, V105, P769, DOI 10.1104/pp.105.2.769; NAKAHASHI Y, 1990, BIOCHEM BIOPH RES CO, V173, P748, DOI 10.1016/S0006-291X(05)80099-3; PERELLA FW, 1988, ANAL BIOCHEM, V174, P437; Rose MD., 1990, METHODS YEAST GENETI; RYTKA J, 1984, BIOCHEM J, V218, P405, DOI 10.1042/bj2180405; Sambrook J., 2002, MOL CLONING LAB MANU; SMITH AG, 1994, J BIOL CHEM, V269, P13405; TAKETANI S, 1990, J BIOL CHEM, V265, P19377; TAKETANI S, 1993, TOHOKU J EXP MED, V170, P1	39	51	53	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 17	1996	271	20					11810	11816		10.1074/jbc.271.20.11810	http://dx.doi.org/10.1074/jbc.271.20.11810			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UL250	8662602	hybrid			2022-12-25	WOS:A1996UL25000038
J	Palmiter, KA; Kitada, Y; Muthuchamy, M; Wieczorek, DF; Solaro, RJ				Palmiter, KA; Kitada, Y; Muthuchamy, M; Wieczorek, DF; Solaro, RJ			Exchange of beta- for alpha-tropomyosin in hearts of transgenic mice induces changes in thin filament response to Ca2+ strong cross-bridge binding, and protein phosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TROPONIN-C; MYOSIN SUBFRAGMENT-1; STRIATED-MUSCLE; ACTIN; CA-2+	Despite its potential as a key determinant of the functional state of striated muscle, the impact of tropomyosin (Tm) isoform switching on mammalian myofilament activation and regulation in the intact lattice remains unclear. Using a transgenic approach to specifically exchange beta-Tm for the native alpha-Tm in mouse hearts, we have been able to uncover novel functions of Tm isoform switching in the heart. The myofilaments containing beta-Tm demonstrated an increase in the activation of the thin filament by strongly bound cross-bridges, an increase in Ca2+ sensitivity of steady state force, and a decrease in the rightward shift of the Ca2+-force relation induced by cAMP-dependent phosphorylation. Our results are the first to demonstrate the specific effects of Tm isoform switching on mammalian thin filament activation in the intact lattice and suggest an important role for Tm in modulation of myofilament activity by phosphorylation of troponin.	UNIV ILLINOIS, COLL MED, DEPT PHYSIOL & BIOPHYS M C 901, CHICAGO, IL 60612 USA; UNIV CINCINNATI, COLL MED, DEPT MOLEC GENET BIOCHEM & MICROBIOL, CINCINNATI, OH 45267 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University System of Ohio; University of Cincinnati					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007692, P01HL046826, R01HL022231, R37HL022231] Funding Source: NIH RePORTER; NHLBI NIH HHS [T32 HL-07692, HL 46826, HL 22231] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALHILLAWI E, 1995, EUR J BIOCHEM, V228, P962; AMPHLETT GW, 1976, FEBS LETT, V63, P22, DOI 10.1016/0014-5793(76)80186-X; CHALOVICH JM, 1982, J BIOL CHEM, V257, P2432; CHIU YL, 1982, AM J PHYSIOL, V243, pC299, DOI 10.1152/ajpcell.1982.243.5.C299; CHO YJ, 1990, J BIOL CHEM, V265, P538; CUDA G, 1993, J CLIN INVEST, V91, P2861, DOI 10.1172/JCI116530; CUMMINS P, 1973, BIOCHEM J, V133, P765, DOI 10.1042/bj1330765; DURAND JB, 1995, ANN MED, V27, P311, DOI 10.3109/07853899509002583; GODT RE, 1982, J GEN PHYSIOL, V80, P279, DOI 10.1085/jgp.80.2.279; GREENFIELD NJ, 1994, PROTEIN SCI, V3, P402; GUO XD, 1994, J BIOL CHEM, V269, P15210; HERZIG JW, 1981, PFLUG ARCH EUR J PHY, V391, P208, DOI 10.1007/BF00596172; HILL TL, 1980, P NATL ACAD SCI-BIOL, V77, P3186, DOI 10.1073/pnas.77.6.3186; Huxley H. E., 1972, COLD SPRING HARB SYM, V37, P361; IIO T, 1985, J BIOCHEM-TOKYO, V98, P261, DOI 10.1093/oxfordjournals.jbchem.a135266; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEHMAN W, 1994, NATURE, V368, P65, DOI 10.1038/368065a0; LEHRER SS, 1994, J MUSCLE RES CELL M, V15, P232; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MCKILLOP DFA, 1993, BIOPHYS J, V65, P693, DOI 10.1016/S0006-3495(93)81110-X; MOSS RL, 1992, CIRC RES, V70, P865, DOI 10.1161/01.RES.70.5.865; Muthuchamy M, 1995, J BIOL CHEM, V270, P30593, DOI 10.1074/jbc.270.51.30593; NAKAJIMATANIGUCHI C, 1995, J MOL CELL CARDIOL, V27, P2053, DOI 10.1016/0022-2828(95)90026-8; OBRIEN EJ, 1975, J MOL BIOL, V99, P461, DOI 10.1016/S0022-2836(75)80138-0; Pagani ED, 1984, METHOD PHARMACOL, V5, P44; PALMITER KA, 1995, BIOPHYS J, V68, P57; PAN BS, 1989, J BIOL CHEM, V264, P8495; PEARLSTONE JR, 1982, J BIOL CHEM, V257, P587; PHILLIPS GN, 1986, J MOL BIOL, V192, P111, DOI 10.1016/0022-2836(86)90468-7; POPP D, 1993, J MOL BIOL, V229, P279, DOI 10.1006/jmbi.1993.1032; SOLARO RJ, 1976, NATURE, V262, P615, DOI 10.1038/262615a0; Solaro RJ, 1996, J MOL CELL CARDIOL, V28, P217; STRASBURG GM, 1985, J BIOL CHEM, V260, P366; SUBRAMANIAM A, 1991, J BIOL CHEM, V266, P24613; SWEENEY HL, 1994, J BIOL CHEM, V269, P1603; TAO T, 1990, SCIENCE, V247, P1339, DOI 10.1126/science.2138356; THEIRFELDER L, 1994, CELL, V77, P701; THOMAS L, 1994, BIOPHYS J, V66, pA310; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WATKINS H, 1995, NEW ENGL J MED, V332, P1058, DOI 10.1056/NEJM199504203321603; ZHANG R, 1995, CIRC RES, V76, P1028, DOI 10.1161/01.RES.76.6.1028; [No title captured]	42	78	78	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 17	1996	271	20					11611	11614		10.1074/jbc.271.20.11611	http://dx.doi.org/10.1074/jbc.271.20.11611			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UL250	8662805	hybrid			2022-12-25	WOS:A1996UL25000005
J	Kato, MV; Sato, H; Tsukada, T; Ikawa, Y; Aizawa, S; Nagayoshi, M				Kato, MV; Sato, H; Tsukada, T; Ikawa, Y; Aizawa, S; Nagayoshi, M			A follistatin-like gene, mac25, may act as a growth suppressor of osteosarcoma cells	ONCOGENE			English	Article						mac25; follistatin; p53; growth suppressor	ACTIVIN-BINDING PROTEIN; MICE; P53; PROTEOGLYCANS; INHIBITION; RECEPTOR; KINASES; P21	mac25, a retinoic acid-inducible gene that is expressed at high levels in senescent epithelial cells, was initially cloned as a gene that is differentially expressed in meningioma, Although the homology of its product with members of family of insulin-like growth factor-binding proteins was suggested, the product also exhibits strong homology to follistatin, an activin-binding protein, However, a domain corresponding to the carboxyl terminus of follistatin is not found in mac25, The carboxyl-terminally truncated form of follistatin, generated by alternative splicing, has stronger activin-binding activity than the complete form, This result suggests that mac25 might act as an activated follistatin, Clonal growth of a p53-deficient osteosarcoma cell line was strongly inhibited when the murine mac25 gene, as well as the p53 gene, was introduced, Resembling activins that belong to the transforming growth factor-beta (TGF-beta) superfamily, mac25 and p53 might associate with similar but distinct targets, namely cyclin-dependent kinase inhibitors. However, there is no evidence for compensation of p53 function by mac25 in the development of p53-deficient mice, as judged from the pattern of expression of mac25 in mice, mac25 might act as a tumor suppressor, modulating signaling of the TGF-beta family, as does alpha-inhibin.	SAITAMA UNIV,FAC SCI,DEPT REGULAT BIOL,URAWA,SAITAMA 338,JAPAN; TOKYO MED & DENT UNIV,DEPT RETROVIRAL REGULAT,DIV MED RES,BUNKYO KU,TOKYO 113,JAPAN; KUMAMOTO UNIV,SCH MED,INST EMBRYOL & GENET,DEPT MORPHOGENESIS,KUMAMOTO 860,JAPAN	Saitama University; Tokyo Medical & Dental University (TMDU); Kumamoto University	Kato, MV (corresponding author), RIKEN,TSUKUBA LIFE SCI CTR,MOLEC ONCOL LAB,3-1-1 KOYODAI,TSUKUBA,IBARAKI 305,JAPAN.		Kato, Mitsuo/D-5411-2009	Kato, Mitsuo/0000-0002-1783-1084				BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; GU Y, 1993, NATURE, V366, P707, DOI 10.1038/366707a0; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; HARPER JW, 1993, CELL, V75, P805; KINGSLEY DM, 1992, CELL, V71, P399, DOI 10.1016/0092-8674(92)90510-J; KOZAK M, 1981, NUCLEIC ACIDS RES, V9, P5233, DOI 10.1093/nar/9.20.5233; LOPEZCASILLAS F, 1993, CELL, V73, P1435, DOI 10.1016/0092-8674(93)90368-Z; MASUDA H, 1987, P NATL ACAD SCI USA, V84, P7716, DOI 10.1073/pnas.84.21.7716; MATHER JP, 1992, P SOC EXP BIOL MED, V201, P1; MATHEWS LS, 1991, CELL, V65, P973, DOI 10.1016/0092-8674(91)90549-E; MATZUK MM, 1995, NATURE, V374, P360, DOI 10.1038/374360a0; MATZUK MM, 1992, NATURE, V360, P313, DOI 10.1038/360313a0; MURPHY M, 1993, CELL GROWTH DIFFER, V4, P715; NAKAMURA T, 1991, J BIOL CHEM, V266, P19432; NAKAMURA T, 1990, SCIENCE, V247, P836, DOI 10.1126/science.2106159; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; PRIVES C, 1994, CELL, V78, P543, DOI 10.1016/0092-8674(94)90519-3; SATO H, 1995, BIOCHEM BIOPH RES CO, V214, P468, DOI 10.1006/bbrc.1995.2310; SELLHEYER K, 1993, P NATL ACAD SCI USA, V90, P5237, DOI 10.1073/pnas.90.11.5237; SHIMASAKI S, 1988, P NATL ACAD SCI USA, V85, P4218, DOI 10.1073/pnas.85.12.4218; SUGINO K, 1993, J BIOL CHEM, V268, P15579; SWISSHELM K, 1995, P NATL ACAD SCI USA, V92, P4472, DOI 10.1073/pnas.92.10.4472; TENDIJKE P, 1994, SCIENCE, V264, P101, DOI 10.1126/science.8140412; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; TSUKADA T, 1993, ONCOGENE, V8, P3313; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0	30	56	60	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR 21	1996	12	6					1361	1364						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UC067	8649839				2022-12-25	WOS:A1996UC06700022
J	Wick, W; Petersen, I; Schmutzler, RK; Wolfarth, B; Lenartz, D; Bierhoff, E; Hummerich, J; Muller, DJ; Stangl, AP; Schramm, J; Wiestler, OD; vonDeimling, A				Wick, W; Petersen, I; Schmutzler, RK; Wolfarth, B; Lenartz, D; Bierhoff, E; Hummerich, J; Muller, DJ; Stangl, AP; Schramm, J; Wiestler, OD; vonDeimling, A			Evidence for a novel tumor suppressor gene on chromosome 15 associated with progression to a metastatic stage in breast cancer	ONCOGENE			English	Article						tumor suppressor gene; breast carcinoma; metastasis; allelic loss; chromosome 15	CELL CARCINOMA; ALLELOTYPE; THROMBOSPONDIN; NM23; HETEROZYGOSITY; ANGIOGENESIS; INHIBITION; EXPRESSION	Loss of heterozygosity (LOH) studies have emerged as a valuable indicator for tumor suppressor genes involved in the formation or progression of carcinomas. We here present data indicating that human chromosome 15 harbours a novel putative tumor suppressor gene which appears to play a role during later stages of carcinogenesis and which may be associated with metastasis in breast cancer. In this study, 153 primary and metastatic carcinomas from 101 patients have been analysed for LOH with 13 polymorphic microsatellite markers on chromosome 15. The tumors included carcinoma of the lung in 49 patients, breast carcinoma in 29, colorectal carcinoma in nine, renal carcinoma in five, pancreatic carcinoma in five, urinary bladder carcinoma in two and prostate carcinoma and ovarial carcinoma in one patient each. LOH15 was seen in 42/99 (42%) informative patients. Tn metastatic tumors, LOH15 was observed in 37/68 (54%). High incidences of allelic losses were detected in metastases from lung (56%), breast (70%) and colorectal (67%) carcinomas. In carcinomas of the breast, there was a significant difference (P<0.01) in LOH15 frequencies between non-metastatic tumors (11%) and brain metastases (70%). Such a difference was not observed on the chromosomal arm 17p which yielded high proportions of LOH in both non metastatic breast tumor (73%) and breast carcinoma metastases (90%). In 16 patients, interstitial deletions could be detected. The common region of overlap extended from D15S231 to D15S641, thus mapping this putative tumor suppressor gene to chromosome 15q14. Our data indicate that a gene on chromosome 15 contributes to the pathogenesis of metastatic carcinoma.	UNIV BONN,MED CTR,DEPT NEUROPATHOL,D-53105 BONN,GERMANY; CHARITE,DEPT PATHOL,BERLIN,GERMANY; UNIV BONN,MED CTR,DEPT OBSTET & GYNECOL,D-53105 BONN,GERMANY; UNIV HOSP FREIBURG,INST PATHOL,FREIBURG,GERMANY; HOSP COLOGNE MERHEIM,DEPT NEUROSURG,D-51109 COLOGNE,GERMANY; UNIV HOSP BONN,DEPT PATHOL,D-53105 BONN,GERMANY; UNIV HOSP BONN,DEPT NEUROSURG,D-53105 BONN,GERMANY	University of Bonn; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; University of Bonn; University of Freiburg; University of Bonn; University of Bonn			Müller, Daniel J./L-4159-2016; Wick, Wolfgang/AAA-2545-2020; Mueller, Daniel Josef/GVT-7899-2022; von Deimling, Andreas/F-7774-2013	Müller, Daniel J./0000-0003-4978-4400; Wick, Wolfgang/0000-0002-6171-634X; Mueller, Daniel Josef/0000-0003-4978-4400; von Deimling, Andreas/0000-0002-5863-540X				BAGAVANDOSS P, 1990, BIOCHEM BIOPH RES CO, V170, P867, DOI 10.1016/0006-291X(90)92171-U; BENDER B, 1994, BIOTECHNIQUES, V16, P204; BEVILACQUA G, 1989, CANCER RES, V49, P5185; BOUKAMP P, 1995, ONCOGENE, V11, P961; BUDOWLE B, 1991, AM J HUM GENET, V48, P137; CAVENEE WK, 1983, NATURE, V305, P779, DOI 10.1038/305779a0; CLIBY W, 1993, CANCER RES, V53, P2393; DEVILEE P, 1991, ONCOGENE, V6, P1705; FIDLER IJ, 1982, SCIENCE, V217, P998, DOI 10.1126/science.7112116; FUJIMORI M, 1991, CANCER RES, V51, P89; GOOD DJ, 1990, P NATL ACAD SCI USA, V87, P6624, DOI 10.1073/pnas.87.17.6624; HAHN M, 1993, CLIN CHEM, V39, P549; LAWLER J, 1986, J CELL BIOL, V103, P1635, DOI 10.1083/jcb.103.5.1635; LEONE A, 1991, CANCER RES, V51, P2490; LOUIS DN, 1992, AM J PATHOL, V141, P777; MORITA R, 1991, CANCER RES, V51, P820; RASHEED BKA, 1995, ONCOGENE, V10, P2243; RASTINEJAD F, 1989, CELL, V56, P345, DOI 10.1016/0092-8674(89)90238-9; ROSENGARD AM, 1989, NATURE, V342, P177, DOI 10.1038/342177a0; Sambrook J., 1989, MOL CLONING; SATO S, 1994, CANCER RES, V54, P5652; SATO T, 1990, CANCER RES, V50, P7184; SHISEKI M, 1994, CANCER RES, V54, P5643; STEEG PS, 1988, CANCER RES, V48, P6550; STEEG PS, 1988, J NATL CANCER I, V80, P200, DOI 10.1093/jnci/80.3.200; TARABOLETTI G, 1990, J CELL BIOL, V111, P765, DOI 10.1083/jcb.111.2.765; TSUCHIYA E, 1992, CANCER RES, V52, P2478; VOGELSTEIN B, 1989, SCIENCE, V244, P207, DOI 10.1126/science.2565047; VONDEIMLING A, 1993, NEUROPATH APPL NEURO, V19, P524; VONDEIMLING A, 1994, INT J CANCER, V57, P676, DOI 10.1002/ijc.2910570511; WEINBERG R, 1993, NEURON, V11, P191, DOI 10.1016/0896-6273(93)90177-S; WEINSTATSASLOW DL, 1994, CANCER RES, V54, P6504	32	101	104	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR 7	1996	12	5					973	978						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UA884	8649814				2022-12-25	WOS:A1996UA88400004
J	Roberts, SS				Roberts, SS			Blood safety in the age of AIDS	FASEB JOURNAL			English	Editorial Material								This series of essays was developed as part of FASEB's efforts to educate the general public and the legislators whom it elects about the benefits of fundamental biomedical research-particularly how investment in such research leads to scientific progress, improved health, and economic well-being. ''Blood Safety in the Age of AIDS'' examines the effects of the AIDS epidemic on the safety of the blood supply. Just as a pebble tossed in a lake sends out ripples that last long after the pebble sinks, the discovery more than a decade ago that the AIDS virus was in the blood supply is still having repercussions on research and transfusion practices. New screening tests for blood and new ways of using one's own blood during surgery are among the steps that have made blood transfusions much safer. Meanwhile, researchers continue tracking down new threats and devising ways to circumvent them. (This is the second article in the series.)										[Anonymous], 1990, READINGS RISK; *COMM STUD HIV TRA, 1995, HIV BLOOD SUPPL AN C; EDELSON E, 1993, POP SCI, V242, P122; EDELSON E, 1993, POP SCI, V242, P108; GALEL SA, 1995, ANNU REV IMMUNOL, V13, P201; Lederberg J., 1992, I MED US COMMITTEE; REVELLE M, 1995, FDA PUBLICATION	7	1	1	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	MAR	1996	10	4					391	402		10.1096/fasebj.10.4.8647338	http://dx.doi.org/10.1096/fasebj.10.4.8647338			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	UE557	8647338				2022-12-25	WOS:A1996UE55700003
J	Goruppi, S; Ruaro, E; Schneider, C				Goruppi, S; Ruaro, E; Schneider, C			Gas6, the ligand of Axl tyrosine kinase receptor, has mitogenic and survival activities for serum starved NIH3T3 fibroblasts	ONCOGENE			English	Article						gas6; axl; growth arrest; growth factors	ARREST-SPECIFIC GENE; GROWTH ARREST; PROTEIN-S; SIGNAL-TRANSDUCTION; CELL-DEATH; MURINE FIBROBLASTS; BLOOD-COAGULATION; SYSTEM; PURIFICATION; EXPRESSION	Reversible growth arrest has been characterised for enhanced expression of a set of genes called gas (growth arrest specific). gas6 product (Gas6) is a secreted protein that was identified as the ligand for the tyrosine kinase receptor Axl. Here we report that Gas6 is able to induce cell cycle division entry in serum starved NIH3T3 cells. This mitogenic activity of Gas6 strictly correlates with its ability to interact with NIH3T3 endogenous Axl receptor since it can be abolished by soluble Axl extracellular domain and activates both Axl intrinsic kinase activity and the downstream MAPK pathway. Moreover when ectopic Axl overexpression is performed by microinjection in serum starved NIH3T3 cells, addition of a non mitogenic level of Gas6 induces selective entry into S phase in Axl overexpressing cells. Interestingly, Axl overexpression per se is not able to induce S phase entry. Finally we present evidences indicating that Gas6 is able to protect serum starved NIH3T3 cells from cell death by apoptosis as induced by complete growth factor depletion. The reported survival activity seems to be independent of Gas6 mitogenic activity, thus implicating a double and separable activity for Gas6 during growth arrest.	LAB NAZL CONSORZIO INTERUNIV BIOTECNOL, I-34012 TRIESTE, ITALY; INT CTR GENET ENGN & BIOTECHNOL, I-34012 TRIESTE, ITALY	International Center for Genetic Engineering & Biotechnology (ICGEB)								AARONSON SA, 1991, SCIENCE, V254, P1146, DOI 10.1126/science.1659742; BARLAT I, 1993, CELL GROWTH DIFFER, V4, P105; BASERGA R, 1994, CELL, V79, P927, DOI 10.1016/0092-8674(94)90023-X; BELLOSTA P, 1995, MOL CELL BIOL, V15, P614; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; BRANCOLINI C, 1992, J CELL BIOL, V117, P1251, DOI 10.1083/jcb.117.6.1251; BRANCOLINI C, 1995, EMBO J, V14, P5179, DOI 10.1002/j.1460-2075.1995.tb00202.x; CORDONCARDO C, 1991, CELL, V66, P173, DOI 10.1016/0092-8674(91)90149-S; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; CRAVEN RJ, 1995, INT J CANCER, V60, P791, DOI 10.1002/ijc.2910600611; DAHLBACK B, 1983, BIOCHEM J, V209, P837, DOI 10.1042/bj2090837; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DELSAL G, 1992, CELL, V70, P595, DOI 10.1016/0092-8674(92)90429-G; DELSAL G, 1994, BIOTECHNIQUES, V16, P134; DOWNING JR, 1989, MOL CELL BIOL, V9, P2890, DOI 10.1128/MCB.9.7.2890; FANTL WJ, 1993, ANNU REV BIOCHEM, V62, P453, DOI 10.1146/annurev.bi.62.070193.002321; FAUST M, 1992, ONCOGENE, V7, P1287; FUJIMOTO J, 1994, ONCOGENE, V9, P693; GASIC GP, 1992, P NATL ACAD SCI USA, V89, P2317, DOI 10.1073/pnas.89.6.2317; GAUDINO G, 1994, EMBO J, V13, P3524, DOI 10.1002/j.1460-2075.1994.tb06659.x; GODOWSKI PJ, 1995, CELL, V82, P355, DOI 10.1016/0092-8674(95)90424-7; GORUPPI S, 1994, ONCOGENE, V9, P1537; GRAHAM DK, 1994, CELL GROWTH DIFFER, V5, P647; GRAHAM DK, 1995, ONCOGENE, V10, P2349; JANSSEN JWG, 1991, ONCOGENE, V6, P2113; JIA R, 1994, J BIOL CHEM, V269, P1839; KERR JFR, 1971, J PATHOL, V105, P13, DOI 10.1002/path.1711050103; LAI C, 1991, NEURON, V6, P691, DOI 10.1016/0896-6273(91)90167-X; LIN YZJ, 1991, ONCOGENE, V6, P639; LUNDWALL A, 1986, P NATL ACAD SCI USA, V83, P6716, DOI 10.1073/pnas.83.18.6716; MANFIOLETTI G, 1993, MOL CELL BIOL, V13, P4976, DOI 10.1128/MCB.13.8.4976; MARK MR, 1994, J BIOL CHEM, V269, P10720; MOUREY RJ, 1994, CURR OPIN GENET DEV, V4, P31, DOI 10.1016/0959-437X(94)90088-4; NEUBAUER A, 1994, BLOOD, V84, P1931; OBRYAN JP, 1995, J BIOL CHEM, V270, P551, DOI 10.1074/jbc.270.2.551; OBRYAN JP, 1991, MOL CELL BIOL, V11, P5016, DOI 10.1128/MCB.11.10.5016; OHASHI K, 1994, ONCOGENE, V9, P699; PELICCI G, 1995, ONCOGENE, V10, P1631; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; PRAT M, 1991, MOL CELL BIOL, V11, P5954, DOI 10.1128/MCB.11.12.5954; PRONK GJ, 1994, MOL CELL BIOL, V14, P1575, DOI 10.1128/MCB.14.3.1575; RAFF MC, 1992, NATURE, V356, P397, DOI 10.1038/356397a0; RESCIGNO J, 1991, ONCOGENE, V6, P1909; Sambrook J, 1989, MOL CLONING LABORATO; SCHER CD, 1982, J CELL PHYSIOL, V113, P211, DOI 10.1002/jcp.1041130205; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SCHNEIDER C, 1982, J BIOL CHEM, V257, P766; SCHNEIDER C, 1988, CELL, V54, P787, DOI 10.1016/S0092-8674(88)91065-3; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; STELLER H, 1995, SCIENCE, V267, P1445, DOI 10.1126/science.7878463; STITT TN, 1995, CELL, V80, P661, DOI 10.1016/0092-8674(95)90520-0; TAMM I, 1991, P NATL ACAD SCI USA, V88, P3372, DOI 10.1073/pnas.88.8.3372; TAMM I, 1990, J CELL PHYSIOL, V143, P494, DOI 10.1002/jcp.1041430314; TAMM I, 1991, J CELL PHYSIOL, V148, P85, DOI 10.1002/jcp.1041480111; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; VARNUM BC, 1995, NATURE, V373, P623, DOI 10.1038/373623a0; Wyllie A H, 1980, Int Rev Cytol, V68, P251	59	244	253	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 1	1996	12	3					471	480						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TV597	8637702				2022-12-25	WOS:A1996TV59700002
J	Hofer, AM; Curci, S; Machen, TE; Schulz, I				Hofer, AM; Curci, S; Machen, TE; Schulz, I			ATP regulates calcium leak from agonist-sensitive internal calcium stores	FASEB JOURNAL			English	Article						mag-fura-2; vanadate; nucleotides; nonhydrolyzable nucleotide analogs	SMOOTH-MUSCLE CELLS; SARCOPLASMIC-RETICULUM; INOSITOL 1,4,5-TRISPHOSPHATE; FLUORESCENT INDICATOR; ADENINE-NUCLEOTIDES; SKELETAL-MUSCLE; RELEASE; CA-2+; CHANNEL; TRANSPORT	Under resting conditions, steady-state [Ca] in agonist-sensitive Ca stores reflects a balance between active uptake (usually mediated by a thapsigargin-sensitive Ca-ATPase of the SERCA family) and passive efflux of Ca. Even though this pump-leak cycle appears to be a common property of Ca-storing organelles, little is known about the nature of the leak pathway, Ca homeostasis in thapsigargin-sensitive internal Ca stores of single permeabilized BHK-21 fibroblasts was examined using digital image processing of compartmentalized mag-fura-2 (a low-affinity Ca indicator), It is shown here that the leak of Ca from internal stores is regulated specifically by the cytosolic ATP concentration, The rate of leak was 3.6 times slower in 0.375 mM [ATP] than in 4 mM [ATP] (Na or Mg salt), These effects were observed in the presence of 0 Ca/EGTA, thapsigargin, heparin, and ruthenium red, and therefore appear to be independent of the Ca-ATPase, the InsP(3) receptor and the ryanodine receptor, The ATP-stimulated leak was seen in a variety of cell types, including rat basophilic leukemia cells and mouse pancreatic acinar cells, Other nucleotides (ADP, GTP, CTP, and UTP) and nonhydrolyzable ATP analogs (AMP-PNP and ATP gamma S) did not reproduce the action of ATP, Changes in cellular metabolism and ensuing alterations in [ATP] will be expected to influence the filling state of internal Ca stores through effects on the passive leak pathway, potentially leading to modulation of Ca signaling and organellar function.	UNIV BARI, IST FISIOL GEN, I-70126 BARI, ITALY; UNIV CALIF BERKELEY, DEPT MOLEC & CELL BIOL, BERKELEY, CA 94720 USA	Universita degli Studi di Bari Aldo Moro; University of California System; University of California Berkeley	Hofer, AM (corresponding author), UNIV SAARLAND, INST PHYSIOL 2, D-66421 HOMBURG, GERMANY.				NIDDK NIH HHS [DK19520] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK019520] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AHNERTHILGER G, 1989, METHOD CELL BIOL, V31, P63; BERS DM, 1994, METHOD CELL BIOL, V40, P3; BEZPROZVANNY I, 1993, NEURON, V10, P1175, DOI 10.1016/0896-6273(93)90065-Y; BOOTH C, 1989, CELL, V59, P729, DOI 10.1016/0092-8674(89)90019-6; CHI WM, 1995, BBA-GEN SUBJECTS, V1243, P513, DOI 10.1016/0304-4165(94)00190-9; CORONADO R, 1994, AM J PHYSIOL, V266, pC1485, DOI 10.1152/ajpcell.1994.266.6.C1485; DEMEIS L, 1992, FEBS LETT, V299, P33, DOI 10.1016/0014-5793(92)80093-V; ENDO M, 1977, PHYSIOL REV, V57, P71, DOI 10.1152/physrev.1977.57.1.71; FERRIS CD, 1990, P NATL ACAD SCI USA, V87, P2147, DOI 10.1073/pnas.87.6.2147; GAMBERUCCI A, 1994, J BIOL CHEM, V269, P23597; GHOSH TK, 1988, J BIOL CHEM, V263, P11075; GHOSH TK, 1991, J BIOL CHEM, V266, P24690; GOULD GW, 1987, BIOCHIM BIOPHYS ACTA, V904, P45, DOI 10.1016/0005-2736(87)90085-X; GUILLEN E, 1995, BIOCHEMISTRY-US, V34, P5472, DOI 10.1021/bi00016a018; HAYNES DH, 1987, PHYSIOL REV, V67, P244, DOI 10.1152/physrev.1987.67.1.244; HIROSE K, 1994, NATURE, V372, P791; HOFER AM, 1994, AM J PHYSIOL, V267, pG442, DOI 10.1152/ajpgi.1994.267.3.G442; HOFER AM, 1995, FASEB J, V9, P788, DOI 10.1096/fasebj.9.9.7601343; HOFER AM, 1993, P NATL ACAD SCI USA, V90, P2598, DOI 10.1073/pnas.90.7.2598; IINO M, 1991, J GEN PHYSIOL, V98, P681, DOI 10.1085/jgp.98.4.681; LYNN S, 1995, FEBS LETT, V367, P23, DOI 10.1016/0014-5793(95)00499-Y; MARTONOSI AN, 1984, PHYSIOL REV, V64, P1240, DOI 10.1152/physrev.1984.64.4.1240; MISSIAEN L, 1993, BIOCHEM BIOPH RES CO, V193, P6, DOI 10.1006/bbrc.1993.1582; MISSIAEN L, 1992, NATURE, V357, P599, DOI 10.1038/357599a0; NEGULESCU PA, 1990, METHOD ENZYMOL, V192, P38; NICOTERA P, 1992, ANNU REV PHARMACOL, V32, P449, DOI 10.1146/annurev.pa.32.040192.002313; PFEIFFER F, 1995, IN PRESS PFLUEGERS A; POZZAN T, 1994, PHYSIOL REV, V74, P595, DOI 10.1152/physrev.1994.74.3.595; PUTNEY JW, 1986, CELL CALCIUM, V7, P1, DOI 10.1016/0143-4160(86)90026-6; PUTNEY JW, 1990, CELL CALCIUM, V11, P611, DOI 10.1016/0143-4160(90)90016-N; RAJU B, 1989, AM J PHYSIOL, V256, pC540, DOI 10.1152/ajpcell.1989.256.3.C540; SAMBROOK JF, 1990, CELL, V61, P197, DOI 10.1016/0092-8674(90)90798-J; SMITH JB, 1985, J BIOL CHEM, V260, P4413; SMITH JS, 1986, J GEN PHYSIOL, V88, P573, DOI 10.1085/jgp.88.5.573; SMITH JS, 1986, BIOPHYS J, V50, P921, DOI 10.1016/S0006-3495(86)83533-0; SMITH PM, 1994, BIOCHEM J, V299, P37, DOI 10.1042/bj2990037; THASTRUP O, 1989, AGENTS ACTIONS, V27, P17, DOI 10.1007/BF02222186; THOMAS D, 1994, METHOD CELL BIOL, V40, P65; TRUMP BF, 1995, FASEB J, V9, P219, DOI 10.1096/fasebj.9.2.7781924; TSIEN R, 1989, METHOD ENZYMOL, V172, P230; WANG JS, 1992, J MEMBRANE BIOL, V130, P163; ZHANG GH, 1990, CELL CALCIUM, V11, P397, DOI 10.1016/0143-4160(90)90051-U	42	69	71	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	1996	10	2					302	308		10.1096/fasebj.10.2.8641563	http://dx.doi.org/10.1096/fasebj.10.2.8641563			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	TY962	8641563				2022-12-25	WOS:A1996TY96200014
J	Masters, BSS				Masters, BSS			Introduction: Cytochrome P450	FASEB JOURNAL			English	Review											Masters, BSS (corresponding author), UNIV TEXAS,HLTH SCI CTR,DEPT BIOCHEM,SAN ANTONIO,TX 78284, USA.							ESTABROOK RW, 1963, BIOCHEM Z, V338, P741; GILLETTE JR, 1957, J PHARMACOL EXP THER, V119, P532; KLINGENBERG M, 1958, ARCH BIOCHEM BIOPHYS, V75, P376, DOI 10.1016/0003-9861(58)90436-3; LU AYH, 1969, J BIOL CHEM, V244, P3714; OMURA T, 1964, J BIOL CHEM, V239, P2370	5	7	7	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	FEB	1996	10	2					205	205		10.1096/fasebj.10.2.8641553	http://dx.doi.org/10.1096/fasebj.10.2.8641553			1	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	TY962	8641553	Bronze			2022-12-25	WOS:A1996TY96200004
J	Weintraub, M; Lin, AY; Franklin, J; Tucker, MA; Magrath, IT; Bhatia, KG				Weintraub, M; Lin, AY; Franklin, J; Tucker, MA; Magrath, IT; Bhatia, KG			Absence of germline p53 mutations in familial lymphoma	ONCOGENE			English	Article						p53; germline mutations; familial lymphoma	TUMOR-SUPPRESSOR GENE; ABNORMAL EXPRESSION; MALIGNANT-LYMPHOMAS; HODGKINS-DISEASE; BREAST-CANCER; LEUKEMIA; RELATIVES; NEOPLASMS; PROTEIN; CELLS	p53, a tumor suppressor gene, is frequently mutated in sporadic human cancer, and inherited mutations in p53 predispose to the early onset of cancer, p53 mutations occur frequently in sporadic lymphoma, and, in mice deficient for p53, lymphoma is the most common type of malignancy, Families with an increased incidence of lymphoma have been described, suggesting an inherited predisposition to lymphoma in these circumstances, To determine whether the predisposition to lymphoma in these families results from germline mutations in p53, we analysed exons 4-11 of the p53 gene in 35 individuals from 19 lymphoma-prone kindreds, We found no germline p53 mutations in any of the individuals tested, However, p53 expression assessed by immunohistochemistry, which suggests mutation, was observed in 35% of the tumor samples from the familial Hodgkin's disease cases and in 13% of the familial non-Hodgkin's lymphoma cases, These results suggest that p53 mutations do not play a critical role in heritable susceptibility to lymphoma, p53 may act by different, non-mutation related mechanisms in this setting, or be involved in late events in the pathogenesis of these tumors.	NCI,PEDIAT BRANCH,NIH,BETHESDA,MD 20892; NCI,GENET EPIDEMIOL BRANCH,NIH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			Tucker, Margaret A/B-4297-2015					BARNES DM, 1992, LANCET, V340, P259, DOI 10.1016/0140-6736(92)92354-I; BHATIA K, 1993, FASEB J, V7, P951, DOI 10.1096/fasebj.7.10.8344493; BHATIA KG, 1992, CANCER RES, V52, P4273; BIRCH JM, 1994, BRIT J CANCER, V70, P1176, DOI 10.1038/bjc.1994.468; BJERRUM OW, 1986, SCAND J HAEMATOL, V36, P398; CESARMAN E, 1993, AM J PATHOL, V143, P845; CHILOSI M, 1994, BLOOD, V84, P4295, DOI 10.1182/blood.V84.12.4295.bloodjournal84124295; DOGLIONI C, 1991, HEMATOL PATHOL, V5, P67; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; FELIX CA, 1992, J CLIN INVEST, V90, P653, DOI 10.1172/JCI115907; GAIDANO G, 1991, P NATL ACAD SCI USA, V88, P5413, DOI 10.1073/pnas.88.12.5413; GLAVAC D, 1993, HUM MUTAT, V2, P404, DOI 10.1002/humu.1380020513; GREENBLATT MS, 1994, CANCER RES, V54, P4855; GUPTA RK, 1993, P NATL ACAD SCI USA, V90, P2817, DOI 10.1073/pnas.90.7.2817; HAIM N, 1982, CANCER, V49, P2197, DOI 10.1002/1097-0142(19820515)49:10<2197::AID-CNCR2820491036>3.0.CO;2-9; HALL PA, 1994, J PATHOL, V172, P1, DOI 10.1002/path.1711720103; HARVEY M, 1993, FASEB J, V7, P918; HILDESHEIM A, 1995, EUR J CANCER, V31A, P125, DOI 10.1016/0959-8049(94)00465-H; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HSU SM, 1981, J HISTOCHEM CYTOCHEM, V29, P577, DOI 10.1177/29.4.6166661; IMAMURA J, 1994, BLOOD, V84, P2412, DOI 10.1182/blood.V84.8.2412.bloodjournal8482412; JOLLY KW, 1994, ONCOGENE, V9, P97; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LI FP, 1969, ANN INTERN MED, V71, P747, DOI 10.7326/0003-4819-71-4-747; MACK TM, 1995, NEW ENGL J MED, V332, P413, DOI 10.1056/NEJM199502163320701; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; MALKIN D, 1992, NEW ENGL J MED, V326, P1309, DOI 10.1056/NEJM199205143262002; OHGAKI H, 1993, INT J CANCER, V54, P408, DOI 10.1002/ijc.2910540310; ORITA M, 1989, P NATL ACAD SCI USA, V86, P2766, DOI 10.1073/pnas.86.8.2766; POTTERN LM, 1991, LEUKEMIA RES, V15, P305, DOI 10.1016/0145-2126(91)90005-E; PROKOCIMER M, 1994, BLOOD, V84, P2391; PROSSER J, 1991, BRIT J CANCER, V63, P181, DOI 10.1038/bjc.1991.44; SAID JW, 1992, AM J PATHOL, V141, P1343; SAMESHIMA Y, 1992, J NATL CANCER I, V84, P703, DOI 10.1093/jnci/84.9.703; SANDER CA, 1993, BLOOD, V82, P1994; SHEFFIELD VC, 1993, GENOMICS, V16, P325, DOI 10.1006/geno.1993.1193; TRUMPER LH, 1993, BLOOD, V81, P3097; VILLUENDAS R, 1993, BLOOD, V82, P3151; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126	39	11	11	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB 1	1996	12	3					687	691						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TV597	8637726				2022-12-25	WOS:A1996TV59700026
J	Zhang, LS; Hung, MC				Zhang, LS; Hung, MC			Sensitization of HER-2/neu-overexpressing non-small cell lung cancer cells to chemotherapeutic drugs by tyrosine kinase inhibitor emodin	ONCOGENE			English	Article						emodin; HER-2/neu; tyrosine kinase; lung cancer; combination therapy	GROWTH-FACTOR-RECEPTOR; NEU ONCOGENE; GENE; EXPRESSION; ADENOCARCINOMA; ACTIVATION; SURVIVAL; P185NEU; ASSAY; LINES	Overexpression of the HER-2/neu proto-oncogene which encodes tyrosine kinase receptor p185(neu), has been observed frequently in many human cancers, including non-small cell lung cancer (NSCLC), and is correlated with poor patient survival in these cancers, In addition, HER-2/neu overexpression in NSCLC is known to induce chemoresistance, Recently, we demonstrated that emodin, a tyrosine kinase inhibitor, suppresses HER-2/neu tyrosine kinase activity in HER-2/neu-overexpressing breast cancer cells and preferentially represses proliferation of these cells, The work described here was carried out to examine (1) whether the tyrosine kinase activity of p185(neu) is required for resistance to chemotherapeutic drugs of HER-2/neu-overexpressing NSCLC cells and (2) whether the tyrosine kinase inhibitor emodin can sensitize these cells to chemotherapeutic drugs. We found that emodin decreased tyrosine phosphorylation of HER-2/neu and preferentially suppressed proliferation of HER-2/neu-overexpressing NSCLC cells. Furthermore, the combination of emodin with cisplatin, doxorubicin or etoposide (VP16) synergistically inhibited the proliferation of HER-2/neu-overexpressing lung cancer cells, whereas low doses of emodin, cisplatin, doxorubicin, or VP16 alone had only minimal antiproliferative effects on these cells, These results indicate that tyrosine kinase activity is required for the chemoresistant phenotype of HER-2/neu-overexpressing NSCLC cells and that tyrosine kinase inhibitors such as emodin can sensitize these cells to chemotherapeutic drugs, The results may have important implications in chemotherapy for HER-2/neu-overexpressing cancers.	UNIV TEXAS, MD ANDERSON CANCER CTR, DEPT TUMOR BIOL, HOUSTON, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center			Hung, Mien-Chie/ABD-5911-2021	Hung, Mien-Chie/0000-0003-4317-4740	NATIONAL CANCER INSTITUTE [R01CA058880, P30CA016672, R01CA060856] Funding Source: NIH RePORTER; NCI NIH HHS [CA 16672, CA 58880, CA 60856] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BORING CC, 1994, CA-CANCER J CLIN, V44, P7, DOI 10.3322/canjclin.44.1.7; CHAN TCK, 1993, BIOCHEM BIOPH RES CO, V193, P1152, DOI 10.1006/bbrc.1993.1746; COUSSENS L, 1985, SCIENCE, V230, P1132, DOI 10.1126/science.2999974; HATA Y, 1994, ONCOL RES, V6, P19; HUNG MC, 1989, P NATL ACAD SCI USA, V86, P2545, DOI 10.1073/pnas.86.8.2545; HUNG MC, 1986, P NATL ACAD SCI USA, V83, P261, DOI 10.1073/pnas.83.2.261; JAYASURIYA H, 1992, J NAT PROD, V55, P696, DOI 10.1021/np50083a026; KERN JA, 1990, CANCER RES, V50, P5184; KUPCHAN SM, 1976, LLOYDIA, V39, P223; Minna JD, 1989, CANCER PRINCIPLES PR, P591; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; MULLER WJ, 1988, CELL, V54, P105, DOI 10.1016/0092-8674(88)90184-5; MUTHUSWAMY SK, 1994, MOL CELL BIOL, V14, P735, DOI 10.1128/MCB.14.1.735; RUBINSTEIN LV, 1990, J NATL CANCER I, V82, P1113, DOI 10.1093/jnci/82.13.1113; SCHECHTER AL, 1984, NATURE, V312, P513, DOI 10.1038/312513a0; SCHNEIDER PM, 1989, CANCER RES, V49, P4968; SEMBA K, 1985, P NATL ACAD SCI USA, V82, P6497, DOI 10.1073/pnas.82.19.6497; Silverberg E., 1988, CA-CANCER J CLIN, V38, P5; SISTONEN L, 1989, J CELL BIOL, V109, P1911, DOI 10.1083/jcb.109.5.1911; TSAI CM, 1995, J NATL CANCER I, V87, P682, DOI 10.1093/jnci/87.9.682; TSAI CM, 1993, J NATL CANCER I, V85, P897, DOI 10.1093/jnci/85.11.897; UDZIAK RM, 1987, P NATL ACAD SCI USA, V84, P7159; WEBB JL, 1963, ENZYMES METABOL INH, V1, P507; WEINER DB, 1990, CANCER RES, V50, P421; YAMAMOTO T, 1986, NATURE, V319, P230, DOI 10.1038/319230a0; YEH SF, 1988, PLANTA MED, P413, DOI 10.1055/s-2006-962484; YU DH, 1993, CANCER RES, V53, P891; YU DH, 1991, ONCOGENE, V6, P1991; YU DH, 1994, CANCER RES, V54, P3260; ZHANG LS, 1995, CANCER RES, V55, P3890	30	113	127	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 1	1996	12	3					571	576						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TV597	8637714				2022-12-25	WOS:A1996TV59700014
J	Roucard, C; Garban, F; Mooney, NA; Charron, DJ; Ericson, ML				Roucard, C; Garban, F; Mooney, NA; Charron, DJ; Ericson, ML			Conformation of human leukocyte antigen class II molecules - Evidence for superdimers and empty molecules on human antigen presenting cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MHC CLASS-II; MAJOR HISTOCOMPATIBILITY COMPLEX; ALPHA-BETA-HETERODIMERS; HLA-DR MOLECULES; INVARIANT-CHAIN; SURFACE EXPRESSION; INTRACELLULAR-TRANSPORT; LYMPHOID-CELLS; PEPTIDE; BINDING	Subpopulations of human leukocyte antigen (HLA) class II molecules were studied in antigen presenting cells, We present evidence for double dimers or ''super-dimers'' of HLA class II molecules that were stable in an SDS solution at room temperature but dissociated when heated to 50 degrees C into 60-kDa alpha beta heterodimers. Development of an immunofluorescence assay allowed us to quantify the expression of HLA antigens as reflected by the number of bound isotype-specific monoclonal antibodies per cell. The total expression of class II (DR, DQ, and DP) augmented B-fold after a 36-h interferon-gamma (IFN gamma) treatment of freshly isolated monocytes, Next, we used a recombinant and fluorescein-conjugated form of the class II-associated invariant chain as a quantitative probe for empty peptide-binding sites, The fraction of empty class II molecules was 0.73-2.9% in resting monocytes but was reduced to 0.12-0.5% of the total after IFN gamma treatment, The fraction of empty sites in B lymphocytes was 0.09-0.36%, The mean number of empty sites per cell were: 6.3 x 10(3) (monocytes), 7.2 x 10(3) (IFN gamma-activated monocytes), 5.2 x 10(2) (B lymphocytes), and 3.6 x 10(3) (Raji B cells), A minor population (4.3-7.4% of total cells), which expressed a much higher number of empty sites, was consistently present in all cell types studied.	INST BIOMED CORDELIERS,HUMAN IMMUNOGENET LAB,INSERM U396,F-75006 PARIS,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Universite Paris Cite			garban, frederic/M-6130-2014	garban, frederic/0000-0003-3981-0839; Mooney, Nuala/0000-0002-3516-6882				AMIGORENA S, 1994, NATURE, V369, P113, DOI 10.1038/369113a0; ARIMILLI S, 1995, J BIOL CHEM, V270, P971, DOI 10.1074/jbc.270.2.971; BAKKE O, 1990, CELL, V63, P707, DOI 10.1016/0092-8674(90)90137-4; BONNEROT C, 1994, EMBO J, V13, P934, DOI 10.1002/j.1460-2075.1994.tb06338.x; BROWN JH, 1993, NATURE, V364, P33, DOI 10.1038/364033a0; BUSCH R, 1990, INT IMMUNOL, V2, P443, DOI 10.1093/intimm/2.5.443; CARREL S, 1981, MOL IMMUNOL, V18, P403, DOI 10.1016/0161-5890(81)90102-4; CASTELLINO F, 1995, IMMUNITY, V2, P73, DOI 10.1016/1074-7613(95)90080-2; CEPPELLINI R, 1989, NATURE, V339, P392, DOI 10.1038/339392a0; CHARRON DJ, 1979, P NATL ACAD SCI USA, V76, P6567, DOI 10.1073/pnas.76.12.6567; CLAESSONWELSH L, 1986, J IMMUNOL, V136, P484; CRESSWELL P, 1994, ANNU REV IMMUNOL, V12, P259, DOI 10.1146/annurev.immunol.12.1.259; DAVIDSON HW, 1991, CELL, V67, P105, DOI 10.1016/0092-8674(91)90575-J; DEMOTZ S, 1990, SCIENCE, V249, P1028, DOI 10.1126/science.2118680; DENZIN LK, 1995, CELL, V82, P155, DOI 10.1016/0092-8674(95)90061-6; ERICSON ML, 1994, J BIOL CHEM, V269, P26531; FARRAR MA, 1993, ANNU REV IMMUNOL, V11, P571, DOI 10.1146/annurev.iy.11.040193.003035; FERMAND JP, 1985, EUR J IMMUNOL, V15, P1183, DOI 10.1002/eji.1830151208; FU XT, 1994, HUM IMMUNOL, V39, P253, DOI 10.1016/0198-8859(94)90268-2; GARBAN F, 1996, IN PRESS BLOOD, V87; GERMAIN RN, 1993, NATURE, V363, P725, DOI 10.1038/363725a0; GERMAIN RN, 1991, NATURE, V353, P134, DOI 10.1038/353134a0; HARDING CV, 1990, NATURE, V346, P574, DOI 10.1038/346574a0; JANEWAY CA, 1992, ANNU REV IMMUNOL, V10, P645, DOI 10.1146/annurev.immunol.10.1.645; KAUFMAN JF, 1984, CELL, V36, P1, DOI 10.1016/0092-8674(84)90068-0; KOCH N, 1991, J IMMUNOL, V147, P2643; KONIG R, 1995, J EXP MED, V182, P779, DOI 10.1084/jem.182.3.779; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; LOTTEAU V, 1990, NATURE, V348, P600, DOI 10.1038/348600a0; MOURITSEN S, 1992, J IMMUNOL, V149, P1987; NADLER SG, 1994, EUR J IMMUNOL, V24, P3124, DOI 10.1002/eji.1830241232; NEEFJES JJ, 1990, CELL, V61, P171, DOI 10.1016/0092-8674(90)90224-3; NEEFJES JJ, 1992, IMMUNOL TODAY, V13, P179, DOI 10.1016/0167-5699(92)90123-O; NEEFJES JJ, 1992, EMBO J, V11, P411, DOI 10.1002/j.1460-2075.1992.tb05069.x; NEWCOMB JR, 1993, J IMMUNOL, V150, P499; NYGARD NR, 1994, J IMMUNOL, V152, P1082; PETERS PJ, 1991, NATURE, V349, P669, DOI 10.1038/349669a0; PINET V, 1995, NATURE, V375, P603, DOI 10.1038/375603a0; QIU Y, 1994, J CELL BIOL, V125, P595, DOI 10.1083/jcb.125.3.595; REID PA, 1992, IMMUNOLOGY, V77, P539; REID PA, 1990, NATURE, V346, P655, DOI 10.1038/346655a0; ROBBINS PA, 1988, J IMMUNOL, V141, P1281; ROCHE PA, 1991, P NATL ACAD SCI USA, V88, P3150, DOI 10.1073/pnas.88.8.3150; ROCHE PA, 1993, P NATL ACAD SCI USA, V90, P8581, DOI 10.1073/pnas.90.18.8581; ROMAGNOLI P, 1993, J EXP MED, V177, P583, DOI 10.1084/jem.177.3.583; SADEGHNASSERI S, 1994, NATURE, V370, P647, DOI 10.1038/370647a0; SADEGHNASSERI S, 1991, NATURE, V353, P167, DOI 10.1038/353167a0; SAKIHAMA T, 1995, P NATL ACAD SCI USA, V92, P6444, DOI 10.1073/pnas.92.14.6444; SANDERSON F, 1994, SCIENCE, V266, P1566, DOI 10.1126/science.7985027; SCHAFER PH, 1994, IMMUNITY, V1, P699, DOI 10.1016/1074-7613(94)90040-X; SETTE A, 1992, J IMMUNOL, V148, P844; Sharrow S., 1991, CURRENT PROTOCOLS IM; SHERMAN MA, 1995, IMMUNITY, V3, P197, DOI 10.1016/1074-7613(95)90089-6; SLOAN VS, 1995, NATURE, V375, P802, DOI 10.1038/375802a0; STERN LJ, 1992, CELL, V68, P465, DOI 10.1016/0092-8674(92)90184-E; TULP A, 1994, NATURE, V369, P120, DOI 10.1038/369120a0; VALITUTTI S, 1995, NATURE, V375, P148, DOI 10.1038/375148a0; WATSON AJ, 1983, NATURE, V304, P358, DOI 10.1038/304358a0; WEST MA, 1994, NATURE, V369, P147, DOI 10.1038/369147a0; WRAIGHT CJ, 1990, J BIOL CHEM, V265, P5787	60	36	36	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 14	1996	271	24					13993	14000		10.1074/jbc.271.24.13993	http://dx.doi.org/10.1074/jbc.271.24.13993			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UQ660	8662817	hybrid			2022-12-25	WOS:A1996UQ66000013
J	Tanaka, S; Ito, T; Wands, JR				Tanaka, S; Ito, T; Wands, JR			Neoplastic transformation induced by insulin receptor substrate-1 overexpression requires an interaction with both Grb2 and Syp signaling molecules	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHATIDYLINOSITOL 3'-KINASE; NCK PROTEIN; SH2 DOMAIN; IRS-1; EXPRESSION; PHOSPHORYLATION; CELLS	The insulin receptor substrate-1 (IRS-1) is the major intracellular substrate of insulin and insulin-like growth factor-I (IGF-I) receptor tyrosine kinase activity, and this protein has been found to be overexpressed in human hepatocellular carcinomas. IRS-1 contains several src homology 2 (SH2) binding motifs that interact following tyrosyl phosphorylation with SH2-containing proteins, and this interaction may be essential for transmitting the growth signal from the cell surface to the nucleus, We have previously reported that overexpression of IRS-1 may induce neoplastic transformation of NIH 3T3 cells. This study examines the role of two SH2-containing molecules, namely the Grb2 adapter and Syp tyrosine phosphatase proteins as important components of the cellular transforming activity of IRS-1. Mutations of tyrosine 897 in the YVNI motif (Y897F) and of tyrosine 1180 in the YIDL motif (Y1180F) reduced the intracellular interaction of IRS-1 with Grb2 and Syp proteins, respectively. Furthermore, a single mutation at either Phe-897 or Phe-1180 substantially but not completely reduced IGF-I-dependent transforming activity of IRS-1, whereas creation of a double mutation of both tyrosine residues (Y897F/Y1180F) strikingly attenuated the transforming activity of IRS-1. Stable expression of the IRS-1 mutant constructs in MH 3T3 cells was associated with a lower level of activation of the mitogen-activated protein kinase kinase (MAPKK)/MAPK cascade following IGF-I stimulation compared with cells stably transfected with the ''wild-type'' IRS-1 gene, These results suggest that IRS-1-induced cellular transformation requires an interaction with both Grb2 and Syp signal transduction molecules since neither interaction alone appears to be required, and this event subsequently leads to activation of the MAPKK/MAPK cascade.	MASSACHUSETTS GEN HOSP,CTR CANC,MOLEC HEPATOL LAB,CHARLESTOWN,MA 02129; HARVARD UNIV,SCH MED,CHARLESTOWN,MA 02129	Harvard University; Massachusetts General Hospital; Harvard University					NATIONAL CANCER INSTITUTE [R01CA035711, R37CA035711] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R37AA002666, R01AA002666, R01AA008169] Funding Source: NIH RePORTER; NCI NIH HHS [CA-35711] Funding Source: Medline; NIAAA NIH HHS [AA-02666, AA-08169] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		BACKER JM, 1992, EMBO J, V11, P3469, DOI 10.1002/j.1460-2075.1992.tb05426.x; BALTENSPERGER K, 1993, SCIENCE, V260, P1950, DOI 10.1126/science.8391166; BASERGA R, 1995, CANCER RES, V55, P249; BESERGA R, 1994, CELL, V79, P927; CHOU MM, 1992, MOL CELL BIOL, V12, P5834, DOI 10.1128/MCB.12.12.5834; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; DIFIORE PP, 1987, CELL, V51, P1063, DOI 10.1016/0092-8674(87)90592-7; FURUSAKA A, 1994, CANCER LETT, V84, P85, DOI 10.1016/0304-3835(94)90361-1; HU QJ, 1995, MOL CELL BIOL, V15, P1169; IRIE K, 1994, SCIENCE, V265, P1716, DOI 10.1126/science.8085159; Ito T, 1996, MOL CELL BIOL, V16, P943; KALEKO M, 1990, MOL CELL BIOL, V10, P464, DOI 10.1128/MCB.10.2.464; KUHNE MR, 1993, J BIOL CHEM, V268, P11479; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LEE CH, 1993, P NATL ACAD SCI USA, V90, P11713, DOI 10.1073/pnas.90.24.11713; LEROITH D, 1995, ANN INTERN MED, V122, P54, DOI 10.7326/0003-4819-122-1-199501010-00009; LI W, 1992, MOL CELL BIOL, V12, P5824, DOI 10.1128/MCB.12.12.5824; LI W, 1994, MOL CELL BIOL, V14, P509, DOI 10.1128/MCB.14.1.509; MACAULAY VM, 1992, BRIT J CANCER, V65, P311, DOI 10.1038/bjc.1992.65; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MILARSKI K, 1994, J BIOL CHEM, V2269, P21239; MYERS MG, 1994, TRENDS BIOCHEM SCI, V19, P289, DOI 10.1016/0968-0004(94)90007-8; MYERS MG, 1992, P NATL ACAD SCI USA, V89, P10350, DOI 10.1073/pnas.89.21.10350; MYERS MG, 1994, MOL CELL BIOL, V14, P3577, DOI 10.1128/MCB.14.6.3577; NISHIYAMA M, 1992, BIOCHEM BIOPH RES CO, V183, P280, DOI 10.1016/0006-291X(92)91640-C; NOGUCHI T, 1994, MOL CELL BIOL, V14, P6674, DOI 10.1128/MCB.14.10.6674; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; PRAGER D, 1994, P NATL ACAD SCI USA, V91, P2181, DOI 10.1073/pnas.91.6.2181; SALCINI AE, 1994, ONCOGENE, V9, P2827; SASAKI Y, 1993, J BIOL CHEM, V268, P3805; SASAKI Y, 1994, BIOCHEM BIOPH RES CO, V199, P403, DOI 10.1006/bbrc.1994.1243; SASAOKA T, 1994, J BIOL CHEM, V269, P13689; SELL C, 1994, MOL CELL BIOL, V14, P3604, DOI 10.1128/MCB.14.6.3604; SELL C, 1993, P NATL ACAD SCI USA, V90, P11217, DOI 10.1073/pnas.90.23.11217; SKOLNIK EY, 1993, SCIENCE, V260, P1953, DOI 10.1126/science.8316835; SUN XJ, 1993, MOL CELL BIOL, V13, P7418, DOI 10.1128/MCB.13.12.7418; SUN XJ, 1992, J BIOL CHEM, V267, P22662; WATERS SB, 1993, J BIOL CHEM, V268, P22231; WHITE MF, 1994, J BIOL CHEM, V269, P1; XIAO S, 1994, J BIOL CHEM, V269, P21244; YAMAUCHI K, 1995, P NATL ACAD SCI USA, V92, P664, DOI 10.1073/pnas.92.3.664; YOKOTE K, 1994, J BIOL CHEM, V269, P15337; YONEZAWA K, 1994, J BIOL CHEM, V269, P4634; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0	46	81	83	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 14	1996	271	24					14610	14616		10.1074/jbc.271.24.14610	http://dx.doi.org/10.1074/jbc.271.24.14610			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UQ660	8662827	hybrid			2022-12-25	WOS:A1996UQ66000099
J	Gadaleta, G; DElia, D; Capaccio, L; Saccone, C; Pepe, G				Gadaleta, G; DElia, D; Capaccio, L; Saccone, C; Pepe, G			Isolation of a 25-kDa protein binding to a curved DNA upstream the origin of the L strand replication in the rat mitochondrial genome	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YEAST TRANSCRIPTION FACTOR; AFFINITY PURIFICATION; SEQUENCE; CURVATURE; REGION	The presence of a curved DNA sequence in the gene for the NADH-dehydrogenase subunit 2 of rat mitochondrial genome, upstream from the origin of the light strand replication have been demonstrated through theoretical analysis and experimental approaches, Gel retardation assays showed that this structure makes a complex with a protein component extracted from the mitochondrial matrix, The isolation and purification of this protein is reported, With a Sepharose CL GB and magnetic DNA affinity chromatography a polypeptide was purified to homogeneity having 25-kDa mass as shown by gel electrophoresis, To functionally characterize this protein, its capability to bind to other sequences of the homologous or heterologous DNA and to specific riboprobes was also investigated, A role for this protein as a trans-acting agent required for the expression of the mammalian mitochondrial genome is suggested.	CNR,CTR STUDIO MITOCONDRI & METAB ENERGET,I-70126 BARI,ITALY	Consiglio Nazionale delle Ricerche (CNR)	Gadaleta, G (corresponding author), UNIV BARI,DEPT BIOCHEM & MOLEC BIOL,VIA ORABONA 4A,I-70126 BARI,ITALY.		D'Elia, Domenica/O-2917-2015	D'Elia, Domenica/0000-0003-3787-3836				BROWN GG, 1986, J MOL BIOL, V192, P503, DOI 10.1016/0022-2836(86)90272-X; CAREY J, 1991, METHOD ENZYMOL, V208, P103; CLAYTON DA, 1992, INT REV CYTOL, V141, P217, DOI 10.1016/S0074-7696(08)62067-7; DIEKMANN S, 1985, J MOL BIOL, V186, P1, DOI 10.1016/0022-2836(85)90251-7; DIEKMANN S, 1987, EMBO J, V6, P4213, DOI 10.1002/j.1460-2075.1987.tb02769.x; EISENBERG H, 1986, TRENDS BIOCHEM SCI, V11, P350, DOI 10.1016/0968-0004(86)90196-9; GABRIELSEN OS, 1989, NUCLEIC ACIDS RES, V17, P6253, DOI 10.1093/nar/17.15.6253; GABRIELSEN OS, 1993, METHOD ENZYMOL, V218, P508; GADALETA G, 1989, J MOL EVOL, V28, P497, DOI 10.1007/BF02602930; GADALETA G, 1995, GENE, V160, P229, DOI 10.1016/0378-1119(95)00122-M; GRAY H, 1992, J BIOL CHEM, V267, P5835; Greenawalt J W, 1974, Methods Enzymol, V31, P310; HAGERMAN PJ, 1985, BIOCHEMISTRY-US, V24, P7033, DOI 10.1021/bi00346a001; HEHMAN GL, 1992, P NATL ACAD SCI USA, V89, P8562, DOI 10.1073/pnas.89.18.8562; KOO HS, 1986, NATURE, V320, P501, DOI 10.1038/320501a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE EH, 1989, P NATL ACAD SCI USA, V86, P9104, DOI 10.1073/pnas.86.23.9104; LILLEY D, 1986, NATURE, V320, P487, DOI 10.1038/320487a0; MAYHOOK AG, 1992, P ROY SOC B-BIOL SCI, V248, P85, DOI 10.1098/rspb.1992.0046; MIZUNO T, 1987, NUCLEIC ACIDS RES, V15, P327; PEPE G, 1989, NUCLEIC ACIDS RES, V17, P8803, DOI 10.1093/nar/17.21.8803; PLASKON RR, 1987, NUCLEIC ACIDS RES, V15, P785, DOI 10.1093/nar/15.2.785; QURESHI SA, 1993, NUCLEIC ACIDS RES, V21, P2801, DOI 10.1093/nar/21.12.2801; SACCONE C, 1993, PRINCIPLES MED BIO B, V1, P37; TRIFONOV EN, 1985, CRC CR REV BIOCH MOL, V19, P89, DOI 10.3109/10409238509082540; WADDELL WJ, 1956, J LAB CLIN MED, V48, P311; WELTER C, 1989, NUCLEIC ACIDS RES, V17, P6077; WONG TW, 1985, CELL, V42, P951, DOI 10.1016/0092-8674(85)90291-0	28	12	12	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 7	1996	271	23					13537	13541		10.1074/jbc.271.23.13537	http://dx.doi.org/10.1074/jbc.271.23.13537			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UP385	8662779	hybrid			2022-12-25	WOS:A1996UP38500036
J	Premont, RT; Matsuoka, I; Mattei, MG; Pouille, Y; Defer, N; Hanoune, J				Premont, RT; Matsuoka, I; Mattei, MG; Pouille, Y; Defer, N; Hanoune, J			Identification and characterization of a widely expressed form of adenylyl cyclase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-GAMMA-SUBUNITS; INSITU HYBRIDIZATION; GS-ALPHA; CLONING; SEQUENCE; BRAIN; DNA; DESENSITIZATION; LOCALIZATION; INHIBITION	A novel mammalian adenylyl cyclase was identified by reverse transcription-polymerase chain reaction amplification using degenerate primers based on a conserved region of previously described adenylyl cyclases (Premont, R. T. (1994) Methods Enzymol, 238, 116-127), The fall-length cDNA sequence obtained from mouse brain predicts a 1353-amino acid protein possessing a 12-membrane spans topology, and containing two regions of high similarity with the catalytic domains of adenylyl cyclases, Comparison of this novel adenylyl cyclase with the eight previously described mammalian enzymes indicates that this type 9 adenylyl cyclase sequence is the most divergent, defining a sixth distinct subclass of mammalian adenylyl cyclases, The AC9 gene has been localized to human chromosome band 16p13.3-13.2. The 8.5-kb mRNA encoding the type 9 adenylyl cyclase is widely distributed, being readily detected in all tissues tested, and is found at very high levels in skeletal muscle and brain, AC9 mRNA is found throughout rat brain but is particularly abundant in hippocampus, cerebellum, and neocortex, An antiserum directed against the carboxyl terminus of the type 9 adenylyl cyclase detects native and expressed recombinant AC9 protein in tissue and cell membranes. Levels of the AC9 protein are highest in mouse brain membranes. Characterization of expressed recombinant AC9 reveals that the protein is a functional adenylyl cyclase that is stimulated by Mg2+, forskolin, and mutationally activated G(s) alpha. AC9 activity is not affected by Ca2+/calmodulim or by G protein beta gamma-subunits. Thus AC9 represents a functional G protein-regulated adenylyl cyclase found in brain and in most somatic tissues.	HOP HENRI MONDOR,UNITE RECH,INSERM U99,F-94010 CRETEIL,FRANCE; HOP ENFANTS LA TIMONE,INSERM U242,UNITE RECH,F-13385 MARSEILLE,FRANCE	Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille	Premont, RT (corresponding author), DUKE UNIV,MED CTR,DEPT MED CARDIOL,BOX 3821,DURHAM,NC 27710, USA.			Matsuoka, Isao/0000-0002-7170-3630; Premont, Richard/0000-0002-8053-5026	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL016037, R01HL016037] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 16037] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BAKALYAR HA, 1990, SCIENCE, V250, P1403, DOI 10.1126/science.2255909; CALI JJ, 1994, J BIOL CHEM, V269, P12190; CASEY PJ, 1989, BIOCHEMISTRY-US, V28, P611, DOI 10.1021/bi00428a029; CHEN JQ, 1993, J BIOL CHEM, V268, P12253; COOPER DMF, 1995, NATURE, V374, P421, DOI 10.1038/374421a0; DEFER N, 1994, FEBS LETT, V351, P109, DOI 10.1016/0014-5793(94)00836-1; DOGGETT NA, 1993, HUMAN GENE MAPPING, P506; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GAO BN, 1991, P NATL ACAD SCI USA, V88, P10178, DOI 10.1073/pnas.88.22.10178; Genetic Computer Group, 1994, PROGR MAN WISC PACK; GERARD RD, 1985, MOL CELL BIOL, V5, P3231, DOI 10.1128/MCB.5.11.3231; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GLATT CE, 1993, NATURE, V361, P536, DOI 10.1038/361536a0; GOLUB EI, 1989, NUCLEIC ACIDS RES, V17, P4902, DOI 10.1093/nar/17.12.4902; GRAZIANO MP, 1989, J BIOL CHEM, V264, P15475; HABER N, 1994, HUM GENET, V94, P69, DOI 10.1007/BF02272844; HELLEVUO K, 1993, BIOCHEM BIOPH RES CO, V192, P311, DOI 10.1006/bbrc.1993.1415; HELLEVUO K, 1995, J BIOL CHEM, V270, P11581, DOI 10.1074/jbc.270.19.11581; HELLEVUO K, 1995, HUM GENET, V95, P197; IWAMI G, 1995, J BIOL CHEM, V270, P12481, DOI 10.1074/jbc.270.21.12481; JACOBOWITZ O, 1994, P NATL ACAD SCI USA, V91, P10630, DOI 10.1073/pnas.91.22.10630; KATSUSHIKA S, 1992, P NATL ACAD SCI USA, V89, P8774, DOI 10.1073/pnas.89.18.8774; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KRUPINSKI J, 1992, J BIOL CHEM, V267, P24858; MATSUOKA I, 1992, J NEUROSCI, V12, P3350; MATTEI MG, 1985, HUM GENET, V69, P268, DOI 10.1007/BF00293038; MONS N, 1994, J NEUROENDOCRINOL, V6, P665, DOI 10.1111/j.1365-2826.1994.tb00633.x; MONS N, 1995, P NATL ACAD SCI USA, V92, P8473, DOI 10.1073/pnas.92.18.8473; Nomura N, 1994, DNA Res, V1, P27, DOI 10.1093/dnares/1.1.27; OLATE J, 1988, J BIOL CHEM, V263, P10394; PARMA J, 1991, BIOCHEM BIOPH RES CO, V179, P455, DOI 10.1016/0006-291X(91)91392-P; PATTERSON JM, 1995, BIOCHEM BIOPH RES CO, V214, P1000; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PIERONI JP, 1995, J BIOL CHEM, V270, P21368, DOI 10.1074/jbc.270.36.21368; PREMONT RT, 1992, ENDOCRINOLOGY, V131, P2774, DOI 10.1210/en.131.6.2774; PREMONT RT, 1992, P NATL ACAD SCI USA, V89, P9809, DOI 10.1073/pnas.89.20.9809; PREMONT RT, 1994, METHOD ENZYMOL, V238, P116; PREMONT RT, 1988, J BIOL CHEM, V263, P16087; PREMONT RT, 1994, J BIOL CHEM, V269, P6832; PREMONT RT, 1990, G PROTEINS, P147; PREMONT RT, 1993, GTPASES BIOL, V2, P189; ROHLFS EM, 1995, J BIOL CHEM, V270, P10723, DOI 10.1074/jbc.270.18.10723; SALOMON Y, 1974, ANAL BIOCHEM, V58, P541, DOI 10.1016/0003-2697(74)90222-X; Sambrook J., 2002, MOL CLONING LAB MANU; SEAMON KB, 1986, ADV CYCLIC NUCL PROT, V20, P1; SEAMON KB, 1981, J CYCLIC NUCL PROT, V7, P201; SIMMOTEIT R, 1991, FEBS LETT, V285, P99, DOI 10.1016/0014-5793(91)80734-K; SUTKOWSKI EM, 1994, BIOCHEMISTRY-US, V33, P12852, DOI 10.1021/bi00209a017; TANG WJ, 1991, SCIENCE, V254, P1500, DOI 10.1126/science.1962211; TAUSSIG R, 1995, J BIOL CHEM, V270, P1, DOI 10.1074/jbc.270.1.1; TAUSSIG R, 1993, SCIENCE, V261, P218, DOI 10.1126/science.8327893; WATSON PA, 1994, J BIOL CHEM, V269, P28893; YOSHIMURA M, 1992, P NATL ACAD SCI USA, V89, P6716, DOI 10.1073/pnas.89.15.6716	53	141	146	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 7	1996	271	23					13900	13907		10.1074/jbc.271.23.13900	http://dx.doi.org/10.1074/jbc.271.23.13900			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UP385	8662814	hybrid			2022-12-25	WOS:A1996UP38500089
J	Liu, PK; Kraus, E; Wu, TA; Strong, LC; Tainsky, MA				Liu, PK; Kraus, E; Wu, TA; Strong, LC; Tainsky, MA			Analysis of genomic instability in Li-Fraumeni fibroblasts with germline p53 mutations	ONCOGENE			English	Review						tumor suppressor gene; germline mutations; chromosome instability; shuttle vector mutagenesis; DNA replication	DNA-POLYMERASE-ALPHA; SIMIAN VIRUS-40 DNA; LARGE-T-ANTIGEN; SHUTTLE VECTOR PLASMID; CELLULAR TUMOR-ANTIGEN; INDUCED POINT MUTATIONS; WILD-TYPE P53; HUMAN-CELLS; ATAXIA-TELANGIECTASIA; REPLICATION INVITRO	Germline p53 mutations are frequently observed in the normal DNA of cancer-prone patients with Li-Fraumeni syndrome (LFS), Fibroblasts from LFS patients develop chromosomal aberrations, loss of cell cycle control, and spontaneous immortalization, We transfected four different mutant p53 genes into human skin fibroblasts from normal donors with two copies of wild-type p53 (p53(wt/wt)), Each mutant p53 expression-plasmid induced genomic instability equivalent to that seen in LFS cells, To test the role of wild-type and mutant p53 alleles in DNA replication and fidelity in LFS cells, we analysed the replication of the SV40-based shuttle vector pZ189 in four types of cells, We used p53(wt/mut) and p53(mut/-) LFS fibroblasts, and p53(-/-) non-LFS cells, Replication of pZ189 in vivo was significantly reduced by the presence of a p53(wt) allele, To show that this was not just due to inhibition of the function of T-antigen in SV40-based replication, we constructed a shuttle vector, pZ402, that contains a mutation in SV40 T-antigen which blocks its ability to interact with p53, Replication of pZ402 in LFS cells was also reduced by the presence of p53(wt), indicating that p53 can inhibit replication by interacting with proteins within the cellular replication machinery, Replicative errors in this shuttle vector are detected as mutations in a marker gene, supF: In addition to supF: mutations, we observed deletion of a portion of the SV40 T-antigen gene in 100% of replicated plasmid pZ189 mutants (supF(-)) from the p53(wt/mut) fibroblasts and in 88% of the supF(-) mutants from the p53(mut/-) (amino acid 175 arg to his) LFS cells, In one cell strain of immortal LFS cells, p53(mut/-), containing a p53 frameshift mutation at amino acid 184, pZ189 replication yielded very few of these deleted shuttle vector plasmids (15%), These large deletions were not detected in plasmids replicated in p53(-/-) non-LFS cells, Saos-2 cells, Replicated plasmids with a normal supF gene were never found to have this large deletion regardless of the cell from which they were derived, Because the supF; gene is not in the same region of the shuttle vector as the T-antigen gene it appears that second, independent gene deletions are frequent when replicative errors in supF occur in cells with a mutant p53, We conclude, therefore, that p53(wt/mut) LFS cells contain an activity that promotes mutations, Such an activity, which is likely to be due to the p53(mut), could result in the high rate of chromosomal instability and allelic loss of the wild-type p53 observed as these cells spontaneously immortalize.	UNIV TEXAS,MD ANDERSON CANC CTR,DIV LAB MED,HOUSTON,TX 77030; UNIV TEXAS,MD ANDERSON CANC CTR,DEPT TUMOR BIOL,HOUSTON,TX 77030; UNIV TEXAS,MD ANDERSON CANC CTR,DEPT EXPTL PEDIAT,HOUSTON,TX 77030; UNIV TEXAS,MD ANDERSON CANC CTR,DEPT EXPTL PEDIAT,HOUSTON,TX 77030; UNIV TEXAS,MD ANDERSON CANC CTR,DEPT MOLEC GENET,HOUSTON,TX 77030	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center				Tainsky, Michael/0000-0002-0261-831X	NATIONAL CANCER INSTITUTE [P01CA034936, P30CA016672, T32CA009299] Funding Source: NIH RePORTER; NCI NIH HHS [CA-16672, P01 CA034936, CA-09299, P01 CA034936-14A1, P30 CA016672, T32 CA009299, CA-P01 34936] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AALTONEN LA, 1993, SCIENCE, V260, P812, DOI 10.1126/science.8484121; AGOFF SN, 1993, SCIENCE, V259, P84, DOI 10.1126/science.8418500; AIZAWA S, 1987, MOL GEN GENET, V208, P342, DOI 10.1007/BF00330463; ARIGA H, 1983, J VIROL, V48, P481, DOI 10.1128/JVI.48.2.481-491.1983; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BARGONETTI J, 1991, CELL, V65, P1083, DOI 10.1016/0092-8674(91)90560-L; BEETT WP, 1994, CANC PERTURBATIONS C; BISCHOFF FZ, 1990, CANCER RES, V50, P7979; BISCHOFF FZ, 1991, ONCOGENE, V6, P183; BISHOP M, 1986, SCIENCE, V235, P305; BOROWIEC JA, 1990, CELL, V60, P181, DOI 10.1016/0092-8674(90)90730-3; BRAITHWAITE AW, 1987, NATURE, V329, P458, DOI 10.1038/329458a0; BREDBERG A, 1987, CARCINOGENESIS, V8, P1923, DOI 10.1093/carcin/8.12.1923; BUBLEY GJ, 1991, MOL CARCINOGEN, V4, P397, DOI 10.1002/mc.2940040512; CARTY MP, 1993, MOL CELL BIOL, V13, P533, DOI 10.1128/MCB.13.1.533; CARTY MP, 1990, MUTAT RES, V232, P141, DOI 10.1016/0027-5107(90)90119-O; CHAN JYH, 1979, P NATL ACAD SCI USA, V76, P814, DOI 10.1073/pnas.76.2.814; CHANG CC, 1981, SOMAT CELL GENET, V7, P235; CLARKE P, 1991, VIROLOGY, V182, P597, DOI 10.1016/0042-6822(91)90600-G; CLEAVER JE, 1989, MUTAT RES, V220, P161, DOI 10.1016/0165-1110(89)90022-5; COMINGS DE, 1973, P NATL ACAD SCI USA, V70, P3324, DOI 10.1073/pnas.70.12.3324; COX LS, 1995, EMBO J, V14, P2099, DOI 10.1002/j.1460-2075.1995.tb07201.x; DELEO AB, 1979, P NATL ACAD SCI USA, V76, P2420, DOI 10.1073/pnas.76.5.2420; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; DORNREITER I, 1990, EMBO J, V9, P3329, DOI 10.1002/j.1460-2075.1990.tb07533.x; DRESLER SL, 1982, BIOCHEMISTRY-US, V21, P2557, DOI 10.1021/bi00539a040; DUTTA A, 1993, NATURE, V365, P79, DOI 10.1038/365079a0; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELIYAHU D, 1984, NATURE, V312, P646, DOI 10.1038/312646a0; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FORD JM, 1995, P NATL ACAD SCI USA, V92, P8876, DOI 10.1073/pnas.92.19.8876; FRIEDMAN PN, 1990, P NATL ACAD SCI USA, V87, P9275, DOI 10.1073/pnas.87.23.9275; FUKUCHI K, 1989, P NATL ACAD SCI USA, V86, P5893, DOI 10.1073/pnas.86.15.5893; GINSBERG D, 1991, P NATL ACAD SCI USA, V88, P9979, DOI 10.1073/pnas.88.22.9979; GREEN AP, 1993, BIOCHEM BIOPH RES CO, V190, P111, DOI 10.1006/bbrc.1993.1018; GUZDER SN, 1995, J BIOL CHEM, V270, P8385, DOI 10.1074/jbc.270.15.8385; HARLOW E, 1981, J VIROL, V37, P564, DOI 10.1128/JVI.37.2.564-573.1981; HARPER JW, 1993, CELL, V75, P805; HARTWELL LH, 1967, J BACTERIOL, V93, P1662, DOI 10.1128/JB.93.5.1662-1670.1967; HARVEY M, 1993, ONCOGENE, V8, P2457; HAY RT, 1989, BIOCHEM J, V258, P3, DOI 10.1042/bj2580003; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; JABERABOANSARI A, 1991, RADIAT RES, V127, P202, DOI 10.2307/3577966; JENKINS JR, 1984, NATURE, V312, P651, DOI 10.1038/312651a0; JENNINGS PA, 1987, EMBO J, V6, P3043, DOI 10.1002/j.1460-2075.1987.tb02610.x; KARASUYAMA H, 1989, J EXP MED, V169, P13, DOI 10.1084/jem.169.1.13; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; KERN SE, 1991, ONCOGENE, V6, P131; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; KIENZLE H, 1989, EUR J BIOCHEM, V184, P181, DOI 10.1111/j.1432-1033.1989.tb15005.x; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; Kolodner Richard D., 1994, Current Opinion in Biotechnology, V5, P585, DOI 10.1016/0958-1669(94)90079-5; KRESS M, 1979, J VIROL, V31, P472, DOI 10.1128/JVI.31.2.472-483.1979; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LAVIGUEUR A, 1991, ONCOGENE, V6, P2197; LEE S, 1995, CELL, V81, P1013, DOI 10.1016/S0092-8674(05)80006-6; LI JJ, 1984, P NATL ACAD SCI-BIOL, V81, P6973, DOI 10.1073/pnas.81.22.6973; LI R, 1993, CELL, V73, P1207, DOI 10.1016/0092-8674(93)90649-B; LIN J, 1991, J VIROL, V64, P2066; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; LIU PK, 1993, MUTAT RES, V288, P229, DOI 10.1016/0027-5107(93)90089-X; LIU PK, 1983, P NATL ACAD SCI-BIOL, V80, P797, DOI 10.1073/pnas.80.3.797; LIU PK, 1984, SCIENCE, V254, P833; LOEB LA, 1991, CANCER RES, V51, P3075; LOEB LA, 1974, CANCER RES, V34, P2311; MACK DH, 1993, NATURE, V363, P281, DOI 10.1038/363281a0; MAH MCM, 1989, CARCINOGENESIS, V10, P2321, DOI 10.1093/carcin/10.12.2321; MAHER VM, 1989, MUTAT RES, V220, P83, DOI 10.1016/0165-1110(89)90013-4; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; MCCORMICK F, 1980, J VIROL, V34, P213, DOI 10.1128/JVI.34.1.213-224.1980; MEEK DW, 1988, MOL CELL BIOL, V8, P461, DOI 10.1128/MCB.8.1.461; MERCER WE, 1982, P NATL ACAD SCI-BIOL, V79, P6309, DOI 10.1073/pnas.79.20.6309; MILLER SD, 1995, MOL CELL BIOL, V15, P6554; MODRICH P, 1991, ANNU REV GENET, V25, P229, DOI 10.1146/annurev.ge.25.120191.001305; MURAKAMI Y, 1992, P NATL ACAD SCI USA, V89, P952, DOI 10.1073/pnas.89.3.952; MURAKAMI Y, 1985, P NATL ACAD SCI USA, V82, P1761, DOI 10.1073/pnas.82.6.1761; MURIEL WJ, 1991, MUTAT RES, V254, P119, DOI 10.1016/0921-8777(91)90002-7; OREN M, 1981, MOL CELL BIOL, V1, P101, DOI 10.1128/MCB.1.2.101; PAN ZQ, 1995, J BIOL CHEM, V270, P22008, DOI 10.1074/jbc.270.37.22008; PARADA LF, 1984, NATURE, V312, P649, DOI 10.1038/312649a0; PARK CH, 1995, J BIOL CHEM, V270, P4896, DOI 10.1074/jbc.270.9.4896; PARRIS CN, 1992, EXP CELL RES, V201, P462, DOI 10.1016/0014-4827(92)90295-J; PELTOMAKI P, 1993, SCIENCE, V260, P810, DOI 10.1126/science.8484120; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; REICH NC, 1983, MOL CELL BIOL, V3, P2143, DOI 10.1128/MCB.3.12.2143; ROGAN EM, 1995, MOL CELL BIOL, V15, P4745; RUNGER TM, 1992, MUTAT RES, V293, P47, DOI 10.1016/0921-8777(92)90007-P; RUSCETTI SK, 1983, J VIROL, V46, P1022, DOI 10.1128/JVI.46.3.1022-1026.1983; SARNOW P, 1982, CELL, V28, P387, DOI 10.1016/0092-8674(82)90356-7; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SEETHARAM S, 1991, NUCLEIC ACIDS RES, V19, P1601, DOI 10.1093/nar/19.7.1601; SEIDMAN MM, 1985, GENE, V38, P233, DOI 10.1016/0378-1119(85)90222-7; SHAY JW, 1995, MOL CELL BIOL, V15, P425, DOI 10.1128/MCB.15.1.425; SIKPI MO, 1992, RADIAT RES, V130, P331, DOI 10.2307/3578378; SPEYER JF, 1965, BIOCHEM BIOPH RES CO, V21, P6, DOI 10.1016/0006-291X(65)90417-1; SPRINGGATE CF, 1973, P NATL ACAD SCI USA, V70, P245, DOI 10.1073/pnas.70.1.245; SRIVASTAVA S, 1990, NATURE, V348, P747, DOI 10.1038/348747a0; STILLMAN B, 1989, ANNU REV CELL BIOL, V5, P197; STILLMAN BW, 1985, MOL CELL BIOL, V5, P2051, DOI 10.1128/MCB.5.8.2051; STRONG LC, 1992, AM J EPIDEMIOL, V135, P190, DOI 10.1093/oxfordjournals.aje.a116271; STURZBECHER HW, 1988, ONCOGENE, V3, P405; TACK LC, 1989, J VIROL, V63, P1310, DOI 10.1128/JVI.63.3.1310-1317.1989; THIBODEAU SN, 1993, SCIENCE, V260, P816, DOI 10.1126/science.8484122; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; WANG EH, 1989, CELL, V57, P379, DOI 10.1016/0092-8674(89)90913-6; WANG P, 1990, CANCER RES, V50, P7527; WANG XW, 1995, NAT GENET, V10, P188, DOI 10.1038/ng0695-188; WEINBERG DH, 1989, P NATL ACAD SCI USA, V86, P9742, DOI 10.1073/pnas.86.24.9742; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; WIGLER M, 1979, CELL, V16, P777, DOI 10.1016/0092-8674(79)90093-X; WINDLE B, 1991, GENE DEV, V5, P160, DOI 10.1101/gad.5.2.160; WOBBE CR, 1985, P NATL ACAD SCI USA, V82, P5710, DOI 10.1073/pnas.82.17.5710; XIONG Y, 1993, GENE DEV, V7, P1572, DOI 10.1101/gad.7.8.1572; YAGI T, 1992, MUTAT RES, V273, P213, DOI 10.1016/0921-8777(92)90082-E; YAMAGUCHI M, 1986, P NATL ACAD SCI USA, V83, P1646, DOI 10.1073/pnas.83.6.1646; YANG JL, 1988, MOL CELL BIOL, V8, P3364, DOI 10.1128/MCB.8.8.3364; YEW PR, 1992, NATURE, V357, P82, DOI 10.1038/357082a0; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7	119	63	63	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN 6	1996	12	11					2267	2278						12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UQ220	8649766				2022-12-25	WOS:A1996UQ22000003
J	Adda, S; Fleischmann, BK; Freedman, BD; Yu, MF; Hay, DWP; Kotlikoff, MI				Adda, S; Fleischmann, BK; Freedman, BD; Yu, MF; Hay, DWP; Kotlikoff, MI			Expression and function of voltage-dependent potassium channel genes in human airway smooth muscle	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECTIFIER K+ CHANNEL; GUINEA-PIG; SUBMUCOSAL ARTERIOLES; IONIC CURRENTS; PORTAL-VEIN; CELLS; CANINE; ARTERY; TRANSMISSION; RELAXATION	Patch clamp and RNA-polymerase chain reaction methods were used to determine the expression of voltage-dependent potassium channel currents and mRNAs in human airway smooth muscle cells, and tension measurements were used to examine the functional role of specific potassium channel gene products in human bronchial smooth muscle, RNA from airway smooth muscle tissue revealed the presence of Kv1.2 (11 kilobases (kb)) and Kv1.5 (3.5 and 4.4 kb) transcripts, as well as Kv1.1 mRNA (9.5 kb), which has not previously been reported in smooth muscle; transcripts from other gene families were not detected. RNA-polymerase chain reaction from cultured human myocytes confirmed that the identified transcripts were expressed by smooth muscle cells, The available voltage-dependent potassium current in human airway myocytes was insensitive to charybdotoxin (200 nM) but blocked by 4-aminopyridine. Dendrotoxin (1-300 nM; inhibits Kv1.1 and Kv1.2 channels), charybdotoxin (10 nM to 1 mu M; inhibits K-Ca, and Kv1.2 channels), and glybenclamide (0.1-100 mu M; inhibits K-ATP channels) had no effect on resting tone, Conversely, 4-aminopyridine increased resting tension with an EC(50) (1.8 mM) equivalent to that observed for current inhibition (1.9 mM). Human airway myocytes express mRNA from several members of the Kv1 gene family; the channel that underlies the predominate voltage dependent current and the regulation of basal tone appears to be Kv1.5.	UNIV PENN, SCH VET MED, DEPT ANIM BIOL, PHILADELPHIA, PA 19104 USA; UNIV PENN, SCH MED, DEPT PATHOL, PHILADELPHIA, PA 19104 USA; SMITHKLINE BEECHAM PHARMACEUT, DEPT PULM PHARMACOL, KING OF PRUSSIA, PA 19406 USA	University of Pennsylvania; University of Pennsylvania; GlaxoSmithKline					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL041084, T32HL007027] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI060921] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL 41084, T32 HL07027] Funding Source: Medline; NIAID NIH HHS [R01 AI060921] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ATTALI B, 1993, J BIOL CHEM, V268, P24283; BECKH S, 1990, EMBO J, V9, P777, DOI 10.1002/j.1460-2075.1990.tb08173.x; BEECH DJ, 1989, J PHYSIOL-LONDON, V418, P293, DOI 10.1113/jphysiol.1989.sp017841; BENHAM CD, 1986, J PHYSIOL-LONDON, V371, P45, DOI 10.1113/jphysiol.1986.sp015961; BOLTON TB, 1985, EXPERIENTIA, V41, P887, DOI 10.1007/BF01970006; BOLTON TB, 1979, PHYSIOL REV, V59, P606, DOI 10.1152/physrev.1979.59.3.606; BOYLE JP, 1992, J PHYSIOL-LONDON, V447, P329, DOI 10.1113/jphysiol.1992.sp019005; BRAYDEN JE, 1992, SCIENCE, V256, P532, DOI 10.1126/science.1373909; BULBRING E, 1987, PHARMACOL REV, V39, P49; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; EDWARDS FR, 1988, J PHYSIOL-LONDON, V404, P437, DOI 10.1113/jphysiol.1988.sp017298; FLEISCHMANN BK, 1993, J PHYSIOL-LONDON, V469, P625, DOI 10.1113/jphysiol.1993.sp019834; GRISSMER S, 1994, MOL PHARMACOL, V45, P1227; HART PJ, 1993, P NATL ACAD SCI USA, V90, P9659, DOI 10.1073/pnas.90.20.9659; HIRST GDS, 1982, J PHYSIOL-LONDON, V333, P53, DOI 10.1113/jphysiol.1982.sp014438; HIRST GDS, 1986, J PHYSIOL-LONDON, V371, P289, DOI 10.1113/jphysiol.1986.sp015975; HIRST GDS, 1989, PHYSIOL REV, V69, P546, DOI 10.1152/physrev.1989.69.2.546; HONDA K, 1987, JPN J PHYSIOL, V37, P333, DOI 10.2170/jjphysiol.37.333; ICHINOSE M, 1994, AM J RESP CRIT CARE, V150, P388, DOI 10.1164/ajrccm.150.2.7519521; ISACOFF EY, 1990, NATURE, V345, P530, DOI 10.1038/345530a0; ITO Y, 1970, J PHYSIOL-LONDON, V211, P445, DOI 10.1113/jphysiol.1970.sp009286; JAN LY, 1992, ANNU REV PHYSIOL, V54, P535, DOI 10.1146/annurev.physiol.54.1.535; JONES TR, 1990, J PHARMACOL EXP THER, V255, P697; KAJIWARA M, 1981, J PHYSIOL-LONDON, V315, P283, DOI 10.1113/jphysiol.1981.sp013748; KOTLIKOFF MI, 1990, AM J PHYSIOL, V259, pL384, DOI 10.1152/ajplung.1990.259.6.L384; KOTLIKOFF MI, 1987, AM J PHYSIOL, V253, pC561, DOI 10.1152/ajpcell.1987.253.4.C561; KUME H, 1989, NATURE, V341, P152, DOI 10.1038/341152a0; MCCANN JD, 1986, J PHYSIOL-LONDON, V372, P113, DOI 10.1113/jphysiol.1986.sp016000; MIURA M, 1992, AM REV RESPIR DIS, V146, P132, DOI 10.1164/ajrccm/146.1.132; OKABE K, 1987, PFLUG ARCH EUR J PHY, V409, P561, DOI 10.1007/BF00584654; OKABE K, 1990, J PHARMACOL EXP THER, V252, P832; OVERTURF KE, 1994, AM J PHYSIOL-CELL PH, V267, pC1231, DOI 10.1152/ajpcell.1994.267.5.C1231; PANETTIERI RA, 1989, AM J PHYSIOL, V256, pC329, DOI 10.1152/ajpcell.1989.256.2.C329; QUAYLE JM, 1993, AM J PHYSIOL, V265, pC1363, DOI 10.1152/ajpcell.1993.265.5.C1363; ROBERDS SL, 1991, P NATL ACAD SCI USA, V88, P1798, DOI 10.1073/pnas.88.5.1798; ROBERTSON BE, 1994, AM J PHYSIOL-CELL PH, V267, pC1589, DOI 10.1152/ajpcell.1994.267.6.C1589; RUPPERSBERG JP, 1990, NATURE, V345, P535, DOI 10.1038/345535a0; SALKOFF L, 1992, TRENDS NEUROSCI, V15, P161, DOI 10.1016/0166-2236(92)90165-5; STANDEN NB, 1989, SCIENCE, V245, P177, DOI 10.1126/science.2501869; TORPHY TJ, 1993, J PHARMACOL EXP THER, V265, P1213; TYTGAT J, 1995, J BIOL CHEM, V270, P24776, DOI 10.1074/jbc.270.42.24776; VILLANOVE X, 1993, AM REV RESPIR DIS, V148, P107, DOI 10.1164/ajrccm/148.1.107; VOLK KA, 1991, J PHYSIOL-LONDON, V439, P751, DOI 10.1113/jphysiol.1991.sp018691; WALSH JV, 1983, CELL CALCIUM, V4, P321, DOI 10.1016/0143-4160(83)90011-8	44	49	55	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 31	1996	271	22					13239	13243		10.1074/jbc.271.22.13239	http://dx.doi.org/10.1074/jbc.271.22.13239			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UN474	8662756	hybrid			2022-12-25	WOS:A1996UN47400085
J	Boffa, LC; Morris, PL; Carpaneto, EM; Louissaint, M; Allfrey, VG				Boffa, LC; Morris, PL; Carpaneto, EM; Louissaint, M; Allfrey, VG			Invasion of the CAG triplet repeats by a complementary peptide nucleic acid inhibits transcription of the androgen receptor and TATA-binding protein genes and correlates with refolding of an active nucleosome containing a unique AR gene sequence	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THYMINE-SUBSTITUTED POLYAMIDE; CONSERVED CORE DOMAIN; AFFINITY-CHROMATOGRAPHY; STRAND-DISPLACEMENT; SODIUM BUTYRATE; C-FOS; DNA; ACTIVATION; CHROMATIN; PNA	The DNA sequence of the genes for the androgen receptor (AR) and TATA-binding protein (TBP), like many other genes encoding transcription factors, contains a series of tandem CAG repeats, Here we explore the capacity of complementary peptide nucleic acids (PNAs) to invade the CAG triplets of the AR and TBP genes in human prostatic cancer cells and show that the PNAs readily entered the nuclei of lysolecithin-permeabilized cells and effectively inhibited sense transcription of unique AR and TBP DNA sequences downstream of the site of PNA;DNA hybridization, but not upstream of that site, These PNAs had Little or no effect on transcription of the c-myc gene, which lacks a CAG triplet domain. Conversely, a PNA complementary to a unique sequence of the c-myc gene did not inhibit transcription of the AR or TBP genes but did inhibit c-myc transcription. Comparisons of PNA effects on sense and antisense transcription of the AR, TBP, and c-myc genes confirm that progression of the RNA polymerase complex beyond the site of PNA DNA hybridization is impaired in both directions. Suppression of the AR gene results in refolding of a transcriptionally active nucleosome containing a unique 17-mer AR DNA sequence.	IST,IST NAZL RIC CANC,DEPT EXPTL ONCOL,I-16132 GENOA,ITALY; ROCKEFELLER UNIV,POPULAT COUNCIL,NEW YORK,NY 10021; ROCKEFELLER UNIV,CELL BIOL LAB,NEW YORK,NY 10021	University of Genoa; IRCCS AOU San Martino IST; Population Council; Rockefeller University; Rockefeller University					EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD016149] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA014908] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA14908] Funding Source: Medline; NICHD NIH HHS [R01 HD16149] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ALLFREY VG, 1991, METHOD CELL BIOL, V35, P315; ALMARSSON O, 1993, P NATL ACAD SCI USA, V90, P7518, DOI 10.1073/pnas.90.16.7518; Ausubel FM, 1994, CURRENT PROTOCOLS MO; BOFFA LC, 1990, EUR J BIOCHEM, V194, P811, DOI 10.1111/j.1432-1033.1990.tb19474.x; BOFFA LC, 1978, J BIOL CHEM, V253, P3364; BOFFA LC, 1995, P NATL ACAD SCI USA, V92, P1901, DOI 10.1073/pnas.92.6.1901; CESARONE CF, 1979, ANAL BIOCHEM, V100, P188, DOI 10.1016/0003-2697(79)90131-3; CHAMBERLAIN NL, 1994, NUCLEIC ACIDS RES, V22, P3182; CHANG CS, 1988, P NATL ACAD SCI USA, V85, P7211, DOI 10.1073/pnas.85.19.7211; CHEN TA, 1990, J MOL BIOL, V212, P481, DOI 10.1016/0022-2836(90)90327-I; CHEN TA, 1987, P NATL ACAD SCI USA, V84, P5252, DOI 10.1073/pnas.84.15.5252; CHENCLELAND TA, 1993, J BIOL CHEM, V268, P1118; CHENCLELAND TA, 1993, J BIOL CHEM, V268, P23409; CHERNY DY, 1993, P NATL ACAD SCI USA, V90, P1667, DOI 10.1073/pnas.90.5.1667; DAHLE CE, 1993, BIOTECHNIQUES, V15, P1102; DEMIDOV VV, 1995, P NATL ACAD SCI USA, V92, P2637, DOI 10.1073/pnas.92.7.2637; DEMIDOV VV, 1994, NUCLEIC ACIDS RES, V22, P5218, DOI 10.1093/nar/22.24.5218; DEMIDOV VV, 1994, BIOCHEM PHARMACOL, V48, P1310, DOI 10.1016/0006-2952(94)90171-6; EGHOLM M, 1993, NATURE, V365, P566, DOI 10.1038/365566a0; EGHOLM M, 1992, J AM CHEM SOC, V114, P1895, DOI 10.1021/ja00031a062; EGHOLM M, 1992, J AM CHEM SOC, V114, P9677, DOI 10.1021/ja00050a068; GASPAR ML, 1990, MOL ENDOCRINOL, V4, P1600, DOI 10.1210/mend-4-10-1600; Gurdon J.B., 1977, Methods Cell Biol, V16, P125; HANVEY JC, 1992, SCIENCE, V258, P1481, DOI 10.1126/science.1279811; HOFFMANN A, 1990, NATURE, V346, P387, DOI 10.1038/346387a0; LINDZEY J, 1994, VITAM HORM, V49, P383; MAHTRE AN, 1993, NAT GENET, V5, P184; MARCU KB, 1992, ANNU REV BIOCHEM, V61, P809, DOI 10.1146/annurev.bi.61.070192.004113; MOLLEGAARD NE, 1994, P NATL ACAD SCI USA, V91, P3892, DOI 10.1073/pnas.91.9.3892; NIELSEN PE, 1991, SCIENCE, V254, P1497, DOI 10.1126/science.1962210; NIELSEN PE, 1993, NUCLEIC ACIDS RES, V21, P197, DOI 10.1093/nar/21.2.197; NIELSEN PE, 1993, ANTI-CANCER DRUG DES, V8, P53; NIELSEN PE, 1994, GENE, V149, P139, DOI 10.1016/0378-1119(94)90422-7; PEFFER NJ, 1993, P NATL ACAD SCI USA, V90, P10648, DOI 10.1073/pnas.90.22.10648; PERUTZ MF, 1994, P NATL ACAD SCI USA, V91, P5355, DOI 10.1073/pnas.91.12.5355; PETERSON MG, 1990, SCIENCE, V248, P1625, DOI 10.1126/science.2363050; PRIOR CP, 1983, CELL, V34, P1038; Sambrook J., 2002, MOL CLONING LAB MANU; SCHOENBERG MP, 1994, BIOCHEM BIOPH RES CO, V198, P74, DOI 10.1006/bbrc.1994.1011; SEALY L, 1978, CELL, V14, P115, DOI 10.1016/0092-8674(78)90306-9; TAN JA, 1988, MOL ENDOCRINOL, V2, P1276, DOI 10.1210/mend-2-12-1276; TILLEY WD, 1990, CANCER RES, V50, P5382; TILLEY WD, 1989, P NATL ACAD SCI USA, V86, P327, DOI 10.1073/pnas.86.1.327; WALKER J, 1990, J BIOL CHEM, V265, P5736; ZHOU Q, 1993, GENE DEV, V7, P180, DOI 10.1101/gad.7.2.180	45	60	64	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 31	1996	271	22					13228	13233		10.1074/jbc.271.22.13228	http://dx.doi.org/10.1074/jbc.271.22.13228			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UN474	8662737				2022-12-25	WOS:A1996UN47400083
J	Groupp, ER; DonovanPeluso, M				Groupp, ER; DonovanPeluso, M			Lipopolysaccharide induction of THP-1 cells activates binding of c-Jun, Ets, and Egr-1 to the tissue factor promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; TRANSCRIPTION FACTOR EGR-1; NF-KAPPA-B; MONOCYTIC DIFFERENTIATION; MONOCLONAL-ANTIBODY; BLOOD MONOCYTES; FACTOR GENE; FOS; EXPRESSION; PHOSPHORYLATION	These studies examine the molecular basis for increased transcription of tissue factor (TF) in THP-1 cells stimulated with lipopolysaccharide (LPS). DNase I footprinting identified six sites of protein-DNA interaction between -383 and the cap site that varied between control and induced extracts. Four footprints show qualitative differences in nuclease sensitivity. Footprints I (-85 to -52) and V (-197 to -175) are induction-specific and localize to regions of the promoter that mediate serum, phorbol ester, partial LPS response (-111 to +14), and the major LPS inducible element (-231 to -172). Electrophoretic mobility shift assays with the -231 to -172 probe demonstrate JunD and Fos binding in both control and induced nuclear extracts; however, binding of c-Jun is only detected following LPS stimulation. Antibody inhibition studies implicate binding of Ets-1 or Ets-2 to the consensus site between -192 and -177, a region that contains an induction-specific footprint. The proximal region (-85 to -52), containing the second inducible footprint, binds Egr-1 following induction. These data suggest that LPS stimulation of THP-1 cells activates binding of c-Jun, Ets, and Egr-1 to the TF promoter and implicates these factors in the transcriptional activation of TF mRNA synthesis.	UNIV PITTSBURGH, DEPT PATHOL, SCH MED, PITTSBURGH, PA 15261 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh					NCRR NIH HHS [1P41RR06009] Funding Source: Medline; NHLBI NIH HHS [1R29HL45621-01A1] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR006009] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL045621] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABATE C, 1991, MOL CELL BIOL, V11, P3624, DOI 10.1128/MCB.11.7.3624; ALTIERI DC, 1988, P NATL ACAD SCI USA, V85, P7462, DOI 10.1073/pnas.85.20.7462; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; AUWERX J, 1991, CELL, V64, P983, DOI 10.1016/0092-8674(91)90322-P; BAICHWAL VR, 1992, GENE DEV, V6, P1493, DOI 10.1101/gad.6.8.1493; BHAT NK, 1990, P NATL ACAD SCI USA, V87, P3723, DOI 10.1073/pnas.87.10.3723; BINETRUY B, 1991, NATURE, V351, P122, DOI 10.1038/351122a0; BOYLE WJ, 1991, CELL, V64, P573, DOI 10.1016/0092-8674(91)90241-P; BRAND K, 1991, MOL CELL BIOL, V11, P4732, DOI 10.1128/MCB.11.9.4732; BUTTICE G, 1993, J BIOL CHEM, V268, P7196; CAO XM, 1990, MOL CELL BIOL, V10, P1931, DOI 10.1128/MCB.10.5.1931; CAO XM, 1993, J BIOL CHEM, V268, P16949; CHEN HM, 1993, J BIOL CHEM, V268, P8230; CHILES TC, 1991, J IMMUNOL, V146, P1730; CONKLING PR, 1988, BLOOD, V72, P128; CORDLE SR, 1993, J BIOL CHEM, V268, P11803; CUI MZ, 1994, ARTERIOSCLER THROMB, V14, P807, DOI 10.1161/01.ATV.14.5.807; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DONOVANPELUSO M, 1994, J BIOL CHEM, V269, P1361; DRAKE TA, 1989, AM J PATHOL, V134, P1087; EDGINGTON TS, 1991, THROMB HAEMOSTASIS, V66, P67; GASHLER AL, 1993, MOL CELL BIOL, V13, P4556, DOI 10.1128/MCB.13.8.4556; GEGONNE A, 1993, EMBO J, V12, P1169, DOI 10.1002/j.1460-2075.1993.tb05758.x; GENG Y, 1994, P NATL ACAD SCI USA, V91, P8602, DOI 10.1073/pnas.91.18.8602; GENG Y, 1993, J IMMUNOL, V151, P6692; GREGORY SA, 1989, MOL CELL BIOL, V9, P2752, DOI 10.1128/MCB.9.6.2752; HAGEN G, 1994, EMBO J, V13, P3843, DOI 10.1002/j.1460-2075.1994.tb06695.x; HAI T, 1991, P NATL ACAD SCI USA, V88, P3720, DOI 10.1073/pnas.88.9.3720; HARTZOG GA, 1993, MOL CELL BIOL, V13, P44, DOI 10.1128/MCB.13.1.44; HIPSKIND RA, 1991, NATURE, V354, P531, DOI 10.1038/354531a0; HROMAS R, 1994, INT J HEMATOL, V59, P257; KHARBANDA S, 1994, J BIOL CHEM, V269, P872; KHARBANDA S, 1991, J CLIN INVEST, V88, P571, DOI 10.1172/JCI115341; KOWENZLEUTZ E, 1994, GENE DEV, V8, P2781, DOI 10.1101/gad.8.22.2781; KUNSCH C, 1992, MOL CELL BIOL, V12, P4412, DOI 10.1128/MCB.12.10.4412; LAMARCO K, 1991, SCIENCE, V253, P789, DOI 10.1126/science.1876836; LYBERG T, 1981, BIOCHEM J, V194, P699, DOI 10.1042/bj1940699; MACKMAN N, 1990, P NATL ACAD SCI USA, V87, P2254, DOI 10.1073/pnas.87.6.2254; MACKMAN N, 1991, J EXP MED, V174, P1517, DOI 10.1084/jem.174.6.1517; MADDEN SL, 1993, ANN NY ACAD SCI, V684, P75, DOI 10.1111/j.1749-6632.1993.tb32272.x; MORRISSEY JH, 1989, OXFORD SURVEYS EUKAR, P67; NGUYEN HQ, 1993, CELL, V72, P197, DOI 10.1016/0092-8674(93)90660-I; NIEMETZ J, 1977, BLOOD, V49, P947; NIEMETZ J, 1971, NATURE-NEW BIOL, V232, P247, DOI 10.1038/newbio232247a0; NIKOLAKAKI E, 1993, ONCOGENE, V8, P833; OETH PA, 1994, MOL CELL BIOL, V14, P3772, DOI 10.1128/MCB.14.6.3772; PANKOV R, 1994, MOL CELL BIOL, V14, P7744, DOI 10.1128/MCB.14.12.7744; PARRY GCN, 1995, ARTERIOSCL THROM VAS, V15, P612, DOI 10.1161/01.ATV.15.5.612; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; RANSONE LJ, 1990, ANNU REV CELL BIOL, V6, P539, DOI 10.1146/annurev.cellbio.6.1.539; RAUSCHER FJ, 1990, SCIENCE, V250, P1259, DOI 10.1126/science.2244209; RYSECK RP, 1991, ONCOGENE, V6, P533; SAKAMOTO KM, 1994, MOL CELL BIOL, V14, P5975, DOI 10.1128/MCB.14.9.5975; SETH A, 1993, ONCOGENE, V8, P1783; SLAPAK CA, 1993, J BIOL CHEM, V268, P12267; TAYLOR FB, 1991, CIRC SHOCK, V33, P127; TAYLOR FB, 1987, J CLIN INVEST, V79, P918, DOI 10.1172/JCI112902; TERNISIEN C, 1993, THROMB HAEMOSTASIS, V70, P800; TSUCHIYA S, 1980, INT J CANCER, V26, P171, DOI 10.1002/ijc.2910260208; VOT PK, ADV CANCER RES, V55, P1; WANG CY, 1994, MOL CELL BIOL, V14, P1153, DOI 10.1128/MCB.14.2.1153; WASYLYK B, 1993, EUR J BIOCHEM, V211, P7, DOI 10.1111/j.1432-1033.1993.tb19864.x; WASYLYK B, 1990, NATURE, V346, P191, DOI 10.1038/346191a0; WATSON DK, 1988, P NATL ACAD SCI USA, V85, P7862, DOI 10.1073/pnas.85.21.7862; WU H, 1994, MOL CELL BIOL, V14, P2129, DOI 10.1128/MCB.14.3.2129; ZHANG DE, 1994, J BIOL CHEM, V269, P11425	66	28	28	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 24	1996	271	21					12423	12430		10.1074/jbc.271.21.12423	http://dx.doi.org/10.1074/jbc.271.21.12423			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UL660	8647847	hybrid			2022-12-25	WOS:A1996UL66000049
J	Hailman, E; Albers, JJ; Wolfbauer, G; Tu, AY; Wright, SD				Hailman, E; Albers, JJ; Wolfbauer, G; Tu, AY; Wright, SD			Neutralization and transfer of lipopolysaccharide by phospholipid transfer protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DENSITY-LIPOPROTEIN CONVERSION; ACUTE PHASE REACTANT; LPS BINDING-PROTEIN; HUMAN-PLASMA; POLYMYXIN-B; CD14; ENDOTOXIN; COMPLEXES; SERUM; CELLS	Phospholipid transfer protein (PLTP) and lipopolysaccharide-binding protein (LBP) are lipid transfer proteins found in human plasma. PLTP shares 24% sequence similarity with LBP. PLTP mediates the transfer and exchange of phospholipids between lipoprotein particles, whereas LBP transfers bacterial lipopolysaccharide (LPS) either to lipoprotein particles or to CD14, a soluble and cell-surface receptor for LPS, We asked whether PLTP could interact with LPS and mediate the transfer of LPS to lipoproteins or to CD14, PLTP was able to bind and neutralize LPS: incubation of LPS with purified recombinant PLTP (rPLTP) resulted in the inhibition of the ability of LPS to stimulate adhesive responses of neutrophils, and addition of rPLTP to blood inhibited cytokine production in response to LPS. Transfer of LPS by rPLTP was examined using fluorescence dequenching experiments and native gel electrophoresis. The results suggested that rPLTP was able to mediate the exchange of LPS between micelles and the transfer of LPS to reconstituted HDL particles, but it did not transfer LPS to CD14. Consonant with these findings, rPLTP did not mediate CD14-dependent adhesive responses of neutrophils to LPS. These results suggest that while PLTP and LBP both bind and transfer LPS, PLTP is unable to transfer LPS to CD14 and thus does not mediate responses of cells to LPS.	ROCKEFELLER UNIV, CELLULAR PHYSIOL & IMMUNOL LAB, NEW YORK, NY 10021 USA; UNIV WASHINGTON, DEPT MED, NW LIPID RES LABS, SEATTLE, WA 98103 USA	Rockefeller University; University of Washington; University of Washington Seattle					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL030086] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI030556] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 30086] Funding Source: Medline; NIAID NIH HHS [AI 30556] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALBERS JJ, 1995, BBA-LIPID LIPID MET, V1258, P27, DOI 10.1016/0005-2760(95)00091-P; ALBERS JJ, 1984, ARTERIOSCLEROSIS, V4, P49, DOI 10.1161/01.ATV.4.1.49; DAY JR, 1994, J BIOL CHEM, V269, P9388; ELSBACH P, 1993, CURR OPIN IMMUNOL, V5, P103, DOI 10.1016/0952-7915(93)90088-A; FREY EA, 1992, J EXP MED, V176, P1665, DOI 10.1084/jem.176.6.1665; GRAY PW, 1989, J BIOL CHEM, V264, P9505; HAILMAN E, 1994, J EXP MED, V179, P269, DOI 10.1084/jem.179.1.269; HAN JH, 1994, J BIOL CHEM, V269, P8172; HAZIOT A, 1994, J ENDOTOXIN RES, V1, P73; JAUHIAINEN M, 1993, J BIOL CHEM, V268, P4032; JIANG XC, 1995, J BIOL CHEM, V270, P17133, DOI 10.1074/jbc.270.29.17133; KUSUNOKI T, 1995, J EXP MED, V182, P1673, DOI 10.1084/jem.182.6.1673; LARRICK JW, 1994, J IMMUNOL, V152, P231; LEE JD, 1992, J EXP MED, V175, P1697, DOI 10.1084/jem.175.6.1697; MASSEY JB, 1985, BIOCHIM BIOPHYS ACTA, V835, P124, DOI 10.1016/0005-2760(85)90038-4; MASUCCIMAGOULAS L, 1995, J CLIN INVEST, V95, P1587, DOI 10.1172/JCI117832; MATZ CE, 1982, J BIOL CHEM, V257, P4535; MCKINNEY MM, 1987, J IMMUNOL METHODS, V96, P271, DOI 10.1016/0022-1759(87)90324-3; MORRISON DC, 1976, IMMUNOCHEMISTRY, V13, P813, DOI 10.1016/0019-2791(76)90181-6; NIKAIDO H, 1987, ESCHERICHIA COLI SAL, V1, P7; RAETZ CRH, 1990, ANNU REV BIOCHEM, V59, P129, DOI 10.1146/annurev.bi.59.070190.001021; RAETZ CRH, 1991, FASEB J, V5, P2652, DOI 10.1096/fasebj.5.12.1916089; RIBI E, 1966, J BACTERIOL, V92, P1493, DOI 10.1128/JB.92.5.1493-1509.1966; Rietschel E T, 1991, Infect Dis Clin North Am, V5, P753; SCHINDLER M, 1979, BIOCHEMISTRY-US, V18, P4425, DOI 10.1021/bi00587a024; SCHUMANN RR, 1990, SCIENCE, V249, P1429, DOI 10.1126/science.2402637; STOKES DC, 1989, J INFECT DIS, V160, P52, DOI 10.1093/infdis/160.1.52; THEOFAN G, 1994, J IMMUNOL, V152, P3623; TOBIAS PS, 1986, J EXP MED, V164, P777, DOI 10.1084/jem.164.3.777; TOBIAS PS, 1989, J BIOL CHEM, V264, P10867; TOBIAS PS, 1995, J BIOL CHEM, V270, P10482, DOI 10.1074/jbc.270.18.10482; TOLLEFSON JH, 1988, J LIPID RES, V29, P1593; TU AY, 1993, J BIOL CHEM, V268, P23098; VANKESSEL KPM, 1994, J IMMUNOL METHODS, V172, P25; WAECHTER DE, 1982, P NATL ACAD SCI-BIOL, V79, P1106, DOI 10.1073/pnas.79.4.1106; WAINWRIGHT NR, 1990, INT CONGR SER, V923, P315; WRIGHT SD, 1991, J EXP MED, V173, P1281, DOI 10.1084/jem.173.5.1281; WRIGHT SD, 1990, SCIENCE, V249, P1431, DOI 10.1126/science.1698311; WURFEL MM, 1995, J EXP MED, V181, P1743, DOI 10.1084/jem.181.5.1743; WURFEL MM, 1994, J EXP MED, V180, P1025, DOI 10.1084/jem.180.3.1025; Yu B, 1996, J BIOL CHEM, V271, P4100	41	151	157	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 24	1996	271	21					12172	12178		10.1074/jbc.271.21.12172	http://dx.doi.org/10.1074/jbc.271.21.12172			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UL660	8647810	hybrid			2022-12-25	WOS:A1996UL66000012
J	Hansen, LH; Wang, XZ; Kopchick, JJ; Bouchelouche, P; Nielsen, JH; Galsgaard, ED; Billestrup, N				Hansen, LH; Wang, XZ; Kopchick, JJ; Bouchelouche, P; Nielsen, JH; Galsgaard, ED; Billestrup, N			Identification of tyrosine residues in the intracellular domain of the growth hormone receptor required for transcriptional signaling and stat5 activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-EXPRESSION; FACTOR-I; CELLS; KINASE; PROTEIN; PHOSPHORYLATION; PROLACTIN; TISSUE; FAMILY; LIVER	The binding of growth hormone (GH) to its receptor results in its dimerization followed by activation of Jak2 kinase and tyrosine phosphorylation of the GH receptor itself, as well as Jak2 and the transcription factors Stat1, -3, and -5. In order to study the role of GH receptor tyrosine phosphorylation in intracellular signaling, we constructed GH receptors in which combinations of tyrosines were mutated to phenylalanines. We identified three tyrosine residues at positions 534, 566, and 627 that were required for activation of GH-stimulated transcription of the serine protease inhibitor (Spi) 2.1 promoter. Any of these three tyrosines is able to independently mediate GH-induced transcription, indicating redundancy in this part of the GH receptor. Tyrosine phosphorylation was not required for GH stimulation of mitogen-activated protein (MAP) kinase activity or for GH-stimulated Ca2+ channel activation since these pathways were normal in cells expressing a GH receptor in which all eight intracellular tyrosines were mutated to phenylalanines. Activation of Stat5 by GH was, however, abolished in cells expressing the GH receptor lacking intracellular tyrosines. This study demonstrates that specific tyrosines in the GH receptor are required for transcriptional signaling possibly by their role in the activation of transcription factor Stat5.	HAGEDORN RES INST, DK-2820 GENTOFTE, DENMARK; OHIO UNIV, EDISON BIOTECHNOL INST, ATHENS, OH 45701 USA; UNIV COPENHAGEN, GENTOFTE HOSP, DEPT CLIN CHEM, DK-2820 GENTOFTE, DENMARK	Novo Nordisk; Hagedorn Research Institute; University System of Ohio; Ohio University; University of Copenhagen; Herlev & Gentofte Hospital				Bouchelouche, Pierre/0000-0002-0441-8194; Nielsen, Jens Hoiriis/0000-0001-8252-3048; Billestrup, Nils/0000-0002-4968-8067				ALLEVATO G, 1995, J BIOL CHEM, V270, P17210, DOI 10.1074/jbc.270.29.17210; ARGETSINGER LS, 1993, CELL, V74, P237, DOI 10.1016/0092-8674(93)90415-M; AZAM M, 1995, EMBO J, V14, P1402, DOI 10.1002/j.1460-2075.1995.tb07126.x; BILLESTRUP N, 1991, ENDOCRINOLOGY, V129, P883, DOI 10.1210/endo-129-2-883; BILLESTRUP N, 1995, P NATL ACAD SCI USA, V92, P2725, DOI 10.1073/pnas.92.7.2725; BILLESTRUP N, 1985, ENDOCRINOLOGY, V116, P1175, DOI 10.1210/endo-116-3-1175; CAMPBELL GS, 1995, J BIOL CHEM, V270, P3974, DOI 10.1074/jbc.270.8.3974; CARTERSU C, 1989, J BIOL CHEM, V264, P18654; COLOSI P, 1993, J BIOL CHEM, V268, P12617; DELEGEANE AM, 1987, MOL CELL BIOL, V7, P3994, DOI 10.1128/MCB.7.11.3994; DOGLIO A, 1989, P NATL ACAD SCI USA, V86, P1148, DOI 10.1073/pnas.86.4.1148; GOODMAN HM, 1981, ENDOCRINOLOGY, V109, P120, DOI 10.1210/endo-109-1-120; GOUILLEUX F, 1994, EMBO J, V13, P4361, DOI 10.1002/j.1460-2075.1994.tb06756.x; GOUILLEUX F, 1995, EMBO J, V14, P2005, DOI 10.1002/j.1460-2075.1995.tb07192.x; GOUJON L, 1994, P NATL ACAD SCI USA, V91, P957, DOI 10.1073/pnas.91.3.957; GRONOWSKI AM, 1994, J BIOL CHEM, V269, P7874; HOU JZ, 1994, SCIENCE, V265, P1701, DOI 10.1126/science.8085155; ILONDO MM, 1994, BIOCHEM BIOPH RES CO, V202, P391, DOI 10.1006/bbrc.1994.1940; ISAKSSON OGP, 1985, ANNU REV PHYSIOL, V47, P483, DOI 10.1146/annurev.ph.47.030185.002411; KELLY PA, 1991, ENDOCR REV, V12, P235, DOI 10.1210/edrv-12-3-235; LEBRUN JJ, 1995, P NATL ACAD SCI USA, V92, P4031, DOI 10.1073/pnas.92.9.4031; LOBIE PE, 1995, J BIOL CHEM, V270, P21745, DOI 10.1074/jbc.270.37.21745; MATHEWS LS, 1986, P NATL ACAD SCI USA, V83, P9343, DOI 10.1073/pnas.83.24.9343; MEYER DJ, 1994, J BIOL CHEM, V269, P4701; MOLDRUP A, 1991, J BIOL CHEM, V266, P17441; MOLLER C, 1992, J BIOL CHEM, V267, P23403; MUI ALF, 1995, EMBO J, V14, P1166, DOI 10.1002/j.1460-2075.1995.tb07100.x; STAHL N, 1995, SCIENCE, V267, P1349, DOI 10.1126/science.7871433; TRAVERSE S, 1992, BIOCHEM J, V288, P351, DOI 10.1042/bj2880351; VANDERKUUR JA, 1994, J BIOL CHEM, V269, P21709; VANDERKUUR JA, 1995, J BIOL CHEM, V270, P21738, DOI 10.1074/jbc.270.37.21738; WAKAO H, 1994, EMBO J, V13, P2182, DOI 10.1002/j.1460-2075.1994.tb06495.x; WANG XY, 1992, J BIOL CHEM, V267, P17390; WANG XY, 1993, J BIOL CHEM, V268, P3573; WANG XZ, 1995, J BIOL CHEM, V270, P6261, DOI 10.1074/jbc.270.11.6261; WANG XZ, 1993, MOL CELL ENDOCRINOL, V94, P89, DOI 10.1016/0303-7207(93)90055-O; WANG YD, 1995, J BIOL CHEM, V270, P7021, DOI 10.1074/jbc.270.13.7021; YOON JB, 1987, J BIOL CHEM, V262, P4284; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	39	96	97	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 24	1996	271	21					12669	12673		10.1074/jbc.271.21.12669	http://dx.doi.org/10.1074/jbc.271.21.12669			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UL660	8647880	hybrid			2022-12-25	WOS:A1996UL66000082
J	Kojima, R; Randall, J; Brenner, BM; Gullans, SR				Kojima, R; Randall, J; Brenner, BM; Gullans, SR			Osmotic stress protein 94 (Osp94) - A new member of the Hsp110/SSE gene subfamily	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PEPTIDE BINDING DOMAIN; HSP70 PROTEIN; ATPASE DOMAIN; CELL-LINE; EXPRESSION	Preservation of cell viability and function in the hyperosmolar environment of the renal medulla is a complex process that requires selective gene expression. We have identified a new member of the heat shock protein (hsp) 70 superfamily that is up regulated in renal inner medullary collecting duct cells (mIMCD3 cells) during exposure to hyperosmotic NaCl stress. Known as osmotic stress protein 94, or Osp94, this 2935-base pair cDNA encodes an 838-amino acid protein that shows greatest homology to the recently discovered hsp110/SSE gene subfamily. Like the hsps, Osp94 has a putative amino-terminal ATP-binding domain and a putative carboxyl-terminal peptide-binding domain. The in vitro translated Osp94 product migrated as a 105-110-kDa protein on SDS-polyacrylamide gel electrophoresis. In mIMCD3 cells, Osp94 mRNA expression was greatly upregulated by hyperosmotic NaCl or heat stress. In mouse kidney, Osp94 mRNA expression paralleled the known corticomedullary osmolality gradient showing highest expression in the inner medulla. Moreover, inner medullary Osp94 expression was increased during water restriction when osmolality is known to increase. Thus, Osp94 is a new member of the hsp110/SSE stress protein subfamily and likely acts as a molecular chaperone.	BRIGHAM & WOMENS HOSP,DIV RENAL,DEPT MED,BOSTON,MA 02115; HARVARD UNIV,SCH MED,BOSTON,MA 02115; MEIJO UNIV,FAC PHARM,DEPT PHARMACOL,NAGOYA,AICHI 468,JAPAN	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Meijo University					NIDDK NIH HHS [DK35930, DK36031] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK036031, R01DK035930] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BECKER J, 1994, EUR J BIOCHEM, V219, P11, DOI 10.1111/j.1432-1033.1994.tb19910.x; BORK P, 1992, P NATL ACAD SCI USA, V89, P7290, DOI 10.1073/pnas.89.16.7290; BURG MB, 1992, J AM SOC NEPHROL, V3, P121; BURG MB, 1995, AM J PHYSIOL-RENAL, V268, pF983, DOI 10.1152/ajprenal.1995.268.6.F983; CHAPPELL TG, 1987, J BIOL CHEM, V262, P746; COHEN DM, 1993, AM J PHYSIOL, V264, pF601, DOI 10.1152/ajprenal.1993.264.4.F601; COHEN DM, 1991, AM J PHYSIOL, V261, pC594, DOI 10.1152/ajpcell.1991.261.4.C594; COHEN DM, 1993, CELLULAR MOL PHYSL C, P363; DASGUPTA S, 1992, EXP EYE RES, V54, P461, DOI 10.1016/0014-4835(92)90058-Z; FATHALLAH DM, 1993, J IMMUNOL, V151, P810; FOLTZ KR, 1993, SCIENCE, V259, P1421, DOI 10.1126/science.8383878; GARCIAPEREZ A, 1991, PHYSIOL REV, V71, P1081, DOI 10.1152/physrev.1991.71.4.1081; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; LEEYOON D, 1995, J BIOL CHEM, V270, P15725, DOI 10.1074/jbc.270.26.15725; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; MILARSKI KL, 1989, J CELL BIOL, V109, P1947, DOI 10.1083/jcb.109.5.1947; MUKAI H, 1993, GENE, V132, P57; NAKAI K, 1992, GENOMICS, V14, P89; NOVER L, 1991, HEAT SHOCK RESPONSE, P41; PARFETT CLJ, 1989, GENE, V82, P291, DOI 10.1016/0378-1119(89)90054-1; RAUCHMAN MI, 1993, AM J PHYSIOL, V265, pF416, DOI 10.1152/ajprenal.1993.265.3.F416; RIPPMANN F, 1991, EMBO J, V10, P1053, DOI 10.1002/j.1460-2075.1991.tb08044.x; SHEIKHHAMAD D, 1994, AM J PHYSIOL, V267, pF28, DOI 10.1152/ajprenal.1994.267.1.F28; SHIRAYAMA M, 1993, MOL GEN GENET, V240, P323, DOI 10.1007/BF00280382; SULSTON J, 1992, NATURE, V356, P37, DOI 10.1038/356037a0; TANAKA K, 1988, BIOCHIM BIOPHYS ACTA, V950, P138, DOI 10.1016/0167-4781(88)90006-1; WANG TF, 1993, J BIOL CHEM, V268, P26049; WELCH WJ, 1992, PHYSIOL REV, V72, P1063, DOI 10.1152/physrev.1992.72.4.1063; WILSON R, 1994, NATURE, V368, P32, DOI 10.1038/368032a0; YANCEY PH, 1988, J COMP PHYSIOL B, V158, P369, DOI 10.1007/BF00695336	31	87	90	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 24	1996	271	21					12327	12332		10.1074/jbc.271.21.12327	http://dx.doi.org/10.1074/jbc.271.21.12327			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UL660	8647834	hybrid			2022-12-25	WOS:A1996UL66000036
J	Redowicz, MJ; Korn, ED; Rau, DC				Redowicz, MJ; Korn, ED; Rau, DC			Nucleotides increase the internal flexibility of filaments of dephosphorylated Acanthamoeba myosin II	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MICROSECOND ROTATIONAL MOTIONS; ACTIVATED ATPASE ACTIVITY; 3 PHOSPHORYLATION SITES; RABBIT PSOAS MUSCLE; HEAVY-CHAIN; ELECTRIC BIREFRINGENCE; STRUCTURAL DIFFERENCE; INTEGRAL-EQUATIONS; SKINNED FIBERS; ACTIN	The actin-activated Mg2+-ATPase activity of Acanthamoeba myosin II minifilaments is dependent both on Mg2+ concentration and on the state of phosphorylation of three serine sites at the C-terminal end of the heavy chains. Previous electric birefringence experiments on minifilaments showed a large dependence of signal amplitude on the phosphorylation state and Mg2+ concentration, consistent with large changes in filament flexibility. These observations suggested that minifilament stiffness was important for function. We now report that the binding of nucleotides to dephosphorylated minifilaments at Mg2+ concentrations needed for optimal activity increases the flexibility by about 10-fold, as inferred from the birefringence signal amplitude increase. An increase in flexibility with nucleotide binding is not observed for dephosphorylated minifilaments at lower Mg2+ concentrations or for phosphorylated minifilaments at any Mg2+ concentration examined. The relaxation times for minifilament rotations that are sensitive to the conformation myosin heads are also observed to depend on phosphorylation, Mg2+ concentration, and nucleotide binding. These latter experiments indicate that the actin activated Mg2+-ATPase activity of Acanthamoeba myosin II correlates with both changes in myosin head conformation and the ability of minifilaments to cycle between stiff and flexible conformations coupled to nucleotide binding and release.	NIDDK,OFF DIRECTOR,NIH,BETHESDA,MD 20892; NHLBI,CELL BIOL LAB,NIH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)			Redowicz, Maria Jolanta/AAM-8020-2020; Korn, Edward D/F-9929-2012; Redowicz, Maria Jolanta/R-4083-2016	Redowicz, Maria Jolanta/0000-0001-5834-471X; Korn, Edward/0000-0003-3867-6295				ATKINSON MAL, 1989, J BIOL CHEM, V264, P4127; BRENNER B, 1991, J PHYSIOL-LONDON, V441, P703, DOI 10.1113/jphysiol.1991.sp018774; COLLINS JH, 1982, J BIOL CHEM, V257, P4529; COLLINS JH, 1980, J BIOL CHEM, V255, P8011; COLLINS JH, 1982, BIOCHEMISTRY-US, V21, P6910, DOI 10.1021/bi00269a045; COLLINS JH, 1981, J BIOL CHEM, V256, P2586; COTE GP, 1984, J BIOL CHEM, V259, P2781; COTE GP, 1981, J BIOL CHEM, V256, P2811; EADS TM, 1984, J MOL BIOL, V179, P55, DOI 10.1016/0022-2836(84)90306-1; EDEN D, 1995, BIOPHYS J S, V68, P372; Fisher A. J., 1995, Biophysical Journal, V68, P19; GANGULY C, 1992, J BIOL CHEM, V267, P20905; GANGULY C, 1990, J BIOL CHEM, V265, P9993; HAMMER JA, 1987, J CELL BIOL, V105, P913, DOI 10.1083/jcb.105.2.913; HIGHSMITH S, 1986, BIOCHEMISTRY-US, V25, P2237, DOI 10.1021/bi00356a058; HIGHSMITH S, 1993, BIOCHEMISTRY-US, V32, P2455, DOI 10.1021/bi00061a001; HIGHSMITH S, 1985, BIOCHEMISTRY-US, V24, P4917, DOI 10.1021/bi00339a029; IRVING M, 1995, NATURE, V375, P688, DOI 10.1038/375688a0; KINOSITA K, 1984, BIOCHEMISTRY-US, V23, P5963, DOI 10.1021/bi00320a012; KUZNICKI J, 1983, J BIOL CHEM, V258, P6011; LUDESCHER RD, 1988, J MOL BIOL, V200, P89, DOI 10.1016/0022-2836(88)90335-X; Mooseker MS, 1995, ANNU REV CELL DEV BI, V11, P633, DOI 10.1146/annurev.cellbio.11.1.633; OSTAP EM, 1993, BIOCHEMISTRY-US, V32, P6712, DOI 10.1021/bi00077a026; OSTAP EM, 1995, BIOPHYS J, V69, P177, DOI 10.1016/S0006-3495(95)79888-5; PARDEE JD, 1982, METHOD ENZYMOL, V85, P164; POLLARD TD, 1973, J BIOL CHEM, V248, P4682; PROVENCHER SW, 1982, COMPUT PHYS COMMUN, V27, P229, DOI 10.1016/0010-4655(82)90174-6; PROVENCHER SW, 1982, COMPUT PHYS COMMUN, V27, P213, DOI 10.1016/0010-4655(82)90173-4; RAU DC, 1993, J BIOL CHEM, V268, P4612; RAU DC, 1993, J BIOL CHEM, V268, P4622; RAYMENT I, 1993, SCIENCE, V261, P50, DOI 10.1126/science.8316857; REDOWICZ MJ, 1994, J BIOL CHEM, V269, P13558; REDOWICZ MJ, 1996, BIOPHYS J, V70, P160; ROOPNARINE O, 1995, BIOPHYS J, V68, P1461, DOI 10.1016/S0006-3495(95)80319-X; SELLERS JR, 1995, PROTEIN PROFILE, V2, P1323; TRYBUS KM, 1994, J MUSCLE RES CELL M, V15, P587, DOI 10.1007/BF00121066; WAKABAYASHI K, 1992, SCIENCE, V258, P443, DOI 10.1126/science.1411537; WALLER GS, 1995, J BIOL CHEM, V270, P15348, DOI 10.1074/jbc.270.25.15348; WIJMENGA SS, 1987, J BIOL CHEM, V262, P15803; XU SE, 1993, J PHYSIOL-LONDON, V461, P283, DOI 10.1113/jphysiol.1993.sp019514	40	7	7	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 24	1996	271	21					12401	12407		10.1074/jbc.271.21.12401	http://dx.doi.org/10.1074/jbc.271.21.12401			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UL660	8647844	hybrid			2022-12-25	WOS:A1996UL66000046
J	Kim, YS; Jo, YY; Chang, IM; Toida, T; Park, Y; Linhardt, RJ				Kim, YS; Jo, YY; Chang, IM; Toida, T; Park, Y; Linhardt, RJ			A new glycosaminoglycan from the giant African snail Achatina fulica	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANOMALOCARDIA-BRASILIANA; FLAVOBACTERIUM-HEPARINUM; ANTICOAGULANT ACTIVITY; HEPARAN-SULFATE; OLIGOSACCHARIDE; ELECTROPHORESIS; PROTEOGLYCANS; GLYCOPROTEIN	A new glycosaminoglycan has been isolated from the giant African snail Achatina fulica. This polysaccharide had a molecular weight of 29,000, calculated based on the viscometry, and a uniform repeating disaccharide structure of -->4)-2-acetyl,2-deoxy-alpha-D-glucopyranose (1-->4)-2-sulfo-alpha-L-idopyranosyluronic acid (1-->. This polysaccharide represents a new, previously undescribed glycosaminoglycan. It is related to the heparin and heparan sulfate families of glycosaminoglycans but is distinctly different from all known members of these classes of glycosaminoglycans. The structure of this polysaccharide, with adjacent N-acetylglucosamine and 2-sulfo-iduronic acid residues, also poses interesting questions about how it is made in light of our current understanding of the biosynthesis of heparin and heparan sulfate. This glycosaminoglycan represents 3-5% of the dry weight of this snail's soft body tissues, suggesting important biological roles for the survival of this organism, and may offer new means to control this pest. Snail glycosaminoglycan tightly binds divalent cations, such as copper(II), suggesting a primary role in metal uptake in the snail. Finally, this new polysaccharide might be applied, like the Escherichia coli K5 capsular polysaccharide, to the study of glycosaminoglycan biosynthesis and to the semisynthesis of new glycosaminoglycan analogs having important biological activities.	UNIV IOWA,COLL PHARM,DIV MED & NAT PROD CHEM,IOWA CITY,IA 52242; SEOUL NATL UNIV,INST NAT PROD RES,SEOUL 110460,SOUTH KOREA	University of Iowa; Seoul National University (SNU)			Wang, Lingchong/G-8417-2011		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL052622] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038060] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL52622] Funding Source: Medline; NIGMS NIH HHS [GM38060] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AL-HAKIM A, 1991, Applied and Theoretical Electrophoresis, V1, P305; BITTER T, 1962, ANAL BIOCHEM, V4, P330, DOI 10.1016/0003-2697(62)90095-7; BURSON SL, 1972, BIOL BULL, V143, P506; DESAI UR, 1993, ANAL BIOCHEM, V213, P120, DOI 10.1006/abio.1993.1394; DIETRICH CP, 1985, BIOCHIM BIOPHYS ACTA, V843, P1, DOI 10.1016/0304-4165(85)90041-8; EDENS RE, 1992, J PHARM SCI, V81, P823, DOI 10.1002/jps.2600810821; Faham S, 1996, SCIENCE, V271, P1116, DOI 10.1126/science.271.5252.1116; GALLAGHER JT, 1985, BIOCHEM J, V230, P665, DOI 10.1042/bj2300665; GALLIHER PM, 1981, APPL ENVIRON MICROB, V41, P360, DOI 10.1128/AEM.41.2.360-365.1981; GODAN D, 1983, PEST SLUGS SNAILS, P3; GOUDSMIT EM, 1972, CHEM ZOOLOGY, V7; GRENON JF, 1980, COMP BIOCHEM PHYS B, V66, P451; GRENON JF, 1981, J EXP MAR BIOL ECOL, V54, P277, DOI 10.1016/0022-0981(81)90162-3; GRIFFIN CC, 1995, CARBOHYD RES, V276, P183, DOI 10.1016/0008-6215(95)00166-Q; HARDINGHAM TE, 1992, FASEB J, V6, P861, DOI 10.1096/fasebj.6.3.1740236; HELLER E, 1976, BIOCHEMISTRY-US, V15, P1194, DOI 10.1021/bi00651a002; HOVINGH P, 1986, BIOCHEM J, V237, P573, DOI 10.1042/bj2370573; IRELAND MP, 1992, J MOLLUS STUD, V58, P157, DOI 10.1093/mollus/58.2.157; JORDAN RE, 1986, ARCH BIOCHEM BIOPHYS, V248, P690, DOI 10.1016/0003-9861(86)90524-2; KAMERLING JP, 1975, BIOCHEM J, V151, P491, DOI 10.1042/bj1510491; KJELLEN L, 1991, ANNU REV BIOCHEM, V60, P443, DOI 10.1146/annurev.bi.60.070191.002303; Kobayashi S., 1964, Bulletin of the Japanese Society of Scientific Fisheries, V30, P893; LIBERTI PA, 1967, ARCH BIOCHEM BIOPHYS, V119, P510, DOI 10.1016/0003-9861(67)90485-7; LINDAHL U, 1994, THROMB RES, V75, P1, DOI 10.1016/0049-3848(94)90136-8; Lindahl U., 1989, HEPARIN, P159; Linhardt R., 1992, CARBOHYDRATESSYNTHET, P385; LINHARDT R, 1994, CURRENT PROTOCOLS MO; LINHARDT RJ, 1992, BIOCHEMISTRY-US, V31, P12441, DOI 10.1021/bi00164a020; LINHARDT RJ, 1988, BIOCHEM J, V254, P781, DOI 10.1042/bj2540781; LINHARDT RJ, 1996, LAB GUIDE GLYCOCONJU; LINHARDT RJ, 1996, CARBOHYDRATES DRUGS; Liu J, 1995, GLYCOBIOLOGY, V5, P765, DOI 10.1093/glycob/5.8.765; LIVINGSTONE DR, 1993, MULUSCA, V1; LOGANATHAN D, 1990, BIOCHEMISTRY-US, V29, P4362, DOI 10.1021/bi00470a015; LOHSE DL, 1992, J BIOL CHEM, V267, P24347; Mathews M. B., 1975, CONNECTIVE TISSUE MA; MITRA D, 1987, BIOCHEM J, V242, P331, DOI 10.1042/bj2420331; MUNIAPPAN R, 1987, PLANT PROT B, V35, P127; Nader H. B., 1989, HEPARIN CHEM BIOL PR, P81; OTSUKAFUCHINO H, 1992, COMP BIOCHEM PHYS C, V101, P607, DOI 10.1016/0742-8413(92)90094-N; PEJLER G, 1987, J BIOL CHEM, V262, P11413; PERVIN A, 1995, GLYCOBIOLOGY, V5, P83, DOI 10.1093/glycob/5.1.83; PERVIN A, 1994, ANAL BIOCHEM, V221, P182, DOI 10.1006/abio.1994.1395; RAZI N, 1995, BIOCHEM J, V309, P465, DOI 10.1042/bj3090465; Roden L., 1972, METHODS ENZYMOLOGY, V28, P73; ROSETT W, 1980, J CLIN MICROBIOL, V11, P30, DOI 10.1128/JCM.11.1.30-34.1980; SCOTT JE, 1991, BIOCHEM J, V274, P699, DOI 10.1042/bj2740699; Toida T, 1996, ELECTROPHORESIS, V17, P341, DOI 10.1002/elps.1150170209; TOIDA T, 1995, GLYCOCONJUGATE, V12, P419; TRUEMAN ER, 1993, MULUSCA, V1; VANKUIK JA, 1986, EUR J BIOCHEM, V160, P621; WILBUR KM, 1993, MULUSCA, V1; YAMADA S, 1992, J BIOCHEM-TOKYO, V112, P440, DOI 10.1093/oxfordjournals.jbchem.a123919	53	101	106	2	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 17	1996	271	20					11750	11755		10.1074/jbc.271.20.11750	http://dx.doi.org/10.1074/jbc.271.20.11750			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UL250	8662607	hybrid			2022-12-25	WOS:A1996UL25000028
J	Liu, SC; Smith, SE; Julian, J; Rohde, LH; Karin, NJ; Carson, DD				Liu, SC; Smith, SE; Julian, J; Rohde, LH; Karin, NJ; Carson, DD			cDNA cloning and expression of HIP, a novel cell surface heparan sulfate/heparin-binding protein of human uterine epithelial cells and cell lines	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIBROBLAST GROWTH-FACTOR; SULFATE PROTEOGLYCAN; RIBOSOMAL-PROTEIN; NUCLEOTIDE-SEQUENCE; MOLECULAR-STRUCTURE; MOUSE EMBRYOS; RECEPTOR; ATTACHMENT; MECHANISM; ADHESION	Heparan sulfate proteoglycans and their corresponding binding sites have been suggested to play an important role during the initial attachment of murine blastocysts to uterine epithelium and human trophoblastic cell lines to uterine epithelial cell lines. Previous studies on RL95 cells, a human uterine epithelial cell line, had characterized a single class of cell surface heparin/heparan sulfate (HP/HS)-binding sites. Three major HP/HS-binding peptide fragments were isolated from cell surfaces by tryptic digestion, and partial amino-terminal amino acid sequence for each peptide fragment was obtained (Raboudi, N., Julian, J., Rohde, L. H., and Carson, D. D. (1992) J. Biol. Chem. 267, 11930-11939). In the current study, using approaches of reverse transcription-polymerase chain reaction and cDNA library screening, we have cloned and expressed a novel, cell surface HP/HS-binding protein, named HP/HS interacting protein (HIP), from RL95 cells. The full-length cDNA of HIP encodes a protein of 159 amino acids with a calculated molecular mass of 17,754 Da and pI of 11.75. Transfection of HIP full-length cDNA into NIH 3T3 cells demonstrated cell surface expression and a size similar to that of HIP expressed by human cells. Predicted amino acid sequence indicates that HIP lacks a membrane spanning region and has no consensus sites for glycosylation. Northern blot analysis detected a single transcript of 1.3 kilobases in both total RNA and poly(A(+)) RNA. Examination of human cell lines and normal tissues using both Northern blot and Western blot analyses revealed that HIP is expressed at different levels in a variety of human cell lines and normal tissues but absent in some cell lines and some cell types of normal tissues examined. HIP has relatively high homology (similar to 80% both at the levels of nucleotide and protein sequence) to a rodent ribosomal protein L29. Thus, members of the L29 family may be displayed on cell surfaces where they may participate in HP/HS binding events.	UNIV TEXAS, MD ANDERSON CANCER CTR, DEPT BIOCHEM & MOLEC BIOL, HOUSTON, TX 77030 USA; UNIV TEXAS, SCH MED, DEPT INTEGRAT BIOL, HOUSTON, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System					EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R37HD025235, R01HD025235] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [P30CA016672] Funding Source: NIH RePORTER; NCI NIH HHS [CA-16672] Funding Source: Medline; NICHD NIH HHS [HD25235] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ABRAHAM JA, 1986, EMBO J, V5, P2523, DOI 10.1002/j.1460-2075.1986.tb04530.x; AOTA S, 1988, NUCLEIC ACIDS RES, V16, pR315, DOI 10.1093/nar/16.suppl.r315; BERNFIELD M, 1992, ANNU REV CELL BIOL, V8, P365, DOI 10.1146/annurev.cb.08.110192.002053; BETTLER B, 1989, P NATL ACAD SCI USA, V86, P7566, DOI 10.1073/pnas.86.19.7566; BLOBEL G, 1975, J CELL BIOL, V67, P852, DOI 10.1083/jcb.67.3.852; BROWN TA, 1987, BIOCHIM BIOPHYS ACTA, V912, P244, DOI 10.1016/0167-4838(87)90095-1; CARDIN AD, 1989, ARTERIOSCLEROSIS, V9, P21, DOI 10.1161/01.ATV.9.1.21; CARSON DD, 1993, DEV BIOL, V155, P97, DOI 10.1006/dbio.1993.1010; COLE GJ, 1986, J CELL BIOL, V102, P403, DOI 10.1083/jcb.102.2.403; COOPER DNW, 1990, J CELL BIOL, V110, P1681, DOI 10.1083/jcb.110.5.1681; DAMORE PA, 1990, CANCER METAST REV, V9, P227, DOI 10.1007/BF00046362; DZIADEK M, 1985, EMBO J, V4, P905, DOI 10.1002/j.1460-2075.1985.tb03717.x; FARACH MC, 1987, DEV BIOL, V123, P401, DOI 10.1016/0012-1606(87)90398-8; Frohman M.A., 1990, PCR PROTOCOLS GUIDE, P28; JACKSON RL, 1991, PHYSIOL REV, V71, P481, DOI 10.1152/physrev.1991.71.2.481; JAMESON BA, 1988, COMPUT APPL BIOSCI, V4, P181; JAYE M, 1986, SCIENCE, V233, P541, DOI 10.1126/science.3523756; JULIAN JA, 1994, DEVELOPMENT, V120, P661; KALLUNKI P, 1992, J CELL BIOL, V116, P559, DOI 10.1083/jcb.116.2.559; KIKUTANI H, 1986, CELL, V47, P657, DOI 10.1016/0092-8674(86)90508-8; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MATSUSHIMA K, 1986, J IMMUNOL, V136, P2883; NOMURA M, 1982, TRENDS BIOCHEM SCI, V7, P92, DOI 10.1016/0968-0004(82)90154-2; OSTVOLD AC, 1992, FEBS LETT, V298, P219, DOI 10.1016/0014-5793(92)80061-K; PORZIO MA, 1977, BIOCHIM BIOPHYS ACTA, V490, P27, DOI 10.1016/0005-2795(77)90102-7; RABOUDI N, 1992, J BIOL CHEM, V267, P11930; ROHDE LH, 1993, J CELL PHYSIOL, V155, P185, DOI 10.1002/jcp.1041550124; Rohde LH, 1996, J BIOL CHEM, V271, P11824, DOI 10.1074/jbc.271.20.11824; RUDERT F, 1993, GENE, V133, P249, DOI 10.1016/0378-1119(93)90647-L; RUOSLAHTI E, 1991, CELL, V64, P867, DOI 10.1016/0092-8674(91)90308-L; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SVOBODA M, 1992, EUR J BIOCHEM, V203, P341, DOI 10.1111/j.1432-1033.1992.tb16555.x; TERADA K, 1995, J BIOL CHEM, V270, P20410, DOI 10.1074/jbc.270.35.20410; VLODAVSKY I, 1991, TRENDS BIOCHEM SCI, V16, P268, DOI 10.1016/0968-0004(91)90102-2; VONHOLT C, 1989, METHOD ENZYMOL, V170, P431; Weber K., 1975, PROTEINS, VI, P179; WILSON O, 1990, J CELL PHYSIOL, V143, P60, DOI 10.1002/jcp.1041430108; XIE WQ, 1991, BIOTECHNIQUES, V11, P324	39	45	50	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 17	1996	271	20					11817	11823		10.1074/jbc.271.20.11817	http://dx.doi.org/10.1074/jbc.271.20.11817			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UL250	8662616	hybrid			2022-12-25	WOS:A1996UL25000039
J	Fraser, SD; WilkesJohnston, J; Browder, LW				Fraser, SD; WilkesJohnston, J; Browder, LW			Effects of c-myc first exons and 5' synthetic hairpins on RNA translation in oocytes and early embryos of Xenopus laevis	ONCOGENE			English	Article						myc; translation; secondary structure; Xenopus	YEAST SACCHAROMYCES-CEREVISIAE; MESSENGER-RNA; SECONDARY STRUCTURE; ORNITHINE DECARBOXYLASE; INITIATION-FACTORS; NONCODING REGION; PROTO-ONCOGENE; EXPRESSION; GENE; INHIBITION	Mammalian c-myc transcripts have long G/C-rich 5' untranslated regions (UTRs) that may fold into secondary structural elements that may impede translation. We have examined the effects of different c-myc first exons, which produce most of the 5' UTR of c-myc transcripts, on translation in Xenopus oocytes and embryos, by placing these structures upstream of a chloramphenicol acetyltransferase (CAT) reporter. Our results demonstrate that the human c-myc first exon inhibits reporter translation in both oocytes and embryos. Unlike their mammalian counterparts, Xenopus c-mycI first exons initiated at either promoter 1 or promoter 2 do not impede translation. We conclude that translation inhibition reported in a previous investigation (Lazarus, 1992. Oncogene, 7:1037) utilizing Xenopus c-mycI 5' non-coding elements was due to the inclusion of non-relevant non-transcribed sequences. Previous investigators have reported that inhibition of translation in Xenopus oocytes by 5' secondary structure is alleviated after fertilization (Lazarus et al., 1988. Oncogene 3:517; Fu et al., 1991. Science 251:807). We repeated the experiments of Fu et al., examining the effects on translation by a highly stable synthetic hairpin. The hairpin severly restricted translation in both oocytes and embryos, indicating that highly stable 5' secondary structure is equally inhibitory in oocytes and embryos.	UNIV CALGARY, DEPT BIOL SCI, CALGARY, AB T2N 1N4, CANADA	University of Calgary								BAIM SB, 1988, MOL CELL BIOL, V8, P1591, DOI 10.1128/MCB.8.4.1591; BERNARD O, 1983, EMBO J, V2, P2375, DOI 10.1002/j.1460-2075.1983.tb01749.x; BETTANY AJE, 1989, YEAST, V5, P187, DOI 10.1002/yea.320050308; BUTNICK NZ, 1985, MOL CELL BIOL, V5, P3009, DOI 10.1128/MCB.5.11.3009; CIGAN AM, 1988, MOL CELL BIOL, V8, P2964, DOI 10.1128/MCB.8.7.2964; DARVEAU A, 1985, P NATL ACAD SCI USA, V82, P2315, DOI 10.1073/pnas.82.8.2315; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; DUMONT JN, 1972, J MORPHOL, V136, P153, DOI 10.1002/jmor.1051360203; EDERY I, 1995, MOL CELL BIOL, V15, P3363; EVANS JP, 1991, METHOD CELL BIOL, V36, P133; FU L, 1991, THESIS U CALGARY CAL; FU LN, 1991, SCIENCE, V251, P807, DOI 10.1126/science.1990443; GALILI G, 1988, J BIOL CHEM, V263, P5764; GRENS A, 1990, J BIOL CHEM, V265, P11810; HITCHCOCK MJM, 1980, ANAL BIOCHEM, V109, P338, DOI 10.1016/0003-2697(80)90657-0; JARAMILLO M, 1990, BIOCHIM BIOPHYS ACTA, V1050, P134, DOI 10.1016/0167-4781(90)90154-T; Kay BK, 1991, METHODS CELL BIOL, V36; KING MW, 1986, MOL CELL BIOL, V6, P4499, DOI 10.1128/MCB.6.12.4499; KING MW, 1991, NUCLEIC ACIDS RES, V19, P5777, DOI 10.1093/nar/19.20.5777; KOZAK M, 1986, P NATL ACAD SCI USA, V83, P2850, DOI 10.1073/pnas.83.9.2850; KOZAK M, 1989, MOL CELL BIOL, V9, P5134, DOI 10.1128/MCB.9.11.5134; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; LASO MRV, 1993, J BIOL CHEM, V268, P6453; LAZARUS P, 1992, ONCOGENE, V7, P1037; LAZARUS P, 1988, ONCOGENE, V3, P517; MANZELLA JM, 1991, J BIOL CHEM, V266, P2383; MANZELLA JM, 1990, J BIOL CHEM, V265, P11817; MELTON DA, 1987, METHOD ENZYMOL, V152, P288; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; NILSEN TW, 1984, MOL CELL BIOL, V4, P2235, DOI 10.1128/MCB.4.10.2235; OLIVEIRA CC, 1993, MOL MICROBIOL, V9, P521, DOI 10.1111/j.1365-2958.1993.tb01713.x; PARKIN N, 1988, MOL CELL BIOL, V8, P2875, DOI 10.1128/MCB.8.7.2875; PRINCIPAUD E, 1991, NUCLEIC ACIDS RES, V19, P3081, DOI 10.1093/nar/19.11.3081; RHOADS RE, 1993, J BIOL CHEM, V268, P3017; SAGLIOCCO FA, 1993, J BIOL CHEM, V268, P26522; SAITO H, 1983, P NATL ACAD SCI-BIOL, V80, P7476, DOI 10.1073/pnas.80.24.7476; TAYLOR MV, 1986, EMBO J, V5, P3563, DOI 10.1002/j.1460-2075.1986.tb04683.x; TCHANG F, 1991, FEBS LETT, V291, P177, DOI 10.1016/0014-5793(91)81277-F; TINOCO I, 1973, NATURE-NEW BIOL, V246, P40, DOI 10.1038/newbio246040a0; VRIZ S, 1989, EMBO J, V8, P4091, DOI 10.1002/j.1460-2075.1989.tb08593.x; XU W, 1994, THESIS U CALGARY CAL; YISRAELI JK, 1989, METHOD ENZYMOL, V180, P42; ZUKER M, 1981, NUCLEIC ACIDS RES, V9, P133, DOI 10.1093/nar/9.1.133	43	12	16	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 21	1996	12	6					1223	1230						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UC067	8649824				2022-12-25	WOS:A1996UC06700007
J	Lovric, J; Moelling, K				Lovric, J; Moelling, K			Activation of Mil/Raf protein kinases in mitotic cells	ONCOGENE			English	Article						Mil/Raf kinases; phosphorylation; cell cycle; mitosis	MAP-KINASE; TYROSINE PHOSPHORYLATION; RAF-1 KINASE; V-RAF; C-MYC; ONCOGENE; CYCLE; EXPRESSION; C-RAF-1; DOMAIN	The c-Raf-1 protein kinase is a major element of several signal transduction pathways and thought to be involved in entry into the S phase of the cell cycle. Here we show that c-Raf-1 as well as the transforming viral fusion protein Gag-Mil, in which most of the amino terminal regulatory region of the avian Raf homologue Mil is deleted, are activated five- to sixfold in mitotic cells. Mitotic activation of Mil/Raf kinase activity correlates with reduced electrophoretic mobility caused by hyperphosphorylation at serine/threonine residues located in the carboxy terminal part of c-Raf-1. Mitotic hyperphosphorylation occurs in various cell-lines indicating that it is ubiquitous. Our data suggest a novel function for Mil/Raf kinases in late stages of the cell cycle.	UNIV ZURICH, INST MED VIROL, CH-8028 ZURICH, SWITZERLAND	University of Zurich				Lovric, Josip/0000-0002-0338-6581				ALESSI DR, 1995, METHOD ENZYMOL, V255, P279; BAGRODIA S, 1994, J BIOL CHEM, V269, P10247; BOOTSMA D, 1964, EXP CELL RES, V33, P301, DOI 10.1016/S0014-4827(64)81035-1; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BUSCHER D, 1993, ONCOGENE, V8, P3323; CANMAN CE, 1995, GENE DEV, V9, P600, DOI 10.1101/gad.9.5.600; CLEVELAND JL, 1994, ONCOGENE, V9, P2217; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; DENHEZ F, 1988, EMBO J, V7, P541, DOI 10.1002/j.1460-2075.1988.tb02843.x; DURKIN JP, 1987, MOL CELL BIOL, V7, P444, DOI 10.1128/MCB.7.1.444; FUMAGALLI S, 1994, NATURE, V368, P871, DOI 10.1038/368871a0; GALAKTIONOV K, 1991, CELL, V67, P1181, DOI 10.1016/0092-8674(91)90294-9; GALAKTIONOV K, 1995, GENE DEV, V9, P1046, DOI 10.1101/gad.9.9.1046; GALLEGO C, 1992, P NATL ACAD SCI USA, V89, P7355, DOI 10.1073/pnas.89.16.7355; GARDNER AM, 1993, J BIOL CHEM, V268, P17896; GUILLOUF C, 1995, ONCOGENE, V10, P2263; GUPTA SK, 1992, J BIOL CHEM, V267, P7987; HEIDECKER G, 1992, ADV CANCER RES, V58, P53, DOI 10.1016/S0065-230X(08)60290-0; HIROYUKI T, 1992, J BIOL CHEM, V267, P20293; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; JAMAL S, 1995, ONCOGENE, V10, P2095; KASID U, 1989, SCIENCE, V243, P1354, DOI 10.1126/science.2466340; LOVRIC J, 1994, FEBS LETT, V343, P15, DOI 10.1016/0014-5793(94)80598-9; MAMON H, 1991, COLD SPRING HARB SYM, V56, P251; MARAIS R, 1995, EMBO J, V14, P3136, DOI 10.1002/j.1460-2075.1995.tb07316.x; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; MOODIE SA, 1994, TRENDS GENET, V10, P44, DOI 10.1016/0168-9525(94)90147-3; MORRISON DK, 1989, CELL, V58, P649, DOI 10.1016/0092-8674(89)90100-1; MUSZYNSKI KW, 1995, J EXP MED, V181, P2189, DOI 10.1084/jem.181.6.2189; QURESHI SA, 1991, J BIOL CHEM, V266, P20594; RADZIWILL G, 1995, P NATL ACAD SCI USA, V92, P1421, DOI 10.1073/pnas.92.5.1421; RAPP UR, 1988, HDB ONCOGENES, P213; SCHRAMM K, 1994, BIOCHEM BIOPH RES CO, V201, P740, DOI 10.1006/bbrc.1994.1763; SETH A, 1993, MOL CELL BIOL, V13, P4125, DOI 10.1128/MCB.13.7.4125; SHIBUYA H, 1992, CELL, V70, P57, DOI 10.1016/0092-8674(92)90533-I; SUTRAVE P, 1984, NATURE, V309, P85, DOI 10.1038/309085a0; TAYLOR SJ, 1994, NATURE, V368, P867, DOI 10.1038/368867a0; TOPP WC, 1981, VIROLOGY, V113, P408, DOI 10.1016/0042-6822(81)90168-9; TROPPMAIR J, 1994, J BIOL CHEM, V269, P7030; TURNER BC, 1993, P NATL ACAD SCI USA, V90, P5544, DOI 10.1073/pnas.90.12.5544; WARENIUS HM, 1994, EUR J CANCER, V30A, P369, DOI 10.1016/0959-8049(94)90258-5; WEDONG H, 1993, P NATL ACAD SCI USA, V90, P10947; WILLIAMS NG, 1992, P NATL ACAD SCI USA, V89, P2922, DOI 10.1073/pnas.89.7.2922; ZIEVE GW, 1980, EXP CELL RES, V126, P397, DOI 10.1016/0014-4827(80)90279-7	44	24	24	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 7	1996	12	5					1109	1116						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UA884	8649803				2022-12-25	WOS:A1996UA88400020
J	Engleman, EG				Engleman, EG			Blood safety in the age of AIDS	FASEB JOURNAL			English	Editorial Material											Engleman, EG (corresponding author), STANFORD UNIV,SCH MED,CTR BLOOD,STANFORD,CA 94305, USA.								0	0	0	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	MAR	1996	10	4					390	390		10.1096/fasebj.10.4.8647337	http://dx.doi.org/10.1096/fasebj.10.4.8647337			1	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	UE557	8647337				2022-12-25	WOS:A1996UE55700002
J	Zheng, S; Ramachandran, B; Haigh, JR; Palos, TP; Steger, K; Howard, BD				Zheng, S; Ramachandran, B; Haigh, JR; Palos, TP; Steger, K; Howard, BD			The induction of ret by Wnt-1 in PC12 cells is atypically dependent on continual Wnt-1 expression	ONCOGENE			English	Article						PC12; Wnt-1; ret; neu	NERVE GROWTH-FACTOR; MESSENGER-RNA; NEURONAL DIFFERENTIATION; PHEOCHROMOCYTOMA CELLS; POSSIBLE INVOLVEMENT; INT-1 PROTOONCOGENE; MAMMARY ONCOGENE; GENE; LINE; TRANSFORMATION	Wild type PC12 pheochromocytoma cells that had been infected with a Wnt-1-carrying virus and thus express Wnt-1 (PC12/Wnt-1) are known to acquire the same hat cell phenotype as that of spontaneously occurring PC12 flat cell variants except that the latter do not presently express Wnt-1. Flat cell variants of PC12 cells exhibit markedly altered morphology and gene expression. In order to assess the possibility that the spontaneously occurring flat cell variants could have been induced in wild type PC12 cells by previous transient expression of the cell's endogenous Wnt-1, we have isolated PC12/Wnt-1 cells expressing little or no Wnt-1, In spite of absent Wnt-1 expression, they retained their flat cell morphology, glutamate/aspartate transporter activity, increased neu mRNA levels and lack of both norepinephrine transporter activity and nerve growth factor-induced differentiation, Thus, Wnt-1 expression is not required to maintain the flat cell phenotype, However, we identified one gene, ret, whose mRNA level in PC12 was not only increased by Wnt-1 expression, but whose increased mRNA level was also dependent on continual Wnt-1 expression, This finding suggests that the induction of vet by Wnt-1 can be used to elucidate the Wnt-induced signalling pathway in mammalian cells.	UNIV CALIF LOS ANGELES,SCH MED,DEPT BIOL CHEM,LOS ANGELES,CA 90095	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA					NATIONAL INSTITUTE OF MENTAL HEALTH [R37MH038633, R01MH038633] Funding Source: NIH RePORTER; NIMH NIH HHS [MH38633] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ANDERSEN JK, 1990, J NEUROCHEM, V55, P559, DOI 10.1111/j.1471-4159.1990.tb04170.x; ANDERSON DJ, 1994, FASEB J, V8, P707, DOI 10.1096/fasebj.8.10.8050669; AVANTAGGIATO V, 1994, CELL GROWTH DIFFER, V5, P305; AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; BOTHWELL MA, 1980, CELL, V21, P857, DOI 10.1016/0092-8674(80)90449-3; BUNONE G, 1995, EXP CELL RES, V217, P92, DOI 10.1006/excr.1995.1067; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DOUGALL WC, 1994, ONCOGENE, V9, P2109; ECHELARD Y, 1994, DEVELOPMENT, V120, P2213; FUNG YKT, 1985, MOL CELL BIOL, V5, P3337, DOI 10.1128/MCB.5.12.3337; GAMETT DC, 1994, FEBS LETT, V351, P335, DOI 10.1016/0014-5793(94)00855-8; GAVIN BJ, 1990, GENE DEV, V4, P2319, DOI 10.1101/gad.4.12b.2319; GOODFELLOW PJ, 1994, CURR OPIN GENET DEV, V4, P446, DOI 10.1016/0959-437X(94)90034-5; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; GUERRERO I, 1988, BIOCHEM BIOPH RES CO, V150, P1185, DOI 10.1016/0006-291X(88)90754-1; GUTMANN DH, 1993, NEURON, V10, P335, DOI 10.1016/0896-6273(93)90324-K; HARPOLD MM, 1979, CELL, V17, P1025, DOI 10.1016/0092-8674(79)90341-6; HERZLINGER D, 1994, DEV BIOL, V166, P815, DOI 10.1006/dbio.1994.1360; HOEBEN RC, 1991, J VIROL, V65, P904, DOI 10.1128/JVI.65.2.904-912.1991; ISSACK PS, 1994, NEUR SOC ABSTR, V20, P1077; IWAMOTO T, 1993, ONCOGENE, V8, P1087; JUE SF, 1992, MOL CELL BIOL, V12, P321, DOI 10.1128/MCB.12.1.321; LATIF F, 1993, SCIENCE, V260, P1317, DOI 10.1126/science.8493574; MASON JO, 1992, MOL BIOL CELL, V3, P521, DOI 10.1091/mbc.3.5.521; MCMAHON AP, 1990, CELL, V62, P1073, DOI 10.1016/0092-8674(90)90385-R; MOON RT, 1993, DEVELOPMENT S, V118, P85; NODA M, 1985, NATURE, V318, P73, DOI 10.1038/318073a0; NUSSE R, 1984, NATURE, V307, P131, DOI 10.1038/307131a0; NUSSE R, 1992, CELL, V69, P1073, DOI 10.1016/0092-8674(92)90630-U; PACHNIS V, 1993, DEVELOPMENT, V119, P1005; PERRIMON N, 1994, CELL, V76, P781, DOI 10.1016/0092-8674(94)90351-4; Pestka S, 1981, Methods Enzymol, V78, P3; RAMACHANDRAN B, 1993, J BIOL CHEM, V268, P23891; Sambrook J., 1982, MOL CLONING LAB MANU, V1; SASSONECORSI P, 1989, MOL CELL BIOL, V9, P3174, DOI 10.1128/MCB.9.8.3174; SCHUCHARDT A, 1994, NATURE, V367, P380, DOI 10.1038/367380a0; SHACKLEFORD GM, 1993, NEURON, V11, P865, DOI 10.1016/0896-6273(93)90116-9; SIEGFRIED E, 1994, BIOESSAYS, V16, P395, DOI 10.1002/bies.950160607; SUGIMOTO Y, 1988, J BIOL CHEM, V263, P12102; TAHIRA T, 1988, BIOCHEM BIOPH RES CO, V153, P1290, DOI 10.1016/S0006-291X(88)81368-8; THOMAS KR, 1990, NATURE, V346, P847, DOI 10.1038/346847a0; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; VANHEYNINGEN V, 1994, NATURE, V367, P319, DOI 10.1038/367319a0; VONDEIMLING A, 1995, BRAIN PATHOL, V5, P153; WILKINSON DG, 1987, CELL, V50, P79, DOI 10.1016/0092-8674(87)90664-7	45	22	25	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB 1	1996	12	3					555	562						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TV597	8637712				2022-12-25	WOS:A1996TV59700012
J	Gurgueira, SA; Meneghini, R				Gurgueira, SA; Meneghini, R			An ATP-dependent iron transport system in isolated rat liver nuclei	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WILSON DISEASE GENE; FERRITIN; INHIBITION; CALCIUM; SUBUNIT; MODEL	A concerted translational control is responsible for maintaining an iron level in the cytosol that is both adequate for the synthesis of iron-containing proteins and does not represent a danger to the cell. However, little is known about how iron level is controlled in the nucleus. Nuclei of rat liver take up iron from ferric citrate by a process that is dependent on ATP. This system shares several properties with known P-type ATPases, suggesting that a P-type ATPase in the nuclear membrane in responsible for iron transport, (i) Adenosine 5'-(beta,gamma-iminodiphosphate), a non-hydrolyzable ATP analogue, does not support iron uptake; (ii) the uptake is strongly inhibited by vanadate; (iii) there is an absolute requirement for Mg2+; and (iv) reagents that oxidize SH groups inhibit uptake, and this inhibition can be prevented by dithiothreitol. The energy of activation for the uptake (11.5 kcal/mol) and the K-m for ATP (0.4 mM) are similar to values for other known cation transport ATPases. Inhibitors of Na+, K+-ATPase, sarcoplasmic reticulum Ca2+-ATPase, proton V-ATPase, and nuclear Ca2+-ATPase have no effect on uptake. Ferric citrate can be replaced by Fe-ATP as a source of iron for the transport system; however, two other stronger iron chelators, Tiron and desferrioxamine, completely inhibit the uptake. Taken together, these data strongly suggest that an Fe-ATPase, distinct from other known P-type ATPase, distinct from other known P-type ATPase, is responsible for iron transport in the nucleus.	UNIV SAO PAULO, INST QUIM, DEPT BIOQUIM, BR-05599970 SAO PAULO, BRAZIL	Universidade de Sao Paulo			GURGUEIRA, SONIA A/G-8775-2012; Meneghini, Rogério/I-2961-2015	Gurgueira, Sonia/0000-0003-2928-1937				AISEN P, 1994, ADV EXP MED BIOL, V356, P31; ANNER BM, 1983, FEBS LETT, V158, P7, DOI 10.1016/0014-5793(83)80665-6; BACHS O, 1992, BIOCHIM BIOPHYS ACTA, V1113, P259, DOI 10.1016/0304-4157(92)90041-8; BAKKEREN DL, 1985, INT J BIOCHEM, V17, P925, DOI 10.1016/0020-711X(85)90177-6; BINGHAM MJ, 1995, J PHYSIOL-LONDON, V482, P583, DOI 10.1113/jphysiol.1995.sp020542; BULL PC, 1993, NAT GENET, V5, P327, DOI 10.1038/ng1293-327; CAIRO G, 1995, J BIOL CHEM, V270, P700, DOI 10.1074/jbc.270.2.700; DEMEIS L, 1980, SARCOPLASMIC RETICUL; FALLER B, 1994, J AM CHEM SOC, V116, P3860, DOI 10.1021/ja00088a022; FENG Y, 1992, J BIOL CHEM, V267, P5817; GORNALL AG, 1949, J BIOL CHEM, V177, P751; HECHTENBERG S, 1993, BIOCHEM J, V289, P757, DOI 10.1042/bj2890757; HENTZE MW, 1995, CURR OPIN CELL BIOL, V7, P393, DOI 10.1016/0955-0674(95)80095-6; HIDALGO E, 1994, EMBO J, V13, P138, DOI 10.1002/j.1460-2075.1994.tb06243.x; INESI G, 1973, J MOL BIOL, V81, P483, DOI 10.1016/0022-2836(73)90518-4; INESI G, 1994, J MEMBRANE BIOL, V141, P1; KAMMLER M, 1993, J BACTERIOL, V175, P6212, DOI 10.1128/JB.175.19.6212-6219.1993; KHOROSHILOVA N, 1995, P NATL ACAD SCI USA, V92, P2499, DOI 10.1073/pnas.92.7.2499; KLAUSNER RD, 1993, CELL, V72, P19, DOI 10.1016/0092-8674(93)90046-S; KOZLOV AV, 1992, FREE RADICAL BIO MED, V13, P9, DOI 10.1016/0891-5849(92)90159-E; KUHN LC, 1994, ADV EXP MED BIOL, V356, P101; KUKIELKA E, 1994, ARCH BIOCHEM BIOPHYS, V308, P70, DOI 10.1006/abbi.1994.1010; LEIBOLD EA, 1988, P NATL ACAD SCI USA, V85, P2171, DOI 10.1073/pnas.85.7.2171; LEINHARD GE, 1973, J BIOL CHEM, V248, P1121; LI CY, 1994, J BIOL CHEM, V269, P10242; LI CY, 1995, BIOCHEMISTRY-US, V34, P5130, DOI 10.1021/bi00015a025; LINGREL JB, 1994, J BIOL CHEM, V269, P19659; MACARA IG, 1980, TRENDS BIOCHEM SCI, V5, P92, DOI 10.1016/0968-0004(80)90256-X; MARSDEN MPF, 1979, CELL, V17, P849, DOI 10.1016/0092-8674(79)90325-8; MENEGHINI R, 1995, CANCER J - FRANCE, V8, P109; MOORE L, 1975, J BIOL CHEM, V250, P4562; NICOTERA P, 1989, P NATL ACAD SCI USA, V86, P453, DOI 10.1073/pnas.86.2.453; OCONNELL M, 1986, BIOCHEM J, V234, P727, DOI 10.1042/bj2340727; PRINCE RC, 1993, TRENDS BIOCHEM SCI, V18, P153; SAGARA Y, 1991, J BIOL CHEM, V266, P13503; SENIOR AE, 1988, PHYSIOL REV, V68, P177, DOI 10.1152/physrev.1988.68.1.177; SKOU JC, 1988, METHOD ENZYMOL, V156, P1; SMITH AG, 1990, HEPATOLOGY, V12, P1399, DOI 10.1002/hep.1840120622; TANZI RE, 1993, NAT GENET, V5, P344, DOI 10.1038/ng1293-344; WEIDEMAN.MJ, 1970, EUR J BIOCHEM, V16, P313, DOI 10.1111/j.1432-1033.1970.tb01086.x	40	37	38	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 7	1996	271	23					13616	13620		10.1074/jbc.271.23.13616	http://dx.doi.org/10.1074/jbc.271.23.13616			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UP385	8662653	hybrid			2022-12-25	WOS:A1996UP38500048
J	Jiang, HP; Kuang, YN; Wu, YP; Smrcka, A; Simon, MI; Wu, DQ				Jiang, HP; Kuang, YN; Wu, YP; Smrcka, A; Simon, MI; Wu, DQ			Pertussis toxin-sensitive activation of phospholipase C by the C5a and fMet-Leu-Phe receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-GAMMA-SUBUNITS; G-PROTEINS; SIGNAL TRANSDUCTION; ALPHA-SUBUNITS; ENZYME-SECRETION; INHIBITION; CELLS; DIMERS; FAMILY	Signal transduction pathways that mediate C5a and fMet-Leu-Phe (fMLP)-induced pertussis toxin (PTx)-sensitive activation of phospholipase C (PLC) have been investigated using a cotransfections assay system in COS-7 cells. The abilities of the receptors for C5a and fMLP to activate PLC beta 2 and PLC beta 3 through the G beta gamma subunits of endogenous G(1) proteins in COS-7 cells were tested because both PLC beta 2 and PLC beta 3 were shown to be activated by the beta gamma subunits of G proteins in in vitro reconstitution assays. Neither or the receptors can activate endogenous PLC beta 3 or recombinant PLC beta 3 in transfected COS-7 cells. However, both receptors can clearly activate PLC beta 2 in a PTx-sensitive manner, suggesting that the receptors may interact with endogenous PTx-sensitive G proteins and activate PLC beta 2 probably through the B beta gamma subunits. These findings were further corroborated by the results that PLC beta 3 could only be slightly activated by G(b)eta(1) gamma(1) or G beta(1) gamma(5) in the co-transfection assay, whereas the G beta gamma subunits strongly activated PLC beta 2 under the same conditions. PLC beta 3 can be activated by G(alpha q), G(alpha11), and G(alpha16) in the cotransfection assay. In addition, the G gamma(2) and G gamma(3) mutants wit substitution of the C-terminal Cys residue by a Ser residue, which can inhibit wild type G beta gamma-mediated activation of PLC beta 2, were able to inhibit C5a or fMLP-mediated activation of PLC beta 2. These G gamma mutants, however, showed little effect on m(1)-muscarinic receptor-mediated PLC activation, which is mediated by the G(q) class of G proteins. These results all confirm that the G beta gamma subunits are involved in PLC beta 2 activation by the two chemoattractant receptors and suggest that in COS-7 cells activation of PLC beta 3 by G beta gamma may not be the primary pathway for the receptors.	UNIV ROCHESTER, DEPT PHARMACOL & PHYSIOL & BIOCHEM, ROCHESTER, NY 14534 USA; CALTECH, DIV BIOL, PASADENA, CA 91125 USA	University of Rochester; California Institute of Technology								AMATRUDA TT, 1991, P NATL ACAD SCI USA, V88, P5587, DOI 10.1073/pnas.88.13.5587; AMATRUDA TT, 1993, J BIOL CHEM, V268, P10139; BECKER EL, 1985, J CELL BIOL, V100, P1641, DOI 10.1083/jcb.100.5.1641; BERSTEIN G, 1992, J BIOL CHEM, V267, P8081; BERSTEIN G, 1992, CELL, V70, P411, DOI 10.1016/0092-8674(92)90165-9; BIRNBAUMER L, 1992, CELL, V71, P1069, DOI 10.1016/S0092-8674(05)80056-X; BIRNBAUMER L, 1990, BIOCHIM BIOPHYS ACTA, V1031, P163, DOI 10.1016/0304-4157(90)90007-Y; BLANK JL, 1992, J BIOL CHEM, V267, P23069; BOKOCH GM, 1984, CELL, V39, P301, DOI 10.1016/0092-8674(84)90008-4; BOYER JL, 1992, J BIOL CHEM, V267, P25451; BOYER JL, 1994, J BIOL CHEM, V269, P2814; BRANDT SJ, 1985, P NATL ACAD SCI USA, V82, P3277, DOI 10.1073/pnas.82.10.3277; CONKLIN BR, 1992, J BIOL CHEM, V267, P31; CRESPO P, 1994, NATURE, V369, P418, DOI 10.1038/369418a0; FEDERMAN AD, 1992, NATURE, V356, P159, DOI 10.1038/356159a0; GERARD C, 1994, ANNU REV IMMUNOL, V12, P775, DOI 10.1146/annurev.iy.12.040194.004015; GERARD C, 1994, CURR OPIN IMMUNOL, V6, P140, DOI 10.1016/0952-7915(94)90045-0; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; HAWES BE, 1994, J BIOL CHEM, V269, P29825; INGLESE J, 1992, NATURE, V359, P147, DOI 10.1038/359147a0; JIANG HP, 1994, J BIOL CHEM, V269, P7593; KATZ A, 1992, NATURE, V360, P686, DOI 10.1038/360686a0; KLEUSS C, 1992, NATURE, V358, P424, DOI 10.1038/358424a0; KLEUSS C, 1991, NATURE, V353, P43, DOI 10.1038/353043a0; KOCH WJ, 1994, P NATL ACAD SCI USA, V91, P12706, DOI 10.1073/pnas.91.26.12706; LEE SB, 1993, J BIOL CHEM, V268, P25952; MURPHY PM, 1994, ANNU REV IMMUNOL, V12, P593, DOI 10.1146/annurev.iy.12.040194.003113; OPPENHEIM JJ, 1991, ANNU REV IMMUNOL, V9, P617, DOI 10.1146/annurev.iy.09.040191.003153; PARK DG, 1993, J BIOL CHEM, V268, P4573; PITCHER JA, 1992, SCIENCE, V257, P1264, DOI 10.1126/science.1325672; POLAKIS PG, 1988, J BIOL CHEM, V263, P4969; PRONIN AN, 1992, P NATL ACAD SCI USA, V89, P6220, DOI 10.1073/pnas.89.13.6220; REUVENY E, 1994, NATURE, V370, P143, DOI 10.1038/370143a0; ROLLINS TE, 1991, P NATL ACAD SCI USA, V88, P971, DOI 10.1073/pnas.88.3.971; SCHWINN DA, 1991, MOL PHARMACOL, V40, P619; SICILIANO SJ, 1990, J BIOL CHEM, V265, P19568; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; SIMONDS WF, 1991, J BIOL CHEM, V266, P5363; SMRCKA AV, 1993, J BIOL CHEM, V268, P9667; SNYDERMAN R, 1990, ADP RIBOSYLATING TOX, P295; STEPHENS L, 1994, CELL, V77, P83, DOI 10.1016/0092-8674(94)90237-2; TANG WJ, 1991, SCIENCE, V254, P1500, DOI 10.1126/science.1962211; UEDA N, 1994, J BIOL CHEM, V269, P4388; VERGHESE MW, 1987, J IMMUNOL, V138, P4374; WICKMAN KD, 1994, NATURE, V368, P255, DOI 10.1038/368255a0; WU DQ, 1993, SCIENCE, V261, P101, DOI 10.1126/science.8316840; WU DQ, 1993, P NATL ACAD SCI USA, V90, P5297, DOI 10.1073/pnas.90.11.5297; WU DQ, 1993, J BIOL CHEM, V268, P3704; WU DQ, 1992, J BIOL CHEM, V267, P25798; WU DQ, 1992, J BIOL CHEM, V267, P1811	50	85	86	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 7	1996	271	23					13430	13434		10.1074/jbc.271.23.13430	http://dx.doi.org/10.1074/jbc.271.23.13430			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UP385	8662841	hybrid			2022-12-25	WOS:A1996UP38500021
J	Winzen, R; Kafert, S; Preiss, B; MyliusSpencker, HA; Resch, K; Holtmann, H				Winzen, R; Kafert, S; Preiss, B; MyliusSpencker, HA; Resch, K; Holtmann, H			Interaction between the mRNA of the 55-kDa tumor necrosis factor receptor and cellular proteins - Possible involvement in post-transcriptional regulation of receptor expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA STABILITY; 3' UNTRANSLATED REGION; URIDINE BINDING-FACTOR; FACTOR TNF RECEPTOR; PHORBOL ESTER; MONOCLONAL-ANTIBODIES; SURFACE EXPRESSION; MOLECULAR-CLONING; UP-REGULATION; SOLUBLE FORM	Numerous effects of tumor necrosis factor are signaled by its 55-kDa receptors, Studying their expression we found that the level of receptor mRNA was decreased during the phorbol ester-induced differentiation of myelomonocytic cell lines, While only minor changes in transcription were noted, the half-life of receptor mRNA in the differentiated cells was markedly decreased, indicating the involvement of post transcriptional regulation, In an electrophoretic mobility shift assay, formation of complexes between radiolabeled receptor mRNA and cellular proteins was observed, The decrease in receptor mRNA levels during phorbol ester-induced differentiation was paralleled by a change in the pattern of those complexes, Protein-RNA interaction was selective, as it was not competed by unrelated RNAs, Yet, certain mRNAs that contain AU-rich sequences, known to be involved in the control of their stability, did compete with the receptor mRNA, although the latter is devoid of such sequences, A region of 18 nucleotides within its coding region was found to contain an element essential for the formation of all complexes and sufficient for the formation of those with lower molecular mass, Adjacent bases were required in addition for the formation of the complexes with higher molecular mass, The results suggest that proteins interacting with this region of the 55-kDa tumor necrosis factor receptor mRNA contribute to the regulation of its expression.	HANNOVER MED SCH,INST MOLEKPHARMAKOL,D-30623 HANNOVER,GERMANY	Hannover Medical School								AMARA FM, 1994, J BIOL CHEM, V269, P6709; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; BEELMAN CA, 1995, CELL, V81, P179, DOI 10.1016/0092-8674(95)90326-7; BEUTLER B, 1986, NATURE, V320, P584, DOI 10.1038/320584a0; BOHJANEN PR, 1991, MOL CELL BIOL, V11, P3288, DOI 10.1128/MCB.11.6.3288; BOLDIN MP, 1995, J BIOL CHEM, V270, P387, DOI 10.1074/jbc.270.1.387; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAKEBUSCH C, 1994, J BIOL CHEM, V269, P32488; BREWER G, 1991, MOL CELL BIOL, V11, P2460, DOI 10.1128/MCB.11.5.2460; BROCKHAUS M, 1990, P NATL ACAD SCI USA, V87, P3127, DOI 10.1073/pnas.87.8.3127; CASEY JL, 1989, EMBO J, V8, P3693, DOI 10.1002/j.1460-2075.1989.tb08544.x; CHEN FY, 1993, EMBO J, V12, P3977, DOI 10.1002/j.1460-2075.1993.tb06075.x; CHODOSH LA, 1986, MOL CELL BIOL, V6, P4723, DOI 10.1128/MCB.6.12.4723; DONISKELLER H, 1979, NUCLEIC ACIDS RES, V7, P179, DOI 10.1093/nar/7.1.179; ENGELMANN H, 1990, J BIOL CHEM, V265, P1531; ENGELMANN H, 1990, J BIOL CHEM, V265, P14497; ESPEVIK T, 1990, J EXP MED, V171, P415, DOI 10.1084/jem.171.2.415; GILLIS P, 1991, J BIOL CHEM, V266, P3172; GROUDINE M, 1981, MOL CELL BIOL, V1, P281, DOI 10.1128/MCB.1.3.281; HABERKERN RC, 1973, BIOCHEMISTRY-US, V12, P2389, DOI 10.1021/bi00737a004; HELLER RA, 1990, P NATL ACAD SCI USA, V87, P6151, DOI 10.1073/pnas.87.16.6151; HOLTMANN H, 1987, J IMMUNOL, V139, P1161; IWAI Y, 1991, J BIOL CHEM, V266, P17959; JONES TR, 1987, MOL CELL BIOL, V7, P4513, DOI 10.1128/MCB.7.12.4513; KEMPER O, 1993, GENE, V134, P209, DOI 10.1016/0378-1119(93)90095-K; KLAUSNER RD, 1993, CELL, V72, P19, DOI 10.1016/0092-8674(93)90046-S; KONIG M, 1991, EUR J IMMUNOL, V21, P1741, DOI 10.1002/eji.1830210723; KRUYS V, 1989, SCIENCE, V245, P852, DOI 10.1126/science.2672333; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LARSSON LG, 1994, ONCOGENE, V9, P1247; LEE W, 1987, NATURE, V325, P368, DOI 10.1038/325368a0; LEEUWENBERG JFM, 1994, J IMMUNOL, V152, P5070; LEVINE TD, 1993, MOL CELL BIOL, V13, P3494, DOI 10.1128/MCB.13.6.3494; LINDSTEN T, 1989, SCIENCE, V244, P339, DOI 10.1126/science.2540528; LOETSCHER H, 1990, CELL, V61, P351, DOI 10.1016/0092-8674(90)90815-V; MALTER JS, 1989, SCIENCE, V246, P664, DOI 10.1126/science.2814487; MALTER JS, 1991, J BIOL CHEM, V266, P3167; MCCARTHY JEG, 1995, TRENDS BIOCHEM SCI, V20, P191, DOI 10.1016/S0968-0004(00)89006-4; MERCER JFB, 1985, NUCLEIC ACIDS RES, V13, P7929, DOI 10.1093/nar/13.22.7929; MULLNER EW, 1989, CELL, V58, P373, DOI 10.1016/0092-8674(89)90851-9; NAKAGAWA J, 1995, P NATL ACAD SCI USA, V92, P2051, DOI 10.1073/pnas.92.6.2051; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; NOPHAR Y, 1990, EMBO J, V9, P3269, DOI 10.1002/j.1460-2075.1990.tb07526.x; PANDEY NB, 1987, MOL CELL BIOL, V7, P4557, DOI 10.1128/MCB.7.12.4557; PANDITA R, 1992, FEBS LETT, V312, P87, DOI 10.1016/0014-5793(92)81416-J; PFEFFER K, 1993, CELL, V73, P457, DOI 10.1016/0092-8674(93)90134-C; PROKIPCAK RD, 1994, J BIOL CHEM, V269, P9261; RAJAGOPALAN LE, 1994, J BIOL CHEM, V269, P23882; ROSS J, 1995, MICROBIOL REV, V59, P423, DOI 10.1128/MMBR.59.3.423-450.1995; ROTHE J, 1993, NATURE, V364, P798, DOI 10.1038/364798a0; ROTHE J, 1993, MOL IMMUNOL, V30, P165, DOI 10.1016/0161-5890(93)90088-S; SACEDA M, 1991, J BIOL CHEM, V266, P17809; SACHS AB, 1993, CELL, V74, P413, DOI 10.1016/0092-8674(93)80043-E; Sambrook J., 2002, MOL CLONING LAB MANU; SCHALL TJ, 1990, CELL, V61, P361, DOI 10.1016/0092-8674(90)90816-W; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SHYU AB, 1989, GENE DEV, V3, P60, DOI 10.1101/gad.3.1.60; SMITH CA, 1990, SCIENCE, V248, P1019, DOI 10.1126/science.2160731; STEPHENS JM, 1992, J BIOL CHEM, V267, P8336; TODARO JG, 1966, SCIENCE, V153, P1253; TRACEY KJ, 1993, ANNU REV CELL BIOL, V9, P317, DOI 10.1146/annurev.cb.09.110193.001533; TREFZER U, 1993, J CLIN INVEST, V92, P462, DOI 10.1172/JCI116589; VAKALOPOULOU E, 1991, MOL CELL BIOL, V11, P3355, DOI 10.1128/MCB.11.6.3355; WHITTEMORE LA, 1990, MOL CELL BIOL, V64, P1329; WINZEN R, 1993, J IMMUNOL, V150, P4346; WINZEN R, 1992, J IMMUNOL, V148, P3454; WISDOM R, 1991, GENE DEV, V5, P232, DOI 10.1101/gad.5.2.232; WODNARFILIPOWICZ A, 1990, P NATL ACAD SCI USA, V87, P777, DOI 10.1073/pnas.87.2.777; YEN TJ, 1988, NATURE, V334, P580, DOI 10.1038/334580a0; YOUNG S, 1991, NUCLEIC ACIDS RES, V19, P2463, DOI 10.1093/nar/19.9.2463; ZHANG W, 1993, MOL CELL BIOL, V13, P7652, DOI 10.1128/MCB.13.12.7652	71	15	15	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 7	1996	271	23					13461	13467		10.1074/jbc.271.23.13461	http://dx.doi.org/10.1074/jbc.271.23.13461			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UP385	8662818	hybrid			2022-12-25	WOS:A1996UP38500026
J	Miyazaki, T; Liu, ZJ; Taniguchi, T				Miyazaki, T; Liu, ZJ; Taniguchi, T			Selective cooperation of HTLV-1-encoded p40(tax-1) with cellular oncoproteins in the induction of hematopoietic cell proliferation	ONCOGENE			English	Article						HTLV-1; p40(tax-1); lck F505; c-myc; bcl-2; IL-2	VIRUS TYPE-I; RECEPTOR-BETA-CHAIN; LEUKEMIA-VIRUS; IL-2 RECEPTOR; HTLV-I; SIGNAL TRANSDUCTION; TRANS-ACTIVATION; LIGAND-BINDING; TAX PROTEIN; C-MYC	Human T cell leukemia virus type 1 (HTLV-1) is the etiologic agent of adult T cell leukemia (ATL). The virus-encoded p40(tax-1), a nuclear oncoprotein, is known to promote transcription of its own as well as a variety of cellular genes, However, the mechanism by which p40(tax-1) promotes lymphocyte transformation is not fully understood, In the present study, we examined whether p40(tax-1) can induce hematopoietic cell proliferation by cooperating with the products of cellular proto-oncogenes; i.e. an activated form of the src-family protein tyrosine kinase p56(lck) (lck F505), c-Myc or Bcl-2, These oncoproteins are critical mediators of interleukin 2 (IL-2)-induced proliferative signals. We show that p40(tax-1) alone cannot render the hematopoietic cell line, BAF-B03, able to proliferate in the absence of cytokines, but it can do so in cooperation with lckF505, or c-Myc but not with Bcl-2.	UNIV TOKYO,FAC MED,DEPT IMMUNOL,BUNKYO KU,TOKYO 113,JAPAN; OSAKA UNIV,INST MOLEC & CELLULAR BIOL,SUITA,OSAKA 565,JAPAN; NIPPON BOEHRINGER INGELHEIM CO LTD,DEPT MOLEC & CELLULAR BIOL,KAWANISHI,HYOGO 66601,JAPAN	University of Tokyo; Osaka University; Boehringer Ingelheim			Miyazaki, Tadaaki/D-9368-2012					ABRAHAM N, 1990, MOL CELL BIOL, V10, P5197, DOI 10.1128/MCB.10.10.5197; AMREIN KE, 1988, P NATL ACAD SCI USA, V85, P4247, DOI 10.1073/pnas.85.12.4247; ARMSTRONG AP, 1993, P NATL ACAD SCI USA, V90, P7303, DOI 10.1073/pnas.90.15.7303; BISSONNETTE RP, 1992, NATURE, V359, P552, DOI 10.1038/359552a0; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; CARON C, 1993, EMBO J, V12, P4269, DOI 10.1002/j.1460-2075.1993.tb06111.x; DOI T, 1989, EUR J IMMUNOL, V19, P2375, DOI 10.1002/eji.1830191229; FUJISAWA J, 1986, EMBO J, V5, P713, DOI 10.1002/j.1460-2075.1986.tb04272.x; GRASSMANN R, 1989, P NATL ACAD SCI USA, V86, P3551; GROSSMAN WJ, 1995, P NATL ACAD SCI USA, V92, P1057, DOI 10.1073/pnas.92.4.1057; HATAKEYAMA M, 1989, CELL, V59, P837, DOI 10.1016/0092-8674(89)90607-7; HATAKEYAMA M, 1991, SCIENCE, V252, P1523, DOI 10.1126/science.2047859; HINUMA Y, 1981, P NATL ACAD SCI-BIOL, V78, P6476, DOI 10.1073/pnas.78.10.6476; HIRAI H, 1994, P NATL ACAD SCI USA, V91, P3584, DOI 10.1073/pnas.91.9.3584; HIRAI H, P NATL ACAD US, V91; INOUE J, 1986, EMBO J, V5, P2883, DOI 10.1002/j.1460-2075.1986.tb04583.x; KIYOKAWA T, 1985, P NATL ACAD SCI USA, V82, P8359, DOI 10.1073/pnas.82.24.8359; KORSMEYER SJ, 1992, IMMUNOL TODAY, V13, P285, DOI 10.1016/0167-5699(92)90037-8; MARTH JD, 1988, MOL CELL BIOL, V8, P540, DOI 10.1128/MCB.8.2.540; MARUYAMA M, 1987, CELL, V48, P343, DOI 10.1016/0092-8674(87)90437-5; MATTHEWS MAH, 1992, MOL CELL BIOL, V12, P1986, DOI 10.1128/MCB.12.5.1986; MINAMI Y, 1993, EMBO J, V12, P759, DOI 10.1002/j.1460-2075.1993.tb05710.x; MIYAZAKI T, 1991, EMBO J, V10, P3191, DOI 10.1002/j.1460-2075.1991.tb04881.x; MIYAZAKI T, 1995, CELL, V81, P223, DOI 10.1016/0092-8674(95)90332-1; MIYOSHI I, 1981, NATURE, V294, P770, DOI 10.1038/294770a0; NEGRINI M, 1987, CELL, V49, P455, DOI 10.1016/0092-8674(87)90448-X; NERENBERG M, 1987, SCIENCE, V237, P1324, DOI 10.1126/science.2888190; PALACIOS R, 1985, CELL, V41, P727, DOI 10.1016/S0092-8674(85)80053-2; PASKALIS H, 1986, P NATL ACAD SCI USA, V83, P6558, DOI 10.1073/pnas.83.17.6558; POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P7415, DOI 10.1073/pnas.77.12.7415; SEIKI M, 1983, P NATL ACAD SCI-BIOL, V80, P3618, DOI 10.1073/pnas.80.12.3618; SHIBUYA H, 1992, CELL, V70, P57, DOI 10.1016/0092-8674(92)90533-I; SHIMOTOHNO K, 1986, P NATL ACAD SCI USA, V83, P8112, DOI 10.1073/pnas.83.21.8112; SUZUKI T, 1993, P NATL ACAD SCI USA, V90, P610, DOI 10.1073/pnas.90.2.610; TANAKA A, 1990, P NATL ACAD SCI USA, V87, P1071, DOI 10.1073/pnas.87.3.1071; TANAKA Y, 1990, JPN J CANCER RES, V81, P225, DOI 10.1111/j.1349-7006.1990.tb02554.x; UCHIUMI F, 1992, MOL CELL BIOL, V12, P3784, DOI 10.1128/MCB.12.9.3784; UCHIYAMA T, 1977, BLOOD, V50, P481, DOI 10.1182/blood.V50.3.481.481; WONGSTAAL F, 1983, NATURE, V302, P626, DOI 10.1038/302626a0; Yoshida M, 1993, Trends Microbiol, V1, P131, DOI 10.1016/0966-842X(93)90127-D; YOSHIDA M, 1982, P NATL ACAD SCI-BIOL, V79, P2031, DOI 10.1073/pnas.79.6.2031; YOSHIDA M, 1987, ANNU REV IMMUNOL, V5, P541, DOI 10.1146/annurev.iy.05.040187.002545; ZHAO LJ, 1991, P NATL ACAD SCI USA, V88, P11445, DOI 10.1073/pnas.88.24.11445	43	15	15	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN 6	1996	12	11					2403	2408						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UQ220	8649781				2022-12-25	WOS:A1996UQ22000018
J	Lewis, JA; Huq, A; Najarro, P				Lewis, JA; Huq, A; Najarro, P			Inhibition of mitochondrial function by interferon	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AEROBIC GLYCOLYSIS; THYROID-HORMONE; CYTO-TOXICITY; TUMOR-CELLS; HELA-CELLS; EXPRESSION; GENES; MECHANISM; NUCLEAR; GROWTH	We showed previously that type I interferon causes a down-regulation of mitochondrial gene expression, We show here that IFN treatment leads to functional impairment of mitochondria, Western blot analysis indicated that interferon treatment reduces the steady-state level of cytochrome b in murine L-929 cells. Interferon produced a reduction in cytochrome c oxidase and NADH-cytochrome c reductase activities of isolated mitochondria as well as inhibiting electron transport in isolated mitochondria and in intact cells. Several mitochondrial mRNAs are affected by interferon treatment in human Daudi lymphoblastoid cells, which are highly sensitive to the antiproliferative effects of interferon, Electron transport in Daudi cells was also inhibited by interferon both in intact cells and isolated mitochondria with a dose response identical to that for the antiproliferative response, In contrast, a Daudi strain resistant to the antiproliferative effects of interferon showed no down-regulation of mRNA expression and no inhibition of electron transport; Possibly as a consequence of the inhibitory effect on mitochondrial gene expression, treatment with interferon causes a reduction in cellular ATP levels, The inhibition of cellular growth by interferon may thus be partly a consequence of a reduction in cellular ATP levels.			Lewis, JA (corresponding author), SUNY HLTH SCI CTR,DEPT ANAT & CELL BIOL,450 CLARKSON AVE,BROOKLYN,NY 11203, USA.				NIGMS NIH HHS [GM4697703] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046977] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMS A, 1975, J GEN VIROL, V28, P207, DOI 10.1099/0022-1317-28-2-207; BERRY MJ, 1985, J BIOL CHEM, V260, P1240; BIBB MJ, 1981, CELL, V26, P167, DOI 10.1016/0092-8674(81)90300-7; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CAPALDI RA, 1988, TRENDS BIOCHEM SCI, V13, P144, DOI 10.1016/0968-0004(88)90073-4; COOPERSTEIN SJ, 1951, J BIOL CHEM, V189, P665; DEGUCHI M, 1995, J INTERF CYTOK RES, V15, P977, DOI 10.1089/jir.1995.15.977; DEMAEYER E, 1988, INTERFERONS OTHER RE, P91; DRAPIER JC, 1988, J IMMUNOL, V140, P2829; GLAICHENHAUS N, 1986, EMBO J, V5, P1261, DOI 10.1002/j.1460-2075.1986.tb04355.x; HAYASHI JI, 1992, SOMAT CELL MOLEC GEN, V18, P123, DOI 10.1007/BF01233159; HEINE UI, 1991, CELL REGUL, V2, P467, DOI 10.1091/mbc.2.6.467; HESS JF, 1991, NATURE, V351, P236, DOI 10.1038/351236a0; HILFENHAUS J, 1976, ARCH VIROL, V51, P87, DOI 10.1007/BF01317837; Hovanessian A G, 1981, Methods Enzymol, V79, P184; LEWIS JA, 1987, LYMPHOKINES INTERFER, P73; LEWIS JA, 1991, INTERFERON PRINCIPLE, P251; LEWIS JA, 1995, CYTOKINES PRACTICAL, P129; LOU J, 1994, J INTERFERON RES, V14, P33, DOI 10.1089/jir.1994.14.33; MINKS MA, 1979, J BIOL CHEM, V254, P5058; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; NELSON BD, 1990, BIOCHIM BIOPHYS ACTA, V1018, P275, DOI 10.1016/0005-2728(90)90266-7; PARSA AT, 1995, HUMAN CHROMOSOMES PR, P292; RACKER E, 1976, J CELL PHYSIOL, V89, P697, DOI 10.1002/jcp.1040890429; SCHATZ G, 1964, BIOCHIM BIOPHYS ACTA, V81, P448, DOI 10.1016/0926-6569(64)90130-0; SCHOLNICK P, 1973, J BIOL CHEM, V248, P5175; SEN GC, 1992, J BIOL CHEM, V267, P5017; SHAN B, 1989, VIROLOGY, V170, P277; SHAN B, 1990, EMBO J, V9, P4307, DOI 10.1002/j.1460-2075.1990.tb07879.x; SLATER TF, 1963, BIOCHIM BIOPHYS ACTA, V77, P383, DOI 10.1016/0006-3002(63)90513-4; TORRONI A, 1990, J BIOL CHEM, V265, P20589; VANITALLIE CM, 1990, ENDOCRINOLOGY, V127, P55, DOI 10.1210/endo-127-1-55; WALLACE DC, 1994, P NATL ACAD SCI USA, V91, P8739, DOI 10.1073/pnas.91.19.8739	33	49	50	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 31	1996	271	22					13184	13190		10.1074/jbc.271.22.13184	http://dx.doi.org/10.1074/jbc.271.22.13184			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UN474	8662694	hybrid			2022-12-25	WOS:A1996UN47400076
J	Szumilo, T; Zeng, YC; Pastuszak, I; Drake, R; Szumilo, H; Elbein, AD				Szumilo, T; Zeng, YC; Pastuszak, I; Drake, R; Szumilo, H; Elbein, AD			Purification to homogeneity and properties of UDP-GlcNAc (GalNAc) pyrophosphorylase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOSYLATION; GLYCOPROTEINS	The pyrophosphorylase that condenses UTP and GlcNAc-1-P was purified 9500-fold to near homogeneity from the soluble fraction of pig liver extracts. At the final stage of purification, the enzyme was quite stable and could be kept for at least 4 months in the freezer with only slight loss of activity. On native gels, the purified enzyme showed a single protein band, and this band was estimated to have a molecular mass of similar to 125 kDa on Sephacryl S-300. SDS-polyacrylamide gel electrophoresis analysis of the enzyme gave three protein bands of 64, 57, and 49 kDa, but these polypeptides are all closely related based on the following, 1) All three polypeptides show strong cross-reactivity with antibody prepared against the 64-kDa band, 2) All three proteins become labeled with either the UDP-GlcNAc photoaffinity probe azido-I-125-salicylate-allylamine-UDP-GlcNAc or a similar UDP-GalNAc photoaffinity probe, and either labeling was inhibited in a specific and concentration-dependent manner by unlabeled UDP-GlcNAc or UI)PGalNAc. Thus, the enzyme is probably a homodimer composed of two 64-kDa subunits, The purified enzyme had an unusual specificity in that, at higher substrate concentrations, it utilized UDP-GalNAc as a substrate as well as UDP-GlcNAc in the reverse direction and GalNAc-1-P as well as GlcNAc-1-P in the forward direction, However, the K-m for the GalNAc substrates was considerably higher than that for GlcNAc derivatives. This activity for synthesizing UDP-GalNAc was not due to epimerase activity since no UDP-GalNAc could be detected when the enzyme was incubated with UDP-GlcNAc for various periods of time. The pyrophosphorylase required a divalent cation, with Mn2+ being best at 0.5-1 mM, and the pH optimum was between 8.5 and 8.9.	UNIV ARKANSAS MED SCI HOSP, DEPT BIOCHEM & MOLEC BIOL, LITTLE ROCK, AR 72205 USA	University of Arkansas System; University of Arkansas Medical Sciences					NHLBI NIH HHS [HL-17783] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL017783] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BALLOU C, 1982, MOL BIOL YEAST SACCH, P361; CARDINI CE, 1953, ARCH BIOCHEM BIOPHYS, V45, P55, DOI 10.1016/0003-9861(53)90404-4; CARRAWAY KL, 1989, BIOESSAYS, V10, P117, DOI 10.1002/bies.950100406; DAVIDSON EA, 1966, AMINOSUGARS, P2; DEVINE PL, 1992, BIOESSAYS, V14, P619, DOI 10.1002/bies.950140909; DRAKE RR, 1992, GLYCOBIOLOGY, V2, P279, DOI 10.1093/glycob/2.4.279; FUKUDA M, 1992, GLYCOCONJUGATES COMP, P379; HAKOMORI SI, 1986, CHEM PHYS LIPIDS, V42, P209, DOI 10.1016/0009-3084(86)90054-X; Harlow E., 1988, ANTIBODIES LABORATOR, P63; HART GW, 1989, ANNU REV BIOCHEM, V58, P841; HEMMING FW, 1974, BIOCH LIPIDS, P39; HOOK M, 1984, ANNU REV BIOCHEM, V53, P847; KARLSSON KA, 1989, ANNU REV BIOCHEM, V58, P309, DOI 10.1146/annurev.bi.58.070189.001521; KAUSHAL GP, 1990, BIOCHEMISTRY-US, V29, P2168, DOI 10.1021/bi00460a030; KORNFELD R, 1976, ANNU REV BIOCHEM, V45, P217, DOI 10.1146/annurev.bi.45.070176.001245; KRIEGER M, 1989, METHOD CELL BIOL, V32, P57; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEHRMAN M A, 1991, Glycobiology, V1, P553, DOI 10.1093/glycob/1.6.553; MUNCHPETERSEN A, 1956, ACTA CHEM SCAND, V10, P928, DOI 10.3891/acta.chem.scand.10-0928; PATTABIRAMAN T, 1961, BIOCHIM BIOPHYS ACTA, V50, P129, DOI 10.1016/0006-3002(61)91068-X; REISSIG JL, 1955, J BIOL CHEM, V217, P959; SRERE P, 1994, TRENDS BIOCHEM SCI, V19, P519, DOI 10.1016/0968-0004(94)90048-5; SRERE PA, 1987, ANNU REV BIOCHEM, V56, P89, DOI 10.1146/annurev.bi.56.070187.000513; STROMINGER JL, 1959, J BIOL CHEM, V234, P1822; SZUMILO T, 1993, J BIOL CHEM, V268, P17943; TREVELYAN WE, 1950, NATURE, V166, P444, DOI 10.1038/166444b0; WHEAT RW, 1966, METHOD ENZYMOL, V8, P60	27	35	37	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 31	1996	271	22					13147	13154		10.1074/jbc.271.22.13147	http://dx.doi.org/10.1074/jbc.271.22.13147			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UN474	8662687	hybrid			2022-12-25	WOS:A1996UN47400071
J	Beard, WA; Minnick, DT; Wade, CL; Prasad, R; Won, RL; Kumar, A; Kunkel, TA; Wilson, SH				Beard, WA; Minnick, DT; Wade, CL; Prasad, R; Won, RL; Kumar, A; Kunkel, TA; Wilson, SH			Role of the ''helix clamp'' in HIV-1 reverse transcriptase catalytic cycling as revealed by alanine-scanning mutagenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANGSTROM RESOLUTION; CRYSTAL-STRUCTURE; MECHANISM; TEMPLATE; KINETICS; DNA; TERMINATION; INHIBITOR; SEQUENCE; BINDING	Residues 259-284 of HIV-1 reverse transcriptase exhibit sequence homology with other nucleic acid polymerases and have been termed the ''helix clamp'' (Hermann, T., Meier, T., Gotte, M., and Heumann, H. (1994) Nucleic Acids Res, 22, 4625-4633), since crystallographic evidence indicates these residues are part of two alpha-helices (alpha H and alpha I) that interact with DNA. Alanine-scanning mutagenesis has previously demonstrated that several residues in alpha H make important interactions with nucleic acid and influence frameshift fidelity. To define the role of alpha I (residues 278-286) during catalytic cycling, we performed systematic site directed mutagenesis from position 277 through position 287 by changing each residue, one by one, to alanine, Each mutant protein was expressed and, except for L283A and T286A, was soluble. The soluble mutant enzymes were purified and characterized, In contrast to alanine mutants of alpha H, alanine substitution in alpha I did not have a significant effect on template . primer (T . P) binding as revealed by a lack of an effect on K-m,K-T . P, K-i for 3'-azido-2',3'-dideoxythymidine 5'-triphosphate, k(off,T . P), and processivity. Consistent with these observations, the fidelity of the mutant enzymes was not influenced. However, alanine mutagenesis of alpha I lowered the apparent activity of every mutant relative to wild-type enzyme, Titration of two mutants exhibiting the lowest activity with T . P (L282A and R284A) demonstrated that these mutant enzymes could bind T . P stoichiometrically and tightly, In contrast, active site concentrations determined from ''burst'' experiments suggest that the lower activity is due to a smaller population of enzyme bound productively to T . P. The putative electrostatic interactions between the basic side chains of the helix clamp and the DNA backbone are either very weak or kinetically silent, In contrast, interactions between several residues of alpha H and the DNA minor groove, 3-5 nucleotides from the 3'-primer terminus, are suggested to be critical for DNA binding and fidelity.	UNIV TEXAS, MED BRANCH, SEALY CTR MOL SCI, GALVESTON, TX 77555 USA; NIEHS, GENET MOLEC LAB, NIH, RES TRIANGLE PK, NC 27709 USA	University of Texas System; University of Texas Medical Branch Galveston; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)			Wilson, Samuel H/E-6644-2019; Kunkel, Thomas A./D-5088-2019	Wilson, Samuel H/0000-0002-1702-5293; Kunkel, Thomas A./0000-0002-9900-1788				ABBOTTS J, 1993, J BIOL CHEM, V268, P10312; BAILLON JG, 1991, NEW BIOL, V3, P1015; BEARD WA, 1994, J BIOL CHEM, V269, P28091; BEARD WA, 1993, BIOCHEMISTRY-US, V32, P9745, DOI 10.1021/bi00088a029; BEBENEK K, 1993, J BIOL CHEM, V268, P10324; BEBENEK K, 1995, J BIOL CHEM, V270, P19516, DOI 10.1074/jbc.270.33.19516; Bebenek K, 1995, METHOD ENZYMOL, V262, P217; BEBENEK K, 1989, J BIOL CHEM, V264, P16948; BOYER PL, 1994, P NATL ACAD SCI USA, V91, P4882, DOI 10.1073/pnas.91.11.4882; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; DIVITA G, 1993, BIOCHEMISTRY-US, V32, P7966, DOI 10.1021/bi00082a018; DIVITA G, 1995, J MOL BIOL, V245, P508, DOI 10.1006/jmbi.1994.0042; GOEL R, 1993, BIOCHEMISTRY-US, V32, P13012, DOI 10.1021/bi00211a009; HERMANN T, 1994, NUCLEIC ACIDS RES, V22, P4625, DOI 10.1093/nar/22.22.4625; JACOBOMOLINA A, 1993, P NATL ACAD SCI USA, V90, P6320, DOI 10.1073/pnas.90.13.6320; JAJU M, 1995, J BIOL CHEM, V270, P9740, DOI 10.1074/jbc.270.17.9740; KATI WM, 1992, J BIOL CHEM, V267, P25988; KOHLSTAEDT LA, 1992, SCIENCE, V256, P1783, DOI 10.1126/science.1377403; KUNKEL TA, 1991, METHOD ENZYMOL, V204, P125; LATHAM GJ, 1994, J BIOL CHEM, V269, P28527; METZGER W, 1993, P NATL ACAD SCI USA, V90, P5909, DOI 10.1073/pnas.90.13.5909; MISRA VK, 1995, P NATL ACAD SCI USA, V92, P4691, DOI 10.1073/pnas.92.10.4691; Nanni Raymond G., 1993, Perspectives in Drug Discovery and Design, V1, P129, DOI 10.1007/BF02171659; PATEL PH, 1995, BIOCHEMISTRY-US, V34, P5351, DOI 10.1021/bi00016a006; PELLETIER H, 1994, SCIENCE, V264, P1891, DOI 10.1126/science.7516580; REARDON JE, 1990, J BIOL CHEM, V265, P20302; REARDON JE, 1992, BIOCHEMISTRY-US, V31, P4473, DOI 10.1021/bi00133a013; REN JS, 1995, NAT STRUCT BIOL, V2, P293, DOI 10.1038/nsb0495-293; Richardson J.S., 1990, PREDICTION PROTEIN S, P1; ROBERTS JD, 1988, SCIENCE, V242, P1171, DOI 10.1126/science.2460925; RODGERS DW, 1995, P NATL ACAD SCI USA, V92, P1222, DOI 10.1073/pnas.92.4.1222; SEEMAN NC, 1976, P NATL ACAD SCI USA, V73, P804, DOI 10.1073/pnas.73.3.804; SMERDON SJ, 1994, P NATL ACAD SCI USA, V91, P3911, DOI 10.1073/pnas.91.9.3911; SPOLAR RS, 1994, SCIENCE, V263, P777, DOI 10.1126/science.8303294; WANG J, 1994, P NATL ACAD SCI USA, V91, P7242, DOI 10.1073/pnas.91.15.7242; WOHRL BM, 1995, BIOCHEMISTRY-US, V34, P5343	36	47	52	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 24	1996	271	21					12213	12220		10.1074/jbc.271.21.12213	http://dx.doi.org/10.1074/jbc.271.21.12213			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UL660	8647817	hybrid			2022-12-25	WOS:A1996UL66000019
J	Lamberg, A; Helaakoski, T; Myllyharju, J; Peltonen, S; Notbohm, H; Pihlajaniemi, T; Kivirikko, KI				Lamberg, A; Helaakoski, T; Myllyharju, J; Peltonen, S; Notbohm, H; Pihlajaniemi, T; Kivirikko, KI			Characterization of human type III collagen expressed in a baculovirus system - Production of a protein with a stable triple helix requires coexpression with the two types of recombinant prolyl 4-hydroxylase subunit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DISULFIDE-ISOMERASE; BETA-SUBUNIT; INSECT CELLS; PROCOLLAGEN; BIOSYNTHESIS; SECRETION; ENZYMES; CHAIN; GENE	An efficient expression system for recombinant collagens would have numerous scientific and practical applications. Nevertheless, most recombinant systems are not suitable for this purpose, as they do not have sufficient amounts of prolyl 4-hydroxylase activity. Pro-alpha 1 chains of human type III collagen expressed in insect cells by a baculovirus vector are reported here to contain significant amounts of 4-hydroxyproline and to form triple-helical molecules, although the T-m of the triple helices was only about 32-34 degrees C. Coexpression of the pro-alpha 1(III) chains with the alpha and beta subunits of human prolyl 4-hydroxylase increased the T-m to about 40 degrees C, provided that ascorbate was added to the culture medium. The level of expression of type III procollagen was also increased in the presence of the recombinant prolyl 4-hydroxylase, and the pro-alpha 1(III) chains and alpha 1(III) chains were found to be present in disulfide-bonded molecules. Most of the triple-helical collagen produced was retained within the insect cells and could be extracted from the cell pellet. The highest expression levels were obtained in High Five cells, which produced up to about 80 mu g of cellular type III collagen (120 mu g of procollagen) per 5 x 10(6) cells in monolayer culture and up to 40 mg/liter of cellular type III collagen (60 mg/liter procollagen) in suspension. The 4-hydroxyproline content and T-m of the purified recombinant type III collagen were very similar to those of the nonrecombinant protein, but the hydroxylysine content was slightly lower, being about 3 residues/1000 in the former and 5/1000 in the latter.	UNIV OULU, DEPT MED BIOCHEM, SF-90220 OULU, FINLAND; UNIV OULU, BIOCTR, COLLAGEN RES UNIT, SF-90220 OULU, FINLAND; UNIV LUBECK, INST MED MOL BIOL, D-23538 LUBECK, GERMANY	University of Oulu; University of Oulu; University of Lubeck			Peltonen, Sirkku/C-3133-2008	Peltonen, Sirkku/0000-0003-0990-1430; Pihlajaniemi, Taina/0000-0002-1664-9045				ALAKOKKO L, 1991, J BIOL CHEM, V266, P14175; BOOTH BA, 1981, BIOCHIM BIOPHYS ACTA, V675, P117, DOI 10.1016/0304-4165(81)90076-3; BREWTON RG, 1994, EXTRACELLULAR MATRIX, P129; BRUCKNER P, 1981, ANAL BIOCHEM, V110, P360, DOI 10.1016/0003-2697(81)90204-9; CAVALLARO JF, 1994, BIOTECHNOL BIOENG, V43, P781, DOI 10.1002/bit.260430813; CHUNG E, 1974, SCIENCE, V183, P1200, DOI 10.1126/science.183.4130.1200; COLOMBATTI A, 1995, J BIOL CHEM, V270, P13105, DOI 10.1074/jbc.270.22.13105; FERTALA A, 1994, BIOCHEM J, V298, P31, DOI 10.1042/bj2980031; FREEDMAN RB, 1994, TRENDS BIOCHEM SCI, V19, P331, DOI 10.1016/0968-0004(94)90072-8; FUJIOKA K, 1995, J CONTROL RELEASE, V33, P307, DOI 10.1016/0168-3659(94)00107-6; GRUENWALD S, 1993, BACULOVIRUS EXPRESSI; HELAAKOSKI T, 1995, P NATL ACAD SCI USA, V92, P4427, DOI 10.1073/pnas.92.10.4427; Kielty Cay M., 1993, P103; Kivirikko K I, 1979, Int Rev Connect Tissue Res, V8, P23; Kivirikko K. I., 1992, POSTTRANSLATIONAL MO, P1; KIVIRIKKO KI, 1993, ANN MED, V25, P113, DOI 10.3109/07853899309164153; KIVIRIKKO KI, 1982, METHOD ENZYMOL, V82, P245; KIVIRIKKO KI, 1989, FASEB J, V3, P1609, DOI 10.1096/fasebj.3.5.2537773; KIVIRIKKO KI, 1967, ANAL BIOCHEM, V19, P249, DOI 10.1016/0003-2697(67)90160-1; KIVIRIKKO KI, 1995, PR MED BIOL, V3, P233; KOIVU J, 1987, J BIOL CHEM, V262, P6447; LUCKOW VA, 1989, VIROLOGY, V170, P31, DOI 10.1016/0042-6822(89)90348-6; MALITSCHEK B, 1991, BIOTECHNIQUES, V11, P177; MAPLES JA, 1985, AM J CLIN PATHOL, V83, P356, DOI 10.1093/ajcp/83.3.356; PIHLAJANIEMI T, 1995, PROG NUCLEIC ACID RE, V50, P225, DOI 10.1016/S0079-6603(08)60816-8; PIHLAJANIEMI T, 1987, EMBO J, V6, P643, DOI 10.1002/j.1460-2075.1987.tb04803.x; Prockop D.J., 1976, BIOCH COLLAGENS, P163; PROCKOP DJ, 1995, ANNU REV BIOCHEM, V64, P403, DOI 10.1146/annurev.biochem.64.1.403; SISSOM J, 1989, BIOCHEM J, V261, P119, DOI 10.1042/bj2610119; TILLET E, 1995, EUR J BIOCHEM, V228, P160, DOI 10.1111/j.1432-1033.1995.tb20245.x; TROMP G, 1989, J BIOL CHEM, V264, P1349; VANDERPLAATS GN, 1993, STRUCT OPTIMIZATION, V6, P1, DOI 10.1007/BF01743168; VEIJOLA J, 1994, J BIOL CHEM, V269, P26746; VERNET T, 1990, J BIOL CHEM, V265, P16661; VUORI K, 1992, P NATL ACAD SCI USA, V89, P7467, DOI 10.1073/pnas.89.16.7467; VUORI K, 1992, EMBO J, V11, P4213, DOI 10.1002/j.1460-2075.1992.tb05515.x; WEINER HL, 1994, P NATL ACAD SCI USA, V91, P10762, DOI 10.1073/pnas.91.23.10762	37	100	102	1	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 17	1996	271	20					11988	11995		10.1074/jbc.271.20.11988	http://dx.doi.org/10.1074/jbc.271.20.11988			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UL250	8662631	hybrid			2022-12-25	WOS:A1996UL25000062
J	Ohta, Y; Hartwig, JH				Ohta, Y; Hartwig, JH			Phosphorylation of actin-binding protein 280 by growth factors is mediated by p90 ribosomal protein S6 kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION; MAP KINASES; PLATELET; FILAMIN; PROTEOLYSIS; FILAMENTS; PATHWAYS	Although Ras-related small GTPases are believed to control cell proliferation and motility through activation of protein kinase cascades, little is known about the intracellular protein targets of activated kinases. Here we show that the p90 ribosomal S6 kinase 2 (RSK2) phosphorylates actin-binding protein (ABP-280) in intact rat 3Y1 fibroblasts. Growth factors such as fetal calf serum, epidermal growth factor, phorbol 12-myristate 13-acetate, and lysophosphatidic acid stimulate the phosphorylation of serine residues in ABP-280 in quiescent 3Y1 cells. Extracts from 3Y1 cells prepared after stimulation by lysophosphatidic acid, fetal calf serum, and epidermal growth factor retain activated protein kinase activity(s) toward ABP-280 in vitro. ABP kinase activities in lysates from lysophosphatidic acid-stimulated 3Y1 cells can be fractionated by MonoQ anion exchange column chromatography into three peaks having ABP kinase activities. One (ABP kinase peak 1) coelutes with the peak of RSK2 as judged by immunoblotting and S6 peptide kinase assays. Two-dimensional phosphopeptide maps show RSK2 phosphorylated ABP-280 to be phosphorylated at the same site(s) as those stimulated by growth factors in vivo. Incubation of ABP kinase peak 1 fractionated from unstimulated cells with activated ERK2 activates latent ABP kinase activity. These results show RSK2 to phosphorylate ABP-280 in vivo.	BRIGHAM & WOMENS HOSP, DIV EXPTL MED, LONGWOOD MED RES CTR, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, BOSTON, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School					NHLBI NIH HHS [HL 56252, HL-19429] Funding Source: Medline; NIDDK NIH HHS [DK38452] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL056252, R01HL019429, R37HL019429] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK038452] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AHN NG, 1990, J BIOL CHEM, V265, P11487; AVRUCH J, 1994, TRENDS BIOCHEM SCI, V19, P279, DOI 10.1016/0968-0004(94)90005-1; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; BLUMER KJ, 1994, TRENDS BIOCHEM SCI, V19, P236, DOI 10.1016/0968-0004(94)90147-3; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CARROLL RC, 1982, BLOOD, V59, P466; CHEN M, 1989, J BIOL CHEM, V264, P14282; DAVIES P, 1977, BIOCHEM BIOPH RES CO, V74, P300, DOI 10.1016/0006-291X(77)91408-5; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DOWNWARD J, 1994, NATURE, V371, P378, DOI 10.1038/371378a0; ERIKSON E, 1988, SEC MESS PHOSPHOPROT, V12, P135; FRESHNEY NW, 1994, CELL, V78, P1039, DOI 10.1016/0092-8674(94)90278-X; GORLIN JB, 1990, J CELL BIOL, V111, P1089, DOI 10.1083/jcb.111.3.1089; GROVE JR, 1993, BIOCHEMISTRY-US, V32, P7727, DOI 10.1021/bi00081a018; HARTWIG JH, 1981, J MOL BIOL, V145, P563, DOI 10.1016/0022-2836(81)90545-3; HARTWIG JH, 1991, J CELL BIOL, V112, P407, DOI 10.1083/jcb.112.3.407; Hartwig JH, 1991, CURR OPIN CELL BIOL, V3, P87, DOI 10.1016/0955-0674(91)90170-4; HOCK RS, 1990, BIOCHEMISTRY-US, V29, P9441, DOI 10.1021/bi00492a019; KAWAMOTO S, 1984, BIOCHEM BIOPH RES CO, V118, P736, DOI 10.1016/0006-291X(84)91456-6; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; NISHIDA E, 1993, TRENDS BIOCHEM SCI, V18, P128, DOI 10.1016/0968-0004(93)90019-J; OHTA Y, 1991, CELL, V67, P275, DOI 10.1016/0092-8674(91)90179-3; OHTA Y, 1988, J BIOL CHEM, V263, P11540; PAPKOFF J, 1994, MOL CELL BIOL, V14, P463, DOI 10.1128/MCB.14.1.463; PELECH SL, 1992, SCIENCE, V257, P1355, DOI 10.1126/science.1382311; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; SEFTON BM, 1981, CELL, V24, P165, DOI 10.1016/0092-8674(81)90512-2; SEGER R, 1994, J BIOL CHEM, V269, P25699; STOKOE D, 1993, BIOCHEM J, V296, P843, DOI 10.1042/bj2960843; UEDA M, 1992, EUR J BIOCHEM, V203, P347, DOI 10.1111/j.1432-1033.1992.tb16556.x; VANCORVEN EJ, 1989, CELL, V59, P45, DOI 10.1016/0092-8674(89)90868-4; WALLACH D, 1978, J BIOL CHEM, V253, P4739; YADA Y, 1990, BIOCHEM BIOPH RES CO, V172, P256, DOI 10.1016/S0006-291X(05)80202-5; YASUTAKA O, 1995, BIOCHEMISTRY-US, V34, P6745, DOI 10.1021/bi00020a020; ZHANG Z, 1988, BIOCHEM BIOPH RES CO, V151, P355, DOI 10.1016/0006-291X(88)90601-8	37	41	43	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 17	1996	271	20					11858	11864		10.1074/jbc.271.20.11858	http://dx.doi.org/10.1074/jbc.271.20.11858			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UL250	8662682	hybrid			2022-12-25	WOS:A1996UL25000045
J	Bocco, JL; Bahr, A; Goetz, J; Hauss, C; Kallunki, T; Kedinger, C; Chatton, B				Bocco, JL; Bahr, A; Goetz, J; Hauss, C; Kallunki, T; Kedinger, C; Chatton, B			In vivo association of ATFa with JNK/SAP kinase activities	ONCOGENE			English	Article						ATF; Jun; kinase; interaction	DNA-BINDING PROTEINS; RESPONSE ELEMENT; LEUCINE ZIPPER; CYCLIC-AMP; JUN; FAMILY; ACTIVATION; CELLS; CREB; PHOSPHORYLATION	The human ATFa proteins belong to the CREB/ATF family of transcription factors. We have previously shown that the ATFa proteins may contribute to the modulation of the transcriptional activity of the Jun/Fos complexes (Chatton ed al. (1994). Oncogene, 9, 375-385). We now show that a protein kinase activity is strongly associated with ATFa in vivo, as revealed by coimmunoprecipitation of ATFa/kinase complexes from whole cell extracts, with antibodies against ATFa. Two independent regions were found to be implicated in kinase binding: a major interaction site is located within the N-terminal 82 residues comprising an important metal-chelating element; a weaker binding site corresponds to the basic sequence element preceding the C-terminal leucine-zipper of ATFa. Induction experiments suggest that each of these ATFa domains may interact with different kinases. The major activity is associated with the ATFa N-terminal domain. Based on its response to various inducers, on both in vitro and in vivo binding assays, and on its immunological properties, this activity most likely corresponds to the 54/55 kDa JNK2 protein. Taken together, these observations suggest that the ATFa proteins, among other CREB/ATF proteins, may be important effecters of cell signalling pathways.	ULP,INST GENET & BIOL MOL & CELLULAIRE,INSERM,CNRS,F-67404 ILLKIRCH GRAFFENS,FRANCE; UNIV CALIF SAN DIEGO,DEPT PHARMACOL,CTR MOLEC GENET,PROGRAM BIOMED SCI,LA JOLLA,CA 92093	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); University of California System; University of California San Diego			CHATTON, Bruno/R-3813-2019	CHATTON, Bruno/0000-0003-4515-7119; Kallunki, Tuula/0000-0002-8571-383X; Bocco, Jose Luis/0000-0002-9682-1270				ABDELHAFIZ HA, 1992, MOL ENDOCRINOL, V6, P2079, DOI 10.1210/me.6.12.2079; ADLER V, 1992, J BIOL CHEM, V267, P17001; BASU M, 1984, NATURE, V311, P477, DOI 10.1038/311477a0; BENBROOK DM, 1990, ONCOGENE, V5, P295; BOCCO JL, 1993, ONCOGENE, V8, P2977; CANO E, 1995, TRENDS BIOCHEM SCI, V20, P117, DOI 10.1016/S0968-0004(00)88978-1; CHATTON B, 1993, MOL CELL BIOL, V13, P561, DOI 10.1128/MCB.13.1.561; CHATTON B, 1994, ONCOGENE, V9, P375; CHATTON B, 1995, BIOTECHNIQUES, V18, P142; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; COHEN P, 1988, METHOD ENZYMOL, V159, P390; DAI TN, 1995, ONCOGENE, V10, P849; DAVIS RJ, 1994, TRENDS BIOCHEM SCI, V19, P470, DOI 10.1016/0968-0004(94)90132-5; DENG TL, 1994, NATURE, V371, P171, DOI 10.1038/371171a0; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; FLINT KJ, 1991, ONCOGENE, V6, P2019; GAIRE M, 1990, NUCLEIC ACIDS RES, V18, P3467, DOI 10.1093/nar/18.12.3467; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; HAI T, 1991, P NATL ACAD SCI USA, V88, P3720, DOI 10.1073/pnas.88.9.3720; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; IVASHKIV LB, 1990, MOL CELL BIOL, V10, P1609, DOI 10.1128/MCB.10.4.1609; KALLUNKI T, 1994, GENE DEV, V8, P2996, DOI 10.1101/gad.8.24.2996; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; KIM SJ, 1992, NATURE, V358, P331, DOI 10.1038/358331a0; KOUZARIDES T, 1989, CANCER CELL-MON REV, V1, P71; KUMAR V, 1988, CELL, V55, P145, DOI 10.1016/0092-8674(88)90017-7; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LEE KAW, 1992, J CELL SCI, V103, P9; LIN YS, 1989, NATURE, V338, P39; LIU F, 1990, CELL, V61, P1217, DOI 10.1016/0092-8674(90)90686-9; LIVINGSTONE C, 1995, EMBO J, V14, P1785, DOI 10.1002/j.1460-2075.1995.tb07167.x; MACGREGOR PF, 1990, ONCOGENE, V5, P451; MAEKAWA T, 1991, ONCOGENE, V6, P627; PAPAVASSILIOU AG, 1995, EMBO J, V14, P2014, DOI 10.1002/j.1460-2075.1995.tb07193.x; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TARTAGLIA J, 1992, AIDS RES HUM RETROV, V8, P1445, DOI 10.1089/aid.1992.8.1445; VANDAM H, 1995, EMBO J, V14, P1798, DOI 10.1002/j.1460-2075.1995.tb07168.x; Wiktor T J, 1992, Biotechnology, V24, P508; YAN MH, 1994, NATURE, V372, P798	44	27	27	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY 2	1996	12	9					1971	1980						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UK498	8649858				2022-12-25	WOS:A1996UK49800016
J	Geng, Y; Eaton, EN; Picon, M; Roberts, JM; Lundberg, AS; Gifford, A; Sardet, C; Weinberg, RA				Geng, Y; Eaton, EN; Picon, M; Roberts, JM; Lundberg, AS; Gifford, A; Sardet, C; Weinberg, RA			Regulation of cyclin E transcription by E2Fs and retinoblastoma protein	ONCOGENE			English	Article						cell cycle; cyclin E transcription; E2F; retinoblastoma protein	CELL-CYCLE; DEPENDENT KINASES; BINDING PROTEIN; CDC2 GENE; EXPRESSION; REPRESSION; CLONING; PHOSPHORYLATION; TRANSACTIVATION; ASSOCIATION	Cyclin E is critical for the advance of cells through the G1 phase of their growth cycle. Transcription of the cyclin E gene is known to be cell cycle-dependent. We have shown previously that mRNA levels of cyclin E are regulated positively by mitogens and negatively by TGF-beta. Much circumstantial evidence implicates both E2F transcription factors and the retinoblastoma protein (pRB) in the control of cyclin E expression. However, the molecular basis of this control has remained unclear. We report here the cloning of the cyclin E promoter and the identification of several putative E2F binding sites within the promoter sequence. We have found that cell cycle regulation of cyclin E transcription is mediated by E2F binding sites present in the promoter. The activity of this promoter can be regulated negatively by pRB. Our results suggest the operation of a positive-feedback loop in late G1 that functions to ensure continued cyclin E expression and pRB inactivation.	WHITEHEAD INST BIOMED RES,CAMBRIDGE,MA 02142; MIT,DEPT BIOL,CAMBRIDGE,MA 02139; FRED HUTCHINSON CANC RES CTR,DEPT BASIC SCI,SEATTLE,WA 98104; DANA FARBER CANC INST,BOSTON,MA 02115	Massachusetts Institute of Technology (MIT); Whitehead Institute; Massachusetts Institute of Technology (MIT); Fred Hutchinson Cancer Center; Harvard University; Dana-Farber Cancer Institute					NCI NIH HHS [R35-CA39826] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R35CA039826] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALMASAN A, 1995, P NATL ACAD SCI USA, V92, P5436, DOI 10.1073/pnas.92.12.5436; BANDARA LR, 1993, EMBO J, V12, P4317, DOI 10.1002/j.1460-2075.1993.tb06116.x; BEIJERSBERGEN RL, 1994, GENE DEV, V8, P2680, DOI 10.1101/gad.8.22.2680; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; COBRINIK D, 1993, GENE DEV, V7, P2392, DOI 10.1101/gad.7.12a.2392; DALTON S, 1992, EMBO J, V11, P1797, DOI 10.1002/j.1460-2075.1992.tb05231.x; DEGREGORI J, 1995, MOL CELL BIOL, V15, P4215; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; DURONIO RJ, 1995, GENE DEV, V9, P1456, DOI 10.1101/gad.9.12.1456; FARNHAM PJ, 1993, BIOCHIM BIOPHYS ACTA, V1155, P125, DOI 10.1016/0304-419X(93)90001-S; FESQUET D, 1993, EMBO J, V12, P3111, DOI 10.1002/j.1460-2075.1993.tb05980.x; GENG Y, 1993, P NATL ACAD SCI USA, V90, P10315, DOI 10.1073/pnas.90.21.10315; GINSBERG D, 1994, GENE DEV, V8, P2665, DOI 10.1101/gad.8.22.2665; GU Y, 1992, EMBO J, V11, P3995, DOI 10.1002/j.1460-2075.1992.tb05493.x; HAMEL PA, 1992, MOL CELL BIOL, V12, P3431, DOI 10.1128/MCB.12.8.3431; HAMEL PA, 1992, ONCOGENE, V7, P693; HARVEY RJ, 1991, NUCLEIC ACIDS RES, V19, P4002, DOI 10.1093/nar/19.14.4002; HATAKEYAMA M, 1994, GENE DEV, V8, P1759, DOI 10.1101/gad.8.15.1759; HELIN K, 1993, GENE DEV, V7, P1850, DOI 10.1101/gad.7.10.1850; HELIN K, 1992, CELL, V70, P337, DOI 10.1016/0092-8674(92)90107-N; HELIN K, 1993, MOL CELL BIOL, V13, P6501, DOI 10.1128/MCB.13.10.6501; HERRERA RE, 1995, UNPUB; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; HSIAO KM, 1994, GENE DEV, V8, P1526, DOI 10.1101/gad.8.13.1526; HUBER HE, 1993, P NATL ACAD SCI USA, V90, P3525, DOI 10.1073/pnas.90.8.3525; IVEYHOYLE M, 1993, MOL CELL BIOL, V13, P7802, DOI 10.1128/MCB.13.12.7802; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; KOFF A, 1991, CELL, V66, P1217, DOI 10.1016/0092-8674(91)90044-Y; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; LAM EWF, 1993, EMBO J, V12, P2705, DOI 10.1002/j.1460-2075.1993.tb05932.x; LATHANGUE NB, 1994, TRENDS BIOCHEM SCI, V19, P108, DOI 10.1016/0968-0004(94)90202-X; LEES JA, 1993, MOL CELL BIOL, V13, P7813, DOI 10.1128/MCB.13.12.7813; LEW DJ, 1991, CELL, V66, P1197, DOI 10.1016/0092-8674(91)90042-W; LUKAS J, 1995, MOL CELL BIOL, V15, P2600; NEUMAN E, 1994, MOL CELL BIOL, V14, P6607, DOI 10.1128/MCB.14.10.6607; NEVINS JR, 1992, SCIENCE, V258, P424; OHTSUBO M, 1995, MOL CELL BIOL, V15, P2612; OHTSUBO M, 1993, SCIENCE, V259, P1908, DOI 10.1126/science.8384376; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; RESNITZKY D, 1995, MOL CELL BIOL, V15, P3463; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; Sambrook J., 1989, MOL CLONING; SARDET C, 1995, P NATL ACAD SCI USA, V92, P2403, DOI 10.1073/pnas.92.6.2403; SHAN B, 1992, MOL CELL BIOL, V12, P5620, DOI 10.1128/MCB.12.12.5620; SLINGERLAND JM, 1994, MOL CELL BIOL, V14, P3683, DOI 10.1128/MCB.14.6.3683; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; VAIRO G, 1995, GENE DEV, V9, P869, DOI 10.1101/gad.9.7.869; VANDENHEUVEL S, 1993, SCIENCE, V262, P2050, DOI 10.1126/science.8266103; ZHU L, 1993, GENE DEV, V7, P1111, DOI 10.1101/gad.7.7a.1111	50	360	372	0	17	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR 21	1996	12	6					1173	1180						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UC067	8649818				2022-12-25	WOS:A1996UC06700001
J	Hagmeyer, BM; Duyndam, MCA; Angel, P; deGroot, RP; Verlaan, M; Elfferich, P; vanderEb, AJ; Zantema, A				Hagmeyer, BM; Duyndam, MCA; Angel, P; deGroot, RP; Verlaan, M; Elfferich, P; vanderEb, AJ; Zantema, A			Altered AP-1/ATF complexes in adenovirus-E1-transformed cells due to E1A-dependent induction of ATF3	ONCOGENE			English	Article						LRF1; ATF; cJun; E1A	TRANSCRIPTION FACTOR E2F; JUN PROTO-ONCOGENE; C-JUN; DNA-BINDING; HETERODIMER FORMATION; RESPONSE ELEMENT; UP-REGULATION; E1A; PROTEINS; CREB	The adenovirus (Ad) E1A proteins alter the expression level and activity of AP-1/ATF transcription factors. Previously we have shown that in AdE1-transformed cells cJun is hyperphosphorylated in its N-terminal transactivation domain, which parallels enhanced transactivation function. To find out whether the interaction between cJun and other cellular proteins is altered, we have searched for proteins which would physically associate with cJun. In this report we show that in AdE1-transformed cells cJun specifically associates with two proteins of 21 and 23 kD. These proteins are not expressed at detectable levels in the parental cells or in cells transformed by oncogenes other than AdE1. The cJun-associated proteins represent different forms of the bZIP transcription factor ATF3, the human homolog of rat LRF1. The expression of ATF3 is induced in AdE1-transformed cells and is a direct effect of the expression of E1A. Through induction of ATF3 expression and the subsequent formation of cJun/ATF3 heterodimers, E1A alters the repertoire of AP-1/ATF factors and may thereby redirect the corresponding gene-expression program. Since the induction of ATF3 is a function of sequences within the transforming 12S-E1A protein, cJun/ATF3 complexes might be involved in establishing cellular transformation by AdE1A.	FORSCHUNGSZENTRUM KARLSRUHE, INST GENET, D-76021 KARLSRUHE, GERMANY; LEIDEN UNIV, MOLEC CARCINOGENESIS LAB, 2300 RA LEIDEN, NETHERLANDS	Helmholtz Association; Karlsruhe Institute of Technology; Leiden University; Leiden University - Excl LUMC			Piris, Miguel A/AAP-1445-2020	Piris, Miguel A/0000-0001-5839-3634				ANGEL P, 1988, CELL, V55, P875, DOI 10.1016/0092-8674(88)90143-2; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; BENBROOK DM, 1990, ONCOGENE, V5, P295; BINETRUY B, 1991, NATURE, V351, P122, DOI 10.1038/351122a0; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BURATOWSKI S, 1989, CELL, V56, P549, DOI 10.1016/0092-8674(89)90578-3; CAO L, 1992, NATURE, V355, P176, DOI 10.1038/355176a0; CARTER R, 1991, ONCOGENE, V6, P229; CHEN BPC, 1994, J BIOL CHEM, V269, P15819; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHU HM, 1994, MOL ENDOCRINOL, V8, P59, DOI 10.1210/me.8.1.59; COBRINIK D, 1993, GENE DEV, V7, P2392, DOI 10.1101/gad.7.12a.2392; DEGROOT R, 1991, MOL CELL BIOL, V11, P192, DOI 10.1128/MCB.11.1.192; DEVOTO SH, 1992, CELL, V68, P167, DOI 10.1016/0092-8674(92)90215-X; DYSON N, 1992, CANCER SURV, V12, P161; GREEN S, 1988, NUCLEIC ACIDS RES, V16, P369, DOI 10.1093/nar/16.1.369; HAGMEYER BM, 1993, EMBO J, V12, P3559, DOI 10.1002/j.1460-2075.1993.tb06030.x; HAGMEYER BM, 1995, BIOESSAYS, V17, P621, DOI 10.1002/bies.950170708; HAI T, 1991, P NATL ACAD SCI USA, V88, P3720, DOI 10.1073/pnas.88.9.3720; HAI TW, 1989, GENE DEV, V3, P2083, DOI 10.1101/gad.3.12b.2083; HERR I, 1994, CARCINOGENESIS, V15, P1105, DOI 10.1093/carcin/15.6.1105; HOEFFLER JP, 1992, J INVEST DERMATOL, V98, pS21, DOI 10.1111/1523-1747.ep12462126; HSU JC, 1993, CANCER RES, V53, P3789; HSU JC, 1992, MOL CELL BIOL, V12, P4654, DOI 10.1128/MCB.12.10.4654; HSU JC, 1991, P NATL ACAD SCI USA, V88, P3511, DOI 10.1073/pnas.88.9.3511; IVASHKIV LB, 1990, MOL CELL BIOL, V10, P1609, DOI 10.1128/MCB.10.4.1609; KITABAYASHI I, 1991, NUCLEIC ACIDS RES, V19, P649, DOI 10.1093/nar/19.3.649; LAMPH WW, 1988, NATURE, V334, P629, DOI 10.1038/334629a0; MEYER TE, 1993, ENDOCR REV, V14, P269, DOI 10.1210/er.14.3.269; OFFRINGA R, 1990, CELL, V62, P527, DOI 10.1016/0092-8674(90)90017-9; QUANTIN B, 1988, NATURE, V334, P538, DOI 10.1038/334538a0; RUDNICKI MA, 1992, CELL, V71, P383, DOI 10.1016/0092-8674(92)90508-A; RYDER K, 1988, P NATL ACAD SCI USA, V85, P8464, DOI 10.1073/pnas.85.22.8464; SCHOLER H, 1986, SCIENCE, V232, P76, DOI 10.1126/science.3006253; SCHRIER PI, 1983, NATURE, V305, P771, DOI 10.1038/305771a0; SHIRODKAR S, 1992, CELL, V68, P157, DOI 10.1016/0092-8674(92)90214-W; VANDAM H, 1990, MOL CELL BIOL, V10, P5857, DOI 10.1128/MCB.10.11.5857; VANDAM H, 1993, EMBO J, V12, P479, DOI 10.1002/j.1460-2075.1993.tb05680.x; VANDEREB AJ, 1992, MALIGNANT TRANSFORMA, P115	39	25	25	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 7	1996	12	5					1025	1032						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UA884	8649793				2022-12-25	WOS:A1996UA88400010
J	Wyllie, FS; Haughton, MF; Bond, JA; Rowson, JM; Jones, CJ; WynfordThomas, D				Wyllie, FS; Haughton, MF; Bond, JA; Rowson, JM; Jones, CJ; WynfordThomas, D			S phase cell-cycle arrest following DNA damage is independent of the p53/p21(WAF1) signalling pathway	ONCOGENE			English	Article						p53; p21(WAF-1); SDI1; CIP1; S phase; checkpoint	ATAXIA-TELANGIECTASIA; P53; REPLICATION; PROTEIN; CHECKPOINT; BLEOMYCIN; KINASES; CANCER	It is now likely that the cyclin-kinase inhibitor, p21(WAF1/SDI1), is,key effector of p53-mediated cell-cycle arrest at the G(1)/S checkpoint following DNA damage. More recently, however, in vitro data has suggested that this pathway may also mediate the acute inhibition of DNA synthesis seen in cells already in S phase. Here we address this question in an intact cell system using normal human diploid fibroblasts in which p53 function is manipulated by expression mutant (ala(143)) introduced vector. Induction of DNA strand breaks in normal control fibroblasts by exposure to bleomycin led as expected to G(1)/S cell cycle arrest, induction of p21(WAF1) and a rapid reduction in the rate of DNA synthesis in cells already in S phase. Stable expression of mutant p53 abrogated the G(1)/S (but not the G(1)/M) cell cycle checkpoint and abolished the induction of p21(WAF1), but had no significant effect on the inhibition of DNA replication in S phase nuclei. We conclude that, despite the in vitro evidence for inhibitory activity on PCNA/polymerase delta, p21(WAF1) induction does not appear to be essential for the acute inhibition of DNA synthesis in the intact cell following strand-break damage in S phase.	UNIV WALES COLL MED,DEPT PATHOL,CRC THYROID TUMOUR BIOL GRP,CARDIFF CF4 4XN,S GLAM,WALES	Cardiff University				Jones, Christopher/0000-0002-5447-8187				BOND JA, 1994, ONCOGENE, V9, P1885; CANMAN CE, 1994, CANCER RES, V54, P5054; CLEAVER JE, 1992, RADIAT RES, V131, P338, DOI 10.2307/3578425; CRAMER P, 1981, NATURE, V291, P671, DOI 10.1038/291671a0; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; HARPER JW, 1995, MOL BIOL CELL, V6, P387, DOI 10.1091/mbc.6.4.387; HARPER JW, 1993, CELL, V75, P805; HARTWELL L, 1992, CELL, V71, P543, DOI 10.1016/0092-8674(92)90586-2; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; KASTAN MB, 1991, CANCER RES, V51, P6304; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LAMB JR, 1989, INT J RADIAT BIOL, V56, P125, DOI 10.1080/09553008914551271; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LARNER JM, 1994, MOL CELL BIOL, V14, P1901, DOI 10.1128/MCB.14.3.1901; LI R, 1994, NATURE, V371, P534, DOI 10.1038/371534a0; LI R, 1994, ONCOGENE, V9, P2261; NAKANISHI M, 1995, J BIOL CHEM, V270, P17060, DOI 10.1074/jbc.270.29.17060; NAVAS TA, 1995, CELL, V80, P29, DOI 10.1016/0092-8674(95)90448-4; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; PAINTER RB, 1980, P NATL ACAD SCI-BIOL, V77, P7315, DOI 10.1073/pnas.77.12.7315; PINES J, 1994, NATURE, V369, P520, DOI 10.1038/369520a0; POVIRK LF, 1991, MUTAT RES, V257, P127, DOI 10.1016/0165-1110(91)90022-N; SHIVJI MKK, 1994, CURR BIOL, V4, P1062, DOI 10.1016/S0960-9822(00)00244-X; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; WAGA S, 1994, NATURE, V369, P207, DOI 10.1038/369207a0; WALTERS RA, 1975, BIOCHEM BIOPH RES CO, V65, P265, DOI 10.1016/S0006-291X(75)80088-X; WRIGHT PA, 1991, ONCOGENE, V6, P1693; WYLLIE FS, 1993, MOL CARCINOGEN, V7, P83, DOI 10.1002/mc.2940070205; WYLLIE FS, 1995, ONCOGENE, V10, P49; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H	32	38	38	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR 7	1996	12	5					1077	1082						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UA884	8649799				2022-12-25	WOS:A1996UA88400016
J	BrownAugsburger, P; Hartshorn, K; Chang, D; Rust, K; Fliszar, C; Welgus, HG; Crouch, EC				BrownAugsburger, P; Hartshorn, K; Chang, D; Rust, K; Fliszar, C; Welgus, HG; Crouch, EC			Site-directed mutagenesis of Cys-15 and Cys-20 of pulmonary surfactant protein D - Expression of a trimeric protein with altered anti-viral properties	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INFLUENZA-A VIRUSES; ALVEOLAR MACROPHAGES; HUMAN NEUTROPHIL; DOMAIN; CELLS; LOCALIZATION; PURIFICATION; LECTINS; CLONING; OPSONIN	Surfactant protein D (SP-D) molecules are preferentially assembled as dodecamers consisting of trimeric subunits associated at their amino termini, The NH2-terminal sequence of each monomer contains two conserved cysteine residues, which participate In interchain disulfide bonds, In order tea study the roles of these residues in SP-D assembly and function, we employed site-directed mutagenesis to substitute serine for cysteine 15 and 20 in recombinant rat SP-D (RsSP-D), lad have expressed the mutant (RrSP-Dser15/20) in Chinese hamster ovary (CRO-RP) cells, The mutant, which was efficiently secreted, bound to maltosyl-agarose, but unlike RrSP-D, was assembled exclusively as trimers. The constituent monomers showed a decreased mobility on SDS-polyacrylamide gel electrophoresis resulting from an increase in the size and sialylation of the N-linked oligosaccharide at Asn-70. Although RrSP-Dser15/20 contained a pepsin-resistant triple helical domain, it showed a decreased T-m, and acquired susceptibility to proteolytic degradation, Like RrSP-D, RrSP-Dser15/20 hound to the hemagglutinin of influenza A. However, it showed no viral aggregation and did not enhance the binding of influenza A to neutrophils (PMN), augment PMN respiratory burst, or protect PMNs from deactivation, These studies indicate that amino-terminal disulfides are required to stabilize dodecamers, and support our hypothesis that the oligomerization of trimeric subunits contributes to the anti-microbial properties of SP-D.	WASHINGTON UNIV,SCH MED,DEPT PATHOL,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DIV DERMATOL,ST LOUIS,MO 63110; BOSTON UNIV,SCH MED,DEPT MED,BOSTON,MA 02118; BOSTON UNIV,SCH MED,DEPT PATHOL,BOSTON,MA 02118	Washington University (WUSTL); Washington University (WUSTL); Boston University; Boston University				Hartshorn, Kevan/0000-0002-7196-7433	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL029594, R01HL044015] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR035805] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL29594, HL44015] Funding Source: Medline; NIAMS NIH HHS [AR35805] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ANDERS EM, 1990, P NATL ACAD SCI USA, V87, P4485, DOI 10.1073/pnas.87.12.4485; AUSUBEL RA, 1992, CURRENT PROTOCOLS MO; COCKETT MI, 1990, BIO-TECHNOL, V8, P662, DOI 10.1038/nbt0790-662; CROUCH E, 1994, J BIOL CHEM, V269, P17311; CROUCH E, 1992, AM J PHYSIOL, V263, pL60, DOI 10.1152/ajplung.1992.263.1.L60; CROUCH E, 1993, J BIOL CHEM, V268, P2976; CROUCH E, 1994, J BIOL CHEM, V269, P15808; CROUCH EC, 1995, AM J RESP CELL MOL, V12, P410, DOI 10.1165/ajrcmb.12.4.7695920; ENGEL J, 1991, ANNU REV BIOPHYS BIO, V20, P137, DOI 10.1146/annurev.biophys.20.1.137; HARTSHORN KL, 1993, J IMMUNOL, V151, P6265; HARTSHORN KL, 1988, J IMMUNOL, V141, P1295; Hartshorn KL, 1996, BLOOD, V87, P3450, DOI 10.1182/blood.V87.8.3450.bloodjournal8783450; HARTSHORN KL, 1994, J CLIN INVEST, V94, P311, DOI 10.1172/JCI117323; HARTSHORN KL, 1993, J CLIN INVEST, V91, P1414, DOI 10.1172/JCI116345; HARTSHORN KL, 1990, BLOOD, V75, P218; HOLMSKOV U, 1995, BIOCHEM J, V305, P889, DOI 10.1042/bj3050889; HOPPE HJ, 1994, FEBS LETT, V344, P191, DOI 10.1016/0014-5793(94)00383-1; HORTON RM, 1993, METHOD ENZYMOL, V217, P270; KUAN SF, 1992, J CLIN INVEST, V90, P97, DOI 10.1172/JCI115861; LIM BL, 1994, J BIOL CHEM, V269, P11820; LU JH, 1992, BIOCHEM J, V284, P795, DOI 10.1042/bj2840795; LU JH, 1993, EUR J BIOCHEM, V215, P793, DOI 10.1111/j.1432-1033.1993.tb18094.x; MIYAMURA K, 1994, BIOCHEM J, V300, P237, DOI 10.1042/bj3000237; OGASAWARA Y, 1995, J BIOL CHEM, V270, P19052, DOI 10.1074/jbc.270.32.19052; Olsen BR, 1991, CELL BIOL EXTRACELLU, P177; ORIORDAN DM, 1995, J CLIN INVEST, V95, P2699, DOI 10.1172/JCI117972; PERSSON A, 1989, BIOCHEMISTRY-US, V28, P6361, DOI 10.1021/bi00441a031; PERSSON A, 1988, BIOCHEMISTRY-US, V27, P8576, DOI 10.1021/bi00423a011; REID KBM, 1993, BIOCHEM SOC T, V21, P464, DOI 10.1042/bst0210464; RUST K, 1991, ARCH BIOCHEM BIOPHYS, V290, P116, DOI 10.1016/0003-9861(91)90597-C; SAARINEN J, 1994, J BIOL CHEM, V269, P18134; SHAPIRO SD, 1993, J BIOL CHEM, V268, P23824; SHAPIRO SD, 1995, J BIOL CHEM, V270, P6351, DOI 10.1074/jbc.270.11.6351; SHIMIZU H, 1992, J BIOL CHEM, V267, P1853; SIRES UI, 1994, BIOCHEM BIOPH RES CO, V204, P613, DOI 10.1006/bbrc.1994.2503; SPISSINGER T, 1991, EUR J BIOCHEM, V199, P65, DOI 10.1111/j.1432-1033.1991.tb16092.x; VOORHOUT WF, 1992, J HISTOCHEM CYTOCHEM, V40, P1589, DOI 10.1177/40.10.1527377; WEIS WI, 1991, SCIENCE, V254, P1608, DOI 10.1126/science.1721241; WEIS WI, 1994, STRUCTURE, V2, P1227, DOI 10.1016/S0969-2126(94)00124-3; WENSTRUP RJ, 1991, J BIOL CHEM, V266, P2590	40	86	87	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 7	1996	271	23					13724	13730		10.1074/jbc.271.23.13724	http://dx.doi.org/10.1074/jbc.271.23.13724			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UP385	8662732	hybrid			2022-12-25	WOS:A1996UP38500064
J	Sorkin, A; Mazzotti, M; Sorkina, T; Scotto, L; Beguinot, L				Sorkin, A; Mazzotti, M; Sorkina, T; Scotto, L; Beguinot, L			Epidermal growth factor receptor interaction with clathrin adaptors is mediated by the Tyr(974)-containing internalization motif	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LYSOSOMAL ACID-PHOSPHATASE; LIGAND-INDUCED INTERNALIZATION; HUMAN-FIBROBLASTS; DOWN-REGULATION; COATED PITS; ENDOCYTIC SYSTEM; INVITRO BINDING; KINASE-ACTIVITY; EGF RECEPTOR; DEGRADATION	The carboxyl-terminal regulatory domain of the epidermal growth factor (EGF) receptor is essential for its endocytosis and interaction with the clathrin-associated protein complex AP-2. To identify AP-2 binding motif in the receptor, several single and multiple-point mutations within the region between residues 966 and 977 of the human EGF receptor were made, and the mutant receptors were expressed in NIH3T3 cells. Mutation of tyrosine 974 alone or together with surrounding residues and the deletion of residues 973-975 essentially eliminated AP-2 co-immunoprecipitation with the EGF receptor, Furthermore, a synthetic peptide corresponding to receptor residues 964-978 blocked AP-2 association with the wild-type EGF receptor, These data suggest that AP-2 has only one high-affinity binding site in the EGF receptor composed of Tyr(974)-containing motif. Receptor mutants that did not bind AP-2 displayed a lower rate of internalization, down-regulation, and turnover compared to wild type receptors when expressed at high levels. However, similar receptor mutants expressed at low levels were internalized and down-regulated as efficiently as wild type receptors, Internalization of the mutant receptors lacking the high-affinity binding site for AP-2 was inhibited by K+-depletion of the cells, indicating that their endocytosis required intact coated pits, We suggest that whereas one mechanism of EGF receptor recruitment into coated pits involves high-affinity binding of AP-2 to Tyr(974)-containing motif, another pathway may be mediated by weak receptor/AP-2 interactions or by proteins other than AP-2.	HOSP SAN RAFFAELE, MOLEC ONCOL LAB, DIBIT, I-20132 MILAN, ITALY; HOSP SAN RAFFAELE, CNR, INST NEUROSCI & BIOMMAGINI, I-20132 MILAN, ITALY	Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; Consiglio Nazionale delle Ricerche (CNR); Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele	Sorkin, A (corresponding author), UNIV COLORADO, HLTH SCI CTR, DEPT PHARMACOL, 4200 E 9TH AVE, DENVER, CO 80262 USA.			Sorkin, Alexander/0000-0002-4446-1920	NIDDK NIH HHS [DK46817] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK046817] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BEGUINOT L, 1984, P NATL ACAD SCI-BIOL, V81, P2384, DOI 10.1073/pnas.81.8.2384; BELTZER JP, 1991, EMBO J, V10, P3735, DOI 10.1002/j.1460-2075.1991.tb04942.x; BOLL W, 1995, CURR BIOL, V5, P1168, DOI 10.1016/S0960-9822(95)00233-8; CARPENTER G, 1976, J CELL BIOL, V71, P159, DOI 10.1083/jcb.71.1.159; CHANG CP, 1993, J BIOL CHEM, V268, P19312; CHEN WS, 1989, CELL, V59, P33, DOI 10.1016/0092-8674(89)90867-2; CHIN DJ, 1989, P NATL ACAD SCI USA, V86, P9289, DOI 10.1073/pnas.86.23.9289; CUPERS P, 1994, J CELL BIOL, V127, P725, DOI 10.1083/jcb.127.3.725; FELDER S, 1992, J CELL BIOL, V117, P203, DOI 10.1083/jcb.117.1.203; FRENCH AR, 1994, J BIOL CHEM, V269, P15749; GILBOA L, 1995, J BIOL CHEM, V270, P7061, DOI 10.1074/jbc.270.13.7061; GLENNEY JR, 1988, CELL, V52, P675, DOI 10.1016/0092-8674(88)90405-9; GLICKMAN JN, 1989, EMBO J, V8, P1041, DOI 10.1002/j.1460-2075.1989.tb03471.x; GORDEN P, 1978, P NATL ACAD SCI USA, V75, P5025, DOI 10.1073/pnas.75.10.5025; HAIGLER HT, 1979, J CELL BIOL, V81, P382, DOI 10.1083/jcb.81.2.382; HANOVER JA, 1984, CELL, V39, P283, DOI 10.1016/0092-8674(84)90006-0; HELIN K, 1991, ONCOGENE, V6, P825; HELIN K, 1991, J BIOL CHEM, V266, P8363; HIGUSHI R, 1990, PCR PROTOCOLS GUIDE, P173; HILLE A, 1992, EUR J CELL BIOL, V59, P106; HOPKINS CR, 1983, J CELL BIOL, V97, P508, DOI 10.1083/jcb.97.2.508; LAMAZE C, 1993, MOL BIOL CELL, V4, P715, DOI 10.1091/mbc.4.7.715; LAMAZE C, 1995, J CELL BIOL, V129, P47, DOI 10.1083/jcb.129.1.47; LARKIN JM, 1983, CELL, V33, P273, DOI 10.1016/0092-8674(83)90356-2; LEHMANN LE, 1992, EMBO J, V11, P4391, DOI 10.1002/j.1460-2075.1992.tb05539.x; LUND KA, 1990, J BIOL CHEM, V265, P15713; MILOSO M, 1995, J BIOL CHEM, V270, P19557, DOI 10.1074/jbc.270.33.19557; NESTEROV A, 1995, P NATL ACAD SCI USA, V92, P8719, DOI 10.1073/pnas.92.19.8719; NESTEROV A, 1995, J BIOL CHEM, V270, P6320, DOI 10.1074/jbc.270.11.6320; OHNO H, 1995, SCIENCE, V269, P1872, DOI 10.1126/science.7569928; OPRESKO LK, 1995, J BIOL CHEM, V270, P4325, DOI 10.1074/jbc.270.9.4325; PEARSE BMF, 1990, ANNU REV CELL BIOL, V6, P151, DOI 10.1146/annurev.cb.06.110190.001055; PEARSE BMF, 1988, EMBO J, V7, P3331, DOI 10.1002/j.1460-2075.1988.tb03204.x; ROBINSON MS, 1994, CURR OPIN CELL BIOL, V6, P538, DOI 10.1016/0955-0674(94)90074-4; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SMYTHE E, 1992, J CELL BIOL, V119, P1163, DOI 10.1083/jcb.119.5.1163; SORKIN A, 1992, J BIOL CHEM, V267, P8672; SORKIN A, 1995, J BIOL CHEM, V270, P619, DOI 10.1074/jbc.270.2.619; SORKIN A, 1993, SCIENCE, V261, P612, DOI 10.1126/science.8342026; SORKIN A, 1993, BIOESSAYS, V15, P375, DOI 10.1002/bies.950150603; SOSA MA, 1993, J BIOL CHEM, V268, P12537; STOSCHECK CM, 1984, J CELL BIOL, V98, P1048, DOI 10.1083/jcb.98.3.1048; TAYLOR JW, 1985, NUCLEIC ACIDS RES, V13, P8765; THOMAS DC, 1994, J BIOL CHEM, V269, P15732; TROWBRIDGE IS, 1993, ANNU REV CELL BIOL, V9, P129, DOI 10.1146/annurev.cb.09.110193.001021; VELU TJ, 1989, MOL CELL BIOL, V9, P1772, DOI 10.1128/MCB.9.4.1772; WATERS CM, 1992, J CELL PHYSIOL, V152, P253, DOI 10.1002/jcp.1041520206; WILEY HS, 1988, J CELL BIOL, V107, P801, DOI 10.1083/jcb.107.2.801; WILEY HS, 1991, J BIOL CHEM, V266, P11083	49	136	139	2	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 7	1996	271	23					13377	13384		10.1074/jbc.271.23.13377	http://dx.doi.org/10.1074/jbc.271.23.13377			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UP385	8662849	hybrid			2022-12-25	WOS:A1996UP38500014
J	Rosenberger, SF; Bowden, GT				Rosenberger, SF; Bowden, GT			Okadaic acid stimulated TRE binding activity in a papilloma producing mouse keratinocyte cell line involves increased AP-1 expression	ONCOGENE			English	Article						okadaic acid; tumor promotion; AP-1; TRE binding; mouse keratinocytes	TUMOR PROMOTER; PROTEIN PHOSPHATASES; GENE-EXPRESSION; C-JUN; PHORBOL ESTERS; FOS; ACTIVATION; INDUCTION; ONCOGENE; PHOSPHORYLATION	The effects of the non-phorbol ester type tumor promoter okadaic acid, a serine-threonine phosphatase inhibitor, on activator protein 1 (AP-1) DNA binding activity were studied in papilloma producing 308 mouse keratinocytes. Okadaic acid increased AP-1 binding to a consensus TPA responsive element (TRE) within 2 h; maximum stimulation was observed at 6 h followed by a gradual decrease to basal levels within 24 h, Jun B, Jun D and Fos B proteins were identified as the major components of the AP-1 complex binding to the TRE element at 6 h, Inhibition of transcription with actinomycin D and inhibition of protein synthesis with cycloheximide abrogated the okadaic acid effect on AP-1 DNA binding, indicating that transcription and translation are required for okadaic acid increased TRE binding activity, Northern and Western blot analyses revealed a correlation between increased AP-1 binding activity and accumulation of jun B, jun D and fos B mRNAs and proteins, These data suggest increased AP-1 expression as principal mechanism of okadaic acid stimulated AP-1 activation in the mouse keratinocytes studied.			Rosenberger, SF (corresponding author), UNIV ARIZONA,HLTH SCI CTR,DEPT RADIAT ONCOL,1501 N CAMPBELL AVE,TUCSON,AZ 85724, USA.				NATIONAL CANCER INSTITUTE [R01CA040584] Funding Source: NIH RePORTER; NCI NIH HHS [CA 40584] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABATE C, 1990, SCIENCE, V249, P1157, DOI 10.1126/science.2118682; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; ANGEL P, 1988, NATURE, V332, P166, DOI 10.1038/332166a0; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; AUWERX J, 1991, CELL, V64, P983, DOI 10.1016/0092-8674(91)90322-P; BERNSTEIN LR, 1992, MOL CARCINOGEN, V6, P221, DOI 10.1002/mc.2940060308; BIALOJAN C, 1988, BIOCHEM J, V256, P283, DOI 10.1042/bj2560283; BROOKS JW, 1995, MOL IMMUNOL, V32, P779, DOI 10.1016/0161-5890(95)00055-J; CARTER R, 1994, ONCOGENE, V9, P2675; CHIU R, 1987, NATURE, V329, P648, DOI 10.1038/329648a0; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COFFER P, 1994, ONCOGENE, V9, P911; COSENZA SC, 1994, J CELL BIOCHEM, V55, P503, DOI 10.1002/jcb.240550410; DATTA R, 1991, CELL GROWTH DIFFER, V2, P43; DICKINSON JA, 1995, CELL IMMUNOL, V165, P92, DOI 10.1006/cimm.1995.1191; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DOMANN FE, 1994, CELL GROWTH DIFFER, V5, P9; DOMANN FE, 1994, MOL CARCINOGEN, V9, P61, DOI 10.1002/mc.2940090202; DONG ZG, 1995, INT J ONCOL, V7, P359; DONG ZG, 1994, P NATL ACAD SCI USA, V91, P609, DOI 10.1073/pnas.91.2.609; FLEISCHMAN LF, 1993, ONCOGENE, V8, P771; GROVERBARDWICK A, 1994, CARCINOGENESIS, V15, P1667, DOI 10.1093/carcin/15.8.1667; GRUDA MC, 1994, ONCOGENE, V9, P2537; HABY C, 1994, BIOCHEM PHARMACOL, V48, P819, DOI 10.1016/0006-2952(94)90061-2; HAYSTEAD TAJ, 1989, NATURE, V337, P78, DOI 10.1038/337078a0; HOLLADAY K, 1992, MOL CARCINOGEN, V5, P16, DOI 10.1002/mc.2940050106; HONKANEN RE, 1991, J BIOL CHEM, V266, P6614; IMBRA RJ, 1987, MOL CELL BIOL, V7, P1358, DOI 10.1128/MCB.7.4.1358; JONAT C, 1990, CELL, V62, P1189, DOI 10.1016/0092-8674(90)90395-U; KARIN M, 1994, CURR OPIN CELL BIOL, V6, P415, DOI 10.1016/0955-0674(94)90035-3; KIM SJ, 1990, CELL REGUL, V1, P269, DOI 10.1091/mbc.1.3.269; KOVARY K, 1991, MOL CELL BIOL, V11, P4466, DOI 10.1128/MCB.11.9.4466; LEE JS, 1994, J BIOL CHEM, V269, P2887; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MONTECLARO FS, 1993, P NATL ACAD SCI USA, V90, P6726, DOI 10.1073/pnas.90.14.6726; MURATA M, 1982, B JPN SOC SCI FISH, V48, P549; NAKAMURA T, 1991, CELL GROWTH DIFFER, V2, P267; NIKOLAKAKI E, 1993, ONCOGENE, V8, P833; PAI SR, 1994, ANTICANCER RES, V14, P985; REZZONICO R, 1995, ONCOGENE, V11, P1069; RIECKMANN P, 1992, BIOCHEM BIOPH RES CO, V187, P51, DOI 10.1016/S0006-291X(05)81457-3; RYDER K, 1988, P NATL ACAD SCI USA, V85, P1487, DOI 10.1073/pnas.85.5.1487; RYSECK RP, 1991, ONCOGENE, V6, P533; SASSA T, 1989, BIOCHEM BIOPH RES CO, V159, P939, DOI 10.1016/0006-291X(89)92199-2; SCHONTHAL A, 1991, ONCOGENE, V6, P423; SMITH MJ, 1992, BLOOD, V79, P2107; STRICKLAND JE, 1988, CANCER RES, V48, P165; SUGANUMA M, 1988, P NATL ACAD SCI USA, V85, P1768, DOI 10.1073/pnas.85.6.1768; TACHIBANA K, 1981, J AM CHEM SOC, V103, P2469, DOI 10.1021/ja00399a082; TANGUAY DA, 1994, CELL IMMUNOL, V158, P281, DOI 10.1006/cimm.1994.1276; THEVENIN C, 1991, J BIOL CHEM, V266, P9363; TSO JY, 1985, NUCLEIC ACIDS RES, V13, P2485, DOI 10.1093/nar/13.7.2485; WESTERMARCK J, 1994, CELL GROWTH DIFFER, V5, P1205; WU WS, 1992, ONCOGENE, V7, P2287; YOSHIOKA K, 1995, P NATL ACAD SCI USA, V92, P4972, DOI 10.1073/pnas.92.11.4972; YOZA BK, 1992, CELL GROWTH DIFFER, V3, P677	56	38	38	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN 6	1996	12	11					2301	2308						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UQ220	8649769				2022-12-25	WOS:A1996UQ22000006
J	Cohen, DM; Gullans, SR; Chin, WW				Cohen, DM; Gullans, SR; Chin, WW			Urea inducibility of egr-1 in murine inner medullary collecting duct cells is mediated by the serum response element and adjacent Ets motifs	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NERVE GROWTH-FACTOR; RENAL EPITHELIAL-CELLS; PROTEIN-BINDING SITE; C-FOS EXPRESSION; REGULATORY FACTOR; IONIZING-RADIATION; TERNARY COMPLEX; MDCK CELLS; GENE; TRANSCRIPTION	The renal medullary solute urea increases transcription and protein expression of the zinc finger-containing transcription factor Egr-1 in a renal epithelial cell-specific fashion, Transient transfection of mIMCD3 cells with a luciferase reporter gene driven by 1.2 kilobases of the murine egr-1 5'-flanking sequence showed 4-fold increase in reporter gene activity with 200 mM urea treatment. The effect of impermeant solutes such as NaCl was much less pronounced, whereas the permeant solute glycerol had no effect, In addition, this same sequence, minus the egr-1 minimal promoter, conferred urea responsiveness to a heterologous (thymidine kinase) promoter. Whereas deletion of two putative AP-1 sites from the sequence had no effect upon urea inducibility, elimination of the five putative serum response elements (SREs) abolished the urea effect. Progressive deletion of the SREs caused a corresponding diminution in urea effect, Two key tandem SREs (SRE-3 and SRE-4), in conjunction with their two adjacent clusters of Ets motifs, were sufficient to confer urea responsiveness to a reporter gene. This response was markedly attenuated in the absence of either cluster of Ets motifs and was abolished if both clusters were deleted. By electrophoretic mobility shift assay, formation of the ternary complex was constitutive and was demonstrable in vitro despite the presence of 200 mosm urea or NaCl. Therefore urea-inducible egr-1 transcription in renal medullary cells is mediated through the SRE and adjacent Ets motifs; ternary complex formation is not inhibited even in the presence of physiological hyperosmolality.	OREGON HLTH SCI UNIV, VET AFFAIRS MED CTR, PORTLAND, OR 97201 USA; BRIGHAM & WOMENS HOSP, DIV RENAL, BOSTON, MA 02115 USA; BRIGHAM & WOMENS HOSP, DIV GENET, BOSTON, MA 02115 USA; BRIGHAM & WOMENS HOSP, HOWARD HUGHES MED INST, BOSTON, MA 02115 USA	Oregon Health & Science University; US Department of Veterans Affairs; Veterans Health Administration (VHA); Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Howard Hughes Medical Institute	Cohen, DM (corresponding author), OREGON HLTH SCI UNIV, DIV NEPHROL, PP262, 3314 SW US VET HOSP RD, PORTLAND, OR 97201 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK036031, K08DK002188] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-36031, DK-02188] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		CHANGELIAN PS, 1989, P NATL ACAD SCI USA, V86, P377, DOI 10.1073/pnas.86.1.377; CHRISTY B, 1989, MOL CELL BIOL, V9, P4889, DOI 10.1128/MCB.9.11.4889; CHRISTY B, 1989, P NATL ACAD SCI USA, V86, P8737, DOI 10.1073/pnas.86.22.8737; CHRISTY BA, 1988, P NATL ACAD SCI USA, V85, P7857, DOI 10.1073/pnas.85.21.7857; COHEN DM, 1993, AM J PHYSIOL, V264, pF601, DOI 10.1152/ajprenal.1993.264.4.F601; COHEN DM, 1991, AM J PHYSIOL, V261, pC594, DOI 10.1152/ajpcell.1991.261.4.C594; COHEN DM, 1994, J BIOL CHEM, V269, P25865; COHEN DM, 1993, AM J PHYSIOL, V264, pF593, DOI 10.1152/ajprenal.1993.264.4.F593; COWLEY BD, 1990, AM J PHYSIOL, V258, pF154, DOI 10.1152/ajprenal.1990.258.1.F154; DALTON S, 1992, CELL, V68, P597, DOI 10.1016/0092-8674(92)90194-H; DATTA R, 1993, P NATL ACAD SCI USA, V90, P2419, DOI 10.1073/pnas.90.6.2419; DATTA R, 1992, P NATL ACAD SCI USA, V89, P10149, DOI 10.1073/pnas.89.21.10149; DEFRANCO C, 1993, MOL ENDOCRINOL, V7, P365, DOI 10.1210/me.7.3.365; GARCIAPEREZ A, 1991, PHYSIOL REV, V71, P1081, DOI 10.1152/physrev.1991.71.4.1081; GILMAN MZ, 1986, MOL CELL BIOL, V6, P4305, DOI 10.1128/MCB.6.12.4305; GREENBERG ME, 1987, MOL CELL BIOL, V7, P1217, DOI 10.1128/MCB.7.3.1217; HANDLER JS, 1993, AM J PHYSIOL, V265, pC1449, DOI 10.1152/ajpcell.1993.265.6.C1449; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; HILL CS, 1993, CELL, V73, P395, DOI 10.1016/0092-8674(93)90238-L; HIPSKIND RA, 1994, GENE DEV, V8, P1803, DOI 10.1101/gad.8.15.1803; HIPSKIND RA, 1991, NATURE, V354, P531, DOI 10.1038/354531a0; ITOH T, 1994, J CLIN INVEST, V93, P2387, DOI 10.1172/JCI117245; JANKNECHT R, 1993, EMBO J, V12, P5097, DOI 10.1002/j.1460-2075.1993.tb06204.x; JANSSENTIMMEN U, 1989, GENE, V80, P325, DOI 10.1016/0378-1119(89)90296-5; LEMAIRE P, 1988, P NATL ACAD SCI USA, V85, P4691, DOI 10.1073/pnas.85.13.4691; LIM RW, 1987, ONCOGENE, V1, P263; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MCMAHON SB, 1995, MOL CELL BIOL, V15, P1086; MILBRANDT J, 1987, SCIENCE, V238, P797, DOI 10.1126/science.3672127; MORRIS CHT, 1988, NUCLEIC ACIDS RES, V16, P8835, DOI 10.1093/nar/16.18.8835; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; PHANDINHTUY F, 1988, EUR J BIOCHEM, V173, P507, DOI 10.1111/j.1432-1033.1988.tb14027.x; PRYWES R, 1986, CELL, V47, P777, DOI 10.1016/0092-8674(86)90520-9; PRYWES R, 1988, P NATL ACAD SCI USA, V85, P7206, DOI 10.1073/pnas.85.19.7206; QURESHI SA, 1991, J BIOL CHEM, V266, P10802; RAO VN, 1989, SCIENCE, V244, P66, DOI 10.1126/science.2539641; RIM M, 1992, ONCOGENE, V7, P2065; RUPPRECHT HD, 1993, AM J PHYSIOL, V265, pF351, DOI 10.1152/ajprenal.1993.265.3.F351; SAKAMOTO KM, 1994, MOL CELL BIOL, V14, P5975, DOI 10.1128/MCB.14.9.5975; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SHAW PE, 1989, CELL, V56, P563, DOI 10.1016/0092-8674(89)90579-5; SMARDO FL, 1992, AM J PHYSIOL, V262, pC776, DOI 10.1152/ajpcell.1992.262.3.C776; SMITH CP, 1995, J CLIN INVEST, V96, P1556, DOI 10.1172/JCI118194; SUBRAMANIAM M, 1989, NATURE, V340, P64, DOI 10.1038/340064a0; SUKHATME VP, 1987, ONCOGENE RES, V1, P343; TAKENAKA M, 1994, J BIOL CHEM, V269, P29379; TERADA Y, 1994, J BIOL CHEM, V269, P31296; TREISMAN R, 1986, CELL, V46, P567, DOI 10.1016/0092-8674(86)90882-2; TREISMAN R, 1994, CURR OPIN GENET DEV, V4, P96, DOI 10.1016/0959-437X(94)90097-3; TREISMAN R, 1992, TRANSCRIPTIONAL REGU, V2, P881; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106; YAMAUCHI A, 1993, AM J PHYSIOL, V264, pF20, DOI 10.1152/ajprenal.1993.264.1.F20; YANCEY PH, 1982, SCIENCE, V217, P1214, DOI 10.1126/science.7112124	53	68	69	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 31	1996	271	22					12903	12908		10.1074/jbc.271.22.12903	http://dx.doi.org/10.1074/jbc.271.22.12903			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UN474	8662677	hybrid			2022-12-25	WOS:A1996UN47400035
J	Fournier, E; Rosnet, O; Marchetto, S; Turck, CW; Rottapel, R; Pelicci, PG; Birnbaum, D; Borg, JP				Fournier, E; Rosnet, O; Marchetto, S; Turck, CW; Rottapel, R; Pelicci, PG; Birnbaum, D; Borg, JP			Interaction with the phosphotyrosine binding domain/phosphotyrosine interacting domain of SHC is required for the transforming activity of the FLT4/VEGFR3 receptor tyrosine kinases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOTHELIAL GROWTH-FACTOR; NUCLEOTIDE EXCHANGE FACTOR; SIGNAL TRANSDUCTION; GRB2; RAS; PROTEINS; EXPRESSION; PHOSPHORYLATION; ASSOCIATION; CELLS	The FLT4 gene encodes two isoforms of a tyrosine kinase receptor, which belongs to the family of receptors for vascular endothelial growth factor. As the result of an alternative processing of primary mRNA transcripts, the long isoform differs from the short isoform by an additional stretch of 65 amino acid residues located at the C terminus and containing three tyrosine residues, Tyr(1333), Tyr(1337), and Tyr(1363). Only the long isoform is endowed with a transforming capacity in fibroblasts. We show that this activity is related to the capacity of the tyrosine 1337-containing sequence to interact with the phosphotyrosine binding domain of the SHC protein. This demonstrates that a functional. property of this newly described domain includes relay of mitogenic signals. In addition, it shows that the same receptor can mediate different functions through the optional binding of the phosphotyrosine binding domain and that the alternative use of this domain is sufficient to direct the signal toward different pathways.	INSERM,U119,MOLEC ONCOL LAB,F-13009 MARSEILLE,FRANCE; UNIV CALIF SAN FRANCISCO,CARDIOVASC RES INST,DEPT MED,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,HOWARD HUGHES MED INST,SAN FRANCISCO,CA 94143; WELLESLEY HOSP,RES INST,TORONTO,ON M5G 1X5,CANADA; UNIV PERUGIA,MONTELUCE POLICLIN,IST CLIN MED 1,I-06100 PERUGIA,ITALY	Institut National de la Sante et de la Recherche Medicale (Inserm); University of California System; University of California San Francisco; Howard Hughes Medical Institute; University of California System; University of California San Francisco; University of Toronto; University Toronto Affiliates; Saint Michaels Hospital Toronto; University of Perugia			Pelicci, Pier Giuseppe/AAL-6572-2020; Rosnet, Olivier/G-3536-2013; Borg, Jean-Paul/AAX-8096-2020	Borg, Jean-Paul/0000-0001-8418-3382; Rosnet, Olivier/0000-0002-3020-910X; Rottapel, Robert/0000-0002-6024-5558				BATZER AG, 1995, MOL CELL BIOL, V15, P4403; BENJAMIN CW, 1994, J BIOL CHEM, V269, P30911; BENLEVY R, 1994, EMBO J, V13, P3302, DOI 10.1002/j.1460-2075.1994.tb06632.x; BIBBINS KB, 1993, MOL CELL BIOL, V13, P7278, DOI 10.1128/MCB.13.12.7278; BLAIKIE P, 1994, J BIOL CHEM, V269, P32031; BORG JP, 1995, ONCOGENE, V10, P973; BORG JP, 1996, IN PRESS MOL ANAL MA; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; BURNS LA, 1993, J BIOL CHEM, V268, P17659; CAMPBELL KS, 1994, P NATL ACAD SCI USA, V91, P6344, DOI 10.1073/pnas.91.14.6344; CHAMPIONARNAUD P, 1991, ONCOGENE, V6, P979; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; CLAESSONWELSH L, 1994, J BIOL CHEM, V269, P32023; CRAPARO A, 1995, J BIOL CHEM, V270, P15689; CUTLER RL, 1993, J BIOL CHEM, V268, P21463; DEVRIES C, 1992, SCIENCE, V255, P989, DOI 10.1126/science.1312256; DIKIC I, 1995, J BIOL CHEM, V270, P15125, DOI 10.1074/jbc.270.25.15125; DILWORTH SM, 1994, NATURE, V367, P87, DOI 10.1038/367087a0; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; EICHMANN A, 1993, MECH DEVELOP, V42, P33, DOI 10.1016/0925-4773(93)90096-G; FONG GH, 1995, NATURE, V376, P66, DOI 10.1038/376066a0; FOURNIER E, 1995, ONCOGENE, V11, P921; GUITON M, 1995, J BIOL CHEM, V270, P20384, DOI 10.1074/jbc.270.35.20384; GUSTAFSON TA, 1995, MOL CELL BIOL, V15, P2500; HABIB T, 1994, J BIOL CHEM, V269, P25248; JOHNSON DE, 1991, MOL CELL BIOL, V11, P4627, DOI 10.1128/MCB.11.9.4627; Joukov V, 1996, EMBO J, V15, P290; KAIPAINEN A, 1993, J EXP MED, V178, P2077, DOI 10.1084/jem.178.6.2077; KAIPAINEN A, 1995, P NATL ACAD SCI USA, V92, P3566, DOI 10.1073/pnas.92.8.3566; KAVANAUGH WM, 1995, SCIENCE, V268, P1177, DOI 10.1126/science.7539155; KAVANAUGH WM, 1994, SCIENCE, V266, P1862, DOI 10.1126/science.7527937; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; LAMBALLE F, 1993, EMBO J, V12, P3083, DOI 10.1002/j.1460-2075.1993.tb05977.x; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; MARENGERE LEM, 1992, J BIOL CHEM, V267, P22779; MAYER BJ, 1992, MOL CELL BIOL, V12, P609, DOI 10.1128/MCB.12.2.609; MCGLADE CJ, 1992, MOL CELL BIOL, V12, P991, DOI 10.1128/MCB.12.3.991; MILLAUER B, 1993, CELL, V72, P835, DOI 10.1016/0092-8674(93)90573-9; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; MUSTONEN T, 1995, J CELL BIOL, V129, P895, DOI 10.1083/jcb.129.4.895; NAGAI K, 1995, J BIOL CHEM, V270, P6824, DOI 10.1074/jbc.270.12.6824; OBERMEIER A, 1994, EMBO J, V13, P1585, DOI 10.1002/j.1460-2075.1994.tb06421.x; PAGES G, 1994, EMBO J, V13, P3003, DOI 10.1002/j.1460-2075.1994.tb06599.x; PAJUSOLA K, 1994, ONCOGENE, V9, P3545; PAJUSOLA K, 1993, ONCOGENE, V8, P2931; PARK JE, 1994, J BIOL CHEM, V269, P25646; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; PETERS KG, 1993, P NATL ACAD SCI USA, V90, P8915, DOI 10.1073/pnas.90.19.8915; PRONK GJ, 1993, J BIOL CHEM, V268, P5748; QUINN TP, 1993, P NATL ACAD SCI USA, V90, P7533, DOI 10.1073/pnas.90.16.7533; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; SALCINI AE, 1994, ONCOGENE, V9, P2827; SEETHARAM L, 1995, ONCOGENE, V10, P135; SEGATTO O, 1993, ONCOGENE, V8, P2105; SHALABY F, 1995, NATURE, V376, P62, DOI 10.1038/376062a0; SIMON MA, 1993, CELL, V73, P169, DOI 10.1016/0092-8674(93)90169-Q; SKOLNIK EY, 1993, SCIENCE, V260, P1953, DOI 10.1126/science.8316835; SONGYANG Z, 1995, J BIOL CHEM, V270, P14863, DOI 10.1074/jbc.270.25.14863; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; TERMAN BI, 1992, BIOCHEM BIOPH RES CO, V187, P1579, DOI 10.1016/0006-291X(92)90483-2; TRUB T, 1995, J BIOL CHEM, V270, P18205; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VANDERGEER P, 1995, CURR BIOL, V5, P404, DOI 10.1016/S0960-9822(95)00081-9; VANDERGEER P, 1995, TRENDS BIOCHEM SCI, V20, P277, DOI 10.1016/S0968-0004(00)89043-X; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; VANDERKUUR J, 1995, J BIOL CHEM, V270, P7587, DOI 10.1074/jbc.270.13.7587; WALTENBERGER J, 1994, J BIOL CHEM, V269, P26988; WERNER S, 1992, MOL CELL BIOL, V12, P82, DOI 10.1128/MCB.12.1.82; YAMAGUCHI TP, 1993, DEVELOPMENT, V118, P489; ZHOU MM, 1995, NATURE, V378, P584, DOI 10.1038/378584a0	71	25	29	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 31	1996	271	22					12956	12963		10.1074/jbc.271.22.12956	http://dx.doi.org/10.1074/jbc.271.22.12956			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UN474	8662748	hybrid			2022-12-25	WOS:A1996UN47400044
J	Gerhartz, C; Heesel, B; Sasse, J; Hemmann, U; Landgraf, C; SchneiderMergener, J; Horn, F; Heinrich, PC; Graeve, L				Gerhartz, C; Heesel, B; Sasse, J; Hemmann, U; Landgraf, C; SchneiderMergener, J; Horn, F; Heinrich, PC; Graeve, L			Differential activation of acute phase response factor/STAT3 and STAT1 via the cytoplasmic domain of the interleukin 6 signal transducer gp130 .1. Definition of a novel phosphotyrosine motif mediating STAT1 activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERFERON-GAMMA RECEPTOR; MOLECULAR-CLONING; EXPRESSION; BINDING; IDENTIFICATION; CELLS	Interleukin-6 (IL-6) and gamma-interferon (IFN gamma) activate an overlapping set of genes via the Jak/STAT pathway, However, at least in human cells, a differential activation of STAT transcription factors was observed: IL-6 activates both acute phase response factor (APRF)/STAT3 and STAT1, whereas IFN gamma leads only to STAT1 activation, All STATs cloned so far contain SH2 domains, Since all cytokine receptors using the Jak/STAT pathway were found to be tyrosine-phosphorylated after ligand binding, it has been proposed that specific phosphotyrosine modules within the cytoplasmic domain of the receptor chains recruit different STAT factors. We have analyzed by mutational studies and by phosphopeptide competition assays which of the tyrosine modules of the IL-6 signal transducer gp130 are capable of recruiting either APRF or STAT1, We found that two of the four tyrosine modules that are important for APRF activation also activate STAT1. For these modules, we propose the new consensus sequence YXPQ. We further present evidence that STAT1 is activated independently from APRF suggesting that gp130 contains multiple independent STAT binding sites, We compare the APRF and STAT1 activation motifs of gp130 with the STAT1 activation moth of the IFN gamma receptor and demonstrate that the specificity of activation can be changed from APRF to STAT1 and vice versa by only two point mutations within a tyrosine module. These data strongly support the concept that the activation of a specific STAT is determined mainly by the phosphotyrosine module, The significance of these findings for other receptor systems is discussed.	RHEIN WESTFAL TH AACHEN,INST BIOCHEM,D-52057 AACHEN,GERMANY; UNIV KLINIKUM CHARITE,INST MED IMMUNOL,D-10098 BERLIN,GERMANY	RWTH Aachen University; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin								AGUET M, 1988, CELL, V55, P273, DOI 10.1016/0092-8674(88)90050-5; AKIRA S, 1994, CELL, V77, P63, DOI 10.1016/0092-8674(94)90235-6; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; [Anonymous], 1989, Ann N Y Acad Sci, V557, P1; ARCONE R, 1991, EUR J BIOCHEM, V198, P541, DOI 10.1111/j.1432-1033.1991.tb16048.x; CAMPBELL GS, 1995, J BIOL CHEM, V270, P3974, DOI 10.1074/jbc.270.8.3974; CHUA AO, 1994, J IMMUNOL, V153, P128; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; FARRAR MA, 1992, P NATL ACAD SCI USA, V89, P11706, DOI 10.1073/pnas.89.24.11706; FU XY, 1992, CELL, V70, P323, DOI 10.1016/0092-8674(92)90106-M; FUKUNAGA R, 1990, P NATL ACAD SCI USA, V87, P8702, DOI 10.1073/pnas.87.22.8702; GEARING DP, 1991, EMBO J, V10, P2839, DOI 10.1002/j.1460-2075.1991.tb07833.x; GREENLUND AC, 1994, EMBO J, V13, P1591, DOI 10.1002/j.1460-2075.1994.tb06422.x; GREENLUND AC, 1995, IMMUNITY, V2, P677, DOI 10.1016/1074-7613(95)90012-8; GUSHCIN D, 1995, EMBO J, V14, P1421; HEIM MH, 1995, SCIENCE, V267, P1347, DOI 10.1126/science.7871432; HEINRICH PC, 1990, BIOCHEM J, V265, P621, DOI 10.1042/bj2650621; HEMMI S, 1994, CELL, V76, P803, DOI 10.1016/0092-8674(94)90355-7; HIBI M, 1990, CELL, V63, P1149, DOI 10.1016/0092-8674(90)90411-7; HOU JZ, 1994, SCIENCE, V265, P1701, DOI 10.1126/science.8085155; LIU Y, 1994, J IMMUNOL, V152, P1821; LUTTICKEN C, 1994, SCIENCE, V263, P89, DOI 10.1126/science.8272872; MURAKAMI M, 1991, P NATL ACAD SCI USA, V88, P11349, DOI 10.1073/pnas.88.24.11349; MURAKAMI M, 1993, SCIENCE, V260, P1808, DOI 10.1126/science.8511589; PENNICA D, 1995, J BIOL CHEM, V270, P10915, DOI 10.1074/jbc.270.18.10915; Roberts A. B., 1990, PEPTIDE GROWTH FACTO, P633; Sambrook J., 2002, MOL CLONING LAB MANU; SHUAI K, 1994, CELL, V76, P821, DOI 10.1016/0092-8674(94)90357-3; SILVENNOINEN O, 1993, NATURE, V366, P583, DOI 10.1038/366583a0; SOH J, 1994, CELL, V76, P793, DOI 10.1016/0092-8674(94)90354-9; STAHL N, 1994, SCIENCE, V263, P92, DOI 10.1126/science.8272873; STAHL N, 1995, SCIENCE, V267, P1349, DOI 10.1126/science.7871433; TAGA T, 1992, FASEB J, V6, P3387, DOI 10.1096/fasebj.6.15.1334470; TAGA T, 1989, CELL, V58, P573, DOI 10.1016/0092-8674(89)90438-8; TAGA T, 1995, CURR OPIN IMMUNOL, V7, P17, DOI 10.1016/0952-7915(95)80024-7; TANNER JW, 1995, J BIOL CHEM, V270, P6523, DOI 10.1074/jbc.270.12.6523; UZE G, 1990, CELL, V60, P225, DOI 10.1016/0092-8674(90)90738-Z; VANSNICK J, 1990, ANNU REV IMMUNOL, V8, P253, DOI 10.1146/annurev.immunol.8.1.253; VIGON I, 1992, P NATL ACAD SCI USA, V89, P5640, DOI 10.1073/pnas.89.12.5640; WAGNER BJ, 1990, EMBO J, V9, P4477, DOI 10.1002/j.1460-2075.1990.tb07898.x; WEGENKA UM, 1994, MOL CELL BIOL, V14, P3186, DOI 10.1128/MCB.14.5.3186; WEGENKA UM, 1993, MOL CELL BIOL, V13, P276, DOI 10.1128/MCB.13.1.276; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; YAMASAKI K, 1988, SCIENCE, V241, P825, DOI 10.1126/science.3136546; YUAN JP, 1994, MOL CELL BIOL, V14, P1657, DOI 10.1128/MCB.14.3.1657; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422	46	225	229	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 31	1996	271	22					12991	12998		10.1074/jbc.271.22.12991	http://dx.doi.org/10.1074/jbc.271.22.12991			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UN474	8662591	hybrid			2022-12-25	WOS:A1996UN47400049
J	Liu, L; Rannels, SR; Falconieri, M; Phillips, KS; Wolpert, EB; Weaver, TE				Liu, L; Rannels, SR; Falconieri, M; Phillips, KS; Wolpert, EB; Weaver, TE			The testis isoform of the phosphorylase kinase catalytic subunit (PhK-gamma T) plays a critical role in regulation of glycogen mobilization in developing lung	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FETAL LUNG; SKELETAL-MUSCLE; MESSENGER-RNA; RAT LUNG; SURFACTANT; EXPRESSION; SEQUENCE; LIVER; IDENTIFICATION; CLONING	In order to identify the form of phosphorylase kinase catalytic subunit expressed in developing lung, degenerate polymerase chain reaction primers were designed based on conserved domains of the two known catalytic subunits, expressed primarily in muscle and testis, Amplification of cDNA from day 19 fetal rat lung followed by cloning and sequence analyses indicated that only the testis isoform of phosphorylase kinase (PhK-gamma T) was detectable in fetal lung. In situ hybridization analyses indicated that expression of PhK-gamma T RNA in developing lung tissue was widespread and not restricted to Type II epithelial cells; PhK-gamma T protein expression was temporally and spatially correlated with expression of PhK-gamma T RNA, PhK-gamma T RNA and protein expression was also characterized in the PhK-deficient glycogen storage dis ease (gsd) rat, PhK-gamma T RNA levels were similar in Type II cells isolated from wild type and gsd/gsd fetuses; in contrast, PhK-gamma T protein was virtually undetectable in gsd/gsd Type II cells and enzyme activity was very low. These results suggest that PhK-gamma T plays a critical role in mobilization of glycogen during fetal lung development and that failure to catabolize glycogen in the gsd/gsd rat is related to an untranslatable PhK-gamma T RNA or unstable protein.	CHILDRENS HOSP, MED CTR, DIV PULM BIOL, TCHRF, CINCINNATI, OH 45229 USA; PENN STATE UNIV, MILTON S HERSHEY MED CTR, DEPT CELLULAR & MOLEC PHYSIOL, HERSHEY, PA 17033 USA	Cincinnati Children's Hospital Medical Center; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health					NICHD NIH HHS [HD20748] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P50HD020748] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BENDER PK, 1987, J BIOL CHEM, V262, P8799; BRESLIN JS, 1993, AM J RESP CELL MOL, V9, P533, DOI 10.1165/ajrcmb/9.5.533; CALALB MB, 1992, J BIOL CHEM, V267, P1455; CAWLEY KC, 1988, NUCLEIC ACIDS RES, V16, P2355, DOI 10.1093/nar/16.5.2355; CAWLEY KC, 1993, J BIOL CHEM, V268, P1194; CHAMBERLAIN JS, 1987, P NATL ACAD SCI USA, V84, P2886, DOI 10.1073/pnas.84.9.2886; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLARK D, 1988, CURR TOP CELL REGUL, V29, P217; CLARK JC, 1995, P NATL ACAD SCI USA, V92, P7794, DOI 10.1073/pnas.92.17.7794; COHEN P, 1983, METHOD ENZYMOL, V99, P243; DAVIDSON JJ, 1992, P NATL ACAD SCI USA, V89, P2096, DOI 10.1073/pnas.89.6.2096; FARRELL PM, 1986, BIOCHIM BIOPHYS ACTA, V878, P159, DOI 10.1016/0005-2760(86)90142-6; HANKS SK, 1989, MOL ENDOCRINOL, V3, P110, DOI 10.1210/mend-3-1-110; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; HARMANN B, 1991, J BIOL CHEM, V266, P15631; ITO T, 1990, J HISTOCHEM CYTOCHEM, V38, P691, DOI 10.1177/38.5.2332626; KIKKAWA Y, 1971, AM J PATHOL, V64, P423; KOZAK M, 1994, BIOCHIMIE, V76, P815, DOI 10.1016/0300-9084(94)90182-1; KOZAK M, 1986, P NATL ACAD SCI USA, V83, P2850, DOI 10.1073/pnas.83.9.2850; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MALTHUS R, 1980, BIOCHEM J, V188, P99, DOI 10.1042/bj1880099; MANISCALCO WM, 1978, BIOCHIM BIOPHYS ACTA, V530, P333, DOI 10.1016/0005-2760(78)90153-4; NEWGARD CB, 1991, BIOCHIM BIOPHYS ACTA, V1090, P333, DOI 10.1016/0167-4781(91)90198-U; Pickett-Gies CA., 1986, ENZYMES, V17, P395; RANNELS SR, 1991, AM J PHYSIOL, V260, pL419, DOI 10.1152/ajplung.1991.260.6.L419; RANNELS SR, 1994, CELL BIOL LAB HDB, P116; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHELLHASE DE, 1989, PEDIATR RES, V26, P167, DOI 10.1203/00006450-198909000-00001; SILVA EFD, 1987, FEBS LETT, V220, P36, DOI 10.1016/0014-5793(87)80871-2; VORBROKER DK, 1995, AM J PHYSIOL-LUNG C, V268, pL647, DOI 10.1152/ajplung.1995.268.4.L647; WEAVER TE, 1988, J APPL PHYSIOL, V65, P982, DOI 10.1152/jappl.1988.65.2.982; Zuker M, 1994, Methods Mol Biol, V25, P267	32	9	10	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 17	1996	271	20					11761	11766		10.1074/jbc.271.20.11761	http://dx.doi.org/10.1074/jbc.271.20.11761			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UL250	8662648	hybrid			2022-12-25	WOS:A1996UL25000030
J	Lougheed, M; Steinbrecher, UP				Lougheed, M; Steinbrecher, UP			Mechanism of uptake of copper-oxidized low density lipoprotein in macrophages is dependent on its extent of oxidation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CELLS; HERITABLE HYPERLIPIDEMIC RABBIT; MOUSE PERITONEAL-MACROPHAGES; SCAVENGER RECEPTOR; ENDOTHELIAL-CELLS; ATHEROSCLEROTIC LESIONS; LIPID-PEROXIDATION; MODIFIED LDL; LIGAND-BINDING; KUPFFER CELLS	Several investigators have reported nonreciprocal cross-competition between unlabeled acetyl low density lipoprotein (LDL) and oxidized LDL for the degradation of the corresponding labeled LDLs. The failure of acetyl LDL to compete fully for the degradation of oxidized LDL has been interpreted as evidence for additional receptor(s) specific for oxidized LDL. In the present study, it is demonstrated that the ability of oxidized LDL to compete for the degradation of acetyl LDL is determined largely by its extent of oxidation. Extensively oxidized LDL competed for 90% of acetyl LDL degradation in murine macrophage, and hence there appears to be no pathway in these cells that is specific for acetyl LDL but not oxidized LDL. The reciprocal situation (competition by acetyl LDL for uptake and degradation of oxidized LDL) proved to be more complicated. Oxidized LDL is known to be susceptible to aggregation, and less than half of the aggregates found in the present experiments were large enough to be removed by filtration or centrifugation at 10,000 x g. When oxidized LDL was prepared under conditions that resulted in minimal aggregation, acetyl LDL competed for greater than 80% of oxidized LDL degradation. With more extensive oxidation and aggregation of LDL, acetyl LDL only competed for about 45% of oxidized LDL degradation, while polyinosinic acid remained an effective competitor. Individual preparations of oxidized LDL that differed in degree of oxidation were separated into aggregated and nonaggregated fractions, and it was shown that both fractions were competed to a similar degree by acetyl LDL in mouse peritoneal macrophages and in Chinese hamster ovary cells transfected with human scavenger receptor type I cDNA, Hence, aggregation by itself did not alter the apparent rate of uptake by the scavenger receptor pathway. These results indicate that the extent of oxidation of LDL affects its mechanism of uptake and that about half of the uptake of very extensively oxidized LDL appears to be via a pathway distinct from the scavenger receptor type I/II. The uptake of very extensively oxidized LDL was not affected by cytochalasin D, an inhibitor of phagocytosis. As well, it was not affected by an antibody to CD36 in human monocyte-derived macrophages or in THP-1 cells, suggesting that this alternate pathway does not involve CD36.	UNIV BRITISH COLUMBIA,DEPT MED,VANCOUVER,BC V5Z 4E3,CANADA	University of British Columbia								ACTON S, 1995, J BIOL CHEM, V269, P21003; ARAI H, 1989, BIOCHEM BIOPH RES CO, V159, P1375, DOI 10.1016/0006-291X(89)92262-6; ARDLIE NG, 1989, ATHEROSCLEROSIS, V76, P117, DOI 10.1016/0021-9150(89)90094-4; ASHKENAS J, 1993, J LIPID RES, V34, P983; BERLINER JA, 1990, J CLIN INVEST, V85, P1260, DOI 10.1172/JCI114562; BICKEL PE, 1992, J CLIN INVEST, V90, P1450, DOI 10.1172/JCI116012; BILHEIMER DW, 1972, BIOCHIM BIOPHYS ACTA, V260, P212, DOI 10.1016/0005-2760(72)90034-3; BJORKHEM I, 1991, ARTERIOSCLER THROMB, V11, P15, DOI 10.1161/01.ATV.11.1.15; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BROWN MS, 1980, J SUPRAMOL STR CELL, V13, P67, DOI 10.1002/jss.400130107; CAREW TE, 1987, P NATL ACAD SCI USA, V84, P7725, DOI 10.1073/pnas.84.21.7725; CUSHING SD, 1990, P NATL ACAD SCI USA, V87, P5134, DOI 10.1073/pnas.87.13.5134; DEJAGER S, 1993, ARTERIOSCLER THROMB, V13, P371, DOI 10.1161/01.ATV.13.3.371; DOI T, 1993, J BIOL CHEM, V268, P2126; EMI M, 1993, J BIOL CHEM, V268, P2120; ENDEMANN G, 1993, J BIOL CHEM, V268, P11811; ESTERBAUER H, 1982, BIOCHEM J, V208, P129, DOI 10.1042/bj2080129; FOX PL, 1987, J BIOL CHEM, V262, P6046; FREEMAN M, 1990, P NATL ACAD SCI USA, V87, P8810, DOI 10.1073/pnas.87.22.8810; FREEMAN M, 1991, P NATL ACAD SCI USA, V88, P4931, DOI 10.1073/pnas.88.11.4931; FROSTEGARD J, 1990, P NATL ACAD SCI USA, V87, P904, DOI 10.1073/pnas.87.3.904; FROSTEGARD J, 1991, ATHEROSCLEROSIS, V90, P119, DOI 10.1016/0021-9150(91)90106-D; FROSTEGARD J, 1992, ARTERIOSCLER THROMB, V12, P461, DOI 10.1161/01.ATV.12.4.461; HABERLAND M, 1988, SCIENCE, V24, P215; HAVEL RJ, 1955, J CLIN INVEST, V34, P1345, DOI 10.1172/JCI103182; HESSLER JR, 1983, ARTERIOSCLEROSIS, V3, P215, DOI 10.1161/01.ATV.3.3.215; HOFF HF, 1992, J BIOL CHEM, V267, P602; HOPPE G, 1994, J CLIN INVEST, V94, P1506, DOI 10.1172/JCI117490; KAMPS JAAM, 1992, ARTERIOSCLER THROMB, V12, P1079, DOI 10.1161/01.ATV.12.9.1079; KHOO JC, 1988, ARTERIOSCLEROSIS, V8, P348, DOI 10.1161/01.ATV.8.4.348; KHOO JC, 1990, J LIPID RES, V31, P645; KITA T, 1987, P NATL ACAD SCI USA, V84, P5928, DOI 10.1073/pnas.84.16.5928; KODAMA T, 1988, P NATL ACAD SCI USA, V85, P9238, DOI 10.1073/pnas.85.23.9238; KODAMA T, 1990, NATURE, V343, P532; LEE KD, 1992, BIOCHIM BIOPHYS ACTA, V1111, P1, DOI 10.1016/0005-2736(92)90267-P; LEPAGE G, 1986, J LIPID RES, V27, P114; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MATSUMOTO A, 1990, P NATL ACAD SCI USA, V87, P9133, DOI 10.1073/pnas.87.23.9133; NICHOLSON A, 1995, THROMB VASC BIOL, V15, P269; NISHIKAWA K, 1990, J BIOL CHEM, V265, P5226; NOZAKI S, 1995, J CLIN INVEST, V96, P1859, DOI 10.1172/JCI118231; OTTNAD E, 1995, P NATL ACAD SCI USA, V92, P1391, DOI 10.1073/pnas.92.5.1391; OTTNAD E, 1992, BIOCHEM J, V281, P745, DOI 10.1042/bj2810745; PALINSKI W, 1989, P NATL ACAD SCI USA, V86, P1372, DOI 10.1073/pnas.86.4.1372; RAJAVASHISTH TB, 1990, NATURE, V344, P254, DOI 10.1038/344254a0; ROHRER L, 1990, NATURE, V343, P570, DOI 10.1038/343570a0; ROSENFELD ME, 1990, ARTERIOSCLEROSIS, V10, P336, DOI 10.1161/01.ATV.10.3.336; SPARROW CP, 1989, J BIOL CHEM, V264, P2599; SPARROW CP, 1992, J CLIN INVEST, V89, P1885, DOI 10.1172/JCI115793; STANTON LW, 1992, J BIOL CHEM, V267, P22446; STEINBERG D, 1989, NEW ENGL J MED, V320, P915; STEINBRECHER UP, 1992, ARTERIOSCLER THROMB, V12, P608, DOI 10.1161/01.ATV.12.5.608; STEINBRECHER UP, 1990, FREE RADICAL BIO MED, V9, P155, DOI 10.1016/0891-5849(90)90119-4; STEINBRECHER UP, 1987, ARTERIOSCLEROSIS, V7, P135, DOI 10.1161/01.ATV.7.2.135; STEINBRECHER UP, 1984, P NATL ACAD SCI-BIOL, V81, P3883, DOI 10.1073/pnas.81.12.3883; UEDA Y, 1993, ATHEROSCLEROSIS, V101, P25, DOI 10.1016/0021-9150(93)90098-F; VANBERKEL TJC, 1991, J BIOL CHEM, V266, P2282; WITZTUM JL, 1991, J CLIN INVEST, V88, P1785, DOI 10.1172/JCI115499; YLAHERTTUALA S, 1989, J CLIN INVEST, V84, P1086, DOI 10.1172/JCI114271; ZHANG HF, 1993, J BIOL CHEM, V268, P5535	60	84	86	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 17	1996	271	20					11798	11805		10.1074/jbc.271.20.11798	http://dx.doi.org/10.1074/jbc.271.20.11798			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UL250	8662601	hybrid			2022-12-25	WOS:A1996UL25000036
J	Hu, YL; Bowtell, DDL				Hu, YL; Bowtell, DDL			Sos1 rapidly associates with Grb2 and is hypophosphorylated when complexed with the EGF receptor after EGF stimulation	ONCOGENE			English	Article						Sos; EGF receptor; Grb2; signal transduction	GUANINE-NUCLEOTIDE EXCHANGE; TYROSINE KINASES; RAS; PROTEIN; ACTIVATION; DOMAIN; BINDS; GENE; SH2	The Son of sevenless (Sos) protein, a guanine nucleotide exchange factor for ras proteins, appears to play a central role in signalling between protein tyrosine kinase receptors and ras. The C-terminal region of Sos binds an adaptor protein, Grb2, which in turn binds to activated receptors including the EGF receptor (EGFR). Although the Sos protein is rapidly phosphorylated following cytokine stimulation, there is no evidence that this alters the enzymatic activity of Sos for ras proteins. Therefore, we investigated whether the ability of Sos1 to form complexes with Grb2 and with the EGF receptor (EGFR) changes following EGF stimulation, as possible mechanism for regulating Sos activity. In contrast to earlier findings, we find that both the association and dissociation of Sos1 with Grb2 is responsive to EGF, Whilst the association of Sos1 and Grb2 following EGF stimulation is not cell type specific, we find that it is dependant on cell density and that the response to EGF differs to that induced by NGF. We find that following EGF stimulation, the Sos1 protein associated with the EGFR is markedly less phosphorylated than the majority of the Sos1 within the cell and there was reduced binding of Grb2 with phosphorylated Sos1 protein in a direct binding assay. A time course analysis showed that Sos1 dissociates from the EGFR more rapidly than does Grb2 following EGF stimulation. Collectively our findings are consistent with the notion that the phosphorylation of Sos1 affects its ability to complex with the EGFR and Grb2.	PETER MACCALLUM CANC INST, TRESCOWTHICK RES CTR, MELBOURNE, VIC 3000, AUSTRALIA; UNIV MELBOURNE, HOWARD FLOREY INST EXPTL PHYSIOL & MED, PARKVILLE, VIC 3052, AUSTRALIA	Peter Maccallum Cancer Center; Florey Institute of Neuroscience & Mental Health; University of Melbourne			Bowtell, David/H-1007-2016; Hu, Yinling/G-5682-2015	Bowtell, David/0000-0001-9089-7525; Hu, Yinling/0000-0002-4795-8537				ARONHEIM A, 1994, CELL, V78, P949, DOI 10.1016/0092-8674(94)90271-2; BLAIKIE P, 1994, J BIOL CHEM, V269, P32031; BOWTELL D, 1992, P NATL ACAD SCI USA, V89, P6511, DOI 10.1073/pnas.89.14.6511; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; CHERNIACK AD, 1994, J BIOL CHEM, V269, P4717; CHERNIACK AD, 1995, J BIOL CHEM, V270, P1485, DOI 10.1074/jbc.270.4.1485; DEVRIESSMITS AMM, 1995, ONCOGENE, V10, P919; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; GROSS E, 1992, NATURE, V360, P762, DOI 10.1038/360762a0; KARLOVICH CA, 1995, SCIENCE, V268, P576, DOI 10.1126/science.7725106; KAVANAUGH WM, 1994, SCIENCE, V266, P1862, DOI 10.1126/science.7527937; LANGLOIS WJ, 1995, J BIOL CHEM, V270, P25320, DOI 10.1074/jbc.270.43.25320; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LIU BX, 1993, ONCOGENE, V8, P3081; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MCCOLLAM L, 1995, J BIOL CHEM, V270, P15954, DOI 10.1074/jbc.270.27.15954; MCCORMICK F, 1994, CURR OPIN GENET DEV, V4, P71, DOI 10.1016/0959-437X(94)90093-0; PORFIRI E, 1994, J BIOL CHEM, V269, P22672; QIU MS, 1992, NEURON, V9, P705, DOI 10.1016/0896-6273(92)90033-A; QUILLIAM LA, 1994, P NATL ACAD SCI USA, V91, P8512, DOI 10.1073/pnas.91.18.8512; RAABE T, 1995, EMBO J, V14, P2509, DOI 10.1002/j.1460-2075.1995.tb07248.x; RAVICHANDRAN KS, 1995, MOL CELL BIOL, V15, P593; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; SIMON MA, 1991, CELL, V67, P701, DOI 10.1016/0092-8674(91)90065-7; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; VANDERGEER P, 1995, CURR BIOL, V5, P404, DOI 10.1016/S0960-9822(95)00081-9; WANG W, 1995, NAT GENET, V10, P294, DOI 10.1038/ng0795-294; WATERS SB, 1995, MOL CELL BIOL, V15, P2791; WELHAM MJ, 1994, J BIOL CHEM, V269, P21165	32	27	27	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 2	1996	12	9					1865	1872						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UK498	8649846				2022-12-25	WOS:A1996UK49800004
J	Sitzmann, J; NobenTrauth, K; Kamano, H; Klempnauer, KH				Sitzmann, J; NobenTrauth, K; Kamano, H; Klempnauer, KH			Expression of B-Myb during mouse embryogenesis	ONCOGENE			English	Article						B-myb; histone H4; mouse development; cell proliferation; spermatogenesis	C-MYB; A-MYB; HEMATOPOIETIC-CELLS; GENE; PROLIFERATION; TRANSCRIPTION; ACTIVATION; XENOPUS	B-myb is a member of the myb family of nuclear sequence-specific DNA-binding proteins which has been highly conserved among vertebrates. B-myb has been implicated in the control of cell proliferation, particularly at the G1/S transition of the cell cycle. So far, most of the work on B-myb has been performed in immortalized cell lines. Since these cells might show aberrant behavior of genes involved in proliferation control we have begun to investigate the role of B-myb in normal cells. As a first step, we have studied the expression of B-myb during mouse development. Here, we show the B-myb is expressed at similar levels during all stages of embryogenesis. In situ hybridization reveals a tight linkage between B-myb expression and proliferative activity (as assessed by the expression of the S-phase specific histone H4 gene) in most tissues and throughout embryonic development. However, B-myb and histone H4 expression are uncoupled during spermatogenesis in the adult mouse. Histone H4 is expressed at high levels in the early spermatogenic progenitor cells but not in successive stages of sperm cell development. By contrast, the highest levels of B-myb expression are found during the intermediate stages of spermatogenesis. Furthermore, we have found that B-myb mRNA isolated from the testis differs in size from that of other tissues. The data presented here strongly support the notion that B-myb plays a general role during proliferation of most cells. Furthermore, our results raise the possibility that the function of B-myb in cells undergoing meiosis may be different from its role in cells dividing mitotically.	MAX PLANCK INST IMMUNBIOL,HANS SPEMANN LAB,D-79108 FREIBURG,GERMANY	Max Planck Society								ARSURA M, 1992, BLOOD, V79, P2708; BOUWMEESTER T, 1992, MECH DEVELOP, V37, P57, DOI 10.1016/0925-4773(92)90015-C; COX KH, 1984, DEV BIOL, V101, P485, DOI 10.1016/0012-1606(84)90162-3; DZIERZAK E, 1995, TRENDS GENET, V11, P359, DOI 10.1016/S0168-9525(00)89107-6; FOOS G, 1994, ONCOGENE, V9, P2481; FOOS G, 1992, EMBO J, V11, P4619, DOI 10.1002/j.1460-2075.1992.tb05564.x; GOLAY J, 1991, BLOOD, V77, P149; GOLAY J, 1994, ONCOGENE, V9, P2469; Graf T, 1992, CURR OPIN GENET DEV, V2, P249, DOI 10.1016/S0959-437X(05)80281-3; KAMANO H, 1996, ONCOGENE, V11, P2575; KLEMPNAUER KH, 1983, J VIROL, V48, P565, DOI 10.1128/JVI.48.3.565-572.1983; LAM EWF, 1993, EMBO J, V12, P2705, DOI 10.1002/j.1460-2075.1993.tb05932.x; LAM EWF, 1992, ONCOGENE, V7, P1185; LIN D, 1994, P NATL ACAD SCI USA, V91, P10079, DOI 10.1073/pnas.91.21.10079; LUSCHER B, 1990, GENE DEV, V4, P2235, DOI 10.1101/gad.4.12b.2235; METTUS RV, 1994, ONCOGENE, V9, P3077; MUCENSKI ML, 1991, CELL, V65, P677, DOI 10.1016/0092-8674(91)90099-K; NOMURA N, 1988, NUCLEIC ACIDS RES, V16, P11075, DOI 10.1093/nar/16.23.11075; OSLEY MA, 1991, ANNU REV BIOCHEM, V60, P827, DOI 10.1146/annurev.biochem.60.1.827; REISS K, 1991, J CELL PHYSIOL, V148, P338, DOI 10.1002/jcp.1041480303; SALA A, 1992, P NATL ACAD SCI USA, V89, P10415, DOI 10.1073/pnas.89.21.10415; SEILERTUYNS A, 1981, J MOL BIOL, V151, P607, DOI 10.1016/0022-2836(81)90426-5; SHENONG GLC, 1990, BIOCHIM BIOPHYS ACTA, V1032, P39, DOI 10.1016/0304-419X(90)90011-O; Sitzmann J, 1995, ONCOGENE, V11, P2273; SITZMANN JH, 1993, J HISTOCHEM CYTOCHEM, V41, P773, DOI 10.1177/41.5.7682230; SITZMANN JH, 1995, BRIT J DERMATOL, V133, P241, DOI 10.1111/j.1365-2133.1995.tb02622.x; SLEEMAN JP, 1993, ONCOGENE, V8, P1931; TAKAHASHI T, 1995, FEBS LETT, V358, P89, DOI 10.1016/0014-5793(94)01402-M; TRAUTH K, 1994, EMBO J, V13, P5994, DOI 10.1002/j.1460-2075.1994.tb06945.x; WATSON RJ, 1993, NUCLEIC ACIDS RES, V21, P267, DOI 10.1093/nar/21.2.267; WILKINSON DG, 1987, DEVELOPMENT, V99, P493	31	65	66	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY 2	1996	12	9					1889	1894						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UK498	8649849				2022-12-25	WOS:A1996UK49800007
J	Dolnikov, A; Ward, RL; Hawkins, NJ; Symonds, G				Dolnikov, A; Ward, RL; Hawkins, NJ; Symonds, G			Apoptosis in v-myc transformation of myelomonocytic cells and its modulation by CSF-1	ONCOGENE			English	Article						v-myc; apoptosis; CSF-1; transformation	C-MYC; ACTIVATES TRANSCRIPTION; PROTEIN; BCL-2; GENE; EXPRESSION; DEATH; LINE; INDUCTION; MAX	c-myc is a proto-oncogene essential for cell growth. When activated, its expression can lead to uncontrolled cell proliferation, transformation and tumorigenesis. The cell line tEMmyc4 is a murine myelomonocytic cell line that was established following transformation by v-myc. It has a high level of v-myc expression and constitutively expresses endogenous CSF-1, the monocytic growth and viability factor. Under growth restricting conditions (high cell density, serum deprivation, heat shock, or dexamethasone addition) cells of this line were found to undergo cell death through apoptosis. The induction of apoptosis by dexamethasone was associated with a decrease in constitutive CSF-1 expression without significant change in v-myc expression. Exogenous CSF-1 rescued these cells from dexamethasone induced-apoptosis. In vivo studies showed that tEMmyc4 cells were tumorigenic in syngeneic animals despite exhibiting some spontaneous apoptosis within the tumour mass. Co-administration of dexamethasone with the tumour cells significantly inhibited tumor development and the administration of dexamethasone to mice with established tumors resulted in tumor regression in all mice. This regression was associated with a high level of apoptosis and necrosis in the tumors. This study shows a correlation between the in vitro and in vivo induction of apoptosis and indicates that cancer cells bearing activated oncogenes may be more sensitive to apoptosis induction by chemotherapeutic agents.	ST VINCENTS HOSP, DEPT MED ONCOL, DARLINGHURST, NSW 2010, AUSTRALIA; ST VINCENTS HOSP, DEPT MED & HAEMATOL, DARLINGHURST, NSW 2010, AUSTRALIA; UNIV NEW S WALES, SCH PHYSIOL & PHARMACOL, SYDNEY, NSW 2052, AUSTRALIA; UNIV NEW S WALES, SCH PATHOL, SYDNEY, NSW 2052, AUSTRALIA	St Vincents Hospital Sydney; St Vincents Hospital Sydney; University of New South Wales Sydney; University of New South Wales Sydney	Dolnikov, A (corresponding author), ST VINCENTS HOSP, DEPT CLIN PHARMACOL & TOXICOL, DARLINGHURST, NSW 2010, AUSTRALIA.		Hawkins, Nicholas J/A-8461-2008; Ward, Robyn L/I-2313-2013	Hawkins, Nicholas J/0000-0002-2204-3189; Ward, Robyn L/0000-0002-6877-8906				ALITALO K, 1983, NATURE, V306, P274, DOI 10.1038/306274a0; AMATI B, 1993, EMBO J, V12, P5083, DOI 10.1002/j.1460-2075.1993.tb06202.x; AMATI B, 1993, CELL, V72, P233, DOI 10.1016/0092-8674(93)90663-B; AMIN C, 1993, MOL CELL BIOL, V13, P383, DOI 10.1128/MCB.13.1.383; ARMELIN HA, 1984, NATURE, V310, P655, DOI 10.1038/310655a0; ASAI A, 1994, J NEURO-ONCOL, V19, P259, DOI 10.1007/BF01053280; ASKEW DS, 1991, ONCOGENE, V6, P1915; BAXTER JD, 1971, SCIENCE, V171, P189, DOI 10.1126/science.171.3967.189; BISSONNETTE RP, 1992, NATURE, V359, P552, DOI 10.1038/359552a0; BONHAM L, 1992, ONCOGENE, V7, P2219; BOURGEOIS S, 1977, CELL, V11, P423, DOI 10.1016/0092-8674(77)90060-5; BRADBURY D, 1992, BLOOD S1, V80, pA924; CHAMBERS SK, 1993, EXP HEMATOL, V21, P1328; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHISHOLM O, 1992, ONCOGENE, V7, P1827; CLARK SC, 1987, SCIENCE, V236, P1229, DOI 10.1126/science.3296190; COHEN JJ, 1993, IMMUNOL TODAY, V14, P126, DOI 10.1016/0167-5699(93)90214-6; DARZYNKIEWICZ Z, 1992, CYTOMETRY, V13, P795, DOI 10.1002/cyto.990130802; DAVIDOFF AN, 1993, EXP HEMATOL, V21, P922; DENG G, 1993, P NATL ACAD SCI USA, V90, P2189, DOI 10.1073/pnas.90.6.2189; DOLNIKOV A, 1995, INT J ONCOL, V6, P633; DOLNIKOV A, 1996, IN PRESS CANCER GENE; EILERS M, 1991, EMBO J, V10, P133, DOI 10.1002/j.1460-2075.1991.tb07929.x; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FACCHINI LM, 1994, CELL GROWTH DIFFER, V5, P637; FUKASAWA Y, 1994, AM J PATHOL, V144, P480; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; HARRINGTON EA, 1994, CURR OPIN GENET DEV, V4, P120, DOI 10.1016/0959-437X(94)90100-7; HELMBERG A, 1995, EMBO J, V14, P452, DOI 10.1002/j.1460-2075.1995.tb07021.x; HOWLES KA, 1994, GENE DEV, V8, P1300; KATO GJ, 1990, MOL CELL BIOL, V10, P5914, DOI 10.1128/MCB.10.11.5914; KOWALIK TF, 1995, J VIROL, V69, P2491, DOI 10.1128/JVI.69.4.2491-2500.1995; LADNER MB, 1987, EMBO J, V6, P2693, DOI 10.1002/j.1460-2075.1987.tb02561.x; LOTEM J, 1993, CELL GROWTH DIFFER, V4, P41; LUSCHER B, 1990, GENE DEV, V4, P2025, DOI 10.1101/gad.4.12a.2025; MARCU KB, 1992, ANNU REV BIOCHEM, V61, P809, DOI 10.1146/annurev.bi.61.070192.004113; NORMAN MR, 1977, CANCER RES, V37, P3785; RAFF MC, 1992, NATURE, V356, P397, DOI 10.1038/356397a0; RUSTGI AK, 1991, NATURE, V352, P541, DOI 10.1038/352541a0; SHAN B, 1994, MOL CELL BIOL, V14, P8166, DOI 10.1128/MCB.14.12.8166; SIBLEY CH, 1974, CELL, V2, P213, DOI 10.1016/0092-8674(74)90013-0; SMITH CA, 1989, NATURE, V337, P181, DOI 10.1038/337181a0; SPENCER CA, 1991, ADV CANCER RES, V56, P1; STANLEY ER, 1977, J BIOL CHEM, V252, P4305; STAPLETON P, 1991, ONCOGENE, V6, P807; WAGNER AJ, 1993, MOL CELL BIOL, V13, P2432, DOI 10.1128/MCB.13.4.2432; WANG YS, 1993, ONCOGENE, V8, P3427; WANG YS, 1993, CELL GROWTH DIFFER, V4, P467; WHITE E, 1991, J VIROL, V65, P2968, DOI 10.1128/JVI.65.6.2968-2978.1991	49	10	10	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 21	1996	12	6					1189	1198						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UC067	8649820				2022-12-25	WOS:A1996UC06700003
J	Riewald, M; Schleef, RR				Riewald, M; Schleef, RR			Human cytoplasmic antiproteinase neutralizes rapidly and efficiently chymotrypsin and trypsin-like proteases utilizing distinct reactive site residues	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERINE PROTEINASE-INHIBITOR; ALPHA-1-PROTEINASE INHIBITOR; MOLECULAR CHARACTERIZATION; NEUTROPHIL ELASTASE; ESCHERICHIA-COLI; ALPHA-2-ANTIPLASMIN; SERPIN; EXPRESSION; OVALBUMIN; MECHANISM	Human cytoplasmic antiproteinase (CAP) is an intracellular serpin that has been reported to utilize Arg(341) as the reactive site P-1 residue to neutralize a broad variety of extracellular serine proteases with trypsin-like specificity. Both native CAP and recombinant CAP purified from Escherichia coli were observed to form SDS-stable complexes not only with I-125-thrombin and I-125-urokinase, but also with I-125-chymotrypsin. Kinetic studies indicated that the amidolytic activity of chymotrypsin is inhibited efficiently and rapidly by CAP in a two-step process with a dissociation constant K-i of an initial loose complex of 3.3 nM, a forward isomerization rate constant k(2) to the tight complex of 0.014 s(-1), and an overall second order association rate constant of 6 x 10(6) M(-1) s(-1) similar to the kinetic constants obtained for the formation of the trypsin-CAP complex. N-terminal amino acid sequencing and mass spectrometry indicated that chymotrypsin interacts with CAP at Met(340), in contrast to thrombin, which interacts as expected at Arg(341). Thus, CAP is the first serpin that has been shown to be capable to inhibit efficiently and with similar association rate constants different proteases at distinct reactive site residues, strongly supporting the notion of a highly mobile and flexible serpin reactive site loop and suggesting that this inhibitor may have evolved separate reactive sites for the specific regulation of different proteolytic activities.	Scripps Res Inst, DEPT VASC BIOL VB1, LA JOLLA, CA 92037 USA	Scripps Research Institute					NHLBI NIH HHS [HL49563, HL45954] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL049563, R01HL045954] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BEATTY K, 1980, J BIOL CHEM, V255, P3931; CHASE T, 1970, METHOD ENZYMOL, V19, P20; CHRISTENSEN S, 1995, J BIOL CHEM, V270, P14859, DOI 10.1074/jbc.270.25.14859; CIECHANOVER A, 1994, CELL, V79, P13, DOI 10.1016/0092-8674(94)90396-4; COUGHLIN P, 1993, P NATL ACAD SCI USA, V90, P9417, DOI 10.1073/pnas.90.20.9417; COUGHLIN PB, 1993, J BIOL CHEM, V268, P9541; CREIGHTON TE, 1989, TRENDS BIOCHEM SCI, V14, P319, DOI 10.1016/0968-0004(89)90159-X; DOUGHERTY WG, 1993, MICROBIOL REV, V57, P781, DOI 10.1128/MMBR.57.4.781-822.1993; EATON DL, 1983, J CELL PHYSIOL, V117, P175, DOI 10.1002/jcp.1041170207; ENGHILD JJ, 1993, BIOCHEM J, V291, P933, DOI 10.1042/bj2910933; FALLER B, 1993, BIOCHEMISTRY-US, V32, P9230, DOI 10.1021/bi00086a031; GOGSTAD GO, 1983, THROMB RES, V31, P387, DOI 10.1016/0049-3848(83)90339-0; HAHM B, 1995, J VIROL, V69, P2534, DOI 10.1128/JVI.69.4.2534-2539.1995; HEDSTROM L, 1992, SCIENCE, V255, P1249, DOI 10.1126/science.1546324; HILL RE, 1987, NATURE, V326, P96, DOI 10.1038/326096a0; HIREL PH, 1989, P NATL ACAD SCI USA, V86, P8247, DOI 10.1073/pnas.86.21.8247; HOPKINS PCR, 1994, SCIENCE, V265, P1893; HUBER R, 1989, BIOCHEMISTRY-US, V28, P8951, DOI 10.1021/bi00449a001; HUNT LT, 1980, BIOCHEM BIOPH RES CO, V95, P864, DOI 10.1016/0006-291X(80)90867-0; KEZDY FJ, 1970, METHOD ENZYMOL, V19, P3; KIRSCHNER RJ, 1980, J BIOL CHEM, V255, P5468; KUMAR S, 1995, TRENDS BIOCHEM SCI, V20, P198, DOI 10.1016/S0968-0004(00)89007-6; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAWRENCE DA, 1995, J BIOL CHEM, V270, P25309, DOI 10.1074/jbc.270.43.25309; LONGSTAFF C, 1991, BIOCHEMISTRY-US, V30, P979, DOI 10.1021/bi00218a014; MATHESON NR, 1991, J BIOL CHEM, V266, P13489; MORGENSTERN KA, 1993, J BIOL CHEM, V268, P21560; MORGENSTERN KA, 1994, BIOCHEMISTRY-US, V33, P3432, DOI 10.1021/bi00177a037; MORRISON JF, 1988, ADV ENZYMOL RAMB, V61, P201; NACHMAN RL, 1976, J BIOL CHEM, V251, P4514; PEMBERTON PA, 1995, J BIOL CHEM, V270, P15832, DOI 10.1074/jbc.270.26.15832; POTEMPA J, 1988, SCIENCE, V241, P699, DOI 10.1126/science.2456616; POTEMPA J, 1994, J BIOL CHEM, V269, P15957; RECHSTEINER M, 1993, J BIOL CHEM, V268, P6065; REMOLDODONNELL E, 1992, P NATL ACAD SCI USA, V89, P5635, DOI 10.1073/pnas.89.12.5635; REMOLDODONNELL E, 1993, FEBS LETT, V315, P105, DOI 10.1016/0014-5793(93)81143-N; Riewald M, 1996, J BIOL CHEM, V271, P7160, DOI 10.1074/jbc.271.12.7160; RIEWALD M, 1995, J BIOL CHEM, V270, P26754, DOI 10.1074/jbc.270.45.26754; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Scott FL, 1996, J BIOL CHEM, V271, P1605, DOI 10.1074/jbc.271.3.1605; SHAPIRO R, 1984, BIOCHEMISTRY-US, V23, P5234, DOI 10.1021/bi00317a022; SHARMA SK, 1981, BIOORG CHEM, V10, P357, DOI 10.1016/0045-2068(81)90049-3; SHIEH BH, 1989, J BIOL CHEM, V264, P13420; SHIEH BH, 1987, J BIOL CHEM, V262, P6055; STONE SR, 1987, ARCH BIOCHEM BIOPHYS, V252, P237, DOI 10.1016/0003-9861(87)90028-2; SUMINAMI Y, 1991, BIOCHEM BIOPH RES CO, V181, P51, DOI 10.1016/S0006-291X(05)81380-4; SUN JR, 1995, BBA-PROTEIN STRUCT M, V1252, P28, DOI 10.1016/0167-4838(95)00108-7; SUN JR, 1995, J BIOL CHEM, V270, P16089, DOI 10.1074/jbc.270.27.16089; WRIGHT HT, 1995, PROTEINS, V22, P210, DOI 10.1002/prot.340220303; YE RD, 1987, J BIOL CHEM, V262, P3718; ZOU ZQ, 1994, SCIENCE, V263, P526, DOI 10.1126/science.8290962	51	26	30	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 14	1996	271	24					14526	14532		10.1074/jbc.271.24.14526	http://dx.doi.org/10.1074/jbc.271.24.14526			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UQ660	8662739	hybrid			2022-12-25	WOS:A1996UQ66000087
J	Oliver, JD; Hresko, RC; Mueckler, M; High, S				Oliver, JD; Hresko, RC; Mueckler, M; High, S			The glut 1 glucose transporter interacts with calnexin and calreticulin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM; PROTEIN TRANSLOCATION; GLYCOPROTEINS; TRANSCRIPTION; CHAPERONE; MEMBRANE; CELL; IP90	Calnexin is an integral membrane protein that acts as a chaperone during glycoprotein folding in the endoplasmic reticulum. Cross-linking studies were carried out with the aim of investigating the interactions of calnexin with glycoproteins in vitro, A truncated version of the integral membrane glycoprotein Glut 1 (GT(155)) was synthesized in a rabbit reticulocyte translation system in the presence of canine pancreatic microsomes, Following immunoprecipitation with an anti-calnexin antiserum, a cross-linker-independent association was observed between GT(155) and calnexin. In addition, the anti-calnexin antiserum immunoprecipitated a W-dependent cross-linking product consisting of GT(155) and a protein of approximately 60 kDa designated CAP-60 (calnexin-associated protein of 60 kDa), Both the GT(155)-calnexin and the GT(155)-CAP-60 interactions were dependent on the presence of a correctly modified oligosaccharide group on GT(155), a characteristic of many calnexin interactions, A GT(155) mutant that was not glycosylated (AGGT(155)) did not associate with calnexin or CAP-60, Calreticulin, the soluble homologue of calnexin, was also shown to interact with GT(155) only when the protein bore a correctly modified oligosaccharide group, Thus, our data show that both calnexin and calreticulin with Glut 1 in a glycosylation-dependent manner.	UNIV MANCHESTER, SCH BIOL SCI, MANCHESTER M13 9PT, LANCS, ENGLAND; WASHINGTON UNIV, SCH MED, DEPT CELL BIOL & PHYSIOL, ST LOUIS, MO 63110 USA	University of Manchester; Washington University (WUSTL)			Mueckler, Mike M/F-6115-2012	High, Stephen/0000-0002-4532-8152	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043695] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK43695] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDERSON KS, 1994, EMBO J, V13, P675, DOI 10.1002/j.1460-2075.1994.tb06306.x; BERGERON JJM, 1994, TRENDS BIOCHEM SCI, V19, P124, DOI 10.1016/0968-0004(94)90205-4; BULLEID NJ, 1988, NATURE, V335, P649, DOI 10.1038/335649a0; DAVID V, 1993, J BIOL CHEM, V268, P9585; DEGEN E, 1991, J CELL BIOL, V112, P1099, DOI 10.1083/jcb.112.6.1099; FRYDMAN J, 1994, NATURE, V370, P111, DOI 10.1038/370111a0; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GILMORE R, 1991, METHOD CELL BIOL, V34, P223; HAMMOND C, 1994, P NATL ACAD SCI USA, V91, P913, DOI 10.1073/pnas.91.3.913; HAMMOND C, 1994, SCIENCE, V266, P456, DOI 10.1126/science.7939687; HAMMOND C, 1994, J CELL BIOL, V126, P41, DOI 10.1083/jcb.126.1.41; HEBERT DN, 1995, CELL, V81, P425, DOI 10.1016/0092-8674(95)90395-X; HELENIUS A, 1994, MOL BIOL CELL, V5, P253, DOI 10.1091/mbc.5.3.253; Helenius Ari, 1992, Trends in Cell Biology, V2, P227, DOI 10.1016/0962-8924(92)90309-B; HIGH S, 1995, PROG BIOPHYS MOL BIO, V63, P233, DOI 10.1016/0079-6107(95)00005-8; HOCHSTENBACH F, 1992, P NATL ACAD SCI USA, V89, P4734, DOI 10.1073/pnas.89.10.4734; HRESKO RC, 1994, J BIOL CHEM, V269, P20482; HURTLEY SM, 1989, ANNU REV CELL BIOL, V5, P277, DOI 10.1146/annurev.cb.05.110189.001425; JACKSON MR, 1994, SCIENCE, V263, P384, DOI 10.1126/science.8278813; KEARSE KP, 1994, EMBO J, V13, P3678, DOI 10.1002/j.1460-2075.1994.tb06677.x; KIM PS, 1995, J CELL BIOL, V128, P29, DOI 10.1083/jcb.128.1.29; MARGOLESE L, 1993, J BIOL CHEM, V268, P17959; MICHALAK M, 1992, BIOCHEM J, V285, P681, DOI 10.1042/bj2850681; NASH PD, 1994, MOL CELL BIOCHEM, V135, P71, DOI 10.1007/BF00925962; NAUSEEF WM, 1995, J BIOL CHEM, V270, P4741, DOI 10.1074/jbc.270.9.4741; NICCHITTA CV, 1993, CELL, V73, P989, DOI 10.1016/0092-8674(93)90276-V; OU WJ, 1993, NATURE, V364, P771, DOI 10.1038/364771a0; PARKER CG, 1995, EMBO J, V14, P1294, DOI 10.1002/j.1460-2075.1995.tb07115.x; PETERSON JR, 1995, MOL BIOL CELL, V6, P1173, DOI 10.1091/mbc.6.9.1173; RAJAGOPALAN S, 1994, SCIENCE, V263, P387, DOI 10.1126/science.8278814; RAJAGOPALAN S, 1994, J EXP MED, V180, P407, DOI 10.1084/jem.180.1.407; SCHREIBER KL, 1994, INT IMMUNOL, V6, P101, DOI 10.1093/intimm/6.1.101; SOUSA MC, 1992, BIOCHEMISTRY-US, V31, P97, DOI 10.1021/bi00116a015; STUEBER D, 1984, EMBO J, V3, P3143, DOI 10.1002/j.1460-2075.1984.tb02271.x; WADA I, 1991, J BIOL CHEM, V266, P19599; WARE FE, 1995, J BIOL CHEM, V270, P4697, DOI 10.1074/jbc.270.9.4697	36	43	44	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 7	1996	271	23					13691	13696		10.1074/jbc.271.23.13691	http://dx.doi.org/10.1074/jbc.271.23.13691			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UP385	8662691	hybrid			2022-12-25	WOS:A1996UP38500060
J	Teckman, JH; Perlmutter, DH				Teckman, JH; Perlmutter, DH			The endoplasmic reticulum degradation pathway for mutant secretory proteins alpha 1-antitrypsin Z and S is distinct from that for an unassembled membrane protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GOLGI-APPARATUS; DIRECTED MUTAGENESIS; BREFELDIN-A; RECEPTOR; VARIANT	We have theorized that a subset of PiZZ alpha 1-antitrypsin (alpha 1-AT)-deficient individuals is more susceptible to liver injury by virtue of second inherited trait(s) or environmental factor(s), which exaggerate the accumulation of mutant alpha 1-AT Z within the endoplasmic reticulum (ER) of Liver cells, Using a complementation approach in which cell Lines from PiZZ individuals with liver disease (''susceptible'' hosts) and from PiZZ individuals without liver disease (''protected'' hosts) are transduced with the mutant alpha 1-AT Z gene, we have recently shown that there is a delay in ER degradation of mutant alpha 1-AT Z protein that is only present in cell lines from susceptible hosts and correlates with the liver disease phenotype. In the present study we examined the specificity of this ER degradation pathway to determine if it is responsible for degrading other misfolded mutants of alpha 1-AT and/or for unassembled membrane proteins. The S mutant of alpha 1-AT and H2a subunit of the asialoglycoprotein receptor (ASGPR H2a) were expressed in skin fibroblast cell lines from susceptible and protected hosts. The results showed in both susceptible and protected hosts that alpha 1-AT S was associated with a delay in secretion as compared with wild type alpha 1-AT. The alpha 1-AT S mutant was retained in ER, albeit to a lesser extent than the alpha 1-AT Z mutant, There was, however, a significant increase in retention of alpha 1-AT S in the ER of susceptible as compared with protected host cells. The same host cell lines were transduced to express an unassembled membrane protein, ASGPR H2a, There was no difference in the kinetics of ER degradation of ASGPR H2a in susceptible as compared with protected hosts, Taken together, the results show that alpha 1-AT S is associated with a defect in biogenesis, intracellular retention, which is similar to but milder than alpha 1-AT Z. Like alpha 1-AT Z, alpha 1-AT S is degraded by a pathway in the ER, which is relatively inefficient in PiZZ individuals with the liver disease phenotype. However, this pathway appears to be different from that previously described for a model unassembled membrane protein.	WASHINGTON UNIV,SCH MED,DEPT PEDIAT,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT PHYSIOL & CELL BIOL,ST LOUIS,MO 63110; CHILDRENS HOSP,DIV GASTROENTEROL & NUTR,ST LOUIS,MO 63110	Washington University (WUSTL); Washington University (WUSTL); St. Louis Children's Hospital				Teckman, Jeffrey/0000-0002-4870-2621	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [T32HD007409] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL037784] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K11DK002379] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL37784] Funding Source: Medline; NICHD NIH HHS [T32 HD07409] Funding Source: Medline; NIDDK NIH HHS [K11DK02379] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BLOOM GS, 1989, J BIOL CHEM, V264, P16083; BRODBECK RM, 1993, J BIOL CHEM, V268, P6771; CARLSON JA, 1988, J CLIN INVEST, V83, P1183; CHENG SH, 1990, CELL, V63, P827, DOI 10.1016/0092-8674(90)90148-8; CRYSTAL RG, 1990, J CLIN INVEST, V85, P1343, DOI 10.1172/JCI114578; CURIEL DT, 1989, J BIOL CHEM, V264, P10477; DONALDSON JG, 1990, J CELL BIOL, V111, P2295, DOI 10.1083/jcb.111.6.2295; DYCAICO MJ, 1988, SCIENCE, V242, P1409, DOI 10.1126/science.3264419; ERIKSSON S, 1986, NEW ENGL J MED, V314, P736, DOI 10.1056/NEJM198603203141202; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; INOUE S, 1992, J BIOL CHEM, V267, P9080; JENSEN TJ, 1995, CELL, V83, P129, DOI 10.1016/0092-8674(95)90241-4; KELLER G, 1985, NATURE, V318, P149, DOI 10.1038/318149a0; KLAUSNER RD, 1990, CELL, V62, P611, DOI 10.1016/0092-8674(90)90104-M; KTISTAKIS NT, 1991, J CELL BIOL, V113, P1009, DOI 10.1083/jcb.113.5.1009; LE AQ, 1992, J BIOL CHEM, V267, P1072; LIPPINCOTTSCHWARTZ J, 1988, CELL, V54, P209, DOI 10.1016/0092-8674(88)90553-3; MILLER AD, 1986, MOL CELL BIOL, V6, P2895, DOI 10.1128/MCB.6.8.2895; NAKAMAYE KL, 1986, NUCLEIC ACIDS RES, V14, P9679, DOI 10.1093/nar/14.24.9679; OWEN MC, 1976, BRIT MED J, V1, P130; Perlmutter D H, 1993, Prog Liver Dis, V11, P139; SHIA MA, 1989, P NATL ACAD SCI USA, V86, P1158, DOI 10.1073/pnas.86.4.1158; SMITH GH, 1987, METHOD ENZYMOL, V151, P534; SVEGER T, 1995, HEPATOLOGY, V22, P514, DOI 10.1002/hep.1840220221; SVEGER T, 1976, NEW ENGL J MED, V294, P1216; WARD CL, 1994, J BIOL CHEM, V269, P25710; WARD CL, 1995, CELL, V83, P121, DOI 10.1016/0092-8674(95)90240-6; WU Y, 1994, P NATL ACAD SCI USA, V91, P9014, DOI 10.1073/pnas.91.19.9014; YUK MH, 1993, J CELL BIOL, V123, P1735, DOI 10.1083/jcb.123.6.1735; YUNG ST, 1992, J CELL BIOL, V116, P57	30	73	75	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 31	1996	271	22					13215	13220		10.1074/jbc.271.22.13215	http://dx.doi.org/10.1074/jbc.271.22.13215			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UN474	8662752	hybrid			2022-12-25	WOS:A1996UN47400081
J	Ding, M; Vandre, DD				Ding, M; Vandre, DD			High molecular weight microtubule-associated proteins contain O-linked N-acetylglucosamine	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHONDROITIN SULFATE PROTEOGLYCAN; IMMUNOCYTOCHEMICAL LOCALIZATION; CYTOPLASMIC PROTEINS; NERVOUS-TISSUE; GLYCOSYLATION; PHOSPHORYLATION; INHIBITION; FILAMENTS; NUCLEAR; BRAIN	We have examined the post-translational modification of high molecular weight microtubule-associated proteins (MAPs) and have shown that MAP1, MAP2, and MAP4 are glycosylated. The presence of carbohydrate residues on these proteins was indicated by labeling with biotin hydrazide following periodate oxidation, a specific and well established method for detecting saccharide moieties on proteins. Both MAP2 and MAP4 were also labeled in vitro by UDP-[H-3]galactose in the presence of galactosyltransferase. Labeling by galactosyltransferase indicated that MAP2 and MAP4 contained terminal nonreducing GlcNAc residues, and they appeared to be O-linked to the proteins as shown by their sensitivity to beta-elimination. Chromatographic analysis showed that the GlcNAc residues were directly linked to the proteins as monosaccharides. Thus, we have added MAP2 and MAP4 to the list of intracellular O-GlcNAc-modified proteins, which includes other cytoskeletal proteins such as cytokeratins 8, 13, and 18 and neurofilament proteins NF-L and NF-M. We further characterized the O-GlcNAc modification of MAP2, and stoichiometric analysis indicated that nearly 10% of the MAP2 isolated from rat brain is modified by O-GlcNAc. However, this estimate is thought to reflect the minimal level of O-GlcNAc modification present on MAP2. We have also shown that both the O-GlcNAc and biotin hydrazide-reactive carbohydrate moieties are located on the projection domain of MAP2. Three O-GlcNAc-containing peaks were observed following fast protein liquid chromatography of a tryptic digest of MAP2, suggesting that multiple modification sites exist. The specific modification sites and functional significance of the O-GlcNAc glycosylation on the high M(r) MAPs remain to be determined.	OHIO STATE UNIV,DEPT CELL BIOL NEUROBIOL & ANAT,COLUMBUS,OH 43210; OHIO STATE UNIV,PROGRAM MOL CELLULAR & DEV BIOL,COLUMBUS,OH 43210	University System of Ohio; Ohio State University; University System of Ohio; Ohio State University					NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS031777] Funding Source: NIH RePORTER; NINDS NIH HHS [NS31777] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AQUINO DA, 1984, J CELL BIOL, V99, P1117, DOI 10.1083/jcb.99.3.1117; AQUINO DA, 1984, J CELL BIOL, V99, P1130, DOI 10.1083/jcb.99.3.1130; BRIONES E, 1985, P NATL ACAD SCI USA, V82, P5776, DOI 10.1073/pnas.82.17.5776; BURG MA, 1994, J NEUROBIOL, V25, P1, DOI 10.1002/neu.480250102; CACERES A, 1990, NATURE, V343, P461, DOI 10.1038/343461a0; CHAKRABORTY A, 1994, BIOCHEMISTRY-US, V33, P6700, DOI 10.1021/bi00187a041; CHOU CF, 1993, J BIOL CHEM, V268, P4465; CHOU CF, 1992, J BIOL CHEM, V267, P3901; DINSMORE JH, 1991, CELL, V64, P817, DOI 10.1016/0092-8674(91)90510-6; DONG DLY, 1993, J BIOL CHEM, V268, P16679; DONG DLY, 1994, J BIOL CHEM, V269, P19321; DUBOIS M, 1956, ANAL CHEM, V28, P350, DOI 10.1021/ac60111a017; HALTIWANGER RS, 1992, BIOCHEM SOC T, V20, P264, DOI 10.1042/bst0200264; HALTIWANGER RS, 1992, J BIOL CHEM, V267, P9005; HART GW, 1989, ANNU REV BIOCHEM, V58, P841; Hyams J. S., 1994, MICROTUBULES; JOLY JC, 1989, J CELL BIOL, V109, P2289, DOI 10.1083/jcb.109.5.2289; KELLY WG, 1993, J BIOL CHEM, V268, P10416; KING IA, 1989, J BIOL CHEM, V264, P14022; KIRSCHNER M, 1986, CELL, V45, P329, DOI 10.1016/0092-8674(86)90318-1; KOBATA A, 1994, METHOD ENZYMOL, V230, P200; LEDESMA MD, 1994, J BIOL CHEM, V269, P21614; MURAMOTO K, 1994, BIOCHEM BIOPH RES CO, V205, P1467, DOI 10.1006/bbrc.1994.2830; OLMSTED JB, 1986, ANNU REV CELL BIOL, V2, P421, DOI 10.1146/annurev.cb.02.110186.002225; OOKATA K, 1995, J CELL BIOL, V128, P849, DOI 10.1083/jcb.128.5.849; ROQUEMORE EP, 1994, METHOD ENZYMOL, V230, P443; SCHAFER IA, 1993, EXP CELL RES, V207, P213, DOI 10.1006/excr.1993.1185; SOLTYS BJ, 1992, BIOCHEM CELL BIOL, V70, P1174, DOI 10.1139/o92-163; THEURKAUF WE, 1982, J BIOL CHEM, V257, P3284; VALLEE R, 1980, P NATL ACAD SCI-BIOL, V77, P3206, DOI 10.1073/pnas.77.6.3206; VALLEE RB, 1986, METHOD ENZYMOL, V134, P124; VANDRE DD, 1991, J CELL SCI, V98, P577; WILCHEK M, 1987, METHOD ENZYMOL, V138, P429; YAN SD, 1994, P NATL ACAD SCI USA, V91, P7787, DOI 10.1073/pnas.91.16.7787	34	56	59	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 24	1996	271	21					12555	12561		10.1074/jbc.271.21.12555	http://dx.doi.org/10.1074/jbc.271.21.12555			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UL660	8647865	hybrid			2022-12-25	WOS:A1996UL66000067
J	Kashiwagi, K; Pistocchi, R; Shibuya, S; Sugiyama, S; Morikawa, K; Igarashi, K				Kashiwagi, K; Pistocchi, R; Shibuya, S; Sugiyama, S; Morikawa, K; Igarashi, K			Spermidine-preferential uptake system in Escherichia coli - Identification of amino acids involved in polyamine binding in PotD protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PUTRESCINE TRANSPORT-SYSTEM; CHROMOSOME; GROWTH; GENES; MAPS	Spermidine-binding sites on PotD protein, a substrate-binding protein in periplasm, in the spermidine-preferential uptake system in Escherichia coli were studied by measuring polyamine transport activities of right-side-out membrane vesicles with mutated PotD proteins prepared by site-directed mutagenesis of the potD gene and by measuring polyamine binding activities of these mutated PotD proteins. Polyamine transport activities of the mutated PotD proteins paralleled their polyamine binding activities. It was found that Trp-34, Thr-35, Glu-36, Tyr-37, Ser-83, Tyr-85, Asp-168, Glu-171, Trp-229, Trp-255, Asp-257, Tyr-293, and Gln-327 of PotD protein were involved in the binding to spermidine. When spermidine uptake activities were measured in intact cells expressing the mutated PotD proteins, it was found that Glu-171, Trp-255, and Asp-257 were more strongly involved in the binding of spermidine to PotD protein than the other amino acids listed above. The dissociation constants of spermidine for the mutated PotD proteins at Glu-171, Trp-255, and Asp-257 increased greatly in comparison with those for the other mutated PotD proteins. Since these three amino acids clearly interact with the diaminopropane moiety of spermidine, the results are in accordance with the finding that PotD protein has a higher affinity for spermidine than for putrescine. Putrescine was found to bind at the position of the diaminobutane moiety of spermidine.	CHIBA UNIV,FAC PHARMACEUT SCI,INAGE KU,CHIBA 263,JAPAN; PROT ENGN RES INST,SUITA,OSAKA 565,JAPAN	Chiba University				Igarashi, Kazuei/0000-0003-3751-3187; PISTOCCHI, ROSSELLA/0000-0003-1304-6270				ADAMS MD, 1989, J BIOL CHEM, V264, P15739; AMES GFL, 1986, ANNU REV BIOCHEM, V55, P397, DOI 10.1146/annurev.biochem.55.1.397; FRYDMAN L, 1992, P NATL ACAD SCI USA, V89, P9186, DOI 10.1073/pnas.89.19.9186; FURUCHI T, 1991, J BIOL CHEM, V266, P20928; HIGGINS CF, 1995, CELL, V82, P693, DOI 10.1016/0092-8674(95)90465-4; KASHIWAGI K, 1990, J BIOL CHEM, V265, P8387; KASHIWAGI K, 1990, J BIOL CHEM, V265, P20893; KASHIWAGI K, 1993, J BIOL CHEM, V268, P19358; KASHIWAGI K, 1991, J BIOL CHEM, V266, P20922; KASHIWAGI K, 1992, P NATL ACAD SCI USA, V89, P4529, DOI 10.1073/pnas.89.10.4529; KASHIWAGI K, 1986, J BACTERIOL, V165, P972, DOI 10.1128/jb.165.3.972-977.1986; KASHIWAGI K, 1988, J BACTERIOL, V170, P3131, DOI 10.1128/jb.170.7.3131-3135.1988; KASHIWAGI K, 1995, J BIOL CHEM, V270, P25377, DOI 10.1074/jbc.270.43.25377; LINDEROTH N, 1983, BIOCHEM BIOPH RES CO, V117, P616, DOI 10.1016/0006-291X(83)91245-7; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Maniatis T., 1982, MOL CLONING LAB MANU, P250; MATSUO Y, 1994, FEBS LETT, V345, P23, DOI 10.1016/0014-5793(94)00435-8; OH BH, 1994, J BIOL CHEM, V269, P4135; OH BH, 1994, J BIOL CHEM, V269, P26323; OLIVER DB, 1982, CELL, V30, P311, DOI 10.1016/0092-8674(82)90037-X; PEGG AE, 1988, CANCER RES, V48, P759; PISTOCCHI R, 1993, J BIOL CHEM, V268, P146; SAMBROOK J, 1989, MOL CLONING LAB MANU, pA1; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAYERS JR, 1992, BIOTECHNIQUES, V13, P592; SCATCHARD G, 1949, ANN NY ACAD SCI, V84, P4767; Sugiyama S, 1996, J BIOL CHEM, V271, P9519, DOI 10.1074/jbc.271.16.9519; Sugiyama S, 1996, ACTA CRYSTALLOGR D, V52, P416, DOI 10.1107/S0907444995011498; TABOR CW, 1984, ANNU REV BIOCHEM, V53, P749, DOI 10.1146/annurev.bi.53.070184.003533; WOLF A, 1994, J BIOL CHEM, V269, P23051; WOLF A, 1995, J BIOL CHEM, V270, P16097, DOI 10.1074/jbc.270.27.16097; YAMAGUCHI K, 1985, MOL GEN GENET, V200, P362, DOI 10.1007/BF00425718; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; YAO NH, 1994, BIOCHEMISTRY-US, V33, P4769, DOI 10.1021/bi00182a004	34	65	66	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 24	1996	271	21					12205	12208		10.1074/jbc.271.21.12205	http://dx.doi.org/10.1074/jbc.271.21.12205			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UL660	8647815	hybrid			2022-12-25	WOS:A1996UL66000017
J	Khoo, KH; Chatterjee, D; Dell, A; Morris, HR; Brennan, PJ; Draper, P				Khoo, KH; Chatterjee, D; Dell, A; Morris, HR; Brennan, PJ; Draper, P			Novel O-methylated terminal glucuronic acid characterizes the polar glycopeptidolipids of Mycobacterium habana strain TMC 5135	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOLIPID ANTIGENS; IDENTIFICATION; TUBERCULOSIS; XENOPI; AVIUM; MICE	Mycobacterium ''habana'' strain TMC 5135, which has been proposed as a vaccine against both leprosy and tuberculosis, is considered to be a strain of serotype I of the recognized species Mycobacterium simiae. We have now shown that each of these strains possesses characteristic polar glycopeptidolipids (GPL) which are sufficiently different to allow unequivocal strain identification. Thin layer chromatographic analysis demonstrated that M. habana synthesizes a family of apolar GPLs and three distinct polar GPLs (pGPL-I to -III) which exhibited migration patterns different from those of M. simiae serotype I (pGPL-Sim). Using a combination of chemical, mass spectrometric, and proton-NMR analyses, the GPLs from M. habana were determined to be based on the same generic structure as those from the M. avium complex, namely N-fatty acyl-D-Phe-(O-saccharide)-D-allo-Thr-D-Ala-L-alaninyl-O-monosaccharide. The de-O-acetylated apolar GPLs contain a 3-O-Me-6-deoxy-Tal attached to the allo-Thr and either a 3-O-Me-Rha or a 3,4-di-O-Me-Rha attached to the alaninol. In the pGPLs, oligosaccharides were found to be attached to the allo-Thr. The oligoglycosyl alditol reductively released from the least polar pGPL-I was fully characterized as L-Fucp alpha 1-->3-(6-O-Me)-D-Glcp beta 1-->3-(4-O-Me)-L-Rhap alpha 1-->3-L-Rhap alpha 1-->2-(3-O-Me)-6-deoxy-Tal. In pGPL-II and -III, the terminal Fuc residue is further 3-O-methylated and 4-O-substituted with an additional 2,4-di-O-Me-D-GlcA and 4-O-Me-D-GlcA, respectively. The corresponding oligosaccharide from pGPL-Sim was shown to be of identical molecular weight 60 pGPL-II but terminating with a 3,4-di-O-Me-GlcA. Enzyme-linked immunosorbent assay-based serological studies using anti-M. habana and anti-M. simiae sera against whole cells and purified pGPLs firmly established the polar GPLs as important antigens and indicated that the terminal epitopes L-Fuc-, 2,4-di-O-Me-D-GlcA, and 4-O-Me-D-GlcA uniquely present in pGPL-I, II, and -III, respectively, confer sufficient specificity for the identification of M. habana as a distinct serotype of M. simiae.	UNIV LONDON IMPERIAL COLL SCI TECHNOL & MED, DEPT BIOCHEM, LONDON SW7 2AY, ENGLAND; COLORADO STATE UNIV, DEPT MICROBIOL, FT COLLINS, CO 80523 USA; NATL INST MED RES, LONDON NW7 1AA, ENGLAND	Imperial College London; Colorado State University; MRC National Institute for Medical Research			Khoo, Kay-Hooi/E-1989-2019	Khoo, Kay-Hooi/0000-0003-2906-406X	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R22AI018357, R37AI018357, R01AI018357] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 18357] Funding Source: Medline; Wellcome Trust Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Wellcome Trust(Wellcome TrustEuropean Commission)		ANZ W, 1969, ZBL BAKT 1 ORIG, V221, P530; Aspinall GO, 1995, ADV CARBOHYD CHEM BI, V51, P169, DOI 10.1016/S0065-2318(08)60194-8; BAESS I, 1982, ACTA PATH MICRO IM B, V90, P101; BAX A, 1986, J AM CHEM SOC, V108, P2093, DOI 10.1021/ja00268a061; BESRA GS, 1994, ZBL BAKT-INT J MED M, V281, P415; BESRA GS, 1993, BIOCHEMISTRY-US, V32, P347, DOI 10.1021/bi00052a043; BLOOM BR, 1992, SCIENCE, V257, P1055, DOI 10.1126/science.257.5073.1055; BRENNAN PJ, 1979, J BIOL CHEM, V254, P4205; Brennan PJ, 1988, MICROBIAL LIPIDS, V1, P-298; CHATTERJEE D, 1988, J BIOL CHEM, V263, P4092; CHATTERJEE D, 1987, J BIOL CHEM, V262, P3528; DELL A, 1994, METHOD ENZYMOL, V230, P108; DENNER JC, 1992, J CLIN MICROBIOL, V30, P473, DOI 10.1128/JCM.30.2.473-478.1992; FINE PEM, 1995, CLIN INFECT DIS, V20, P11, DOI 10.1093/clinids/20.1.11; GERWIG GJ, 1978, CARBOHYD RES, V62, P349, DOI 10.1016/S0008-6215(00)80881-2; GUPTA HP, 1979, INDIAN J EXP BIOL, V17, P1190; JOLLES P, 1961, B SOC CHIM BIOL, V43, P177; KHOO KH, 1995, CARBOHYD RES, V276, P449, DOI 10.1016/0008-6215(95)00184-U; KHOO KH, 1993, CARBOHYD RES, V244, P205, DOI 10.1016/0008-6215(83)85002-2; Lopez Marin L M, 1993, Eur J Biochem, V215, P859, DOI 10.1111/j.1432-1033.1993.tb18103.x; MACKENZIE SL, 1975, J CHROMATOGR, V111, P413, DOI 10.1016/S0021-9673(00)99292-6; MARIN LML, 1991, BIOCHEMISTRY-US, V30, P10536, DOI 10.1021/bi00107a024; MARIN LML, 1992, BIOCHEMISTRY-US, V31, P11106, DOI 10.1021/bi00160a021; MEISSNER G, 1975, AM REV RESPIR DIS, V111, P196; NOORDEEN SK, 1994, INT J LEPROSY, V62, P278; RAVIGLIONE MC, 1995, JAMA-J AM MED ASSOC, V273, P220, DOI 10.1001/jama.273.3.220; RIVIERE M, 1993, EUR J BIOCHEM, V214, P395, DOI 10.1111/j.1432-1033.1993.tb17935.x; SCHAEFER WB, 1967, AM REV RESPIR DIS, V96, P115; Singh N B, 1985, Indian J Lepr, V57, P278; SINGH NB, 1991, INT J LEPROSY, V59, P317; SINGH NB, 1989, INFECT IMMUN, V57, P653, DOI 10.1128/IAI.57.2.653-655.1989; VALDIVIA JA, 1971, B HIGIENE EPIDEMIOLO, V9, P65; YANAGHIHARA DL, 1985, J CLIN MICROBIOL, V21, P569, DOI 10.1128/JCM.21.4.569-574.1985	33	23	24	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 24	1996	271	21					12333	12342		10.1074/jbc.271.21.12333	http://dx.doi.org/10.1074/jbc.271.21.12333			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UL660	8647835	hybrid			2022-12-25	WOS:A1996UL66000037
J	Luescher, IF; Romero, P; Kuznetsov, D; Rimoldi, D; Coulie, P; Cerottini, JC; Jongenee, CV				Luescher, IF; Romero, P; Kuznetsov, D; Rimoldi, D; Coulie, P; Cerottini, JC; Jongenee, CV			HLA photoaffinity labeling reveals overlapping binding of homologous melanoma-associated gene peptides by HLA-A1, HLA-A29, and HLA-B44	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CLASS-I MOLECULES; ANTIGENIC PEPTIDES	Melanoma-associated genes (MAGEs) encode tumor-specific antigens that can be recognized by CD8(+) cytotoxic T lymphocytes. To investigate the interaction of the HLA-Al-restricted MAGE-1 peptide 161-169 (EADPT-GHSY) with HLA class I molecules, photoreactive derivatives were prepared by single amino acid substitution with N-beta-[iodo-4-azidosalicyloyl]-L-2,3-diaminopropionic acid. These derivatives were tested for their ability to bind to, and to photoaffinity-label, HLA-A1 on C1R.A1 cells. Only the derivatives containing the photoreactive amino acid in position 1 or 7 fulfilled both criteria. Testing the former derivative on 14 lymphoid cell lines expressing over 44 different HLA class I molecules indicated that it efficiently photoaffinity-labeled not only KLA-A1, but possibly also HLA-A29 and HLA-B44. MAGE peptide binding by HLA-A29 and HLA-B44 was confirmed by photoaffinity labeling with photoreactive MAGE-3 peptide derivatives on C1R.A29 and C1R.B44 cells, respectively. The different photoaffinity labeling systems were used to assess the ability of the homologous peptides derived from MAGE 1, -2, -3, -4a, -4b, -6, and -12 to bind to HLA-A1, KLA-A29, and HLA-B44. All but the MAGE-2 and MAGE-12 nonapeptides efficiently inhibited photoaffinity labeling of HLA-A1, which is in agreement with the known HLA-A1 peptide-binding motif (acidic residue in P3 and C-terminal tyrosine). In contrast, photoaffinity labeling of HLA-A29 was efficiently inhibited by these as well as by the MAGE-3 and MAGE-6 nonapeptides. Finally, the HLA-B44 photoaffinity labeling, unlike the HLA-A1 and HLA-A29 labeling, was inhibited more efficiently by the corresponding MAGE decapeptides, which is consistent with the reported HLA-B44 peptide-binding motif (glutamic acid in P2, and C-terminal tyrosine or phenylalanine). The overlapping binding of homologous MAGE peptides by HLA-A1, A29, and B44 is based on different binding principles and may have implications for immunotherapy of MAGE-positive tumors.	LUDWIG INST CANC RES,BRUSSELS BRANCH,B-1200 BRUSSELS,BELGIUM	Ludwig Institute for Cancer Research	Luescher, IF (corresponding author), LUDWIG INST CANC RES,LAUSANNE BRANCH,CHEMIN BOVERESSES 155,CH-1066 EPALINGES,SWITZERLAND.		Romero, Pedro/S-6015-2017	Romero, Pedro/0000-0002-9688-2882; Jongeneel, Cornelis Victor/0000-0002-3922-1906; Kuznetsov, Dmitry/0000-0002-9972-947X				ABAGYAN R, 1994, J COMPUT CHEM, V15, P488, DOI 10.1002/jcc.540150503; ALEXANDER J, 1989, IMMUNOGENETICS, V29, P380, DOI 10.1007/BF00375866; ANJUERE F, 1995, ANAL BIOCHEM, V229, P61, DOI 10.1006/abio.1995.1379; BARBER LD, 1995, CURR BIOL, V5, P179, DOI 10.1016/S0960-9822(95)00039-X; BJORKMAN PJ, 1990, ANNU REV BIOCHEM, V59, P253, DOI 10.1146/annurev.bi.59.070190.001345; BOON T, 1994, ANNU REV IMMUNOL, V12, P337, DOI 10.1146/annurev.immunol.12.1.337; BRODSKY FM, 1982, J IMMUNOL, V128, P129; DELGUERCIO MF, 1995, J IMMUNOL, V154, P685; DEPLAEN E, 1994, IMMUNOGENETICS, V40, P360, DOI 10.1007/BF01246677; DESMET C, 1994, IMMUNOGENETICS, V39, P121, DOI 10.1007/BF00188615; DIBRINO M, 1994, J IMMUNOL, V152, P620; DIBRINO M, 1995, BIOCHEMISTRY-US, V34, P10130, DOI 10.1021/bi00032a005; DUPONT B, 1987, IMMUNOBIOLOGY HLA, V1; FALK K, 1994, IMMUNOGENETICS, V40, P238, DOI 10.1007/BF00167086; FLEISCHHAUER K, 1994, TISSUE ANTIGENS, V44, P311, DOI 10.1111/j.1399-0039.1994.tb02401.x; FLEISCHHAUER K, 1990, NEW ENGL J MED, V323, P1818, DOI 10.1056/NEJM199012273232607; GAUGLER B, 1994, J EXP MED, V179, P921, DOI 10.1084/jem.179.3.921; KUBO RT, 1994, J IMMUNOL, V152, P3913; LEVINE JE, 1994, TISSUE ANTIGENS, V44, P174, DOI 10.1111/j.1399-0039.1994.tb02376.x; LUESCHER IF, 1991, NATURE, V351, P72, DOI 10.1038/351072a0; LUESCHER IF, 1992, J IMMUNOL, V148, P1003; PEITSCH MC, 1993, INT IMMUNOL, V5, P233, DOI 10.1093/intimm/5.2.233; RAMMENSEE HG, 1995, IMMUNOGENETICS, V41, P178, DOI 10.1007/BF00172063; SAPER MA, 1991, J MOL BIOL, V219, P277, DOI 10.1016/0022-2836(91)90567-P; SIDNEY J, 1995, J IMMUNOL, V154, P247; SRIVASTAVA PK, 1993, ADV CANCER RES, V62, P153, DOI 10.1016/S0065-230X(08)60318-8; TRAVERSARI C, 1992, J EXP MED, V176, P1453, DOI 10.1084/jem.176.5.1453; VANDERBRUGGEN P, 1994, EUR J IMMUNOL, V24, P2134; VANDERBRUGGEN P, 1991, SCIENCE, V254, P1643, DOI 10.1126/science.1840703; YOUNG ACM, 1995, FASEB J, V9, P26, DOI 10.1096/fasebj.9.1.7821756	30	21	22	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 24	1996	271	21					12463	12471		10.1074/jbc.271.21.12463	http://dx.doi.org/10.1074/jbc.271.21.12463			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UL660	8647853	hybrid			2022-12-25	WOS:A1996UL66000055
J	Fourcin, M; Chevalier, S; Guillet, C; Robledo, O; Froger, J; PouplardBarthelaix, A; Gascan, H				Fourcin, M; Chevalier, S; Guillet, C; Robledo, O; Froger, J; PouplardBarthelaix, A; Gascan, H			gp130 transducing receptor cross-linking is sufficient to induce interleukin-6 type responses	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEUKEMIA INHIBITORY FACTOR; CILIARY NEUROTROPHIC FACTOR; IL-6 SIGNAL TRANSDUCER; MOLECULAR-CLONING; ONCOSTATIN-M; DA CELLS; HEMATOPOIETIC PROGENITORS; GROWTH-FACTOR; STEM-CELLS; FACTOR LIF	gp130 transducing receptor is involved in the formation of high affinity receptors for the cytokines of the interleukin-6 (IL-6) family. Recruitment of gp130 by IL-6 associated to its receptor leads to the dimerization of the transducing component, In the present study we did characterize the B-S12 monoclonal antibody raised against gp130 and able to elicit IL-6 type biological activities. B-S12 antibody triggered strongly the proliferation of TF1 and XG1 hematopoietic cell lines and was able to increase the synthesis of acute phase proteins in HepG2 hepatoma cell line. B-S12 also behaved as a synergistic factor with granulocyte-macrophage colony-stimulating factor for both proliferation and differentiation of CD34-positive hematopoietic cell progenitors. By using a symmetric enzyme-linked immunosorbent assay, allowing the detection of dimeric forms of soluble gp130, we found that addition of B-S12 to gp130 led to its dimerization. Analysis of the tyrosine phosphorylation events in gp130 and Jak kinase family members revealed that B-S12 quickly induced the phosphorylation of gp130 in a neural derived cell line, and that Jak1 and Jak2 were also recruited. In conclusion, we show that gp130 cross-linking with the B-S12 monoclonal antibody was sufficient to generate functional IL-6 type responses in hematopoietic, neural, and hepatic cells.	CHU ANGERS,BIOL CELLULAIRE LAB,F-49033 ANGERS,FRANCE	Universite d'Angers; Centre Hospitalier Universitaire d'Angers								ALEXANDER WS, 1995, EMBO J, V14, P5569, DOI 10.1002/j.1460-2075.1995.tb00244.x; BAUMANN H, 1994, MOL CELL BIOL, V14, P138, DOI 10.1128/MCB.14.1.138; BAUMANN H, 1993, J BIOL CHEM, V268, P8414; CHEREL M, 1995, BLOOD, V86, P2534; CONOVER JC, 1993, DEVELOPMENT, V119, P559; DAVIS S, 1993, SCIENCE, V260, P1805, DOI 10.1126/science.8390097; DAVIS S, 1991, SCIENCE, V253, P59, DOI 10.1126/science.1648265; DECHIARA TM, 1995, CELL, V83, P313, DOI 10.1016/0092-8674(95)90172-8; FOURCIN M, 1994, EUR J IMMUNOL, V24, P277, DOI 10.1002/eji.1830240143; GAULDIE J, 1987, P NATL ACAD SCI USA, V84, P7251, DOI 10.1073/pnas.84.20.7251; GEARING DP, 1987, EMBO J, V6, P3995, DOI 10.1002/j.1460-2075.1987.tb02742.x; GEARING DP, 1992, SCIENCE, V255, P1434, DOI 10.1126/science.1542794; GEARING DP, 1991, EMBO J, V10, P2839, DOI 10.1002/j.1460-2075.1991.tb07833.x; HIBI M, 1990, CELL, V63, P1149, DOI 10.1016/0092-8674(90)90411-7; HILTON DJ, 1994, EMBO J, V13, P465; IHLE JN, 1995, TRENDS GENET, V11, P69, DOI 10.1016/S0168-9525(00)89000-9; KISHIMOTO T, 1992, SCIENCE, V258, P593, DOI 10.1126/science.1411569; KITAMURA T, 1989, J CELL PHYSIOL, V140, P323, DOI 10.1002/jcp.1041400219; KLEIN B, 1989, BLOOD, V73, P517; KOPF M, 1994, NATURE, V368, P339, DOI 10.1038/368339a0; LAI CF, 1995, J BIOL CHEM, V270, P14847, DOI 10.1074/jbc.270.25.14847; LEARY AG, 1990, BLOOD, V75, P1960; LECRON JC, 1993, CLIN EXP IMMUNOL, V92, P23; LIN LFH, 1989, SCIENCE, V246, P1023, DOI 10.1126/science.2587985; LUST JA, 1992, CYTOKINE, V4, P96, DOI 10.1016/1043-4666(92)90043-Q; LUTTICKEN C, 1994, SCIENCE, V263, P89, DOI 10.1126/science.8272872; MASU Y, 1993, NATURE, V365, P27, DOI 10.1038/365027a0; MOREAU JF, 1988, NATURE, V336, P690, DOI 10.1038/336690a0; MORELLA KK, 1995, J BIOL CHEM, V270, P8298, DOI 10.1074/jbc.270.14.8298; MURAKAMI M, 1991, P NATL ACAD SCI USA, V88, P11349, DOI 10.1073/pnas.88.24.11349; MURAKAMI M, 1993, SCIENCE, V260, P1808, DOI 10.1126/science.8511589; MUSASHI M, 1991, BLOOD, V78, P1448; NAKAMURA Y, 1994, NATURE, V369, P330, DOI 10.1038/369330a0; NELSON BH, 1994, NATURE, V369, P333, DOI 10.1038/369333a0; PAONESSA G, 1995, EMBO J, V14, P1942, DOI 10.1002/j.1460-2075.1995.tb07186.x; PAUL SR, 1990, P NATL ACAD SCI USA, V87, P7512, DOI 10.1073/pnas.87.19.7512; PENNICA D, 1995, J BIOL CHEM, V270, P10915, DOI 10.1074/jbc.270.18.10915; PENNICA D, 1995, P NATL ACAD SCI USA, V92, P1142, DOI 10.1073/pnas.92.4.1142; POLI V, 1994, EMBO J, V13, P1189, DOI 10.1002/j.1460-2075.1994.tb06368.x; SMITH AG, 1988, NATURE, V336, P688, DOI 10.1038/336688a0; STAHL N, 1994, SCIENCE, V263, P92, DOI 10.1126/science.8272873; STAHL N, 1995, SCIENCE, V267, P1349, DOI 10.1126/science.7871433; STEWART CL, 1992, NATURE, V359, P76, DOI 10.1038/359076a0; SUI XW, 1995, P NATL ACAD SCI USA, V92, P2859, DOI 10.1073/pnas.92.7.2859; TANIGUCHI T, 1995, SCIENCE, V268, P251, DOI 10.1126/science.7716517; VERFAILLIE C, 1991, BLOOD, V77, P263; WARD LD, 1994, J BIOL CHEM, V269, P23286; WATOWICH SS, 1994, MOL CELL BIOL, V14, P3535, DOI 10.1128/MCB.14.6.3535; YAMAMORI T, 1989, SCIENCE, V246, P1412, DOI 10.1126/science.2512641; YAMASAKI K, 1988, SCIENCE, V241, P826; YIN TG, 1992, J EXP MED, V175, P211, DOI 10.1084/jem.175.1.211; ZARLING JM, 1986, P NATL ACAD SCI USA, V83, P9739, DOI 10.1073/pnas.83.24.9739	52	24	29	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 17	1996	271	20					11756	11760		10.1074/jbc.271.20.11756	http://dx.doi.org/10.1074/jbc.271.20.11756			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UL250	8662709	hybrid			2022-12-25	WOS:A1996UL25000029
J	Kramer, JA; Krawetz, SA				Kramer, JA; Krawetz, SA			Nuclear matrix interactions within the sperm genome	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAMMALIAN SPERMATOZOA; ATTACHMENT REGIONS; DNA; GENES; LOOPS; REPLICATION; DOMAIN; SITES; CHROMATIN; ANCHORAGE	Analysis of the haploid expressed human PRM1 --> PRM2 --> TNP2 genic domain has revealed two regions of attachment to the sperm nuclear matrix. These sperm nuclear matrix attachment regions delimit the DNase I-sensitive domain of this haploid expressed locus. The domain is intermediately associated with but not attached to the nuclear matrix. DNase I-sensitive genes within the mature sperm nucleus, such as protamine 1, protamine 2, transition protein 2, alpha-globin, and beta-actin, display this intermediate affinity for the sperm nuclear matrix. This may denote their role in templating the male genome prior to fertilization, thus ensuring the formation of a viable male pronucleus during early embryonic development.	WAYNE STATE UNIV, SCH MED, CS MOTT CTR HUMAN GROWTH & DEV, DETROIT, MI 48102 USA	Wayne State University	Kramer, JA (corresponding author), WAYNE STATE UNIV, SCH MED, DEPT OBSTET & GYNECOL, CTR MOL MED & GENET, DETROIT, MI 48102 USA.		krawetz, stephen/GQQ-3308-2022		NICHD NIH HHS [1R01HD2850401A1] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD028504] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BARONE JG, 1994, J ANDROL, V15, P139; BASKIN Y, 1995, SCIENCE, V268, P1564, DOI 10.1126/science.7777854; BOULIKAS T, 1993, J CELL BIOCHEM, V52, P14, DOI 10.1002/jcb.240520104; CHOUDHARY SK, 1995, J BIOL CHEM, V270, P8755, DOI 10.1074/jbc.270.15.8755; CIEJEK EM, 1983, NATURE, V306, P607, DOI 10.1038/306607a0; COCKERILL PN, 1986, CELL, V44, P273, DOI 10.1016/0092-8674(86)90761-0; DALTON S, 1986, NUCLEIC ACIDS RES, V14, P6507, DOI 10.1093/nar/14.16.6507; DIJKWEL PA, 1988, MOL CELL BIOL, V8, P5398, DOI 10.1128/MCB.8.12.5398; DOGGETT NA, 1995, NATURE, V377, P335; FEY EG, 1988, P NATL ACAD SCI USA, V85, P121, DOI 10.1073/pnas.85.1.121; GASSER SM, 1986, CELL, V46, P521, DOI 10.1016/0092-8674(86)90877-9; GATEWOOD JM, 1987, SCIENCE, V236, P962, DOI 10.1126/science.3576213; GERDES MG, 1994, J CELL BIOL, V126, P289, DOI 10.1083/jcb.126.2.289; GREENSTEIN RJ, 1988, DNA-J MOLEC CELL BIO, V7, P601, DOI 10.1089/dna.1988.7.601; GUO B, 1995, P NATL ACAD SCI USA, V92, P10526, DOI 10.1073/pnas.92.23.10526; JARMAN AP, 1988, EMBO J, V7, P3337, DOI 10.1002/j.1460-2075.1988.tb03205.x; KALANDADZE AG, 1990, BIOCHEM BIOPH RES CO, V168, P9, DOI 10.1016/0006-291X(90)91667-H; KRAMER JA, 1995, MAMM GENOME, V6, P677, DOI 10.1007/BF00352382; KRAMER JA, 1996, IN PRESS GENOMICS; LEVYWILSON B, 1989, J BIOL CHEM, V264, P21196; MIELKE C, 1990, BIOCHEMISTRY-US, V29, P7475, DOI 10.1021/bi00484a017; NELSON JE, 1994, J BIOL CHEM, V269, P31067; PHILIPSEN S, 1990, EMBO J, V9, P2159, DOI 10.1002/j.1460-2075.1990.tb07385.x; PHIVAN L, 1988, EMBO J, V7, P655, DOI 10.1002/j.1460-2075.1988.tb02860.x; STIEF A, 1989, NATURE, V341, P343, DOI 10.1038/341343a0; VOGELSTEIN B, 1980, CELL, V22, P79, DOI 10.1016/0092-8674(80)90156-7; WARD WS, 1990, BIOCHEM BIOPH RES CO, V173, P20, DOI 10.1016/S0006-291X(05)81015-0; WARD WS, 1989, CHROMOSOMA, V98, P153, DOI 10.1007/BF00329678; WARD WS, 1993, BIOL REPROD, V48, P1193, DOI 10.1095/biolreprod48.6.1193; ZLATANOVA J S, 1992, Critical Reviews in Eukaryotic Gene Expression, V2, P211	30	78	79	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 17	1996	271	20					11619	11622		10.1074/jbc.271.20.11619	http://dx.doi.org/10.1074/jbc.271.20.11619			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UL250	8662749	hybrid			2022-12-25	WOS:A1996UL25000007
J	Rehrauer, WM; Kowalczykowski, SC				Rehrauer, WM; Kowalczykowski, SC			The DNA binding site(s) of the Escherichia coli RecA protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SINGLE-STRANDED-DNA; GENETIC-RECOMBINATION; NEUTRON-SCATTERING; CRYSTAL-STRUCTURE; CATALYTIC DOMAIN; AMINO-ACIDS; RAS PROTEIN; EF-TU; COMPLEXES; LOCATION	Photochemical cross-linking has been used to identify residues in the Escherichia coli RecA protein that are proximal to and may directly mediate binding of DNA. Ultraviolet irradiation promotes specific and efficient cross-linking of the RecA protein to poly(deoxythymidylic) acid. Cross-linked peptides remaining covalently attached to the polynucleotide following proteolytic digestion with trypsin correspond to amino acids 61-72, 178-183, and 233-243 of the RecA protein primary sequence. Their location and surface accessibility in the crystal structure, along with the behavior of various recA mutants, support the assignment of the cross-linked regions to the DNA binding site(s) of the RecA protein. Functional overlap of amino acids 61-72 with an element of the ATP binding site suggests a structural mechanism by which nucleotide cofactors allosterically affect the RecA nucleoprotein filament.	UNIV CALIF DAVIS, MICROBIOL SECT, DIV BIOL SCI, DAVIS, CA 95616 USA; UNIV CALIF DAVIS, SECT MOL & CELL BIOL, DIV BIOL SCI, DAVIS, CA 95616 USA; NORTHWESTERN UNIV, SCH MED, DEPT MOLEC BIOL, CHICAGO, IL 60611 USA	University of California System; University of California Davis; University of California System; University of California Davis; Northwestern University					NIAID NIH HHS [AI-18987] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI018987] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BENIGHT AS, 1991, BIOCHIMIE, V73, P143, DOI 10.1016/0300-9084(91)90197-9; BERCHTOLD H, 1993, NATURE, V365, P126, DOI 10.1038/365126a0; BRENNER SL, 1988, J MOL BIOL, V204, P959, DOI 10.1016/0022-2836(88)90055-1; BRUNGER AT, 1990, P NATL ACAD SCI USA, V87, P4849, DOI 10.1073/pnas.87.12.4849; CASSUTO E, 1980, P NATL ACAD SCI-BIOL, V77, P3962, DOI 10.1073/pnas.77.7.3962; CLARK AJ, 1973, ANNU REV GENET, V7, P67, DOI 10.1146/annurev.ge.07.120173.000435; CLARK AJ, 1965, P NATL ACAD SCI USA, V53, P451, DOI 10.1073/pnas.53.2.451; COX MM, 1981, P NATL ACAD SCI-BIOL, V78, P6018, DOI 10.1073/pnas.78.10.6018; DICAPUA E, 1989, BIOCHEMISTRY-US, V28, P3287, DOI 10.1021/bi00434a025; DICAPUA E, 1990, J MOL BIOL, V214, P557, DOI 10.1016/0022-2836(90)90198-U; EGELMAN EH, 1986, J MOL BIOL, V191, P677, DOI 10.1016/0022-2836(86)90453-5; EGELMAN EH, 1989, SCIENCE, V245, P404, DOI 10.1126/science.2667137; GRIFFITH J, 1985, BIOCHEMISTRY-US, V24, P158, DOI 10.1021/bi00322a022; HEUSER J, 1989, J MOL BIOL, V210, P473, DOI 10.1016/0022-2836(89)90124-1; JONG EAM, 1989, J MOL BIOL, V206, P133; JURNAK F, 1985, SCIENCE, V230, P32, DOI 10.1126/science.3898365; KARLIN S, 1996, IN PRESS J BACTERIOL; KJELDGAARD M, 1992, J MOL BIOL, V223, P721, DOI 10.1016/0022-2836(92)90986-T; KONOLA JT, 1995, J BIOL CHEM, V270, P8411, DOI 10.1074/jbc.270.15.8411; KONOLA JT, 1994, J MOL BIOL, V237, P20, DOI 10.1006/jmbi.1994.1206; KOWALCZYKOWSKI SC, 1987, J MOL BIOL, V193, P97, DOI 10.1016/0022-2836(87)90630-9; KOWALCZYKOWSKI SC, 1994, ANNU REV BIOCHEM, V63, P991, DOI 10.1146/annurev.biochem.63.1.991; KOWALCZYKOWSKI SC, 1995, P NATL ACAD SCI USA, V92, P3478, DOI 10.1073/pnas.92.8.3478; KOWALCZYKOWSKI SC, 1991, ANNU REV BIOPHYS BIO, V20, P539, DOI 10.1146/annurev.bb.20.060191.002543; KOWALCZYKOWSKI SC, 1994, MICROBIOL REV, V58, P401, DOI 10.1128/MMBR.58.3.401-465.1994; LAUDER SD, 1991, J BIOL CHEM, V266, P5450; MCENTEE K, 1979, P NATL ACAD SCI USA, V76, P2615, DOI 10.1073/pnas.76.6.2615; MENETSKI JP, 1985, J MOL BIOL, V181, P281, DOI 10.1016/0022-2836(85)90092-0; MENETSKI JP, 1988, BIOCHEMISTRY-US, V27, P1205, DOI 10.1021/bi00404a021; MORIMATSU K, 1995, EUR J BIOCHEM, V228, P772, DOI 10.1111/j.1432-1033.1995.0772m.x; MORIMATSU K, 1995, ADV BIOPHYS, V31, P23, DOI 10.1016/0065-227X(95)99381-X; OGAWA T, 1993, SCIENCE, V259, P1896, DOI 10.1126/science.8456314; PAI EF, 1989, NATURE, V341, P209, DOI 10.1038/341209a0; PRASAD BVV, 1987, J MOL BIOL, V193, P579; RECORD MT, 1978, Q REV BIOPHYS, V11, P103, DOI 10.1017/S003358350000202X; REHRAUER WM, 1993, J BIOL CHEM, V268, P1292; ROCA AI, 1990, CRIT REV BIOCHEM MOL, V25, P415, DOI 10.3109/10409239009090617; Shetlar M.D., 1980, PHOTOCHEMICAL AND PHOTOBIOLOGICAL REVIEWS, V5, P105; SHETLAR MD, 1984, PHOTOCHEM PHOTOBIOL, V39, P125, DOI 10.1111/j.1751-1097.1984.tb03417.x; SHIBATA T, 1979, P NATL ACAD SCI USA, V76, P5100, DOI 10.1073/pnas.76.10.5100; SKINNER MM, 1994, P NATL ACAD SCI USA, V91, P2071, DOI 10.1073/pnas.91.6.2071; STASIAK A, 1982, NATURE, V299, P185, DOI 10.1038/299185a0; Stasiak A, 1988, GENETIC RECOMBINATIO, P265; STORY RM, 1993, SCIENCE, V259, P1892, DOI 10.1126/science.8456313; STORY RM, 1992, NATURE, V355, P374, DOI 10.1038/355374a0; STORY RM, 1992, NATURE, V355, P318, DOI 10.1038/355318a0; SUNG P, 1994, SCIENCE, V265, P1241, DOI 10.1126/science.8066464; TONG L, 1991, J MOL BIOL, V217, P503, DOI 10.1016/0022-2836(91)90753-S; UHLIN BE, 1981, J BACTERIOL, V148, P386, DOI 10.1128/JB.148.1.386-390.1981; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WANG WB, 1988, J BACTERIOL, V170, P4823, DOI 10.1128/jb.170.10.4823-4827.1988; WANG WB, 1986, J BACTERIOL, V168, P901, DOI 10.1128/jb.168.2.901-910.1986; WILLIAMS KR, 1991, METHOD ENZYMOL, V208, P516; WILSON DH, 1990, J BIOL CHEM, V265, P7351; YONESAKI T, 1985, EMBO J, V4, P3321, DOI 10.1002/j.1460-2075.1985.tb04083.x; YU X, 1992, J MOL BIOL, V227, P334, DOI 10.1016/0022-2836(92)90702-L; YU X, 1993, J MOL BIOL, V232, P1, DOI 10.1006/jmbi.1993.1363; YU X, 1990, BIOPHYS J, V57, P555, DOI 10.1016/S0006-3495(90)82571-6	58	43	44	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 17	1996	271	20					11996	12002		10.1074/jbc.271.20.11996	http://dx.doi.org/10.1074/jbc.271.20.11996			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UL250	8662640	hybrid			2022-12-25	WOS:A1996UL25000063
J	Berkowitz, EA; Hissong, MA; Lee, DC				Berkowitz, EA; Hissong, MA; Lee, DC			Transcriptional and post-transcriptional induction of the TGF alpha gene in transformed rat liver epithelial cells	ONCOGENE			English	Article						TGF alpha; transcription; DNase 1 hypersensitivity; mRNA stability	GROWTH-FACTOR-ALPHA; HUMAN PANCREATIC-CANCER; TRANSGENIC MICE; C-MYC; MESSENGER-RNA; HUMAN KERATINOCYTES; FACTOR RECEPTOR; PHORBOL ESTER; HEPATOCELLULAR-CARCINOMA; DEVELOPMENTAL EXPRESSION	Although TGF alpha mRNA and protein are frequently elevated in neoplastic cells, neither the level at which deregulation occurs nor the mechanism(s) responsible have been well characterized. As a first step, we examined the induction of TGF alpha mRNA in two series of clonally-derived rat liver epithelial cell lines that were transformed either by exposure to chemical carcinogen or stable transfection of activated Ha-ras. We found that steady-state levels of TGF alpha mRNA in both series of transformed lines were induced 25- to 50-fold over those in the respective normal parental cells. This induction, which occurred without amplification of the TGF alpha gene, was accompanied by at least a five- to 10-fold increase in transcription along the entire length of the gene with no evidence of a transcriptional attenuation or arrest mechanism in the normal cells. Analysis of the TGF alpha promoter and flanking regions did not support a correlation between the extent of methylation and the level of expression, but did reveal several DNase I hypersensitive sites spanning from -14 to +8 kilobases. Two of these sites were differentially observed in cells displaying high and low TGF alpha gene transcription, while a third site correlated with TPA-induced expression. Finally, measurement of TGF alpha mRNA decay in the presence of Actinomycin D revealed a consistent 1.5- to 3.2-fold increase in the half-life of the TGF alpha transcript in the various transformed cell lines. These results indicate that transformation-mediated induction of TGF alpha gene expression in rat liver epithelial cells occurs through both transcriptional and post-transcriptional mechanisms, but is primarily the result of TGF alpha promoter activation.	UNIV N CAROLINA,SCH MED,LINEBERGER COMPREHENS CANC CTR,CHAPEL HILL,NC 27599; UNIV N CAROLINA,SCH MED,DEPT MICROBIOL & IMMUNOL,CHAPEL HILL,NC 27599	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine					NATIONAL CANCER INSTITUTE [R01CA043793] Funding Source: NIH RePORTER; NCI NIH HHS [CA43793] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; BARNARD JA, 1994, J BIOL CHEM, V269, P22817; BARTON CM, 1991, J PATHOL, V163, P111, DOI 10.1002/path.1711630206; BASERGA R, 1994, CELL, V79, P927, DOI 10.1016/0092-8674(94)90023-X; BEDELL MA, 1995, GENE DEV, V9, P455, DOI 10.1101/gad.9.4.455; BENTLEY DL, 1986, NATURE, V321, P702, DOI 10.1038/321702a0; BJORGE JD, 1989, J BIOL CHEM, V264, P4021; BLASBAND AJ, 1990, MOL CELL BIOL, V10, P2111, DOI 10.1128/MCB.10.5.2111; BOCKMAN DE, 1992, GASTROENTEROLOGY, V103, P1883, DOI 10.1016/0016-5085(92)91448-D; CHEN XR, 1992, ONCOGENE, V7, P1805; CHEN XR, 1994, ONCOGENE, V9, P3179; CHINSKY JM, 1989, J BIOL CHEM, V264, P14561; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CIARDIELLO F, 1990, J CELL BIOCHEM, V42, P45, DOI 10.1002/jcb.240420105; CIARDIELLO F, 1990, CELL GROWTH DIFFER, V1, P407; CIARDIELLO F, 1988, MOL ENDOCRINOL, V2, P1202, DOI 10.1210/mend-2-12-1202; COFFEY RJ, 1992, CELL GROWTH DIFFER, V3, P347; COFFEY RJ, 1987, NATURE, V328, P817, DOI 10.1038/328817a0; DEMPSEY PJ, 1992, GASTROENTEROLOGY, V103, P1950, DOI 10.1016/0016-5085(92)91455-D; DERYNCK R, 1987, CANCER RES, V47, P707; DRUMMOND IA, 1992, SCIENCE, V257, P674, DOI 10.1126/science.1323141; DURNAM DM, 1983, ANAL BIOCHEM, V131, P385, DOI 10.1016/0003-2697(83)90188-4; FILMUS J, 1993, ONCOGENE, V8, P1017; FINZI E, 1992, AM J PATHOL, V141, P643; GANSS R, 1994, EMBO J, V13, P3083, DOI 10.1002/j.1460-2075.1994.tb06607.x; GODWIN AK, 1990, ONCOGENE, V5, P1231; GREWAL T, 1992, MOL CELL BIOL, V12, P2339, DOI 10.1128/MCB.12.5.2339; GROSS DS, 1988, ANNU REV BIOCHEM, V57, P159, DOI 10.1146/annurev.bi.57.070188.001111; GROSS-BELLARD MM, 1973, EUR J BIOCHEM, V36, P32, DOI 10.1111/j.1432-1033.1973.tb02881.x; GUNNING P, 1983, MOL CELL BIOL, V3, P787, DOI 10.1128/MCB.3.5.787; HALEY JD, 1991, J BIOL CHEM, V266, P1746; HALTER SA, 1992, AM J PATHOL, V140, P1131; HAMBURGER AW, 1993, P SOC EXP BIOL MED, V202, P64; HAN VKM, 1987, MOL CELL BIOL, V7, P2335, DOI 10.1128/MCB.7.7.2335; HU JM, 1992, CELL GROWTH DIFFER, V3, P577; HUBER BE, 1988, ONCOGENE, V3, P245; IMLER JL, 1988, NATURE, V332, P275, DOI 10.1038/332275a0; JACK J, 1991, DEVELOPMENT, V113, P735; JAKOBOVITS EB, 1988, MOL CELL BIOL, V8, P5549, DOI 10.1128/MCB.8.12.5549; JHAPPAN C, 1990, CELL, V61, P1137, DOI 10.1016/0092-8674(90)90076-Q; LAU JLT, 1988, J UROLOGY, V139, P170, DOI 10.1016/S0022-5347(17)42347-0; LEE DC, 1985, NATURE, V313, P489, DOI 10.1038/313489a0; LEE DC, 1995, PHARMACOL REV, V47, P51; LEE LW, 1991, CANCER RES, V51, P5238; LEE SW, 1991, J INVEST DERMATOL, V97, P106, DOI 10.1111/1523-1747.ep12478503; LIU C, 1988, CANCER RES, V48, P850; LIU C, 1990, BRIT J CANCER, V62, P425, DOI 10.1038/bjc.1990.311; LUETTEKE NC, 1988, BIOCHEMISTRY-US, V27, P6487, DOI 10.1021/bi00417a043; LYNCH MJ, 1993, CANCER RES, V53, P4041; MACAULAY VM, 1992, BRIT J CANCER, V65, P311, DOI 10.1038/bjc.1992.65; MARZLUFF WF, 1985, TRANSCRIPTION TRANSL, P89; MATSUI Y, 1990, CELL, V61, P1147, DOI 10.1016/0092-8674(90)90077-R; MCCARTHY SA, 1995, GENE DEV, V9, P1953, DOI 10.1101/gad.9.16.1953; MCGEADY ML, 1989, ONCOGENE, V4, P1375; MECHTI N, 1991, MOL CELL BIOL, V11, P2832, DOI 10.1128/MCB.11.5.2832; MIETTINEN PJ, 1995, NATURE, V376, P337, DOI 10.1038/376337a0; MILLER H, 1989, MOL CELL BIOL, V9, P5340, DOI 10.1128/MCB.9.12.5340; MUELLER SG, 1989, MOL ENDOCRINOL, V3, P976, DOI 10.1210/mend-3-6-976; MURAKAMI H, 1993, CANCER RES, V53, P1719; NEPVEU A, 1986, EMBO J, V5, P2859, DOI 10.1002/j.1460-2075.1986.tb04580.x; NITSCH D, 1993, MOL CELL BIOL, V13, P4494, DOI 10.1128/MCB.13.8.4494; NOVICKI DL, 1983, IN VITRO CELL DEV B, V19, P191; OWEN RD, 1990, P NATL ACAD SCI USA, V87, P3866, DOI 10.1073/pnas.87.10.3866; OWEN RD, 1990, MOL CELL BIOL, V10, P1; PITTELKOW MR, 1989, J BIOL CHEM, V264, P5164; QIAN S, 1991, EMBO J, V10, P1415, DOI 10.1002/j.1460-2075.1991.tb07662.x; RAPPOLEE DA, 1988, SCIENCE, V241, P1823, DOI 10.1126/science.3175624; RAYMOND VW, 1989, CANCER RES, V49, P3608; REDDY MA, 1992, MOL ENDOCRINOL, V6, P1051, DOI 10.1210/me.6.7.1051; RHODES SJ, 1993, GENE DEV, V7, P913, DOI 10.1101/gad.7.6.913; ROSENTHAL A, 1986, CELL, V46, P301, DOI 10.1016/0092-8674(86)90747-6; SAEKI T, 1991, MOL ENDOCRINOL, V5, P1955, DOI 10.1210/mend-5-12-1955; SALOMON DS, 1987, J CELL PHYSIOL, V130, P397, DOI 10.1002/jcp.1041300313; SANDGREN EP, 1990, CELL, V61, P1121, DOI 10.1016/0092-8674(90)90075-P; SANDGREN EP, 1995, CANCER RES, V55, P3915; SANDGREN EP, 1993, MOL CELL BIOL, V13, P320, DOI 10.1128/MCB.13.1.320; SCHMIEGEL W, 1993, P NATL ACAD SCI USA, V90, P863, DOI 10.1073/pnas.90.3.863; SHANKAR V, 1989, MOL CARCINOGEN, V2, P1, DOI 10.1002/mc.2940020102; SHIN TH, 1992, MOL CELL BIOL, V12, P3998, DOI 10.1128/MCB.12.9.3998; SIBILIA M, 1995, SCIENCE, V269, P234, DOI 10.1126/science.7618085; SINGH P, 1993, GASTROENTEROLOGY, V105, P1218, DOI 10.1016/0016-5085(93)90971-E; SOUTTOU B, 1994, CELL GROWTH DIFFER, V5, P615; SPORN MB, 1980, NEW ENGL J MED, V303, P878, DOI 10.1056/NEJM198010093031511; STROM SC, 1991, DIGEST DIS SCI, V36, P642, DOI 10.1007/BF01297033; TAKAGI H, 1992, J CLIN INVEST, V90, P1161, DOI 10.1172/JCI115936; TAKAGI H, 1993, CANCER RES, V53, P4329; TANAKA S, 1991, AM J PATHOL, V139, P123; THREADGILL DW, 1995, SCIENCE, V269, P230, DOI 10.1126/science.7618084; TSAO MS, 1985, AM J PATHOL, V118, P306; TSAO MS, 1985, CANCER RES, V45, P5134; TWARDZIK DR, 1982, SCIENCE, V216, P894, DOI 10.1126/science.6177040; TWARDZIK DR, 1993, VIROLOGY, V124, P201; VASSAR R, 1992, MOL CELL BIOL, V12, P4643, DOI 10.1128/MCB.12.10.4643; WATANABE S, 1987, P NATL ACAD SCI USA, V84, P1258, DOI 10.1073/pnas.84.5.1258; WILCOX JN, 1988, MOL CELL BIOL, V8, P3415, DOI 10.1128/MCB.8.8.3415; WU C, 1980, NATURE, V286, P854, DOI 10.1038/286854a0; YEH YC, 1987, CANCER RES, V47, P896	97	11	11	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY 2	1996	12	9					1991	2002						12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UK498	8649860				2022-12-25	WOS:A1996UK49800018
J	Shimizu, S; Eguchi, Y; Kamiike, W; Matsuda, H; Tsujimoto, Y				Shimizu, S; Eguchi, Y; Kamiike, W; Matsuda, H; Tsujimoto, Y			Bcl-2 expression prevents activation of the ICE protease cascade	ONCOGENE			English	Article						bcl-2; bcl-x; ICE; CPP32; Yama; apoptosis	PROGRAMMED CELL-DEATH; HUMAN FOLLICULAR LYMPHOMA; CHROMOSOMAL BREAKPOINT; GROWTH-FACTOR; C-ELEGANS; GENE; SURVIVAL; ENZYME; CED-3	The Bcl-2 family and the ICE family of cysteine proteases play important roles in regulating cell death. We show here that induction of cell death by a Ca2+ ionophore or hypoxia results in increased levels and activity of active ICE(-like) proteases and the subsequent activation of CPP32/Yama(-like) proteases, and that inhibition of these protease activities reduces the extent of cell death, Overexpression of the anti-apoptotic proteins Bcl-2 or Bcl-x(L) inhibits the cell death and the activation of ICE(-like) and CPP32/Yama(-like) proteases, indicating that Bcl-2 and Bcl-x(L) act upstream of these proteases. We also show that specific inhibition of ICE(-like) proteases in vivo prevents activation of CPP32/Yama(-like) proteases, whereas inhibition of CPP32/Yama(-like) proteases does not prevent activation of TCE(-like) proteases, suggesting the existence of a protease cascade in vivo that requires ICE(-like)proteases for activation of CPP32/Yama(-like) proteases. Induction of necrotic cell death by KCN also induces activation of ICE(-like) proteases but not of CPP32/Yama(-like) proteases, and Bcl-2 and Bcl-x(L) inhibit the activation and the cell death, suggesting that the functional site of Bcl-2 and Bcl-x(L) is also upstream of ICE(-like) proteases in at least some forms of necrosis.	OSAKA UNIV, SCH MED, DEPT SURG 1, SUITA, OSAKA 565, JAPAN; OSAKA UNIV, SCH MED, DEPT PHYSIOL 1, SUITA, OSAKA 565, JAPAN; OSAKA UNIV, SCH MED, DEPT MED GENET, SUITA, OSAKA 565, JAPAN	Osaka University; Osaka University; Osaka University								BAKHSHI A, 1985, CELL, V41, P899, DOI 10.1016/S0092-8674(85)80070-2; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; CLEARY ML, 1985, P NATL ACAD SCI USA, V82, P7439, DOI 10.1073/pnas.82.21.7439; ELLIS HM, 1986, CELL, V44, P817, DOI 10.1016/0092-8674(86)90004-8; ENARI M, 1995, NATURE, V375, P78, DOI 10.1038/375078a0; ENARI M, 1995, EMBO J, V14, P5201, DOI 10.1002/j.1460-2075.1995.tb00204.x; FAUCHEU C, 1995, EMBO J, V14, P1914, DOI 10.1002/j.1460-2075.1995.tb07183.x; FERNANDESALNEMRI T, 1994, J BIOL CHEM, V269, P30761; GAGLIARDINI V, 1994, SCIENCE, V263, P826, DOI 10.1126/science.8303301; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; HENGARTNER MO, 1994, CELL, V76, P665, DOI 10.1016/0092-8674(94)90506-1; HENGARTNER MO, 1992, NATURE, V356, P494, DOI 10.1038/356494a0; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; KAMENS J, 1995, J BIOL CHEM, V270, P15250, DOI 10.1074/jbc.270.25.15250; KUIDA K, 1995, SCIENCE, V267, P2000, DOI 10.1126/science.7535475; LOS M, 1995, NATURE, V375, P81, DOI 10.1038/375081a0; MARTIN SJ, 1995, CELL, V82, P349, DOI 10.1016/0092-8674(95)90422-0; MILLIGAN CE, 1995, NEURON, V15, P385, DOI 10.1016/0896-6273(95)90042-X; MIURA M, 1993, CELL, V75, P653, DOI 10.1016/0092-8674(93)90486-A; MONAGHAN P, 1992, J HISTOCHEM CYTOCHEM, V40, P1819, DOI 10.1177/40.12.1453000; MUNDAY NA, 1995, J BIOL CHEM, V270, P15870, DOI 10.1074/jbc.270.26.15870; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; NUNEZ G, 1990, J IMMUNOL, V144, P3602; PEZZELLA F, 1990, AM J PATHOL, V137, P225; RAY CA, 1992, CELL, V69, P597, DOI 10.1016/0092-8674(92)90223-Y; SHIMIZU S, 1995, NATURE, V374, P811, DOI 10.1038/374811a0; SHIMIZU S, 1996, IN PRESS CAN RES; SHIMIZU S, 1996, IN PRESS ONCOGENE; SINGER II, 1995, J EXP MED, V182, P1447, DOI 10.1084/jem.182.5.1447; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; THORNBERRY NA, 1992, NATURE, V356, P768, DOI 10.1038/356768a0; TSUJIMOTO Y, 1989, ONCOGENE, V4, P1331; TSUJIMOTO Y, 1986, P NATL ACAD SCI USA, V83, P5214, DOI 10.1073/pnas.83.14.5214; TSUJIMOTO Y, 1985, SCIENCE, V228, P1440, DOI 10.1126/science.3874430; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; WALKER NPC, 1994, CELL, V78, P343, DOI 10.1016/0092-8674(94)90303-4; YAUN J, 1993, CELL, V75, P641; YUAN JY, 1990, DEV BIOL, V138, P33, DOI 10.1016/0012-1606(90)90174-H	39	275	281	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN 6	1996	12	11					2251	2257						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UQ220	8649764				2022-12-25	WOS:A1996UQ22000001
J	Mateu, MG; Valero, ML; Andreu, D; Domingo, E				Mateu, MG; Valero, ML; Andreu, D; Domingo, E			Systematic replacement of amino acid residues within an Arg-Gly-Asp-containing loop of foot-and-mouth disease virus and effect on cell recognition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; GLYCOPROTEIN-IIB-IIIA; GLYCINE-ASPARTIC ACID; MAJOR ANTIGENIC SITE; SEROTYPE-C; RGD; ADHESION; FIBRONECTIN; BINDING; SEQUENCE	The conserved Arg-Gly-Asp (RGD) motif found in a hypervariable, mobile antigenic loop of foot-and-mouth disease virus (FMDV) is critically involved in virus attachment to cells by binding to an integrin, probably related to alpha(nu)beta(3). Here we describe (i) the synthesis of 241 15-mer peptides, which represent this loop of FMDV (isolate C-S8c1) and single variants in which each amino acid residue was replaced by 16 others and (ii) the inhibitory activity of these peptides on the ability of FMDV C-S8c1 to recognize and infect susceptible cells. This approach has allowed a first detailed evaluation of the specificity of each residue within a RGD containing protein loop on cell recognition. The results indicate that, in addition to the exquisitely specific RGD triplet, two highly conserved Leu residues located at positions +1 and +4 downstream of the RGD and, to a lesser extent, the residue at position +2 are the only critical and specific determinants within the loop in promoting cell recognition of a viral ligand. The results support the proposal that, in spite of their involvement in antibody recognition, RGD and other FMDV loop residues are remarkably conserved because of their essential role in cell recognition.	UNIV AUTONOMA MADRID,CSIC,CTR BIOL MOLEC SEVERO OCHOA,E-28049 MADRID,SPAIN; UNIV BARCELONA,DEPT QUIM ORGAN,E-08028 BARCELONA,SPAIN	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); University of Barcelona			Mateu, Mauricio/ABF-2146-2021; Andreu, David/I-4359-2014; Domingo, Esteban/K-3937-2014	Mateu, Mauricio/0000-0002-2915-1529; Andreu, David/0000-0002-6317-6666; Domingo, Esteban/0000-0002-0573-1676				ACHARYA R, 1989, NATURE, V337, P709, DOI 10.1038/337709a0; ALBERICIO F, 1990, J ORG CHEM, V55, P3730, DOI 10.1021/jo00299a011; AUMAILLEY M, 1991, FEBS LETT, V291, P50, DOI 10.1016/0014-5793(91)81101-D; BAXT B, 1990, Virus Genes, V4, P73, DOI 10.1007/BF00308567; BERINSTEIN A, 1995, J VIROL, V69, P2664, DOI 10.1128/JVI.69.4.2664-2666.1995; BOOTHROYD JC, 1982, GENE, V17, P153, DOI 10.1016/0378-1119(82)90068-3; BORREGO B, 1993, J VIROL, V67, P6071, DOI 10.1128/JVI.67.10.6071-6079.1993; CAMARERO JA, 1993, FEBS LETT, V328, P159, DOI 10.1016/0014-5793(93)80985-4; CHANG KH, 1992, J GEN VIROL, V73, P621, DOI 10.1099/0022-1317-73-3-621; CHERNY RC, 1993, J BIOL CHEM, V268, P9725; DENNIS MS, 1993, PROTEINS, V15, P312, DOI 10.1002/prot.340150308; DICKINSON CD, 1994, J MOL BIOL, V236, P1079, DOI 10.1016/0022-2836(94)90013-2; Domingo E., 1990, Applied Virology Research, V2, P233; DOMINGO E, 1992, CURR TOP MICROBIOL, V176, P33; DSOUZA SE, 1991, TRENDS BIOCHEM SCI, V16, P246, DOI 10.1016/0968-0004(91)90096-E; Feigelstock DA, 1996, VACCINE, V14, P97, DOI 10.1016/0264-410X(95)00180-9; FOX G, 1989, J GEN VIROL, V70, P625, DOI 10.1099/0022-1317-70-3-625; HAAS TA, 1994, CURR OPIN CELL BIOL, V6, P656, DOI 10.1016/0955-0674(94)90091-4; Harber J, 1995, VIROLOGY, V214, P559, DOI 10.1006/viro.1995.0067; HAUTANEN A, 1989, J BIOL CHEM, V264, P1437; HEALY JM, 1995, BIOCHEMISTRY-US, V34, P3948, DOI 10.1021/bi00012a012; Hernandez J, 1996, J GEN VIROL, V77, P257, DOI 10.1099/0022-1317-77-2-257; HERNANDEZ J, 1992, J GEN VIROL, V73, P213, DOI 10.1099/0022-1317-73-1-213; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; KOIVUNEN E, 1994, J CELL BIOL, V124, P373, DOI 10.1083/jcb.124.3.373; KOIVUNEN E, 1993, J BIOL CHEM, V268, P20205; KREZEL AM, 1994, SCIENCE, V264, P1944, DOI 10.1126/science.8009227; Lazarus Robert A., 1993, Current Opinion in Biotechnology, V4, P438, DOI 10.1016/0958-1669(93)90009-L; LEA S, 1994, STRUCTURE, V2, P123, DOI 10.1016/S0969-2126(00)00014-9; LEAHY DJ, 1992, SCIENCE, V258, P987, DOI 10.1126/science.1279805; LOGAN D, 1993, NATURE, V362, P566, DOI 10.1038/362566a0; MARTINEZ MA, 1991, VIROLOGY, V184, P695, DOI 10.1016/0042-6822(91)90439-I; MASON PW, 1994, P NATL ACAD SCI USA, V91, P1932, DOI 10.1073/pnas.91.5.1932; MATEU MG, 1995, VIROLOGY, V210, P120, DOI 10.1006/viro.1995.1323; MATEU MG, 1992, EUR J IMMUNOL, V22, P1385, DOI 10.1002/eji.1830220609; MATEU MG, 1995, VIRUS RES, V38, P1, DOI 10.1016/0168-1702(95)00048-U; MATEU MG, 1990, J GEN VIROL, V71, P629, DOI 10.1099/0022-1317-71-3-629; MATEU MG, 1989, P NATL ACAD SCI USA, V86, P5883, DOI 10.1073/pnas.86.15.5883; MEYER RF, 1994, VIRUS RES, V32, P299, DOI 10.1016/0168-1702(94)90079-5; NOVELLA IS, 1993, FEBS LETT, V330, P253, DOI 10.1016/0014-5793(93)80883-V; OBARA M, 1988, CELL, V53, P649, DOI 10.1016/0092-8674(88)90580-6; ONEIL KT, 1992, PROTEINS, V14, P509, DOI 10.1002/prot.340140411; PALMENBERG AC, 1989, MOL ASPECTS PICORNAV, P211; PARRY N, 1990, NATURE, V347, P569, DOI 10.1038/347569a0; Pereira H.G., 1981, VIRUS DISEASES FOOD, P333; PIERSCHBACHER MD, 1987, J BIOL CHEM, V262, P17294; RIEDER E, 1994, J VIROL, V68, P5296, DOI 10.1128/JVI.68.8.5296-5299.1994; ROIVAINEN M, 1991, J VIROL, V65, P4735, DOI 10.1128/JVI.65.9.4735-4740.1991; ROIVAINEN M, 1994, VIROLOGY, V203, P357, DOI 10.1006/viro.1994.1494; ROWE CA, 1993, THESIS U READING; RUOSLAHTI E, 1988, ANNU REV BIOCHEM, V57, P375, DOI 10.1146/annurev.bi.57.070188.002111; RUOSLAHTI E, 1987, SCIENCE, V238, P491, DOI 10.1126/science.2821619; SAYLE RA, 1995, TRENDS BIOCHEM SCI, V20, P374, DOI 10.1016/S0968-0004(00)89080-5; SCARBOROUGH RM, 1991, J BIOL CHEM, V266, P9359; SEKIGUCHI K, 1982, ARCH VIROL, V74, P53, DOI 10.1007/BF01320782; SOBRINO F, 1983, VIROLOGY, V128, P310, DOI 10.1016/0042-6822(83)90258-1; SOTERIADOU KP, 1992, J BIOL CHEM, V267, P13980; STANWAY G, 1994, J VIROL, V68, P8232, DOI 10.1128/JVI.68.12.8232-8238.1994; SUROVOI AY, 1988, SOVIET J BIOORG CHEM, V14, P965; TRANQUI L, 1989, J CELL BIOL, V108, P2519, DOI 10.1083/jcb.108.6.2519; Valero M L, 1995, Biomed Pept Proteins Nucleic Acids, V1, P133; VERDAGUER N, 1995, EMBO J, V14, P1690, DOI 10.1002/j.1460-2075.1995.tb07158.x; VOSLOO W, 1992, EPIDEMIOL INFECT, V109, P547, DOI 10.1017/S0950268800050536; VOSLOO W, 1995, EPIDEMIOL INFECT, V114, P203, DOI 10.1017/S0950268800052055; WHITE JM, 1993, CURR BIOL, V3, P596, DOI 10.1016/0960-9822(93)90007-B; WICKHAM TJ, 1993, CELL, V73, P309, DOI 10.1016/0092-8674(93)90231-E; XUAN JW, 1995, J CELL BIOCHEM, V57, P680, DOI 10.1002/jcb.240570413	67	112	129	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 31	1996	271	22					12814	12819		10.1074/jbc.271.22.12814	http://dx.doi.org/10.1074/jbc.271.22.12814			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UN474	8662712	hybrid			2022-12-25	WOS:A1996UN47400021
J	Modur, V; Zimmerman, GA; Prescott, SM; McIntyre, TM				Modur, V; Zimmerman, GA; Prescott, SM; McIntyre, TM			Endothelial cell inflammatory responses to tumor necrosis factor alpha - Ceramide-dependent and -independent mitogen-activated protein kinase cascades	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; SIGNAL-TRANSDUCTION; FACTOR-RECEPTOR; FAMILY MEMBERS; SPHINGOMYELINASE; MONOCYTOGENES; INTERLEUKIN-8; RESISTANT; INFECTION; CYTOKINES	Ceramide generation by stimulated sphingomyelinase activity has been implicated in tumor necrosis factor alpha (TNF) signaling of apoptosis and differentiation. We examined the role of ceramide in a major action of TNF: the initiation of inflammatory events. Sphingomyelinase C at high levels induced inflammatory protein expression in endothelial cells resulting in leukocyte adhesion, but the pattern of induction of adhesion molecules (E-selectin, ICAM-1, VCAM-1) and cytokines (interleukins 6 and 8) differed from that induced by TNF. TNF induced only a small increase in ceramide: using lower doses of sphingomyelinase to mimic this we found that small amounts of ceramide did not induce protein expression, but still rapidly activated Raf-1, mitogen-activated protein/extracellular regulated kinase (ERK) kinase (MEK) and ERKs. TNF additionally caused rapid p38 and JNK-1 mitogen-activated protein kinase activation and efficient NF-kappa B translocation, which could not be achieved even by high levels of ceramide. Thus activation of the ERK: cascade alone is an incomplete endothelial cell stimulus, and the TNF receptor generates at least two signals: Raf-1 activation, which could be ceramide-dependent; and ceramide-independent efficient NF-kappa B translocation and activation of p38 and JNK-1 mitogen-activated kinases.	UNIV UTAH,NE HARRISON CARDIOVASC RES & TRAINING INST,DEPT MED,SALT LAKE CITY,UT 84112; UNIV UTAH,DEPT PATHOL,SALT LAKE CITY,UT 84112; UNIV UTAH,PROGRAM HUMAN MOL BIOL & GENET,SALT LAKE CITY,UT 84112	Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah					NCI NIH HHS [CCSG 3P30 CA 42014-09] Funding Source: Medline; NHLBI NIH HHS [HL 50513] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA042014] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDRIEU N, 1994, BIOCHEM J, V303, P341, DOI 10.1042/bj3030341; BELKA C, 1995, EMBO J, V14, P1156, DOI 10.1002/j.1460-2075.1995.tb07099.x; BETTS JC, 1994, J BIOL CHEM, V269, P8455; BEVILACQUA MP, 1993, J CLIN INVEST, V91, P379, DOI 10.1172/JCI116210; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; CANO E, 1995, TRENDS BIOCHEM SCI, V20, P117, DOI 10.1016/S0968-0004(00)88978-1; COLLINS T, 1993, LAB INVEST, V68, P499; COLLINS T, 1995, FASEB J, V9, P899, DOI 10.1096/fasebj.9.10.7542214; CRUZ R, 1995, FASEB J, V9, pA127; DBAIBO GS, 1993, J BIOL CHEM, V268, P17762; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; DEWITT DL, 1988, P NATL ACAD SCI USA, V85, P1412, DOI 10.1073/pnas.85.5.1412; DRESSLER KA, 1992, SCIENCE, V255, P1715, DOI 10.1126/science.1313189; FENNELL DF, 1991, ARTERIOSCLER THROMB, V11, P97, DOI 10.1161/01.ATV.11.1.97; HANNUN YA, 1994, J BIOL CHEM, V269, P3125; HELLER RA, 1994, J CELL BIOL, V126, P5, DOI 10.1083/jcb.126.1.5; KASZUBSKA W, 1993, MOL CELL BIOL, V13, P7180, DOI 10.1128/MCB.13.11.7180; KOLESNICK R, 1994, CELL, V77, P325, DOI 10.1016/0092-8674(94)90147-3; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIN AN, 1995, SCIENCE, V268, P286, DOI 10.1126/science.7716521; LINARDIC CM, 1994, J BIOL CHEM, V269, P23530; MACHLEIDT T, 1994, J BIOL CHEM, V269, P13760; MACKAY F, 1993, J EXP MED, V177, P1277, DOI 10.1084/jem.177.5.1277; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MATSUSAKA T, 1993, P NATL ACAD SCI USA, V90, P10193, DOI 10.1073/pnas.90.21.10193; MCEVER RP, 1995, J BIOL CHEM, V270, P11025, DOI 10.1074/jbc.270.19.11025; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; Mollby R., 1978, BACTERIAL TOXINS CEL, P367; OLIVERA A, 1992, J BIOL CHEM, V267, P26121; PATEL KD, 1994, J CLIN INVEST, V94, P631, DOI 10.1172/JCI117379; PFEFFER K, 1993, CELL, V73, P457, DOI 10.1016/0092-8674(93)90134-C; POBER JS, 1990, PHYSIOL REV, V70, P427, DOI 10.1152/physrev.1990.70.2.427; PUSHKAREVA M, 1995, IMMUNOL TODAY, V16, P294, DOI 10.1016/0167-5699(95)80184-7; RAINES MA, 1993, J BIOL CHEM, V268, P14572; READ MA, 1994, J EXP MED, V179, P503, DOI 10.1084/jem.179.2.503; REDDY SAG, 1994, J BIOL CHEM, V269, P25369; ROTHE J, 1993, NATURE, V364, P798, DOI 10.1038/364798a0; SALEEM A, 1995, J IMMUNOL, V154, P4150; SCHUTZE S, 1992, CELL, V71, P765, DOI 10.1016/0092-8674(92)90553-O; SLOWIK MR, 1993, AM J PATHOL, V143, P1724; STEIN B, 1993, MOL CELL BIOL, V13, P7191, DOI 10.1128/MCB.13.11.7191; STEIN B, 1993, MOL CELL BIOL, V13, P3964, DOI 10.1128/MCB.13.7.3964; TARTAGLIA LA, 1993, CELL, V74, P845, DOI 10.1016/0092-8674(93)90464-2; WESTWICK JK, 1994, J BIOL CHEM, V269, P26396; WESTWICK JK, 1995, J BIOL CHEM, V270, P22689, DOI 10.1074/jbc.270.39.22689; WEYRICH AS, 1995, J CLIN INVEST, V95, P2297, DOI 10.1172/JCI117921; WIEGMANN K, 1994, CELL, V78, P1005, DOI 10.1016/0092-8674(94)90275-5; WIEGMANN K, 1992, J BIOL CHEM, V267, P17997; WINSTON BW, 1995, P NATL ACAD SCI USA, V92, P1614, DOI 10.1073/pnas.92.5.1614; YAN MH, 1994, NATURE, V372, P798; ZIMMERMAN GA, 1990, J CELL BIOL, V110, P529, DOI 10.1083/jcb.110.2.529; ZIMMERMAN GA, 1993, AM J RESP CELL MOL, V9, P573, DOI 10.1165/ajrcmb/9.6.573; ZIMMERMAN GA, 1985, J CLIN INVEST, V76, P2235, DOI 10.1172/JCI112232	55	211	214	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 31	1996	271	22					13094	13102		10.1074/jbc.271.22.13094	http://dx.doi.org/10.1074/jbc.271.22.13094			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UN474	8662702	hybrid			2022-12-25	WOS:A1996UN47400063
J	Oppermann, M; Freedman, NJ; Alexander, RW; Lefkowitz, RJ				Oppermann, M; Freedman, NJ; Alexander, RW; Lefkowitz, RJ			Phosphorylation of the type 1A angiotensin II receptor by G protein-coupled receptor kinases and protein kinase C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RENAL MESANGIAL CELLS; SITE-DIRECTED MUTAGENESIS; POLYPHOSPHOINOSITIDE HYDROLYSIS; PHOSPHOINOSITIDE HYDROLYSIS; HOMOLOGOUS DESENSITIZATION; DOWN-REGULATION; MOBILIZATION; INHIBITORS; PATHWAYS	The type 1A angiotensin II receptor (AT(1A)-R), which mediates cardiovascular effects of angiotensin II, has been shown to undergo rapid agonist-induced desensitization. We investigated the potential role of second messenger-activated kinases and G protein-coupled receptor kinases (GRKs) in the regulation of this receptor. In 293 cells transfected with the AT(1A)-R, a 3-min challenge with angiotensin II engendered a 46% decrease in subsequent angiotensin II-stimulated phosphoinositide hydrolysis in intact cells. This agonist-induced desensitization correlated temporally and dose-dependently with the phosphorylation of the receptor to a stoichiometry of 1 mol of phosphate/mol of receptor, as assessed by immunoprecipitation of receptors from cells metabolically labeled with P-32(i). Agonist-induced receptor phosphorylation was reduced by 40-50% by either overexpression of a dominant negative K220R mutant GRK2 or treatment of the cells with the protein kinase C (PKC) inhibitor staurosporine, in a virtually additive fashion. Cellular overexpression of GRK2(K220R) not only inhibited agonist-induced AT(1A)-R phosphorylation, but also prevented receptor desensitization, as assessed by angiotensin II-stimulated GTPase activity in membranes prepared from agonist-treated and control cells. In contrast, PKC inhibition by staurosporine did not affect homologous desensitization of the AT(1A)-R. Overexpression of GRKs 2, 3, or 5 significantly augmented the agonist-induced AT(1A)-R phosphorylation 1.5- to 1.7-fold (p < 0.001). These findings suggest a role for receptor phosphorylation by one or several GRKs in the rapid agonist-induced desensitization of the AT(1A)-R.	DUKE UNIV, MED CTR, DEPT MED, HOWARD HUGHES MED INST, DURHAM, NC 27710 USA; DUKE UNIV, MED CTR, DEPT BIOCHEM, DURHAM, NC 27710 USA; EMORY UNIV, SCH MED, DEPT MED, DIV CARDIOL, ATLANTA, GA 30322 USA	Duke University; Howard Hughes Medical Institute; Duke University; Emory University			Lefkowitz, Robert/AAW-2649-2021		NHLBI NIH HHS [HL16037, HL03008] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL016037, R37HL016037] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABDELLATIF MM, 1991, CIRC RES, V69, P800, DOI 10.1161/01.RES.69.3.800; BARAK LS, 1994, J BIOL CHEM, V269, P2790; BARKER S, 1995, FEBS LETT, V369, P263, DOI 10.1016/0014-5793(95)00725-O; BOULAY G, 1994, ENDOCRINOLOGY, V135, P2130, DOI 10.1210/en.135.5.2130; BRASS LF, 1992, J BIOL CHEM, V267, P6044; CASSEL D, 1976, BIOCHIM BIOPHYS ACTA, V452, P538, DOI 10.1016/0005-2744(76)90206-0; COTECCHIA S, 1992, J BIOL CHEM, V267, P1633; DUNLAY R, 1990, AM J PHYSIOL, V258, pF223, DOI 10.1152/ajprenal.1990.258.2.F223; FREEDMAN NJ, 1995, J BIOL CHEM, V270, P17953, DOI 10.1074/jbc.270.30.17953; GASC JM, 1994, HYPERTENSION, V24, P531, DOI 10.1161/01.HYP.24.5.531; GIERSCHIK P, 1994, METHOD ENZYMOL, V237, P13; Griendling K K, 1994, Adv Pharmacol, V28, P269, DOI 10.1016/S1054-3589(08)60498-6; HALLER H, 1990, BIOCHEM J, V270, P375, DOI 10.1042/bj2700375; HUNYADY L, 1994, J BIOL CHEM, V269, P31378; INGLESE J, 1993, J BIOL CHEM, V268, P23735; ISHII K, 1994, J BIOL CHEM, V269, P1125; ITO M, 1995, P NATL ACAD SCI USA, V92, P3521, DOI 10.1073/pnas.92.8.3521; KAI H, 1994, HYPERTENSION, V24, P523, DOI 10.1161/01.HYP.24.4.523; KONG GH, 1994, J BIOL CHEM, V269, P13084; LEFKOWITZ RJ, 1993, CELL, V74, P409, DOI 10.1016/0092-8674(93)80042-D; LOHSE MJ, 1993, BIOCHIM BIOPHYS ACTA, V1179, P171, DOI 10.1016/0167-4889(93)90139-G; LOHSE MJ, 1990, J BIOL CHEM, V265, P3202; MURPHY TJ, 1991, NATURE, V351, P233, DOI 10.1038/351233a0; OCHSNER M, 1993, EUR J PHARM-MOLEC PH, V245, P15, DOI 10.1016/0922-4106(93)90164-5; OHYAMA K, 1992, BIOCHEM BIOPH RES CO, V189, P677, DOI 10.1016/0006-291X(92)92254-U; PALSRYLAARSDAM R, 1995, J BIOL CHEM, V270, P29004, DOI 10.1074/jbc.270.48.29004; PEACH MJ, 1986, KIDNEY HORMONES, P273; PEI G, 1995, MOL PHARMACOL, V48, P173; PFEILSCHIFTER J, 1988, BIOCHIM BIOPHYS ACTA, V969, P263, DOI 10.1016/0167-4889(88)90061-4; PFEILSCHIFTER J, 1990, FEBS LETT, V261, P307, DOI 10.1016/0014-5793(90)80578-7; PFEILSCHIFTER J, 1989, BIOCHEM J, V262, P285, DOI 10.1042/bj2620285; PIPPIG S, 1993, J BIOL CHEM, V268, P3201; PREMONT RT, 1994, J BIOL CHEM, V269, P6832; ROTH NS, 1991, P NATL ACAD SCI USA, V88, P6201, DOI 10.1073/pnas.88.14.6201; SEFTON BM, 1991, METHOD ENZYMOL, V201, P245; SMIT MJ, 1992, BRIT J PHARMACOL, V107, P448, DOI 10.1111/j.1476-5381.1992.tb12766.x; THOMAS WG, 1995, J BIOL CHEM, V270, P207, DOI 10.1074/jbc.270.1.207; YAMANO Y, 1992, BIOCHEM BIOPH RES CO, V187, P1426, DOI 10.1016/0006-291X(92)90461-S	38	206	209	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 31	1996	271	22					13266	13272		10.1074/jbc.271.22.13266	http://dx.doi.org/10.1074/jbc.271.22.13266			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UN474	8662816	hybrid			2022-12-25	WOS:A1996UN47400089
J	Torres, M; Ye, RD				Torres, M; Ye, RD			Activation of the mitogen-activated protein kinase pathway by fMet-Leu-Phe in the absence of Lyn and tyrosine phosphorylation of SHC in transfected cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FORMYL PEPTIDE RECEPTOR; SIGNAL TRANSDUCTION; HUMAN NEUTROPHILS; RAS; GRB2; STIMULATION; DOMAIN; BINDS	The chemotactic peptide f-Met-Leu-Phe (fMLP) stimulates leukocyte functions through binding and activation of a specific G-protein-coupled formyl peptide receptor (FPR), Recent studies have shown that stimulation of neutrophils with fMLP induces the activation of two members of the mitogen-activated protein kinase (MAP kinase) family, ERK1 and ERK2, through mechanisms that are not completely understood but may involve the phosphorylation of the adapter protein SHC by the Src-related kinase Lyn. In this study, transfected fibroblasts expressing the rabbit FPR were used to investigate further the role of Lyn and SHC phosphorylation in fMLP-stimulated MAP kinase activation. Stimulation of transfected cells with fMLP resulted in the time- and dose-dependent increase in tyrosine phosphorylation and activation of ERK1 and ERK2 and the activation of MEK, the MAP kinase/ERK kinase, The activation of both ERKs and MEK was inhibited by preincubation of the cells with pertussis toxin, indicating that activation was dependent upon a G(i)/G(o)-like protein that couples to the receptor. Our data also show that, unlike neutrophils, FPR-transfected fibroblasts do not. express the Src-related kinase Lyn. In the absence of Lyn, fMLP stimulation did not result in an increased tyrosine phosphorylation of the adapter protein SHC, whereas it was still able to induce MAP kinase activation. These data suggest that Lyn and SHC are not the only upstream signals for activation of the MAP kinase/ERK pathway by fMLP and demonstrate the potential application of the FPR-transfected cells for the delineation of additional signaling mechanisms stimulated by rMLP.	Scripps Res Inst, RES INST, DEPT IMMUNOL, LA JOLLA, CA 92037 USA	Scripps Research Institute	Torres, M (corresponding author), UNIV SO CALIF, CHILDRENS HOSP LOS ANGELES,RES INST,DEPT PEDIAT, 4650 SUNSET BLVD, MS57, LOS ANGELES, CA 90027 USA.		Ye, Richard/O-5223-2016; Ye, Richard/ABF-2413-2020	Ye, Richard/0000-0002-2164-5620; Ye, Richard/0000-0002-2164-5620	NIAID NIH HHS [AI33503] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R56AI033503, R01AI033503] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALBLAS J, 1993, J BIOL CHEM, V268, P22235; ALESSANDRINI A, 1992, P NATL ACAD SCI USA, V89, P8200, DOI 10.1073/pnas.89.17.8200; BOKOCH GM, 1995, BLOOD, V86, P1649, DOI 10.1182/blood.V86.5.1649.bloodjournal8651649; BUHL AM, 1995, J BIOL CHEM, V270, P19828, DOI 10.1074/jbc.270.34.19828; CAZAUBON SM, 1994, J BIOL CHEM, V269, P24805; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; CHEN YH, 1994, J BIOL CHEM, V269, P27372; CRESPO P, 1994, NATURE, V369, P418, DOI 10.1038/369418a0; DING JB, 1993, J BIOL CHEM, V268, P17326; Downey G P, 1995, Curr Opin Hematol, V2, P76; EDER M, 1993, EMBO J, V12, P1647, DOI 10.1002/j.1460-2075.1993.tb05810.x; ERICKSON AK, 1990, J BIOL CHEM, V265, P19728; FAURE M, 1994, J BIOL CHEM, V269, P7851; FELLER SM, 1994, TRENDS BIOCHEM SCI, V19, P453, DOI 10.1016/0968-0004(94)90129-5; FLORDELLIS CS, 1995, J BIOL CHEM, V270, P3491, DOI 10.1074/jbc.270.8.3491; GARDNER AM, 1993, J BIOL CHEM, V268, P17896; GAUDRY M, 1995, BLOOD, V86, P3567, DOI 10.1182/blood.V86.9.3567.bloodjournal8693567; GRINSTEIN S, 1992, J BIOL CHEM, V267, P18122; HAWES BE, 1995, J BIOL CHEM, V270, P17148, DOI 10.1074/jbc.270.29.17148; HONDA Z, 1994, J BIOL CHEM, V269, P2307; INDIK ZK, 1995, BLOOD, V85, P1175, DOI 10.1182/blood.V85.5.1175.bloodjournal8551175; KEYSE SM, 1995, BBA-MOL CELL RES, V1265, P152, DOI 10.1016/0167-4889(94)00211-V; KNAUS UG, 1995, SCIENCE, V269, P221, DOI 10.1126/science.7618083; KOCH WJ, 1994, J BIOL CHEM, V269, P6193; KOCH WJ, 1994, P NATL ACAD SCI USA, V91, P12706, DOI 10.1073/pnas.91.26.12706; KUSUNOKI T, 1992, BIOCHEM BIOPH RES CO, V183, P789, DOI 10.1016/0006-291X(92)90552-V; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; LU DJ, 1993, BLOOD CELLS, V19, P343; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; MURPHY PM, 1994, ANNU REV IMMUNOL, V12, P593, DOI 10.1146/annurev.iy.12.040194.003113; OHMICHI M, 1994, J BIOL CHEM, V269, P3783; PACE AM, 1995, MOL BIOL CELL, V6, P1685, DOI 10.1091/mbc.6.12.1685; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; PHILIPS MR, 1993, SCIENCE, V259, P977, DOI 10.1126/science.8438158; PTASZNIK A, 1995, J BIOL CHEM, V270, P19969, DOI 10.1074/jbc.270.34.19969; QUEHENBERGER O, 1992, J BIOL CHEM, V267, P19757; ROLLET E, 1994, J IMMUNOL, V153, P353; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; SCHLESSINGER J, 1993, TRENDS BIOCHEM SCI, V18, P2732; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; THOMASON PA, 1994, J BIOL CHEM, V269, P16525; THOMPSON HL, 1993, BIOCHEM J, V290, P483, DOI 10.1042/bj2900483; THOMPSON HL, 1994, J BIOL CHEM, V269, P9486; TORRES M, 1993, J IMMUNOL, V150, P1563; VANBIESEN T, 1995, NATURE, V376, P781, DOI 10.1038/376781a0; VERGHESE M, 1986, BIOCHEM BIOPH RES CO, V138, P887, DOI 10.1016/S0006-291X(86)80579-4; WIESMULLER L, 1994, CELL SIGNAL, V6, P247, DOI 10.1016/0898-6568(94)90030-2; WORTHEN GS, 1994, J CLIN INVEST, V94, P815, DOI 10.1172/JCI117401; YE RD, 1993, J IMMUNOL, V150, P1383	51	17	19	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 31	1996	271	22					13244	13249		10.1074/jbc.271.22.13244	http://dx.doi.org/10.1074/jbc.271.22.13244			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UN474	8662760				2022-12-25	WOS:A1996UN47400086
J	DeMaria, CT; Brewer, G				DeMaria, CT; Brewer, G			AUF1 binding affinity to A+U-rich elements correlates with rapid mRNA degradation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA STABILITY; SEQUENCES; POLY(A); PROTEIN; INVITRO; REGION	Rapid degradation of many labile mRNAs is regulated in part by an A+U-rich element (ARE) in their 3'-untranslated regions. Extensive mutational analyses of various AREs have identified important components of the ARE, such as the nonamer motif UUAUUUAUU, two copies of which serve as a potent mRNA destabilizer. To investigate the roles of trans-acting factors in ARE-directed mRNA degradation, we previously purified and molecularly cloned the RNA binding protein AUF1 and demonstrated that both cellular and recombinant AUF1 bind specifically to AREs as shown by UV cross-linking assays in vitro. In the present work, we have examined the in vitro RNA-binding properties of AUF1 using gel mobility shift assays with purified recombinant His(6)-AUF1 fusion protein. We find that ARE binding affinities of AUF1 correlate with the potency of an ARE to direct degradation of a heterologous mRNA, These results support a role for AUF1 in ARE directed mRNA decay that is based upon its affinity for different AREs.	WAKE FOREST UNIV, BOWMAN GRAY SCH MED, DEPT IMMUNOL & MICROBIOL, WINSTON SALEM, NC 27157 USA	Wake Forest University; Wake Forest Baptist Medical Center					NATIONAL CANCER INSTITUTE [P30CA012197] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI007401] Funding Source: NIH RePORTER; NCI NIH HHS [CA12197] Funding Source: Medline; NIAID NIH HHS [T32-AI07401] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AKASHI M, 1994, BLOOD, V83, P3182; BEELMAN CA, 1995, CELL, V81, P179, DOI 10.1016/0092-8674(95)90326-7; BERNSTEIN P, 1989, TRENDS BIOCHEM SCI, V14, P373, DOI 10.1016/0968-0004(89)90011-X; BREWER G, 1988, MOL CELL BIOL, V8, P1697, DOI 10.1128/MCB.8.4.1697; BREWER G, 1991, MOL CELL BIOL, V11, P2460, DOI 10.1128/MCB.11.5.2460; BREWER G, 1989, MOL CELL BIOL, V9, P1996, DOI 10.1128/MCB.9.5.1996; BURD CG, 1994, SCIENCE, V265, P615, DOI 10.1126/science.8036511; CAPUT D, 1986, P NATL ACAD SCI USA, V83, P1670, DOI 10.1073/pnas.83.6.1670; CAREY J, 1991, METHOD ENZYMOL, V208, P103; CARTER BZ, 1991, LAB INVEST, V65, P610; CHEN CYA, 1994, MOL CELL BIOL, V14, P8471, DOI 10.1128/MCB.14.12.8471; EHRENMAN K, 1994, GENE, V149, P315, DOI 10.1016/0378-1119(94)90168-6; Greenberg ME, 1993, CONTROL MESSENGER RN, P199, DOI 10.1016/B978-0-08-091652-1.50013-X; HADCOCK JR, 1989, J BIOL CHEM, V264, P19928; JONES TR, 1987, MOL CELL BIOL, V7, P4513, DOI 10.1128/MCB.7.12.4513; KENAN DJ, 1994, TRENDS BIOCHEM SCI, V19, P57, DOI 10.1016/0968-0004(94)90033-7; KOEFFLER HP, 1980, BLOOD, V56, P344; LAGNADO CA, 1994, MOL CELL BIOL, V14, P7984, DOI 10.1128/MCB.14.12.7984; MCCARTHY JEG, 1995, TRENDS BIOCHEM SCI, V20, P191, DOI 10.1016/S0968-0004(00)89006-4; Pande A, 1996, J BIOL CHEM, V271, P8493, DOI 10.1074/jbc.271.14.8493; PELTZ S W, 1991, Critical Reviews in Eukaryotic Gene Expression, V1, P99; ROSS J, 1995, MICROBIOL REV, V59, P423, DOI 10.1128/MMBR.59.3.423-450.1995; SACHS AB, 1993, CELL, V74, P413, DOI 10.1016/0092-8674(93)80043-E; SCHIAVI SC, 1992, BIOCHIM BIOPHYS ACTA, V1114, P95, DOI 10.1016/0304-419X(92)90009-N; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SHYU AB, 1991, GENE DEV, V5, P221, DOI 10.1101/gad.5.2.221; SWARTWOUT SG, 1989, MOL CELL BIOL, V9, P288, DOI 10.1128/MCB.9.1.288; TREMMEL KD, 1996, KEYSTONE S MOL BIOL, P47; WILSON T, 1988, NATURE, V336, P396, DOI 10.1038/336396a0; ZHANG W, 1993, MOL CELL BIOL, V13, P7652, DOI 10.1128/MCB.13.12.7652; ZUBIAGA AM, 1995, MOL CELL BIOL, V15, P2219	31	235	239	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 24	1996	271	21					12179	12184		10.1074/jbc.271.21.12179	http://dx.doi.org/10.1074/jbc.271.21.12179			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UL660	8647811	hybrid			2022-12-25	WOS:A1996UL66000013
J	Longo, VD; Gralla, EB; Valentine, JS				Longo, VD; Gralla, EB; Valentine, JS			Superoxide dismutase activity is essential for stationary phase survival in Saccharomyces cerevisiae - Mitochondrial production of toxic oxygen species in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; YEAST; GENE; METALLOTHIONEIN; BIOSYNTHESIS; SENSITIVITY; DEHYDRATASE; METABOLISM; EVOLUTION; MUTATION	Yeast lacking copper-zinc superoxide dismutase (CuZnSOD), manganese superoxide dismutase (SOD), catalase T, or metallothionein were studied using long term stationary phase (10-45 days) as a simple model system to study the roles of antioxidant enzymes in aging. In well aerated cultures, the lack of either SOD resulted in dramatic loss of viability over the first few weeks of culture, with the CuZnSOD mutant showing the more severe defect. The double SOD mutant died within a few days. The severity reversed in low aeration; the CuZnSOD mutant remained viable longer than the manganese SOD mutant. To test whether reactive oxygen species generated during respiration play an important role in the observed cellular death, growth in nonfermentable carbon sources was measured, All strains grew under low aeration, indicating respiratory competence, High aeration caused much reduced growth in single SOD mutants, and the double mutant failed to grow. However, removal of respiration via another mutation dramatically increased short term survival and reversed the known air-dependent methionine and lysine auxotrophies. Our results suggest strongly that mitochondrial respiration is a major source of reactive oxygen species in vivo, as has been shown in vitro, and that these species are produced even under low aeration.	UNIV CALIF LOS ANGELES,DEPT CHEM & BIOCHEM,LOS ANGELES,CA 90095	University of California System; University of California Los Angeles			Valentine, Joan S/B-6665-2008	Valentine, Joan S/0000-0002-7174-925X	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK046828] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK46828] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AGARWAL S, 1994, P NATL ACAD SCI USA, V91, P12332, DOI 10.1073/pnas.91.25.12332; BENOV L, 1995, ARCH BIOCHEM BIOPHYS, V322, P291, DOI 10.1006/abbi.1995.1465; BILINSKI T, 1985, BIOCHEM BIOPH RES CO, V130, P533, DOI 10.1016/0006-291X(85)90449-8; BLUM J, 1985, ARCH BIOCHEM BIOPHYS, V240, P500, DOI 10.1016/0003-9861(85)90056-6; BOVERIS A, 1982, SUPEROXIDE DISMUTASE, V2, P15; CARLIOZ A, 1986, EMBO J, V5, P623, DOI 10.1002/j.1460-2075.1986.tb04256.x; CHANCE B, 1979, PHYSIOL REV, V59, P527, DOI 10.1152/physrev.1979.59.3.527; CLARKE CF, 1991, J BIOL CHEM, V266, P16636; DEVRIES S, 1987, BIOCHIM BIOPHYS ACTA, V895, P205, DOI 10.1016/S0304-4173(87)80003-4; DO TQ, 1996, IN PRESS P NATL ACAD; FARR SB, 1986, P NATL ACAD SCI USA, V83, P8268, DOI 10.1073/pnas.83.21.8268; FORMAN HJ, 1982, FREE RADICAL BIO MED, V5, P65; FRIDOVICH I, 1986, ARCH BIOCHEM BIOPHYS, V247, P1, DOI 10.1016/0003-9861(86)90526-6; GARDNER PR, 1991, J BIOL CHEM, V266, P19328; GARDNER PR, 1991, J BIOL CHEM, V266, P1478; GRALLA EB, 1991, J BACTERIOL, V173, P5918, DOI 10.1128/jb.173.18.5918-5920.1991; GRALLA EB, 1992, ADV GENET, V30, P251, DOI 10.1016/S0065-2660(08)60322-3; GUIDOT DM, 1995, J CLIN INVEST, V96, P1131, DOI 10.1172/JCI118100; GUIDOT DM, 1993, J BIOL CHEM, V268, P26699; HEIKKILA RE, 1976, ANAL BIOCHEM, V75, P356, DOI 10.1016/0003-2697(76)90089-0; HEIKKILA RE, 1985, CRC HDB METHODS OXYG, P233; HILL JE, 1986, YEAST, V2, P163, DOI 10.1002/yea.320020304; HOLLIDAY R, 1995, UNDERSTANDING AGING, P41; IMLAY JA, 1991, MOL GEN GENET, V228, P410, DOI 10.1007/BF00260634; Kaiser C. S., 1994, METHODS YEAST GENETI, P207; KIRKWOOD TBL, 1991, PHILOS T R SOC B, V332, P15, DOI 10.1098/rstb.1991.0028; KIRKWOOD TBL, 1977, NATURE, V270, P301, DOI 10.1038/270301a0; KONO Y, 1982, J BIOL CHEM, V257, P5751; KUO CF, 1987, J BIOL CHEM, V262, P4724; LARSEN PL, 1993, P NATL ACAD SCI USA, V90, P8905, DOI 10.1073/pnas.90.19.8905; LIU XF, 1992, J BIOL CHEM, V267, P18298; Luck H., 1974, ESTIMATION CATALASE, V885; MUELLER DM, 1988, J BIOL CHEM, V263, P5634; NISHIDA CR, 1994, P NATL ACAD SCI USA, V91, P9906, DOI 10.1073/pnas.91.21.9906; RABIZADEH S, 1995, P NATL ACAD SCI USA, V92, P3024, DOI 10.1073/pnas.92.7.3024; ROTHSTEIN RJ, 1980, GENETICS, V94, P871; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; SOHAL RS, 1995, J BIOL CHEM, V270, P15671, DOI 10.1074/jbc.270.26.15671; THIELE DJ, 1986, MOL CELL BIOL, V6, P1158, DOI 10.1128/MCB.6.4.1158; THIELE DJ, 1986, SCIENCE, V231, P854, DOI 10.1126/science.3080806; WARNER HR, 1994, FREE RADICAL BIO MED, V17, P249, DOI 10.1016/0891-5849(94)90080-9; WERNERWASHBURNE M, 1993, MICROBIOL REV, V57, P383, DOI 10.1128/MMBR.57.2.383-401.1993	42	437	447	0	37	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 24	1996	271	21					12275	12280		10.1074/jbc.271.21.12275	http://dx.doi.org/10.1074/jbc.271.21.12275			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UL660	8647826	hybrid			2022-12-25	WOS:A1996UL66000028
J	Tiffany, HL; Handen, JS; Rosenberg, HF				Tiffany, HL; Handen, JS; Rosenberg, HF			Enhanced expression of the eosinophil-derived neurotoxin ribonuclease (RNS2) gene requires interaction between the promoter and intron	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GRANULE DEFICIENCY; 1ST INTRON; TRANSCRIPTIONAL REGULATION; MOLECULAR-CLONING; CATIONIC PROTEIN; COLLAGEN GENE; HL-60 CELLS; ELEMENTS; SEQUENCE; CONTAINS	The eosinophil-derived neurotoxin (EDN/RNS2) is a member of the mammalian ribonuclease gene family and is one of four proteins found in the large specific granules of human eosinophilic leukocytes. The gene encoding EDN consists of two exons, including a noncoding exon 1, separated by a single intron from the coding sequence in exon 2. We have identified a functional promoter of the EDN gene and shown that optimal expression depends on interaction between the pro meter and one or more sequence elements found in the single intron. Cells of the clone 15 eosinophilic variant of the human promyelocytic HL-60 cell line were transfected with constructs that included the promoter region of the EDN gene alone, promoter with exon 1, and promoter with both exon 1 and the intron positioned 5' to the chloramphenicol acetyltransferase (CAT) reporter gene (constructs referred to as PrCAT, PrExCAT, and PrExInCAT, respectively). Although reporter gene activity from either PrCAT or PrExCAT was only 2-3 fold higher than baseline (CAT alone), inclusion of the single intron (PrExInCAT) resulted in a 28-fold increase in reporter gene activity in uninduced clone 15 cells, and an 80-fold in activity when clone 15 cells were induced to differentiate toward eosinophils with butyric acid. The intron-mediated enhancer activity was reproduced in other human hematopoietic cell lines (K562, Jurkat, U937, and HL-60), but was not found in human 293 kidney cells, suggesting that the function of the enhancer element(s) may be tissue-specific. A significant portion of the observed enhancer activity resides in the first 60 base pairs the the intron, which includes consensus binding sites for both AP-1 and NF-ATp transcription factors, and a 15-base pair segment that is identical to a sequence found in the promoter of the gene encoding the neutrophil granule protein, lactoferrin. The noncoding exon 1/single intron/coding exon 2 genomic structure is a common feature among the mammalian ribonucleases; this finding suggests the possibility of a conserved mechanism of regulation in this gene family.	NIAID,HOST DEF LAB,NIH,BETHESDA,MD 20892; GEORGE WASHINGTON UNIV,GRAD PROGRAM GENET,WASHINGTON,DC 20052	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); George Washington University								ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; Ausubel FM, 1995, SHORT PROTOCOLS MOL, V3rd; BAINTON DF, 1992, INFLAMMATION BASIC P, P303; BORNSTEIN P, 1988, J BIOL CHEM, V263, P1603; CARSANA A, 1988, NUCLEIC ACIDS RES, V16, P5491, DOI 10.1093/nar/16.12.5491; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; FISCHKOFF SA, 1984, J EXP MED, V160, P179, DOI 10.1084/jem.160.1.179; FISCHKOFF SA, 1988, LEUKEMIA RES, V12, P679, DOI 10.1016/0145-2126(88)90103-8; GALLIN JI, 1982, BLOOD, V59, P1317; GALLIN JI, 1985, ANNU REV MED, V36, P263; GOMOLIN HI, 1993, BLOOD, V82, P1868; HAMANN KJ, 1989, GENE, V83, P161, DOI 10.1016/0378-1119(89)90414-9; HAMANN KJ, 1990, GENOMICS, V7, P535, DOI 10.1016/0888-7543(90)90197-3; HENKEL G, 1992, J IMMUNOL, V149, P3239; HIGUCHI R, 1990, PCR PROTOCOLS, pCH2; JOHNSTON JJ, 1992, BLOOD, V79, P2998; KURACHI K, 1985, BIOCHEMISTRY-US, V24, P5494, DOI 10.1021/bi00341a032; LEIDEN JM, 1993, ANNU REV IMMUNOL, V11, P539, DOI 10.1146/annurev.iy.11.040193.002543; LI MS, 1995, BIOCHEM J, V305, P921, DOI 10.1042/bj3050921; LOMAX KJ, 1989, J CLIN INVEST, V83, P514, DOI 10.1172/JCI113912; NAKAJIMAIIJIMA S, 1985, P NATL ACAD SCI USA, V82, P6133, DOI 10.1073/pnas.82.18.6133; NAKANO T, 1992, ONCOGENE, V7, P527; PAHL HL, 1993, J BIOL CHEM, V268, P5014; PLAETINCK G, 1990, J EXP MED, V172, P683, DOI 10.1084/jem.172.3.683; POGULIS RJ, 1993, J BIOL CHEM, V268, P2493; RAO A, 1994, IMMUNOL TODAY, V15, P274, DOI 10.1016/0167-5699(94)90007-8; RIPPE RA, 1989, MOL CELL BIOL, V9, P2224, DOI 10.1128/MCB.9.5.2224; ROSENBERG HF, 1989, P NATL ACAD SCI USA, V86, P4460, DOI 10.1073/pnas.86.12.4460; ROSENBERG HF, 1989, J EXP MED, V170, P163, DOI 10.1084/jem.170.1.163; ROSENBERG HF, 1993, BLOOD, V82, P268, DOI 10.1182/blood.V82.1.268.bloodjournal821268; SAMUELSON LC, 1991, NUCLEIC ACIDS RES, V19, P6935, DOI 10.1093/nar/19.24.6935; SAWADA S, 1994, CELL, V77, P917, DOI 10.1016/0092-8674(94)90140-6; Spry CJ, 1988, EOSINOPHILS COMPREHE; STAUDT LM, 1991, ANNU REV IMMUNOL, V9, P373; SUN ZJ, 1995, J BIOL CHEM, V270, P1462, DOI 10.1074/jbc.270.3.1462; TAVERNIER J, 1991, CELL, V66, P1175, DOI 10.1016/0092-8674(91)90040-6; TIFFANY HL, 1995, J LEUKOCYTE BIOL, V58, P49; TOURMENTE S, 1993, INSECT BIOCHEM MOLEC, V23, P137, DOI 10.1016/0965-1748(93)90092-7; YAMAGUCHI Y, 1994, J BIOL CHEM, V269, P19410	39	31	31	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 24	1996	271	21					12387	12393		10.1074/jbc.271.21.12387	http://dx.doi.org/10.1074/jbc.271.21.12387			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UL660	8647842	hybrid			2022-12-25	WOS:A1996UL66000044
J	Lin, AW; Chang, CC; McCormick, CC				Lin, AW; Chang, CC; McCormick, CC			Molecular cloning and expression of an avian macrophage nitric-oxide synthase cDNA and the analysis of the genomic 5'-flanking region	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							L-ARGININE; INTERFERON-GAMMA; PURIFICATION; CALMODULIN; FERREDOXIN; REDUCTASE; BINDING; GENE; LIPOPOLYSACCHARIDE; OXIDOREDUCTASE	We report the first nonmammalian inducible nitric-oxide synthase (NOS) cDNA obtained from chicken macrophages. It exhibits an open reading frame encoding 1,136 amino acid residues, predicting a protein of 129,648-Da molecular mass. The deduced NOS protein sequence showed 66.6%, 70.4%, 54.2%, and 48.7% sequence identity to mouse and human inducible NOS and to two constitutive NOSs from rat brain and bovine endothelium. Overall, NOS appears to be a moderately conserved protein. Northern analysis showed that chicken iNOS mRNA is approximately 4.5 kilobases (kb), a size similar to mammalian inducible NOS. Analysis of 3.2 kb of 5'-flanking sequence of the chicken iNOS gene showed a putative TATA box at 30 base pairs (bp) upstream of the transcription initiation site. The functional importance of the upstream region was determined by transient expression of deletion constructs, An endotoxin regulatory region was located exclusively within 300 bp upstream of the transcription initiation site, This is in contrast to the two distinct sites identified in the mouse macrophage NOS promoter. Transcription factor binding sites such as NF-kappa B, PEA1, PEA3, and C/EBP were identified. Using a NF-kappa B inhibitor, we showed that NF-kappa B is indeed involved in the induction of chicken iNOS gene by lipopolysaccharide. Our results suggest that NF-kappa B is a common regulatory component in the expression of both mammalian and nonmammalian iNOS genes.	CORNELL UNIV,DIV NUTR SCI,ITHACA,NY 14853	Cornell University								ANDREWS SC, 1992, FEBS LETT, V302, P247, DOI 10.1016/0014-5793(92)80452-M; BACHMANN S, 1995, AM J PHYSIOL-RENAL, V268, pF885, DOI 10.1152/ajprenal.1995.268.5.F885; BEUG H, 1979, CELL, V18, P375, DOI 10.1016/0092-8674(79)90057-6; BILLIAR TR, 1992, J LAB CLIN MED, V120, P192; BREDT DS, 1992, NEURON, V8, P3, DOI 10.1016/0896-6273(92)90104-L; BREDT DS, 1990, P NATL ACAD SCI USA, V87, P682, DOI 10.1073/pnas.87.2.682; BREDT DS, 1991, NATURE, V351, P714, DOI 10.1038/351714a0; CATTELL V, 1993, EXP NEPHROL, V1, P265; CHARLES IG, 1993, P NATL ACAD SCI USA, V90, P11419, DOI 10.1073/pnas.90.23.11419; CHARTRAIN NA, 1994, J BIOL CHEM, V269, P6765; CHO HJ, 1992, J EXP MED, V176, P599, DOI 10.1084/jem.176.2.599; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CORBETT JA, 1993, P NATL ACAD SCI USA, V90, P1731, DOI 10.1073/pnas.90.5.1731; COYLE P, 1995, BIOCHEM J, V309, P25, DOI 10.1042/bj3090025; deVera ME, 1996, P NATL ACAD SCI USA, V93, P1054, DOI 10.1073/pnas.93.3.1054; DIMMITT SB, 1995, CLIN EXP PHARMACOL P, V22, P204, DOI 10.1111/j.1440-1681.1995.tb01981.x; EVANS T, 1992, P NATL ACAD SCI USA, V89, P5361, DOI 10.1073/pnas.89.12.5361; FELDMAN PL, 1993, CHEM ENG NEWS, V20, P26; GELLER DA, 1993, P NATL ACAD SCI USA, V90, P3491, DOI 10.1073/pnas.90.8.3491; GIBALDI M, 1993, J CLIN PHARMACOL, V33, P488, DOI 10.1002/j.1552-4604.1993.tb04694.x; GREEN LC, 1982, ANAL BIOCHEM, V126, P131, DOI 10.1016/0003-2697(82)90118-X; HIBBS JB, 1991, RES IMMUNOL, V142, P565, DOI 10.1016/0923-2494(91)90103-P; HOFFMAN M, 1991, SCIENCE, V253, P1788; HOLMQVIST BI, 1994, NEUROSCI LETT, V171, P205, DOI 10.1016/0304-3940(94)90640-8; IGNARRO LJ, 1987, P NATL ACAD SCI USA, V84, P9265, DOI 10.1073/pnas.84.24.9265; IGNARRO LJ, 1990, ANNU REV PHARMACOL, V30, P535, DOI 10.1146/annurev.pa.30.040190.002535; ISCHIROPOULOS H, 1992, ARCH BIOCHEM BIOPHYS, V298, P446, DOI 10.1016/0003-9861(92)90433-W; JANSSENS SP, 1992, J BIOL CHEM, V267, P14519; KARPLUS PA, 1991, SCIENCE, V251, P60, DOI 10.1126/science.1986412; KARPLUS PA, 1984, BIOCHEMISTRY-US, V23, P6576, DOI 10.1021/bi00321a046; KNOWLES RG, 1994, BIOCHEM J, V298, P249, DOI 10.1042/bj2980249; KUGIYAMA K, 1990, NATURE, V344, P160, DOI 10.1038/344160a0; LAMAS S, 1992, P NATL ACAD SCI USA, V89, P6348, DOI 10.1073/pnas.89.14.6348; LENARDO MJ, 1989, CELL, V58, P227, DOI 10.1016/0092-8674(89)90833-7; LOWENSTEIN CJ, 1993, P NATL ACAD SCI USA, V90, P9730, DOI 10.1073/pnas.90.20.9730; LYONS CR, 1992, J BIOL CHEM, V267, P6370; MARCINKIEWICZ J, 1995, EUR J IMMUNOL, V25, P947, DOI 10.1002/eji.1830250414; MARLETTA MA, 1993, J BIOL CHEM, V268, P12231; MARSDEN PA, 1992, FEBS LETT, V307, P287, DOI 10.1016/0014-5793(92)80697-F; MCCORMICK CC, 1988, P NATL ACAD SCI USA, V85, P309, DOI 10.1073/pnas.85.2.309; MCMILLAN K, 1992, P NATL ACAD SCI USA, V89, P11141, DOI 10.1073/pnas.89.23.11141; MONCADA S, 1992, ACTA PHYSIOL SCAND, V145, P201, DOI 10.1111/j.1748-1716.1992.tb09359.x; MUROHARA T, 1994, AM J PHYSIOL-HEART C, V267, pH2441, DOI 10.1152/ajpheart.1994.267.6.H2441; NAKANE M, 1993, FEBS LETT, V316, P175, DOI 10.1016/0014-5793(93)81210-Q; NATHAN C, 1992, FASEB J, V6, P3051, DOI 10.1096/fasebj.6.12.1381691; NATHAN C, 1994, J BIOL CHEM, V269, P13725; NISHIDA K, 1992, J CLIN INVEST, V90, P2092, DOI 10.1172/JCI116092; NISHIMURA JS, 1995, BIOCHEM BIOPH RES CO, V210, P288, DOI 10.1006/bbrc.1995.1659; PORTER TD, 1985, P NATL ACAD SCI USA, V82, P973, DOI 10.1073/pnas.82.4.973; RADOMSKI MW, 1993, ADV EXP MED BIOL, V344, P251; REGULASKI M, 1996, P NATL ACAD SCI USA, V92, P9072; RIBEIRO JMC, 1993, SCIENCE, V260, P539, DOI 10.1126/science.8386393; SCHMIDT HHHW, 1994, CELL, V78, P919, DOI 10.1016/0092-8674(94)90267-4; SCHMIDT HHHW, 1991, P NATL ACAD SCI USA, V88, P365, DOI 10.1073/pnas.88.2.365; SESSA WC, 1992, J BIOL CHEM, V267, P15274; SHETA EA, 1994, J BIOL CHEM, V269, P15147; SNYDER SH, 1992, SCI AM, V266, P68, DOI 10.1038/scientificamerican0592-68; SNYDER SH, 1992, SCIENCE, V257, P494, DOI 10.1126/science.1353273; STARK ME, 1992, GASTROENTEROLOGY, V103, P1928, DOI 10.1016/0016-5085(92)91454-C; STUEHR DJ, 1991, P NATL ACAD SCI USA, V88, P7773, DOI 10.1073/pnas.88.17.7773; SUNG YJ, 1991, J LEUKOCYTE BIOL, V50, P49, DOI 10.1002/jlb.50.1.49; TAMIR H, 1963, ARCH BIOCHEM BIOPHYS, V102, P249, DOI 10.1016/0003-9861(63)90178-4; VORHERR T, 1993, BIOCHEMISTRY-US, V32, P6081, DOI 10.1021/bi00074a020; WILSON AC, 1977, ANNU REV BIOCHEM, V46, P573, DOI 10.1146/annurev.bi.46.070177.003041; XIE QW, 1994, J BIOL CHEM, V269, P4705; XIE QW, 1992, SCIENCE, V256, P225, DOI 10.1126/science.1373522; XIE QW, 1993, J EXP MED, V177, P1779, DOI 10.1084/jem.177.6.1779	67	112	118	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 17	1996	271	20					11911	11919		10.1074/jbc.271.20.11911	http://dx.doi.org/10.1074/jbc.271.20.11911			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UL250	8662618	hybrid			2022-12-25	WOS:A1996UL25000053
J	Wang, BL; Mysliwiec, T; Krainc, D; Jensen, RA; Sonoda, G; Testa, JR; Golemis, EA; Kruh, GD				Wang, BL; Mysliwiec, T; Krainc, D; Jensen, RA; Sonoda, G; Testa, JR; Golemis, EA; Kruh, GD			Identification of ArgBP1, an Arg protein tyrosine kinase binding protein that is the human homologue of a CNS-specific Xenopus gene	ONCOGENE			English	Article						Arg; Xlan4; Abl; SH3 domain; proline-rich motif	MURINE LEUKEMIA-VIRUS; FLUORESCENCE INSITU HYBRIDIZATION; C-ABL; CELL-CYCLE; SIGNAL-TRANSDUCTION; DROSOPHILA-ABL; DOMAIN; DNA; LOCALIZATION; PHOSPHATASE	Arg and c-Abl represent the mammalian members of the Abelson family of nonreceptor protein-tyrosine kinases. To gain insight into the biological role of Arg we used the two-hybrid approach to identify interacting proteins. Using a C-terminal segment of Arg we identified a novel protein, ArgBP1 (Arg binding protein 1). ArgBP1 contains a C-terminal SH3 domain, several PEST sequences, a serine rich domain and an SH3 binding site. ArgBP1 is ubiquitously expressed as two transcripts of similar to 2.2 kb and similar to 8kb with highest levels in brain, heart and testis. The association of ArgBP1 with Arg in living cells was confirmed by coimmunoprecipitation in cotransfected COS cells. Analysis of the mechanism of association indicated that the ArgBP1 SH3 domain binds to a C-terminal Arg SH3-binding site, and that an N-terminal ArgBP1 proline-rich sequence binds to the Arg SH3 domain. Immunostaining indicated that the subcellular localization of ArgBP1 is cytoplasmic. The similarity of the ArgPB1 expression pattern and subcellular localization to those of Arg and the potential for a highly specific and potentially strong association mediated by two pairs of SH3 domain/proline-rich motif interactions, suggest that ArgBP1 is likely to be a regulator and/or effector of Arg function.	FOX CHASE CANC CTR, DEPT MED ONCOL, PHILADELPHIA, PA 19111 USA; UNIV PENN, DEPT BIOL, PHILADELPHIA, PA 19104 USA; FOX CHASE CANC CTR, DIV BASIC SCI, PHILADELPHIA, PA 19111 USA; HARVARD UNIV, CHILDRENS HOSP, SCH MED, DEPT NEUROL, BOSTON, MA 02115 USA; VANDERBILT UNIV, MED CTR, DEPT PATHOL, NASHVILLE, TN 37232 USA	Fox Chase Cancer Center; University of Pennsylvania; Fox Chase Cancer Center; Harvard University; Boston Children's Hospital; Harvard Medical School; Vanderbilt University				Golemis, Erica/0000-0003-3618-3673	NATIONAL CANCER INSTITUTE [P30CA006927, R29CA063366, R01CA057273, R55CA057273, R01CA063366] Funding Source: NIH RePORTER; NCI NIH HHS [CA06927, CA57273, CA63366] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BEN-NERIAH Y, 1986, CELL, V44, P577, DOI 10.1016/0092-8674(86)90267-9; COOPER JA, 1993, CELL, V73, P1051, DOI 10.1016/0092-8674(93)90634-3; FAN YS, 1990, P NATL ACAD SCI USA, V87, P6223, DOI 10.1073/pnas.87.16.6223; FAZIOLI F, 1993, EMBO J, V12, P3799, DOI 10.1002/j.1460-2075.1993.tb06058.x; FELLER SM, 1994, EMBO J, V13, P2341, DOI 10.1002/j.1460-2075.1994.tb06518.x; FRANZ WM, 1989, EMBO J, V8, P137, DOI 10.1002/j.1460-2075.1989.tb03358.x; GALLO KA, 1994, J BIOL CHEM, V269, P15092; GERTLER FB, 1989, CELL, V58, P103, DOI 10.1016/0092-8674(89)90407-8; GERTLER FB, 1995, GENE DEV, V9, P521, DOI 10.1101/gad.9.5.521; GERTLER FB, 1993, GENE DEV, V7, P441, DOI 10.1101/gad.7.3.441; GOLEMIS EA, 1994, CURRENT PROTOCOLS MO; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; HENKEMEYER MJ, 1987, CELL, V51, P821, DOI 10.1016/0092-8674(87)90105-X; HOFFMANN FM, 1989, CURR TOP MICROBIOL, V147, P1; HOFFMANN FM, 1991, TRENDS GENET, V7, P351, DOI 10.1016/0168-9525(91)90254-F; HOWELL BW, 1994, MOL CELL BIOL, V14, P5402, DOI 10.1128/MCB.14.8.5402; JACKSON P, 1989, EMBO J, V8, P449, DOI 10.1002/j.1460-2075.1989.tb03397.x; KIPREOS ET, 1990, SCIENCE, V248, P217, DOI 10.1126/science.2183353; KIPREOS ET, 1992, SCIENCE, V256, P382, DOI 10.1126/science.256.5055.382; KONOPKA JB, 1985, MOL CELL BIOL, V5, P3116, DOI 10.1128/MCB.5.11.3116; KRUH GD, 1990, P NATL ACAD SCI USA, V87, P5802, DOI 10.1073/pnas.87.15.5802; LAEMMLI UK, 1968, MOL GEN GENET, V101, P333, DOI 10.1007/BF00436231; MATTIONI T, 1995, ONCOGENE, V10, P1325; MORRIS JF, 1991, ONCOGENE, V6, P2339; Mysliwiec T, 1996, ONCOGENE, V12, P631; PENDERGAST AM, 1993, CELL, V75, P175, DOI 10.1016/S0092-8674(05)80094-7; PEREGO R, 1991, ONCOGENE, V6, P1899; PINKEL D, 1986, P NATL ACAD SCI USA, V83, P2934, DOI 10.1073/pnas.83.9.2934; Rechsteiner M, 1990, Semin Cell Biol, V1, P433; REDDY BA, 1992, MECH DEVELOP, V39, P143, DOI 10.1016/0925-4773(92)90041-H; REN RB, 1994, GENE DEV, V8, P783, DOI 10.1101/gad.8.7.783; RENSHAW MW, 1988, MOL CELL BIOL, V8, P4547, DOI 10.1128/MCB.8.10.4547; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; ROSEN MK, 1995, NATURE, V374, P477, DOI 10.1038/374477a0; SAKAI R, 1994, EMBO J, V13, P3748, DOI 10.1002/j.1460-2075.1994.tb06684.x; SAWYERS CL, 1994, CELL, V77, P121, DOI 10.1016/0092-8674(94)90240-2; SHIELDS A, 1979, CELL, V18, P955, DOI 10.1016/0092-8674(79)90208-3; SHTIVELMAN E, 1986, CELL, V47, P277, DOI 10.1016/0092-8674(86)90450-2; SRINIVASAN A, 1981, P NATL ACAD SCI-BIOL, V78, P2077, DOI 10.1073/pnas.78.4.2077; SUPERTIFURGA G, 1993, EMBO J, V12, P2625, DOI 10.1002/j.1460-2075.1993.tb05923.x; TESTA JR, 1992, CYTOGENET CELL GENET, V60, P247, DOI 10.1159/000133350; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VANETTEN RA, 1989, CELL, V58, P669, DOI 10.1016/0092-8674(89)90102-5; WANG JYJ, 1983, MOL CELL BIOL, V3, P773, DOI 10.1128/MCB.3.5.773; WANG JYJ, 1993, CURR OPIN GENET DEV, V3, P35, DOI 10.1016/S0959-437X(05)80338-7; WELCH PJ, 1993, CELL, V75, P779, DOI 10.1016/0092-8674(93)90497-E	46	33	34	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 2	1996	12	9					1921	1929						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UK498	8649853				2022-12-25	WOS:A1996UK49800011
J	Lebel, M; Bertrand, R; MesMasson, AM				Lebel, M; Bertrand, R; MesMasson, AM			Decreased Fas antigen receptor expression in testicular tumor cell lines derived from polyomavirus large T-antigen transgenic mice	ONCOGENE			English	Article						transgenic mice; polyomavirus large T-antigen; Fas antigen receptor; testicular cells	VIRUS EARLY PROTEINS; DIFFERENTIAL DISPLAY; MOLECULAR-CLONING; SURFACE ANTIGEN; MESSENGER-RNAS; FIBROBLASTS; ONCOGENE; MEMBER; GENE; CDNA	MT-PVLT-10 transgenic mice express large T-antigen of polyomavirus under the control of the mouse metallothionein-1 promoter and males of this transgenic line develop testicular tumors at advanced ages. The differential display technique was employed to compare mRNA expression from immortalized cell lines derived from normal or adenomatous testis from MT-PVLT-10 transgenic males. Using this technique, a complementary DNA fragment corresponding to the mouse Fas antigen receptor was recovered from normal testicular cells but not from tumor cells. RNAse protection assays with the Fas antigen specific fragment confirmed its differential expression. Normal testicular cells from the transgenic animals responded to treatment of interferon-gamma by increasing the expression of Fas antigen specific mRNA and were sensitive to the proliferative inhibitory effect of anti-Fas antibody in vitro. This proliferative inhibition was characterized by an accumulation of cells in S phase of the cell cycle. In contrast, the testicular tumor cells did not respond to either interferon-gamma or to anti-Fas antibody in vitro. These results suggest that the loss of proliferative inhibitory effect mediated by the Fas antigen pathway in tumor cells may be an important step in testicular tumor progression in the MT-PVLT-10 transgenic mice.	UNIV MONTREAL,INST CANC MONTREAL,CTR RECH LOUIS CHARLES SIMARD,MONTREAL,PQ H2L 4M1,CANADA	Universite de Montreal				Mes-Masson, Anne-Marie/0000-0002-6498-266X				ADACHI M, 1993, P NATL ACAD SCI USA, V90, P1756, DOI 10.1073/pnas.90.5.1756; ASSELIN C, 1985, J VIROL, V56, P958, DOI 10.1128/JVI.56.3.958-968.1985; ASSELIN C, 1983, MOL CELL BIOL, V3, P1451, DOI 10.1128/MCB.3.8.1451; BAUTCH VL, 1989, MOL BIOL MED, V6, P309; BAUTCH VL, 1987, CELL, V51, P529, DOI 10.1016/0092-8674(87)90122-X; BONAVIDA B, 1995, OVARIAN CANC, V3, P295; BRUNNER T, 1995, NATURE, V373, P441, DOI 10.1038/373441a0; CHALIFOUR LE, 1990, ONCOGENE, V5, P1719; CHALIFOUR LE, 1992, MOL CARCINOGEN, V5, P178, DOI 10.1002/mc.2940050304; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V13, P2633; FISHER GH, 1995, CELL, V81, P935, DOI 10.1016/0092-8674(95)90013-6; GRIEP AE, 1989, GENE DEV, V3, P1075, DOI 10.1101/gad.3.7.1075; GUY CT, 1992, MOL CELL BIOL, V12, P954, DOI 10.1128/MCB.12.3.954; ITOH N, 1991, CELL, V66, P233, DOI 10.1016/0092-8674(91)90614-5; JENSEN NA, 1989, MOL BIOL MED, V6, P493; JU ST, 1995, NATURE, V373, P444, DOI 10.1038/373444a0; LEBEL M, 1994, EXP CELL RES, V213, P12, DOI 10.1006/excr.1994.1167; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; LIANG P, 1992, CANCER RES, V52, P6966; LIANG P, 1993, NUCLEIC ACIDS RES, V21, P3269, DOI 10.1093/nar/21.14.3269; MERCILLE S, 1994, BIOTECHNOL BIOENG, V44, P1140, DOI 10.1002/bit.260440916; MURAKAMI T, 1995, CANCER RES, V55, P3093; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; OEHM A, 1992, J BIOL CHEM, V267, P10709; OGASAWARA J, 1993, NATURE, V364, P806, DOI 10.1038/364806a0; OWENSCHAUB LB, 1994, CANCER RES, V54, P1580; PERRAS JP, 1993, CYTOMETRY, V14, P441, DOI 10.1002/cyto.990140414; RASSOULZADEGAN M, 1983, P NATL ACAD SCI-BIOL, V80, P4354, DOI 10.1073/pnas.80.14.4354; RASSOULZADEGAN M, 1982, NATURE, V300, P713, DOI 10.1038/300713a0; RIMOLDI D, 1990, EXP CELL RES, V191, P76, DOI 10.1016/0014-4827(90)90038-C; SAKATSUME M, 1995, J BIOL CHEM, V270, P17528, DOI 10.1074/jbc.270.29.17528; Sambrook J., 2002, MOL CLONING LAB MANU; SMERDELY P, 1993, ENDOCRINOLOGY, V133, P2403, DOI 10.1210/en.133.5.2403; SUDA T, 1993, CELL, V75, P1169, DOI 10.1016/0092-8674(93)90326-L; WATANABEFUKUNAGA R, 1992, J IMMUNOL, V148, P1274; WATANABEFUKUNAGA R, 1992, NATURE, V356, P314, DOI 10.1038/356314a0; ZHENG DQ, 1994, ONCOGENE, V9, P3345	37	29	31	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR 7	1996	12	5					1127	1135						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UA884	8649805				2022-12-25	WOS:A1996UA88400022
J	Clarke, MSF; Feeback, DL				Clarke, MSF; Feeback, DL			Mechanical load induces sarcoplasmic wounding and FGF release in differentiated human skeletal muscle cultures	FASEB JOURNAL			English	Article						skeletal muscle hypertrophy; differentiation	FIBROBLAST GROWTH-FACTOR; MDX MOUSE MUSCLE; CARDIAC MYOCYTES; GENE-EXPRESSION; TISSUE-CULTURE; CELLS; HYPERTROPHY; LOCALIZATION; ACTIVATION; MYOFIBERS	The transduction mechanism (or mechanisms) responsible for converting a mechanical load into a skeletal muscle growth response are unclear, In this study we have used a mechanically active tissue culture model of differentiated human skeletal muscle cells to investigate the relationship between mechanical load, sarcolemma wounding, fibroblast growth factor release, and skeletal muscle cell growth, Using the Flexcell Strain Unit we demonstrate that as mechanical load increases, so too does the amount of sarcolemma wounding. A similar relationship was also observed between the level of mechanical load inflicted on the cells and the amount of bFGF (FGF2) released into the surrounding medium. In addition, we demonstrate that the muscle cell growth response induced by chronic mechanical loading in culture can be inhibited by the presence of an antibody capable of neutralizing the biological activity of FGF. This study provides direct evidence that mechanically induced, sarcolemma wound-mediated FGF release is an important autocrine mechanism for transducing the stimulus of mechanical load into a skeletal muscle growth response.			Clarke, MSF (corresponding author), NASA, LYNDON B JOHNSON SPACE CTR, BIOMED OPERAT & RES BRANCH SD4, MUSCLE RES LAB, BLDG 37, HOUSTON, TX 77058 USA.							BAKER KM, 1990, AM J PHYSIOL, V259, pH610, DOI 10.1152/ajpheart.1990.259.2.H610; BANES A, 1987, FASEB J, V46, P2017; BENES AJ, 1985, J CELL SCI, V75, P35; CLARKE MSF, 1994, BIOTECHNIQUES, V17, P1118; CLARKE MSF, 1992, J CELL SCI, V102, P533; CLARKE MSF, 1995, CIRC RES, V76, P927, DOI 10.1161/01.RES.76.6.927; CLARKE MSF, 1993, J CELL SCI, V106, P121; DARR KC, 1987, J APPL PHYSIOL, V63, P1816, DOI 10.1152/jappl.1987.63.5.1816; DAVIES PF, 1993, CIRC RES, V72, P239, DOI 10.1161/01.RES.72.2.239; DEVOL DL, 1990, AM J PHYSIOL, V259, pE89, DOI 10.1152/ajpendo.1990.259.1.E89; DIMARIO J, 1989, SCIENCE, V244, P688, DOI 10.1126/science.2717945; DIMARIO J, 1988, DIFFERENTIATION, V39, P42, DOI 10.1111/j.1432-0436.1988.tb00079.x; FLANAGAN MF, 1991, CIRC RES, V68, P1458, DOI 10.1161/01.RES.68.5.1458; Guthridge M, 1992, GROWTH FACTORS, V6, DOI 10.3109/08977199209008871; INGJER F, 1979, EUR J APPL PHYSIOL, V40, P197, DOI 10.1007/BF00426942; KU PT, 1993, MOL BIOL CELL, V4, pH39; MacDougall J., 1986, HUMAN MUSCLE POWER, P269; McNeil Paul L., 1993, Trends in Cell Biology, V3, P302, DOI 10.1016/0962-8924(93)90012-P; MCNEIL PL, 1992, AM J PATHOL, V140, P1097; MORROW NG, 1990, J CLIN INVEST, V85, P1816, DOI 10.1172/JCI114640; PADUA RR, 1993, GROWTH FACTORS, V8, P291, DOI 10.3109/08977199308991574; PARKER TG, 1990, J CLIN INVEST, V85, P507, DOI 10.1172/JCI114466; RAPRAEGER AC, 1991, SCIENCE, V252, P1705, DOI 10.1126/science.1646484; SADOSHIMA J, 1993, CELL, V75, P977, DOI 10.1016/0092-8674(93)90541-W; SCHWARTZ MA, 1993, J CELL BIOL, V120, P1003, DOI 10.1083/jcb.120.4.1003; SPEIR E, 1992, CIRC RES, V71, P251, DOI 10.1161/01.RES.71.2.251; TESCH PA, 1988, MED SCI SPORT EXER, V20, pS132, DOI 10.1249/00005768-198810001-00008; VANDENBURGH HH, 1990, AM J PHYSIOL, V259, pC232, DOI 10.1152/ajpcell.1990.259.2.C232; VANDENBURGH HH, 1989, AM J PHYSIOL, V256, pC674, DOI 10.1152/ajpcell.1989.256.3.C674; VANDENBURGH HH, 1988, IN VITRO CELL DEV B, V24, P166, DOI 10.1007/BF02623542; VANDENBURGH HH, 1991, AM J PHYSIOL, V260, pC475, DOI 10.1152/ajpcell.1991.260.3.C475; YAMADA S, 1989, MED SCI SPORT EXER, V21, pS173; [No title captured]; [No title captured]	34	96	98	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	1996	10	4					502	509		10.1096/fasebj.10.4.8647349	http://dx.doi.org/10.1096/fasebj.10.4.8647349			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	UE557	8647349				2022-12-25	WOS:A1996UE55700014
J	Perris, R; Perissinotto, D; Pettway, Z; BronnerFraser, M; Morgelin, M; Kimata, K				Perris, R; Perissinotto, D; Pettway, Z; BronnerFraser, M; Morgelin, M; Kimata, K			Inhibitory effects of PG-H/aggrecan and PG-M/versican on avian neural crest cell migration	FASEB JOURNAL			English	Article						neural crest; cell migration; proteoglycans; aggrecan; versican	CHONDROITIN SULFATE PROTEOGLYCANS; NEURITE OUTGROWTH; CARTILAGE PROTEOGLYCANS; CHICK-EMBRYO; ADHESION; CHONDROGENESIS; COLLAGEN; REGION	Aggrecans and PG-M/versicans represent two newly defined families of hyaluronan-binding proteoglycans for which the function is still poorly understood, Using the avian neural crest as a model system, we have examined the molecular mechanisms entailed in the cell-proteoglycan interaction during embryonic cell motility. Both the primary cartilage aggrecan of the avian embryo (PG-H/aggrecan) and the largest variant of the avian mesenchymal versican (PG-M/versican V0) failed to support neural crest cell adhesion and migration when topographically immobilized onto the substrate, Conversely, solely the PG-H/aggrecan, and similar aggrecans from other species, counteracted the migration-promoting effect of a number of matrix molecules lacking proteoglycan affinity, This inhibitory effect was not reproduced by the isolated glycosaminoglycan chains, the isolated core protein, the reduced and alkylated macromolecule, or the aggrecan in which the G1 hyaluronan-binding domain had been inactivated with hyaluronan fragments or antibodies, Limited depolymerization of the side chains and preincubation of the PG-H/aggrecan with anti-glycosaminoglycan antibodies differentially reduced the inhibitory activity of the proteoglycan on cell motility, The results demonstrate a diverse inhibitory effect of aggrecans and PG-H/versicans on embryonic cell movement and show that the inhibitory action of aggrecans is independent of substrate binding, is depedent on a G1 domain-mediated association of the intact proteoglycan with cell surface-bound hyaluronan, and is differentially mediated by its glycosaminoglycan side chains.	UNIV CALIF IRVINE,CTR DEV BIOL,IRVINE,CA 92717; LUND UNIV,DEPT MED & PHYSIOL CHEM,S-22100 LUND,SWEDEN; AICHI MED UNIV,INST MOLEC SCI MED,NAGAKUTE,AICHI 48011,JAPAN	University of California System; University of California Irvine; Lund University; Aichi Medical University	Perris, R (corresponding author), REFERENCE CTR ONCOL,DIV EXPT ONCOL 2,VIA PEDEMONTANA OCCIDENTALE 12,I-33081 AVIANO,PN,ITALY.		Pettway Unno, Zoe/J-3020-2013	Bronner, Marianne/0000-0003-4274-1862; Pettway Unno, Zoe/0000-0002-5176-185X	NICHD NIH HHS [HD 15527] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD015527] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BJORNSSON S, 1993, ANAL BIOCHEM, V210, P292, DOI 10.1006/abio.1993.1198; BRENNAN MJ, 1983, CANCER RES, V43, P4302; COLE GJ, 1991, NEURON, V7, P1007, DOI 10.1016/0896-6273(91)90345-Z; DOU CL, 1994, J NEUROSCI, V14, P7616; ERICKSON CA, 1993, DEV BIOL, V159, P60, DOI 10.1006/dbio.1993.1221; HALBERG DF, 1988, J BIOL CHEM, V263, P9486; KIMATA K, 1986, J BIOL CHEM, V261, P3517; KITCHEN JR, 1995, BIOCHEM J, V309, P649, DOI 10.1042/bj3090649; KNOX P, 1979, J CELL SCI, V40, P77; KNUDSON CB, 1993, FASEB J, V7, P1233, DOI 10.1096/fasebj.7.13.7691670; LALLIER T, 1994, DEV BIOL, V162, P451, DOI 10.1006/dbio.1994.1101; MORGELIN M, 1992, J BIOL CHEM, V267, P14275; OAKLEY RA, 1994, DEVELOPMENT, V120, P103; OOHIRA A, 1991, J NEUROSCI, V11, P822; PERRIS R, 1990, DEV BIOL, V137, P1, DOI 10.1016/0012-1606(90)90002-Z; PERRIS R, 1991, DEVELOPMENT, V111, P583; PERRIS R, 1987, J CELL BIOL, V105, P2511, DOI 10.1083/jcb.105.6.2511; PERRIS R, 1991, TRENDS GLYCOSCI GLYC, V3, P166; PETTWAY Z, 1990, DEV BIOL, V142, P335, DOI 10.1016/0012-1606(90)90354-L; RICH AM, 1981, NATURE, V293, P224, DOI 10.1038/293224a0; SALEQUE S, 1993, GLYCOBIOLOGY, V3, P185, DOI 10.1093/glycob/3.2.185; SHINOMURA T, 1993, J BIOL CHEM, V268, P14461; SHINOMURA T, 1983, J BIOL CHEM, V15, P9316; SNOW DM, 1990, EXP NEUROL, V109, P111, DOI 10.1016/S0014-4886(05)80013-5; SOMMARIN Y, 1983, BIOCHEM J, V214, P777, DOI 10.1042/bj2140777; SORRELL JM, 1993, MATRIX, V13, P351, DOI 10.1016/S0934-8832(11)80040-5; SUGIURA N, 1993, J BIOL CHEM, V268, P15779; YAMAGATA M, 1989, J BIOL CHEM, V264, P8012	28	75	77	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	FEB	1996	10	2					293	301		10.1096/fasebj.10.2.8641562	http://dx.doi.org/10.1096/fasebj.10.2.8641562			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	TY962	8641562				2022-12-25	WOS:A1996TY96200013
J	Iwamoto, T; Pan, Y; Wakabayashi, S; Imagawa, T; Yamanaka, HI; Shigekawa, M				Iwamoto, T; Pan, Y; Wakabayashi, S; Imagawa, T; Yamanaka, HI; Shigekawa, M			Phosphorylation-dependent regulation of cardiac Na+/Ca2+ exchanger via protein kinase C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SODIUM-CALCIUM EXCHANGE; SMOOTH-MUSCLE CELLS; PHORBOL ESTERS; DYNAMIC PROPERTIES; NA+-CA2+ EXCHANGE; ANGIOTENSIN-II; STEADY-STATE; HEART-CELLS; RAT-HEART; MYOCYTES	The cardiac Na+/Ca2+ exchanger (NCX1) plays a major role in the extrusion of Ca2+ from cardiomyocytes, We studied the role of protein phosphorylation in the regulation of cardiac NCX1 using CCL39 stably overexpressing the canine cardiac NCX1 and rat neonatal cardiomyocytes, In both cell types, the NCX1 protein immunoprecipitated with a chicken anti-NCX1 antibody exhibited a significant basal phosphorylation that was further enhanced by treatment with endothelin-l, acidic fibroblast growth factor, phorbol 12-myristate 13-acetate, or okadaic acid, In contrast, calphostin C, K252a, or EGTA inhibited the phosphorylation, The phosphorylation occurred on two major tryptic phosphopeptides (Pi and P2) exclusively on serine residues, Evidence is presented suggesting that P2 was derived from an N-terminal half (amino acids 240-475) of the central cytoplasmic domain of NCX1 and was phosphorylated directly by protein kinase C (PKC), The agents that increased NCX1 phosphorylation significantly enhanced both the forward and reverse modes of Na+/Ca2+ exchange. This exchange activation exhibited a very good correlation with the NCX1 phosphorylation, In NCX1-transfected cells, PKC down-regulation following prolonged exposure to phorbol 12-myristate 13-acetate abolished the acidic fibroblast growth factor induced activation of exchange activity, On the other hand, cell ATP depletion reduced the exchange activity and abolished the effects of the above agents on exchange activity, These results indicate that the cardiac NCX1 is upregulated by PKC-catalyzed phosphorylation, The cardiac NCX1 thus could play an important role in the previously reported negative inotropic actions of phorbol esters and other PKC-activating agents.	NATL CARDIOVASC CTR,RES INST,DEPT MOLEC PHYSIOL,SUITA,OSAKA 565,JAPAN; KANEBO LTD,NEW DRUG RES LABS,OSAKA 534,JAPAN	National Cerebral & Cardiovascular Center - Japan			Imagawa, Toshiaki/A-4255-2012					BAKER PF, 1969, J PHYSIOL-LONDON, V200, P431, DOI 10.1113/jphysiol.1969.sp008702; BERS DM, 1991, ANN NY ACAD SCI, V639, P375, DOI 10.1111/j.1749-6632.1991.tb17326.x; BRIDGE JHB, 1990, SCIENCE, V248, P376, DOI 10.1126/science.2158147; CAPOGROSSI MC, 1991, CIRC RES, V69, P540, DOI 10.1161/01.RES.69.2.540; CAPOGROSSI MC, 1990, CIRC RES, V66, P1143, DOI 10.1161/01.RES.66.4.1143; COLLINS A, 1992, J PHYSIOL-LONDON, V454, P27, DOI 10.1113/jphysiol.1992.sp019253; CONDRESCU M, 1995, J BIOL CHEM, V270, P9137, DOI 10.1074/jbc.270.16.9137; DIPOLO R, 1991, ANN NY ACAD SCI, V639, P100, DOI 10.1111/j.1749-6632.1991.tb17294.x; DIPOLO R, 1994, AM J PHYSIOL, V266, pC1382, DOI 10.1152/ajpcell.1994.266.5.C1382; DOERING AE, 1994, J PHYSIOL-LONDON, V480, P9, DOI 10.1113/jphysiol.1994.sp020336; EDES I, 1990, CIRC RES, V67, P394, DOI 10.1161/01.RES.67.2.394; FURUKAWA KI, 1988, J BIOL CHEM, V263, P8058; GASSMANN M, 1990, FASEB J, V4, P2528, DOI 10.1096/fasebj.4.8.1970792; HARTMANN M, 1992, EUR J PHARM-MOLEC PH, V226, P225, DOI 10.1016/0922-4106(92)90065-4; HAWORTH RA, 1987, CIRC RES, V60, P586, DOI 10.1161/01.RES.60.4.586; HILGEMANN DW, 1992, J GEN PHYSIOL, V100, P905, DOI 10.1085/jgp.100.6.905; HILGEMANN DW, 1990, NATURE, V344, P242, DOI 10.1038/344242a0; HILGEMANN DW, 1992, J GEN PHYSIOL, V100, P933, DOI 10.1085/jgp.100.6.933; ITO H, 1993, J CLIN INVEST, V92, P398, DOI 10.1172/JCI116579; IWAMOTO T, 1995, J BIOL CHEM, V270, P8996, DOI 10.1074/jbc.270.15.8996; IWATA Y, 1994, FEBS LETT, V355, P65, DOI 10.1016/0014-5793(94)01174-5; KOFUJI P, 1994, J BIOL CHEM, V269, P5145; LALLEMAIN G, 1984, J BIOL CHEM, V259, P5809; LEATHERMAN GF, 1987, AM J PHYSIOL, V253, pH205, DOI 10.1152/ajpheart.1987.253.1.H205; LEVITSKY DO, 1994, J BIOL CHEM, V269, P22847; LI ZP, 1994, J BIOL CHEM, V269, P17434; MATSUOKA S, 1995, J GEN PHYSIOL, V105, P403, DOI 10.1085/jgp.105.3.403; MATSUOKA S, 1993, P NATL ACAD SCI USA, V90, p3P870; MISHINA M, 1984, NATURE, V307, P604, DOI 10.1038/307604a0; NAKASAKI Y, 1993, J BIOCHEM-TOKYO, V114, P528, DOI 10.1093/oxfordjournals.jbchem.a124211; NICOLL DA, 1990, SCIENCE, V250, P562, DOI 10.1126/science.1700476; PETERS KG, 1992, NATURE, V358, P678, DOI 10.1038/358678a0; PIJUAN V, 1993, AM J PHYSIOL, V264, pC1066, DOI 10.1152/ajpcell.1993.264.4.C1066; SHAM JSK, 1995, P NATL ACAD SCI USA, V92, P121, DOI 10.1073/pnas.92.1.121; SMITH JB, 1990, AM J PHYSIOL, V259, pC302, DOI 10.1152/ajpcell.1990.259.2.C302; WIER WG, 1990, ANNU REV PHYSIOL, V52, P467; WIKMANCOFFELT J, 1991, AM HEART J, V122, P786, DOI 10.1016/0002-8703(91)90526-N; YAMAUCHI T, 1983, EUR J BIOCHEM, V132, P15, DOI 10.1111/j.1432-1033.1983.tb07319.x; YUAN SH, 1987, CIRC RES, V61, P372, DOI 10.1161/01.RES.61.3.372	39	170	172	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 7	1996	271	23					13609	13615		10.1074/jbc.271.23.13609	http://dx.doi.org/10.1074/jbc.271.23.13609			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UP385	8662755	hybrid			2022-12-25	WOS:A1996UP38500047
J	Nicoll, DA; Hryshko, LV; Matsuoka, S; Frank, JS; Philipson, KD				Nicoll, DA; Hryshko, LV; Matsuoka, S; Frank, JS; Philipson, KD			Mutation of amino acid residues in the putative transmembrane segments of the cardiac sarcolemmal Na+-Ca2+ exchanger	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SODIUM-CALCIUM EXCHANGE; NA-CA EXCHANGE; ALPHA-SUBUNIT; FUNCTIONAL EXPRESSION; MEMBRANE PATCHES; TRANSPORT; NA,K-ATPASE; SITE; ION; K+	We have examined the role of conserved regions and acidic or basic residues located in the putative transmembrane segments of the cardiac sarcolemmal Na+-Ca2+ exchanger by site-directed mutagenesis, The alpha-1 and alpha-2 repeats are transmembrane regions of internal similarity, which are highly conserved among Na+-Ca2+ exchangers. We find that Na+-Ca2+ exchange activity is highly sensitive to mutagenesis in the alpha-repeats. Mutation at residues Ser 109, Ser-110, Glu-113, Ser-139, Asn-143, Thr-810, Ser-811, Asp-814, Ser-818, or Ser-838 resulted in loss of exchanger activity. Mutation at residues Thr-103, Gly-108, Pro-112, Glu-120, Gly-138, Gly-809, Gly-837, and Asn-842 resulted in reduced exchanger activity, and altered current-voltage relationships were observed with mutations at residues Gly-138 and Gly-837. Only mutation at residue Ser-117 appeared to leave exchanger activity unaffected. Thus, the alpha-repeats appear to be important components for ion binding and translocation. Another region implicated in exchanger function is a region of similarity to the Na+,K+ pump (Nicoll, D.A., Longoni, S., Philipson, K. D. (1990) Science 250, 562-565). Mutations at two residues in the pump-like region, Glu-199 and Thr-203, resulted in nonfunctional exchangers, while mutation at two other residues, Glu-196 and Gly-200, had no effect. The role of acidic and basic residues in the transmembrane segments was also examined. Mutation of several basic residues (Arg-42, His-744, Lys-751, Lys-797, and His-858) did not affect exchange activity. Of the acidic residues located outside of the alpha-repeat and pump-like regions (Asp-740, Asp-785, and Asp-798), only mutation at Asp-785 resulted in reduction of exchanger activity.	UNIV CALIF LOS ANGELES,SCH MED,DEPT PHYSIOL,LOS ANGELES,CA 90095; UNIV CALIF LOS ANGELES,SCH MED,DEPT MED,LOS ANGELES,CA 90095	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Nicoll, DA (corresponding author), UNIV CALIF LOS ANGELES,SCH MED,CARDIOVASC RES LABS,3645 MRL BLDG,LOS ANGELES,CA 90095, USA.			Hryshko, Larry/0000-0003-1079-8549	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL049101] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL49101] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BAKER PF, 1969, J PHYSIOL-LONDON, V200, P431, DOI 10.1113/jphysiol.1969.sp008702; BERS DM, 1994, METHOD CELL BIOL, V40, P3; Blaustein M P, 1974, Rev Physiol Biochem Pharmacol, V70, P33, DOI 10.1007/BFb0034293; CANESSA CM, 1993, J BIOL CHEM, V268, P17722; CLARKE DM, 1993, J BIOL CHEM, V268, P18359; DIPOLO R, 1991, ANN NY ACAD SCI, V639, P100, DOI 10.1111/j.1749-6632.1991.tb17294.x; ELLING CE, 1995, NATURE, V374, P74, DOI 10.1038/374074a0; GMAJ P, 1979, BIOCHEM J, V178, P549, DOI 10.1042/bj1780549; Hilgemann Donald W., 1995, P307; HILGEMANN DW, 1990, NATURE, V344, P242, DOI 10.1038/344242a0; HILGEMANN DW, 1989, PFLUG ARCH EUR J PHY, V415, P247, DOI 10.1007/BF00370601; HILGEMANN DW, 1992, J PHYSIOL-LONDON, V454, P59, DOI 10.1113/jphysiol.1992.sp019254; HRYSHKO LV, 1993, BIOCHIM BIOPHYS ACTA, V1151, P35, DOI 10.1016/0005-2736(93)90068-B; KANO I, 1990, BIOCHEM CELL BIOL, V68, P1262, DOI 10.1139/o90-187; KIMURA J, 1986, NATURE, V319, P596, DOI 10.1038/319596a0; KIMURA M, 1993, J BIOL CHEM, V268, P6874; KOFUJI P, 1994, J BIOL CHEM, V269, P5145; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LEE SL, 1994, J BIOL CHEM, V269, P14849; LEVITSKY DO, 1994, J BIOL CHEM, V269, P22817; LI Z, 1994, J BIOL CHEM, V269, P1734; LI ZP, 1991, J BIOL CHEM, V266, P1014; LINGREL JB, 1994, J BIOL CHEM, V269, P19659; LONGONI S, 1988, AM J PHYSIOL, V255, pC870, DOI 10.1152/ajpcell.1988.255.6.C870; MATSUOKA S, 1995, J GEN PHYSIOL, V105, P403, DOI 10.1085/jgp.105.3.403; MATSUOKA S, 1992, J GEN PHYSIOL, V100, P963, DOI 10.1085/jgp.100.6.963; MATSUOKA S, 1993, P NATL ACAD SCI USA, V90, P3870, DOI 10.1073/pnas.90.9.3870; NICOLL DA, 1990, SCIENCE, V250, P562, DOI 10.1126/science.1700476; PORZIG H, 1993, AM J PHYSIOL, V265, pC748, DOI 10.1152/ajpcell.1993.265.3.C748; REILANDER H, 1992, EMBO J, V11, P1689, DOI 10.1002/j.1460-2075.1992.tb05219.x; STRYNADKA NCJ, 1989, ANNU REV BIOCHEM, V58, P951, DOI 10.1146/annurev.bi.58.070189.004511; TONEY MD, 1993, SCIENCE, V261, P756, DOI 10.1126/science.8342040; Valdivia C., 1995, Biophysical Journal, V68, pA410; VILSEN B, 1993, FEBS LETT, V333, P44, DOI 10.1016/0014-5793(93)80372-2	34	124	128	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 7	1996	271	23					13385	13391		10.1074/jbc.271.23.13385	http://dx.doi.org/10.1074/jbc.271.23.13385			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UP385	8662775	hybrid			2022-12-25	WOS:A1996UP38500015
J	Perrella, MA; Patterson, C; Tan, L; Yet, SF; Hsieh, CM; Yoshizumi, M; Lee, ME				Perrella, MA; Patterson, C; Tan, L; Yet, SF; Hsieh, CM; Yoshizumi, M; Lee, ME			Suppression of interleukin-1 beta-induced nitric-oxide synthase promoter/enhancer activity by transforming growth factor-beta 1 in vascular smooth muscle cells - Evidence for mechanisms other than NF-kappa B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERFERON-GAMMA; GENE-EXPRESSION; LIPOPOLYSACCHARIDE; PROMOTER; SEQUENCE; SHOCK; FOS	Nitric-oxide synthases (NOS) utilize L-arginine to produce NO, a potent vasodilator that contributes to the regulation of vascular tone. We demonstrated previously that transforming growth factor (TGF)-beta 1 down-regulates inducible NOS after its induction by interleukin (IL)-1 beta by decreasing the rate of inducible NOS gene transcription. In the present study we transfected reporter plasmids containing various lengths of the inducible NOS 5'-flanking region into primary cultured rat aortic smooth muscle cells and stimulated the cells with IL-1 beta or vehicle. IL-1 beta increased the activity of the plasmid containing -1485 to +31 of the inducible NOS gene by more than 10-fold, indicating the presence of IL-1 beta-responsive elements. Further deletion analysis revealed that a construct containing -234 to +31 of the inducible NOS gene contained the majority of promoter/enhancer activity after IL-1 beta stimulation. Mutation of the NF-kappa B site within this region partially reduced IL-1 beta-inducible activity; however, a large portion of activity remained independent of the NF-kappa B site. TGF-beta 1 suppressed promoter/enchancer activity after IL-1 beta stimulation, and this suppression was complete in the construct with a mutated NF-kappa B site. In addition, TGF-beta 1 did not decrease the binding of nuclear proteins to the NF-kappa B site. These data suggest that the ability of TGF-beta 1 to suppress inducible NOS promoter/enhancer activity occurs through a site(s) other than the NF-kappa B motif in vascular smooth muscle cells.	HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA 02115; BRIGHAM & WOMENS HOSP,DIV PULM,BOSTON,MA 02115; BRIGHAM & WOMENS HOSP,DIV CARDIOVASC,BOSTON,MA 02115	Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital	Perrella, MA (corresponding author), HARVARD UNIV,SCH PUBL HLTH,CARDIOVASC BIOL LAB,BLDG 2,677 HUNTINGTON AVE,BOSTON,MA 02115, USA.		Yet, Shaw-Fang/B-1067-2010; Yet, Shaw-Fang/O-8583-2019	Yet, Shaw-Fang/0000-0001-9097-3962	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K08HL003194] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053249] Funding Source: NIH RePORTER; NHLBI NIH HHS [KO8HL03194] Funding Source: Medline; NIGMS NIH HHS [R01GM53249] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		EPSTEIN FH, 1993, NEW ENGL J MED, V328, P106; FEN Z, 1993, BIOCHEMISTRY-US, V32, P7932, DOI 10.1021/bi00082a014; GHOSH G, 1995, NATURE, V373, P303, DOI 10.1038/373303a0; GUNTHER S, 1982, J CELL BIOL, V92, P289, DOI 10.1083/jcb.92.2.289; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; IGNARRO JJ, 1990, ANN REV PHARM TOXICO, V30, P535; KERR LD, 1990, CELL, V61, P267, DOI 10.1016/0092-8674(90)90807-Q; KILBOURN RG, 1990, P NATL ACAD SCI USA, V87, P3629, DOI 10.1073/pnas.87.9.3629; KIMES BW, 1976, EXP CELL RES, V98, P349, DOI 10.1016/0014-4827(76)90446-8; LEE ME, 1990, J BIOL CHEM, V265, P10446; LEE ME, 1991, J BIOL CHEM, V266, P19034; LOWENSTEIN CJ, 1993, P NATL ACAD SCI USA, V90, P9730, DOI 10.1073/pnas.90.20.9730; MACMICKING JD, 1995, CELL, V81, P641, DOI 10.1016/0092-8674(95)90085-3; MARTIN E, 1994, J EXP MED, V180, P977, DOI 10.1084/jem.180.3.977; MAUVIEL A, 1993, CURR BIOL, V3, P822, DOI 10.1016/0960-9822(93)90216-B; MONCADA S, 1991, PHARMACOL REV, V43, P109; MULLER CW, 1995, NATURE, V373, P311, DOI 10.1038/373311a0; NATHAN C, 1994, CELL, V78, P915, DOI 10.1016/0092-8674(94)90266-6; NAVA E, 1992, J CARDIOVASC PHARM, V20, pS132, DOI 10.1097/00005344-199204002-00037; Palmer R M, 1993, Curr Opin Nephrol Hypertens, V2, P122, DOI 10.1097/00041552-199301000-00018; PARRILLO JE, 1993, NEW ENGL J MED, V328, P1471, DOI 10.1056/nejm199305203282008; PERRELLA MA, 1994, J BIOL CHEM, V269, P14595; Sambrook J., 2002, MOL CLONING LAB MANU; SPINK J, 1995, J BIOL CHEM, V270, P29541, DOI 10.1074/jbc.270.49.29541; VODOVOTZ Y, 1993, J EXP MED, V178, P605, DOI 10.1084/jem.178.2.605; WEI XQ, 1995, NATURE, V375, P408, DOI 10.1038/375408a0; XIE QW, 1994, J BIOL CHEM, V269, P4705; XIE QW, 1992, SCIENCE, V256, P225, DOI 10.1126/science.1373522; XIE QW, 1993, J EXP MED, V177, P1779, DOI 10.1084/jem.177.6.1779; YOSHIZUMI M, 1995, MOL CELL BIOL, V15, P3266	30	75	76	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 7	1996	271	23					13776	13780		10.1074/jbc.271.23.13776	http://dx.doi.org/10.1074/jbc.271.23.13776			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UP385	8662809				2022-12-25	WOS:A1996UP38500071
J	Schaefer, A; Magocsi, M; Stocker, U; Fandrich, A; Marquardt, H				Schaefer, A; Magocsi, M; Stocker, U; Fandrich, A; Marquardt, H			Ca2+/calmodulin-dependent and -independent down-regulation of c-myb mRNA levels in erythropoietin-responsive murine erythroleukemia cells - The role of calcineurin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA; CYCLOSPORINE-A; PHOSPHATASE-ACTIVITY; PROTEIN PHOSPHATASE; SIGNALING PATHWAYS; GENE-TRANSCRIPTION; DIFFERENTIATION; CALCIUM; EXPRESSION; ACTIVATION	Down-regulation of c-myb mRNA levels by [Ca2+](i)-increasing agents (A23187, thapsigargin, cyclopiazonic acid) and erythropoietin-responsive murine erythroleukemia cell line, ELM-I-1. The Ca2+-induced suppression of c-myb trifluoperazine and calmidazolium, as well as by cyclosporin A, an inhibitor of the Ca2+/calmodulin-dependent protein phosphatase 2B (calcineurin). KN-62, an inhibitor of Ca2+/calmodulin-dependent protein kinases, did not antagonize the Ca2+-mediated decrease in c-myb mRNA. In cyclosporin A-treated ELM-I-1, cells, a close correlation could by demonstrated between the antagonization of the calcineurin phophatase activity. On the other hand, FK506, which did not inhibit calcineurin activity in ELM-I-1 cells, failed to prevent the Ca2+-mediated decrease in c-myb mRNA. The erythropoietin-induced down-regulation of c-myb mRNA levels could be demonstrated also in the presence of EGTA and was resistant to calmodulin antagonists and cyclosporin A. In addition, no increase in [Ca2+](i), was observed in ELM-I-1 cells in response to erythropoietin. Cyclosporin A inhibited the Ca2+-induced hemoglobin production, while the erythropoietin-mediated increase in hemoglobin synthesis was not affected. The results indicate that the Ca2+-induced decrease in c-myb mRNA and increase in hemoglobin synthesis is mediated by calcineurin, while these effects of erythropoietin occur independently of Ca2+ in ELM-I-1 cells. Calcineurin may be involved in the regulation of c-myb expression in erythroid precursor cells and Ca2+ signals via calcineurin may positively modulate the differentiation inducing action of erythropoietin.	FRAUNHOFER DEPT TOXICOL & ENVIRONM MED,D-20146 HAMBURG,GERMANY; NATL INST HEMATOL BLOOD TRANSFUS & IMMUNOL,H-1113 BUDAPEST,HUNGARY		Schaefer, A (corresponding author), UNIV HAMBURG,DEPT TOXICOL,SCH MED,GRINDELALLEE 117,D-20146 HAMBURG,GERMANY.							ALBERTS AS, 1994, MOL CELL BIOL, V14, P4398, DOI 10.1128/MCB.14.7.4398; BENDER TP, 1987, SCIENCE, V237, P1473, DOI 10.1126/science.3498214; BLUMENTHAL DK, 1986, J BIOL CHEM, V261, P8140; BUSFIELD SJ, 1992, BLOOD, V80, P412; CHERN Y, 1990, J BIOL CHEM, V266, P2009; CHERN YJ, 1991, BLOOD, V78, P991, DOI 10.1182/blood.V78.4.991.bloodjournal784991; CHEUNG JY, 1992, J CLIN INVEST, V90, P1850, DOI 10.1172/JCI116061; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLIPSTONE NA, 1992, NATURE, V357, P695, DOI 10.1038/357695a0; COHEN P, 1989, ANNU REV BIOCHEM, V58, P453, DOI 10.1146/annurev.bi.58.070189.002321; COHEN P, 1989, J BIOL CHEM, V264, P21435; ENSLEN H, 1994, J BIOL CHEM, V269, P20872; ENSLEN H, 1994, J BIOL CHEM, V269, P15520; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FRUMAN DA, 1992, EUR J IMMUNOL, V22, P2513, DOI 10.1002/eji.1830221008; FRUMAN DA, 1992, P NATL ACAD SCI USA, V89, P3686, DOI 10.1073/pnas.89.9.3686; GIETZEN K, 1982, BIOCHEM J, V207, P541, DOI 10.1042/bj2070541; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; GROBLEWSKI GE, 1994, J BIOL CHEM, V269, P15111; HAGIWARA M, 1992, CELL, V70, P105, DOI 10.1016/0092-8674(92)90537-M; KAYE RE, 1992, P NATL ACAD SCI USA, V89, P8542, DOI 10.1073/pnas.89.18.8542; KONKEL DA, 1979, CELL, V18, P865, DOI 10.1016/0092-8674(79)90138-7; KUBO M, 1994, SCHWIMMUNOL, V5, P179; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUFTIG RB, 1977, J VIROL, V23, P799, DOI 10.1128/JVI.23.3.799-810.1977; MAJELLO B, 1986, P NATL ACAD SCI USA, V83, P9636, DOI 10.1073/pnas.83.24.9636; MILLER BA, 1989, BLOOD, V73, P1188; MOCHIZUKI H, 1993, J BIOL CHEM, V268, P9143; MULKEY RM, 1994, NATURE, V369, P486, DOI 10.1038/369486a0; OKEEFE SJ, 1992, NATURE, V357, P692, DOI 10.1038/357692a0; OSTERTAG W, 1972, NATURE-NEW BIOL, V239, P231, DOI 10.1038/newbio239231a0; PATEL HR, 1992, J BIOL CHEM, V267, P21300; REDDY CD, 1989, P NATL ACAD SCI USA, V86, P7326, DOI 10.1073/pnas.86.19.7326; REN HY, 1994, J BIOL CHEM, V269, P19633; SAWADA T, 1992, EXP HEMATOL, V20, P629; SCHAEFER A, 1993, J BIOL CHEM, V268, P10876; SCHAEFER A, 1994, J BIOL CHEM, V269, P8786; SCHREIBER SL, 1992, CELL, V70, P365, DOI 10.1016/0092-8674(92)90158-9; SCHWANINGER M, 1993, J BIOL CHEM, V268, P23111; SHENG M, 1991, SCIENCE, V252, P1427, DOI 10.1126/science.1646483; SHIOZAKI M, 1990, LEUKEMIA RES, V14, P287, DOI 10.1016/0145-2126(90)90137-X; SOBIESZCZUK PW, 1989, NUCLEIC ACIDS RES, V17, P9593, DOI 10.1093/nar/17.23.9593; SPIVAK JL, 1992, EXP HEMATOL, V20, P283; SYTKOWSKI AJ, 1993, ERYTHROPOIETIN MOL P, P254; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; TODOKORO K, 1988, P NATL ACAD SCI USA, V85, P8900, DOI 10.1073/pnas.85.23.8900; TOKUMITSU H, 1990, J BIOL CHEM, V265, P4315; TSIEN RY, 1982, J CELL BIOL, V94, P325, DOI 10.1083/jcb.94.2.325; WATSON RJ, 1988, ONCOGENE, V2, P267; ZOBEL A, 1991, ONCOGENE, V6, P1397	52	20	21	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 7	1996	271	23					13484	13490		10.1074/jbc.271.23.13484	http://dx.doi.org/10.1074/jbc.271.23.13484			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UP385	8662717	hybrid			2022-12-25	WOS:A1996UP38500029
J	Silva, JC; Minto, RE; Barry, CE; Holland, KA; Townsend, CA				Silva, JC; Minto, RE; Barry, CE; Holland, KA; Townsend, CA			Isolation and characterization of the versicolorin B synthase gene from Aspergillus parasiticus - Expansion of the aflatoxin B-1 biosynthetic gene cluster	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NORSOLORINIC ACID; DIHYDROBISFURAN FORMATION; SACCHAROMYCES-CEREVISIAE; VERSICONAL ACETATE; CRYSTAL-STRUCTURE; GLUCOSE-OXIDASE; LIVER-CANCER; CELL-FREE; CONVERSION; STERIGMATOCYSTIN	Versicolorin B synthase catalyzes the side chain cyclizatian of racemic versiconal hemiacetal (7) to the bisfuran ring: system of (-)-versicolorin B (8), an essential transformation in the aflatoxin biosynthetic pathway of Aspergillus parasiticus. The dihydrobisfuran an is key to the mutagenic nature of aflatoxin B-1 (1), The protein, which skews 58% similarity and 38% identity with glucose oxidase from Aspergillus niger, possesses an amino-terminal sequence homologous to the ADP-binding region of other flavoenzymes. However, this enzyme does not require flavin or nicotinamide cofactors for its cyclase activity, The 643-amino acid native enzyme contains three potential sites for W-linked glycosylation, Asn-Xaa-Thr or Asn-Xaa-Ser. The cDNA and genomic clones of versicolorin B synthase were isolated by screening the respective libraries with random-primed DNA probes generated from an exact copy of an internal vbs sequence. This probe was created through polymerase chain reaction by using nondegenerate polymerase chain reaction primers derived from the amino acid sequences of peptide fragments of the enzyme. The 1985-base genomic rbs DNA sequence is interrupted by one intron of 53 nucleotides. Southern blotting, nucleotide sequencing, and detailed restriction mapping of the vbs-containing genomic clones revealed the presence of omtA, a methyltransferase active in the biosynthesis, 3.3 kilobases upstream of vbs and oriented in the opposite direction from vbs. The presence of omtA in close proximity to obs supports the theory that the genes encoding the aflatoxin biosynthetic enzymes in A, parasiticus are clustered.	JOHNS HOPKINS UNIV, DEPT CHEM, BALTIMORE, MD 21218 USA	Johns Hopkins University			Barry, Clifton E/ABE-7992-2020; Barry, III, Clifton/H-3839-2012	Barry, Clifton E/0000-0002-2927-270X; Barry, III, Clifton/0000-0002-2927-270X; Minto, Robert/0000-0001-7070-6832	NIEHS NIH HHS [ES 01670] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES001670] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ADYE J, 1964, BIOCHIM BIOPHYS ACTA, V86, P418, DOI 10.1016/0304-4165(64)90077-7; AGUILAR F, 1993, P NATL ACAD SCI USA, V90, P8586, DOI 10.1073/pnas.90.18.8586; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; ANDERSON JA, 1990, MYCOPATHOLOGIA, V110, P31, DOI 10.1007/BF00442767; ANDERSON JA, 1994, MYCOPATHOLOGIA, V126, P169, DOI 10.1007/BF01103771; ASPLIN F. D., 1961, Veterinary Record, V73, P1215; Ausubel F.M., 1992, SHORT PROTOCOLS MOL; Ausubel FM, 1994, CURRENT PROTOCOLS MO; BAERTSCHI SW, 1988, J AM CHEM SOC, V110, P7923; BARNES WM, 1994, P NATL ACAD SCI USA, V91, P2216, DOI 10.1073/pnas.91.6.2216; BENNETT JW, 1980, CAN J MICROBIOL, V26, P706, DOI 10.1139/m80-121; BENNETT JW, 1975, AGR FOOD CHEM, V23, P1132; BHATNAGAR D, 1988, BIOCHIMIE, V70, P743, DOI 10.1016/0300-9084(88)90103-4; BOEL E, 1984, EMBO J, V3, P1581, DOI 10.1002/j.1460-2075.1984.tb02014.x; BROLST SW, 1993, CAN J CHEM, V72, P200; CAMPBELL TC, 1990, CANCER RES, V50, P6882; CAVENER DR, 1992, J MOL BIOL, V223, P811, DOI 10.1016/0022-2836(92)90992-S; CHANG PK, 1993, APPL ENVIRON MICROB, V59, P3273, DOI 10.1128/AEM.59.10.3273-3279.1993; CHATTERJEE M, 1994, J ORG CHEM, V59, P4424, DOI 10.1021/jo00095a016; CIHLAR RL, 1980, NUCLEIC ACIDS RES, V8, P793; CLEVELAND TE, 1987, APPL ENVIRON MICROB, V53, P1711, DOI 10.1128/AEM.53.7.1711-1713.1987; CLEVELAND TE, 1967, CAN J MICROBIOL, V33, P1108; Cole R. J., 1981, HDB TOXIC FUNGAL MET, P1; Dickens J, 1977, MYCOTOXINS HUMAN ANI, P99; DOBSON MJ, 1982, NUCLEIC ACIDS RES, V10, P2625, DOI 10.1093/nar/10.8.2625; EATON DL, 1994, ANNU REV PHARMACOL, V34, P135, DOI 10.1146/annurev.pa.34.040194.001031; ESSIGMANN JM, 1977, P NATL ACAD SCI USA, V74, P1970; FELENBOK B, 1988, GENE, V73, P385, DOI 10.1016/0378-1119(88)90503-3; FREDERICK KR, 1990, J BIOL CHEM, V265, P3793; GELBOIN HV, 1966, SCIENCE, V154, P1205, DOI 10.1126/science.154.3753.1205; GOPALAKRISHNAN S, 1990, BIOCHEMISTRY-US, V29, P10438, DOI 10.1021/bi00498a002; GURR SJ, 1990, GENE STRUCTURE EUKAR, P93; HATSUDA Y, 1971, AGR BIOL CHEM TOKYO, V35, P411; HECHT HJ, 1993, J MOL BIOL, V229, P153, DOI 10.1006/jmbi.1993.1015; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HORNG JS, 1989, APPL ENVIRON MICROB, V55, P2561, DOI 10.1128/AEM.55.10.2561-2568.1989; HSIEH DPH, 1973, BIOCHEM BIOPH RES CO, V52, P992, DOI 10.1016/0006-291X(73)91035-8; HSIEH DPH, 1976, J AGR FOOD CHEM, V24, P1170, DOI 10.1021/jf60208a018; HSU IC, 1991, NATURE, V350, P427, DOI 10.1038/350427a0; KELLER NP, 1993, APPL ENVIRON MICROB, V59, P479, DOI 10.1128/AEM.59.2.479-484.1993; KELLER NP, 1995, APPL ENVIRON MICROB, V61, P3628, DOI 10.1128/AEM.61.10.3628-3632.1995; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; LAMARK T, 1991, MOL MICROBIOL, V5, P1049, DOI 10.1111/j.1365-2958.1991.tb01877.x; LEE LS, 1971, J AM OIL CHEM SOC, V48, P93, DOI 10.1007/BF02635696; LI JY, 1993, BIOCHEMISTRY-US, V32, P11507, DOI 10.1021/bi00094a006; Lillehoj E.B., 1977, MYCOTOXINS HUMAN ANI, P107; LIN BK, 1992, ARCH BIOCHEM BIOPHYS, V293, P67, DOI 10.1016/0003-9861(92)90366-5; LLOYD AT, 1991, MOL GEN GENET, V230, P288, DOI 10.1007/BF00290679; LOECHLER EL, 1988, J BIOMOL STRUCT DYN, V5, P1237, DOI 10.1080/07391102.1988.10506467; LUNDBERG KS, 1991, GENE, V108, P1, DOI 10.1016/0378-1119(91)90480-Y; Maniatis T., 1982, MOL CLONING; MARTIN CN, 1977, NATURE, V267, P863, DOI 10.1038/267863a0; MCGUIRE SM, 1989, J AM CHEM SOC, V111, P8308, DOI 10.1021/ja00203a058; MCGUIRE SM, 1993, BIOORG MED CHEM LETT, V3, P653, DOI 10.1016/S0960-894X(01)81247-6; NEAL GE, 1973, NATURE, V244, P432, DOI 10.1038/244432a0; NIELSON KB, 1994, STRATEGIES MOL BIOL, V7, P27; PAPA KE, 1982, J GEN MICROBIOL, V128, P1345; PAPA KE, 1978, MYCOLOGIA, V70, P766, DOI 10.2307/3759356; PAPA KE, 1984, CAN J MICROBIOL, V30, P68, DOI 10.1139/m84-012; PEERS FG, 1976, INT J CANCER, V17, P167, DOI 10.1002/ijc.2910170204; RAMBOSEK J, 1987, CRIT REV BIOTECHNOL, V6, P357, DOI 10.3109/07388558709089387; SAUNDERS FC, 1972, CANCER RES, V32, P2487; SKORY CD, 1993, APPL ENVIRON MICROB, V59, P1642, DOI 10.1128/AEM.59.5.1642-1646.1993; SKORY CD, 1992, APPL ENVIRON MICROB, V58, P3527, DOI 10.1128/AEM.58.11.3527-3537.1992; SMITH RF, 1992, PROTEIN ENG, V5, P35, DOI 10.1093/protein/5.1.35; STEYN PS, 1979, J CHEM SOC P1, V1, P451; TOWNSEND CA, 1988, J AM CHEM SOC, V110, P318, DOI 10.1021/ja00209a066; TOWNSEND CA, 1989, TETRAHEDRON, V45, P2263, DOI 10.1016/S0040-4020(01)83431-1; TOWNSEND CA, 1982, J AM CHEM SOC, V104, P6154, DOI 10.1021/ja00386a070; TOWNSEND CA, 1988, J CHEM SOC CHEM COMM, P726, DOI 10.1039/c39880000726; TOWNSEND CA, 1988, J ORG CHEM, V53, P2472, DOI 10.1021/jo00246a015; TOWNSEND CA, 1992, ENVIR SCI R, V44, P141; TRAIL F, 1994, APPL ENVIRON MICROB, V60, P4078, DOI 10.1128/AEM.60.11.4078-4085.1994; van Rensburg S J, 1990, J Environ Pathol Toxicol Oncol, V10, P11; VIDALCROS A, 1994, EUR J BIOCHEM, V219, P985, DOI 10.1111/j.1432-1033.1994.tb18581.x; Watanabe CMH, 1996, J ORG CHEM, V61, P1990, DOI 10.1021/jo952056v; WORLEY KC, 1995, GENOME RES, V5, P173, DOI 10.1101/gr.5.2.173; YABE K, 1989, APPL ENVIRON MICROB, V55, P2172, DOI 10.1128/AEM.55.9.2172-2177.1989; YABE K, 1991, APPL ENVIRON MICROB, V57, P1340, DOI 10.1128/AEM.57.5.1340-1345.1991; YABE K, 1993, APPL ENVIRON MICROB, V59, P2486, DOI 10.1128/AEM.59.8.2486-2492.1993; YABE K, 1991, AGR BIOL CHEM TOKYO, V55, P1907, DOI 10.1080/00021369.1991.10870849; YU JJ, 1993, APPL ENVIRON MICROB, V59, P3564, DOI 10.1128/AEM.59.11.3564-3571.1993; YU JJ, 1995, APPL ENVIRON MICROB, V61, P2365, DOI 10.1128/AEM.61.6.2365-2371.1995	83	50	55	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 7	1996	271	23					13600	13608		10.1074/jbc.271.23.13600	http://dx.doi.org/10.1074/jbc.271.23.13600			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UP385	8662689	hybrid			2022-12-25	WOS:A1996UP38500046
J	Eytan, GD; Regev, R; Oren, G; Assaraf, YG				Eytan, GD; Regev, R; Oren, G; Assaraf, YG			The role of passive transbilayer drug movement in multidrug resistance and its modulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							P-GLYCOPROTEIN; TRANSMEMBRANE CHANNEL; PLASMA-MEMBRANE; TRANSPORT; CELLS; GRAMICIDIN; VERAPAMIL; PROGESTERONE; LIPOSOMES	The successful lowering of the intracellular concentration of multidrug resistance (MDR)-type drugs by P-glycoprotein (Pgp) relies on its ability to overcome the passive influx rate of each MDR-type drug, Thus, the aim of the present work was to study the effect of passive transbilayer drug movement on the multidrug resistance and its modulation, Fluorescence quenching studies indicated that whereas the Pgp substrate rhodamine 123 traverses an artificial lipid membrane with a lifetime of 3 min, the transbilayer movement rate of the MDR modulators, quinidine and quinine, was too fast to be detected with present methods. Transbilayer movement rates of drugs and modulators were estimated from their equilibration rate throughout artificial multilamellar vesicles, The equilibration rate of five selected modulators was faster than the equilibration rate of five representative MDR-type drugs tested, which was comparable with the rate of rhodamine 123 equilibration, Moreover, the carrier-type peptide ionophore, valinomycin, which is freely mobile in the membrane, inhibited Pgp-mediated efflux of rhodamine 123 from MDR cells, In contrast, the channel-forming ionophore gramicidin D, a Pgp substrate that flip-flops slowly across the membrane, did not modulate cellular Pgp activity, Pgp, with a turnover number of about 900 min(-1) can keep pace with the influx of an MDR-drug like rhodamine 123 exhibiting a transbilayer movement with a lifetime of minutes, On the other hand, Pgp would fail to protect MDR cells against cytotoxic drugs that are freely mobile through biological membranes and that re-enter cells faster than their Pgp-mediated active efflux rate, The relatively fast transbilayer movement exhibited by MDR modulators suggest that in contrast to MDR-type drugs, MDR modulators traverse the plasma membrane faster than the maximal expulsion rate of Pgp.			Eytan, GD (corresponding author), TECHNION ISRAEL INST TECHNOL,DEPT BIOL,IL-32000 HAIFA,ISRAEL.							BENZ R, 1976, J MEMBRANE BIOL, V27, P171, DOI 10.1007/BF01869135; Borgnia MJ, 1996, J BIOL CHEM, V271, P3163, DOI 10.1074/jbc.271.6.3163; BROXTERMAN HJ, 1989, FEBS LETT, V247, P405, DOI 10.1016/0014-5793(89)81380-8; CABRAL DJ, 1987, BIOCHEMISTRY-US, V26, P1801, DOI 10.1021/bi00381a002; CHABNER BA, 1990, CANC CHEMOTHERAPY PR; COLLANDER RUNAR, 1933, ACTA BOT FENNICA, V11-, P1; DROI S, 1995, EUR J BIOCHEM, V228, P1020; Eytan GD, 1996, J BIOL CHEM, V271, P3172, DOI 10.1074/jbc.271.6.3172; EYTAN GD, 1994, J BIOL CHEM, V269, P26058; FREI E, 1985, CANCER RES, V45, P6523; GOTTESMAN MM, 1988, J BIOL CHEM, V263, P12163; GOTTESMAN MM, 1993, ANNU REV BIOCHEM, V62, P385, DOI 10.1146/annurev.bi.62.070193.002125; HOLLO Z, 1994, BBA-BIOMEMBRANES, V1191, P384, DOI 10.1016/0005-2736(94)90190-2; HORIO M, 1989, J BIOL CHEM, V264, P14880; JAIN MK, 1985, BIOCHIM BIOPHYS ACTA, V818, P356, DOI 10.1016/0005-2736(85)90010-0; NEYFAKH AA, 1988, EXP CELL RES, V178, P513, DOI 10.1016/0014-4827(88)90419-3; OCONNELL AM, 1990, SCIENCE, V250, P1256, DOI 10.1126/science.1700867; OLSON F, 1979, BIOCHIM BIOPHYS ACTA, V557, P9, DOI 10.1016/0005-2736(79)90085-3; Overton E, 1902, ARCH GESAMTE PHYSIOL, V92, P115, DOI 10.1007/BF01659618; RAMU A, 1983, CANCER RES, V43, P5533; SCHLEMMER SR, 1994, J BIOL CHEM, V269, P31059; SCHWARTZ MA, 1978, BIOCHEMISTRY-US, V17, P837, DOI 10.1021/bi00598a014; SHAPIRO AB, 1995, J BIOL CHEM, V270, P16167, DOI 10.1074/jbc.270.27.16167; SHAPIRO AB, 1994, J BIOL CHEM, V269, P3745; SHAROM FJ, 1993, J BIOL CHEM, V268, P24197; SKOVSGAARD T, 1978, CANCER RES, V38, P1783; SPEELMANS G, 1994, BIOCHEMISTRY-US, V33, P13761, DOI 10.1021/bi00250a029; SZOKA F, 1978, P NATL ACAD SCI USA, V75, P4194, DOI 10.1073/pnas.75.9.4194; TSURUO T, 1981, CANCER RES, V41, P1967; UEDA K, 1992, J BIOL CHEM, V267, P24248; URBATSCH IL, 1994, BIOCHEMISTRY-US, V33, P7069, DOI 10.1021/bi00189a008; URRY DW, 1971, P NATL ACAD SCI USA, V68, P672, DOI 10.1073/pnas.68.3.672; URRY DW, 1971, P NATL ACAD SCI USA, V68, P1907, DOI 10.1073/pnas.68.8.1907; WARR JR, 1988, CANCER RES, V48, P4477; YANG CPH, 1989, J BIOL CHEM, V264, P782; YUSA K, 1989, CANCER RES, V49, P5002	36	158	164	1	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 31	1996	271	22					12897	12902		10.1074/jbc.271.22.12897	http://dx.doi.org/10.1074/jbc.271.22.12897			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UN474	8662680	hybrid			2022-12-25	WOS:A1996UN47400034
J	Fujiwara, K; OkamuraIkeda, K; Motokawa, Y				Fujiwara, K; OkamuraIkeda, K; Motokawa, Y			Lipoylation of acyltransferase components of alpha-ketoacid dehydrogenase complexes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCINE CLEAVAGE SYSTEM; ESCHERICHIA-COLI; H-PROTEIN; DIHYDROLIPOAMIDE ACYLTRANSFERASES; MOLECULAR-CLONING; ACID; SEQUENCE; EXPRESSION; SITE; PURIFICATION	Lipoic acid is a prosthetic group of the acyltransferase components of the pyruvate, alpha-ketoglutarate, and branched chain alpha-ketoacid dehydrogenase complexes, protein X of the eukaryotic pyruvate dehydrogenase complex, and H-protein of the glycine cleavage system, We have purified lipoyl-AMP:N-epsilon-lysine lipoyltransferase I and II from bovine liver mitochondria employing apoH-protein as an acceptor of lipoic acid (Fyjiwara, K., Okamura-Ikeda, K,, and Motokawa, Y, (1994) J. Biol, Chem. 269, 16605-16609). In this study, we demonstrated the lipoylation of the lipoyl domains of the mammalian pyruvate (LE2p), alpha-ketoglutarate (LE2k), and branched chain alpha-keto acid (LE2b) dehydrogenase complexes using the purified lipoyltransferase I and II, Lipoyltransferase I and II lipoylated LE2p and LE2k as efficiently as H-protein, but the lipoylation rate of LE2b was extremely low, Comparison of amino acid sequences surrounding the lipoylation site of these proteins shows that the conserved glutamic acid residue situated 3 residues to the N-terminal side of the Lipoylation site is replaced by glutamine (Gln-41) in LE2b. When Gln-41 of LE2b was changed to Glu, the rate of lipoylation increased about 100-fold and became comparable to that of LE2p and LE2k The replacement of the glutamic acid residue of LE2p (Glu-169) and LE2k (Glu-40) by glutamine resulted in decrease in the lipoylation rate more than 100-fold, These results suggest that the glutamic acid residue plays an important role in the lipoylation reaction possibly functioning as a recognition signal, Gly-27 and Gly-54 of LE2k are also well conserved among the lipoyl domains of the alpha-ketoacid dehydrogenase complexes and H-protein, The mutagenesis experiments of these residues indicated that the glycine residue situated 11 residues to the C-terminal side of the Lipoylation site (Gly-54 of LE2k) is important for the folding of lipoyl domain, and that existence of a small residue such as Gly or Cys at the position is essential for the lipoylation of these proteins.	UNIV TOKUSHIMA,INST ENZYME RES,TOKUSHIMA 770,JAPAN	Tokushima University								BROOKFIELD DE, 1991, FEBS LETT, V295, P13, DOI 10.1016/0014-5793(91)81373-G; FUJIWARA K, 1992, J BIOL CHEM, V267, P20011; FUJIWARA K, 1979, ARCH BIOCHEM BIOPHYS, V197, P454, DOI 10.1016/0003-9861(79)90267-4; FUJIWARA K, 1994, J BIOL CHEM, V269, P16605; FUJIWARA K, 1991, FEBS LETT, V293, P115, DOI 10.1016/0014-5793(91)81164-4; FUJIWARA K, 1990, J BIOL CHEM, V265, P17463; FUJIWARA K, 1995, METHOD ENZYMOL, V251, P340, DOI 10.1016/0076-6879(95)51137-7; GREEN JDF, 1995, J MOL BIOL, V248, P328, DOI 10.1006/jmbi.1995.0225; GRIFFIN TA, 1988, J BIOL CHEM, V263, P14008; GRIFFIN TA, 1990, J BIOL CHEM, V265, P12104; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LEONDELRIO A, 1994, J BIOL CHEM, V269, P22964; LI SJ, 1992, J BIOL CHEM, V267, P856; MATUDA S, 1992, BIOCHIM BIOPHYS ACTA, V1131, P114, DOI 10.1016/0167-4781(92)90109-D; MORRIS TW, 1994, J BIOL CHEM, V269, P16091; NAKANO K, 1991, J BIOL CHEM, V266, P19013; PERHAM RN, 1991, BIOCHEMISTRY-US, V30, P8501, DOI 10.1021/bi00099a001; QUINN J, 1993, BIOCHEM J, V289, P81, DOI 10.1042/bj2890081; REED LJ, 1990, J BIOL CHEM, V265, P8971; REED LJ, 1958, J BIOL CHEM, V232, P123; Sambrook J., 2002, MOL CLONING LAB MANU; TSUNODA JN, 1967, ARCH BIOCHEM BIOPHYS, V118, P395, DOI 10.1016/0003-9861(67)90366-9; WALLIS NG, 1994, J MOL BIOL, V236, P209, DOI 10.1006/jmbi.1994.1130	24	43	45	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 31	1996	271	22					12932	12936		10.1074/jbc.271.22.12932	http://dx.doi.org/10.1074/jbc.271.22.12932			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UN474	8662700	hybrid			2022-12-25	WOS:A1996UN47400040
J	Solis, D; Romero, A; Kaltner, H; Gabius, HJ; DiazMaurino, T				Solis, D; Romero, A; Kaltner, H; Gabius, HJ; DiazMaurino, T			Different architecture of the combining site of the two chicken galectins revealed by chemical mapping studies with synthetic ligand derivatives	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GALACTOSIDE-BINDING LECTIN; AMINO-ACID-SEQUENCE; LACTOSE; SPECIFICITY; INTESTINE; TISSUES; CLONING; COMPLEX; PROTEIN; CDNA	The detailed comparison of the carbohydrate-binding properties of related galectins from one organism can be facilitated by the application of an array of deliberately tailored methyl beta-lactoside derivatives. Focusing on chicken due to its expression of two galectins as a model for this approach, the combining-site architecture of the lectin from adult liver (CL-16) is apparently homologous to that previously observed for bovine galectin-1 (Solis, D., Jimenez-Barbero, J., Martin-Lomas, M., and Diaz-Maurino, T. (1998) Eur. J. Biochem. 223, 107-114). Besides preservation of the key interactions and minor differences, the lectin from adult intestine (CL-14) is able to accommodate an axial HO-3 at the glucose moiety. Homology-based modeling enabled us to tentatively attribute the observed differences to a slightly different orientation of pivotal side chains in the binding pocket due to distinct substitutions of amino acid residues in the variable region within the carbohydrate-recognition domain. Thus, the results suggest-overlapping but distinct ranges of potential ligands for the two chicken lectins and provide new information on their relationship to mammalian galectins. The described approach is suggested to be of relevance to design pharmaceuticals with enhanced selectivity to a certain member within a family of related lectins.	UNIV MUNICH,TIERARZTL FAK,INST PHYSIOL CHEM,D-80539 MUNICH,GERMANY	University of Munich	Solis, D (corresponding author), CSIC,INST QUIM FIS ROCASOLANO,SERRANO 119,E-28006 MADRID,SPAIN.		Solís, Dolores/E-5992-2015; Romero, Antonio/K-5754-2014	Solís, Dolores/0000-0002-8148-1875; Romero, Antonio/0000-0002-6990-6973; Gabius, Hans-Joachim/0000-0003-3467-3900; Kaltner, Herbert/0000-0003-4680-8411				ABBOTT WM, 1989, BIOCHEM J, V259, P283, DOI 10.1042/bj2590283; AHMED H, 1994, GLYCOBIOLOGY, V4, P545, DOI 10.1093/glycob/4.5.545; BARONDES SH, 1994, CELL, V76, P597, DOI 10.1016/0092-8674(94)90498-7; BARONDES SH, 1994, J BIOL CHEM, V269, P20807; BEYER EC, 1982, J CELL BIOL, V92, P23, DOI 10.1083/jcb.92.1.23; BEYER EC, 1980, J BIOL CHEM, V255, P4236; BRUNGER AT, 1992, X PLOR MANUAL VERSIO; CASTAGNA LF, 1994, J NEUROSCI RES, V37, P750, DOI 10.1002/jnr.490370609; FEIZI T, 1985, NATURE, V314, P53, DOI 10.1038/314053a0; FERSHT AR, 1985, NATURE, V314, P235, DOI 10.1038/314235a0; KAYSER K, 1995, ROUX ARCH DEV BIOL, V204, P344, DOI 10.1007/BF02179503; KNIBBS RN, 1993, J BIOL CHEM, V268, P14940; LEFFLER H, 1986, J BIOL CHEM, V261, P119; LIAO DI, 1994, P NATL ACAD SCI USA, V91, P1428, DOI 10.1073/pnas.91.4.1428; LOBSANOV YD, 1993, J BIOL CHEM, V268, P27034; ODA Y, 1993, J BIOL CHEM, V268, P5929; OGUCHI H, 1990, CANCER COMMUN, V2, P311; OHYAMA Y, 1986, BIOCHEM BIOPH RES CO, V134, P51, DOI 10.1016/0006-291X(86)90525-5; RIVERASAGREDO A, 1991, EUR J BIOCHEM, V197, P217, DOI 10.1111/j.1432-1033.1991.tb15902.x; SAKAKURA Y, 1990, J BIOL CHEM, V265, P21573; SCHNELLER M, 1995, CELL IMMUNOL, V166, P35, DOI 10.1006/cimm.1995.0005; SOLIS D, 1993, EUR J BIOCHEM, V214, P677, DOI 10.1111/j.1432-1033.1993.tb17968.x; SOLIS D, 1994, EUR J BIOCHEM, V223, P107, DOI 10.1111/j.1432-1033.1994.tb18971.x; SOLIS D, 1996, IN PRESS GLYCOSCIENC; SPARROW CP, 1987, J BIOL CHEM, V262, P7383; STREET IP, 1986, BIOCHEMISTRY-US, V25, P6021, DOI 10.1021/bi00368a028; WOYNAROWSKA B, 1994, J BIOL CHEM, V269, P22797	27	79	81	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 31	1996	271	22					12744	12748		10.1074/jbc.271.22.12744	http://dx.doi.org/10.1074/jbc.271.22.12744			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UN474	8662681	hybrid			2022-12-25	WOS:A1996UN47400010
J	Wu, YY; Bradshaw, RA				Wu, YY; Bradshaw, RA			Induction of neurite outgrowth by interleukin-6 is accompanied by activation of Stat3 signaling pathway in a variant PC12 cell (E2) line	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NERVE GROWTH-FACTOR; ACUTE-PHASE RESPONSE; NEURONAL DIFFERENTIATION; INTERFERON-ALPHA; TYROSINE KINASE; PROTEIN; BINDING; GENE; COMPLEXES; ISGF-3	PC12-E2 cells, a stable variant subcloned from native cell populations, produce neurites in a rapid, transcription-independent manner upon exposure to nerve growth factor (NGF) or basic fibroblast growth factor (bFGF). They also give a similar morphological response to interleukin-6 (IL-6), which is, however, transcription-dependent and with a slower onset, a phenomenon basically not observed in native PC12 cells, The response profile of PC12-E2 cells to NGF and bFGF is similar to that observed for native PC12 cells pre-exposed (primed) to NGF, and such cells also respond to IL-6 in a fashion indistinguishable from PC12-E2 cells, Mechanistically, NGF and bFGF induce a sustained phosphorylation and activation of ERK1 and ERK2 in both cells, while IL-6 produces only a transient and weak tyrosine phosphorylation, However, it does stimulate a prolonged and biphasic tyrosine phosphorylation and nuclear translocation of Stat3 (signal transducers and activators of transcription 3; at least 24 h) and, to a lesser extent, Stat1. Gel shift and supershift analyses confirm that IL-6 predominantly activates Stat3 (and some Stat1) and stimulates sis-inducilble element binding activity, Other members of the same cytokine subfamily, including ciliary neurotrophic factor and leukemia inhibitory factor, also cause a transient initial phase of tyrosine phosphorylation and activation of Stat1 and Stat3 (up to 1 h) but fail to stimulate a second phase of response and do not produce significant neurites. These results suggest that sustained signaling of either STAT or ERK pathways in PC12-E2 cells leads to induction of neuronal differentiation. However, only the latter is effective in native PC12 cells as the activation of Stat3 and Stat1 in native PC12 cells by IL-6 fails to induce neuronal differentiation. Thus, the response of PC12-E2 cells to IL-6 suggests the constitutive expression of a required factor(s) for differentiation, that is induced in native PC12 cells by NGF or bFGF (possibly by ERK activation), but not by IL-6 via Janus kinase/STAT activation. This factor(s), which has a sufficient half-life to allow primed cells to remain responsive to IL-6 for several days, is necessary but not sufficient for differentiation (as measured by neurite proliferation) to occur.	UNIV CALIF IRVINE,COLL MED,DEPT BIOL CHEM,IRVINE,CA 92717	University of California System; University of California Irvine			Bradshaw, Ralph A/K-1515-2013		NIA NIH HHS [AG 09735] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R01AG009735] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; BOULTON TG, 1994, J BIOL CHEM, V269, P11648; BOULTON TG, 1995, P NATL ACAD SCI USA, V92, P6915, DOI 10.1073/pnas.92.15.6915; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURSTEIN DE, 1978, P NATL ACAD SCI USA, V75, P6059, DOI 10.1073/pnas.75.12.6059; CAMPBELL IL, 1993, P NATL ACAD SCI USA, V90, P10061, DOI 10.1073/pnas.90.21.10061; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; DAVID M, 1995, SCIENCE, V269, P1721, DOI 10.1126/science.7569900; DITTRICH E, 1994, J BIOL CHEM, V269, P19014; FANTL WJ, 1993, ANNU REV BIOCHEM, V62, P453, DOI 10.1146/annurev.bi.62.070193.002321; FRY MJ, 1993, PROTEIN SCI, V2, P1785, DOI 10.1002/pro.5560021102; FU XY, 1992, P NATL ACAD SCI USA, V89, P7840, DOI 10.1073/pnas.89.16.7840; Glass David J., 1993, Trends in Cell Biology, V3, P262, DOI 10.1016/0962-8924(93)90054-5; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; Greene LA., 1982, ADV CELL NEUROBIOL, V3, P373, DOI [10.1016/B978-0-12-008303-9.50016-5, DOI 10.1016/B978-0-12-008303-9.50016-5]; GUSCHIN D, 1995, EMBO J, V14, P1421, DOI 10.1002/j.1460-2075.1995.tb07128.x; HEINRICH PC, 1990, BIOCHEM J, V265, P621, DOI 10.1042/bj2650621; HOPKINS SJ, 1995, TRENDS NEUROSCI, V18, P83; IHLE JN, 1995, ANNU REV IMMUNOL, V13, P369, DOI 10.1146/annurev.iy.13.040195.002101; KISHIMOTO T, 1994, CELL, V76, P253, DOI 10.1016/0092-8674(94)90333-6; KUSHIMA Y, 1992, NEUROSCI RES, V13, P267, DOI 10.1016/0168-0102(92)90039-F; LORD KA, 1991, MOL CELL BIOL, V11, P4371, DOI 10.1128/MCB.11.9.4371; LOTAN M, 1994, FASEB J, V8, P1026, DOI 10.1096/fasebj.8.13.7926367; LUTTICKEN C, 1995, FEBS LETT, V360, P137, DOI 10.1016/0014-5793(95)00076-L; LUTTICKEN C, 1994, SCIENCE, V263, P89, DOI 10.1126/science.8272872; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MATSUDA T, 1995, J BIOL CHEM, V270, P11037, DOI 10.1074/jbc.270.19.11037; MOBLEY WC, 1976, BIOCHEMISTRY-US, V15, P5543, DOI 10.1021/bi00670a019; MURAKAMI M, 1993, SCIENCE, V260, P1808, DOI 10.1126/science.8511589; MURPHY PG, 1995, J NEUROSCI, V15, P5130; NAKAJIMA K, 1991, MOL CELL BIOL, V9, P4605; NARAZAKI M, 1994, P NATL ACAD SCI USA, V91, P2285, DOI 10.1073/pnas.91.6.2285; OBERMEIER A, 1994, EMBO J, V13, P1585, DOI 10.1002/j.1460-2075.1994.tb06421.x; PANG L, 1995, J BIOL CHEM, V270, P13585, DOI 10.1074/jbc.270.23.13585; PATTERSON PH, 1993, CELL, V72, P123, DOI 10.1016/S0092-8674(05)80032-7; QIU MS, 1992, NEURON, V9, P705, DOI 10.1016/0896-6273(92)90033-A; RAFFIONI S, 1995, J BIOL CHEM, V270, P7568, DOI 10.1074/jbc.270.13.7568; ROTHWELL NJ, 1995, TRENDS NEUROSCI, V18, P130, DOI 10.1016/0166-2236(95)93890-A; SADOWSKI HB, 1993, NATURE, V362, P79, DOI 10.1038/362079a0; SATOH T, 1988, MOL CELL BIOL, V8, P3546, DOI 10.1128/MCB.8.8.3546; SAVAGE CR, 1972, J BIOL CHEM, V247, P7609; SCHIEMANN WP, 1995, P NATL ACAD SCI USA, V92, P5361, DOI 10.1073/pnas.92.12.5361; SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201; SCHINDLER C, 1992, P NATL ACAD SCI USA, V89, P7836, DOI 10.1073/pnas.89.16.7836; STAHL N, 1994, SCIENCE, V263, P92, DOI 10.1126/science.8272873; STAHL N, 1993, CELL, V74, P587, DOI 10.1016/0092-8674(93)90506-L; STEFFENSEN SC, 1994, BRAIN RES, V652, P149, DOI 10.1016/0006-8993(94)90329-8; SUEN KL, 1993, MOL CELL BIOL, V13, P5500, DOI 10.1128/MCB.13.9.5500; TRAVERSE S, 1992, BIOCHEM J, V288, P351, DOI 10.1042/bj2880351; WANG Y, 1994, MOL BIOL CELL, V5, P819, DOI 10.1091/mbc.5.7.819; WARD LD, 1994, J BIOL CHEM, V269, P23286; WEGENKA UM, 1994, MOL CELL BIOL, V14, P3186, DOI 10.1128/MCB.14.5.3186; WEGENKA UM, 1993, MOL CELL BIOL, V13, P276, DOI 10.1128/MCB.13.1.276; WEN A, 1995, CELL, V82, P241; WONG VV, 1995, J BIOL CHEM, V270, P313, DOI 10.1074/jbc.270.1.313; WU YY, 1995, J CELL PHYSIOL, V164, P522, DOI 10.1002/jcp.1041640310; Wu YY, 1996, J BIOL CHEM, V271, P13033, DOI 10.1074/jbc.271.22.13033; WU YY, 1993, J CELL BIOL, V121, P409, DOI 10.1083/jcb.121.2.409; YAMADA M, 1994, BRAIN RES, V643, P173, DOI 10.1016/0006-8993(94)90023-X; YUAN JP, 1994, MOL CELL BIOL, V14, P1657, DOI 10.1128/MCB.14.3.1657; ZHANG XK, 1995, SCIENCE, V267, P1990, DOI 10.1126/science.7701321; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422	62	90	92	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 31	1996	271	22					13023	13032		10.1074/jbc.271.22.13023	http://dx.doi.org/10.1074/jbc.271.22.13023			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UN474	8662645				2022-12-25	WOS:A1996UN47400054
J	Perelroizen, I; Didry, D; Christensen, H; Chua, NH; Carlier, MF				Perelroizen, I; Didry, D; Christensen, H; Chua, NH; Carlier, MF			Role of nucleotide exchange and hydrolysis in the function of profilin in actin assembly	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOUND ADENOSINE 5'-TRIPHOSPHATE; LOW-AFFINITY SITES; ATP HYDROLYSIS; F-ACTIN; ACANTHAMOEBA PROFILIN; ADP-ACTIN; POLYMERIZATION; FILAMENTS; BINDING; MECHANISM	Profilin, an essential G-actin-binding protein, has two opposite regulatory functions in actin filament assembly. It facilitates assembly at the barbed ends by lowering the critical concentration (Pantaloni, D., and Carlier, M.-F. (1993) Cell 75, 1007-1014); in contrast it contributes to the pool of unassembled actin when barbed ends are capped. We proposed that the first of these functions required an input of energy. How profilin uses the ATP hydrolysis that accompanies actin polymerization and whether the acceleration of nucleotide exchange on G-actin by profilin participates in its function in filament assembly are the issues addressed here. We show that 1) profilin increases the treadmilling rate of actin filaments in the presence of Mg2+ ions; 2) when filaments are assembled from CaATP-actin, which polymerizes in a quasireversible fashion, profilin does not promote assembly at the barbed ends and has only a G-actin-sequestering function; 3) plant profilins do not accelerate nucleotide exchange on G-actin, yet they promote assembly at the barbed end. The enhancement of nucleotide exchange by profilin is therefore not involved in its promotion of actin assembly, and the productive growth of filaments from profilin-actin complex requires the coupling of ATP hydrolysis to profilin-actin assembly, a condition fulfilled by Mg-actin, and not by Ca-actin.	CNRS,ENZYMOL LAB,F-91198 GIF SUR YVETTE,FRANCE; ROCKEFELLER UNIV,PLANT MOLEC BIOL LAB,NEW YORK,NY 10021; INST MOL AGROBIOL,SINGAPORE,SINGAPORE	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; Rockefeller University; National University of Singapore			Christensen, Helen/F-5053-2012	Christensen, Helen/0000-0003-0435-2065; Christensen, Hans Erik Molager/0000-0002-9540-8679				BRENNER SL, 1988, J BIOL CHEM, V258, P5013; Carlier Marie-France, 1994, Seminars in Cell Biology, V5, P183, DOI 10.1006/scel.1994.1023; CARLIER MF, 1987, J BIOL CHEM, V262, P3052; CARLIER MF, 1986, J BIOL CHEM, V261, P785; CARLIER MF, 1984, J BIOL CHEM, V259, P9983; CARLIER MF, 1986, J BIOL CHEM, V261, P778; CARLIER MF, 1988, J BIOL CHEM, V263, P817; CARLIER MF, 1991, J BIOL CHEM, V266, P1; CARLIER MF, 1986, J BIOL CHEM, V261, P2041; COMBEAU C, 1988, J BIOL CHEM, V263, P17429; GERSHMAN LC, 1984, BIOCHEMISTRY-US, V23, P2199, DOI 10.1021/bi00305a015; GIEHL K, 1994, EUR J BIOCHEM, V226, P681, DOI 10.1111/j.1432-1033.1994.tb20096.x; GOLDSCHMIDTCLERMONT PJ, 1992, MOL BIOL CELL, V3, P1015, DOI 10.1091/mbc.3.9.1015; GOLDSCHMIDTCLERMONT PJ, 1991, J CELL BIOL, V113, P1081, DOI 10.1083/jcb.113.5.1081; HAUGWITZ M, 1994, CELL, V79, P303, DOI 10.1016/0092-8674(94)90199-6; HUG C, 1995, CELL, V81, P591, DOI 10.1016/0092-8674(95)90080-2; KARAKESISOGLOU I, 1996, IN PRESS CELL MOTIL; KINOSIAN HJ, 1993, J BIOL CHEM, V268, P8683; KOUYAMA T, 1981, EUR J BIOCHEM, V114, P33; LAL AA, 1984, J BIOL CHEM, V259, P3061; LARSSON H, 1988, BIOCHIM BIOPHYS ACTA, V953, P95, DOI 10.1016/0167-4838(88)90013-1; MALM B, 1984, FEBS LETT, V173, P399, DOI 10.1016/0014-5793(84)80813-3; MARCHAND JB, 1995, J CELL BIOL, V130, P331, DOI 10.1083/jcb.130.2.331; MITCHISON TJ, 1992, MOL BIOL CELL, V3, P1309, DOI 10.1091/mbc.3.12.1309; MOCKRIN SC, 1980, BIOCHEMISTRY-US, V19, P5359, DOI 10.1021/bi00564a033; NISHIDA E, 1985, BIOCHEMISTRY-US, V24, P1160, DOI 10.1021/bi00326a015; PANTALONI D, 1993, CELL, V75, P1007, DOI 10.1016/0092-8674(93)90544-Z; PERELROIZEN I, 1995, J BIOL CHEM, V270, P1501, DOI 10.1074/jbc.270.4.1501; PERELROIZEN I, 1994, BIOCHEMISTRY-US, V33, P8472, DOI 10.1021/bi00194a011; POLLARD TD, 1981, J CELL BIOL, V88, P654, DOI 10.1083/jcb.88.3.654; POLLARD TD, 1984, BIOCHEMISTRY-US, V23, P6631, DOI 10.1021/bi00321a054; PRING M, 1992, BIOCHEMISTRY-US, V31, P1827, DOI 10.1021/bi00121a035; SUN HQ, 1995, J CELL BIOL, V129, P147, DOI 10.1083/jcb.129.1.147; SUN HQ, 1995, CURR OPIN CELL BIOL, V7, P102, DOI 10.1016/0955-0674(95)80051-4; THERIOT JA, 1993, CELL, V75, P835, DOI 10.1016/0092-8674(93)90527-W; TOBACMAN LS, 1983, J BIOL CHEM, V258, P3207; WEGNER A, 1981, J MOL BIOL, V153, P681, DOI 10.1016/0022-2836(81)90413-7; WEGNER A, 1976, J MOL BIOL, V108, P139, DOI 10.1016/S0022-2836(76)80100-3; WRIGGERS W, 1995, BIOPHYS J, V68, P284	39	127	131	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 24	1996	271	21					12302	12309		10.1074/jbc.271.21.12302	http://dx.doi.org/10.1074/jbc.271.21.12302			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UL660	8647830	hybrid			2022-12-25	WOS:A1996UL66000032
J	Vallone, B; Bellelli, A; Miele, AE; Brunori, M; Fermi, G				Vallone, B; Bellelli, A; Miele, AE; Brunori, M; Fermi, G			Probing the alpha(1)beta(2) interface of human hemoglobin by mutagenesis - Role of the FG-C contact regions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; SINGULAR VALUE DECOMPOSITION; RESOLUTION X-RAY; HUMAN DEOXYHEMOGLOBIN; ALLOSTERIC MECHANISM; SUBUNIT DISSOCIATION; ESCHERICHIA-COLI; LIGAND-BINDING; OXYGEN BINDING; INTERSUBUNIT	The allosteric transition of hemoglobin involves an extensive reorganization of the alpha(1) beta(2) interface, in which two contact regions have been identified. This paper concerns the effect of two mutations located in the ''switch'' (alpha C3 Thr --> Trp) and the ''flexible joint'' (beta C3 Trp --> Thr). We have expressed and characterized one double and two single mutants: Hb alpha T38W/beta W37T, Hb beta W37T, and Hb alpha T38W, whose structure has been determined by crystallography. We present data on: (i) the interface structure in the two contact regions, (ii) oxygen and CO binding kinetics and cooperativity, (iii) dissociation rates of deoxy tetramers and association rates of deoxy dimers, and (iv) the effect of NaI on deoxy tetramer dissociation rate constant. All the mutants are tetrameric and T-state in the deoxygenated derivative. Reassociation of deoxygenated dimers is not modified by interface mutations. DeoxyHb alpha T38W dimerizes 30% slower than HbA; Hb beta W37T and Hb alpha T38W/beta W37T dissociate much faster. We propose a binding site for I- at the switch region. The single mutants bind O-2 cooperatively; the double one is almost non-cooperative, a feature confirmed by CO binding. The functional data, analyzed with the two-state model, indicate that these mutations reduce the value of the allosteric constant L(0).	UNIV ROMA LA SAPIENZA,DEPT BIOCHEM SCI A ROSSI FANELLI,I-00185 ROME,ITALY; UNIV ROMA LA SAPIENZA,CNR,CTR BIOL MOLEC,I-00185 ROME,ITALY; MRC,MOLEC BIOL LAB,CAMBRIDGE CB2 2QH,ENGLAND	Sapienza University Rome; Consiglio Nazionale delle Ricerche (CNR); Sapienza University Rome; MRC Laboratory Molecular Biology			Miele, Adriana E./F-4083-2011; Vallone, Beatrice/F-4174-2012; Bellelli, Andrea/D-2785-2009	Miele, Adriana E./0000-0002-4637-2606; VALLONE, Beatrice/0000-0003-0058-9049; Brunori, Maurizio/0000-0002-7795-1635				ACKERS GK, 1992, SCIENCE, V255, P54, DOI 10.1126/science.1553532; AMICONI G, 1989, J BIOL CHEM, V264, P17745; [Anonymous], 1968, J CRYST GROWTH, DOI [rg/10.1016/00220248(68)900717, DOI 10.1016/0022-0248(68)90071-7]; ANTONINI E, 1968, J BIOL CHEM, V243, P1816; Antonini E., 1971, HEMOGLOBIN MYOGLOBIN; BALDWIN J, 1979, J MOL BIOL, V129, P175, DOI 10.1016/0022-2836(79)90277-8; BELLELLI A, 1994, METHOD ENZYMOL, V232, P56; BELLELLI A, 1990, J BIOL CHEM, V265, P18898; BRIEHL RW, 1970, J BIOL CHEM, V245, P544; Brunori M, 1981, Methods Enzymol, V76, P582; DELLANO JJM, 1993, J BIOL CHEM, V268, P27004; EDELSTEI.SJ, 1970, J BIOL CHEM, V245, P4372; FANELLI AR, 1958, ARCH BIOCHEM BIOPHYS, V77, P478; FERMI G, 1984, J MOL BIOL, V175, P159, DOI 10.1016/0022-2836(84)90472-8; FERMI G, 1981, ATLAS PROTEIN SEQUEN, V2; GACON G, 1977, FEBS LETT, V82, P243, DOI 10.1016/0014-5793(77)80593-0; GIBSON QH, 1967, J BIOL CHEM, V242, P4678; GIBSON QH, 1987, J BIOL CHEM, V262, P516; GOLUB GH, 1970, NUMER MATH, V14, P403, DOI 10.1007/BF02163027; GRAY R, 1975, J BIOL CHEM, V249, P2879; HASHIMOTO M, 1993, BIOCHEMISTRY-US, V32, P13688, DOI 10.1021/bi00212a038; HENRY ER, 1992, METHOD ENZYMOL, V210, P129; HOFFMAN SJ, 1990, P NATL ACAD SCI USA, V87, P8521, DOI 10.1073/pnas.87.21.8521; HOPFIELD JJ, 1971, J MOL BIOL, V61, P424; HUISMAN THJ, 1992, INT INFORMATION CTR, V16, P127; IP SHC, 1976, BIOCHEMISTRY-US, V15, P654, DOI 10.1021/bi00648a032; ISHIMORI K, 1992, BIOCHEMISTRY-US, V31, P3256, DOI 10.1021/bi00127a030; JONES CM, 1992, BIOCHEMISTRY-US, V31, P6692, DOI 10.1021/bi00144a008; KAVANAUGH JS, 1992, BIOCHEMISTRY-US, V31, P4111, DOI 10.1021/bi00131a030; KAVANAUGH JS, 1992, BIOCHEMISTRY-US, V31, P8640, DOI 10.1021/bi00151a034; KELLETT GL, 1970, NATURE, V227, P921, DOI 10.1038/227921a0; KOMIYAMA NH, 1995, NATURE, V373, P244, DOI 10.1038/373244a0; MCGOVERN P, 1976, J BIOL CHEM, V251, P7871; MONOD J, 1965, J MOL BIOL, V12, P88, DOI 10.1016/S0022-2836(65)80285-6; NAGAI K, 1985, P NATL ACAD SCI USA, V82, P7252, DOI 10.1073/pnas.82.21.7252; NAGEL RL, 1972, BIOCHEM BIOPH RES CO, V48, P959, DOI 10.1016/0006-291X(72)90702-4; PERUTZ MF, 1987, ACCOUNTS CHEM RES, V20, P309, DOI 10.1021/ar00141a001; PERUTZ MF, 1974, BIOCHEMISTRY-US, V13, P2163, DOI 10.1021/bi00707a026; PERUTZ MF, 1993, J MOL BIOL, V233, P536, DOI 10.1006/jmbi.1993.1530; SASAKI J, 1978, J BIOL CHEM, V253, P87; SAWICKI CA, 1976, J BIOL CHEM, V251, P1533; SCHAAD O, 1993, CR ACAD SCI III-VIE, V316, P564; SHAANAN B, 1983, J MOL BIOL, V171, P31, DOI 10.1016/S0022-2836(83)80313-1; SZABO A, 1978, P NATL ACAD SCI USA, V75, P2108, DOI 10.1073/pnas.75.5.2108; SZABO A, 1972, J MOL BIOL, V251, P1533; VALLONE B, 1993, FEBS LETT, V324, P117, DOI 10.1016/0014-5793(93)81375-A; VANDEGRIFF KD, 1991, J BIOL CHEM, V266, P17049; WEBER RE, 1993, J APPL PHYSIOL, V75, P2646, DOI 10.1152/jappl.1993.75.6.2646; WIEDERMANN BL, 1975, J BIOL CHEM, V250, P5273; YAMAOKA K, 1971, BLOOD, V30, P730; ZHANG J, 1996, IN PRESS J MOL BIOL	51	24	24	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 24	1996	271	21					12472	12480		10.1074/jbc.271.21.12472	http://dx.doi.org/10.1074/jbc.271.21.12472			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UL660	8647854	hybrid			2022-12-25	WOS:A1996UL66000056
J	Hudson, KR; Vernallis, AB; Heath, JK				Hudson, KR; Vernallis, AB; Heath, JK			Characterization of the receptor binding sites of human leukemia inhibitory factor and creation of antagonists	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CILIARY NEUROTROPHIC FACTOR; COLONY-STIMULATING FACTOR; IL-6 SIGNAL TRANSDUCER; GROWTH-HORMONE RECEPTOR; ONCOSTATIN-M; HUMAN INTERLEUKIN-6; MOLECULAR-CLONING; COMPONENT GP130; LIF RECEPTOR; CELLS	Residues in human leukemia inhibitory factor (hLIF) crucial for binding to both the human LIF receptor (R) and gp130 were identified by analysis of alanine scanning mutants of hLIF in assays for both receptor binding and bioactivity. The region of hLIF most important for binding to the hLIF-R is composed of residues from the amino terminus of the D-helix, carboxyl terminus of the B-helix, and C-D loop. This site forms a distinct surface at the end of the four-helix bundle in the tertiary structure of the closely related murine LIF. The two residues of hLIF that contribute the majority of free energy for hLIF-R binding, Phe-156 and Lys-159 are surrounded by other residues which have only a moderate impact. This arrangement of a few key residues surrounded by less important ones is analogous to the functional binding epitope of human growth hormone for its receptor. A second region of hLIF that includes residues from the carboxyl terminus of the D-helix and A-B loop also had a weak influence on hLIF-R binding. Residues in hLIF from both the A- and C-helices are involved in binding the gp130 co-receptor. Abolition of the gp130 binding site in hLIF created antagonists of LIF action.	UNIV OXFORD,DEPT BIOCHEM,CRC GROWTH FACTOR GRP,OXFORD OX1 3QU,ENGLAND; UNIV BIRMINGHAM,DEPT BIOCHEM,BIRMINGHAM B15 2TT,W MIDLANDS,ENGLAND	University of Oxford; University of Birmingham								ALTMANN SW, 1995, J BIOL CHEM, V270, P2233, DOI 10.1074/jbc.270.5.2233; BAUMANN H, 1993, J BIOL CHEM, V268, P8414; BAZAN JF, 1991, NEURON, V7, P197, DOI 10.1016/0896-6273(91)90258-2; BAZAN JF, 1990, IMMUNOL TODAY, V11, P350, DOI 10.1016/0167-5699(90)90139-Z; BRAKENHOFF JPJ, 1990, J IMMUNOL, V145, P561; CLACKSON T, 1995, SCIENCE, V267, P383, DOI 10.1126/science.7529940; COSMAN D, 1993, CYTOKINE, V5, P95, DOI 10.1016/1043-4666(93)90047-9; CUNNINGHAM BC, 1993, J MOL BIOL, V234, P554, DOI 10.1006/jmbi.1993.1611; CUNNINGHAM BC, 1991, SCIENCE, V254, P821, DOI 10.1126/science.1948064; CUNNINGHAM BC, 1989, SCIENCE, V244, P1081, DOI 10.1126/science.2471267; DAVIS S, 1993, SCIENCE, V260, P1805, DOI 10.1126/science.8390097; DAVIS S, 1991, SCIENCE, V253, P59, DOI 10.1126/science.1648265; DU XX, 1994, BLOOD, V83, P2023; DUBRIDGE RB, 1987, MOL CELL BIOL, V7, P379, DOI 10.1128/MCB.7.1.379; ERNST M, 1994, EMBO J, V13, P1574, DOI 10.1002/j.1460-2075.1994.tb06420.x; ESCARY JL, 1993, NATURE, V363, P361, DOI 10.1038/363361a0; FONTAINE V, 1993, EUR J BIOCHEM, V211, P749, DOI 10.1111/j.1432-1033.1993.tb17605.x; FUH G, 1992, SCIENCE, V256, P1677, DOI 10.1126/science.256.5064.1677; GEARING DP, 1992, NEW BIOL, V4, P61; GEARING DP, 1992, SCIENCE, V255, P1434, DOI 10.1126/science.1542794; GEARING DP, 1991, EMBO J, V10, P2839, DOI 10.1002/j.1460-2075.1991.tb07833.x; GEARING DP, 1992, CIBA F SYMP, V167, P245; Harlow E., 1988, ANTIBODIES LAB MANUA; HEATH JK, 1992, NATURE, V359, P17, DOI 10.1038/359017a0; HIBI M, 1990, CELL, V63, P1149, DOI 10.1016/0092-8674(90)90411-7; HILL CP, 1993, P NATL ACAD SCI USA, V90, P5167, DOI 10.1073/pnas.90.11.5167; HILTON DJ, 1988, ANAL BIOCHEM, V173, P359, DOI 10.1016/0003-2697(88)90200-X; HILTON DJ, 1994, EMBO J, V13, P4765, DOI 10.1002/j.1460-2075.1994.tb06802.x; IP NY, 1992, CELL, V69, P1121, DOI 10.1016/0092-8674(92)90634-O; KISHIMOTO T, 1992, SCIENCE, V258, P593, DOI 10.1126/science.1411569; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KRUSE N, 1992, EMBO J, V11, P3237, DOI 10.1002/j.1460-2075.1992.tb05401.x; LAYTON MJ, 1994, J BIOL CHEM, V269, P17048; LEEBEEK FWG, 1992, J BIOL CHEM, V267, P14832; LOPEZ AF, 1992, EMBO J, V11, P909, DOI 10.1002/j.1460-2075.1992.tb05129.x; MALIK N, 1989, MOL CELL BIOL, V9, P2847, DOI 10.1128/MCB.9.7.2847; MATTHEWS DJ, 1995, BLOOD, V85, P38, DOI 10.1182/blood.V85.1.38.bloodjournal85138; MCDONALD NQ, 1995, EMBO J, V14, P2689, DOI 10.1002/j.1460-2075.1995.tb07269.x; MEREAU A, 1993, J CELL BIOL, V122, P713, DOI 10.1083/jcb.122.3.713; Metcalf D, 1992, GROWTH FACTORS, V7, DOI 10.3109/08977199209046921; MIYAJIMA A, 1993, BLOOD, V82, P1960; MOREAU JF, 1988, NATURE, V336, P690, DOI 10.1038/336690a0; Mossmann T., 1983, J IMMUNOL METHODS, V65, P55; MOTT HR, 1995, CURR OPIN STRUC BIOL, V5, P114, DOI 10.1016/0959-440X(95)80016-T; NAGATA S, 1991, Progress in Growth Factor Research, V3, P131, DOI 10.1016/S0955-2235(05)80004-3; NAKAMURA Y, 1994, NATURE, V369, P330, DOI 10.1038/369330a0; NARAZAKI M, 1993, BLOOD, V82, P1120, DOI 10.1182/blood.V82.4.1120.bloodjournal8241120; OWCZAREK CM, 1993, EMBO J, V12, P3487, DOI 10.1002/j.1460-2075.1993.tb06023.x; PANAYOTATOS N, 1995, J BIOL CHEM, V270, P14007, DOI 10.1074/jbc.270.23.14007; PAONESSA G, 1995, EMBO J, V14, P1942, DOI 10.1002/j.1460-2075.1995.tb07186.x; PENNICA D, 1995, J BIOL CHEM, V270, P10915, DOI 10.1074/jbc.270.18.10915; PENNICA D, 1995, P NATL ACAD SCI USA, V92, P1142, DOI 10.1073/pnas.92.4.1142; PIQUETPELLORCE C, 1994, EXP CELL RES, V213, P340, DOI 10.1006/excr.1994.1208; ROBINSON RC, 1994, CELL, V77, P1101, DOI 10.1016/0092-8674(94)90449-9; Sambrook J., 2002, MOL CLONING LAB MANU; SAVINO R, 1994, EMBO J, V13, P5863, DOI 10.1002/j.1460-2075.1994.tb06931.x; SAVINO R, 1993, P NATL ACAD SCI USA, V90, P4067, DOI 10.1073/pnas.90.9.4067; SIMMONS DL, 1993, CELLULAR INTERACTION; SMITH AG, 1988, NATURE, V336, P688, DOI 10.1038/336688a0; SMITH DB, 1989, GENE ASMT, V77, P5189; SOMERS W, 1994, NATURE, V372, P478, DOI 10.1038/372478a0; SPRANG SR, 1993, CURR OPIN STRUC BIOL, V3, P815, DOI 10.1016/0959-440X(93)90144-A; STAHL N, 1993, J BIOL CHEM, V268, P7628; STAHL N, 1994, SCIENCE, V263, P92, DOI 10.1126/science.8272873; STAHL N, 1993, CELL, V74, P587, DOI 10.1016/0092-8674(93)90506-L; STEWART CL, 1992, NATURE, V359, P76, DOI 10.1038/359076a0; TAGA T, 1989, CELL, V58, P573, DOI 10.1016/0092-8674(89)90438-8; TAGA T, 1992, P NATL ACAD SCI USA, V89, P10998, DOI 10.1073/pnas.89.22.10998; TAMURA T, 1993, P NATL ACAD SCI USA, V90, P11924, DOI 10.1073/pnas.90.24.11924; TANIGUCHI T, 1995, SCIENCE, V268, P251, DOI 10.1126/science.7716517; TAVERNIER J, 1995, P NATL ACAD SCI USA, V92, P5194, DOI 10.1073/pnas.92.11.5194; THOMA B, 1994, J BIOL CHEM, V269, P6215; WARD LD, 1994, J BIOL CHEM, V269, P23286; WARE CB, 1995, DEVELOPMENT, V121, P1283; WATOWICH SS, 1992, P NATL ACAD SCI USA, V89, P2140, DOI 10.1073/pnas.89.6.2140; YIN TG, 1993, J IMMUNOL, V151, P2555	77	88	93	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 17	1996	271	20					11971	11978		10.1074/jbc.271.20.11971	http://dx.doi.org/10.1074/jbc.271.20.11971			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UL250	8662595	Green Accepted, hybrid			2022-12-25	WOS:A1996UL25000060
J	Kurihara, T; Bravo, R				Kurihara, T; Bravo, R			Cloning and functional expression of mCCR2, a murine receptor for the C-C chemokines JE and FIC	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MONOCYTE CHEMOATTRACTANT PROTEIN-1; MOLECULAR-CLONING; GROWTH-FACTOR; SECRETORY PROTEIN; GENE ENCODES; CYTOKINE; FAMILY; CDNA; MCP-3; SEQUENCE	The C-C chemokines human monocyte chemoattractant protein-1 and -3 (MCP-1 and MCP-3) and mouse JE and FIC are potent activators of monocytes. Several receptors for MCP-1 and MCP-3 have been cloned from human monocytic cell lines, and one of these receptors, CCR2B, binds both MCP-1 and MCP-3. Thus far, no murine receptors for JE or FIC have been reported. We have cloned a novel murine C-C chemokine receptor, designated mouse CCR2 (mCCR2), from the mouse monocyte cell line WEHI265.1. The predicted 373-amino acid sequence of mCCR2 shows highest identity (80%) with CCR2B. When stably expressed in human embryonic kidney 293 cells, mCCR2 specifically bound I-125-JE with high affinity. FIC was less potent than JE in competing I-125-JE binding to mCCR2-expressing cells, while three other mouse chemokines, MIP-1 alpha, C10, and N51/KC, did not compete. mccr2 mRNA expression was detected in elicited peritoneal macrophages as well as in several mouse organs. The cloning of mCCR2 provides an important tool to investigate monocyte/macrophage responses to JE and FIC, to identify other targets for their action, and potentially to study models of CCR2 function in the mouse.	BRISTOL MYERS SQUIBB PHARMACEUT RES INST,DEPT ONCOL,PRINCETON,NJ 08543	Bristol-Myers Squibb								BAGGIOLINI M, 1994, ADV IMMUNOL, V55, P97; BENBARUCH A, 1995, J BIOL CHEM, V270, P22123, DOI 10.1074/jbc.270.38.22123; CARRASCO D, 1994, DEVELOPMENT, V120, P2991; Chang H C, 1989, Int Immunol, V1, P388, DOI 10.1093/intimm/1.4.388; CHARO IF, 1994, P NATL ACAD SCI USA, V91, P2752, DOI 10.1073/pnas.91.7.2752; COCHRAN BH, 1983, CELL, V33, P939, DOI 10.1016/0092-8674(83)90037-5; COMBADIERE C, 1995, J BIOL CHEM, V270, P16491, DOI 10.1074/jbc.270.28.16491; DAVATELIS G, 1988, J EXP MED, V167, P1939, DOI 10.1084/jem.167.6.1939; FRANCI C, 1995, J IMMUNOL, V154, P6511; FUENTES ME, 1995, J IMMUNOL, V155, P5769; FURUTANI Y, 1989, BIOCHEM BIOPH RES CO, V159, P249, DOI 10.1016/0006-291X(89)92430-3; GAO JL, 1995, J BIOL CHEM, V270, P17494, DOI 10.1074/jbc.270.29.17494; GAO JL, 1993, J EXP MED, V177, P1421, DOI 10.1084/jem.177.5.1421; HEINRICH JN, 1994, MOL CELL BIOL, V14, P2849, DOI 10.1128/MCB.14.5.2849; HEINRICH JN, 1993, MOL CELL BIOL, V13, P2020, DOI 10.1128/MCB.13.4.2020; KOCH AE, 1992, J CLIN INVEST, V90, P772, DOI 10.1172/JCI115950; KULMBURG PA, 1992, J EXP MED, V176, P1773, DOI 10.1084/jem.176.6.1773; MILLER MD, 1992, CRIT REV IMMUNOL, V12, P17; MINTY A, 1993, EUR CYTOKINE NETW, V4, P99; MURPHY PM, 1994, ANNU REV IMMUNOL, V12, P593, DOI 10.1146/annurev.iy.12.040194.003113; MYERS SJ, 1995, J BIOL CHEM, V270, P5786, DOI 10.1074/jbc.270.11.5786; NALKAN NA, 1991, J CLIN INVEST, V88, P1121; NEOTE K, 1993, CELL, V72, P415, DOI 10.1016/0092-8674(93)90118-A; OPDENAKKER G, 1993, BIOCHEM BIOPH RES CO, V191, P535, DOI 10.1006/bbrc.1993.1251; OPPENHEIM JJ, 1991, ANNU REV IMMUNOL, V9, P617, DOI 10.1146/annurev.iy.09.040191.003153; OQUENDO P, 1989, J BIOL CHEM, V264, P4133; ORLOFSKY A, 1991, CELL REGUL, V2, P403, DOI 10.1091/mbc.2.5.403; POST TW, 1995, J IMMUNOL, V155, P5299; ROLLINS BJ, 1989, MOL CELL BIOL, V9, P4687, DOI 10.1128/MCB.9.11.4687; ROLLINS BJ, 1988, P NATL ACAD SCI USA, V85, P3738, DOI 10.1073/pnas.85.11.3738; ROLLINS BJ, 1991, MOL CELL BIOL, V11, P3125, DOI 10.1128/MCB.11.6.3125; RUTLEDGE BJ, 1995, J IMMUNOL, V155, P4838; RYSECK RP, 1989, EXP CELL RES, V180, P266, DOI 10.1016/0014-4827(89)90230-9; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SOZZANI S, 1995, J LEUKOCYTE BIOL, V57, P788, DOI 10.1002/jlb.57.5.788; THIRION S, 1994, BIOCHEM BIOPH RES CO, V201, P493, DOI 10.1006/bbrc.1994.1729; van der Eb A J, 1980, Methods Enzymol, V65, P826; VANDAMME J, 1992, J EXP MED, V176, P59, DOI 10.1084/jem.176.1.59; YLAHERTTUALA S, 1991, P NATL ACAD SCI USA, V88, P5252, DOI 10.1073/pnas.88.12.5252; YOSHIMURA T, 1989, FEBS LETT, V244, P487, DOI 10.1016/0014-5793(89)80590-3	40	98	105	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 17	1996	271	20					11603	11606		10.1074/jbc.271.20.11603	http://dx.doi.org/10.1074/jbc.271.20.11603			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UL250	8662823	hybrid			2022-12-25	WOS:A1996UL25000003
J	Lee, MO; Dawson, MI; Picard, N; Hobbs, PD; Pfahl, M				Lee, MO; Dawson, MI; Picard, N; Hobbs, PD; Pfahl, M			A novel class of retinoid antagonists and their mechanism of action	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACID RECEPTOR-ALPHA; THYROID-HORMONE; X-RECEPTOR; RESPONSE PATHWAYS; CONFORMATIONAL-CHANGES; DNA-BINDING; CELLS; EXPRESSION; PROMOTER; ELEMENT	Retinoids regulate a broad range of biological processes through two subfamilies of nuclear retinoid receptors, the retinoic acid receptors (RARs) and the retinoid X receptors (RXRs). Recently, we reported a novel type of retinoic acid antagonist (SR11335) and showed that this compound can inhibit retinoic acid (RA) induced activation of a human immunodeficiency virus type 1 (HIV-l) promoter construct that contains a special RA response element (RARE). We have now further characterized the antagonism mediated by SR11335 and of newly synthesized structurally related compounds, Two compounds, SR11330 and SR11334, which are poor transactivators, also showed antagonist activities, inhibiting all-trans RA (tRA) and g-cis-RA. The retinoids inhibited transcriptional activation of RAR/RXR heterodimers effectively, while inhibition of RXR homodimers was less efficient. Inhibition was observed on several RAREs, including the TREpal, beta RARE, apoAI-RARE, and CRBPI-RARE, In addition, the antag.nists inhibited tRA-induced differentiation of HL-60 cells, The antagonist did not interfere with DNA binding of the receptors. In limited proteolytic digestion assays, SR11335 induced resistance of the receptors to proteolysis, but the pattern of the degradation was not altered from that induced by tRA, suggesting that these antagonists induce their biological effects by competing with agonists for binding to RARs, thereby preventing the induction of conformational changes of the receptors necessary for transcriptional activation.	SIDNEY KIMMEL CANC CTR,LA JOLLA,CA 92037; SRI INT,DIV LIFE SCI,MENLO PK,CA 94025	SRI International								ALLAN GF, 1992, J BIOL CHEM, V267, P19513; ALLAN GF, 1992, P NATL ACAD SCI USA, V89, P11750, DOI 10.1073/pnas.89.24.11750; APFEL C, 1992, P NATL ACAD SCI USA, V89, P7129, DOI 10.1073/pnas.89.15.7129; BEEKMAN JM, 1993, MOL ENDOCRINOL, V7, P1226; BENDIK I, 1995, J BIOL CHEM, V270, P3107, DOI 10.1074/jbc.270.7.3107; DAWSON MI, 1993, RETINOIDS PROGR RES, P205; DAWSON MI, 1993, RETINOIDS BIOL CHEM; GHAZAL P, 1992, P NATL ACAD SCI USA, V89, P7630, DOI 10.1073/pnas.89.16.7630; GLASS CK, 1988, CELL, V54, P313, DOI 10.1016/0092-8674(88)90194-8; GRAUPNER G, 1989, NATURE, V340, P653, DOI 10.1038/340653a0; HASHIMOTO Y, 1989, MOL ENDOCRINOL, V3, P1046, DOI 10.1210/mend-3-7-1046; HOFFMANN B, 1990, MOL ENDOCRINOL, V4, P1727, DOI 10.1210/mend-4-11-1727; HUAN BF, 1992, P NATL ACAD SCI USA, V89, P9059, DOI 10.1073/pnas.89.19.9059; HUSMANN M, 1992, BIOCHEM BIOPH RES CO, V187, P1558, DOI 10.1016/0006-291X(92)90480-9; KANEKO S, 1991, MED CHEM RES, V1, P220; KEIDEL S, 1994, MOL CELL BIOL, V14, P287, DOI 10.1128/MCB.14.1.287; KLIEWER SA, 1992, NATURE, V355, P446, DOI 10.1038/355446a0; KUROKAWA R, 1993, GENE DEV, V7, P1423, DOI 10.1101/gad.7.7b.1423; KUROKAWA R, 1994, NATURE, V371, P528, DOI 10.1038/371528a0; LARGMAN C, 1989, BLOOD, V74, P99; LEE MO, 1994, P NATL ACAD SCI USA, V91, P5632, DOI 10.1073/pnas.91.12.5632; LEHMANN JM, 1991, CANCER RES, V51, P4804; LEHMANN JM, 1992, SCIENCE, V258, P1944, DOI 10.1126/science.1335166; LEID M, 1992, CELL, V68, P377, DOI 10.1016/0092-8674(92)90478-U; LOTAN R, 1980, BIOCHIM BIOPHYS ACTA, V605, P33, DOI 10.1016/0304-419X(80)90021-9; MAIO JJ, 1988, J VIROL, V62, P1398, DOI 10.1128/JVI.62.4.1398-1407.1988; MANGELSDORF DJ, 1992, GENE DEV, V6, P329, DOI 10.1101/gad.6.3.329; Morris-Kay G., 1992, RETINOIDS NORMAL DEV; NAGPAL S, 1993, EMBO J, V12, P2349, DOI 10.1002/j.1460-2075.1993.tb05889.x; ORCHARD K, 1993, J ACQ IMMUN DEF SYND, V6, P440; PFAHL M, 1994, VITAM HORM, V49, P327; PFAHL M, 1990, METHOD ENZYMOL, V153, P256; POLI G, 1992, P NATL ACAD SCI USA, V89, P2689, DOI 10.1073/pnas.89.7.2689; PREDKI PF, 1994, MOL ENDOCRINOL, V8, P31, DOI 10.1210/me.8.1.31; ROTTMAN JN, 1991, MOL CELL BIOL, V11, P3814, DOI 10.1128/MCB.11.7.3814; SAKASHITA A, 1993, BLOOD, V81, P1009; SPORN MB, 1994, RETINOIDS, V2; TRAN P, 1992, MOL CELL BIOL, V12, P4666, DOI 10.1128/MCB.12.10.4666; TURPIN JA, 1992, J IMMUNOL, V148, P2539; TZUKERMAN M, 1991, MOL ENDOCRINOL, V5, P1983, DOI 10.1210/mend-5-12-1983; YU VC, 1991, CELL, V67, P1251, DOI 10.1016/0092-8674(91)90301-E; ZECHEL C, 1994, EMBO J, V13, P1425, DOI 10.1002/j.1460-2075.1994.tb06396.x; ZEICHNER SL, 1992, J VIROL, V66, P2268, DOI 10.1128/JVI.66.4.2268-2273.1992; ZHANG XK, 1993, TRENDS ENDOCRIN MET, V4, P156, DOI 10.1016/1043-2760(93)90105-N; ZHANG XK, 1992, NATURE, V358, P587, DOI 10.1038/358587a0; ZHANG XK, 1992, NATURE, V355, P441, DOI 10.1038/355441a0	46	24	24	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 17	1996	271	20					11897	11903		10.1074/jbc.271.20.11897	http://dx.doi.org/10.1074/jbc.271.20.11897			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UL250	8662628	hybrid			2022-12-25	WOS:A1996UL25000051
J	Leedman, PJ; Stein, AR; Chin, WW; Rogers, JT				Leedman, PJ; Stein, AR; Chin, WW; Rogers, JT			Thyroid hormone modulates the interaction between iron regulatory proteins and the ferritin mRNA iron-responsive element	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							3' UNTRANSLATED REGION; MESSENGER-RNA LEVELS; TRANSLATIONAL CONTROL; BINDING-PROTEIN; SERUM FERRITIN; RECEPTOR; CELLS; HYPERTHYROIDISM; DETERMINANT; DEGRADATION	The cytoplasmic iron regulatory protein (IRP) modulates iron homeostasis by binding to iron-responsive elements (IREs) in the transferrin receptor and ferritin mRNAs to coordinately regulate transferrin receptor mRNA stability and ferritin mRNA translational efficiency, respectively. These studies demonstrate that thyroid hormone (T-3) can modulate the binding activity of the IRP to an IRE in vitro and in vivo. T-3 augmented an iron-induced reduction in IRP binding activity to a ferritin IRE in RNA electrophoretic mobility shift assays using cytoplasmic extracts from human liver hepatoma (HepG2) cells. Hepatic IRP binding to the ferritin IRE also diminished after in vivo administration of T-3 with iron to rats. In transient transfection studies using HepG2 cells and a human ferritin IRE-chloramphenicol acetyltransferase (H-IRE-CAT) construct, T-3 augmented an iron-induced increase in CAT activity by similar to 45%. RNase protection analysis showed that this increase in CAT activity was not due to a change in the steady state level of CAT mRNA. Nuclear T-3-receptors may be necessary for this T-3-induced response, because the effect could not be reproduced by the addition of T-3 directly to cytoplasmic extracts and was absent in CV-1 cells which lack T-3-receptors. We conclude that T-3 can functionally regulate the IRE binding activity of the IRP. These observations provide evidence of a novel mechanism for T-3 to up-regulate hepatic ferritin expression, which may in part contribute to the elevated serum ferritin levels seen in hyperthyroidism.	BRIGHAM & WOMENS HOSP,HOWARD HUGHES MED INST,DEPT MED,DIV GENET,BOSTON,MA 02115; BRIGHAM & WOMENS HOSP,HOWARD HUGHES MED INST,DEPT MED,DIV HEMATOL ONCOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,BOSTON,MA 02115	Harvard University; Brigham & Women's Hospital; Howard Hughes Medical Institute; Harvard University; Brigham & Women's Hospital; Howard Hughes Medical Institute; Harvard University; Harvard Medical School	Leedman, PJ (corresponding author), UNIV WESTERN AUSTRALIA,ROYAL PERTH HOSP,DEPT MED,BOX X2213 GPO,PERTH,WA 6001,AUSTRALIA.		Leedman, Peter J/O-4044-2014	Rogers, Jack/0000-0003-1262-8578				CASEY JL, 1989, EMBO J, V8, P3693, DOI 10.1002/j.1460-2075.1989.tb08544.x; CASEY JL, 1988, SCIENCE, V240, P924, DOI 10.1126/science.2452485; Constanzo F, 1986, NUCLEIC ACIDS RES, V14, P721; Deshpande U R, 1992, Thyroidology, V4, P93; DRAPIER JC, 1993, EMBO J, V12, P3643, DOI 10.1002/j.1460-2075.1993.tb06038.x; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; GOOSSEN B, 1992, MOL CELL BIOL, V12, P1959, DOI 10.1128/MCB.12.5.1959; GRAY NK, 1994, EMBO J, V13, P3882, DOI 10.1002/j.1460-2075.1994.tb06699.x; GUO B, 1994, J BIOL CHEM, V269, P24252; HASHIMOTO T, 1989, ENDOCRINOL JAPON, V36, P873; HENDERSON BR, 1993, J BIOL CHEM, V268, P27327; HENDERSON BR, 1994, J BIOL CHEM, V269, P17481; HENTZE MW, 1989, SCIENCE, V244, P357, DOI 10.1126/science.2711187; IWASA Y, 1990, BIOCHEM BIOPH RES CO, V167, P1279, DOI 10.1016/0006-291X(90)90662-7; JUMP DB, 1982, BIOCHEM BIOPH RES CO, V104, P701, DOI 10.1016/0006-291X(82)90693-3; KLAUSNER RD, 1993, CELL, V72, P19, DOI 10.1016/0092-8674(93)90046-S; KRANE IM, 1991, MOL ENDOCRINOL, V5, P469, DOI 10.1210/mend-5-4-469; KUBOTA K, 1993, CLIN INVESTIGATOR, V72, P26; LEEDMAN PJ, 1995, MOL ENDOCRINOL, V9, P375, DOI 10.1210/me.9.3.375; LIEBOLD EA, 1988, P NATL ACAD SCI USA, V85, P2171; MACARON CI, 1982, ANN INTERN MED, V96, P617, DOI 10.7326/0003-4819-96-5-617; Maniatis T, 1989, DECONTAMINATION DILU; MANO H, 1994, J BIOL CHEM, V269, P1591; MELEFORS O, 1993, J BIOL CHEM, V268, P5974; MULLNER EW, 1988, CELL, V53, P815, DOI 10.1016/0092-8674(88)90098-0; NARAYANAN CS, 1992, J BIOL CHEM, V267, P17296; Oppenheimer J. H., 1983, MOL BASIS THYROID HO; PANTOPOULOS K, 1995, P NATL ACAD SCI USA, V92, P1267, DOI 10.1073/pnas.92.5.1267; PANTOPOULOS K, 1995, EMBO J, V14, P2917, DOI 10.1002/j.1460-2075.1995.tb07291.x; ROGERS JT, 1990, J BIOL CHEM, V265, P14572; ROGERS JT, 1994, NUCLEIC ACIDS RES, V22, P2678, DOI 10.1093/nar/22.13.2678; ROSENTHAL N, 1987, METHOD ENZYMOL, V152, P704; SAMANIEGO F, 1994, J BIOL CHEM, V269, P30904; SAMUELS HH, 1979, ENDOCRINOLOGY, V105, P80, DOI 10.1210/endo-105-1-80; SAP J, 1986, NATURE, V324, P635, DOI 10.1038/324635a0; SLEIGH MJ, 1986, ANAL BIOCHEM, V156, P251, DOI 10.1016/0003-2697(86)90180-6; TAKAMATSU J, 1985, J CLIN ENDOCR METAB, V61, P672, DOI 10.1210/jcem-61-4-672; TANG CK, 1992, J BIOL CHEM, V267, P24466; VANDEVYVER FL, 1982, ANN INTERN MED, V97, P930, DOI 10.7326/0003-4819-97-6-930_3; WALDEN WE, 1989, J BIOL CHEM, V264, P13765; WEINBERGER C, 1986, NATURE, V324, P641, DOI 10.1038/324641a0; WINKELMANN JC, 1981, SCIENCE, V213, P569, DOI 10.1126/science.6166047; WOLFF EC, 1964, THYROID GLAND, V1, P237; YEN PM, 1993, ENDOCR J, V1, P461	44	70	74	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 17	1996	271	20					12017	12023		10.1074/jbc.271.20.12017	http://dx.doi.org/10.1074/jbc.271.20.12017			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UL250	8662626	hybrid			2022-12-25	WOS:A1996UL25000066
J	Lovric, J; Radziwill, G; Moelling, K				Lovric, J; Radziwill, G; Moelling, K			Specific association of Mil/Raf proteins with a 34 kDa phosphoprotein	ONCOGENE			English	Article						Mil/Raf kinase; phosphorylation; associated proteins; cell cycle; stimulation; cellular transformation	RAF-1 PROTEIN; MAP KINASE; PHOSPHORYLATION	Mil/Raf protein kinases are intermediates in signaling pathways leading to differentiation, mitogenesis and cellular transformation. To gain insight into the activity of Mil/Raf kinases at the molecular level we aimed to identify proteins specifically interacting with Mil/Raf proteins. A phosphoprotein of 34 kDa (pp34) was found to be associated with c-Raf as well as with viral and activated forms of Mil/Raf proteins in exponentially growing interphase cells. pp34 association was not detectable in mitotic cells. Serum stimulation or coexpression of activated Ras led to decreased electrophoretic mobility of pp34 complexed to Mil/Raf proteins while serum starvation rendered pp34 undetectable. Moreover, the association with pp34 became undetectable in parallel with the onset of morphological cellular transformation caused by overexpression of a constitutively activated mutant of c-Raf in an inducible expression system. Thus, the association of Mil/Raf proteins with pp34 is altered in the course of cell cycle progression, serum stimulation and cellular transformation. These events represent hallmarks of cellular Mil/Raf functions, rendering pp34 a candidate protein involved in Mil/Raf function.	UNIV ZURICH,INST MED VIROL,CH-8028 ZURICH,SWITZERLAND	University of Zurich				Lovric, Josip/0000-0002-0338-6581				BEIMLING P, 1994, BIOCHEM BIOPH RES CO, V204, P841, DOI 10.1006/bbrc.1994.2536; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; DENT P, 1995, MOL CELL BIOL, V15, P4125; FREED E, 1994, SCIENCE, V265, P1713, DOI 10.1126/science.8085158; GALAKTIONOV K, 1995, GENE DEV, V9, P1046, DOI 10.1101/gad.9.9.1046; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; GUPTA SK, 1992, J BIOL CHEM, V267, P7987; HAFNER S, 1994, MOL CELL BIOL, V14, P6696; HEIDECKER G, 1992, ADV CANCER RES, V58, P53, DOI 10.1016/S0065-230X(08)60290-0; JAMAL S, 1995, ONCOGENE, V10, P2095; JANSEN HW, 1984, NATURE, V307, P281, DOI 10.1038/307281a0; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LI SF, 1993, P NATL ACAD SCI USA, V90, P9247, DOI 10.1073/pnas.90.20.9247; LOVRIC J, 1994, FEBS LETT, V343, P15, DOI 10.1016/0014-5793(94)80598-9; LOVRIC J, 1996, IN PRESS ONCOGENE; MARAIS R, 1995, EMBO J, V14, P3136, DOI 10.1002/j.1460-2075.1995.tb07316.x; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; MCGREW BR, 1992, ONCOGENE, V7, P33; MOELLING K, 1984, NATURE, V312, P558, DOI 10.1038/312558a0; MOODIE SA, 1994, TRENDS GENET, V10, P44, DOI 10.1016/0168-9525(94)90147-3; RADZIWILL G, 1995, P NATL ACAD SCI USA, V92, P1421, DOI 10.1073/pnas.92.5.1421; Rommel C, 1996, ONCOGENE, V12, P609; SAMUELS ML, 1993, MOL CELL BIOL, V13, P6241, DOI 10.1128/MCB.13.10.6241; SCHRAMM K, 1994, BIOCHEM BIOPH RES CO, V201, P740, DOI 10.1006/bbrc.1994.1763; SCHRAVEN B, 1994, J BIOL CHEM, V269, P29102; SCHULTZ AM, 1985, VIROLOGY, V146, P78, DOI 10.1016/0042-6822(85)90054-6; SIGAL CT, 1993, MOL CELL BIOL, V13, P3084, DOI 10.1128/MCB.13.5.3084; STANCATO LF, 1993, J BIOL CHEM, V268, P21711; WILLIAMS NG, 1994, CANCER METAST REV, V13, P105, DOI 10.1007/BF00690421	30	2	2	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR 7	1996	12	5					1145	1151						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UA884	8649807				2022-12-25	WOS:A1996UA88400024
J	Takle, LA; Knowles, MA				Takle, LA; Knowles, MA			Deletion mapping implicates two tumour suppressor genes on chromosome 8p in the development of bladder cancer	ONCOGENE			English	Article						chromosome 8; loss of heterozygosity; bladder cancer; tumour suppressor gene; microsatellite polymorphism	TRANSITIONAL CELL-CARCINOMA; COLORECTAL-CANCER; POLYMORPHISMS; LOCI	Chromosome 8 loss of heterozygosity (LOH) in cancer of the urinary bladder is associated with high tumour grade and stage. We have screened 193 cases of transitional cell carcinoma (TCC) of the bladder using 30 microsatellite polymorphisms on chromosome 8. Forty three cases (22%) showed LOH on 8p, the majority of which (72%) had lost the entire short arm. Using 12 tumours with partial deletions of 8p, we have defined a minimum telomeric region of deletion between D8S264 and D8S133 (8p21.1-pter). We also found LOH in the region 8p11.2-12, where we have defined at least one centromeric target for deletion within a 4 cM interval. Two tumours were identified with loss of the telomeric region only, whereas all cases with loss in the centromeric region also had telomeric deletion. Chromosome 8p deletions have also been described in prostate, colorectal, hepatocellular, lung and endometrial carcinoma and collecting duct carcinoma of the kidney. It has been postulated that loss or inactivation of at least 2 tumour suppressor genes on 8p may play an important role in progression of both prostate and colorectal carcinomas. The regions of deletion eve have identified in bladder tumours are compatible with these, suggesting that at least two genes on 8p may play a role in the development of many common solid tumours. Our findings significantly refine the localisation of the more centromeric of these loci.	MARIE CURIE RES INST,MOLEC GENET LAB,OXTED RH8 0TL,SURREY,ENGLAND					Knowles, Margaret/0000-0002-9363-8657				ATKIN NB, 1985, CANCER GENET CYTOGEN, V15, P253, DOI 10.1016/0165-4608(85)90169-4; BABU VR, 1987, CANCER RES, V47, P6800; BERGER CS, 1986, CANCER GENET CYTOGEN, V23, P1, DOI 10.1016/0165-4608(86)90145-7; BOVA GS, 1993, CANCER RES, V53, P3869; CANNIZZARO LA, 1987, CYTOGENET CELL GENET, V46, P589; CARTWRIGHT RA, 1982, LANCET, V2, P842; CUNNINGHAM C, 1993, ONCOGENE, V8, P1391; CUNNINGHAM C, 1994, BRIT J CANCER, V70, P18, DOI 10.1038/bjc.1994.243; DOBASHI Y, 1994, CANCER RES, V54, P2827; EMI M, 1992, CANCER RES, V52, P5368; FRANKE S, 1994, BIOCHEM BIOPH RES CO, V199, P52, DOI 10.1006/bbrc.1994.1192; FUJINO T, 1994, CANCER RES, V54, P4294; FUJIWARA Y, 1994, GENE CHROMOSOME CANC, V10, P7, DOI 10.1002/gcc.2870100103; FUJIWARA Y, 1993, CANCER RES, V53, P1172; FUJIWARA Y, 1995, ONCOGENE, V10, P891; GIBAS Z, 1984, CANCER RES, V44, P1257; GIBAS Z, 1986, CANCER GENET CYTOGEN, V19, P229, DOI 10.1016/0165-4608(86)90051-8; GRANBERGOHMAN I, 1984, CANCER GENET CYTOGEN, V11, P69, DOI 10.1016/0165-4608(84)90100-6; GYAPAY G, 1994, NAT GENET, V7, P246, DOI 10.1038/ng0694supp-246; HICKMAN D, 1994, BIOCHEM J, V297, P441, DOI 10.1042/bj2970441; ICHIKAWA T, 1994, CANCER RES, V54, P2299; JONES TA, 1993, CYTOGENET CELL GENET, V63, P35, DOI 10.1159/000133497; KEEN AJ, 1994, ONCOGENE, V9, P2083; KELEMEN PR, 1994, GENE CHROMOSOME CANC, V11, P195, DOI 10.1002/gcc.2870110308; KERANGUEVEN F, 1995, ONCOGENE, V10, P1023; KNOWLES MA, 1994, CANCER RES, V54, P531; KNOWLES MA, 1993, ONCOGENE, V8, P1357; MACGROGAN D, 1994, GENE CHROMOSOME CANC, V10, P151, DOI 10.1002/gcc.2870100302; OHATA H, 1993, GENE CHROMOSOME CANC, V7, P85, DOI 10.1002/gcc.2870070204; PROCTOR AJ, 1991, ONCOGENE, V6, P789; RISCH A, 1995, HUM MOL GENET, V4, P231, DOI 10.1093/hmg/4.2.231; SCHOENBERG M, 1995, GENE CHROMOSOME CANC, V12, P76, DOI 10.1002/gcc.2870120115; Spurr N. K., 1995, Cytogenetics and Cell Genetics, V68, P147, DOI 10.1159/000133908; TOMFOHRDE J, 1992, GENOMICS, V14, P144, DOI 10.1016/S0888-7543(05)80297-6; TRAPMAN J, 1994, CANCER RES, V54, P6061; VANNI R, 1988, CANCER GENET CYTOGEN, V30, P35, DOI 10.1016/0165-4608(88)90090-8; WANG LM, 1992, CANCER RES, V52, P4824; WEINBERG RA, 1991, SCIENCE, V254, P1138, DOI 10.1126/science.1659741; YAREMKO ML, 1994, GENE CHROMOSOME CANC, V10, P1, DOI 10.1002/gcc.2870100102	39	81	82	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR 7	1996	12	5					1083	1087						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UA884	8649800				2022-12-25	WOS:A1996UA88400017
J	Menke, AL; Riteco, N; vanHam, RCA; deBruyne, C; Rauscher, FJ; vanderEb, AJ; Jochemsen, AG				Menke, AL; Riteco, N; vanHam, RCA; deBruyne, C; Rauscher, FJ; vanderEb, AJ; Jochemsen, AG			Wilms' Tumor 1 splice variants have opposite effects on the tumorigenicity of adenovirus-transformed baby-rat kidney cells	ONCOGENE			English	Article						Wilm's tumor; WT1; adenovirus, tumorigenicity; serum-dependency	ZINC FINGER PROTEIN; GENE WT1; EXPRESSION; SUPPRESSOR; BINDING; LOCUS; P53; INDUCTION; ANTIGEN; PRODUCT	The Wilms' Tumor 1 gene (WT1) encodes a transcription factor of the zinc-finger family, As a result of alternative RNA splicing, the gene can be expressed as four polypeptides which differ in the presence or absence of two stretches of amino acids: one of 17 residues (17aa) just N-terminal of the four zinc-fingers and of three residues (K-T-S) between zinc finger 3 and 4. In this study, four human cDNA constructs encoding the Wilms' tumor 1 splice variants were stably transfected into adenovirus-transformed baby rat kidney (Ad-BRK) cells. The in vivo produced WT1 proteins that lacked the KTS residues were found to bind efficiently to both the Egr-1 consensus sequence and the recently described WTE DNA sequence, as determined by electrophoretic mobility shift assays. Our studies show distinct effects of the different WT1 isoforms. Expression of the WT1 (-/+) protein, lacking the 17aa insert, strongly suppressed the tumorigenic phenotype of the Ad-BRK cells. Intriguingly, expression of the WT1 (-/-) protein, lacking both inserts, increased the tumor growth rate. In contrast to the growth in vivo, the growth rate of the transfectants in tissue culture is not influenced by any of the WT1 isoforms. However, the suppression of tumorigenicity appears to be correlated with a reduced ability of the cells to grow in serum-free medium.	LEIDEN UNIV,SYLVIUS LABS,MOLEC CARCINOGENESIS LAB,2300 RA LEIDEN,NETHERLANDS; WISTAR INST ANAT & BIOL,PHILADELPHIA,PA 19104	Leiden University; Leiden University - Excl LUMC; The Wistar Institute			Menke, Aswin/AAC-6809-2021	Menke, Aswin/0000-0002-0724-0897				AMIN KM, 1995, AM J PATHOL, V146, P344; BAUER M, 1987, J VIROL, V61, P1821, DOI 10.1128/JVI.61.6.1821-1827.1987; BERNARDS R, 1982, VIROLOGY, V120, P422, DOI 10.1016/0042-6822(82)90042-3; BICKMORE WA, 1992, SCIENCE, V257, P235, DOI 10.1126/science.1321494; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRENNER B, 1992, ONCOGENE, V7, P1431; BRENNER BM, 1990, J AM SOC NEPHROL, V1, P127; BRIEGER J, 1994, LEUKEMIA, V8, P2138; BRUENING W, 1992, NAT GENET, V1, P144, DOI 10.1038/ng0592-144; BRUENING W, 1993, CANCER INVEST, V11, P393, DOI 10.3109/07357909309018871; CALL KM, 1990, CELL, V60, P509, DOI 10.1016/0092-8674(90)90601-A; DRUMMOND IA, 1994, MOL CELL BIOL, V14, P3800, DOI 10.1128/MCB.14.6.3800; EKBLOM P, 1980, DEV BIOL, V74, P263, DOI 10.1016/0012-1606(80)90429-7; GESSLER M, 1992, GENOMICS, V12, P807, DOI 10.1016/0888-7543(92)90313-H; HABER DA, 1993, SCIENCE, V262, P2057, DOI 10.1126/science.8266105; HABER DA, 1991, P NATL ACAD SCI USA, V88, P9618, DOI 10.1073/pnas.88.21.9618; HARLOW E, 1985, J VIROL, V55, P533, DOI 10.1128/JVI.55.3.533-546.1985; HASTIE ND, 1994, ANNU REV GENET, V28, P523; KONG A, 1993, HUM MOL GENET, V2, P1967; KREIDBERG JA, 1993, CELL, V74, P679, DOI 10.1016/0092-8674(93)90515-R; LARSSON SH, 1995, CELL, V81, P1; MADDEN SL, 1993, ONCOGENE, V8, P1713; MADDEN SL, 1991, SCIENCE, V253, P1550, DOI 10.1126/science.1654597; MAHESWARAN S, 1993, P NATL ACAD SCI USA, V90, P5100, DOI 10.1073/pnas.90.11.5100; MENKE AL, 1995, INT J CANCER, V63, P76, DOI 10.1002/ijc.2910630115; MENSSEN HD, 1995, LEUKEMIA, V9, P1060; MIWA H, 1992, LEUKEMIA, V6, P405; MORRIS JF, 1991, ONCOGENE, V6, P2339; NAKAGAMA H, 1995, MOL CELL BIOL, V15, P1489; PRITCHARDJONES K, 1991, ONCOGENE, V6, P2211; PRITCHARDJONES K, 1990, NATURE, V346, P194, DOI 10.1038/346194a0; RAUSCHER FJ, 1990, SCIENCE, V250, P1259, DOI 10.1126/science.2244209; RAUSCHER FJ, 1993, FASEB J, V7, P896, DOI 10.1096/fasebj.7.10.8393820; REDDY JC, 1995, J BIOL CHEM, V270, P10878, DOI 10.1074/jbc.270.18.10878; RODECK U, 1994, INT J CANCER, V59, P78, DOI 10.1002/ijc.2910590116; RUPPRECHT HD, 1994, J BIOL CHEM, V269, P6198; SABATTINI P, 1995, MOL CELL BIOL, V15, P1060; SHARMA PM, 1992, CANCER RES, V52, P6407; STEEGENGA WT, 1995, VIROLOGY, V212, P543, DOI 10.1006/viro.1995.1512; STEWART CL, 1982, P NATL ACAD SCI-BIOL, V79, P4098, DOI 10.1073/pnas.79.13.4098; VANDENHEUVEL SJL, 1993, J VIROL, V67, P5226, DOI 10.1128/JVI.67.9.5226-5234.1993; VANLEER EHG, 1993, EXP NEPHROL, V1, P292; WALKER C, 1994, CANCER RES, V54, P3101; WANG ZY, 1995, ONCOGENE, V10, P415; WANG ZY, 1995, ONCOGENE, V10, P1243; YEW PR, 1992, NATURE, V357, P82, DOI 10.1038/357082a0; ZANTEMA A, 1985, MOL CELL BIOL, V5, P3084, DOI 10.1128/MCB.5.11.3084; ZHOU YL, 1994, P NATL ACAD SCI USA, V91, P4165, DOI 10.1073/pnas.91.10.4165	48	42	46	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB 1	1996	12	3					537	546						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TV597	8637710				2022-12-25	WOS:A1996TV59700010
